



# ACTA MEDICA SCANDINAVICA

SUPPLEMENTUM 473

## LUNG CLEARANCE AND OF MONO- AND DI-DISPERSED AEROSOLS DETERMINED BY PROFILE SCANNING AND WHOLE-BODY COUNTING

*A study on normal and SO<sub>2</sub> exposed rabbits*

By  
BO HOLMA

# ACTA MEDICA SCANDINAVICA

has been published since 1919 as a continuation of Nordiskt Medicinskt Arkiv, founded in 1869 by Axel Key. The first volume of Acta Medica Scandinavica is therefore numbered LII (52).

The chief editors have been Axel Key 1869—1900, C. G. Santesson 1901—1915, I. Holmgren 1916—1937 and Birger Strandell 1938 to date.

Acta Medica Scandinavica publishes original research papers in the field of internal medicine. Priority will be given to authors from countries which are represented on the editorial board. Contributors from those countries should submit their papers to a representative of the country in question. Contributors from other countries should send their papers to the Editor at the address below.

Submission of a manuscript for publication will be held to imply that the paper has not been published elsewhere and that, if accepted, it will not be republished in any other journal in the same or similar form without the Editor's written consent.

Papers will be published in English, French or German at the authors' choice, followed by a summary in English.

The manuscripts shall be in final form as submitted. They shall be typewritten with double spacing and broad left hand margin.

If a paper exceeds 16 printed pages the cost for the excess pages shall be borne by the author. No paper shall exceed 24 printed pages.

## SUBSCRIPTION

The annual subscription to the journal, covering two volumes, each of 6 numbers, is 110 Sw. crowns or US \$27.25 including postage, in the Scandinavian countries and in Holland 120 Sw. crowns.

*Address for subscriptions and all communications*

ACTA MEDICA SCANDINAVICA

P. O. Box 2032 Stockholm 2

---

Requests to duplicate copies of numbers that have gone astray can only be considered if made within a fortnight of the receipt of the following number.

From the Department of Hygiene Karolinska Institutet  
and the Department of Environmental Hygiene National Institute  
of Public Health Stockholm Sweden

LUNG CLEARANCE  
OF MONO- AND DI-DISPERSE  
AEROSOLS DETERMINED  
BY PROFILE SCANNING  
AND WHOLE-BODY COUNTING

*A study on normal and SO<sub>2</sub> exposed rabbits*

By  
BO HOLMA





# CONTENTS

Introduction	5	CHAPTER 4 <i>Choice of animal and exposure technique</i>	36
CHAPTER 1 <i>General Background</i>	7	Choice of animal	36
Lung clearance	7	Exposure technique	36
Alveolar clearance mechanisms	8	CHAPTER 5 <i>Measurement technique</i>	39
Tracheobronchial clearance mechanisms	10	Description of the apparatus	39
Clearance via the lymphatic system	11	Profile scanning apparatus	39
Lung clearance as a whole	11	Whole body counter	45
Earlier methods for studying lung clearance	12	Characteristics of the apparatus	46
Scope of the present investigation	13	Collimator apparatus no 1,	47
CHAPTER 2 <i>Production of aerosols</i>	15	Collimator apparatus no 2	47
Choice of aerosol	15	Collimator, apparatus nos 3 and 4	49
Heterodisperse gelatin aerosols tagged with Au <sup>198</sup>	15	Whole body counter	50
Mono and di disperse aerosols tagged with Au <sup>198</sup> and Sc <sup>46</sup>	16	Validity of the measurement method for lung clearance studies	50
Condensation method for n octadecanol particles	16	Profile scanning apparatus no 1	50
Spinning disc method for polystyrene particles	18	Profile scanning apparatus no 2	51
CHAPTER 3 <i>Translocation solubility retention and phagocytosis of the aerosol particles</i>	22	Profile scanning apparatus nos 3 and 4	57
Gelatin particles tagged with Au <sup>198</sup>	22	Discussion	58
N-octadecanol particles tagged with Au <sup>198</sup>	23	CHAPTER 6 <i>Evaluation of the measurements</i>	61
Polystyrene particles tagged with Au <sup>198</sup> or Sc <sup>46</sup>	23	Profile scan curves	61
Leaching	24	Surface measurement with a planimeter	62
Retention and translocation	24	Height measurement of lung fraction	62
Phagocytosis of polystyrene particles in vitro	31	Discussion	66
		Whole body measurement	67
		Mathematical models	67
		Discussion	73
		CHAPTER 7 <i>Application of the methods</i>	74
		Experimental conditions	74

## Results and comments

The course of clearance and its different phases 78 Intra and interindividual variations 80 Significance of particle size 80 Correlation between different phases of clearance 81 Clearance after exposure to sulphur dioxide 81

77	CHAPTER 8 <i>General discussion</i>	86
	Summary	88
	Acknowledgements	90
	Appendix	91
	References	93

## INTRODUCTION

The lung's ability to rid itself of deposited material—lung clearance—is one of the mechanisms which protects the organism from injurious effects of air pollutants. This defence mechanism, comprising various physiological functions, thus determines the time during which different agents can exert their effect in the lung. The transport of secretions assisted by ciliary motility is a major mechanism responsible for elimination of foreign matter from the lung. Elimination is also effected by phagocytosis and by diffusions or direct penetration of the material in question to the interstitial tissues where it can accumulate in the lymphatics and/or enter the bloodstream. Diffusion is most important for soluble substances and the other mechanisms are more concerned with the elimination of solid or semi insoluble substances. Lung clearance is also affected by the physiological and pathological status of the organism.

Numerous investigations of lung clearance have been made but many problems remain unanswered. Some of the results are contradictory and the discrepancies have been explained in terms of differences in methodology, experimental animal used, observation time etc. Generally speaking, however, it can be said that lung clearance has an initial rapid phase and a slower subsequent course. However, the initial phase has not been adequately investigated due to the lack of suitable methods. There are results which indicate that large particles have a faster clearance than small ones, although in a few

experiments the reverse was reported. The intra and interindividual variation of lung clearance has not been investigated except for one study that concerned only the alveolar clearance of submicronic particles. The effect of gaseous air pollutants on lung clearance has been reported in only one study performed on sacrificed animals.

The above questions are considered in the present study with monodisperse aerosols. The dependence of lung clearance on particle size was investigated using two discrete particle sizes simultaneously on one and the same animal. The intra and interindividual variations of the two phases of this lung function and the effect of a gaseous air pollutant ( $\text{SO}_2$ ) on lung clearance in live animals were also investigated.

Chapter 1 surveys data from the literature concerning important findings about the mechanisms involved in lung clearance and also deals with various methods that have been used to study lung clearance with particular reference to methods for external measurement. This is followed by a presentation of the problem investigated and the arrangement of the experiments conducted by the present author. A subsequent chapter deals with the production and characteristics of the test aerosols used. A separate chapter is devoted to the technique of exposure and this is followed by a presentation of the measuring technique, the validity of the apparatus for these studies and methods for evaluating the measurements obtained. In conclusion, an account is given of some

applications of the present measuring technique in lung clearance studies with comments on the significance of particle size in test results and the importance of intra- and

interindividual variations in this lung function. The suitability of the method for studying effects on lung clearance is illustrated using rabbits exposed to  $\text{SO}_2$ .

## GENERAL BACKGROUND

## Definitions

In keeping with the definitions laid down by the Subcommittee on Inhalation Hazards (62) *deposition* is used here to refer to the amount of inhaled material that remains in the respiratory tract after expiration. By *retention* is meant the amount or fraction of the deposited material that remains in the respiratory tract at any given time. Thus deposition is the same as initial retention. The transport of material out of the lungs via the trachea is termed *clearance* and the removal of material to other tissues *translocation*.

In the present work, the term *lung clearance* refers to the clearance of the lower respiratory tract i.e. the tracheobronchial and pulmonary compartments as defined by the Task Group on Lung Dynamics (96).

By *aerosol* is meant solid particles or liquid drops distributed in air and of such a particle size that gravitational and diffusional forces impart sufficient stability for the system to be classified as an air suspension. Aerosols are described as *monodisperse* if the particles are sufficiently similar in size for them to behave—as a unit and concerning the parameter being investigated—in a manner typical of the mean particle size. A *bidisperse aerosol* is one containing a mixture of two different sizes of monodisperse particles.

The measurement data concerning the size of aerosol particles is given in terms of their *count median diameter (CMD)* unless other

wise stated. The abbreviation MMAD stands for the particles *mass median aerodynamic diameter* i.e. the mass of a unit density sphere with the same settling velocity as the particle in question (96).

## Lung clearance

There is a lack of detailed data concerning lung clearance mechanisms (46-96). A brief description will therefore be given of generally accepted principles and experimental findings concerning the complex of various functions that are known or presumed to be involved in this function of the lung. The references given here are by way of illustration and do not pretend to be complete. This field has been systematically reviewed by the Task Group on Lung Dynamics (96) and by Hatch & Cross (47).

Even though the mechanisms involved in the total clearance process have not always been investigated in an entirely satisfactory manner, lung clearance is considered to comprise at least the following functions: transport of secretion, promoted by ciliary activity; endocytosis; resorption; and direct penetration of particles through the lung parenchyma.

However, clearance is not a uniform process in the different parts of the respiratory tract. Alveolar clearance, for instance, differs entirely from the clearance mechanisms in the nasal, buccopharyngeal and tracheobronchial sections.

### *Alveolar clearance mechanisms*

Although the mechanisms responsible for the transport of solid particles deposited in the alveoli are somewhat obscure it is known that the greater part will be carried to the mucociliary transport mechanism of the bronchi while a smaller fraction finds its way into the interstitial tissue and lymphatics from where a minor quantity enters the bloodstream. Part of the material may be translocated directly to the blood depending on its solubility *in vivo*.

It is not clear which mechanism or mechanisms are responsible for transporting the particles from the alveoli to the related parts and no generally accepted solution has yet been found to certain questions raised by the earliest research in this field. In particular there is the problem of the mechanisms that contribute to the transport of particles from the interstitial tissue with the related questions concerning the structure of the alveolar walls, the origin of the phagocytes, the respiratory tracts and their role in this association.

Some investigations suggest that particles move directly into the interstitial tissue without the help of phagocytes; this has been reported by Gross & Westcott (43). However, if the phagocytosis is inherent a positive mechanism since it makes it more difficult for the particles to penetrate the cell membranes. Others such as Cassaret (18) consider that particles do penetrate to the interstitial tissue with the help of phagocytic cells.

A point of controversy concerns the origin of phagocytic cells particularly the macrophages. A large number of investigators are of the opinion that these cells are to be strictly regarded as cells which are formed and supported by stem cells (44). For example, Fickel *et al.* (45) have experimentally shown that the cells which the blood contains will be able to

be fixed by marker chromosomes. They demonstrated that about 2/3rds of the lung macrophages displayed the same specific chromosomes that indicated their hematopoietic origin.

Gross (42) argued that alveolar clearance is dependent upon phagocytosis of the macrophages. This was demonstrated by LaBelle & Brigger (65) in a study on the rat in which they found that the elimination of carbon particles was correlated to the number of free phagocytes in the lungs. Secker (93) showed that cytotoxic substances such as quartz elicit a marked increase in alveolar cells and in the degree of mitosis among these whereas such effects are not obtained with "inert" material. Quartz and other cytotoxic particles that undergo phagocytosis lead to destruction of the phagocytes and produce changes in the alveolar walls that enable these particles to penetrate to the interstitial tissue and the lymphatics (60, 93, 103). "Inert" particles however do not destroy the phagocytes (89) and can be found in live cells on the bronchial epithelium (93). The "inert" particles are removed chiefly via the transport of secretions in the bronchi while a larger proportion of the cytotoxic particles end up in the lymph system. The entry to the lymph system is said by e.g. Macklin (67) and Cassaret (18) to lie in the small bronchioles.

According to these studies the cytopathogenic properties of the particles are of considerable importance for their penetration to the interstitial tissue and their transport in the lymph system. The presence of such particles may also affect the elimination of other "inert" particles. The cytopathogenic effect of a highly reactive substance such as quartz has for instance been shown by Kleinmeyer & Finkelstein (61) to lower the elimination and to raise the penetration of

interstitial tissue of an "inert" substance in experiments with  $\text{TiO}_2$  and corundum

LaBelle & Brieger (64) found that the addition of carbon particles accelerated the clearance of a low initial deposition of biologically active particles (uranium dioxide) from the rat lung. The retention after 24 or 48 hours fell steadily as the amount of carbon particles deposited rose in the interval 0.005–1.5 mg. A larger deposition of carbon particles reduced the rate of clearance again. Bair & Henney (10) were unable to increase the clearance of inhaled  $\text{Ce}^{144}\text{O}_2$  particles in the rat through the inhalation of carbon particles. On the other hand the inhalation of graphite particles is reported by Friedberg & Polley (37) to block the elimination of quartz. Furthermore LaBelle & Brieger (65) found that the rate of clearance was directly correlated to the number of free phagocytes in the rat lung. From another study reported by Thomas (97) concerning rats subjected to prolonged exposure to uranium dioxide it seems that "the kinetics of loss from the lung are a function of the amount present at any time regardless of when it was deposited".

The results of the above investigations indicate that the inhalation of a substance that affects one or several of the clearance mechanisms may protect the lungs against an injurious effect of another substance. Studies have accordingly been made of the protective effect of various substances primarily against attack by  $\text{SiO}_2$ .

The reticuloendothelial system (RES) has been stimulated experimentally with the aim of influencing clearance by Fern (33) who demonstrated that pulmonary clearance in the rat is related to the functional state of the RES. He also found that climatological factors affect pulmonary clearance which is retarded by prolonged exposure to cold.

Accelerated clearance of  $\text{SiO}_2$  is elicited by polyvinylpyridin N oxide (P 204) which appears to act through a protective effect on the phagocytes (61, 83, 93). This agent causes  $\text{SiO}_2$  particles to behave as an "inert" substance which may prevent penetration to the lymphatics.

While the phagocytic cells i.e. the macrophages defend the organism from injurious effects of inhaled dust they are of still greater importance as a defence against bacterial infections. The efficiency of this clearance mechanism is demonstrated by the fact that the lung in spite of the presence of bacteria in the air is sterile under normal conditions.

The clearance of viable bacteria varies with their strain but is generally so efficient that a large proportion are removed from the lungs within a matter of hours apparently largely due to the activity of the macrophages (41).

The tension in the surface active film that covers the alveoli has been investigated in vitro by Mendenhall *et al.* (69). Their work suggests that this surface active film assists the penetration of fluid from the alveoli to the bloodstream during exhalation and in the opposite direction during inhalation. This would facilitate the gaseous exchange and also help to rid the alveoli from their own and foreign matter since the new surface active matter supplied to the alveoli at each respiratory cycle displaces the material supplied during the preceding cycle towards the ciliated epithelium.

Another theory put forward by Gross (42) is that the film of fluid covering the alveoli varies in viscosity with the surface layer having the highest viscosity since this is where evaporation occurs. At each inhalation this layer would lag behind the less viscous layer beneath it. The more viscous layer would then be pushed upwards out of



the alveoli during subsequent expirations by newly formed viscous volumes

A theory suggested by Antweiler (4) is that peripheral surface liquids are transported to the ciliated parts by a suction caused by the ciliary motility

#### *Tracheobronchial clearance mechanisms*

The principle feature of the tracheobronchial clearance mechanism is a transportation of secretion that is promoted by the ciliary motility

The cilia beat rapidly in an oral direction and recover more slowly. The number of beats per minute is approximately 1 000 in man (31), 1 100 in the rabbit (26) and 1 300 in the rat trachea (25). As a result of the ciliary movements the mass of secretion lying on top of the cilia is transported in an oral direction towards the larynx. This transport may be effected by the tips of the cilia which lie in the more viscous layer of the secretion (52).

The cilia have been observed to beat in an axial direction in the calf trachea with deviations at the bronchial apertures and the vocal cords (12). It has also been found that particles are transported with secretion spirally in some cases (13) and axially (19) in others in the trachea. Furthermore the stream of secretion splits up at bronchial apertures where there may also be whirls in which particles are liable to remain for some time just as they are in "islands" of squamous epithelium (34).

The lack of cilia on the vocal cords and the anterior commissure of the larynx and their presence on the posterior commissure suggests that the secretion passes by the latter route.

The total cross section of the respiratory tract tapers little towards the alveoli and consequently the amount of secretion per unit

length should increase in an oral direction. This relationship is offset however, by an acceleration in the transport of secretion (52) in an oral direction.

Antweiler (4) has shown that different types of particles placed on the surface of tracheas from a number of different animals were transported at a uniform rate of about 15 mm/min and that this rate was not influenced by the character of the material, its size, weight or form. It therefore seems that the clearance achieved by ciliary activity is independent of particle size. Particle size does on the other hand affect deposition and consequently the amount eliminated may vary with this parameter. Some experiments have shown that the trachea is cleared of inhaled particles within 1 to 2 hours (95).

The motility of the cilia is affected by the composition of the secretion. An increased viscosity retards their movement and thereby reduces the beat frequency. The ciliary beat is also correlated to the temperature and humidity of the air. Further details concerning the morphology and physiology of the cilia have been published by Dalhamn (25), Sleight (91) and Rivera (81).

The transport of secretion is influenced by other mechanisms as well. Dilatation and contraction during breathing may contribute to this transport. Although bronchial peristalsis has been demonstrated in some investigations (99), it is probably of secondary importance compared with the mucociliary transport mechanism.

The speed of the air flow may also contribute to the transport of particles out of the lung. Coughing may cause drops of secretion to be ejected from the respiratory tract. Forced inhalation on the other hand may result in drops of secretion with concomitant particles being displaced further down the respiratory tract.

### *Clearance via the lymphatic system*

It is not clear where or by what mechanism or mechanisms particles enter the capillaries of the lymph system, but the translocation of particles to this system seems to be related to their toxicity (44-58-93)

As a rule the lymphatics receive only a small proportion of matter deposited in the lungs (96) though the amount varies considerably for different substances. The transportation of particles in this system is a slow process with a half life reckoned in years (60-62, 98). Large differences have been noted and the presence of cytopathogenic particles has been shown to increase the proportion up to 56% compared with a normal figure of 1% for the elimination of inert deposits via the lymphatic system (59). About 50% of quartz deposited in the lungs finds its way to the lymphatics (58).

### *Lung clearance as a whole*

Lung clearance as defined earlier can generally be described as the sum of at least two processes that occur at different rates. Initially there is a rapid phase with a half life of hours. This is followed by a slower phase (or phases) with a half life of weeks to months partly depending upon the nature of the material. Ciliary activity is presumably the major factor during the initial phase while the subsequent phase (phases) probably involves chiefly the transport of matter from the deepest part of the lungs.

As a rule lung clearance has been described only with respect to its course after the initial rapid phase. Certain conclusions can however be drawn about total clearance from investigations concerning the slower phase or phases. Inadequate data about the initial phase chiefly affect calculations of the level at which the slower phase starts in relation to the initial deposition.

The rate of total clearance is dependent upon the physical-chemical properties of the particles (75), particularly their solubility *in vivo*. Differences have been noted in the clearance of different substances, this has been reviewed by the Task Group on Lung Dynamics (96). The slower phase of clearance presents a typical pattern for the particles of a particular substance and may vary considerably between different substances.

In studies with heterodisperse aerosols of different sizes between 0.3 and 11  $\mu\text{m}$ , however, LaBelle & Brieger (14-64) found that the rate of clearance increased with the size of the particles; they interpreted this as being due to the depth of deposition and not the particles solubility. Harper & Morton (45) also found that bacterial spores tagged with an isotope were eliminated from the guinea pig more rapidly in the 4 and 6  $\mu\text{m}$  sizes than in the 1  $\mu\text{m}$  size. Similar results have been reported by Stockinger *et al.* (92) for inhalation studies in the rat, using ca. 2.6  $\mu\text{m}$  MMAD and ca. 0.45  $\mu\text{m}$  MMAD uranium oxide particles. Moreover Albert & Arnet (1) conducted experimental studies with the inhalation of iron oxide powder tagged with  $\text{Fe}^{59}$  in man and found that the 3.4-4.3  $\mu\text{m}$  particles were eliminated to a greater extent than the 1.4-2.3  $\mu\text{m}$  particles during the first 2-4 hours.

On the other hand, Bar & Willard (9) found that the smaller sizes were eliminated more rapidly than the larger sizes of 0.64, 3.3 and 4.3  $\mu\text{m}$  MMAD particles of  $\text{Pu}^{239}\text{O}_2$  in the dog, and Thomas (97) found the same for 0.21 and 0.42  $\mu\text{m}$  MMAD particles of neobrium-9.

In all the studies referred to above comparisons between the rates of clearance for different particle sizes in man or animals have not been studied simultaneously in the same subject.

In studies on the dog with various radio active particles Morrow *et al* (73) stressed the importance of frequent observations during the first six hours of clearance in order to determine the initial retention in a satisfactory manner. Their studies showed the initial phase of clearance of submicronic particles to be a complex, variable phenomenon. To record it however they used a fixed unilateral location for the detector (over the thorax) which owing to the dependence of such measurements upon distance may explain the increase in activity measured during the first few hours. The measurements reported by Albert & Arnett (1) were subject to the same technical complications. Consequently these studies cannot be used to determine the half life of the initial phase of lung clearance. Moreover apart from the last two reports no investigations have provided sufficient data from the first hours after exposure for it to be possible to evaluate the initial phase.

Cember *et al* (21-23) report that the soft beta radiations from  $S^{35}$  in radioactive barium sulfate particles do not affect the lung clearance in rats given up to 233 mc initially. They also found (20-22) no injurious effect from a calculated total dose of 74 000 rep from particles deposited in the rat lung indicating that irradiation up to this level from dispersed foci in the lung does not interfere with lung clearance. These and other investigations summarised by Hatch & Gross (47) show "that spatial separation of the radiation may reduce rather than increase the hazard from inhalation of relatively insoluble radioactive particles".

Data concerning lung clearance in man are based primarily upon observations of individuals accidentally exposed to radioactive aerosols. A few experimental studies have however been published (1-74)<sup>1</sup> the clearance is reported to be initially rapid and sub

sequently slower. The slow clearance phase for submicronic particles was very consistent in four individuals (74).

### Earlier methods for studying lung clearance

Lung clearance has been studied with many different methods most of which have involved experiments on animals sacrificed in groups at different intervals after exposure to an aerosol the retention of which in the lungs was then determined by chemical, bacteriological or radioactive analysis. Such methods have the advantage that one can localise and make quantitative determinations of the amount of material retained in different parts of the lungs. Moreover they are the only methods available at present for certain substances such as carbon and  $SiO_2$ . On the other hand they have the disadvantage of requiring large series of animals for the experiments and one cannot study either intra and interindividual variations or the effect of different substances on the course of clearance in the same individual on different occasions.

There has therefore been a need for methods by which the course of lung clearance can be studied for small initial deposits in one and the same animal as a result increasing attention has been paid in recent years to methods for external radiological measurement of aerosol retention.

Such methods were first used to follow the elimination of radioactive matter in individuals accidentally exposed to such aerosols or gases. This was done for instance by Martinelli *et al* (68) on six persons accidentally exposed to  $RaSO_4$ , using a scintillation detector surrounded by a lead collimator with a cone shaped top and a circular aperture. The projection of this aperture described a

<sup>1</sup> While this monograph was at the printers lung clearance studies using mono-disperse aerosols in man were reported by Albert *et al* (3a).

circle 15 cm in diameter at a height of 10 cm above a mobile table placed over the collimator. The patient lay supine on the table which could be moved to give a step-wise scanning of the patient's body. The total gamma activity in the lungs could then be estimated by integrating the areas under the scan curves and comparing these with the scan area for a known point source of Ra placed in a phantom.

Apart from the investigations presented here experimental studies using profile scanning for the determination of lung clearance have been made only by LaBelle *et al* (66) who took up such studies with the method introduced by Friberg & Holma (36). In studies on mice Bair *et al* (58, 11) used a "scintillation counter designed to monitor either the whole mouse or any increment along the length of the mouse. This scanning unit had an unsatisfactory resolution and no attempt was made to evaluate lung clearance from the scan curves. These were simply used to demonstrate the distribution of activity in the mouse at different times. Stuart (94) also used profile scanning to demonstrate the distribution of activity from particles of  $\text{Pm}_2^{147}\text{O}_3$  inhaled by dogs.

In other lung clearance studies both clinical and experimental on animals and man a stationary detector or detectors has been placed over the thorax (13a, 34, 73, 74). In those cases in which repeated measurements were made during the first hour or hours of clearance the results generally demonstrated an increase in activity probably because this measurement technique is affected by changes in the distribution of the particles within the lungs. As a rule this source of error has been avoided by limiting the study of clearance to its course after the initial rapid phase.

These examples serve to illustrate one of the difficulties in following the entire course of clearance in an adequate manner and, in particular, the difficulty of evaluating the initial retention and hence the necessity of making frequent observations during the first hours after exposure.

Since technical difficulties rule out the direct determination *in vivo* of the pulmonary retention of particles tagged with alpha irradiating isotopes indirect methods have been developed for this purpose on the basis of faecal and urinary analyses (6).

### Scope of the present investigation

From the literature it will be seen that much work has been done on the slower secondary phase of lung clearance whereas data concerning the rapid initial phase are far from complete. Although certain results suggest that lung clearance is affected by variations in particle size this parameter has not been investigated at all closely. Variations in lung clearance on different occasions in the same individuals have only been investigated in one study concerning alveolar clearance of sub-micron particles in six dogs by Gibb & Morrow (38). Furthermore there has been only one report (88) of experiments performed with the classical method on sacrificed animals concerning the effect on lung clearance of gaseous air pollutants.

The present monograph describes the development of a profile scanning technique and reports the results of lung clearance studies on normal animals and animals exposed to sulphur dioxide with particular reference to the influence of particle size and biological variations.

Profile scanning was chosen as being superior to methods for external measure

ment that involve a fixed detector. When using slit collimators profile scanning thus diminishes the problem of interference from activity in neighbouring organs in small animals, it is also relatively independent of displacement of the test aerosol in the lungs and it reproduces the distribution of activity in the animal's body.

The method was first tried out on rabbits exposed to a heterodisperse aerosol and its suitability was tested by comparing these results with measurements of activity on isolated lungs.

The method was subsequently used to

study lung clearance after exposure to mono and di-disperse aerosols (an octadecanol aerosol tagged with radioactive gold and polystyrene aerosols tagged with radioactive gold and radioactive scandium). These aerosols were produced by means of a modification of LaMer's condensation method as well as by a spinning disc technique.

Only the first week or so of lung clearance could be studied with the profile scanning technique and consequently an open type of whole body counter was included in the equipment so that the clearance process could be studied over several months.

## PRODUCTION OF AEROSOLS

### Choice of aerosol

The proper selection of a test aerosol for the study of lung clearance is dependent upon the purpose for which the study is intended and the method of measurement to be employed. If the intention is to study the clearance of a particular substance, this substance should be used for the test aerosol, and this will limit the choice of measurement technique. In the case of external measurements, the test aerosol has to be tagged with some suitable radioactive isotope that does not affect the aerosol in other respects. This rules out many substances, including  $\text{SiO}_2$  and carbon dust.

In studies using animals, the particles in the test aerosol should be tagged in a manner that will allow initial retentions in the microgram range to be measured. Moreover, since clearance varies with the size of the particles, these should be monodisperse and/or have a reproducible size distribution.

The choice of particle material and measurement technique is further limited in clearance studies with different particle sizes by the condition that these should as far as possible represent the same substance and form of particle. The different sizes should also preferably be studied simultaneously in the same individual. Obviously, toxicological aspects as well as production techniques will govern the choice of materials for the particles.

The choice of a suitable particle size will primarily depend upon the clearance mecha-

nism or mechanisms to be studied, as both the depth of deposition and phagocytosis are related to particle size.

N-octadecanol and polystyrene were selected for the production of the above mentioned particles by the condensation and spinning disc techniques. With the exception of the preliminary study, all the investigations by the author were conducted with monodisperse aerosols having particle sizes of 3, 4 and 6  $\mu\text{m}$ . The aerosols used are described below together with the techniques for their production.

### Heterodisperse gelatin aerosols tagged with $\text{Au}^{198}$

In order to test the suitability of the profile scanning technique for recording activity retained in the lungs, a preliminary study was conducted with a heterodisperse aerosol.

#### Method and results

The heterodisperse particles were produced from a colloidal suspension (GCS 1) of radioactive metallic gold ( $\text{Au}^{198}$ ) obtained from Amersham England and stabilised with gelatin. It had a pH of 4–6 and the particles' mean diameter was 3.5 nm. The gold concentration was 10 mg per millilitre with a chemical purity greater than 99.5%. The specific activity was 10 mc per millilitre.

The aerosol was obtained from a simple spray in which the airstream followed a circular path, the radius of which diminished successively. Hence the largest particles were retained in the generator. The aerosol particles obtained had a mean diameter of 1.5  $\mu\text{m}$ ,  $\sigma = 2.4$  as measured from photographs taken with a light microscope.

## Mono and disperse aerosols tagged with $\text{Au}^{199}$ and $\text{Sc}^{45}$

In principle one can produce monodisperse aerosols either by condensation or by dispersion of the substances in question (28-40). The solution or suspension has been dispersed in principle by the formation of droplets using a mechanical influence in the form of gravitation, centrifugation or the application of electrostatic forces in the liquid. Since the mechanical systems require less sensitive apparatus, it is these which have been most used, particularly the spinning disc generators. These are most suitable for producing relatively large particles (1-100  $\mu\text{m}$ ) while smaller sizes (0.1-1  $\mu\text{m}$ ) are obtained better with the condensation generators in which the substance is condensed onto condensation nuclei.

### Condensation method for n-octadecanol particles

Monodisperse aerosols were first used in biological investigations by Wilson & LaMer (100) to study deposition in man. For this purpose they produced hygroscopic particles by means of a condensation method previously described by Sinclair & LaMer (90). The present author has employed monodisperse solid particles in the study of lung clearance since 1963 (52).

The condensation method used for the production of particles for lung clearance studies by the author was a modification of the technique described by Sinclair & LaMer (90) and has previously been published (29). Briefly it works as follows:

### Method

A generator produces condensation nuclei which are introduced together with a carrier gas into a heated glass boiler (Fig. 1) containing liquid coat-

ing material with saturated vapour above the liquid surface. The nuclei are conveyed by the carrier gas into another bulb with a higher temperature than the first one, here the vapour is superheated before passing out of the system through a chimney where the vapour rapidly condenses on the nuclei forming a monodisperse aerosol. This method is suitable for making monodisperse radioactive aerosols provided the isotope can be introduced either in the nuclei or in the coating material. It proved possible to have the isotope in the condensation nuclei but not in the coating material used in this study.




Fig. 1. Diagram of the aerosol generator used for the production of monodisperse aerosols by the condensation method. A: nuclei generator. B: LaMer device.

$\text{Au}^{199}$  and  $\text{Sc}^{45}$  are isotopes which fulfill the necessary requirements and n-octadecanol was chosen as a coating substance. It is only very slightly reactive, is insoluble in water and weak mineral acids and has a melting point of  $35^\circ\text{C}$ , which means sufficient solidity at body temperature and a considerable vapour pressure at temperatures of  $150$ - $200^\circ\text{C}$ .

It became apparent that a suitable way of introducing the nuclei into the LaMer system was to spray a solution of gold or scandium in the coating material into the first glass bulb.

The nuclei generator was made of brass and consisted of a cylinder with a conical bottom and a lid fitted with a pipe for the nitrogen. The capillary was attached to the pipe and its upper end was situated directly opposite the nitrogen outlet on the pipe. This outlet was a round hole 0.3 mm in diameter. The generator was heated to a temperature between  $110^\circ$  and  $150^\circ\text{C}$  and produced a




Fig 2 Photomicrograph of an n-octadecanol disperse aerosol. Mean particle sizes 3.1 and 7.5  $\mu\text{m}$

polydisperse aerosol in the first bulb when nitrogen under pressure was passed over one end of the capillary the outer end of which was immersed in the solution.

Since both gold chloride and scandium chloride display a certain chemical instability the material in the nuclei generator could not be made more concentrated than 0.5 per cent of either substance. At this concentration the solution is stable for at least one hour at a temperature of 150°C. At higher concentrations there is sedimentation of reduced metallic gold or precipitation of scandium oxide in the nuclei generator. Owing to further dilution of the nuclei material in the first glass bulb the maximum concentration of the radioactive material in the final aerosol is about 0.14 per cent corresponding to an activity of about 1.4  $\mu\text{C Au}^{198}/\text{mg}$  aerosol.

When the droplets are led into the first bulb at a higher temperature the n-octadecanol evaporates and the gold or scandium material present forms condensation nuclei for the final aerosol.

The size of the particles will depend in principle upon the relationship between the concentrations of the vapour and the condensation nuclei. In practice these two factors depend upon several variables. Thus variations can be made in the capillary diameter, the temperature and gas pressure in the nuclei generator and the temperature and rate of flow of the carrier gas in the LaMer device.

The solution to be used in the generator was prepared as follows: 100 mg of  $\text{HAuCl}_4 \cdot 3\text{H}_2\text{O}$  (or 169 mg of  $\text{ScCl}_3$ ) was dissolved in 3 ml of




Fig 3 Electron micrograph of a monodisperse n-octadecanol aerosol with a mean particle size of 4.5  $\mu\text{m}$

warm ethanol and poured into 10 g of octadecanol at a temperature of 120°C. A homogeneous solution was formed and the ethanol evaporated.

### Results

The particle size was varied from 1 to 10  $\mu\text{m}$  and the standard deviation was of the order of 0.2 to 0.5  $\mu\text{m}$  for the sizes used; this gives an average coefficient of variation of 5 to 20 per cent.

Fig 2 shows a mixture of two sizes of monodisperse particles: 3.1  $\mu\text{m}$  tagged with  $\text{Au}^{198}$  and 7.5  $\mu\text{m}$  tagged with  $\text{Sc}^{46}$ .

Studies of the particles with an electron microscope showed that they were either round or irregular. Both kinds are shown in Fig 3.

### Discussion

This study showed that the condensation method can be used for the production of solid radioactive particles in a size range of interest for studies of lung clearance and that the radioactive tagging can be done with two isotopes ( $\text{Au}^{198}$  and  $\text{Sc}^{46}$ ) having photopeaks that are clearly distinguishable by gamma spectrophotometry.

The method has certain disadvantages



however when it comes to producing the highly active aerosols that are necessary for the study of low retentions. In the first place there are only a few suitable substances that are not excessively reactive for biological purposes. The number of substances is further limited by the need for a low vapour pressure a melting point above the body temperature and the capacity to withstand heating in air or some other atmosphere (inert gas) to a sufficiently high temperature (generally above 100°C) for the saturation pressure to be high enough for the method to function properly.

It is possible to tag the condensation nuclei upon which condensation occurs as was done in the present study. In this case however, good monodispersity requires that these nuclei are small in relation to the particles formed. A reasonable activity per particle can still be achieved by using an isotope with a high activation cross section.

The advantages of the condensation method include the absence of interference from particles of another size e.g. the satellite particles obtained with the spinning disc generator. The disadvantages include the difficulty of obtaining a particular particle size as and when required. This is due to a complex interaction between a large number of parameters such as the temperature and the rate of gas flow in the various containers of the apparatus as well as the temperature gradient and type of flow (laminar) in the condensation volume, the rate of flow and a constant supply of condensation nuclei. Keeping all these factors constant places great demands upon the design and operation of the apparatus.

### Spinning disc method for polystyrene particles

The use of spinning disc generators to produce monodisperse radioactive aerosols for biological investigations was first reported by Albert *et al* (2) followed by the present author working with Kajland, Edfors & Friberg (36).

The following description concerns the production of the polystyrene particles that were used in the investigations presented in Chapter 7.

#### Method

The particles were produced with a spinning disc (Fig. 4) which was a modification of the apparatus (36) used for the production of polymethylmethacrylate particles. In principle the isotope material together with other particle material was dissolved or suspended in a solvent that was then fed at a constant rate to the centre of a rotating disc by means of an electrically driven syringe. When the liquid was thrown off from the periphery two sizes of drops formed namely monodisperse main drops and smaller satellite drops. The latter were arrested and evacuated by an opposing airstream in the slit through which the particles passed after leaving the disc. This airstream was so regulated that for all practical purposes only the main drops were able to pass through the slit, thanks to their greater mass and hence their greater inertia. These drops with an initial size of approx. 60  $\mu\text{m}$ , were then carried on a descending airstream while the solvent evaporated leaving material in the form of more or less spherical solid particles.

The 6  $\mu\text{m}$  particles were produced from a solution of 0.1% polystyrene and 0.012–0.006% gold chloride ( $\text{Au}^{198}$ ) in xylene. Just before the particles were produced the gold chloride was transformed into colloidal gold by bringing the solution rapidly to the boil.

The 3  $\mu\text{m}$  particles were produced from a solution of 0.01% polystyrene and 0.005–0.001% scandium acetylacetonate ( $\text{Sc}^{45}$ ) in xylene. The particles were produced in separate spinning-disc units driven at a speed of 21 000 r.p.m. in both cases.

The concentrations of colloidal gold and scandium acetylacetonate in the finished particles were




Fig. 4 Diagram of the spraying device (see text)

approximately 1 and 10-20% respectively which means that the 6 and 3  $\mu\text{m}$  CMD particles measured approximately 63 and 31  $\mu\text{m}$  MMAD respectively.

Both types of particles were collected on millipore filters and then suspended in a known volume (2 cc) of a 50 per cent alcohol water solution or a pure water solution by means of ultrasonic vibrations (90 kHz) for approximately one minute. The concentration of the particles in this solution was ascertained by counting the number of particles per cubic millimetre in a Burk counting chamber. After profile scanning (see Chapter 5) of a known amount of the suspension planimetry of the profile area obtained was calculated as the number of profile area units per 1000 particles. This measure was subsequently used to evaluate the size of the initial retention in the rabbit.

The aerosol was regenerated by passing the particle suspension through a simple spray up into an 18 litre exposure chamber that was connected to the surrounding air via an absolute filter (Fig. 18).

## Results

The monodispersity as characterised by the coefficient of variation showed a range of 5-10% for 3 and 6  $\mu\text{m}$  CMD particles.

The particles were studied in the optical as well as the electron microscope. 3  $\mu\text{m}$  particles tagged with  $\text{Sc}^{46}$  are shown in Fig. 5 as seen through both microscopes while a mixture of 6 and 3  $\mu\text{m}$  polystyrene particles tagged with  $\text{Au}^{198}$  and  $\text{Sc}^{46}$  respectively is shown in Fig. 6 as seen through the light microscope.

Fig. 7 shows 6  $\mu\text{m}$  polystyrene particles. Two satellite particles are indicated by arrows. In all the experiments satellites amounted to less than 15% by count of the main particles.




Fig 5 Electron micrograph (left, particles shadowed with silver) and photomicrograph (right) of monodisperse polystyrene aerosol without treatment with ultrasonic vibrations. Mean particle size  $3.0 \mu\text{m}$




Fig 6 Photomicrograph of di-disperse polystyrene particles from two separate spinning disc filters before treatment with ultrasonic vibrations. Mean sizes  $\blacksquare$  and  $\circ$   $3 \mu\text{m}$



Fig 7 Photomicrograph of monodisperse polystyrene particles after suspension in water by ultrasonic vibration. Mean size  $\blacksquare$   $\mu\text{m}$ . Two satellites are indicated by arrows

### Discussion

As demonstrated by these and Albert *et al*'s experiments (2, 3) the spinning disc generator can be used with suspensions or solutions of solid substances in fluids to produce monodisperse particles with a high specific radioactivity that are suitable for the study of lung clearance. The size of the primary drops can be varied between 20 and 100  $\mu\text{m}$  chiefly by adjusting the speed of the rotating disc. Final particle sizes down to approximately 1.0  $\mu\text{m}$  can be obtained by varying the dilution of the dissolved material in the fluid. The purity of the base fluid is most important here since this determines the maximum dilution and consequently the size of the smallest particles that can be obtained.

This method can be used to produce final particles with a high content of the isotope material and hence a high degree of radio-

activity. A variety of materials are available for the production of particles since the apparatus can be used for all liquids having a low viscosity as well as for suspensions and solutions in these. The chief disadvantage is the formation of satellite drops.

In order to avoid satellite particles it is necessary for the fluid to be introduced at a low rate of flow onto the disc, and to have the airstream that evacuates satellite drops properly adjusted and evenly distributed around the periphery. It is also important that the capillary supplying the fluid is placed exactly over the centre of the disc, as otherwise the rotation produces a disturbance in the form of drops on the capillary. The surface treatment of the disc is also important as is the quality of the turbine that drives the disc particularly at high speeds.

## TRANSLOCATION, SOLUBILITY, RETENTION AND PHAGOCYTOSIS OF THE AEROSOL PARTICLES

The solubility retention and propensity to phagocytose displayed by the aerosol particles may affect their translocation as well as their clearance in general. Although the following experiments cannot claim to be exhaustive they provide sufficient data to indicate the methods validity besides throwing some light on the differences in deposition and phagocytosis between 6 and 3  $\mu\text{m}$  particles.

The solubility and translocation of the gelatin particles are dealt with first in conjunction with the methodological tests of the profile scanning unit. Data concerning leaching translocation retention and phagocytosis are then reported from experiments involving the use of the 6 and 3  $\mu\text{m}$  particles. The particle characteristics of the octadecanol aerosol are considered only briefly because this aerosol was not utilised in the experiments reported here.

### Gelatin particles tagged with $\text{Au}^{199}$

#### Method

Male rabbits were sacrificed in groups of four by giving pentobarbital intravenously at different intervals (0.25 0.5 1 2 4 8 and 16 hours) after exposure via a tracheal tube to the hetero-disperse gelatin particles tagged with colloidal gold ( $\text{Au}^{199}$ ). The following organs were then immediately removed, wet ashed in concentrated  $\text{HNO}_3$  evaporated to 10 ml and measured in a well counter for their activity: liver spleen kidney about 3 cm of the right femur a piece of the parietal bone oesophagus trachea stomach in testes blood urine and lungs.

The activity in the gastrointestinal tract was found to be so considerable when measured with a conventional scaler technique (using a scintillation detector in a simple lead shield) that it was not subject to further analysis.

#### Results

In no case did the activity in the liver spleen adrenals blood urine or other organs exceed 0.1 % of the activity in the lung.

The activities in the oesophagus and trachea expressed as a percentage of the lung activity are shown in Table 1. The activity in the oesophagus was found to be 0.1 % or less in approximately half the cases; values exceeding 1 % were found in only 5 cases. The values for the trachea varied considerably but in only 2 cases did they exceed 10 % of the activity in the lung.

#### Discussion

The negligible activity observed in isolated organs after resorption had occurred to other organs means that one can ignore the direct translocation to these from the lungs. Thus in specific organs—in particular the liver where it is known that gold supplied parenterally can accumulate—no gold could be demonstrated. In electron microscopic studies on the rat Gieseke (39) showed that colloidal gold particles injected intratracheally have an intracellular location in the alveolar cytoplasm after 3 hours where they remain for a certain unspecified

TABLE 1 Activity in the esophagus and trachea in percent of the activity in the lung at different times after the end of exposure

	Time after the end of exposure in hours						
	¼	½	1	2	4	8	16
Activity in esophagus in percent of lung activity	<0.1	0.1	0.3	0.3	<0.1	<0.1	<0.1
	<0.1	3.3	0.2	1.2	<0.1	0.1	<0.1
	2.4	0.2	<0.1	0.7	0.4	0.5	0.2
	<0.1	0.7	1.1	6.3	0.2	0.1	<0.1
Activity in trachea in percent of lung activity	3.5	13.1	1.9	1.8	0.7	2.5	0.4
	0.9	2.0	10.3	0.5	0.2	3.4	<0.1
	1.5	4.6	5.2	0.3	<0.1	0.2	3.5
	1.7	1.0	1.5	0.9	0.2	0.1	0.7

time. Moreover Meneely *et al.* (70) have shown that after transtracheal instillation of radioactive gold colloid in the lung of dogs little if any of the colloid enters the blood stream.

During profile scanning (see Chapter 5) a scan peak was observed above the stomach quite soon after exposure and later above the intestines. One can therefore assume that a decline in the "lung peak" is essentially due to the inhaled gold being cleared from the respiratory organs via the trachea.

#### N octadecanol particles tagged with Au<sup>199</sup>

The leaching of gold (Au<sup>199</sup>) in various media (water, weak acids, rabbit serum) was investigated and it was found that the tagging isotope was relatively firmly embedded in the octadecanol particles. Consequently there should be no considerable leakage of the isotope when the particles are in lung tissue. Certain results have already been published (29, 56) and no further details will be reported here as clearance studies with octadecanol particles were not included in the present investigation.

#### Polystyrene particles tagged with Au<sup>199</sup> or Sc<sup>46</sup>

Polystyrene was chosen for the production of mono- and di-disperse particles by the spinning disc method because of its solubility in volatile solvents such as aromatic hydrocarbons (e.g. toluene and xylene) as well as its insolubility in water, weak acids, aqueous alkalis and alcohol. Moreover it has been reported that polystyrene particles are "not toxic and non antigenic" (so far as present procedures can determine) and there is no indication that they are metabolised or cause histologic or cellular damage (86, 87).

In the lung clearance studies (Chapter 7) the polystyrene particles were regenerated to an aerosol from a 50 % alcohol water solution. Alcohol was included because this made it easier to obtain a suspension of the particles. However the 3 µm particles used in these experiments were tagged with Sc<sup>46</sup> in scandium acetylacetonate which is soluble in alcohol. Leaching of this isotope from the particles was therefore investigated and the same was also done in the case of the 6 µm colloidal gold particles tagged with Au<sup>199</sup>. Furthermore the translocation of these tagging isotopes from particles deposited in the

lungs was investigated as was phagocytosis of these particles by lung macrophages *in vitro*

### Leaching

The study was made on 3  $\mu\text{m}$  particles in 10 and 16 % concentrations of scandium acetyl acetate with a specific activity of 760  $\mu\text{C}/\text{mg}$  Sc. The particles produced by the spinning disc technique were collected on duralon millipore filters from which they were transferred to small test tubes with a marten hair brush together with 2 cc 50 % alcohol water solution from a pipette. The test tubes were then measured in a multichannel gamma spectrometer (AB Atomenergiteknisk Studsvik). Before and after remaining in this alcohol solution for various periods up to 2 hours the suspension was treated with ultra sound before being rinsed with 20 cc of the same alcohol solution in a funnel containing a fibre glass absolute filter underneath a cellulose millipore filter (pore size 0.8  $\mu\text{m}$ ). Weak suction by water was used to assist filtration. The total eluate was then measured in the same apparatus as above and its activity in relation to the activity in the filtered volume was taken as a measure of the percentage leaching of  $\text{Sc}^{46}$  from the particles. Five experiments gave an average leaching of 1.6 % with a maximum of 1.9 and a minimum of 1.3 %.

In other similar experiments leaching of less than 1 % has been obtained for both  $\text{Au}^{198}$  and  $\text{Sc}^{46}$  using the same concentration of alcohol as above as well as aqua fortis and 0.1 N HCl.

Albert *et al* (3) have also performed leaching studies on lucite particles tagged with acetylacetonate of  $\text{Cr}^{51}$ ,  $\text{Fe}^{59}$ ,  $\text{Zr}^{95}$  and  $\text{Nb}^{95}$ . They found negligible leaching of the isotopes in a physiological solution during a period of several weeks.

### Retention and translocation

This study was done to evaluate the relationship between retention of 5 and 3  $\mu\text{m}$  CMD (6.3 and 3.1  $\mu\text{m}$  MMAD) particles at different levels in the rabbit lung as well as any translocation of the tagging isotopes in these particles.

### Method

The investigations were performed on 15 male rabbits with a normal rectal temperature weighing about 3 kg. Each of the animals was exposed simultaneously to monodisperse 3 and 5  $\mu\text{m}$  polystyrene particles tagged with  $\text{Sc}^{46}$  and  $\text{Au}^{198}$  respectively. During the exposure which lasted about 10 minutes and occurred via a tracheal tube under anaesthesia (Nembutal Abbot approximately 3 mg/kg bodyweight) the animal was placed in a whole body respirator. This made it possible to adjust the respiratory volume individually to roughly 25 cc with a constant rate of about 20 breaths per minute.

The aerosol which the animal inhaled from a simple exposure chamber (Fig. 18) was produced by spraying a water suspension containing the radioactive 3 and 6  $\mu\text{m}$  particles.

In order to obtain approximately the same deposition in the lungs of the different animals, the accumulated activity in the lungs was checked with a scintillation detector coupled to a ratemeter placed under the thorax (Fig. 18).

Each animal was subjected to profile scanning in apparatus no. 4 (see Chapter 5) as soon as possible after the end of exposure. The animals were divided into three groups of five rabbits each. The first group (rabbits 01-05) were sacrificed immediately after the profile scanning and the other two (rabbits 21-25 and 721-725) 11 and 72 hours later respectively. Immediately after a second profile scanning. Various organs were then removed. The lungs from the animals in the 1st and 3rd groups being taken without allowing them to collapse. These lungs were dehydrated (Fig. 8) by keeping them inflated to roughly their normal size with paraformaldehyde vapour and compressed air using a heating lamp to accelerate the process. A parallelepiped (Fig. 9) was cut from the lower lobe of each lung in such a way that a secondary bronchus appeared at one end while the



Fig 8 Formalin fixed air dried lung of rabbit (see text)

longitudinal axis ran in roughly the same direction as this bronchus. The outer end thus contained the alveolar region facing the inferior margin. One such specimen was taken from the left inferior lobe and one from the right in each of the animals in these two groups. Each specimen was divided into four pieces of approximately the same size (Fig 10) and the activity from  $\text{Au}^{199}$  and  $\text{Sc}^{45}$  respectively was measured in each piece using a well type  $3'' \times 3''$  NaI crystal coupled to a 512 channel pulse level analyser. The mean weight of the specimens was found to be 77 mg  $\sigma = 45$ .

In order to reduce variations arising from differences in the weights of the specimens and the initial depositions in the lungs, the calculated weights of the particle sizes for each piece in a specimen were divided both by the weight of the specimen and by the size of the initial deposition in the lung. The measures of activity were converted into weights of particle material by assessing the activity in known amounts of the same particle material with activity measurement and profile scanning of the same sample.

After these measurements the specimens were returned to their parent lungs and these, as well as the trachea (from about 1 cm cranial of the bifurcation to just below the cricoid cartilage), oesophagus, liver, spleen and kidneys (the last three together) were homogenised in 20–30 cc of equal parts of gently heated  $\text{HNO}_3$  and  $\text{H}_2\text{SO}_4$ . The samples were diluted with water to 50 cc and stored in 500 cc round bottomed flasks. Urine was collected from the 3rd group of animals which had been kept in metabolism cages and was divided into portions of 50 cc in similar vessels. The activity in these samples was measured with a  $3'' \times 3''$  NaI



Fig 9 Parallelepiped cut out of the lower lobe of the right lung shown in Fig 8. The specimen has been cut to show that its axis runs parallel to the axis of the secondary bronchus (to the right in the figure)



Fig 10 The parallelepiped in Fig 9 cut into four pieces to show how the different specimens for the retention studies were obtained (see text)

crystal in the same apparatus as the pieces of lung mentioned above (the measurements were made by AB Atomenergi, Stockholm).

The activity in the trachea and oesophagus was calculated as a percentage of that in the lung. The correlation between the activity measured in the isolated and homogenised lungs and the estimate from the lung scan fraction on the profile curves is reported in Chapter 6. The results given below concern the retention study mentioned above and the translocation of the tagging isotopes to the spleen, liver and kidneys in relation to the amounts of each isotope initially deposited, as well as the percentage of the isotopes in the trachea and oesophagus in relation to the activity in the lungs at the same time.



$\mu\text{g}$  particles  
per 100  $\mu\text{g}$  tissue




Fig 11 The amount of monodisperse 3 and 6  $\mu\text{m}$  polystyrene particles in the different lung specimens at 0 and 72 hours after inhalation. The vertical scale gives the amount of particles in the specimen in  $\mu\text{g}$  per 100  $\mu\text{g}$  of tissue divided by the value of initial retention in the lung of these particles. *a* — *d* refer to the specimens cut out of the lungs *a* referring to the most peripheral specimen and *d* to the one containing the secondary bronchus (see text and Fig 10)

## Results

The mean weights of 6 and 3  $\mu\text{m}$  particles in the specimens cut out of the lungs from two groups of five rabbits are shown in the bar diagram in Fig 11 (each specimen from one lower lobe has been added to its pair from the other lung)

It will be seen that the 6  $\mu\text{m}$  particles have a maximum in a region just peripheral to the secondary bronchus while the 3  $\mu\text{m}$  particles are deposited more in the alveolar regions having an approximately equal retention in each of the three most peripheral specimens. After 72 hours there is little change in the

most peripheral piece *a* while both sizes display a reduction that increases towards the bronchi being significant in pieces *c* and *d* (*t* test  $p < 0.02$  and  $< 0.01$ ). This change is more pronounced for the larger particles both in terms of weight and on a percentage basis. The latter relationship is illustrated in Fig 12 which shows that the percentage reduction from 0 to 72 hours increases towards the bronchi and is greater for 6 than for 3  $\mu\text{m}$  particles.

Fig 13 gives the ratios between the amounts of 6  $\mu\text{m}$  and 3  $\mu\text{m}$  particles at 0 and 72 hours in the specimens and in the

Reduction in  
per cent of  
initial value




Fig 12 The percentage amount of 6 and 3  $\mu\text{m}$  polystyrene particles eliminated from the different lung specimens (see Fig 11 and text) in 72 hours after inhalation. The reduction is greater for the 6  $\mu\text{m}$  particles compared with the 3  $\mu\text{m}$  particles except in the most peripheral specimen. Both sizes of particle are reduced more in specimens containing larger bronchi.

trachea in relation to the corresponding initial ratios in the lungs as assessed by profile scanning. It will be seen that the differences between the ratios at 0 and 72 hours grow larger towards the trachea. The figure also demonstrates the predominance of 6  $\mu\text{m}$  particles in the bronchial pieces and in the trachea at 0 hours.

Fig 14 shows the retention in the lungs at different intervals after exposure compared with the initial values calculated from the scan curves. It was found that the larger particles were cleared from the lungs more rapidly than the smaller ones.

In the case of the trachea the activity measurements (cf Table 2) show that the 6  $\mu\text{m}$  particles were initially deposited there

to a greater extent than the 3  $\mu\text{m}$  particles. This is also indicated by the scan curves. Thus in Fig 15 which shows the distribution of the initial deposition of the two particles in rabbit no 724 tracheal activity was demonstrated for the 6  $\mu\text{m}$  particles tagged with  $\text{Au}^{198}$  but not for the 3  $\mu\text{m}$  particles tagged with  $\text{Sc}^{46}$ . Table 3 gives the activities in the trachea as percentages of the activity in the lung for both isotopes. These data show that the first measurements for  $\text{Au}^{198}$  and  $\text{Sc}^{46}$  amount to maxima of 73 and 22 % respectively. At 2 hours the corresponding figures are 22 and 12 % and after 72 hours 0.4 and 0.14 %.

The radioactivity of the tagging isotopes in the liver, spleen and kidneys as well as in urine is shown in Table 2. It will be seen that only negligible quantities (averaging 0.8 and 0.2 % of  $\text{Au}^{198}$  and  $\text{Sc}^{46}$  respectively of the amounts initially deposited in the lungs) could be found in these organs and in the total urine collected during 72 hours. It will also be seen that the activities in the oesophagus were never more than 0.8 and 0.1 % for  $\text{Au}^{198}$  and  $\text{Sc}^{46}$  respectively.

### Discussion

These experiments show that the 6  $\mu\text{m}$  particles are deposited more in the bronchial sections compared with the 3  $\mu\text{m}$  particles. Moreover, the larger particles disappeared more rapidly than the smaller ones from the trachea and bronchi as well as from the lungs as a whole.

These results cannot be directly compared with those from other studies, chiefly owing to the considerable differences in exposure

\* The data for rabbit 21 (33.4 and 45.1 %) have been excluded because of a technical error during dissection (cf p 65).




Fig 13 The ratio between the amount of 6 and 3  $\mu$ m particles in relation to the initial retention in the lung (means for specimens from right and left lung in 5 rabbits) The amount of 6  $\mu$ m particles in relation to 3  $\mu$ m particles dominates in the bronchial pieces and still more so in the trachea The letters a — d are for Fig 11 e refers to the trachea

Percentage of  
mean initial  
lung retention

○ 3  $\mu$ m particles  
● 6  $\mu$ m particles  
] Range of observed values




Fig 14 The amount of 3 and 6  $\mu$ m polystyrene particles at different times in the lungs of rabbits as a percentage of the initial value The 6  $\mu$ m particles are eliminated to a greater extent than the 3  $\mu$ m particles




Fig 15 The scan curves for rabbit no 724 in the study mentioned in the text. The curves were recorded immediately after exposure to a di-disperse 6 and 3  $\mu\text{m}$  polystyrene aerosol via a tracheal tube. There is a laryngo tracheal deposition of the 6  $\mu\text{m}$  but not the 3  $\mu\text{m}$  particles.

and measurement techniques. The picture of deposition presented here does in fact largely correspond with that reported by Palm *et al* (79) and Taplin *et al* (95), who found that the larger particles were deposited more than the smaller ones in the upper part of the respiratory tract in experimental animals.

The more rapid elimination in the higher reaches of the respiratory tract is also in line with Taplin *et al*'s (95) report that P32 tagged *B. subtilis* spores (0.5—1.5  $\mu\text{m}$ ) are eliminated from the rabbit trachea in one to two hours but remain in the lung parenchyma for at least seventy-two hours.

The present results concerning the size of the retention in the trachea and lungs at 0 hours may have been influenced to some extent by the displacement of the secretion containing the particles towards the trachea during the interval between the sacrifice of the animal and the cessation of ciliary activity with the addition of fixative. Such a displacement would mainly affect the assessment of activities in trachea and lung particularly the initial values. This circumstance may explain the results of the activity measurements of these organs. Comparing the scan curves taken just before the animals (01—05) were sacrificed with the subsequent activity measurements it will be found that the activity in the trachea was considerably higher on the latter occasion. Moreover a corresponding reduction of the lung activities in these animals was revealed by the correlation study (cf Fig 46). This displacement of activity from the lung to the trachea could have been partly avoided by clamping the trachea at the bifurcation during the dissection instead of just below the cricoid cartilage as was done here. The present procedure was adopted to facilitate preparation of the lungs for the special dehydration technique. This technique which

TABLE 2 Retention and translocation of 3 and 6  $\mu$ m LMD polystyrene particles tagged with  $^{109}\text{Au}$  and  $^{45}\text{Sc}$ 

Rabbit no	Initial retention			Post exposure time (hrs)	Radioactivity in organs in percent of initial activity in lung				Radioactivity in organs in percent of activity in lung at the same time					
	cm	μm	μc		Lung		Liver spleen and kidneys		Urine 0-72 hrs sample		Trachea		Oesophagus	
					Au109	Sc46	Au109	Sc46	Au109	Sc46	Au109	Sc46		
01	5.7	2.1	11	10							72.6	2.7	0.10	0.01
02	1.1	1.2	9	5							13.5	5.6	0.09	0.12
03	6.5	1.5	15	6.5							68.7	21.7	0.09	0.02
04	6.5	1.3	9	5							70.3	9.1	0.05	0.02
05	7.6	1.3	12	5.5							36.7	10.1	0.05	0.05
Mean	6.0	1.5	10.8	6.4							58.4	10.0	0.11	0.04
21	3.8	1.5	11	6		92.5					34.0 <sup>1</sup>	45.1 <sup>1</sup>	0.06	0.01
22	3.8	2.2	10	9		71.8	91.2				0.5	0.5	0.01	0.06
23	2.7	2.0	6	8		81.9	92.5				22.0	11.8	0.15	0.05
24	4.8	1.9	11	8		50.1	90.0				2.1	6.8	0.02	0.01
25	6.2	1.1	11	15		72.7	87.8				5.2	3.5	0.02	0.12
Mean	4.3	1.7	11.2	7.1		66.9	90.9				12.4	5.6	0.10	0.05
721	3.6	1.7	11	11	72	70.0	92.6	0.54	0.15	0.26	0.02	0.05	0.11	0.01
722	4.6	3.1	9	13	72	17.6	83.3	1.30	0.22	0.61	0.12	0.11	0.79	0.01
723	3.5	1.9	10	16	72	15.3	52.8	1.16	0.16	0.30	0.22	0.11	0.02	0.004
724	1.5	1.8	25	7	72	39.0	87.8	0.31	0.16	0.12	0.12	0.11	0.002	0.01
725	1.2	3.3	18	11	72	29.6	68.4	0.79	0.11	0.21	0.39	0.13	0.02	0.01
Mean	3.1	3.0	14.5	12.2		43.5	77.0	0.92	0.16	0.50	0.25	0.10	0.19	0.01

<sup>1</sup> These values which were subject to technical error during dissection (see p. 65) are not included in the mean.

has not previously been used for retention studies carries the advantage that any part of the lung can be excised and examined for the material retained in it

The translocation studies indicate that the tagging isotopes were relatively securely embedded in the particles. This was also demonstrated by the leaching experiments reported earlier in this chapter. The liver, kidneys and spleen were chosen as representative organs together with the urine since it is in these sites that the translocation of soluble radioactive substances deposited in the lungs has been reported to occur by several authors.

The negligible degree of translocation of the lung radioactivity from these tagged polystyrene particles may be taken to indicate that these have been cleared from the lungs via the bronchi and trachea. This means that recordings of the residual retention of such particles in the lungs at different times can be used as a measure of their clearance from the lungs.

The activity that happens to be passing through the oesophagus during a recording of the activity in the lungs naturally represents a source of error in these measurements. However in the present studies as well as those with heterodisperse gelatin particles tagged with colloidal  $Au^{198}$  the activity demonstrated in the oesophagus was of no practical significance. On the other hand this is no indication of the amount of activity that is swallowed and thus passes the lung region but simply of the activity that remains after the quantities swallowed have passed by. By using the profile scanning technique it is possible to determine the time when such quantities pass the lungs. In some cases this can be detected from the resultant interference on the scan curves before and after such transport has taken place.

## *Phagocytosis of polystyrene particles in vitro*

Although the part played by phagocytosis in lung clearance is still being debated it has been established that different particle materials and particle sizes are phagocytosed to different degrees and that phagocytosed particles are to be found both in the walls of the respiratory tract and in the interstitial tissue lymph ducts and lymph glands. Having undergone phagocytosis the particles may be affected so that for instance their solubility is altered (18).

Various principles and methods have been applied to the study of phagocytosis in vitro (76-101). The technique introduced by Myrvik *et al* (77) and its several modifications have been most used in recent years. One such modification was employed in the following investigations into the phagocytosis of different sizes of polystyrene particles by lung macrophages.

### *Method*

Phagocytes (macrophages) were collected from rabbit lungs with a technique described by Myrvik *et al* (77). A rabbit was sacrificed by injecting air into a ear vein. The lung was removed with the trachea clamped in order to prevent blood entering the specimen and was rinsed with a warm physiological NaCl solution (37°C). After the heart had been removed the lung was cleaned with gauze and about 40 ml Hank's saline solution (37°C) was injected into each of the main bronchi to inflate the lobes. The trachea was unclamped and the lung was gently massaged. The liquid was then collected in a large centrifuge tube and the process with Hank's solution was repeated. The two tubes were then centrifuged for 20 min at 1500 r.p.m. The liquid was decanted and the cell mass resuspended in 3 ml physiological NaCl solution before repeating the centrifugation. The liquid was again decanted and the cell mass resuspended in 2 ml of Hank's solution. The viability of the cells was then checked by vital staining (equal parts of cell suspension and 1% eosin solution).

The suspension was found to contain a total of about 12-16 million macrophages. For the studies of phagocytosis 0.15 cc of the cell suspension was pipetted onto a number of scratched circular cover glasses (28 sq mm) and left to settle for 40 minutes after which the glasses were decanted and rinsed in Hanks solution. The cover glasses were then placed in small Petri dishes (inner diameter 18 mm depth 8 mm) and 0.5 cc of a particle suspension was added consisting of Parker 199 solution 25% autologous rabbit serum penicillin (100 iu/ml) and monodisperse polystyrene particles (pure untagged or tagged with inactive or active material i.e.  $\text{Au}^{198}$  and  $\text{Sr}^{90}$ ). The Petri dishes were covered with a lid and stored in a thermostat at 37°C.

The total number of cells, the number of these that had phagocytosed particles and the number of particles that had undergone phagocytosis were all calculated for a particular unit of area (the visible field in direct observations and the corresponding 0.52 sq mm of the cover glass on photographs taken with a light microscope and enlarged 320 times). A sufficient number of fields were counted in this way to give about 700 cells for the assessment of the degree of phagocytosis i.e. the number performing phagocytosis in relation to the total number of cells on the surface in question. The ratio of cells to particles averaged 1:4 (see Table 1 in the Appendix).

In order to guard against an erroneous assessment of the number of phagocytosed particles a control series equivalent to the above was produced using cells killed with formalin. It was found that not more than 1% of the total number of cells had particles that coincided with their projection.

Four series of experiments (A, B, C and D) were performed with polystyrene particles. Table 1 gives the code numbers used in the studies of phagocytosis for the various combinations of particle materials and sizes. The 1.5  $\mu\text{m}$  particles were satellites of the 6  $\mu\text{m}$  particles and were deliberately included in these studies in order to compare the degree of phagocytosis of the different sizes of particles. The monodispersity of both the 3 and 6  $\mu\text{m}$  particles showed a coefficient of variation of <10%. The particles tagged with  $\text{Au}^{198}$  or  $\text{Sr}^{90}$  had an average specific activity of approx. 0.1-0.5 and 0.5  $\mu\text{Ci}/100,000$  particles respectively. In the case of the particles tagged with  $\text{Au}^{198}$  the activity came from both the 6  $\mu\text{m}$

particles and their satellites but the calculation was based on the 6  $\mu\text{m}$  particles only.

The phagocytosis of carbon particles (approximately 0.5-2.5  $\mu\text{m}$ ) was studied (series F) in the manner described above in order to compare the phagocytosis of these and the polystyrene particles.

## Results

Results for the various series are given in the Appendix (Table 1) together with the concentrations of the particles and phagocytes. About 95% of the cells were viable at the start of the experiments and this figure had generally dropped only about 1 or 2% by the end.

The degree of phagocytosis in the different series after 1 1/2 hours is shown in Fig. 16 in terms of the number of cells performing phagocytosis as a percentage of the total number of cells per square millimeter. The degree of phagocytosis after 3 hours was practically the same. It will be seen that the highest degree of phagocytosis involved the smallest polystyrene particles (approximately 20%) and that the lowest level of phagocytosis was displayed by the largest of the tagged particles (6  $\mu\text{m}$ ). No pronounced differences could be found in the degree of phagocytosis between the different sizes of untagged particles. A light microscopic photograph (Fig. 17) illustrates the predominance of 1.5  $\mu\text{m}$  particles in the macrophages compared with 6  $\mu\text{m}$  particles.

Owing to the small number of independent experiments with the different sizes of particles the results have not been subjected to statistical analysis.

The result of the separate study concerning phagocytosis of 0.5-2.5  $\mu\text{m}$  carbon particles is also shown in Fig. 16. There is a marked difference in the degree of phagocytosis between these particles and those of polystyrene.

Percentage  
phagocytes  
with particles




Fig 16 The degree of phagocytosis of 1.5, 3 and 6  $\mu\text{m}$  polystyrene particles by rabbit lung macrophages determined as the percentage of macrophages that have taken up one or more particles in vitro. The code for the symbols is given in Table 3.

TABLE 3 Code for particle sizes and combinations in the study of phagocytosis

A II = 3 $\mu\text{m}$	polystyrene particles untagged
A III = 1.5 and 6 $\mu\text{m}$	polystyrene particles untagged
A IV = 1.5, 3 and 6 $\mu\text{m}$	polystyrene particles untagged
B II = 3 $\mu\text{m}$	polystyrene particles tagged with Sc
B III = 1.5 and 6 $\mu\text{m}$	polystyrene particles tagged with Au
B IV = $\begin{cases} 3 \mu\text{m} \\ 1.5 \text{ and } 6 \mu\text{m} \end{cases}$	polystyrene particles tagged with Sc polystyrene particles tagged with Au
C II = 3 $\mu\text{m}$	polystyrene particles tagged with $\text{Sc}^{46}$
C III = 1.5 and 6 $\mu\text{m}$	polystyrene particles tagged with $\text{Au}^{199}$
C IV = $\begin{cases} 3 \mu\text{m} \\ 1.5 \text{ and } 6 \mu\text{m} \end{cases}$	polystyrene particles tagged with $\text{Sc}^{46}$ polystyrene particles tagged with $\text{Au}^{199}$
D IV = 1.5, 3 and 6 $\mu\text{m}$	polystyrene particles tagged with $\text{Sc}^{46}$
E I = 0.5, 2.5 $\mu\text{m}$	carbon particles





Fig 17 Photomicrograph of phagocytosis of 0.6 and 1.5  $\mu\text{m}$  polystyrene particles by rabbit lung macrophages. Particles can be seen intra- and intercellularly. The macrophages contain more smaller than larger particles.

## Discussion

These results should be assessed in the light of the method employed. *In vitro* studies of phagocytosis on glass receptacles clearly do not represent conditions *in vivo*. From a review of methods for such studies (101) it appears that phagocytosis is promoted if allowed to proceed on a base of freshly excised tissue, e.g., lung specimens fixed with formalin or on an inert surface such as that of moistened filter paper; the phagocytes can then ingest the particles by trapping them against the walls.

Scratched glass (the bottoms of small glass bowls) was used as a base for the phagocytes in the present method. According to Myrvik *et al.* (77) about  $16 \times 10^6$  million cells can be obtained from the lungs with this technique, a range that embraces the total of 12–16 million cells obtained in the present study. According to Myrvik's investigations, the great majority of these cells are macrophages; less than 0.1% are polymorphonuclear cells and still fewer are small lymphocytes. A preponderance of macrophages was also found in the present series.

The results cannot be compared directly with those obtained by other authors since the latter have been derived from other types of phagocytes and the methods have also varied.

There are, however, indications that the rate of phagocytosis is higher for the larger polystyrene latex particles of different sizes in the range 0.514–1.171  $\mu\text{m}$  as shown by Schoenberg *et al.* (87). After these particles had been introduced intravenously into rabbits, the larger ones disappeared more rapidly from the bloodstream, an effect that was ascribed to phagocytosis in the reticuloendothelial system. Krenis & Strauss (63) also found signs that phagocytosis declines with the size of polystyrene latex particles in the range 0.264–1.171  $\mu\text{m}$  in that oxygen uptake increased with increasing particle size for phagocytic leucocytes from human blood. No increment was found in leucocytic respiration for the smaller particles and this was interpreted as indicating that there is little or no phagocytosis of the smallest particles. Schoenberg *et al.* (87) consider, however, that since phagocytosis involves the expenditure of energy, the smaller particles may enter the cells more easily, but they are also ejected at a more rapid rate because the extrusion of particles from the phagocytic cells also requires energy; these circumstances may lead to the apparent observation of a greater phagocytosis of larger particles.

Fenn (32) found that leucocytes from rat peritoneum ingested carbon particles of 4–5  $\mu\text{m}$  more readily than those of 2–3  $\mu\text{m}$ . He interpreted this as being due to the phagocytic cells having a better chance of coming into contact with the larger particles. This is unquestionably correct, but there must exist a limit above which phagocytosis declines for purely mechanical reasons; hence there should be a certain optimal size of particle.

that gives a maximal rate of phagocytosis. This size will probably be displaced upwards for particle materials that are "susceptible" to the phagocytes. This is also suggested by Mudd *et al's* (76) observation that small emulsion drops are readily and completely ingested by macrophages whereas on larger drops the macrophages spread to positions determined by the balance between surface forces and their own resistance to deformation. Jötten & Marwyck (55) also suggest "that dust particles must not exceed  $8\text{ }\mu\text{m}$  as those larger than this are poorly phagocytized or perhaps not at all".

In the light of these reports the present results may be said to indicate that optimal phagocytosis of the tagged polystyrene particles should occur at a size below or around  $1.5\text{ }\mu\text{m}$ . Further investigations are required

however, as well as studies on smaller sizes of particle before this figure can be established.

A comparison between the phagocytosis of carbon and polystyrene particles shows that the former stimulate phagocytosis to a considerably greater extent than the latter.

The difference in the degree of phagocytosis between the tagged and untagged  $6\text{ }\mu\text{m}$  particles has not been further investigated. It should however be noted that not many experiments were conducted with untagged particles. It is also worth mentioning that the lower phagocytosis of large particles was particularly pronounced if they were tagged with gold. The same difference between sizes of particles was found in the experiments in which all sizes of particle were tagged with scandium.



Fig 17 Photomicrograph of phagocytosis of 6 and 15  $\mu\text{m}$  polystyrene particles by rabbit lung macrophages. Particles can be seen intra and inter cellularly. The macrophages contain more smaller than larger particles.

## Discussion

These results should be assessed in the light of the method employed. In vitro studies of phagocytosis on glass receptacles clearly do not represent conditions in vivo. From a review of methods for such studies (101) it appears that phagocytosis is promoted if allowed to proceed on a base of freshly excised tissue e.g. lung specimens fixed with formalin or on an inert surface such as that of moistened filter paper. The phagocytes can then ingest the particles by trapping them against the walls.

Scratched glass (the bottoms of small glass bowls) was used as a base for the phagocytes in the present method. According to Myrvik *et al* (77) about 8–16 million cells can be obtained from the lungs with this technique, a range that embraces the total of 12–16 million cells obtained in the present study. According to Myrvik's investigations the great majority of these cells are macrophages, less than 0.1% are polymorphonuclear cells and still fewer are small lymphocytes. A pre dominance of macrophages was also found in the present series.

The results cannot be compared directly with those obtained by other authors since the latter have been derived from other types of phagocytes and the methods have also varied.

There are however indications that the rate of phagocytosis is higher for the larger polystyrene latex particles of different sizes in the range 0.514–1.171  $\mu\text{m}$  as shown by Schoenberg *et al* (87). After these particles had been introduced intravenously into rabbits the larger ones disappeared more rapidly from the bloodstream, an effect that was ascribed to phagocytosis in the reticuloendothelial system. Krenis & Strauss (63) also found signs that phagocytosis declines with the size of polystyrene latex particles in the range 0.264–1.171  $\mu\text{m}$  in that oxygen uptake increased with increasing particle size for phagocytic leucocytes from human blood. No increment was found in leucocytic respiration for the smaller particles and this was interpreted as indicating that there is little or no phagocytosis of the smallest particles. Schoenberg *et al* (87) consider however that since phagocytosis involves the expenditure of energy the smaller particles may enter the cells more easily but they are also ejected at a more rapid rate because the extrusion of particles from the phagocytic cells also requires energy. These circumstances may lead to the apparent observation of a greater phagocytosis of larger particles.

Fenn (32) found that leucocytes from rat peritoneum ingested carbon particles of 4–5  $\mu\text{m}$  more readily than those of 2–3  $\mu\text{m}$ . He interpreted this as being due to the phagocytic cells having a better chance of coming into contact with the larger particles. This is unquestionably correct but there must exist a limit above which phagocytosis declines for purely mechanical reasons; hence there should be a certain optimal size of particle.

The choice of exposure technique lies between inhalation via the mouth the nose or a tracheal tube or else the particles can be introduced to the lungs by means of intra tracheal injections

If the aerosols are inhaled via the mouth or nose a great deal of the particles will be deposited there. Their subsequent transport through the oesophagus may make it impossible to follow the initial phase of lung clearance by external measurement.

Both tracheal injections and inhalation via a tracheal tube naturally have the disadvantage of not being physiological. Tracheal injections are usually performed by introducing a narrow tube or capillary down into the trachea and then injecting the particles suspended in a fluid. This technique has the further disadvantage that the particles are not distributed in the same manner as in normal inhalation. Moreover the tube may affect the mucosa, secretion and other physiological conditions while the alveolar fluid and permeability may be altered by the suspension. The method has in fact been criticised by several researchers who report that the conditions for retention and deposition differ from those during normal inhalation (5 13 16 17 19 37 57 71).

Inhalation via a tracheal tube gives a better distribution of the particles in the lungs though this is still not identical with the distribution under normal conditions. For one thing the animal has to be anaesthetised and this plus the mechanical irritation from the tube alters the respiration (99) moreover turbulence from the vocal cords is reduced and the introduction of a tracheal tube may affect the secretion and possibly injure the mucosa as well.

Although the mucoserous glands could not be stimulated experimentally by local irritation of the tracheal mucosa (35) this does

not mean that a mechanical irritation cannot have such an effect. Nadel & Widdicombe (78) have reported that mechanical irritation of the laryngeal mucosa has the effect of increasing airway resistance. Concerning an effect on the secretion however they point out that "the rapid recovery of total lung resistance to control values makes it unlikely that bronchial secretion of mucus was involved".

Several reflexes have been described for the smooth musculature the blood circulation and the respiratory dynamics in the respiratory tract (24 78 99) and contraction of the glottis has been reported as one of the results of mechanical irritation of the tracheal epithelium (99).

The tracheal epithelium is highly susceptible to trauma and, even though it has a good healing capacity (50 51) its sensitivity serves to emphasise the disadvantage of introducing a tracheal tube in studies of lung clearance.

Tracheal intubation was nevertheless used in the present investigations to facilitate a study of the initial rapid phase of clearance without any disturbance from material deposited in the nose mouth or nasopharynx. As already mentioned deposition in these regions would lead to an early increase in the activity in the oesophagus and interfere with the measurement of the initial clearance from the lung.

When studying lung clearance for different sizes of particle simultaneous single animals as well as whole animal effects with exposed and control animals are the consequences of introducing a tracheal tube should be approximately the same for different sizes of particle and both for control and experimental animals respectively.

In order to obtain a measure of the amount of particles present, the amount of particles



*Fig 19* Plastic moulds for keeping the rabbits in a fixed position during profile scanning with apparatus nos 1 and 2

tional scaler measurements of retention on isolated lungs. The chief disadvantage was the dependence on distance. Therefore to improve the technique several modifications were developed.

In the second apparatus a focusing slit collimator was introduced to reduce the dependence on distance while still placing the detector unilaterally. This arrangement improved the isosensitivity characteristics. In the light of this experience two focussing collimators and larger crystals were incorporated in the apparatus.

The validity of the results obtained using the latest profile scanning units is based on experience gained with the earlier apparatus and consequently all four arrangements will be presented below. It should be mentioned

however that the applied experiments with the apparatus reported in Chapter 7 were conducted with the most developed unit (apparatus no 4).

During the measurements the animal was placed in a special mould (Figs 19 20) which permitted only minor movements of the head. This was done to ensure equivalent measuring conditions on different occasions. Profile curves that reproduce the distribution of activity over the animal's length were obtained by coupling a recorder to the detector via a ratemeter. The evaluation of these results was facilitated by selecting a relatively long time constant in relation to the scanning rate. This means that the scan curves have a more even course at the expense of the amplitude of the deflection of the re-




Fig 20 Plastic moulds for keeping the rabbits in a fixed position during profile scanning with apparatus nos 3 and 4

order. In all cases the operating conditions for the detectors photomultiplier were adjusted to the activities in question. The apparatus was calibrated daily by performing measurements on known standard specimens.

#### *Apparatus no 1*

The first profile scanning unit (Fig 21) was fitted with a detector (Tracerlab P 20QG) with an NaI crystal ( $1'' \times 1''$ ) placed under the animal and a slit shaped lead collimator (LKB 337035) with the slit confined by a superimposed rectangular lead shield with an aperture of  $2 \times 50$  mm. The detector was connected via a ratemeter (Tracerlab SC 79 205) to a recorder (Varian G 11 A/A<sub>2</sub>) into which the paper was fed at a constant rate. A relatively long time constant (40 sec) was selected for the ratemeter in order to

minimise the statistical variation in the count rate.

The detector, vertically orientated was mounted on a carriage fitted to a longitudinal screw in the stand. This screw driven by a synchronous motor caused the detector to travel at a constant rate of 0.5 cm/min along the under side of the animal. After scanning the detector could be returned to its initial position to start a new scanning in a cranio-caudal direction. The field of measurement i.e. the animal's thorax region lay 2.5–9.0 cm above the collimator.

#### *Apparatus no 2*

Apparatus no 1 was improved by using a specially designed slit "focusing" collimator (Fig 22). In this case the scintillation detector (Tracerlab P 20 QG) equipped




Fig 21 Diagram of profile scanning apparatus no 1 (see text)

with an NaI crystal ( $1'' \times 1''$ ) was coupled to a writer (Varian G 11 A) via a ratemeter (Tracerlab SC 34 A) with a time constant of 40 sec. Chart speed was 0.6 cm/min.

The detector was mounted in the same way as in the first unit using a carriage fitted with a longitudinal screw and driven at a constant rate along the animal by a synchronous motor. After scanning the detector could be returned to its initial position either automatically or manually. Scanning could

be performed at a single constant rate (2.5 cm/min). The field to be measured lay 2.5–9.0 cm above the collimator.

### Apparatus no 3

This profile scanning unit (Figs 23, 24) was fitted with two opposed focusing slit lead collimators in the same plane, each with a scintillation detector (Harshaw integral line assembly type 1258/a) having a  $3'' \times 2''$  NaI crystal. The movements of the collimators and recordings were synchronised. The count rate was read via a two channel gamma spectrometer (Swedish Atomic Energy Co type 3203), with each channel coupled to a writer (Varian G 11 A). The ratemeters operated with a time constant of 40 sec. The photo peak for  $\text{Au}^{198}$  was read at 0.41 keV and for  $\text{Sc}^{46}$  at 0.89 keV with a channel width of 20 keV in both cases. The photo multipliers of the detectors operated under matched conditions adjusted to the activities in question.




Fig 22 Focusing slit collimator used in profile scanning apparatus no 2




Fig. 23 Diagram of profile scanning apparatus no. 3 (see text)




Fig. 24 Photograph of profile scanning apparatus no. 4 (see text)






Fig. 25 The  $\gamma$  spectrum of  $\text{Au}^{198}$  and  $\text{Sc}^{46}$  measured with a  $3'' \times 3''$  NaI crystal. The position and boundaries of the three channels used for reading the  $\gamma$ -energies of the two isotopes simultaneously are given with vertical lines. The channel at  $0.89 \text{ MeV} \pm 0.05$  is used for reading the counts of  $\text{Sc}^{46}$  from its photopeak. The channel at  $0.58 \text{ MeV}$  takes up as many counts from  $\text{Sc}^{46}$  as is represented in the channel at position  $0.41 \text{ MeV}$ —the photopeak of  $\text{Au}^{198}$ . This is arranged by justifying the width of the channel at  $0.58 \text{ MeV}$  in such a way that the area representing the counts of  $\text{Sc}^{46}$  in this channel will be as large as that in the channel at  $0.41 \text{ MeV}$  (these areas are shaded in the figure). The counts of the photopeak of  $\text{Au}^{198}$  in the channel at  $0.41 \text{ MeV} \pm 0.05$  are then read as the difference between the total counts and those coming from the  $\text{Sc}^{46}$  in this channel. In apparatus no. 4 this was arranged automatically: the counts in the  $0.58 \text{ MeV}$  channel being subtracted from the total counts in the  $0.41 \text{ MeV}$  channel. The number of counts from  $\text{Au}^{198}$  that occur in the  $0.58 \text{ MeV}$  channel is negligible.




Fig 26 Diagram of the whole body counter

#### Apparatus no 4

A further improvement was achieved by having a third channel in the measuring unit of apparatus no 3. This third channel was coupled to give an automatic reduction of the interference from the energy spectrum of  $\text{Sc}^{46}$  at the level at which the photo peak for  $\text{Au}^{198}$  was read. This was done by setting the third channel with a suitable width to a level between 0.41 keV (the photopeak of  $\text{Au}^{198}$ ) and 0.65 keV (the limit for the first relatively steep decline in the gamma energy spectrum of  $\text{Sc}^{46}$ ). The activity measured in the third channel could thereby be adjusted so as to be equivalent to the interference from  $\text{Sc}^{46}$  in the channel for  $\text{Au}^{198}$  (Fig 25). A channel width of 100 keV was used for the channels at photopeaks of 0.41 and 0.89 keV respectively.

#### Whole body counter

The long term studies of lung clearance were





Fig 27  $\text{Au}^{198}$  isoresponse curves in air obtained with the slit collimator of profile scanning apparatus no 1



*Fig 28 Au<sup>199</sup> scan and isoresponse curves in air obtained with the focusing slit collimator of profile scanning apparatus no 2. The figures in the scan curves refer to the distance between the collimator and the point source. The figures in the isoresponse curves refer to equal count rates.*

performed with an open type of whole body counter designed and constructed at this Institute (Fig 26) and consisting of a 3"  $\times$  3" NaI crystal surrounded by a lead collimator with a conical aperture pointing downwards. The collimator was mounted on a stand at a height of 60 cm above a sheet of iron 15 cm thick. The collimator and iron sheet effectively screened the direct background radiation, which was thus only 0.07 cps in the Sc<sup>46</sup> channel. The detector was powered by a high tension unit (Oltronix LS 524) and was coupled to a scaler (Philips PW 4032) and timer (Philips PW 4052).

**Characteristics of the apparatus**  
In order to make an adequate assessment of the measurements obtained, it is necessary to know about the various characteristics of the apparatus. The characteristics of the various profile scanning units are considered below on the basis of investigations conducted on radioactive specimens in air and water as well as on specimens in frozen rabbit cadavers.

Apparatus no 1 was used to test the applicability of the profile scanning technique in lung clearance studies. The isosensitivity of the collimator in air was studied




Fig 49  $\text{Au}^{198}$  scan and isoresponse curves in water obtained with the fo-using slit collimator of profile scanning apparatus no 2 The figures in the scan curves refer to the distance between the collimator and the point source The figures in the isoresponse curves refer to equal count rates

The characteristics of apparatus no 2 were investigated in greater detail The isosensitivities in air and water were determined for apparatuses nos 3 and 4

#### *Collimator, Apparatus no 1*

The isoresponse curves are shown in Fig 27 with respect to the isosensitivity in air for  $\text{Au}^{198}$  The curves represent count rate levels for a point shaped  $\text{Au}^{198}$  specimen in a vertical plane centered on and at right angles to the collimator aperture The isoresponse

curves were plotted from measurements of the count rate from a point shaped  $\text{Au}^{198}$  specimen placed in a total of about 60 different positions in the measuring plane

#### *Collimator Apparatus no 2*

##### *Selectivity*

The collimator's selectivity was determined with stepwise  $\text{Au}^{198}$  scan curves and isoresponse curves in air and water (Figs 28 29) In the latter case this was done to simulate the conditions for external measurements

## MEASURING PLANE




Fig 30 Diagram to show the different planes referred to in the study of the response characteristics of the collimator in profile scanning apparatus no 2

on rabbits since the biological tissues change the energy spectrum of the radiation that reaches the detector (85)

For these studies, point shaped specimens (ca  $2 \mu\text{c}$ ) were placed in selected positions in a measuring plane at right angles to the collimator aperture and the collimator plane (Fig 30). The stationary scan curves thus describe the count rate obtained when the specimens are in different positions in the measuring plane. The isoresponse curves indicate equal count rates in this measuring plane with the highest count rate (set at 100%) directly in front of the collimator aperture and at 0 cm above this. The isoresponse curves in water were obtained by placing a plastic container (PVC) approximately 2 mm thick with its base 1 cm above the collimator plane and carrying out the measurements as above. The highest count rate set at 100% is represented in this case by a point immediately in front of the collimator aperture and 1 cm above this.

## Variation with distance

The variation with distance when recording the activity from a point source of  $\text{Au}^{198}$  was established by means of dynamic measurements (recording of scan curves) with the specimen placed at five selected heights over the centre of the aperture. The results are shown in Fig 31. The maximum recorded difference amounts to  $\pm 27\%$  when the activity from a point source is moved a maximum distance towards or away from the collimator from the mean height of the measuring area. Repeated measurements with the same position for the specimen gave variations in the measurements that correspond to a standard deviation of  $\pm 2.6\%$ . This is shown in Fig 31 by the shaded area. This standard deviation may be regarded as the error of method for the measuring procedure.

Area of scan curve in percent




Fig 31 Detector system response shown as a function of the distance between a point source ( $\text{Au}^{198}$ ) and the focusing slit collimator of profile scanning apparatus no 2. The shaded area shows the standard deviation  $\pm 2.6\%$  of repeated measurements of the area of scan curves obtained from the point source.

### *Power of resolution*

The power of resolution was defined as the distance between two specimens that results in a profile curve with two maxima such that the smaller maximum exceeds the minimum between the two peaks by at least three times the range of the background variation in at least 4 out of 5 consecutive measurements

The collimator's power of resolution was determined using Au<sup>198</sup> specimens in 1 mm plastic tubes all with the same activities but paired in different lengths namely 1 12 5 25 and 50 mm These were placed in line with each other at selected heights in the measuring plane parallel to the collimator plane The distance between the specimens was varied and five continuous as well as five stepwise scanings were performed for each distance

The nearer the two specimens approached one another the more the profile curves overlapped until it became impossible to distinguish two separate fractions In the continuous measurements this occurred when the distance between the point shaped specimens was 11 and 18 mm at 2 5 and 8 5 cm respectively over the collimator In the stepwise measurements the corresponding figures were 2 and 12 mm at 2 5 and 8 5 cm respectively over the collimator

The limiting values for the resolution of the point shaped and the other specimens are given in Fig 32 for the continuous measurements and in Fig 33 for the measurements performed by stepwise scanning

The curves obtained by continuous scanning were evaluated planimetrically as described in Chapter 6 (page 62) using a template designed for these scan curves The evaluation of the profile curve of the point source scanned first gave the same spread as did measurements on equivalent isolated

specimens when the distances between the point source specimens were greater than the values given in Fig 32 This means that if the occurrence of two separate profile curves i e approximately equivalent concentrations of radioactivity, is indicated by a curve having two maxima conforming with the above conditions the area of each fraction can be measured with the same degree of accuracy as for measurements of independent curves This is done by covering the area of the fraction scanned first with the template and obtaining the area of the second fraction by subtracting the area of the first from the total area of the profile curve Owing to the time factor in the ratemeter the second fraction is overlapped more by the first than vice versa and consequently it can not be screened off with a template as the first fraction

Since the relevant experiments showed that the distance between the scan fractions for the larynx lungs and stomach amounts to several centimeters it should be possible to distinguish between two nearby fractions from scan curves obtained from Sc<sup>46</sup> with an adequate margin in experimental studies on animals

### *Collimator, apparatus nos 3 and 4*

The Sc<sup>46</sup> isoresponse curves in air and water of this collimator arrangement are shown in Figs 34 and 35 The study in water was performed to simulate conditions in biological tissue A comparison of Figs 34 and 35 with Figs 28 and 29 shows that the new arrangement gives an approximately equivalent collimation

The coefficient of variation for measurements of point source standards ( $\pm 5\%$ ) of Au<sup>198</sup> and Sc<sup>46</sup> is shown in Fig 36 Readings of 50 nc Au<sup>198</sup> have e g an error of approximately 15%




Fig 32 Limiting values for the distance resolution of pairs of  $Au^{199}$  sources of different lengths by continuous scanning with apparatus no 2 (see text)

### Whole body counter

The only factor investigated for the whole body counter was its isosensitivity to  $Sc^{46}$  in air. The curves were evaluated from measurements of the count rate from a point source of  $Sc^{46}$  placed in more than 100 different positions in the measuring planes investigated. The isoresponse curves are shown in Figs 37 and 38 for two mutually perpendicular planes through and parallel to the axis of the collimator.

### Validity of the measurement method for lung clearance studies

To test the use of profile scanning units for evaluating the retention of test aerosols in the lungs, 11 different times studies were per-

formed correlating this technique with activity measurements on isolated lungs. A number of studies were also carried out on rabbit phantoms to investigate the power of resolution of the instrument with respect to activities in nearby organs etc.

### Profile scanning apparatus no 1

Correlation between profile scanning and radioactivity measurements on isolated lungs

### Method

Studies were performed using the 28 rabbits for the investigation of the tagging isotopes translocation from gelatin particles (Chapter 3). During the exposure which lasted for about 30 min the rabbits were kept in plastic bags in order to prevent their fur from becoming contaminated. After the exposure the plastic bags were removed and the







Fig 33 Limiting values for the distance resolution of pairs of  $Au^{198}$  sources of different lengths by continuous scanning with apparatus no 2 (see text)

animals were placed in special plastic moulds (Fig 19) designed to fit their body in the resting position. The animals were immobilised by these moulds being only able to move their heads vertically a couple of centimeters. At different intervals after exposure ( $\frac{1}{4}$   $\frac{1}{2}$  1 2 4 8 and 16 hours) the animals were sacrificed in groups of 4 immediately after three profile scanings had been performed with apparatus no 1 the ratemeter being set at a time constant of 10 sec. The animals were killed with pentobarbital given intravenously the lungs and other tissues were removed at once washed in concentrated  $H_2O_2$  and evaporated to 10 ml.

The profile curves were evaluated by planimetry as described in Chapter 6.

Since the profile scanning was performed immediately before the animals were sacrificed a direct comparison could be made between the two methods for measuring the activity in the lungs.

## Results

Fig 39 shows the correlation between measurements of the activity in the lungs made directly from isolated lungs and by profile counting over the lungs in the living animal. The coefficient of correlation was 0.97.

### Profile scanning apparatus no 2

*Evaluation of different distributions of radio activity studied in rabbit phantoms*

### Lung surface and bronchial activities

In order to determine the maximum variation between the scan curve areas for activity






Fig 34  $\text{Au}^{199}$  isoresponse curves in air for the collimators in profile scanning apparatus nos 3 and 4. The different planes studied are shown up on the left.




Fig 35  $\text{Au}^{199}$  isoresponse curves in water for the collimators in profile scanning apparatus nos 3 and 4. The different planes studied are shown up to the left.




Fig 36 The coefficient of variation for the area of scan curves obtained from an absolute calibrated ( $\pm 5\%$ ) standard point source of Au<sup>198</sup> and Sc<sup>46</sup> (from profile scanning apparatus no 4)




Fig 37 Sc<sup>46</sup> isoresponse curves in air for the collimator in the whole body counter




Fig 38 Sc<sup>46</sup> isoresponse curves in air for the collimator in Fig 37 in a perpendicular plane

Profile scanning  
arbitrary units




Fig 39 Scatter diagram and regression line demonstrating the correlation between radioactivity measured by scaler technique on isolated lungs and planimetrically evaluated areas of lung scan curves obtained with profile scanning apparatus no 1

ities deposited in extreme positions in the lung experiments were performed using 4 rabbit lungs. A comparison was performed between activities on the surface and in the bronchi of lung phantoms.

After the lungs had been dissected free inflated to normal size and dried two of them were cut up into horizontal sections approximately  $\frac{1}{2}$  cm wide. Equal amounts of activity (approximately  $4 \mu\text{C}$ ) were then applied bronchially (from 1 cm over the carina down to and including the fourth bronchial division) in as similar a manner as possible to both specimens using a micrometer syringe. The other two lung specimens had the same amount of activity evenly applied to their surfaces. Rabbit phantoms were produced by sacrificing rabbits with pentobarbital placing them in measuring moulds and then refrigerating them at  $-40^{\circ}\text{C}$ .

The frozen animals were sawn lengthwise into two halves after which the lungs were chiselled out and replaced with the specimens described above. These had been painted with a thin layer of plastics to protect them from moisture.

Profile scanning of these phantoms show

ed that the scan curve area from the bronchial activity was 17% larger than the corresponding value for the "peripheral" activity i.e. that applied to the surface of the lung specimens.

### Activity in lungs and stomach

Lungs prepared in the same way as above were used in an attempt to determine the influence of known amounts of activity located in different parts of the stomach upon readings of a known activity in the lung.

In these experiments 5 sacrificed rabbits were frozen to  $-40^{\circ}\text{C}$  and then sawn lengthwise into two halves after which the lungs were chiselled out. Lung phantoms with bronchial activity (approximately  $5 \mu\text{C}$ ) and impregnated with plastics were placed in three of these rabbits. The other two received lung specimens with the activity (approximately  $4 \mu\text{C}$ ) distributed over the surface. Point sources of activity—46 and 91% re




Fig 40 The diagram in the lower part of the figure illustrates the effect of a point source of  $\text{Au}^{198}$  in different positions in the stomach region on the simultaneously scanned activity in a lung phantom with bronchial application of  $\text{Au}^{198}$ . The different positions of the point source are indicated in the upper part of the figure. The activity of the point source was approximately 46 % of the activity in the lungs.

spectively of the lung activity in the "bronchial" and "peripheral" lung phantoms—were placed in different positions in and outside the stomach and the effect of this on the recordings of lung activity was studied.

The interference from activity evenly distributed in the stomach was studied in the same way except that the stomach chiselled out from the rabbit phantom was replaced by an oblong rubber bladder filled with a gold chloride solution tagged with  $\text{Au}^{198}$  amounting to 77 and 91 % of the activity in the bronchial and peripheral lung phantoms respectively.

The results are illustrated in Figs 40 and 41 which show that a point shaped activity—situated ventrally against the diaphragm—of the same size as the activity in the "peripheral" lung specimen gives an increment of approximately 14 % to the reading of the lung activity. In reality however this site is occupied by the liver. The increment 1 cm caudally of this position was negligible. In the case of bronchial activity in the lung specimens an increment of 10 % was ob-




Fig 41 The same diagram as in Fig 40 with  $\text{Au}^{198}$  applied to the surface of the lung phantom. The activity of the point source was approximately 91 % of the activity in the lungs.

tained when the point source lay against the diaphragm.

The readings of activity in the lungs were not affected by activity evenly distributed in the stomach phantoms and amounting to 77—91 % of the lung activity.

**Activity in lungs and trachea**  
 A similar study was made of the interference from activity in a trachea phantom on a lung phantom in which the activity (approximately  $4 \mu\text{C}$ ) was distributed "bronchially". The trachea phantom's activity was evenly dis-

tributed in this and amounted to 42 % of activity in the lung specimen. In this case area of the lung scan curve increased only 7 %.

#### *Profile scanning apparatus nos 3 and*

No studies were made concerning the validity of measurements performed with the apparatuses. Nor do such studies appear to be necessary considering that these were superior to apparatus no 2 (which was investigated) with respect to factors such

dependence on distance and isoresponse of the detector system

### Discussion

The analyses of isolated lungs confirm the assumption that the "lung peak" observed in profile counting was in fact due to the radioactivity in the lung

The correlation with the scaler technique showed that profile scanning is an appropriate method for lung clearance studies on experimental animals provided that the selectivity of the collimator reduces the interference from activity in adjacent organs to an acceptable level

The primary advantages of external methods for measuring lung clearance in vivo compared with conventional techniques on sacrificed animals is that clearance can be followed and repeated studies be performed on one and the same animal and that consequently one requires a smaller number of animals. Another advantage is that transport of particles from one organ to another can be studied with a single detector

Profile scanning is not dependent on exact equivalent geometry concerning the animal's location in relation to the detector system as is the case when using a stationary detector system. In the latter case the measuring field often cannot include the entire lung owing to the risk of including parts of the stomach as well

A disadvantage of profile scanning is that one cannot study such small amounts of radioactivity as with a fixed detector. The method is therefore chiefly confined to the study of clearance immediately after exposure and during the first week or so after this

Another disadvantage common to all methods for external measurement is that one cannot determine the exact location of the amounts retained. As a rule moreover no

direct measure is obtained of the initial de position which consequently has to be calculated by extrapolation of the values for retention in different intervals after exposure

The variation with distance is of course a disadvantage in unilateral recording of the radioactivity from a source in an organ particularly if the source comes extremely close to or far away from the detector. The further away the detector moves from the organ, the smaller becomes the difference between the recordings of activity from the nearest and furthest parts of the measurement area at the same time as the efficiency and power of resolution for the measurements deteriorate

In the present study with apparatus no. 2 the variation for the measurement area in question amounted to  $\pm 27\%$  in recordings of the activity from a point source moved to the extreme dorsal or ventral positions from the centre of the measurement area. Owing to the symmetry of the lungs this disadvantage can be offset to some extent by placing the detector against the animal's side or by using two or more detectors placed symmetrically around the animal. Still better conditions are obtained by using focusing collimators, which are less dependent upon distance as was done in apparatuses nos. 3 and 4

The experiments with apparatus no. 2 and frozen rabbit phantoms show that the difference between equal amounts of activity applied "peripherally" and "bronchially" respectively to dried lung specimens amounted to only 17% for such extreme distributions. The investigations presented in Chapter 3 show that the redistribution of the retention of 3 and 6  $\mu\text{m}$  particles between the initial phase and 72 hours after exposure is nothing like as great as the conditions represented by these phantom studies. Consequently the difference in recordings of activity from the




Fig. 42 Profile scan curves from rabbits exposed to 3 and 6  $\mu\text{m}$  polystyrene tagged with  $\text{Sc}^{46}$  and  $\text{Au}^{198}$  respectively. The radioactivity is gradually transferred from the lung area (L) to the larynx (La) and then to the stomach (S) area later on it disappears. This transportation process is faster for the bigger particles. In this animal the remaining radioactivity of the two isotopes was confined to the lung area after 8 days from then on lung clearance can be accurately measured by whole body counting.

aerosol initially retained in the lung after inhalation via a tracheal tube compared with possible distributions in the lung at different times after this will not give rise to such large discrepancies in practical experiments as those noted here.

The collimator used in apparatus no. 2 and the technique employed for distinguishing between the different fractions of the profile curves have made it possible to record the activity in the lungs without any essential interference from activities in adjacent organs such as the larynx, trachea and stomach. In the phantom studies when the activity in the trachea amounted to 42 % of that in the lung specimen the increment to the lung

scan curve was only 7 %. Although no direct conclusions can be drawn from the investigations reported and discussed in Chapter 3 the data do suggest that the disturbance from activities in the trachea during an initial phase of clearance can approach the same magnitude as noted here provided that the activity is evenly distributed in the trachea.

The phantom studies also showed that even with an extremely unfavourable location of the activity in the stomach—a point source against the ventral side of the diaphragm amounting to 91 % of the activity in the lungs—the readings of “bronchially” distributed activity in the lungs were affected by less than 10 %.



The maximum effect of interference from the transport of activity in the oesophagus on readings of lung activity will correspond to the amount that passes through the oesophagus during measurement. In the investigations reported in Chapter 3 only negligible activities were noted in the oesophagus. Moreover, since profile scanning makes it possible to detect any larger quantities that pass through the oesophagus, the interference from these can be avoided.

With the aerosol in question, the crystal (NaI 1"  $\times$  1") and the collimator in apparatus no. 2, studies were limited to initial retentions in the milligramme range (53). Apparatuses nos. 3 and 4 permitted studies of clearance with initial retentions down to 0.2  $\mu$ g. At the expense of poorer resolution, a wider aperture could be used to increase the efficiency of the measurements. However, the planimetric evaluation of the profile curves (cf. Chapter 6) would be more difficult and consequently a relatively high power of resolution was chosen, even though this meant using a relatively slow scanning rate.

In order to follow lung clearance in live animals over periods running into months, one needs to be able to measure small amounts of radioactivity. This can be done with a whole body counter as a complement to profile scanning. Whole body measurements cannot be used for this purpose as long as there is interference from radioactivity in other organs. It can, however, be employed once profile scanning has shown that the lungs contain the greater part of the radioactivity in the animal. Fig. 42 illustrates how this time can be determined. The figure reproduces profile scan curves from a rabbit exposed simultaneously to 6 and 3  $\mu$ m polystyrene particles tagged with  $\text{Au}^{198}$  and  $\text{Sc}^{46}$  respectively, and demonstrates how the radioactivity moves from the lungs to the laryngeal region and from there to the gastrointestinal tract. Later, day 8 in this case, radioactivity is found only in the lungs. Beyond this time period, whole body measurements will accurately reflect the lung clearance.

## EVALUATION OF THE MEASUREMENTS

## Profile scan curves

The curves recorded with the profile scanning technique represent the distribution of the radioactive tagging substance along the length of the animal studied. The appearance of the curves varies with the time that has elapsed since exposure to the test aerosols. As a rule several different fractions can be distinguished corresponding to concentrations of the tagging substance in different parts of the animal. These fractions generally overlap to some extent. Fig. 42 provides an example of the appearance of scan curves for an animal 7 and 40 minutes, 3 hours and 8 days after the end of exposure to a di-disperse (6 and 3  $\mu\text{m}$ ) polystyrene aerosol. The figure illustrates how the lung fraction decreases with time as the activity is displaced towards the larynx and later down into the stomach and intestines.

For a particular distribution of the activity in the direction of scanning, both the surface under the curve and its height are proportional to the activity scanned. This can be verified mathematically for instance for activity concentrated to a point. Both relationships have been utilised for evaluating the lung activity and their validity has been tested in a series of experiments in which the lungs of exposed rabbits were measured by profile scanning immediately before being removed, wet ashed in  $\text{HNO}_3$  and measured for their total radioactivity using a conventional technique.

Overlapping by nearby fractions compli-

cates the evaluation of the scan curves particularly if a time lag is involved in the form of a time constant to minimise the statistical variation in the count rate. The time constant causes a lag in the scan curves in relation to the location of the activity measured. The effect of this however is the same for all scan curves that do not overlap each other. A scan curve that is overlapped by another curve positioned before it in time will however, get a reduced lag. The degree of this reduction depends on the distances between the different sources and the relations between their activities as well as on the isoreponse characteristics of the collimator system used. Allowance must be made for these circumstances if the locations of the activities are to be determined exactly. This was not the aim in the present investigation. The identification of the main fractions e.g. larynx, lung and stomach is not however affected. The distance between e.g. the larynx peak and the lung peak on the scan curves is approximately three times the time constant. It has been found that these factors do not reduce the time lag in the lung peak to any measurable extent for the relation of activities found in the studies performed.

The overlapping considerably complicates the mathematical relationship mentioned above making it difficult to perform a mathematical analysis of the conditions involved. The surface distribution of the different fractions must therefore be determined

empirically on the basis of principles derived from experiments

#### *Surface measurement with a planimeter*

The area of the lung scan fractions was calculated by reconstructing the appearance of the isolated fractions and measuring their area with a planimeter

Templates were specially constructed for evaluating these areas. For each isotope studied a template was designed on the basis of a number of independent scan curves obtained from exposed rabbits in which the aerosol was deposited only in the lungs. These scan curves thus reproduced the true appearance of the lung fraction i.e. without interference from radioactivity in other organs. Profile curves from lungs with different retentions were compared (Fig 43) and it was found that if a curve was shifted sideways its shape between the point of inflection and the base line was very similar to this distance on a higher curve. This circumstance made it possible to construct templates with which the curve of the lung fraction could be isolated from curves of overlapping fractions.

The validity of the planimetric calculation of lung scan curves obtained in this way has been presented above (cf p 51). The experiments demonstrated that the two methods gave similar results the correlation coefficient being 0.97. Fig 44 *A* illustrates how the lung fraction was separated from adjacent fractions on a profile scan curve obtained in the experiments on animals.

The study on rabbit phantoms (cf p 55) using a point source of radioactivity placed in various positions in the gastric region showed that this did not interfere with the readings of radioactivity in the lung when the latter was distributed bronchially or on the surface.

Percentage of  
full scale




Fig 43 Scan curves from animals with different retentions of 3  $\mu$ m  $\text{Sc}^{46}$  tagged polystyrene particles showing the almost identical slope between the base line and inflection point on one curve and the same distance on the lower part of the next larger curve

#### *Height measurement of lung fraction*

Since the planimetric calculations are time consuming an attempt was made to develop a more simple method for evaluating the profile curves. For this purpose curves obtained from animals measured in the same way were classified into the following five main types

- 1 A pure lung fraction
- 2 A lung and a "larynx" fraction
- 3 A lung and a stomach fraction
- 4 A "larynx" a lung and a stomach fraction

Scale

L Lung fraction

La Larynx

S Stomach

Pixel size  $6 \mu\text{m}$

Tagged with Au 98




Fig 44 A the lung fraction area (a) on an original scan curve screened off from the total scan curve using a template constructed on the basis of the curves in Fig 43. The template is used to draw the line from the point of inflection down to the baseline on the profile curve as shown in the figure. B the height (b) of the lung fraction measured after allowing for the influence of radioactivity in the larynx and stomach. Both scan curves were obtained from the same animal with an interval of approximately 15 minutes.

### 5 Complex curves (indistinguishable fractions)

Examples of the various types of profile curves are shown in Fig 45.






A computerised study was made of the correlation between the area *a* of the lung fraction as calculated planimetrically and the peak height *b* of the fraction above the background level.

In the case of type 1 curves in which there was no interference from adjacent fractions a direct comparison could be made between *b* and *a*.

For types 2 and 4 interference from the laryngeal and gastric regions respectively had to be eliminated before the height of the lung fraction could be calculated. A number of "larynx" scan curves were studied in order to establish the size of this interference. The method previously employed for constructing templates with which to isolate the lung

scan fractions could only be used in the very few cases in which the laryngeal fraction was relatively isolated. Instead therefore the most probable appearance of the caudal side of the laryngeal fraction was estimated from the discharge function of the ratemeter condenser at the time constant used. The shape of the curve obtained in this way was then used in the same manner as for the lung scan fractions to reconstruct the appearance of the fraction from its caudal point of inflection to the background level. The height of the lung fraction could now be measured as the vertical distance between its maximum and its intercept with the curve of the laryngeal fraction (Fig 44 B).

Type 3 curves besides being treated in the same way as types 2 and 4 were also analysed for the probable appearance of the oral side of the stomach fraction which was plotted in a similar manner. In most cases the stomach scan curve did not overlap as far as



I-V = Different types  
of scan-curves

L = Lung fraction  
La = Larynx  
S = Stomach  
I = Interstine

Fig 45 Main types of profile scan curves obtained from different animals (see text)

TABLE 4 Correlation between height measurement and planimetric evaluation of scan curves

Type of scan curve	Number of observations		Coefficient of correlation		Standard deviation of $b$ given $a$ (mm)		h axis intercept in mm	
	Au <sup>198</sup>	Sc <sup>46</sup>	Au <sup>198</sup>	Sc <sup>46</sup>	Au <sup>198</sup>	Sc <sup>46</sup>	Au <sup>198</sup>	Sc <sup>46</sup>
1	18	57	0.98	0.99	1.7	2.9	2.4	2.1
2	199	198	0.99	0.99	3.9	4.2	2.3	1.6
3	173	220	0.99	0.99	3.3	3.1	2.5	0.4
4	317	268	0.98	0.99	3.4	3.4	1.5	1.5
5	38		0.92		7.1		0.0	

to the perpendicular through the peak of the lung scan curve

Type 5 curves were analysed in the same way as type 4. The results were somewhat unreliable, however, because very approximate estimations had to be made.

The correlation study showed that the heights were proportional to the surface areas of the lung fraction. The correlation coefficients between  $b$  and  $a$  for the different types of scan curves are given in Table 4 together with the standard deviation for  $b$  at a given  $a$  and the intercept with the  $b$  axis.

The height of the scan curves in the experiments varied between 15 and 125 mm. Table 4 shows that the intercepts on the  $b$  axis are small compared with the standard deviations, indicating that the use of height instead of planimetric data does not introduce any considerable systematic error. Such errors can be avoided entirely by using a regression line to convert the height data into areas corresponding to those obtained by planimetry.

The studies of deposition and translocation reported in Chapter 3 provided a direct comparison between the height of the lung scan fractions measured in the above manner and the activity in isolated lungs. The correlation of these data is shown in Fig. 46. It will be seen that the Au<sup>198</sup> levels for rabbits

01–05 (which were sacrificed soon after exposure to 3 and 6  $\mu$ m monodisperse polystyrene particles tagged with Sc<sup>46</sup> and Au<sup>198</sup> respectively) are clearly separated from the other levels as is the data for rabbit 21 sacrificed two hours after exposure. A deviation was expected in the case of rabbits 01–05 because it took about 30 minutes to sacrifice the animals and remove their lungs without allowing them to collapse. Since these particles have a high initial rate of clearance, a certain amount of radioactivity may have disappeared from the lungs during this time. Data on the larger particles in these rabbits were therefore excluded from the correlation calculations. In the case of the smaller particles tagged with Sc<sup>46</sup>, the levels at zero time were included in the correlation calculations because, as shown by the retention study, they have a lower deposition than the larger particles at the tracheobronchial level.

The activity from Au<sup>198</sup> in the trachea of rabbit 21 amounted to 33.4% of that in the lung at the same time (Table 2). On the scan curve recorded just before the animal was sacrificed, however, the height of the lung fraction was approximately twice that of the tracheal fraction, indicating that a large proportion of the Au<sup>198</sup> activity was transferred to the trachea when the lung was

Profile scan  
of lung  
Height in  
arbitrary units





Fig. 46 Scatter diagrams and regression lines demonstrating the correlation between the radioactivity of  $Au^{198}$  and  $Sc^{46}$  (in 6 and 3  $\mu m$  particles respectively) as measured by scaler technique on isolated lungs (homogenised in  $HNO_3$  and  $H_2SO_4$ ) and as evaluated from the height of the lung scan curves obtained with profile scanning apparatus no. 4. \* rabbit no. 21.  $\circ$  the group of animals killed at zero time after exposure. The discrepancies are explained in the text.

manipulated during dissection. This transfer may have taken place for instance with the bronchial secretion which contained most of the particles tagged with  $Au^{198}$ . Under these circumstances the data from this rabbit were excluded when calculating the correlation reported in Fig. 46.

### Discussion

Essentially three techniques have been used for evaluating the different fractions of scan curves. The fractions have been divided by perpendiculars through the minimum levels between the peaks or their true appearance has been reconstructed, i.e. their appearance after eliminating the effect of adjacent frac-

tions. In other cases particularly when recordings have been made with a short time constant the peak height of the fraction above the base line has been used. The last two methods have proved applicable in the present studies. The first one was not suitable because the time constant used for the ratemeter produced a lag in the curves resulting in a skew distribution. Consequently, a perpendicular division of the fractions meant that the part cut away from the fraction in question was not fully compensated for by the inclusion of part of the adjacent fraction.

The area under the scan curve and the height of the curve are proportional to the activity scanned. In a mathematical analysis

this means that evaluations based on the area or height of the lung fraction curve are not completely correct unless any changes in the distribution of activity in the lung occur uniformly along the longitudinal axis

Such deviations from this characteristic distribution of activity certainly do exist between the distribution of aerosols retained in the lungs of different individuals and at different times in a single individual (cf pp 24—31). As the present correlation studies show, however, this distortion appears to be negligible with the measuring technique used.

Measuring the height of the lung fraction is a simpler procedure than the planimetric evaluation of its area. Both methods are affected by changes in the position of the animal, attempted licking etc. or variations in the detectors rate of travel. Scan curves subject to errors of this sort have not been included in the analysis. Moreover, a few scan curves incorporating other disturbances of unknown origin (resulting in type 5 curves) were also excluded from the lung clearance studies reported in Chapter 7. Curves excluded for these reasons comprised about 2—3 % of all those obtained.

Variations in the count rate of background activity were so small that they did not interfere with the evaluation of the area or peak height of the scan curves. This is clear from the correlation studies in which any interference from such variations is included in the recorded data.

#### Whole body measurement

Whole body measurement was started when profile scanning showed that no appreciable amounts of activity remained in the gastrointestinal tract. As a rule this occurred 5—10 days after the exposure to test aerosols. It was not possible to follow the long term

clearance of the 6  $\mu\text{m}$  particles tagged with  $\text{Au}^{198}$  owing to the short half life of this isotope. Studies with the whole body counter were thus limited to the clearance of 3  $\mu\text{m}$  particles tagged with  $\text{Sc}^{46}$  during rather more than one month after exposure.

During these measurements the animals were placed in special moulds which prevented them from changing position. The measuring times which were calculated so that the statistical error in the observations was less than 2 % amounted to 10—30 minutes. The results were corrected for the physical decay of the isotope and converted into the same type of arbitrary units as for the profile scanning data.

#### Mathematical models

In most studies concerning the lung clearance of solid particles that are relatively insoluble in biological tissue the course of clearance has been described from the amount retained in the lung after a certain time. In other investigations in which data have been collected concerning the retention at different times a simple exponential function or a number of such functions have been fitted to the observations of lung clearance notwithstanding differences in aerosol materials, animals and measurement techniques (1, 7, 8, 62, 65, 73, 98).

The majority of these studies have been confined to the later phases of lung clearance. Only a few reports have been published concerning the initial rapid phase. The difficulties experienced in interpreting this initial phase have probably been due to the distance dependence of the fixed detector system used. It has often been found for instance that the measured values increase during the first hour or hours after exposure (1) possibly due to redistribution of the particles in the lungs.



Although exponential functions make it easier to find biological explanations for the course of lung clearance there is no evidence to show that such functions represent the best mathematical models for describing the course of lung clearance for solid particles except in cases where the relevant mechanisms display an exponential course. It has been shown for instance that the number of free phagocytes in the lungs is directly correlated to the retention of particles and that both parameters display an exponential elimination (65). Since the mechanisms involved in clearance are superimposed the various terms in an exponential function cannot be automatically ascribed to specific clearance mechanisms.

An adequate test of different mathematical models accommodation of clearance data requires a large number of readings for the retention at different times separated—particularly during the initial phase—by only short intervals. Frequent observations during the first hour or hours of clearance are also necessary owing to the rapid course of this phase in order to calculate the initial retention by extrapolation to the end of the exposure period. This means that the mathematical function applied will be of decisive importance for the evaluation of the initial deposition.

The observations obtained from the lung clearance studies presented in Chapter 7 were derived by the procedure of measuring the height of the scan curves. They were corrected for the relevant sensitivity of the rate meter, the physical decay of the isotopes and (in the di-disperse studies) for the effect of superimposition of the energy spectrum of  $\text{Sc}^{46}$  in the  $\text{Au}^{198}$  channel in the gamma spectrometer (achieved automatically with the apparatus employed in the studies presented here). The mathematical model  $Y =$


$A e^{\alpha t} + B e^{\beta t}$  was fitted to these corrected data expressed in arbitrary units, with the help of an iterative adjustment programme in the computer.

The whole body measurements which started after or, in some cases simultaneously with the last measurements by profile scanning were fitted to a simple exponential function, partly in order to evaluate clearance during this period and partly so that these data could be converted into a common scale for profile scanning and whole body measurement. In the latter case the sum of two exponential functions was fitted to the combined observations in order to elucidate the method's ability to describe the entire course of clearance. The initial value obtained from this mathematical model was set at 100 % and all the observations were standardised to this figure.

An example of the mathematical model's approximation to the observations for profile scanning measurements of lung clearance up to 150 hours is given in Fig. 47 for 3 and 6  $\mu\text{m}$  monodisperse polystyrene particles. The course of clearance is shown on a linear scale to make it easier to observe the differences in the clearance of the two sizes of particle.

Fig. 48 reproduces the fit of the mathematical model for observations obtained during the first three hours after exposure to the above mentioned di-disperse aerosol and Fig. 49 does the same for the interval 0—1 000 hours with profile scanning and whole body measurement. Fig. 50 shows the same clearance course as in Fig. 49 on a semi logarithmic scale in order to illustrate the exponential character of clearance.

In many cases the first observation is off the regression line of the rapid phase of clearance. No statistical evaluation can be made on the basis of these isolated values. In the light of studies concerning the rate at



*Fig 47* The simultaneous lung clearance of 3 and 6  $\mu$ m polystyrene particles. The values up to 150 hours after exposure to the particles were obtained with profile scanning apparatus no 4. The sum of two exponential functions was fitted to the observed values and the regression lines are shown. The figures in the diagram refer to the number of the rabbits in the experiment presented in Chapter 7. The interval between the two exposures was ca. 8 weeks.

## Control group 2nd test aerosol exposure




Fig -8 The simultaneous lung clearance of 3 and 6  $\mu$ m polystyrene particles during the first three hours after exposure to the aerosol. Note that the first plot in nearly all the experiments lies above the regression line. The figures in the diagram refer to the number of the rabbits in the experiment presented in Chapter 7.

# Control group

## 1st test aerosol exposure

Percentage of initial  
lung retention

3  $\mu$ m particles observed values  
— Regression lines




Fig. 49 Lung clearance of 3  $\mu$ m polystyrene particles. The lung retentions were recorded by profile scanning and whole body measurements. The regression lines (the sum of two exponential functions) are shown. The figures in the diagrams refer to the same group of animals as in Figs. 47 and 48.

# Control group 1st test aerosol exposure




Fig 50 The same data as in Fig 49 plotted on a semilogarithmic scale

which secretion and particles are transported in the trachea (84) it is reasonable to suppose that this is an indication of a very rapid clearance (a half life of some 10 minutes) connected with matter deposited in the trachea. Each observation lasts 5—10 minutes in profile scanning and consequently the technique cannot be used to study this phenomenon in greater detail.

By fitting the same mathematical model to all the clearance data a uniform basis is created for assessing these provided they are comparable with respect to the time of the first, the frequency of subsequent and the duration of the observations.

One of the advantages of fitting mathematical models to clearance data is that the constants included in the functions can be used for statistical processing. The exponential functions also make it possible to compare the rates of elimination and the percentage of the total clearance process in the various phases of clearance.

### Discussion

The investigations presented here show that profile scanning as a means of measuring the retention of radioactively tagged aerosols in the lungs is a suitable method for studying the lung clearance of such particles. The use of two detectors placed on either side of the animal reduced the interference—possibly due to the redistribution of the particles in the lungs—that occurs in external measurement with unilateral recording of the radioactivity from tagged particles deposited in the lungs. In all external methods for

measuring lung clearance the results can be affected by interference from transport of the substance studied through the oesophagus. In this respect, profile scanning has the advantage that this transport can be observed. In keeping with all other methods for external measurement profile scanning cannot however be used to detect translocation or storage of the substance in the lymphatic system in the thorax and consequently one can only study transport from the lungs as a whole.

The profile scan curves can be evaluated planimetrically as described above or by a relatively simple procedure by measuring the height of the lung scan curve. The latter technique is less time consuming than the former. To describe the process of lung clearance from the data obtained, one can estimate either the time after exposure at which different levels of retention are reached, the half life of total clearance or its slower phase. This procedure however may introduce indeterminable errors particularly if the data display a large spread. The course of clearance has therefore been visualised by fitting various mathematical models to the data for calculating the regression line. The choice of mathematical model is decisive for the interpretation of the expression obtained for the clearance process. As mentioned under "Mathematical models" a common method is to fit the sum of two or more exponential functions to the observed values. This tradition has been followed in the present study although there is no definite evidence to show that these models give the best picture of the clearance function.

## APPLICATION OF THE METHODS

The methods reported in previous chapters have been used to determine lung clearance in rabbits. Since the original report by Friberg & Holma in 1961 (36), the methods for studying lung clearance have undergone continuous development as discussed in previous chapters. The results of the earlier investigations will not be reported in detail, some have been presented in previous chapters. The most advanced techniques have been used to determine lung clearance in normal and  $\text{SO}_2$  exposed rabbits. Sulphur dioxide was used for the study because of its significance as an industrial pollutant and also because it has featured so prominently in the discussion concerning air pollution in general.

## Experimental conditions

The experiments were conducted with 14 male rabbits<sup>1</sup> (weight approximately 3.5 kg) divided into two groups of seven animals each. The experimental set up is shown in Fig. 51.

The rabbits' body temperatures and weights

<sup>1</sup> The experiments were originally designed for 16 rabbits divided into two groups of 8 animals each. However, one rabbit in the group exposed to  $\text{SO}_2$  died in connection with anaesthesia prior to re-exposure to the test aerosol. Moreover, one of the rabbits in the control group developed paralysis in a hind leg and was sacrificed. An autopsy performed at the National Veterinary Institute showed "degeneration of medullary sheath in spinal chord and peripheral nerves". The temperature and weight of the animals were recorded during the experiments and found to be normal.

were monitored daily approximately one week prior to the start of the experiments to exclude sick animals.

The production of the disperse test aerosol (6 and 3  $\mu\text{m}$  polystyrene particles tagged with  $\text{Au}^{198}$  and  $\text{Sc}^{46}$  respectively), the exposure technique and the measurement of lung clearance were performed as described in the preceding chapters. The duration of exposure to the test aerosol varied between 5 and 10 minutes. In order to evaluate the particle characteristics of the test aerosol, a certain volume of air in front of the animal's mouth was collected on millipore filters during exposure. These filters were then analysed for the presence of particle aggregates by examination with the light microscope. The total incidence of particle aggregates was found to be ca. 5% and ca. 3% for the 6  $\mu\text{m}$  and 3  $\mu\text{m}$  particles respectively.

Two weeks after the experimental and control groups had been exposed to the test aerosol, the former group was exposed to 10 ppm  $\text{SO}_2$  for 16 hours a day in the chamber illustrated in Fig. 52. 10%  $\text{SO}_2$  from a cylinder was diluted with air to 10 ppm in a special mixing chamber before the intake to the exposure chamber. The content of  $\text{SO}_2$  in the latter was checked conductometrically with 2 hourly samples throughout exposure. These analyses showed a mean of 10 ppm  $\pm$  1 ppm. The distribution of the sulphur dioxide content in the chamber displayed no appreciable concentration gradient. During the experiments the air temperature of the




Fig 31 Experimental design for the study of lung clearance in normal and SO exposed rabbits

chamber was ca 20°C and the relative humidity ca 20—30 %. The control group of animals was kept in a similar exposure chamber and exposed to fresh air under corresponding conditions and times

The experimental and control animals were re exposed to the di disperse test aerosol after about six and eight weeks respectively

Profile scanning performed with apparatus no 4 (cf Chapter 5) was started 1—2 minutes after the end of exposure to the test aerosol. The first lung fractions on the profile curves were obtained after 5—10 minutes. Scanning was then repeated every tenth to fifteenth minute during the next 3 or 4 hours and subsequently at intervals of 10 hours during the next 2 to 3 days and once a day thereafter. Once the initial phase was over three scans were performed in succession on each occasion. The profile scanning continued for approximately two weeks with some of the rabbits. Others were only observed for about one week because they had a lower initial retention of Au<sup>198</sup> (cf Tables 3—6 in the Appendix). This short observa-

tion period applies to the scanings after the first exposure to the test aerosol. In order to obtain uniform observation periods for all the rabbits the results are based on a period of 6 days in all cases

Whole-body measurements were started at the time when profile scanning showed that there was no appreciable radioactivity in the gastrointestinal tract. As a rule this occurred 5—10 days after exposure to the test aerosol (Fig 42). Only the 3  $\mu$ m particles tagged with Sc<sup>46</sup> were studied with the whole body counter because the half life of Au<sup>198</sup> made it impossible to study the 6  $\mu$ m particles which were tagged with this isotope. Lung clearance of the 3  $\mu$ m particles was followed with this technique for approximately 6 weeks. In order to establish a uniform basis for the different animals an observation period of four weeks has been included in calculating the results

The sum of two exponential functions was fitted to the data from the profile scanning measurements using a computer and an iterative least squares estimation programme






Fig 32 Diagram of the exposure chambers

The results from the whole body measurements were treated in two ways. First they were combined with the data from the profile scanning measurements as described in the chapter on mathematical models and, second they were treated separately by fitting a simple exponential function to the observed values. Since it was desired to study whether the interjection of exposure to  $\text{SO}_2$  affects the slower phase of clearance, this exposure was started at the time of the

transfer from profile scanning to whole body measurement. For this reason, the whole body measurements were evaluated separately as described above.

In the following presentation of the results the suffices <sub>p</sub> and <sub>w</sub> are used in connection with the regression parameters in the expression  $Y = A e^{\alpha t} + B e^{\beta t}$  to refer to profile scanning measurements and whole body measurements respectively. In the mathematical model  $Y$  is the fraction

of the intercept value remaining at given times ( $t$ ) in hours and  $e$  is the natural logarithm base  $A$  and  $B$  are the percent of the intercept value  $\lambda$  ( $t = 0$ ) for the first and second phase of clearance respectively. The  $\alpha$  and  $\beta$  constants refer to the slopes of the first and second phase respectively. The results of the investigation will be discussed under the following headings:

- 1 The course of clearance and its different phases
- 2 Intra and inter individual variations
- 3 Significance of particle size
  - a) Clearance of different sizes of particle
  - b) Correlation between regression parameters for different particle sizes
- 4 Correlation between different phases of clearance
- 5 Clearance after exposure to sulphur dioxide

### Results and comments

The two phases of lung clearance as evaluated from the profile scanning measurements are shown in Tables 5–8. The mean values for alpha coefficients are shown in Table 5, the beta coefficients in Table 6 and the intercept of the second phase ( $B$ ) with the  $y$  axis in Table 7. Data concerning beta coefficients obtained from whole body measurements are given in Table 8.

The dose of radiation received by the lung tissue assuming complete absorption of the irradiation from the beta decay averaged approximately 18 rad, the highest mean for a group being 55 rad.

### *The course of clearance and its different phases*

The course of clearance and its different phases are illustrated in Fig. 53 *A* for the two phases for 3  $\mu$ m particles as determined by profile scanning and in Fig. 53 *B* for the slower phase using the whole body counting technique. The individual curves were calculated mathematically (see Chapter 6) from the empirical data of the control group after the first exposure to the aerosol. It will be seen that clearance is characterised by a rapid initial phase and a secondary slower phase. The course of clearance demonstrated largely agrees with earlier results published by the author (53–54) as well as with the results of other researchers referred to in Chapter 6 where mathematical models are discussed.

The half lives of the two phases are illustrated in Fig. 54 in which the slopes for the different phases relate to the 3  $\mu$ m particles in the control group after the first exposure to the test aerosol. Here again one sees a rapid initial phase and a slower second phase; moreover, the slope of the slower phase as calculated from whole body measurements is somewhat lower than that obtained by profile scanning, probably due in part to differences in the length of observation periods. The intercept data given in Table 7 show that the second phase is responsible for the greatest proportion of the total elimination of the smaller particles, while the corresponding elimination of the larger particles is less; consequently the first phase eliminates more of the larger particles than of the smaller ones. This may be taken as indicating that the larger particles are deposited at the tracheobronchial level to a greater extent than the smaller ones.

Further investigations are required before one can establish with certainty which clearance mechanisms are chiefly responsible for

TABLE 5 Means of  $\alpha_p$  coefficients obtained from profile scanning measurements

Exposure	Control group		Experimental group	
	3 $\mu\text{m}$	6 $\mu\text{m}$	3 $\mu\text{m}$	6 $\mu\text{m}$
I	0.47	0.49	0.32	0.42
II	0.47	0.51	0.46	0.49
S	$\pm 0.07$		$\pm 0.06$	

S = Average standard error of individual mean

TABLE 6 Means of  $\beta_p$  coefficients obtained from profile scanning measurements

Exposure	Control group		Experimental group	
	3 $\mu\text{m}$	6 $\mu\text{m}$	3 $\mu\text{m}$	6 $\mu\text{m}$
I	0.0037	0.0041	0.0036	0.0048
II	0.0027	0.0029	0.0041	0.0054
S	$\pm 0.0003$		$\pm 0.0005$	

S = Average standard error of individual mean

TABLE 7 Means of B (the intercept for the slower phase) obtained from profile scanning measurements

Exposure	Control group		Experimental group	
	3 $\mu\text{m}$	6 $\mu\text{m}$	3 $\mu\text{m}$	6 $\mu\text{m}$
I	59	40	64	37
II	58	31	63	42
S	$\pm 4$		$\pm 5$	

S = Average standard error of individual mean

TABLE 8 Means of  $\beta_w$  coefficients obtained from whole body measurements

Exposure	Control group	Experimental group
	3 $\mu\text{m}$	3 $\mu\text{m}$
I	0.0012	0.0017
II	0.0013	0.0016
S	$\pm 0.0001$	

S = Average standard error of individual mean





Fig 53 (A) Mean and individual lung clearance curves for the control rabbits after the first aerosol exposure obtained by profile scanning (B) Mean and individual curves of the slower phase of lung clearance for the same animals obtained by whole body measurement

the different phases. However since the rate of mucociliary transport is relatively rapid (84) this should be the clearance mechanism that is chiefly responsible for the rapid initial elimination of the aerosols deposited in the related parts of the respiratory tract and thus represented by the intercept (A) of the first term in the mathematical function used. The study of retention (pp 24-31) supports this assumption as it indicates that the alveolar clearance mechanisms do not play a significant part in the initial phase; thus the retention recorded in the peripheral parts of the lung did not change appreciably during the first 72 hours.






Fig 54 Mean and individual slopes for the different phases of lung clearance in the control rabbits after the first test aerosol exposure. Upper diagram: The first phase obtained by profile scanning. Middle diagram: The second phase obtained by profile scanning. Lower diagram: The second phase obtained by whole body measurement. Note the differences in the time scales.

It is more difficult to relate the slower phase of clearance to particular mechanisms even if, as a consequence of the discussion on the first phase, these should be found in nonciliated regions. Further experimental studies are required for this as well as to

determine whether Brägger (15) is correct in stating that "the early rapid clearance is not limited to removal of bronchial deposits as Collet has suggested"

### *Intra and inter individual variations*

It will be seen from the data presented above that there is considerable variation between individual animals. It would be interesting to know whether this variation is essentially conditioned by characteristics of the individual expressed as a certain stability in the course of clearance at different times. This individual consistency can be estimated by analysing the relationship between the "inter rabbit" and the "intra rabbit" variability. It should however be noted that in this type of experimental design the "intra rabbit variability" cannot be distinguished from the experimental error. Under the circumstances it is nevertheless the closest measure obtainable of the "intra rabbit variation". In the case of the alpha coefficient for the experimental group the "inter rabbit variation" was greater ( $p < 0.001$ ) than the estimated experimental error. For the alpha constant in the control group the relationship bordered on significance ( $0.10 > p > 0.05$ ). In the case of the beta coefficient the difference was significant in the experimental group ( $0.05 > p > 0.01$ ) but not in the control group. Although the results were not significant throughout it can be considered that the present experimental design is preferable to a direct inter group comparison without allowing for the preexposure values of each group.

In a previous study in rabbits with  $4 \mu\text{m}$  n-octadecanol particles the author (53) was not able to find any larger inter than intra individual variations. This may have been due to the larger initial retention (mg) in these

rabbits. In studies concerning the "alveolar clearance" of submicronic iron oxide particles, Gibb & Morrow (38) found good reproducibility of the mean biological half time in a group of six dogs re-exposed 6 months after the first exposure. The standard deviation for data from the first exposure was 5 % and for data from the second exposure 25 %.

### *Significance of particle size*

#### *Clearance of different sizes of particle*

The difference in the course of clearance between 3 and  $6 \mu\text{m}$  particles obtained by the profile scanning technique is shown in Fig. 55 which gives the regression line for the mean values of the control group and the exposed group before exposure to  $\text{SO}_2$ .

An analysis of variance was performed on the combined results for the experimental and control animals. The differences in the alpha constant bordered on significance ( $0.10 > p > 0.05$ ) and those in the beta constant were significant ( $0.05 > p > 0.01$ ).

The results show that the difference observed is partly ascribable to differences in the rate of clearance for the different sizes of particles (as expressed in differences in alpha and beta constants) but that other factors are also involved. Thus the fact that the initial clearance of  $6 \mu\text{m}$  particles is greater than that of  $3 \mu\text{m}$  particles seems to be largely ascribable to a larger amount of the former being deposited in the tracheo-bronchial parts of the respiratory tract which agrees with the results reported in Chapter 3. As far as the initial phase is concerned the result agrees with reports that there is no difference in the rate of transport of different sized particles applied directly to the trachea (4). The differences in lung clearance patterns for the particles used was 10 be





Fig 55 The simultaneous lung clearance of 3 and 6  $\mu\text{m}$  polystyrene particles during the first 150 hours after exposure Upper diagram Regression curves of means for the animals in the control group Lower diagram Regression curves of means for the animals in the experimental group The figure shows the difference in lung clearance between the two particle sizes

expected in the light of data already referred to from the literature (cf p 11) although except by the author (54) no investigations had been made earlier either with mono disperse aerosols or simultaneously in one and the same animal with two different monodisperse particle sizes

#### *Correlation between regression parameters for different particle sizes*

In spite of differences in deposition and clearance rates between the different sized particles it has already been noted that there

is reason to suppose that the same mechanisms in principle are responsible for the clearance of both sizes If this is the case one would expect to find a correlation between  $\alpha_p$  for 3 and 6  $\mu\text{m}$  as well as between  $\beta_p$  for the two sizes in the same animal

The correlations obtained for  $\alpha_p$  and  $\beta_p$  are shown in Fig 56 A and B The product moment correlation coefficient for  $\alpha_p$  was 0.77 ( $p < 0.001$ ) in a one sided test for  $\beta_p$  it was 0.49 ( $0.05 > p > 0.01$ )

These correlations show that there is good agreement between the two sizes concerning the rate of both the initial and the later phase of clearance

#### *Correlation between different phases of clearance*

A further question is whether or not there is a correlation between the rapid and slower phases of clearance as expressed in  $\alpha_p$  and  $\beta_p$  coefficients The existence of such a relationship would indicate the presence of a factor common to both clearance mechanisms The product moment correlation between  $\alpha_p$  and  $\beta_p$  was 0.61 ( $0.05 > p > 0.01$ ) for 3  $\mu\text{m}$  particles in a two sided test the correlation was not significant ( $r = 0.26$ ) for 6  $\mu\text{m}$  particles (Fig 56 C and D)

#### *Clearance after exposure to sulphur dioxide*

The situation before and after exposure to  $\text{SO}_2$  is illustrated in Fig 57 which shows the mean curves of lung clearance for the 3 and 6  $\mu\text{m}$  particles obtained by the profile scanning for both the control and experimental groups The pre and postexposure data for each animal were compared to determine the effect of  $\text{SO}_2$  exposure The differences between these data were then subjected in an




Fig. 6. Comparison of data obtained after the first test aerosol exposure in the control and experimental groups. The correlation was studied between (A) the  $\alpha$  coefficients for 6 and 3  $\mu$ m polystyrene particles ( $r=0.77$ ,  $p<0.001$ ), (B) the  $\beta$  coefficients for the same particle sizes ( $r=0.49$ ,  $0.05 > p > 0.01$ ), (C) the  $\alpha$  coefficients for the 3  $\mu$ m particles ( $r=0.061$ ,  $0.03 > p > 0.01$ ) and (D)  $\beta$  coefficients for the 6  $\mu$ m particles ( $r=0.26$ ).

analysis of the two particle sizes being tested independently. A comparison between control and experimental groups showed no significant difference with respect to the  $\alpha$  coefficient for both sized particles. A significant difference ( $0.05 > p > 0.01$ ) was demonstrated for the  $\beta_p$  in the clearance of 3  $\mu$ m particles (Fig. 58). A similar trend was found for the  $\beta_p$  of the 6  $\mu$ m particles. The differences found were ascribable in part to an increase in the  $\beta_p$  constant in the

exposed group and partly to a decrease in the control group. It is clear that a knowledge of changes in the control group was essential in determining the effects of  $SO_2$  in the experimental group. This emphasizes the necessity of studying both control and experimental groups before as well as after exposure.

An analysis of variation of the  $\beta_p$  constant for the control and experimental groups showed a significant difference for the 3  $\mu$ m particles during the first 30 days of exposure.




Fig 57 The regression curves of mean lung clearance values for 3 and 6  $\mu$ m polystyrene particles (control and experimental groups) before and after SO<sub>2</sub> exposure

but no such differences could be found for the period between the 40th and the 70th day of exposure to SO<sub>2</sub> (Fig 59)

The study shows that SO<sub>2</sub> (10 ppm—16 hours per day) accelerates the slower phase of lung clearance of 3  $\mu$ m polystyrene particles during the first 6 weeks. This effect diminished during the next 4 weeks. Although the mechanisms of lung clearance affected by the SO<sub>2</sub> exposure remain obscure, the initially increased rate of secondary phase of clearance of 3  $\mu$ m and 6  $\mu$ m particles indicates that the effect is more pronounced at the pulmonary level. As increased secretion is an early manifestation of inflammation and it has been demonstrated that pulmonary oedema in inflamed lung increases particle removal (47), such a mechanism may be responsible for the in-

creased rate of lung clearance reported here. Subsequent inflammatory changes, i.e. epithelial proliferation with crypt formation and changes in the characteristics of the secretion have been demonstrated by Dalhamn to reduce the rate of secretory transport (25). These changes could explain the decrease in clearance observed during the 6—10 week period.

The changes in lung clearance observed here are essentially in agreement with those reported by Vyskocil *et al* (102), which showed a significant increase in the rate of lung clearance of quartz dust in rabbits after exposure for one month to 50% sulphuric acid aerosol and a decrease (though not significant) after exposure for one year. The histological effects were more pronounced



Before SO<sub>2</sub> exposure

After SO<sub>2</sub> exposure

— Individual slopes exposed group  
 — Individual slopes control  
 — Mean slopes exposed  
 — Mean slopes control

Percentage of intercept value




Fig 58 Mean and individual slopes for the second phase of lung clearance of 6 and 3  $\mu\text{m}$  polystyrene particles (control and experimental groups) obtained from the profile scannings before and after SO<sub>2</sub> exposure

at alveolar level than in the trachea after one year Schlipkoter & Brockman (88) also used the classical method on sacrificed animals and found that the elimination of SiO<sub>2</sub> dust was decreased in rats which were exposed to SO<sub>2</sub> gas for one month prior to and one

month after the dust exposure The different result may be explained by differences in the animals and particle materials as well as by different intensities of exposure — continuous contra 16 hours a day




Fig 59 Mean and individual slopes for the second phase of lung clearance of 3  $\mu$ m polystyrene particles (control and experimental groups) obtained from the whole-body countings during the first 30 days and between the 40th and 70th day of SO<sub>2</sub> exposure

## GENERAL DISCUSSION

The investigations presented in this study show that measurement of the retention of radioactively tagged aerosols in the lungs by means of profile scanning can be applied to the study of the clearance of such particles from the lung. The area of the lung scan curves evaluated planimetrically in the manner described or by measurement of the peak height of the lung fraction can be used to determine the amount of retention of the particles in the lung.

One of the advantages of profile scanning is that compared with other techniques for external measurement it is less affected by changes in position of the activity within the volume being studied. Moreover, the method makes it possible to establish the time when the lung becomes the only organ containing a major proportion of the substance being investigated and hence the stage at which one is justified in measuring lung clearance by means of whole body counting. The two methods therefore make it possible to follow lung clearance from its initial phase through several months.

Translocation to or storage of a radioactive substance in the lymphatic system of the lungs cannot be detected by external measurement which can only be used to study the transport from the whole of the thorax. Although this limitation does exist there is no reason to expect any significant storage in the lymphatics of the lung unless the particles in question are highly cytotoxic.

The condensation and spinning disc meth-

ods used to produce monodisperse radioactively tagged ( $\text{Au}^{198}$  and  $\text{Sc}^{46}$ ) particles of n-octadecanol and polystyrene have been shown to be suitable for lung clearance studies with external measuring techniques.

The observed difference in the clearance of the different sized particles (3 and 6  $\mu\text{m}$ ) seems to be chiefly ascribable to differences in the depth of deposition. In part the difference was due to the fact that the larger particles were eliminated more during the initial phase of clearance because they were deposited to a greater extent on the ciliated epithelium. But the difference was also due to the rate of clearance for the secondary phase being faster for the larger particles than for the smaller ones. A similar though not definitely significant difference was also found for the initial phase. Different clearance rates for 6 and 3  $\mu\text{m}$  particles were demonstrated both by the clearance studies and by the study of the retention of monodisperse particles at different levels in the lung. The latter study showed that the larger particles were deposited more in the trachea and bronchi than the smaller ones. The findings also indicated that the amount of initial retention of both particle sizes in the pulmonary region remains essentially unchanged during the first 72 hours. The rate of elimination for both sized particles increased successively from the periphery of the lung towards the trachea, the increase being greater for the larger particles both quantitatively and on a percentage basis.

The different rates of clearance for 3 and

6  $\mu\text{m}$  particles during the slower phase cannot be explained by the studies performed though the study of the phagocytosis of polystyrene particles by lung macrophages in vitro indicated that the 3  $\mu\text{m}$  particles were phagocytosed to a greater extent than the 6  $\mu\text{m}$  particles. This may be an indication that the smaller particles are affected by phagocytosis at the non ciliated parts of the lung in a way that reduces their clearance rates. One possibility for this is that the alveolar lining cells per se are phagocytic.

The intra and inter individual variations demonstrated emphasize the advantage of evaluating the clearance of different particle sizes simultaneously in the same animal since this keeps both the time factor and the biological variations under control. It also points to the desirability of making comparative experiments on both control and experimental animals before as well as after exposure to the substance being investigated. This design used to study the effect of  $\text{SO}_2$  (10 ppm—16 hours a day during ca 10 weeks) on lung clearance of 6 and 3  $\mu\text{m}$

particles showed no effect on the initial phase of clearance after 5 weeks of  $\text{SO}_2$  exposure but an accelerating effect on the slower phase for the 3 and the 6  $\mu\text{m}$  particles during the first 6 weeks of  $\text{SO}_2$  exposure. This effect on the slower phase was diminished by exposure beyond 6 weeks. The results suggest that the initial effects of  $\text{SO}_2$  on lung clearance are more pronounced at the pulmonary than the tracheo bronchial level.

An experimental design using two particle sizes one being more tracheo-bronchial and the other more pulmonary in deposition can thus be used to determine the site of action of the agents on lung clearance. Furthermore the use of two different tagged monodisperse particles e.g. one highly and the other slightly susceptible to phagocytosis can be of value for studying the relative importance of various mechanisms involved in total lung clearance. Evaluating the changes in clearance of different test aerosols by stimulating or blocking individual components might provide valuable complementary data in such studies.

## GENERAL DISCUSSION

The investigations presented in this study show that measurement of the retention of radioactively tagged aerosols in the lungs by means of profile scanning can be applied to the study of the clearance of such particles from the lung. The area of the lung scan curves evaluated planimetrically in the manner described or by measurement of the peak height of the lung fraction can be used to determine the amount of retention of the particles in the lung.

One of the advantages of profile scanning is that, compared with other techniques for external measurement it is less affected by changes in position of the activity within the volume being studied. Moreover the method makes it possible to establish the time when the lung becomes the only organ containing a major proportion of the substance being investigated and hence the stage at which one is justified in measuring lung clearance by means of whole body counting. The two methods therefore make it possible to follow lung clearance from its initial phase through several months.

Translocation to or storage of a radioactive substance in the lymphatic system of the lungs cannot be detected by external measurement which can only be used to study the transport from the whole of the thorax. Although this limitation does exist there is no reason to expect any significant storage in the lymphatics of the lung unless the particles in question are highly cytotoxic.

The condensation and spinning disc meth-

ods used to produce monodisperse radioactively tagged ( $\text{Au}^{198}$  and  $\text{Sc}^{46}$ ) particles of n-octadecanol and polystyrene have been shown to be suitable for lung clearance studies with external measuring techniques.

The observed difference in the clearance of the different sized particles (3 and 6  $\mu\text{m}$ ) seems to be chiefly ascribable to differences in the depth of deposition. In part the difference was due to the fact that the larger particles were eliminated more during the initial phase of clearance because they were deposited to a greater extent on the ciliated epithelium. But the difference was also due to the rate of clearance for the secondary phase being faster for the larger particles than for the smaller ones. A similar though not definitely significant difference was also found for the initial phase. Different clearance rates for 6 and 3  $\mu\text{m}$  particles were demonstrated both by the clearance studies and by the study of the retention of monodisperse particles at different levels in the lung. The latter study showed that the larger particles were deposited more in the trachea and bronchi than the smaller ones. The findings also indicated that the amount of initial retention of both particle sizes in the pulmonary region remains essentially unchanged during the first 72 hours. The rate of elimination for both sized particles increased successively from the periphery of the lung towards the trachea the increase being greater for the larger particles both quantitatively and on a percentage basis.

The different rates of clearance for 3 and

ticles did not differ significantly from each other. The second slower phase, however, was faster for the larger particles. For the two particle sizes there was a correlation between their rates of clearance in the first and second phase. A correlation was also found between the rates of clearance in the first and second clearance phase for the 3  $\mu$ m particles.

The question whether the lung clearance rate was influenced by individual components was studied by comparing the intra- and interindividual variations by means of an analysis of variance.

The results showed that for the two clearance phases the interindividual variations were significantly greater than the estimated experimental error in one of the groups. In the other group this relationship bordered on significance for the first clearance phase while no significance was found for the second phase.

The effect of  $\text{SO}_2$  (10 ppm—16 hours a day during ca. 10 weeks) on lung clearance of a dispersed aerosol (6 and 3  $\mu$ m particles) was evaluated by comparing the exposed with the control group. No effect was seen on the first phase during 5 weeks of  $\text{SO}_2$  exposure. An accelerating effect was, however, observed during the first six weeks of the slower phase of the 3  $\mu$ m particles and the 6  $\mu$ m particles. Prolonged exposure—more than 6 weeks—diminished this effect on the slower phase.

In order to further elucidate the possible difference in retention between the different particle sizes the retentions of the monodisperse 3 and 6  $\mu$ m particle sizes were com-

pared at different levels of the lung and at different times after exposure using a new technique based on scalar measurements on selected specimens cut out from formalin-fixed and air-dried lung preparations. The findings indicate that the initial retentions of both particle sizes in the alveoli remain essentially unchanged during the first 72 hours. The larger particles were found to be deposited more in trachea and bronchi than the smaller ones. This study also demonstrates that the larger particles were eliminated more rapidly than the smaller ones from the lung. The rate of elimination for both sized particles increased successively from the periphery of the lung towards the trachea, the increase being greater for the larger particles both quantitatively and on a percentage basis.

In order to study whether the phagocytosis was notably different for different particle sizes—and also to what extent the phagocytosis of the polystyrene particles used differed from that of carbon particles—an experiment was performed according to the *in vitro* method introduced by Myrnes *et al.* measuring the extent to which 1.5  $\mu$ m carbon particles as well as 1.5, 3.0 and 6.0  $\mu$ m polystyrene particles underwent phagocytosis by rabbit lung macrophages. As for the particle sizes the results indicate that the smaller particles were more susceptible to phagocytosis than the larger ones. A comparison with carbon particles showed that these undergo phagocytosis to a considerably greater extent than do particles of polystyrene of equivalent size.

## ACKNOWLEDGEMENTS

This investigation was carried out at the Department of Hygiene at the Karolinska Institutet and the Department of Environmental Hygiene at the National Institute of Public Health

The publication of this study provides me with an opportunity of expressing my thanks to all those who have assisted me in various ways

Sincere gratitude is extended to Professor Lars Friberg M D head of the above mentioned departments not only for directing my attention to the study of the problems involved in the field of lung clearance but also for his never failing engagement in my work. Without his personal support and encouragement the present work would never have been completed

For interesting views on the subject under investigation for many stimulating discussions and skilled technical guidance I thank Anders Kajland Master of Physics, Department of Environmental Hygiene at the National Institute of Public Health who showed me never failing interest in my work.

I am also indebted to Rune Cederlof Ph D Associate Professor at the Department of Environmental Hygiene at the National Institute of Public Health for help with the statistical evaluation of the data

My thanks go to Lars Linnman Master of Chemistry for preparing the computer program and to Klas Philipson Bachelor of Science for help with the production of polystyrene particles and mathematical calculations as well as to Marie Louise Edfors Bachelor of Science for assistance during one part of my work.

One of my warmest thanks goes to my 1st laboratory assistant Mrs Margot Lundborg for unflagging interest and very skilful assistance in both the laboratory and administrative aspects of my work

My thanks are due to Mr Per Ake Hellstrom engineer for the construction and manufacture of equipment Lennart Tomenius Med Kand for assistance with the study of retention Misses Ulla Zetterlind and Bent Hansson laboratory assistants, and Mrs Ingegerd Brodie for drawing the figures

In the early stages of this work I had Mrs Margaretha Akesson as my 1st laboratory assistant and Mr Conny Sandholm as technical assistant To both of them I wish to express my thanks

For critical suggestions in the manuscript I thank Phil Hall M D Department of Medicine Western Reserve University Cleveland USA

My thanks also go to Mrs Britta Sahlin Head of the Typing Department at the National Institute of Public Health, and to her staff for never failing cooperation and to Mr Patrick Hort for his translation of this work

The financial support for this study has been provided by the US National Institute of Health, Division of Air Pollution (Grant No AP 00212) and by the Swedish Medical Research Council (Project No 26x 18) as well as by the Folksam's forskningsnämnd and by Gustav and Thyra Svensson's Minnesfond AB Atomenergi kindly placed premises at my disposal for the production of radioactive particles

# APPENDIX

TABLE 1 *Phagocytosis of polystyrene particles of different sizes*

Experiment Code symbols given in Table 7	Phago- cytes per sq. mm	Phagocyte particles			Phagocytes that performed phago- cytosis (%)	Particles phagocyto- sed in 15 hours (%)		
		1.5 $\mu$ m	3 $\mu$ m	6 $\mu$ m		1.5 $\mu$ m	3 $\mu$ m	6 $\mu$ m
A II	850		18		20		27	
	850		110		22		26	
	400		18		30		48	
	1280		15		24		54	
Mean	845		178		24		39	
A III	850	12		15	37	116		85
	850	12		15	33	136		45
	400	14		18	44	86		39
Mean	700	125		160	38	113		56
A IV	850	12	15	14	35	64	26	49
	850	12	17	14	40	135	22	20
	400	13	14	15	39	79	46	38
Mean	700	123	153	143	38	94	31	36
B II	1680		18		25		47	
	1250		16		36		110	
	1080		14		38		107	
Mean	1337		160		33		88	
B III	1450	12		12	27	142		54
	1450	12		12	29	184		63
	1680	11		14	31	201		75
	850	15		15	29	74		50
	1080	13		12	37	170		42
Mean	1306	126		130	31	154		57



Experiment Code symbols given in Table 2	Phago- cytes per sq mm	Phagocyte particles			Phagocytes that performed phago- cytosis (%)	Particles phagocyto- sed in 15 hours (%)		
		15 $\mu$ m	3 $\mu$ m	6 $\mu$ m		15 $\mu$ m	3 $\mu$ m	6 $\mu$ m
B IV	1450	12	16	12	35	119	62	21
	1450	12	16	12	46	188	61	56
	1680	14	15	13	35	74	35	39
	1080	15	15	13	39	89	34	34
	1250	12	16	14	44	127	81	48
Mean	1386	130	156	129	40	119	55	40
C II	1190		15		23		68	
	950		17		22		50	
	470		112		36		44	
Mean	870		180		27		54	
C III	950	14		14	30	129		22
	470	16		18	39	77		24
	1190	12		13	44	229		98
	950	17		16	30	66		06
Mean	890	148		153	36	125		38
C IV	1190	12	12	13	24	77	57	14
	950	12	13	12	30	101	45	07
Mean	1070	12	125	125	27	89	51	11
D IV	1190	12	12	13	23	67	70	17
	950	12	13	15	35	124	62	12
	470	17	14	17	46	110	71	35
	1680	13	14	14	45	130	38	25
Mean	1073	123	133	148	37	108	60	22
E I*	1480	18			92			
	400	123			89			
	850	162			100			
	850	133			92			
	400	178			98			
Mean	756	1308			942			

\* Particle size 0.5—2.5  $\mu$ m

TABLE 2 Code to Table 1 for particle sizes and combinations in the study of phagocytosis

A II = 3 $\mu$ m	polystyrene particles untagged
A III = 1.5 and 6 $\mu$ m	polystyrene particles untagged
A IV = 1.5, 3 and 6 $\mu$ m	polystyrene particles untagged
B II = 3 $\mu$ m	polystyrene particles tagged with Sc
B III = 1.5 and 6 $\mu$ m	polystyrene particles tagged with Au
B IV = $\begin{cases} 3 \mu\text{m} \\ 1.5 \text{ and } 6 \mu\text{m} \end{cases}$	$\begin{cases} \text{polystyrene particles tagged with Sc} \\ \text{polystyrene particles tagged with Au} \end{cases}$
C II = 3 $\mu$ m	polystyrene particles tagged with Sc <sup>45</sup>
C III = 1.5 and 6 $\mu$ m	polystyrene particles tagged with Au <sup>199</sup>
C IV = $\begin{cases} 3 \mu\text{m} \\ 1.5 \text{ and } 6 \mu\text{m} \end{cases}$	$\begin{cases} \text{polystyrene particles tagged with Sc}^{45} \\ \text{polystyrene particles tagged with Au}^{199} \end{cases}$
D IV = 1.5, 3 and 6 $\mu$ m	polystyrene particles tagged with Sc <sup>45</sup>
E I = 0.5–2.5 $\mu$ m	carbon particles

TABLE 3 Data concerning the lung clearance of 3 and 6  $\mu\text{m}$  CMD polystyrene particles for the experimental group after the first test aerosol exposure

Rabbit no	Initial radioactivity ( $\mu\text{C}$ )		Initial retention ( $\mu\text{g}$ )		First phase of lung clearance				Second phase of lung clearance			
					% of initial retention (A)*		Half lives in hours		% of initial retention (B)*		Half lives in hours	
	$5 \times 10^4$	Au <sup>199</sup>	3 $\mu\text{m}$	6 $\mu\text{m}$	3 $\mu\text{m}$	6 $\mu\text{m}$	3 $\mu\text{m}$	6 $\mu\text{m}$	3 $\mu\text{m}$	6 $\mu\text{m}$	3 $\mu\text{m}$	6 $\mu\text{m}$
1	0.5	7.8	0.1	8.8	30.2	48.2	13.9	11	69.8	51.8	253	161
2	0.4	6.0	0.1	4.4	25.5	52.6	3.5	11	75.4	47.4	284	155
3	0.7	3.9	0.1	3.0	40.1	62.7	1.3	11	59.9	37.3	235	131
4	0.2	6.9	0.1	6.6	52.0	75.5	2.8	17	52.2	24.5	207	277
5	0.4	4.9	0.1	4.9	41.9	59.0	1.3	11	58.1	41.0	174	100
6	1.1	11.6	1.2	2.9	25.0	59.9	4.6	25	75.0	40.1	299	151
7	0.5	7.0	1.0	3.1	40.9	70.2	0.9	12	59.1	29.8	117	91
8	0.2	2.1	0.5	1.3	44.9	73.6	2.6	17	55.1	26.4	124	159
Mean	0.5	6.3	0.4	4.4	37.6	62.7	3.8	19	63.1	37.3	212	151

\* A and B = Intercept for the first and second phase respectively

TABLE 4 Data concerning the lung clearance of 3 and 6  $\mu$ m CMD polystyrene particles for the control group after the first test aerosol exposure

Rabbit no	Initial radioactivity ( $\mu$ c)		Initial retention ( $\mu$ g)		First phase of lung clearance				Second phase of lung clearance			
					% of initial retention		Half lives in hours		% of initial retention		Half lives in hours	
	$S_{c-10}$	$A_{1000}$	3 $\mu$ m	6 $\mu$ m	3 $\mu$ m	6 $\mu$ m	3 $\mu$ m	6 $\mu$ m	3 $\mu$ m	6 $\mu$ m	3 $\mu$ m	6 $\mu$ m
11	1.2	19.9	0.7	3.17	37.7	37.2	1.8	1.8	6.3	42.8	1.69	1.69
12	1.3	14.6	0.8	3.10	25.0	16.5	3.2	2.0	75.0	53.5	2.55	2.10
13	0.5	4.1	0.3	6.8	49.3	55.8	1.7	1.7	50.7	14.2	1.69	1.87
14	0.6	5.0	0.3	10.5	56.7	68.2	1.5	2.2	49.3	31.8	1.82	1.17
15	0.6	8.7	0.3	18.6	43.1	61.6	0.8	0.7	56.9	35.1	1.6	1.41
16	0.7	3.4	0.7	6.8	38.2	64.5	1.1	1.2	61.8	35.5	1.69	2.17
17	0.9	18.0	0.9	45.8	27.0	70.7	1.9	1.6	73.0	39.3	2.10	1.54
18	1.5	23.2	1.6	21.2	31.9	72.7	1.5	1.4	68.1	27.3	2.99	1.11
Mean	0.9	12.2	0.7	22.3	38.6	61.3	1.7	1.6	62.1	38.7	2.05	1.71

\*  $\Lambda$  and  $H$  = Intercept for the first and second phase respectively

TABLE 5. Data concerning the lung clearance of 3 and 6  $\mu\text{m}$  CND polystyrene particles for the experimental group after the second test-irradiation exposure

Rabbit no	Initial radioactivity ( $\mu\text{C}$ )		Initial retention ( $\mu\text{R}$ )		First phase of lung clearance				Second phase of lung clearance			
					% of initial retention ( $\Delta$ ) <sup>a</sup>		Half lives in hours		% of initial retention ( $\Pi$ ) <sup>a</sup>		Half lives in hours	
	$6.46$	$\Delta \times 10^3$	3 $\mu\text{m}$	6 $\mu\text{m}$	3 $\mu\text{m}$	6 $\mu\text{m}$	3 $\mu\text{m}$	6 $\mu\text{m}$	3 $\mu\text{m}$	6 $\mu\text{m}$	3 $\mu\text{m}$	6 $\mu\text{m}$
1	13	189	10	327	298	465	99	63	712	535	118	111
2	10	57	08	103	410	315	08	14	560	195	152	198
3	08	199	04	122	461	634	11	15	759	366	20	179
4	15	200	15	160	250	426	139	15	750	571	169	159
5	—	—	—	—	—	—	—	—	—	—	—	—
6	19	204	09	173	550	902	58	28	150	198	275	143
7	11	190	21	31	506	623	07	05	191	377	131	91
8	17	197	19	318	276	593	30	25	721	117	155	173
Mean	14	181	13	181	367	578	50	24	653	122	161	140

<sup>a</sup>  $\Delta$  and  $\Pi$  = Intercept for the first and second phase respectively

TABLE 6 Data concerning the lung clearance of 3 and 6  $\mu\text{m}$  CMI polystyrene particles for the control group after the second test aerosol exposure

Rabbit no	Initial radioactivity ( $\mu\text{C}$ )		Initial retention ( $\mu\text{g}$ )		First phase of lung clearance				Second phase of lung clearance			
					% of initial retention (A)*		Half lives in hours		% of initial retention (B)*		Half lives in hours	
	$3\ \mu\text{m}$	$6\ \mu\text{m}$	$3\ \mu\text{m}$	$6\ \mu\text{m}$	$3\ \mu\text{m}$	$6\ \mu\text{m}$	$3\ \mu\text{m}$	$6\ \mu\text{m}$	$3\ \mu\text{m}$	$6\ \mu\text{m}$	$3\ \mu\text{m}$	$6\ \mu\text{m}$
11	12	19.0	0.7	10.2	34.4	47.7	2.4	1.8	65.6	32.3	332	300
12	12	17.4	0.7	9.7	39.7	36.7	1.2	1.1	60.3	63.3	226	180
13	13	19.0	0.7	12.3	62.1	59.3	1.1	1.0	37.9	40.7	250	247
14	14	20.4	0.8	11.4	54.0	69.1	0.9	1.1	46.0	30.9	238	278
15	19	19.2	1.1	18.4	33.2	43.8	1.3	1.1	66.8	56.2	218	233
16	13	17.4	0.9	15.9	32.1	36.8	4.7	1.9	67.9	63.2	578	365
17	14	18.1	0.8	19.7	35.9	46.5	2.7	2.4	64.1	53.5	206	175
Mean	14	18.6	0.8	14.4	41.6	48.6	2.0	1.5	58.4	51.4	293	254

\* A and B = Intercept for the first and second phase respectively

# REFERENCES

- 1 ALBERT R E and ARNETT L C Clearance of radioactive dust from the human lung A M A Arch Industr Health 12 99 1955
- 2 ALBERT R E SALAM A S and PETROW H Clearance of radioactive particles in man Techniques for preparation of particles XIVth International Congress of Occupational Health International Congress Series No 62 Vol II p 526 Excerpta Medica Foundation Madrid 1963
- 3 ALBERT R E PETROW H G SALAM A S and SPIEGELMAN J R Fabrication of monodisperse lucite and iron oxide particles with a spinning disk generator Health Phys 10 933 1964
- 3a ALBERT R E, LIPPMANN M SPIEGELMAN J LIUZZI A and NELSON N The deposition and clearance of radioactive particles in the human lung Arch Environ Health 14 10 1967
- 4 ANTWEILER H von Über die Funktion des Flimmerepithels der Luftwege ins besondere unter Staubbelastung Beitr Si likoseforsch 3 509 1958
- 5 BAIR, W J TEMPLE L A WILLARD D H TERRY J L and GRAYBEAL A Deposition and retention of Ru<sup>106</sup>O<sub>2</sub> following administration of Ru<sup>106</sup>O<sub>2</sub> to mice by inhalation and intratracheal injection Document HW 52285 1957
- 6 BAIR W J Translocation and excretion of pulmonary deposited plutonium oxide Document HW 46636 1958
- 7 BAIR W J Deposition retention translocation and excretion of radioactive particles In Inhaled Particles and Vapours 197 C N Davies (ed) Pergamon Press Oxford 1961
- 8 BAIR W J WILLARD D H and TEMPLE L A The behavior of inhaled Ru<sup>106</sup>O<sub>2</sub> particles.- Document HW 64139 1960
- 9 BAIR W J and WILLARD D H Plutonium inhalation studies III Effect of particle size and total dose on retention and translocation Document HW 68845 1961
- 10 BAIR W J and HENNACY R A Removing inhaled radioactive particles Document HW 72500 1961
- 11 BAIR W J and DILLEY J V Pulmonary clearance of <sup>59</sup>Fe<sub>2</sub>O<sub>3</sub> and <sup>81</sup>Cr<sub>2</sub>O<sub>3</sub> in rats and dogs exposed to cigarette smoke (a) Second International Symposium on Inhaled Particles and Vapours Cambridge 28 Sept to 1 Oct 1965 Pergamon Press Oxford
- 12 BARCLAY A E and FRANKLIN K J The rate of excretion of indian ink, injected into the lungs J Physiol 90 482 1937
- 13 BERKE H L and DiPASQUA A C The distribution and excretion of polonium<sup>210</sup> after inhalation Document UR 495 University of Rochester NY 1957
- 14 BRIEGER H and LaBELLE C W The fate of inhaled particulates in the early postexposure period A M A Arch Industr Health 19 510 1959
- 15 BRIEGER H The fate of inhaled particles Arch Environ Health 8 57 1963
- 16 CARLETON H M The pulmonary lesions produced by the inhalation of dust in guinea pigs J Hyg 22 439 1923
- 17 CASARETT L J Deposition retention and fate of inhaled polonium 210 in rats Document UR 552 University of Rochester NY 1959
- 18 CASARETT L J Mechanism of clearance of inhaled particulates from the lung U S Atom Energy Comm Washington 1023 137 1959
- 19 CASARETT L J and MILLEY M S

- Alveolar reactivity following inhalation of particles *Health Phys* 10 1003 1964
- 20 CEMBER H HATCH T F., WATSON J A. and GRUCCI T Pulmonary effects from radioactive barium sulfate dust. *A M A Arch Industr Health* 12 628 1955
  - 21 CEMBER H HATCH T F., WATSON J A GRUCCI T and BELL, M The elimination of radioactive barium sulfate particles from the lung *A M A Arch Industr Health* 13 170 1956
  - 22 CEMBER H WATSON J A and GRUCCI T M Pulmonary radiation effects as a function of absorbed energy distribution *Amer Industr Hyg Ass Q* 17 397 1956
  - 23 CEMBER H WATSON J A and NOVAK, M E The influence of radioactivity and lung burden on the pulmonary clearance rate of barium sulfate *Amer Industr Hyg Ass J* 27 27 1961
  - 24 CONROE J H Jr Physiology of respiration Year Book Medical Publishers Inc., 1965
  - 25 DALHAMN T Mucous flow and ciliary activity in the trachea of healthy rats and rats exposed to respiratory irritant gases *Acta Physiol Scand* 36 Suppl 123 1956
  - 26 DALHAMN T The determination in vivo of the rate of ciliary beat in the trachea. *Acta Physiol Scand* 49 242 1960
  - 27 DALHAMN T., HOLMA B and TOME NIUS L In vitro studies of the cytotoxic action of ethanol vapour in relation to its concentration in tracheal tissue *Acta Pharmacol et Toxicol* 1967 (to be published)
  - 28 DAVIES C. N (ed.) Aerosol science Academic Press London 1966
  - 29 EDFORS M L FRIBERG L. HOLMA B and KAJLAND A A di-disperse octadecanol aerosol with nuclei of  $\text{Au}^{198}$  and  $\text{Sc}^{46}$  respectively XIVth International Congress of Occupational Health International Congress Series No 62 Vol II p 522 Excerpta Medica Foundation Madrid 1963
  - 30 ENGEL S Comparative anatomy and pulmonary cleansing mechanisms in man and certain experimental animals *Health Phys* 10 967 1964
  - 31 EWERT G On the mucus flow rate in the human nose *Acta Otolaryng Suppl* 200 1965
  - 32 FENN W O The phagocytosis of solid particles II Carbon *J Gen Physiol* 3 465 1921
  - 33 FERIN J Pulmonary clearance after deposition of aerosols Medical Works No V/1 Publishing House of the Slovak Academy of Sciences Bratislava 1966
  - 34 FISH M R Inhalation of uranium aerosols by mouse rat, dog and man In *Inhaled Particles and Vapours* p 151 C. N Davies (ed.) Pergamon Press Oxford 1961
  - 35 FLOREY H., CARLETON H M and WELLS A. Q Mucus secretion in the trachea *Brit J Exp Path.* 13 269 1932
  - 36 FRIBERG L and HOLMA B External measurement of lung clearance *Arch. Environ Health* 3 420 1961
  - 37 FRIEDBERG K. D and POLLEY H 9 Messung der Staubelimination in der Lunge und deren Beeinflussung im Tierexperiment *Beitr Silikoseforsch.* 3 129 1958
  - 38 GIBB F R. and MORROW P E. Alveolar clearance in dogs after inhalation of an iron 59 oxide aerosol *J Appl Physiol* 17 479 1962
  - 39 GIESEKAMP H Elektronenoptische Beobachtung der Stoffaufnahme in die Alveolarwand *Verh. Deutsch. Ges. Path.* 41 336 1957
  - 40 GREEN H L and LANE W R Particulate clouds Dusts smokes and mists H & F N Spon Ltd London 1957
  - 41 GREEN G M and KASS M H Mechanisms of resistance to bacterial infection in the lung Second International Symposium on Inhaled Particles and Vapours Cambridge 28 Sept to 1 Oct 1965 Pergamon Press Oxford.
  - 42 GROSS P The Mechanism of dust clearance from the lung A theory *Amer J Clin Path.* 23 116 1953
  - 43 GROSS P and WESTRICK, M The permeability of lung parenchyma to particulate matter *Amer J Path* 30 195 1954



- 44 GROSS P and HATCH T Pneumoconiosis The requirements for lymphatic dust transport *Int Arch Gewerbepath* 19 660 1962
- 45 HARPER G J and MORTON J D The respiratory retention of bacterial aerosols Experiments with radioactive spores *J Hyg* 51 372 1953
- 46 HATCH T Respiratory dust retention and elimination Proceedings of the Pneumoconiosis Conference Johannesburg p 113 1959 A J Orenstein (ed) J and A Churchill Ltd London 1960
- 47 HATCH T F and GROSS P Pulmonary deposition and retention of inhaled aerosols Academic Press New York 1964
- 48 HILDING A C Ciliary streaming in the bronchial tree and the time element in carcinogenesis *New Eng J Med* 256 634 1957
- 49 HILDING A C Ciliary streaming through the larynx and trachea *J Thorac Cardiovasc Surg* 37 108 1959
- 50 HILDING A C Experimental studies on some little understood aspects of the physiology of the respiratory tract and their clinical importance *Trans Amer Acad Otolaryng* 65 475 1961
- 51 HILDING A C and HILDING J A Tolerance of the respiratory mucous membrane to trauma Surgical swabs and intratracheal tubes *Ann Otolaryng* 71 453 1962
- 52 HILDING A C Phagocytosis mucous flow and ciliary action *Arch Environ Health* 8 61 1963
- 53 HOLMA B The intra and interindividual variations of lung clearance of a mono disperse n-octadecanol aerosol in rabbits XIVth International Congress of Occupational Health International Congress Series No 62 Vol II p 919 Excerpta Medica Foundation Madrid 1963
- 54 HOLMA B Short term lung clearance in rabbits exposed to a radioactive di disperse (6 and 3  $\mu$ ) polystyrene aerosol Second International Symposium on Inhaled Particles and Vapours Cambridge 28 Sept to 1 Oct 1965 Pergamon Press Oxford
- 55 JÖTTEN K W and MARWICK C van The phagocytosis of industrial dusts in tissue cultures *Brit J Industr Med* 9 173 1952
- 56 KAJLAND A EDFORS M L FRIBERG L and HOLMA B Radioactive mono disperse test aerosols and lung clearance studies *Health Phys* 10 941 1964
- 57 KLOSTERKÖTTER W von Tierexperimentelle Untersuchungen über die Gewebswirkung von feinkörnigem Gamma Aluminiumoxyd *Arch Hyg Bakt* 143 85 1959
- 58 KLOSTERKÖTTER W and BÜDEMANN G Animal experiments on the elimination of inhaled dust In *Inhaled Particles and Vapours* p 327 C N Davies (ed) Pergamon Press Oxford 1961
- 59 KLOSTERKÖTTER W von und EINBRODT H J 18 Untersuchungen über den Einfluss von Quarz auf die Retention Penetration und Elimination eines inerten Staubes In *Ergebnisse von Untersuchungen auf dem Gebiet der Staub und Silikosebekämpfung im Steinkohlenbergbau* Band 5 S 101 1965
- 60 KLOSTERKÖTTER W und EINBRODT H J Quantitative tierexperimentelle Untersuchungen über den Abtransport von Staub aus den Lungen in die regionalen Lymphknoten *Arch Hyg Bakt* 149 367 1965
- 61 KLOSTERKÖTTER W und EINBRODT H J Retention penetration and elimination of inhaled dusts Second International Symposium on Inhaled Particles and Vapours Cambridge 28 Sept to 1 Oct 1965 Pergamon Press Oxford
- 62 KORNBERG H A Effects of inhaled radioactive particles Report of the Subcommittee on Inhalation Hazards Committee on Pathologic Effects of Atomic Radiation Publication 848 National Academy of Sciences—National Research Council Washington D C 1961
- 63 KRENIS L J and STRAUSS B Effect of size and concentration of latex particles on respiration of human blood leucocytes *Proc Exp Biol Med* 107 748 1961
- 64 LABELLE C W and BRIEGER H Synergistic effects of aerosols II Effects on rate of clearance from the lung A M A

- Arch Industr Health 20 100 1959
- 65 LABELLE C W and BRIEGER H Pat  
terns and mechanisms in the elimination  
of dust from the lung In *Inhaled Partic-  
les and Vapours* p 356 C N Davies  
(ed) Pergamon Press Oxford 1961
  - 66 LABELLE C W BEVILACQUA M and  
BRIEGER H Synergistic effects of  
aerosols IV Therapeutic elimination of  
inhaled radioactive particles J Occup  
Med 10 391 1964
  - 67 MACKLIN C C Pulmonary sumps dust  
accumulations alveolar fluid and lymph  
vessels Acta Anat, 23 1 1955
  - 68 MARINELLI L D NORRIS W F GUS  
TAFSON P F and SPEARMAN T W  
Transport of radium sulfate from the lung  
and its elimination from the human body  
following single accidental exposures Ra-  
diology 61 903 1953
  - 69 MENDELHALL R M Pulmonary mecha-  
nics Some physical and biochemical fac-  
tors Arch Environ Health, 6 74 1963
  - 70 MENEELY G R AUERBACH S H  
WOODCOCK, C. C. KORY R C. and  
HAHN H F Transbronchial instillation  
of radioactive gold colloid in the lung of  
the dog Distribution studies survival and  
pathology Amer J Med Sci 222 172  
1953
  - 71 MORROW P E and DELLA ROSA R J  
The fate of polonium<sup>210</sup> colloid and  
polonium<sup>210</sup> tagged silver particles follow-  
ing intratracheal administration to rabbits  
Document UR 478 University of Roches-  
ter N Y 1956
  - 72 MORROW P E and GIBB F R The de-  
position of a submicronic aerosol in the  
respiratory tract of dogs Amer Industr  
Hyg Ass J 19 196 1958
  - 73 MORROW P E GIBB F R and JOHN-  
SON L Clearance of insoluble dust from  
the lower respiratory tract Health Phys  
10 543 1964
  - 74 MORROW P E, GIBB F R and GA-  
ZIOGLU K The clearance of dust from  
the lower respiratory tract of man An  
experimental study Second International  
Symposium on Inhaled Particles and Va-  
pours Cambridge 28 Sept to 1 Oct 1963  
Pergamon Press Oxford
  - 75 MORROW P E GIBB F R and LEACH  
L J The clearance of uranium dioxide  
dust from the lungs following single and  
multiple inhalation exposures Health  
Phys 12 1217 1966
  - 76 MUDD S McCUTCHEON M and  
LUCKE H Phagocytosis Physiol Rev  
14 210 1934
  - 77 MYRVIK, Q N LEAKE H S and FARISS  
H Studies on pulmonary alveolar mac-  
rophages from the normal rabbit A tech-  
nique to procure them in a high state of  
purity J Immun 86 128 1961
  - 78 NADEL J A and WIDDICOMBE J G  
Reflex effects of upper airway irritation  
on total lung resistance and blood pres-  
sure J Appl Physiol 17 861 1962
  - 79 PALM P E McNERNEY J M and  
HATCH T Respiratory dust retention  
in small animals A M A Arch Industr  
Health, 13 355 1956
  - 80 PINKETT M O, COWDREY C. R. and  
NOWELL P C Mixed hematopoietic  
and pulmonary origin of "alveolar mac-  
rophages" as demonstrated by chromo-  
some markers Amer J Path 48 839  
1966
  - 81 POLICARD A COLLET A and REUET  
NORMAND C Utilisation du chat dans  
l'etude experimentale des pneumoconioses  
Second International Symposium on In-  
haled Particles and Vapours Cambridge  
28 Sept to 1 Oct 1963 Pergamon Press  
Oxford
  - 82 Medical radioisotope scanning Proceedings  
of a seminar jointly organized by the In-  
ternational Atomic Energy Agency and the  
World Health Organization, Vienna 25—  
27 Febr 1959 IAEA, Vienna 1959
  - 83 RASCHE, H and ULMER, W T Reactions  
of alveolar phagocytes to aerosols during  
short time exposures to dust Second In-  
ternational Symposium on Inhaled Particles  
and Vapours Cambridge 28 Sept to 1 Oct  
1963 Pergamon Press Oxford
  - 84 RIVERA, J A Calia cultured epithelium,  
and ciliary activity Pergamon Press New  
York, 1962

- 44 GROSS P and HATCH T Pneumoconiosis The requirements for lymphatic dust transport. *Int Arch Gewerbepath* 19 660 1962
- 45 HARPER G J and MORTON J D The respiratory retention of bacterial aerosols Experiments with radioactive spores *J Hyg* 51 372 1953
- 46 HATCH T Respiratory dust retention and elimination Proceedings of the Pneumoconiosis Conference Johannesburg p 113 1959 A J Orenstein (ed) J and A Churchill Ltd London 1960
- 47 HATCH T F and GROSS P Pulmonary deposition and retention of inhaled aerosols Academic Press New York 1964
- 48 HILDING A C Ciliary streaming in the bronchial tree and the time element in carcinogenesis *New Eng J Med* 256 634 1957
- 49 HILDING A C Ciliary streaming through the larynx and trachea *J Thorac Cardiovasc Surg* 37 108 1959
- 50 HILDING A C Experimental studies on some little understood aspects of the physiology of the respiratory tract and their clinical importance *Trans Amer Acad Otolaryng* 65 475 1961
- 51 HILDING A C and HILDING J A Tolerance of the respiratory mucous membrane to trauma Surgical swabs and intratracheal tubes *Ann Otolaryng* 71 455 1962
- 52 HILDING A C Phagocytosis mucous flow and ciliary action *Arch Environ Health* 6 61 1963
- 53 HOLMA B The intra and interindividual variations of lung clearance of a mono-disperse n-octadecanol aerosol in rabbits XIVth International Congress of Occupational Health International Congress Series No 62 Vol II p 919 Excerpta Medica Foundation Madrid 1963
- 54 HOLMA B Short term lung clearance in rabbits exposed to a radioactive di-disperse (6 and 3  $\mu$ ) polystyrene aerosol Second International Symposium on Inhaled Particles and Vapours Cambridge 28 Sept to 1 Oct 1965 Pergamon Press Oxford
- 55 JÖTTEN A W and MARWICK C van The phagocytosis of industrial dusts in tissue cultures *Brit J Industr Med* 9 173 1952
- 56 KAJLAND A EDFORS M L FRIBERG L and HOLMA B Radioactive mono-disperse test aerosols and lung clearance studies *Health Phys* 10 941 1964
- 57 KLOSTERKÖTTER W von Tierexperimentelle Untersuchungen über die Gewebewirkung von feinkörnigem Gamma-Aluminiumoxyd *Arch Hyg Bakt* 143 85 1959
- 58 KLOSTERKÖTTER W and BÜNEMANN G Animal experiments on the elimination of inhaled dust In *Inhaled Particles and Vapours* p 327 C N Davies (ed) Pergamon Press Oxford 1961
- 59 KLOSTERKÖTTER W von und EINBRODT H J 18 Untersuchungen über den Einfluss von Quarz auf die Retention Penetration und Elimination eines inerten Staubes In *Ergebnisse von Untersuchungen auf dem Gebiet der Staub- und Silikosebekämpfung im Steinkohlenbergbau* Band 5 S 101 1965
- 60 KLOSTERKÖTTER W und EINBRODT H J Quantitative tierexperimentelle Untersuchungen über den Abtransport von Staub aus den Lungen in die regionalen Lymphknoten *Arch Hyg Bakt* 149 367 1965
- 61 KLOSTERKÖTTER W und EINBRODT H J Retention penetration and elimination of inhaled dusts Second International Symposium on Inhaled Particles and Vapours Cambridge 28 Sept to 1 Oct 1965 Pergamon Press Oxford
- 62 KORNBERG H A Effects of inhaled radioactive particles Report of the Subcommittee on Inhalation Hazards Committee on Pathologic Effects of Atomic Radiation Publication 848 National Academy of Sciences—National Research Council Washington D C 1961
- 63 KRENIS L J and STRAUSS B Effect of size and concentration of latex particles on respiration of human blood leucocytes *Proc Exp Biol Med* 107 748 1961
- 64 LABELLE C W and BRIEGER H Synergistic effects of aerosols II Effects on rate of clearance from the lung *A M A*





# ACTA MEDICA SCANDINAVICA

SUPPLEMENTUM 474

## ON EPIDEMIOLOGIC METHODS FOR RECORDING ISCHAEMIC HEART DISEASE

*by*

PER BJURULF, TORSTEN GARLIND AND  
NILS H STERNBY

---

LUND 1967

# ACTA MEDICA SCANDINAVICA

has been published since 1919 as a continuation of Nordiskt Medicinskt Arkiv founded in 1869 by Axel Key. The first volume of Acta Medica Scandinavica is therefore numbered LII (52).

The chief editors have been Axel Key 1869—1900 C. G. Santesson 1901—1915 I. Holmgren 1916—1957 and Birger Strandell 1958 to date.

Acta Medica Scandinavica publishes original research papers in the field of internal medicine. Priority will be given to authors from countries which are represented on the editorial board. Contributors from those countries should submit their papers to a representative of the country in question. Contributors from other countries should send their papers to the Editor at the address below.

Submission of a manuscript for publication will be held to imply that the paper has not been published elsewhere and that, if accepted, it will not be republished in any other journal in the same or similar form, without the Editor's written consent.

Papers will be published in English, French or German at the author's choice, followed by a summary in English.

The manuscripts shall be in final form as submitted. They shall be written with double spacing and broad left hand margin.

If a paper exceeds 16 printed pages, the cost for printing shall be borne by the author. No paper shall exceed 24 printed pages.

## Subscription

The annual subscription to the journal covers 12 numbers. In 1960 Sw. crowns or U.S. \$ 27.25 in Scandinavian countries and in Holland 120 Sw. crowns.

Address for subscriptions and all

ACTA MEDICA SCANDINAVICA

P.O. Box 2032, Stockholm

Requests for duplicate copies of numbers that have been considered if made within a fortnight of the receipt of the issue.

**ACTA MEDICA SCANDINAVICA**

**SUPPLEMENTUM 474**

**FROM THE DEPARTMENTS OF SOCIAL AND PREVENTIVE MEDICINE  
(HEAD PROF G LINDGREN) AND PATHOLOGY (HEAD PROF F LINELL)  
UNIVERSITY OF LUND GENERAL HOSPITAL, MALMÖ**

**ON EPIDEMIOLOGIC  
METHODS FOR RECORDING ISCHAEMIC  
HEART DISEASE**

**BY**

**PER BJURULF, TORSTEN GARLIND AND  
NILS H STERNBY**

**LUND 1967**



# ACTA MEDICA SCANDINAVICA

has been published since 1919 as a continuation of Nordiskt Medicinskt Arkiv, founded in 1869 by Axel Key. The first volume of Acta Medica Scandinavica is therefore numbered LII (52).

The chief editors have been Axel Key 1869—1900 C. G. Santesson 1901—1915 I. Holmgren 1916—1957 and Birger Strandell 1958 to date.

Acta Medica Scandinavica publishes original research papers in the field of internal medicine. Priority will be given to authors from countries which are represented on the editorial board. Contributors from those countries should submit their papers to a representative of the country in question. Contributors from other countries should send their papers to the Editor at the address below.

Submission of a manuscript for publication will be held to imply that the paper has not been published elsewhere and that, if accepted, it will not be republished in any other journal in the same or similar form, without the Editor's written consent.

Papers will be published in English, French or German at the authors' choice, followed by a summary in English.

The manuscripts shall be in final form as submitted. They shall be typewritten with double spacing and broad left-hand margin.

If a paper exceeds 16 printed pages, the cost for the excess pages shall be borne by the author. No paper shall exceed 24 printed pages.

## Subscription

The annual subscription to the journal, covering two volumes, each of 6 numbers, is 140 Sw. crowns or US \$ 27.25, including postage in the Scandinavian countries and in Holland 120 Sw. crowns.

*Address for subscriptions and all communications*

ACTA MEDICA SCANDINAVICA

P. O. Box 2052 Stockholm 2

---

Requests for duplicate copies of numbers that have gone astray can only be considered if made within a fortnight of the receipt of the following number.

# Contents

Introduction	5
Chapter I	<i>Prerequisites, material and representativity</i> 7
	Prerequisites 7
	Material 8
	Representativity 9
Chapter II	<i>Methods</i> 22
	Clinical data 22
	Post mortem data 24
	Statistical methods 24
Chapter III	<i>Anamnestic data of ischaemic heart disease and electrocardiographic recordings</i> 25
	Anamnestic ischaemic heart disease symptoms 25
	Definition of symptoms of ischaemic heart disease 25
	Distribution of typical and atypical symptoms 27
	Electrocardiographic changes 29
	Definition of electrocardiographic changes 29
	Relation between anamnestic symptoms of ischaemic heart disease and electrocardiographic changes 31
	Comments 36
Chapter IV	<i>Ischaemic heart disease demonstrated post mortem</i> 38
	Relation between lesions of coronary arteries and of myocardium 38
	Comments 41
Chapter V	<i>Relation between anamnestic symptoms and post mortem findings</i> 44
	Coronary and myocardial lesions in the absence of anamnestic symptoms of ischaemic heart disease 44
	Coronary and myocardial lesions in angina pectoris 48
	Coronary and myocardial lesions in different types of anamnestic symptoms of infarction 51
	Comments 52

Chapter VI	<i>Relation between electrocardiographic changes and post mortem evidence of ischaemic heart disease</i>	56
	Myocardial lesions in association with different types of electrocardiographic changes	56
	Previous electrocardiographic changes	57
	Recent electrocardiographic changes	59
Chapter VII	<i>Anamnesis and electrocardiogram in epidemiological diagnosis of ischaemic heart disease</i>	62
	The myocardium in subjects with agreement between anamnesis and electrocardiogram	62
	The myocardium in subjects with disagreement between anamnesis and electrocardiogram	65
	Comments	65
Chapter VIII	<i>Factors impairing sensitivity and specificity of the method</i>	67
	Group without symptoms of ischaemic heart disease but with post mortem evidence of infarction (silent infarction)	67
	Group with symptoms of ischaemic heart disease but without post mortem evidence of ischaemic heart disease	78
	Comments	83
Chapter IX	<i>Specificity sensitivity and validity of typical and atypical clinical symptoms and certain electrocardiographic criteria</i>	85
Chapter X	<i>General discussion and conclusions</i>	89
	Summary	95
	References	97

## Introduction

The clinical picture of angina pectoris and myocardial infarction is often unequivocal. It has however recently been realized that a fair number of cases run an atypical course (2). Thus the pain regarded as characteristic may vary considerably in site and intensity and in some instances there may be no symptoms at all (1, 2). This gives rise to problems in the recording of ischaemic heart disease (IHD) in epidemiological studies. For the uncharacteristic symptoms are sometimes difficult to distinguish from manifestations of other diseases of the chest and the upper part of the abdomen. Therefore if such symptoms are accepted as evidence of IHD it may result in other diseases to some extent being erroneously diagnosed as IHD.

These uncharacteristic symptoms were discussed by a study group appointed by WHO. It was decided by the group that a diagnosis of angina pectoris based on the broad definitions employed in clinical medicine—which aims at the diagnosis of 100 % of cases—would cover too many borderline or atypical cases to be con-

ducive to reproducible results in an epidemiological study (5). This study group thus feels that the atypical cases should not be accepted. In various questions and problems to be elucidated by epidemiological studies it is of interest to have a method capable of separating off one group in which most of the individuals really have a given disease e.g. IHD. The use of such a method however often implies that the group judged as not having IHD will include several cases with the disease. This, on the other hand, can have certain disadvantages when it is desired to separate off *also* a group as free as possible from IHD.

This stresses the importance of good knowledge of different qualities of the methods when adapting them for a given purpose. Of greatest importance then is the interplay between validity, precision, sensitivity, specificity and reproducibility (these terms are used in the sense defined by the above mentioned study group (3)).

The present knowledge of this interplay seems rather scanty and this was the reason why the present investigation was undertaken.

In this study we intended to assess the specificity and the sensitivity of recommended criteria regarding IHD and further how the acceptance of atypical symptoms as signs of IHD would affect these qualities of the diagnostic instrument

## Prerequisites, material and representativity

### Prerequisites

The ideal way to evaluate anamnestic symptoms and electrocardiographic changes in epidemiologic studies would be to select the series randomly from the living population. Such a sample would have to be large because of the fairly low incidence of IHD. The symptoms and signs should then be compared with the results of a method reflecting or directly demonstrating coronary and myocardial lesions. But most of the methods available for demonstrating and recording IHD *in vivo* are feasible in such a study still appear to have various inherent sources of error difficult to evaluate. This would limit the value of such an investigation. Demonstration of IHD with the accuracy desirable for the purpose in view thus still seems possible only in a post mortem series.

The most suitable method then would be a long term prospective study of a representative group examined at relatively short intervals for symptoms and signs of IHD. After death all the relevant findings made *intra vitam* should be compared with those made *post mortem*. But objections may be raised also against such a procedure. For instance it would

be difficult and probably not always possible to record the symptoms between the last follow up and death which may be a very informative period. Moreover such a procedure would require a high autopsy rate.

Investigations of this type are however, in progress in various parts of the world (2, 66, 67). Since most of these investigations have not yet been concluded and since the autopsy frequency has often been low the results hitherto obtained do not allow any generally valid conclusions.

In Malmö a town in the south of Sweden with some 250 000 inhabitants a prospective investigation of this type is planned as a link in a search for aetiological factors and as a basis for preventive measures. Such a combination is useful from a practical point of view. Malmö is well suited for such an investigation because it is a one hospital town and because such a high percentage of residents of Malmö dying there are autopsied. These were the chief reasons why WHO recommended Malmö for epidemiologic investigations.

When planning this prospective study it was however clear that the combination of search for aetiological factors and health survey in the same

study required thorough knowledge of the specificity and sensitivity of the criteria used. It was therefore decided to perform a retrospective investigation in an autopsy series from Malmö and then first assess the specificity and sensitivity of previously recommended criteria of IHD (3, 4, 5) and then in an attempt to increase the sensitivity of the diagnostic instrument add the so called atypical symptoms as mentioned in the introduction.

In such a retrospective investigation the autopsy frequency should be high and the examination technique and recording of the findings at autopsy should be really satisfactory especially concerning the heart and the vessels. Moreover hospital records should be detailed regarding the history of the heart and technically satisfactory electrocardiograms should be available in a high percentage of the cases.

To check whether these requirements could be satisfied in the planned series the hospital records of some 50 cases were selected at random from the total material. The information given in the hospital records proved sufficient to allow assessment of history of the heart in some 70 % of the random sample. Electrocardiography had been done in roughly equal percentage and as a rule with 12 leads including 3 standard leads (I, II and III), 3 unipolar limb leads (aVR, aVL and aVF) and 6 unipolar chest leads (V<sub>1</sub>, V<sub>2</sub>, V<sub>3</sub>, V<sub>4</sub>, V<sub>5</sub> and V<sub>6</sub> or V<sub>7</sub>). This was considered sufficient to warrant the retrospective investigation.

It should however, be emphasized that the anamnestic data obtained in this way are not comparable to information obtained by questionnaires regarding the possibility of standardization and inter individual comparability. This point is discussed further in the section on methods.

## Material

The material consisted of all residents of Malmö who had died between Jan 1 1961 and March 31, 1962. But since this group included fairly few subjects below 60 years the series was supplemented by corresponding subjects below 60 years during the period April 1, 1962 to September 30 1962. The entire series thus consisted of 2 880 subjects. The autopsy frequency and the number of cases in which clinical data were available are given in Tables 1 a and b, where the cases are grouped according to age and sex. Of the entire series 2 023 (70 %) were autopsied the frequency being lowest in the ages above 80 years. The death certificates of the 857 (30 %) subjects who had not been autopsied were studied and the causes of death noted are discussed in association with the evaluation of the representativity of the material. No search was made for hospital records of these subjects. Of the 584 subjects who had been autopsied but whose hospital records had not been judged 116 had died before the age of 10 years, 77 had died from accidents, 98 had committed suicide and the remaining 293 had died of natural death (Table II). Of these

Table Ia Autopsy frequency in Malmö during study period and number of cases in which clinical data were available

Age in years	Dead No	Autopsied		Clinical data		With clinical and autopsy data	
		No	% of all in the age class	No	% of all in the age class	No	% of all in the age class
0—9	118	116	(98 %)				
10—19	29	25	(86 %)	11	(38 %)	11	(38 %)
20—29	31	31	(91 %)	9	(26 %)	9	(26 %)
30—39	69	57	(83 %)	24	(35 %)	23	(33 %)
40—49	160	141	(88 %)	89	(56 %)	87	(54 %)
50—59	309	309	(86 %)	203	(57 %)	201	(66 %)
60—69	408	395	(79 %)	307	(62 %)	302	(61 %)
70—79	782	539	(69 %)	442	(57 %)	433	(56 %)
80—89	713	378	(53 %)	319	(45 %)	308	(43 %)
90—	118	33	(28 %)	31	(26 %)	28	(24 %)
all ages	2 880	2 023	(70 %)	1 435	(50 %)	1 402	(49 %)

subjects 92 had died at the General Hospital but their records could not be traced

The final material for the comparison between clinical data and post mortem findings consisted of 1 402 cases. The sex distribution was more equal than in the total material partly because more boys than girls had died before the age of 10 years and because the group of subjects examined at the department of forensic medicine who rarely had any hospital records included more men than women (Tables Ia and b II and III)

### Assessment of representativity

Originally it was intended to let the test cover all deaths in the population during a certain period of time. But acceptance of a case in the final material required that the hospital records were available and that autopsy

Table II Causes of death of subjects who were autopsied but on whom clinical data were not available (584 cases) 116 of the cases included in this group had died before the age of 10

	Males	Females
Not accident	254	155
Accident (not traffic)	35	7
Traffic accident	25	10
Suicide	68	30

Table III Type of autopsy in cases where the cause of death was not accidental or suicidal but where no clinical data were available (409 cases)

	Males	Females
Forensic <sup>1</sup>	132	75
Other (age at death > 10 yr)	53	33
Other (age at death < 10 yr)	69	41

<sup>1</sup> i.e. at the department of forensic medicine



Table 1 b Autopsy frequency and number of cases in which clinical data were available grouped according to sex

Age in years	Males				Females				
	Autopsied		Clinical data		Autopsied		Clinical data		
	No	% of all in the age class	No	% of all in the age class	No	% of all in the age class	No	% of all in the age class	
0-9	73	72	(99 %)		43	44	(98 %)		
10-19	14	13	(93 %)	6	(43 %)	12	(80 %)	5	(33 %)
20-29	21	18	(86 %)	3	(14 %)	13	(100 %)	6	(46 %)
30-39	41	34	(76 %)	12	(27 %)	23	(90 %)	12	(50 %)
40-49	83	70	(84 %)	32	(39 %)	71	(92 %)	57	(74 %)
50-59	223	191	(86 %)	103	(47 %)	118	(87 %)	98	(72 %)
60-69	304	237	(78 %)	176	(58 %)	158	(81 %)	131	(68 %)
70-79	406	250	(70 %)	233	(58 %)	252	(67 %)	209	(50 %)
80-89	283	157	(55 %)	129	(46 %)	221	(51 %)	190	(44 %)
90-99	30	14	(36 %)	13	(33 %)	19	(24 %)	18	(23 %)
all ages	1491	1092	(73 %)	711	(48 %)	931	(67 %)	726	(52 %)

Table IV Age, social class and civil status of those who were not autopsied and of those who were autopsied, grouped according to availability of clinical records. Subjects below 10 years of age excluded

	Not autopsied	Autopsied clin. records available	Autopsied clin. records not available
Age mean $\pm$ SD	77 $\pm$ 11.8	69 $\pm$ 16.0	60 $\pm$ 17.3
Median age	80	81	61
Social class I	34 (4%)	8 (5%)	29 (6%)
II	206 (71%)	405 (73%)	173 (37%)
III	207 (74%)	309 (21%)	149 (30%)
Unknown or uncertain	402 (47%)	651 (45%)	128 (27%)
Civil status			
Unmarried	161 (19%)	299 (15%)	105 (23%)
Married	254 (33%)	244 (37%)	221 (48%)
Widow(er)	347 (41%)	406 (25%)	88 (19%)
Divorced	21 (5%)	76 (5%)	49 (10%)
Unknown	6 —	2 —	— —

had been done. Some cases did not fulfil these requirements and were therefore excluded. There was however some information available about all the excluded groups. This information could be used in the evaluation of the effect of selection.

Thus in all cases the age, sex, civil status and social class (judged according to profession), mode of death, place of death and death certificate with noted cause of death were known. In the group autopsied at the department of forensic medicine also the results of autopsy were known, and there the heart and vessels had been examined in the same way as in the rest of the material.

A further group was excluded from some parts of the final treatment of the data, namely those autopsied cases in which hospital records were available but not complete enough to give

satisfactory anamnestic information on IHD.

As the purpose of the present investigation was limited and required only comparisons of the characteristics within and between certain groups of the material, in the assessment of the representativity attention should be directed above all to the effect of selection on the distribution of these characteristics between and within the groups. The results in the present study cannot be used to ascertain frequencies, ranges of variation or other parameters in the living population.

#### *Bias due to supplementation of the series*

The fact that during a certain period only subjects who had died below 60 years of age were accepted meant a

Table 1 Comparison between following groups regarding civil status distribution among consecutive age classes in per cent [absolute number in brackets] Subjects below 30 years and subjects of unknown civil status (6) excluded

1 Not autopsied

	Age class						
	30-39	40-49	50-59	60-69	70-79	80-89	90-
Single	— (4)	32 % (6)	14 % (7)	14 % (14)	21 % (52)	18 % (60)	12 % (10)
Married	— (6)	53 (10)	76 (38)	61 (64)	42 (102)	17 (53)	10 (8)
Widow(er)	—	—	—	13 (13)	31 (78)	58 (193)	73 (61)
Divorced	— (1)	16 (3)	6 (3)	7 (7)	5 (12)	6 (21)	5 (4)

2 Autopsied and clinical records available

	30-39	40-49	50-59	60-69	70-79	80-89	90-
Single	21 % (5)	11 % (8)	13 % (26)	13 % (39)	14 % (62)	15 % (49)	22 % (7)
Married	71 (17)	78 (69)	74 (151)	67 (204)	49 (212)	24 (79)	5 (2)
Widow(er)	— (1)	— (1)	6 (12)	15 (45)	32 (143)	56 (182)	71 (22)
Divorced	— (1)	12 (11)	6 (13)	5 (13)	5 (22)	3 (11)	—

3 Autopsied but clinical records unavailable

a Natural deaths

	30-39	40-49	50-59	60-69	70-79	80-89	90-
Single	— (3)	23 % (3)	17 % (10)	13 % (9)	20 % (17)	16 % (8)	—
Married	— (4)	63 (14)	71 (42)	60 (41)	44 (37)	20 (10)	— (1)
Widow(er)	—	—	—	19 (13)	27 (23)	62 (31)	— (1)
Divorced	— (2)	10 (2)	12 (7)	6 (4)	8 (7)	4 (2)	—

b Accidental deaths

	30-39	40-49	50-59	60-69	70-79	80-89	90-
Single	—	— (2)	17 % (3)	— (1)	— (1)	— (1)	—
Married	— (3)	— (7)	44 (8)	— (8)	— (1)	—	—
Widow(er)	— (2)	—	—	— (1)	—	— (4)	—
Divorced	—	— (3)	39 (7)	— (1)	—	—	—

c Suicides

	30-39	40-49	50-59	60-69	70-79	80-89	90-
Single	22 % (4)	33 % (7)	22 % (6)	— (2)	—	—	—
Married	61 (11)	70 (6)	63 (17)	— (6)	—	—	—
Widow(er)	— (1)	—	11 (3)	— (1)	— (6)	— (2)	—
Divorced	— (2)	33 (7)	— (1)	— (2)	—	—	—

Table 11 Place of death of subjects not autopsied compared with place of death of subjects who were autopsied and whose clinical records were available

	Not autopsied	Autopsied
Malmö General Hospital	24 (3 %)	1 330 (93 %)
Malmö sjukhem (geriatric department)	387 (46 %)	70 (5 %)
Malmö östra sjukhus (mental hospital)	63 (7 %)	30 (2 %)
Other hospitals	35 (4 %)	2 —
At home	225 (27 %)	3 —
Elsewhere	90 (10 %)	— —
Unknown	26 (3 %)	— —

certain selection. This effect can, however, be readily eliminated either by excluding such individuals or by grouping the material according to age in the analysis of those problems in which the material should be representative also regarding age or in which values corrected for age are desired.

#### *Bias due to exclusion of subjects who were not autopsied*

In the evaluation of this group attention was directed first to social factors which were compared with corresponding factors in the final series (Tables IV and V). In addition data on place and mode of death and cause of death recorded in the death certificate were analyzed (Tables VI, VII and VIII).

As expected the average age of the subjects not autopsied was higher than that in the final material (Table IV,  $t=12.6$ ,  $p<0.01$ ). No significant difference (Table IV,  $\chi^2=7.33$ ,  $p>0.05$ , fig 3) could be demonstrated between these two groups concerning the distribution of the subjects among social

classes (for criteria see section on Methods). On the other hand the groups did differ in respect of civil status in that those not autopsied included more persons who had been living alone mainly because of a higher frequency of widows and widowers. This difference may be explained by the above demonstrated difference in age between the two series so that the older a subject is the more likely he or she is to be a widower or a widow. This assumption was corroborated by comparison of age matched subjects (Table V) which showed no difference regarding civil status between the series.

As expected the two series differed substantially regarding the place of death (Table VI). Most of those in the final series had died at Malmö General Hospital while most of those who had not been autopsied had died at a geriatric department or at home. In both series a few had died from accidents or had committed suicide (Table VII).

An important question in the evaluation of the representativity is whether differences existed between

Table VII Cause of death of subjects not autopsied compared with cause of death of subjects who were autopsied and whose clinical records were available

	Not autopsied	Autopsied
Not accident	821 (97%)	1423 (99%)
Accident (not traffic)	17 (2%)	6 —
Traffic accident	1 —	— —
Suicide	9 (1%)	3 —

the causes of death in the two series. To check this point the causes of death judged from the diagnoses in the death certificates in the two groups were compared (Table VIII). The death certificates of those who had not been autopsied had been issued by doctors who had been looking after the patient or who had been called in immediately before or after death. The fact that these doctors had issued certificates of death without requesting *post mortem* examination ought to imply that they thought the cause of death satisfactorily explained by the clinical symptoms. The death certificates in the final series were issued by the pathologists who had performed the autopsies and in these cases their definitive death certificates were used. It is clear from Table VIII that the two groups differed substantially from one another above all regarding the frequency of malignant diseases and of pulmonary embolism as the main cause of death. Diagnoses of various types of malignant diseases were much more common in the final series which may be explained by the fact that subjects with malignant diseases are often cared for at hospital until death and secondly that malig-

nant diseases may sometimes remain concealed until autopsy. It is also clear that all malignant diseases discovered at autopsy were entered in the death certificate even when such diseases were not the cause of death. Also pulmonary embolism was noted much more often in the final group (16%) than among those who were not autopsied (less than 1%). This difference is of course, due to the better possibilities of detecting the condition at autopsy.

In this investigation the diagnoses of atherosclerotic disease of the heart is of most interest. In both series a diagnosis of recent myocardial infarctus was equally common. A large number of cases in both series were described as having cardiosclerosis. The import of this diagnosis made by a physician issuing a death certificate on the basis of symptomatic evidence differs from that made by a pathologist who has performed the autopsy and who has given cardiosclerosis as a contributory cause of death. Whether made *ante mortem* or *post mortem* the diagnosis is not a well defined one and its meaning probably varies from one examiner to another. Nevertheless the overall frequency of manifestations of

Table 1 III Diagnoses in death certificates of those who were not autopsied compared with those who were autopsied and whose clinical records were available

	Not autopsied	Autopsied
Total	819	1 402
<i>Malignant disease</i>	93 (11 %)	591 (41 %)
<i>Heart disease</i>		
Recent infarction (incl thrombosis)	102 (12 %)	152 (11 %)
Old infarction	2 —	9 —
Cardiosclerosis	223 (26 %)	142 (10 %)
General atherosclerosis	43 (5 %)	232 (16 %)
Combinations of above conditions	37 (4 %)	100 (7 %)
Hypertension	40 (5 %)	115 (8 %)
Decompensation of the heart	132 (15 %)	43 (3 %)
<i>Mors subita</i>	9 (1 %)	1 —
Myocardosis + myocarditis	17 (2 %)	1 —
Vitium org cordis	12 (1 %)	56 (4 %)
<i>Diseases of C.V.S.</i>		
Cerebral thrombosis	71 (8 %)	181 (13 %)
Hemiplegia	34 (4 %)	2 —
Cerebral arteriosclerosis	44 (5 %)	23 (2 %)
Cerebral apoplexy	10 (1 %)	—
Cerebral haemorrhage	33 (4 %)	37 (2 %)
Combinations of above conditions	9 (1 %)	9 —
Subarachnoid haemorrhage	1 —	23 (6 %)
Senile dementia	33 (4 %)	1 —
Senility + marasmus	74 (9 %)	21 (1.5 %)
<i>Gastro intestinal tract</i>		
Ulcer or status after ulcer	3 —	43 (3 %)
Inflammatory conditions	2 —	33 (2 %)
Gangrene—ileus—volvulus	1 —	30 (2 %)
Peritonitis + other disease	3 —	36 (2 %)
Total	(1 %)	(10 %)
<i>Disease of respiratory tract</i>		
Pneumonia + bronchitis	193 (23 %)	410 (28 %)
Unspecific pulm dis + pleurisy	9 (1 %)	37 (2 %)
Pulm tb + tertiary tb	2 —	22 (1.5 %)
Pulm tb cum other respir disease	— —	19 (1.5 %)
<i>Renal diseases</i>		
Glomerulonephritis	— —	10 —
Pyelonephritis	9 (1 %)	92 (6 %)
Other renal disease	19 (2 %)	39 (3 %)
Uraemia	8 (1 %)	36 (2 %)

	Not autopsied	Autopsied
<i>Liver disease</i>		
Hepatitis	— —	2
Cirrhosis	2 —	42 (3 %)
Other	2 —	22 (1.5 %)
Gallstone	2 —	16 (1 %)
<i>Diabetes</i>		
Reported	45 (3 %)	49 (3 %)
With renal compl	— —	8 —
<i>Palm embolism</i>	5 —	231 (16 %)
<i>Sepsis</i>	10 (1 %)	54 (4 %)
Total number of diagnoses	1,339	2,970
Number of diagnoses per individual	1.6	2.1

atherosclerosis in the heart was roughly the same in both groups. Cardiac incompetence was noted much more often in the death certificates issued in cases not examined *post mortem*, probably because pathologists do not as a rule pay so much attention to symptoms as the clinician.

The cause of death given in the death certificates of the group not autopsied was usually one of the following diseases: pneumonia, malignant disease, diseases of the heart or diseases of the brain and cerebral vessels. The death certificates of those who had been autopsied included also diseases of the kidney, liver and gastro-intestinal tract. The death certificates of those not autopsied also naturally often included ill defined diagnoses based on symptoms, e.g. senility, atherosclerosis, cardiac incompetence, sudden death, hemiplegia and stroke. This illustrates some difficulties when comparing and evaluating the occurrence of diseases in the two series.

As mentioned above there might be a real difference between the frequency of malignant disease in the two series. Such a difference can affect the frequencies of atherosclerotic diseases because a negative statistical correlation has been reported between cancer and atherosclerosis (10). Even if this correlation was not causal but due to the effect of mechanisms which may be taken together under the name Berkson's fallacy (6, 7) such factors may impair the representativity of the sample regarding the purpose of this study.

The two series also probably differ regarding type of IHD symptoms. According to information received from general practitioners in Malmö, it is the rule to refer patients with clear cut myocardial infarction to hospital (43). This means that the atherosclerotic heart diseases noted in the death certificates of the series that had not been autopsied could have run an atypical course more often than in the series that had been examined *post*

*mortem*. This implies a further selection because cases with typical IHD symptoms would then be overrepresented and those with an atypical clinical picture underrepresented in the final series.

In summary the exclusion of the subjects not autopsied could have affected the representativity of the final series. Those excluded were, on the average older and many had died at home for the chronically sick. It also seems possible that this exclusion may result in an overrepresentation of cases with typical symptoms and underrepresentation of those with atypical symptoms of IHD in the final series.

*Bias due to exclusion of autopsied cases in which no hospital records were available*

The next group excluded from the original material consisted of cases that had been autopsied but in which hospital records were not available. It is clear from Tables II and III that this group consisted largely of subjects who had been examined *post mortem* at the department of forensic medicine and had died from accidents or had committed suicide or had died at home or elsewhere outside the hospital. The individuals in this group were on the average younger than in the final series ( $t=10.4$   $p<0.01$  Table IV). This group also comprised more individuals belonging to social classes II and III than the other groups in the primary material (Table IV) partly explainable by possibilities to clarify a larger pro-

portion in this group according to social group. No attempts were made to find an explanation for this difference. This group also contained a large proportion of unmarried and divorced subjects and a smaller proportion of widows and widowers (Table IV).

The lower average age was due mainly to the group that had died from accidents or committed suicide (Table V). The smaller proportion of widowers and widows was probably due to the difference in the average age of the series (Table V). As mentioned in an earlier section the older an individual the higher the probability of his or her married partner having died. The higher frequency of divorced subjects can be traced to those in the 30–49 year group who had died from accidents or had committed suicide ( $\chi^2=11.0$   $p<0.01$  fig 1, compared with the final series).

A question that then arises is whether and in what way these excluded subjects differ from the final material in respect of ischaemic heart disease (Table IV). No great differences in *post mortem* findings were found. In the males there were probably more individuals with old scars in the final series ( $\chi^2=4.8$  fig 1  $p<0.05$ ). In the females the tendency to more recent infarctions among the excluded cases was not significant ( $\chi^2=2.1$  fig 1  $p>0.05$ ). In the evaluation of the comparison it should be observed that the average age in the excluded group was lower. But no correction for this bias was made because it was not of relevant interest in the present study.



Table 11 Comparison between following groups regarding myocardial changes demonstrated at autopsy

1 Autopsied and clinical data available      2 Autopsied but clinical data unavailable

	1		2	
	Males	Females	Males	Females
Total (those with uncertain autopsy data excluded)	690	705	292	147
No myocardial changes	401 (58 %)	507 (71 %)	180 (62 %)	96 (65 %)
Recent infarction	39 (6 %)	23 (3 %)	20 (7 %)	18 (12 %)
Myocardial scar > 1 cm	131 (19 %)	80 (11 %)	37 (12 %)	17 (12 %)
Diffuse fibrosis	26 (4 %)	31 (4 %)	16 (5 %)	7 (5 %)
Scar + recent infarction	61 (9 %)	39 (5 %)	17 (6 %)	3 (2 %)
Recent infarction + diffuse fibrosis	8 (1 %)	5 (1 %)	4 (1 %)	—
Scar — diffuse fibrosis	19 (3 %)	15 (2 %)	16 (5 %)	11 (4 %)
Combination of recent infarction scar and diffuse fibrosis	4 —	5 (1 %)	2 —	—
Uncertain data	(20)	(18)	(11)	(12)
Age				
arithmetic mean $\pm$ SD	69.0 $\pm$ 13.5	69.7 $\pm$ 15.0	61.7 $\pm$ 13.2	68.0 $\pm$ 12.6
median	71	72	63	72
Total number with recent infarction	110 (16 %)	72 (10 %)	43 (15 %)	21 (14 %)
Total number with scars	218 (32 %)	138 (19 %)	72 (25 %)	26 (18 %)

In the interpretation of the findings however it is of greater interest to separate off and examine more homogeneous groups within this excluded series. The series was therefore divided into the following fairly homogeneous group a) those autopsied at the department of forensic medicine and who had not died from an accident or committed suicide b) those who were autopsied at the hospital but whose hospital records could not be traced and c) those who had died from accidents or had committed suicide.

The cases of non accidental deaths examined at the department of forensic medicine (group 2 a Table 11) in-

cludes several instances of *sudden death*, a diagnosis which according to the recommendations of the American Heart Association for example is interpreted as a sign of probable IHD. It was also found as might be assumed *a priori* that many in this group had recent infarcts 25 % of the men and 22 % of the women (Table 11). Of much greater interest however is the high frequency of infarction scars in this group 39 % of the men and 28 % of the women had such scars (larger than 1 cm) in the myocardium. Most of these subjects had probably not been cared for at hospital because of myocardial infarction. This means that several

Table V Frequency of myocardial changes in following groups of subjects who were autopsied but on whom clinical data were unavailable

1 Autopsy at department of pathology

2 Autopsy at department of forensic medicine

a Natural cause of death (subjects below 10 years excluded)

b Accidents and suicides

	1	2 a	2 b	
	Dept of path	Dept of forensic med		
		Death not accidental or suicidal		Death accidental or suicidal
		Males	Females	
Total (those with uncertain autopsy data excluded)	92	129	69	148
No changes	56 (61 %)	50 (37 %)	31 (45 %)	137 (93 %)
Recent infarction	6 (6 %)	11 (14 %)	14 (20 %)	—
Myocardial scar > 1 cm	10 (11 %)	20 (19 %)	13 (19 %)	6 (4 %)
Diffuse fibrosis	4 (4 %)	9 (7 %)	5 (7 %)	5 (3 %)
Recent infarction + scar	8 (9 %)	11 (8 %)	1 (1 %)	—
Recent infarction + diffuse fibrosis	2 (2 %)	2 (1 %)	—	—
Scar + diffuse fibrosis	4 (4 %)	13 (10 %)	5 (7 %)	—
Recent infarction + scar + diffuse fibrosis	2 (2 %)	1 (1 %)	—	—
Uncertain data	—	(3)	(5)	(9)
Age				
arithmetic mean $\pm$ SD	68.0 $\pm$ 13.4	64.7 $\pm$ 13.2	69.0 $\pm$ 12.6	58.4 $\pm$ 17.4
median	70	65	73	60
Total number with recent infarction	18 (20 %)	32 (25 %)	15 (22 %)	—
Total number with scars	24 (26 %)	50 (39 %)	19 (28 %)	6 (4 %)

of the cases probably ran an atypical course with the result that the exclusion of the group had a selective effect on the final material forming the basis of the present investigation.

Those subjects who were autopsied at hospital but whose hospital records could not be traced (group 1 Table V) did not differ essentially from the final series in respect of distribution of different types of IHD changes found at autopsy. It would therefore appear that the effect of the

exclusion of this group from the final material may be ignored in the evaluation of the results.

Those who had met with fatal accidents or had committed suicide (group 2 b Table V) showed a much lower frequency of all types of myocardial changes of IHD than the other series in this material a fact which appears natural mainly because of the cause of death and partly because they were as a rule younger. Six subjects i.e. 4 % of the 157 cases in this

group, had scars after myocardial infarction. No other relevant disease was found at autopsy.

It is thus clear from the results that the exclusion of those cases where the subjects were autopsied but where clinical records were not available had a selective effect on the final series. The group of interest in this respect is that of sudden deaths. In this group also previous infarctions seemed to have been rather common and probably in many cases to have run in atypical course. This accentuates the previously mentioned bias due to underrepresentation of IHD with an atypical course.

It is more difficult to evaluate the bias produced by exclusion of those who had met with a fatal accident or had committed suicide. The effect of excluding this group is more complex, and it probably influenced both the specificity and the sensitivity of the criteria studied.

#### *Bias due to exclusion of cases with hospital records containing insufficient information on the anamnesis of IHD*

As mentioned in some cases it was difficult to judge the history of IHD because of incomplete data in the hospital records. In 316 (22 %) of the cases in which the hospital records were available the latter did not contain sufficient data in this respect. These subjects were autopsied and this provided a possibility of judging the selective effect of excluding those with incomplete records.

In order to evaluate this bias, the evidence of IHD found at autopsy in this group were compared with the corresponding findings in two other groups namely one consisting of all cases with informative hospital records regarding symptoms of IHD and a subgroup within this group consisting of those who had denied symptoms of IHD. It was found that though those subjects with incomplete hospital records were, on the average older, they had fresh myocardial infarction and scars less often than those subjects whose records contained informative anamnestic data ( $\chi^2=14.8$  fig 1  $p<0.01$ ), ( $\chi^2=4.2$  fig 1  $p<0.05$ ) (Table VI). This difference could mainly be referred to more individuals having both old and recent infarctions in the final series ( $\chi^2=21.5$  fig 1  $p<0.01$ ).

The group with incomplete hospital records had however as expected more cases with both old and recent myocardial infarctions than the group that had denied symptoms of IHD (Table VI). Thus regarding both recent and old infarctions this group occupied an intermediate position between the two reference groups. The incompleteness of the notes on symptoms of IHD in these cases was probably due partly to the examiners' not having taken the histories properly and partly to the inability of the patients to give information e.g. patients with cerebral vascular disease. Of the recent myocardial changes in this group most had occurred but had not been diagnosed while the patients were in hospital which suggests that

*Table VI Comparison regarding myocardial changes of IHD demonstrated at autopsy between one group with insufficient and one group with sufficient clinical data regarding IHD anamnesis*

	Insufficient clin data regarding IHD	Sufficient clin data regarding IHD	
		Denied IHD symptoms	Total
Total (those with uncertain autopsy data excluded)	316	708	1078
No myocardial changes	210 (68 %)	593 (82 %)	692 (64 %)
Recent infarction	14 (4 %)	6 (1 %)	48 (4 %)
Myocardial scar >1 cm	20 (7 %)	64 (9 %)	150 (14 %)
Diffuse fibrosis	20 (6 %)	23 (3 %)	37 (3 %)
Recent infarction+scar	6 (2 %)	13 (2 %)	91 (9 %)
Recent infarction+diffuse fibrosis	—	2 (—)	11 (1 %)
Scar+diffuse fibrosis	5 (2 %)	2 (1 %)	29 (3 %)
Recent infarction+scar+diffuse fibrosis	1 (—)	2 (—)	8 (1 %)
Age			
arithmetic mean $\pm$ SD	74.2 $\pm$ 11.6		67.6 $\pm$ 11.6
median	76		69
Total number of recent infarctions	21 (7 %)	20 (3 %)	161 (15 %)
Total number of scars	67 (21 %)	81 (12 %)	200 (27 %)

many of them had run an atypical course

It has thus been shown that when some groups were excluded from the primary material which comprised all subjects in a population who had died during a certain period the exclusion had a biasing effect. The average values and other characteristics can therefore probably not be regarded as representative of the primary material. This bias was of relevant importance because it probably resulted in an underrepresentation of cases with atypical symptoms of IHD and of cases where the myocardial infarction passed without notable symptoms.

This phenomenon has a systematic effect on the evaluation of various criteria used in the epidemiological method. It leads to underestimation of false negative diagnoses with consequent overestimation of the sensitivity of the method. The estimation of false positive diagnoses is however affected less because this estimation is based on comparisons of postmortem findings of IHD within groups characterized by different types of symptoms of IHD.

The data presented in this chapter must be borne in mind in the evaluation of the results of the following analyses especially of those in Chapters VII and IX.

## Methods

## Clinical data

The hospital records of the last 25 years—or more if considered necessary—of all subjects who had been autopsied and included in the primary material were analysed. This analysis was facilitated by the fact that Malmö is a one hospital town. The analysis was performed by a single person who was unaware of the *post mortem* findings. All together 3 633 hospital records (= spells in hospital) of 1 437 subjects were studied (Table VII). All the records were searched for information on IHD, electrocardiography, blood pressure and other clinical data of interest. The findings were coded according to a code devised specially for the purpose (26). As to the symptoms of IHD the criteria regarded as typical and recommended by WHO for epidemiological use (3, 4, 5) were called typical while IHD symptoms of other types and with other precipitating mechanisms were judged as atypical. The grounds for evaluation and exact definitions are given in detail in the chapter on the results with respect to symptoms of IHD. In the evaluation of the electrocardiograms

the Minnesota code criteria were used (13). The classification of certain subgroups used in this study is given in the chapter on results.

The hospital records were analysed during a 2 year period. To reduce variation liable to occur in the judgement during such a long period, the criteria to be used were defined as precisely as possible on the basis of a preliminary study of 50 randomly selected cases (26). The coded data were transferred to IBM punch cards which were repeatedly checked for transfer errors.

Table VII Distribution of records analysed (spells in hospital) among different departments

Medical	1 067
Surgical (incl. chest and plastic)	903
Infection (which serves also partly as dept. of med. and of respir. diseases)	412
Chronic diseases	322
Other geriatric units	97
Radiologic	166
Orthopedic	180
Gynaecologic	106
Others	330
<b>Total</b>	<b>3 633</b>

Table VIII Social class grouping Scheme devised at the Department of Sociology Lund 1953

	Code number		Code number
<i>Social group I</i>		Civil servants (of lower grade) II	18
Larger farmers	01	Elementary school teachers	19
Industrialists wholesale merchants		Captains (master mariners)	20
directors managers	02	Higher domestic service	21
Executives in high position	03	Independent professions II	22
High civil servants and officers of the armed forces	04	Other industrial occupations and tradesmen	23
Independent occupations I	05	Miscellaneous II	24
Houseowners I	06		
Miscellaneous I	07	<i>Social group III</i>	
		Farm foremen etc	30
<i>Social group II</i>		Crofters etc	31
Farm owners	10	Other farm labourers	32
Leaseholders and farmers	11	Seamen	33
Farmers sons and sons in law living at home	12	Fishermen	34
Artisans	13	Foresters and timberfloaters	35
Dealers (small)	14	Other workers	36
Foremen	15	Civil servants of lower grade III	37
Clerks	16	Low domestic service	38
Shop assistants	17	Miscellaneous III	39

Data on the patients' age, civil status and occupation were obtained from the death certificates. The subjects were classified in occupational groups according to a scheme devised at the Department of Sociology, University of Lund (stencil 1953 Table VIII).

Information obtained retrospectively from hospital records has certain inherent sources of error. These are best seen on comparison with an imaginary situation in which the same information is obtained from questionnaires. This will show that the largest source of error in the hospital records is the lack of standardization of the history taking and entries

which may make it difficult to obtain strictly comparable data. In the present investigation this source of error was counterbalanced to some extent by the fact that the Malmö hospital is a teaching hospital and the entries are more complete and made in a more uniform way than otherwise. The majority of the patients had been examined by internists at the department of medicine or by heart specialists before an operation.

In some respect the hospital records give more exact information than questionnaires because data are available from various spells in hospital covering a long period of time. Such records give information e.g. on the

anamnesis of the patient at the actual time of infarction. It should be emphasized that the purpose was not to make comparisons with other series but comparisons within one and the same series to get information about the validity of anamnestic data as a link in planning a prospective study.

In about 300 cases the hospital records were unsatisfactory regarding data on IHD. In roughly the same number of cases electrocardiograms were missing or not technically satisfactory. These cases formed a special group which was discussed previously in association with analysis of the representativity of the series.

### Postmortem data

The autopsies were performed according to a standardised technique and the protocols were dictated during the actual examination of the organs. Several organs including the recent myocardial infarctions or suspected necroses were routinely examined microscopically. The autopsy findings were taken from the autopsy protocols codified according to the code list and transferred to IBM punch cards.

The coronary and cerebral arteries were slit up, dissected and examined for old or recent thrombi as well as for advanced stenosis. In about half of the cases the vessels were dissected from surrounding tissue by the same

prosector the other half, by the prosectors who happened to be on duty. Advanced stenosis was said to be present if the diameter of the vascular lumen was reduced by more than 50%. The adventitia was removed and the vessels were fixed in neutral formalin for about 24 hours and placed in plastic bags containing a small amount of neutral formalin (61-62). The vessels were classified in a fixed state and within the bags with respect to type and extent of atherosclerosis according to the method of Sjövall and Wilman (11) with minor modifications. As the material was stored it could be judged within a relatively short time in order to reduce the risk of variation of judgement. The reproducibility of the grading was checked in a small series.

### Statistical methods

In this study relevant data on the clinical and autopsy findings and grading of atherosclerosis were transferred to a single punch card.

Conventional statistical methods were used. The frequency of clinical and/or autopsy data was not regularly compared with the corresponding findings in other investigations because the criteria and the methods used often differ from one series to another and thereby limit the value of such comparisons.

## Anamnestic data of ischaemic heart disease and electrocardiographic recordings

The final material consisted of largely equal numbers of men and women who did not differ significantly from one another in respect of age (Fig 1). The distribution according to social class, civil status and mode of death is given in the description of the analysis of the representativity of the material (Tables IV, V, VI, VIII).

### Anamnestic IHD symptoms

#### *Definition of symptoms of IHD*

As typical *angina pectoris* was accepted in accordance with recommendations by an expert group from WHO (5) effort angina is defined by Rose (63). These symptoms are defined as follows:

Chest pain or discomfort with these characteristics:

- 1 The site must include *either* the sternum (any level) *or* the left arm and left anterior chest (defined as the anterior chest wall between the levels of clavicle and lower end of sternum)
- 2 It must be provoked by either hurrying or walking uphill (or by

walking on the level for those who never attempt more)

- 3 When it occurs on walking it must make the subject either stop or slacken pace unless trinitrin (nitroglycerine or a similar drug) is taken
- 4 It must disappear on a majority of occasions in 10 minutes or less from the time when the subject stands still

As typical *infarction* the criteria recommended by WHO for possible infarction (5, 63) were used. One or several attacks of severe pain across the front of the chest lasting for 30 minutes or more.

The atypical symptoms may consist of deviations of all or any of the characteristics described as typical of IHD (1, 2, 15, 17, 20, 21, 24, 32, 33). The pain may thus be missing entirely both in *angina pectoris* (sine dolore) and *infarction*. *Pain equivalents* can arise in the form of discomfort or a feeling of compression. These equivalents were included in the definition given by Rose. An equivalent not included is the symptom the patient describes as shortness of breath.






Fig. 1 Age and sex distribution of material

on exertion a symptom which is usually judged as a respiratory symptom. But if it could be shown that this symptom is not combined with hyperventilation but causes superficial respiration without increased respiratory frequency it can be a pain equivalent. This symptom is not simply an equivalent but also often combined with pain (44). Further the site of pain may vary. It commonly occurs e.g. in the jaw or neck. The symptoms may also be referred to the right side. Scars after operations or chronic inflammatory conditions are thought to be places to which the individual often refers his coronary symptoms. This applies particularly to scars after operations on the biliary tract or stomach (1).

The precipitating mechanism can sometimes not be demonstrated (spontaneous angina). It may be psychic stress postural exposure to cold or recumbent position (15). Angina pectoris precipitated by a meal is judged by certain authors as a sign of advanced coronary disease (15) while others believe that it has not a particularly poor prognosis (33). Opinions differ in the same way regarding the prognostic significance of nocturnal angina. Exposure to cold may be a precipitating factor. Then local cooling, such as of the face or by holding a piece of ice in one hand may trigger off angina pectoris (15, 19). This is a form which may be isolated. The type of angina which is combined with a psychic stress is not believed to have a

poor prognosis (15-33). The difficulties of drawing the line between pain suggesting angina pectoris and that suggesting myocardial infarction have also been mentioned (15-32-33).

*Atypical angina pectoris* was said to be present when pain or discomfort was described in the same area as in the typical cases but with the following precipitating mechanisms: cold, emotional exertion, a meal and recumbent position. Those variants with shortness of breath were also assigned to this group. Pain in areas not typical of coronary pain according to Rose (63) were not accepted as atypical angina but were assigned to the group of uncertain cases.

Patients with an attack of sudden pallor, sweating, sometimes combined with a sensation of discomfort in the chest, a tendency to lie down and a tendency to faint were classified as having *atypical infarctions*. No definite limits were drawn regarding the duration of the symptoms because the duration was seldom given in the records and exclusion of a case because of lack of precision in this respect would have implied the exclusion of too many cases with a history of infarction.

If a subject had had typical angina pectoris he was classified as such even if he also had had co-existing atypical symptoms. On the other hand a subject with atypical or typical angina pectoris could be judged as having both atypical and typical infarction.

Anamnestic symptoms of IHD were said to be absent only if a note had

been made in the patient's record that he had denied having pain in the chest or if it was obvious that he had been doing heavy labour without symptoms referable to the heart until admission. In the cases where the records contained no notes about the condition of the heart the information was said to be incomplete and as mentioned above these cases were assigned to a special group.

### *Distribution of atypical and typical symptoms*

172 (12%) cases had typical angina pectoris. Of these subjects 100 were males and 72 females. The clinical picture in these cases was fairly homogenous and there was therefore no reason to subgroup. In 70 (5%) of the subjects (40 men and 30 women) the angina pectoris had been atypical. The group was heterogeneous from the point of view of symptoms and subdivision for further analysis would have been of interest. But the group was too small for such subdivision. A third group of angina pectoris comprised cases with status anginosus defined as more or less continuous retrosternal pain for more than one day and increasing on exertion and not disappearing completely during rest or treatment with nitroglycerine. Only 7 subjects (3 men and 4 women) had shown such a clinical picture.

The infarction episodes were grouped as mentioned into typical and atypical and into previous and recent. From an epidemiological point of view previous episodes of infarction are of

Table VII Relation between different forms of angina pectoris and different types of anamnestic symptoms of myocardial infarction

	Angina pectoris				
	None	Atypical	Typical	Status anginosus	Uncertain data
Total (those with uncertain data excluded)	841	66	162	7	(331)
Anamnestic symptoms of infarction					
None	562 (91 %)	42 (61 %)	66 (39 %)	1	(15)
Atypical previous	6 (1 %)	1	2 (1 %)	—	—
Typical previous	18 (2 %)	9 (14 %)	18 (11 %)	—	—
Atypical, recent	12 (1 %)	2 (3 %)	2 (1 %)	1	(1)
Typical recent	35 (4 %)	8 (12 %)	33 (20 %)	5 (70 %)	(7)
Combinations	8 (1 %)	4 (6 %)	48 (29 %)	—	—
Uncertain data	(13)	(4)	(3)	—	(307)

greater interest because acute infarction is rarely found in such studies.

Only in 9 cases (less than 1 %) could signs of previous atypical infarction be demonstrated. In 5 of the cases the subjects had attended the hospital because of their symptoms sooner or later after the episode. Eighteen had had recent symptoms referable to this type of infarction without pain. In 45 cases (3 %) the patients had had previous typical episodes of infarction and 88 (6 %) recent symptoms of typical infarction. Sixty had had both a previous and a recent infarction. In most of these with recurrent infarction (54 cases) the attacks had been typical on both occasions. Only one subject had had atypical attacks on both occasions. Five had combinations of atypical and typical symptoms of infarction.

Invariably symptoms of IHD were more common among the men than among the women. The ratio in each

of the groups was about 10:7 (for details see Tables VIII and IX). It seems that this difference cannot be ascribed to a skew sex distribution or differences in ages (Fig. 1). It probably reflects a real difference between the sexes regarding the tendency to develop IHD. This difference is well known and is larger in the lower than in the higher age groups.

As known angina pectoris is often ushered in by infarction and angina pectoris is often complicated by infarction. This was also the case in the present material (Table X), where 36 % with atypical angina pectoris and 61 % of the cases with typical angina were combined with an episode of infarction of some kind.

It has been claimed that the atypical course is due to certain individuals having a reduced capacity to experience pain (1, 15). If this were the case a given individual should have recurrences of the same type of infarction

and atypical angina pectoris should more often be combined with atypical infarction and the typical form of angina pectoris should not be combined with atypical infarction. But no such uniform pattern could be demonstrated among those with recurrent infarction or in the relation between angina pectoris and infarction (Table XIV). This argues against this hypothetical explanation of the atypical course.

Status anginosus was combined with a picture of recent infarction in 6 of the 7 cases which fits in with the opinion that it is a preinfarction state.

### Electrocardiographic changes

Electrocardiographic studies were included in the analysis in order to get this objective method compared with anamnestic symptoms and post mortem findings.

#### *Definition of electrocardiographic changes*

In most of the cases in which electrocardiographic recordings were available 12 leads had been used namely 3 standard leads (I, II and III), 3 unipolar limb leads (aVR, aVL, aVF) and 6 Wilson precordial leads (V<sub>1</sub>, V<sub>2</sub>, V<sub>3</sub>, V<sub>4</sub>, V<sub>5</sub> and V<sub>6</sub> or V<sub>7</sub>). All cardiograms available in each case were checked and judged.

Classification groups based on the criteria of the Minnesota code (13) were separated off. This code is based on the same isolated electrocardiographic changes as are judged in clinical

practice, but to enable standardisation of judgement and to obtain comparable values certain numerical values respectively quotients are given which are codified so that they can be transferred to IBM punch cards. As for Q, QS and T the code is constructed in such a way that changes are classified in decreasing order of severity.

The electrocardiographic changes were however not coded in the different classes according to the Minnesota code. Instead clusters of these criteria, defined later, were used in expectation of the modifications of this code in progress (5).

From an epidemiological point of view it is of special interest to examine electrocardiographic abnormalities after previous myocardial injuries. In view of the nature of the series it was therefore thought advisable to divide the series into cases with old and cases with recent electrocardiographic changes. The electrocardiographic changes were classified as old if they had been demonstrated during previous spells in hospital or previous visits to the outpatient department. Furthermore abnormalities seen in recent electrocardiograms were classified as old if no clinical signs or symptoms of active myocardial infarction had been demonstrated at the time of the recording of the electrocardiogram. The electrocardiographic changes were classified as recent if previous electrocardiograms had been normal and the change had supervened recently, even in the absence of clinical signs or symptoms of myocardial infarction.

Table VI Distribution of recent electrocardiographic changes according to sex (Figures in brackets denote corresponding number in the Minnesota code)

	Numbers and percentages	
	Males	Females
Normal ECG	711 193 (27 %)	724 185 (26 %)
Not normal but no signs of infarction (VI 1-4 VII 2-3 VIII 0-9 IX 2-9)	102 (14 %)	69 (10 %)
S-T depression (IV 1)	152 (21 %)	201 (28 %)
Pattern of myocardial infarction (I 1-2 IV 4 V 1-2 I 3/V 3)	83 (11 %)	48 (7 %)
Left bundle branch block or diffuse myocardial damage (VII 1 IX 1)	21 (3 %)	30 (4 %)
ECG missing or technically unsatisfactory	159 (22 %)	189 (26 %)

In addition electrocardiographic abnormalities were judged as recent if continuous changes had occurred during the last spell in hospital or if coexisting signs or symptoms of myocardial infarction had been demonstrated. This means that the clinical picture influenced the classification of the electrocardiographic abnormalities as previous or recent.

In the naming of the different groups it was presumed on the basis of clinical experience that some of the criteria in the Minnesota code were more specific for myocardial infarction than others.

The following classification was used (figures in brackets refer to corresponding groups of the Minnesota code).

#### Previous electrocardiographic changes

- 1 Normal electrocardiogram
- 2 Electrocardiogram not normal but no change according to 3 or 4

- (group 2 thus includes *e.g.* AV block, disturbed rhythm, right bundle branch block and other small electrocardiographic abnormalities VI 1-4, VII 2-3, VIII 0-9 IX 0 2-9)
- 3 Infarction pattern with different localization (Q and QS and pathological R wave reduction according to I 1-2, T according to V 1-2 and V 3 if I 3 is also present)
  - 4 Diffuse injury or injury difficult to locate (left bundle branch block, VII 1 low voltage IX 1)

#### Recent electrocardiographic changes

- 1 Normal electrocardiogram
- 2 Not normal but no change according to 3-5
- 3 Myocardial strain (ST decrease of 1 mm or more IV 1)
- 4 Infarction pattern with different localization (Q and QS and pathological R wave reduction I 1-2 S-I increase IV 4 T wave V 1-2 V 3 if I 3 is also present)

Table VII Distribution of previous electrocardiographic changes according to sex (Figures in brackets denote corresponding number in Minnesota code)

	Numbers and percentages	
	Males	Females
Normal ECG	711 301 (42 %)	724 301 (42 %)
Not normal but no signs of infarction (VI 1—4 VII 2—3 VIII 0—9 IX 2—0)	120 (18 %)	139 (19 %)
Pattern of myocardial infarction (I 1—2 V 1—2 I 3/V 3)	80 (12 %)	88 (8 %)
Left bundle branch block or diffuse myocardial damage (VII 1 IX 1)	43 (7 %)	43 (6 %)
ECC missing or technically unsatisfactory	102 (21 %)	181 (20 %)

5 Diffuse injury or injury difficult to locate (left bundle branch block VII 1 low voltage IX 1)

The third category of column I respectively V of the Minnesota code is the least specific Q QS and T pattern was thus included only when they occurred simultaneously S—T decrease in association with previous electrocardiographic abnormalities was not codified because no valid information was available about simultaneous treatment if any with digitalis

In contrast to what is usual when employing the Minnesota code several cases were judged on the basis of consecutive electrocardiographic sequences taken during the same spell in hospital Therefore in some cases the evaluation was firmer than would have been possible by an isolated electrocardiogram

Tables VI and VII give the frequencies of the different electrocardiographic changes distributed according to sex These frequencies are only

of value for describing properties in the present series

### Relationship between anamnestic symptoms of IHD and electrocardiographic changes

Both the anamnesis and electrocardiography have inherent sources of error as diagnostic instrument Various pathological conditions in the chest and in the upper abdomen can anamnestically simulate coronary heart disease and some diseases of the lung and brain can produce electrocardiographic abnormalities resembling those of myocardial injury (18) One might therefore *a priori* expect a certain discrepancy between the results obtained by the two methods

The analysis was made in the following way It was first judged to what extent the electrocardiogram agreed with what could be expected from the symptoms of IHD It was

also judged whether any discrepancy existed in this respect between cases with typical respectively atypical symptoms and whether any differences in the electrocardiographic pattern existed between cases with anamnestic symptoms of angina pectoris respectively of myocardial infarction. The following presentation is based on the results summarized in Tables VII a-c.

In the group who had denied anamnestic symptoms of IHD 15 % had conduction disorders and arrhythmias and 33 % had S-T depressions 1 mm or more. In view of the composition of the series these figures were to be expected. Most of these changes were probably due to causes other than IHD and then mainly to the effect of digitalis and electrolyte changes. Thus 108 subjects in the final series had taken digitalis occasionally or continually during their last spell in hospital. It was however not thought desirable to exclude those cases in which digitalis had been given but the effect of such treatment was judged separately in each case where it might have influenced the results. In the group who had denied anamnestic symptoms of IHD 2 % had electrocardiographic signs of recent myocardial infarction and 3 % had recently acquired left bundle branch block. Previous electrocardiographic changes were more common in this group. Thus 13 % had previous changes including a pattern of infarction, left sided bundle branch block or diffuse myocardial injury.

Among the cases with angina pec-

toris one might expect changes of infarction to be rather common because this condition is often combined with episodes of infarction (Table XIV). To facilitate the analysis of the cases with angina pectoris those with and without infarction episodes respectively were analysed separately. Of the group with angina pectoris without an infarction episode, about 30 % had signs of previous pattern of infarction whether the angina pectoris had been typical or atypical. Among the cases with typical angina pectoris there were many more in which the recent electrocardiogram showed S-T depression (1 mm or more) (61 %) than among those with atypical angina pectoris (39 %  $\chi^2=5.6$  fig 1  $p<0.05$ ) or without IHD amnesia (33 %  $\chi^2=19.9$  fig 1,  $p<0.01$ ). This difference could perhaps be due to the fact that there were more patients with typical angina pectoris who had been treated with digitalis than among those with atypical angina pectoris respectively among those without a history of IHD. This hypothesis is supported by the fact that the difference found between the two types of angina pectoris disappeared on elimination of the influence of the cases that had received digitalis ( $\chi^2=2.3$  fig 1  $p>0.05$ ). On the other hand the significant difference persisted between cases with typical angina pectoris and cases without anamnestic symptoms of IHD even after elimination of the influence of those treated with digitalis ( $\chi^2=12.3$  fig 1  $p<0.01$ ). This suggests that also other factors may be of significance and in the

Table VIII 1 CG in different types of anamnestic symptoms of IHD Number in brackets denote numbers in Minnesota code I expected ECG changes are enclosed Cases with ECG missing or technically unsatisfactory are not included in totals and percentages

1 No anamnestic symptoms of IHD and atypical angina pectoris

	No IHD in anamnesis	Atypical angina pectoris			Total
		With previous infarction in anamnesis	With recent infarction in anamnesis	With previous infarction and recent infarction in anamnesis	
Total	571	10	10	1	30
Recent I CG changes					
Normal I CG	270 (47%)	3	—	—	11 (20%)
Not normal I CG but no signs of infarction (VI 1—4 VII 2—3 VIII 0—9 IX 2—9) S—T depression (IV 1)	96 (15%)	2	—	1	0 (17%)
Infarction pattern (I 1—2 IV 1 V 1—2 I 9/9 3)	187 (33%)	4	1	1	14 (39%)
Left bundle branch block or diffuse myocardial damage (VII 1 IX 1)	12 (2%)	1	8	2	5 (14%)
I CG missing or technically unsatisfactory (101)	16 (3%)	—	1	—	— (7)
Previous I CG changes					
Normal I CG	531	10	8	1	19
Not normal I CG but no signs of infarction (VI 1—4 VII 2—3 VIII 0—9 IX 2—9) S—T depression (I 1—2 V 1—2 I 9/9 3)	186 (36%)	3	11	—	22 (50%)
Infarction pattern (I 1—2 V 1—2 I 9/9 3)	170 (32%)	2	1	—	7 (18%)
Left bundle branch block or diffuse myocardial damage (VII 1 IX 1)	33 (6%)	1	1	1	3 (13%)
I CG missing or technically unsatisfactory (178)	77 (6%)	1	3	—	5 (13%)
		—	(2)	—	(0)



Table VII b Typical angina pectoris

Typical angina pectoris				
	With previous infarction in anaesthesia	With recent infarction in anaesthesia	With previous and recent infarction in anaesthesia	Without infarction in anaesthesia
Total	20	11	42	62
<i>Recent ECG changes</i>				
Normal ICG	7 (35%)	1 (3%)	3 (7%)	8 (13%)
Not normal ICG but no signs of infarction				
VI 1-4 VII 2-3 VIII 0-9 IX 2-9	2 (10%)	7 (10%)	8 (19%)	13 (21%)
S-T depression (IV I)	5 (10%)	1 (3%)	4 (9%)	34 (55%)
Infarction pattern (I 1-2 II 4 V 1-2 I 3/4 3)	—	24 (77%)	19 (45%)	1 (2%)
I left bundle branch block or diffuse myocardial damage (VII I IX I)	3 (15%)	2 (6%)	8 (19%)	2 (3%)
ICG missing or technically unsatisfactory	—	(1)	(4)	(1)
<i>Previous ECG changes</i>				
Normal ECG	20	29	47	65
Not normal ECG but no signs of infarction	4 (20%)	16 (55%)	3 (6%)	27 (42%)
VI 1-4 VII 2-3 VIII 0-9 IX 2-9	2 (10%)	7 (24%)	2 (4%)	18 (28%)
Infarction pattern (I 1-2 V 1-2 I 3/4 3)	10 (50%)	5 (17%)	34 (72%)	12 (18%)
I left bundle branch block or diffuse myocardial damage (VII I IX I)	4 (20%)	1 (3%)	8 (17%)	8 (12%)
ECG missing or technically unsatisfactory	—	(6)	—	(1)

Table VIII c With anamnestic symptoms of infarction without anamnestic

	Atypical		Typical		Con- clusions
	Previous	Recent	Previous	Recent	
Total	6	11	18	31	8
<i>Recent ECG changes</i>					
Normal ECG	1	2	5 (28%)	2 (6%)	—
Not normal ECG but no signs of infarction (VI 1-4 VII 2-3 VIII 0-0 IX 2-0)	3	1	6 (33%)	2 (6%)	—
S-T depression (IV 1)	1	—	7 (39%)	3 (10%)	1
Infarction pattern (I 1-2 IV 4 V 1-2 I 3/V 3)	1	0	—	24 (73%)	4
I left bundle branch block or diffuse myocardial damage (VII 1 IV 1)	—	2	—	2 (6%)	3
ECG missing or technically unsatisfactory	—	(1)	—	(2)	—
<i>Previous ECG changes</i>					
Normal ECG	6	11	18	27	8
Not normal ECG but no signs of infarction (VI 1-4 VII 2-3 VIII 0-0 IX 2-0)	1	7	5 (27%)	18 (67%)	2
Infarction pattern (I 1-2 V 1-2 I 3/V 3)	2	0	5 (27%)	3 (10%)	1
I left bundle branch block or diffuse myocardial damage (VII 1 IV 1)	4 (50%)	1	6 (33%)	2 (7%)	3
ECG missing or technically unsatisfactory	—	—	2 (10%)	2 (7%)	2
		(1)		(8)	

light of the characteristics in the respective groups it seems reasonable to assume that the cause was partly the occurrence of real IHD.

In those cases where the history of angina pectoris had been complicated by previous episodes of infarction there were as expected, more often (50—70%) signs of previous infarction or left bundle branch block in the electrocardiogram without any certain difference between different forms of angina pectoris. In the group with angina pectoris and recent infarction episode expected electrocardiographic changes were common (83—90%) without any significant difference in frequency between typical and atypical angina pectoris. Only rarely did those with angina and recent infarction episode have a normal electrocardiogram. In those cases where angina pectoris was combined with repeated episodes of infarction the expected electrocardiographic changes were often found without any certain difference between the two types of angina pectoris.

The cases with isolated previous episodes of infarction showed the expected electrocardiographic changes in about 50% without any difference between typical and atypical infarction. Neither was any difference found in this respect between subjects with recent infarction (79 and 72%). Subjects with recurrent infarction without angina pectoris had largely the expected electrocardiographic changes.

## Comments

This analysis showed a large discrepancy between the anamnesis of IHD and electrocardiographic changes in the form of arrhythmias and S—T depressions. It appears probable, as will later be apparent that these changes were fairly non specific as far as IHD is concerned. This raises the question to what extent the results are conclusive for population studies. In the present series there were a number of sources of error e.g. effect of medicine and electrolyte disturbances, while the frequency of such sources of error would probably be small in a population study with representative material in respect of age. This means that S—T depressions and to a certain extent arrhythmias and conduction disorders may be much more specific of IHD in such an investigation. If the population study is concerned mainly with the higher age groups, however these sources of error may increase substantially, especially in areas where digitalis and diuretics are used for wide indications. This should be considered both in the planning of population studies and in the interpretation of the results.

In the present study cases with discrepancies between the anamnesis of IHD and expected electrocardiographic recordings are of greater interest than those in which there was no such discrepancy. In this chapter we have reported discrepancies: cases who had denied anamnestic symptoms of IHD had electrocardiographic changes indicative of IHD in 15% and

cases with a history of a previous infarction episode or angina pectoris had normal electrocardiograms in about 25 %. The importance of these discrepancies will be studied in a later chapter where a comparison is made between postmortem findings in the different groups characterized by dis-

crepancies between their anamnesis and electrocardiographic pattern.

Of special interest for one of the purposes of this study is that no sure difference could be demonstrated in the comparison of electrocardiographic changes between cases with typical and atypical symptoms.

## Ischaemic heart disease demonstrated post mortem

IHD according to definition is a condition with decreased transport of blood to the myocardium implying an insufficient supply of oxygen to the muscle of the heart. The condition is believed to be due mainly to vascular changes of atherosclerotic nature which *per se* or by favouring thrombotic complications causes obstruction or occlusion of one or more coronary arteries. Obstruction is believed to cause a temporary ischaemic condition usually without accompanying myocardial necrosis and this condition produces symptoms largely in the form of angina pectoris. Occlusion is believed to result in myocardial necrosis and then the clinical picture of myocardial infarction. Opinions differ on various stages in this process. The role played by atherosclerosis has been questioned (30-39). Thrombosis has been regarded as secondary to myocardial infarction (38) and the role played by hypoxaemia respectively necrosis in the causation of clinical symptoms has been discussed (1-14, 15).

To enable a differentiated analysis the changes in the coronary arteries and in the myocardium were studied

in the present investigation. Only the severe changes of the coronary arteries were included because the purpose was mainly to reveal associations between the clinical findings and morphological signs of IHD. The term 'no special vascular changes' is therefore to be understood as the absence of severe stenosis or thrombosis and most of these cases had atherosclerotic changes of the coronary arteries, sometimes widespread.

### Relation between lesions of the coronary arteries and of the myocardium

The types and frequencies of coronary and myocardial changes are given in Tables XVIII a and b. Both types of changes were more common in the men than in the women. This fits in with the results previously presented regarding anamnestic and electrocardiographic evidence of IHD. The figures agree well with those found in previous investigations in Malmö (49-64). The results presented in these tables give information only on the present series and will not be discussed further.

Table VIII a Severe coronary lesions demonstrated at autopsy in males and females

	Males 711		Females 726	
No arterial changes of this type	486	68 %	577	79 %
Fresh thrombosis	44	6 %	20	3 %
Old thrombosis	17	2 %	10	1.5 %
Severe stenosis	78	11 %	63	9 %
Old and fresh thrombosis	10	1.5 %	5	1 %
Stenosis and fresh thrombosis	22	3 %	14	2 %
Stenosis and old thrombosis	20	3 %	6	1 %
Stenosis+old+fresh thrombosis	5	1 %	1	—
Uncertain postmortem data	29	4 %	30	4 %

As expected a covariation was found between the coronary and myocardial lesions. The covariation was however not complete. Advanced vascular changes were most often associated with myocardial lesions while advanced myocardial lesions were often seen without associated severe vascular changes. The findings are given in detail in Table XIX and Fig 2.

For simplicity Fig 2 is semi schematic. Thus cases with myocardial infarction associated with advanced diffuse myocardial fibrosis were assigned to the respective groups of infarction. In groups with only one case with fibrosis the case was not included. Those cases in which no post mortem data were available or in which the results of autopsy were not clearly defined were excluded before calculation of the frequencies.

*Appearance of the myocardium in different coronary lesions* In 13 % of

Table VIII b Myocardial lesions demonstrated at autopsy in males and females

	Males 711		Females 726	
No myocardial changes	401	56 %	507	70 %
Recent infarction	39	5 %	23	3 %
Myocardial scar >1 cm	134	19 %	80	11 %
Diffuse fibrosis	26	4 %	31	4 %
Recent and old infarction	61	8.5 %	39	5 %
Recent infarction and diffuse fibrosis	6	1 %	5	1 %
Old infarction and diffuse fibrosis	10	3 %	15	2 %
Recent infarction+old infarction+diffuse fibrosis	4	0.5 %	5	1 %
Uncertain postmortem data	21	3 %	21	3 %
Total with recent infarction <sup>a</sup>	110	16 %	72	10 %
Total with old infarction <sup>a</sup>	218	32 %	139	12 %

<sup>a</sup> Percentage calculated after exclusion of cases with uncertain postmortem data

receding ombos



recession ombos	84 /
old ombos (scar)	10 /
no mycelial chag	6 /

old ombos



recession ombos	4 /
old ombos (scar)	83 /
no mycelial chag	13 /

recession



recession ombos	88 /
old ombos	4 /
severe stomas	10 /
old stomas or thomb	22 /

old ombos (scar)



recession ombos	4 /
old ombos	12 /
severe stomas	23 /
old stomas or thomb	60 /

old ombos (thombos)



recession ombos	13 /
old ombos (scar)	26 /
recession old ombos (scar)	1 /
mycelial chag	13 /

old ombos (scar)



recession ombos	9 /
old ombos (scar)	40 /
recession old ombos (scar)	10 /
mycelial chag	10 /
mycelial chag	23 /

old ombos (stomas)



old ombos	62 /
old ombos	12 /
recession old ombos	13 /
severe stomas	26 /
no stomas or thomb	9 /




Fig. 7. Relation between coronary arterial stenosis or thrombosis and myocardial changes

the cases with old thrombosis or combined old and recent thrombosis no myocardial changes could be demonstrated. In 6% was the myocardium of normal appearance in the presence of recent thrombosis. No myocardial lesions were found in 23% of the cases with severe stenosis.

*Coronary lesions in the presence of myocardial infarction.* In 60% of all cases with myocardial scars no particular vascular lesion was demonstrated. This figure is somewhat higher than that reported in other series (12, 17, 46). This may, however, be due to the selection of such series which usually consist of cases with clinically diagnosed myocardial infarction. Among the cases with myocardial scars the commonest arterial lesion was severe stenosis (23%) while old occluding thrombi were

found in only 13%. In subjects with recent myocardial infarction the vascular changes were more common, namely 36%, with recent occluding thrombi which in some cases were combined with old thrombosis or severe stenosis. It is remarkable that in 18% of the cases with recent infarction only severe stenosis was demonstrated. In 22% no relevant coronary arterial changes were seen, a frequency agreeing largely with those found in previous investigations (12, 17, 46). Among the cases with both recent infarction and myocardial scars severe stenosis without other vascular changes was found in 24% and no arterial changes in 9%.

#### Comments

The fact that occlusion of a coronary artery need not produce myocardial



*Table VII* Comparison between coronary arterial and myocardial changes demonstrated at autopsy (see fig 2)

	Total	No spec arterial changes	1 fresh thromb	Old thromb	Severe stenosis	1 fresh + old thromb	1 fresh severe stenosis	Old thromb + severe stenosis	1 fresh + old thromb + severe stenosis	Uncertain post mortem data
Total		1003	61	27	141	13	36	26	6	57
No myocardial changes	109	813	4	3	31	2	1	3	—	17
Recent myocardial infarction	62	13	29	1	7	2	7	1	—	—
Scar > 1 cm	211	150	1	15	16	1	6	3	1	3
Advanced diffuse fibrosis	17	10	1	1	14	—	—	—	—	1
Recent infarction + scar	101	10	23	4	23	7	22	12	5	1
Recent infarction + diffuse fibrosis	11	2	3	—	3	—	—	—	—	1
Scar + diffuse fibrosis	31	13	—	3	11	—	—	3	—	—
Uncertain post mortem data	10	6	—	—	—	—	—	—	—	34

infarction has been explained by the assumption that the occlusion has developed gradually and that collaterals have had time to develop (12-50). This mechanism can partly explain the cases with recent thrombosis and coexisting stenosis without consequent myocardial infarction. In cases with out stenosis occlusion without consequent myocardial necrosis may perhaps be due to a good collateral circulation as an anatomical variant it having been shown that several cases without signs of IHD *post mortem* sometimes have well functioning collaterals (20, 43). It should also be borne in mind that myocardial lesions possible to detect with routine methods do not occur until several hours after the acute occlusion.

The pathogenesis of severe coronary vascular stenosis has been widely discussed. In most cases it is probably a purely atherosclerotic narrowing but the hypothesis has been suggested that the stenosis is usually due to mural thrombi initially occluding or obstructing the lumen which are afterwards organised and lined with intima (40). Careful microscopical studies appear to support this assumption (39, 20). This mechanism would perhaps explain why scars after infarcts are associated with only severe arterial

stenosis in so many cases (23 % in this study) and also explain the pathogenesis of the myocardial infarction in these cases. But the fairly large number of recent infarcts with only severe arterial stenosis weighs against the general validity of this hypothesis.

The incorporation of a thrombus in the vascular wall may perhaps also explain why scars after infarcts are so often seen in the absence of severe coronary arterial lesions (60 % in this study). The occluding thrombus may have retracted or recanalized and become lined with intima to such an extent that even severe stenosis no longer persists. Another explanation is that in spite of the careful examination of the arteries made in this study old thrombi may have been missed. Some authors suggest the possibility of transient coronary arterial spasm as a cause of myocardial infarction but this possibility is not widely accepted (for survey see 38). Another possibility is that some infarcts are not of atherosclerotic origin (20-48).

The poor agreement between myocardial infarcts and coronary vascular lesions should be borne in mind in the interpretation of coronary angiograms especially in patients with symptoms of IHD without definite angiographic signs of stenosis.

## Relation between anamnestic symptoms and post mortem findings

This chapter concerns the relation between anamnestic symptoms of IHD and the morphological changes demonstrated post mortem in the coronary arteries and myocardium. The significance of coronary arterial lesions without associated myocardial lesions will also be discussed.

In the analysis the series was divided into groups with various combinations of typical and atypical symptoms (Table XX). The frequency distribution of various myocardial changes was studied in the respective groups. In the further analysis each group was subdivided into cases with and without myocardial lesions after which the number with various arterial changes was analysed (Tables XX a, b and c).

### Coronary and myocardial lesions in the absence of anamnestic symptoms of IHD

In the evaluation of the epidemiological method the number of false negative diagnoses is of importance, i.e. those who were erroneously judged as not having the disease. It was found

that all together 14 % (109 cases) of the cases without anamnestic symptoms of IHD had myocardial infarction. The majority (82 cases, 11 %) of these had only scars after infarcts, 10 (1 %) had only recent infarcts while 17 (2 %) had both recent and old myocardial infarcts.

Of the cases without symptoms of IHD and without myocardial lesions, 23 (4 %) had severe coronary stenosis. It can however be questioned whether such stenosis had any haemodynamic effect of clinical significance. Further, two cases had both recent and old thrombi and one an old thrombus and severe stenosis. These cases with thrombosis but without anamnestic symptoms and without myocardial lesions are of interest in the discussion of the importance of the collateral circulation mentioned in a previous section. But the combination in question was seen in only 3 cases which limits the value of the finding.

Subjects who had myocardial infarction at autopsy and who had denied IHD symptoms are as mentioned of interest in the evaluation of an epidemiological method because they impair the sensitivity of the anam-



Table 11b Atypical angina pectoris

Atypical angina pectoris						
	With previous infarction in anamnesis	With recent infarction in anamnesis	With previous and recent infarction in anamnesis	Without infarction in anamnesis		
<i>Myocardial changes</i>	9	10	3	43		
No myocardial changes	5	1	—	15 (35 %)		
Recent infarction	—	2	—	2 (5 %)		
Scar > 1 cm	2	1	1	18 (42 %)		
Diffuse fibrosis	—	—	—	9 (7 %)		
Scar and recent infarction	1	3	2	2 (5 %)		
Recent infarction and diffuse fibrosis	—	1	—	—		
Scar + diffuse fibrosis	1	1	—	3 (7 %)		
Recent infarction + scar + diffuse fibrosis	—	1	—	—		
Uncertain postmortem data	(1)	—	(1)	(2)		
<i>Coronary arterial changes</i>	9	10	3	43		
No changes	5	1	—	15		29 (67 %)
Fresh thrombosis	—	—	—	—		5 (12 %)
Old thrombosis	1	—	—	—		1
Severe stenosis	—	3	1	—		4 (9 %)
Fresh and old thrombosis	—	1	—	—		1
Fresh thrombosis and severe stenosis	—	—	—	—		—
Old thrombosis and severe stenosis	—	1	—	—		—
Old and fresh thrombosis + severe stenosis	—	—	1	—		3 (7 %)
Uncertain postmortem data	(1)	—	—	—		—
			(1)	(3)		(3)

Table 1V c With infarction in anamnesis without angina pectoris

	Typical infarction in anamnesis			
	Atypical infarction in anamnesis			
	Previous infarction in anamnesis	Recent infarction in anamnesis	Previous infarction in anamnesis	Recent infarction in anamnesis
<i>Myocardial changes</i>	0	12	17	32
No myocard changes	1	4	7 (41 %)	6 (19 %)
Recent infarction	—	4	2 (12 %)	11 (34 %)
Scar > 1 cm	—	2	5 (29 %)	5 (16 %)
Diffuse fibrosis	—	—	1 (6 %)	1
Scar and recent infarction	1	—	1 (6 %)	7 (22 %)
Recent infarction and diffuse fibrosis	—	1	—	2 (6 %)
Scar + diffuse fibrosis	1	1	1 (6 %)	—
Recent infarction + scar + diffuse fibrosis	—	—	—	—
Uncertain postmortem data	—	—	—	—
			(1)	(3)
				1
				(2)
<i>Coronary arterial changes</i>	0	11	17	32
No changes	1	4	6	6 (10 %)
Fresh thrombosis	—	—	—	15 (47 %)
Old thrombosis	—	—	2 (12 %)	—
Severe stenosis	—	—	1 (6 %)	—
Fresh and old thrombosis	1	4	2 (12 %)	5 (16 %)
Fresh thrombosis and severe stenosis	1	1	—	—
Old thrombosis and severe stenosis	—	—	—	—
Old and fresh thrombosis + severe stenosis	—	—	—	4 (12 %)
Uncertain postmortem data	1	—	—	1
	—	(1)	(1)	(3)
				1
				(2)

nostic method. This group will be analysed separately in a later section (page 67).

### Coronary and myocardial lesions in angina pectoris

Of the patients with angina pectoris combined with a history of infarction the course of the infarction was atypical in only a few. Neither did atypical angina pectoris prove to be more frequently combined with an atypical course of the infarction. Therefore all cases with a previous history of infarction irrespective whether they had run a typical or atypical course were pooled. This was also done with those with recent episodes of infarction.

Of the subjects with typical angina pectoris with previous and/or recent myocardial infarction the frequency of expected myocardial changes was about 70 %.

Of individuals with typical angina pectoris without anamnestic episodes of infarction there was myocardial scars in about 50 %. In 27 cases (41 %) there were no myocardial lesions. Among those several cases of severe arterial stenosis may be expected but only 3 had severe stenosis. Thus severe stenosis not associated with myocardial infarction seemed not to be a common cause of angina pectoris in this series. On the other hand myocardial scars were found in 51 % of the cases with typical angina pectoris without anamnestic symptoms of myocardial infarction.

The results obtained in the group with atypical angina pectoris were largely the same as those found in subjects with typical angina. Of those with atypical angina and with previous symptoms of infarction myocardial and coronary vascular changes were somewhat less common (55 %), but the difference was not statistically significant ( $\chi^2=0.92$  fig. 1,  $p>0.05$ ). Since the various subgroups were fairly small further analysis was not possible. It was, however of interest to note that of the subjects with atypical angina without anamnestic symptoms of myocardial infarction and which had no myocardial lesions post mortem (15 cases), none had severe coronary stenosis.

### Comments

Of the entire group with typical or atypical angina pectoris 53 showed no myocardial lesions. Of these only 3 had coronary arterial stenosis. Thus, in 50 of the cases with anamnestic symptoms suggestive of MI in the form of angina no coronary or myocardial changes had been seen. This suggests that the symptoms might be due to factors other than MI. These cases are of interest in the evaluation of the epidemiological method because they represent a systematic source of error which reduces the specificity of the anamnestic criterion. To form an opinion of the background of these cases they were analysed separately and are discussed in a later section (page 78).

The results may also be used as a

basis for the discussion of the significance of coronary arterial stenosis as the cause of the symptom angina pectoris. As previously mentioned only advanced stenosis was considered since most subjects above 50 years have atherosclerotic changes of the coronary arteries. Thus classification of cases into two groups with and without atherosclerosis is of no interest in the evaluation of presumed clinical sequelae. It was shown previously (Table VII, Fig. 2) that coronary artery thrombosis and/or myocardial lesions are more common among cases with advanced coronary stenosis. This result is in agreement with the consensus of opinion that stenosis predisposes to myocardial infarction. But the significance of coronary stenosis in the causation of the symptom of angina pectoris in subjects without myocardial infarction is not quite clear (14). As previously mentioned coronary arterial stenosis was found in 6% of the subjects with angina pectoris without myocardial infarction. This is roughly the same percentage as in the group who had denied anamnestic symptoms of IHD and it did not differ significantly from the frequency in the group with neither anamnestic symptoms of IHD nor myocardial lesions ( $\chi^2 = 0.42$  fig. 1  $p > 0.05$ ). This means that in this series judged in retrospect no definite association was found between angina pectoris and the occurrence of coronary arterial stenosis without myocardial infarction. In previous investigations of the relations between clinical symptoms and the

post mortem findings also a high frequency of scars has been found in the series with angina pectoris (14, 50, 65), but the significance of coronary arterial stenosis in the absence of myocardial infarction has however not been made the subject of a systematic study.

A question that then arises is whether subjects with angina pectoris and myocardial scars have arterial stenosis more often than subjects with anamnestic symptoms of infarction and myocardial scars. This proved to be the case (Table VIII). It was also of interest to note that concerning the occurrence of arterial stenosis also cases with atypical angina pectoris more closely resembled those with only anamnestic symptoms of infarction or silent infarctions.

The typical picture of angina pectoris is thus more often associated with arterial stenosis than other anamnestic symptoms of IHD, a finding in accord with the generally accepted conception. But the arterial stenosis in these cases was associated with myocardial scars even when the subject's history contained no notes of any infarction.

This prompts the question: Why have most of these cases with angina pectoris and coronary stenosis also myocardial scars though they have no anamnestic symptoms of infarction? Two possibilities may be discussed. It has been suggested that angina pectoris is always ushered in by myocardial infarction (17, 51) and this would agree with Duguid's opinion that severe vascular stenosis is



Table VII 1 Distribution of coronary stenosis among cases with different MHD anamnesis Only cases with myocardial scar are included

	1 No MHD in anamnesis	2 Atypical angina + infarction in anamnesis	3 Atypical angina without infarction in anamnesis	4 Typical angina + infarction in anamnesis	5 Typical angina without infarction in anamnesis	6 Infarction in anamnesis without angina pectoris
a With coronary stenosis without thrombosis Others	21 (17 %) 103	4 (2, %) 13	4 (16 %) 21	27 (29 %) 70	18 (47 %) 20	17 (21 %) 50
b With coronary stenosis + stenosis and thrombosis Without stenosis	27 (22 %) 97	6 (78 %) 10	7 (28 %) 16	20 (52 %) 47	21 (55 %) 17	23 (36 %) 10

II Matrices showing  $\chi^2$  values on mutually comparison between the various groups of symptoms with regard to presence of coronary stenosis The figures refer to 31 mp from groups according to I letters denote vascular groups under 3

	1	2	3	4	5	6	a	Intervals of significance
1	—	0.6	0.0	3.8	14.9	1.0	$\chi^2_{200}$ 1.81	$p=0.07$
2	1.0	—	0.5	0.1	2.3	0.1	$\chi^2_{200}$ 6.67	$p=0.01$
3	0.5	0.1	—	1.5	6.5	0.2	$\chi^2_{200}$ 10.8	$p=0.001$
4	0.7	1.1	4.4	—	4.7	1.6		
5	15.6	1.4	4.5	0.2	—	8.0		
6	4.6	0.0	0.6	7.5	3.4	—		
b								

not generally of atherosclerotic origin but most often a sequel after thrombosis (40). It might thus be imagined that coronary pain is due to a myocardial scar. It is however, difficult to find evidence for this hypothesis in the present conception of the origin of the pain in IHD (for survey see 15-28). In the light of the electrocardiographic recordings in attacks of angina pectoris it has been suggested that every attack of pain in angina pectoris is due to necrosis of a small area of the heart muscle (14). The accumulation of several small necrotic foci may cause myocardial scarring in all cases of real angina pectoris. This mechanism would also be able to explain why the repeated small attacks of pain can cease in a patient with angina pectoris after an attack of myocardial infarction. It might perhaps be due to the stenosed artery becoming occluded with consequent necrosis of its entire area of supply. This might also to a certain extent explain why coronary pain is generally absent in acute myocarditis or in chemically induced hypoxia *eg* by carbon monoxide (15-28).

### Coronary and myocardial lesions in different types of anamnestic symptoms of infarction

As mentioned patients with a history of infarction were divided into two groups according to whether the course was typical or atypical and each group was subgrouped according

to whether the infarction was previous or recent (Table XXc).

Among the cases where the symptoms satisfied Rose's criteria of previous infarction myocardial scars were found in 41 % (7 cases). Two subjects had a fresh infarction which had thus produced only insignificant symptoms. Seven subjects (41 %) had no myocardial changes and 11 of these had no coronary stenosis either. Thus this group included 35 % with a false positive diagnosis.

The group with atypical previous infarction consisted of only 6 cases including 5 with myocardial scars after infarction but in 1 case there were neither myocardial nor coronary changes. The group was too small to warrant any conclusions.

The cases with recent infarction with a typical course were 3 times as common as those with an atypical course. Of the 12 cases with an atypical course recent myocardial lesions were found in 5 scars after infarction in 3 and no myocardial changes in 4. None of these 4 subjects had severe coronary changes. The diagnosis in these 4 cases was thus falsely positive. Of the 35 cases in the group with typical anamnesis of recent infarction fresh myocardial changes were found in 20. Six cases had only myocardial scars or diffuse fibrosis. Of those 6 without myocardial changes 1 had recent coronary arterial thrombosis, 1 severe stenosis while 3 showed no coronary changes.

The 2 cases with fresh coronary thrombosis had a clinical picture resembling that seen during an actual

attack of myocardial infarction but no infarct was demonstrable not even on microscopical examination. This suggests that demonstrable myocardial changes had not had time to develop. This is a source of error that should be borne in mind when considering the use of myocardial changes as criteria of IHD at autopsy. After correction for this source of error and the exclusion of 3 cases with uncertain *post mortem* data it was found that 69 % of the cases with an anamnesis of recent typical infarction had expected myocardial changes, while 9 % (3 cases) had neither coronary nor myocardial changes. In these 3 cases then the diagnosis had been false positive.

Of those with combined previous and recent anamnestic infarcts good agreement was found with the *post mortem* findings.

A question of interest in the evaluation of the method is whether these anamnestic criteria have the same validity for men as for women. This was analyzed and the results are given in Tables VIII and IX. The cases with angina pectoris and those with anamnestic symptoms of infarction were judged separately irrespective of any coexisting infarction anamnesis or angina pectoris. In the various subgroups with anamnestic symptoms of IHD there was an insignificant tendency for more false positive diagnoses among the women.

## Comments

Of interest in the elaboration of the epidemiological method and various problems related to IHD is that the cause of angina pectoris is believed by some investigators to be partly different from that of myocardial infarction. Angina pectoris is believed to be mainly secondary to atherosclerosis while myocardial infarction is supposed to be a thrombotic complication and the two diseases would appear in different age groups and social classes (41). Moreover myocardial infarction has been described as responsible for the increase in the frequency of IHD in recent decades while the frequency of angina pectoris is believed not to have increased so substantially (41). This is an interesting hypothesis especially because if it is correct it would justify a differentiated elaboration of preventive measures. But the results presented above showed that the two groups overlapped considerably in respect of vascular changes. The above hypothesis will be tested in further detail in a future paper.

The results set forth in this chapter also showed that the use of only myocardial changes as *post mortem* evidence of IHD introduces only a slight error in this series. This applies to both angina pectoris and previous and recent infarctions. In the following arterial changes will therefore be analyzed only in special cases.

Table VIII Myocardial changes demonstrated at autopsy in different types of angina pectoris in males and females

	No angina pectoris anamnesis	Atypical angina pectoris	Typical angina pectoris	Status anginosus
<b>a Males</b>	<b>399</b>	<b>37</b>	<b>98</b>	<b>2</b>
No myocardial changes	281 (70 %)	10 (27 %)	16 (16 %)	—
Recent infarction ± rupture	16 (4 %)	2 (5 %)	11 (11 %)	1
Myocard scar > 1 cm	50 (14 %)	16 (43 %)	31 (32 %)	—
Advanced diffuse fibrosis	14 (3 %)	1 —	3 (3 %)	—
Recent infarction + myocard scar	31 (8 %)	0 (13 %)	20 (20 %)	1
Recent infarction + diffuse fibrosis	3 (1 %)	—	3 (3 %)	—
Myocard scar + diffuse fibrosis	6 (1 %)	3 (8 %)	8 (8 %)	—
Recent infarction + myocard scar + diffuse fibrosis	3 (1 %)	—	1 (1 %)	—
Uncertain postmortem data	(11)	(3)	(2)	(1)
<b>b Females</b>	<b>430</b>	<b>29</b>	<b>69</b>	<b>4</b>
No myocardial changes	300 (80 %)	12 (41 %)	16 (23 %)	—
Recent infarction ± rupture	10 (2 %)	3 (7 %)	2 (3 %)	—
Myocard scar > 1 cm	30 (8 %)	6 (21 %)	16 (23 %)	1
Advanced diffuse fibrosis	13 (3 %)	3 (7 %)	4 (6 %)	—
Recent infarction + myocard scar	9 (2 %)	3 (10 %)	21 (30 %)	3
Recent infarction + diffuse fibrosis	2 —	1	2 (3 %)	—
Myocard scar + diffuse fibrosis	6 (1 %)	2 (7 %)	4 (6 %)	—
Recent infarction + myocard scar + diffuse fibrosis	—	1 (3 %)	4 (6 %)	—
Uncertain postmortem data	(14)	(1)	(1)	—

Table XVIII Myocardial changes seen postmortem in cases with different types of anamnestic symptoms of infarction

	No infarction in anamnestic	Atypical previous infarction	Typical previous infarction	Atypical recent infarction	Typical recent infarction	Combination of previous and recent infarction
<b>a. Males</b>	401	0	20	12	52	34
No myocard changes	292 (72 %)	1	7 (27 %)	—	5 (10 %)	—
Recent infarction ± rupture	4 (1 %)	—	1	6 (50 %)	19 (36 %)	1
Myocard scar ≥ 1 cm	67 (17 %)	4	10 (15 %)	3 (20 %)	5 (10 %)	12 (16 %)
Advanced diffuse fibrosis	16 (4 %)	—	—	—	1	—
Recent infarction + myocard scar	11 (3 %)	1	4 (15 %)	1	20 (38 %)	15 (44 %)
Recent infarction + diffuse fibrosis	2	—	—	1	—	3 (8 %)
Myocard scar + diffuse fibrosis	10 (2 %)	—	4 (15 %)	1	1	■ (5 %)
Recent infarction + myocard scar + diffuse fibrosis	■	—	—	—	1	1
Uncertain postmortem data	(9)	—	(2)	—	(3)	(4)
<b>b. Females</b>	460	3	16	8	31	20
No myocard changes	370 (80 %)	2	8 (47 %)	4	2 (6 %)	—
Recent infarction ± rupture	6 (1 %)	—	1	1	7 (23 %)	—

Myocard scar > 1 cm	52 (11 %)	—	4 (23 %)	—	2 (6 %)	2 (10 %)
Advanced diffuse fibrosis	15 (3 %)	—	2 (12 %)	—	—	—
Recent infarction + myocard scar	10 (2 %)	1	—	—	14 (45 %)	13 (65 %)
Recent infarction + diffuse fibrosis	—	—	—	—	3 (9 %)	2 (10 %)
Myocard scar + diffuse fibrosis	7 (1 %)	—	1	—	2 (6 %)	1 (5 %)
Recent infarction + myocard scar + diffuse fibrosis	—	—	—	1	1	2 (10 %)
Uncertain postmortem data	(3)	—	(11)	—	(2)	(2)

## Relation between electrocardiographic changes and post mortem evidence of ischaemic heart disease

As previously mentioned classification groups based on the criteria of the Minnesota code were used. These groups were selected *a priori* against the background of results obtained in other investigations and considerations reported largely in association with the presentation of the Minnesota code (12, 13, 14, 17, 18 and 23). It would of course be of interest to study each subcategory separately and on the basis of the results find out which combination best satisfies the demands of specificity and sensitivity in this series. It is intended to carry out such an analysis after conclusion of the modification of the Minnesota code in progress (5).

Various investigations have been published of post mortem findings in cases with different electrocardiographic changes. Most of the series consisted of selected cases with clinical signs of myocardial infarction and the electrocardiographic criteria are often not defined which makes it difficult to compare the results. Because of this and the fact that the purpose of the present investigation was to judge electrocardiography as one of several instruments used in the

epidemiological method for recording IHD comparisons with previously published results have only been made when they could give further information or elucidate the results obtained. The present series was also biased not only because of the selection criteria used (see chapter I) but also because those with suspected IHD were probably examined more often with electrocardiography than those without. As a rule however, electrocardiography had been done routinely.

### Myocardial lesions in association with different types of electrocardiographic changes

In this section the series are grouped according to previous and recent electrocardiographic changes and according to sex (Table XXX and XXX). In the assessments the figures referring to cases with recent myocardial infarction in the table of previous electrocardiographic changes are less important and those with old lesions are of less interest in the table showing recent electrocardiographic abnormalities.

Of interest in this comparison is the number of cases with myocardial infarction in the group with normal electrocardiograms *i.e.* the number with false negative diagnosis which reflects the lack of sensitivity of the method. Further the number of false positive diagnosis *i.e.* cases with electrocardiographic changes but without myocardial scars is of interest because it reflects the lack of specificity of the criterion.

#### *Previous electrocardiographic changes*

Of the cases with a normal electrocardiogram 16 % had myocardial scars. A significant sex difference was found in this respect 21 % of the men with normal electrocardiograms had myocardial scars compared with 11 % of the women ( $\chi^2 = 12.0$  fig 1,  $p < 0.01$ ). But such a comparison does not give a correct picture of the sensitivity of the criterion because *post mortem* evidence of IHD was more common in the men than in the women. This means that if the criterion is equally sensitive for both sexes the group with normal electrocardiograms will comprise more cases with *post mortem* evidence of IHD in the men. This number should instead be referred to the total number with myocardial scars in either sex. Even then however the difference will be probably significant (34 % compared with 24 %  $\chi^2 = 3.85$  fig 1,  $p = 0.05$ ). The criteria in question are therefore probably more sensitive for women.

In the group with electrocardiographic changes in the form of con-

duction disorders and arrhythmias there were many individuals without myocardial scars (60 %). But this group included more cases with myocardial scars than did the group with a normal electrocardiogram especially among the women. The criterion is thus fairly nonspecific. If this criterion is not accepted as a sign of IHD more cases with real IHD will be referred to those who are judged as not having IHD according to electrocardiographic criteria and thereby further decrease the sensitiveness of the method. As previously mentioned the method of selection of the present series probably influenced the validity of this criterion because the number of cases treated with digitalis and the shift in electrolytes was greater than it would have been in a more representative sample of the population.

Of the subjects with previous electrocardiographic signs of infarction 37 % showed no myocardial scars and most of these had a normal myocardium (23 %). A significant difference was found between the sexes in this respect. In the males myocardial scars were more common ( $\chi^2 = 10.3$  fig 1,  $p < 0.01$ ). This criterion of old myocardial damage was thus less specific for women than for men in the present series.

The cases with left bundle branch block and low voltage were assigned to a special group. Only a few cases with low voltage were included and therefore the group may broadly speaking be regarded as consisting of subjects with leftsided bundle branch block. This group is important be-



Table 1111 Myocardial changes seen postmortem in cases with different types of previous electrocardiographic changes

	Normal ECG	Not normal but no signs of infarction V I 1-4 V II 2-3 V III 0-9 V 1 2-9	Infarction pattern of ant and/or lat wall I 1-2 V 1-2 V 1-2 I 3/V II	Infarction pattern of post wall I 1-2 V 1-2 I 3/V II	Left bundle branch block or diffuse myocard changes V II 1 IV 1
<b>a Males</b>	293	123	46	33	46
No myocard changes	197 (67 %)	74 (60 %)	9 (20 %)	4 (12 %)	14 (30 %)
Recent infarction ± rupture	20 (7 %)	2 (2 %)	1	2 (6 %)	5 (11 %)
Myocard scar > 1 cm	41 (14 %)	28 (23 %)	20 (43 %)	9 (27 %)	11 (24 %)
Advanced diffuse fibrosis	11 (4 %)	9 (6 %)	1	—	2 (4 %)
Recent infarction + myocard scar	14 (5 %)	5 (4 %)	10 (22 %)	12 (36 %)	9 (20 %)
Recent infarction + diffuse fibrosis	11 (4 %)	—	1	2 (6 %)	1
Myocard scar + diffuse fibrosis	4 (1 %)	5 (4 %)	4 (8 %)	3 (9 %)	2 (4 %)
Recent infarction + myocard scar + diffuse fibrosis	1	—	—	1	2 (4 %)
Uncertain postmortem data	(8)	(1)	(3)	(3)	(2)
<b>b Females</b>	293	134	28	23	41
No myocard changes	238 (81 %)	111 (83 %)	13 (46 %)	8 (35 %)	14 (32 %)
Recent infarction ± rupture	—	—	—	—	—

	14 (5%)	5 (4%)	2 (7%)	2 (9%)	2 (5%)
Advanced diffuse fibrosis					
Recent infarction + myocard scar	11 (4%)	9 (7%)	5 (17%)	4 (17%)	9 (21%)
Recent infarction + diffuse fibrosis	1	—	1	1	2 (5%)
Myocard scar + diffuse fibrosis	—	5 (4%)	1	4 (17%)	2 (5%)
Recent infarction + myocard scar + diffuse fibrosis	—	—	2	1	—
Uncertain postmortem data	(8)	(5)	(9)	(—)	(—)

cause it is large 47 % had no myocardial scars and most of these had no myocardial changes (30 %) No difference with sex was found ( $\chi^2 = 0.20$  fig 1  $p > 0.05$ ) The criterion is less specific than the electrocardiographic signs called infarction pattern (page 30) ( $\chi^2 = 4.93$ ,  $df$  1,  $p < 0.05$ ) but as expected much more specific than conduction disorders and arrhythmias ( $\chi^2 = 57.8$  fig 1,  $p < 0.01$ )

### Recent electrocardiographic changes

The cardiographic criteria given appear to be more sensitive for recent than for old myocardial damage. Thus of all the men with recent infarction only 10 % belonged to the group with a normal electrocardiogram (Table VVV). The corresponding figure for women was 11 %. The criteria comprising conduction disorders, arrhythmias and S—T depression are as expected non specific signs of recent myocardial injury with 8 % having recent infarctions in both sexes which is slightly higher than in the group with normal electrocardiograms. But because of the large total number in these groups the sensitivity is considerably reduced if these cases are assigned to the group not judged as having myocardial damage on the basis of the appearance of the electrocardiogram. The number of undiagnosed recent infarctions then increases to 30 % in the men and to 35 % in the women. Signs of local myocardial lesions, infarction pattern appear to be rather specific with false positive diagnosis only in 17 % of the men and

Table 111 Myocardial changes seen postmortem in cases with different types of recent electrocardiographic changes

	Normal 1 (6)	Not normal but no signs of infarction VI 1-4 VII 2-3 VIII 0-9 IX 2-9	S-T depression IX 1	Infarction pattern of ant wall I 1-2 IV 4 V 1-2 I 3/V 3	Infarction pattern of post wall I 1-2 IV 4 V 1-2 I 3/V 3	Left bundle branch block or diffuse myocardial changes VIII 1 IX 1
<i>n</i> <i>Values</i>	186	97	150	42	33	24
No myocardial changes	138 (74%)	54 (56%)	83 (55%)	8 (19%)	3 (9%)	0 (37%)
Recent infarction ± rupture	5 (3%)	—	5 (3%)	9 (21%)	10 (29%)	4 (16%)
Myocardial scar > 1 cm	29 (16%)	31 (32%)	37 (25%)	6 (14%)	4 (11%)	4 (16%)
Advanced diffuse fibrosis	8 (4%)	3 (3%)	8 (5%)	—	1	—
Recent infarction + myocardial scar	3 (2%)	3 (3%)	7 (5%)	17 (40%)	15 (43%)	5 (21%)
Recent infarction + diffuse fibrosis	—	2 (2%)	1	1	1	1
Myocardial scar + diffuse fibrosis	2 (1%)	3 (3%)	10 (7%)	1	1	—
Recent infarction + myocardial scar + diffuse fibrosis	1	1 (1%)	—	—	—	1
Uncertain postmortem diagnosis	(6)	(1)	(2)	(2)	(3)	(—)
Left bundle	183	70	191	27	24	31
No myocardial changes	159 (86%)	39 (56%)	137 (71%)	7 (26%)	2 (8%)	12 (39%)
		2 (3%)	6 (3%)	7 (26%)	3 (13%)	2 (6%)

Myocard scar > 1 cm	11 (6 %)	12 (17 %)	53 (17 %)	2 (7 %)	1	7 (23 %)
Advanced diffuse fibrosis	9 (5 %)	8 (12 %)	6 (3 %)	—	1	—
Recent infarction + myocard scar	3 (2 %)	5 (7 %)	6 (3 %)	9 (33 %)	16 (67 %)	6 (19 %)
Recent infarction + diffuse fibrosis	—	1	—	—	1	2 (6 %)
Myocard scar + diffuse fibrosis	2 (1 %)	2 (3 %)	6 (3 %)	1	—	2 (6 %)
Recent infarction + myocard scar + diffuse fibrosis	—	—	—	1	—	—
Uncertain postmortem data	(—)	(—)	(10)	(—)	(—)	(3)

27 % of the women. Left bundle branch block was as expected less specific: it gave a false positive diagnosis in 55 % of the men and 68 % of the women. In none of these groups was the numerical difference between men and women statistically significant.

## Anamnesis and electrocardiogram in epidemiological diagnosis of ischaemic heart disease

In epidemiological studies electrocardiographic signs have been recommended as more reliable and more objective than anamnestic criteria (35). It is of course important for the evaluation of the epidemiological method to know what significance should be attached to differences between the two methods since they are often applied simultaneously. In the present section the distribution of post mortem findings of IHD was studied in the following groups with different combinations of electrocardiographic changes and history, namely

- 1 without anamnestic symptoms of IHD and with a normal electrocardiogram
- 2 with anamnestic symptoms of IHD and corresponding electrocardiographic changes
- 3 with anamnestic symptoms of IHD but with a normal electrocardiogram
- 4 without anamnestic symptoms of IHD but with electrocardiographic changes of the type seen in myocardial infarction

The results are given in Tables XVI a and b

Signs according to the Minnesota code I 1—2, IV 4 V 1—2, I 3/V 3 and VII 1 and IX 1 which mean Q and QS pattern, S—T increase, pathological R wave progression, T wave change left bundle branch block and low QRS amplitude, were accepted as criteria of myocardial damage. As previously shown S—T depression conduction disorders and arrhythmia are not very specific and cases with these changes were excluded from the present analysis. As this exclusion affects the sensitivity and the specificity evaluation, only the frequency of correct and false positive diagnosis was studied.

### *The myocardium in subjects with agreement between anamnesis and electrocardiogram*

Of the individuals with a normal electrocardiogram and without symptoms of IHD, 89 % showed no morphological signs of IHD. If diffuse fibrosis is not taken as a sign of IHD, the number without IHD in this group will be 93 %. In those cases where both the anamnesis and the electro

Table 1111 Myocardial changes seen post mortem in cases with different combinations of electrocardiographic changes and amnesic symptoms of IHD  
a Agreement between amnesia and ECG

	Without amnesia sympt and normal ECG	Previous in farcion in amnesia + ECG changes of previous infarcion	Recent in farcion in amnesia + ECG changes of recent infarcion	Previous + recent in farcion in amnesia + ECG changes of previous and recent infarcion	Agreed post without in farcion in amnesia + ECG signs of S-T de previous infarcion
Total	251	75	100	29	9
No myocard changes	224 (89 %)	8 (11 %)	6 (6 %)	—	1
Recent infarcion	2 (1 %)	2 (3 %)	25 (23 %)	—	—
Myocard scar > 1 cm	33 (5 %)	22 (20 %)	9 (8 %)	2 (7 %)	4
Diffuse fibrosis	0 (0 %)	—	—	—	—
Recent infarcion + myocard scar	1	27 (10 %)	35 (40 %)	21 (72 %)	1
Recent infarcion + diffuse fibrosis	—	5 (7 %)	7 (6 %)	4 (11 %)	—
Scar + diffuse fibrosis	1	8 (11 %)	4 (4 %)	—	1
Recent infarcion + scar + diffuse fibrosis	1	3 (1 %)	1 (3 %)	2 (7 %)	—
Uncertain postmortem data	(5)	(7)	(6)	(3)	—
Agreement between expected an demonstrated autopsy findings	89 %	80 %	92 %	79 %	75 %

Table VIII b Myocardial changes seen postmortem in cases with anamnestic symptoms of IHD but normal ECG and in cases with ECG changes of myocardial infarction but without anamnestic symptoms of IHD

	Recent in fraction in anamnesis + normal ECG	Previous in fraction in anamnesis + normal ECG	Previous + recent in fraction in anamnesis + normal ECG	Angina pectoris + normal ECG	Recent in fraction in ECG but without anamnestic symptoms	Previous in fraction in ECG but without anamnestic symptoms	Previous + recent in fraction in ECG without anamnestic symptoms
Total	22	29	4	16	29	47	16
No myocard changes	2 (9%)	10 (34%)	—	7 (44%)	21 (72%)	30 (64%)	12 (75%)
Recent infarction	4 (18%)	1 (3%)	—	—	—	1 (2%)	—
Myocard scars > 1 cm	8 (36%)	9 (31%)	2	8 (40%)	4 (14%)	5 (11%)	2 (12%)
Diffuse fibrosis	1 (5%)	2 (7%)	—	1 (6%)	—	3 (6%)	—
Recent infarction + myocard scar	3 (14%)	6 (21%)	1	—	3 (11%)	4 (9%)	2 (12%)
Recent infarction + diffuse fibrosis	2 (9%)	—	—	—	—	1 (2%)	—
Scar + diffuse fibrosis	—	1 (3%)	1	—	—	2 (4%)	—
Recent infarction + scar + diffuse fibrosis	2 (9%)	—	—	—	—	1 (2%)	—
Uncertain postmortem diagnosis	(1)	(3)	—	(5)	—	(2)	—
Agreement between expected and demonstrated autopsy findings	30%	55%		50%	11%	26%	12%

cardiogram argued for infarction expected changes were found in 76 and 80 %. Thus as supposed the frequency of false positive and false negative diagnoses in these groups was low.

### The myocardium in subjects with poor agreement between anamnesis and electrocardiogram

Among individuals with anamnestic symptoms of IHD but with a normal electrocardiogram post mortem evidence of IHD was found in 50 and 55 % in case of recent respectively previous history of infarction (Table IIIb). When only electrocardiographic signs of myocardial damage had been noted and the patient had denied symptoms of IHD expected myocardial changes were found in only 11—26 % at post mortem. This difference was statistically significant ( $\chi^2=8.7$  fig 1,  $p<0.01$ ,  $\chi^2=6.8$  fig 1,  $p<0.01$ ).

The above mentioned differences in diagnostic efficacy between anamnesis and electrocardiogram are artificially low because only the expected myocardial changes were estimated. Of those with anamnestic symptoms of only recent infarction many showed myocardial scars as the only finding or in combination with fresh infarction (59 %) and of those with a history of only previous infarction recent infarction was found post mortem in 24 %. This reflects the well known clinical experience that infarction has a strong tendency to recur.

In addition further support was obtained for the previously demonstrated phenomenon that the clinical symptoms are liable to vary in type from time to time in one and the same patient. The course may sometimes be so insidious that the symptoms are not regarded as referable to the heart or are simply forgotten while a later infarction in the same individual may run a dramatic course an observation reported also by Snow (17).

### Comments

The results provide a basis for certain considerations concerning the sensitivity and specificity of the method. If anamnestic signs of IHD combined with a normal cardiogram are accepted a further 62 cases with post mortem evidence of IHD would be diagnosed while 19 without IHD would be accepted as IHD. This means an increase of the sensitivity without any essential reduction of the specificity. Further if electrocardiographic signs of infarction (as defined above on page 62) in subjects who had denied symptoms of IHD were accepted it would mean the diagnosis of a further 28 cases with IHD demonstrated post mortem and 63 falsely accepted as IHD. A moderate increase in sensitivity would thus imply a relatively large loss of specificity.

The results show further that it is possible not only to obtain a group with a true high frequency of the disease but also which is probably of interest from an epidemiological point of view to distinguish a group which



is fairly free from the disease. Even in this material it was possible to distinguish these extreme groups so that they comprised a relative large proportion of the series. In addition a number of intermediate groups were obtained with IHD with varying degree of probability. These intermediate groups consisted above all of individuals who had denied anamnestic symptoms of IHD but who were

separated from this group because of electrocardiographic changes judged as fairly nonspecific.

The results suggest that the anamnesis is the most important method in the diagnosis of IHD while electrocardiography as an independent method does not appear to contribute essentially to the firmness of the diagnosis. It has, however, great value as a supplementary method.

## Factors impairing sensitivity and specificity of the method

The factors reducing sensitivity and specificity of the method are referable to two groups of individuals: those with a false negative diagnosis of IHD, i.e. those in whom IHD was not diagnosed with anamnesis or electrocardiogram but in which autopsy showed myocardial infarction and those with a false positive diagnosis, i.e. those judged as having IHD from anamnesis and electrocardiogram but in whom autopsy showed no morphological signs of IHD. Attempts were therefore made to find a method for correcting for these sources of error. This was thought possible if certain characteristics might be demonstrable in individuals in these two groups—characteristics distinguishing them from the other cases in the group. It appears reasonable *a priori* to assume that these two groups are not homogenous but are due to several aetiological factors which might produce manifestations separately or possibly in combination with one another.

### Cases without symptoms of IHD but with post mortem evidence of infarction (*silent infarction*)

The definition of silent infarction varies from author to author. In the Framingham study (2) supervised electrocardiographic signs of myocardial lesions without anamnestic symptoms referable to the heart were taken as a sign of silent infarction. In some post mortem investigations all cases in which the physician when requesting post mortem had not noted myocardial infarction but in which myocardial lesion was found were classified as silent (23-24).

In the present investigation myocardial infarction was said to be silent if at the time of the last admission to hospital the patients had denied having had symptoms referable to the heart and if he had been cared for previously at Malmö General Hospital no signs of IHD had been noted in his records. This means either that the patients have had no symptoms interpreted as cardiac symptoms or that any symptoms they might have had were such that the patients did

not recall them. Neither should they have had any electrocardiographic abnormalities suggesting myocardial infarction according to the definition given in page 62. Recent myocardial infarction or myocardial scars more than 1 cm in diameter should further have been demonstrated post mortem. Cases with only diffuse myocardial fibrosis were not accepted.

In an epidemiological investigation these cases introduce a systematic source of error because they are assigned to the group judged as not having IHD. This means that when the group judged as having IHD is compared with that judged as not having IHD these cases tend to mask differences which might be related to IHD factors.

The reason why myocardial infarction does not always produce symptoms has been the subject of various investigations. The theoretical basis of the suggestions offered are however often less convincing, owing to the lack of control series. Subjects with amnesic symptoms of myocardial infarction verified post mortem would be suitable as controls. If another type of controls is used it will probably be difficult to decide whether differences, if any, were due to factors related to IHD or whether they were related to the fact that IHD in these cases was asymptomatic. In the present series the control cases used consisted of those which had had typical amnesic symptoms of infarction (for definition see page 2a) and in which autopsy had revealed myocardial infarcts. The comparison

was also limited to previous myocardial infarctions.

In previously published series two fundamentally different approaches were used in the search for the causes. Firstly attempts were made to explain why the myocardial infarction ran silent, secondly it has been assumed that the symptoms were equally severe as in the overt cases but for some reason or other had not been noted or interpreted by the subject in the same way.

It has been tentatively suggested that these silent infarcts occur in the silent zones of the myocardium. But the fact that no relation has been found between the course and the site of the damage weighs heavily against this hypothesis (28). It has also been assumed that certain subjects have a high pain threshold (1, 2, 28) and thereby experience the pain in a different way. But this is difficult to bring in line with the fact that as mentioned one infarction in a person may be asymptomatic while a later one in the same person run a very dramatic course. Further it has been postulated that in elderly individuals the course of myocardial infarction is less dramatic than in young ones and that the former are more liable to forget a previous attack of pain (24, 36). But no difference in age distribution could be demonstrated (Fig. 3) between cases with silent infarction and those with infarction which has given clinical symptoms (here called symptomatic infarction) in the present series ( $t=0.42$   $p<0.05$ ). Nor was any significant difference found when the




Fig 3 Age distribution in cases with myocardial infarction post mortem divided in anamnestic silent and symptomatic cases. No significant difference in age or age distribution could be demonstrated

data were classed according to sex and compared in a corresponding way ( $t=0.20$   $p>0.05$   $t=0.75$   $p>0.05$ ). The fact that no age difference could be found and that the numerical difference was so small facilitates further comparisons.

It has also been assumed that silent infarctions occur mainly in patients with arterial hypertension. This hypothesis is based on the fact that the individuals in series with silent infarction usually have large hearts (21-24). In the present investigation however no difference in the frequency of hypertension was demon-

strated between the two series (Table III a). But a significant difference was found in the heart weight in both sexes (Table III b) with a lower weight in cases with silent infarction than in the controls with symptoms on their infarction. This seems to argue against the cited results (21-24). But it need not. The difference may be due to differences in the control series. When cases of silent infarction were compared with those without IHD it was found that also in the present series the heart weight was significantly increased in the men but not in the women. If Evans et al (21) in

Table VIII Comparison between hypertension variables in symptomatic infarction and in silent infarctions

	Males		Females	
	Symptomatic infarction	Silent infarction	Symptomatic infarction	Silent infarction
<i>a. Diagnosis of hypertension</i>				
Normal blood pressure	21	22	1	16
High blood pressure complications not studied	5	8	4	5
High blood pressure without complications	2	—	1	—
High blood pressure only with enlarged heart	—	—	—	2
High blood pressure with enlarged heart and renal changes or changes in ocular fundi	4	6	1	8
Malignant hypertension	—	—	—	1
Incomplete data	(1)	(2)	—	(1)
Total	32 (33)	36 (37)	14	31 (32)
	$\chi^2=0.24$ <i>df</i> 2 $p>0.05$		$\chi^2=2.7$ <i>df</i> 2 $p>0.05$	
<i>b. Heart weight</i>				
	$4.63 \pm 1.27$	$3.6 \pm 1.10$	$4.11 \pm 1.12$	$3.45 \pm 1.09$
	$t=3.19^{**}$		$t=1.73^*$	
<i>c. Thickness of left ventricular wall</i>				
	$4.9 \pm 1.26$	$4.09 \pm 1.0$	$4.67 \pm 0.97$	$4.10 \pm 0.92$
	$t=0.60$		$t=0.54$	
<i>d. Thickness of right ventricular wall</i>				
	$3.77 \pm 1.33$	$3.61 \pm 1.61$	$3.67 \pm 1.00$	$3.30 \pm 1.17$
	$t=0.14$		$t=0.08$	

\* Not absolute values; provisional values used

their evaluation of high heart weight compared it with normal heart weight in series of mixed sex their results could be explained and would agree with those in the present investigation. But they do not state how they calculated their reference heart weight or how large it was. As mentioned above, however, differences between cases with and without IHD should reflect factors associated with IHD and not the type of course of IHD. In the present series the heart weight in subjects with silent infarc-

tion was smaller than in those with symptomatic infarction. This, however, does not necessarily mean that hypertension was more common in the latter. Other important factors capable of influencing the weight of the heart are organic valvular disease, bodybuild and physical training. Only in one case was there a clinical history of valvular disease (aortic stenosis) among the cases with symptomatic infarction. Among the cases with silent infarction were 2 with a clinical history of valvular heart disease.

which had been interpreted as a combined aortic valvum and a congenital valvum respectively. Post mortem examination showed a further case of aortic stenosis among those with symptomatic infarction and the clinical diagnosis in the two above mentioned cases with silent infarction were verified. Even after these cases had been excluded there was a statistically significant difference in heart weight between the two groups. Thus it seems as if organic valvular heart disease did not cause the difference in heart weight.

It appears *a priori* to be reasonable to assume that the differences in blood pressure in the general circulation may have been of significance in the causation of the differences in heart weight. As mentioned however no statistically significant difference could be found in the frequency of arterial hypertension even if there was a weak tendency for hypertension to be more common among the women with symptomatic infarction. If those cases with a high blood pressure were excluded the difference in heart weight in the males would persist in the females, a numerical difference would also persist but it would not be statistically significant. If the difference in heart weight is due to a high blood pressure it should be reflected in differences in the thickness of the wall of the left ventricle. But no such difference was demonstrable (Table XXXVII c). Nor could any difference be demonstrated in the thickness of the wall of the right ventricle (Table XXXII d). This reduces the validity of

the significant difference in heart weight between the two groups. A third possible explanation of the difference in heart weight might be differences in body build and physical fitness which however were not studied.

Summing up no evidence was found in support of the assumption that hypertension should be a causal factor of silent infarction more than in overt infarction. Nor could any evidence be demonstrated for the assumption that a difference in blood pressure is the cause of the increased heart weight in subjects with symptomatic infarctions compared with the subjects with silent infarction.

It has been claimed by some authors that there is no true difference in the clinical picture of patients with silent infarctions and of those with symptomatic infarctions and various reasons had been given why these cases do not behave in the same way. One factor might be that some individuals will not accept a symptom as a symptom of heart disease because it would mean the acceptance of a serious diagnosis (47). Such a hypothesis is however impossible to test in the present series. Further it has been claimed that heart pain can be concealed by impairment of the sensorium often be cause of a cerebrovascular insult. No difference could however be demonstrated in respect of *intra vitam* or *post mortem* evidence of cerebrovascular insult (Table XXXIII a c and d). It has also been postulated that pain can be misinterpreted by the subjects who have some other chronic painful

**Table XVIII Cerebral vascular lesion and clinical and postmortem signs of atherosclerosis in cases with symptomatic and silent myocardial infarction**

	Males		Females	
	Symptomatic infarction	Silent infarction	Symptomatic infarction	Silent infarction
<i>Clinical data</i>				
<b>a Cerebral vascular lesion</b>				
Without signs of vascular lesion	22	27	4	15
With signs of vascular lesion	10	11	10	10
Uncertain data	(1)	—	—	—
Total	32 (33)	38	14	31
			$\chi^2=1.54$ fig 1 $p>0.05$	
<b>b Intermittent claudication</b>				
Without signs of claudication	30	37	13	31
With signs of claudication or amputation	2	2	1	—
Uncertain data	(1)	(1)	—	—
Total	32 (33)	37 (38)	14	31
<i>Postmortem data</i>				
<b>c Cerebral vessels</b>				
Without signs of changes in cerebral arteries	27	31	8	20
Fresh or old thrombosis	4	—	4	11
Severe stenosis	1	2	2	—
Aneurysm or rupture	—	1	—	—
Uncertain data	(1)	(1)	—	—
Total	32 (33)	37 (38)	14	31
<b>d Cerebral infarction</b>				
Without cerebral infarction	25	29	9	16
Recent infarction	3	1	4	9
Old infarction	1	3	1	5
Status lacunaris	—	1	2	3
Cerebral atrophy	2	2	2	2
Uncertain data	(1)	—	—	—
Total	31 (33)	38	14	31
<b>e Atherosclerosis</b>				
	$t$ $p$		$t$ $p$	
Aortic arch	$3.03 \pm 0.81$	$3.08 \pm 0.79$	$3.39 \pm 0.85$	$2.71 \pm 0.67$
	$0.20 >0.05$		$2.22 <0.01$	
Aortic aorta	$3.36 \pm 0.91$	$3.62 \pm 0.86$	$4.31 \pm 0.80$	$3.65 \pm 0.92$
	$0.21 >0.05$		$2.24 <0.05$	
Left desc. cor. artery	$3.11 \pm 0.82$	$3.21 \pm 0.73$	$3.07 \pm 1.19$	$2.41 \pm 1.04$
	$0.90 >0.05$		$1.61 >0.05$	
Left circ. cor. art.	$2.75 \pm 1.09$	$2.61 \pm 1.01$	$2.43 \pm 1.31$	$1.80 \pm 1.10$
	$0.80 >0.05$		$1.29 >0.05$	
Right cor. artery	$2.91 \pm 0.71$	$2.86 \pm 1.06$	$2.30 \pm 1.12$	$2.00 \pm 1.21$
	$0.70 >0.05$		$1.20 >0.05$	

$t$  denotes Student's  $t$  test and  $p$  probability of deviation of  $t$  from nil is due to chance

Table XXV Comparison regarding frequency of gallstone in cases with symptomatic and silent infarction

	Males		Females	
	Symptomatic infarction $\chi^2$	Silent infarction	Symptomatic infarction $\chi^2$	Silent infarction
Without anamnestic symptoms suggesting gallstone	26	35	7	26
With anamnestic symptoms suggesting gallstone or operated upon for gall stone	6 0.20 $\chi^2$ 1 $p > 0.05$	2	7 6.45 $\chi^2$ 1 $p < 0.01$	5
No gallstone at autopsy	14	24	3	11
Gallstone or status after operation for gallstone	18 3.10 $\chi^2$ 1 $p < 0.01$	13	11 0.88 $\chi^2$ 1 $p > 0.05$	20

disease the coronary pain then being referred to the usual sort of pain *e.g.* gallstone or peptic ulcer (15-28). But no difference was found regarding the frequency of anamnestic symptoms of ulcer and of evidence of ulcer post mortem (these data are not included in the tables). On the other hand differences were found in the frequency of gallstone (Table XXV). The difference however weighed against the above hypothesis. In subjects with silent infarction both in the men and the women anamnestic symptoms and post mortem findings of gallstone were less common than in the subjects with symptomatic cardiac infarction. This numerical difference was statistically significant only regarding the frequency of gallstone found in the men post mortem and symptomatic gall

stone in the women (Table XXV). This difference can hardly be a manifestation of competing selective factors which go under the common name of Berkson's fallacy (6-7) but presumably represent a biologically meaningful relation.

Other conditions of the heart such as cardiac incompetence and auricular fibrillation have been thought to be able to mask myocardial infarction (21-23-24). But no difference was found in the males or in the females regarding the number with cardiac incompetence ( $\chi^2 = 0.40$   $\chi^2$  1  $p > 0.05$ ,  $\chi^2 = 2.0$   $\chi^2$  1  $p > 0.05$ ). The problem of auricular fibrillation was not studied because the control cases were not suitable in this connection.

In the present analysis it was shown that the heart weight is higher in



subjects with symptomatic cardiac infarction. This could not be explained by any difference in the frequency of vascular heart disease. Neither was any evidence produced for a high blood pressure being the cause of the differences. It is therefore possible that differences in body build may explain the difference in heart weight between the subjects with silent and with symptomatic infarctions. These bodybuild factors which can influence the heart weight have previously been shown to be related to the severity of atherosclerosis in the coronary vessels (24). Now if bodybuild factors are responsible for the difference in heart weight, one might expect a difference in coronary atherosclerosis in such a way that atherosclerosis was not so severe among cases with silent infarction. Such differences were also found in certain vascular areas. In women there was significantly more advanced atherosclerosis of the aortic arch and of the abdominal aorta and a systematic tendency, not statistically significant for atherosclerosis of the coronary vessels to be more advanced in subjects with symptomatic infarction. No differences in these respects were found among the men (Table XXIII c). It was of interest to test whether this difference could be ascribed to the morphologically relevant changes in cases with severe stenosis and occlusions. It is clear from Table XXX and Fig. 4 that individuals with myocardial scars but without any IHD atherosclerosis less often had severe coronary lesions. This result can be mentioned above be due partly to

the assumption that in earlier thrombus in the coronary vessels had retracted or become recanalised and lined with intima (38, 39, 40). Also the results in other published investigations argue for atherosclerosis and thrombotic complications being less common in cases with silent infarctions. On careful post mortem examination at which special attention was given to the size of the infarctions it was shown that, unlike large scars scars less than 2 cm appeared not to be so intimately related to the atherosclerosis of the coronary vessels as the large scars (20-48). In another post mortem examination of an infarction series in which cases with and without occlusion of the coronary vessels were compared the myocardial lesions in the cases without occlusions tended to be small isolated and not associated with such striking clinical symptoms as the cases with thrombosis (12).

These results support the hypothesis that in patients with silent infarction the lesion to some extent might less often be caused by atherosclerosis and thrombotic complications as in cases with symptomatic infarction. Also the relation between gallstone and the symptomatic infarction suggests in respective whether this relation is a manifestation of two symptoms of a disorder of the cholesterol metabolism or some other condition that the silent infarctions to a certain extent have different aetiology from that of the clinically symptomatic cases.

The pathogenesis of these myocardial scars without clinical symptoms is of course of interest. This may be




Fig 4 Grade of atherosclerosis in cases with symptomatic and silent infarction in females

sequelae after acute intimal swelling or bleedings which have regressed (38). They might also be scars after myocarditis. But such scars are rarely of this localized type (53). No evidence

were obtained that these changes were of rheumatic type or conditions after septic emboli. The possibility of metabolically induced necrosis (30-53) remains.

Table 1. Results of the analysis of variance for the effect of the type of the material on the results of the analysis.

Source of variation	Between materials		Within materials		Total	Degrees of freedom	Mean square	F-value	Probability	Type of material
	Sum of squares	Mean square	Sum of squares	Mean square	Sum of squares					
Between materials	14.0	14.0	1.1	1.1	15.1	1	14.0	1.1	0.30	Infected
Within materials	1.1	1.1	1.1	1.1	2.2	1	1.1	1.1	0.30	Infected
Total	15.1	15.1	2.2	2.2	17.3	2	8.65	8.65	0.01	Infected
Error	1.1	1.1	1.1	1.1	2.2	1	1.1	1.1	0.30	Infected
Corrected total	14.0	14.0	1.1	1.1	15.1	1	14.0	1.1	0.30	Infected

The results of the analysis of variance for the effect of the type of the material on the results of the analysis are shown in Table 1. The results of the analysis of variance for the effect of the type of the material on the results of the analysis are shown in Table 1.

Source of variation	Between materials		Within materials		Total	Degrees of freedom	Mean square	F-value	Probability	Type of material
	Sum of squares	Mean square	Sum of squares	Mean square	Sum of squares					
Between materials	14.0	14.0	1.1	1.1	15.1	1	14.0	1.1	0.30	Infected
Within materials	1.1	1.1	1.1	1.1	2.2	1	1.1	1.1	0.30	Infected
Total	15.1	15.1	2.2	2.2	17.3	2	8.65	8.65	0.01	Infected
Error	1.1	1.1	1.1	1.1	2.2	1	1.1	1.1	0.30	Infected
Corrected total	14.0	14.0	1.1	1.1	15.1	1	14.0	1.1	0.30	Infected




Fig. 3. Grade of atherosclerosis in cases with symptomatic and silent infarction in males

These results may imply a limitation of the possibility of using myocardial scars as a definite sign of IHD if the term IHD is to mean sequelae after atherosclerotic and thrombotic conditions of the heart. Myocardial scars alone as a criterion would thus probably result in too many false negative diagnoses. The frequency of false positive diagnoses would probably be affected less. Certain observations suggest that these errors of the method can be corrected to a certain extent if only scars larger than 3 cm in diameter be accepted as a criterion of IHD of this type (20-48) but as assessment of the error of such a procedure requires further investigation.

Pathogenic factors discussed in previous publications on silent infarctions were not found to be of any significance in the present series which may to a certain extent be due to the fact that the term is defined in a different way with the result that the series differ in composition. No characteristics over and above those possibly related to a lower degree of coronary atherosclerosis could be demonstrated in cases of silent infarction.

### Cases with symptoms of ischaemic heart disease but without post mortem evidence of the condition

In these cases there were anamnestic symptoms simulating those of IHD. In an epidemiological investigation these cases introduce a systematic source of error with reduction of the

specificity of the method. This implies a tendency to mask differences related to risk of IHD.

A systematic analysis of these cases in all symptom groups separately would be of interest, but there were not enough cases of this type in the groups with anamnestic symptoms of infarction to allow conclusive results (Table XX). Moreover, it was not considered advisable to take together cases from different symptom groups because of the possibility of different causal factors simulating different symptoms of IHD. The group with false positive diagnosis in the individuals with angina pectoris was judged to be large enough for analysis. Therefore, this analysis was confined to cases with clinical symptoms judged as angina pectoris but without coronary or myocardial changes at autopsy.

Suitable as controls are age and sex matched subjects without post mortem signs of IHD. The controls were selected in the following way: For each subject with angina pectoris like symptoms we accepted next autopsied individual of the same sex and at most 3 years younger or older at the time of death and who had no clinical signs of IHD or no myocardial or coronary changes compatible with IHD.

One might a priori expect cases of atypical angina to be overrepresented among those cases with symptoms falsely interpreted as IHD but no significant difference was found between cases with typical and atypical angina pectoris regarding the frequency of

false positive diagnosis ( $\chi^2 = 1.41$ ,  $df = 1$ ,  $p > 0.05$ )

Mainly two mechanisms might be imagined in the causation of angina pectoris like symptoms namely extracardiac changes producing recurrent pain resembling that of angina pectoris and pathological conditions involving the heart and thereby precipitating symptoms conceived as angina pectoris. Among the extracardiac causes diseases of the gallbladder and the stomach may be considered the heart by its gastrocoronary and cholangio coronary reflexes (15) then acting as a resonator of the pain in these organs (28). Further it has been shown that pulmonary emboli are often conceived as IHD (23). Also pneumonia emphysema and cor pulmonale might produce IHD like symptoms and a segment syndrome due to compression of the root of a spinal nerve can produce pain simulating that of IHD. There are other less common diseases from which IHD pain must be differentiated.

Hypertension and valvular heart disease by their effect on the heart may produce pain difficult to distinguish from true angina pectoris (46). By a partly different mechanism anemia is also believed to cause angina pectoris (54) but probably only in the presence of a coronary vascular stenosis (15).

#### *Conditions capable of simulating angina pectoris*

Table XXXI gives a comparison between the patients with IHD like

symptoms and controls of some of the conditions believed to be capable of simulating angina pectoris. The frequency of clinical signs and post mortem evidence of peptic ulcer and of gallstone and autopsy findings of pulmonary embolism and pneumonia was studied. Neither among the men nor among the women was any difference found. It was astonishing that the number of cases with pulmonary embolism was so low among the subjects with symptoms simulating IHD. This might however have been due to the fact that a comparison was made of angina pectoris like symptoms. It is probable that pulmonary emboli more often simulated myocardial infarction.

Thus no evidence was produced for the possibility that peptic ulcer and gallstone pulmonary embolism and pneumonia had produced symptoms diagnosed as angina pectoris in this series.

#### *Hypertension and valvular heart disease as cause of angina pectoris like symptoms*

It is quite likely that other diseases than atherosclerosis involving the heart or the circulation can produce symptoms resembling angina pectoris. Cases of hypertension and valvular heart disease producing such symptoms have often been described (46, 33). These observations agree with clinical experience. Also in the present series cases with hypertension and enlarged hearts were overrepresented among patients with symptoms simulating angina pectoris. In the males there were 30% with hypertension compared with 16% in the

Table VIII Frequency of gallstone and gastric or duodenal ulcer in patients with angina pectoris like symptoms and in controls

	Males		Females	
	Angina like symptoms	Controls	Angina like symptoms	Controls
<b>a Gastric or duodenal ulcer</b>				
<i>Clinical data</i>				
No anamnestic symptoms	20	17	19	19
Symptoms of gastritis	1	1	—	—
Clin. diag. gastric ulcer	—	2	1	1
Duodenal ulcer	—	2	1	1
Melena USS	2	1	1	1
Uncertain data	—	—	—	—
	$\chi^2=1.31$		$p>0.05$	
<i>Postmortem data</i>				
No signs of ulcer	20	13	16	16
Recent ulcer	2	4	1	1
Scar after ulcer	1	4	2	2
Other gastro intestinal diseases	—	2	1	3
	$\chi^2=2.09$		$p>0.05$	
<b>b Gallstone</b>				
<i>Clinical data</i>				
No anamnestic symptoms	22	21	13	17
Clinical signs of gallstone	1	2	1	1
<i>Postmortem data</i>				
No gallstones	14	13	8	11
Gallstones	9	9	14	16
<b>c Pulm embolism and pneumonia</b>				
Without signs of pulm emb	10	20	18	19
With signs of pulm emb	4	3	4	3
Without signs of pneumonia or severe bronchitis	11	17	13	11
With signs of pneumonia or severe bronchitis	9	6	7	11
			$\chi^2=1.50$	
			$p>0.05$	
<b>d Valvular heart defect clinically diagnosed</b>				
No	18	23	20	22
Yes	4	—	2	—
<i>Demonstrated post mortem</i>				
No	18	23	19	22
Yes	4	—	4	—

Table XXXI Various hypertension variables in cases with angina pectoris like symptoms and in controls

	Males		Females	
	Angina like symptoms	Controls	Angina like symptoms	Controls
<i>a. Diagnosis of hypertension</i>				
Normal blood pressure	15	17	7	10
High blood pressure complications not studied	1	2	7	8
High blood pressure without complications	—	—	—	—
Only with enlarged heart	1	—	1	1
With enlarged heart and renal changes or changes in ocular fundi	0	3	4	—
Malignant hypertension	—	—	—	—
Incomplete data	—	1	1	1
Total	23	22 (23)	22	22
<i>b. Heart weight</i>				
	439 ± 130 t=1.84	361 ± 152 p<0.05	300 ± 80 t=0.52	286 ± 93 p>0.05
<i>c. Thickness of left ventricular wall<sup>1</sup></i>				
	4.73 ± 1.13 t=2.97	3.73 ± 1.15 p<0.01	4.48 ± 0.60 t=1.37	4.14 ± 1.00 p>0.05
<i>d. Thickness of right ventricular wall<sup>1</sup></i>				
	3.77 ± 1.54 t=2.02	2.90 ± 1.12 p<0.05	3.29 ± 0.70 t=2.50	2.71 ± 0.72 p<0.01

<sup>1</sup> Not absolute values provisional values used

controls, the corresponding figures for the females being 23 % and 16 %. These differences were however, not statistically significant. Further the cases with angina pectoris like symptoms included 8 with valvular heart disease which was not seen in any of the controls. If, in these cases the hypertension and valvular heart disease had contributed to the symptoms referable to the heart they should have influenced the weight of the heart. Most of the males with symptoms resembling angina pectoris re-

ally had heavier hearts (Table XXXII). This difference can be referred to both the thickness of the wall of the left ventricle and that of the right ventricle (Tables XXXII a b and c). In the females the difference was found only in the thickness of the right ventricular wall (Table XXXII c). To check whether cases with valvular heart disease and hypertension were responsible for the higher heart weight and the difference in the thickness of the ventricular wall these cases were excluded. After the



1 cases with organic heart disease had been excluded from the male group, the difference in heart weight was reduced and no longer statistically significant ( $t=1.27$ ,  $p>0.05$ ), but still probably significant regarding the thickness of the left wall ( $t=2.32$ ,  $p<0.05$ ) and the right wall ( $t=1.87$ ,  $p<0.05$ ). When also male cases that had a high blood pressure were excluded from this group and from the controls, the numerical difference was only small regarding the heart weight ( $t=0.20$ ,  $p>0.05$ ) and the thickness of the right wall was numerically, on the average, somewhat larger among the controls. Yet the difference regarding the left wall ( $t=1.72$ ,  $p<0.05$ ) was still probably significant. After the 1 cases with valvular heart disease in the female group had been excluded the difference in the thickness of the right wall persisted ( $t=2.40$ ,  $p<0.05$ ). When also the cases with hypertension were excluded from both the cases with angina pectoris like symptoms and from the controls in females no difference in the thickness of the right ventricular wall persisted ( $t=0.0$ ,  $p>0.05$ ).

The larger number of cases with valvular heart disease and hypertension in the group with symptoms interpreted as signs of angina pectoris thus seems to be able largely to explain the difference in heart weight and in the thickness of the ventricular walls shown on comparison with the controls. Since the cases with valvular heart disease and hypertension had such a strong effect on the mass of the heart muscle it was tempting to

assume that this could explain the angina pectoris like symptoms in these cases. This point was considered to be due to the fact that the increased demand for blood by the enlarged heart could not be satisfied in cases of valvular heart disease and hypertension with the generally increased demands on the oxygen transport that is present in these cases (15).

As is well known aortic stenosis causes angina pectoris like symptoms. This conception is supported by the types of clinically diagnosed valvular heart disease among subjects with angina pectoris like symptoms. Of the 6 cases 4 had aortic valvular disease including stenosis in 2 insufficiency in 1 and combined disorder in 1. 1 had mitral stenosis and 1 an unclassifiable type. Aortic valvular disease appears to be overrepresented on comparison of the distribution between clinically diagnosed aortic and mitral valvular disease in the entire series. The difference was, however, not statistically significant ( $\chi^2=0.8$ ,  $df=1$ ,  $p>0.05$ ). At autopsy the 4 cases of aortic disease and mitral disease were verified but 3 cases of mitral disease were also discovered which makes the distribution between different types of valvular diseases equal. It agrees with the distribution of the disease of the aortic and mitral valves in the entire series found *post mortem*.

Among the men with angina pectoris like symptoms there was also a systematic but not significant tendency for the coronary atherosclerosis to be more advanced than in the controls (Table XXXIII). The difference was reduced considerably when cases with hypertension were excluded which suggests that a high blood pressure can have produced an effect in this respect too as mentioned above.

Table XXVIII Clinical signs of cerebral vascular lesion and postmortem evidence of atherosclerosis in cases with angina pectoris like symptoms and in controls

	Males		Females	
	Angina pectoris like symptoms	Controls	Angina pectoris like symptoms	Controls
<b>a Clinical signs of cerebral vascular lesions</b>				
Without signs of cerebral vascular lesion	17	15	13	15
With signs of cerebral vascular lesion	6	7	8	7
Uncertain data	—	1	1	—
Total	23	23 (23)	21 (22)	22
<b>b Cerebral infarction seen post mortem</b>				
No cerebral infarction	19	21	14	18
Recent infarction	3	2	5	—
Old infarction	1	—	1	—
Status lacunaris	—	—	—	3
Combinations	—	—	2	1
Uncertain data	—	—	—	—
Total	23	23	22	22
<b>c Atherosclerosis</b>				
Aortic arch	2.30 ± 1.00 t = 0.34 p > 0.05	2.56 ± 0.79	3.18 ± 0.50 t = 0.76 p > 0.05	2.95 ± 0.85 3.81 ± 0.85
Abd aorta	3.13 ± 1.20 t = 0.34 p > 0.05	2.96 ± 0.79	3.82 ± 0.77 t = 0.03 p > 0.05	3.81 ± 0.85
Left desc cor art	2.65 ± 1.28 t = 1.12 p > 0.05	2.00 ± 1.12	2.82 ± 0.64 t = 0.45 p > 0.05	2.67 ± 0.93
Left circ cor art	2.00 ± 1.41 t = 1.21 p > 0.05	1.30 ± 1.13	2.09 ± 1.17 t = 0.30 p > 0.05	1.95 ± 0.89
Right cor art	2.26 ± 1.26 t = 1.44 p > 0.05	1.43 ± 1.25	2.50 ± 1.00 t = 0.80 p > 0.05	2.09 ± 1.18

coronary atherosclerosis was never so advanced as to cause substantial stenosis of the coronary arteries

### Comments

The results show that certain common painful conditions in the chest and in the upper part of the abdomen are

not especially common in patients with symptoms falsely interpreted as angina pectoris. On the other hand there was reason to assume that subjects with valvular heart disease and hypertension with cardiac enlargement contributed to the symptoms simulating angina pectoris in the absence of severe coronary stenosis

or myocardial scars after infarction. In this series, then, this might have been so in 11 of the 23 cases in the males and in 9 of 22 cases in the females. As to the remaining cases nothing was found to explain the angina pectoris like symptoms.

In almost half of the cases with false positive diagnosis then certain well defined characteristics could be distinguished which might be used to reduce the number of false positive diagnoses. As to hypertension however, certain difficulties arise. This condition is believed to have an atherogenic effect and to be an aetiological factor of IHD. This means an overrepresentation of cases with symptoms of true IHD among those sub-

jects who had hypertension with the result that it is difficult to decide which are true and which are false. Neither is electrocardiography of differential diagnostic value because one of the requirements for the false pain is believed to be thickening of the left ventricular wall and in these conditions there are often cardiographic changes sometimes difficult to distinguish from those of myocardial damage. Cases with valvular heart disease might however, offer a possibility of correction. It is thus probable that the symptoms of IHD in younger subjects with valvular heart disease and an enlarged heart is less often due to true IHD.

## Specificity, sensitivity and validity of typical and atypical clinical symptoms and certain electrocardiographic criteria

If a pilot study is to be used in the assessment of the magnitude of the sources of error of an epidemiological method the series should be as representative as possible of the population in question. It seems difficult however to assess the errors of the methods for diagnosing IHD in a representative group because the possibilities of judging the true occurrence of IHD in such a series are limited. One must therefore resort to *post mortem* series which implies the introduction of various selective factors (cf chapter I). These factors should be considered in the evaluation of the results.

The *specificity* is the ability of the criteria to exclude the possibility of the disease in a person not affected with it. The term thus designates the quotient between the number of healthy subjects screened out by the method as healthy in a given series and the true number of healthy subjects in the series (55-56).

*Sensitivity* measures the ability of the criteria to detect all cases of a given disease in a given series and designates to the percentage of true positives detected (55-56).

The sum of the two percentages

sensitivity and specificity is a diagnostic score and gives supplementary information (5a). If this sum is 100 it means that the criterion is the same as a random selection. If it is 200 it means that the method can identify all cases of a given disease without any missed diagnosis or overdiagnosis. Of these two numbers 100 is an important limit at which the criterion should be regarded as valueless. It would however not be advisable to report only the diagnostic score or an analogous index (57) because one would then lose the valuable information obtainable from a comparison between the rate of specificity and sensitivity (55-58).

*Validity* is more difficult to describe and it designates the extent to which the criterion measures the particular attribute it is intended to measure (3). In this case one can with reservation for that set forth above (page 78) regarding the limitation of the autopsy method postulate that IHD demonstrated *post mortem* is a valid sign of "true IHD". The percentage of *post mortem* diagnoses in a criterion group reflects an important aspect of the validity of the criterion.

The present analysis was confined

Table XXXI Sensitivity, specificity and validity of certain criteria of IHD

	Total	With out IHD post mortem	With IHD post mortem	Speci- ficity	Sensi- tivity	Agreement between clinical signs and post mortem findings
<b>a Anamnesis</b>						
1 IHD anamnesis according to clinical	703	1	137	91%	46%	61%
With IHD anamnesis ac- cording to Rose	866	11	161			
As under 1 and atypical anamnesis	768	99	169	87%	3%	67%
With IHD anamnesis	809	103	11			
<b>1 IECG changes</b>						
1 Signs of infarction (accord- ing to Minnesota-code 1-1-2)						
V 1-2 I S V 3	130	4	87	91%	71%	67%
With atypical changes	931	14	209			
As under 1 and left bundle branch block	777	20	170	89%	41%	3%
With atypical changes	811	11	13			
3 As under 1 and other changes in form of rhythm and con- duction disorders 1-1-2						
V 1-3 V 1-2 V 1-3						
IHD 0-2 V 1-3	49	20	708	62%	69%	42%
With atypical changes	567	41	96			

to previous infarctions and anginal  
pains and therefore myocardial  
scars after infarction were the only  
criteria used for demonstrating IHD  
post mortem. The fact that the occur-  
rence of coronary stenosis was not in-  
cluded as a criterion implies as men-  
tioned previously only a minor source  
of error (p. 48).

Table XXXI gives the specificity  
and sensitivity of the typical symp-  
toms of IHD. The table also shows  
the variation of these qualities of the

method when also atypical symptoms  
were accepted as signs of IHD. The  
lower half of the table gives an an-  
alysis of the various electrocardio-  
graphic signs of previous myocardial  
damage.

As previously mentioned the data  
in the clinical records were sometimes  
not precise enough to allow satisfac-  
tory analysis. These uncertain cases  
were excluded in this analysis. This  
explains the differences between the  
number of cases studied for anam-

nostic symptoms and those in which electrocardiograms were studied

Of those with typical symptoms of IHD 65 % had scars after infarction. The criterion of typical symptoms, however, catches only 46 % of all those with such scars in the present series. 9 % of those without IHD postmortem have typical IHD symptoms (specificity 91 %). The values found for specificity and sensitivity give a diagnostic score of 137 for the typical symptoms. If also atypical symptoms be accepted as signs of IHD it will probably increase the number of false positive diagnosis (4 %  $\chi^2 = 5.2$  fig 1  $p < 0.05$ ). At the same time it will increase the sensitivity considerably (13 %  $\chi^2 = 10.0$  fig 1  $p < 0.01$ ). This increases the diagnostic score to 146.

As previously shown (page 21) the selective factors affecting this post mortem series probably implies an overrepresentation of cases with typical symptoms in relation to those with atypical symptoms. This in turn suggests that the increase demonstrated in the sensitivity when also atypical cases were accepted would have been greater if a material had been available that was more representative of symptoms of IHD. This would probably not have so great effect on the specificity.

Electrocardiographic changes indicating local damage (according to definition) have a high specificity probably higher than that of the typical IHD symptoms ( $\chi^2 = 4.57$  fig 1  $p < 0.05$ ). At the same time however its sensitivity is low. Only one fourth

of all cases with infarct scars were detected. This means a low diagnostic score (118). If also those cases with left bundle branch block are included the specificity would be lower (6 %,  $\chi^2 = 14.8$  fig 1  $p < 0.01$ ). This is compensated by a considerable increase in sensitivity (20 %  $\chi^2 = 27.4$  fig 1,  $p < 0.01$ ). This would increase the diagnostic score to 132. If also a number of electrocardiographic changes such as arrhythmias and conduction disorders are also accepted the specificity will be reduced considerably. Every third subject without post mortem signs of IHD would be judged as having IHD. At the same time it would increase the sensitivity and 69 % of all cases in which post mortem showed IHD would be diagnosed. Owing to this increase in sensitivity the diagnostic score of these criteria would be 134. Despite an equally high score this constellation of criteria cannot be recommended because of the poor balance between specificity and sensitivity. This exemplifies the disadvantage of judging the criteria by the score only.

The increase in sensitivity of the criterion left bundle branch block is strikingly large. This is probably partly due to the high average age of the series. As previously mentioned (page 36) certain qualities of this series presumably decrease the specificity of some electrocardiographic criteria, i.e. conduction disorders and arrhythmias.

The criterion used at autopsy of IHD in this study was a myocardial scar larger than 1 cm in diameter. As

mentioned this probably implies a source of error if IHD is to be understood only as a sequela after coronary atherosclerosis and thrombosis (page 78). This source of error causes systematic underestimation of the sensitivity of the criteria but should affect specificity only to a lesser extent. Since the main purpose of the present chapter was to compare the sensitivity of various criteria this systematic source of error is probably of minor importance. In all groups it will consist of a roughly equally large number of in-

dividuals with a false negative diagnosis.

In those investigations where these results are to be used as a basis for the elaboration of a method in population investigations the numerical value of sensitivity and specificity should be regarded as information of orienting nature. It is then important to take account of deviating properties of the post mortem series. The higher the age groups to be examined the more representative the afore mentioned results will probably be.

## General discussion and conclusions

The question was whether atypical symptoms of IHD should be included as criteria of IHD in epidemiological studies. This question is important because such cases have proved fairly common (1, 2). The answer depends on how this would influence the balance between specificity and sensitivity of the anamnestic method. Since the atypical symptoms are not easy to distinguish from those of other diseases in the chest and upper abdomen it would probably result in an overdiagnosis of IHD, i.e. it would reduce the specificity of the method. In the choice of criteria it is of interest to know the size of this decrease of specificity in relation to the improvement of the method obtained by diagnosing an increased percentage of true IHD cases.

In the present investigation these problems were studied in a post mortem series in which anamnestic data and electrocardiograms were judged retrospectively. The study was a preparatory step in a planned prospective population investigation in Malmö. Symptoms of IHD included in the definitions recommended by WHO for epidemiological use were regarded as

typical (see page 25). Symptoms not included in these definitions were regarded as atypical (see page 27).

Of the cases in the present investigation with symptoms of IHD the latter were atypical in 28 %. This percentage was if anything fictitiously low for the material consisted mainly of a hospital series, i.e. a series in which an overrepresentation of cases with typical symptoms must be expected (page 21). This assumption is supported also by the higher frequency of myocardial scars in the subjects who had been autopsied at the department of forensic medicine and who had probably not been admitted to Malmö general hospital for previous myocardial infarction. They were therefore not included in the final series (see page 18).

The above assumption is supported further by the causes of death noted in the death certificates of those subjects who had died at home or at hospital for the chronic sick and were not autopsied and therefore not included in this series (see page 15).

Of greatest interest in a population study are the methods used for record



ing previous infarctions and angina pectoris. One might *a priori* expect that cases with previous infarction are more difficult to detect than those with a recent infarction—this also proved to be the case in the present series. Moreover, the frequency of false positive diagnosis was as expected somewhat higher among cases with atypical clinical pictures than in those in whom the disease had run a typical course (Table XX). The acceptance of cases with atypical symptoms (Table XXIV) produced a moderate decrease in the specificity and a marked increase in the sensitivity of the anamnestic method.

Electrocardiographic changes interpreted as signs of old myocardial damage (page 30) appears to be a valuable supplementary criterion and increases the validity of coexisting anamnestic symptoms. Changes arguing for local damage have a high degree of specificity, but such changes were found in only 21% of the cases with myocardial scars. That the sensitivity of this criterion is low has also been shown in population studies (3). The reason why the sensitivity is so low is probably partly that myocardial infarction does not always cause electrocardiographic changes of that type and secondly that such changes sometimes occur only in the acute phase and then regresses (60). It is also of interest to note that the electrocardiographic changes of this type in subjects who had denied anamnestic symptoms of IHD appear to have low validity (Table XXIV). No conclusive analysis of the criterion

ST depression was performed because the series included many cases treated with digitalis and/or with disorders of the electrolyte balance.

Earlier it has been reported that specificity tends to vary inversely with the sensitivity (cf 55-56). This was the case also concerning the criteria of IHD that were studied. The group of individuals decreasing the specificity was, however readily distinguished from the group that caused the decreased sensitivity. It was therefore considered of interest to study these groups in detail to check whether it is possible to correct for the error of the method causing the decrease of the specificity and sensitivity.

The source of error responsible for the decrease in specificity is the false positive diagnosis of IHD i.e. cases with IHD like symptoms but without signs of IHD *post mortem*. As mentioned above it is tempting to assume that other diseases of the chest and upper abdomen e.g. pneumonia, chronic bronchitis, pulmonary emboli, peptic ulcer or gallstone can cause pain erroneously interpreted as IHD. This assumption was checked in the cases of angina pectoris but no evidence for the above assumption could be found in this series. On the other hand hypertension and valvular heart disease were more common in these cases than in sex and age matched controls. These conditions were considered of pathogenetic importance because patients with these diseases had a higher average heart weight

than the controls and because an abnormally large heart muscle might perhaps be involved in the causation of the above mentioned symptoms. In about half of the cases with a false positive diagnosis the heart weight was increased. It is however questionable whether the presence of hypertension with enlargement of the heart can be used as a correction factor because hypertension is also believed to be an atherogenic factor. This means that true IHD could be expected more common among individuals with hypertension and enlargement of the heart. The exclusion of subjects with hypertension and enlargement of the heart from the group diagnosed as IHD would thus mean the exclusion of several cases with true IHD. Evidence is however available that hypertension has a stronger coronary atherogenic effect in women than in men (22-53). This implies that a certain differentiation might be possible. But before applying such a procedure the magnitude of the error introduced should be assessed. Cases with valvular heart disease might however provide a possibility for correcting factors increasing the specificity of the method.

The source of error reducing the sensitivity of the method is due to the false negative diagnosis of IHD i.e. cases in which myocardial scars were seen at autopsy in subjects without anamnestic symptoms of IHD or electrocardiographic signs of IHD.

Various factors may be capable of masking symptoms of IHD. It has

thus been suggested that subjects with silent infarction consist mainly of old individuals with blunted perception of pain (28) or with hypertension (14) or of individuals who have had both myocardial infarction and vascular insult the latter disease making it difficult to obtain a satisfactory history of the heart symptoms (14). These factors however did not appear to be of importance in the present series but reservation should be made for the cases that were not included in the final evaluation because of inability to give a satisfactory history. It appears difficult however to type the symptoms of IHD in such cases which can therefore not be classified as asymptomatic according to the used definition of the term.

The group with silent infarction differed however in one respect from the symptomatic cases. The atherosclerosis tended to be less severe and the most advanced type with occlusion and severe stenosis was significantly less common. This was considered to argue for the silent infarctions possibly being caused to a certain extent by factors other than coronary atherosclerosis and related conditions. These results suggest that if the purpose of the method is to detect sequelae after coronary atherosclerosis and related conditions the use of myocardial scars larger than 1 cm in diameter as criteria of IHD would mean a systematic underestimation of the sensitivity of the anamnestic methods and electrocardiographic criteria. This methodological error however appears to be rather un-

important in comparisons between different criteria in one and the same investigation.

It is also probable that several of these cases of infarction which might perhaps not have been of coronary atherosclerotic origin differed in size from other infarcts. They seem mostly to be within the range of 1-3 cm diameter (12-20-48). But further investigations are necessary to ascertain the limits and the error when these results are used for correction purposes.

In the present investigation cases with atypical clinical symptoms represented a considerable proportion of the cases with previous or chronic MI. The anamnestic method seems to be able to distinguish them with only a moderately loss of specificity and at the same time with a substantial increase in sensitivity. In the application of these results the aim of the epidemiological method must be considered. If the epidemiological investigation is to be understood in its original limited sense, comparison between populations in geographically different areas, special considerations must be taken into account. Of primary importance is then that the criteria correspond to the same underlying mechanism equally often in all areas studied. The validity of the criteria should be equal in the respective areas. This can cause problems concerning a certain part of the atypical cases. Some of these individuals experience their symptoms as "shortness of breath". This implies that the frequency of chronic bronchitis and

emphysema will give rise to problems even if the discriminating distinction is applied that they should not have hyperpnoea. This problem is illustrated by an epidemiological investigation of miners and non-miners in South Wales (15). In that investigation it was stated that the history is difficult to interpret because "the discomfort of extreme breathlessness may be only too readily confused with the pain or discomfort of myocardial ischaemia". From the cited investigation it is clear that the diagnostic capacity of the anamnestic method is higher in the younger than in the older age groups. This applies in particular to miners in whom respiratory symptoms are common. It appears that in the cited investigation no attempt was made to subdivide the groups of anamnestic symptoms and to assess the relative diagnostic value of the individual symptoms a procedure, which however would have been difficult because they could only be compared with the electrocardiographic recordings.

It is against this background that one should consider the statement made by an expert group in WHO. The epidemiologist will often be more interested in the repeatability of his observations than in their validity if the two qualities cannot be combined. He will also as a rule be interested in the specificity rather than the sensitivity of the indices he uses since he will be willing in general to discard atypical or debatable manifestations of a disease in order to obtain results comparable with those obtained by

other workers. He will hope that the indices chosen will detect a rather constant fraction of the disease present in any population even though a fairly large number of probable cases may be discarded.

The concession made in the introduction to the demands placed on validity may be questioned. If it is not known what one is really measuring it would be difficult to interpret the findings.

The results reported by Higgins (35) and those obtained in the present investigation however argue to a certain extent against the assumption that highly specific methods for the anamnestic diagnosis of IHD can give a fairly constant percentage of those with true IHD. The exclusion of the cases with atypical symptoms probably implies the exclusion of a varying proportion of cases of coronary disease. A possible alternative would be to state the number of cases with atypical symptoms per se and typical symptoms per se. This would make it possible for every epidemiologist better to study the distribution of certain and probable respectively doubtful manifestations of IHD.

These objections do not apply to the same extent to local electrocardiographic signs of myocardial damage provided the population is not selected from an area with a high incidence of trypanosomiasis for example. On the other hand the frequency of ST depressions is influenced by the frequency of the use of digitalis medication—a factor of great importance in higher ages especially in women.

Since the indication for treatment with digitalis appears to vary from one area to another this is of importance in comparisons. In some series attempts have been made to eliminate the influence of this factor by excluding subjects treated with digitalis. But this introduces another source of error for many of these individuals probably have IHD which is a common cause of cardiac incompetence in high ages. Exclusion of these individuals would therefore imply the exclusion of a group with a high frequency of IHD and this would influence the results in the remaining group.

The term epidemiological however is no longer limited to comparisons between different geographical areas but also comprises comparisons between different groups in the same population e.g. social groups, occupational groups and groups selected according to dietary and smoking habits and symptoms of disease (25). In such intra and intergroup studies it is often of value to distinguish one group with a high frequency of the disease and another group without symptoms or signs of the disease. This however increases the requirement of knowledge of the properties of the criteria.

It is clear from the above that no well defined general method can be recommended. In the planning of an epidemiological study the methods used must be devised with the due consideration to the composition of the material and the purpose of the investigation. Besides evaluation of the validity of the method the ratio

between the specificity and sensitivity must also be considered and then the results presented here may serve as a basis.

In the choice of method internationally recommended criteria should, of

course be preferred. In most cases various criteria can be used simultaneously to distinguish several groups and thereby provide the possibilities of comparisons within groups in the same series and with other series.

## Summary

Recent investigations have shown that atypical symptoms of ischaemic heart disease (IHD) are fairly common. This gives rise to problems in the evaluation of the disease in population studies. This retrospective investigation was undertaken to elucidate questions bearing on these problems.

The study is a preparatory link in a planned prospective population study in Malmö a town of 250,000 inhabitants. Malmö offers a favourable opportunity for a combined clinical-pathological study of this type because it is a one hospital town.

Originally the series consisted of all individuals who had died during one and a half year in Malmö (2880 individuals). 1435 of these cases had both autopsies and clinical records. In about 1050 the clinical records fulfilled the requirements for the intended analysis.

The exclusion of some groups might influence the representativity regarding symptoms of IHD and this bias was analysed as was the validity of the data from the hospital records.

Anamnestic data, electrocardiographic recordings and the results of

laboratory studies were obtained from the hospital records and compared with the results of a careful autopsy at which special attention was given to the cardiovascular system.

Of the same 1000 individuals 286 had old myocardial scars. Of these 40% denied ever having had heart symptoms. Of those who reported heart symptoms 74% had had typical symptoms and 26% had had atypical symptoms. The anamnestic criteria defined by Rose and recommended by WHO were called typical (page 25). Pain in other regions and other precipitating factors were accepted as atypical symptoms (page 27).

When the cases with atypical symptoms were assigned to the group with typical symptoms to form a total group with anamnestic symptoms of IHD the sensitivity of the anamnestic method increased and then 59% instead of 46% of all cases with post mortem signs of IHD were diagnosed. At the same time a probable decrease of the specificity was noted from 91 to 87% which means that 13% instead of 9% of those who did not show evidence of IHD *post mortem* had been judged as having IHD. Thus

when the cases with atypical symptoms were excluded it meant a considerable decrease in the sensitivity of the anamnestic method, while when these symptoms were accepted as signs of IHD it implied some decrease of the specificity.

The value of anamnestic symptoms in relation to that of electrocardiographic changes is discussed. In the present series the anamnestic method appeared to be valuable as a diagnostic procedure, while changes in the resting electrocardiogram (classified according to the criteria of the Minnesota code) increase the value of an anamnestic symptom but are of poor validity in the absence of anamnestic symptoms of IHD. The anamnestic symptoms and electrocardiographic changes appeared to be more specific throughout in males than in females.

Of the specificity reducing group of the cases with angina pectoris, i.e. those with angina pectoris like symptoms but in whom post mortem examination revealed no signs of IHD about half had valvular heart disease and hypertension and the results suggest that these conditions might be the cause of the angina pectoris like symptoms. No evidence was produced of other diseases in the thoracic cavity or upper abdomen such as pneumonia, bronchitis, pulmonary embolism or peptic ulcer simulating IHD in the group with angina pectoris.

As to the sensitivity decreasing group, i.e. cases without IHD in their history or electrocardiographic changes but with myocardial scars seen post mortem (silent infarction) previously suggested masking factors such as high age, cerebral insult or hypertension were not found to be of importance in this series. The results suggest that coronary atherosclerosis and related factors are less advanced in these cases with silent infarction than in those with symptoms and autopsy signs of infarction. Possible etiologic factors other than atherosclerosis for some of these cases are discussed.

The role played by atypical symptoms in comparisons between different geographical areas is discussed.

In the choice of method and in the subdivision of the material for comparisons within and between groups with different IHD symptoms the relation between specificity and sensitivity of the criteria and the reproducibility must be decided upon with due regard to the problem to be studied. In this choice internationally recommended methods should be given preference but special criteria should sometimes be adopted. The results of this retrospective study provide a basis for this choice in the planned prospective study in Malmö.

# References

- 1 Cooper, H R Atypical symptoms in myocardial infarction J Florida Med Ass 51 581—583 1961
- 2 Stokes III J and T Dawber The "silent coronary" The frequency and clinical characteristics of unrecognized myocardial infarction in the Framingham Study Ann Int Med 50 1359—1369 1959
- 3 WHO Chronicle 16 437—444 1962
- 4 WHO Chronicle 17 15—21 1963
- 5 WHO Chronicle 17 5—61 1963
- 6 Berkson J Limitation of the application of fourfold table analysis to hospital data Biometrics Bull 2 47—53 1945
- 7 Mainland, D The risk of fallacious conclusions from autopsy data on the incidence of diseases with applications to heart disease Am Heart J 45 644—654 1953
- 8 Linell F och J Soderstrom Synpunkter på vardet av dödsorsaks och sjukdoms statistik Sv Lakartidn 60 2895—2911 1963
- 9 WHO Techn Rep ser No 143 Classification of Atherosclerotic Lesions Geneva 1958
- 10 Juhl S Cancer and atherosclerosis Negative correlation Acta Path et Microbiol Scand 37 167—181 1955
- 11 Sjovall H und G Wihman Beobachtungen über die Arteriosklerose in Schweden samt einem Beitrag zur Frage der Lipoidose der Arterienintima Acta Path et Microbiol Scand Suppl 20 1934
- 12 Allison H Rodriguez F Higgins E Leddy J Abelman W Ellis L and S Robbins Clinicopathologic correlations in coronary atherosclerosis Four hundredthirty patients studied with post mortem coronary angiography Circulation 27 170—184 1963
- 13 Blackburn H Keys A Simonson E, Rautaharju P and S Punar The electrocardiogram in population studies A classification system. Circulation 21 1160—1175 1960
- 14 Evans W Diseases of the heart and arteries E & S Livingstone Ltd Edinburgh and London 1964
- 15 Gorlin R Pathophysiology of cardiac pain Circulation 32 138—148 1965
- 16 Bjurulf P Atherosclerosis and body build with special reference to size and number of subcutaneous fat cells Acta Med Scand Suppl 349 1959
- 17 Snow P Jones V and A Daber A clinicopathologic study of coronary disease Brit Heart J 18 43—441 1956
- 18 Verhave J Electrocardiograms simulating myocardial infarction Rocky Mountain Med J 61 40—43 1964
- 19 Blomkvist G The Frank lead exercise electrocardiogram A quantitative study based on averaging technique and digital computer analysis Acta Med Scand Suppl 440 1965
- 20 Schwartz C and J Mitchell The relation between myocardial lesions and coronary artery disease I An unselected necropsy study Brit Heart J 24 761—784 1962
- 21 Evans W and G Sutton Painless cardiac infarction Brit Heart J 18 259—272 1956



- 22 *Bjurulf, P* Atherosclerosis in different parts of the arterial system *Am Heart J* 68 41—50 1964
- 23 *Paton H* The accuracy of diagnosis of myocardial infarction A clinicopathological study *Am J Med* 23 761—768 1957
- 24 *Johnson W, Achor R, Burchell H and J Edwards* Unrecognized myocardial infarction *Arch Int Med* 103 253—261 1959
- 25 *Smoking and Health* Report of the advisory Committee to the Surgeon General of the Public Health Public health service publication No 1103 1964 D van Nostrand Comp Inc New Jersey New York
- 26 *Bjurulf P, Garlind T and N H Sternby* Code list for clinical and autopsy data in the Malmö study Stencil Lund 1964
- 27 *Bachran C and Th Bublin* A chest pain Questionnaire for use in epidemiological investigations of ischemic heart disease *Israel Med J* 23 227—232 1964
- 28 *Hochrein W* Der Herzschmerz Hippokrates III 681—687 1961
- 29 *Saphir O* In Pathology of the heart Ed S F Gould 2nd ed Thomas Springfield Ill 1960
- 30 *Selye H* The chemical prevention of cardiac necroses Ronald Press New York 1958
- 31 *Dahlström F* Intervju och enkätteknik 2 uppl Natur och kultur Stockholm 1960
- 32 *Holman A* Das intermediäre koronarsyndrom drohende und rudimentäre Herzinfarkte *Med Klinik* 57 1321—1327 1962
- 33 *Plotkin M* Coronary heart disease Paul Huber New York 1957
- 34 *Linllyn J* Angina pectoris A clinical study with special reference to neurosurgical treatment *Acta Med Scand* 1950 vol 139 suppl 243
- 35 *Higgins I, Cochrane H and A Thomas* Epidemiological studies of coronary disease *Brit J prev soc Med* 17 153—165 1963
- 36 *Fisner M and M Schuler* Warum übersehen wir Myocardinfarkte? *Deutsche Med Wochenschrift* 14 767—771 1965
- 37 *Forssman, B and H Lindstedt* The post coronary patient *J Psychosomat Res* 3 89—169 1958
- 38 *Sinapov D* Morphologische Probleme der koronarthrombose *Deutsche Med Wochenschrift* 14 776—781 1965
- 39 *Pickering G* Pathogenesis of myocardial and cerebral infarction Nodular arteriosclerosis *Brit Med J* 1 517—528 1964
- 40 *Duguid J B* In Connective Tissue Thrombosis and atherosclerosis Ed I H Page Acad Press New York 1959
- 41 *Acheson R* Etiology of coronary heart disease in old men *Brit J prev soc Med* 15 49—60 1961
- 42 *Blorck, G, Sievers J and G Blomkvist* Studies in myocardial infarction in Malmö 1935—1954 II Infarction rate by occupational group *Acta Med Scand* 162 81—97 1958
- 43 *Blorck G, Blomkvist, G and J Sievers* Studies in myocardial infarction in Malmö 1935—1954 IV Myocardial infarcts in the hospital in relation to coronary heart disease in the population *Acta Med Scand* 165 1—15 1959
- 44 *Nomenclature and criteria of disease of the heart and blood vessels* Ed S New York American Heart Association Inc 1953 p 77
- 45 *Chapelle de la C* (Editorial) The recognition of angina pectoris *Circulation* 21 1061—1064 1960
- 46 *Zoll P, Wessler S and H Blumgart* Angina pectoris A clinical and pathological correlation *Am J Med* 11 331—347 1954
- 47 *Olin H and T Hachett* The denial of chest pain in 32 patients with acute myocardial infarction *J A M A* 190 977—981 1961
- 48 *Vitchell J and C Schwartz* The relation between myocardial lesions and coronary artery disease II A selected group of patients with massive cardiac necrosis or scarring *Brit Heart J* 25 1—24 1963
- 49 *Söderström J* An autopsy study on myocardial infarction in Malmö 1954 to

- 1959 with some remarks on the difficulties of epidemiological studies of coronary heart disease *Acta Med Scand* 169 619-634 1961
- 50 Blumgart H, Schleutinger W and H Davis Studies on the relation of clinical manifestations of angina pectoris coronary thrombosis and myocardial infarction to the pathological findings with particular reference to the significance of the collateral circulation *Am Heart J* 19 1-91 1910
  - 51 Herrick J B and F R Nutt Angina pectoris *J A M A* 70 67 1918 cit in Snow
  - 52 Gabler C *Myokardose Myokarditis Morphologie und Pathogenese* Jeb G Fischers Verlag Jena 1963
  - 53 Bjurulf P Unpublished data
  - 54 Wilius F A and H Z Criffin The anginal syndrome in pernicious anaemia *Am J Med Sci* 174 30 1927 Cit Gorlin
  - 55 Thorner R and Q Remoin Principles and procedures in the evaluation of screening for disease *Public Health Monograph No 67* Washington D C Gov Ptg Office 1961
  - 56 Collen M, Rubin L, Neyman J, Dantig G, Baer R and I Siegelauk Automated multiphasic screening and diagnosis *Am J Public Health* 54 741-100 1964
  - 57 Youden W Index for rating diagnostic tests *Cancer* 3 32-35 1950
  - 58 Lindgärd H and C H Hjortso Critical aspects on the use of indices in physical anthropology *Kungl Fysiogr Sällsk* 14 1953 23 No 8
  - 59 Blackburn H Quoted in Nomenclature criteria and methods for investigations on coronary disease and hypertension Stencil composed as working programme for a conference in Stockholm on March 15 and 16 1963 and arranged by Swedish association of cardiologists in collaboration with the Swedish National association against Heart and Chest Diseases and the insurance company FOLKSAM
  - 60 Andersson V and O Skjeggstad The electrocardiogram in patients with previous myocardial infarction *Acta Med Scand* 176 123-126 1961
  - 61 Holman R L, McGill H C Jr, Strong J P and J C Geer Techniques for studying atherosclerotic lesions *Laboratory Invest* 7 42-47 1959
  - 62 Lemura K, Sternby N, Vanöckel R, Vihert A and I Kagan Crading atherosclerosis in aorta and coronary arteries obtained at autopsy *Bull Wild Hlth Org* 31 297-320 1961
  - 63 Rose G The diagnosis of ischaemic heart pain and intermittent claudication in field surveys *Bull Wild Hlth Org* 27 643-649 1962
  - 64 Cederquist L and J Soderstrom Papillary muscle rupture in myocardial infarction A study based upon an autopsy material *Acta Med Scand* 170 287-292 1964
  - 65 Hallén A Angina pectoris A clinical study with special reference to surgical treatment *Suppl* 323 *Acta Chir Scand*
  - 66 Lannel W H, Dawber T H, Friedman C D, Cleannon W E and P McNamee Risk factors in coronary heart disease *Annals Int Med* 61 888-899 1964
  - 67 Epstein F H The epidemiology of coronary heart disease *J Chron Dis* 18 733-774 1965







# ACTA MEDICA SCANDINAVICA

SUPPLEMENTUM 475

MITRAL INCOMPETENCE AS A  
COMPLICATION OF ACUTE  
MYOCARDIAL INFARCTION

BY

JUHANI HEIKKILÄ

# ACTA MEDICA SCANDINAVICA

has been published since 1919 as a continuation of Nordiskt Medicinskt Arkiv founded in 1869 by Axel Key The first volume of Acta Medica Scandinavica is therefore numbered LII (52)

*The chief editors have been* Axel Key 1869—1900 C. G. Santesson 1901—1915 I. Holmgren 1916—1957 and Birger Strandell 1958 to date

Acta Medica Scandinavica publishes original research papers in the field of internal medicine Priority will be given to authors from countries which are represented on the editorial board Contributors from those countries should submit their papers to a representative of the country in question Contributors from other countries should send their papers to the Editor at the address below

Submission of a manuscript for publication will be held to imply that the paper has not been published elsewhere and that if accepted it will not be republished in any other journal in the same or similar form without the Editor's written consent

Papers will be published in English French or German at the authors choice followed by a summary in English

The manuscripts shall be in final form as submitted They shall be typewritten with double spacing and broad left hand margin

If a paper excess 16 printed pages the cost for the excess pages shall be borne by the author No paper shall exceed 24 printed pages

## Subscription

The annual subscription to the journal covering two volumes each of 6 numbers is 140 Sw crowns or U S \$ 27.25 *including postage* in the Scandinavian countries and in Holland 120 Sw crowns

*Address for subscriptions and all communications*

ACTA MEDICA SCANDINAVICA

P O Box 2052 Stockholm 2

---

Requests for duplicate copies of numbers that have gone astray can only be considered if made within a fortnight of the receipt of the following number

**To the memory of my father**





ACTA MEDICA SCANDINAVICA

SUPPLEMENTUM 475

FROM THE FIRST MEDICAL CLINIC, UNIVERSITY OF HELSINKI,  
AND FROM THE WIHURI RESEARCH INSTITUTE,  
HELSINKI, FINLAND

# MITRAL INCOMPETENCE AS A COMPLICATION OF ACUTE MYOCARDIAL INFARCTION

BY

JUHANI HEIKKILÄ

ACADEMIC DISSERTATION

TO BE PRESENTED WITH THE ASSENT OF THE FACULTY OF MEDICINE OF THE  
UNIVERSITY OF HELSINKI FOR PUBLIC EXAMINATION IN AUDITORIUM XIV ON  
JUNE 2, 1967, AT 12 O'CLOCK NOON



# CONTENTS

Acknowledgements	7
Chapter I Introduction	9
Chapter II Survey of the literature	11
Chapter III Object of the present investigation	20
Chapter IV Methods	21
Chapter V Material	26
Chapter VI Auscultatory and phonocardiographic characteristics of mitral systolic murmur	29
Chapter VII Comparison of findings in patients with and without mitral incompetence	50
A Clinical findings	50
B Electrocardiography	65
C Radiology	75
Chapter VIII Hemodynamic investigation	83
Chapter IX Autopsy findings	99
Chapter X Follow up study	112
Chapter XI Concluding remarks	118
Chapter XII Summary	124
References	127
Appendix	141



## ACKNOWLEDGEMENTS

The topic of the present investigation was suggested to me by my chief, Professor Pentti I. Halonen M.D., head of the First Medical Clinic, University of Helsinki and the Wihuri Research Hospital. I wish to express my sincere thanks for his valuable and kind advice during my clinical studies and in the course of the present work.

I am grateful to Professor Ilmari Vartiainen M.D., head of the Second Medical Clinic, University of Helsinki, and Professor Esko Nikkila, M.D., head of the Third Medical Clinic, University of Helsinki, for allowing me to study patients admitted to those clinics. Professor Harald Teir, M.D., head of the Institute of Pathology, placed the facilities of the Institute at my disposal and gave me permission to carry out the dissection studies.

To my friends and colleagues Docent Kalevi Pyörälä, M.D., and Dr. Pentti Siltanen, M.D., I extend my warmest thanks for being my untiring and critical teachers in clinical cardiology and for their interest and help in the present study. Associate Professor Antti Läsalo, M.D., offered many useful suggestions and other colleagues have given me valuable encouragement.

I am indebted to Mr. Einar Luksela for drawing the figures, to Mrs. Camilla Hopea for preparing the histological specimens and to Miss Aino Nikupaavo, M.A., for checking the references. Mr. Timo Partanen, M.Sc., performed the statistical calculations. Mr. Paul Sjöblom, M.A., checked and partially translated the text and Mr. Kingsley Hart, M.A. (Cantab.) undertook the final revision of the English.

My thanks go to the nurses of the wards, the staff of the cardiovascular research laboratory and the radiological department for their help during the clinical investigation.

My thanks are also due to Lääkintäsaatio Oy for lending a phonocardiograph for the clinical study, and to Burroughs Wellcome & Co., London, for supplying Vasoxine® used in the hemodynamic study.

This study was aided by a grant from the Finnish Heart Association.

Helsinki, March 1967

*Juhami Heikkilä*



## INTRODUCTION

There is perhaps in the animal frame no more beautiful example of the adaptation of structure to the function to be accomplished than is afforded by the auriculo ventricular valves. The insertion of the cords into the fleshy columns instead of directly into the muscular walls, is apparently not to give greater power of resistance to the pressure of the blood during the systole, but to furnish a means of shortening the attachments of the curtains when, with the contraction of the ventricle the walls are more closely approximated. Were it not for this arrangement the free fold of the mitral, for instance, would fall back towards the auricle during the systole and the two curtains not being properly adjusted the blood would flow into the auricular cavity. By the action of the muscular columns, however, the cords are drawn upon as the parietes of the ventricle approximate, and the curtains are kept in apposition and tightly stretched across the aperture so as effectually to close it.

This penetrating description of the function of the papillary muscles by Thomas B. Peacock dates from 1865. The correctness of the theory has later been confirmed by means of modern physiological research.

The leakproof closing of the mitral valve during systole depends on the flawless structure and function not only of the valve leaflets themselves but also of all the other anatomical structures involved — the supporting annulus of the mitral orifice, the chordae tendinae, the papillary muscles, the left ventricular wall and the atrial myocardium.

The initial phase of the closing mechanism begins during the atrial contraction at the end of diastole. This augments the filling of the ventricle. With the intraventricular pressure rising the chordae tighten simultaneously as the distance between the mitral annulus and the base of the papillary muscles increases. Thus the

cusps of the mitral valve are prepared for closing and in fact, they close loosely at this final diastolic stage. Regarded as factors contributing to the closing process are the abrupt arresting of the diastolic blood flow and the flow accelerated by the atrial systole together with the eddies produced by it. The ventricular systole begins with the isometric contraction of the papillary muscles. This anchors the valve leaflets against the systolic rise of the intraventricular pressure and tightly occludes the mitral orifice. During the ejection phase as the volume of the ventricle decreases, the active contraction of the papillary muscles apparently takes up the ballooning thus induced on the atrial side. The considerable active diminishing of the circumference of the mitral orifice as a result of the contraction of the ventricle further ensures the strength of the competence of the valve.

Because the closing mechanism of the



mitral valve is both structurally and functionally highly complicated it is vulnerable to numerous pathological processes. As a consequence of any inadequate functioning of the valve and its supporting structures, a mitral incompetence develops.

Anatomical conditions that frequently cause extensive damage to the mitral valve have been long known. The most important of them are rheumatic and bacterial inflammations causing deformation and substance loss of the valve cusps as well as shrinkage or breakage of the chordae. The valve structure may have various congenital defects. The role played by the active contraction of the mitral annulus in the closing mechanism may be eliminated by advanced calcification. If a papillary muscle is ruptured, most commonly in connection with a chest injury or in myocardial infarction, the consequence is a sudden catastrophe in the functioning of the heart, most often fatal.

In contrast to the organic injuries to the valve structure easily observed at autopsy, increasing attention has been paid to the mitral incompetence resulting from a structurally unchanged but functionally impaired mitral valve. And indeed it is only since the development of appropriate

instruments that it has become possible to investigate the phenomenon closely.

Myocardial infarction may produce sudden and often severe difficulties in the ability of the heart to function as a pump to maintain circulation. Evidence of acute mitral incompetence caused by various ischemic mechanisms, has emerged as one possible factor impairing the efficient pumping action of the ischemic heart. Mitral incompetence associated with ischemic heart disease might be either structural or functional — or a combination of these two mechanisms.

The occurrence of mitral incompetence as a complication of myocardial infarction has been long known. The prevalence of this complication and its clinical features do not, however, emerge clearly from the previous studies dealing with the subject. The character of hemodynamic disorders also remains to be elucidated. In the present study, an effort has been made to clarify by means of a prospective investigation the occurrence and the clinicopathologic features of mitral incompetence as a consequence of acute myocardial infarction.

A preliminary report of the results of this study has been published (1967).

## SURVEY OF THE LITERATURE

## CLINICAL OBSERVATIONS

SYSTOLIC MURMUR ASSOCIATED WITH  
MAJOR COMPLICATIONS OF  
MYOCARDIAL INFARCTION

The appearance of a loud systolic murmur during the course of acute myocardial infarction is fairly uncommon, and it has been described as generally being associated with major complications of infarction with the exception of pericarditis. These sudden and often fatal complications causing systolic murmurs are perforation of the interventricular septum, rupture of the papillary muscle, rupture of the heart and aneurysm of the heart.

*Perforation of the interventricular septum*  
This has been reported in over 200 cases (Sager 1934, Bond 1953, Malone and Parkes 1955, Sanders *et al* 1956). Brunn (1923) made the first clinical diagnosis which was confirmed at autopsy. Usually on the 3rd or 4th day, in connection with an infarct extending to the area of the septum a loud pansystolic murmur appears which is typical of the ventricular septal defects. This is accompanied in some 50 % of the cases by a systolic thrill. Simultaneously, the patient's general condition worsens rapidly after a sudden, severe right sided heart failure. Pulmonary plethora in the chest radiograph can help diagnosis. More than half the patients die within a week of heart failure, and only about a tenth of them survive two months.

*Rupture of a papillary muscle, or rupture of the chordae tendinae* — which extremely seldom occurs as a complication of myocardial infarction — also immediately brings on a severe heart failure,

almost invariably left sided. The murmur generally appears 2 to 4 days after the onset of the infarction, and it is typical of a substantial mitral incompetence being pansystolic, apical, and radiating toward the axilla but also, deceptively, often toward the aortic area (Craddock and Mahe 1953, Sanders *et al* 1957). Usually there is no thrill. The posterior papillary muscle of the left ventricle ruptures considerably more often than the anterior one. Sudden mitral incompetence terminates fatally in over half the patients within the first 24 hours. Approximately 90 cases of ruptured papillary muscles have been described (Cederqvist and Soderstrom 1964). The first antemortem diagnosis was made by Davison in 1947.

*Rupture of the heart* causes some 10 % of the hospital deaths from acute myocardial infarction (Gans 1951, Nesvadba 1955, Maher *et al* 1956, Griffith *et al* 1961). Rupture of the heart most commonly occurs between the 2nd and 4th day after onset, and only very seldom after a period of three weeks. A myocardial rupture is almost without exception a complication that terminates fatally within a few minutes or at most, hours and therefore can only rarely be diagnosed clinically. The symptoms include signs of severe tamponation of the heart, in some case reports a systolic murmur has been described (Reznikoff 1922, Massey and Drake 1948, Bishop and Logue 1950, Uzum 1950).

*Aneurysm of the heart* as a clear anatomical finding after infarction appears in some

20 % of the cases at autopsy (Schlichter *et al* 1951 Abrams *et al* 1963) whereas dynamic aneurysm consisting of a systolic bulging of the ventricular wall after weakening by ischemic damage can be observed and registered in up to 100 % of the patients during the acute stage of infarction with permanent signs remaining in more than half of the patients (Prinzmetal *et al* 1919, Gregg 1950, Schwedel *et al* 1950, Sampson *et al* 1956, Suh and Eddleman 1959, Davis *et al* 1962, Hurstman and Lofstrom 1963, Rörvik 1963, Schweizer *et al* 1965).

A clinical consequence is often a distinct heart failure. Pathological pulsation of the heart is reported as having been observed clinically in 10 % of the patients (Vakil 1955, Logue and Hurst 1966b); moreover the diagnosis is supported by permanently elevated ST segments in the electrocardiogram, deformation of the heart shadow and paradoxical motion in radiological examination. In connection with an aneurysm it is possible at times to hear a varying systolic or diastolic murmur (Scherf and Brooks 1919, Slapak 1952, Riederer and Themel 1955, Vakil 1955, Plotz 1957). The murmur has most often been attributed to mitral incompetence but sometimes to the flow of blood in and out of the aneurysm or to pericardial friction.

#### INCIDENCE OF SYSTOLIC MURMUR IN MYOCARDIAL INFARCTION

With the exception of the above mentioned severe complications of myocardial infarction the literature contains very scant references to the occurrence of a systolic murmur in clinical studies of myocardial infarction. Bean (1930) mentions a systolic murmur as having been detected in 3 % of 170 patients. Jacoby (1951) observed that a systolic murmur was present in 11 patients out of 54 examined. Malt and Rembergen (1955) found it in 2 % of 114 patients. Yater *et al* (1955) found it in 3 % of 135 patients.

A systolic murmur, which in 32 patients was heard over the mitral area. All the murmurs were transient, none were considered characteristic of any definite valvular lesion. In these studies except for its frequency, no detailed description of the murmur or a possible explanation of its origin has generally been given. Accordingly no conclusion concerning the origin whether aortic or mitral can be drawn.

According to the observations of Schimert *et al* (1960), the systolic murmur of aortic sclerosis established before the onset of infarction is apt to disappear completely during the hypotension or shock stage of the initial phase of infarction as the cardiac output decreases. This ejection type murmur can be heard again as the circulatory conditions gradually return to normal and the stroke volume rises.

The pingsystolic apical murmur often detected after reinfarctions or after the development of congestive heart failure has customarily been explained as a relative mitral incompetence resulting from dilatation of the failing left ventricle (Laubry and Soulié 1950, Friedberg 1966). Laubry and Soulié (1950) explained this mechanism by pointing out that the gallop rhythm frequently accompanied the appearance and disappearance of the apical murmur of relative mitral incompetence. This murmur has frequently been mentioned but its incidence has not been discussed. The systolic murmur of a mitral incompetence ascribed to ventricular dilatation occurring in conjunction with infarction was already described by Vaguez (1921) who reported it to be meso- or pingsystolic, seldom pingsystolic, apical, unradiant, and fairly faint.

#### ISCHEMIC PAPILLARY MUSCLE DYSFUNCTION AS A CAUSE OF MITRAL INCOMPETENCE

Reports on clinical series of mitral incompetence without papillary muscle rupture in association with ischemic heart disease are few in number and often some

what cursory (Grotel 1940 Nezhin and Shamesova 1951, Froment *et al* 1955, Phillips *et al* 1963 a, 1963 b Orlando *et al* 1964, Segal and Likoff 1964 Bashour 1965, Chiesa *et al* 1965, Raftery *et al* 1966, Soulie *et al* 1966)

In addition to these series mostly consisting of materials studied in retrospect a few case reports have been published (Soulie and Gerbeaux 1939, Hope and Askey 1952 Luisada and Szatkowski 1960 Burch *et al* 1963 Mazzitello 1964, Clinicopathological conference at the Postgraduate Medical School of London 1965 Holloway *et al* 1965 Tavel *et al* 1965, Fluck *et al* 1966) So far no systematic prospective studies on the occurrence, clinical characteristics and subsequent course of mitral incompetence developing in association with acute myocardial infarction have been presented

Several authors (Bristowe 1861, Peacock 1865, Gee 1870, Heveling 1871 Chabardes 1878 Gibson 1898) in the 19th century published occasional case reports in which mechanical failure or "fatty degeneration" of papillary muscles was shown to be the cause of clinically observed mitral incompetence. In those days of course the concept of myocardial infarction had not yet been clarified beyond the stage of 'myomalacia'

Castex (1931, 1933) presented eight patients with a faint 'mesosystolic' murmur (filling part of the systole), in connection with myocardial infarction as a distinct clinical entity. The murmur was mesosystolic or mesotelesystolic in patients with damage to the posterior wall of the heart and protosystolic in apical infarctions. Castex presented his observations in contradiction to previous contentions by Barie (1912) and Potam that a mesosystolic murmur was invariably non-organic and usually extracardial. Vaquez (1921) also stated that the question was one of a possible functional mitral incompetence only and not an organic impairment. Castex (1932) expounded the

mechanism of the murmur however, in the light of the vortices autoctonos theory of Bondi (1927, 1928 a, b), according to which the discrepancy between the vigorous contraction of the healthy infundibular part of the myocardium and the poor motility of the damaged often dilated region of the infarction, induced eddies in the cavity of the left ventricle, thereby giving rise to the murmur. From Castex's clinic a few case reports interpreted according to his way of thinking also appeared (diCio and Battro 1933, Lorenzo *et al* 1934 Lorenzo and Boto 1936)

However in the light of later research it can be assumed that the cause of the murmur in at least some of the patients described by Castex was a mitral valvular leak caused by an ischemic functional disorder of a papillary muscle. For example, in Fig. 2 (Castex 1933), apart from the extensive scarring of the left ventricle the papillary muscle appears to be scarred and considerably shrunk.

It was Bosco (1935) who was the first to contend, on the strength of his illuminating coronary arteriogram radiographic investigations that the mechanism of the mesosystolic murmur occurring in connection with infarction was a functional disorder of the papillary muscles resulting from their deficient blood supply. No clinical series was described, chief stress being laid on the pathologic anatomic investigations relating to the blood vessels of the papillary muscles.

Subsequent to Castex's clinical study, which may have touched upon the category of mitral incompetence and Bosco's unequivocal thesis, the possibility of mitral incompetence resulting from ischemic damage to the supporting structures of the mitral valve has not been seriously considered.

#### *Incidence of murmur*

The incidence of mitral incompetence as a consequence of myocardial infarction has been treated in only two stud-

ies based on a large material. The Russian Grotel (1940), in his work on acute myocardial infarction mentions an incidence of 50 % which was astonishingly high in view of the syndrome's being fairly unknown before then. However, Froment *et al* (1955) also observed the systolic murmur of a mitral incompetence in 48 of 189 patients with myocardial infarction and drew attention to the possibility of a mitral incompetence occurring probably because of functional impairment of a papillary muscle in a normal sized heart and without heart failure. This observation proved contrary to the previously common assumption that relative mitral incompetence was secondary to dilatation of the heart and its annulus caused by heart failure. Unfortunately, the material of Froment *et al* has not been analyzed further than is shown in Table 1.

Hochrein (1937) remarked that Caster's observation concerning the localizing value of the apical systolic murmur attendant upon infarction appeared in the light of his own investigations to possess keine allgemeine Gültigkeit.

#### *Characteristics of the murmur*

The ejection type or "diamond shaped" systolic murmur, with a delayed onset only after a phase of the isovolumetric contraction confirmed phonocardiographically, was described as a characteristic finding in ischemic papillary muscle dysfunction in 13 patients by Burch *et al* (1963) and Phillips *et al* (1963a). Another

typical feature shared by all these patients was electrocardiographic changes attributed to infarction of the anterolateral papillary muscle of the left ventricle. Together they composed an electrocardiographic auscultatory syndrome easily recognized clinically. The ejection type murmur was fairly loud, apical and apt to radiate toward the axilla though in four patients it radiated toward the aortic area. The origin of this murmur in the mitral valve was demonstrated by a decrease in its intensity in the amyl nitrite test.

An ejection type but late systolic and more crescendo-shaped murmur is also mentioned by Segal and Likoff (1964) as having been observed in 20 patients with anterior myocardial infarction but without aneurysm. All 3 patients described by Tavel *et al* (1965) also had a late systolic murmur. In one of them it began with a non ejection click. But although the authors connected the murmur of two of the patients with definite coronary heart disease, the case reports reveal that in both the murmur had appeared several years before the symptomatic chest pains, thus throwing some doubt on the connection.

According to the majority of writers, most of the murmurs appearing in association with myocardial infarction would seem, however, to be pansystolic (Grotel 1940, Nezlin and Shamesova 1951, Froment *et al* 1955, Friedland and Ishleder 1960, Orlando *et al* 1964, Raftery *et al* 1966). The pansystolic murmur is apt to exhibit various types in phonocardi-

Table 1 Occurrence of mitral incompetence after myocardial infarction in material of Froment *et al* (1955)

	Number of infarctions	Number of patients with mitral incompetence	Mitral incompetence with dilatation of the heart	Mitral incompetence without dilatation of the heart
Anterior infarction	113	15 (13 %)	14	1 (0.8 %)
Infarction	76	11 (43 %)	12	21 (27 %)

graphy and even to vary in the same patient (Bashour 1965). In 5 patients with myocardial infarction who belonged to a series of 23 patients with acute subvalvular mitral incompetence (Raftery *et al* 1966), the murmur was invariably pansystolic with a mid systolic crescendo.

The intensity of the murmur varies and has generally been reported to be fairly loud or sometimes as rather faint (Grotel 1940).

Grotel (1940) and Phillips *et al* (1963 a) further mention having detected late systolic apical murmurs which could be heard transiently only during attacks of angina pectoris. Similarly, Bolechowski and Poplewski (1964) described a loud, musical pansystolic murmur during angina pectoris that disappeared when the pain subsided. Post mortem examination disclosed several post infarction scars in the posterior wall of the left ventricle. According to the observations of Grotel (1940) and Nezhlin and Shamesova (1951) the murmur gradually increases in intensity during the days immediately following its appearance and does not suddenly become loud as in conditions of rupture of a papillary muscle.

There are only scanty reports on the time of onset of murmur as most of the studies made have been retrospective in character. Among Castex's (1931, 1933) patients, the mero-systolic murmur appeared on the 4th or 5th day. In 8 patients out of 10 with severe myocardial infarction involving papillary muscles and terminating fatally, the murmur described by Nezhlin and Shamesova (1951) appeared between the 3rd and 7th day after the onset of the disease. According to Grotel (1940), the murmur is even apt to develop within a few hours after the symptoms of infarction have been noticed and generally within 24 to 28 hours.

The murmur has generally been described as permanent but it can also be transient (Castex 1931, 1933, Grotel 1940) and as pointed out in the foregoing

merely brought on by angina pectoris. The location has nearly always been described as apical, with a tendency for transmission to the axilla, but occasionally radiation toward the aortic area (Grotel 1940, Nezhlin and Shamesova 1951, Phillips *et al* 1963 a, Raftery *et al* 1966).

#### *Clinical significance*

The significance of a mitral valvular leakage as a result of myocardial infarction varies. Froment *et al* (1955) emphasize the possibility of a lack of heart failure. Similarly the patients studied by Burch *et al* (1963) and Phillips *et al* (1963 a), who for the most part had only a subtransmural myocardial damage were in fairly good condition. Neither did the ejection type or late systolic murmur discussed by Holloway *et al* (1965) and Tavel *et al* (1965) have any relation to heart failure.

On the other hand Bashour (1965) stresses the susceptibility of patients to severe heart failure, while Nezhlin and Shamesova (1951) view this complication as exceedingly grave, leading almost inevitably to fatal heart failure. Pulmonary edema was the initial symptom in all the patients described by Raftery *et al* (1966). The possibility of bacterial endocarditis complicating mitral incompetence even when caused by myocardial infarction was suggested by Bashour (1965).

#### *Radiological findings*

Radiological examination of the chest may reveal the size of the heart to be normal or conspicuously enlarged (Grotel 1940, Froment *et al* 1955, Phillips *et al* 1963 a, Raftery *et al* 1966). Grotel (1940) and Froment *et al* (1955) specifically emphasize normal heart size as pointing to a malfunction of the papillary muscle and as evidence against the mechanism of mitral annular dilatation. Raftery *et al* (1966) note that the left atrium remains normal in size or enlarges only negligibly in acute mitral incompetence, despite

very severe hemodynamic disorders

#### *Electrocardiographic changes*

In most studies the occurrence of mitral incompetence has been maintained to be more common in cases of inferior or posterior infarction than in those of anterior infarction (Castex 1933, Grotel 1940, Nezhin and Shamesova 1951, Froment *et al* 1955, Orlando *et al* 1964, Bashour 1965, Raftery *et al* 1966, Soulie *et al* 1966, Burch *et al* (1963), Phillips *et al* 1963 a, b) and Segal and Lukoff (1964) deal with anterior myocardial infarction only. Dolgoplosk (1956) found electrocardiographic signs of right ventricular overloading to be common in connection with this syndrome.

Phillips *et al* (1963 b) maintain that infarction of the anterolateral papillary muscle of the left ventricle can be reliably diagnosed from an electrocardiogram. The changes include a slight or a marked depression of junction J and a concave or convex upward deformity in the ST segment which may or may not be

accompanied by a negative T wave. Furthermore in the majority of the tracings changes in the TU segment or the U wave were observed. In both patients of Holloway *et al* (1965) the type II (Phillips *et al* 1963 b) changes of the ST-T deflection were present. U wave changes had already been regarded previously as specific signs of papillary muscle damage (Furbetta *et al* 1956).

However, it is hard to understand how the changes described by Phillips *et al* (1963 b) could be specifically distinguished from the electrocardiographic changes present in subendocardial damage, with or without involvement of the papillary muscles, to the wall of the left ventricle (Cook *et al* 1957). The ischemic changes found in the majority of patients studied by Phillips *et al* (1963 a, b) were limited and stationary, non transmural and without Q waves. In acute transmural infarction the afore mentioned electrocardiographic signs would not seem to be operable on account of the extensive electric changes of injury and ischemia.

### **AUTOPSY FINDINGS AND MECHANISM OF MITRAL INCOMPETENCE**

The earliest thesis on the part played by malfunction of the papillary muscles in mitral incompetence without papillary muscle rupture in connection with myocardial infarction is, as already mentioned, that comprising the conclusions arrived at by Bosco in 1935 on the basis of the coronary radiographic investigation on the blood supply of the papillary muscles. Soulie and Gerbeaux (1933) also mention this possibility of functional impairment of the papillary muscles although they finally regard the eddies produced in the

blood stream or the mechanical hindrance to coapting of mitral leaflets caused by the large mural thrombus found at autopsy as the cause of the murmur.

Nezhin and Shamesova (1951) have thoroughly elucidated the pathologic-anatomical changes involved in myocardial infarction complicated by an acute mitral incompetence. Papillary muscle necrosis was observed in 20 % of the cases. They pointed out the greater vulnerability of the posterior papillary muscle and discuss this observation with reference to the

anatomy of the coronary blood vessels. The same conclusion was reached by Orlando *et al* (1964) and Bashour (1965). Like most of the case reports, these studies generally stress the importance of necrosis or of ischemia of the papillary muscle, usually posterior as a mechanism of a mitral incompetence as contrasted with the previously held view of the relative mitral incompetence secondary to dilatation of the heart.

Burch *et al* (1963) and Bashour (1965) present a further mechanism in which even a healthy papillary muscle attached to an infarcted and aneurysmatic area of the left ventricle may result in inadequate closure of the mitral valve. This is due to the paradoxical outward bulge that occurs during systole pulling the site of attachment of the papillary muscle away from the mitral ring. In the gradual process of dilatation undergone by the heart the papillary muscles are capable of hypertrophying and, by lengthening, adapting themselves to the increased distance from the mitral ring without leakage occurring. In acute dilatation such a compensating mechanism is obviously not possible.

In their series of 4 patients Soulie *et al* (1966) emphasize the importance of the fibrosis and shrinkage occurring as the end result of the ischemic destruction of the papillary muscle in producing severe permanent mitral incompetence as do Phillips *et al* (1963 a), Bashour (1965), and Marton (1966).

Recently Moller *et al* (1966) described mitral incompetence associated with congenital aortic stenosis. The mechanism of mitral incompetence was considered to be extensive infarct and fibrotic changes in the papillary muscles and the subendocardial myocardium caused by inadequate coronary circulation. The same mechanism of mitral incompetence traceable to the damaged papillary muscles can also be observed when the left coronary

artery arises anomalously from the pulmonary artery (Voren *et al* 1964).

From the viewpoint of the pathologist, retromitral infarcts often leave no harmful effects (Bargmann and Doerr 1963). Still if the infarct extends to the area of the papillary muscles and the heart becomes slightly aneurysmatic, the consequent slackening of the papillary muscle and the posterior wall of the left ventricle is attended by extra valvular mitral incompetence and enlargement of the left atrium.

In an autopsy study of 41 patients who had died of myocardial infarction Arkhangelskiy (1959) found necrotic damage to the papillary muscles of the left ventricle in over 50 %. Both papillary muscles were involved in 25 % of the patients regardless of the location of the infarct. Total necrosis and sclerosis were commoner in the posterior papillary muscle. In the papillary muscles of control subjects who had died without infarction from hypertension or atherosclerosis changes were not always found and if they were they consisted of slight sclerotic foci. Oeser (1954) observed an involvement of the posterior papillary muscle in 20 % of patients who had died of myocardial infarction.

DePasquale and Burch (1966) found gross scars in one or both papillary muscles in 21 % of 420 consecutive autopsies in men. Acute infarction of the papillary muscles was present in 4 %. The authors suggest associating these findings with common apical systolic murmurs in elderly subjects. Careful pathologic anatomical studies made by Fulton (1965) revealed that the papillary muscles which must be classified as subendocardial tissue, are sensitive to ischemic changes.

By contrast, Schoenmackers (1965) could not find clear association between papillary muscle infarcts and acute mitral incompetence.



## HEMODYNAMIC STUDIES

Hemodynamic changes investigated by cardiac catheterization in patients with mitral incompetence after myocardial infarction (excluding papillary muscle ruptures) had been reported in only 4 patients before the present study was started (Luisada and Szatkowski 1960 Mazzitello 1964 Holloway *et al* 1965). As awareness of this complication has rapidly grown during the past two years, further observations have been made with respect to changes in hemodynamic conditions (Bashour 1965 Rastier *et al* 1966 Soulie *et al* 1966 Fluck *et al* 1966). A total of 10 patients have figured in reports published on catheterization studies.

The investigations prove the existence of hemodynamically significant mitral in-

competence. The *r* wave of the left atrium was generally over 40 mm Hg (15–65) and the end-diastolic pressure of the left ventricle had risen.

The left ventricular cine angiograms revealed a substantial regurgitation into the left atrium from the site of one mitral cusp or the other and frequently a systolic prolapse of the valve into the left atrium (Mazzitello 1964 Holloway *et al* 1965 Bashour 1965 Soulie *et al* 1965 Rastier *et al* 1966 Fluck *et al* 1966). One patient was successfully operated on by inserting an artificial mitral valve prosthesis when the clinical course and hemodynamic studies revealed intractable mitral regurgitation after acute myocardial infarction (Fluck *et al* 1966).

## EXPERIMENTAL STUDIES

**Myocardial ischemia.** The effects on cardiac function of experimental occlusion of branches of the circumflex and of the anterior descending branch of the left coronary artery in 17 dogs were studied by Bailas (1965). Pressures were measured in the heart chambers, and left ventricular angiography was performed on three of the animals. In 9 (53%) of the 17 animals with evidence of severe myocardial injury and left ventricular failure, mitral regurgitation of a significant degree was observed. A systolic thrill was palpable in all nine animals. Mitral incompetence was explained by the failure of the ischemic papillary muscles to contract and their inappropriate position when left ventricular failure produced acute ventricular dilatation.

**Papillary muscle damage.** Hider *et al* (1955, 1966) studied the effects on dogs of an ethanol injection in the papillary muscles. Control dogs were injected in the

lateral wall of the left ventricle. Of the 11 experimental animals, 3 showed immediate mitral incompetence leading to pulmonary edema and two of them died. After three months the combined early and late incidence of mitral incompetence was 7 out of the 11 dogs (64%) in the experimental group and 1 (atriotomy scar deforming the anterior mitral leaflet) out of 10 in the control group. Mitral regurgitation was estimated by left atrial pressure curves and by an Evans blue injection in the left ventricle and withdrawal from the left atrium. A tendency was further observed in the experimental group towards less efficient isometric contraction of the left ventricle. In the view of the authors the results supported the predominant role of the papillary muscles during the isometric rather than the ejection phase of the ventricular systole.

Studies of Mantz (1967) also showed in connection with mitral valve replace-

ment surgery the importance of papillary muscles for the contractility of the left ventricle

*To sum up* there are few studies on mitral incompetence as a consequence of acute myocardial infarction and most of them deal with small series of patients studied retrospectively. In the light of the results presented both the clinical features and the character of the murmur itself are inconsistent and variable. On the other hand there are clear indications that the

functional impairment of the papillary muscles manifesting in various ways is the critical factor in the appearance of mitral incompetence. Pathologic anatomical and experimental investigations suggest that the clinical frequency of mitral incompetence should be higher than has usually been reported. Few hemodynamic studies have been published and they deal with selected patients only. In them, mitral incompetence has on the whole been found to be of a significant degree.

## OBJECT OF THE PRESENT INVESTIGATION

The object of the present investigation was to study the clinical features and the significance of mitral incompetence as a complication of acute myocardial infarction. The main emphasis was given to clarifying the following problems.

- The prevalence of mitral incompetence as a complication of acute myocardial infarction.
- The time of onset and the characteristics of the murmur of the mitral incompetence.
- The possible differences between anterior and posterior infarction with respect to the occurrence and character of the mitral systolic murmur.
- The clinical features in patients with

myocardial infarction complicated by an acute mitral incompetence as compared with those in patients without mitral incompetence during the acute phase of the disease.

- The underlying mechanism of a mitral incompetence.
- The severity of the hemodynamic changes in mitral incompetence resulting from myocardial infarction as revealed by cardiac catheterization studies during the convalescence stage.
- The permanence of a mitral systolic murmur and the long-term effects of mitral incompetence in patients with myocardial infarction.

## METHODS

A DEFINITIONS AND EVALUATION  
OF CLINICAL FINDINGS

The result of a clinical examination depends a great deal on how accurately a symptom or sign is defined and on this definition being maintained for otherwise the information yielded by the examination would disintegrate in uncertainty and the significance of the result would remain difficult to evaluate. On the other hand taking into account only such signs that very conspicuously deviate from the normal often gives a one-sided and erroneous picture of the matter under examination. In the following the most important clinical concepts and the criteria applied to them will be defined and explained.

**Myocardial infarction** is defined as an area of necrosis in the myocardium resulting from cessation of the coronary blood supply or of insufficient below the myocardial demand and is associated with a distinct venous clinical picture.

The clinical picture is characterized by a severe prolonged subternal chest pain often radiating to the shoulders and hands independent of physical exertion. It tends to be attended by left ventricular failure and shock, marked electrocardiographic changes, rising body temperature, elevated erythrocyte sedimentation rate and leucocyte count and an increase in certain cell enzymes.

In the present study the infarction diagnosis was determined if the clinical picture was consistent with myocardial infarction and/or a pattern of electrocardiographic changes in myocardial infarction were observed either as pathological Q waves together with ST-segment and T wave changes indicative of injury or only fresh distinct ST-segment and T wave changes indicative of subtransmural infarction. Laboratory tests were used to support the diagnosis if the erythrocyte sedimentation rate rose by 10 mm an hour or more, the white blood cell count over 9,000 mm<sup>3</sup> and the serum GOT over 40 units (Wroblewski 1959) which was the upper limit of the laboratory. In most patients the serum LDH levels were likewise determined. However the clinical picture in conjunction with unequivocal electrocardiographic changes was regarded as justifying a diagnosis although the laboratory tests did not change to a pathological degree. Insofar as the electrocardiographic changes were only non-specific

the patient was included in the study only if the clinical picture was characteristic of infarction and attended by appreciable changes in the laboratory tests and if no other disease could be observed to be responsible for these changes.

The severity of myocardial infarction was graded by a coronary prognostic index described by Peel *et al.* (1962).

**Comments.** The clinical picture of myocardial infarction may as is well known be exceedingly varied. The chest pain generally lasts over half an hour but the duration can be shorter or the pain may not be present at all in as many as 20 to 25% of the patients (Evans and Sutton 1956, Lee *et al.* 1957, Johnson *et al.* 1959, Stokes and Dawber 1959, Lundberg *et al.* 1960). Painless infarction is especially common in elderly patients (Pathy 1967). The pain may be quite severe or take the form only of a vague feeling of pressure or discomfort, the radiation of the pain may be atypical or lacking. Painless myocardial infarction may manifest itself as arrhythmia, sudden heart failure, collapse or a cerebrovascular accident. Accordingly patients admitted to hospital with these symptoms as well were kept under observation at first for possible definitions of myocardial infarction.

**Angina pectoris** is defined as a clinical symptom complex produced by an insufficient blood supply to the myocardium but without clearly noticable myocardial necrosis with its distinct venous clinical picture.

Typical of the clinical picture are brief provokable subternal pain or pressure attacks provoked by physical or emotional effort and relieved by nitroglycerin.

In the present study the foregoing definition was used, emphasis was laid on the association with physical or emotional stress although the character of the pain sometimes deviated from the usual.

**Coronary insufficiency** preinfarction angina, intermittent coronary syndrome, is a poorly defined condition as a clinical copathological concept which has been regarded as a transitional form between myocardial infarction and angina pectoris. Physiologically coronary insufficiency is simply a deficient capacity of the coronary blood vessels — for a multitude of reasons — to carry out the function

of transporting blood to the myocardium. It may of course vary in degree and the result range from massive necrosis of the myocardium with the characteristic clinical picture to only transient ischemia and angina pectoris.

In this study the clinical concept of "coronary insufficiency" embraced those patients whose chest pain of more than 20–30 minutes duration lasted longer than in angina pectoris but who lacked the laboratory signs of myocardial infarction and who showed only non-specific ST-segment and/or T wave changes electrocardiographically which may be due to subendocardial ischemia as well as necrosis.

**Comments.** Dividing patients into clearly defined angina pectoris and myocardial infarction categories is not always easy although it would of course, be desirable. It is understandable that in the clinicopathological picture there must be a sliding scale of changes ranging from an ischemic myocardium to an extensive necrosis. Lack of blood supply over a sufficiently long period of time may cause only diffuse generally subendocardially situated minor patches of necrosis (Buchne *et al* 1935, Snors *et al* 1956, Wood 1961, Resnik 1952, Allison *et al* 1963, Proger and Naima 1963, Pruitt *et al* 1963, Logue and Hunt 1966 b) which fail however to appear in the clinical picture as changes definitely distinguishable from ischemia.

Owing to the vagueness of the clinical concept these patients have however been omitted from the diagnostic sphere of myocardial infarction in the present study in the knowledge of the evident possibilities of errors in selection.

**Heart failure** is defined as a deficient capacity of the heart to pump blood in relation to the metabolic needs of the tissues and the amount of venous return. By *congestive heart failure* is meant the condition in which a pathologic congestion of blood occurs in the veins and capillaries as a consequence of heart failure together with an abnormally profuse transudation of fluid into the tissues mainly owing to increased hydrostatic pressure.

Clinically in right-sided heart failure the venous blood accumulating behind the heart stretches the veins and capillaries of the systemic circulation the venous pressure rises because of this and in part of the compensatory sympathetic isometric vasoconstriction. Increase in the tissue fluid is manifested as edema. In left-sided heart failure the distention of the pulmonary veins and capillaries is followed by transudation of fluid into the interstitium of the pulmonary tissue stiffening it or into the alveoles resulting in pulmonary edema unless the capacity of the lymphatic circulation suffices to remove the excessive fluid.

In the present study bedside signs of congestive heart failure were interpreted as follows. Clinical signs ascribed to congestive heart failure of left ventricular origin: dyspnea at rest, orthopnea and

and attacks of nocturnal dyspnea, attacks of wheezing in the absence of pulmonary disease, persistent sinus tachycardia of over 110 beats/min. Signs of pulmonary edema: rapid forced respiration, cough with or without frothy blood and moist rales over entire lung fields. Clinical signs ascribed to congestive heart failure of right ventricular origin: rise of jugular venous pressure over 5 cm above the level of the sternal angle, enlarged often tender liver and peripheral sacral or ankle edema in the absence of a local disease.

**Comments.** Transient or persistent left ventricular failure very often occurs in connection with myocardial infarction. This is easily apt to remain unrecognized especially at an acute stage on account of the patient's crucial condition. For this reason special care was taken to detect moist rales by careful listening especially to the lower parts of the lungs turning the patient slightly on his side. An effort was made not to misinterpret the rhonchi of bronchial secretions often heard during the first respiratory excursions as moist rales. As this investigation included patients with acute myocardial infarction often developing mitral incompetence the otherwise reliable sign of ventricular gallop (Lewis 1962) could not be used to denote myocardial failure.

When the histories were recorded the cardiac functional capacity of the patients was graded I to IV by the criteria of the NYHA (1953). It is obvious that some overlapping is possible between the symptoms of congestive heart failure and of angina pectoris as exertional dyspnea can be only a subjective symptom of both conditions (Gidchrist 1951, Muller and Rorvik 1958, Pathy 1967).

**Shock** is defined as a state of circulatory failure in which the cardiovascular system is incapable of meeting the metabolic needs of the cells. In *cardiogenic shock* the deficiency of the peripheral circulation is due to weakness of the heart as well as to reflex vasoconstriction. The clinical picture is characterized by systemic arterial hypotension, peripheral vasoconstriction and the signs of poor tissue perfusion resulting from them.

In this study the clinical criteria of shock applied were lowering of the systolic blood pressure below 90 mm Hg for over 30 minutes together with one or more of the following signs: pallor, cyanosis, cold and moist skin, feeble pulse, restlessness and confusion, decreased urinary output. Shock was graded as mild, moderate and severe and scored according to Peel *et al* (1962) as 1, 5 or 7.

**Comments.** Definitions of the concept and degree of severity of shock vary (see discussion in chapter VII). Scored 1 shock in the present investigation was not always accompanied by a decrease of systolic blood pressure below 90 mm Hg but was transient disappearing within 15 to 30 minutes. The states of shock scored 5 and 7 were unequivocal in the present writer's view, the score of 7 being

used when vasopressor drugs were given as therapeutic agents

*Hypertension* is defined as a symptom characterized by abnormally high systemic arterial pressure which is considered to be associated with pathological alterations of the cardiovascular system.

Clinically high arterial pressure does not generally bring on symptoms until provoked by complications in the cardiovascular system. No universal agreement regarding the borderline between normal and pathologic values exists (Humerfelt 1963). Blood pressure readings regarded as normal values rise with age (Mastar and Lasser 1961).

In the present study a patient was considered to have hypertension if values exceeding 160/100 mm Hg were repeatedly measured in hospital or if anamnesic data disclosed hypertension and its magnitude and the mode of treatment.

*Comments* The initial phase of myocardial infarction is often associated with considerable increase of systemic arterial pressure (Wright *et al* 1954; Gilbert *et al* 1954) or more usually a decrease (Laubry and Soulié 1950; Wright *et al* 1954) frequently to the point of a state of shock. The systemic arterial pressure of a patient affected with hypertension can become normal after infarction although usually in about two-thirds of the patients a slow rise back to the pathological level takes place gradually (Wright *et al* 1954; Ball *et al* 1955; Friedberg 1966). For this reason blood pressure values recorded only in hospital particularly those measured only occasionally are apt to give a misleading idea of the prevalence of hypertension among infarction patients.

*Paradoxical cardiac pulsation* is a clinical finding which is associated with ischemic partial loss of contractility of the myocardium and with myocardial insufficiency.

In palpation the paradoxical pulsation is recognized in the precordium as a systolic outward movement instead of the normal retraction separate from the apex beat. In ischemic damage it is most easily found between the third and fourth ribs midway between the medioclavicular line and the sternum; sometimes it may be found near the epigastrium and sometimes only as a sustained heaving apical impulse in which case it is impossible to distinguish from the change of the apical impulse associated with hypertrophy of the left ventricle (Davie *et al* 1952).

The normal apical impulse is located at the fifth intercostal space or medially from it or within 10 cm to the left of the midline. It is felt as a slight brief early systolic thrust (Davie *et al* 1962; Rorvik 1963). With enlargement of the heart it shifts laterally. In hypertrophy of the left ventricle it takes on an even pansystolic heave without any abrupt initial thrust.

In the present study a paradoxical pulsation was deemed to be present if it was found to be distinctly separate from the apical impulse or outside its

assumed location and to be a pansystolic or almost pansystolic local movement of the precordium causing an outward bulge. A heaving apical impulse was not classified as a paradoxical pulsation except when the systolic bulge accompanying it reached up to the third intercostal space between the medioclavicular line and the midline. Any uncertain palpation finding was noted as negative. The location of the apical impulse was measured from its midpoint. The precordium was examined by lightly pressing with the palm of the hand against it during a held expiratory apnea.

*Comments* The critically important factor in recognizing a paradoxical pulsation is in the present author's view palpation of the precordium by applying a careful and correct technique. It can be detected through painstaking examination in myocardial infarction much more frequently than usually reported (Vakl 1955; Logue and Hunt 1966b) as also pointed out by Suh and Eddleman (1959). Differentiation between an apical impulse and a left parasternal lift caused by right ventricular hypertrophy is not generally difficult (Logan *et al* 1967).

*Mitral incompetence* is produced by systolic regurgitation of blood through the leaking left atrioventricular valve from the left ventricle into the left atrium.

*Systolic murmur of mitral incompetence* is the hallmark of mitral incompetence and it may be the only sign of slight incompetence of the mitral valve which otherwise might because of its slowness, be demonstrable only by cardiac catheterization and cinecardiography of the left ventricle (Leighton *et al* 1966). A murmur is generated during the regurgitant flow vibrations in the wake of the jet being forced back into the atrium (Bruns 1959). The typical murmur of mitral incompetence is high pitched and pansystolic starting immediately from first heart sound and continuing to the aortic component of second heart sound or beyond it because the great pressure gradient and thereby the regurgitation of blood between the left ventricle and the left atrium continues throughout the entire systole including the isovolumetric contraction and relaxation (Leatham 1953; a; b; Bruns 1959; Perloff and Harvey 1952; Bleifer *et al* 1960).

The murmur is apical, local or radiating toward the axilla and softened in inspiration. A pansystolic murmur may vary in shape. Sometimes the murmur starts immediately with first heart sound but fills only the early and mid portion of systole (protomesosystolic) tapering off before closure of the aortic valve (Briden and Leatham 1953; Holdack and Wolf 1966; Ilmurzynska 1966). Occasionally the murmur of mitral incompetence may be purely late systolic when associated with papillary-chordal disease (Phillips *et al* 1963; a; Barlow *et al* 1963; Humphries 1964; Segal and Lakoff 1964) or of ejection type located more

centrally at the left sternal border (Phillips *et al* 1963 a, Lusada 1965, Criley *et al* 1966). Sometimes it is transmitted to the aortic area (Osgund *et al* 1961, Sleeper *et al* 1962, Burchell 1963, Mercer and Walters 1965). The murmur of marked mitral incompetence is generally associated with third heart sound and with short rapid diastolic flow murmur.

In the present study the appearance of the murmur described in the foregoing after a silent period of varying duration in connection with myocardial infarction was regarded as a sign of mitral incompetence and was the sole criterion in placing patients in group I defined as acute mitral incompetence developing after myocardial infarction (AMI).

**Comments.** An apical high frequency pansystolic murmur may be regarded as diagnostic to mitral incompetence, although of low intensity (Brudger and Leatham 1953, Mounsey and Bridgen 1954, Leatham 1958 a, b, McKusick 1958, Perloff and Harvey 1962, Ravin 1967). Difficulties may arise when the murmur of mitral incompetence rarely presents itself as ejection type and radiates to the aortic area. The murmur of aortic stenosis or sclerosis (Bruns and van der Hauwaert 1958, Bruns 1959) may again be found also at the apex or only audible there (Wood 1958). This murmur is however generally harsher definitely of the ejection type and usually radiating to the neck. In valvular aortic stenosis the ejection click or valvular calcification may help in determining the aortic origin of the murmur. The murmur of aortic stenosis is chiefly apical only in the subaortic type of stenosis (Soulie *et al* 1963, Braunwald *et al* 1964). Other positive clinical signs of this disease are usually evident although sometimes differentiation from mitral incompetence is difficult (Rafiey *et al* 1966). Moreover mitral incompetence is a usual sequelae of hypertrophic muscular subaortic stenosis.

**Innocent ejection type murmur** is usually an early systolic soft ejection type murmur at the left sternal border radiating to the pulmonary area. The murmur usually has a rather vague maximal point of intensity. It is profoundly affected by respiratory excursions and by changes of body position. It does not radiate to the axilla. An innocent murmur is rare after childhood and adolescence in older patients generally an extracardiac factor causing a hyperkinetic circulatory state or large stroke volume is found such as for instance anaemia, tachycardia, fever, thyrotoxicosis or bradycardia (Leatham 1958 a, b, Humphries and McKusick 1962, Shabetai 1963, Weaver and Walker 1964).

The murmur of tricuspid incompetence is pansystolic but its location is at the lower sternum with increasing intensity in inspiration (Zeh 1959). Positive jugular venous and hepatic pulses are also helpful in diagnosis.

**Pericardial friction rub** is characteristically manifested as rubbing sounds of variable intensity being generally present in both systole and diastole. It is often (10–20%) found transiently in acute myocardial infarction during the first few days (Hochrein 1937, Mintz and Katz 1947, Yater *et al* 1948, Laubry and Soulié 1950, Wright *et al* 1954, Motz 1957, Friedberg 1966). Sometimes only a faint high frequency systolic sound of friction is present which is hard to differentiate from a murmur. But generally marked alterations in intensity, location and timing occur during changes of position or the respiratory phase or become evident in the course of a few days enabling the auscultatory finding to be classified as a pericardial friction rub.

It is unavoidable that some overlapping is possible in classifying a faint ejection type medium frequency parasternal or apical murmur as being of aortic or of mitral valve origin especially when the aortic valvular murmur may be inaudible during the sometimes low output state in the initial phase of myocardial infarction (Schumert *et al* 1960, Spencer and Greiss 1962). This applies however only to murmurs of the ejection or short decrescendo type of low intensity. Pericardial friction and the innocent ejection murmur of tachycardia as well as the murmur of tricuspid incompetence can usually be differentiated without any difficulty from the murmur of mitral incompetence.

## STATISTICAL TECHNIQUES

Standard statistical techniques have been used in this study. In testing differences between two sample means normal probability function has been applied for large samples and *t* ratio for small samples. Differences between more than two sample means have been tested with the *F* test. Existence of correlation in contingency tables has been tested by chi square and Fisher exact probability tests. The degree of correlation between dichotomous and continuous variables has been measured with a bivariate correlation coefficient. The sign test based on the binomial distribution has been used in testing significance of class frequencies in one-sample cases. Probabilities above 0.05 have been considered not significant.

## B. CLINICAL EXAMINATION PROCEDURE

All the patients included in the material of the present study were examined by the author personally. On the day of admission or the following day a detailed history of earlier cardiovascular diseases was taken and the duration and grade of these disturbances evaluated. During hospitalization a clinical examination was performed daily during the first ten days and thereafter every other day until the patient was dis-

charged. The average duration of hospitalization was four weeks.

A thorough bedside examination was performed to reveal any signs of alterations in the cardiovascular system in the course of treatment especially to detect signs of heart murmurs congestive heart failure and paradoxical cardiac pulsation. A meticulous auscultation of the entire precordium was performed with the patient in supine and left lateral positions to detect murmurs and gallop sounds as well as changes in first and second heart sounds. A search for murmurs in the carotid and femoral arteries was also made. The presence of arrhythmias was noted. When murmurs were found they were recorded by direct writing external

phonocardiography if possible.

Conventional 12 lead electrocardiograms were taken and laboratory tests made according to the scheme in which an electrocardiogram was taken and the leucocytes and serum GOT and LDH were determined every day during the first four days in hospital and thereafter every fifth day until the patient was discharged. The ESR was determined on the first third and fifth days in hospital and thereafter together with other tests.

Routine radiological examinations of the heart and lungs were performed on all patients in the Department of Radiology by means of postero-anterior and lateral pictures 2-4 weeks after admission.



## MATERIAL

### A PATIENTS

Clinical study of the patients during the acute phase of myocardial infarction was performed between June 1965 and March 1966. The patients had been admitted to the First and Second Medical Clinics of the University of Helsinki, and to two male wards of the Third Medical Clinic of the University of Helsinki.

The majority of the patients arrived at the hospital from the city or its environs within a few hours after the appearance of the subjective symptoms.

In order to obtain the most reliable possible picture of the incidence of mitral incompetence brought on by acute myocardial infarction it is obviously important to avoid selection of the patient series. With this in mind, the author at first included unselectively for the purposes of investigation and examined all the patients consecutively admitted to hospital as actual or suspected cases of myocardial infarction.

If the possibility of the myocardial infarction was considered after the initial examination but the clinical picture remained doubtful the patient was tentatively included in the examination procedure for about a week to verify the presence or absence of acute myocardial infarction by means of the clinical course, the pattern of serial electrocardiography and by means of the data from the clinical laboratory. If the criteria of myocardial infarction as defined in the foregoing (Chapter IV) were not met the patient was excluded from further observation and inclusion in the patient

series.

For every patient, the author himself decided whether the results of the examinations met the criteria of infarction, regardless of the stand taken by the physician in attendance.

*Comments.* Owing to the character of ischemic heart disease all the clinical materials relating to myocardial infarction are more or less selective. The first sign of acute coronary disease may be sudden death caused by cardiac arrest, so naturally such patients never reach the hospital for examination. A small proportion of the patients do not apply for admission because of the slightness of their symptoms. In some 15% of the patients, myocardial infarction develops without typical symptoms. A painless, "mute" infarction is apt to be wholly overlooked or to manifest itself as arrhythmia, acute heart failure, collapse or an acute cerebrovascular accident (Pathy 1967). In order to avoid the possibility of this unintentional selection, the patients presenting these symptoms were also kept under observation for a week to discover a possible myocardial infarction.

It is often difficult to draw the line in diagnosis between myocardial infarction proper and prolonged angina pectoris or acute coronary insufficiency and selection in this respect could substantially alter the character of the myocardial infarction material being investigated. The criteria used to solve this problem in the present investigation are presented in the preceding chapter.

### EXCLUDED PATIENTS

Patients were not included in the investigation if

- more than three days had passed since the estimated onset of the infarction before admission to hospital
- the patient died of acute myocardial infarction before three days of hospital observation had passed
- the afore mentioned criteria applied to acute myocardial infarction were not met

### B GROUPING BY AUSCULTATORY FINDINGS

The total number of patients admitted to the various wards for treatment of actual or suspected myocardial infarction and initially kept under observation for a week or less was 306. Of these initially observed subjects, 96 were excluded from the patient series analyzed in this study because they did not meet the requirements of infarction diagnosis or for other reasons described in the preceding section.

The series clinically studied thus comprises 210 patients with acute myocardial infarction. The patients were placed in the following five groups according to their earlier history and on the basis of

auscultatory observations made during the course of examinations.

Group 1 consisted of 117 patients with acute mitral incompetence as a complication of acute myocardial infarction the MIMI group. The constant or transient murmur of mitral incompetence described in the previous chapter, served as a criterion.

Group 2 consisted of 70 patients who had no heart murmur excluding pericardial friction or had developed none during their stay in hospital.

Group 3 consisted of 6 patients who had a constant murmur of mitral incompetence on admission which could be thought to have originated in conjunction with an earlier infarction.

Group 4 comprised 7 patients who since admission had also had a constant murmur of mitral incompetence, the etiology of which could not be traced on the basis of the available information.

Group 5 comprised 10 patients who had loud precordial murmur of aortic stenosis or aortic sclerosis so that it was not possible clinically to find the possible development or existence of faint mitral systolic murmur.

The distribution of the patient material into the five groups mentioned is shown

### TOTAL NUMBER OF PATIENTS




Fig. 1 Presentation of the patient series

in Fig 1. It is self evident that a closer study of groups 3-5 would not have shed additional light on the characteristics of acute mitral incompetence occurring as a complication of myocardial infarction. Accordingly, the later detailed analysis was carried out with groups 1 and 2 which together included 187 patients.

### CONTROL PATIENTS

As stated, the object of this study was to investigate a certain complication of myocardial infarction, the prevalence and characteristics of the mitral incompetence occurring as a result of myocardial

infarction. Therefore, there exists no control patient material parallel with the myocardial infarction material. The "control patients" thus perforce consisted of patients characterized by the presence of acute myocardial infarction without the systolic murmur of mitral incompetence on admission or during the course of hospital treatment.

### C AGE AND SEX DISTRIBUTION

Age distribution in the patient groups is shown in Fig 2 and in Tables 2 and 3. The distribution of patients with and without mitral incompetence according to age was quite similar in both groups, the cumulative age distribution curves being almost identical.

The number of males and females appears in Table 3, which shows their distribution into different age groups. In males the incidence of acute MIMI was highly significantly ( $p < 0.001$ ) lower than in females.

Table 2 Age distribution in the patient groups

Group	No. of patients	Age years	
		Range	Mean
MIMI	117	33-78	55.3
No murmur	70	36-85	57.3
Total series	210	33-86	56.9

Fig 2 Age distribution in the patient groups




Table 3 Distribution according to age and sex in patients with and without mitral incompetence

Sex	Age years						Total
	30-39	40-49	50-59	60-69	70-79	80-89	
<i>Males</i>							
Mitral incompetence	5	24	30	25	7	11	91 (58%)
No murmur	5	12	21	22	4	1	65 (42%)
<i>Females</i>							
Mitral incompetence	1	5	6	12	2	0	26 (84%)
No murmur	0	0	1	3	1	0	5 (16%)

## AUSCULTATORY AND PHONOCARDIOGRAPHIC CHARACTERISTICS OF MITRAL SYSTOLIC MURMUR

### METHODS

#### A AUSCULTATION

##### GENERATION OF MURMURS

Murmurs result from pressure gradients which are capable of accelerating the flow of blood to the extent of creating vortices. Such vortices and almost periodic fluctuations of blood downstream from any obstacle as well as perhaps flitter mechanism are considered to be responsible for most murmurs (McDonald 1952 Bruns 1961 Laurens 1964 Rodbard 1964) although some aspects continue to be somewhat controversial.

Factors intimately related to murmur production include the diameter of the flow channel and sudden even though slight changes of this diameter the viscosity of the blood and one of the most important determinants is the stream velocity. The stream velocity in turn is directly dependent on the square root of the pressure gradient which again depends on the volume flow per unit cross section area of the orifice (Rodbard 1964).

##### CLASSIFICATION OF MITRAL SYSTOLIC MURMURS

Leatham (1958 a, b) has stressed the close dependence of the pattern of the systolic murmur on the quality and quantity of hemodynamic alterations. Clinically the classification of the type of systolic murmur is based on the timing of the murmur in relation to first and second heart sounds and on its intensity in various parts of systole.

Murmurs are broadly classified in pansystolic regurgitant and in ejection type murmurs. When pansystolic murmur occurs regurgitation of blood takes place during systole from a high pressure area back to a low pressure area. The pressure gradient already exists during the isovolumetric contraction and extends to the isovolumetric relaxation thus causing a murmur throughout the whole systole.

Ejection type systolic murmurs do not otherwise fill the whole systole. They indicate an obstruction in the flow of blood or an acceleration of the velocity of the blood stream during the early systolic ejection. Pansystolic murmurs are thus invariably pathological, the ejection type

may also be innocent as a result of an increase in cardiac output and/or stroke volume for physiological reasons.

##### TYPE OF MURMUR

Mitral systolic murmurs are classified in different ways (Lusada 1965 Holladay and Wolf 1966) depending on the timing of the murmur and the position of the peak intensity in systole. Perloff and Harvey (1962) classified mitral systolic murmurs into six types according to phonocardiographic findings.

In the present study mitral systolic murmurs are classified into three main types and eight subgroups on the basis of the timing and shape of the murmur.

*Timing.* The *pansystolic* murmur fills the whole systole, starting immediately from first heart sound and continuing to second sound usually an aortic component at the apex or beyond.

A murmur is defined as *protomesosystolic* (early mid-systolic) if the beginning of the murmur is not separated from first heart sound but ceases definitively before second heart sound. On the whole this type of protomesosystolic murmur may also be included in the pansystolic group on account of its generative mechanism since the murmur begins as early as the stage of isovolumetric contraction.

The *ejection type* murmur begins after a silent delay following first heart sound and is peaked or diamond shaped.

*Form.* Pansystolic murmurs were further classified according to their form into plateau (even intensity) crescendo (increasing) decrescendo (decreasing) and crescendo-decrescendo (peaking) types.

The protomesosystolic murmurs were classified into decrescendo and crescendo-decrescendo types according to their form.

The subgrouping of the ejection type murmur was not based on form but on timing which was either early systolic (ending before second heart sound) or late systolic (continuing to second heart sound).

The classification of murmur according to the timing and form of the murmurs into main

and sub-groups as shown in Fig. 3

The pattern of murmurs found in auscultation was used in recording the results

## PANSYSTOLIC

PLATEAU



CRESCENDO



DECRESCENDO



CRESCENDO-DECRESCENDO



## PROTOMESOSYSTOLIC

DECRESCENDO



CRESCENDO-DECRESCENDO



## EJECTION

EARLY



LATE



Fig. 3 Classification of mitral systolic murmurs

### OTHER MURMUR CHARACTERISTICS

The location and transmission direction of a murmur are quite helpful in clinical evaluation of the origin of the murmur. In determining the location and transmission generally accepted principles were applied (Shah *et al.* 1964).

The determination of the intensity of the murmur is based on arbitrary classification and includes possibilities of error associated with the characteristics of hearing. Matters are no surer however in phonocardiography. In the present study the scale of 1 to 6 for murmur intensity as presented by Levine and Harvey (1953) was adopted. It has generally been found to be fairly reliable after gaining experience of it.

The frequency of the murmur was defined as low, medium or high.

### FACTORS LIMITING ACCURACY OF AUSCULTATION

Clinical auscultation is a subjective auditory sensation and it involves the interpretation of the sounds and murmurs detected in the subjects examined. Thus many of the characteristics of the subject the stethoscope and the observer affect the accuracy of the auscultation finding.

**Sound transmission.** The transmission of a sound from its site of origin in the heart or blood vessel to the chest depends on many to some extent poorly known factors. These vary from person to person (see McKusick 1958, Onofre *et al.* 1960, Lusaada 1965). The sound travels in the blood in the direction of moving at the time of its production in the cardiovascular system. The sound also radiates into the surrounding tissues. Before its arrival at the skin of the chest the heart sound or murmur is damped by the different transmission characteristics of tissues and is reflected in the interfaces of the thoracic structures. The intensity decreases in direct proportion to the square of distance. The structure of the chest and the thickness of the subcutaneous fat, the position of the heart in the chest, diseases of the cardiopulmonary system such as fluid effusions and emphysema, thus appreciably affect the transmission of sounds. Not only the intensity of the murmur but also its frequency and duration are apt to change during the transmission. Accordingly, the intra and extracardial phonocardiographic findings may vary in the same subject and vary even more from one patient to another. Transmission of high frequency murmurs is poor and these may be only weakly detected intracardially (Segal *et al.* 1964, Leigh *et al.* 1966). Best transmitted are the 150–300 cps sounds (Feruglio 1962, Zalter *et al.* 1963). Deep inspiration attenuated the murmur intensity by 50% and in expiration an increase of 15% over apnea or quiet respiration was found in a study where an intracardiac sound generator was used in man (Feruglio 1962). The effect of changing distance was probably an important factor.

The quality of the stethoscope is an important factor in auscultation. A Rappaport Sprague stethoscope equipped with an open bell and with a diaphragm end piece was used in the present study (Rappaport and Sprague 1941, Ongly *et al.* 1960).

**Auditory system.** It is often forgotten that the basic instrument of auscultation is the human ear (Lusaada 1965). The total vibration energy generated by the action of the heart occurs mainly in the low frequency area (Butterworth and Keppert 1966) and only about 10% lies above the auditory threshold. An important part of the vibrations is thus subliminal and inaudible, which otherwise can be felt by palpation or registered as ultra low frequency displacement or acceleration tracing. Although the human auditory range is 16–16 000 cps, maximum hearing sensitivity is limited to

the area between 1 000 and 2 000 cps (Fletcher and Munson 1933). Below this accuracy falls rapidly as the range of the heart sounds are reached (10–800). Thus the ear needs 100 times greater sound pressure to hear a sound of 100 cps than one of 1 000 cps. Sound pressures of audible heart murmurs are about 25–65 decibels the maximum sensitivity of the ear in this area is at 100 cps (Rappaport and Sprague 1942 Butterworth *et al* 1960 Ongley *et al* 1960).

In the hearing ability of the ear there is a logarithmic distortion so that with sounds of the same intensity those of higher frequency seem louder than those of lower frequency. Thus comparing the intensities of high and low frequency heart murmurs involves certain difficulties.

On the other hand the human hearing mechanism is capable of selective interpretation as are other sensory systems. Otherwise the tremendous constant sensory input would quickly tire the integrating centres of the brain (Livingston 1959). This ability to perceive selectively helps greatly in blocking out disturbing and meaningless perception such as that of respiratory sighs and background noise when listening to weak heart sounds and murmurs.

The varying characteristics of the auditory system in different observers may explain some of the differences in auscultation findings.

**Background noise.** The level of background noise can profoundly alter the recognition of heart sounds and murmurs especially if the observer is not particularly concentrating on listening. According to the studies of Groom (1956) background noise is constantly 60–70 decibels in clinical and hospital wards. Groom points out that a sound heard in a quiet room would have to be amplified 12 times in order to become audible under the average noise conditions in a hospital ward. Obviously this phenomenon was a factor of the utmost importance in the present investigation when heart sounds and murmurs often of poor magnitude were studied.

#### TECHNIQUE OF AUSCULTATION

The art of auscultation is not an inherent skill. Careful technique, an ability to concentrate and to tune in to selective auscultation procedure and the interpretation of findings in terms of altered pathophysiology are acquired only by thorough training as has repeatedly been emphasized (Levine and Harvey 1959 Ongley *et al* 1960 Harvey 1964 Ravin 1967). These factors are obviously important in obtaining the full value of auscultation as a method of bedside examination.

#### AUSCULTATION PROCEDURE

The patients were examined daily during their first ten days in hospital and thereafter every

second day until discharged. First the precordium was palpated for the apical impulse and any paradoxical pulsation or palpable shock of third heart sound. After the first examination of the patient in the supine position he was turned to the left lateral position and the apical area was again thoroughly auscultated. It was some times only in this way that a faint systolic apical murmur or gallop sound could be recognized. Simple measures to diminish ward noise were taken whenever possible. The selective auscultation method was used concentrating only on one part of the heart cycle at a time. The carotid arteries were auscultated. Then the character of first heart sound was studied and compared in second sound at the apex. The intensity of the aortic and pulmonary components of second heart sound was noted with the diaphragm at the left sternal border in the third intercostal space. The splitting of second heart sound was carefully sought during slow deep respiratory excursions. Broader splitting than the usual physiological respiratory splitting was considered pathological. Then the lower precordium was examined with the bell of a stethoscope to detect any third or fourth heart sound. The bell was applied to the skin with only very light pressure to prevent any air leak which is often a critical measure in detecting weak gallop sounds. The left lateral parasternal area was auscultated with the diaphragm with firm pressure to discover regurgitant murmurs of the semilunar valves. Finally a meticulous search was made for systolic murmurs in the parasternal and apical areas. Sometimes an apical thrust caused a systolic thudding sound when the bell end piece was used but with the diaphragm this auscultatory artifact was easily excluded. The type of murmur was plotted as were also any changes occurring in the murmur pattern during the course of observation.

### B PHONOCARDIOGRAPHY

#### APPARATUS

All the phonocardiograms were recorded with the same type of apparatus Mingograph 31 B (Elema Schöander AB Sweden). The filters are of the high pass type and the apparatus has an amplifying system to compensate for the lowering of intensity when the frequency of the murmur rises. The direct jet ink writer apparatus has a linear response up to 500 cps. The nominal frequencies of the filters were 35 70 140 (logarithmic) and 250 cps. Phonocardiograms were recorded by all the filters every time to obtain selective sensitivity for both low frequency (third and fourth heart sounds) and high frequency (systolic murmurs) phenomena on recording (Fig. 4). The paper speed was 100 mm/sec. or sometimes 50 mm/sec.

Phonocardiograms of the pharmacodynamic investigation carried out in connection with the cardiac catheterization were recorded by Sanborn devices described in detail in Chapter VIII

### RECORDING PROCEDURE

All the phonocardiograms were recorded by the author. This was done whenever possible when a murmur was detected. For the purpose of ascertaining the intra-observer error in auscultation the murmur was drawn on paper and the presence or absence of third and fourth heart

examining several cardiac cycles in which constant time relations and form of murmur were clearly visible. The same method was employed in recognizing third and fourth sounds. Rather faint fourth sounds were also noted. The same classification as in auscultation was used for the murmur types.

### ACCURACY OF PHONOCARDIOGRAPHY

The same limiting factors of sound transmission as those discussed under the heading of auscultation also apply to phonocardiography. Thus murmurs registered by intracardiac phonocardiography




Fig 4 Phonocardiograms showing the importance of filter selection for recording a faint murmur of high frequency. With a 200 cps high pass filter band the murmur grade 2 in auscultation was not registered at all but is clearly present in the recording made with a 400 cps filter band.

sound was noted before recording. As recordings were usually made only to document an apical murmur of mitral incompetence developing after myocardial infarction this phonocardiographic comparison of increased intensity or splitting of second heart sound is unfortunately not available.

An air transmission type microphone was lightly held by hand at the point of maximal intensity of murmur. Often the patient had to be turned to the left lateral position to obtain a better murmur amplitude in the recording. Appropriate amplification was chosen to gain a clear picture of the murmur type. Usually maximum amplification that did not however distort the base line by an inappropriate signal noise ratio had to be used because of a faint high frequency systolic murmur. The patient was asked to stop respiration after normal expiration for a while during recording. A standard lead II of an electrocardiogram was always used as a reference recording.

### INTERPRETATION

In the interpretation of phonocardiographic recordings the murmur pattern was determined from several heart cycles. Care was taken not to interpret artifacts such as respiratory sighs as a murmur. This was easily accomplished by

may not be recorded by external phonocardiography (Segal *et al* 1964, Leighton *et al* 1966) and the murmur pattern may be distorted during transmission to the wall of the chest (Leighton *et al* 1966). The sharply filtered band of the phonocardiograph may take only a small spectrum of murmur vibrations and so change the type as compared to the auscultatory finding (Fig 5). In this study it also became clearly evident that the ear is more sensitive than phonocardiography in the recognition of murmurs of poor magnitude when of high frequency. This is also mentioned by Schrire *et al* (1961), Friedberg (1966) and Lunsada and DiBartolo (1961) who used special experimental phonocardiograph apparatus to solve this registration problem. Many times great difficulties were encountered in recording a pansystolic faint but distinctly and unmistakably audible high frequency murmur. On the other hand, owing to the characteristics of phonocardiographs and the human auditory system there is no problem in obtaining recordings of low frequency third or fourth heart sounds barely audible in auscultation.

From the point of view of method it is obvious that although phonocardiographic records were taken only for documentation if a murmur was found to have developed no external phono-




Fig 5 Phonocardiogram showing a marked ex diastolic high frequency late systolic crescendo of a pansystolic murmur of mitral incompetence

cardiography would have detected any high-frequency mitral systolic murmurs more sensibly than careful auscultation. Equally obviously matters are reversed when third and fourth heart sounds are studied. In 211 comparisons 11% of third and 10% of fourth heart sounds present in phonocardiography were missed by auscultation. The type of murmur was misinterpreted in 6 instances.

A large proportion of the murmurs of poor magnitude made classification of the type of mitral systolic murmur by the method of Perloff and Harvey (1957) impracticable in this study and therefore the same classification as in auscultation was used in the phonocardiographic interpretations.

## RESULTS

### 1. INCIDENCE OF ACUTE MITRAL SYSTOLIC MURMUR (Fig 1)

A permanent or transient murmur consistent with mitral incompetence resulting from acute myocardial infarction (MI) developed in 117 patients during hospital observation. In 70 patients no murmurs were detected throughout this time with the exception of a few constant carotid systolic murmurs which could not be heard outside the base of the heart, and one patient (No 164) with a murmur of mild aortic insufficiency. One patient (No 180) who developed tricuspid incompetence (section 7) was included in the no-murmur group. Patient groups 3, 4 and 5 (Fig 1) contained in the total material are not analyzable when estimating the incidence of acute mitral incompetence as a complication of myocardial infarction. Accordingly, the percentage of mitral incompetence is 63% of the 187 patients in groups 1 and 2, and 56% of the total material. The true incidence of MI in the present material thus falls somewhere between these two percentage figures.

Pericardial friction rub was observed in 14 patients of the MI group and in 5 no-murmur patients.

### 2. TIME OF ONSET OF MITRAL SYSTOLIC MURMURS (Fig 2)

*All mitral systolic murmurs.* The first day of its being noticed was taken as the time of onset of a murmur from the estimated onset of myocardial infarction. The time of onset of the murmurs for the entire mitral incompetence group was mainly within the first 5 days of illness. After that the murmur appeared fairly often between the 6th and 9th days but thereafter only seldom. During the first 10 days 87% of the murmurs had appeared and thus during the remaining time only 13%. The first day included 7 patients who already had a murmur on






Fig 6 Time of onset of mitral systolic murmur in 117 patients. The column for the first day includes seven patients with murmur present on admission but considered to be acute for the reasons explained in the text

admission but 4 of these were classified as acute MIMI (Case Nos 3, 32, 87 and 108) on the basis of subsequent disappearance and re appearance, (Fig 7) and 3 (Nos 8, 10 15) because the autopsy examination revealed no other alteration except severe fresh destruction of papillary muscle as an explanation of mitral systolic murmur

**Transient and inconstant mitral systolic murmurs (Fig 7)** The time of onset of transient murmurs did not differ from that of constant murmurs. The duration of a transient murmur varied from 1 to 24 days, the mean being 10 days. The group with an inconstant murmur consists of the patients in whom the murmur could not be heard continuously during the observation period but in whom there were silent periods of varying duration. However, the murmur was still present on the patient's discharge from hospital. Fig 7 indicates the variation in time of onset and the duration of the silent periods. The principal trend was a murmur of

brief duration with an early appearance, which after a few days re appeared as constant and often as a different type (see section 4)

### 3 MAIN CHARACTERISTICS OF MURMURS (Table 4)

**Prevalent type** The prevalent type of murmur in the MIMI group was chiefly pansystolic (91%), and only a small proportion of the murmurs were mainly protomesosystolic (3 patients), Fig 3. Other ejection type murmur occurred often as a variant type (section 4). Of the sub types, the pansystolic plateau type (Fig 8) was overwhelmingly the most prevalent occurring more often than all the other types combined (57%). Next most common among the sub types was the pansystolic decrescendo (Fig 9), which accounted for 20%, followed by the crescendo type (Fig 10), with 9%. No mainly decrescendo type of protomesosystolic murmur was observed, all 3





Fig 7 Occurrence of the transient (upper group) and unconstant (lower group) mitral systolic murmurs. The presence of only an ejection type murmur in the group of transient murmurs (in 2 patients carrying a crescendo or ejection type) or the change of an initially ejection type murmur to a pansystolic one in the group of unconstant murmurs is indicated by +.

Table 4 *Main characteristics of mitral systolic murmur at hospital*

Type	Intensity			Location			Transmission			Frequency		Persistence			Total
	1	2	3	Apex	LSB	Apex	Apex	LSB	None	High	Me- dium	Con- stant	Incon- sistent	Tran- sient	
<i>Panistol</i>															
Placard	8	19	18	4	65	1	1	15*	20*	37	51**	13	16	6	67 (57%)
Crescendo	1	3	5	2	11	0	0	7	3	1	11	0	8	3	11 (9%)
Decrescendo	9	13	1	0	19	1	3	2	6	15	17	6	12	6	23 (20%)
Cresc decrease	0	5	1	0	6	0	0	3*	3*	2	4	2	1	1	6 (5%)
Total	18	60	25	4	101	2	4	27*	32*	53	86**	21	26	12	107 (91%)
(15%) (51%) (21%) (3%) (106%) (2%) (3%) (23%) (27%) (47%) (74%) (18%) (59%) (22%) (10%)															
<i>Protomorphologic</i>															
Decrescendo	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0 (0%)
Cresc decrease	0	0	3	0	1	1	1	0	1	2	1	2	3	0	3 (3%)
Total	0	0	3	0	1	1	1	0	1	2	1	2	3	0	3 (3%)
<i>Ejection</i>															
Early	2	2	2	0	4	1	1	0	1	2	3	3	1	2	6 (5%)
Late	0	1	0	0	0	0	1	0	0	1	0	1	0	1	1 (1%)
Total	2	3	2	0	4	1	2	0	4	3	3	4	3	3	7 (6%)
Total	20	63	30	4	106	4	7	27*	37*	60	90**	27	75	15	117 (100%)
(17%) (54%) (26%) (5%) (91%) (3%) (6%) (23%) (32%) (51%) (77%) (23%) (64%) (23%) (13%)															
LSB left sternal border															

\* Transmission to both axilla and left sternal border in some of patients

\*\* 7 patients with medium high frequency murmur included

\*\*\* 5 patients with inconstantly audible transient murmur not included




Fig 8 Phonocardiogram showing the common plateau type high frequency pansystolic murmur of mitral incompetence

Fig 10 Phonocardiogram representing the crescendo-type pansystolic murmur. This is evident in a tracing obtained through a filter sensitive to high frequencies (250). With a filter of a nominal frequency of 70 cps not sensitive to high frequencies the crescendo character is not recorded. A kymocardiogram (KCG) confirmed the finding of a marked paradoxical cardiac pulsation (stippled area)






Fig 9 Phonocardiogram of a decrescendo type mitral systolic murmur pansystolic in auscultation






Fig 11 Phonocardiogram of a protomesosystolic crescendo-decrescendo type murmur. The murmur changed transiently to a louder pansystolic plateau type several times during several attacks of anginal pain (Table 7 case No 37)

patients with a protomesosystolic murmur having the crescendo-decrescendo type (Fig 11)

It is obvious that the line dividing the decrescendo type of murmur according to pansystolic or protomesosystolic duration must be a somewhat elusive one. Phonocardiography did not help deal with this problem since for technical reasons (see *Methods*) a faint decrescendo murmur might appear to be protomesosystolic in phonocardiography notwithstanding its extension over the whole systole in auscultation.

Ejection type murmurs mainly had a

short early systolic timing (Figs 3, 12). A late systolic murmur as the prevalent type was noted in only one patient with a transient murmur of 18 days duration (Fig 13). In one patient the first manifestation of an inconstant murmur was a late systolic murmur, which after lasting a few hours disappeared completely, only to be replaced later the same day by a permanent early systolic or sometimes pansystolic murmur.

*Prevalent intensity of murmurs* (Table 4, Fig 15). In the main the murmurs were of a somewhat low intensity, chiefly grade 2 (54%) the second most common




Fig 12 Two examples of distinct ejection type medium frequency apical mitral systolic murmurs ascribed to an ischemic dysfunction of the papillary muscle. Both murmurs later changed to a definitely pansystolic type




Fig 13 Phonocardiogram of a purely late systolic type of murmur. The murmur disappeared after 18 days.

being grade 3 (26%), then grade 1 (17%) and finally grade 4 (3%). A fairly loud prevalent intensity, grade 3 or over thus occurred in less than a third of the patients (29%). The final prevalent intensity of murmur varied somewhat so that in grade 1 it was 1–2 (8 patients), in grade 2 2–3 (13 patients), while in grade 3 the murmur occurred occasionally in 5 patients often at grade 4 intensity. No

murmur over grade 4 in intensity was noted.

Pansystolic murmurs were correlated with loud (grade 3 or 4) intensity ( $p < 0.01$ ) whereas this was not the case with the ejection type or protomesosystolic murmur. The loud murmurs all those of grade 4 and most of grade 3 were of the pansystolic plateau crescendo or crescendo-decrescendo type (Fig 14). On




Fig 14 Phonocardiogram of a crescendo-decrescendo type pansystolic murmur of mitral incompetence. The mid systolic peak became more prominent when the intensity of the murmur was increased by an infusion of methoxamine.

the other hand, the intensity of the decrescendo murmurs was only once over grade 2

No correlation was found between murmur intensity and severity of mitral incompetence as judged clinically or by hemodynamic investigation

Relation of the heart volume to the intensity of the murmur showed that in enlarged hearts the murmur was more often loud, 65 % of the grade 3 or 4 murmurs occurred in enlarged hearts while 66 % of the grade 1 or 2 murmurs occurred in normal sized hearts

*Location, transmission and frequency of murmurs and their sub types* (Table 4) The location of mitral systolic murmurs developing as a consequence of acute myocardial infarction was nearly always apical (91 %) This was also true in many instances of the ejection-type murmur Only occasionally was the location at the

left sternal border in the third or fourth intercostal space, there were 4 such patients In 7 patients the maximum intensity occurred between the apex and the midline

*Transmission of murmur* The most common finding was that the murmur was not transmitted (51 %), as may be expected with murmurs of mainly low intensity Transmission was more common to the left sternal border (32 %) than to the axilla (23 %) No protomesosystolic or ejection type murmur was transmitted to the axilla The transmission of a murmur to the left sternal border was sometimes extended to the aortic or pulmonary area The crescendo-type murmur was rather often transmitted to the axilla, and it was invariably apical

*High frequency* was almost as common a finding in the investigation of the murmurs (77 %) as were pansystolic duration




Fig 15 Relation of the murmur type to its location, pitch and loudness. Ejection-type group includes protomesosystolic murmurs

Table 5 *Relation of intensity of murmur to permanence of murmur*

Permanence	Intensity		Total
	Grade 1 or 2	Grade 3 or 4	
Constant	47 (57 %)	28 (87 %)	5 (64 %)
Inconstant	22 (26 %)	5 (15 %)	27 (23 %)
Transient	14 (17 %)	1 (3 %)	15 (13 %)
Total	83 (100 %) (71 %)	34 (100 %) (29 %)	117 (100 %)

and apical localization. A medium frequency was relatively more common in the ejection type murmurs. The crescendo type always had a high frequency.

Fig 15 presents a correlation of murmur type with its location and frequency. An analysis was made not only of the prevalent characteristics but also of the different types, locations and frequencies of murmurs in the same subject at different times. This was done when it became evident during the course of the investigation that the pansystolic murmur was generally apical and of high frequency, whereas the ejection type (or protomesosystolic) murmur appeared to be associated more with a parasternal location and to be of medium frequency; the type of murmur was even apt to vary in the same patient (see *Appendix*). These definite correlations are apparent from Fig 15 and are highly significant ( $p < 0.001$ ) for the pansystolic murmur. In the ejection type or protomesosystolic murmur the distribution was more often in a left sternal border location and of medium frequency, although the difference was not significant.

*Permanence of murmur* (Table 4). The murmur was permanently audible without any disappearance after its development during hospitalization in not more than two-thirds of the patients (64 %). Transient murmurs which disappeared after varying periods (Fig 7) were observed in 15 patients (13 %). The remaining pa-

tients had inconstant murmurs and the incidence was 23 % (not including 5 patients with an inconstantly present transient murmur).

Crescendo-type murmurs were never transient. Transient murmurs were usually of the plateau, decrescendo or ejection type. Constant murmurs were not often of the decrescendo type which was common in the inconstant group.

Table 5 shows that loud murmurs, e.g. grade 3 or 4, were significantly ( $p < 0.01$ ) more commonly permanent than fainter murmurs.

*Transient and inconstant murmurs* were characterized by being more of the decrescendo type, fainter and transmitted to the left sternal border and of medium frequency.

*Patients who died in hospital* all (with one exception) had pansystolic, usually high-frequency and rather loud murmurs (8 out of 19 grade 3 or 4) without total papillary muscle rupture.

#### 4. VARIABILITY OF MURMUR CHARACTERISTICS DURING HOSPITALIZATION

The murmur that appeared was not constant in character but showed great variability in type and intensity during the course of observation.

*Change of type* (Table 6). The incidence of variation in type was high. Of the murmurs in 117 patients with MIM only 67 (57 %) were permanently of the same type. The ejection type was the most



Table 6 Variation types of murmur

		VARIATION TYPES OF MURMUR						Total number of mur- murs which presented variation in type		Total	
		<i>Pansystolic</i>				<i>Protomesosystolic</i>					
		Plateau	Crescendo	Decrescendo	Crescendo- decrecendo	Decrescendo	Crescendo- decrecendo				
TRANSIENT TYPES OF MURMUR	<i>Pansystolic</i>										
	Plateau	(43)	6	5	1	2	4	6	24	67	
	Crescendo	4	(6)					1	5	11	
	Decrescendo	4	1	(12)		1		5	11	23	
	Crescendo-decrescendo	2	1		(2)			1	4	■	
	<i>Protomesosystolic</i>										
	Decrescendo					(0)			0	0	
	Crescendo-decrescendo	1					(1)	1	2	3	
	<i>Ejection</i>										
	Early	1		2				(2)	1	4	6
Late								(1)	0	1	
Total number of variation types of murmur		12	8	7	1	3	4	14	1	50	117

common 28%) as a variant type i.e. the type from which or into which the prevalent type changed (see also *Appendix*).

A phenomenon often noted was that the first transient murmur appearing in the inconstant murmur group was of the ejection or protomesosystolic type and that with the development of a constant murmur the type had changed to pansystolic. This was observed in 8 of the 27 patients 30% in the inconstant group.

Fig 7. In the total material the ejection-type or protomesosystolic murmur of 12 patients became pansystolic — thus in addition to the 5 in the inconstant group in 4 patients it occurred without intermittent disappearance of the murmur — while the reverse occurred in only 2 patients. The type of constant murmur changed less frequently (39%) than did the type of the inconstant or transient murmur 50%, although the

difference was not significant statistically.

*Change of intensity* (Figs 16 and 17). The intensity of the murmur changed almost as often (47%) as it remained the same and then generally to a low intensity (Fig 16). A common occurrence was the gradual increase in loudness of the murmur within a few days (Fig 17). Fig 16 shows the profile of incidence of the different murmur intensities when first noticed in comparison with the prevalent intensity. The frequency of occurrence of faint murmurs decreased and that of loud murmurs increased markedly. In many instances the increase was quite distinct e.g. from grade 1 to 3 or to 4 as was observed in 15 patients. After the prevalent intensity had been established, a decrease in intensity was observed in 9 patients and only once by more than one grade (excluding transient murmurs, Fig 7).

*Change of main location* was very infre-




Fig 16 Changes in the intensity of the mitral systolic murmur in hospital

quent. The apical murmur shifted in only 3 patients to the left sternal border and conversely a murmur located in the left sternal border shifted to the apex in 5 patients. In most instances the ejection type murmurs became pansystolic simultaneously (Fig 7).

Change of frequency was hardly ever found. When it did occur it was also usually connected with a change of type: pansystolic and high frequency and ejection type and medium frequency were mutually connected (Fig 15).




Fig 17 Phonocardiographic tracings showing the gradual change of the character of the mitral systolic murmur which developed 7 days after estimated onset of the myocardial infarction. When appearing the murmur was grade 1-2 and of medium frequency. The murmur gradually gained in loudness to grade 4 and changed predominantly to a high-pitched while the plateau type changed to crescendo-decrescendo.




Fig 18 A comparison of the murmur characteristics in patients with anterior or posterior myocardial infarction

### 3 MURMUR OF ACUTE MITRAL INCOMPETENCE IN ANTERIOR AND POSTERIOR MYOCARDIAL INFARCTION

*Extent of infarction and type of murmur*  
In the MIMI group there were relatively more transmural infarctions in a posterior location (56%) than in an anterior location (26%).

The plateau type murmur was significantly ( $p < 0.01$ ) associated with trans-

mural infarction as compared with subtransmural extent. Crescendo type occurred with one exception always with transmural infarction. 8 of a total of 23 pansystolic decrescendo murmurs occurred in association with subtransmural infarction.

*Characteristics of murmur (Fig 18)* The following characteristics of an acute mitral systolic murmur appeared to have a ten-




Fig 19 Phonocardiograms confirming the transient increase in the intensity of the mitral systolic murmur during a spontaneous attack of angina pectoris. The even plateau type was changed to a more waven character. The heart rate and blood pressure were not altered.

dency to be connected with the site of the infarction although the differences could not be statistically demonstrated.

Anterior infarction, more often subendocardial decrescendo or ejection type or protomesosystolic, inconstant, faint, located in or transmitted to the left sternal border.

Posterior infarction, more often transmural pansystolic plateau-crescendo,

constant, loud, apical, and transmission to axilla.

#### 6 TRANSIENT CHANGES IN CHARACTER OF MITRAL SYSTOLIC MURMURS DURING SPONTANEOUS ANGINAL PAIN (Table 7, Fig 19)

In 8 patients with acute myocardial infarction an opportunity was afforded to observe transient and, with the relief of the pain, reversible auscultatory changes in murmurs associated with spontaneous

Table 7 Transient changes in murmur of mitral incompetence during attacks of severe anginal pain

Case number	Type		Intensity		Frequency		Changes in blood pressure (B P) and heart rate (H R.)	
	No pain—Pain	No pain—Pain	No pain—Pain	No pain—Pain	No pain—Pain	No pain—Pain	No pain—Pain	No pain—Pain
37	*Protomeso	—Plateau	2—3	3	Medium	—High	B P 160/110	—110/—
7	—	—Plateau	0—2	2	—	—High	H R 90	—100
104	*Plateau	—Crescendo	2—3	3	Medium—High	—High	—	—
95	Plateau	—Crescendo	3—4	4	(High)	—(High)	H R 50	—90
34	(Decrescendo—Decrescendo)	(Decrescendo—Decrescendo)	0—1	—2	Medium—High	—High	—	—
94	(Plateau—Plateau)	(Plateau—Plateau)	0—1	—2	Medium—High	—High	B P 115/60	—100/—
11	(Plateau—Plateau)	(Plateau—Plateau)	3—4	4	(High)	—(High)	—	—
87	(Decrescendo—Decrescendo)	(Decrescendo—Decrescendo)	1—2	2	(High)	—(High)	—	—
Main change during pain	Mainly plateau or crescendo		Always louder by 1 or 2 grades		Always high frequency		No constant change	

\* Several observations




Fig 20 Phonocardiogram of a high frequency pansystolic murmur of tricuspid incompetence which developed on the 8th day after the onset of the myocardial infarction. The murmur was of grade 1-2 in expiration increasing to grade 3 in inspiration. A marked positive jugular venous pulse appeared simultaneously with the murmur. Hepatic pulsation was present.

severe anginal pain. The trend during the pain was mostly to the plateau or crescendo type of previously absent, pansystolic or protomesosystolic murmur to an increase of murmur intensity by 1 or 2 grades and always a change to high frequency. No constant changes in blood pressure were found; a tendency to a faster heart rate during the attack of pain was noted.

#### 7 TRICUSPID INCOMPETENCE

On the 8th day after the onset of infarction one patient (No 180) developed a characteristic pansystolic murmur of isolated tricuspid incompetence in the lower sternal area with an increase of murmur intensity from grade 1 or 2 in expiration to grade 3 in inspiration. A positive jugular venous pulse (Fig 20) and a hepatic pulsation developed at the same time. An apical murmur was present

of grade 1 to 2 always apical, predominant transmission to axilla, high frequency and naturally of constant occurrence. Changes of type were observed in 2 patients.

**Coronary insufficiency.** Alongside the research material consisting of infarction patients proper, the author kept under prolonged observation 7 patients who were classified as belonging to the 'coronary insufficiency' group (see Methods). These 7 patients developed the murmur indicative of mitral incompetence 1-5 days after the onset of an acute attack. It was invariably pansystolic, grade 2 or 3, apical, and transmitted to the left sternal border if transmission occurred (4 patients). The murmur was always high frequency and did not change in type from its pansystolic plateau (once a decrescendo type was noted). In all the patients it eventually remained permanent after a period of inconstancy at first in 2 of them.

#### 8 CHARACTER OF MITRAL SYSTOLIC MURMUR CAUSED BY EARLIER MYOCARDIAL INFARCTION (GROUP 3) OR IN CONNECTION WITH "CORONARY INSUFFICIENCY"

**Previous MIMI.** The murmur in patients of group 3 (not included in the detailed analysis) had the following features: inten-

## DISCUSSION

Two of the most impressive findings of this study concerning the characteristics of the murmur of mitral incompetence as a complication of acute myocardial infarction would seem to be its great prevalence and its marked variability and dynamic features.

**Incidence:** No prospective systematic studies of the incidence of the mitral systolic murmur as a sequela of acute myocardial infarction are available. Most of the earlier reports, dealing with small series (see Chapter II) used the retrospective approach and seem to consist of patients with rather marked hemodynamic changes. The report published by Froment *et al* (1955) however points to a high frequency of this complication of acute myocardial infarction in their clinical material. The present results revealed a prevalence comparable to that reported as early as 1940 by Grotel in his work on acute myocardial infarction.

This high prevalence of mitral incompetence is not, however as surprising as the lack of clinical studies might indicate and is to be anticipated when considered in the light of autopsy data (Arkhangelsky 1959) and experimental works (Bailas 1965, Hider *et al* 1965) as well as of acute hemodynamic alterations of myocardial infarction (see Chapter XI). It is quite clear that this high incidence of findings would not have been possible without particular searching for murmurs by meticulous auscultation. Predominantly, the murmurs were faint, in addition to which the circumstances of pursuing the study in the hospital wards included disturbing noises.

The murmur observed in the majority of the patients was typical and diagnostic of mitral incompetence (Mounsey and Bridgen 1954, Leatham 1958 a, b, McKusick 1958, Ongley *et al* 1960, Ravin 1967), and, furthermore a shorter or longer totally silent period before the appearance

of the murmur cancels out most causes other than mitral incompetence. The harsh, atypical ejection type murmur of mitral incompetence at the apex or the left sternal border may be confused with the murmur of aortic sclerosis (Mounsey 1957, Bruns and van der Hauwaert 1958, Schumert *et al* 1960, Spencer and Greiss 1962). However this type of mitral systolic murmur was rather rare.

An uncertain factor of greater significance in evaluating the development of the murmur of mitral incompetence would be present if a previously present pansystolic murmur of mitral incompetence would disappear under the initial shock, as may occur in a case of ejection type systolic murmur of aortic origin. This does not however, occur, although the intensity most often quietens down for hemodynamic reasons (Braunwald *et al* 1957, 1958). The persistence of the murmur is related to the persistence of the clear systolic pressure gradient on the level of the atrioventricular valve causing the regurgitant flow, notwithstanding the marked decrease in blood pressure (Hultgren and Leo 1959, Lewis 1962, Harrison and Dexter 1963).

In the present series the intensity of the murmur often simultaneously increased despite a marked decrease in the systolic blood pressure. This stresses the dominance of the mechanism of ischemic damage over the hemodynamic factors affecting the regurgitation.

**Intensity:** Special emphasis must be laid on the low intensity of the murmur of mitral incompetence following acute myocardial infarction.

It may be asked whether the observation of a faint, grade 1 or 2 mitral systolic murmur has any significance. The fact is that such a faint murmur is often apt to be the only sign (Nixon and Wooler 1963 b, Leighton *et al* 1966) of the added burden inflicted on an already damaged heart by the useless flow of blood back and forth resulting from a mitral valvular

leak. This can lead to irreversibly progressive left ventricular failure (see Chapter VII).

The intensity of  $\text{M}$  murmur does not necessarily have any correlation to the severity of the mitral incompetence, it may even be lacking in hemodynamically very severe mitral incompetence, known as "silent mitral incompetence" (Logan and Turner 1952, Bridgen and Leatham 1953, McDonald *et al* 1957, Moraes *et al* 1957, Schrite *et al* 1961, Logan *et al* 1967). This is obvious enough, as the velocity of the regurgitant jet, rather than a large volume flow, is the most important determinant of murmur intensity (Bruns 1959).

This lack of correlation between murmur intensity and the clinical or hemodynamic evaluation of the severity of MIMI was also clearly evident in the present investigation. A murmur intensity of grade 1 or 2 was observed in connection with marked regurgitation (e.g. cases 67 and 84, *Appendix*, and Chapter VIII).

The low intensity of the murmur and also its only gradual gain in loudness from very faint to in some instances, fairly loud as also noted by Nezhlin and Shamesova (1951), are contrary to the loud sudden, harsh murmur caused by avulsion of a papillary muscle.

The low intensity of the mitral systolic murmur is obviously related to the predominantly somewhat slight regurgitation and decreased contractile velocity and power of the left ventricle observed in ischemic damage (Braunwald *et al* 1957, Ross *et al* 1960, Rushmer *et al* 1963).

The time of onset of the murmur was distributed over a fairly wide range. A murmur was by no means an immediate manifestation of acute myocardial infarction. The most important portion appeared during the first 5 days, this is consistent with the times of onset reported by other investigators (Grotel 1940, Nezhlin and Shamesova 1951, Gorlin 1966). The

somewhat delayed onset of MIMI seems to coincide with the most extensive necrotic changes in the myocardium, which take place a few days after the onset of the ischemic damage (Edmondson and Hoxie 1942, Lodge Patch 1951, Bargmann and Doerr 1963). A similar timetable is also to be noted in the major destructive complications discussed earlier, e.g. ventricular septum perforation, papillary muscle disruption and myocardial rupture.

The type of the mitral systolic murmur was predominantly pansystolic, characteristic of mitral incompetence, which means regurgitation throughout systole. The pansystolic type of murmur was also observed by the majority of other investigators (Grotel 1940, Nezhlin and Shamesova 1951, Orlando *et al* 1964, Bashour 1965, Raftery *et al* 1966, Soulie *et al* 1966).

The murmur of papillary muscle dysfunction described by Burch *et al* (1963) and Phillips *et al* (1963a) was of the clear cut ejection type, but most of their patients seemed to be suffering from chronic ischemic heart disease, only a few patients having had acute myocardial infarction.

Ejection type murmurs similar to the diamond shaped murmur described by these writers occurred in the present study in many instances during the very first few days of infarction. Later often after a temporary disappearance, the murmur definitely changed in type to pansystolic. The first phase of the regurgitation might be related to the circumstance of a papillary muscle being rendered incapable of shortening during the ejection phase as a consequence of ischemia, although still able to generate tension during the initial isovolumetric phase of the systole (Burch *et al* 1963). This mechanism obviously causes an ejection-type murmur. In the second phase the total loss of contractile power caused by extensive necrotic destruction of papillary

muscle would allow the development of a pansystolic type murmur (For further mechanisms of regurgitation, see Chapter XI)

The decrescendo type of murmur often seemed, like the ejection type, to indicate a mild degree of mitral incompetence when judged by the character of the murmur. The decrescendo type of murmur — pansystolic or protomesosystolic — has been recognized as usually indicating only insignificant mitral incompetence (Gorlin *et al* 1952, Hultgren and Leo 1959, Nager *et al* 1964, Holldack and Wolf 1966, Ilmurzynska 1966). Otherwise it was the crescendo type of murmur that was most frequently observed in association with marked regurgitation (See also the section on murmur types at follow up Chapter X)

Transient murmur changes during in tense anginal pain, without consistent changes in heart rate or blood pressure would further support the view that a mechanism of ischemic malfunction of the papillary muscle operates in murmur generation

The recent view that the late systolic murmur is usually related to disease of the chordal papillary muscle apparatus (Humphries 1964, Segal and Likoff 1964, Phillips *et al* 1963 a, Barlow and Bosman 1966, Criley *et al* 1966) is consistent with the observations of its occurrence in the present study

*Site of infarction* The auscultatory characteristics of murmurs suggest that damage to the posterior papillary muscle is more serious than damage to the anterior papillary muscle. This suggestion is consistent with the higher incidence of involvement of the posterior papillary muscle in the autopsy findings in the present as well as earlier studies (Nezlin and Shamesova 1951, Orlando *et al* 1964, Bashour 1965)

The direction of radiation of the murmur in anterior and posterior myocardial infarction was different from that generally described in patients with chorda tendinae ruptures or rheumatic valvular disease. The murmur in posterior infarctions radiated predominantly to the axilla in the present study and not to the aortic area (Edwards and Burchell 1958, Osmundson *et al* 1961, Sleeper *et al* 1963, Burchell 1963, Menges *et al* 1964, Raftery *et al* 1966). This might be ascribed to louder intensity of the murmur in the cases described. On the other hand the mitral systolic murmur associated with anterior infarction had more of a tendency to radiate to the aortic area, as in cases with anterior chordal rupture (Shapiro and Weiss 1959, Miller and Pearson 1959) and as in anterior papillary muscle dysfunction (Phillips *et al* 1963 a). The transmission of faint murmurs may be easier to the left sternal border than to the axilla, where the lung a poor sound conductor, interposes (Leighton *et al* 1966)

*To sum up*, the high prevalence of mitral incompetence and the marked variability of the intensity and type of murmur, together with its frequently transient and inconstant character may be directly related to the basic background mechanism, an ischemic myocardial injury, which often varies in extent and severity from moment to moment. The contractile function and size of the left ventricle, and the function of the papillary muscles in their various phases of contraction, are susceptible to ischemic impairment in varying degrees. This explains the highly variable auscultatory characteristics of mitral incompetence caused by acute myocardial infarction.



## COMPARISON OF CLINICAL FINDINGS IN PATIENTS WITH AND WITHOUT MITRAL INCOMPETENCE

### CLINICAL FINDINGS

#### PREDISPOSING FACTORS IN THE DEVELOPMENT OF MITRAL INCOMPETENCE

##### PREVIOUS CORONARY HEART DISEASE

The patients' previous symptoms of coronary heart disease and the occurrence of certain other diseases of the cardiovascular system were studied in order to find possible predisposing factors in the development of mitral incompetence. In this respect, as in the later comparisons, only groups 1 and 2, consisting of 187 patients, were compared for the reasons given in the foregoing (see Chapter V).

*Angina pectoris* No differences could be detected between the MIMI and no-murmur groups in the occurrence or duration of earlier angina pectoris. Angina pectoris had been experienced by slightly more than half the subjects, 58% in the MIMI and 54% in the no-murmur group.

*Myocardial infarction* A previous attack of infarction appeared to make a patient more susceptible to the development of a mitral incompetence in connection with reinfarction. 72% of the MIMI patients and 84% of the no-murmur patients had first infarctions, the reinfarction figures being 28% and 16% respectively. However, the difference was not significant. The total number of patients with reinfarctions was 44 out of 187 patients (24%).

##### OTHER DISEASES OF THE CARDIOVASCULAR SYSTEM

The occurrences of hypertension, con-

gestive heart failure, intermittent claudication and/or signs of peripheral arterial disease, cerebrovascular accidents and diabetes mellitus were analyzed.

*Major peripheral arterial disease* Manifestations, such as intermittent claudication, or murmurs or absent pulsations in large peripheral arteries (17%) or cerebrovascular accidents (5%), did not differ in relative incidence in either group of patients. These diseases affected 22% of the patients.

There were 11 patients with diabetes, of whom 9 belonged to the MIMI group. Only definite, manifest diabetes was included in the analysis, and not prediabetes or, of course, transient glucosuria observed on its own in association with infarction, since the material in this respect had been non-uniformly studied. The difference was not, however, statistically significant.

*Heart failure* of NYHA grade II or more in the patients' history of subjective symptoms was found in 16 patients in the MIMI and 6 in the no-murmur group, with no significant difference.

*Hypertension* was found to have a significantly ( $p < 0.01$ ) higher incidence among MIMI patients (33%) than among those in the no-murmur group (14%). On the other hand, there was no significant difference within the groups as regards systolic or diastolic hypertension and the distribution of their degree of severity. Hypertension was present in 49 of the total of 187 patients (26%).

# SEVERITY OF ACUTE MYOCARDIAL INFARCTION (Fig 21)

The severity of myocardial infarction was estimated on the basis of the coronary prognostic index developed by Peel *et al* (1962). This estimation made upon the patient's admission to hospital, takes into account in part the afore mentioned factors from his medical history and in addition his initial clinical situation. The distribution in the different severity groups was remarkably uniform among both MIMI and no-murmur patients (Fig 21).




Fig 21 Distribution of the coronary prognostic index in patients with and without mitral incompetence. No difference was evident between the patients groups.

The laboratory tests yielded the following average results in the MIMI and the no-murmur groups of patients. The average maximal erythrocyte sedimentation rates were 51 mm/hour in the MIMI group and 44 in the no-murmur group. The maximal white cell counts were 15,000 and 11,800 in  $\text{mm}^3$ , and the maximal serum GOT in the MIMI group was 228 and in the no-murmur group 124 units.

# CLINICAL SEQUELAE OF MITRAL INCOMPETENCE

**Degree of mitral incompetence.** As a background for the findings to be described in the following, together with their possible connection with mitral valvular incompetence, Table II presents the severity, as judged clinically, of mitral incompetence following myocardial infarction. However, it must be pointed out that in many instances the easy estimation of the hemodynamic severity of mitral incompetence becomes an exceptionally difficult task when mitral incompetence is superimposed on acute myocardial infarction.

The generally used clinical signs indicating severe mitral incompetence with reasonable accuracy are sustained and hyperdynamic apical impulse, soft first heart sound, prominent ventricular gallop and diastolic flow murmur, loud pansystolic apical murmur transmitted to the axilla, low arterial pulse pressure, splitting of second heart sound and an increase in its pulmonary component and electrocardiographic signs of left ventricular and atrial hypertrophy (Bridgen and Leatham 1953, Wood 1954, Harvey *et al* 1957, McKusick 1958, Hubbard *et al* 1959, Bentivoglio *et al* 1961, Perloff and Harvey 1962, Nixon 1961, 1963, Nixon and Wooler 1963 a, b, Humphries 1964, Deliyannus *et al* 1964). However, most of these findings also occur in acute myocardial infarction. A pansystolic apical murmur is a hallmark of mitral incompetence, and though a loud murmur usually indicates a large regurgitation (Gorlin *et al* 1952, Wade *et al* 1952, Abelman *et al* 1953), bad mistakes can happen if its intensity is correlated directly to the amount of regurgitation (see Chapter VI). What actually remains is only a hyperdynamic left ventricular impulse.

Table II presents the assessment of marked mitral incompetence to be present in 20 patients which is 17% of the whole group. Thus, hemodynamically, regurgi-

Table 8 *Severity of mitral incompetence evaluated by clinical judgment and its relation to acute mortality*

Degree of MIMI	Number of patients	Died in hospital
Marked	20 (17%)	8 (40% of 20)
Slight	97 (83%)	13 (12% of 97)
Total	117	21

Table 9 *Incidence and severity of cardiovascular shock*

Degree of shock	Mitral incompetence	No murmur
None	82 (70%)	49 (70%)
Mild (score 1)	7 (6%)	4 (6%)
Moderate (score 5)	17 (15%)	8 (11%)
Severe (score 7)	11 (9%)	9 (13%)
	(24%) (30%)	(24%) (30%)

Table 10 *Incidence of congestive heart failure at hospital*

Heart failure	Mitral incompetence	No murmur
left	57* constant 25 transient 32*	25 constant 8 transient 17
Acute left and right	15 constant 8 transient 7	6 constant 3 transient 3
right	4 constant 1 transient 3	3 constant 1 transient 2
Delayed left and right	22* 0 1	5 0 0
	23* (20%)	5 (7%)
Total number of patients with heart failure	89 (76%)	39 (56%)
No heart failure	28 (24%)	31 (44%)
Total	117	70

\*Includes 10 patients with acute transient failure who later developed delayed failure

tation appeared to be somewhat on the insignificant side in the majority of the patients. On the other hand, the great significance of the severe mitral incompetence is demonstrated by the exceedingly high mortality in this group, 40 %, as compared to the corresponding mortality figure for the slight incompetence group, 12 %.

**Cardiogenic shock** (Table 9) Both the incidence and the severity of cardiogenic shock were identical in patients with and without mitral incompetence developing after myocardial infarction. Actual shock (scores 5 and 7) occurred in 24 % in each group. Mild shock, with a score of 1,

which occurred in 6 % in both groups, is a vague concept. It has been included in the table because it was used in determining the coronary prognostic index, though strictly speaking (see *Methods*, Chapter IV) its inclusion within the concept of shock is open to dispute. Shock appeared almost invariably on the first or the second day after onset of infarction and before the murmur of mitral incompetence was observed, in only two instances were shock and murmur found to occur in a patient simultaneously. Accordingly, shock neither predisposes a patient to MIMI nor is a consequence of it. Terminal shock observed in dying




Fig. 22. Relation of the time of onset of the clinical signs of congestive heart failure to the appearance time of the mitral systolic murmur. If the first day is excluded (first dotted line) the heart failure seems predominantly to follow MIMI. Incidence of the persistent or delayed heart failure (appearing in the second week or later, second dotted line) was significantly ( $p < 0.01$ ) higher in the MIMI patients than in the patients without mitral systolic murmur in whom the heart failure generally appeared during the two first days.

patients, was not included in the analysis

*Congestive heart failure* (Table 10, Fig 22) Congestive heart failure was classified arbitrarily for detailed consideration as acute and as delayed failure, with the latter being regarded as starting during the second week or later. Acute failure was divided into two categories — transient when it disappeared within a few days, and permanent when it persisted beyond a period of 16 days.

Signs of congestive heart failure were observed quite frequently occurring in 76% of the MIMI patients and 56% of those in the no murmur group (Table 10). The heart failure was predominantly left sided. Acute development of heart failure was observed in two-thirds (65%) of the MIMI group and in half (49%) of the no-murmur group, a difference which was significant at the level of  $p < 0.02$ . The groups differ more significantly ( $p < 0.01$ ) from each other if one considers only the acute constant or delayed left ventricular failure combined, whereupon the percentages were 48 and 24 (Fig 22).

The no-murmur group was otherwise characterized by acute often only tran-

sient, left-sided heart failure, while what was typical of the MIMI group was the continuation of acute left sided heart failure and the frequent occurrence of delayed failure. This situation is shown in Fig 22, where the time of onset of heart failure or the rapid deterioration of an existing failure has been plotted against the time of onset of mitral incompetence. The heart failures present on admission, 15 patients in the MIMI and 14 in the no murmur group, have been excluded in order to obtain more valid data. The failures in the no murmur group appeared in 13 of the 25 patients on the first day of illness. If the first day failures are left out of the MIMI group, the signs of heart failure seemed to appear or to worsen rapidly in fairly close connection with the appearance of mitral incompetence or thereafter. Delayed failure (20%) appeared without exception in this way (e.g., following MIMI), and in the no murmur group there were only 5 instances (7%) of delayed appearance of left ventricular failure ( $p < 0.05$ ).

The use of digitalis gives some indication of the presence of heart failure, and

Table 11 Relation of severe pulmonary edema to acute mitral incompetence

Time relations	Number of patients	Onset of pulmonary edema days after infarction	Hypertension	Pressor amine used	Died	Recovered
Pulmonary edema before mitral incompetence	6 (-1)*	1 ± 0	3	3	1	0
Mitral incompetence before pulmonary edema	8**	4.1 ± 3.2	6	3	7	1
Pulmonary edema in patients without mitral incompetence	5	1 ± 0	1	1	1	4
Total	19		10	7	9	10

\*One patient had initial but transient pulmonary edema and after development of MIMI a recurrence occurred which proved fatal.

\*\*In 7 patients the marked mitral incompetence was probably the major cause of the pulmonary edema.

Table 12 Patients with pulmonary edema following acute mitral incompetence

Case number	Duration of MIMI before onset of the pulmonary edema days	Duration of the pulmonary edema days	Fate of patient	Hypertension	Use of pressor amine
99	4	1	Died	—	—
4	3	3	Died	+	+
5	3	3	Died	+	+
2	1	3	Died	—	—
17	1	3	Died	—	+
8	$\frac{1}{2}$	4	Died	+	—
117	$\frac{1}{2}$	2	Recovered	+	—
12	simultaneous	6 hours	Died	+	—

although the criteria obviously vary, they were nevertheless the same for both groups of subjects. Digitalis was used more commonly in the MIMI group (68 %) than in the no-murmur group (40 %).

*Acute pulmonary edema* (Tables 11 and 12) Acute pulmonary edema often appeared on the very first day of illness, as did shock or less severe signs of left ventricular failure. A total of 19 patients (10 %) suffered pulmonary edema. Of these in 6 in the MIMI group and in all 5 in the no murmur group the edema developed during the first day of illness.

All 8 patients who only later developed pulmonary edema were from the MIMI group and in 7 of these patients the presence of acutely developed mitral incompetence was regarded on clinical grounds as definitely contributing to the development of pulmonary edema. In these patients the degree of MIMI was already clinically estimated as marked before the pulmonary edema developed. Table 11 presents the relation of pulmonary edema to mitral incompetence. When the pulmonary edema appeared before the MIMI, its duration was only 1–2 days, with a good response to treatment.

Otherwise the pulmonary edema appearing after (average  $4.1 \pm 3.2$  days after onset of infarction) the development of

MIMI (Table 12) was resistant to treatment and the majority of the patients died the difference in mortality being significant ( $p < 0.01$ ) when compared with the other two groups.

The part played by hypertension in the development of pulmonary edema in patients with mitral incompetence seemed apparent, 9 of the 39 in this group with hypertension having developed pulmonary edema, whereas only 1 patient of the 10 with hypertension in the no-murmur group was so affected. The difference was not, however, statistically significant. The use of pressor amines to elevate lowered blood pressure in connection with pulmonary edema after the development of mitral incompetence would seem to have contributed to increased mortality, although the small number of patients involved made statistical analysis impossible.

*Blood pressure* did not differ significantly between patient groups in initial or stabilized phases at hospital. In MIMI group the values of systolic pressure were  $140 \pm 30$  mm Hg in the initial phase before development of the murmur and  $138 \pm 23$  in the stabilized phase 3–4 weeks from onset. In the no-murmur group the respective figures were  $132 \pm 22$  and  $130 \pm 25$  mm Hg.

Table 13 Arrhythmias during stay in hospital

Arrhythmia	Mitral incompetence	No murmur	Total
Total number of patients	117	70	187
None	37 (32%)	35 (50%)	72 (39%)
Sinus tachycardia	27* (23%)	7** (10%)	34 (18%)
Premature beats	47 (40%)	21 (30%)	68 (36%)
Supraventricular tachycardia	2 (2%)	2 (3%)	4 (2%)
Atrial fibrillation or flutter	8 (7%)	5 (7%)	13 (7%)
Nodal rhythm	1 (1%)	1 (1%)	2 (1%)
Heart block	12 (10%)	5 (7%)	19 (9%)
First degree	2 (2%)	2 (3%)	4 (2%)
Second degree	6 (5%)	2 (3%)	8 (4%)
Complete	4 (3%)	1 (1%)	5 (3%)

\* 15 died      \*\* 1 died

Arrhythmias (Table 13) were observed in daily clinical examination and routine electrocardiograms in 62% of the patients. They were significantly ( $p < 0.01$ ) more frequent in the MIMI than the no-murmur group. Sinus tachycardia was highly significantly ( $p < 0.001$ ) connected with MIMI and with acute mortality. Complete heart block developed in 4 patients in the MIMI and 1 in the no-murmur group. These were treated successfully by transvenous endocardial pacing until the sinus rhythm returned. One patient (No. 124) developed a permanent

complete heart block, requiring the application of an implantable pacemaker.

No difference in incidence or character of the apical impulse was found when comparing the MIMI and no-murmur groups. It was not palpable in 44% of both groups. Heaving apical thrust was present in 8 patients with mitral incompetence and 7 without mitral systolic murmur. A location at a distance of 10 cm or more from the midline was found in 40% and 37%, respectively.

Paradoxical cardiac pulsation (Figs 23 and 24) could be recognized frequently at




Fig. 23 Three kinetocardiographic tracings (KCG) with phonocardiographic references to illustrate the phenomenon of the paradoxical cardiac pulsation. The first curve reveals the normal inward retraction of the apical impulse after an initial brief outward thrust. The second tracing shows a moderate systolic outward bulge (stippled area); lasting not over the whole systole. The third record represents a marked parastolic bulge.




Fig 24 Relation of the paradoxical cardac pulsation to the appearance of the mitral systolic murmur. Paradoxical pulsation was a frequent bedside finding (51%) and developed significantly more commonly in the MIMI group. Its onset time was within  $\pm 1$  day (dotted line) the same as the onset of the murmur in a half of the patients.

bedside examination the total incidence of this palpatory finding was 51%. It was present significantly ( $p < 0.01$ ) more commonly in the MIMI group (65%) than in the no murmur group (43%). During the course of hospital observation it developed as a new finding in 49 (42%) MIMI patients and 15 (21%) no-murmur patients; this difference being also significant ( $p < 0.01$ ). The bulge was moderate in one third of the patients and marked in two thirds of both groups. Occurrence with constant mitral systolic murmurs was more frequent (74%) than with only inconstant or transient murmurs (60%).

In Fig 24 the time of onset of the paradoxical pulsation has been plotted against the time of onset of mitral incompetence in the 49 patients in whom both

developed during the observation period (the 27 MIMI patients with paradoxical pulsation on admission are excluded). Mitral systolic murmur and paradoxical pulsation appeared on the same day with a variation of  $\pm 1$  day in half of the patients or in 24 out of 49. In 40 patients a kinetocardiographic analysis of precordial pulsation showed a close agreement with the palpation finding.

*Changes in first and second heart sounds* (Table 14). Softening of first sound fainter than second sound at the apex was observed in 19% of the MIMI group and in 3% of the no-murmur group or in a total of 24 patients. The pulmonary component of second heart sound was estimated to be accentuated in 39 patients. This was noted in 27% of the MIMI and 10% of the no-murmur patients.



Table 14 Changes in first and second heart sounds

	Mitral incompetence	No murmur	P
Total number of patients	117	70	
1st sound diminished (1-2 at apex)	22 (19%)	2 (3%)	<0.01
Pulmonary component of the 2nd sound accentuated	32 (27%)	7 (10%)	<0.01
Pulmonary component of the 2nd sound accentuated with broad splitting of the 2nd sound	20 (17%)	1 (1%)	<0.01
2nd sound broadly splitting but pulmonary component not accentuated	0	0	

Among these patients with an accentuated pulmonary component, a broader than usual physiological splitting of second heart sound during inspiration was found in 63% of the patients in the MIMI and in 14% of the no-murmur group. All these differences were significant ( $p < 0.01$ ). Curiously enough, pathologic split-

ing without simultaneous increase in loudness of the pulmonary component of second heart sound was never observed. The changes developed in about half the patients after development of MIMI, while in about half they were already present on admission. In the no-murmur group the changes were usually present on ad-




Fig. 25 Relation of the time of onset of third and fourth heart sounds to the onset of mitral incompetence and their incidence. Third heart sound developed chiefly after the appearance of the mitral systolic murmur. The appearance of the atrial gallop sound was early without clear relation to the MIMI. 3rd sound constant MIMI, 3rd sound inconstant MIMI, 4th sound constant MIMI, 4th sound inconstant MIMI, 3rd sound no murmur, 4th sound no murmur.

mission, with their development during the observation period taking place in only an occasional instance

*Occurrence of third or fourth heart sounds* (Fig 23) was observed by auscultation in 57 % of the patients in groups 1 and 2, in 62 % of the MIMI patients and in 47 % of the no-murmur patients

Third heart sound was recognized transiently or constantly in 60 (32 %) patients, occurring in the patients with MIMI in 38 % and in the patients without mitral systolic murmur in 23 %, the significance of the difference was at the level of  $p < 0.05$ . If only newly-developed ventricular gallops are considered excluding those patients with the gallop present on admission, the figures were total 23 %, MIMI 28 % and no-murmur group 14 %. Groups 1 and 2 differed significantly at a level of  $p < 0.05$

Fourth heart sound was heard in 73 patients (39 %), in the MIMI group in 41 % (newly developing 33 %) and in the no-murmur group in 36 % (newly developing 25 %), with no significant statistical difference

Both third and fourth heart sounds in the same patient occurred in 20 % in the MIMI and 13 % in the no-murmur group

As previously noted (Chapter VI) third and fourth heart sounds were not over diagnosed, but 2 % of third and 10 % of fourth heart sounds were missed

Fig 25 relates the onset time of third and fourth heart sounds to the time of onset of the mitral systolic murmur. Comparison is available from 28 MIMI patients (16 excluded because the gallop was present on admission) and 9 no-murmur patients (7 excluded) with third heart sound, and from 34 (14 excluded) MIMI patients and 15 (10 excluded) no-murmur patients with fourth heart sound

It is evident that third sound appeared mostly at or after the onset of the murmur of mitral incompetence. The appearance time of third sound was thus broadly

distributed in many instances it appeared rather late

Fourth sound did not seem to have any clear relation to the appearance of the mitral systolic murmur and was earlier in origin than third sound. In the no-murmur group the distribution of fourth sound was likewise earlier than that of third sound. However the delayed appearance of third sound was found much more commonly in the MIMI than in the no-murmur group, as was the situation with the signs of congestive heart failure

*Reinfarction groups* It was previously (p 50) noted that an earlier infarction seemed to have a predisposing effect on the development of mitral incompetence in connection with reinfarction. Therefore, some of the most distinct changes already found in patient groups 1 and 2 were re-analyzed with reference to reinfarction

The murmur characteristics did not differ clearly from those found in patients with first infarction although with a single exception the murmur was invariably pansystolic. Heart failure and paradoxical pulsation did not differ from the data already gathered but hypertension was commoner in MIMI reinfarction (42 %) than MIMI first infarction (29 %). A smaller difference was found in the no-murmur group 18 % in reinfarction and 14 % in first infarction

## DISCUSSION

### INCIDENCE OF VARIOUS CLINICAL FINDINGS

The incidence of the various clinical bedside findings, observed in the present study was generally of the same order as in many very large series (Master *et al* 1937, 1942, Rathe 1942, Mintz and Katz 1947, Yater *et al* 1948, Doscher and Poin dexter 1950, Laubry and Soulie 1950, Jakobs 1951, Wright *et al* 1954, Ball *et al* 1955, Lee *et al* 1957, Plotz 1957, Jakobs 1958, Malach and Rosenberg 1958, Sievers 1963, Friedberg 1966)

Considerably more often than has been generally reported however, signs of congestive heart failure, third and fourth heart sound and paradoxical cardiac pulsation occurred. The discrepancies in numbers may be attributed to the frequently very different criteria applied by different investigators, while, on the other hand special attention was paid in the frequent examinations carried out in the present study to these often transient clinical signs. The incidence figures refer to groups 1 and 2 for purposes of comparison and they obviously differ to a slight extent from those calculated from the entire series.

#### PREDISPOSING FACTORS IN MIMI

Predisposing factors in the development of mitral incompetence as a result of myocardial infarction extracted from the patients' earlier medical history seemed to be hypertension, previous myocardial infarction and manifest diabetes, of these only hypertension in a significant degree. Otherwise peripheral arterial disease and angina pectoris could not be proved as having such an effect.

The greater tendency of *reinfection* to be attended by the complication of mitral incompetence appears only natural, for in most instances conspicuous coronary artery changes are present while furthermore a portion of the myocardium has been previously destroyed. *Reinfarction* thus has a directly greater chance of injuring the supporting structures of the mitral valve i.e. either the papillary muscles or by inducing aneurysm or general dilatation of the heart. On the other hand a coronary artery occlusion may remove the barely sufficient collateral circulation from the portion of the left ventricle critically important to the closure of the mitral valve.

*Hypertension* as a contributing factor accelerating atherosclerotic changes appears obvious on the evidence of both experimental and clinical investigations

(Dawber *et al* 1957, Schettler 1961, Moses 1963). Its influence as a predisposing factor in the development of a mitral incompetence may come from this source.

On the other hand, the added pressure load on the heart leads to the hypertrophy of the muscle fibres. Consequently the nutrition of the myocardium is impaired considerably in response to the relative coronary arterial insufficiency (Vnell 1951, Linzbach 1960). The disturbance in microcirculation is greatest in the subendocardial portions, due to the anatomy of the coronary vessels and intravascular and intramyocardial pressure relations (Johnson and DiPalma 1939, Schutz 1956, Laszt and Müller 1958, Müller 1962, Salisbury *et al* 1963 a). In these subendocardial layers of the left ventricle, the oxygen tension is lower than in the outer parts (Moss 1966), and ischemic changes easily develop. Arosemena *et al* (1966) in 80 non coronary cases of hypertrophy of the left ventricle found a significant degree of infarction of the papillary muscles and the adjacent left ventricular wall. This was believed to be the result of impaired myocardial perfusion.

*Diabetes* has evidently an adverse effect on the development of atherosclerotic lesions and furthermore may be related to microangiopathy. Among diabetes the myocardial damage caused by infarction is more extensive and the disease more serious than is the general rule (Partamian and Bradley 1965).

*Coronary prognostic index.* The very great variability known to prevail in the clinical picture of myocardial infarction has resulted in attempts to assess it by means of different clinical indices (Helander 1950, Russek *et al* 1951, Schnur 1953). The coronary prognostic index values obtained by the method of Peel *et al* (1962) correlated well with the acute mortality of the myocardial infarction patients in hospital recorded in the present study.

The completely uniform distribution in the different degrees of severity of the

index used for both the MIMI and the no murmur patients indicates that the severity of myocardial infarction as clinically judged at the initial stage is no determining factor in the development of mitral incompetence. This finding is further supported by the evidence of an equal incidence of initial heart failure and shock in both groups of patients. The result emphasizes the significance of an infarct of perhaps small extent but strategically important location with reference to papillary muscles. The even distribution of the coronary prognostic index in both groups also points to the lack of selectivity in the material from this point of view, providing a sound basis for further comparison of the findings.

#### CLINICAL SEQUELAE OF MIMI

**Cardiogenic shock** The reports on the incidence of shock vary quite considerably 8–58 % which is understandable owing to the difficulty of defining the clinical conception (Master *et al* 1937, Bean 1938, Yater *et al* 1948, Wright *et al* 1954, Binder *et al* 1955, Agress and Binder 1957, Friedberg 1966). The average incidence has been regarded as involving one quarter of the patients which was also found in the present investigation (24 %). Shock was the initial disturbance in this study, in line with the general view.

Hemodynamic disturbances in cardiogenic shock are marked in both coronary and systemic circulation. A marked decrease in cardiac output and stroke volume, by 25–80 % is the invariable result (Wegria *et al* 1954, Gilbert *et al* 1954, Agress and Binder 1957, Wollheim and Schneider 1958, Malmcrona 1964, Gunnar *et al* 1966). Remarkably enough this profound circulatory disturbance did not have any effect, however on the development of MIMI.

The decrease in coronary perfusion in shock has a damaging effect on the heart, though the lessening of the pressure load in hypotension reduces the burden of

work on the heart. These changes might conceivably cancel out their effects from the standpoint of the heart's susceptibility to injury. Experimental support to this view is given by the investigations of Opdyke and Foreman (1947) and of Gregg (1962) on coronary circulation in shock.

**Congestive heart failure** was a more frequent finding (68 %) in this study than has been generally reported: the average incidence in previous studies being from a third to half of the patients. However, Friedberg (1966) and Logue and Hurst (1966 a) emphasize that signs of left sided heart failure are often overlooked. Further, recent radiological and pulmonary function studies in acute myocardial infarction indicate that pulmonary congestion and impairment of ventilatory function are very common. These changes are obviously due to acute left ventricular failure (Fauda *et al* 1957, Zatzchni and Nussbaum 1963, Uthgenant 1964, McNicol *et al* 1965, Valentine *et al* 1966). The results of the radiological examinations performed in the course of the present study likewise showed a frequent occurrence of signs of pulmonary venous hypertension.

The initial incidence of left ventricular failure on admission, or developing during the first day, was not higher in the MIMI group (29 %) than among no-murmur patients (39 %). Otherwise, the perpetuation and worsening of initial heart failure as well as the development of clinical signs of delayed left ventricular failure, delayed pulmonary edema and third heart sound were definitely and significantly associated with the development of mitral incompetence. In contrast to the MIMI group, the heart failure in the no-murmur group was more often only initial and transient.

Although in the majority of patients the mitral incompetence was clinically judged to be somewhat insignificant, it would thus seem that even a slight

added measure of futile volume work resulting from it had the effect of generating considerable functional difficulties in an acutely damaged left ventricle.

Acute pulmonary edema had the same relation to MI as the less marked manifestations of left ventricular failure. Pulmonary edema during the first day after the onset of infarction was of equal incidence in both groups. Any subsequent development of pulmonary edema occurred in almost all the patients only after prior development of acute mitral incompetence. Such delayed pulmonary edema following MI was difficult to treat and usually proved fatal.

Systemic arterial hypertension is a frequent contributing factor to pulmonary edema in myocardial infarction (Master *et al* 1937, Plotz 1957) and in the present study it seemed to exercise a particularly important effect if the patient had developed pulmonary edema following MI. The last resort would seem to be treatment of this grave multitude of complications with pressor amines (see also Chapter XI). It is obvious that the rising of the peripheral systemic arterial resistance with pressor amines substantially increased the regurgitant flow through the incompetent mitral valve (Wiggers and Feil 1922, Braunwald *et al* 1957, Jose *et al* 1964, Linsada 1965). In the presence of pulmonary edema in a patient with mitral incompetence following acute myocardial infarction this treatment must virtually always prove to be a fatal procedure.

This serious situation could be reasonably explained by the frequent initial mechanical failure of the heart as a pump after myocardial infarction (Malmcrona 1964). Thus the acute additional demand of the regurgitant flow becomes intolerable. The markedly diminished contractile power of the left ventricle, combined with mitral incompetence obviously often leads to a progressive and eventually fatal vicious cycle (see also Chapter XI). Thus all therapeutic measures liable to increase

regurgitation must be deemed contraindicated.

The gloomy course run by a small proportion of the patients developing MI as was comparable to the fatalities in the series of Nezhlin and Shamesova (1951), Bashour (1963), Chiesa *et al* (1965) and Raftery *et al* (1966) also lay stress on the occurrence of significant heart failure.

Gallop sounds were also detected fairly frequently (57 %) in auscultation, confirmed by phonocardiography, as compared with reports of their incidence varying between 5–28 % of the patients with acute myocardial infarction (Bean 1938, Master and Friedman 1942, Rathe 1942, Shillito *et al* 1942, Yater *et al* 1948, Jakobs 1951, Wright *et al* 1954, Weitzman 1955, Malach and Rosenberg 1958). In part, this can be attributed to the fact that third or fourth sound is sometimes transiently audible for only a few days. However Master and Friedman (1942) in their phonocardiographic investigation revealed the presence of fourth sound in 83 % (audible gallop in 33 %) and third sound in 47 % (audible gallop in 11 %) in myocardial infarction.

Friedberg (1966) also emphasizes that the gallop is often transiently audible at the initial stage in approximately one quarter of the patients. He further states that while third sound is generally accepted as a sign of heart failure, fourth sound is not associated with it. The results in the present study were fundamentally the same. Patients with MI had more often gallop sounds — the ventricular gallop being more common, significant at the level of  $p < 0.05$  — than did the patients without mitral systolic murmur, in whom these occurred transiently during the first days in hospital.

Third heart sound is generally accepted as a sign of heart failure (Lewis 1962). On the other hand it is associated with significant mitral incompetence owing to the increase in rapid diastolic filling (Leatham 1958a, Nixon 1961, Yager *et al* 1964).

The final mechanism of the generation of third heart sound is still in dispute. A connection with sudden tautening of the chordae tendinae (Nixon 1961, 1963; Nixon and Wooler 1963 b) and with active and passive ventricular relaxation and volume pressure accommodation has recently been suggested (Grayzel 1960, Grevasse *et al* 1962, Arevalo *et al* 1964). In any case, the ventricular gallop is a clinical sign present in diastolic overloading of the ventricle if hyperkinetic states and younger age groups are excluded (McKusick 1958).

The occurrence of third heart sound more commonly in the MIMI group, and predominately only after the development of mitral incompetence would point to its connection with regurgitation. Otherwise the occurrence and time of onset of congestive heart failure bore the same relation to MIMI. Probably both these factors causing diastolic overloading of the left ventricle were operating (McKusick *et al* 1955; Parry and Mounsey 1961).

*Fourth heart sound* as a sign of an atrial overload (Ongley *et al* 1960) did not have so intimate a relation as third sound to the appearance of the MIMI and the higher incidence in the MIMI group was not significant. Fourth heart sound can occasionally be heard in normal subjects (Seçall 1962). Nevertheless, its frequent early development during the course of acute myocardial infarction would indicate strain or some other abnormality of the left ventricular myocardium (Butterworth and Reppert 1966). The mechanism of the atrial gallop in myocardial infarction has been ascribed to diminished ventricular distensibility by the ischemic damage (Weitzman 1955, Kincaid Smith and Barlow 1959, Parry and Mounsey 1961). An abnormally large atrial wave in kinetocardiography or apexcardiography is a frequent finding in an ischemic heart disease (Benchmol and Dimond 1962, Dimond and Benchmol 1963, Schweitzer *et al* 1965, Ginn *et al* 1967).

*First heart sound* Recent studies suggest that the most important factor affecting the intensity of first heart sound is the contractility of the myocardium (Sakamoto *et al* 1965). Accordingly, the weakening of first heart sound in myocardial infarction is natural, if not invariable (Mister and Friedman 1942, Laubry and Soulie 1950). First heart sound in mitral incompetence has been variously described, its diminished intensity has usually been related to marked regurgitation (Bridgen and Leatham 1953, Wood 1954, McKusick 1958, Perloff and Harvey 1962, Nager *et al* 1964). In the light of the present study, it is significantly more frequently diminished in the MIMI group than in the no murmur group, although the general incidence of the lowered intensity was not impressive.

*Second heart sound* Increased loudness of the pulmonary component of second heart sound, and its pathologically broad splitting were significantly ( $p < 0.01$ ) more frequent in the MIMI than the no murmur group.

The increased intensity of the pulmonary component can be reasonably ascribed to the more common occurrence of left ventricular failure and to the regurgitant flow (Ross *et al* 1958, Bentioglio *et al* 1958). The broadened splitting of second sound was always associated with accentuation of the pulmonary component, in the no murmur group its occurrence was quite infrequent.

A shortened left ventricular ejection time causing earlier closure of the aortic valve in mitral incompetence (Bridgen and Leatham 1953, Perloff and Harvey 1962, Humphries 1964) would readily explain the splitting. Nixon and Wagner (1962), however, presented evidence of another type of response of the left ventricle in mitral regurgitation. If the end diastolic pressure was elevated the duration of the ejection of the left ventricle was at its upper normal range or prolonged. The probable mechanism might

also be left ventricular failure leading to failure of the right ventricle and thus to its prolonged ejection time. Both mechanisms would be consistent with the intimate relation of splitting to accentuation of the pulmonary component.

The association of broad splitting with accentuation of the pulmonary component of second sound in the MIMI group would indicate that regurgitation is not wholly insignificant, as it adds to pulmonary venous hypertension.

No paradoxical splitting of second heart sound (Murchak and Gorlin 1963) was recognized. Friedberg (1966) criticized reports of paradoxical splitting in infarction assuming the error to be in the misinterpretation of atrial gallop and first heart sound as paradoxical splitting.

*Paradoxical cardiac pulsation* is an invariable result of an ischemically damaged heart in experimental studies (Tennant and Wiggers 1935, Murray 1947, Prinzmetal *et al* 1919, Gregg 1950). This dynamic aneurysm can be recorded most reliably by kinetocardiography in up to 100% of the patients with acute myocardial infarction (Suh and Eddleman 1959, Davie *et al* 1962, Schweitzer *et al* 1965) and often by radiological methods.

Schwedel *et al* 1950, Sampson *et al* 1956, Kurtzman and Lofstrom 1963, Tumanovskii and Grmash 1963). However, this has been reported as occurring very infrequently (30%) as a clinical palpation finding (Vikil 1955, Suh and Eddleman 1959, Davie *et al* 1962, Rorvik 1961, Logue and Hurst 1966 b).

In the present study, however, the recognition of paradoxical pulsation, often of a marked degree, was frequent (51%) and was an impressive finding revealed by careful examination. A kinetocardiographic comparison of 40 patients resulted in a close correlation to the palpatory finding.

Paradoxical pulsation developed significantly more often ( $p < 0.01$ ) in the MIMI group. There was a close relation between the onset of paradoxical pulsation and the onset of mitral incompetence.

Often, even in daily examination of a patient, a paradoxical pulsation on palpation and the emergence of the murmur of mitral incompetence in auscultation in a previously murmurless heart, might appear on the same day as a new finding. The cause is not so evident, for the appearance of a dynamic aneurysm from ischemic damage, the onset of mitral incompetence and heart failure were all intimately related in terms of time to each other.

It is evident that either mitral incompetence (Tucker *et al* 1955, Davie *et al* 1962, Deliyannis *et al* 1964, Logan *et al* 1967) or heart failure (Davie *et al* 1962, Harrison 1965) has a distinctly predisposing effect on the appearance of palpable paradoxical pulsation. Probably, larger volume changes in addition to underlying ischemic dynamic aneurysm are involved.

To sum up, there seem to be some factors related to inefficient microcirculation of subendocardial layers of the left ventricle including papillary muscles, which have a predisposing effect on the development of mitral incompetence as a complication of acute myocardial infarction.

Acute initial hemodynamic changes, or the severity of infarction, are not related to the development of MIMI. This stresses the importance of the site rather than the size of the infarction, as, for example, damage to the papillary muscle, or its supporting ventricular wall, which play an important part in adequate mitral valve closure. Although clinically usually slight in degree, MIMI is quite frequently associated with various clinical findings pointing to failure of the left ventricle.

Mitral incompetence following acute myocardial infarction had a very wide clinical spectrum. Severe mitral incompetence superimposed acutely on myocardial infarction may lead to fatal pulmonary edema. On the other hand, a transient mitral systolic murmur without any associated clinically detectable disturbances might be the sole manifestation of this complication.

# COMPARISON OF CLINICAL FINDINGS IN PATIENTS WITH AND WITHOUT MITRAL INCOMPETENCE

## ELECTROCARDIOGRAPHY

### METHODS

#### APPARATUS AND PROCEDURE

Electrocardiograms were taken by the clinical laboratory as a hospital routine. Direct writing ink jet electrocardiographs were generally used. Conventional 12 leads I II III aVR aVL aVF and  $V_{1-4}$  were taken during the first four days daily and thereafter on every fifth day of each patient's stay in hospital. The paper speed was 50 mm/sec. The calibration was checked after every recording. The synchronism of the simultaneously recorded canals could be checked from simultaneous calibration deflections. The correction for inappropriate calibration was always made in the final calculation of amplitudes.

#### ANALYSIS AND MEASUREMENTS

All the electrocardiograms were analyzed by the author for the site and extent of infarction: left ventricular hypertrophy, signs of left atrial overloading in the P wave and for arrhythmias and conduction disturbances.

#### LOCALIZATION AND EXTENT OF MYOCARDIAL INFARCTION

After a review of the standard textbooks dealing with electrocardiography (Sodi Pallares and Calder 1956; Massie and Walsh 1960; Holzmans 1961; Lamb 1965) to establish the localization criteria used in myocardial infarction, the diversity of methods and nomenclature soon became evident, showing conflicts and inaccuracies. The criteria presented by Lipman and Massie (1965) based chiefly on the investigations of Sodi Pallares and his co-workers (see Lipman and Massie 1965) seemed to be the most concise and logically stated and were therefore adopted for the purposes of this study.

#### LOCALIZATION OF INFARCTION

**ANTEROSEPTAL** (middle third of the septum after Sodi Pallares). Abnormal Q wave preceding rS deflection in  $V_{1-3}$  or QS in  $V_{1-3}$ . Absence of normal q in leads  $V_4$  and  $V_5$ . The changes

are ascribed to loss of activation vector I forces.

**ANTERIOR**. The presence of initial R in lead  $V_1$  and persistent q waves in leads  $V_1$  and  $V_2$  (vector I forces undisturbed). The appearance of an abnormal Q wave in one or more of the next three leads  $V_2$ ,  $V_3$  and  $V_4$  (lower third of septum). An abnormal right to left decrease in the relative amplitudes of the R waves without their disappearance in precordial leads to the left of lead  $V_2$  (epicardial infarction of the right lower septal mass). If an intramural portion of the right septal mass is infarcted a qR complex is recorded in leads  $V_3$  and  $V_4$ , but the R wave appears late (0.05 second) without slurring and no peri-infarction block is present. QS complexes in leads  $V_2$  to  $V_4$  and initial R wave (absent septal q) in leads  $V_5$  and  $V_6$  indicate the most important infarction of the lower two-thirds of the septum (anteroseptal + anterior).

**ANTEROLATERAL**. Abnormal Q waves in leads  $V_2$  and  $V_6$  or in leads  $V_2$  to  $V_6$  as well as in leads aVL and I. In high anterolateral localization changes are present only in leads I and aVL.

**EXTENSIVE ANTERIOR** (lower two-thirds of septum and infarction of left free wall). Abnormal Q waves present in all chest leads (except occasionally lead  $V_1$ ) in lead aVL and in lead I.

**INFERIOR**. Abnormal Q waves in leads II, III and aVF or in III and aVF. In leads III and aVF rs or rSR complexes instead of Q waves.

**INFEROLATERAL**. Criteria of inferior infarction and abnormal Q waves in lead  $V_4$  and sometimes in leads I, aVL and  $V_6$ .

**POSTEROLATERAL**. A tall wide R wave in  $V_{1-3}$  with an R/S ratio greater than 1 and abnormal Q waves in lead  $V_6$  and sometimes in leads I, aVL and  $V_5$ .

**STRICTLY POSTERIOR**. Abnormal Q waves do not appear in any of the conventional leads. RSR configuration (rSr, rSR or rSR) or a tall slurred wide R wave with an R/S ratio greater than or equal to 1 in  $V_{1-3}$ . Tall R waves in leads  $V_1$  and  $V_2$  and possibly in lead  $V_3$  and the appearance of septal and of left ventricular morphology in leads  $V_{4-6}$ .

#### EXTENT OF INFARCTION

The criteria of transmural and also of epicardial



and intramural infarction have been presented in the foregoing

Subendocardial infarction does not generally produce pathologic Q waves (Cool *et al* 1958). Diagnosis is based on typical ST segment and T wave changes in serial tracings. In this study the extent of myocardial infarction was classified as transmural or subtransmural; the latter designation including patients with electrocardiographic signs of subendocardial, intramural or epicardial infarction.

#### ABNORMAL Q WAVES

The criteria of abnormal Q waves as presented in Coldberger (1951), Barker (1952) and Sodi-Pallares and Calder (1956) were used in the analysis of Q waves.

#### LEFT VENTRICULAR HYPERTROPHY

The QRS-criteria of Manning and Smiley (1964) for left ventricular hypertrophy were adopted. The heights of the R waves in leads I and III, aVL,  $V_1$  and  $V_5$  were measured and the sums of the R waves and of the S wave in  $V_1$  and the R wave in lead  $V_5$  or  $V_6$  calculated.

#### LEFT ATRIAL OVERLOADING

The following currently accepted methods of P wave analysis were used: P wave duration, P terminal vector in the frontal plane and P terminal force  $V_1$  (Morris *et al* 1964).

The duration of the P wave in standard limb leads usually lead II was measured. A duration of over 0.11 seconds was considered pathological (Lipman and Mascoe 1962). No correction was made for the heart rate or age of the patient.

P terminal vectors in the frontal plane were calculated from the P waves in leads I and II and in leads aVL and aVF. The mean of these two vectors usually of about the same magnitude was utilized as the final vector angle. The amplitudes were measured to an accuracy of 0.1 mm from the top of the atrial deflection to the top of the base line if the form and timing of the peak indicated it to be definitely in the terminal part of the P wave. If the P wave was rounded its height was measured at the line of division between the middle and the last third of the P wave duration which was usually 0.03 to 0.04 seconds backwards from the cessation point of the P wave deflection. This method was used to obtain the amplitude of the pure terminal part of the P wave and not the summation of the initial and terminal parts of the P wave (P wave mean vector Sodi-Pallares *et al* 1965). The amplitudes were measured by means of a fine lined grid and applied to a hexaxial system to estimate the magnitude of the vector angle (Grant 1957). The symmetric hexaxial system can be better used for atrial vectors (Holzmänn 1961) than the corrected axial system for QRS vectors

(Lamb 1965). An angle of  $-30^\circ$  of the P terminal vector in a frontal plane was used as the upper limit of the normal (Gooch *et al* 1966).

P terminal force in the frontal plane Precordial lead  $V_1$  was used for measurements. The P terminal force was calculated from the duration and amplitude of the terminal deflection of the P wave as described by Morris *et al* (1964). By means of a fine lined grid the small durations and amplitudes were quite easily and reproducibly measured.

The terminal P wave vectors in the frontal plane and P terminal forces were analyzed from tracings recorded before MIAMI on some of the first 5 days usually days 1-3 from the onset of infarction. Values after the development of MIAMI were obtained from tracings taken during the 3-4 weeks subsequent to the onset of infarction. In patients without any murmur the tracings of a comparable time were used. In patients who died in hospital it was usually necessary to utilize the second tracing taken earlier than the third or fourth weeks after the onset of infarction or at least one taken following the development of mural incompetence. The third calculation was made from the follow up electrocardiograms.

Values of over  $-0.03$  mm sec were considered pathological.

#### COMMENTS

**Myocardial infarction.** The reliability in the study of Simonson *et al* (1966) was as follows: The presence of infarction was recognized least frequently (60%) in posterior wall infarction and most frequently in anterior+posterior wall infarction (94%) while in anterior wall infarction a correct diagnosis was made in 68%. Of the total material 84% of the myocardial infarctions were recognized solely on the basis of an electrocardiogram. False positives in the frequency of 13% were caused by a bundle branch block and by left ventricular hypertrophy. Thirteen studies reviewed showed a reliability varying between 22 and 100% according to post mortem examinations.

The accuracy of right localization of myocardial infarction was much lower than recognition of infarction from one electrocardiographic tracing being about 50% regardless of site (anterior, posterior, anterior+posterior and subtotal were analyzed). Several authors state that the reliability of electrocardiographic localization varies considerably with the site of infarction being from 100% in lower septal to 0-5% in lateral infarctions (Sodi-Pallares *et al* 1963, Pruitt *et al* 1963).

The diagnostic accuracy of electrocardiography in myocardial infarction is limited by the size and site of the infarction, several simultaneous infarctions (causing the phenomenon of electrical countercoup), conduction disturbances, hypertrophy of the left ventricle and previous ischemic changes (Pruitt *et al* 1963).

On the other hand the electrical changes in serial tracings typical of ischemic injury and necrosis and restitution considerably facilitate electrocardiographic diagnosis of infarction at the acute stage.

The foregoing comments refer to the diagnostic accuracy of electrocardiography. It is evident that supported by the clinical picture and the laboratory results the diagnosis of acute myocardial infarction will substantially improve. This does not of course apply to the localization of infarction for which electrocardiography remains the only clinical procedure.

**Left ventricular hypertrophy.** The QRS criteria of Manning and Smiley (1964) were considered to give the most reliable results because they take into account the physique which can substantially alter the amplitudes especially of precordial tracings (Kalty and Lepeschkin 1965).

In comparing study of the accuracy of electrocardiography with vectorcardiography made by Simonson *et al* (1966) a correct diagnosis of left ventricular hypertrophy was made in 67 % of the cases by ECG. In 15 articles reviewed in this paper the reliability of the electrocardiographic diagnosis of left ventricular hypertrophy on the basis of autopsy material varied in larger series between 32 and 76 %. Most of the authors used the criteria of Sokolow and Lyon (1949). The false positives accounted for 3.9 % in the study of Simonson *et al* (1966); in the papers reviewed this was 0–8 % by the QRS criteria only.

In the present study of myocardial infarction the sensitivity of the electrocardiogram in detecting left ventricular hypertrophy is obviously diminished to a marked degree. ST segment and T wave changes cannot be used and the sensitivity of QRS criteria is diminished by the loss of viable muscle mass.

**Left atrial overloading.** Many calculations have been proposed for the establishing of reliable criteria for left atrial enlargement (see Morris *et al* 1964). Of these the P terminal force described by Morris *et al* (1964) is simply accurately and reproducibly measured ( $\pm 0.01$  mm sec) and its sensitivity as an indicator of left atrial overloading seems to be quite good (Gooch *et al* 1966). The P terminal force mainly measures the electrical force of the left atrium in a horizontal plane. Any cardiac electrical vector has a spatial direction. In addition an atrial dilatation may take different directions. To obtain a comparison of vector magnitudes and their alterations also in the frontal plane they were calculated according to the hexaxial system. The method is however rather cumbersome and possesses a limit of accuracy of only about 15 (Hiss *et al* 1960).

## RESULTS

### ELECTROCARDIOGRAPHIC SIGNS OF MYOCARDIAL INFARCTION

**Localization** (Table 15, Fig. 26). In 117 patients developing mitral incompetence as a complication of myocardial infarction (group 1), there was no difference in the incidence of anterior (anteroseptal, anteroseptal + anterior, anterior, anterolateral, extensive anterior) localization of infarction (51 %) as compared to posterior (inferior, inferolateral, inferoposterior, inferoposterolateral, posterolateral, strictly posterior) localization (49 %). On the other hand in the no-murmur patients (group 2) a marked difference did exist, consisting mainly of anterior infarctions (73 %), posterior localization in this group being much less frequent (27 %), as judged by electrocardiography.

In the MIMI group the relative frequencies of all the sublocations of posterior infarction and extensive anterior infarction were greater than in the no-murmur group, where all the other anterior sublocations were more common.

**Extent** (Table 15). Transmural myocardial infarction occurred in a total of 144 of 187 patients (77 %), and the total frequencies were equal in both MIMI and no-murmur groups. Transmural infarction was slightly more common (56 %) in the posterior location in MIMI patients, and significantly more common (72 %) in the anterior location of no-murmur patients. The anterior location was much more commonly recognized by electrocardiography in subtransmural infarctions involving both groups of patients.

### LEFT VENTRICULAR HYPERTROPHY

A diagnosis naturally had to be based solely on QRS criteria, and most often only precordial leads met them. The ECGs of 33 patients (18 %) met the criteria of Manning and Smiley (1964) for left ventricular hypertrophy and of these all but 5 further met the much

Table 15 Location and extent of myocardial infarction according to electrocardiography

Location of infarction	Mitral incompetence			No murmur			Total
		Trans mural	Subtrans mural	Trans mural	Subtrans mural		
Anteroseptal	1 (1%)	0	1	3 (4%)	2	1	4 (2%)
Anterior	8 (7%)	6	2	6 (9%)	5	1	14 (7%)
Anteroseptal - anterior	20 (17%)	13	7	17 (24%)	13	4	37 (20%)
Anterolateral	11 (9%)	4	7	12 (17%)	7	5	23 (12%)
Extensive anterior	20 (17%)	17	3	13 (11%)	12	1	33 (18%)
Total anterior	60 (51%)	40	20	51 (73%)	39	12	111 (59%)
Inferior	17 (15%)	15	2	5 (7%)	4	1	22 (12%)
Inferolateral	16 (14%)	13	3	6 (9%)	3	3	22 (12%)
Inferoposterior	6 (5%)	5	1	2 (3%)	1	0	8 (4%)
Inferoposterolateral	12 (10%)	12	0	5 (7%)	5	0	17 (9%)
Posterolateral	5 (4%)	4	1	0 (0%)	0	0	5 (3%)
Strictly posterior	1 (1%)	1	0	1 (1%)	1	0	1 (1%)
Total posterior	57 (49%)	50	7	19 (27%)	15	4	76 (41%)
Total	117	90	27	70	54	15	187

used criteria of Sokolow and Lyon (1949). In the MIMI group there were 22 patients (19%) and in the no-murmur group 11 patients (16%) in whom an electrocardiographic diagnosis of left ventricular hypertrophy could be made during the acute phase of infarction.




Fig 26 Relation of the site of the myocardial infarction as judged by electrocardiography to the presence or absence of mitral incompetence

#### LEFT ATRIAL OVERLOADING (Table 16 Figs 27-31)

The duration of the P wave was over 0.11 sec in a total of 68 patients (36%). This was observed in 39% of the patients in the MIMI group and in 31% of the ones without any mitral systolic murmur. The duration was longest mostly in lead II. The form of these P waves of long duration was mainly bifid or double peaked but only rarely were they of high amplitude.

P terminal vector in the frontal plane (Table 16, Fig 27). Calculations were made from the data on 99 patients with acute mitral incompetence where electrocardiograms were available before and after the development of MIMI. Analyses of 63 no murmur patients were made in a comparable time.

On the average the vector angle in the MIMI group did not differ significantly from that in the no murmur group before discovery of the mitral systolic murmur and after the appearance of the mitral incompetence, whereas at follow up examination it was significantly lower

MITRAL INCOMPETENCE  
○ NO MURMUR






Fig 27 Terminal P wave vectors in the frontal plane related to mitral incompetence following acute myocardial infarction. No apparent change was present.



○ NO MURMUR  
● MITRAL INCOMPETENCE

Table 16 *P wave changes of left atrial overloading in patients with and without mitral incompetence*

Time of examination	Mitral incompetence	No murmur	P
<i>P terminal vector in frontal plane degrees</i>			
1-5 day	41 ± 21	45 ± 27	N S
3-4 week	40 ± 20	39 ± 23	N S
Follow up	38 ± 25	46 ± 24	<0.05
<i>P terminal force mm sec</i>			
1-5 day	0.021 ± 0.029	-0.021 ± 0.019	N S
3-4 week	0.031 ± 0.032	-0.017 ± 0.021	<0.001
Follow up	0.022 ± 0.026	-0.014 ± 0.018	<0.05

N S not significant

in the MIMI group than in the no murmur group

There was no notable shift between the different periods in either group. The incidence of pathological P terminal frontal vectors less than +30° before and after the development of MIMI and on follow up was as follows: before MIMI on some of days 1-5 22%, after MIMI in the third or fourth weeks, 21%, on follow up 20%, and no murmur 22%, 26%, and 21% respectively.

*P terminal force* (Table 16, Figs 28-31). In contrast to the rigid picture presented by the vectors in the frontal plane, marked changes were observed in the P terminal force in studying the values before and after the appearance of the mitral incompetence.

In statistical analysis, the difference between the MIMI and no murmur groups was non significant in the initial phase, but highly significant ( $p = 0.001$ ) during the third or fourth week and probably significant ( $p < 0.05$ ) on follow up. In the MIMI group, the mean P terminal force was significantly ( $p = 0.01$ ) higher after the development of mitral incompetence than before its onset. At corresponding times of examination no significant difference existed in the no murmur group. The difference was also clearly present in the study of the incidence of pathological values over  $-0.03$  mm sec (Morris *et al* 1964). Fig

29. The initial situation was the same in the MIMI (21%) and in the no murmur group (23%), but after the appearance of the mitral incompetence a substantial increase was observed in the MIMI group (39%) while in the no murmur group during the corresponding time the pathological values declined (17%). The difference remained during the follow up phase, in the MIMI group there was a slight decline (33%) and in the no-




Fig 29 Incidence of the pathological P terminal forces (over 0.03 mm sec) in patients with or without mitral incompetence




Fig 30 Values of P terminal forces of the patients dying in hospital related to the presence or absence of mitral incompetence

murmur group a steeper one (7 %).

In statistical analysis where the presence or absence of mitral incompetence was related to P terminal force in the pooled MIMI and no-murmur groups the groups differed at the significance level of  $p < 0.05$  in the third or fourth weeks and  $p < 0.001$  on follow up.

The same trend in the increase of P terminal force is seen in Fig 30 which refers to the patients of the MIMI and no-murmur groups who died in hospital. In the MIMI group a distinct acute increase in the normal or pathological initial value occurred, the increase from a mean of  $-0.025$  to  $-0.071$  mm sec being statistically significant ( $p < 0.01$ ). In the no-murmur group the change was not consistent, in many instances, no change could be seen or even a decline took




Fig 31 Electrocardiograms recorded before (A) and 1.50 days following (B) the onset of an acute mitral incompetence as a sequela of an infero posterolateral myocardial infarction. Note the acute development of a markedly pathological P wave in lead  $V_1$ . The P terminal force changed from  $-0.025$  to  $-0.17$  mm sec. The P terminal vector in the frontal plane was not conspicuously changed.

place and in the statistical calculation the change from a mean of  $-0.032$  to  $-0.042$  mm sec was non significant.

There is reason to emphasize the occurrence of strong shifts even during a few days observation (Figs 30, 31).

In addition to the extra burden imposed on the left atrium by acute mitral incompetence, changes of blood pressure values (Sodi Pallares and Calder 1956, Lubbeck *et al* 1963, Ross 1963) and heart failure (Sutnick and Soloff 1962, Miron and Mazzei 1965, Sitar 1965) could also produce similar effects. In determining the part played by heart failure in addi-

tion to mitral incompetence, the changes in the P terminal force determined by the serial correlation coefficients of P terminal force/mitral incompetence and P terminal force/congestive heart failure were about the same,  $-0.24$  and  $-0.25$  ( $n$  163) in the third or fourth weeks of illness, and  $-0.27$  and  $-0.31$  ( $n$  126) on follow up. The systolic blood pressures did not differ significantly in either patient groups when the values on some of days 1-5 from onset were compared to pressures measured during the third and fourth weeks after onset of infarction. It may be worth repeating that the values of the P terminal force changed inconsistently in patients who died in the no murmur group although they had in many instances had very marked heart failure (Fig. 30).

#### OTHER ELECTROCARDIOGRAPHIC FINDINGS

Total LBBB occurred in the MIMI group 3 times, and in the no murmur group once while the total RBBB occurred twice in either group. Right atrial overloading was observed once in both groups. Simultaneous total LBBB and RBBB was not found. An intraventricular conduction disturbance with a QRS duration of 0.12 sec or more, which could not be classified as a bundle branch block on either side was noted in 5 MIMI and 3 no murmur patients. Perinfarction blocks were not analyzed. Intraventricular conduction disturbances seemed to be a bad omen, all but 1 of 8 patients who had or developed this electrocardiographic sign died in hospital.

#### DISCUSSION

*The location of infarction.* Contrary to the earlier statements that posterior myocardial infarction is a much commoner cause of mitral incompetence (Nezlin and Shamesova 1951; Froment *et al* 1955; Bashour 1965) or that the anterior location wholly predominates (Burch *et al*

1963; Phillips *et al* 1963 a, b; Segal and Likoff 1964), no difference in the frequencies of anterior and posterior site could be found in the present investigation as MIMI patients were concerned.

This discrepancy might be explained by the more common occurrence of transient, faint and atypical murmurs of mitral incompetence in anterior infarction (see Chapter VI). Such murmurs may have been missed without daily auscultation, or explained on other grounds. In posterior infarction the murmur tended to be more typically pansystolic at the apex as well as louder and more constant. This is consistent with the more common transmural extent of posterior infarction, leading perhaps to more severe papillary muscle damage (Chapter IX) than when the anterior wall was involved. Otherwise the anterior location was significantly more common in the no murmur group.

These findings nevertheless finally indicate that posterior infarction is a commoner cause of MIMI than anterior infarction, although the difference is clear only in the total patient series and in the degree of mitral incompetence.

Hence the results of the present study partially combine the findings of reports ascribing predominantly posterior or predominantly anterior location of the lesion in mitral incompetence to the involvement of the papillary muscle (Chapter II). Posterior infarction seems to destroy the neighbouring papillary muscle more extensively than does anterior infarction. Less severe mechanical dysfunction of the ischemic anterior papillary muscle often causes only transient and slight regurgitation. Vulnerability and more extensive destruction of the posterior than of the anterior papillary muscle was definitely evident in the present autopsy study (Chapter IX).

*Left ventricular hypertrophy.* There was no difference in the frequency of the left ventricular hypertrophy between the MI-

MI group and the no murmur patients during the acute phase of infarction. However, a marked tendency to develop or exaggerate previous signs of LVH in the MIMI group was observed in the follow-up phase (Chapter X).

The low frequency of positive findings as compared to the incidence of hypertension and to the autopsy findings stresses the unreliability of electrocardiographic diagnosis of this condition in the presence of myocardial infarction.

**Left atrial overloading** The P wave is generally assumed to be generated by electrical activation of the right and left atrial musculature (Hecht and Woodbury 1950, Wenger and Hofmann-Credner 1952, Reynolds 1953, Puech *et al* 1954, Sodi-Pallares *et al* 1965), although a radically controversial explanation has recently been presented (Radner 1966).

Activation of the left atrium occurs normally 0.04–0.05 seconds after the onset of the right atrial activation. Thus pathological changes in the terminal portion of the P wave have been considered to reflect the verified changes of left atrial hypertrophy, dilatation or muscular damage. Changes have been most often observed in acquired valvular diseases, the most extreme changes occurring in mitral stenosis. A good correlation has been usually found in pathological, radiological and hemodynamic studies between the structural and functional alterations undergone by the left atrium and the changes occurring in the P wave (Berliner and Master 1938, Hecht and Woodbury 1950, Bradley and Marriott 1956, Soloff and Zatzuchni 1958, Dines and Parkin 1959, Arwidsson *et al* 1960, Morris *et al* 1964).

Evidence of rapid and sensitive P terminal wave changes has recently emerged in hypertension, left ventricular failure, myocardial infarction and exercise. These have been explained on the grounds of left atrial strain or dilatation and a posterior shift of the terminal P wave vector (Sutnick and Soloff 1962, Lubeck

*et al* 1963, Ross 1963, Cortes 1963, Sitar 1965, Desrochers and Proulx 1965).

Only a few reports have been published on P wave alterations in acute myocardial infarction (Master 1933, Bloom and Gilbert 1942, Vill 1949, Katz 1949, Lepeschkin 1957, Gross 1963, Miori and Mazzei 1965, Sitar 1965). Increased duration or notching of the P wave is said to occur infrequently and is attributed to acute left ventricular failure or increased sympathetic tone.

However, in the only two systematic investigations carried out in addition to Master's (1933) Miori and Mazzei (1965) and Sitar (1965) observed the P wave alterations to be quite common in acute myocardial infarction. The P wave recorded in lead V<sub>1</sub> appeared to reflect the pathological changes most sensitively. These changes were ascribed to failure of the left ventricle. In many instances, they were transient. To the more permanent changes Sitar (1965) applied a guarded prognosis, as had previously been done by Bloom and Gilbert (1942).

The results of the present investigation point to frequent and very rapid changes in the P terminal force in acute myocardial infarction. This sign of probable left atrial strain developed significantly more frequently and was more marked in degree among MIMI patients than those of the no-murmur group.

The P wave on admission was often pathological also in the no-murmur group. Later normalization of the P terminal force in this group would suggest in the main only transient and reversible initial hemodynamic strain caused by the acute myocardial damage. The same relationship was noted in the atrial gallop (Chapter VII A).

By contrast in the MIMI group the electrocardiographic changes in the P wave progressed after the development of mitral incompetence. This is reasonable when one considers the added volume of work of both the left atrium and the



left ventricle with the frequent development of congestive heart failure leading to a rise in both the volume and the pressure loads in the left atrium.

The P terminal force was superior in sensitivity when compared to the change of direction of the P terminal vector in the frontal plane. The findings of Abilskov (1957) and of Sutnick and Soloff (1962) pointed in the same direction in comparing the P terminal force to the mean atrial vector. When the P terminal force took a pathological course the P terminal vector in the frontal plane shifted — not always toward lower but often also toward higher values, and vice versa. This could be explained by the major change being a posterior rotation of the P vector in the horizontal plane (Sano *et al* 1957, Martins de Oliveira and Zimmer *et al* 1959, Sutnick and Soloff 1962, Morris *et al* 1964) whereas a simultaneous change in the frontal plane might have been up or down.

The results of these very acute terminal P wave changes in the present study are contrary to the observations of Gooch *et al* (1966) who found the frontal plane terminal vector to be more sensitive than the P terminal force. Their patients however had a conspicuously enlarged left atrium as a consequence of valvular heart disease. Altered anatomical size and position of the left atrium might

affect the P wave differently from the acute electromechanical strain in a predominantly normal sized left atrium. An insignificant shift of the mean P terminal vector in the frontal plane to the left was observed in the MIMI group. This shift was in the opposite direction to the deviation of the mean P wave mean vector in coronary patients observed by Gross (1963) to be to the right from normal. This change was ascribed to chronic ischemic damage and thus to loss of electrical force generated by the left atrium.

The acute marked changes of the P terminal force in a pathological direction, as observed in the present study, had the same significance pointing to a guarded prognosis as in the findings of Sitar (1965).

To sum up the frequency of electrocardiographic location of the anterior and posterior myocardial infarction was equal in patients who developed mitral incompetence after acute myocardial infarction. The anterior infarction dominated in the group without mitral incompetence. Subendocardial infarction can well be associated with development of mitral incompetence. The magnitude of P terminal force was significantly correlated with development of MIMI and often rapid changes seemed to have some prognostic significance.

## COMPARISON OF CLINICAL FINDINGS IN PATIENTS WITH AND WITHOUT MITRAL INCOMPOTENCE

### RADIOLOGY

#### METHODS

All the patients underwent a radiological examination of the chest during the mobilization stage of treatment 2 to 4 weeks after the onset of infarction. The radiographs were studied to estimate the volume of the heart, the degree of enlargement of its chambers, the changes in the large blood vessels and particularly the pulmonary signs of left sided heart failure.

The generally used teleradiographic ellipsoid approximation method of measuring the volume of the heart (Liljestrand *et al* 1939, Jonell 1939) was applied in the present study with certain modifications. The pictures were taken according to routine clinical procedure in the erect position with moderate inspiration and without correlation to the cardiac cycle. The exposures for postero-anterior and lateral pictures were not simultaneous. The focal distance was chiefly 1.5 meters for both projections but in one clinic some of the patients were examined with a 2.0-m focal distance. Therefore to obtain comparable volumes a correction calculation for magnification caused by divergent rays was made (Kleipzig and Frisch 1955). The final coefficients used including magnification and assumed ellipsoidal shape of the heart were 0.41 for the 1.5 m and 0.44 for the 2.0 m focal distance. Domenet *et al* (1963) and Evans and Carpenter (1964) used the constant 0.41 after studying a large number of subjects to ascertain among other things the influence of the heart film distance. Jonell (1939) had a slightly higher value of 0.42 and Amundsen (1959) a slightly lower one of 0.40.

In order to achieve maximum accuracy in calculating the heart volume the present author outlined the heart as a figure resembling an ellipse (Kleipzig and Frisch 1955). On the top of this drawing a regular ellipse drawn on a transparent sheet and measuring 12 x 16 cm was placed. By means of this model which was provided with centigrade longitudinal and transverse axes at right angles it was possible to place rapidly and accurately on the heart shadow itself the longitudinal and transverse axes situated perpendicular to each other. The depth was measured from the anterior border of the heart in the direction of

the beams to the posterior border or if this was not visible to the border indicated by the barium swallow.

Heart volumes were calculated in relation to the body surface area. This was obtained from a nomogram based on the formula of DuBois and DuBois (1916).

The size of the chambers of the heart was graded from 0 to 3 as follows:

Left atrium

0 — normal

1 — slight but no longer normal indentation in the lateral view of the esophagus

2 — distinct displacement of the esophagus with the auricular appendage often visible

3 — prominent enlargement of the atrium and a double contour at the border of the right auricle

Left ventricle

0 — normal

1 — slight rounding of the apex and a straightening-out of the ventricle-diaphragm angle

2 — distinct enlargement and displacement downward or outward in frontal and lateral views as well as increased heart volume

3 — marked enlargement

Right atrium and ventricle

Corresponding principles were applied as in estimating the size of the left atrium and ventricle.

The signs of left sided heart failure in the pulmonary circulation were estimated according to the principles presented by Short (1955), Grainger (1958), Steiner (1958, 1959), Harley (1961), Simon (1961), Lavender and Doppen (1962), Lavender *et al* (1962), Loeve *et al* (1953) as follows:

0 — normal

1 a — venodilatation in the lower and middle fields and/or slight hilar or pulmonary clouding

1 b — marked venodilatation in all the pulmonary fields and/or distinct clouding

2 — venoconstriction in the lower fields attended by marked venodilatation in the upper fields causing reversal of the normal vascular pattern. Septal or A lines and/or hydrothorax.

### 3 — distinct alveolar pulmonary edema

The diameter of the right descending branch of the pulmonary artery was measured as far as its limits could be distinguished in the middle of the interstitial edema.

All the estimations were made as double determinations expecting those involving heart volumes in which the double determinations were made to measure the intra-observer error from 52 pairs of pictures selected at random after earlier markings had been wiped off. No inter-observer error was determined as the analyses were made by the author alone.

Relative heart volumes of over 500 ml/m<sup>2</sup> of BSA for men and over 450 ml/m<sup>2</sup> of BSA for women were considered pathological (Liljestrand *et al* 1939, Jonzell 1939, Maurea *et al* 1905, Nylén 1957, Musshoff *et al* 1958, Amundsen 1959).

Similarly normal respiration has no appreciable effect on volume (Jonzell 1939, Lind 1950, Kjellberg *et al* 1951, Nylén 1957).

The position of the subject under examination often has considerable effect on the volume in an upright position the heart is smaller and more sensitive to any change in the heart volume depending upon orthostatic changes in venous return and heart rate (Kjellberg *et al* 1949, Kjellberg 1952, Musshoff and Reindell 1956, Linderholm and Strandell 1958, Holmgren and Överfors 1960). Physical training markedly affects the heart volume which increases with an increase of red blood cell mass (Kjellberg *et al* 1949, Musshoff *et al* 1958).

Åxén *et al* (1946) investigated the total error of the method including its technical and physiological aspects and obtained a result of only 3.4 %.

## ACCURACY OF RADIOLOGICAL HEART VOLUME MEASUREMENT

### Technical considerations

The ellipsoid approximation method of heart volume determination seems to be astonishingly accurate when tested by comparing the radiological volume with the autopsy displacement volume or with tomographical calculations (Lind 1950, Friedman 1951, Gebhardt 1957, Evans and Carpenter 1963) the error being under 3 %.

The reproducibility from double determinations is good showing deviations of 3–5 % (Åxén *et al* 1946, Kjellberg *et al* 1951, Linderholm and Strandell 1958, Amundsen 1959, Holmgren and Överfors 1960). In the present study the significant (at a level of  $p < 0.001$ ) discriminant volume was 20 ml as determined from duplicate contour drawings and calculations from 52 unselected pairs. The mean absolute heart volume was 947 ml in the first and 962 ml in the second estimation. The difference ranged from 0 to 90 ml and the standard error of the change was 61 ml. For relative volumes the error is obviously considerably smaller.

Adherence to fixed points in measuring the long and the short axes of the heart as described by Jonzell (1939) has obvious disadvantages if no correction is made for the axis deviation from the right angle. The method used here for perpendicular axis determination on a drawn ellipse in comparison with the routine radiological procedure of measuring them from fixed points without any angle correction often yielded a difference of as much as 100 ml in heart volume.

### Physiological factors

The error originating from the heart cycle in the determination of the heart volume as revealed by a comparison of pictures taken during peak systole and diastole is reduced when unsynchronized pictures are taken at random.

## RESULTS

**Heart volume** The pictures were taken 2–4 weeks after the onset of infarction. 101 (86 %) pictures involving MIMI and 61 (87 %) involving no-murmur patients were available, for patients who died in hospital before the mobilization stage, no pictures were usually available.

The heart size was about of the same magnitude in both MIMI and no murmur groups (Tables 17 and 18). The heart volumes were over 500 ml/m<sup>2</sup> of BSA in 68 of 162 patients (42 %), 45 of them (45 %) from the MIMI group and 23 (38 %) from the no-murmur group. The enlargement was usually moderate 600 ml/m<sup>2</sup> of BSA being exceeded by only 12 MIMI and 8 no murmur patients. In the majority (55 %) of the MIMI patients the heart volume was notably within normal limits about 2 or 3 weeks after the murmur had developed (Figs 32 and 33).

The differences in heart volume in patient groups with anterior myocardial infarction were immaterial (Tables 17 and 18) but with posterior infarction the heart size in the MIMI group was significantly larger than in the no murmur group. In the MIMI group, enlarged hearts were found in 39 % with anterior infarction and in 51 % with posterior infarction.




Fig 32 Heart volumes in hospital and on follow-up patients with and without mitral incompetence 500 ml/m<sup>2</sup> of BSA indicated by the dotted lines was used as an upper limit of the normal. Over half the MIMI patients had a normal heart volume in hospital with a slight tendency to enlarge on follow-up

Table 17 Heart volumes in patients with and without mitral incompetence

	Heart volume ml/m <sup>2</sup> of BSA mean $\pm$ SD				Total	
	Anterior infarction At hospital	At follow up	Posterior infarction At hospital	At follow up	At hospital	At follow up
Mitral incompetence	487 $\pm$ 125 n 56	510 $\pm$ 149 n 49	528 $\pm$ 101 n 45	521 $\pm$ 91 n 37	505 $\pm$ 308 n 101	515 $\pm$ 126 n 86
No murmur	517 $\pm$ 124 n 42	501 $\pm$ 116 n 30	454 $\pm$ 81 n 18	460 $\pm$ 79 n 17	498 $\pm$ 113 n 60	488 $\pm$ 106 n 52
P	NS	NS	< 0.001	< 0.05	NS	NS

NS non-significant



Fig 33 Gradual enlargement of the heart in a patient with mitral incompetence as a sequela of acute myocardial infarction. At the onset of the murmur heart volume was normal. At autopsy despite marked enlargement of the heart circumference of the mitral annulus was normal (95 mm). Note also the appearance of signs of progressive pulmonary venous congestion

Table 18 Size of heart related to site of infarction in patients with and without mitral incompetence

Heart volume ml m <sup>2</sup> of PS4	Mitral incompetence		No murmur	
	Location of infarction		Location of infarction	
	Anterior	Posterior	Anterior	Posterior
MO	34 (61%)	22 (49%)	24 (56%)	14 (78%)
(V)	22 (39%)	23 (51%)	19 (44%)	4 (22%)
Total	56	45	43	18

Table 19 Relationship between radiological pulmonary signs of left sided heart failure and mean pulmonary capillary wedge pressures obtained at cardiac catheterisation

Radiological finding	Mean pulmonary capillary wedge pressure mmHg			Total
	0-10	11-20	21 or over	
Venous dilatation				
slight	5 (56%)	7 (58%)	1 (25%)	13
marked	2 (22%)	4 (33%)	3 (75%)	9
Venocongestion	0	2 (17%)	2 (50%)	4
Septal lines	2 (22%)	5 (42%)	4 (100%)	11
Hilus clouding	4 (44%)	10 (83%)	4 (100%)	18
Pulmonary clouding	4 (44%)	5 (42%)	4 (100%)	13
Total	9	12	4	25

The radiological heart volume of patients who died in hospital was usually large. Of the 21 MIMI patients who died 7 underwent a radiological examination 5 of them being found to have an enlarged heart while 5 of the 11 fatal cases in the no murmur group were radiologically examined 3 of them being found to have a heart volume over 500 ml/m<sup>2</sup> of BSA.

*Size of the left ventricle (Fig 34)* No differences were observed between the groups of patients, the enlargement generally being only slight. A distinct grade 2-3 enlargement was registered in 45% of the patients in the MIMI group and in 34% of those in the no murmur group.

*Size of the left atrium (Fig 34)* The radiological size of the left atrium, as estimated from plain chest radiographs was in the main remarkably normal in

both groups of patients — 48% in the MIMI and 53% in the no murmur group. Only negligible enlargement, with a small rounding and an indentation in the esophagus, was found in an additional 20% of the MIMI and 24% of the no murmur patients. Thus the left atrium of about three fourths of the patients in both groups was normal or nearly normal.

*Right atrium and ventricle* The right atrium was estimated to be enlarged in 18% of the MIMI and in 16% of the no murmur patients, while an enlargement of the right ventricle was noted in 24% and 21%, respectively.

*Pulmonary signs of left sided heart failure (Figs 33-35)* Changes in the pulmonary vessels and tissue spaces were very common among patients with acute myocardial infarction. In only 30 (30%) of




Fig 34 Radiological findings

the MIMI and 27 (14%) of the no-murmur patients were definite changes in pulmonary circulation consistent with left-sided heart failure estimated to be absent. These figures include borderline changes and if these changes are considered to indicate incipient pulmonary venous congestion then only 7 MIMI and 6 no-murmur patients were left

definitely without any radiological pulmonary changes of heart failure.

Clear-cut pulmonary venous dilatation as a manifestation of pulmonary venous hypertension was observed in 56% of the MIMI and in 45% of the no-murmur patients. Marked pulmonary venous dilatation alone in both upper and lower fields without more severe changes was




Fig 35 A chest radiograph showing a small ventricular aneurysm confirmed by a cine fluorographic examination. Severe pulmonary venous congestion. A marked paradoxical ecdiastolic pulsation was felt at the time of the onset of only grade 1 pansystolic crescendo murmur (SM) of mitral incompetence. Third heart sound was easily palpable as a sudden shock also evident in the kymocardiography. Stippled area represents the pansystolic bulge.

found in 9 patients in the MIMI and 5 in the no-murmur group, these are therefore included in the number referring to slight or moderate venous dilatation (grade 1).

More marked grade 2 changes in the pulmonary signs (Fig 3c) were also present slightly more commonly in the MIMI (21 %) than in the no-murmur group (15 %) already at this stage with the situation tending to deteriorate on follow up examination (Chapter V). Septal lines were detected in 18 % of the MIMI and 10 % of the no-murmur patients.

Severe alveolar pulmonary edema was present at the time of the radiological examination in 3 MIMI and 3 no-murmur patients.

Most of the patients who died in hospital had evidenced conspicuous changes of left-sided heart failure corresponding to grade 2-3; this was true of 9 of the 12 MIMI and 4 of the 6 no-murmur patients.

The right descending branch of the pulmonary artery had a diameter of the same order in both groups, it ranged between 12-19 mm with a mean of 14.7 mm, among the members of the MIMI group and between 12-22 mm, with a mean of 14.7 mm, among those of the no-murmur group. A pathological enlargement over 16 mm (Lavender and Doppman 1962) was noted in 13 % of the MIMI patients and in 8 % of the no-murmur patients.

Aortic sclerosis, as estimated from plain pictures, was of the same incidence in both groups. No changes were found in 26 % of the MIMI or in 18 % of the no-murmur group. Demonstrable aortic dilatation or visible calcification was detected in 40 % of the MIMI and in 58 % of the no-murmur patients, the rest having an increased density of the degree generally interpreted as a radiological sign of aortic sclerosis.

Left ventricular aneurysm of small or mo-

derate size (Fig 3b) was found in 9 % of patients in the MIMI group and in 5 % in the no-murmur patients.

## DISCUSSION

Three important findings resulted from the radiological examination of the heart and lungs performed 2-4 weeks after the onset of myocardial infarction.

Firstly, in most patients mitral incompetence developed after myocardial infarction with the heart of normal size. Thus, the mechanism of mitral incompetence obviously could not, as has generally been assumed, be secondary to mitral annular dilatation brought on by enlargement of the left ventricle. Furthermore, many of the patients in the no-murmur group were found to have considerably enlarged hearts without any sign of mitral incompetence. The annular dilatation mechanism of mitral incompetence has been criticized by Levy and Edwards (1962), who ascribed incompetence instead to an inappropriate alignment of the papillary muscles to a more obtuse angle in the dilating left ventricle. This would necessitate a marked degree of acute enlargement. Moreover, the mitral annular ring is part of the strong fibrous skeleton of the heart, where dilatation as a result of muscular damage would not be expected.

Acute left ventricular dilatation (Sarnoff and Berglund 1954, Mullins *et al* 1966) could, however, be one mechanism of regurgitation, inappropriate positioning of the papillary muscles might actually make them too short by having their attachment areas pulled down to a greater distance from the valvular orifice in the dilated ventricle (Bailas 1965). Clinical investigations of this problem are not, however, available.

Thus, the normal size of the heart in the majority of the patients suggests that the regurgitation mechanism represents functional or anatomical ischemic destruc-

tion of the supporting structures of the mitral valve, i.e. papillary muscles as most important structures

Reports on the size of the heart in cases of myocardial infarction indicate, in agreement with the findings of the present study that this can very often be normal (Waris *et al* 1966). Mitral incompetence of short duration did not apparently change the heart volume during hospitalization, the effect at follow up being a slight tendency to enlargement. The finding of Froment *et al* (1955) that mitral incompetence as a sequela of myocardial infarction occurs in the presence of anterior infarction usually only in enlarged hearts (Table 1) could not be substantiated (Tables 17 and 18), the result was the opposite in the present study.

Secondly, the size of the left atrium was mostly normal in patients who developed mitral incompetence. This was also the finding in the series of acute subvalvar mitral incompetence investigated by Raftery *et al* (1966), and Kennedy *et al* (1966), as confirmed by cine cardioangiography. Accordingly the normal size of the left atrium does not exclude the possible presence of even a marked degree of mitral incompetence.

Enlargement of the left atrium and of the left ventricle is usually interpreted as a common and reliable radiological sign of significant mitral incompetence (Abelmann *et al* 1953, Wood 1954, Priest *et al* 1962). Nevertheless serious criticism has been directed against the exclusion of a substantial mitral incompetence on the basis of normal size of the left atrium (Bentivoglio *et al* 1961, Khalaf *et al* 1962, Braunwald and Awe 1963). Similarly, the size of the left ventricle can just as easily be normal as enlarged in patients with significant mitral incompetence (Abelmann *et al* 1953, Ross *et al* 1958, Steiner *et al* 1963). Definite enlargement of the left atrium and left ventricle is a natural consequence of any marked

hemodynamic disorder straining the two chambers, but seems to be the result of a prolonged hemodynamic burden. In addition, rheumatic changes in the myocardium of the left atrium and ventricle could, for example, be a factor of no little significance in causing the enlargement. Consequently, any estimation of the hemodynamics of the mitral incompetence in the light of the size of these chambers is unreliable (Cobbs *et al* 1957, Shillingford 1962, Logan *et al* 1967), and, as far as acute changes are concerned quite impossible.

Thirdly, subtle radiological signs of left-sided heart failure after a myocardial infarction were extremely frequently present, and in more severe form in patients with acute mitral incompetence, further worsening in MIMI patients during the follow up phase (Chapter V).

The first but frequently overlooked sign of left-sided heart failure is pulmonary venous dilatation following pulmonary venous hypertension (Short 1956, Simon 1961, Logue *et al* 1963). This is caused by increased filling pressure when the left ventricle (or atrium) fails as a pump and the end diastolic pressure rises in consequence (Lewis *et al* 1953). Hemodynamic studies (Lavender *et al* 1962) have shown that pulmonary venodilatation develops when the mean pressure of the left atrium rises above 10 mm Hg. Clinically, this phase is altogether symptomless (Wood 1956) except for the radiological finding.

Dilatation of the pulmonary veins occurs initially in the lower fields on which hydrostatic pressure also exerts an effect, and gradually also in the upper fields whereupon only the normally inconspicuous veins can be clearly distinguished from the pulmonary arteries. In the study of Logue *et al* (1963) there was no venous dilatation in only 10 % of the patients when other clinical signs of left-sided heart failure were present. Under prolonged strain a vasoconstriction of the



lower fields gradually develops as a consequence of complex hydrodynamic and neurohumoral series of occurrences (West 1965 1966). The increased venous pressure gradually induces oozing of fluid into the pulmonary tissue and the interstitial edema gives a hazy, clouded appearance to the perivascular areas and the whole pulmonary tissue. This is often attributed merely to a poor radiological technique.

When the pulmonary capillary pressure rises above 18–20 mm Hg the septal lines described by Kerley (1933) appear (Grainger 1958). They are induced by the edema and the fibrous septa. Dilatation of the pulmonary lobular septa and its main branches occurs gradually with increasing pulmonary pressure. Intra alveolar edema, with its pronounced radiological changes (Jackson 1951) is the last and well known step in the pulmonary failure.

The present study revealed that prominent pulmonary signs of left sided heart failure can often be detected even when the heart has not been enlarged, as also emphasized by Zatuchni and Nussbaum (1963, Logue and Hurst 1966a). Logue et al (1963) reported that in its initial stages left sided heart failure could be much more sensitively perceived radiologically than clinically, in one fourth of the patients subsequently confirmed left

sided heart failure was first noticed in radiological examination only.

Evidence was cited earlier (p 61) that left-sided heart failure appears to be almost universally present in acute myocardial infarction, as revealed by pulmonary function studies and blood gas analysis. In the present study, the results of clinical findings and hemodynamic investigations carried out on follow up (Table 19), agreed well with the common occurrence of the radiological signs of left sided heart failure.

Equal incidence of aortic sclerosis in both patient groups does not support the view that a murmur of aortic sclerosis would in fact have been interpreted erroneously as an atypical ejection type mitral systolic murmur (Chapter VI).

To sum up 55% of the patients in whom mitral incompetence developed in connection with myocardial infarction had normal heart volume. This refutes the common assumption that the mechanism of murmur is secondary to mitral annular distention. The size of the left atrium does not enlarge acutely even under a severe hemodynamic burden. Signs of pulmonary venous congestion after acute myocardial infarction were extremely common even with a normal size of heart, and more so in patients with acute mitral incompetence.

## HEMODYNAMIC INVESTIGATION

## PATIENTS

Twenty five patients were successfully obtained for voluntary inclusion in the hemodynamic investigation

*Marked mitral incompetence* was estimated to be present in 6 patients. In 5 of the 6 patients the condition was judged to be marked on clinical grounds but the original estimation of somewhat slight mitral incompetence in one patient had to be revised after cardiac catheterization study. This patient had only a grade I apical pansystolic murmur but a very hyperdynamic left ventricular impulse.

*Slight mitral incompetence* was present clinically in 12 patients, and was confirmed by hemodynamic study.

*No murmur patients* 7 patients were examined. 6 from the clinical no-murmur group yielded no signs of mitral incompetence but were found to have congestive heart failure varying by the NYHA criteria from grade I to IV. The seventh patient had had a mitral systolic murmur in hospital that was no longer present during the follow up study when the catheterization was performed.

## METHODS

## ESTIMATION OF SEVERITY OF MITRAL INCOMPETENCE

It is generally agreed that no single method can reliably and accurately measure quantitatively the mitral regurgitation in an individual patient despite various attempts made with radiological hemodynamic and dye dilution techniques in addition to clinical evaluation (Shillingford 1962). Of these methods left ventricular high-speed cine-cardioangiography obviously most nearly ap-

proaches the desired standard of quantitative discrimination (Ross and Criley 1962 Rees *et al* 1963 Logan *et al* 1967). The left atrial direct or indirect pulmonary capillary wedge pressure curve (PCW) often accomplishes a rough gradation of the regurgitant volume (Lagerlof and Werko 1949 Dexter *et al* 1950 Wade *et al* 1952 Gorlin *et al* 1952, Kent *et al* 1954 Wells 1958, although errors are not uncommon (Wiggers 1953 Ross *et al* 1958 1960 Braunwald and Awe 1963).

In the present investigation, right heart catheterization was chosen as a safe method for the hemodynamic study of patients in the convalescent stage of myocardial infarction.

In order to improve the accuracy of the method a pharmacodynamic methoxamine test was applied. This method has repeatedly been demonstrated as also giving sensitive recognition of a slight degree of mitral regurgitation.

For lack of an efficient cine-cardioangiographic apparatus it was not considered feasible to use left ventriculography in patients with ischemic heart disease and only slight mitral incompetence or none at all.

All the cardiac catheterization studies were carried out by the author.

## PRINCIPLES OF THE LEFT ATRIAL PRESSURE CURVE ALTERATIONS

Blood regurgitating from the left ventricle in the low-capacity left atrium and pulmonary veins usually produces characteristic changes in the pressure of the left atrium. These can be studied indirectly from the pressure curve obtained by wedging the catheter into a peripheral branch of the pulmonary artery (Lagerlof and Werko 1949).

Alteration of the pressure curve can range through all the degrees related to the amount of regurgitation from almost normal to a gradual levelling-off of the x descent and a heightening of the v peak so as eventually to approach the form of the ventricular pressure curve (Hamer *et al* 1959 Ross *et al* 1960 Werko 1962 Kaplan 1966).

An increased systolic distention of the left atrium and a rapid unobstructed diastolic flow through the atrioventricular orifice steepen the y descent of

and filling phase of the left ventricle (Wiggers 1922 Lagerlof and Werko 1949 Gorlin 1952 Nixon and Wooler 1963b). Various studies of the left atrial pressure levels in the course of their change have been closely correlated to the amount of the flow (Owen and Wood 1955 Morrow). The left ventricular diastolic pressure rises conspicuously because the distended left atrium expels the increased blood by improved efficiency (Jones and others 1963). Competence of the left ventricle is not developed (Ross *et al.* 1958).

#### MECHANISM OF THE PHARMACODYNAMIC TEST

Less than one-half of the forward flow from the left ventricle is one important determinant of the amount of the regurgitant stroke volume through the leaking mitral valve (Wiggers and Feil 1922 Goddard and Williams 1954 Daniels 1958 Braunwald *et al.* 1955 Jones *et al.* 1964).

The effect of pressor agents in augmenting left atrial repulsion by rising peripheral systemic arterial resistance has been demonstrated by external and intracardiac phonocardiography (Endryns and Bartova 1962 Perloff and Harvey 1962 Leda *et al.* 1966 Leighton *et al.* 1966) by direct and indirect left atrial pressures (Braunwald *et al.* 1958 Stanfield and Yu 1960) and by the dye dilution technique (Yu *et al.* 1961 Rutishauser *et al.* 1963 Tanenbaum and Pfaff 1963 Jones *et al.* 1964). The normal left atrial pressure curve occasionally present in slight mitral incompetence is usually unmistakably changed by pressor agents to that of mitral incompetence (Ross *et al.* 1960 Leighton *et al.* 1966).

Methoxamine was used in the present study because it increases systemic arterial resistance and consequently blood pressure without anyotropic effect on the myocardium in addition to which it has no effect on the pulmonary arterial pressure or pulmonary vasoconstriction (Ross *et al.* 1960 Yu *et al.* 1961 Tanenbaum and Pfaff 1963 Leda *et al.* 1966). The effect was registered simultaneously by both pulmonary capillary edge pressure and external phonocardiography. An index of over 35% of the increment of the peak deduced by the increment of systolic arterial pressure has usually been reported to indicate the presence of hemodynamically significant mitral incompetence (Stanfield and Yu 1960).

The magnitude of mitral incompetence increases in consistency with increased regurgitant flow. The aortic and systolic effect on murmurs of relative intensity (Lutada 1965 Leda *et al.* 1966).

#### ESTIMATION OF OXYGEN CONSUMPTION

To determine the oxygen consumption expended air was collected for seven minutes by means of

an airtight mask, a low resistance valve system and tubing into a Douglas bag. The collected air in the bag was emptied by folding into a dry gasometer. The volume of  $O_2$  consumption was calculated from the oxygen content of the expired air and the room air.

#### OXYGEN SATURATION AND CONTENT OF BLOOD SAMPLES

The oxygen saturation of blood samples was determined with an Elema oxymeter. The hemoglobin was analyzed as oxyhemoglobin by the cyanmethemoglobin technique. The oxygen content of each sample was determined by a nomogram using a hemoglobin concentration and an oxygen saturation. The normal arteriovenous oxygen difference at rest varies between 3 and 5 volume% (Holmgren *et al.* 1957) slowly increasing in older age groups (Granath *et al.* 1964).

#### CARDIAC OUTPUT

The direct Fick principle of calculating the cardiac output from the oxygen consumption and arteriovenous oxygen difference was applied and the result expressed as a cardiac index. The normal cardiac index varies between 3 and 4.5 l/min/m<sup>2</sup> of BSA (Dexter *et al.* 1950 Wade and Bishop 1962 Bayer *et al.* 1967). In this laboratory the normal values varied from 2.7 to 6.1 mean 4.6 l/min/m<sup>2</sup> of BSA.

#### PRESSURE RECORDING

**Equipment.** Command type woven nylon USCI single lumen end hole catheters of size 7 F or disposable size 6 F were used in the right side cardiac catheterization. Pressures were transduced by the electrical Sanborn pressure transducer 267 B which was connected to a Carter preamplifier 350-3000 and recorded by a 4 channel Sanborn polybeam recording system (508) with optical galvanometers on photographic film. A rapid developer attached to the recorder made visible recordings available instantaneously.

**Recording.** An undamped recording was usually used and only occasionally was a damped system used to reduce 30-40 cps catheter resonance. The electrocardiogram lead II, external phonocardiogram, intravascular pressure curve and pressure zero-level were recorded simultaneously. Full scale sensitivity was generally used in the pressure recording. The film speed was 25 mm/sec in aortic pressures and 100 mm/sec when recording pulmonary capillary edge (PCWE) pressure. Electrical damping was used to obtain mean pressures. The calibration was registered after each recording both electrically and hydrostatically. The zero-level stability was always checked before and after each pressure recording. The zero level used was 10 cm above table level.

The normal levels in this laboratory were compared with those stated by others (Kaplan 1966) PCW systolic 8-14 diastolic 4-8 mean 6-11, pulmonary artery systolic under 30 right ventricular diastolic under 7, right atrial mean under 8

**Phonocardiograph equipment** A crystal contact type, high impedance Sanborn 350-1700-C 10 microphone with a frequency response of over 1000 cps was used, connected to a heart sound preamplifier 350-1700 III The following octave related high pass filters were used, mostly 200 cps band flat  $\pm 3$  db between 200 cps and 1 kc with a damping of 24 db at 100 cps and 60 db at 25 cps A 400 cps band was sometimes used to detect high frequency murmurs with greater sensitivity but often the inappropriate noise signal ratio obtained with this high frequency band necessitated changing over to a 200 cps cut-off band to enhance clarity

**Procedure** Right sided cardiac catheterization was performed in the morning with the patient in a state of fasting following premedication with 25 mg promethazine chloride Phenergan® A heart sound microphone was strapped to the point of maximal murmur intensity With the help of an oscilloscope appropriate filter and amplification were selected and maintained without further change A catheter was introduced into the right or the left basilic vein and advanced into the heart under television control Blood samples were withdrawn from the superior and inferior caval veins and from the right atrium to exclude shunts At least three blood samples were drawn from the pulmonary artery trunk for arteriovenous oxygen difference calculation The brachial artery was punctured by a hypodermic needle for arterial blood sample and pressure recording

The pressures in the right atrium right ventricle and pulmonary artery were recorded before wedging the catheter into the peripheral branch of the right or the left pulmonary artery When a soft number 6 F disposable catheter was used it was sometimes necessary to stiffen it with metal guide wire as used in the percutaneous Seldinger technique (1953) before adequate positioning in the wedging was achieved

After the basal PCW pressure level had been registered injections measuring 1-2 mg at a time of methoxamine chloride Vasovine®, Burroughs Wellcome & Co 20 mg having been diluted in 20 ml of physiological saline were given through the catheter Generally after a 3-4 mg injection a response was obtained consisting of a rise in systolic arterial pressure of not less than 10 mm Hg as measured repeatedly by brachial cuff and bradycardia Patients complained at the same time of slight feeling of pressure chill, goose flesh or a need to void which was helpful in determining the effect and dose of the drug Immediately after these signs the PCW pressure and phonocardiogram were recorded

in the same way as the previous control curve the blood pressure being measured immediately after the PCW recording by cuff or often also by an intravascular pressure recording The effect of the drug was very transient lasting only 2 or 3 minutes In most patients repetition of the pressor test after some ten minutes yielded a reproducible response in PCW pressure Oxygen consumption was determined after the pressure recordings and was thus not quite simultaneous with the blood sampling

## COMMENTS

### CARDIAC OUTPUT DETERMINATION

No determination was made of the methodical error of oxygen consumption in the present study but in similar systems it has been shown to correspond to a coefficient of variation within a few per cent (Granath 1965) The error of a single determination of blood oxygen saturation was 2.4%, and the error of hemoglobin concentration determination 0.6% determined from successively withdrawn samples The methodical error of direct Fick cardiac output determination usually falls within 10% (Wade and Bishop 1962 Werko 1964) This includes both the analytical error and biological variations of the subject examined

The basal state is essential for cardiac output determination in conditions of right-sided heart catheterization the error arising from this factor has been observed to be within 20% (Wade and Bishop 1962 Granath 1965 Bevegård *et al* 1966)

### PRESSURE MEASUREMENTS

Pulmonary capillary wedge pressure and simultaneously recorded external phonocardiographic tracings are markedly affected by respiration (Kaplan 1966) Therefore the recordings were always carried out similarly at end-expiration respiratory apnea The characteristic valid form of pulmonary capillary pressure curve has been reported as being obtained in between about 70 and 90% of the patients (Werko 1964) In the present series at least slight heart failure was present in most of the patients and by distending the left atrium and the pulmonary venous channels it probably facilitated obtaining valid PCW curves (Ross *et al* 1960 Braunwald and Awe 1963 Kaplan 1966) The form of the PCW pressure curve was monitored on the oscilloscope with full scale sensitivity and if the curve did not prove representative another pulmonary arterial branch was wedged (Bell *et al* 1962)

Varying statements about the validity of the pulmonary capillary wedge pressure curve in reflecting the left atrial pressure curve have been made but it has generally been recognized as being quite closely related to the left atrium pressure wave form and level in man provided

unrepresentative tracings are excluded (reviewed by Werko 1962 1964 and Kaplan 1966)

The uniform dynamic response obtained with commonly used catheter systems has been shown usually not to exceed 8–20 cps (Fry *et al* 1957 Pietmme 1963). However a uniform dynamic response of up to 5–8 cps has been considered to be adequate when only systolic and diastolic pressures without rapid rates of change are measured (Ellis *et al* 1951 Wood *et al* 1954). Careful debubbling of the pressure chambers was routine procedure in obtaining undamped

curves. Non-linearity of the recording system on a full scale was not over 2 %

#### COMPLICATIONS

One patient (No. 67) developed an RBBB during the course of catheterization. This patient had had intermittent RBBB during hospital treatment of the acute phase of myocardial infarction. Another patient with marked regurgitation developed pulmonary edema after a dose of 3 mg methoxamine. A good response was achieved by routine treatment.

Table 20 Hemodynamic data at rest in 25 patients: no murmur 7 MIMI slight 12 MIMI marked 6

	Mean	S.D.	P
Oxygen consumption ml/min			
No murmur	225	33	
MIMI slight	252	33	
MIMI marked	311	54	< 0.01
A – V O <sub>2</sub> difference vol %			
No murmur	4.8	1.3	
MIMI slight	4.8	1.0	
MIMI marked	6.7	1.2	< 0.01
Cardiac index l/min/m <sup>2</sup> of BSA			
No murmur	2.9	1.3	
MIMI slight	3.0	0.8	
MIMI marked	2.6	0.5	N.S.
Forward stroke volume ml/min			
No murmur	79	35	
MIMI slight	84	29	
MIMI marked	48	17	N.S.
Pulmonary vascular resistance units			
No murmur	1.3	0.9	
MIMI slight	1.3	0.7	
MIMI marked	2.4	1.4	N.S.
Right atrial mean pressure mm Hg			
No murmur	5	3	
MIMI slight	5	3	
MIMI marked	7	5	N.S.
Pulmonary artery mean pressure mm Hg			
No murmur	16	2	
MIMI slight	19	6	
MIMI marked	38	13	< 0.001

N.S. non significant

■ values are based on F test

## RESULTS

### HEMODYNAMICS AT REST

The results of the hemodynamic investigation of patients with slight or marked MIMI as compared with the results obtained in the no-murmur group are presented in Tables 20 and 21 and in Figs 36 and 37.

It is evident that the ■ patients with marked mitral incompetence suffered from much more severe circulatory disturbances than the others. The hemodynamic alterations in the group of patients with slight mitral incompetence varied but were mainly comparable to the degree of the disturbance resulting from heart failure, observed in patients without mitral incompetence.

Heart rate, oxygen consumption, arteriovenous oxygen difference, pulmonary artery and wedge pressures, differed significantly or highly significantly in the

variance test when the marked MIMI group was compared with the groups of patients with slight or no mitral incompetence.

The values of systolic arterial pressure, cardiac index, forward stroke volume, pulmonary vascular resistance and right atrial pressure also tended to deviate more from the normal in the marked MIMI group than in the others, although statistically not significantly.

The arterial blood oxygen saturation was below normal, 96 %, in 11 patients in all but one patient in the marked MIMI group, and in 3 patients in the slight MIMI and 3 in no-murmur groups. In no patient did the form of the right atrial pressure curve reveal any signs of tricuspid incompetence. The mean right atrial pressure was increased abnormally in only 4 patients. The pulmonary arterial systolic pressure exceeded 30 mm Hg in 4 patients in the marked mitral incompetence group, in 4 patients with slight mitral incompetence and in 1 patient without mitral systolic murmur.

The form of the pulmonary capillary wedge pressure (Table 22) was abnormal at rest, suggestive of mitral incompetence in all the 6 patients in the marked mitral incompetence group but in only 3 patients in the slight mitral incompetence group. In 8 patients with slight MIMI, the form of the pulmonary capillary wedge pressure curve could not be differentiated from the normal, while in 1 patient (No 43) it was uncharacteristic of the left atrial pressure curve and invariably similar though taken from several pulmonary artery branches. In all the no-murmur patients the PCW form was normal though its pressure level might be high.

It is evident from the Table 21 and Fig 37 that in the marked mitral incompetence group the pressures were generally highly abnormal, but in several patients with slight mitral incompetence, the range was about the same as in patients without mitral incompetence. It is noteworthy




Fig 36 Cardiac index and arteriovenous oxygen difference obtained at cardiac catheterization.

Table 21 *Precursor response in pulmonary capillary wedge pressure at methoxamine test in 25 patients, no murmur 7 MIMI slight 12 MIMI marked 6*

	CONTROL			METHOXAMINE		
	Mean	S D	P	Mean	S D	P
Systolic systemic arterial pressure mm Hg						
No murmur	129	29		153	35	
MIMI slight	150	26		174	20	
MIMI marked	139	37	N S	154	42	N S
Heart rate beats/min						
No murmur	69	21		52	14	
MIMI slight	69	11		58	11	
MIMI marked	94	16	< 0.01	93	22	< 0.001
a wave mm Hg						
No murmur	15	4		20	5	
MIMI slight	16	5		22	7	
MIMI marked	32	9	< 0.001	39	7	< 0.001
v peak, mm Hg						
No murmur	14	4		14	5	
MIMI slight	15	6		15	10	
MIMI marked	34	15	< 0.001	36	17	< 0.001
y trough mm Hg						
No murmur	9	4		14	4	
MIMI slight	10	4		15	4	
MIMI marked	19	8	< 0.01	25	8	< 0.001
PCW mean mm Hg						
No murmur	10	3		15	4	
MIMI slight	11	4		16	5	
MIMI marked	26	8	< 0.001	34	9	< 0.001
Ry/s						
No murmur	2.1	0.7		1.7	0.5	
MIMI slight	2.0	0.9		1.9	0.8	
MIMI marked	4.0	0.8	< 0.001	5.0	1.1	< 0.001
Ry/meanPCW						
No murmur	3.0	0.9		2.3	0.9	
MIMI slight	2.5	0.9		2.8	1.3	
MIMI marked	5.9	1.5	< 0.001	7.6	1.8	< 0.001

N S non-significant

P values are based on F test

that though the pressures among the no-murmur patients had also slightly or, in two cases, appreciably risen compared to the normal values, the form of the pressure curve nevertheless remained normal. No

ventricularization type form of pulmonary capillary wedge pressure curve was ever detected at rest, but one appeared after a methoxamine test (Fig 38). Although the *v* peak was apt to reach the extreme




Fig 37 Values of v peaks, y troughs and means of the pulmonary capillary wedge pressure curves and their response to methoxamine in patients with and without mitral incompetence




Fig 38 Ventricular, aortic type response in the pulmonary capillary wedge pressure induced by methoxamine. Increased mitral regurgitant flow, also resulted in louder mitral systolic murmur. The rise of the systolic arterial pressure was only slight. Film speed 100 mm/sec



high of 40–60 mm Hg, it did not appear until rather late in systole (Fig 39).

*Indices of the PCIV pressure curve* The ratio of the velocity of the  $y$  descent to the  $v$  peak,  $Ry/v$ , and to the mean PCIV pressure,  $Ry/\text{meanPCW}$ , was highly abnormal in all the patients in the marked mitral incompetence group and normal

in all the members of the no-murmur group. In the patients with slight incompetence there was some variation between pathological and normal values. Generally, however, they were normal in this group, there being only 5 exceptions.

*Murmur intensity and type related to peak  $v$  wave pressure* No definite correlation with the height of the  $v$  peak and the intensity of the mitral systolic murmur was observed (Fig 40). For example, in the marked incompetence group, there was one patient with only a grade 1 plateau-type murmur and a  $v$  peak of 25 mm Hg, while in another with a grade 1–2 crescendo murmur, the  $v$  peak was 48 mm Hg (Fig 41), and otherwise one patient with a grade 4 murmur had a  $v$  peak of 20 mm Hg. All the murmurs in the marked MIMI group registered a pansystolic plateau or crescendo type, while in the members of the slight MIMI group all the four subtypes of pansystolic murmur — plateau, crescendo, decrescendo and crescendo-decrescendo — were observed.




Fig 40 Relation of the height of the  $v$  peak to the intensity of the mitral systolic murmur




Fig 39 The pulmonary capillary wedge pressure tracing shows a highly peaked late  $v$  wave further intensified by administration of methoxamine. The rise of the diastolic pressure level by methoxamine was significant but the increased mitral regurgitant flow pre-empted an acute pulmonary edema. Film speed 100 mm/sec.

## PHARMACODYNAMIC TEST

The heart rate (Table 21) was initially high (94) in marked mitral incompetence group and tended to slow down only insignificantly (93) after a methoxamine injection, in 2 patients it rose, the mean change being only  $-13 \pm 15.9\%$

In patients with a slight incompetence or none at all, the heart rate invariably slowed down, the mean change being  $-13.5 \pm 8.4\%$  and  $-24.1 \pm 10.7\%$  respectively. The differences were significant ( $p < 0.01$ ). No ectopic beats were observed as being produced by methoxamine.

The rise in systolic arterial pressure, (Table 21) again, was slightly lower in patients with marked mitral incompetence as compared to the patients with slight or no mitral incompetence. These differences however, were not significant. The increase was  $11.2 \pm 5.3\%$  in the marked mitral incompetence group,  $16.8 \pm 6.1\%$  in the group with slight incompetence, and  $18.4 \pm 4.8\%$  in the no-murmur group.

The arteriovenous oxygen difference was not determined systematically, but it increased in all the cases examined while the methoxamine maintained its effect.

Pulmonary capillary wedge pressures (Table 21, Fig. 37). The *a* wave rose slightly in all the patients, however, highly significantly in the marked MIMI group.

The rise in the *v* peak was appreciable in the patients with marked mitral incompetence. In one patient the *v* peak rose from 60 to 86 mm Hg in response to a small methoxamine dose (Fig. 39), this precipitated an immediate pulmonary edema which responded rapidly to the usual treatment. In patients in the slight mitral incompetence group, the rise was less steep.

In patients without any murmur, the rise in the *v* peak was slightest and concomitant with the increase of the whole PCW pressure level.

The rise in the *y* level, presumably reflecting a myocardial failure, was not so

conspicuous ( $p < 0.01$ ) as the rise in the *z* peak ( $p < 0.001$ ) among the patients in the marked mitral incompetence group when compared with the other groups (Fig. 37).

The change in PCW mean pressure was similar to that in the *y* level.

The ratio of the increment of the *v* peak to the increment of systolic arterial pressure,  $\Delta v / \Delta A$ , was invariably pathological in the marked incompetence group ranging from 70 to 250%, mean 128% (Fig. 42). In the group with slight incompetence, it ranged from 7 to 113% the mean being 46%. In 5 of the 11 patients (in 1 patient the test failed for




Fig. 42 Ratio of the increment of *v* peak to the increment of systolic arterial pressure ( $\Delta v / \Delta A$ ) in the methoxamine test. Dotted line represents the upper limit of the normal reported by Stanfield and Yu (1960).

technical reasons), it fell to a normal range below 35% (Stanfield and Yu 1960).

Among all but one of the no-murmur patients the ratio was normal (mean 29%), the single exception registering a value of 67%. This patient had marked heart failure and the whole PCW pressure level

Table 22 Influence of the pharmacodynamic test on the form of the pulmonary capillary pressure (PCW) curve and on mitral systolic murmur

CASE NUMBER	PRESSURE TRACING		PHONOCARDIOGRAPHY		AUSCULTATION	
	Form of the PCW pressure curve consistent with mitral incompetence		Murmur intensity enhanced by methoxamine		Character of the murmur	
	Control	Enhanced by methoxamine			Grade	Type
			Marked mitral incompetence			
				+	2-3	Plateau
	(+)	+		+	0-1	Plateau
51	+	+		+	3-4	Crescendo
67	+	+		+	4	Plateau-crescendo
121	(+)	+		+	4	Plateau
95	+	+		+	1-2	Crescendo
99	+	+		+		
84	+	+		+		
			Slight mitral incompetence			
				(+)	3	Crescendo-decrescendo
	(+)	+		+	2	Plateau
59	(+)	+		-	3	Crescendo-decrescendo
116	-	-		+	2	Plateau
43	-	(+)		+	2	Decrescendo
93	-	+		-	2	Decrescendo
40	(+)	+		(+)	1	Decrescendo
96	-	(+)		-	2	Decrescendo
41	-	-		(+)	2-3	Decrescendo
47	-	-		(+)	2	Ejection-decrescendo
85	-	(+)		+	2	Plateau
50	-	(+)		(+)		
92	-	-		-		
52	-	-		-		
			No mitral incompetence			
				-		No murmur
139	-	-		-		No murmur
140	-	-		-		No murmur
167	-	-		-		No murmur
44	-	-		-		No murmur
141	-	-		-		No murmur
161	-	-		-		No murmur
136	-	-		-		No murmur

+ marked  
(+) slight  
- none




Fig 41 Considerable alteration of the pulmonary capillary wedge pressure curve to the pattern of mitral incompetence in a patient with only a grade 1-2 high frequency crescendo pansystolic murmur (Fig 35). The murmur is barely visible in an external phonocardiography under the effect of methoxamine. Note loud third heart sound. Film speed 100 mm/sec

rose noticeably without causing the definitely normal form of the PCW curve to disappear

The indices of the pressure curve,  $R_3/v$  and  $R_3/\text{mean PCW}$ , increased among the patients in the mitral incompetence group, though slightly decreasing in 2 patients while among the no-murmur patients it decreased, with only 1 increase being registered

Form of the pulmonary capillary wedge pressure curve (Table 22) The characteristic form of the pressure curve observed in patients with mitral incompetence was invariably intensified by methoxamine in the marked mitral incompetence group (Fig 43). In the no murmur group the normal form of the curve occasionally became more clear cut as the amplitudes rose slightly but in no instance did it deviate from the normal form in the direction of mitral incompetence by a rise in the  $v$  peak in relation to the  $a$  peak or by a rise in the  $x$  level (Fig 44). By contrast, in the slight mitral incompetence group the initial tracing indicating mitral incompetence was further augmented in

all 3 patients while in 5 patients with mitral systolic murmur exhibiting the normal form of pressure curve at rest, it changed to one indicating mitral incompetence only after a methoxamine infusion (Figs 45 and 46). In 3 patients included in the slight MIMI group no definite change occurred in the normal PCW pressure curve apart from a general rise in the pressure level

The phonocardiogram tracings (Table 22) showed increased murmur intensity in all the 6 patients with marked mitral incompetence and in 9 of the 12 patients in the slight mitral incompetence group (Figs 38, 39, 41, 43). 3 patients in the latter group developed no observable intensification of the apical systolic murmur. However, one of them did have a typical PCW pressure curve consistent with mitral incompetence as further enhanced by methoxamine. One patient (No 43) registered an uncharacteristic PCW curve, but on the third day after the onset of the infarction he had developed a constant grade 3-4 apical pansystolic murmur, and fluoroscopy revealed a rapid early




Fig 43 Methoxamine induced alterations suggestive of mitral incompetence, observed in external phonocardiography and in a pulmonary capillary wedge pressure (PCW) curve. The murmur intensity was markedly increased, decrescendo type in the control tracing was changed to plateau-erescendo with an extension of the murmur over second heart sound (arrows). Initially the completely normal PCW curve lost the x descent and developed a high peak and a steepened y descent, changes being clearer with increasing dose of the drug. A conspicuously elevated diastolic pressure level was interpreted to indicate acute left ventricular failure. Film speed 100 mm/sec




Fig 44 Pulmonary capillary pressure in a patient without mitral systolic murmur. The methoxamine administration did not change the normal form of the curve. The reflex bradycardia was marked. Film speed 100 mm/sec




Fig 45 Change of the normal pulmonary capillary pressure curve to the pattern suggestive of mitral incompetence (heightening of the x peak) by methoxamine in a patient with a slight mitral incompetence. Film speed 100 mm/sec




Fig 46 Left ventricular cardioangiography reveals the very thin posterior wall of the left ventricle (dotted lines). A marked paradoxical pulsation was present (Fig 23 the last tracing). The pharmacodynamic test resulted in a clear elevation of the *v* peak characteristic of mitral incompetence. Film speed 25 mm/sec.

systolic expansion of considerable amplitude of the left atrium. Mitral incompetence thus seemed probable. Another patient (No 47) who exhibited no changes of pressure or murmur intensity in the pressor amine test had developed a constant apical pansystolic high frequency grade 3 murmur on the 16th day after the onset of infarction, thus the only finding that pointed to mitral incompetence was the characteristic murmur.

**Left ventricular cardioangiography.** For reasons explained earlier (Methods) left ventricular angiography was performed only once. Right sided catheterization had confirmed clinically slight to moderate mitral incompetence in this patient. The left ventricle was entered retrogradely via the femoral artery by application of the Seldinger (1953) technique. Pictures were taken in the right oblique position using the serial exchanger with a maximum speed of 6 frames a second. No visible regurgitant jet was observed but the posterior

wall of the myocardium was conspicuously thinned (Fig 46) and the posterior mitral leaflet seemed to bulge toward the left atrium during the systole.

## DISCUSSION

**Degree of hemodynamic changes.** Evidence of a markedly varying degree of mitral incompetence could be obtained in 16 of the 18 MIMI patients included in the hemodynamic investigation. This result was accomplished by means of a pulmonary capillary wedge pressure curve determination and of pharmacodynamic phonocardiography. Changes characteristic of mitral incompetence were disclosed in 6 patients only by the infusion of methoxamine which augmented the regurgitation (Leighton *et al* 1966).

The results of the hemodynamic study at rest showed that in all 6 patients classified as having a marked regurgitation the hemodynamic disturbance was fairly

severe. The manifestations were a clearly altered PCW pressure curve and unequivocal signs of left-sided heart failure, hyperventilation, tachycardia, an increased arteriovenous oxygen difference, a lowered or low normal forward cardiac index, and a conspicuously depressed forward stroke volume. The pulmonary vascular resistance was not generally raised, reflecting a rise in the observed elevated pulmonary artery pressure, to have been induced passively by the regurgitation. The signs of right-sided heart failure were rare.

In contrast, in patients with only slight mitral incompetence, the hemodynamic changes varied in degree and proved mostly to be minor ones, approaching the findings observed in patients without mitral incompetence.

The patients without mitral incompetence were characterized by changes consistent with left-sided heart failure of varying degrees.

*Pulmonary capillary wedge pressure curves* in patients with clinically marked mitral incompetence were characteristic of significant mitral regurgitation. Although the  $v$  peaks were often high, they occurred late in systole, with a normal  $x$  descent position (Nixon and Wagner 1962). Only once was a ventricularization type of pressure curve observed after a pressor amine test (Raferty *et al.* (1966), in their acute subvalvar mitral incompetence series, noted the same phenomenon, and their explanation of "tight incompetence" with severe regurgitation to a normal-sized uncompliant left atrium is evidently also in agreement with the present investigation.

A low level of  $v$  peak does not always indicate slight regurgitation, in that compliance of the left atrium and its pressure-volume characteristics can definitely alter the response (Ross *et al.* 1960, Braunwald and Awe 1963, Werko 1964, Raferty *et al.* 1966). At low atrial pressure levels, the  $v$  peak may be only insensitively altered by a substantial regurgitant flow. At an

increased mean pressure level, the rise in the  $v$  peak caused by regurgitation appears more readily.  $V$  peaks exceeding  $a$  waves have been reported as occurring in left ventricular failure or pulmonary hypertension without evidence of mitral incompetence (Lagerlof and Werkö 1949, Eliasch 1952). Otherwise, Jacono *et al.* (1961) observed signs of acute mitral incompetence in experimental pulmonary edema precipitated by a rise in systemic arterial pressure.

In the present study,  $v$ -wave changes were associated with the murmur of mitral incompetence, both of which usually were altered characteristically by methoxamine. In no murmur patients with marked heart failure, oscillations of the  $m$  and  $n$  peaks exceeded the normal but did not have any shallowing of the  $x$  descent or peaking of the  $s$  wave substantially higher than the  $a$  wave. (In this laboratory direct or indirect left atrial pressure curves simulating mitral incompetence have not been encountered in patients studied for aortic valve disease if mitral incompetence actually could not be demonstrated.)

These inaccuracies of pressure curve analysis again emphatically illustrate the value of an effective left ventricular cine cardiography in the study of the mode and grade of the mitral regurgitant flow.

The level of the  $y$  trough, reflecting left ventricular diastolic pressure, was generally above normal. This is generally assumed to be a sign of left ventricular failure, although other factors involved in ventricular dynamics might elevate it (Braunwald and Ross 1963).

*Methoxamine test.* The value of the methoxamine test in making slight mitral incompetence recognizable by increasing the intensity of the murmur and by inducing typical pressure curve alterations was clearly demonstrated in the present study when applied to patients, the level and form of whose initial pulmonary capillary wedge pressure curves were quite normal.

By its lack of an inotropic effect, methoxamine by increasing the pressure load of the heart augments any underlying signs of heart failure (Harrison *et al* 1964). In the present study, a failing heart often increased the arterial blood pressure only slightly when peripheral resistance increased and, instead of reflex bradycardia, the acutely provoked heart failure resulted in tachycardia. This response was observed in certain patients with only marked mitral incompetence. Exceptionally, it is also apt to lead to erroneous interpretations of the methoxamine test as indicating mitral incompetence, when the left atrial pressure and the  $v$  peak rise noticeably in conjunction with only a slight rise in the systemic arterial pressure, if the form of the left atrial or PCW pressure curve is not simultaneously analyzed. Changes in the  $R_2/v$  and  $R_1/\text{meanPCW}$  ratios clearly differed in different directions in patients with and without mitral regurgitation.

The potential danger in using the pressor amine test, especially a drug without any inotropic effect, is related to the powerful way it increases the mitral regurgitant flow. This was observed in one patient who developed acute pulmonary edema after a small dose of methoxamine.

*Murmur type and intensity.* The murmurs in patients with hemodynamically marked mitral incompetence were of the pansystolic plateau or crescendo type, and in patients with slight regurgitation mainly of the plateau or decrescendo type (Table 22). This confirmed the earlier clinical impression (Chapter VI).

The poor correlation of the murmur intensity to the degree of regurgitation was remarkable. In two patients with marked incompetence the murmur intensities were only grade 1 and grade 1-2. This finding agrees with the importance of the stream velocity in the generation of a murmur (Bruns 1959, Rodbard 1964). Obviously, only a faint murmur is generated by the large regurgitant stroke

volume ejected slowly through a widely gaping orifice (Schrirer *et al* 1961). The velocity of the ejection is further retarded in MIM patients by the reduced contractile speed of the damaged myocardium (Gleason and Braunwald 1964).

*The dynamics of regurgitation.* The determinants of the mitral regurgitant stroke volume are the size of the leaking opening, the contractility of the left ventricle, the systemic arterial resistance and the inertia of the blood (Wiggers and Feil 1922, Rodbard and Williams 1954, Braunwald *et al* 1957, 1958, Jose *et al* 1964).

In myocardial infarction, the waste of the contractile energy must be an important factor in augmenting mitral regurgitation. The regurgitant volume again adds a strain to the damaged myocardium and the consequent dilatation further impairs the ventricular function curve (Sarnoff and Berglund 1954, Case *et al* 1954). This series of events could be a dynamic counterpart to the structural mechanism of mitral incompetence begetting mitral incompetence proposed by Levy and Edwards (1962). This probable dynamic mechanism might accelerate the rapid, often fatal deterioration of the pumping capacity of the heart when acute significant mitral incompetence is superimposed on an acutely damaged failing left ventricle.

On the other hand, the remarkable tendency of the mitral incompetence brought on by ischemic damage to the muscular supporting structures of the mitral valve to lessen or disappear, was observed in the follow up study. This might also be attributed to a slow gain of better myocardial contractility after the acute phase had subsided. The related factors are probably a diminishing of the ischemic and edematous paralyzed area of the myocardium by the healing process and perhaps the development of collateral circulation (Chapter VI). These circumstances suggest that the condition of the wall of the left ventricle has con-



siderable significance in the mechanism of MIMI, in addition to the varying degree of anatomical destruction sustained by the papillary muscle itself

*To sum up* the hemodynamic severity of the mitral incompetence which develops after acute myocardial infarction can vary in degree from the barely detectable to the extremely severe even without rupture of the papillary muscle. The

severity of the regurgitation cannot be predicted from the intensity of the murmur. Hemodynamic changes caused by the infarct *per se* add to the difficulty of estimating the degree of mitral incompetence. The depressed function curve of the ischemic myocardium might be an important factor in determining the amount of regurgitation in addition to the structural destruction of the muscular support of the mitral valve itself.

## AUTOPSY FINDINGS

## MATERIAL AND METHODS

## MATERIAL

Out of the total of 187 patients 34 died in hospital. In 30 of the cases it was possible to examine the heart at autopsy. 19 of them had had an acute mitral systolic murmur, while the remaining 11 had had none. One patient (No 190) with mitral incompetence that had developed during the previous infarction (group 3) was also examined. The time of death was about the same in both groups and varied between 3 to 53 days after the onset of infarction, the mean being 17 days. The murmur of mitral incompetence had appeared at various times between the 1st and the 17th day, in 3 patients it was present on admission to hospital (see p. 34).

One patient (No 51) who died one and half years after myocardial infarction and development of mitral incompetence was also examined at autopsy.

## METHODS

The grade of anatomical stenosis in the main trunks of the coronary arteries was determined by carefully opening them all the way to the periphery according to the technique presented by Hudson (1962). The following classification was used:

- 0 — no changes
- 1 — stenosis of the lumen not filling half of it
- 2 — change obstructing 50 % or more of the lumen
- 3 — total occlusion

The site of any recent coronary occlusion was noted. The predominance of the coronary artery

distribution was determined according to the relation of the right coronary artery and the left circumflex branch to the crux of the heart as right balanced or left dominated (Schlesinger 1940).

The heart valves were then studied: the atrio-ventricular valves via the opened atria and after cutting the apex cup transversally to determine the state of the mitral leaflets, chordae tendinae and papillary muscles *in situ* before opening the heart further. In order to determine accurately the site of the myocardial infarct, the heart was cut perpendicular to the long axis of the left ventricle into 5 or 6 transversal slices. The site of recent and earlier infarction changes was ascertained and the size indices calculated from the measured length and width of the lesions. The macroscopic state of the right and left ventricular papillary muscles was examined. The mitral annulus was measured with a conical device and again after the annulus was cut open. The left and right ventricular wall thicknesses were measured. Attention was further paid to the occurrence of mural thrombosis, ventricular aneurysm, mitral annulus calcification and of pericarditis.

After the macroscopic examination of the heart both papillary muscles were fixed in formalin and after processing embedded in paraffin. The slides were prepared on 3 or 4 different transversal levels from the up-rud portion and base of both papillary muscles and stained by the van Gieson technique. All hearts except one (No 4) were examined by the author. The histologic preparations were examined without any knowledge of the name of the patient concerned. An experienced pathologist also studied the slides for evidence of necrosis in the papillary muscles.

## RESULTS

The results of the autopsy examination of the hearts are presented in Table 23. The following main findings and deductions were made:

Table III Autopsy findings

Case number	Bed no.	Right	Left	Left desc	Coronary artery occlusion	Coronary artery predominance	Site of vessel infarct	Size index of infarct	Extent of section of papillary muscle		Heart weight g	Thickness of left ventricular wall mm	Circumference of infarct mm	Disease of mitral valve	Calcification of mitral annulus	Aneurysm	Mitral rhegmatism	Pericarditis
									Anterior	Posterior								
1	7	3	2	2	Right	Right	Post sept + ant	56	+	+	550	15/5	110	—	—	—	—	+
2	7	1	1	3	Left ant desc	Right	Anteroseptal	35	—	—	440	13/6	108	—	—	—	—	+
3	4	2	2	1	Right + left desc	Right	Posterior	35	+	+	470	15/6	110	—	—	—	—	+
4	11	0	0	2	Left ant desc	Right	Anteroseptal	56	+	+	720	25/5	norm	—	—	—	—	—
5	8	2	1	1	Right	Right	Posterior	20	+	+	500	20/5	112	—	—	—	—	—
6	47	2	3	3	Left ant desc + circ	Balanced	Anteroseptal	14	—	—	400	16/5	112	—	—	—	—	—
7a	4	2	0	3	Left ant desc	Right	Anteroseptal	20	+	+	410	14/5	95	—	—	—	—	—
8	3	3	2	3	Right	Right	Postero epial	48	+	+	670	25/6	120	—	—	—	—	—
9a	3	3	2	3	Right + left ant desc	Right	Posterior + ant	78	+	+	530	15/5	116	—	—	—	—	—
10	13	3	1	0	Right	Right	Posterior	16	—	—	470	14/5	117	—	—	—	—	—
11	6	3	0	0	Right	Right	Posterior	30	+	+	415	14/5	100	—	—	—	—	—
12	16	1	2	2	Left ant desc + circ	Left	Posterior	42	+	+	630	20/4	115	—	—	—	—	—
13	51	3	0	2	Right	Balanced	Anteroseptal	36	—	—	810	26/5	115	—	—	—	—	—
14	3	1	1	1	Right	Right	Posterior	64	+	+	585	20/5	128	—	—	—	—	—
15	4	2	2	2	Left ant desc	Balanced	Anterior + post	9	+	+	150	16/5	114	—	—	—	—	—
16	53	3	1	1	Right	Right	Posterior	64	+	+	400	15/7	105	—	—	—	—	—
17	8	2	3	2	Left circ	Balanced	Posterior	49	+	+	480	16/5	115	—	—	—	—	—
18	11	3	1	3	Left circ	Left	Lateral	36	+	+	530	17/5	108	—	—	—	—	—
19	8	2	3	2	Left ant desc	Balanced	Anterolateral	40	+	+	390	15/4	90	—	—	—	—	—

*Posterior + ant*






Fig 47 A set in an anterior plane from the heart of a patient with an acute mitral incompetence following myocardial infarction. The posterior papillary muscle (P) is damaged by an extensive posterior infarction. Photographs at low power (3 x) and at greater magnification (80 x) of the posterior papillary muscle reveal an extensive destruction with coagulation necrosis and nuclear debris (van Gieson). L = anterior papillary muscle. R = right ventricle. LV = left ventricle.




Fig 48 A section in an anterior plane from the heart of a patient with aortic stenosis. An extensive aneurysm has not reached the anterior papillary muscle due to its very lateral position in the left ventricle. A lower power (3x) photomicrograph shows placement of only a small medial segment (arrow) of the anterior papillary muscle. At greater magnification (80x) only a patchy network of the muscle fibers was evident (see Fig 47). For abbreviations see Fig 47.

(Fig 47), and when the infarct was anteriorly situated in the MIMI group the anterior papillary muscle was often significantly damaged. In the no murmur group, although an anterior myocardial infarct might be quite extensive, it did not reach the anterior papillary muscle in 8 cases, and involved it only partially on the anteromedial side in 3 cases (Fig 48, Table 24).

These macroscopic findings, which established an infarct reaching or failing to reach the papillary muscle, were thus quite strongly correlated ( $p < 0.01$ ) to the observed presence or absence of a mitral systolic murmur.

The correlation between the pathologic anatomical and electrocardiographic estimates of the site of a myocardial lesion was good.

The size index of recent myocardial wall damage was slightly, but non significantly, higher in the MIMI group,  $40 \pm 19 \text{ cm}^2$ , the corresponding observation for the no murmur group being  $34 \pm 22 \text{ cm}^2$ .

The heart weight was usually above normal, the mean being  $526 \pm 37 \text{ g}$  in the MIMI group and  $483 \pm 35 \text{ g}$  in the no murmur group. The difference between the groups was significant ( $p < 0.01$ ).

The left ventricular wall had a mean thickness of  $17 \pm 2 \text{ mm}$  in the MIMI group and  $16 \pm 2 \text{ mm}$  in the no murmur group. The difference was non significant. In 3 MIMI and 3 no murmur cases the right ventricle was thicker than 5 mm.

The mitral valve exhibited no pathological changes except for occasionally small degenerative nodules in the valve leaflets. No chordal rupture or other damage was detected.

**The mitral annulus** The circumference of the mitral annulus was the same — and within a normal range — in both the mitral incompetence and no-murmur groups. In the MIMI group it ranged 95–128 mm with a mean of 110 mm and in the no murmur group 98–128 mm, the mean being 112 mm.

**Other findings** A definite ventricular aneurysm of medium size was detected in two cases involving mitral incompetence and one with no murmur. Pericardial affection was observed in 5 MIMI patients and in 4 patients belonging to the no murmur group (total 30 %). Severe mitral annular calcification was present in one case (No 7). Heart rupture occurred in 3 cases in the MIMI group, 2 of them in the posterior upper wall and the 1 in the anterior lower wall. Mural thrombosis was a common finding despite the prompt initiation of anticoagulant therapy. It was found in 53 % of the autopsy examinations. Left ventricular mural thrombosis usually apical was present in 53 % of the patients in the MIMI group and in 55 % of the members of the no murmur group. In no case were signs detected of the mural thrombus having anatomically prevented closing of the mitral valve leaflets.

#### PATHOLOGY OF PAPILLARY MUSCLES

Patients with the murmur of mitral incompetence developing during the clinical course. Appreciable, macroscopically visible necrosis affecting over half the papillary muscle mass was present in 16 of 19 patients (84 %). These changes were noted in 12 cases (75 %) in the posterior, in 8 cases (50 %) in the anterior, and in 4 cases (25 %) in both papillary muscles.

Three of the patients had no visible necrosis in the papillary muscles. In one case (No 12), the murmur of mitral incompetence developed after electrocardiographic evidence of the progression of a recent inferior infarct to the inferoseptal region had been observed, the patient died of pulmonary edema 6 hours later. In another patient (No 6) a macroscopically healthy (but microscopically somewhat necrosed) anterior papillary muscle was attached to the site of a moderate sized aneurysm resulting from a recent anterior infarct (Fig 49).

Table 24 *Degree of the structural destruction of the papillary muscles of the left ventricle in patients who died in hospital*

Case number	Macroscopic necrosis		Microscopic necrosis		Remarks
	Anterior	Posterior	Anterior	Posterior	
<i>Patients with acute mitral incompetence</i>					
1	—	+	—	+	
2	+	—	+	+	
3	—	+	+	+	
4	+	+	+	+	
5	—	+	+	+	
6	—	—	+	—	Papillary muscle attached to site of aneurysm
7 a	+	—	+	+	
8	—	+	+	+	
9 a	—	+	+	+	
10	—	+	—	—	
11	—	+	+	+	
12	—	—	—	—	Died 6 hours after development of MIMI
13	—	—	(+)	(+)	Transient murmur
14	—	+	+	+	Transient murmur
15	+	—	+	—	
16	+	+	+	+	
17	(+)	+	+	+	
18	+	+	+	+	
19	+	—	+	+	
<i>Patients without mitral incompetence</i>					
20	—	—	(+)	(+)	
21	—	—	—	—	
22	(+)	—	(+)	(+)	Only tip of papillary muscle necrosed
23	—	—	+	—	
24	—	—	—	—	
25	—	—	—	—	
26	(+)	—	(+)	—	Segmental necrosis
27	—	—	(+)	—	
28	—	—	(+)	(+)	
29	(+)	—	(+)	(+)	Segmental necrosis
30	—	—	(+)	(+)	

+ total or subtotal

(+) scattered lesions less than half of cross section areas

— normal finding

The third patient (No 13) had only a transient murmur

No case of total disruption of the papillary muscle appeared. One patient (No 17) had a partially ruptured and consequently considerably elongated posterior papillary muscle. This change was

ascribed to the sudden inception of a loud murmur of grade 4 indicative of mitral incompetence 5 days after the onset of infarction (Fig 50). Death was caused by pulmonary edema resistant to treatment.

The heart of one patient with mitral



(Fig 47), and when the infarct was anteriorly situated in the MIMI group the anterior papillary muscle was often significantly damaged. In the no-murmur group, although an anterior myocardial infarct might be quite extensive it did not reach the anterior papillary muscle in 8 cases, and involved it only partially on the anteromedial side in 3 cases (Fig 48, Table 24).

These macroscopic findings, which established an infarct reaching or failing to reach the papillary muscle, were thus quite strongly correlated ( $p < 0.01$ ) to the observed presence or absence of a mitral systolic murmur.

The correlation between the pathologic anatomical and electrocardiographic estimates of the site of a myocardial lesion was good.

The size index of recent myocardial wall damage was slightly, but non significantly, higher in the MIMI group  $40 \pm 19 \text{ cm}^2$ , the corresponding observation for the no-murmur group being  $34 \pm 22 \text{ cm}^2$ .

The heart weight was usually above normal the mean being  $526 \pm 37 \text{ g}$  in the MIMI group and  $483 \pm 35 \text{ g}$  in the no-murmur group, the difference between the groups was significant ( $p < 0.01$ ).

The left ventricular wall had a mean thickness of  $17 \pm 2 \text{ mm}$  in the MIMI group and  $16 \pm 2 \text{ mm}$  in the no murmur group. The difference was non significant. In 3 MIMI and 3 no-murmur cases the right ventricle was thicker than 5 mm.

The mitral valve exhibited no pathological changes except for occasionally small degenerative nodules in the valve leaflets. No chordal rupture or other damage was detected.

**The mitral annulus.** The circumference of the mitral annulus was the same — and within a normal range — in both the mitral incompetence and no-murmur groups. In the MIMI group it ranged 95–128 mm with a mean of 110 mm and in the no murmur group 98–128 mm, the mean being 112 mm.

**Other findings.** A definite ventricular aneurysm of medium size was detected in two cases involving mitral incompetence and one with no murmur. Pericardial affection was observed in 5 MIMI patients and in 4 patients belonging to the no-murmur group (total 30 %). Severe mitral annular calcification was present in one case (No 7). Heart rupture occurred in 3 cases in the MIMI group, 2 of them in the posterior upper wall and the 1 in the anterior lower wall. Mural thrombosis was a common finding despite the prompt initiation of anticoagulant therapy. It was found in 53 % of the autopsy examinations. Left ventricular mural thrombosis, usually apical was present in 53 % of the patients in the MIMI group and in 55 % of the members of the no murmur group. In no case were signs detected of the mural thrombus having anatomically prevented closing of the mitral valve leaflets.

#### PATHOLOGY OF PAPILLARY MUSCLES

*Patients with the murmur of mitral incompetence developing during the clinical course.* Appreciable, macroscopically visible necrosis affecting over half the papillary muscle mass was present in 16 of 19 patients (84 %). These changes were noted in 12 cases (75 %) in the posterior, in 8 cases (50 %) in the anterior, and in 4 cases (25 %) in both papillary muscles.

Three of the patients had no visible necrosis in the papillary muscles. In one case (No 12), the murmur of mitral incompetence developed after electrocardiographic evidence of the progression of a recent inferior infarct to the inferoseptal region had been observed, the patient died of pulmonary edema 6 hours later. In another patient (No 6) a macroscopically healthy (but microscopically somewhat necrosed) anterior papillary muscle was attached to the site of a moderate sized aneurysm resulting from a recent anterior infarct (Fig 49).




Fig 50 Phonocardiogram and auscultation findings from a 58-year-old male who developed a haemoglobinemia of the lungs (S4) at the apex 5 days after the onset of the infarction. The data lae de haemoglobinemia was caused from intractable pulmonary edema. An infarction of the right ventricle (ECG in Fig 31) was found to be partially ruptured (arrow). Phonocardiograms (28 and 58 x) repeated during the course of the postoperative pulmonary embolism. Anterior pulmonary embolism (A) = also partially damaged by infarction.

infarction. No other consistent differences except location of the infarction were observed in the autopsy findings between patients with and those without mitral incompetence.

The mitral annular circumferences were within normal values in both groups excluding the annular dilatation mechanism of regurgitation.

There was a rather high prevalence

of mural thrombosis. It was usually apical, however, and no part of the thrombus was found upon examination in any patient to reach between the mitral valve leaflets and thereby prevent the right apportion — which was one possibility in a case described by Soule and Gerbeaux (1939). Further, the relative occurrence of mural thrombosis was about the same in patients without a murmur.



Fig 51 Fibrotic changes in the anterior (A) and posterior (P) papillary muscles resulting from previous infarction. The development of MI/II (Fig 50) was followed by a steadily progressing heart failure with markedly enlarged heart volume (Fig 33). Mitral incompetence was confirmed at cardiac catheterization (Fig 38). Circumference of the mitral annulus was 9.5 cm. In addition the anteroapical region was occupied by a 2.5 cm thick organized mural thrombus (T). Photomicrograph shows an extensive fibrosis of the anterior papillary muscle (3 x van Gieson).

Mitral incompetence was mainly associated with the presence of a posterior infarct. The occurrence of an anterior infarct with one exception in all the patients without mitral systolic murmur was remarkable.

The critical factor in the development of mitral incompetence in the present investigation seemed to be the presence or absence of significant destruction of one or both papillary muscles by the infarct or distention of its attachment site by an aneurysm forming in the left ventricular wall (Burch *et al* 1963).

Another theoretical mechanism could be the loss of active contractility of the

mitral orifice (Hurvitt 1953, Davis and Kinmonth 1963) through muscular damage to the base of the ventricle. This functional loss of the annular area of the left ventricle can sometimes lead to mitral incompetence without dilatation when it is immobilized by massive calcification (Simon and Liu 1954, Korn *et al* 1962). However in many cases both posterior and anterior infarcts were situated rather low in the ventricular wall. Thus, the only pathologic anatomical factor intimately related to mitral incompetence was ischemic papillary muscle damage resulting from infarction.

### *Importance of site and extent of infarct*

The location of an infarct and its relation to the topographical position of especially the anterior papillary muscle in the left ventricle was of decisive importance in the development of mitral incompetence (Figs 47 and 48)

Posterior or inferior infarct almost invariably involves the posterior papillary muscle (Arkhangelsky 1959) which lies posteriorly near the junction of the free ventricular wall and the interventricular septum

Otherwise the topographical position of the anterior papillary muscle lies on the anterolateral free wall of the left ventricle. This position was observed not to be constant but remarkably varied in the present study. The anterior papillary muscle does not usually lie at the point opposite to the posterior papillary muscle but more or less laterally. In some instances, the anterior papillary muscle was found to have a conspicuously lateral position so that the lines connecting the posterior and anterior papillary muscles to the midpoint of the left ventricular cavity almost formed a right angle (Fig 48)

This marked topographical variation in the position of the anterior papillary muscle could explain the fact that it is possible to have an extensive anterior myocardial infarct destroying nearly half the left ventricular wall circumference but still not involving the anterior papillary muscle if it is situated in a very lateral position (Fig 48). Consequently, no mitral incompetence develops. If the anterior papillary muscle was more medially situated it might more easily be involved by an antero-septal or anterior infarct extending more or less to the free wall of the left ventricle.

In posterior infarction this variability of the position of the papillary muscle proved to be only negligible; its more medial position almost always ensures that it is involved in posterior infarction.

In purely lateral infarcts, the anterior papillary muscle would be more commonly included in the area of the infarct. This location of infarct, however, seems to be rare (Johnson *et al* 1959).

Although in the MIMI group the size index of myocardial lesions was slightly higher, a small infarct involving the papillary muscle could produce mitral incompetence as easily as an extensive infarct. This is comparable to the frequent occurrence of MIMI in patients with subendocardial infarction, as observed in clinical series. All the patients had transmural or intramural lesions at autopsy.

*Degree of papillary muscle destruction* The development of mitral incompetence seemed to demand the destruction of a large portion of the papillary muscle. In 3 of the 11 patients without murmur of mitral incompetence, macroscopic evidence of necrosis in the anterior papillary muscle was observed. The area of necrosis was, however, segmental and involved only a minor part of the papillary muscle with the main bulk of muscle remaining unaltered (Fig 48).

Two patients in the MIMI group without conspicuous papillary muscle necrosis had only a transient murmur of mitral incompetence which could be explained by borderline ischemic dysfunction of papillary muscle without total or permanent function loss (Burch *et al* 1963) or by acute transient dilatation of the heart pulling down the papillary muscles. The end result of papillary muscle destruction by infarction is total fibrosis and function loss of scarred contracted papillary muscle (Fig 51) causing permanent regurgitation (Soulie *et al* 1966; Marton 1966). On the whole, mitral incompetence developed at the time when the most severe necrotic myocardial changes had occurred. This is not an immediate consequence of a curtailment of the blood supply (Bargmann and Doerr 1963). The same tendency

has been noted in instances of papillary muscle rupture or ventricular septal perforation by an infarct (Chapter II)

*Blood supply of papillary muscles* The three major coronary artery trunks supplying the papillary muscles have been clearly described (Gross 1921, Spalteholz 1924, Bosco 1935), as have recently the vascular channels at the intramyocardial level (Fulton 1965, James 1965, Estes *et al* 1966). The anterior papillary muscle is supplied chiefly by the left circumflex coronary artery and to some extent by the left anterior descending branch. The circulation to the posterior papillary muscle is more variable, depending on the distribution of the "coronary artery predominance" (Schlesinger 1940). Blood to the posterior papillary muscle is mainly supplied by the right coronary artery, as the pattern of right predominance is far more common than the left (Campbell 1929, Schlesinger 1940, Fulton 1965, Lkoff *et al* 1965). In left predominance, the left circumflex coronary artery serves the branches to the posterior papillary muscle. This effect of the predominance of coronary circulation explains the frequent involvement of the posterior papillary muscle by occlusion of the right coronary artery.

The mode and type of smaller vessels entering the papillary muscles of the left ventricle from the epicardial coronary arteries have been penetratingly revealed by the micro-radiographic technique in the studies of Fulton (1965) and Estes *et al* (1966). The epicardial arteries are arborized perpendicularly to the main vessel and these branches then plunge into the myocardium. Two types of smaller intramyocardial vessels can be recognized. The branches can rapidly divide into smaller vessels forming a fine meshwork of vessels 400 to 1500 microns in diameter (Class A vessels of Estes *et al*), after which these divide further within the area of the outer two-thirds of the myocardium. Other large branches

(Class B) extend in the direction of the ventricular cavity, with only slight forking and without narrowing the lumen. These vessels enter the extensive subendocardial network of the large caliber vessels.

The papillary muscles derive their circulation from the penetrating arteries directly from the epicardial arterial trunks and the subendocardial plexus. Each papillary muscle is supplied by several vessels in a segmental manner. Generally the tip, mid portion and base of the papillary muscles receive their own large artery from the epicardial arteries, which also extend branches to the subendocardial plexus. Occasionally, the many folds of the trabeculae between the papillary muscle and the myocardial wall carry these vessels to the papillary muscle.

In a myocardial infarct, the vascular supply of the papillary muscles is stopped by the obstruction of class B vessels, which results in extensive destruction of papillary muscle. Some circulation can take place from the subendocardial plexus of anastomoses (Mitchell and Schwartz 1963, Fulton 1965, Estes *et al* 1966).

In older patients, nonspecific fibrosis of unknown cause is often scattered through the myocardium and the papillary muscles. This is in many instances associated with thickening of the small vessels and an anastomotic overgrowth of the class A vessels (Mitchell and Schwartz 1963, Estes *et al* 1966), but the large vessels penetrating to the papillary muscles remain unaltered.

The segmental blood supply to papillary muscles could obviously explain the findings of partial destruction of the papillary muscles, as observed in some of the hearts in the no-murmur group. Thus, a small, medial, infarcted segmental portion could have been supplied by an occluded anterior descending branch but the main portion was saved structurally and functionally by an uninterrupted main supply of blood from

the left circumflex artery. This varying extent of necrosis was not observed in the posterior papillary muscle to the same extent, destruction of the posterior papillary muscle was usually fairly complete. The observation that the anterior papillary muscle has a better collateral circulation than the posterior papillary muscle (James 1965) agrees well with the clinical and autopsy findings of the present study.

*To sum up* the findings at autopsy indicated the importance of marked

ischemic papillary muscle destruction in the development of mitral incompetence as a consequence of acute myocardial infarction. The site of a myocardial infarct in relation to the papillary muscles determines the extent of the damage of muscular structures necessary for competent closure of the mitral valve during systole. The more frequent and extensive damage sustained by the posterior papillary muscle is due to the topographical position and the peculiarities of the blood supply to each of the papillary muscles.

## FOLLOW-UP STUDY

## PATIENTS AND EXAMINATION

## PATIENTS

An effort was made to arrange follow up examinations for all patients discharged from hospital, in order to observe the permanence and characteristics of the murmur of mitral incompetence as well as the effect of permanent mitral incompetence on the clinical features.

The follow up examinations were carried out between 2-11 months after the onset of infarction, the period was generally 6 months. For practical reasons it was not possible to fix the same period for the follow up examination of all patients.

88 of the 117 patients who had been found to have developed mitral incompetence in connection with myocardial infarction during the period of hospital observation, and 53 of the 70 members of the no-murmur group reported for follow up examination. 21 MIMI and 13 no-murmur patients had died in hospital between the time of discharge from hospital and the period of follow up examination; the deaths were 5 and 1, respectively. In the MIMI group there were 3 patients Nos 7, 7a, 9 9a and III 81a) who were soon rehospitalized because of reinfarction and were included in the patient series. These 3 were excluded from the follow up study of first infarctions because only a few weeks had elapsed since infarction.

## EXAMINATION PROCEDURE

The patients attended the outpatients' clinic. The same research methods were employed as during the period of hospital observation. In recording the case histories, attention was paid to the degree of angina pectoris, congestive heart failure and the use of digitalis. In the physical examination, signs of congestive heart failure were looked for, the heart was palpated to reveal any paradoxical pulsation and auscultated for the presence of murmurs and gallop sounds. The blood pressure was measured with the patient in a supine position at the final stage of the examination. Conventional 12 lead electrocardiogram and phonocardiographic tracings were taken by the author from all the patients after which a chest teleroentgenogram examination was performed by the Radiological Department.

## RESULTS

## INCIDENCE OF PERMANENT MITRAL INCOMPETENCE

In the MIMI group there were 102 patients with permanent mitral incompetence at death or on discharge from hospital. 15 patients had had only a transient murmur during hospitalization. Of 83 patients with murmur of mitral incompetence on discharge 75 participated in the follow up study (2 having died, 3 not reporting for examination and 3 having been excluded for reasons given in the foregoing).

The murmur was found to persist in 53 patients and to have disappeared in 20 (27%). Accordingly the murmur was observed to be transient — already disappearing in hospital or within the next few months — in a total of 33 patients out of 117 (30%).

Of the 70 patients with no mitral systolic murmur (group 2) 33 patients participated in the study. 46 of them were still without a murmur — one had a soft ejection type systolic murmur probably induced by tachycardia on the left sternal border and in the pulmonary region but 11 of the patients had developed a systolic murmur indicative of mitral incompetence without having suffered a reinfarction during the period between hospital discharge and the follow up examination.

#### CHARACTERISTICS OF A PERMANENT MITRAL SYSTOLIC MURMUR

The type of murmur as compared with

its prevalent type during the patient's stay in hospital is presented in Table 23. The marked variability in the type of murmur observed in hospital was also evident at the follow up examination. In only 14 instances (23%) did a permanent murmur remain unchanged in type (out of 33 patients involved) at the time of follow up as compared to 67 (57% out of 117) during the observation period in hospital.

No crescendo murmur had disappeared although changes to other pansystolic types were common. 20% of the plateau type of pansystolic murmurs had disappeared and in only 11 patients did it remain permanently of the same type; changes to the decrescendo or ejection type being most common. The decrescendo type of pansystolic murmur disappeared relatively most frequently. No late systolic murmur was present and only 1 unchanged early systolic ejection type murmur was observed.

Table 23. Type of murmur at follow-up

	TYPE OF MURMUR AT FOLLOW UP									
	Pansystolic				Protomesosystolic			Ejection		Total
	Plateau	Crescendo	Decrescendo	Crescendo-decrescendo	Plateau	Decrescendo	Early	Late	Plateau	
<b>Pansystolic</b>										
Plateau	(8)	4	11		1	1	4		21	41
Crescendo	2	(2)	1	1		1			5	0
Decrescendo	1	1	(2)		2	1		1	6	15
Crescendo-decrescendo			2	(1)			1		3	5
<b>Protomesosystolic</b>										
Decrescendo					(0)				0	0
Crescendo-decrescendo						(0)			0	0
<b>Ejection</b>										
Early		1	1				(1)		2	5
Late									0	0
Total number of murmur types in which previous type changed	3	6	15	1	3	3	5	1	3	22






Fig 52 Changes in the intensity of the mitral systolic murmur on follow-up

The intensity of the murmur usually decreased as compared to the intensity registered in hospital (Fig 52). In addition to 20 patients with a decrease of intensity to nil, there were 20 patients whose murmur had lessened in intensity. In 10 instances the murmur had become louder than during hospital observation, and in 25 (45%) of the patients the intensity remained unchanged. Grade 3 or 4 murmur did not as a rule disappear.

**Changes in location and frequency** The point of maximal intensity of murmur did not vary, in only 2 patients was there a slight shift from the apex to the area between the apex and the left sternal border, and in 1 a shift from this area to the left sternal border was observed.

In 10 patients the murmur frequency changed from high to medium in 9, and from medium to high in 1.

**Relation of the permanence of a murmur at hospital to its presence on follow-up** It seemed that a constant murmur in hospital did not disappear easily (23%) as compared to an inconstant murmur (45%), although not statistically significantly.

#### MITRAL SYSTOLIC MURMURS DEVELOPING IN PATIENTS ORIGINALLY INCLUDED IN THE NO MURMUR GROUP

In 11 patients from the no-murmur group who developed mitral incompe-

tence, the murmur was usually apical (5). High frequency was registered in 4 instances, grade 2 in 5, and grade 3 in 1. The murmur was pansystolic in half these patients, 2 exhibiting the crescendo and 1 the decrescendo type, the ejection type occurring in another half.

In groups 3 to 5 the murmur was unchanged, apart from minor variations in intensity.

#### OTHER CLINICAL FINDINGS

**Angina pectoris** occurred more frequently than before myocardial infarction but it did not differ clearly in occurrence or severity in patients with or without mitral systolic murmur. Its frequency was estimated to be 73% in the MIMI group as compared to 81% in the no murmur group.

**Reinfarction** had occurred in 4 patients with mitral incompetence and in 3 patients with no murmur.

**Congestive heart failure** Subjective symptoms of congestive heart failure were not relatively more common in the MIMI group (41%) than in the no-murmur group (40%). Grade IV incapacitating heart failure was much more common however, in patients with mitral incompetence. It was observed in 10 patients (28%) in the MIMI group.

but in only 2 patients (10%) in the no-murmur group. In clinical examination 36% of the MIMI patients were found to have pulmonary rales, as compared to 28% of the no-murmur group which included the 6 patients with newly developed mitral incompetence among those having rales. Signs of congestive heart failure permanently present both during hospitalization and on follow up were observed in 27% of the MIMI and 9% of the no-murmur group.

12 patients in the MIMI group and 7 in the no-murmur group complained of no symptoms of heart failure, although marked pulmonary moist rales and/or peripheral edema could be detected at the examination. Digitalis was used by 49% of patients in the MIMI group and by 34% in the no-murmur group. There were no noticeable differences between the two groups in the incidence of permanently absent congestive heart failure, the reappearance at the follow up examination of transient failure observed in hospital, and the development of heart failure only during the follow up period.

In 37 patients whose mitral incompetence was transient or had disappeared, the signs of congestive heart failure (33 examined at follow up), had vanished with approximately the same incidence as in the patients with a permanent murmur.

*Paradoxical cardiac pulsation* also proved to be a more permanent finding in the MIMI group on follow up. 40 patients than in patients without mitral systolic murmur, 11 patients. The difference was highly significant ( $p < 0.001$ ).

*Follow up changes in gallop sounds.* Third heart sound had about the same incidence on follow up in both the MIMI (28%) and the no-murmur groups (25%). The percentages recorded during the hospital period were 38 and 23 respectively.

Fourth heart sound was more closely connected with the acute phase of

infarction. It was present in only 13% of the MIMI patients and 11% of the no-murmur ones on follow-up, while the respective percentages recorded in hospital were 41 and 36.

*Changes in electrocardiographic findings.* No consistent differences were observed between the MIMI and no-murmur groups in the degree of ischemic changes in the electrocardiograms. Static and limited extension of the ischemic changes as well as their regression or massive extension had the same incidence in both groups.

Left ventricular hypertrophy developed or became more marked in 14 patients in the MIMI group, and in only 2 patients in the no-murmur group.

11 patients with permanent mitral incompetence developed a P wave duration previously normal of over 0.11 sec, while in the no-murmur group this occurred only in 1 patient. The changes in P terminal force and terminal P vector in frontal plane are shown in Figs 27, 28, 29. The marked difference in the P terminal force that developed after MIMI as compared to the patients without mitral systolic murmur persisted during follow up.

One patient with mitral incompetence had developed total LBBB. Persistent ST segment elevations in the electrocardiogram, pointing to myocardial aneurysm, were observed in 10 MIMI and 7 no-murmur patients.

*Radiological findings.* There was a significant ( $p < 0.01$ ) tendency for heart volume to enlarge in the MIMI group (Figs 32 and 33) as compared to the no-murmur patients in the MIMI group  $490 \pm 102$  ml/m<sup>2</sup> of BSA at hospital and  $515 \pm 126$  ml/m<sup>2</sup> of BSA at follow up, in the no-murmur group the figures were  $478 \pm 79$  and  $488 \pm 106$  ml/m<sup>2</sup> of BSA, respectively. In patients with transient murmurs this tendency was not observed.

No distinct differences were detected in the size of the left ventricle. The

frequency of left ventricular enlargement increased by 21 % in the MIMI group and by 19 % in the no murmur group. On the other hand, the size of the left atrium enlarged more often (23 %) in the MIMI group than in the no murmur group (12 %). Similarly, a demonstrable difference did exist in the grade of the radiological signs of left sided heart failure. The pulmonary changes of left sided heart failure (85 %) were usually constant in the no murmur group when the follow up phase was compared to the period of hospital treatment, whereas in the patients with mitral incompetence (79 %) a change to more marked failure was observed. The frequency of conspicuous pulmonary venous dilatation increased by 20 % in the MIMI group and by 8 % in the no murmur group. The figures with septal lines were 13 % and 8 %, respectively.

### DISCUSSION

*Murmur characteristics* The present follow up study further confirmed the great variability of the characteristics of the murmur of mitral incompetence observed during hospital treatment. The murmur of acute mitral incompetence after myocardial infarction disappeared in one third of the patients, combining the transient murmurs occurring during the hospital period and the murmurs that disappeared during follow up. The constant and loud murmurs disappeared less often than the faint and inconstant ones, which suggests a more marked functional disturbance of the mitral valve in the former.

During hospital observation, it was found that the murmur often appeared first as an ejection type before changing to a pansystolic one, especially in the inconstant murmur group. In the pure transient murmur group it was often only of the ejection type (Fig 7). At follow up the ejection or decrescendo pansystolic type of murmur tended to

disappear, while part of the plateau, crescendo or crescendo decrescendo types tended to change to an ejection or decrescendo type (25 %).

These findings suggest that the ejection type, early or late, protomesosystolic and pansystolic decrescendo types of murmur associated with mitral incompetence could signify rather minor regurgitation. By contrast, the pansystolic plateau, crescendo or crescendo decrescendo types of murmur were observed in connection with both slight and marked incompetence. This finding was further supported by the results of the present hemodynamic investigation, it has also been reported by others (Gorlin *et al* 1952, Hultgren and Leo 1959, Nager *et al* 1964, Holldack and Wolf 1966, Leighton *et al* 1966, Ilmurzynska 1966).

The earlier unreported, marked variability of the mitral systolic murmur after myocardial infarction and its often transient occurrence is understandable on the basis of the greatly varied extent of ischemic damage and functional disturbance in the muscular supporting structures of the mitral valve apparatus. The state of myocardial contractile power might be an important factor in determining the irreversibility of reversibility of mitral incompetence (see also Chapters VI and XI).

In the no murmur group the development of clinically slight mitral incompetence without infarction was occasionally observed during follow up. All the patients, however, had moderate or severe angina pectoris, hence, some slight additional damage to the papillary muscle closure mechanism was possible. It is noteworthy in this connection that during the primary study involving 'coronary insufficiency' alone, 7 patients developed constant mitral incompetence (p 46). These results show that slight ischemic lesions, often confined to the subendocardial layer, are also capable of causing papillary mitral incompetence.

*Objective signs of congestive heart failure* were more prevalent clinically and radiologically in patients with mitral incompetence, despite the fact that the mitral incompetence was mostly slight in degree judged on clinical grounds.

Third heart sound persisted in one quarter of the patients in both groups being a little less frequent than in the acute period. Obviously, slight mitral incompetence was not usually its only cause during follow up, the probability is, rather, that the chief cause was cardiac failure (McKusick 1958, Lewis 1962). On the other hand fourth heart sound was detected only in about one tenth of the patients in both groups, although this sound was quite frequently present during the early acute phase. It might only be a sign of acute hemodynamic alterations and atrial overloading in the acute phase of infarction as discussed in Chapter VII.

The remarkably persistent *paradoxical pulsation* in the MIMI group, as compared to the no-murmur group during follow up cannot be explained solely on the grounds of the presence of congestive heart failure (Harrison 1965) or ischemic bulge (Suh and Eddleman 1959, Davie *et al* 1962, Schweitzer *et al* 1965)

but seemed to be connected with the mitral valvular incompetence itself. The added total stroke volume of mitral incompetence would probably make the underlying ischemic bulge more easily palpable and recordable, or the heaving of the left atrium could simulate an ischemic paradoxical bulge (Tucker *et al* 1955, Davie *et al* 1962, Logan *et al* 1967).

*To sum up* the mitral incompetence developing as a result of acute myocardial infarction was obviously of considerably variable severity and often represented a rather unstable phenomenon. Thus, the development of permanent severe mitral incompetence as a sequela of the acute phase of myocardial infarction was not common because of a tendency for the condition to change to intractable, often fatal heart failure. At the other extreme the slight incompetence from a minor disturbance of the muscular support of the mitral valve often lessened in severity and frequently completely disappeared. This somewhat slight incompetence, however, was not without clinical significance as proved by the frequency of clinical and radiological signs of congestive heart failure.

## CONCLUDING REMARKS

The aim of the concluding discussion is to sum up briefly and to stress the clinical implications of mitral incompetence developing after acute myocardial infarction. Consideration is also given to the consequences of coronary circulatory alterations affecting the performance of the

left ventricle, which are probably related to the development of mitral incompetence. For more detailed comments on the clinical, hemodynamic and pathologic-anatomical findings, the reader is referred to the discussions in the relevant chapters.

## CLINICAL IMPLICATIONS

### MURMUR CHARACTERISTICS

**Incidence** The severe complications causing the appearance of systolic murmur attending a myocardial infarction — perforation of the interventricular septum, rupture of the papillary muscle, rupture of the heart and left ventricular aneurysm — are well known but rare, though not exceptional. It is only in recent years that the functional disorder of the mitral valve caused by an ischemic dysfunction of the papillary muscle without rupture has gained clinical attention.

The prevalence of this ischemic functional impairment of the competence of the mitral valve seems to be unexpectedly high among patients with acute myocardial infarction. Only two reports (Groth 1940, Froment *et al* 1955) give an incidence worth more than a case report. In the present study, the incidence of acute mitral incompetence was observed to be over half the patients with acute myocardial infarction consecutively admitted to hospital. This high incidence

is in good agreement with the prevalence of involvement of the papillary muscles observed at autopsy (Arkhangelsky 1959) and with the results of experimental studies (Bailas 1965, Hider *et al* 1965). The murmur was observed as appearing predominantly during the first five days, when the necrotic changes are maximal (Bargmann and Doerr 1963). In some patients a transient ejection type murmur ascribed to ischemic dysfunction of the papillary muscle developed as early as the first few hours of ischemia.

**Intensity** Recognition of this complication demands considerable effort and careful auscultation. There are two reasons for this: mitral incompetence may sometimes be of very short duration, only hours or days, and a mitral systolic murmur can be, and usually is, somewhat faint in intensity. Only rarely, in a third of the patients, was it grade 3 or more in the scale of 6. Thus, a murmur can easily be missed in ward examination because of the usual marked background noise

unless it is specifically looked for. Despite its sometimes transient and faint nature, the characteristic pansystolic apical high frequency murmur of mitral incompetence can usually be distinguished with out difficulty from the pericardial friction rub when listened to over a period of several days.

It should be emphasized that the faintness of the murmur in no way indicates insignificance. A murmur of only grade 1 or 2 can be caused by hemodynamically severe mitral regurgitation. This clinical impression was confirmed by the hemodynamic portion of the present study and was stressed preliminarily by Gorlin (1966). This is contrary to the general view of the murmur being rather loud (Phillips *et al* 1963 a, Bashour 1965, Raftery *et al* 1966), a natural conclusion in retrospective studies. Obviously, a murmur of marked regurgitation can usually be readily detected if it is grade 3 or 4 though there are the important exceptions mentioned in the foregoing. Commonly, the murmur is at first rather faint and only gradually gains in intensity.

**Type.** Contrary to the reports describing the murmur associated with papillary muscle involvement as being characteristically of an ejection type (Burch *et al* 1963, Phillips *et al* 1963 a, Segal and Likoff 1964), the findings in this investigation indicate its character to be typical of the murmur attending mitral incompetence — pansystolic, with a high frequency at the apex. These findings are in agreement with those of other investigators (Grotel 1940, Nezhin and Shamesova 1951, Froment *et al* 1955, Bashour 1965, Raftery *et al* 1966).

However, mitral incompetence following myocardial ischemia or infarction seems to be one of the commonest causes of an atypical ejection type murmur of mitral regurgitation located at the left sternal border with occasional radiation to the aortic area (Luisada 1965). This atypical murmur observed in about 10 %

of the patients in the present series as the main type and was the most prevalent as a variant type (28 %), could obviously give rise to difficulties in distinguishing it from murmurs of aortic origin (Schimert *et al* 1960), if it is not a late systolic variant. Transient occurrence and an eventually frequent change of the ejection type murmur to a pansystolic one at the apex can help recognition of a leaking mitral valve as the cause of this type of murmur.

This frequent later change of an initially ejection type murmur to the pansystolic type, as observed in the present study, though not previously reported, would correspond well to the advancement of an initially only ischemic partial mechanical contraction failure of the papillary muscle (Burch *et al* 1963), slowly developing in succeeding days to a more extensive necrosis and total loss of function. In the same way as a decrescendo murmur (Nager *et al* 1964, Holldack and Wolf 1966, Ilmurzynska 1966), the ejection type indicates only a slight regurgitation. This is frequently reversible in ischemic dysfunction of the mitral valve closure and is more common in anterior infarction (Phillips *et al* 1963 a, Segal and Likoff 1964).

**Variability.** In addition to the often inconstant occurrence of the murmur, observed in one fourth of the patients, the frequently interchanging types of the mitral systolic murmur in the same patient (43 %) provide further evidence of the dynamic character of the underlying mechanism — structural or only functional ischemic damage to the muscular support of the mitral valve.

#### CLINICAL SIGNIFICANCE

The clinical significance of the mitral incompetence caused by an infarction of the papillary muscle or of its supporting ventricular wall varies markedly and is obviously related to the amount of the regurgitant flow.

The development of mitral incompetence is not however, directly related to

of coronary perfusion leading to a regional transmural or subendocardial infarct that includes the papillary muscle. Changes in the general coronary circulation, to be considered later, may contribute to this local damage, but only exceptionally do they seem to be the sole cause of mitral incompetence.

Accordingly, the topographical position of both papillary muscles in the left ventricle and the site of the infarct chiefly determine the extent of papillary muscle involvement.

The association of mitral incompetence with the damage of the posterior papillary muscle (Nezlin and Shamesova 1951, Froment *et al* 1955, Orlando *et al* 1964, Bashour 1965, Raftery *et al* 1966) was confirmed. This investigation convincingly demonstrated that the anterior papillary muscle escapes significant infarction more often because of its lateral topographical position in relation to the extent of involvement of the free left ventricular wall by anterior infarction.

**Distribution of coronary arteries.** The predominance of the coronary artery distribution seems to have some bearing on the destruction of the posterior papillary muscle. In right predominance, present in between 60 and 80 % of the cases (Campbell 1929, Schlesinger 1940, Likoff *et al* 1965, Fulton 1965), the posterior papillary muscle derives its blood supply almost exclusively from the right coronary artery. In this case, the posterior infarction resulting from occlusion of the left circumflex coronary artery would not destroy the posterior papillary muscle, which would probably occur in left predominance. The scater collateral circulation to the posterior papillary muscle makes it more vulnerable to extensive ischemic damage than the anterior papillary muscle with its blood supply deriving from both left circumflex and anterior descending coronary arteries (James 1965). These relations might explain the more common occurrence of transient and atypical ejec-

tion type murmurs as an indication of slight regurgitation in an anterior as compared to a posterior infarction.

**Regurgitation mechanisms.** An ischemic but not necrosed papillary muscle may generate tension in the isovolumetric phase of ventricular contraction, preventing mitral regurgitation during this time, but it fails to contract and shorten during the following ejection phase and thereupon causes regurgitation and ejection type murmur (Burch *et al* 1963). A papillary muscle totally destroyed structurally would allow bulging of the corresponding mitral leaflet into the left atrium immediately at the isovolumetric phase of systole with regurgitation throughout systole. This obviously produces pansystolic murmur. The same mechanism could also be in operation, causing a pansystolic murmur, when the papillary muscle is attached to the site of an anatomic or dynamic aneurysm, or when an acute general left ventricular dilatation pulls the papillary muscles down (Levy and Edwards 1962, Burch *et al* 1963, Bailas 1965).

#### HEMODYNAMIC FACTORS

**Coronary circulation.** An acute coronary occlusion leads to profound alterations in the local and general myocardial blood supply and in left ventricular dynamics (Orias 1932, Case *et al* 1954, Wegria *et al* 1954, Gregg and Fisher 1963, Rushmer *et al* 1963, Malmcrona 1964, Bailas 1965, Gunnar *et al* 1966, Mullins *et al* 1966). The determinant of the coronary flow is the coronary driving pressure (Kautus and Gregg 1959, Cross *et al* 1961, Gregg and Fisher 1963). This varies with coronary arterial pressure, coronary vessel vasomotor tone (which is invariably decreased in ischemic injury) and intramyocardial tissue pressure.

Coronary arterial pressure is universally reduced by arterial hypotension. In the part of the artery distal to the occlusion it must decrease considerably, resulting in local myocardial damage.

**Myocardial perfusion** Furthermore, general subendocardial ischemia may be induced by the following mechanisms. Intramyocardial pressure normally exceeds the intracavitary pressure in the subendocardial layers, decreasing in an epicardial direction (Laszt and Muller 1958, Muller 1962). Thus higher intramural pressure retards the coronary blood flow, especially during systolic contraction. Tissue oxygen tension is lower in the subendocardial layers than in the epicardial muscle (Moss 1966). When the left ventricular diastolic pressure is increased over 25 mm Hg and at the same time the coronary arterial pressure is decreased below 70 mm Hg, the intramyocardial pressure overcomes the coronary driving pressure in the entire circumferential subendocardial layer. Cessation of coronary circulation in these areas leads to general inner layer ischemia (Salisbury *et al* 1963 a). The contractility of these subendocardial muscle layers including the papillary muscles is disturbed and chordal tension is reduced (Salisbury *et al* 1963 b). The malfunctioning of the papillary muscles as induced by ischemia might thus cause mitral incompetence (Bailas 1965).

**Heart dilatation** Otherwise, stretching of the myocardium in acute left sided heart failure following a coronary occlusion (Mullins *et al* 1966) is also liable to lead to some impairment of the coronary capillary circulation (Kattus and Gregg 1959) and contribute to myocardial ischemia.

Acute left heart dilatation (Mullins *et al* 1966) with or without papillary muscle ischemic dysfunction could bring on mitral incompetence by pulling down the papil-

lary muscles and thus preventing the adequate apposition of the mitral leaflets (Bailas 1965). These two mechanisms, both of them frequently reversible, would reasonably explain the occurrence of initial, often transient, mitral systolic murmurs.

This series of hemodynamic alterations could be an important mechanism in perpetuating and promoting a fatal vicious cycle in mitral incompetence following acute ischemic myocardial damage, especially when added to the further inadvertent effect of hypodynamic ventricular contraction in augmenting the regurgitant flow (Wiggers and Feil 1922, Rodbard and Williams 1954, Braunwald *et al* 1957, Gleason and Braunwald 1962, Jose *et al* 1964). — Initial left ventricular failure and shock are common in acute myocardial infarction and connected with hemodynamic mechanisms of general inner layer ischemia experimentally proved in the foregoing. However, in the present clinical study they did not appear to provide the main underlying mechanism involved in permanent mitral incompetence, at least. This emphasizes the importance of papillary muscle damage resulting from local myocardial destruction.

It may be stated that the development of mitral incompetence following acute myocardial infarction or ischemia is a frequent clinical manifestation of the pathophysiology of acute coronary heart disease. Its highly variable expression is consistent with the underlying cause ischemic heart disease with its remarkably variable structural and functional pathophysiological picture.



## SUMMARY

Occurrence and clinical characteristics of mitral incompetence developing as a complication of acute myocardial infarction ('MIMI') were investigated in a series of 210 patients with acute myocardial infarction consecutively admitted to hospital. The character and the pathophysiological mechanism of the mitral systolic murmur like the clinical implications and the nature of the hemodynamic disturbance of the mitral incompetence were the main objects of the clinicopathological study.

The patients were observed in thorough daily examinations by the author for the first ten days, and thereafter every other day until discharged. Particular attention was paid to recognizing clinical signs of the congestive heart failure: paradoxical cardiac pulsation and the auscultatory findings of the heart. Murmurs detected were recorded by phonocardiography. Hemodynamic investigations were performed in the convalescent stage on 25 patients with or without acutely developed mitral incompetence, and consisted of right side cardiac catheterization augmented with a pharmacodynamic methoxamine test. Autopsy study of the hearts of 30 patients who died in hospital was made with special reference to the extent of the myocardial infarct and involvement of the papillary muscles of the left ventricle. A follow up after an average of 6 months from the acute phase was carried out to determine the permanence of the mitral incompetence and the clinical progress of the patients.

The main results were as follows:

The prevalence of acute mitral systolic murmur as a complication of myocardial infarction was fairly high, 117 patients developed a new murmur generally within 5 days after the onset of the myocardial infarction. 70 patients had or developed no murmur of mitral incompetence, and in 23 patients the murmur present on admission could not be considered to have been developed recently. Pericardial friction rub was present in 10 % and aortic systolic murmur in 10 % of the patients. The murmur of mitral incompetence was mostly faint, being grade 3 or 4 in the scale of 6 in only one third of patients, thus the murmur can easily escape detection if not meticulously looked for. The faintness of the murmur did not however indicate an invariably insignificant regurgitation as became evident on the basis of clinical findings and cardiac catheterization data.

The mitral systolic murmur exhibited a remarkably variable characteristics in its occurrence, type, intensity and permanence, even in one and the same patient. Although the murmur of mitral incompetence was overwhelmingly (91 %) apical pansystolic in type, an ejection type as an initial or variation type occurred frequently, with common later transformation to pansystolic. Moreover if the murmur disappeared later, this happened easily with ejection or decrescendo type murmurs or in pansystolic murmurs first changing to these types. In one third of the patients the acute mitral incompe-

tence disappeared in hospital (13 %) or during the subsequent months (17 %). The characteristics of the murmur and the result of the hemodynamic study showed a correlation between the ejection or decrescendo type murmurs and only a slight regurgitation.

The variable expression of the murmur is in agreement with its underlying cause: ischemic heart disease with its markedly varying pathophysiological picture.

The clinical features of this syndrome have a wide spectrum. The significantly predisposing factor in the development of mitral incompetence was hypertension and probable predisposing factors were previous infarction and diabetes. The clinical, or pathologic anatomical, severity of the infarction was not related directly to the occurrence of mitral incompetence. The mitral incompetence was estimated as hemodynamically severe in 17 % of patients. Various clinical and radiological signs of left sided heart failure and paradoxical cardiac pulsation occurred very frequently in the patients with acute myocardial infarction, and significantly more commonly in the group with mitral incompetence, often with close time relations. In a small portion of patients the acute marked volume load of mitral incompetence superimposed on the acutely damaged left ventricle was obviously an intolerable occurrence, resulting in irreversible pulmonary edema and death.

The size of the heart was normal in 55 % of patients with mitral incompetence. The left atrium did not dilate acutely. The P wave of electrocardiogram showed rapid alterations suggestive of left atrial overloading, most sensitively detected by P terminal force and with significant correlation to the appearance of mitral regurgitation and hemodynamic strain.

In the hemodynamic investigation 11 patients had signs of marked mitral regurgitation and severe congestive left ventricular failure whereas 12 patients

had a degree of mitral incompetence barely detectable and the hemodynamic alterations were mainly similar to the findings of heart failure observed in 7 patients without mitral incompetence. The value of pharmacodynamic pressor amine test in the recognition of slight mitral regurgitation was clearly evident.

The critically important determinant in the development of mitral incompetence was convincingly shown to be extensive structural destruction of one or both papillary muscles of the left ventricle. Vulnerability of the posterior papillary muscle was apparent. The frequent escape of the anterior papillary muscle from major damage was observed to be due to its lateral topographical position in the left ventricle in relation to the site of anterior infarcts. All but one 11 patients without mitral incompetence had anterior infarcts without extensive involvement of the papillary muscle in a single case.

In 17 of the 19 patients (90 %) with mitral incompetence the papillary muscle predominantly posterior (63 %) was extensively destroyed or attached to the site of ventricular aneurysm, obviously pulling it down during systole with consequent failure of the mitral valve to close. The mechanical failure of the papillary muscle of various modes thus seems to be the cause of the acute mitral incompetence. The often observed occurrence of ejection type murmur in the initial phase of infarction might be ascribed to ischemic and only partial mechanical contraction failure of the papillary muscle, the subsequent change to pansystolic type being obviously related to the progress of ischemia to necrosis and total loss of function.

However, the functional capacity of the whole left ventricle enters into the mechanism of regurgitation in addition to the papillary muscle damage. A fatal vicious cycle may be initiated and maintained by hemodynamic alterations involving waste of contractile speed and strength of the ischemically injured left ventricle.

further enhancing regurgitation. Otherwise, the mitral incompetence was frequently unstable and transient. The reversibility was probably related to gain of contractile power and diminishing ischemia of the left ventricle, provided that papillary muscle was not severely damaged with the eventual development of scarring fibrosis.

Mitral incompetence is a common complication of acute myocardial infarction. Its high prevalence and the great variability in its clinical features and severity are not astonishing when considered as an expression of malfunction of the muscular supporting structures of the mitral valve, which are themselves susceptible to ischemic damage of varying degree.

## REFERENCES

- ABELMANN W H, ELLIS L B and HARKEN D E. The diagnosis of mitral regurgitation. An evaluation of clinical criteria fluoroscopy phonocardiogram auricular esophagogram and electrokymogram *Amer J Med* 15 5 1953
- ABILDSKOV J A. A quantitative study of the electrocardiographic effects of atrial enlargement *Amer Heart J* 53 55 1957
- ABRAMS D L, EDELSTEIN A, LYRIA M III and MILLER A J. Ventricular aneurysm. A reappraisal based on a study of sixty five consecutive autopsied cases *Circulation* 27 164 1963
- AGRESTI C M and BINDER M J. Cardiogenic shock *Amer Heart J* 54 408 1957
- ALLISON R B, RODRIGUEZ F L, HIGGINS E A, Jr, LEDDY J P, ABELMANN W H, ELLIS L B and ROBBINS S L. Clinicopathologic correlations in coronary atherosclerosis. Four hundred thirty patients studied with postmortem coronary angiography *Circulation* 27 170 1963
- AMUNDSEN P G. The diagnostic value of conventional radiological examination of the heart in adults *Acta radiol (Stockh)* Suppl 181 1959
- AREVALO F, MEYER E C, MACCANON D M and LUBADA A A. Hemodynamic correlates of the third heart sound *Amer J Physiol* 207 319 1964
- ARHANGELSKIY A V. Changes of papillary cardiac muscles in myocardial infarction (Russian with English summary) *Arkh Pat* 21 48 1959
- ARSPFEMEN, E, MOLLER J H and EDWARDS J E. Scarring of papillary muscles in left ventricular hypertrophy (Abstract) *Circulation* 34 Suppl III 46 1966
- ARWIDSSON H, LAZO S and GREWIK K E. Correlation between mitral P wave and left atrial volume determined by angiography *Cardiologia (Basel)* 37 255 1960
- ASKEY J M. Spontaneous rupture of a papillary muscle of the heart. Review with eight additional cases *Amer J Med* 9 528 1950
- AXÉN O, LINDGREN E. and MALMSTRÖM G. Till kannedom om maffelen vid Liljestrand Lysholm Nylin Zachrissons method for hjärt volymbestämning *Nord Med* 29 592 1946
- BALLAS N. Functional mitral insufficiency in acute myocardial ischemia. *Amer J Cardiol* 16 807 1965
- BALL, C O T, BILLINGS F T Jr, FURMAN R H, BROTHERS G B, THOMAS J and MENZELY G R. The functional circulatory consequences of myocardial infarction. A biostatistical analysis following Wiggers schema *Circulation* 11 749 1955
- BARCMANN W and DOERR W (ed). *Das Herz des Menschen*. Vol 2 Thieme Stuttgart 1953
- BARTÉ Cat by Castet (1931 1933)
- BARKER J M. The unipolar electrocardiogram. A clinical interpretation. Appleton Century Croft. New York 1952
- BARLOW J B and BOSMAN C A. Aneurysmal protrusion of the posterior leaflet of the mitral valve. An auscultatory-electrocardiographic syndrome *Amer Heart J* 71 166 1966
- BASHOUR F A. Mitral regurgitation following myocardial infarction. The syndrome of papillary mitral regurgitation. *Dis Chest* 48 113 1965
- BAYER, O, LOOGEN F and WOLTER H H. *Die Herzkatheterisierung bei angeborenen und erworbenen Herzfehlern*. Ed. 2 Thieme Stuttgart 1967
- BEAN W H. Infarction of the heart. II Symptomatology of acute attack. *Ann intern Med* 11 2086 1938
- BELL, A L L, Jr, HAYNES W F Jr, SHIMOMURA, S and DALLAS H F. Influence of catheter tip position on pulmonary wedge pressure *Circulation Res* 10 215 1962
- BECHTOLD, A. and DIMOND E. G. The apex cardiogram in ischaemic heart disease *Brit Heart J* 24 581 1962
- BENTIVOGLIO L, URICCHIO J and GOLDBERG H. Clinical and hemodynamic features of advanced rheumatic mitral regurgitation. review of sixty five patients *Amer J Med* 30 372 1961
- BENTIVOGLIO L, URICCHIO J F and LIKOFF W. The paradox of right ventricular enlargement in mitral insufficiency *Amer J Med* 24 193 1958
- BERLINER K. and MASTER, A. M. Mitral stenosis. A correlation of electrocardiographic and pathologic observations *Arch. intern Med.* 61 39 1938

- BEVEGÅRD ■ CLONTZAS E JONSSON B and KARLÖF, I Deviation from basal state during catheterization of the right and left sides of the heart *Scand J clin Lab Invest* 18 473, 1966
- BYDER M J RYAN, J A., Jr MARCUS S MUGLER F, Jr STRANGE, D and AGREST, C M Evaluation of therapy in shock following acute myocardial infarction *Amer J Med* 18 622 1955
- DISHOP L and LOGUE, B External rupture of the heart causing a systolic murmur and thrill *J Amer med Ass* 144 757, 1950
- BLEIFER S DACK S GRISHMAN A and DONOSO E The auscultatory and phonocardiographic findings in mitral regurgitation *Amer J Cardiol* 5 836, 1960
- BLOOM N and GILBERT D The auricular complex in coronary thrombosis *Amer Heart J* 24 602 1942
- BOLECHOWSKI I and POPLEWSKI, Przemyslaw, szmer muzyyczny w dusznicy bolesnej (A transient musical systolic murmur audible during the anginal pain Case report) (Polish with English summary) *Kardiol pol* 7 311 1964
- BOND V F Jr WELFARE C R LIDE T N and McMILLAN R L Perforation of the interatrial septum following myocardial infarction *Ann intern Med* 38 706 1953
- BONDI S Wiedergabe und Erklärung der Geräusche bei Fehlern der Mitralklappe *Klin Wschr* 6 1 47 1927
- BONDI ■ Die Geräuschbildung bei Herzfehlern und die Wirbelablosungstheorie *Klin Wschr* 7 11 1377 1928 a
- BONDI S Physik und Klinik der Herzgeräusche *Wien klin Wschr* 41 1577 1623 1928 b
- BOSCO G La doctrina sobre el mecanismo del soplo metosistólico *Arch Med interna* 1 316 1935
- BRADLEY S M and MARRIOTT H J L Intra atrial block *Circulation* 14 1073 1956
- BRAUNWALD E and AWE W C The syndrome of severe mitral regurgitation with normal left atrial pressure *Circulation* 27 29 1963
- BRAUNWALD E LAURENCE C T ROCKOFF S D ROSS J Jr and MORROW A C Idiopathic hypertrophic subaortic stenosis I A description of the disease based upon an analysis of 64 patients *Circulation* 30 Suppl IV 3 1964
- BRAUNWALD E and ROSS J Jr The ventricular end-diastolic pressure Appraisal of its value in the recognition of ventricular failure in man *Amer J Med* 34 147 1963
- BRAUNWALD E WELCH G H Jr and MORROW A C The effect of acutely increased systemic resistance on the left atrial pressure pulse A method for the clinical detection of mitral insufficiency *J clin Invest* 37 33 1958
- BRAUNWALD E WELCH G and SARNOFF S Hemodynamic effects of quantitatively varied experimental mitral regurgitation *Circulat Res* 5 539 1957
- BRIDGEN W and LEATHAM A Mitral incompetence *Brit Heart J* 15 55, 1953
- BRISTOVE J S On mitral regurgitation arising independently of organic disease of the valve *Brit & For Med chir Rev* 28 215 1851
- BRUNY F Zur Diagnostik der erworbenen Rupture der Kammercheidewand des Herzens *Wien Arch inn Med* 6 533 1923
- BRUNS D L A general theory of the causes of murmurs in the cardiovascular System *Amer J Med* 27 360 1959
- BRUNS D L and van der HAUWAERT L G The aortic systolic murmur developing with increasing age *Brit Heart J* 20 370 1958
- BUCHNER F WESER A and HAAGER ■ Koronarinfarkt und Koronarinsuffizienz Thieme Leipzig 1953
- BURCH G E DePASQUALE N F and PHILLIPS J H Clinical manifestations of papillary muscle dysfunction *Arch intern Med* 112 112 1953
- BURCHELL H B Possibly unrecognized forms of heart disease *Circulation* 29 1153 1963
- BUTTERWORTH J S CHASSIN M R McGRATH R and REPERT E H Cardiac auscultation including audio visual principles Ed 2 Grune & Stratton New York 1960
- BUTTERWORTH J S and REPERT E H Auscultation of the heart *In The heart* J W Hurst and R ■ Logue (ed) McGraw Hill, New York 1966
- CAMPBELL, J S Stereoscopic radiography of the coronary system *Quart J Med* 27 247 1929
- CASE R B BERGLUND E and SARNOFF S J Ventricular function II Quantitative relationship between coronary flow and ventricular function with observations on unilateral failure *Circulat Res* 2 319 1954
- CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL Case 31302 *New Engl J Med* 233 132 1945
- CASPER M R Sobre soplos mero sistólicos *Pren méd argent* 18 782 1931
- CASPER M R Los soplos del corazón *Pren méd argent* 19 1153 1932
- CASPER M R Les souffles méso-systoliques *Arch Mal Coeur* 26 444 1933
- CEDERQVIST L and SÖDERSTRÖM J Papillary muscle rupture in myocardial infarction A study based upon an autopsy material *Acta med scand* 176 287 1964
- CHABARDÉS R Étude sur l'étiologie et la pathogénie de l'insuffisance mitrale Thèse Montpellier 1878
- CINZA F GIORGETTI C and PISTELLI G Soffio sistólico como sequele de infarto miocárdico Studio fonocardiográfico ed importanza clinica *Kardiol Prat* 26 363 1965
- CIO A V di and BATTRO A Valor del soplo metosistólico en el diagnóstico del infarto del

- miocardio *Pres méd argent* 70 150 1933
- CLINICOPATHOLOGICAL CONFERENCE A case for diagnosis demonstrated at the Postgraduate Medical School of London *Brit med J* 11 803 1965
- CORRS H W SHILLINGFORD J F and STEINER R E The size of the left atrium in conditions other than mitral heart disease *Brit Heart J* 19 495 1957
- COOK R W EDWARDS J F and PRUITT R D Electrocardiographic changes in acute subendocardial infarction I Large subendocardial and large nontransmural infarcts II Small subendocardial infarcts *Circulation* 18 603 612 1958
- CORTES F M Acute atrial overloading a response to stress *Amer J med Sci* 246 443 1963
- CRADDOCK W L and MAIZE G A Rupture of papillary muscle of heart following myocardial infarction Differential criteria from perforation of interventricular septum *J Amer med Ass* 151 884 1953
- CREVASE L WHEAT M W WILSON J R LEEDS R F and TAYLOR W J The mechanism of the generation of the third and fourth heart sounds *Circulation* 25 635 1962
- CURLEY J M LEWIS K B HUMPHRIES O N and ROSS R S Prolapse of the mitral valve clinical and cine angiocardiographic findings *Brit Heart J* 28 488 1966
- CROSS C E RIESEN E A and SALISBURY P F Coronary driving pressure and vasomotor tone as determinants of coronary blood flow *Circulat Res* 9 589 1961
- DAVE J C LANGLEY J O DODSON W H and ENDREMAN E E Jr Clinical and kinesiographic studies of paradoxical precordial motion *Amer Heart J* 63 775 1962
- DAVILA J C Hemodynamics of mitral insufficiency Observations from clinical and experimental surgery Symposium on mitral regurgitation (Part II) *Amer J Cardiol* 2 135 1958
- DAVIS P K B and KIMMORTH J B The movements of the annulus of the mitral valve *J Cardiovasc Surg (Torino)* 4 427 1963
- DAVISON S Spontaneous rupture of papillary muscle of heart *J Mt Sinai Hosp* 74 941 1947
- DAWBER T R MOORE F E and MANN G V Measuring the risk of coronary heart disease in adult population groups II Coronary heart disease in the Framingham study *Amer J publ Hlth* 47 Suppl pt 2 4 1957
- DELIYANIS A A GILLAM P M H MOUNSEY I D and STEINER R E The cardiac impulse and the motion of the heart *Brit Heart J* 26 396 1964
- DEPASCALE N H and BURCH G E The necropsy incidence of gross scars of acute infarction of the papillary muscles of the left ventricle *Amer J Cardiol* 17 169 1966
- DESROCHERS A and PROUET J Dilatation auriculaire Critères électrocardiographiques *Un med Can* 94 1023 1965
- DEXTER L DOW J W HAYNES F W WITT TENBERGER J L FEBERS B G GOODALE W T and HELLEMS H K Studies of the pulmonary circulation in man at rest Normal variations and the interrelations between increased pulmonary blood flow elevated pulmonary arterial pressure and high pulmonary capillary pressures *J clin Invest* 29 602 1950
- DIWIDY E G and BESCHIMOL A Correlation of intracardiac pressure and precordial movement in ischaemic heart disease *Brit Heart J* 25 389 1963
- DINES D E and PARKIN T W Some observations on P wave morphology in precordial lead V<sub>1</sub> in patients with elevated left atrial pressures and left atrial enlargement *Proc Mayo Clin* 34 401 1959
- DOLGOPLOSK A Changes of electrocardiogram in infarction of papillary muscle (In Russian) *Klin Med (Moskva)* 34 41 1956
- DOMENET J G FIANS D W and HOWARTH F H Clinical experience with radiological determination of heart volume *Brit Heart J* 25 575 1963
- DOSCHER N and POINDESTER C A Myocardial infarction without anticoagulant therapy Deaths emboli and an analysis of factors influencing mortality *Amer J Med* 8 623 1950
- DOUGLAS D M Mitral regurgitation with mobile valve cusps *Brit med J* 1 191 1953
- DUBON D and DEBON E F A formula to estimate the approximate surface area if height and weight be known *Arch intern Med* 17 863 1916
- EDMONDSON H A and HODGE H J Hypertension and cardiac rupture A clinical and pathological study of seventy two cases in thirteen of which rupture of the interventricular septum occurred *Amer Heart J* 24 719 1942
- EDWARDS J E and BURCHELL H B Endocardial and intimal lesions (jet impact) as possible sites of origin of murmurs *Circulation* 18 946 1958
- ELIASCH H The pulmonary circulation at rest and on effort in mitral stenosis *Scand J clin Lab Invest* 4 Suppl 4 1 1952
- ELLIS F J CATER O H and WOOD E H An intracardiac manometer Its evaluation and application *Circulation* 3 390 1951
- ENDRYS J and BARTOVA A Pharmacological methods in the phonocardiographic diagnosis of regurgitant murmurs *Brit Heart J* 24 207 1962
- ESTES E H DALTON F M ENTMAN M L DIXON H H and HACKEL D H The anatomy and blood supply of the papillary muscles of the left ventricle *Amer Heart J* 71 356 1966
- EVANS D W and CARPENTER P B Error involved in radiological heart volume determination by the ellipsoid approximation technique *Brit*

- Heart J 27 429 1965
- EVANS D W and SUTTON G C. Painless cardiac infarction. Brit Heart J 18 259 1966
- FALDA, C. PACE G and TIRONE E. Lingorgo polmonare nell'infarto miocardico. Minerva Med. 48 3256 1957
- FERUGLIO G A. An intracardiac sound generator for the study of the transmission of heart murmurs in man. Amer Heart J 63 232 1962
- FLETCHER H and MILTON W A. Loudness its definition, measurement and calculation. J acoust Soc. Amer 5 82 1933
- FLOCK, D C. TAUBMAN J O. GLELAND W P and MOUNSEY, J P D. Acute mitral incompetence after acute myocardial infarction with successful early treatment by mitral valve prosthesis. Lancet II 1052 1966
- FRIEDBERG C. H. Diseases of the heart Ed 3 Saunders Philadelphia 1966
- FRIEDLAND C. and FUHLERER H L. El estudio fonomecanocardiografico de pacientes con infarto del miocardio no reciente Arch Inst Cardiol. Méx. 30 467 1960
- FRIEDMAN C. E. Heart volume myocardial volume and total capacity of the heart cavities in certain chronic heart diseases Acta med. scand. 140 Suppl 257 1961
- FROMENT R, GONTIN A, GALLAVARDIN L, CAHEN P, PERRIN A. and HAYOTTE A. Formes anatomiques et cliniques de oblitérations coronariennes. Rapp 30e congr franç méd (Alger 1953) F Kirsch and J de Bruix (ed.) (Faculté de Médecine de Lyon) Paris 1955
- FRY D L, NOBLE F W and MALLOS A J. An evaluation of modern pressure recording systems. Circulat Res 5 40 1957
- FULTON W F M. The coronary arteries Thomas Springfield, Ill. 1965
- FURBETTA D, BUTALANI A, SANTUCCI F and SOLINAS P. Abnormality of the U wave and of the T L segment of the electrocardiogram. The syndrome of the papillary muscles. Circulation 14 1129 1956
- GANN, R. H. Acute myocardial infarction with rupture of the ventricle. Amer Heart J 41 332 1951
- GERHARDT W. Eine neue Methode der roentgenologischen Herzvolumenbestimmung mit Hilfe des simultanen Schichtverfahren im Vergleich mit den bisher üblichen Methoden. Klin. Wschr 2 1119 1957
- GEE S. Auscultation and percussion together with the other methods of physical examination of the chest. Walton. London 1870
- GIBSON, G A. Diseases of the heart and aorta. Penland Edinburgh 1898
- GILBERT R P, GOLDBERG M. and GRIFFIN J. Circulatory changes in acute myocardial infarction. Circulation 9 847 1954
- GILCHRIST A. R. Refresher course for general practitioners. Coronary artery disease - I The clinical syndromes. Brit med. J 1 874 1961
- GINN W M, SHERWIN H W, HARRISON W K. and BAKER B M. Apexcardiography. Use in coronary heart disease and reproducibility. Amer Heart J 73 168 1957
- GLEASON W L. and BRAUNWALD E. Studies on the first derivative of the ventricular pressure pulse in man. J clin. Invest 41 80 1962
- GOLDBERGER E. Heart disease. Its diagnosis and treatment. Lea & Febiger Philadelphia 1951
- GOOCH A S, CALATAYUD J B, GORMAN P A, SALVENDY J L. and CACERES C. A. Leftward shift of the terminal P forces in the ECG associated with left atrial enlargement. Amer Heart J 71 727 1966
- GORLIN R. Pain in the chest of sudden onset associated with a cardiac murmur. New Engl J Med. 275 1244 1966
- GORLIN R, LEWIS H M, HAYNES F W and DETTER L. Studies of the circulatory dynamics at rest in mitral valvular regurgitation with and without stenosis. Amer Heart J 43 357 1952
- GRAMER R. G. Pulmonary hypertension. A Symposium. III. Interstitial pulmonary oedema and its radiological diagnosis. A sign of pulmonary venous and capillary hypertension. Brit J Radiol. 31 201 1958
- GRANATH A. Mitral valvotomy. A clinical and hemodynamic pre and postoperative study. Acta med. scand. 178 Suppl. 433 1965
- GRANATH A, JOHNSON B and STRANDELL, T. Circulation in healthy old men studied by right heart catheterization at rest and during exercise in supine and sitting position. Acta med. scand. 176 425 1964
- GRANT R. P. Clinical electrocardiography. McGraw Hill New York 1957
- GRAYZEL, J. Gallop rhythm of the heart. I. Atrial gallop, ventricular gallop and systolic sounds. Amer J Med. 29 578 1960
- GREGG D E. Coronary circulation in health and disease. Lea & Febiger Philadelphia 1960
- GREGG D E. Hemodynamic factors in shock. In Shock, pathogenesis and therapy. An international symposium. Stockholm 1961. Spona by GIBA, K. D. Bock (ed.) Springer Berlin 1962
- GREGG D E. and FISHER L. C. Blood supply to the heart. In Handbook of physiology W F Hamilton and P Dow (ed.) Sect. 2 Circulation vol. II Amer Physiol Soc. Washington D C 1963
- GRIFFITH G C, HEGGE B and OSLATH R. W. Factors in myocardial rupture. An analysis of two hundred and four cases at Los Angeles County Hospital between 1924 and 1959. Amer J Cardiol 8 792 1961
- GROOM D. The effect of background noise on cardiac auscultation. Amer Heart J 57 781 1956
- GROSS D. The duration of the P wave in coronary artery disease. Cardiologia (Basel) 43 115 1963

- GROSS H and ENGELBERG H Essential hypertension A comparison of the hypertensive and non hypertensive phases following coronary thrombosis *Amer J med Sci* 199 621 1940
- GROSS L The blood supply to the heart in its anatomical and clinical aspects Hoeber New York 1921
- GROTEL D M Ostroj infarkt miokarda I Le ningradskij Medicinskiy Institut im Acad S F Pavlova Leningrad 1940
- GLANAR R M CRUZ A BOSWELL J Co B S PIETRAS R J and TORIV J R Jr Myocardial infarction with shock Hemodynamic studies and results of therapy *Circulation* 33 753 1966
- HAMER A J ROY H H and DOW J W Determinants of left atrial pressure pulse in mitral valve disease *Circulation* 19 257 1959
- HARLEY H R S The radiological changes in pulmonary venous hypertension with special reference to the root shadows and lobular pattern *Brit Heart J* 23 75 1961
- HARRISON D C and DEXTER L The evaluation of patients who develop recurrent cardiac symptoms after mitral valvuloplasty *Amer Heart J* 65 583 1963
- HARRISON C GLICK G GOLDBLATT A and BRAUNWALD E Studies on cardiac dimensions in intact unanesthetized man IV Effects of isoproterenol and methoxamine *Circulation* 29 186 1964
- HARRISON T R Some unanswered questions concerning enlargement and failure of the heart Grady Reddick memorial lecture *Amer Heart J* 69 100 1965
- HARVEY W P Technique and art of auscultation In The theory and practice of auscultation 9th Hahnemann symp B L Segal (ed) Davis Philadelphia 1964
- HARVEY W P CORRADO M and PERLOFF J Some newer or poorly recognized auscultatory findings of the heart Symposium on cardiovascular sound. *Circulation* 16 414 1957
- HECHT H H and WOODBURY L A Excitation of human auricular muscle and the significance of the intrinsincoid deflection of the auricular electrocardiogram *Circulation* 2 377 1950
- HEIKKILÄ J Mitral incompetence complicating acute myocardial infarction *Brit Heart J* 29 162 1967
- HELANDER S The prognosis of myocardial infarction and the comparability of different infarction materials *Cardiologia (Basel)* 15 347 1950
- HEVELING A Über Insuffizienz der Mitralis und Stenose am linken Ostium atrio-ventriculare Thesis Berlin 1871
- HIDER C F TAYLOR D E M and WADE J D The effect of papillary muscle damage on atrio-ventricular valve function in the left heart *Quart J exp Physiol* 50 15 1965
- HIDER C F TAYLOR D E M and WADE J H Action of the mitral and aortic valves in vivo studied by endoscopic cine photography *Quart J exp Physiol* 51 372 1966
- Hess R C LAMB L E and ALLEN M F Electrocardiographic findings in 67 375 asymptomatic subjects V Normal values *Amer J Cardiol* 6 200 1960
- HOCHREIN M Der Myokardinfarkt Erkennung Behandlung und Verhütung Steinkopff Dresden 1937 (Kreislauß Bucherei vol 1)
- HOLLDACK K and WOLF D Atlas and kurzgefasstes Lehrbuch der Phonocardiographie und verwandter Untersuchungsmethoden Ed 3 Thieme Stuttgart 1966
- HOLLOWAY D H WHALEN R E and McINTOSH H D Systolic murmur developing after myocardial ischemia or infarction Differential diagnosis *J Amer med Ass* 191 888 1965
- HOLMGREN A JONSSON H LEVANDER M LINDERHOLM H SJÖSTRAND T and STRÖM G Low physical working capacity in suspected heart cases due to inadequate adjustment of peripheral blood flow (vasoregulatory asthma) *Acta med scand* 158 413 1957
- HOLMGREN A and ÖRTENGREN G O Heart volume at rest and during muscular work in the supine and in the sitting position *Acta med scand* 167 267 1960
- HOLZMANN M Klinische Elektrokardiographie Ed 4 Thieme Stuttgart 1961
- HOPE R B and ASKEY J M Necrosis of a cardiac papillary muscle following infarction with incomplete rupture *Amer Heart J* 44 306 1952
- HUBBARD T F DUNCAN F L and VES D D A phonocardiographic study of the apical diastolic murmurs in pure mitral insufficiency *Amer Heart J* 57 223 1959
- HUDSON R E H Cardiovascular pathology Vol 1 Arnold London 1963
- HULTGREN H and LEO T Phonocardiographic features of combined mitral stenosis and insufficiency *Medicine (Baltimore)* 38 103 1959
- HUMERFERT S B J An epidemiological study of high blood pressure with special reference to the influence of blood pressure and age on cardiac signs and symptoms *Acta med scand* 175 Suppl 407 1963
- HUMPHRIES J O N Diagnosis of pure mitral regurgitation In The theory and practice of auscultation 9th Hahnemann symp B L Segal (ed) Davis Philadelphia 1964
- HUMPHRIES J O N and MCKUSICK V A The differentiation of organic and innocent systolic murmurs *Progr cardiovasc Dis* 5 152 1962
- HURWITT E Mitral stenosis. *Amer J Med* 18 216 1953
- ILMURZYŃSKA K Szmer protomeo systoliczny jako wyraz niedomykalności zastawki dwudziel



- nej (The protomesosystolic murmur as a sign of mitral insufficiency) *Pol Tyg Lek* 21 697 1966
- JACKSON F The radiology of acute pulmonary oedema *Brit Heart J* 13 503 1951
- JACOBS A Zur Klinik des Herzinfarkts *Arch Kreisl Forsch* 29 88 1958
- JACOBS T P The initial attack of acute myocardial infarction *Ann intern Med* 34 114 1951
- JACONO A, KAPLAN M and LUSADA A A Relative mitral insufficiency as a factor of paroxysmal pulmonary edema *Cardiologia (Basel)* 39 1 1961
- JAMES T A Anatomy of the coronary arteries in health and disease *Circulation* 30 1020 1963
- JOHNSON J R and DiPALMA J R Intramyocardial pressure and its relation to aortic blood pressure *Amer J Physiol* 125 234 1939
- JOHNSON W J, ACHOR R W P, BURCHELL H II and EDWARDS J E Unrecognized myocardial infarction *Arch intern Med* 103 253 1959
- JONES J W, RACHLEY C F, BRUCELE R A, DODGE H T, COBB L A and SANDLER H Left ventricular volumes in valvular heart disease *Circulation* 29 887 1964
- JONELL S A method for the determination of the heart size by teleroenigenography (a heart volume index) *Acta radiol (Stockh)* 20 325 1939
- JOSE A H, TAYLOR R R and BERNSTEIN L The influence of arterial pressure on mitral incompetence in man *J clin Invest* 43 2094 1964
- KAPLAN S Pressure curve analysis *In* *Intra vascular catheterization* H A Zimmerman (ed) Ed 2 Thomas Springfield Ill 1966
- KATTUS A A and GREGG D F Some determinants of coronary collateral blood flow in the open chest dog *Circulat Res* 7 628 1959
- KATZ L N *Electrocardiography* Ed 3 Lea & Febiger Philadelphia 1949
- KENNEDY J W, BAXLEY W A and DODGE H T Hemodynamics of ruptured chordae tendinae (Abstract) *Circulation* 34 Suppl 111 142 1966
- KERLEY J P *Radiology in heart disease* *Brit med J* 11 594 1933
- KHALAF J D, CHAPMAN C H and ERNST R The cinefluorographic approach to the diagnosis of mitral regurgitation *Progr cardiovascular Dis* 5 230 1962
- KILTY S E and LEFESCHWIK E Effect of body build on the QRS voltage of the electrocardiogram in normal men Its significance in the diagnosis of left ventricular hypertrophy *Circulation* 31 77 1965
- KINCAID SMITH P and BARLOW J The aortic sound in hypertension and ischaemic heart disease With reference to its timing and mode of production *Brit Heart J* 21 479 1959
- KJELLBERG S R The roentgenologic determination of heart volume *Acta med scand* 145 Suppl 277 25 1952
- KJELLBERG S R, LONROTH H and RUDHE U The effect of various factors on the roentgenological determination of the cardiac volume *Acta radiol (Stockh)* 35 413 1951
- KJELLBERG S R, RUDHE U and SJOSTRAND T The relation of the cardiac volume to the weight and surface area of the body, the blood volume and the physical capacity for work *Acta radiol (Stockh)* 31 113 1949
- KLEPZIG II and FRISCH P *Röntgenologische Herzvolumenbestimmung in Klinik und Praxis* Thieme Stuttgart 1965
- KORN D, DESANCTIS R W and SELL S Massive calcification of the mitral annulus A clinico-pathological study of fourteen cases *New Engl J Med* 267 900 1962
- KURTZMAN R S and LOPSTROW J E Detection and evaluation of myocardial infarction by image amplification and cinefluorography *Radiology* 81 57 1963
- LAGERLOF H and JEWELL L Studies on the circulation of blood in man VI The pulmonary capillary venous pressure pulse in man *Scand J clin Lab Invest* 147 1949
- LAUB L E *Electrocardiography and vectorcardiography Instrumentation fundamentals and clinical applications* Saunders Philadelphia 1965
- LAET L and MÜLLER A Der myokardiale Druck *Helvet physiol pharmacol Acta* 16 88 1958
- LAUBRY C and SOLLET P Les maladies des coronaires Ed 2 Masson & Cie Paris 1950
- LALRENS P Considerations sur l'origine des bruits du coeur *Acta cardiol (Brux)* 19 327 1961
- LAVENDER J P and DOFFMAN J The hilum in pulmonary venous hypertension *Brit J Radiol* 35 303 1962
- LAVENDER J P, DOFFMAN J, SHAWDON H and STEINER R E Pulmonary veins in left ventricular failure and mitral stenosis *Brit J Radiol* 35 293 1962
- LEATHAM A Auscultation of the heart *Lancet* 11 703 757 1958 a
- LEATHAM A Systolic murmurs *Circulation* 17 601 1958 b
- LEE K T, THOMAS W A, RABIN E R and O'NEAL R M Clinical and anatomic features in five hundred patients with fatal acute myocardial infarction *Circulation* 15 197 1957
- LEIGHTON R F, PAGE W L, GOODWIN R S, MOLPAR W, WOODLEY C F and RYAN J M Mild mitral regurgitation Its characterization by intracardiac phonocardiography and pharmacologic responses *Amer J Med* 41 168 1966
- LEPESCHWIK E *Das Electrocardiogram* Ed 3 Steinkopff Dresden 1957

- LEVINE S and HARVEY W P Clinical auscultation of the heart Ed 2 Saunders Philadelphia 1959
- LEVY M J and EDWARDS J F Anatomy of mitral insufficiency *Progr cardiovasc Dis* 5: 119 1962
- LEWIS B M HOUSSEY H E J HAYNES F W and DEXTER L The dynamics of both right and left ventricles at rest and during exercise in patients with heart failure *Circulat Res* 1: 312 1953
- LEWIS D H Phonocardiography In *Handbook of physiology* W F Hamilton and P Dow (ed) Sect 2 Circulation vol I Amer Physiol Soc Washington D C 1962
- LIXOFF W HASPARAN H SEGAL B L NOVACK P and LEHMAN J Clinical correlation of coronary arteriography *Amer J Cardiol* 16: 159 1965
- LILJESTRAND G LYSHELM E NYLIN C and ZACHRISSON G G Normal heart volume in man *Amer Heart J* 17: 406 1939
- LIND J Heart volume in normal infants: A roentgenological study *Acta radiol (Stockh)* Suppl 82 1950
- LINDBERG H A BERKSON D STAMLER J and POINDEXTER A Totally asymptomatic myocardial infarction: An estimation of its incidence in the living population *Arch intern Med* 106: 628 1960
- LINDERHOLM H and STRANDELL T Heart volume in the prone and erect positions in certain heart cases *Acta med scand* 162: 247 1958
- LINDBACH A J Die pathologische Anatomie des Herzensuffizienz In *Handbuch der inneren Medizin* L Mohr R Staehelin G von Bergmann and others eds Vol 9 pt 1 Ed 4 Springer Berlin 1960
- LIPMAN H S and MASSIE E Clinical scalar electrocardiography Ed 5 Year Book Med Publ Chicago 1965
- LEVINSOHN R B Central control of receptors and sensory transmission systems In *Handbook of physiology* J Field H V Magoun and V E Hall (ed) Sect 1 Neurophysiology vol I Amer Physiol Soc Washington D C 1959
- LONGE PATECH I The ageing of cardiac infarcts and its influence on cardiac rupture *Brit Heart J* 13: 37 1951
- LOGAN A and TURNER R The diagnosis of mitral incompetence accompanying mitral stenosis: Review of eleven cases treated surgically *Lancet* II: 593 1952
- LOGAN A TURNER R W D and KITCHIN A H Surgical treatment of mitral incompetence *Brit Heart J* 29: 1 1967
- LOGUE R B and HURST J W Etiology and clinical recognition of heart failure In *The heart* J W Hurst and R B Logue (ed) McGraw Hill New York 1966 a
- LOGUE R B and HURST J W Clinical recognition of coronary atherosclerosis and its complications In *The heart* J W Hurst and R B Logue (ed) McGraw Hill New York 1966 b
- LOCLE R H ROGERS J V Jr and GAY B B Jr Subtle roentgenographic signs of left heart failure *Amer Heart J* 65: 464 1963
- LORENZO R and BOTO D Soplo mero-sistólico proto-meso-sistólico en un infarto de tipo punta *Comprensión necropsica* *Pren méd argent* 24: 435 1936
- LORENZO R EVI-FRANDE E and BAILA M R La unidad del soplo mero-sistólico para localizar un infarto del miocardio cuya expresión electrocardiográfica no entra dentro de los esquemas considerados como típicos *Pren méd argent* 21: 1780 1934
- LUBECK I HEINE K and HOLSTEIN J Veränderungen der P Form im Elektrokardiogramm bei Blutdrucksenkung *Z ges inn Med* 18: 241 1963
- LUSADA A A From auscultation to phonocardiography *Mosby* St Louis 1965
- LUSADA A A and SZATKOWSKI J Relative vs organic mitral insufficiency *Amer J Cardiol* 5: 111 1960
- LUSADA A A and DEBARTOLO G High frequency phonocardiography *Amer J Cardiol* 8: 51 1951
- MCDONALD D A The occurrence of turbulent flow in the rabbit aorta *J Physiol (London)* 118: 340 1952
- MCDONALD L DEVALY J B Jr RABINOWITZ M and DEXTER L Clinical physiological and pathological findings in mitral stenosis and regurgitation *Medicine (Baltimore)* 36: 237 1957
- MCCLUSKEY A Cardiovascular sound in health and disease *Williams & Wilkins* Baltimore 1958
- MCCLUSKEY A WEBB G and HUMPHRIES J O' and REID J A On cardiovascular sound: Further observations by means of spectral phonocardiography *Circulation* 11: 849 1955
- MCNICOL M W KIRBY E J BHOOJA K D EVEREST M E PRICE H V and FREEDMAN S F Pulmonary function in acute myocardial infarction *Brit med J* 11: 1270 1965
- MAHER J F MALLORY G H and LAURENZ G A Rupture of the heart after myocardial infarction *New Engl J Med* 255: 1 1956
- MALACH M and ROSENBERG M Acute myocardial infarction in a city hospital I: Clinical review of 264 cases *Amer J Cardiol* 1: 682 1958
- MALMCRONA R Haemodynamics in myocardial infarction *Acta med scand* 175 Suppl. 417 1964
- MALOVE R G S and PARKES W E Rupture of the interventricular septum *Brit Heart J* 17: 448 1955
- MANTINI E Papillary muscles as determinants of

- left ventricular contractility (Abstract) *Amer J Cardiol* 19 324 1967
- MANNING, G W and SMILEY J R QRS voltage criteria for left ventricular hypertrophy in a normal male population *Circulation* 29 224 1964
- MARTINS DE OLIVEIRA J and ZIMMERMAN H A Auricular overloadings Electrocardiographic analysis of 193 cases *Amer J Cardiol* 3 453 1959
- MARTON F Mitrahinsufficiens *Nord Med* 76 1205 1966
- MASSEY F C and DRAKE W L Spontaneous rupture of the heart due to myocardial infarction *Amer J Med* 5 775 1948
- MASSIE E and WALSH T J Clinical vector cardiography and electrocardiography Year Book Publ Chicago 1960
- MASTER A M P wave changes in acute coronary occlusion *Amer Heart J* 8 462 1933
- MASTER A M DACK S and JAFFE H L Coronary thrombosis An investigation of heart failure and other factors in its course and prognosis *Amer Heart J* 13 330 1937
- MASTER A M DACK S and JAFFE H L Follow up studies in coronary artery occlusion I Degree of recovery symptoms and physical signs *N Y St J Med* 42 413 1942
- MASTER A M and FRIEDMAN R A Phonocardiographic study of the heart sounds in acute coronary occlusion *Amer Heart J* 24 196 1942
- MASTER A M CARFIELD C I and WALTERS M B Normal blood pressure and hypertension new definitions Lea & Febiger Philadelphia 1952
- MASTER A M and LASER R P Blood pressure elevation in the elderly patients In *Hypertension Recent advances 2nd Hahnemann symp* A N Brent and J H Moyer (ed) Lea & Febiger Philadelphia 1961
- MAUREA C NYLIN G and SOILBERGER A Normal heart volume *Acta cardiologica (Brux)* 10 336 1955
- MAZZITELLO W F Papillary muscle paralysis *Marquette med Rev* 30 143 1964
- MENGES II Jr ANKENY J L and HELLERSTEIN H K The clinical diagnosis and surgical management of ruptured mitral chordae tendinae *Circulation* 30 8 1964
- MERCER E N and WALTERS M B Mitral regurgitation simulating aortic stenosis *Canad med Ass J* 93 413 1965
- MILLER R Jr and PEARSON R J Jr Mitral insufficiency simulating aortic stenosis Report of an unusual manifestation of Marfan's syndrome *New Engl J Med* 260 1210 1959
- MINTZ S and KATZ L N Recent myocardial infarction Analysis of five hundred and seventy two cases *Arch intern Med* 80 203 1947
- MIORI R and MAZZEI G Il quadro elettrocardiografico di ingrandimento atriale sinistro in corso di infarto miocardico e il suo significato *Minerva cardiologia europ* 13 65 1965
- MITCHELL J R A and SCHWARTZ C J The relation between myocardial lesions and coronary artery disease II A selected group of patients with massive cardiac necrosis or scarring *Brit. Heart J* 25 1 1963
- MOLLER J H NAKIS A and EDWARDS J E Infarction of papillary muscles and mitral insufficiency associated with congenital aortic stenosis *Circulation* 34 87 1966
- MORAN II J RICHART T S FRITZ A J ACERPE P W DAVILA J C and CLOVER R P The production of chronic experimental mitral insufficiency *Ann Surg* 145 500 1957
- MORRIS J J Jr ESTES E H Jr WHALEN R E THOMPSON H K Jr and MCINTOSH H D P wave analysis in valvular heart disease *Circulation* 29 242 1964
- MORROW A G BRAUNWALD M HALLER J A and SHARP E H Left atrial pressure pulse in mitral valve disease A correlation of pressures obtained by transbronchial puncture with the valvular lesion *Circulation* 16 399 1957
- MOSES C Atherosclerosis Mechanism as a guide to prevention Lea & Febiger Philadelphia 1963
- MOSS A J Intramyocardial oxygen tensions (Abstract) *Circulation* 34 Suppl III 176 1966
- MOUNSEY P Determination of success after mitral valvotomy Role of circulatory obstruction of the myocardium and of other factors *Brit med J* 11 311 1957
- MOUNSEY P and BRIDGEN W The apical systolic murmur in mitral stenosis *Brit Heart J* 16 255 1954
- MULLER A Physiologie des Coronarkreislaufes *Cardiologia (Basel)* 40 62 1962
- MULLER O and RORVICK K Hemodynamic consequences of coronary artery disease with observations during anginal pain and on the effect of nitroglycerine *Brit Heart J* 20 302 1958
- MULLINS C B PAYNE R M and MITCHELL J H Volume changes of the left ventricle following experimental coronary artery occlusion (Abstract) *Circulation* 34 Suppl III 177 1966
- MURRAY G The pathophysiology of the cause of death from coronary thrombosis *Ann Surg* 126 523 1947
- MUSCHOFF K and REINDELL H Zur Röntgenuntersuchung des Herzens in horizontaler und vertikaler Körperstellung I Der Einfluss der Körperstellung auf das Herzvolumen *Dtsch Med Wschr* 81 1001 1956
- MUSCHOFF K REINDELL H KLEPZIG H FRISCH P EMMERICH J KONIG K STEIN H BAUMGARTEN B and MOYER F Zur Normalgröße des gesunden Herzens *Fortsch Röntgenstr* 88 88 1958
- NAGER F KAUFMANN G and SCHAUB F

- Die Leistungsfähigkeit mechanokardiographischer Untersuchungen in der Erfassung der Mitralsuffizienz und ihres Schweregrades unter besonderer Berücksichtigung der kombinierten Mitralklappen Cardiolgia (Basel) 44 218 1964
- NEVADBA P Die Herzruptur nach Myokardinfarkt Cardiolgia (Basel) 26 103 1955
- NEW YORK HEART ASSOCIATION Nomenclature and criteria for diagnosis of diseases of the heart and blood vessels By the criteria committee of New York Heart Association Inc Ed 5 New York 1953
- NEZLIN V E and SHAMESOVA L G Infarction of papillary muscles: clinical and anatomicopathologic observations (In Russian) Klin Med. (Moskva) 29 51 1951
- NIXON P G F The third heart sound in mitral regurgitation Brit Heart J 23 677 1961
- NIXON P G F The genesis of the third heart sound Amer Heart J 63 712 1963
- NIXON P G F and WAGNER G R The duration of left ventricular systole in mitral incompetence Brit Heart J 24 464 1962
- NIXON P G F and WOOLER G H Left ventricular filling pressure gradient in mitral insufficiency Phases of diastole in various syndromes of mitral valvular disease Brit Heart J 25 382 1963 a
- NIXON P G F and WOOLER G H Phases of diastole in various syndromes of mitral valvular disease Brit Heart J 25 393 1963 b
- NOREY G R, RACHIB G, MOLLER J H, AMPLATZ K, ADAMS P Jr and EDWARDS J E Anomalous origin of the left coronary artery from the pulmonary trunk with special reference to the occurrence of mitral insufficiency Circulation 30 171 1964
- NUZUM F H Auscultatory evidence of cardiac rupture Amer Heart J 39 909 1950
- NYLIN G The clinical applicability of roentgenological heart volume Determination with special reference to residual blood Acta cardiologica (Brux) 17 588 1957
- OSER E Beitrag zu Frage der Abrisse von Papillarmuskeln Zbl allg Path path Anat 91 453 1954
- OSGLEY P A, SPRAGUE H B, RAPAPORT M H and NADAS A H Heart sounds and murmurs A clinical and phonocardiographic study Grune & Stratton New York 1960
- OPDYKE D F and FOREMAN R C A study of coronary flow under conditions of hemorrhagic hypotension and shock Amer J Physiol 148 726 1947
- ORLIS O The dynamic changes in the ventricles following ligation of the ramus descendens anterior Amer J Physiol 100 629 1932
- ORLANDO M D, WOOLLEY C F, SCARFELLI H and RYAN J M Mitral valve regurgitation caused by infarcted papillary muscles A report of fifteen cases (Abstract) Ann intern. med 61 801 1964
- OSMONDSON H J, CALLAGHAN J A and EDWARDS J F Ruptured mitral chordae tendinae Circulation 23 42 1951
- OWEN S G and WOOD P A new method of determining the degree or absence of mitral obstruction An analysis of the diastolic part of indirect left atrial pressure tracings Brit Heart J 17 41 1955
- PARRY E and MOLNÉY P Gallop sounds in hypertension and myocardial ischaemia modified by respiration and other manoeuvres Brit Heart J 23 393 1961
- PARTAMIAN J O and BRADLEY R F Acute myocardial infarction in 258 cases of diabetes Immediate mortality and five year survival New Engl J Med 273 455 1965
- PATNY M S Clinical presentation of myocardial infarction in the elderly Brit Heart J 22 190 1967
- PEACOCK T H Valvular disease of the heart Churchill London 1865
- PEEL A A F, SEMPLE T, WANG I, LANCASTER W M and DALL J L G A coronary prognostic index for grading the severity of infarction Brit Heart J 24 745 1962
- PERLOFF J K and HARVEY W P Auscultatory and phonocardiographic manifestations of pure mitral regurgitation Progr cardiovasc Dis 5 172 1962
- PHILLIPS J H, BURCH H E and DEPASQUALE V P The syndrome of papillary muscle dysfunction Its clinical recognition Ann intern Med 59 503 1963 a
- PHILLIPS J H, DEPASQUALE V P and BURCH G E The electrocardiogram in infarction of the anterolateral papillary muscle Amer Heart J 67 338 1963 b
- PREME T E Pressure measurement electrical pressure transducers Progr cardiovasc Dis 5 574 1963
- PLÖTZ M H Coronary heart disease: angina pectoris myocardial infarction Hoeber Harper New York 1957
- POTAIN P C E Cited by Casser (1932 1933)
- PRIEST E A, FINLAYSON J K and SHORT H S The x ray manifestations of the heart and lungs of mitral regurgitation Progr cardiovasc Dis 5 219 1962
- PRINZMETAL M, SCHWARTZ L L, CORDAY E, SPRITZLER R, BERGMAN H C and KRUGER H E Studies on coronary circulation VI Loss of myocardial contractility after coronary artery occlusion Ann intern Med 31 429 1949
- PROGER S and NAIMI S Acute and chronic coronary heart disease Progr cardiovasc Dis 6 1 1963
- PRUITT R D, DENNIS W and KINARD S A The difficult electrocardiographic diagnosis of myocardial infarction Progr cardiovasc Dis 6 85 1963

- PUECH, P., ESCLAVESAT M. SODI-PALLARES D. and CINEROS F. Normal auricular activation in the dog's heart *Amer Heart J* 47 174 1954
- RADNER S. Potentialgenesen for elektrokardiogrammet P. Ågor. XIII Medicinska Riksstämman 1-4 December 1966 Stockholm 1966
- RAFTERY E. B. OALLEY C. M. and GOODWIN J. F. Acute subvalvar mitral incompetence *Lancet* II 360 1966
- RAPPAPORT M. H. and SPRAGUE H. B. Physiologic and physical laws that govern auscultation and their clinical application. The acoustic stethoscope and the electrical amplifying stethoscope and stethograph *Amer Heart J* 27 257 1941
- RAPPAPORT, M. B. and SPRAGUE H. B. The graphic registration of the normal heart sounds *Amer Heart J* 23 591 1942
- RATHE H. W. Myocardial infarction. Clinical features and prognosis *J Amer med Ass* 120 99 1942
- RAVIN, A. Auscultation of the heart. Ed. 2 Lloyd-Luke 1967
- REES R. S. O. JEFFERSON, K. E. and HARRIS A. M. Cine angiocardiology of the mitral valve. *Brit Heart J* 27 498 1965
- RESNIK, W. H. The significance of prolonged anginal pain (preinfarction angina) *Amer Heart J* 63 290 1962
- REZNIKOFF P. The auscultatory sign in a case of spontaneously rupturing heart *J Amer med Ass* 78 1296 1922
- REYNOLDS G. The atrial electrogram in mitral stenosis *Brit Heart J* 15 250 1953
- RIEDERER J. and THEISEL K. G. Zur Diagnose und Differentialdiagnose eines Herzwandaneurysmas mit Ruptur und Pseudodivertikelbildung des Perikards *Cardiologia (Basel)* 27 44 1955
- ROBBARD S. The production and physical qualities of sound in the cardiovascular system. In: The theory and practice of auscultation 9th Hahnemann symposium B. L. Segal (ed.) Davis Philadelphia 1964
- ROBBARD S. and WILLIAMS F. The dynamics of mitral insufficiency *Amer Heart J* 48 521 1954
- RORVE, K. Apexcardiography, phonocardiography and ballistocardiography - their diagnostic and prognostic significance in coronary heart disease *Acta med scand.* 174 Suppl. 404 1963
- ROSEMAN M. D. Painless myocardial infarction. A review of the literature and analysis of 220 cases *Ann. intern. Med.* 41 1 1954
- ROSS C. Effect of hypertension on P wave of the electrocardiogram. *Brit Heart J* 23 460 1963
- ROSS J. JR. BRAUNWALD E. and MORROW A. G. Clinical and hemodynamic observations in pure mitral insufficiency *Amer J Cardiol* 2 11 1958
- ROSS J. JR. COOPER T. and LOMBARDO C. R. Hemodynamic observations in experimental mitral regurgitation *Surgery* 47 795 1960
- ROSS, R. S. and CRILEY J. M. Contrast radiography in mitral regurgitation *Progr cardiovasc Dis* 5 195 1962
- ROSS R. S. CRILEY J. M. and EPSTEIN E. J. Cinecardiographic studies of sound production by diseased and prosthetic aortic valves. In: The theory and practice of auscultation 9th Hahnemann symposium B. L. Segal (ed.) Davis Philadelphia 1964
- ROUSSEAU R. F. WATSON, N. HARDING D. and BAKER D. Effects of acute coronary occlusion on performance of right and left ventricles in intact unanesthetized dogs *Amer Heart J* 66 522 1963
- RUSSEK, H. I. ZOHMAN B. L. DOERNER A. V. RUSSEK, A. S. and WHITE L. G. Age and survival in cases of acute myocardial infarction *J Amer med Ass* 147 1731 1951
- RUTISHAUSER W. ALSLEBEN V. and HEGGLIN R. Verstärkung der Mitral Klappeninsuffizienz und von Links-rechts Shunts durch Hypertensionsinflation. Nachweis mit der peripheren Farbstoffverdünnungsmethode *Klin Wschr* 41 1020 1963
- SAGER, R. V. Coronary thrombosis. Perforation of the infarcted interventricular septum *Arch intern Med* 53 140 1934
- SAKAMOTO T. KINUKAWA, R. MACCANON D. M. and LUGADA A. A. Hemodynamic determinants of the amplitude of the first heart sound *Circulat Res* 16 45 1965
- SALISBURY P. F. CROSS C. E. and RIEBEN P. A. Distensibility and water content of heart muscle before and after injury *Circulat Res* 8 788 1960
- SALISBURY P. F. CROSS C. E. and RIEBEN P. A. Acute ischemia of inner layers of ventricular wall *Amer Heart J* 66 630 1963 a
- SALISBURY P. F. CROSS C. E. and RIEBEN P. A. Chorda tendinae tension *Amer J Physiol* 203 385 1963 b
- SAMPSON J. J. FELTON L. R. GOETZ A. A. SOLOMON B. and AXELRAD B. Portable serial roentgenkymography in acute myocardial infarction *Circulation* 13 729 1956
- SANDERS R. J. KERN W. H. and BLOUNT S. G. Jr. Perforation of the interventricular septum complicating myocardial infarction *Amer Heart J* 51 736 1956
- SANDERS R. J. NEUBERGER K. T. and RAVIN A. Rupture of papillary muscles. Occurrence of rupture of the posterior muscle in posterior myocardial infarction. *Dis Chest* 31 316 1957
- SANO T. HELLERSTEIN H. K. and VAYDA, E. Pectoral loop in health and disease as studied by the technique of electrical dissection of the vectorcardiogram (differential vectorcardiography) *Amer Heart J* 53 854 1957
- SARNOFF S. J. and BERGLUND E. Ventricular function. I. Starling's law of the heart studied

- by means of simultaneous right and left ventricular function curves in the dog *Circulation* 9 706 1954
- SCHERF D and BROOKS A. M. The murmurs of cardiac aneurysm. *Amer J med Sci* 218 389 1949
- SCHETTLE G (ed.) *Arteriosklerose Ätiologie Pathologie Klinik und Therapie* Thieme Stuttgart 1961
- SCHMERT G, SCHMIDLER W, SCHWAB H and EBERL J. Die Coronarerkrankungen Coronarinsuffizienz Angina pectoris und Herzinfarkt. In *Handbuch der Inneren Medizin* L. Mohr R. Stachelin G. von Bergman and oth eds Vol. 9 pt 3 Springer Berlin 1960
- SCHLANT R. C. Altered physiology of the cardiovascular system in heart failure. In *The heart* J. W. Hurst and R. H. Logue (ed.) McGraw Hill New York 1966
- SCHLESINGER M. J. Relation of anatomic pattern to pathologic conditions of the coronary arteries. *Arch. Path.* 30 403 1940
- SCHLICHTER J, HELLERSTEIN H. A. and KATZ L. N. Aneurysm of the heart A correlative study of one hundred and two proved cases. *Medicine* (Baltimore) 33 43 1954
- SCHNUR S. Mortality rates in acute myocardial infarction II A proposed method for measuring quantitatively severity of illness on admission to the hospital. *Ann. intern. Med.* 39 1018 1953
- SCHOENMACKERS J. Pathologische Anatomie des insuffizienten Herzklappenapparates. *Verh. d. Ges. Kreisf. Forsch.* 31 15 1965
- SCHRIER G, VOGELPOEL, L. and NELLEN M. SWANEPOEL, A. and BECK W. Silent mitral incompetence. *Amer Heart J* 61 723 1961
- SCHUTZ E. Über den Einfluss des intraventrikulären systolischen Druckes auf die koronar durchblutung. *Z. Kreisf. Forsch.* 45 708 1956
- SCHWEDEL J. H. SAMET P. and MEDVICK H. Electrocardiographic studies of abnormal left ventricular pulsations. *Amer Heart J* 40 410 1950
- SCHWEIZER, W. BERTRAM R. V. and REIST P. Kinetocardiography in coronary artery disease. *Brit. Heart J* 27 263 1965
- SEGAL, B. L. and LIKOFF W. Late systolic murmur of mitral regurgitation. *Amer Heart J* 67 757 1964
- SEGAL, B. L. NOVACK, P. and KASPARIAN H. Intracardiac phonocardiography. *Amer J Cardiol* 13 188 1964
- SEGALL, H. N. Heart sounds and murmurs in 400 normal subjects. *Canad med Assoc J* 87 377 1962
- SELDINGER S. I. Catheter replacement of the needle in percutaneous arteriography—a new technique. *Acta radiol. (Stockh.)* 39 368 1953
- SHABETAI R. and MARSHALL, W. J. Systolic murmurs. *Amer Heart J* 65 412 1963
- SHAH F. M., SLODKI E. J. and LUNADA, A. A. A revision of the classic areas of auscultation of the heart A physiologic approach. *Amer J Med* 36 293 1964
- SILAPRO H. A. and WEISS D. R. Mitral insufficiency due to ruptured chordae tendinae simulating aortic stenosis. *New Engl J Med* 261 272 1959
- SILLINGFORD J. H. The estimation of severity of mitral incompetence. *Progr. cardiovasc. Dis.* 5 248 1962
- SILLITO F. H., CHAMBERLAIN F. L. and LEVY R. L. Cardiac infarction The incidence and correlation of various signs with remarks on prognosis. *J. Amer. med. Ass.* 118 779 1942
- SHORT D. S. Radiology of the lung in left heart failure. *Brit Heart J* 18 233 1956
- SIEVERS J. Myocardial infarction. Clinical features and outcome in three thousand thirty six cases. *Acta med. scand.* 175 Suppl. 496 1953
- SIMON M. The pulmonary vessels in incipient left ventricular decompensation. Radiologic observations. *Circulation* 21 183 1951
- SIMON M. A. and LIU S. F. Calcification of the mitral valve annulus and its relation to functional valvular disturbance. *Amer Heart J* 49 497 1954
- SIMONSON H., TUNA N., OKAMOTO N. and TOSHIMA H. Diagnostic accuracy of the vectorcardiogram and electrocardiogram. A cooperative study. *Amer J Cardiol* 17 829 1966
- SITAR J. The clinical significance of the P — sinuscardiale in left ventricular myocardial infarctions. *Cor et Vasa (Praha)* 7 301 1965
- SLAPAK L. Über das Aneurysma im Bereich des Septum interventriculare cordis. *Cardiologia (Basel)* 21 120 1952
- SLEEPER J. C., ORIGIN E. S. and MCINTOSH H. H. Mitral insufficiency simulating aortic stenosis. *Circulation* 5 428 1952
- SNOW P. J. D., JONES A. M. and DABER K. S. A clinico-pathological study of coronary disease. *Brit. Heart J* 18 435 1956
- SODI PALLARES D., BISTENI A., CISNEROS F., DE MICHELI A., MEDRANO G. A. and TESTELLI M. H. Reliability of the electrocardiogram in diagnosis of myocardial infarction. In *Coronary heart disease. 7th Hahnemann symp.* W. Likoff and J. H. Moyer (ed.) Grune & Stratton New York 1963
- SODI PALLARES D., BISTENI A., MEDRANO G. A. and de LEON J. P. Correspondence course on electrocardiography and vectorcardiography (Deductive method). Instituto Nacional de Cardiologia Mexico 1963
- SODI PALLARES, D. and CALDER R. M. New bases of electrocardiography. Mosby St. Louis 1956
- SOKOLOV M. and LYON T. F. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. *Amer Heart J* 37 161 1919

- SOLOFF L. A. and ZATLICHN J Cardiac chamber volumes and their significance in rheumatic heart disease with isolated mitral stenosis *Circulation* 18 783 1958
- SOULIF P ACAR J FORMAN J and BEN ISMAEL M Le syndrome Pseudostenose aortique insuffisance mitrale *Arch Mal Coeur* 56 945 1963
- SOULIF P and GERBEAUX J Notes à propos des souffles systoliques dans la symptomatologie de certains infarctus du myocarde *Gaz méd Fr* 46 205 1939
- SOULIF P, MORIN B ACAR J FORMAN J and CARAMANIAN M Insuffisance mitrale par fibrose ischémique des piliers *Arch Mal Coeur* 59 694 1966
- SPELTZHOFF W Die Arterien der Herz wand anatomische Untersuchungen an Menschen und Tierherzen Huzel Leipzig 1924
- SPEYER M P and GREISS F C Dynamics of ventricular ejection *Circulat Res* 10 274 1962
- STANFIELD C A. and LE P N Hemodynamic effects of methoxamine in mitral valve disease *Circulat Res* 8 839 1960
- STEINER R E Pulmonary hypertension A symposium II Radiological appearances of the pulmonary vessels in pulmonary hypertension *Brit J Radiol* 31 188 1958
- STEINER R E The roentgenology of pulmonary manifestations in mitral heart disease and left heart failure *Progr cardiovasc Dis* 2 1 1959
- STEINER R E DINSVORE R and PARIZEL G Mitral regurgitation *Clin Radiol* 14 113 1963
- STOKES J III and DAWBER T R The silent coronary The frequency and clinical characteristics of unrecognized myocardial infarction in the Framingham study *Ann intern Med* 50 1359 1959
- SUN SOON KYO and EDDLEMAN E E Jr Kinetocardiographic findings of myocardial infarction *Circulation* 19 531 1959
- SUTNICK A I and SOLOFF L A Posterior rotation of the atrial vector An electrocardiographic sign of left ventricular failure *Circulation* 26 919 1962
- TAKENBAUM H L and PRAFF W W Effect of pressor amines on experimental intracardiac shunts and valvular regurgitation *Dis Chest* 44 480 1963
- TAVEL M E CAMPBELL R W and ZIMMER J F Late systolic murmurs and mitral regurgitation *Amer J Cardiol* 15 719 1965
- TENNANT R and WIGGERS, C J Effect of coronary occlusion on myocardial contraction *Amer J Physiol* 112 351 1935
- TUCKER W T KNOWLES J L and EDDLEMAN E E Jr Mitral insufficiency cardiac mechanics as studied with the kinetocardiogram and ballistocardiogram *Circulation* 17 278 1955
- TUMANOVSKI M M and GARMASH V V Electrokytographische und roentgenkytographische investigation of patients with myocardial infarction *Cor at Vasa (Praha)* 5 90 1963
- UEDA H SAKAMOTO T UOZUMI Z INOUE K KAWAI N and YAMADA T The use of methoxamine as a diagnostic aid in clinical phonocardiography *Jap Heart J* 7 204 1966
- UNGERMANN H Ergebnisse roentgenologischer Lungenuntersuchungen bei frischem Herzinfarkt *Med. Klin* 59 1738 1964
- VAGUEZ H Maladies du coeur Bailliere & Fils Paris 1921
- VANL, R J Ventricular aneurysms of the heart Preliminary report on some new clinical signs *Amer Heart J* 49 934 1955
- VALENTINE P A FLUCK D C MOUNIEY J P D, REID D SHILLINGFORD J P and STEINER R E Blood gas changes after acute myocardial infarction *Lancet* 11 837 1966
- VILL H Störungen der Erregungsbildung und Erregungsleitung bei Myokardinfarkt II Kreisforsch 39 168 1949
- VIVELL, O Durchstromungsversuche am Coronar system bei normalem hypertrophischem und atrophischem Herzmuskel *Beitr path Anat* 111 125 1951
- WADE G WERKO, L ELIASCH H GIDLUND A. and LAGERLOF H The haemodynamic basis of the symptoms and signs in mitral valvular disease *Quart J med N* 21 361 1952
- WADE O L and BRIDG J M Cardiac output and regional blood flow Blackwell Oxford 1962
- WARR E K, SUTONEN L and HIMANKA E Heart size and prognosis in myocardial infarction *Amer Heart J* 71 187 1966
- WEAVER W F and WALKER C H M Innocent cardiovascular murmurs in the adult A 16 years follow up *Circulation* 29 702 1964
- WEGRA R FRANK C W MISRARY G A. WAGO H H MILLER R and CASE R B Immediate hemodynamic effects of acute coronary artery occlusion *Amer J Physiol* 177 123 1954
- WEINBERG S L REYNOLDS R W ROSENMAN R H and KATZ L N Electrocardiographic changes associated with patchy myocardial fibrosis in the absence of confluent myocardial infarction *Amer Heart J* 40 745 1950
- WEITZMAN D The mechanism and significance of the auricular sound *Brit. Heart J* 17 70 1955
- WELLS II G The diagnosis of mitral incompetence from left atrial pressure curves *Brit Heart J* 20 321 1958
- WENGER R and HOFMANN CRENNER D Observations on the atria of the human heart by direct and semidirect electrocardiography *Circulation* 5 670 1952
- WERKO L The dynamics and consequences of stenosis or insufficiency of the cardiac valves In Handbook of physiology W F Hamilton and P Dow (ed.) Sect 2 vol 1 Amer Physiol Soc Washington D C 1962

- WERKO L. Mitral valvular disease. Hemodynamic studies of the consequences for the circulation Almqvist & Wiksell Stockholm 1964
- WEST J B Influence of hydrostatic pressure in the pulmonary circulation. Symposium on pulmonary circulation Jap Heart J 7 350 1966
- WEST J B Perivascular edema a factor in pulmonary vascular resistance Amer Heart J 70 570 1965
- WIGGERS C J and FEN, H Cardiodynamics of mitral insufficiency Heart 9 149 1922
- WOLLHEIM E. and VOELLER J Hypertonie In Handbuch der inneren Medizin L. Mohr R. Stachelin G von Bergmann and oth. eds Vol. 9 pt 5 Ed. 4 Springer Berlin 1960
- WOLLHEIM E. and SCHNEIDER, K. W Zur Hamodynamik nach Myokardinfarkt Arch Kreisl Forsch 28 171 1958
- WOOD E. H LEUSEN I R. WARNER H R and WRIGHT J L. Measurement of pressures in man by cardiac catheters Circulat Res 2 294 1954
- WOOD P An appreciation of mitral stenosis Part I Clinical features Part II Investigations and results Brit med J 1 1051 1113 1954
- WOOD P Diseases of heart and circulation III 2 Eyre & Spottiswoode London 1956
- WOOD P Aortic stenosis Amer J Cardiol 1 553 1958
- WOOD P Acute and subacute coronary insufficiency Brit med J 1 1779 1961
- WRIGHT I S MARPLE C. D and BECK, D F Myocardial infarction Its clinical manifestations and treatment with anticoagulants A study of 1031 cases Publ for Amer Heart Ass by Grune & Stratton New York 1954
- WRÓBLEWSKI F The clinical significance of transaminase activities of serum. Amer J Med 27 911 1959
- YATER W M TRUHM A H BROWN W G FITZGERALD R P GESLER M. A. and WILCOFF B B Coronary artery disease in man eighteen to thirty nine years of age Amer Heart J 36 334 481 683 1948
- YU P Y FINLAYSON J K. and LURIA M. N Indicator-dilution curves during methoxamine infusion in patients with mitral valvular disease Circulat Res 9 319 1961
- YURCHAK P M and GORLIN R. Paradoxical splitting of the second heart sound in coronary heart disease New Engl J Med. 269 741 1963
- ZALTER R HARDY H G. and LUSADA, A. A. Acoustic transmission characteristics of the thorax. J Appl Physiol 18 428 1963
- ZEH E. Die Diagnose der Trikuspidalinsuffizienz. Arch Kreisl Forsch. 30 127 1959
- ZATICHNI J and VUSBALM J Recognition of acute myocardial infarction by portable chest roentgenogram. Amer J med. Sci. 245 78 1963





# APPENDIX

## Abbreviations

### Arrhythmia

AF	atrial fibrillation
APB	atrial premature beat
HB 1 2 3	Heart block 1st 2nd or 3rd degree
Nod	nodal rhythm
PB	premature beat
ST	sinus tachycardia
SVT	supraventricular tachycardia
VFB	ventricular premature beat

### Phonocardiography

- type of murmur misinterpreted in auscultation
- no difference

### Electrocardiography

- ICD intra-ventricular conduction disturbance

# CLINICAL ANALYSIS OF PATIENT SERIES

History																
Case number	Age years	Sex	Age at previous	No of previous infarcts	Cardiac disease	Blood pressure mmHg	Grade of attack	Pulmonary disease	Heart failure Left Right Aortic Delayed	Heart failure Left Right Aortic Flow p	Asymptomatic	Coronary angiogram revascularization	Paroxysmal palpitation	Pericardial effusion rub	Heart sound normal (D)	Second sound accentuated (+) or split (%)

## GROUP 1 ACUTE MITRAL INCOMPETENCE PATIENTS EXAMINED AT AUTOPSY

1	61	M	+	0		120 -	0	LRad	ST	VPB	14	+	+			
2	43	M	+	0		90	5	+	Ld	ST VPB	18	+	+			+
3	30	M	+	0	Claudication	150/90	0		Ld		7					
4	61	M	+	0	Hypertension	102/	7	+	LRad	ST AF	24			+		
5	40	M	+	0	Hypert. Rh myocard	100/	7	+	Ld	ST	22	+	+			
6	37	M	+	0	Hypertension	110/90	0		Lad	VPB	18					
7	37	F	+	1	Hypert. Fail Hypertol	110/75	0		Lad	VPB	14	+	+			
7a	63	F	+	1	Hypert. Fail Hypertol	100	5		Lad	ST	26	+	+			
8	60	M	+	2	Hypert. Failure	115/	0	+	LRad	ST	20	+	+			
9	49	M	+	1	Hypert. Diabetes	110/80	5		LRad	HB2 VPB	23	+	+			+ S
9a	49	M	+	2	Hypert. Diab. Fail	80	7		Lad		21	+				+
10	61	M	+	0	Failure	140/80	0		Lad	VPB	14				D	
11	78	M	+	0		140/40	1		LRa		12	+				
12	72	M	+	0	Hypert. Fail. Perif. art.	180/100	5	+	Lad	SVT	12					
12	47	M	+	0	Hypert. Failure	0/160	0		Lad	FB HB1	11	+				
14	31	M	+	0		115/80	0		Lad	HB2	12					+ S
15	85	M	+	0		93/70	1		LRad		13	+	+			
16	5	F	+	2	Hypert. Diabetes	140/60	7		Lad	HB2	27	+	+			
17	33	M	+	0		90/0	7		Lad	VPB	11	+	+			
18	70	M	+	1		170/5	7	+	LRad	APB VPB	11	+	+			
19	39	F	+	0		110	7		La	HB3 VPB	21	-				

## GROUP 2 NO MURMUR, PATIENTS EXAMINED AT AUTOPSY

20	34	M	+	0		130/90	0		VPB		8	+				
1	6	F	+	0	Hypert. Failure	160/100	0		Rad	VPB AF	18	+				+
21	47	M	+	0		130/40	0		La		9	+	+			
23	60	M	+	0		90/25	7		LRa	FB	1					
24	38	M	+	0	Diabetes	110/80	1		Lad	AF	18	+	+			
25	64	M	+	0	Failure Diabetes	115/90	7		LRad	AF	24	+	+			
26	62	F	+	0		105/	0		Lad	VPB	14	+	+			
27	64	M	+	1	Hypertension		5	+	La	VPB t od	25	+	+			
28	59	M	+	2		130/70	0			FB	11	+	+			
29	54	M	+	0		120/90	7				18	+	+			
30	64	M	+	0		115/75	1		Lad		11	+	+			

## GROUP 3 ACUTE MITRAL INCOMPETENCE

31	57	F	+	0	Hypertension	130/85	1		Lad	RJ	VPB	18	+			+ S
32	4	M	+	0		120/80	0		Ld	FB	13	+				
33	31	M	+	0		135/90	0		Ld	FB	8	+	+			
34	34	M	+	0	Claudication	130/90	0		Lad		7	+				+ S
35	69	M	+	0	Hypert. Claudic. Cor. vas.	160/90	0		LRad	AF HB2 APB	18	+	+			
36	58	M	+	1		130/80	0		Lad	HB2	15	+				
37	59	M	+	0		125/85	7		Ld	VR	VPB	20	+	+		
38	61	M	+	2	Hypert. Fail Diab	160/105	5		Ld	ST	18	+			D	
39	67	M	+	0	Hypert. Cor. vas.	140/100	5		Ra	Nod AF VPB	25	+	+			
40	50	M	+	0		130/80	5			VPB	13	+	+			
41	60	M	+	0	Hypertension	145/80	0		Lad	AF	14	+			D	+
42	65	M	+	0	Hypert. Diabetes	180/100	0		La		11	+	+			
43	69	M	+	0	Hypert. Claudic. Cor. vas.	155/100	0		Lad		15	+				+ S
44	68	F	+	0	Hypertension	150/85	0		Lad	FB	13	+				
45	67	F	+	0	Hypertension	160/90	0		Lad		8	+				
46	39	M	+	0	Hypertension	110/100	5		Lad		6	+			D	+ S
47	64	M	+	0	Claudication	130/80	0		Lad		10	+				

M trial crystal c murmur										Electrocardiography					Rad o-logy	
Lead	Lead	Lead	Lead	Lead	Lead	Lead	Lead	Lead	Lead	Lead	Lead	Lead	Lead	Lead	Lead	Lead
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
1	Apex	LSB	H	1	2-3					240	T	Infsept	LAH LVH ICD			
1	Apex	LSB	H	1	2-3					278	T	Ant	LAH ICD			
1	Apex	LSB	H	1	1-3					116	T	Inf	LAH	500		
1	Apex	LSB	H	1	1-3					460	T	ExtAnt	LAH ICD			
1	Apex	LSB	H	1	1-3					1545	T	Infsept				
1	Apex	LSB	H	1	1-3					98	T	Antsept Ant	LAH LVH	560		
1	Apex	LSB	H	1	1-3					180	T	PostLat	LAH	590		
1	Apex	LSB	H	1	1-3					3300	T	Ant AntLat				
1	Apex	LSB	H	1	1-3					336	T	Inf	LAH ICD			
1	Apex	LSB	H	1	1-3					333	T	InfLat		660		
1	Apex	LSB	H	1	1-3					1330	T	Inf		850		
1	Apex	LSB	H	1	1-3					8	T	InfPost		810		
1	Apex	LSB	H	1	1-3					224	T	InfPostLat	LAH			
1	Apex	LSB	H	1	1-3					42	T	Inf pt	LAH LVH ICD			
1	Apex	LSB	H	1	1-3					430	T	ExtAnt	LAH LVH	840		
1	Apex	LSB	H	1	1-3					305	T	InfPostLat	LAH			
1	Apex	LSB	H	1	1-3					86	T	ExtAnt				
1	Apex	LSB	H	1	1-3					270	T	InfPostLat	LVH	340		
1	Apex	LSB	H	1	1-3					1400	T	PostLat	LAH			
1	Apex	LSB	H	1	1-3						T	PostLat	LAH ICD			
1	Apex	LSB	H	1	1-3					25	T	ExtAnt	LAH ICD			
1	Apex	LSB	H	1	1-3					120	T	ExtAnt				
1	Apex	LSB	H	1	1-3					316	T	Antsept Ant		80		
1	Apex	LSB	H	1	1-3					45	T	Antsept	LVH	500		
1	Apex	LSB	H	1	1-3					62	T	Antsept	LVH LBBB			
1	Apex	LSB	H	1	1-3					200	T	ExtAnt				
1	Apex	LSB	H	1	1-3					80	T	ExtAnt				
1	Apex	LSB	H	1	1-3					158	T	Ant				
1	Apex	LSB	H	1	1-3					26	T	ExtAnt	LAH ICD	400		
1	Apex	LSB	H	1	1-3					26	T	AntLat	LVH			
1	Apex	LSB	H	1	1-3					260	T	ExtAnt	LAH			
1	Apex	LSB	H	1	1-3					190	T	ExtAnt	LAH	710		
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3											
1	Apex	LSB	H	1	1-3		</									

Table continued

History																			
Care number	Age	Sex	Angina pectoris	No. of previous attacks	Cardiac auscultation	Blood pressure mm Hg	Grade of shock	Pulmonary examination	Physical examination	ECG	Roentgen examination	Coronary angiography	Pathological findings	Pathological findings	Pathological findings	Pathological findings	Pathological findings	Pathological findings	Pathological findings
48	4	F	+	0	Hypertension	110/80	0	Rad				11	+						
49	55	M	+	0		100/70	0	Ld			APB	10	+						
50	62	M	+	0	Fallopian Cyst	115/60	0				APB	15							4
51	41	M	+	0		110/80	1	Ld	L			10	+						
52	4	M	+	0		105/80	0	Ld	L	ST		8							
53	32	M	+	1	Caudal aorta	140/80	0					10							4
54	71	M	+	2	Hypertension	160/90	1	LRad	L			18							
55	73	F	+	0	Pericarditis	145/100	0	Ld	L	FB		11							
56	49	M	+	0		100/80	0	Ld	L	ST	FB	12							3
57	52	M	+	0		110/65	5	Ld	L	ST	FB	17							3
58	66	M	+	0	Pericarditis	145/80	0					8							
59	55	M	+	0		140/80	0	Ld	L			5							4
60	45	M	+	0		140/80	0					5							
61	52	F	+	0		110/80	1	Ld	L	ST		15							4
62	58	M	+	0		120/95	0	Ld	L			10							
63	68	F	+	0	Hypertension	150/100	0	Ld	L			10							
64	41	M	+	0	Hypertension	180/115	0					10							
65	54	M	+	0	Hypertension	140/90	0	Ra	L	FB		10							4
66	58	M	+	0		110/80	5	LRa	L	FB	HB2 ST	12							3
67	53	M	+	0		110/75	0	Ld	L			9							3
68	36	M	+	0	Hypertension	175/105	0	Ld	L			4							3
69	61	M	+	0	Coronary artery disease	115/80	7	Ld	L	SVT	FB	27							4
70	56	M	+	0		100/70	0	LRa	L	FB		6							3
71	43	M	+	0	Pericarditis	120/80	0					5							
72	47	M	+	0		120/80	0					7							
73	43	M	+	0		100/80	0	LRa	L	ST	FB	6							3
74	49	M	+	2		20/80	0					7							
75	66	F	+	1	Hypertension	160/80	0	Ld	L			11							
76	55	M	+	1		150/75	0	Ld	L			11							
77	49	F	+	0	Hypertension	90/80	5	Ld	L			12							
78	55	F	+	0	Hypertension	0/0	0	Ld	L	FB		12							
79	64	F	+	0	Diabetes	150/70	0	Ld	L			3							
80	44	M	+	0		125/85	0	Ld	L	FB		6							3
81	32	M	+	1	Hypertension	145/90	0					10							4
81a	51	M	+	1	Hypertension	140/105	0	Ld	L			15							3
82	56	M	+	1		150/80	0	Ld	L	ST	FB	16							4
83	51	M	+	1	Fallopian Cyst	130/90	0	Ld	L	ST	FB	12							3
84	44	M	+	1		100/80	0					10							
85	44	M	+	1		130/85	0	LRa	L	FB		2							1
86	47	M	+	0		125/80	0					1							6
87	63	F	+	0	Hypertension	145/90	0	Ld	L			9							
88	45	M	+	0		150/110	5	Ld	L	ST		13							3
89	60	F	+	0		100/70	0	Ld	L	ST		10							4
90	64	M	+	0		140/90	5	Ld	L			7							
91	61	M	+	0	Pericarditis	140/70	0					3							4
92	55	M	+	0		20/80	0					4							
93	41	M	+	2	Hypertension	100/85	0					4							3
94	54	M	+	0	Hypertension	100/70	0	Ld	L			5							
95	44	F	+	1		145/90	0	Ld	L	FB		17							5
96	40	M	+	0		100/75	0	Ld	L			3							
97	81	M	+	0	Diabetes	120/80	0	Ld	L			4							
98	63	M	+	0		150/75	0	Ld	L	FB		6							3
99	62	M	+	0	Hypertension	190/90	0	Ld	L	AF	FB	11							3
100	41	M	+	0		40/70	0					5							4
101	65	M	+	0		140/80	0	LRa	L			8							3
102	74	F	+	0		125/80	0	Ld	L			9							
103	61	F	+	0		180/75	0	Ld	L	LR		7							4

[illegible]

Table continued

History																			
Case number	Age	Sex	Angina pectoris	History of previous infarction	Cardiac catheterization	End pressure mmHg	Coronary flow	Coronary catheterization	Left atrial catheterization	Right atrial catheterization	Left ventricular catheterization	Angiogram	Coronary pressure catheterization	Pericardial catheterization	Pericardial catheterization	First round of treatment	Second round of treatment	Third round of treatment	Overall result
104	64	M	+	0	Fa ha e Claud e	120 80	0	Lad				FB	20	+	+	D			3
105	53	M	+	+	1	Claud ca on	150 70		Lad	LR		VPB	12	+	+		+		3
106	64	M	+	+	0	Claud ca on	125 80		Lad			ST VPB	21	+	+		+		3
107	60	F	+	+	0	Pe fa t	135 85												
108	61	F	+	+	0	Fa ha e Pe fa t	125 75										+		3
109	53	M	+	0	0	Hype p d e m a	120 90	0	Lad	LR	AP	ST	13	+			+		3
110	42	F	+	0		115 55	0						7	+					
111	72	M	+	+	0	Hype en on	175/100	0				FB	14	+					4
112	5	M	+	+	1	Claud ca on	140 85	0		L		AF VPB	14						
113	58	M	+	+	0		140 80	0									+		4
114	43	M	+	+	0		130 40	0	LRa			ST			+				
115	50	M	+	+	0		120 90	0					9	+		D			
116	54	M	+	+	0		160 90	0	Ld	L		ST APB	13	+		D			3
117	44	F	+	+	0	Hype t Fa il ure	1 0 80	+				ST	16	+		D			3
118	62	M	+	+	0	Hype t Ce asc	140 80	0		LR			12	+					
119	54	F	+	+	0		105 65		Lad	LR	VPB		14	+			+		
120	51	M	+	+	0	Fa ha e Claud	180 85	+	Lad	L	VPB		16						
121	51	M	+	+	0		110 65	+	Lad	L	HBI			+					3
122	48	M	+	+	0		140 70	0		R			15						
123	50	M	+	+	0	Fa ha e Ce asc	130 90	0					21						3
124	38	F	+	+	0		115 85	0	Ld	L	HBI		20						
125	55	M	+	+	0		110 70	+	Ld	L	HBI		21						

## GROUP 2 NO MURMUR

126	55	M	+	0	Fa asc	165 90	0	+	Ld	L			11						4
127	55	M	+	0		150 85	0						0						
128	61	M	+	0		150 70	0					FB	8						4
129	65	M	+	0		146 95	0		Ld				8						4
130	54	M	+	+	1	Claud ca on	150 90	0				ST VPB	14						
131	54	M	+	+	0	Claud ca on	155 90	0				VPB	6						
132	56	M	+	0		110 70	0		Ld	L			5						
133	58	M	+	0	Hype Fa l Ce asc	250 130	0		Ld	L	ST		15						3
134	76	M	+	0	Hype en on	180 80	0		LRad	L	HBI VPB		15						4
135	73	F	+	0		140 80	0	+	Lad	L	AF		13						
136	47	M	+	2	Fa ha e Pe fa	110/80	1		Lad		VPB		15						4
137	47	M	+	0		155 90	0		Ld	L	ST		3						3
138	60	M	+	0	Claud ca on	140 80	0												
139	40	M	+	0		110 70	5						1						
140	56	M	+	0		105 70	0						5						
141	5	M	+	0		130 90	5		Ld			SVT HBI	17	+					3
142	55	M	+	0		12 75	0					FB	5						
143	62	M	+	0		120 70	0		Ld	L			16				+		4
144	78	M	+	0		1 0 85	0		Ld	L	ST FB								
145	53	M	+	0	Co	145 100	0						4	+					
146	57	M	+	0		105 70	5		Ld				15						
147	53	M	+	0		150 90	0		Ld				5	+					1
148	53	M	+	0		80 60	1		Ld				7						
149	64	M	+	0		130 8	0						5						
150	69	M	+	0	Fa asc	150 85	7		L		VPB		17						
151	39	M	+	0		145 100	0						4	+			+		4
152	49	M	+	0	Rh myocard a	110/70	0		Ld				8						4
153	47	M	+	0		130 0	0						2	+					+
154	55	F	+	0	Hype en on	170/105	0		Ra	L			11						
155	65	F	+	0		150/100	0						5						
156	53	M	+	0	Hype t Claud e	125 80	0		Lad	L			11	+					4
157	69	M	+	0		155	0		Ld	L			12						

[illegible]









# ACTA MEDICA SCANDINAVICA

SUPPLEMENTUM 476

## CURRENT TRENDS IN DIABETES MELLITUS

*In Honour Of*  
NIELS H KRARUP

*With and Papers*  
*On The Occasion Of His Sixtieth Birthday*  
Jy 14 1967

COPENHAGEN 1967

# ACTA MEDICA SCANDINAVICA

has been published since 1919 as a continuation of Nordiskt Medicinskt Arkiv, founded in 1869 by Axel Key. The first volume of Acta Medica Scandinavica is therefore numbered LII (52).

The chief editors have been Axel Key 1869-1900, C. G. Santesson 1901-1915, I. Holmgren 1916-1957 and Birger Strandell 1958 to date.

Acta Medica Scandinavica publishes original research papers in the field of internal medicine. Priority will be given to authors from countries which are represented on the editorial board. Contributors from those countries should submit their papers to a representative of the country in question. Contributors from other countries should send their papers to the Editor at the address below.

Submission of a manuscript for publication will be held to imply that the paper has not been published elsewhere and that, if accepted, it will not be republished in any other journal in the same or similar form, without the Editor's written consent.

Papers will be published in English, French or German at the authors' choice, followed by a summary in English.

The manuscripts shall be in final form as submitted. They shall be typewritten with double spacing and broad left hand margin.

If a paper exceeds 16 printed pages, the cost for the excess pages shall be borne by the author. No paper shall exceed 24 printed pages.

## Subscription

The annual subscription to the journal, covering two volumes, each of 8 numbers is 140 Sw. crowns or U. S. \$ 27.75, including postage, in the Scandinavian countries and in Holland 120 Sw. crowns.

*Address for subscriptions and all communications*

ACTA MEDICA SCANDINAVICA

P. O. Box 2052 Stockholm 2

---

Requests for duplicate copies of numbers that have gone astray can only be considered if made within a fortnight of the receipt of the following number.

## **CURRENT TRENDS IN DIABETES MELLITUS**



ACTA MEDICA SCANDINAVICA

*Supplementum No 476*

# CURRENT TRENDS IN DIABETES MELLITUS

*In Honour Of*

NIELS B KRARUP

*Dedicated Papers*

*On The Occasion Of His Sixtieth Birthday*

*July 14, 1967*

Copenhagen 1967





## EDITORIAL

The present collection of original studies is dedicated to N. B. Krarup on the occasion of his sixtieth birthday.

The volume aims at providing a survey of present scientific activity in diabetes research in Denmark. The editorial committee has therefore collected contributions from a number of investigators actively engaged in this field of research. Some of these contributors have not collaborated directly with N. B. Krarup in a professional capacity, and the editorial committee is particularly grateful to them for their participation. As a result of their contributions, it has been possible to widen the scope of this volume.

The special nature of the subject has necessarily limited the circle of contributors and excluded scientific contributions from a number of N. B. Krarup's former and present pupils. These and other colleagues who wished to contribute to the publication of this dedicatory volume in some other manner have been listed in the *tabula gratulatoria*.

The printing of this volume has been made possible by  
financial support from

NORDISK INSULINLABORATORIUM

A/S FERROSAN

NYT NORDISK FORLAG - ARNOLD BUSCK A/S

## TABULA GRATULATORIA

EDNAR AMMUNDSEN  
ESTHER AMMUNDSEN  
ANNEMARIE AMRIS  
AKSEL HARRESTRUP ANDERSEN  
HJELD ANDERSEN  
TORBEN ANDERSEN  
MOGENS ANDREASSEN  
POVL H ANDRESEN  
VAGN F ASKROG  
POUL ASTRUP  
AXEL BOECK AUBERT  
HELGE BADEN  
POUL BECHGAARD  
HOLGER BEGTRUP  
JØRGEN BICHEL  
JENS BING  
JØRGEN BJERRUM  
BERTEL VON BOYSDORFF  
ERIK BREDÅHL  
BENDT BROAGER  
PEKKA BRUMMER  
GEORG C BRUN  
KNUD BROCHNER-MORTENSEN  
THOMAS CASTBERG  
AUGUST CHRISTENSEN  
LAURIDS KORSGAARD CHRISTENSEN  
JENS E. CHRISTOFFERSEN  
EBBA CLAUSEN

WILLY DAM  
H. GOSTA DAMIDSEN  
FRANS DJORUP  
JOHAN EGENSE  
ANTON FLØYSTRUP  
MOGENS FOG  
TORBEN FRANCIS  
AAGE GJERSØE  
ERIK GODTFREDSEN  
HARALD GORMSEN  
JOHANNES O. HAGELSTEN  
ANDERS TYBJERG HANSEN  
ERIK HART HANSEN  
PER FROM HANSEN  
TORBEN SVEND HANSEN  
PER HANSEN  
EIGIL JUEL HENNINGSEN  
ERIK HENRIKSEN  
ALFRED HEY  
KARNA HILDEN  
TAGE HILDEN  
KNUD HOJGAARD  
KURT IVERSEN  
CHARLES JACOBSEN  
MOGENS JERSILD  
TORBEN JERSILD  
ANTON JERVALL  
INGE JESPERSEN

CHARLES JOHANSEN  
TRYGVE KAHRS  
HOTHER LUND KNUDSEN  
ARNE R. KROGSGAARD  
TEIT KÆRV  
KARL HENRIK KOSTER  
LANDSFORENINGEN FOR SUKKERSIGE  
HENRIK F. LANGE  
NIELS A. LASSEN  
KARL LEHMANN  
OLE LINDENEG  
JØRGEN LORENZEN  
STEFFEN LUND  
ASGER LUNN  
VILLARS LUNN  
HANS LOU  
INGEBORG LOU  
KAREV LOUS  
PER LOUS  
KJELD LYNGBORG  
VALDEMAR MADSEN  
DET MEDICINSKE SELSKAB  
I KØBENHAVN  
OTTO METZ  
EINAR MEULENGRACHT  
JOHANNES MOSBECH  
G. MYHRMANN  
STEN MØLLERTZ  
ANDREJ MYSCHEZKY

BENT MØLLER  
ERLING ERFURTH NIELSEN  
OLE NIELSEN  
SVEND NORREGAARD  
WILHELM T. L. OHLSSON  
MARCUS OTTSEN  
KNUD A. RASMUSSEN  
KNUD AA. RASMUSSEN  
OLAF ROMCKE  
FLEMMING RAASCHOU  
KAI SCHMIDT  
MICHAEL SCHWARTZ  
KNUD-ERIK SJØLIN  
ERIK SKINHØJ  
MOGENS SPRECHLER  
CHRISTIAN MYGIND SØRENSEN  
OSCAR THORDARSON  
NIELS TYGSTRUP  
KJELD TØRNING  
AAGE WARMING-LARSEN  
JØRGEN WANSCHER  
ERIK WASSEN  
PER WISING  
KJ. VISKUM  
HELGE WØRNING  
FRANCIS ZACHARIAE  
ALFRED ZACHO  
KNUD AAS

# CONTENTS

Vels B. Krarup	11
Introduction By Knud Lundbæk	12
Genetic perspectives in diabetes mellitus B. Ben Har'el	17
Autoimmunological aspects of diabetes mellitus By Torsten Deckert	20
The state of insulin in plasma By Jens Lyngsøe	43
Iodine labelling in the study of the biochemistry of insulin By K. Brunfeld	53
Insulin action on the central nervous system By Ole J. Rasmussen	5
Observations on the influence of glucose upon subcutaneous adipose tissue blood flow By F. Quasthoff, O. Andee Lassen, V. A. Lassen and S. Lærin Nielsen	85
Insulin: Desirable and undesirable effects By Jacob E. Poulsen	91
Postprandial blood sugar rise in diabetes B. M. Jørgensen	101
Extraparacrine and intrapancratic action of antidiabetic sulfonylureas: A review By Jørgen Madsen	109
The in vivo reactions of the small blood vessels to diabetes mellitus By Jørn Ditzel	125
Capillary diffusion capacity for sodium in skeletal muscle in long term juvenile diabetes mellitus By Jens Tranter Jensen, Joseph S. Alpert, Guisela del Pozo and Vels A. Lassen	135
Coagulability in diabetes By Flemming Jørgensen and Hansson	14
Long term experimental insulin-deficiency diabetes: A model of diabetic angiopathy? By Knud Lundbæk, T. Steen Olsen, H. Orlin, and P. O. Oslerby Hansen	15
Causes of perinatal death in diabetic pregnancies: A clinicopathological analysis By Lars Møller Pedersen and Jørgen Pedersen	155
Subject index	183



## NIELS KRARUP

Niels Byorn Krarup on his sixtieth birthday July the 15th 1957 is an impressive personality within the field of Danish internal medicine, well-known among his colleagues in the medical world, and in wide circles outside.

Internal medicine of the last thirty years has been dominated by its increasing progress and new approaches to diagnostic and therapeutic problems. During these years Niels Krarup has become a leading figure among Danish internists due to his vast knowledge, merit in his clinical intuition and sharpness of observation. The open and unreserved mind of Niels Krarup, his interest in human behaviour, his broad experience and ability for firm and just decisions inevitably made him an appreciated adviser not only to his colleagues but also to many other groups depending on medical knowledge.

In his daily life Niels Krarup is head of Medical Department C in the new section of our old Bispebjerg Hospital, one of the municipal hospitals of Copenhagen. At the same time he is an associate professor, a teacher in clinical medicine for the medical students. These are his two principal activities within a broad spectrum of medical and non-medical interests, not only within science but also covering many other aspects of our culture and often in doing a direct appeal to the public in the current debate on the problems of our society.

Niels Krarup was born to a life in medicine. His father Jens Kristian Byorn Krarup M.D. was a highly qualified pediatrician and at the same time a physician and practitioner of the good old danish folk medicine, a man who yielded an enormous amount of work, and for whom it was part of his life that with ever-lasting care and sense of duty he should be at his patients disposal day and night.

This sense of duty came naturally to Niels Krarup in his own education and training as a physician and as a defender of the individual patient. Niels Krarup's mother was a Heerfordt and related to the well-known contrabassist.

In 1932 Niels Krarup graduated and entered the medical profession. The need and demand for medical research in these years was great, with even greater expectations of therapeutic results. It was a happy coincidence, therefore, when Niels Krarup was given the opportunity of working with H.C. Hagedorn at the Nordic Insulin Laboratorium in the practical development of protamine insulin and its administration in the treatment of diabetes mellitus.

Niels Krarup's theoretical studies and practical clinical activity at Niels Steensens Hospital developed into a life-long and profound interest in the pro-





# INTRODUCTION

*Knud Lundbæk*

Diabetes mellitus as a subject for scientific investigation dates from the middle of the 19th century. It was inaugurated by the brilliant studies of Claude Bernard in carbohydrate physiology, the numerous clinico-chemical investigations of ketoacidosis by Kussmaul, Gerhardt and others, and by an ever increasing flow of clinical studies of the natural history of diabetes mellitus, including, already at the time, observations on diabetic vascular disease by Marchal de Calvi and the first descriptions of diabetic retinopathy, which appeared shortly after Helmholtz's invention of the ophthalmoscope.

It is evident that from the very beginning the study of diabetes mellitus was established as an area of research uniting in collaboration and discussion investigators from many disciplines, clinicians as well as non-clinicians.

It also appears that three of the major subdivisions of diabetes research were already under discussion a hundred years ago: the physiology of the diabetic state, the metabolic derangement in diabetic patients, and diabetic angiopathy. The fourth was introduced in 1889 by Mering and Minkowski's pancreatectomy in diabetes, opening the way which today has led to the study of diabetes mellitus as an endocrine disease.

The greatest event in the history of diabetes research was, of course, the discovery of insulin by Banting and Best in 1922. In 1935 Hagedorn produced the first long acting insulin preparation, the clinical effects of which were studied in detail by N. H. Krarup.

The last 30 years have witnessed an immense expansion in all fields of diabetes research. High lights of immediate practical importance include the zinc insulin, sulfonylurea and biguanides, as well as a much better understanding of how to handle the problems of diabetes and pregnancy. Our knowledge of the course and prognosis of diabetes mellitus has been increased, especially regarding the development of the sinister vascular abnormalities which determine the fate of today's diabetic patient. Mass investigations of whole populations have revealed surprising new facts in the field of diabetes epidemiology, and the difficult problems of the inheritance of the disease are coming to the fore. An understanding of the minute details of the changes in intermediary metabolism in diabetes has grown concurrently with the tremendous growth in biochemical research in general and its application to the study of human diabetes, as well as to the study of spontaneous diabetes in animals and the many varieties of ex-

perimental diabetes. The introduction of assay methods for blood hormones, especially the immunological techniques, has now made it possible to consider the pathogenesis of the diabetic state as an abnormality of the secretion or action of insulin and other hormones on various tissues.

The contributions of Danish diabetologists to this volume *in honorem* N. B. Krarup reflect the extensiveness and the many-sidedness of diabetes research. They range all the way from classical clinical studies to experimental clinical, physiological and biochemical investigations, the authors trying to answer or at least to elucidate a number of pertinent questions.

What is the mode of inheritance in diabetes mellitus? Are juvenile and late-onset diabetes genetically different conditions? (Harvald). Should diabetes be included in the fashionable group of autoimmune diseases: i.e. are there reasons to believe that diabetes or long term diabetic manifestations are due to the formation of auto-antibodies against insulin? (Deckert). What is plasma insulin? Are there several kinds of insulin circulating in the blood, with different biological and physiological characteristics? (Lyngsoe). What happens to insulin when it is labelled with radioactive iodine for use as a tool in biochemical or clinical research? (Brunfeldt). What is the physiological significance of the action of insulin on the central nervous system? (Rafaelen). How should we interpret the increase in fatty tissue blood flow during acute intravenous injection of concentrated glucose solutions in con-

trast to the fall observed after slow infusion? (Quaride et al.).

Important therapeutic problems are reviewed. What is the balance of wanted and unwanted effects of the insulin preparations available today? (Poulsen). Why is it that blood sugar rises to a higher level after breakfast than after meals at other times of the day? (Jersild). How does sulfonylurea work to produce hypoglycemia? (Joop Madsen).

Diabetic angiopathy is discussed from several points of view. What is the evidence for a demonstrable functional abnormality of the capillaries early in the course of diabetes mellitus? (Ditzel). What is the significance of the increased capillary diffusion capacity for sodium ions shown to be present in long term diabetes? (Trap-Jensen et al.). And what is the role of abnormal coagulability in the development of diabetic angiopathy? (Valdorf-Hansen). What can we learn about diabetic angiopathy from observations on vascular changes in long term experimental diabetes in animals? (Lundbæk et al.).

Finally, what are, and what were in an earlier period, the principle causes of perinatal death in diabetic pregnancy? (Molsted Pedersen and J. Pedersen).

It is hoped that this collection of essays will be of interest to diabetologists as well as to research workers in related fields of medicine and basic disciplines. It also affords a picture of some of the subjects—not all—that occupy the mind of some—not all—of the Danish investigators working in the field of diabetes mellitus today.

## GENETIC PERSPECTIVES IN DIABETES MELLITUS

by

*Bent Harvald*

Diabetes mellitus presents some of the most intriguing problems in clinical genetics. In spite of the abundance of accumulated data it has not yet been possible to establish the mode of inheritance with any degree of certainty. All attempts at fitting in diabetes with any known Mendelian system seem to imply the disregard of important evidence. Among the impediments to a proper genetic analysis, the most serious is ignorance with regard to the nature of the basic defect. Moreover, it is unknown whether the defect is the same in all cases so heterogeneity cannot be excluded.

The incidence of diabetes in the general population is not well defined, especially with regard to the older age classes where borderline cases are numerous and the diagnosis not very clear-cut. The broad period of manifestation from early childhood to old age and the different ages of onset in the two sexes necessitate adjustments. These factors complicate the testing of any genetic hypothesis drawing on the concept of gene frequencies in the general population and the expected frequencies in different groups of relatives.

### *Importance of genetic factors, twin studies*

Observations of single pairs of monozygotic twins concordant with regard to diabetes, where the disease runs nearly identical courses in both twins, have been frequently reported ever since the turn of the century, leaving the impression of a high concordance rate in monozygotic twins. This has been confirmed in several twin series, collected more or less systematically (5, 49, 42, 43, 39, 20, 17).

In 1938 Thénberg (40) published the first series of diabetic twins collected in accordance with the principles laid down by Luxenburger (22) for unbiased sampling in twin studies. Out of 49 monozygotic (MZ) pairs 19 showed clinical concordance, in 10 of the discordant pairs glucose tolerance tests were performed in the clinically unaffected partners, 13 of whom were classified as having an abnormal curve of diabetic type, whereas 6 were normal. In 11 discordant pairs the test could not be applied because the unaffected partners had died by the time of the investigation. The corresponding figures for 86

dizygous (DZ) pairs were as follows: 9 pairs were clinically concordant, 11 were concordant after glucose tolerance test and 35 were discordant. Glucose tolerance tests could not be applied in 31 cases.

The difference between MZ and DZ pairs is highly significant. Certainly the clinical concordance in MZ twins is far from unity, but it must be taken into consideration that the unaffected partners have been observed only through a limited span of years after the onset of diabetes in the proband.




Fig. 1

Morbid risk of co-twins of diabetic twin probands calculated according to Nyholm & Helweg-Larsen (7). Juvenile in this figure indicates diabetes in the twin proband diagnosed before the age of 50 years. The risk for the general population has been calculated by Deglund (8) on the basis of Fitzgerald et al.'s series (1).

In a population of about 8,000 pairs of twins born in Denmark (14, 15) in the years 1870–1910 and followed up from birth and all through their life, 97 cases of diabetes have been diagnosed in MZ twins, 154 cases in DZ same-sexed twins and 139 cases in DZ different-sexed pairs. At the time of investigation 58 of the 97 MZ co-twins were known to have diabetes, contrary to 14 out of 154 co-twins in the DZ same-sexed pairs and 12 out of 139 co-twins in the DZ different-sexed pairs. As the age distribution in the three groups of twins is very similar, the concordance rates can be directly compared, showing a highly significant difference between MZ and DZ same-sexed pairs.

In the discordant pairs, 7 unaffected MZ co-twins and 11 unaffected DZ co-twins had their fasting blood sugar repeatedly examined, and in cases where it was normal or borderline, glucose tolerance tests were performed (32). 4 of the 7 MZ co-twins and 1 of the 11 DZ co-twins showed a clearly diabetic pattern.

As diabetes must be expected to manifest itself later in some of the unaffected co-twins, it was found of value to estimate the morbid risk of the co-twins by a life table procedure (27). It appears from fig. 1 that the morbid risk approaches 100 per cent in MZ co-twins, but the standard deviation is considerable. In the DZ co-twins the morbid risk in all age classes is significantly lower, reaching a level at about 20 per cent. In early-onset diabetes the MZ co-twins develop the disease at an earlier age than the MZ co-twins of late-onset diabetics.

These different twin studies justify the conclusion that the appearance or non appearance of diabetes is totally or nearly totally determined by genes, and the environmental factors are more or less confined to influencing the time of onset and probably also the course of the disease

#### *Family studies, recessive inheritance*

The well recognized familial concentration of cases of diabetes mellitus has been placed on a more sound statistical basis through several systematic family studies (3, 1, 28, 21, 13, 38, 41, 18, 12, 19, 26, 33, 34, 7, 6). Diverse simple genetic mechanisms have been suggested, but most authors assign a simple Mendelian recessive mode of inheritance to the predisposition for diabetes (36, 37, 38).

Under the assumption that all diabetes is due to one and the same recessive gene, the gene frequency in Western populations should be expected to be very high, thus the morbid risk in an

English population (10) has been estimated to be over 10 per cent at the age of 80 years, which means a gene frequency above 30. Calculated on this basis the morbid risk in sibs of diabetics is over 40 per cent, in the offspring it is 30 per cent at the age of 80 years. One tenth of these cases will appear before the age of 40. Thus, with this very high gene frequency in the general population the disease expectancies in sibs and offspring do not differ very much.

A comparison between age specific morbid risks for sibs and offspring in three existing materials is given in table 1.

The figures do not directly contradict the hypothesis of recessivity as the standard deviations are rather large, especially those of the risk figures for offspring. On the other hand, a simple recessivity theory cannot without difficulty explain the apparent heterogeneity. Thus the morbid risk both for sibs and offspring of late-onset diabetics does not differ significantly from that of the general population before the age of 40, where

TABLE 1

*Comparison between morbid risk of diabetes in sibs and offspring*

	Sibs	Offspring
Morbid risk at the age of 15 years		
Probands with juvenile diabetes mellitus (Degenbol 1965)	3.70 ± 0.98 %	2.78 ± 1.66 %
Morbid risk at the age of 40 years		
Probands with severe diabetes mellitus nearly all juvenile (Grunnet 1957)	5.70 ± 1.28 %	9.46 ± 3.47 %
Morbid risk at the age of 40 years		
Probands with late onset diabetes mellitus (Harris 1950)	0.58 ± 0.04 %*	1.38 ± 0.39 %*

\* Calculation by Degenbol 1965

it is only about one tenth of the morbid risk for sibs and offspring of juvenile diabetics. This difference between relatives of juvenile and late-onset diabetics is even more clearly demonstrated by the risk curves (fig 2). For both types of diabetics the curves for offspring and sibs seem to lie very near to each other.

A critical test for the recessivity theory is afforded by the findings in the offspring of conjugal diabetics. If all cases are due to recessive inheritance involving the same locus all the offspring of two affected parents should themselves be affected. The following crude figures have been reported:

Pincus & White 1934 (29) 30/137  
Steiner 1936 (39) 9/30  
West and Post 1962 (48/30) 13/161  
Simpson 1964 (34) 5/173  
Cooke et al 1966 (4) 16/362

These figures immediately seem to be incompatible with the hypothesis of simple recessive inheritance. Analysis with due regard to age composition confirms this impression (34, 4).

Neel & al (25) have analysed the offspring of different marriage types: diabetes  $\times$  diabetes, diabetes  $\times$  normal, normal  $\times$  normal, with application of glucose and cortisone glucose tolerance tests (10). Highly significant aberrations of the mean tolerance curve from that of the normal controls could be demonstrated in offspring of conjugal diabetics and offspring of diabetes  $\times$  normal marriages. In this latter group simple recessivity would involve a bimodal distribution of the test results which however could not be demonstrated. On the assumption that an abnormal glucose tolerance test or cortisone glucose tolerance test is an indication of prediabetes, more than 50 per cent of the offspring of the diabetes  $\times$  normal crosses could be considered as affected. This is a clear excess over expectation if the disease should be due to homozygosity for a recessive gene occurring at a single locus unless the frequency of the gene in the population is as high as 50. Especially in youths, however, the value of the glucose tolerance test or the cortisone glucose tolerance test in detecting prediabetic conditions is questionable and some authors have failed to demonstrate any difference between young unaffected




Fig 2

Most of the relatives of diabetics compared with the general population. Offspring of conjugal diabetics: Degnbøl's series 6 Sibs of juvenile diabetics: Degnbøl's series 6 Offspring of late-onset diabetics: Harriss's series 13 Sibs of late-onset diabetics: Harriss's series 13 Calculation by Degnbøl of General Population: Fitzgerald et al's series 11 Calculation by Degnbøl of

near relatives of diabetics and normal controls (23, 26)

Increased consanguinity in parents of juvenile diabetics has been reported by Harris (13), but the comparability of his series with the control series used (consanguinity in hospital inmates, studied by Bell (2)) is questionable. Von Kries (18) in an extensive series of diabetics was not able to confirm Harris' results. Steinberg & Wilder (38) found a higher consanguinity between parents of late onset diabetics than between parents of juvenile diabetics. The interpretation of the figures is not easy, however. Under the assumption of a frequency of the diabetes gene of 10 and with about 0.5 per cent marriages between first cousins in the general population, only about 0.8 per cent of all recessive homozygotes in this population should be expected to be derived from first cousin marriages. Thus it will be very difficult to register with certainty a difference of consanguinity between parents of diabetics and the general population. Furthermore the population pattern changes from one generation to the next and from one area to the other.

The recessivity theory has to some extent been supported by observations in animals with spontaneous diabetes. In the house mouse a type of diabetes combined with obesity has been described with a clearly recessive mode of inheritance (16). Diabetes in the Chinese hamster (24, 50) seems to be much more similar to human diabetes. It was originally thought that diabetes in the Chinese hamster was also due to a single recessive gene, but this has not been confirmed by later breeding experiments

and the somewhat complicated genetic situation agrees rather with multifactorial inheritance. Thus diabetes in hamsters represents all degrees of severity. The infertility of the severely affected animals, however, is an obstacle to genetic experimentation.

Insulin isolated from the serum of untreated juvenile diabetics has been found more resistant to destruction by a crude rat muscle insulinase than insulin from normal controls, the insulin of parents of juvenile diabetics shows an insulinase resistance in between (31). These results indicate some structural change in the diabetic insulin molecule. The series published so far, however, are limited and the findings need further confirmation.

#### *Combined recessivity and dominance*

The morbid risk in sibs and offspring of late-onset diabetics does not differ significantly from that of the general population before the age of 40, contrary to the morbid risk in sibs and offspring of juvenile diabetics, which in the younger age groups is 5-10 times that of the general population (cf. fig. 2). This point was first stressed by Harris (13) and has been verified in later materials (12, 6). It led Harris to the conclusion that diabetes is genetically heterogeneous. As the correlation of age of onset within sibships is high, but low between parents and children, Harris advanced the hypothesis that patients with mild late-onset diabetes are heterozygous for the same gene, which in homozygous form gives rise to a severe early onset diabetes. This theory is very attractive and fits in well with many empirical ratios.



1) With a gene frequency in the general population of 0.5–1.0, predisposition for the mild type of diabetes should be expected in 10–20 per cent of the population—in accordance with the observed morbid risk of 12 per cent at the age of 40

2) The parents of juvenile diabetics should be expected to be either heterozygotes or homozygotes whereas only one parent of late-onset diabetics must necessarily carry the gene. Thus the number of clinically affected parents of juvenile diabetics should be expected to be about twice as high as that of parents of late-onset diabetics. The empirical figures from Steinberg & Wilder's material (38) calculated by Degenbol (5) are

Risk at the age of 50 of parents of juvenile diabetics 1.62 per cent,

Risk at the age of 50 of parents of late-onset diabetics 0.88 per cent

3) Among the offspring of juvenile diabetics 5–10 per cent should be expected to develop early-onset diabetes, which is in agreement with observation.

In other respects, however, Harris hypothesis does not explain observed data. Thus about 30 per cent of sibs of juvenile diabetics should be expected to be similarly affected, which is three times the observed number. 3–6 per cent of sibs of late-onset diabetics should be expected to develop juvenile diabetes. This is more than three times the observed figure. The morbid risks for sibs till the age of 40 are rather well established figures in both groups. Thus the discrepancy between expectancy and ob-

servation makes it necessary to discard this hypothesis in spite of its merit of simplicity.

### *Irregular dominant inheritance*

Irregular dominance of one single gene was proposed as a theoretic possibility first by Levit & Pessikova (21), later supported by V. Kries (18). The ratios observed in different groups of relatives with approximately the same percentage of affected sibs and offspring are consistent with this hypothesis, presupposing an extreme phenotypical variability and low penetrance. The varying expressivity of the gene could be partly an effect of environment, partly of modifying genes. Modifying genes and common environment could explain the age correlation within sibships.

A precise test of the dominance theory is not possible at present. The hypothesis would be strengthened if some sort of bimodal distribution with regard to one or other trait could be demonstrated among the sibs and offspring of diabetics. The study of the distribution of glucose tolerance by Neel & al (25) failed to demonstrate such bimodality.

The dominance theory has been strongly supported by the studies of Vahlance-Owen and his collaborators (44, 45, 46, 47) who have demonstrated the existence of an insulin antagonistic system associated with plasma albumin. Excessive antagonism of this type has been found in patients with juvenile as well as late-onset diabetes. Moreover, clinically unaffected relatives of diabetics have a high plasma 'synalbumin' antagonism. Thus, about half the sibs

and half the offspring have been found to be "synalbumin positive", suggesting inheritance as a dominant trait. Only a minor part of the 'synalbumin positive' relatives had an overt carbohydrate intolerance.

These findings have been confirmed by Erlich & al (8), who among 27 sibs of diabetic children found 11 with excessive antagonism. The biochemical character of the synalbumin antagonist is not definitely established, but some observations indicate that the antagonist is identical with the B-chain of the insulin molecule (9).

The data published so far do not allow a strict genetic analysis. Insulin antagonism is a quantitative trait, thus in 5 per cent concentration the plasma albumin from all subjects has an antagonistic effect. The limit between normal and excessive antagonism is an arbitrary one. Therefore the absolute numbers of relatives with excessive antagonism must be estimated with reserve. A multifactorial trait may feign monomerism if the arbitrary limit between normal and abnormal is adequately placed. The demonstration of a bimodal distribution of the actual quantitative estimate of insulin antagonism would in this respect be of crucial importance.

Among 28 patients with coronary occlusion Vallance Owen and Ashton (47) found excessive insulin antagonism in 19, compared with 6 out of 28 controls of the same age. These findings indicate that high insulin antagonism is a very common finding, at least in the older age groups.

The causal relationship between excessive insulin antagonism and diabetes

has not been definitely established. To decide whether insulin antagonism is a suitable biochemical marker to ascertain the diabetic genotype, long term observations will be necessary. Thus it is of interest to find out to which extent clinically unaffected individuals with excessive insulin antagonism will develop diabetes later on.

### *Multifactorial inheritance*

In their study of glucose tolerance in offspring of diabetics, Neel & al (25) found a distribution not differing significantly from unimodality. On this basis they suggested a hypothesis of complex multigenic inheritance involving additive effect of genes at several different loci. Multigenic inheritance would readily explain several data:

1) High concordance in MZ twins (approaching 100 per cent) combined with a very much lower concordance in DZ twins (about 20 per cent)

2) Morbid risks for sibs and offspring of approximately the same size

3) Higher morbid risk for sibs if one or both parents are also diabetic. Thus Steinberg & Wilder (38) found the following incidences for sibs:

Both parents unaffected	4.7 per cent
One parent diabetic	11.4 per cent
Both parents diabetic	16.0 per cent

It should be stressed that these figures are not risk figures, and they have not been corrected for age.

A simple multifactorial system, however, does not account for the low risk of juvenile diabetes in sibs and offspring of late-onset diabetics. This age specificity would presuppose a more complex system with additional genes determining the age of onset.

The distribution of secondary cases of diabetes in different groups of relatives suggests that the mode of inheritance may be different in juvenile and late onset diabetes. In Grunnet's series (12) 11 probands with severe early-onset diabetes had more than one affected relative in the ascending line. In 10 of these families the secondary cases were either on the maternal or the paternal side, only in one were family members of both sides affected. 7 probands with mild late-onset diabetes had more than one affected relative in the ascending line. In 5 of these families the secondary cases were found on both maternal and paternal side. This difference is statistically significant ( $P < 0.01$ ). The late-onset diabetes is the one which tallies best with a multifactorial pattern.

#### *The diabetic genotype*

Convincing evidence has been accumulated to the point that non-diabetic relatives of diabetics differ from the average population in many respects. A comprehensive anthropological study by Nilsson (26) elucidates this problem. Relatives of diabetics were found to be taller and heavier than the controls, with increased skeletal sturdiness. The same was the case in young diabetics examined before the onset of diabetes. Female diabetics over the age of 50 had given birth to more children than non-diabetic women.

Children of mothers who developed diabetes afterwards, had a birth weight on an average 400 g over normal. This may partly be ascribed to the higher weight of these mothers and partly to the higher average parity number, but there are some suggestions that the high birth weight of these children of pre-diabetic mothers may at least to some extent be due to the diabetic genotype. Thus, children of prediabetic fathers and children who later on developed diabetes themselves also had an average birth weight significantly over normal.

The assessment of the phenotypical characteristics of the diabetic genotype is difficult, however, so long as a reliable biochemical marker is not available. The study of unaffected MZ co-twins of diabetics is theoretically a sound approach, but the high concordance in MZ twins impedes the collection of a sufficient sample for conclusive analysis.

#### COMMENTS

The present status leaves an impression of confusion. Without any doubt genetic factors play the major role in the aetiology of diabetes, juvenile as well as late-onset. There is much evidence that these two types of diabetes are genetically different. Late-onset diabetes in many respects behaves as a multifactorial trait due to additive effect of genes at several loci, thus it presents all degrees of severity, the less severe cases by far outnumbering the severe ones. Irregular dominance, however, cannot be excluded, in which case several modifying genes must be active. From a clinical point of view juvenile diabetes is much

more similar to a monomeric disease entity. The onset of the disease is rather abrupt and the majority of cases after a short period of time reach a level where insulin activity of plasma approaches zero and all insulin must be supplied from without. In this respect juvenile diabetes resembles an inborn error of metabolism due to a single enzymatic defect. Formal genetic analysis, as well as the biochemical demonstration of a plasma synalbumin antagonist, favour dominance, but neither recessivity nor multifactorial inheritance can be totally ruled out.

Several points need further elucidation. The determination of plasma insulin activity and insulin antagonism in clinically unaffected partners of MZ twin pairs discordant with respect to diabetes will be of crucial importance in the evaluation of excessive insulin antagonism as a biochemical marker of the diabetic genotype. More family studies of this trait are necessary for the performance of a strict genetic analysis, including longitudinal studies of non-diabetic relatives with excessive synalbumin antagonism, in order to establish the constancy and significance of this trait in the single individual. Studies more or less on the same lines are desirable with regard to insulinase resistance of insulin in diabetics and their relatives.

In future clinico-genetic studies the heterogeneity problem should be considered carefully. The morbid risk figures for several groups of relatives have been indicated only with a high degree of uncertainty because of insufficient data. Thus, follow-up studies are needed of 1) offspring of juvenile diabetics

followed up to middle and old age, 2) sibs of juvenile diabetics followed up to old age, 3) offspring of late-onset diabetics followed up to old age. Moreover, the existing series of 4) offspring of conjugal juvenile diabetics are of limited size and do not allow calculation of good risk figures for this very important group.

Reliable morbid risk figures for different ethnic groups would be of major importance for the elucidation of the heterogeneity problem. It is well known that the incidence of diabetes differs much from one population to another. This is true both in juvenile and in late-onset diabetes. It would now be of interest to know whether the incidence of juvenile and of late-onset diabetes in a given population are always lowered or increased more or less to the same degree. If this is not the case, i.e. if for instance a high incidence of late-onset or mild diabetes can be found together with a low incidence of juvenile and severe diabetes, this would give strong support to the heterogeneity hypothesis.

Family studies of clinical subgroups might also be informative, for example genetic studies of early-onset diabetics with low insulin requirement.

Studies of this type, however, may not result in any significant clarification. It is more probable that conclusive progress on the genetic front must await basic pathophysiological advances.

## SUMMARY

The elaboration of the genetic theory in diabetes must take some well-established data into consideration.

1) The concordance in MZ twins approaches unity both in juvenile and late-onset diabetes. The concordance in MZ twins is significantly higher than that of DZ same-sexed twins.

2) The morbid risk of offspring and siblings of juvenile diabetes is nearly of the same order of magnitude—about 3 per cent till the age of 15, 5–10 per cent till the age of 40.

3) The morbid risks of offspring and siblings of late-onset diabetes are of nearly the same order of magnitude and do not differ significantly from that of the general population until after the age of 40.

Juvenile and late-onset diabetes are probably genetically different but this question as well as the question of the mode of inheritance cannot be solved until a reliable biochemical marker of the diabetic genotype has been found. The syngammin insulin antagonist system is perhaps an approach in this direction.

#### ACKNOWLEDGMENTS

Supported by grants from the National Institute of Health and the National Foundation.

#### REFERENCES

1. V. M. W. *Ann Intern Med* 6: 177, 1933.
2. Bell J. *Ann Intern Med* 10: 30, 1910–31.
3. C. L. *Br J Med* 7: 38, 1919.
4. C. L. *Br J Med* 7: 38, 1919.
5. C. L. *Br J Med* 7: 38, 1919.

6. Degnol II. *Pr e Essay* University of Copenhagen 1965.
7. Diabetes Society Working Party. *Br J Med* 7: 1, 1960–1965.
8. Ehrlich H. M. Martin J. M. & Slonevsky I. *Diabetes* 14: 438, 1965.
9. Finck J. W. Malters R. J. & Vallance O. *Br J Med* 7: 94, 150, 1965.
10. Fajan S. S. & Conn J. W. *Diabetes* 3: 296, 1954.
11. Fitzgerald M. C. Malins J. M. O'Sullivan D. J. & Wall M. *Quart J Med* 30: 57, 1961.
12. Grunnet J. *Heredity in Diabetes Mellitus* Copenhagen 1957.
13. Harris H. *Ann F gen* 15: 95, 1950–51.
14. Harvald B. & Hauge M. In J. V. Neel M. W. Slaw & W. J. Schull (ed.) *Genetics and the Epidemiology of Chronic Diseases* Washington D. C. 1965, pg. 77.
15. Harvald B. & Hauge M. Unpublished data, 1967.
16. Inalls A. M. Decker M. M. & Snell C. D. *J Hered* 41: 317, 1950.
17. Joslin E. P. & White P. In E. P. Joslin H. F. Root P. White A. Marble & C. Bailey. *The Treatment of Diabetes Mellitus* Lea & Febiger Philadelphia 2nd ed. 1957, pg. 57.
18. Krey I. von. *Ztschr Mensch Vererb und Konstitution Lehre* 31: 406, 1953.
19. Lamy M. Frzal J. & Crocely J. de. *Acta Franc Stud Clin Biol* 2: 907, 1957.
20. Leber H. *Fisbar* 3: 33, 1938.
21. Levit S. G. & Penskova I. A. *Proc Max N. Co. Medico Biological Research Institute* 3: 137, 1934.
22. Luebeck H. *Ztschr Neurol Psychiat* 116: 297, 1958.
23. Mackler H. S. & Fletcher A. E. *J A M A* 103: 204, 1934.
24. Meier H. & Yerganian C. *Proc Soc Exp Biol & Med* 100: 810, 1959.
25. Neel J. V. Fajans S. S. Conn J. W. & D. L. In J. V. Neel M. W. Slaw & W. J. Schull (ed.) *Genetics and the Epidemiology of Chronic Diseases* Washington D. C. 1965, pg. 105.
26. Neel J. V. *Genetic and Constitutional*

- Aspects of Diabetes Mellitus Acta Med Scand Suppl* 375 Lund 1962
- 27 Nyholm M & Helweg-Larsen H F *Acta Genet* 5 25 1954
  - 28 Pincus G & White P *Am J Med Sci* 186 1 1933
  - 29 Pincus G & White P *Am J Med Sci* 188 782 1934
  - 30 Post R H *Diabetes* 11 56 1962
  - 31 Roy C C Elliott R B Shapcott D J & O'Brien D *Lancet* ii 1433 1966
  - 32 Ræbld I Unpublished data 1967
  - 33 Simpson N E *Ann Hum Genet* 26 1 1962
  - 34 Simpson N E *Diabetes* 13 462 1964
  - 35 Steinberg A G *Ann N Y Acad Sci* 82 197 1959
  - 36 Steinberg A G *Diabetes* 10 269 1961
  - 37 Steinberg A G In B S Leibel & G A Wrenshall (ed) *On Nature and Treatment of Diabetes* Excerpta Medica Foundation Amsterdam 1965 pg 601
  - 38 Steinberg A G & Wilder R M *Am J Hum Genet* 4 113 1952
  - 39 Steiner F *Deutsche Arch f Klin Med* 178 497 1936
  - 40 Then Berg H *Arch Rassenbiologie* 32 287 1938
  - 41 Thompson M W & Watson E M *Diabetes* 1 268 1952
  - 42 Umber F *Dtsch Med Wochenschrift* 15 544 1934
  - 43 Umber F *Münchener Med Wochenschr* 2 1479 1939
  - 44 Vallance-Owen J *Diabetes* 5 248 1956
  - 45 Vallance Owen J In *Ciba Foundation Colloquia on Endocrinology* Vol 15 pg 217 1964
  - 46 Vallance Owen J In B S Leibel & G A Wrenshall (ed) *On the Nature and Treatment of Diabetes* Excerpta Medica Foundation Amsterdam 1965 pg 340
  - 47 Vallance-Owen J & Ashton W L *Diabetes* 12 356 1963
  - 48 West H M *Diabetes* 9 379 1960
  - 49 White P Joslin E P & Pincus G *J A M A* 103 105 1934
  - 50 Yerganian G In B S Leibel & G A Wrenshall (ed) *On the Nature and Treatment of Diabetes* Excerpta Medica Foundation Amsterdam 1965 pg 612



# AUTOIMMUNOLOGICAL ASPECTS OF DIABETES MELLITUS

by

*Torsten Deckert*

The molecular structure of the polypeptide, insulin, is well known, and insulin has been successfully synthesized. An analysis of the amino acid sequence has shown that the primary structure of the insulin molecule presents only small differences from one animal species to another (fig 1 and 2). In spite of this,

however, the injection of insulin from one animal species into another animal species can give rise to the formation of antibodies (14). Insulin antibodies can also be demonstrated in man after treatment with pig or ox insulin for 1-2




Figure 1 The structure of ox insulin

Fig 1

Primary structure of ox insulin

	A <sub>10</sub> - A <sub>20</sub>	A <sub>10</sub> - B <sub>20</sub>
Insulin	1 ser	1 al
act. whale 5 and	al ser	th ala
heep 1 mil	al gly	1 ala
bovine 1 mil	thr - gly	thr ala
porcine-whale 1 mil	thr ser	thr al
pig 1 mil	thr ser	thr al
rabbit 1 mil	th ser	thr ser
h. m. 1 island	th ser	thr thr

Figure 2.

Spe 1 ser 11 thr of 1 aln.

The table shows the main acid is characteristic for species. positionally situated: A<sub>10</sub> - A<sub>20</sub> - B<sub>20</sub>.

Fig 2

Differences in primary structure of insulin from different animals



months. The demonstration of insulin antibodies in diabetics has raised the question whether the pathogenesis of diabetes may be conditional on the presence of insulin antibodies, and whether some of the complications of long standing diabetes are the result of immunological reactions between insulin and insulin antibodies, whether, in short, diabetes mellitus may be regarded as an autoimmune disease.

For diabetes mellitus to be considered as an autoimmune disease, it is necessary that the diabetic organism should respond with immunological reactions to contact with its own species specific components, and that these immunological reactions should lead to tissue damage.

Various mechanisms may be imagined which might bring about autoimmune reactions: 1) a modification of the molecular structure of species specific components; 2) absence of tolerance, and 3) an alteration in the function of the immunological apparatus.

#### *Changes in the molecular structure of the insulin molecule*

Insulin in particular has of course been in the limelight among those species-specific components which might become heterologous as a result of changes in the molecular structure.

Very little is known of the biosynthesis of insulin in the beta-cells of islet tissue



47 and it is uncertain whether the synthesis of insulin and/or the insulin release mechanism is abnormal in diabetes. It is well known, however, that the majority of diabetics who acquire

the disease after the age of 40 years have an abnormal glucose tolerance, in spite of a high serum insulin concentration (5). The explanation of this phenomenon could be that maturity-onset diabetics secrete a biologically inferior insulin.

There was no difference, however, in the appearance of crystals of insulin extracted from the pancreas of elderly deceased diabetics and deceased non-diabetics, respectively (fig. 3). Nor could any difference be demonstrated immunologically, and the preparations showed an identical ability to lower the blood sugar level in rabbits (8) (fig. 4 and 5). A comparison of the immunological reactivity of serum insulin in diabetics and non-diabetics likewise showed no differences (15).

To date, therefore, it has not been possible to demonstrate any structural differences between insulin from non-diabetics and insulin from diabetics. Modifications of insulin are known, however, which deviate so strongly from the normal structure of insulin that they only react very slightly with the insulin antibodies against normal crystalline ox, pig or human insulin. Examples of this are guinea-pig insulin (25, 34) and fully iodinated insulin (4, 7).

With the techniques employed in immunological studies, it will be difficult to reveal serum insulin modifications with a pronounced degree of deviation. In spite of the investigations mentioned above, therefore, the possibility cannot be excluded that in diabetics, small amounts of insulin are produced which from an immunological point of view have a pronounced degree of deviation. However, with the methods which are



*Fig III*

Photomicrograph of insulin crystal suspension  
 above human insulin from non-diabetics  
 below human insulin from stable diabetics  
 (from Brunfeldt et al 1966)




Fig 11

Inhibition of the reaction between pig insulin antibody and  $^{125}\text{I}$  pig insulin with  
 — crystalline insulin from non diabetics  
 x—x crystalline insulin from stable diabetics  
 (from Brunfeldt et al 1966)

employed for studying insulin antibodies, it should be possible to reveal antibodies against such an insulin preparation, provided it possessed at least a minimum immunological relationship with crystalline insulin. As it has not been possible to reveal such antibodies (see later), the possibility of such an insulin being produced must be regarded as minimal. Furthermore, considering the smallness of the insulin molecule, it must be regarded as unlikely that the beta cells in diabetics synthesize an "insulin" which differs so much from normal insulin that a cross reaction with normal insulin antibodies cannot occur at all.




Fig 1

Hypoglycaemic activity of  
 o—o crystalline insulin from non-diabetics  
 x—x crystalline insulin from stable diabetics  
 20  $\mu\text{g}$  crystalline insulin/kg was injected into the marginal ear vein of 8 rabbits in cross-over experiments (from Brunfeldt et al 1966)

### *Isoantibodies*

As no immunological differences could be demonstrated either between insulin from diabetics and non-diabetics or between pancreatic insulin and serum insulin (15), it is striking that isomunization with insulin has repeatedly proved possible. It has proved possible to immunize both pigs, cows, sheep and rats with species specific insulin (6, 27, 31, 44-50), and preliminary studies suggest that this is also the case in man (16). It was considered that the use of adju-

vant (14) or protamine (31) would have the effect of modifying the insulin molecule and thus making it antigenic (4). However, it has also been possible to immunize pigs by means of daily injections of an acid solution of crystalline pig insulin (6, 50), i.e. without the use of adjuvant (fig 6). On the other hand it has not been possible so far to isomunize animals by using neutral solutions of highly purified insulin without adjuvant (50). The possibility cannot be excluded therefore, that the inflammatory tissue reaction elicited by daily in-



*Fig 11*

Immunoelectrophoresis and autoradiography of pig serum to which approximately 100 µg  $^{125}\text{I}$  pig insulin has been added per ml serum

A autoradiography of serum before treatment with insulin

B autoradiography of serum after treatment with pig insulin

The arrow indicates  $^{125}\text{I}$  insulin bound to gamma globulin (from Brunfeldt & Deckert 1964)

jections of unphysiological fluids (43) may be of significance for the response of the organism to the injected insulin. Likewise, the unphysiologically high concentration of antigen at the site of injection may be of significance (14, 31, 44). Finally, it should be mentioned that most commercial preparations of insulin contain strongly antigenic impurities, which can potentiate the formation of antibody by insulin (14).

### *Humoral insulin antibodies*

Just as it has proved impossible to demonstrate changes in the insulin molecule in diabetics, so it has proved impossible to demonstrate with certainty the presence of insulin antibodies in diabetics not treated with insulin. If the pathogenesis of diabetes depended on an alteration in the molecular structure of insulin, with resulting formation of antibodies, insulin antibodies would be expected to be found. In non insulin-treated diabetics, the complement-consumption test has actually been found positive in 58 per cent of the cases, but it was

also positive in 26 per cent of non diabetics (11). The experimental results were interpreted as expressing complement-binding to a serum protein insulin complex. It should also be mentioned that in three diabetics not treated with insulin, gamma globulins were demonstrated which when labelled with fluorescein isothiocyanate and dripped on to fresh human pancreatic tissue resulted in fluorescence of beta cells (33). However, it is possible that the phenomenon is non-specific.

All other investigations undertaken with radioactive isotope labelled human or pig insulin as antigen have given negative results (14) (table 1).

There is thus no evidence for the presence of humoral antibodies in diabetics prior to the commencement of insulin treatment. It should once more be mentioned, however, that the investigations undertaken are only able to reveal antibodies which correspond with the normally occurring antigenic determinants of pig, ox or human insulin. It will only be possible to reveal the formation of antibody directed against newly

TABLE 1

*Results of experiments with  $^{125}\text{I}$  insulin for insulin antibody detection in different groups of diabetics and non diabetics*

Number of patients investigated	Group	Insulin treatment	Labelled insulin used as antigen	Insulin antibodies found in serum (percentage)
26	juvenile diabetics	none	pig	0
11	elderly diabetics	none	pig	0
45	non-diabetics	none	pig	0
6	juvenile and elderly diabetics	none	human	0
11	non-diabetics	none	human	0
5	diabetics	all	human	100
93	diabetics	all	pig	100

formed determinants in the insulin molecule provided there is an antigenic relationship between these determinants and the determinants of the genuine antigen

### *Cellular insulin antibodies*

Even though it has not been possible to demonstrate humoral insulin antibodies in diabetics not treated with insulin, the possibility of cell bound antibodies being present cannot be excluded. Federlin et al (23) demonstrated the presence of lymphocytes sensitized against insulin in patients with insulin allergy. In some cases, these lymphocyte bound antibodies were found before humoral insulin antibodies could be demonstrated. This is in agreement with the observation that insulin allergy directed towards highly purified insulin may be found in patients who do not have humoral insulin antibodies (14). In diabetics not treated with insulin, however, no sensitized lymphocytes could be demonstrated. It should also be emphasized that the erythematous, warm, indolent, slightly elevated injection infiltrations, about 2.5 to 3 cm in size, which occur in some diabetics and which must be regarded as a delayed hypersensitivity reaction of the tuberculin type, are never seen immediately after the commencement of insulin treatment, but only after the lapse of some days, or some weeks before the humoral insulin antibodies can usually first be demonstrated.

### *Insulinitis*

As stated, autoantibodies and/or im-

munologically abnormal insulin could not be demonstrated in diabetics. Certain pathological lesions in the pancreas, however, localized in and around the islets in animals and man, have kept the discussion open on the question of the autoimmune genesis of diabetes. There are three different findings. 1) infiltration of eosinophil leucocytes, particularly peripheral to but also in the hypertrophic islet tissue of the pancreas in infants born to diabetic mothers, 2) infiltration of round cells and polymorphonuclear leucocytes in and around the islet tissue in juvenile diabetics who died in the course of 6 months after the disease was diagnosed, and 3) infiltration of round cells and/or polymorphonuclear leucocytes and/or eosinophil leucocytes in the pancreas of animals which have been actively or passively immunized with insulin.

Re 1) infants born to diabetic mothers and dying during the perinatal period, show infiltration of eosinophil leucocytes around hypertrophic islet tissue. This lesion has been familiar for a long time, and its specificity must now be considered established. The reason for the changes, however, is still unclear. There seems to be no relationship between the occurrence of humoral insulin antibodies and the development of eosinophil infiltrates around the islet tissue, as even considerable infiltrates can be seen in infants whose diabetic mothers have never been treated with insulin (46), and in whom insulin antibodies therefore usually do not arise. It is possible that these lesions should be regarded as a reaction to an islet mass which is proliferating strongly on account of hyper-

glycaemia They can hardly be regarded as harmful to function, as it has been shown that infants born to diabetic mothers produce considerably more insulin following intravenous injection of glucose than do normal infants (26) (fig 7)

Re 2) Inflammatory pathological lesions in the islet tissue in persons who have died with a relatively recently diagnosed diabetes have previously been observed only rarely (35, 41) After the autoimmune hypothesis was put forward, however, interest naturally increased considerably (40, 29) Thus, Gepts (24) states having seen leucocyte infiltration in 15 out of 22 cases of juvenile diabetes with a duration of less than 6 months The lesions always appear to be accompanied by changes in the cells of the islet tissue, such as shrinkage and cell degeneration (41) The manifestation is independent of the ad-

ministration of insulin (37) It is likewise noted (29, 37) that lymphocyte infiltration is not found in and around *all* the islets of Langerhans in an affected pancreas This argues against the presence of immunological processes The possibility cannot be rejected that the lymphocyte infiltration is a reaction to a cell degeneration of particularly rapid onset Neither humoral nor cellular antibodies in the islet tissue could be demonstrated in diabetics not treated with insulin Thus, there are no good grounds for assuming that the pathological changes described as insulitis should be based on immunological reactions

Re 3) Pathological lesions have been described repeatedly in and around the islet tissue in animals who have either been actively or passively immunized with insulin (28, 32, 44, 48, 49, 50) In some animals, these changes appear as a massive round cell infiltration, in other cases as an infiltration of eosinophil cells in and around the islet tissue, and in still other animals as a diffuse infiltration of polymorphonuclear leucocytes in the pancreas It is probable that these reactions are a direct or indirect sequel to an antigen antibody reaction, whereas they are hardly an expression of a toxic effect of the antigen antibody complex (28) It should be mentioned, however, that the majority of commercially available insulin preparations contain antigenic impurities, which do not have an antigenic relationship with insulin, but originate from the pancreas and therefore can confuse the picture to a high degree, provided the insulin preparation used for the experiments is not highly purified (14) Nor can the




Fig 111

Plasma insulin in infants of non-diabetics and of diabetic mothers at birth (cord blood) and during the first few hours of life in the fasting state before and after a rapid glucose injection through an umbilical vein catheter (umbilical vein blood) (from Jørgensen et al 1965)

possibility be excluded that the lesions are non specific and determined by the sudden considerable strain on the production of insulin, with cell death as a sequel. This is supported by experiments which show that pathological changes in islet tissue with round cell infiltration only occur in rabbits which had become diabetic during the active immunization with insulin, while immunized rabbits without diabetes had normal pancreas histology (48). In partly pancreatectomized animals, however, made diabetic by injection of pituitary extract, no round cell infiltration was observed in the islet tissue, in spite of a considerable drain on the insulin production (18).

It is difficult to make comparisons between the various pathological lesions described as insulitis, since they originate from different individuals and animal species. There are both peri insular infiltrations of eosinophil leucocytes, intra-insular round cell infiltrations or infiltration of polymorphonuclear leucocytes. No evidence can be brought forward to refute the conclusion that a common feature of the lesions is that they are a sequel of antigen antibody reactions in and around the islet tissue. Further studies must be made with respect to demonstration of bound insulin antibodies in the pancreas especially in man, before the question can be settled.

#### *Manifestations of long-standing diabetes*

It was suggested by Berson et al (3) already in 1956 that certain manifestations of long-standing diabetes might be due to immunological reactions condi-

tional on the presence of insulin antibodies. Since then, however, it has been possible to establish that there is no relationship between the demonstration of humoral insulin antibodies and the manifestations of long term diabetes (14). It has now also been confirmed that both nodular glomerulosclerosis and proliferative retinopathy can be found in diabetics who have never received insulin treatment (19), and who are therefore unable to show the presence of humoral insulin antibodies. Thus, the presence of cellular autoantibodies must also be assumed here, if pathological changes in the retina and kidneys of diabetics are to be explained on the basis of immunological reactions between insulin and insulin antibodies. There are two findings which have kept the discussion open on this topic: 1) the demonstration of components in the kidneys, placenta and retina which can bind fluoresceinated insulin (2, 10, 12), and 2) the production of pathological lesions in the kidneys of animals immunized with insulin (38).

Re 1) Demonstration of insulin-binding to pathological lesions in the retina and renal tissue is almost always done on formalin fixed tissue with fluoresceinated insulin (2, 12). However, the formation of non specific insulin-binding components during the treatment of tissue proteins with formalin and alcohol cannot be excluded (1). Furthermore, during the fluorescence marking of the insulin a change takes place in the insulin molecule, which signifies at any rate a physico-chemical modification, and in many cases also involves an alteration in the immunological characteristics (42). The studies by



Berns et al (2), therefore, at best suggest a binding of insulin to those tissue components in the kidneys which are also outstanding for their PAS-positivity. But on the one hand components which bind fluoresceinated insulin do not occur exclusively in diabetic kidneys (22), and on the other hand it is still not proven that these tissue components contain insulin antibodies. It has indeed been demonstrated that nodules in nodular glomerulosclerosis (13, 9), thickened basement membranes in the skin (36) and diabetic microaneurisms (13) all contain gamma globulins, but whether insulin is bound to these gamma-globulins in the PAS positive materials, and whether the gamma globulins contain insulin antibodies in diabetics not treated with insulin, is not known. It has been shown that in diabetics, those components in the kidneys which bind fluoresceinated insulin far from always bind fluoresceinated anti gamma globulin, which they ought to do provided they were antibodies and thereby immunoglobulins. It is more probable, therefore, that insulin is bound to another component in these tissues, possibly a denatured protein. In insulin treated diabetics, however, it must be assumed that at the sites where serum gamma globulins can be demonstrated in the tissue, insulin antibodies must also occur, but it is quite uncertain whether nodular glomerulosclerosis results from the binding of insulin to sessile antibodies, or from the deposition of circulating insulin-insulin antibody complexes. Parker et al (42) were unable to demonstrate binding of fluoresceinated insulin to glomeruli of guinea pigs with a high insulin antibody

titer. This suggests, rather, that the deposition of humoral insulin antibodies in glomeruli of insulin treated diabetics is a sequel of disease in the glomeruli, and not its cause.

Re 2) In non diabetic animals injected with crystalline insulin or protamine zinc insulin, it has not proved possible to elicit glomerular changes of a type similar to those seen in diabetic glomerulosclerosis (38, 51). On the other hand, glomerular changes have been described in animals following immunization with insulin emulsified in Freund's adjuvant (38). These changes, however, could also be produced by the injection of Freund's adjuvant alone (38), just as the injection of other substances such as albumin and protamine can give rise to similar changes in the kidneys (17, 30). The changes observed must thus be considered non specific. Repeated injections of insulin antibodies into rats resulted in hyperglycaemia and acidosis, but no glomerulosclerosis like lesions (28). There is thus nothing to suggest that the manifestations of long term diabetes in the kidneys and retina are due to insulin-insulin antibody reactions.

#### *Other autoimmuneological mechanisms*

The discussion so far has only been concerned with the possibility that the insulin molecule in diabetics becomes antigenic by a modification. Other possibilities for the origin of autoimmunity in diabetes mellitus will now be briefly mentioned.

It was stated in the introduction that autoimmuneological processes can also

arise on the basis of absence of tolerance. This requires that the insulin molecule does not circulate through the lymphatic apparatus of the organism until the processes which lead to immunological tolerance have terminated. A study of foetal pancreas, however, has shown that beta-cells can be found in only 10-week old foetuses (45), and determination of the insulin in blood specimens from abortions has shown that insulin is present in the blood at a very early stage of foetal life. Absence of tolerance is therefore unlikely.

An alteration in the function of the immunological apparatus could likewise be considered as causing the autoimmune processes in diabetes. In this connexion, it is of interest that both pernicious anaemia (39) and thyroiditis (21) occur more frequently in a diabetic population than in a normal population, just as in juvenile diabetes in particular, parietal cell antibodies and thyroid antibodies can be found considerably more frequently than in normal subjects (39). It must again be remembered, however, that neither circulating nor cellular insulin antibodies could be demonstrated in diabetics not treated with insulin. It is possible that the higher incidence of autoantibodies in diabetics must rather be considered a sequel of the degenerative, vascular changes associated with diabetes, which undoubtedly lead to tissue damage and leakage, and thereby make it possible for certain molecules to come into contact with antibody producing cells, they would otherwise be excluded from. In the same way, autoimmune processes, with renal tissue components as antigen, could be

considered to contribute to the pathogenesis of the diabetic nephropathy.

For the time being, the concept must be rejected that diabetes mellitus arises, or the complications of long-term diabetes develop, as a result of the formation of autoantibodies against insulin.

## SUMMARY

The question is examined whether diabetes mellitus can arise, or whether the manifestations of long-standing diabetes can develop, on the basis of autoimmune mechanisms.

It is pointed out that no immunological differences have been found between insulin from diabetics and insulin from non-diabetics. Nor has it been possible to demonstrate insulin antibodies in diabetics not treated with insulin.

However, isomunization can occur following subcutaneous injection of insulin in physiological doses without the use of adjuvant. It has also been shown that the insulin antibodies formed can react with islet insulin, resulting in histologically demonstrated lesions in the islet tissue. It is probable that local tissue reactions and the unphysiologically high insulin concentration at the site of injection are the reason for the injected insulin being regarded as an antigen in these cases.

The cause of the lesions described under the designation 'insulitis' in juvenile diabetics is still not elucidated.

There is no definite support for the belief that insulin-insulin antibody reactions contribute to the development of the manifestations of long standing diabetes.

## REFERENCES

- 1 Berns A W Hrata Y Blumenthal H T *J Clin Lab Med* 60 535 59 1967
- 2 Berns A H Oens C T Hrata Y Blumenthal H T *Diabetes* 11 308 317 1962
- 3 Berson S A Yalow R S Bauman A Rothschild M A *New Engl J Clin Invest* 35 170-190 1956
- 4 Berson S A Yalow R S *Science* 139 844-845 1963
- 5 Berson S A Yalow R S *Diabetes* 14 549 572 1965
- 6 Brunfeldt K Deckert T *Acta Endocrinol* 47 367 370 1964
- 7 Brunfeldt K Jorgensen K R *Acta Endocrinol* 1966 In press
- 8 Brunfeldt K Deckert T Hrajenbuhl C *In preparation*
- 9 Burkholder P M *Diabetes* 14 755 770 1965
- 10 Burstein R Berns A W Hrata Y Blumenthal H T *Am J Obst & Gyn* 86 66 76 1963
- 11 Chetty M P Watson K C *Lancet* I 67 69 1965
- 12 Coleman S L Becker B Canaan S Rosenbaum L *Diabetes* 11 375-377 1962
- 13 Coleman S L Becker B *Am J Ophthalmol* 55 239 241 1963
- 14 Deckert T *Insulin Antibodies* Thesis Munksgaard Copenhagen 1964
- 15 Deckert T Jorgensen K R *Acta Endocrinol* 53 673-680 1966
- 16 Deckert T Poulsen J E Unpublished results
- 17 Dixon F J Feldman J D Vazquez J J *J Exp Med* 113 899 920 1961
- 18 Duff G L *Am J Med Sci* 210 381 38 1945
- 19 Ellenberg M *JAMA* 183 926-930 1963
- 20 Elliot R B O'Brien D Ray C C *Diabetes* 14 780-787 1965
- 21 Engelson G Aronsson B *Thyroids in juvenile diabetes* *Second Annual Meeting of the European Ass for the Study of Diabetes* Aarhus 1966
- 22 Farrant P C Shedden W I H *Diabetes* 14 274 278 1965
- 23 Federlin K Ggl I Dtschune t H Henemann G Pfeiffer H F Zellgebundene Antikörper gegen Insulin *Second Annual Meeting of the European Ass for the Study of Diabetes* Aarhus 1966
- 24 Gepts W *Diabetes* 14 619 633 1965
- 25 Hales C N A comparison of the immunological properties of antisera to human and ovine insulin *British Insulin Manufacturers Coll On the Immunology of Insulin* London 1965
- 26 Jørgensen K R Deckert T Molsted Pedersen C Pedersen J *Acta Endocrinol* 52 154 167 1966
- 27 Korec R *Diabetologia* 1 76 1965
- 28 Lacy P E Wright P H *Diabetes* 14 634-642 1965
- 29 LeCompte P M *Arch Path* 66 450-457 1958
- 30 Lenti G Pellegrin A Sangu F Pagano G *Studies on diabetes nephropathy* *Second Annual Meeting of the European Ass for the study of Diabetes* Aarhus 1966
- 31 Lockwood D H Prout T E *Metabolism* 14 530-538 1965
- 32 Logothetopoulos J *Diabetes* 15 205 211 1966
- 33 Mancin A M Vecchi A Constanzi G Zampa G A *Lancet* I 1189 1191 1965
- 34 Mann C B *Studies on the neutralization of guinea pig insulin by antibodies to insulin produced in the same species* *British Insulin Manufacturers Coll on the Immunology of Insulin* London 1965
- 35 McLean N Ogilvie R F *Diabetes* 8 83 91 1959
- 36 Melin H *Acta Med Scand Suppl* 423 1964
- 37 Meyenburg H *Schwe Med Wsch* 21 554 557 1940
- 38 Mohos S C Hennigar G R Fogelman J A *J Exp Med* 118 667 680 1963
- 39 Moore J M Nelson J McE *Lancet* II 645-647 1963
- 40 Nagler W Taylor H *JAMA* 184 723 725 1963

- 41 Ogihara R F *Ciba Found Coll on Endocrinol* 15 49-66 1964
- 42 Parker J W Elewitch F R Grodsky G M *Proc Soc Exp Med* 113 48-53 1963
- 43 Poulsen J E Werner A K Biopsies of insulin injected tissue from diabetics *Sec ond Annual Meeting of the European Ass for the Study of Diabetes Aarhus* 1966
- 44 Renold A E Soeldner Stuart J Stenke J *Ciba Found Coll on Endocrinol* 15 122-134 1964
- 45 Robb P *Quart J Exper Physiol* 46 335-343 1961
- 46 Silverman J C *Diabetes* 12 528-537 1963
- 47 Taylor, K W *Ciba Found Coll on Endocrinol* 15 89-94 1964
- 48 Toreson W E Feldman III Lee J C, Grodsky G M *Am J Clin Path* 42 531 1964
- 49 Wattenwyl N V Burgi H *Schweiz Med Wschr* 94 314-316 1964
- 50 Werner, A V Poulsen J E Deckert T Brunfeldt K In preparation
- 51 Ørskov H Steen Olsen T Nielsen K Rafaeisen O J Lundbæk K *Diabetologia* 1 172-179 1965



## THE STATE OF INSULIN IN PLASMA

by

Jens Lyngsøe

In recent years, a number of studies have attempted to solve the problems of the biological and physical characteristics of the plasma insulin, and have thrown light on the important question whether insulin exists in more than one form in normal plasma. These investigations have been made in part using bioassays, mainly the rat-diaphragm and the rat epididymal fat methods, in part using the immunoassay described by Berson and Yalow or modifications hereof. Studies using bioassays have shown the presence in plasma of different forms of insulin like activity (ILA)\*, which can be separated in various ways, such as by addition of insulin antibody (anti insulin) to plasma, extraction with acid ethanol, treatment of plasma with cation exchange resin, and electrophoresis. However, the methods mentioned have not succeeded in separating different forms of insulin activity which can be determined by the immunoassay of Berson and Yalow. It has therefore been maintained that the different forms of ILA found in plasma do not represent different forms of plasma in-

sulin, but other plasma factors with insulin like activity.

The present paper attempts to review the studies which have investigated the biological and physical characteristics of the different forms of plasma ILA and of the plasma insulin activity which is measured by the immunoassay.

### *Immunologically active insulin*

Insulin is found in plasma in a form in which it can react with insulin-antibody using the technique developed by Berson and Yalow (58). The insulin values found by this and similar methods (28, 31, 43) correspond quite well to the values of "suppressible ILA" (see page 44) found by the rat epididymal fat method (12, 39, 40, 46). Simultaneous determinations of suppressible ILA and plasma insulin measured by the immunoassay have shown identity between the values found with the two methods (53), and it is therefore highly probable that they measure the same form of plasma insulin. This form of insulin in plasma has been called "immunologically active insulin" (38).

The physical properties of the immunologically active plasma insulin have

\*) ILA: the activity which can be measured by a biological method for determining insulin

been elucidated in recent years. Electrophoretic studies using starch gel have shown that it moves in the pre albumin zone corresponding to the electrophoretic mobility of insulin labeled with  $I^{131}$  (10). Investigations with ultracentrifugation of plasma show that most of the immunologically active insulin is found in the supernatant above the albumin layer, and that insulin  $I^{131}$  is distributed in an identical manner (10, 34). Gel filtration studies using Sephadex G 75 seem to indicate that the molecular weight of immunologically active plasma insulin and insulin  $I^{131}$  is of the same order of magnitude and lower than the molecular weight of albumin (55).

The investigations cited suggest that the immunologically active plasma insulin probably circulates in plasma in a form in which it is not bound to plasma proteins of high molecular weight, and in which it has the same physical characteristics as pure pancreatic insulin added to plasma.

It has constantly been found that the amount of immunologically active insulin in plasma increases after oral glucose administration in normal subjects. After intravenous glucose administration the immunologically active plasma insulin increases almost instantaneously 48%, and when the glucose concentration falls the immunologically active plasma insulin decreases, with a half life between 5 and 15 minutes (49, 60). In pancreatectomized dogs, it falls in the immunologically active plasma insulin has been recorded shortly after the operation (22, 50). Studies on the same animal species have shown that the activity of this form of insulin is much higher in

the pancreatico-duodenal vein than in the femoral artery, both in the fasting state and after the administration of glucose (40). These results show that the immunologically active insulin is produced in the pancreas, and the evidence suggests that this form of plasma insulin plays a major role in the regulation of the blood glucose level.

### *Non suppressible ILA*

Several investigations with the rat epididymal fat method have shown that in normal plasma, only part of the activity measured by this method is inhibited after addition of insulin antibody, which totally suppresses the biological activity of pure pancreatic insulin. The plasma ILA which is not inhibited by anti insulin has been called "non suppressible ILA", and the ILA which is inhibited "suppressible ILA".

The physical characteristics of the non-suppressible ILA in plasma have been investigated recently by Froesch and coworkers (Table 1). Electrophoretic studies have shown that the non suppressible ILA is located in alpha<sub>2</sub> and beta globulins (13, 24), and gel filtration of plasma using Sephadex indicates that the molecular weight is between 70,000 and 150,000 (13). The group mentioned have succeeded in isolating a substance from plasma which has the same biologic characteristics as non suppressible ILA. Their investigations on this "purified non suppressible ILA" have shown that the molecular weight of this substance depends on the pH of the solution in which it is dissolved. At acid pH the molecular weight

TABLE 1  
*Biological and physical characteristics of different forms of IIA*

	Biological activity				Inactivation with cysteine or glutathione	Heat inactivation	Extraction with acid ethanol	Auto-insulin inactivation		Electrophoretic mobility	Molecular weight	Is experimental diabetes	After intravenous glucose administration
	in vivo		in vitro					Without acid-ethanol extraction	After acid-ethanol extraction				
	RD	REF	RD	REF									
appressed I A	+	+	+	+	(+)	0	+	0	0	beta globulin	70 000-150 000	-	II
	25	25	25	25	13 25	15	13 46		13			47	20
								(+)	46			0	
										alpha 2 beta globulin		56	
										15			
in serum	+	+	+	+	(+)		+	+	(+)	beta gamma globulin	Like albumin		-
	1	1	5 20 31	30	8		6	51	6	4	4		5
								(+)	4 30				
ethanol-insoluble plasma	+	+	+	+	+		+		(+)	Albumin	300 000-1 000 000	-	+
	8	8	14 25 34	25 34	15			1 20 50	14 33			20	20
			(+)					54				(-)	
								0			7000-14 000		
								14 19 34			14 23		
of action			+	+				+		Albumin		-	-
			14	17 21 27				21 34		alpha 1 globulin		4	46
								(+)	36				
of action			+	+				+		beta gamma globulin		0	0
			11 34	9 17 21				21 36				4	21 20
			II	27 27				(+)	36				
			21										

Abbreviations + positive response (+) incomplete response - decrease II no response

II 7000, and at alkaline pH 100,000 to 200,000 (24) Froesch and coworkers have suggested that the substance forms polymers at alkaline pH and that the polymers dissociate at acid pH. In an attempt to show whether the purified

non-suppressible IIA has the same structure as insulin the investigators have treated II with performic acid, which splits insulin into the A- and B-chain. With this method it was not possible to show any A-chain in the purified



non suppressible ILA, but the technique used in these studies was not so sensitive as to exclude the possibility of minute amounts of A chain being present (13)

The biological characteristics of non-suppressible ILA in plasma are not different from those of insulin (Table 1) Both *in vitro* and *in vivo*, non suppressible ILA has the same effect on the metabolism of rat diaphragm and rat epididymal fat as insulin (25) Inactivation studies with cysteine and glutathione have shown a partial inhibition of the activity of non suppressible ILA, but treatment with both urea and glutathione inhibits the activity completely Heating to 80° C does not cause a decrease in the activity of non-suppressible ILA (13)

Investigations in normal individuals have shown that non suppressible ILA in plasma is unchanged after intravenous and oral glucose administration (12, 39, 40, 45), and it is so far unknown whether it plays any part in the regulation of the normal blood sugar

Various attempts have been made to elucidate the site where non suppressible ILA is produced in the organism There is evidence suggesting that it is formed in the liver (40, 46) and it has been suggested that non suppressible ILA represents a transformation product of insulin (46) However, liver perfusion studies do not support this theory (35, 52)

In pancreatectomized cats, a slow fall in plasma ILA, probably non suppressible, is recorded after the operation (26), while no decrease has been found in dogs (50) Alloxan treatment of rats induces a fall in non suppressible ILA

in plasma (23), and so does infusion of anti insulin (47) Thus, the weight of the evidence supports the theory that intact beta cells are necessary for the production of non suppressible ILA, but it does not prove that non suppressible ILA is a form of insulin

### *Insulin complex*

The terms "insulin complex" and "bound insulin" have been used alternately by Antoniadis and his co-workers to describe a substance in plasma with insulin like activity and with the ability to be absorbed on a cation exchange resin (Dowex 50×8) The insulin complex can be eluted from the resin by using an alkaline or acid medium, and if eluted with acid it is inactive on rat diaphragm but not on rat epididymal fat (29) Since the ILA of plasma treated with the cation exchange resin is unchanged after the treatment, it has been concluded that the insulin complex in untreated plasma is without insulin like activity (4) These observations have been confirmed since, in the only publication in which the resin method has been applied to plasma by investigators not taking part in the original studies (51)

In later publications, Antoniadis has investigated the properties of the insulin complex (Table 1) In electrophoretic studies it has been found in the beta-gamma globulin area, and after gel-filtration on Sephadex G 100 it appears with the albumin fraction, which proves that the molecular weight is considerably higher than that of the insulin monomer (6)

The biological activity of the insulin complex has been investigated *in vivo* and *in vitro* on rat diaphragm and rat epididymal fat, and has been found not to differ from that of insulin (5, 7, 30, 51). The ILA of the insulin complex disappears after treatment with reduced glutathione (6), and addition of anti-insulin results in a partial inhibition of the ILA (6, 30, 51). After acid-ethanol extraction of the insulin complex, the ILA of the extract is likewise partially suppressible (6). These results justify the conclusion that the insulin complex contains insulin, but not the conclusion that all of its insulin like activity is caused by insulin.

The organ which produces the insulin complex, and the biological role of this substance, is at the present moment unknown. Based on very few investigations, Antoniadou has suggested that it is produced in the liver (5), but no other studies of this important problem have been published. After the intravenous administration of glucose, the same investigator found a sharp decrease in the amount of insulin complex in the serum, and he suggested that a dissociation of insulin from the complex took place (3). No proof of this theory has been presented so far.

#### *ILA in acid ethanol extracts of plasma*

Several studies have investigated the ILA in plasma treated with acid ethanol, the extraction method which for a long time has been used for the isolation of insulin from pancreas. Different modifications of the method have been used, some investigators extracting plasma

with hydrochloric acid in ethanol (2, 3, 18), while trichloroacetic acid (TCA) in ethanol has been used in other studies (1, 2, 8, 34).

In the technique used by Davidson and coworkers, the mixture of plasma and acid ethanol is dialyzed against a Gey and Gey buffer immediately after mixing (18). The resulting suspension of denatured protein has a high ILA on mouse diaphragm (18) and rat epididymal fat (44), and ILA is present both in the protein precipitate and in the buffer (18, 44). The ILA is not suppressed by anti-insulin (19) but is destroyed by cysteine treatment (18). The protein suspension does not contain factors which stimulate or inhibit the action of insulin on mouse diaphragm (18). In dogs, Davidson and coworkers found a rapid decline in the ILA of the extracts after pancreatectomy (20). In man, this ILA increases after the administration of glucose (20, 44).

The acid-ethanol extraction method of Scott and Fischer has been used in two studies in pancreatectomized dogs. Persistence of plasma ILA which could be extracted with this method was noted in both investigations and both studies showed that a considerable part of the ILA extracted was suppressed by anti-insulin (50, 54).

The technique of using TCA-ethanol for the extraction of plasma was originally used for the isolation of the synalbumin antagonist (57), and several studies have confirmed the presence in the extract of an insulin antagonist active on rat diaphragm (1, 2, 32). However, other investigators using the same method did not find antagonistic activ-

ity in the extract, on the contrary they have shown that it has a considerable ILA on rat diaphragm *in vitro* (14, 33). No satisfactory explanation has so far been presented for these discrepancies. ILA has consistently been found in the TCA-ethanol extracts using the rat epididymal fat method (1, 8, 33, 34), and a single investigation has shown that the extract has ILA on both rat diaphragm and rat epididymal fat *in vivo* (8). N-ethylmaleimide, which suppresses the action of insulin on the rat epididymal fat, completely inhibits the ILA of TCA-ethanol extracts (16). Several attempts have been made to suppress the ILA of the extracts with anti-insulin, but the results are confusing. Some investigators have shown a partial inhibition of the ILA (1, 33), while no or inconstant suppression has been found in other studies (16, 34).

Lipniz and Stein have drawn attention to the phenomenon that albumin prepared with TCA-ethanol stimulates the action of insulin on rat epididymal fat (34). The nature of this insulin stimulating effect is unknown, but it is of interest that on dilution of the albumin extract, the dose response curve is parallel to that of insulin (16).

Few studies have been published on the physical properties of the ILA in the TCA-ethanol extracts. It has been found that the extracts contain immunologically pure albumin, and Sephadex fractionation of the protein indicates a molecular weight over 300,000 (16). After Sephadex fractionation of the extracts, ILA is found both in the fractions containing the high molecular proteins and in the fractions containing substances

with a lower molecular weight (16), in contrast to the original observation in which ILA was found only in the latter fractions (33).

The investigations on the ILA of acid ethanol extracts of plasma do not allow any conclusions to be drawn. The results are to a large extent contradictory, probably because different modifications of the extraction methods have been used. However, it is important to stress that the acid ethanol method of Scott and Fischer extracts a substance from the plasma of pancreatectomized dogs, which biologically and immunologically has the same properties as insulin.

#### *ILA in electrophoretically separated plasma protein fractions*

Not all investigations of ILA in electrophoretically separated plasma protein fractions have used the same electrophoretic techniques, nor have the methods used for the treatment of the protein fractions after the separation been identical. Some investigators have dialyzed the protein fractions against water at room temperature, which increases the ILA of the fractions (36), while others have omitted this step. For these reasons, only some of the studies are comparable.

Several investigators working with similar electrophoretic techniques have shown that the ILA in serum is distributed with one maximum in the albumin-alpha-1-globulin ("A fraction") and another in the beta gamma globulins ("B-fraction") (17, 21, 37, 56). Although a single observation seems to indicate that the ILA in the B fraction is inactive on rat diaphragm *in vitro* (21),

most investigations show that the ILA in both the A- and B fraction are active on both rat diaphragm and rat epididymal fat *in vitro* (9, 11, 17, 27, 37, 56)

Studies using anti insulin have succeeded in showing a suppression of the ILA in both A and B fractions, but while some investigators have found a complete suppression after addition of anti insulin (21, 56) other studies have shown only partial inhibition of the ILA (36)

The biological role of the ILA in the A and B fractions is not known After administration of glucose, no change is noted in the ILA of the B fraction in peripheral venous blood (21, 39) Ten minutes after the intravenous administration of glucose, a fall is seen in the ILA of the A fraction (10), but an increase has been found 30 minutes after oral glucose administration (21) Since the level of the ILA of the A fraction seems to depend on the serum glucose concentration, it is natural to assume that this form of ILA may be of importance in the regulation of the serum glucose Support for this hypothesis may be gained from the observation that a retention of ILA in the A fraction seems to take place in the peripheral tissues (40)

In dogs, the ILA of the A and B fraction has been measured at different sites in the circulation, in an attempt to elucidate where these forms of ILA are produced in the organism (40) This study showed higher ILA of the B fraction in blood from the pancreatico-duodenal vein than in arterial blood The ILA of the A fraction tended to be

higher in the pancreatico-duodenal vein than in the artery After pancreatectomy, dogs show a slow fall in the ILA of the A fraction, while the ILA of the B fraction has a tendency to decrease (42) These experiments suggest that the ILA of the A and B fractions is produced in the pancreas

## DISCUSSION

The studies which have been cited on immunologically determined insulin and ILA in plasma raise the question whether plasma insulin exists in more than one form The investigations on 'suppressible' and 'non suppressible' ILA, on 'free' and 'complex' insulin, and on ILA of 'A and B fractions', have separately demonstrated two different forms of ILA in plasma However, both the rat diaphragm method and the rat epididymal fat method which have been used in these studies are non specific, and the demonstration of two forms of ILA in plasma can therefore not be considered a proof that different forms of plasma insulin exist

Using the resin method, Antonmades has isolated the 'insulin complex', and several investigators have found that it contains a substance with ILA, which is suppressed by anti insulin (Table 1) Since the insulin complex is without any insulin activity measured by the immunoassay (10, 34), the studies show that the insulin complex contains suppressible ILA which is without activity in the immunoassay

Several investigators have found ILA in electrophoretically separated beta-gamma globulin fractions (Table 1)

which have no insulin activity when determined by the immunoassay (10, 59) Since the beta gamma globulins contain ILA which is suppressed by anti insulin, this ILA must be without activity in the immunoassay

It has been found in dogs, that plasma insulin determined by the immunoassay disappears shortly after pancreatectomy (22, 50) However, acid ethanol extracts of plasma from these animals contain ILA which is suppressed by anti insulin (50, 54) Since acid ethanol extraction of plasma causes no increase in the amount of plasma insulin which can be recorded by the immunoassay (28, 34), these investigations show that plasma from pancreatectomized dogs contains suppressible ILA which is without activity in the immunoassay

Thus, three different types of investigations have all led to the conclusion that plasma contains suppressible ILA which is inactive in the immunoassay Besides insulin, no substance is known which has suppressible ILA on the rat epididymal fat pad The studies therefore permit the conclusion that plasma contains a form of insulin which is without activity in the immunoassay, and that at least two different forms of insulin must exist in plasma, one which is recorded by the immunoassay and one which is not These forms of plasma insulin have been designated immunologically active and immunologically inactive plasma insulin (38)

The investigations cited previously raise the question whether the immunologically inactive plasma insulin which is isolated by acid ethanol extraction, resin treatment and electrophoretic sep-

aration is an entity, or whether different forms of immunologically inactive insulin exist in plasma Our present knowledge does not permit any definite conclusions to be drawn Although the insulin complex and the ILA of the B fractions seem to have identical biological properties and electrophoretic mobility, their response to intravenously administered glucose is different (Table 1)

Two studies on ILA in electrophoretically separated serum proteins have shown that the albumin alpha 1-globulin fraction, which probably contains the immunologically active plasma insulin, and which has no insulin stimulating effect (41, has an insulin like activity which is much higher than the level of immunologically active plasma insulin (21, 39, 40) These results, and the investigations on the effect of warm dialysis on the level of suppressible ILA in the albumin alpha-1-globulin (36), suggest that in addition to immunologically inactive insulin these protein fractions contain immunologically inactive insulin Thus, the possibility cannot be excluded that two types of immunologically inactive insulin are present in plasma

The physical state of the immunologically inactive plasma insulin has been scantily investigated, but a single observation suggests that it has a molecular weight which is considerably higher than that of the insulin monomer (6) It has therefore been suggested that this form of plasma insulin is in some way bound to a high molecular weight protein If this is the case, it is not surprising that the immunologically inactive plasma insulin does not have any activity in the

immunoassay, and has a different biological half-life from that of the immunologically active insulin (26, 42)

#### ACKNOWLEDGEMENT

Supported by grants from King Christian X Foundation

#### REFERENCES

- Alp H & Recant L *Metabolism* 13 609 1964
- Alp H & Recant L *J Clin Invest* 44 870 1965
- Antoniades H N & Gundersen K *Endocrinology* 68 36 1961
- Antoniades H N, Beigelman P M, Tranquada R B & Gundersen K *Endocrinology* 69 46 1961
- Antoniades H N, Bougas J A, Cameron Davalos R. & Pyle H M *Diabetes* 13 230 1964
- Antoniades H N, Huber A M, Boshell B R, Saravis C A & Gershoff S N *Endocrinology* 76 709 1965
- Antoniades H N, Huber A M, Gershoff S N *Diabetologia* 1 195 1965
- Antoniades H N & Gershoff S N *Diabetes* 15 655 1966
- Beigelman P M & Onoprienko I S *Diabetes* 8 438 1959
- Berson S A & Yalow R S *Amer J Med* 40 676 1966
- Bolinger R E, v d Geld H & Willebrands A F *Metabolism* 8 39 1959
- Burgi H, Ramseier E B, Froesch E R, Bally P & Labhart A *Helv med Acta* 29 527 1962
- Burgi H, Muller W A, Hummel R E, Labhart A & Froesch E R *Biochem Biophys Acta* 121 349 1966
- Cameron J S, Keen H & Menzinger G *Lancet* II 74 1964
- Cameron J S, Boyns D R, Jarrett R J & Keen H *Diabetologia* 2 86 1966
- Cameron J S, Boyns D R, Jarrett R J & Keen H *Diabetologia* 2 91 1966
- Clausen J, Gjedde F & Jorgensen K *Proc Soc Exp Biol Med* 112 778 1963
- Davidson J K & Haast R E *Lancet* II 656 1963
- Davidson J K, Haast R E & Best C H *Diabetes* 12 448 1963
- Davidson J K, Ashworth M A, Lin H J, Rappaport A M & Haast, R E in I *Congress of the International Diabetes Fed Excerpta Med* (Amsterdam) 1964 pag 40
- Ditschuneit H, Cuendet R & Pfeiffer E F *Path Biol* 12 148 1964
- Egdahl R. H. & Goldberg H *Surgery Gynec Obstet* 114 202 1962
- Froesch, E R, Burgi H, Muller W A & Labhart A *Schweiz Med Wochschr* 94 309 1964
- Froesch E R, Burgi H & Muller W A *Proc Symp on the transport function of plasma proteins* Paris 1965 Elsevier (Amsterdam) 1966 pag 75
- Froesch E R, Muller W A, Burgi H, Wahogel M & Labhart A *Biochem Biophys Acta* 121 360 1966
- Gjedde F in Brolin Helman & Knutson *The structure and metabolism of the pancreatic islets* Pergamon press (Oxford) 1964 pag 469
- Glieman J *Diabetes* 14 643 1965
- Grodsky G M & Forsham P H *J Clin Invest* 39 1070 1960
- Gundersen K & Antoniades H N *Proc Soc Exp Biol Med* 104 411 1960
- Gundersen K & Lin H J *Diabetes* 14 805 1965
- Heding L *Proceeding of the conference on problems and use of labeled proteins* Euratom Brussel 1966 pag 345
- Jervell J *Acta physiol scand* 63 33 1965
- Keen, H *Diabetes* 12 406 1963
- Kipnis D M & Stein M F in *LIB4 found symp Endocr* vol 15 Churchill (London) 1964 pag 156
- Kopetz K, Burgi H, Froesch E R & Schwarz *Diabetologia* 2 104 1966
- Lyngsøe J *Acta med Scand* 174 589 1963
- Lyngsøe J *Acta med Scand* 175 401 1964
- Lyngsøe J *Seruminsulin A review Acta med Scand* vol 179 suppl 441 1965
- Lyngsøe J & Lundbæk K *Acta med Scand* 180 677 1966

- 40 Lyngsoe J, Adams L C, Greep J M & Field R A *Acta Endocr* 54 141 1967
- 41 Lyngsoe J *Unpublished observation* 1966
- 42 Lyngsoe J & Davidson J K *Unpublished observation* 1966
- 43 Morgan C R & Lazarow A *Diabetes* 12 15 1963
- 44 Power L, Lucas C & Conn J W *Metabolism* 14 110 1965
- 45 Saman A, Stillman D & Fraser R *Lancet* II 1288 1962
- 46 Saman A, Fraser R & Dampster J W *Diabetes* 12 339 1963
- 47 Saman A & Fraser R *Brit Med J* 2 482 1964
- 48 Samols E *Lancet* I 462 1965
- 49 Samols F & Marks V *Lancet* II 700 1966
- 50 Schoeffling H, Ditschuneit H, Petzoldt R, Bever J, Pfeiffer E F, Sirek A, Geering H & Sirek O V *Diabetes* 14 558 1965
- 51 Shaw W V & Shuey E W *Biochemistry* 2 28b 1963
- 52 Siess E, Teinzer A, Struck, E & Wieland, O *Diabetologia* 1 21-27, 1965
- 53 Sonksen P H, Ellis J, Lowy, C, Rutherford A & Nabarro J D N *Diabetologia* 1 77 1965
- 54 Steinke J, Sirek, A, Lauris, V, Lukens F D & Renold A E *J Clin Invest* 41 1699, 1962
- 55 Steinke J & Soeldner J S *In Leibel & Wrenshall The nature and treatment of diabetes* *Excerpta Medica* (Amsterdam) 1965 p 213
- 56 Taylor H W & Randle P J *J Endocr* 19 221 1959
- 57 Vallance Owen J & Lilley M D *Lancet* I 804 1961
- 58 Yalow H S & Berson S A *J Clin Invest* 39 1157, 1960
- 59 Ørskov H *Personal communication* 1965
- 60 Ørskov H & Christensen N J *Lancet* II 701 1966

## IODINE-LABELLING IN THE STUDY OF THE BIOCHEMISTRY OF INSULIN

by

*K. Brunfeldt*

### INTRODUCTION

A relationship between diabetes mellitus and the pancreas was first described by the English physician Cawley in 1788 (12). He established that infections of the pancreas that caused atrophy could lead to the development of diabetes.

In 1869 the German histologist Langerhans (36) discovered that throughout the external secreting tissue of the pancreas there was scattered a diverging type of tissue. This has since been named the islets of Langerhans after the discoverer. In man this tissue constitutes approximately 1 per cent of the weight of the pancreas, and the islets are present to the number of 1-2 million.

In rodents the pancreas has a diffuse shape and it is therefore possible through a minor incision in the abdominal wall of living mice to exteriorize a lobe of that part of the pancreas that adheres to the spleen. This can be performed with preservation of the blood supply. On examination under a microscope it

can be seen that the islets of Langerhans are richly vascularized, and that the capillaries in the islet tissue have an approximately 50 per cent larger diameter than the capillaries in the surrounding external secreting tissue. A plastic injection of the vessels also shows this difference in the diameter of the capillaries (fig. 1) (5). It has been known for some time that the islets of Langerhans contain zinc ions, this may be demonstrated by chelate formation with, for example, dithizone (40). The precipitation of zinc dithizonate can be observed in the living specimen after an intravenous injection of a dithizone emulsion (5).

The importance of the islet tissue in the regulation of the glucose concentration in the blood was, as is well known, first demonstrated by Banting and Best in 1922 (2) by the preparation of an active extract of pancreas from dogs where the external secreting tissue was atrophied by ligation of the excretory duct of the pancreas to the duodenum. The isolation of the active component, insulin, as crystals was performed by Abel in 1926 (1). The primary structure of insulin (fig. 2) was fully elucidated by

\*) Given in German as a lecture at the Rheinisch Westfälische Technische Hochschule Aachen, West Germany, on the 15th of November 1966 by invitation of Deutsches Wollforschungsinstitut.



Sanger and collaborators in 1955 (48). The synthesis of insulin was completed in 1963 by Zahn and collaborators (43) and also by Katsoyannis and Dixon and collaborators (33). Fully synthetic crystalline ox insulin was obtained by a Chinese group under the leadership of Wang Yu in 1965 (35).

In the following a synopsis of the biochemistry of insulin is presented in order to indicate the possibilities of the use of iodine labelled insulin (fig. 3).

### Biosynthesis

Experiments with minced  $\beta$  cell tissue from *Lophius piscatorius* are thought to

show that the A chain and B chain of insulin are separately synthesized and that the synthesis follows the generally accepted principle for the anabolism of proteins (25). A single chain precursor analogous to, for example chymotrypsinogen should therefore be out of the question. The combination of the two chains presumably does not require a particularly complicated cellular mechanism, as it is possible *in vitro* to obtain yields of about 50 per cent (30). It is however, to be regarded as probable that the combination *in vivo* takes place by an enzymatically controlled process. It has been suggested that glutathi-



Fig. 1

Plastoid preparation showing the capillary network of an islet of Langerhans and the surrounding external secreting tissue in the mouse (125x).



**Fig. 2**  
**The primary structure of pig insulin**


one-TNP transhydrogenase, which has been demonstrated in the islets of Langerhans, might participate in the process (37).

### Storage and secretion

The storing of insulin takes place in the cytoplasm of the  $\beta$ -cells, possibly in the form of strongly polymerized zinc complexes (41). Apart from the fact that insulin is secreted as a function of the concentration of the blood glucose, the secretory mechanism must be regarded as unknown.

### Peripheral processes

Today, despite a thorough knowledge of the chemistry of insulin, there are still many fundamental questions about the biochemistry of insulin that remain unsolved. For example it is not known if insulin be normally transported bound to a blood component. Also unknown is its degree of polymerization and thus its real molecular weight in a biological environment (34). It has been demonstrated that insulin can be broken down in the liver by enzymatic reduction of the



**Fig 3**  
A diagram of the significant biochemical processes of insulin

S-S bonds, but whether a special destruction process exists for insulin is not yet known (50). However, the greatest of the unsolved problems lies in the ignorance of the reaction with which insulin carries out its hormonal effect. Many hypotheses have been put forward to explain the mechanism, particularly in connection with the transport of glucose. But no definite experimental basis is believed at present to give unequivocally a picture of the nature of the action of the mechanism. Similarly, it is not known if insulin carries out its hormonal effect by reacting with one or several receptor systems in the cell.

To a small degree, insulin is excreted in both the normal and the diabetic organism through the kidney (31).

### *Iodine labelling*

In the study of what happens to insulin in the organism, extensive use is made of insulin labelled with the radioactive isotopes  $^{127}\text{I}$  and  $^{131}\text{I}$ . It should be made clear, however, that a derivative of insulin is thus employed containing a foreign atom. The consequences of this will be illustrated by the examples given in the following.

Even as early as 1936 it had been shown by Harrington and Neuberger (23), that it was possible to iodinate insulin with the stable isotope  $^{127}\text{I}$  without demonstrable destruction. At the low degree of iodination that is normally used in the labelling of insulin for biochemical investigations the iodine is preferentially substituted in the tyrosine residues. In human pig and ox insulin these are located as A14, A19, B16 and

B26. On the addition of larger amounts of iodine, a substitution also takes place in the histidine residues (45). The histidine residues in the three species mentioned are located as B5 and B10. This reaction takes place some 30–100 times slower than the reaction with the tyrosine residues (39). The tyrosine residues can be both mono- and di-substituted in the orthoposition relative to the hydroxyl group (fig. 4). The substitution with the second atom of iodine takes place approximately 30 times slower than the first, calculated from the concentration of the respective phenolate ions (42). Iodination of the phenylalanine residues or formation of thyroxine has not been demonstrated using the mild iodinating methods that are employed in the labelling of insulin.

On the other hand the iodine may be bound to the insulin molecule by non-covalent bonds, which is shown by the following experiment. By iodination of insulin with  $\text{I}_2^-$  at a given dripping rate and by addition of quantities of iodine corresponding to degrees of iodination of 10, 12, 15 and 20 I/mole, free iodine could only be shown in the reaction mixture with Thio Michler's ketone by the addition of  $\text{I}_2^-$  corresponding to degrees of iodination above 7 I/mole. After a few minutes' stirring following the completion of the iodination, the reaction for free iodine was on the other hand negative. However, the looser bound iodine was removed by the subsequent gel filtration and drying as the analytical values were 9.2, 9.6, 10.3 and 10.8 I/mole. It is not known how this interaction takes place, but bonding by inclusion seems to be a theoretical possibility.




Fig 4

Substitution possibilities for iodine into various groups of the insulin molecule

Generally, the iodination is performed at an alkaline pH, in that the reaction with the tyrosine residues is an electrophilic substitution certainly involving a quinoid intermediate. The  $\text{I}^-$  that is released by the reaction is separated from the protein together with the other low molecular components of the reaction-mixture by gel filtration on Sephadex G 25. In gel filtration the insulin may be completely deizinked (7). The buffers used for the elution in the gel filtration of micro-quantities must contain 1 per cent albumin in order to avoid adsorption onto glass and column material. The presence of the albumin also reduces the radiation-induced damage of the insulin. By monitoring the radioactivity in the effluent from the column a simple method is obtained for investigating if the iodination has taken place stoichiometrically correct and if any artefacts have occurred. This ought always to be carried out in connexion with iodination on a microscale with carrier free isotope solutions. This is because the production of these is still not under complete control, which could discernibly influence the iodination.

The first radioactive iodine isotope that became generally accessible was  $^{131}\text{I}$ . This isotope radiates a powerful  $\gamma$ -component of 364 keV (82 per cent) and a  $\beta^-$  with an energy of 610 keV (87 per cent) whereby  $^{131}\text{I}$  is transformed to  $^{131}\text{Xe}$ . Because of this high energy the isotope is easy to trace, this is important if scanning, for example, is to be carried out after a paper electrophoretic fractionation. Half life is, however, only eight days and, therefore, the labelling process must be repeated often.

Generally, the iodination is performed at an alkaline pH, in that the reaction with the tyrosine residues is an electrophilic substitution certainly involving a quinoid intermediate. The  $\text{I}^-$  that is released by the reaction is separated from the protein together with the other low molecular components of the reaction-mixture by gel filtration on Sephadex G 25. In gel filtration the insulin may be completely deizinked (7). The buffers used for the elution in the gel filtration of micro-quantities must contain 1 per cent albumin in order to avoid adsorption onto glass and column material. The presence of the albumin also reduces the radiation-induced damage of the insulin. By monitoring the radioactivity in the effluent from the column a simple method is obtained for investigating if the iodination has taken place stoichiometrically correct and if any artefacts have occurred. This ought always to be carried out in connexion with iodination on a microscale with carrier free isotope solutions. This is because the production of these is still not under complete control, which could discernibly influence the iodination.


It should also be remembered that "carrier free" preparations of this isotope also contain  $^{127}\text{I}$  and  $^{131}\text{I}$ . The relative abundance of the three isotopes is approximately 20, 20 and 60.

Nowadays,  $^{125}\text{I}$  is generally employed in labelling: this is a pure  $\gamma$  emitter with an energy of 35 Kev (100 per cent) and a half life of 60 days. Degradation takes place by electron capture to  $^{125}\text{Te}$  over the metastable  $^{125m}\text{Te}$  ( $\lambda$  ray 27 Kev). The measurement of these relatively weak energies will, with the use of a scintillation system with a wellcounter, cause but little difficulty.

As a rule the isotope is supplied as  $\text{I}^-$  in a weak alkaline solution and various methods have been used for the oxidation to  $\text{I}_2$ . As a high specific activity is normally required the aim is that as large a part of the isotope as possible reacts with the protein. Oxidation to iodine can take place by the addition of the isotope to an  $\text{I}_2$  solution. This method is, however, not particularly suitable as it is essential to have an excess of  $\text{I}^-$  to ensure that  $\text{I}_2$  is held in solution. With a ratio of  $\text{I}_2/\text{I}^-$  of 1:4 only 1/6 of the radioactivity will be incorporated in the protein. Iodination with an  $\text{I}_2$  solution is mild and if a low specific activity is required this is the method that is applicable. In another method that was earlier much used  $\text{I}^-$  is oxidized with  $\text{IO}_3^-$  and the released iodine extracted with  $\text{CH}_2\text{Cl}_2$  or  $\text{CHCl}_3$  that is slowly added to an aqueous solution of insulin whilst stirring vigorously. By this method it is possible for theoretically half of the added radioactivity to be used in the labelling of the protein. In iodination with small quantities of iodine the yield is, how-

ever, reduced considerably (6). In addition, the strong emulsion formation together with the high volatility of the iodine and the non polar solvent make this method less suitable.

Where high specific radioactivity is required the method most used today is that of Hunter and Greenwood (1962) (26). Oxidation of  $\text{I}^-$  takes place with an excess of chloramine-T, so that a large part of the  $\text{I}^-$  that is released during the substitution process is reoxidized, and so up to 90 per cent of the radioactivity is incorporated in the insulin molecule.



The iodination is carried out in the ampoule in which the radioactive isotope is delivered in a volume of 10–20  $\mu\text{l}$ . The iodination normally takes place on 10  $\mu\text{g}$  insulin dissolved in 50  $\mu\text{l}$ . The reaction time after the addition of chloramine-T is 1 minute. The oxidation is halted by sodium disulphite ( $\text{Na}_2\text{S}_2\text{O}_3$ ), whereby any possible excess of  $\text{I}_2$  is converted to  $\text{I}^-$ . The use of an oxidation agent involves the possibility of destruction, but carried out correctly this method gives excellent results for the iodination of insulin. This is possibly because the SH group is not found in this protein. In order to avoid the use of an oxidation agent electrolytically liberated iodine has been employed (47).

### *Location of iodine in the insulin molecule*

Fraenkel Conrat and Fraenkel Conrat (1950) (18) have shown that the method of iodination is of importance for the distribution of the iodine in the insulin molecule. This was demonstrated by iodinating to nearly the same degree using two different procedures. A difference in the amount of monoiodo- and diiodo-tyrosine residues appeared as well as a difference in the biological activity.

A Iodination with an excess of  $I_3^-$  and halting the reaction with disulphate

B Iodination by slow addition of  $I_3^-$

	TYR	MIT	DIT	% Biological activity
A	44	23	33	27
B	50	32	18	67

de Zoeten (1959) (54) has shown that the iodine is not equally located in the four tyrosine residues. After sulphite cleavage the A- and B-chains were separated by paper electrophoresis. The A-chain was cleaved by chymotrypsin between tyr14 and glu NH $\cdot$ 15, and the B-chain by trypsin between arg22 and gly23. By these means the four tyrosine residues A14, A19, B16 and B26 were located each in its own chain fragment. By paper electrophoresis the chain fragments were then separated, and the iodine content determined by measurement of the radioactivity from  $^{131}I$ . With the help of this technique it could be shown that by iodination with  $I_3^-$  at pH 9.2 to 0.2–3 I/mole the iodine was incorporated to a higher degree in

the A-chain than in the B-chain (55). By complete hydrolysis with pancreatin and chymotrypsin it was shown that the content of diiodo-tyrosine also was considerably greater in the A-chain than in the B-chain. Of the individual tyrosine residues B16 was the least reactive (56). These studies were developed by others investigating the distribution by iodination at other pH values. By iodination to 0.7 I/mole at pH 1–5 only about 10 per cent of the iodine was incorporated in the B-chain, whilst at pH 9–11 15–45 per cent in the B-chain was shown. B26 in particular showed a large increase in reactivity while B16 was still of low reactivity even at pH 11 (14). It was also shown that iodination in 8 M urea reduced the difference in reactivity of the four tyrosine residues. An equality of reactivity was, however, first achieved after the splitting of the S-S bonds by performic acid. This indicates that a certain folded structure exists even in 8 M urea (15).

After iodination of 10  $\mu g$  insulin at pH 8.6 by the method of Hunter and Greenwood, it could be shown that a larger part of the iodine, about 25 per cent, is incorporated in the B-chain by iodination to about 0.7 I/mole than by iodination with  $I_3^-$  (27). This indicates that this method is perhaps less mild than the previously mentioned where iodine is slowly added or liberated.

Iodination under special conditions with ICl has been performed at pH 1 where insulin has the tendency to form fibrils. Here, 6 I/mole at the most could be taken up, even on the addition of a quantity of iodine equivalent to 20 I/mole. Moreover, on iodination with up to 1

I/mole almost all of the iodine was in incorporated in the A chain. It is presumed that fibrillation is involved and protects one of the B-chain's tyrosine residues under these conditions of iodination (49).

### *Influence of iodination on the chemical properties of insulin*

Formerly one was not aware of the radical alterations which iodination could bring about in the chemical properties of insulin. The electronegative properties of iodine and the size of the electron shell (53 electrons) should be kept in mind as well as the size of the iodine atom, which is nearly equal in size to the benzene ring (fig. 5).

The electronegative properties of iodine can easily be shown by the decrease in the  $pK$  value of the phenolic OH-group that is brought about by substitution in tyrosine. In free tyrosine  $pK$  is 10.1, by mono-substitution it is reduced to 8.2 and by di-substitution to 6.5 (24), (20). The  $pK$  value of the phenolic

OH groups in the tyrosine residues of the insulin molecule is somewhat increased because of the proximity of other negative charges. So three of the tyrosine residues have a  $pK$  value of 10.4, whilst the fourth, which is probably hydrogen bonded, has a  $pK$  value of 11.4 (28). In accordance with these increased values in relation to free tyrosine, a mean  $pK$  value for the di-substituted tyrosine residues of 7.9 has been determined from measurements of insulin with a degree of iodination of 11 I/mole (21). As all tyrosine residues are not di-substituted at this degree of iodination, this determination of  $pK$  value is probably too high.

The effect of the substitution by iodine is not, however, restricted to the phenolic OH group, in that it is also possible to show an electronegative effect on the protons in orthoposition to the iodine. By proton magnetic resonance (PMR) measurements, a downfield displacement can be shown of similar size for the absorption frequencies for the 2 protons in monoiodo-tyrosine as well as the 2- and




Fig. 5

Stuart Brickley model of 3-iodo-L-tyrosine

protons in diiodo-tyrosine. The measurements were carried out on the amino acids dissolved in trifluoroacetic acid (fig 6) (7).

The UV absorption of tyrosine alters greatly with iodination, in that the absorption is shifted towards the longer wave lengths and is increased. For pH values where the dissociation of the phenolic OH group begins to take place, the absorption will shift towards the longer wave lengths as well for nonsubstituted as for substituted tyrosine. The alteration in the absorption can be used as an estimation of the degree of iodination (7). This is shown by measurements of the absorption spectra of iodinated insulin preparations (fig 7).

Iodine substitution possibly exerts an influence on the conformation of the insulin molecule as a result of the size of the iodine atom and/or by the reduction of the pK value of the phenolic OH-groups. The increased dissociation capacity especially by di substitution would thus mean that the hydrogen bonds which the tyrosine residues are involved in, if at all, will break at a physiological pH. Measurement of circular dichroism seems to show that the iodination exerts an influence on the conformation of the insulin molecule. In non iodinated pig insulin a degree of helicity of 26 per cent was found, while in dezinked insulin 19 per cent and in insulin iodinated to 4 and 8 I/mole 12 per cent was demonstrated at pH 9 (10).

A relationship between zinc and insulin has long been acknowledged because of the ease with which insulin crystallizes with  $Zn^{++}$  as rhombohedral crystals. The bonds between  $Zn^{++}$  and insu-




Fig 6

PMR spectra of A) L tyrosine 95 mg in 500  $\mu$ l trifluoroacetic acid (TFA) B) 3 moniodo-L tyrosine 95 mg in 700  $\mu$ l TFA C) 3 5 diiodo-L tyrosine 142 mg in 700  $\mu$ l TFA Reference III  $\mu$ l tetramethylsilane. Signals 1—Reference 2— $CH_2$  3— $CH$  4 and 5—Aromatic protons and  $NH_3^+$  6—Protons in ortho position relative to I (2 protons) 7— $NH_3^+$  8—Protons in ortho position relative to I (2 and 6 protons)

lin are, however, relatively weak. Thus the insulin and  $Zn^{++}$  are separated completely or partly by electrophoresis in certain commonly used buffer solutions (7) (fig 8).

Iodination, particularly at the higher degrees of iodination, clearly diminishes the capacity of insulin to bind  $Zn^{++}$ . In fig 9 this is shown by paper electropho-






Fig 7

UV spectra of amorphous insulin and iodinated insulin B-J in TRIS—borate buffer pH 9. Iodine content (gram atoms per mole) B 1 C 2 D 3 F 4 G 5 H 7 J 8 Concentration 0.04 % ml

resis in a barbiturate buffer at pH 9 of iodinated insulin with addition of  $^{65}\text{Zn}$  containing  $\text{ZnCl}_2$ . The added quantity of  $\text{Zn}^{2+}$  was equivalent to the normal content in crystalline insulin that is 0.5 per cent. The effect begins to make it self felt at 3–4 I/mole, then eventually at a degree of iodination of 9.6–10.3 I/mole the capacity to bind  $\text{Zn}^{2+}$  is completely lost. If the imidazole groups of the histidine residues are destroyed by photo-oxidation at  $8^\circ\text{C}$  with methylene blue as photosensitizer the insulin completely loses the capacity to bind  $\text{Zn}^{2+}$  by electrophoresis under the above mentioned conditions. On the other hand a carbamylation of the N terminals seem to be of little or no importance. This shows that especially the imidazole groups of the histidine residues are of importance for the binding of  $\text{Zn}^{2+}$ . Iodination of the histidine residues is therefore probably the reason for the reduced capacity of the iodinated preparations to bind  $\text{Zn}^{2+}$  (10).

#### Effect of iodination on biological activity

A decisive complication for the use of iodinated insulin in biological experiments is the reduction of the hormonal effect even at low degrees of iodination. By intravenous injection in rabbits it was demonstrated that 2–3 per cent of the original effect remained by iodination to 10.3 I/mole but no effect at 10.8 I/mole. By measurements of the glucose utilization on isolated fat cells of rats it was demonstrated that a reduction to 1 per cent of the original activity took place at 4 I/mole and only a trace of the activity at 5 I/mole (9). The isolated fat cells were produced from




Fig 8

Agar electrophoresis of  $^{125}\text{I}$ -labelled pig insulin in different buffers A - TRIS boric acid pH 9.1 B - TRIS boric acid EDTA pH 8.9 C - Glycine NaOH pH 10.0 D - Barbiturate pH 8.6 The agar gel was prepared by mixing equal parts of a 2% agar solution and the respective buffer solution Sample 0.125 mg insulin in 5  $\mu\text{l}$  volume Voltage 120 volts Duration 75 min Temperature 22°C Fixation by drying Stain Amido Black - From top to bottom Record of radioactivity (Geiger tube) Autoradiograph (Codirex X-ray plate exposure 7 days) Agar electrophorogram Application point is marked by an arrow

adipose tissue of rats by treatment with collagenase (46), (19). In principle the method is the same as that in the fat pad method, in that the quantity of  $^{14}\text{C}$  from  $^{14}\text{C}$ -glucose is taken to be an indication of the hormonal activity. The fat cell method is, in comparison with other biological methods, very precise and allows a large number of measurements per working day.

The difference between the results of the two methods might mean that in the intact organism some deiodination took

place. However, activity has been demonstrated (29) at degrees of iodination higher than 4 I/mole with the rat fat-pad and rat diaphragm methods. An unspecified adsorption onto the surface of the cells could not be the reason for the low activity shown by the fat cell method as the addition of a considerable quantity did not produce a large increase of glucose utilization. The reason seems to be, therefore, that the surfaces of the fat cells are altered by the collagenase treatment so that they react different-




Fig 9

The effect of iodination on the  $Zn^{++}$  binding capacity of insulin estimated by paper electrophoresis with addition of  $^{65}ZnCl_2$ . From top to bottom: Record of radioactivity; Autoradiograph (Cordrex X-ray plate exposure 14 days); Paper electrophorogram. Application point is marked by an arrow.

ly to a derivatization of insulin from the way in which they react in the isolated tissue or intact organism.

The reduction of the biological effect following iodination is in itself no proof that the tyrosine residues are the active centres in the insulin molecule. It is thus possible that the iodination of these involves alteration of the conformation—perhaps due to a breakdown of external hydrogen bonds—and that this alteration of conformation restricts the insulin from reaching the cellular receptor or from reacting with it. The altered charge values due to iodination might also be a cause. The highly iodinated preparations

do not seem to react at all with the cellular receptor, for with the above mentioned intravenous injection in rabbits no hyperglycemia with quantities equimolar to 40  $\mu g$  (1 unit) crystalline insulin per kg has been traced.

Even at low degrees of iodination the reduction of the biological activity complicates the interpretation of the experiments aimed at illuminating the distribution of insulin in the organism. This is partly because the distribution of iodine between the individual molecules is not uniform and partly because the ease of tracing the molecules is proportional to the number of incorporated iodine




Fig 10

Density gradient electrophoresis of 20 mg 127 131 I insulin 1 I/mole TRIS borate buffer with sucrose as gradient material pH 9.0 250 volts 8 mA run for 65 hours at 25°C

Detection of migration on left to right upwards in the column

A) By emptying the column the effluent was monitored for UV absorption at 254 mμ using an LKB 4700 UV cord and for radioactivity using a Geiger tube — UV absorption radioactivity

B) UV absorption of the original sample 520 μg/ml at pH 9.0 (left) and pairs of adjacent 2 ml fractions of effluent (middle and right). The number on the curves is the lower fraction number of the pair of fractions pooled. Buffer without sucrose and fractions nos 99 100 were used respectively as references for the original sample and the fractions

atoms in the molecules with the most altered biological properties. The heterogeneous distribution of iodine must be expected because of the many substitution possibilities (80) (see 3<sup>4</sup>-1) based on the four tyrosine residues. It can be shown that there really is heterogeneity by density gradient electrophoretic fractionation at pH 9 of a preparation containing 1 I/mole (fig 10). The iodination was undertaken by slowly dripping in an  $I_2$  solution at 0°C and with

vigorous stirring so that a distribution as uniform as possible was achieved. The relatively high UV absorption at 311 mμ of the most rapidly migrating fractions as against the less rapid shows that the iodine content is larger in the more rapid fractions. The larger iodine content of these fractions is also indicated by the higher specific radioactivity of these (7).

#### *In vivo experiments*

<sup>125</sup>I labelled insulin of low degrees of

iodination has been used for tracing the rate at which insulin disappears from the site of injection (4)

Iodinated insulin has also been used to investigate the distribution of insulin in different organs. Experiments with iodinated ribonuclease seem, however, to be distributed in a similar manner to insulin (17)

By perfusion experiments it was shown that insulin of low degrees of iodination was not demonstrably removed in its passage through the liver, whilst this was markedly the case with insulin iodinated to 8 I/mole (38). The distribution of  $^{125}\text{I}$ -labelled insulin in striated rat musculature has recently been investigated. Rat femoral musculature was incubated in a Krebs-Ringer bicarbonate solution containing  $^{125}\text{I}$  labelled insulin. An association to sarcolemma was shown, however there is no certainty that an iodinated insulin preparation that was homogenous and that had full biological activity was used, nor can artefacts deriving from unspecified binding be excluded (16)

### *Immunological properties*

Berson et al. (1956) (3) and Welsh et al. (1956) (51) showed that  $^{125}\text{I}$  labelled insulin was eliminated more slowly from the circulation of diabetic patients who had been treated with insulin than from nontreated subjects. The reason proved to be the presence in the blood stream of antibodies directed against insulin.

Formation of antibodies after treatment with insulin preparations had already been shown, but it was believed

that the antibodies were produced by the more highly molecular proteins that were to be found as contamination in insulin preparations. However, it is now known with certainty that even the insulin molecule can have antigenic properties when the difference in the amino-acid composition between the homologous and the heterologous insulin is of the same order as between ox- and pig insulin. On the other hand, it must still be regarded as uncertain whether a difference in a single amino acid or immunization with insulin from the same species can occur. A weak admixture of species foreign insulin or an alteration in some of the insulin molecules during the preparative process is possibly the cause of the positive results that have been achieved. Whether auto-immunization is a possible cause of diabetes mellitus must be regarded as a completely unanswered question.

The detection of antibodies takes place by the addition of  $^{125}\text{I}$ - or  $^{131}\text{I}$ -labelled insulin to serum and by a separation of the free from the antibody bound insulin after it has been allowed to stand. This separation was originally undertaken by paper electrophoresis alone or combined with chromatography. The distribution of the labelled insulin was determined by scanning of the radioactivity. Berson and collaborators showed in their work that iodine labelled insulin and unlabelled insulin compete for the binding to the insulin antibodies. This observation formed the foundation for the quantitative method, which was developed for the determination of the physiologically occurring quantities of insulin in plasma, Yalow and Berson

(1959) (52), Yalow and Berson (1960) (53) By addition of increasing quantities of non labelled insulin it was demonstrated that decreasing quantities of labelled insulin were bound to the antibodies By comparing the values thus found with the competitive effect of an unknown sample, the concentration of the insulin could be determined

The electrophoretic separation procedure are, however, elaborate and the measurements of the radioactivity that must be made by integration of the scanning curve is time-consuming and not particularly exact It is, however, possible to make a separation of free insulin and antibody bound insulin by adding a precipitating antiserum reacting with the insulin antibodies and perform the separation by centrifugation or filtration through microporous filters (fig 11), Morgan and Lazarow (1962) (44), and Hales and Randle (1963) (22) It is easy to measure the radioactivity retained on the filters by placing them in test tubes and using a scintillation well counter system By adding increasing amounts of the non labelled insulin, thus dimin-




Fig 11

The principle of the double antibody immunoassay using preprecipitating technique




Fig 12

Standard curve for immunoassay of insulin obtained by the addition of known amounts of unlabelled pig insulin. Pig insulin antiserum was used for insulin binding.

ishing the antibody-bound radioactivity, a standard curve of the shape shown in fig 12 is obtained. By taking the maximum reactive part of  $^{125}\text{I}$ - or  $^{131}\text{I}$  insulin as 100 per cent, the accuracy expressed as SEM of duplicate determinations is on an average found to be  $\pm 0.6$  per cent precipitated radioactivity, by count is normally produced by immunizing using  $10^4$  pulses. The insulin antiserum is normally produced by immunizing guinea pigs, and the precipitating antiserum by immunizing rabbits with a  $\gamma$  globulin preparations of guinea pig serum.

The use of yet another immunological reaction increases the possibility of error. This can, however, be avoided by simple precautions (8). One source of error in the determination of insulin in plasma is that a cross-reaction may take place between the precipitating antibodies and the  $\gamma$  globulins in plasma or serum whose insulin concentration is to

be determined. If such a cross-reaction occurs, some of the precipitating antibodies are taken up. At lower concentrations of the precipitating antiserum this is alleged to cause a low yield of the insulin-insulin antibody complex, resulting in insulin values that are too high (22). In our laboratory we have not been able to confirm this observation, but found that the cross-reaction set in at high concentrations of the precipitating antibody. This results in an increased precipitation due to a decrease in the excess of the precipitating antibody. The reason for this result is that the formation of the soluble complexes between the insulin antibodies and the precipitating antibodies, because of the excess of the latter, is reduced. Disagreement between the results of the two investigations may be due to individual differences between the precipitating antisera employed. The influence of the cross-reaction on the results of the precipitation can, however, be avoided by allowing the insulin antibodies to react with the precipitating antibodies before reacting with the insulin (22). The reaction between the insulin antibodies and the precipitating antibodies has no effect on the reaction of the insulin antibodies with insulin. The distance between the bonds to the insulin and the precipitating antibodies thus seems to be large.

A second source of error in the double antibody method is the influence of complement on the immunological reactions. By pre-precipitation the complement can restrict the reaction between the precipitated insulin antibodies and insulin, resulting in artificially increased values of the insulin concentration. If pre-precipitation is not used, the com-

plement will directly influence the precipitation reaction. The influence of the complement is completely negated by the addition of a heparin preparation with anti-complement effect, by lengthy storage at  $-20^{\circ}\text{C}$  or by dilution (8). Addition of EDTA will also suspend the effect (44).

Because of the extreme exactitude of the double-antibody method it is possible to examine the influence of derivatization on the reaction between insulin and insulin antibodies even when the alterations in the insulin molecule are small. It has thus been possible to examine the influence of iodination on the reaction between insulin and insulin antibodies at degrees of iodination from 0-10.8 I/mole. At a degree of iodination of 2 I/mole a reduced reactivity with the insulin antibodies could be traced from the extent to which  $^{125}\text{I}$  substituted insulin was able to compete with  $^{125}\text{I}$ -insulin with a degree of iodination of about 0.7 I/mole. The effect of the increasing degree of iodination was progressive, but even at a degree of iodination at which the histidine residues were iodinated to a considerable extent, it could be shown that insulin was reacting, though only weakly, with insulin antibodies (9).

#### *Determination of insulin in plasma and urine*

In the following, some examples will be given of the use of the double-antibody method for the determination of insulin in plasma and urine. The examples given are from investigations carried out in our laboratory (32) and (31). The

variation in the concentration of plasma insulin in six normal persons to whom 1 g of glucose per kg of body weight had been administered perorally can be seen in fig 13. It will be observed that a parallel can be traced between the concentration of the insulin and the concentration of the glucose. Another example, fig 14, shows the concentration of plasma insulin in a non diabetic obese patient to whom 80 g of glucose had been administered perorally. It will be observed that an even steeper rise—to 13–1400  $\mu$ units/ml—takes place. When the diet was reduced to 1000 kilo-cal *per diem* a clear reduction of insulin secretion could be detected.

In a determination of the concentration of plasma insulin during a glucose-tolerance test on a newly diagnosed juvenile diabetic, a certain insulin concentration was shown, but here the administration of glucose only caused a very slight increase in the insulin concentration, fig 15. In this patient the insulin concentra-




Fig 13

Blood glucose ---- and plasma insulin — concentration in 6 normal persons during oral glucose tolerance test 1 g d glucose was administered per kg body weight

tion was sufficient for the disease to be treated for a while by diet. Later, however, the insulin secretion was reduced further and insulin treatment became necessary.

That diabetes embraces at least two




Fig 14

Blood glucose - - and plasma insulin — concentrations in an obese non diabetic patient during oral glucose tolerance test before and after restriction of diet to 1000 kilo-cal per day 80 g of d glucose was administered. Weight before food restriction January 13th 1964 133.8 kg and after January 27th 1964 129.6 kg



different forms of disease may be seen from comparison of fig 15 and fig 16. In the latter the concentration of plasma insulin is plotted for an elderly, somewhat overweight diabetic patient receiving glucose. In this case a somewhat increased fasting level value and a continuing rise of both the concentration of insulin and the concentration of blood glucose can be shown.

It is interesting to note the difference between intravenous and peroral administration of glucose in their effect on insulin secretion, fig 17. In the case of intravenous injection only a slight and brief increase was observed, whereas the peroral administration brings about a considerable increase in secretion. This seems to indicate that when glucose is assimilated from the intestines a factor is liberated which increases the secretion of insulin, and this may possibly be of a hormonal character.

The double-antibody method may also be employed for the determination of the insulin concentration in urine. With

eleven normal persons it could be shown that when they were on a non-standardized diet they had an average secretion of  $14 \times 10^3$  units every 24 hours. In normal subjects a stimulation of the endogenous insulin production could also be detected under glucose administration. For diabetics a noticeable increase could be observed after treatment with insulin (31).

The great sensitivity with which it is possible to determine alterations in the reaction with insulin antibodies as a result of derivatization may also be exploited in investigations as to whether there is a difference between the extracted and the circulating insulin. If such a difference exists, the standard curves for the two insulins will not be identical, since the reaction with homologous antiserum will be stronger. Whereas the results plotted for the dilution series of the insulin that is used for immunization as a function of the expected concentration will give a rectilinear function, a divergent structure of the




Fig 15

Blood glucose -- at 3 plasma insulin — concentrations in a juvenile diabetic patient during a tolerance test. 1 g of d glucose was administered per kg body weight

antigen will result in an upward convex curve. By employing this method it was shown that at least the bulk of the circulating and immunologically demonstrable insulin in normal obese and diabetic subjects is identical with extracted




Fig 16

Blood glucose and plasma insulin concentrations in a maturity onset stable diabetic patient during oral glucose tolerance test. 1 g of d glucose was administered per kg body weight




Fig 17

Blood glucose and plasma insulin concentrations following A) intravenous injection of 100 ml 25% d glucose and B) peroral administration of 1 g d glucose per kg body weight in a patient on whom has been performed vagotomy + pyloroplasty

human insulin (13). It could also be shown that crystallized insulin extracted from the pancreas of stable onset diabetic patients and non-diabetic patients showed immunological identity (11).

## CONCLUSION

Even though labelling of insulin with radioactive iodine isotopes has increased our knowledge of what happens to insulin in the organism, there still remains a great unanswered question concerning the working mechanism of insulin. While little decisive progress has been made in this area with the employment of iodine-labelled insulin, it is possible that this is due to the alteration which derivatization brings about, and the heterogeneity with which iodination takes place. The use of an insulin incorporating  $^3\text{H}$  bound to carbon, or  $^{14}\text{C}$  or  $^{35}\text{S}$  in predetermined positions in the insulin molecule is naturally a considerably more attractive proposition for a biochemist than the use of an insulin derivative in which labelling is carried out by means of an atom that is not originally found in the insulin molecule.

The possibility of producing well-defined derivatives also affords exciting prospects for further research into the working mechanism of insulin. It is therefore not surprising that the attention of the scientific world is directed towards those centres in which research on the organic-chemical synthesis of insulin is being carried out. Professor Helmut Zahn and his collaborators occupy a prominent position in this field, not simply because of the scientific results achieved but also because of the free-

dom with which these results are made available for further advances.

Let us finally return to the point of departure of this lecture: the disease diabetes mellitus. Of the 800 million people who live in Europe and the USA, an estimated 13 million suffer from this disease to such a degree that they must be treated with insulin. The serious complications that so often, unfortunately, accompany this disease, such as retinopathy—which may lead to blindness—and nephropathy—which can destroy completely the function of the kidney—urge us on to make greater efforts to solve the two fundamental problems: the cause of the disease, and the mechanism of the hormonal effect of insulin.

Our enthusiasm at our knowledge of the insulin molecule may however have seduced us into concentrating upon this single molecule. In our present state of knowledge there seems to be no doubt that hereditary predispositions lie behind the occurrence of the disease, and we should, therefore, perhaps turn our attention away from the insulin molecule and the reactions directly linked with it to the more central processes in the function of the  $\beta$ -cell of the islets of Langerhans.

## REFERENCES

- 1 Abel J J *Proc nat Acad Sci U S A* 12 132 1926
- 2 Banting F G & Best C H *J Lab Clin Med* 7 251 1922
- 3 Berson S A Yalow R S Bauman A Rotschild M A & Newerly H *J Clin Invest* 30 170 1956
- 4 Binder C Jørgensen K & Nielsen Aa V *Excerpta Medica Int Congr Ser* 74 104 1964

- 5 Brunfeldt K, Hunhammer K & Skouby A P *Acta Endocrin* (Kbh) 29 473 1958
- 6 Brunfeldt, K & Deckert T *Acta Endocrin* (Kbh) 47 353 1964
- 7 Brunfeldt K *Science Tools* 12 (5 & 17) 1965
- 8 Brunfeldt K & Jorgensen K R *Acta Endocrin* (Kbh) 54 347, 1967
- 9 Brunfeldt K, Hansen H A & Jorgensen K R *Acta Endocrin* (Kbh) in press
- 10 Brunfeldt K, Hansen B A & Hørris Nielsen J To be published
- 11 Brunfeldt K, Deckert T & Krayenbuhl Ch To be published
- 12 Cawley T *London Med J* 9 219 1788
- 13 Deckert T & Jorgensen K R *Acta Endocrin* (Kbh) 53 673, 1966
- 14 van Doesburgh J T S V Diss Leiden 1962
- 15 van Doesburgh J T S V & Havinga H *Biochim Biophys Acta* 87 96 1964
- 16 Edelman P M & Schwartz I L *Am J Med* 40 695 1966
- 17 Elgee N J & Williams R H *Diabetes* 4 87 1955
- 18 Fraenkel Conrat J & Fraenkel Conrat H *Biochim Biophys Acta* 5 89 1950
- 19 Glemann J *Diabetologia* in press
- 20 Greenstein J P & Winitz M *Chemistry of the Amino Acids* Vol 1 p 487 John Wiley & Sons London 1961
- 21 Gruen L, Laskowski M & Sheraga H A *J Biol Chem* 234 2050 1959
- 22 Hales C N & Randle P J *Biochem J* 111 137 1963
- 23 Harrington C R & Neuburger A *Biochem J* 30 809 1936
- 24 Hughes H L *Ann N Y Acad Sci* 70 3 1957
- 25 Humbel R E *Proc nat Acad Sci U S A* 53 853 1965
- 26 Hunter W M & Greenwood F C *Nature* 194 495 1962
- 27 Hørris Nielsen J Unpublished
- 28 Inada Y *J Biochem* (Tokyo) 49 217 1961
- 29 Izzo J L, Roncone V, Izzo M J & Bale W F *J Biol Chem* 239 3749 1964
- 30 Jiang R Q, Du Y C & Tsou C L *Scientia Sinica* 12 452 1963
- 31 Jorgensen K R *Acta Endocrin* (Kbh) 51 400 1966
- 32 Jorgensen K R To be published
- 33 Katsourian P G & Dixon G W quoted in *Chem and Eng News* 21/10 45 1963
- 34 Kralj M E *The Action of Insulin on Cells* p 160 Academic Press London New York 1961
- 35 Kung Y T, Du Y C, Huang W T, Chen C C, Ke L T, Hu S C, Jiang R Q, Chu S Q, Wu C I, Hsu J Z, Chang W C, Cheng L L, Li H S, Wang Y, Loh T P, Chi A H, Li C H, Shi P T, Yieh Y H, Tang K L & Hsing C Y *Scientia Sinica* 14 1710 1963
- 36 Langerhans P Diss Berlin 1869
- 37 Lazarow A *Rec Progr Hormone Res* 19 489 1963
- 38 Lee N D *Endocrinology* 65 347 1959
- 39 Li C H *J Am Chem Soc* 66 225 1944
- 40 Maske H *Ztschr f Naturforsch* 8 96 1953
- 41 Maske H *Experientia* 11 122 1955
- 42 Meyberry W E & Bertoli D *J org Chem* 30 2029 1965
- 43 Meienhofer J, Schnabel E, Bremer H, Brunkhoff O, Zabel R, Sroka W, Klosterneyer H, Brandenburg D, Okuda T & Zahn H *Ztschr f Naturforsch* 18b 1120 1963
- 44 Morgan C R & Lazarow A *Proc Soc Exptl Biol* 110 29 1962
- 45 Niemann E *Labelled Proteins in Tracer Studies* p 43 EUR 2950 d f e Conference in Pisa 1966
- 46 Rodbell M *J Biol Chem* 239 2 1964
- 47 Rosa U, Massaglia A, Pennisi G F, Rossi C A & Cozzani J *Labelled Proteins in Tracer Studies* p 225 EUR 2950 d f e Conference in Pisa 1966
- 48 Ryle A P, Sanger F, Smith L F & Kitai R *Biochem J* 60 541 1965
- 49 Springell P H *Nature* 191 1372 1961
- 50 Tomizawa H H *J Biol Chem* 237 428 1962

- 51 Welsh G W Henley E D Williams R H & Cox R W *Am J Med* 21 325 1956
- 52 Yalow R S & Berson S A *Nature* 184 1648 1959
- 53 Yalow R S & Berson S A *J Clin Invest* 39 1157, 1960
- 54 de Zoeten L W Diss, Leiden, 1959
- 55 de Zoeten L W & de Bruin, O A *Rec Trav Chim* 80 907 1961
- 56 de Zoeten L W & Havinga E *Rec Trav Chim* 80 917, 1961

## INSULIN ACTION ON THE CENTRAL NERVOUS SYSTEM

by

Ole J Rafaelsen

### INTRODUCTION

This paper is concerned with the evidence of the *direct* action of insulin on the central nervous system. It is *not* concerned with the *indirect* action of insulin on brain *secondary* to insulin action elsewhere leading to changed composition of metabolite content in the arterial blood sent to the brain, the most obvious change being a reduction in the arterial glucose offered to the central nervous system. Furthermore, this paper is not concerned with the evidence for a diabetic encephalopathy or with the consequence of prolonged and/or repeated hypoglycemia as demonstrated by neuropathological examination. Insulin action on the peripheral nervous system and peripheral diabetic neuropathy will only be touched on for comparison.

The topic has been reviewed elsewhere, including the problem of a direct or an indirect action of a hormone on a target tissue (32, 34). I have chosen here to tabulate some of the pertinent findings, and I will focus the discussion on some recent findings which have added much to an understanding of this problem.

In 1961 Chowers, Lavy and Halpern (5) from Israel reported that insulin administered intracisternally in dogs caused a fall in glucose content both of the cerebrospinal fluid and of the blood. The fall was noted during the first 30 minutes after the insulin injection and was a maximum 90 to 120 minutes after administration of the hormone. The reduction was both absolutely and relatively more pronounced in cerebrospinal fluid (50 mg per cent) than in blood (36 mg per cent), and it also lasted longer before preinjection values were regained in cerebrospinal fluid glucose content than in blood glucose. This finding indicated to the authors a direct effect of insulin on brain structure. In the same study they injected radioactive insulin labeled with  $^{131}\text{I}$  intracisternally, and the investigators were unable to detect radioactivity in peripheral blood during the first 8 hours after introduction of labeled insulin intracisternally. It was concluded that insulin was unable to pass the barrier between cerebrospinal fluid and blood, and that the fall in systemic blood glucose values was mediated via insulin action on some brain structure. It was suggested that insulin in these experiments stimulated para-

## SOME STUDIES OF INSULIN ACTION ON THE CNS

*A. Animal tissues in vitro*

Preparation	Parameter studied	Investigators	Comments
Brain slice (rat)	Glucose uptake 10% increase	Rafaelsen (1961 b)	Only in 'first' brain slice and with high insulin conc.
do	Glucose conversion to carbon dioxide: no effect	Beloff, Cham et al. (1956)	
do	Glycogen formation: no effect	Melliwin & Tresize (1956)	
do	Glucose incorporation into lipid: no effect Acetate incorporation into lipid: 100% increase	Grossi et al. (1962)	
Anterior pituitary (calf & rat)	Glucose uptake: 25% increase Alloxan diabetes: reduced glucose uptake normalized by insulin <i>in vivo</i>	Goodner & Freinkel (1961)	
Spinal cord (rat)	Glucose uptake: 25 to 100% increase Alloxan diabetes: reduced glucose uptake normalized by insulin <i>in vitro</i>	Rafaelsen (1958, 1961 a)	Insulin effective in conc. down to 100 $\mu$ U/ml
do	Glucose conversion to carbon dioxide and glycogen formation: no effect	Rafaelsen & Clausen (1961)	
do	Glucose incorporation into lipid: no effect Acetate incorporation into lipid: 150% increase	Rafaelsen, Adams & Field (unpublished)	

sympathetic centers in the brain stem, leading to vagal stimulation of the pancreas subsequent insulin release followed by increased glucose uptake in the periphery and thereby fall of blood glucose values. The authors thus assumed that the effect of insulin after intracisternal application was a *direct* effect on glucose uptake in the central nervous system and an *indirect* effect via vagal stimulation on the rest of the organism.

The same authors have in 1966 (6) added supporting evidence to this hypothesis by performing the same type of experiment on vagotomized dogs, where again a significant fall in glucose values in cerebrospinal fluid was obtained, but now only a slight, insignificant fall in blood glucose values.

The importance of these experiments in a broader view is closely connected with the question whether insulin does

*B Infusion and perfusion studies*

Preparation	Parameter studied	Investigators	Comments
Infusion of hexoses and pentoses (rat)	Distribution volume in brain no effect	Park et al (1955 1957)	
Infusion of hexoses and pentoses (cat)	Distribution volume in brain increased	Sacks & Bakshy (1957)	
Perfusion of isolated brain (cat)	Glucose uptake no or slight increase	Geiger et al (1954 1956) Allweiss & Magnes (1958)	
Cerebral arterio venous difference (homo)	Glucose disappearance no increase	Himwich et al (1941)	Interpretation difficult as cerebral blood flow was not determined
	Glucose disappearance up to 50 % increase	Genes (1961)	
Cerebral blood flow determination (Kety Schmidt or modifications) (homo)	After insulin alone decrease of cerebral glucose uptake	Kety et al (1948 a & b) Gottstein et al (1963)	
do	Demonstration of glucose threshold in brain which is insulin sensitive	Butterfield et al (1966)	
do	After glucose infusion Slight increase of cerebral glucose uptake After glucose insulin infusion 50 % increase of cerebral glucose uptake	Gottstein et al (1965 1966)	Reduced cerebral glucose uptake by cerebral arterio-sclerosis and diabetic encephalopathy—markedly increased by glucose insulin infusion

cross the barriers surrounding the central nervous system, be it the blood brain barrier or the cerebrospinal fluid blood barrier. In other studies where  $^{125}\text{I}$  insulin was injected intravenously into rats or human beings, no radioactivity was found in brain substance of the rat or in spinal fluid of man within the

first 2 hours of injection (8, 19, 25), the conclusions were similar to those of Chowder et al, *i.e.*, that insulin was unable to cross these barriers. From a physico-chemical point of view, however, it is unlikely that insulin with a molecular weight of 12,000 or more should be able to make this crossing in detectable



*C. Spinal fluid studies*

Preparation	Parameters studied	Investigators	Comments
Insulin injected intracisternally (dogs)	Spinal fluid glucose decrease Blood glucose decrease Decrease greater in spinal fluid than in blood	Clowers et al (1961-1966)	In vagotomized dogs similar decrease in spinal fluid glucose but now insignificant decrease in blood glucose
Spinal fluid (crude) (homo)	Rat epididymal fat pad technique no insulin like activity	Mahon et al (1962) Schrader & Wengert (1962) Deckert, Lingsøe & Rafaelsen (1966)	
Spinal fluid (conc) (homo)	Rat epididymal fat pad technique now demonstrable insulin like activity	Deckert, Lingsøe & Rafaelsen (1966)	
Spinal fluid (crude & conc) (homo)	Immuno-assay Insulin activity 10% of blood values	Deckert, Lingsøe & Rafaelsen (1966)	
Intravenous injection of $^{131}\text{I}$ insulin (homo)	No radioactivity demonstrable in spinal fluid	Elgee et al (1954) Mahon et al (1962)	

amounts within a few hours. This does indicate that insulin ultimately can cross barriers in amounts sufficient to exert an important action on central nervous system structures, but the problem cannot be elucidated by means of directly labeled insulin with a biological half-life of half an hour after intracisternal injection. Insulin-like activity has been demonstrated in human cerebrospinal fluid (7). It was demonstrated by immuno-assay that crude spinal fluid contained some 10 per cent of the activity of plasma from the same source, whereas parallel determinations indicated that the epididymal fat pad was unable to detect these amounts of insulin-like activity,

thus confirming negative results obtained by other authors (25-38). After concentration of these spinal fluid samples, insulin-like activity was measurable both with immuno-assay and with epididymal fat pad technique. Calculation of transfer rates of insulin from blood to brain and cerebrospinal fluid awaits the availability of insulin truly labeled with  $^{14}\text{C}$  or  $^{35}\text{S}$  in the amino acid structures of the molecule.

Chowers et al suggested parasympathetic brain centers as a possible site of action for a direct effect of insulin on the central nervous system. This may only be one of many. Goodner and Freinkel (15) have demonstrated insulin effects on anterior pituitary tissues

from rat and calf, both after *in vitro* and *in vivo* administration of this hormone. Glucose uptake was increased by 25 per cent when anterior pituitary tissue from intact animals was incubated with insulin, and conversion of glucose to carbon dioxide and incorporation in to lipid was also increased. Glucose uptake of pituitary tissue from rats rendered diabetic by alloxanization or pancreatectomy was reduced, and it could be normalized by insulin injection into the rats before sacrifice. The results are in many aspects similar to results obtained with isolated rat spinal cord (29, 30), and they may be aspects of general metabolic properties of central nervous tissue. It is at any rate very interesting that direct insulin effects have been demonstrated on tissues so centrally placed in endocrine homeostasis. One might even speculate that insulin reaches the pituitary tissue faster than other parts of the central nervous system, due to the special properties of the hypophyseal vascular bed.


In passing it may be mentioned that Levi Montalcini and co-workers (24) have demonstrated insulin action *in vitro* on growth of isolated mouse sympathetic and sensory spinal ganglia. Even if these ganglia do not belong to the central nervous system, it is a noteworthy finding, especially in connection with the hypothesis by Chowder and co-workers of insulin action on parasympathetic structures. The number of insulin sensitive tissues and structures grows fast, soon it will be more exclusive to be insulin-insensitive!

Two groups of researchers have recently presented evidence for a direct effect

of insulin on brain glucose uptake in man (4, 16, 17). Both groups have used brain blood flow determinations according to the principles of Kety and Schmidt (21) as a frame of reference in order to ascertain that changes in glucose uptake were not due to changes in cerebral blood flow. Butterfield and co-workers had in earlier investigations demonstrated an insulin sensitive threshold for glucose uptake of tissues of the forearm and they have now combined these studies with parallel studies of brain metabolism. Their studies showed a similar and insulin sensitive threshold for glucose uptake by brain tissue, but the threshold in brain was lower than in the forearm, and it responded more slowly to insulin. The experimental design in these experiments does not compensate for insulin hypoglycemia, and the demonstration of the insulin sensitive glucose threshold in brain is therefore more indirect, but its characterization as being lower and more slowly reacting to insulin may explain some of the previous failures to demonstrate direct action of insulin on brain glucose uptake in man.

The most conclusive evidence to date of a direct effect of insulin on the human brain has been presented by Gottstein and co-workers (16, 17). These investigators have studied patients without any symptom or sign of brain disorder, patients with cerebrovascular diseases, and diabetic patients without and with diabetic complications. In all their investigations, basal values for cerebral blood flow (CBF), cerebral oxygen uptake (CMRO<sub>2</sub>) and cerebral glucose uptake (CMRglucose) were first obtained

## BRAIN BLOOD FLOW AND METABOLISM IN NORMALS, ARTERIO-SCLEROTICS AND DIABETICS



25-35 minutes later during the same investigations renewed determinations were made after intravenous infusion of glucose, glucagon, insulin or glucose

plus insulin. Some of their results are shown in Figure 1.

It is seen that the basal values are in good agreement with the results obtained

ed by other workers. Glucose was administered intravenously at a constant rate of 15 ml/min of a 50 per cent solution to a final volume of 60 ml. The intravenous infusion of glucose led to a considerable increase of blood glucose values, but brain flow, oxygen uptake and cerebral vascular resistance were essentially unchanged. Cerebral glucose uptake was slightly increased, but statistical analysis showed that the increase was not significant. Each group of patients studied comprised from 6 to 12 individuals. Intravenous administration of glucagon caused very small changes in the values for brain blood flow and metabolism under consideration here. Insulin administered intravenously in a dose to reduce blood glucose values to 50 per cent caused a reduction in brain glucose uptake by a similar percentage, but brain oxygen uptake was nearly unchanged, indicating combustion of other metabolites besides glucose under such circumstances.

The situation where insulin is introduced alone is unsuited to determine the direct effect of insulin on the brain, as the glucose offered to the brain by the arterial blood is markedly reduced, due to the action of the very same insulin on other organ systems. It is only by the combined infusion of glucose and insulin that light is shed on this problem. It is seen from the figure that the combined intravenous infusion of glucose and insulin—in spite of a smaller increase in blood glucose levels compared to glucose infusion alone—leads to a 50 per cent increase of brain glucose uptake. As the cerebral oxygen uptake was unchanged, as was cerebral respiratory quotient, it

is evident that the extra glucose taken up was not oxidized. Its probable fate will be discussed later.

The results obtained by Gottstein and co-workers in patients with cerebrovascular diseases are also remarkable. Basal values in the patients showed a 20 per cent reduction in CBF, a 25 per cent reduction in CMRO<sub>2</sub>, and a 50 per cent reduction in CMRglucose, all compared to basal values in patients without cerebrovascular disorders. Intravenous infusion of glucose plus insulin did not influence CBF or CMRO<sub>2</sub>, whereas CMRglucose rose to near normal values. This increase was statistically very significant, as were increases in cerebral RQ and the quotient CMRglucose/CMRO<sub>2</sub>. Also in diabetic patients the German group found reductions in basal values of CMRglucose which were markedly influenced by insulin infusion. The reduction of basal CMRglucose was much more pronounced in diabetics with diabetic long term complications than in patients without such complications, as was the effect of intravenous insulin administration.



The above-mentioned findings by Gottstein and co-workers represent a major advance in the demonstration of direct action of insulin on human brain. Of particular interest is the dissociation of glucose and oxygen uptake of brain after insulin infusion and also in basal uptake in patients with cerebral vascular disorders, both diabetic and non-diabetic, as it is here assumed that the disturbances demonstrated in the diabetic patients with complications are at least partly due to vascular lesions of brain vessels, i.e., a diabetic encephalopathy.

(36) In the diabetic patients more oxygen is taken up by the brain than is necessary for the oxidative consumption of the glucose taken up, after glucose-insulin infusion more glucose is taken up in normals, and after insulin infusion in diabetics, than can be accounted for by the oxygen taken up during the same period. When the glucose uptake is small, the brain must turn to other substances to satisfy its most urgent metabolic needs, and on the other hand it must be assumed that the excess glucose taken up under the influence of insulin is to a great extent quickly converted to other substances. This might be amino acids, lipid precursors or glycogen. Several investigators have demonstrated in recent years that glucose very quickly enters the amino-acid pool in brain. Vrba et al. (39) found after intravenous injection of radioactive glucose into rats that already 30 minutes later 75 per cent of the radioactive glucose taken up by brain had entered the amino acid pool. It is thus probable that a major part of the extra glucose taken up by brain after glucose-insulin infusion enters the amino acid pool and that part of it may be used for protein synthesis. It may also be supposed that in diabetic patients with complications, where glucose uptake is insufficient to cover oxidative metabolic needs, amino acids in the brain are metabolized to cover the gap. In the patients with cerebrovascular lesions of a non-diabetic nature similar events may take place, but here a certain breakdown of brain lipids is possible, as basal values for cerebral RQ were found moderately decreased. It is obvious that continuous use of brain amino acids or lipids

for immediate metabolic needs may have the most detrimental influence on brain function and brain structure. Future research may reveal to what extent the well known histopathological changes of cerebral arteriosclerosis and the more recently demonstrated histopathological changes in brain of patients with long term diabetes are to be explained along the lines mentioned here.

In peripheral nerve and spinal cord, metabolic derangements have been demonstrated which may have implications for insulin action on brain. Insulin *in vitro* increases glucose uptake of rat spinal cord (29, 30) and of rat and rabbit sciatic nerve (9, 10). In sciatic nerve, Adams and Field (1) found a depression of the activity of the acetic thiokinase enzyme system, necessary for acetylation of Co-A as the first step in the synthesis of fatty acid from acetate, to approximately 30 per cent of that found in nerves from normal animals. Insulin *in vitro* could not restore this enzymic function. Further evidence of the important role of the acetic thiokinase block in diabetic nerve was the demonstration by the same workers that if acetate labelled acetyl Co A was used as substrate, there was no impairment of incorporation of label into fatty acid in the diabetic tissue, and the capacity for *in vitro* enhancement with added insulin was regained (10). Defective mechanisms for glucose incorporation into lipid and glycogen in diabetic rat sciatic nerve and spinal cord might lead to increased metabolization via other pathways. The same workers have now (11) demonstrated a four to sixfold increase in the intracellular concentrations of

the sorbitol pathway and of free intracellular glucose in the sciatic nerves and spinal cord of alloxan diabetic rats. The sorbitol pathway converts D glucose to D fructose without phosphorylation or requirement for ATP



The accumulation of the products of the sorbitol pathway may indicate that sorbitol cannot easily leave nervous tissues and that the capacity to metabolize fructose is limited. As a consequence, the accumulation may exert a harmful effect by osmosis or otherwise. It is noteworthy that whereas the relative increase of products of the sorbitol pathway is similar in rat sciatic nerve and in rat spinal cord, the absolute values are from 2 to 10 times lower in spinal cord than in sciatic nerve. If it is assumed that the values in brain are similar to those in spinal cord (or even lower), a hypothesis may be advanced to explain some clinical and pathological findings. The more pronounced accumulation of metabolites like those of the sorbitol pathway in *peripheral* nerve may lead to lesions of a metabolic, non vascular type relatively early in the course of diabetic ill-

ness. These lesions may be partly reversible if the metabolic pattern in the nerves is restored by therapy or by means still unknown. In the central nervous system, on the other hand, these metabolic derangements may be less harmful, and the quantities of waste-products piling up are much smaller. Only later in the course of diabetes, when vascular changes become prominent also in the brain, the central nervous system will start to suffer severely due to the reduction in glucose uptake and the intermittent or constant wear and tear on the amino acid pool and brain proteins to satisfy urgent metabolic needs. Thus, with our present knowledge, diabetic encephalopathy is likely to be linked to vascular changes.

Insulin has for many years been used in the treatment of the major psychoses and its effectiveness in many cases has vaguely been explained as due to the induced hypoglycemic coma. This can now be re-evaluated in the light of direct insulin action on the brain and especially on cerebral protein metabolism. Insulin is a hormone, and it is reasonable to believe that many other hormones exert direct effect on brain metabolism and function. It has been demonstrated that thyroxine influences oxidative processes in brain mitochondria and many other demonstrations will probably follow, e.g., with steroid hormones.

The elucidation of insulin and other hormone effects on brain will have theoretical and practical consequences in many fields of medicine.

## REFERENCES

- 1 Adams L C & Field R A *Proc Fifth Congr Int Diab Fed* 74 94 1964
- 2 Allweis C & Magnes J *J Neurochem* 2 326 1958
- 3 Beloff Chain, A Catanzaro R Chain E II Masu I & Pocchiari F *Proc roy Soc B* 144 22 1956
- 4 Butterfield W J H, Abrams M E Sells R A Sterky G & Whiclow, M J *Lancet* 1 557 1966
- 5 Chowers I Lavy S & Halpern L *Exp Neurol* 3 197 1961
- 6 Chowers I Lavy S & Halpern L *Exp Neurol* 14 383 1966
- 7 Deckert J Lyngsøe, J & Rafaelsen O J Insulin in human cerebrospinal fluid Paper read at the 2 meeting of the European Diabetes Association, Aarhus 1966
- 8 Elgee N J Williams R H & Lee N D *J clin Invest* 33 1252 1954
- 9 Field R A & Adams L C *Medicine* 43 275 1964
- 10 Field R A *Diabetes* 15 696 1966
- 11 Gabbay K H Merola L O & Field R A *Science* 151 209 1966
- 12 Geiger A Magnes J, Taylor R M & Veralli M *Amer J Physiol* 177 138 1954
- 13 Geiger A Yamasaki S & Lyons R *Amer J Physiol* 184 239 1956
- 14 Genes S G *Usb sovrem Biol* 51 188 1961
- 15 Goodner C J & Freinkel N *J clin Invest* 40 261 1961
- 16 Gottstein U Held K Sebening H & Walpurg G *Klin Wschr* 43 965 1965
- 17 Gottstein L & Held K *Klin Wschr* 45 18 1967
- 18 Gottstein L & Held K The effect of insulin on cerebral metabolism of normal persons and diabetics IIIrd Internat Sympos on Cerebral Circulation Salzburg October 1966 in press at Charles C Thomas Lau derdale USA
- 19 Haugaard N Vaughan M, Haugaard, S & Stadie W C *J biol Chem* 208 549 1954
- 20 Himwich H E Bowman K M Daly C Fazekas J F Wortis J & Goldfarb, W *Amer J Physiol* 132 640 1941
- 21 Kety S S & Schmidt, C F *Amer J Physiol* 143 53, 1945
- 22 Kety S S, Woodford R B Harmel H M Freyhan F A, Appel K E & Schmidt C F *Amer J Psychiat* 104 765 1948 a
- 23 Kety S S Pols H D, Nadler C S & Schmidt, C F *J clin Invest* 27 500 1948 b
- 24 Levi Montalcini R In The molecular basis of some aspects of mental activity (Ed Walaas O) Academic Press New York, 1967
- 25 Mahon W A Steinke J McKhann G M & Mitchell M L *Metabolism* 11 416, 1962
- 26 McIlwain H & Tresize M A *Biochem J* 63 250 1956
- 27 Park C R & Johnson, L H *Amer J Physiol* 182 17, 1955
- 28 Park C R, Johnson L H Wright J H & Batsel H *Amer J Physiol* 191 13 1957
- 29 Rafaelsen O J *Lancet* II 941, 1958
- 30 Rafaelsen O J *J Neurochem* 7 83 1961 a
- 31 Rafaelsen O J *J Neurochem* 7 45 1961 b
- 32 Rafaelsen O J *Metabolism* 10 99 1961 c
- 33 Rafaelsen O J & Clausen T *J Neurochem* 7 52 1961
- 34 Rafaelsen O J The direct and indirect actions of insulin on the central nervous system In The molecular basis of some aspects of mental activity (Ed Walaas, O) Academic Press New York 1967
- 35 Rafaelsen O J Adams L C & Field R A Insulin effect in vitro on acetate incorporation into lipids of isolated rat spinal cord (To be published)
- 36 Reske Nielsen E Lundbæk K & Rafael sen O J *Diabetologia* 1 233, 1965
- 37 Sacks J & Bakshy S *Amer J Physiol* 189 339 1957
- 38 Schrader A & Weinges F *Klin Wschr* 40 344 1962
- 39 Vrba R Gautonde M K & Richter D *J Neurochem* 11 465 1962

## OBSERVATIONS ON THE INFLUENCE OF GLUCOSE UPON SUBCUTANEOUS ADIPOSE TISSUE BLOOD FLOW

by

*F Quaade, O Andree Larsen N A Lassen and  
S Levin Nielsen*

The fact that depot fat constitutes an organ with a lively metabolic activity has been well established for more than a decade, but so far quantitative studies of adipose tissue metabolism *in vivo* have been rendered difficult by the lack of a practical method for determining the perfusion rate.

As described in a previous publication (2), the blood flow through human subcutaneous adipose tissue (FBF) can be measured by the local clearance technique using radioactive xenon as the indicator.

### *Method*

100  $\mu$ C  $\text{Xe}^{133}$  dissolved in 0.1 ml sterile isotonic saline was injected slowly through a very fine needle into the middle of the adipose tissue layer of the abdomen, a little below and lateral to the umbilicus. To avoid the artifact of the injection trauma, recording of the  $\text{Xe}^{133}$  clearance was not started until about one hour after the injection. The disappearance rate of the isotope was

registered with two NaI(Tl) crystals (5 cm in diameter) placed over the depot in the horizontal and vertical plane respectively. In this way movements of the patient leading to an erroneous clearance curve could easily be detected. The counts were registered on a conventional scaler with 100 sec intervals during every second minute for the next 1-3 hours.

The calculations of the FBF-values are based on the assumptions that the area injected is homogenous with respect to blood perfusion and inert gas solubility, and that the diffusion equilibrium between fatty tissue and capillary blood is maintained.

The theoretical and experimental reasons for making these assumptions, and the mathematical foundation of the calculation of FBF have been described in detail previously (1, 2). In the initial study comprising 69 examinations in 55 adult human subjects, the fasting FBF values averaged 2.63 ml/100 g min, with a standard deviation of 1.72.

The normal fasting FBF values having



thus been established, the present study concerned the possible influence upon this parameter of an excess of glucose administered either intravenously or perorally

The patients studied ranged in age from 20 to 79 years and were in varying states of nutrition, from - 17 to + 50 per cent overweight (3). Apart from a mild obesity in some patients, none suffered from metabolic or circulatory diseases.

The investigations took place in the morning, and the patients were fasting. About one hour after injection of the xenon depot, a peripheral vein was punctured and isotonic saline was infused with a rate of 0.5 ml per min. The fasting venous clearance was recorded during 40-60 min, whereafter the saline was exchanged with a glucose solution of either 10 or 20 per cent. In this way the discomfort due to the venipuncture could not influence the flow registration. The venous clearance was measured during the following 1-2 hours, and in this period capillary blood samples were taken for blood sugar analysis. The peroral glucose was given in

the course of a few minutes as a 50 per cent solution.

### Results

Our first series comprised seven subjects (table I), who were given 1000 ml 10 per cent glucose, i.e. 400 calories, intravenously in the course of 15 minutes. As will be seen from the table, the response was extremely variable. In two patients FBF remained unchanged, while in five the clearance rate increased within a few minutes after the start of the infusion, and FBF values from 46 to 600 per cent above the fasting values were reached.

When the infused glucose calories were doubled, i.e. 1000 ml 20 per cent glucose in the course of 15 minutes (table II), the entire group of 14 subjects responded with an increase in blood flow, ranging from 111 to 900 per cent (fig. 1).

In order to check the possibility that simple plasma volume expansion might be responsible for these findings, 500 ml 10 per cent Rheomacrodex® in isotonic saline was infused in three subjects (ta-

TABLE I  
*Glucose 400 calories intravenously during 15 minutes*

Case no.	Age years	Height Weight index*) cm	Fasting FBF) ml 100 g min	After glucose FBF) ml 100 g min	Difference FBF) %
53	20	-17	2.10	5.30	+152
14	23	-2	2.91	5.46	+88
15	23	-2	8.63	12.65	+46
17	23	-2	5.45	5.45	0
18	23	-9	7.48	7.48	0
22	49	+14	0.63	1.21	+92
29	33	+21	0.50	3.50	+600

\*) According to Natvig II (1956)

) Fatty tissue blood flow

TABLE II  
Glucose 800 calories intravenously during 15 minutes

Case no	Age years	Height Weight (adv.) %	Fasting FBF ) ml 100 g min	After glucose FBF ) ml 100 g min	Difference FBF ) %
5	41	+4	1.15	11.50	+900
6	42	+14	4.25	10.93	+157
32	48	+15	1.78	4.49	+152
33	46	+21	1.00	3.30	+230
34	44	+18	0.90	6.00	+567
35	53	+4	7.50	15.81	+111
36	37	+27	1.72	7.07	+311
37	29	+23	2.01	9.89	+392
38	56	+9	1.61	6.21	+285
39	21	-10	5.00	17.74	+255
40	45	+5	0.98	5.81	+493
41	32	+47	0.75	5.29	+605
42	53	+7	1.32	2.82	+114
47	60	+11	3.22	23.89	+642

) According to Natvig II (1956) \* ) Fatty tissue blood flow




Fig 1

$Xe^{133}$  clearance curve from a 42 year old normal fasting man showing the effect of an intravenous infusion of 1000 ml 20 per cent glucose during about 15 minutes

TABLE III

*Rheomacrodex® 500 ml 10 % intravenously during 15 minutes*

Case no	Age years	Height Weight index ) cm	Fasting FBF ) ml 100 g min	After Rheomacrodex FBF ) ml 100 g min	Difference FBF ) %
7	42	+34	1.84	1.84	0
8	57	+50	1.10	1.10	0
II	53	+48	1.15	1.15	0

) According to Natvig H (1956)      \*) Fatty tissue blood flow

TABLE IV

*Glucose oral intake*

Case no	Age years	Height Weight index ) cm	Glucose calories	Fasting FBF ) ml 100 g min	After glucose FBF ) ml 100 g min	Difference FBF ) %	Maximum blood sugar level mg%
37	59	+16	400	2.70	2.70	0	226
39	37	+21	400	3.20	1.50	-53	144
42	60	+13	400	3.80	1.60	-58	214
38	59	+21	800	0.90	0.90	0	227
40	61	-20	800	11.20	4.40	-61	234
41	37	+21	800	5.00	2.20	-56	182
80	42	+33	800	1.86	1.15	-38	-

) According to Natvig H (1956)      \*) Fatty tissue blood flow

TABLE V

*Glucose 800 calories intravenously during 60 minutes*

Case no	Age years	Height Weight index ) cm	Fasting FBF ) ml 100 g min	After glucose FBF ) ml 100 g min	Difference FBF ) %	Maximum blood sugar level mg%
43	62	+43	2.17	0.48	-78	720
44	58	-1	6.87	4.43	-36	950
46	74	+10	3.46	0.95	-76	269

) According to Natvig H (1956)      \*) Fatty tissue blood flow

TABLE VI

*Mannitol 500 ml 25 % intravenously during 15 minutes*

Case no	Age years	Height Weight index ) cm	Fasting FBF ) ml 100 g min	After Mannitol FBF ) ml 100 g min	Difference FBF ) %
77	67	+18	7.46	31.80	326
78	79	-15	3.29	12.71	286
79	57	+13	1.87	3.74	100
80	59	+5	0.48	1.73	260

) According to Natvig H (1956)      \*) Fatty tissue blood flow

ble III) No change in FBF was seen in these experiments

However, when glucose was administered by mouth, either 400 or 800 calories (table IV), none of the seven subjects thus treated responded with an increase in xenon clearance in two subjects FBF was unaltered, while in four there was even a decrease of 53 to 61 per cent

The possibility thus presented itself again that the observations in the infusion experiments were after all due to the unphysiological nature of the procedure, especially the rapidity of the infusion. Infusion of 1000 ml 20 per cent glucose (800 calories) during one hour (table V) in three subjects was followed by a decrease in FBF, the values falling from 36 to 78 per cent of the fasting value

The fact that the effect on FBF of intravenous glucose seemed to depend upon the infusion rate made it necessary to test the likely possibility of a simple hemodynamic cause. This time a solution comparable in osmotic effect to the glucose infusions was used. 500 ml 25 per cent Mannitol solutions was infused intravenously during 15 minutes in four patients. In all cases the infusion of this osmotically active substance was followed by a marked increase in FBF, starting about the end of the infusion and lasting 30-40 minutes. The increase ranged from 100 to 326 per cent (table VI) of the fasting values

### Discussion

The two major metabolic functions of adipose tissue are 1) the assimilation of

carbohydrates and lipids for triglyceride synthesis and storage, and 2) the mobilization of lipid as free fatty acids. *A priori*, it did not seem unlikely that either of these activities might be reflected in adipose tissue blood flow measurements. In preliminary experiments, where liquid meals of varying composition were given to patients, we did in fact register FBF increases, and the present studies were planned so as to avoid the possible influence of an activated gastrointestinal tract, to eliminate the specific dynamic action of proteins, and to observe the effect of metabolizable carbohydrate alone. The demonstration in normal persons of FBF variations under these conditions would offer further scope for investigation, especially as regards the reaction to hormones (insulin, glucagon, norepinephrine), and the response in diabetes and various types of human obesity.

Our data indicate that the lipogenic process which is known to be accelerated in the presence of insulin and surplus of available glucose is not accompanied by an accelerated fatty tissue blood flow, and the FBF increases observed after rapid intravenous glucose infusions must be explained as caused by an intravascular osmotic effect. When glucose is administered under more physiological conditions, by mouth or in slow infusion, there seems to be a tendency for fatty tissue blood flow to decrease. The possibility thus presents itself that free fatty acid release is a determining factor for fatty tissue blood flow, which will decrease if lipolysis is reduced in the presence of abundant glucose. The data presented in this paper are neither nu-

merous nor consistent enough to decide how the observed blood flow decreases should be interpreted, and the question whether in fact variations in lipolysis are reflected in adipose tissue blood flow must await further experiments for its solution

### SUMMARY

The blood flow through human subcutaneous adipose tissue of the abdomen has been measured by the local clearance technique using  $\text{Xe}^{133}$  as the indicator. In a series of 55 normal subjects in various states of nutrition the blood flow averaged 2.63 ml/100 g min (SD = 1.7).

Intravenous infusion of 1000 ml 20 per cent glucose during 15 minutes re-

sulted in an increase in fatty tissue blood flow ranging from 110 to 900 per cent of the fasting values. The blood flow decreased about 50 per cent after a similar amount of glucose given either intravenously during one hour or taken by mouth. The increase in flow seemed to be due to the osmotic effect of the rapidly infused glucose, as the infusion of 1000 ml 25 per cent Mannitol also provoked a pronounced increase in fatty tissue blood flow.

### REFERENCES

1. Larsen O. A. & Lassen N. A. *Scand J Clin Lab Invest* suppl 93: 46, 1967.
2. Larsen O. A., Lassen N. A. & Quaade F. *Acta physiol scand* 66: 337, 1966.
3. Natvig H. New height weight tables for Norwegian women and men. *Landsforening for Kosthold og Helse* Oslo 1956.

## INSULIN

### DESIRABLE AND UNDESIRABLE EFFECTS

by

*Jacob E Poulsen*

The introduction of insulin in 1922 must still be considered one of the most important medical advances of the century. It has not only added many years to the lives of millions of diabetics, but for a multitude of people it has turned the existence of an invalid, in starvation and constant danger, into an almost normal life in the family as well as in society, where now only a few occupations are not open to diabetics.

Numerically, diabetes is really a mass disease. From sporadic group studies it may be estimated that about 1 per cent of humanity is affected. If this is taken to apply to all populations, about 30 million people are diabetic. Among somatic diseases this can only be exceeded by certain tropical diseases, such as malaria and bilharziasis, and by nutritional diseases—in the western world overnutrition and in Africa and Asia undernutrition.

Only about 30–40 per cent of diabetics are dependent upon permanent insulin therapy, while the remainder need it only periodically in the event of intercurrent diseases and surgical procedures, to tide them safely over the critical epi-

sodes. Thus, to all diabetics insulin is either a permanent necessity or a security. After the advent of insulin, the life-time of diabetics has been prolonged. This applies particularly to children and adolescents, whose survival prior to the insulin era was 2 or 3 years, while now it is 25–30 years and still increasing.

From the time of the first biological demonstration of the hypoglycaemic effect of pancreatic extract by Banting and Best in July 1921, intensive research has been going on to clarify the chemistry, physiology, and pharmacology of insulin.

Most progress seems to have been made by the chemists as insulin was the first protein to be crystallized in 1926, by J J Abel, and its amino acid sequence was elucidated in 1955 by F Sanger, who also demonstrated certain species differences. Lastly, insulin was also the first protein to be synthesized. This has been done by three different teams within the past 3 years (H Zahn of Aachen, P Katsouris of U S A, and Wong Hu of Peking). Chemists have displayed quite a special interest in

insulin, which had represented a special challenge to them by virtue of its great medical significance. Its small molecular size and its easily demonstrable biological properties have no doubt contributed to this great interest.

The physiological effects of insulin still remain unelucidated, but hypotheses on its effect at the molecular level have not been wanting.

In addition to the hypoglycaemic effect, the diabetic organism was soon found to exhibit other phenomena following administration of insulin, viz decrease or cessation of ketosis, increase in muscle and fatty tissue, normal growth of diabetic children, increased resistance to infections, and a possibility of carrying through pregnancy. These observations go to show the anabolic effect of insulin, also confirmed *in vitro* in which it is possible to demonstrate the promoting action of insulin upon the formation of glycogen, fatty acid and protein from low molecular metabolites such as glucose, pyruvate, acetate and amino acids.

Whether this stimulation of macromolecular synthesis is due exclusively to the easily demonstrable increased transport of the named low-molecular metabolites from the extra- to the intracellular compartment, or whether this process is caused also by a direct intracellular activity of insulin, is still an open question. Recent physiological theories have of course included also the microarchitecture of the cells.

Cori's interpretation (1946) of insulin action as a stimulation of hexokinase activity in muscles has been revived recently (1966) by S. Bessmann's model of the insulin effect, in which insulin is

believed to effect mechanical binding between mitochondria and the cytoplasmic hexokinase in the muscles or glucokinase in the liver. This sets up a system in which glucose is phosphorylated, converting ATP into ADP. ADP is necessary for oxidative phosphorylation, and in diabetes the metabolic anomalies may be explained as deficient regeneration of ADP. This view may also explain why insulin is not needed for the glucose metabolism in the brain, as in the cells of the brain the hexokinase is bound to the large intracellular particles.

### *Clinical Use*

In the early insulin era there were numerous problems concerning the production of suited injection preparations for daily use. This was the first time that the pharmaceutical industry was faced with the problem of developing an injection medicine which was to be administered by the patients themselves over long periods.

The first preparations were in the form of tablets or powder which had to be dissolved before use. Partly because of this procedure and partly because the pancreatic extract also contained substances other than insulin, there would often be local reactions, in some cases abscess formation, at the sites of injection.

In 1924, insulin was dispensed as a sterile solution in ampoules, and this reduced the main local complaints following the injections. However, a few days after the commencement of insulin therapy, reddening and swelling at the injection sites were not uncommon, but

these complaints subsided with continued use

As the insulins were rid of unwanted associated proteins, the effect of the injections became more rapid and more short lasting. Especially in children and adolescents, it was apparent that the effect of the evening injection was too brief to keep the morning blood sugar at the desired level and to keep the patients free of ketonuria in the morning.

It was an important advance, therefore, when H C Hagedorn, Norman Jensen, N B Krarup, and I Wodstrup, in 1936 (9), gave their report on the first long acting insulin preparation. This made it possible

- (1) to reduce the daily dose of insulin,
- (2) to reduce the glycosuria and ketonuria, and
- (3) to reduce the hypoglycaemic attacks

N B Krarup, in his thesis from 1936 (11), gave a thorough analysis of the clinical effect of protamine insulin. During the intervening 30 years there has of course been progress in the production of insulins, but strangely enough protamine insulin still has its prominent place among the insulin preparations of to-day.

From 1946, protamine insulin was sold as a crystalline product whose crystals have a shape quite different from insulin crystals. Protamine is used only in 10 per cent of the weight of the insulin for producing the isophanic crystalline protamine insulin. It has been elucidated that protamine is split by plasmin whereupon insulin is released from the injected depot. Zinc inhibits this enzymatic process and furthermore

makes the insulin less soluble. This has been utilized in the protamine zinc insulins (8), in zinc insulin suspensions, and in zinc insulin crystals as in the Lente series (10).

It is a drawback of all insulins that they do not release insulin from the depots according to the requirements of the body at all times, as does the normally functioning pancreas, but that the insulin is released from the depot in a manner characteristic of each preparation. It is important, therefore, to know how to utilize the possibilities afforded by the different preparations for individualized insulin therapy.

It now appears to be generally accepted that it is a great advantage to be able to use mixtures of regular insulin and long acting insulin in cases of juvenile diabetes of some duration. The insulin sensitivity is relatively low during the early morning hours, presumably related to the diurnal variation in adrenocortical function, which shows maximum plasma levels of cortisol in the early morning.

The use of insulin in psychiatry is outside my scope, but in spite of recent years enormous, almost alarming, development in the field of psychopharmacology, insulin treatment is still in use in various mental diseases.

### *Undesirable Effects of Insulin*

Insulin induced hypoglycaemia and its symptoms have been known from the earliest days of insulin. In spite of the development in insulin preparations, the physicians' familiarity with the hypoglycaemic syndrome and widespread ed



ucation of the insulin treated diabetic by doctors, popular articles and the efforts of diabetic associations, hypoglycaemic attacks still constitute a problem in the treatment of diabetes

The symptom complex of hypoglycaemia stems mainly from the central nervous system. The explanation is that the metabolism of the CNS depends almost exclusively on glucose as a source of energy, but it has only a small store of glycogen. The nervous system has a great demand for energy and a great oxygen consumption. During hypoglycaemia the oxygen saturation of the blood is satisfactory, but nevertheless the symptom complex is similar to anoxia arising to the reduced possibility of procuring glucose to burn.

The first signs are due to the release of adrenaline and manifest themselves as sweating, an increased pulse rate, slightly elevated blood pressure, pupillary dilatation, hunger, and trembling. These signs are so striking that most diabetics can arrest the further development of the hypoglycaemia by taking carbohydrate. Unfortunately, a number of diabetics do not notice these initial symptoms, and therefore cannot take measures in time. The initial signs are most marked when the fall of blood sugar is rapid, and therefore they may be less noticeable when slow acting insulins are used. Incidentally, the symptom complex manifests itself as blurring of cortical function in the form of lacking concentration and change of mood, often into a contrary attitude, also to therapeutic suggestions from the surroundings. The patients may develop mental confusion, and in the event of more pro-

found disturbances somnolence, loss of consciousness, grimacing, clonic spasms and deep coma, during which the Babinski sign is positive. The symptom complex often develops rapidly in connection with unusual physical activity, as a rule some hours after the last major meal. Full blown hypoglycaemic coma calls for glucose intravenously, possibly injection of glucagon. In some cases we have furnished the mothers of diabetic children with glucagon which they can give their children, if they have difficulty in getting medical aid quickly.

Hypoglycaemia with a blurred cortical function is of course a risk to the patient as well as to others in our highly developed technical society, not least in traffic. Nevertheless, it seems to be uncommon in the Scandinavian countries for diabetics to be involved in major traffic accidents, no doubt because diabetic drivers are carefully instructed and because they know that they may lose their driving licence in the event of a traffic accident caused by a hypoglycaemic state.

Most insulin reactions subside without permanent complaints, in most cases resulting only in headache for a few hours. In extremely rare cases they may cause permanent damage to the central nervous system, e.g. hemiplegia or aphasia. Death in hypoglycaemia following therapeutic doses is rare. Insulin has been used for suicidal purposes, but then usually in enormous doses.

The pathological changes in the brain following fatal hypoglycaemia are reminiscent of the changes seen after fatal anoxia, with scattered ischaemic haemorrhages.



if the blood levels of ketone have been elevated during the hours prior to hypoglycaemia (Fig 3)

Owing to this phenomenon, the breath of unconscious hypoglycaemic patients may smell of acetone, and this may lead

to the hasty diagnosis of a hyperglycaemic ketoacidotic state, with therapeutic consequences which may prove fatal to the patient

The unphysiological route of administering insulin has in some cases caused




Fig 3

Blood s. c.

nia following insulin. During hypoglycemia there is an increase in the ketonemia




Fig 3

The same patient as in Fig 2 after the cessation of the ketosis. A very slight increase in the ketonemia is now observed



*Fig 4*

NSH 11781/65 ♀ born 1937 Diabetes 25 years

Injection pads after injections in the same area during many years



*Fig 5*

NSH 11059/65 ♀ born 1950 Diabetes 1964

Lipodystrophia following insulin injections in one year




Fig 6

WSH 10856/65 ♂ 111 years diabetes 1 year Insulin treatment for one year

Bopsy of insulin injected subcutaneous area 200 $\times$  PAS + HA

The cells vary considerably in size. Streaks of connective tissue elements and infiltrating cells are observed. Augmentation of vessel wall thickness (A. Werner WSH)



Fig 7


Same as Fig 6. Closer view. Detail 400 $\times$

Cellular infiltration consists of eosinophilic and neutrophilic leukocytes

lymphocytes and histiocytes

The thickened appearance of vessel walls and fat cell membranes is obvious

A. Werner WSH



*Fig 8*

From the same patient as Fig 6

Subcutaneous tissue PAS + HA 215 x

Incubation with iodine 125 labelled insulin and subsequent autoradiograph exposure  
Binding of I 125 insulin to fat cell membranes and vessel walls with a distinct increase  
of PAS positive substance (A. Werner, MSH)



*Fig 9*

Same preparation as Fig 8

Binding of fluorescence isothiocyanate-conjugated insulin to vessel walls  
and fat cell membranes

Segmentary distribution of the fluorescence could be noted in the vessels 215 x



local abnormalities at the sites of injection, especially in patients who do not change the sites of injection sufficiently often. In some instances this may result in thickening of the skin and subcutaneous tissue, at times assuming a monstrous degree, as seen in Fig 4. In the case, depicted, subcutaneous tissue to an amount of 400 g and 250 g was removed at the patient's wish, to normalize the contours of the thighs. The excised tissue showed pronounced changes, lobulated fatty tissue with connective tissue strands and minor haemorrhages of varying age.

In other cases there may be wasting of fatty tissue, i.e. lipodystrophy, in the injected areas or nearby, as shown in Fig 5. This latter phenomenon of lipodystrophy is most marked in children and women, while it is rare in men, perhaps because of their usually thinner layer of subcutaneous fat.

Both of these local effects of the insulin injections naturally give rise to cosmetic complaints, but it has also been found that after injection into the thickened areas, the effect of insulin is incalculable and erratic. In recent years we have removed cutaneous and subcutaneous biopsies from the injection sites in several cases, and the specimens have shown considerable tissue changes (12).

The biopsies from the thickened areas exhibit fat cells of very unequal and partly very large size. There are strands of connective tissue and also cellular infiltration by lymphocytes, macrophages, plasma cells and eosinophilic leukocytes. The walls of the smaller vessels appear to be thickened with proliferation of

endothelial cells and abnormal increase of PAS positive material in the vessel wall (Fig 6 and 7).

In the lipodystrophic areas there is almost total loss of fatty tissue and degenerative changes of the connective tissue. Studies have also been carried out after treatment of the tissue section with  $I^{125}$ -labelled insulin (1) in a concentration of 150 units per ml for 30 min, rinsing, drying, and autoradiography (Fig 8). Similar studies have been performed by fluorescein-conjugated insulin (14) in the named concentration and examination in ultraviolet light (Fig 9).

These studies showed marked binding of the two labelled insulin preparations, a binding which could be prevented by preceding treatment with non labelled insulin. Biopsies from outside the injected areas showed less marked binding of insulin to the vessels and tissue membranes.

Using labelled insulin, it has been possible since 1956 to demonstrate the occurrence of insulin antibodies in the blood of insulin-treated patients (2). Since then, extensive studies have been performed in this field (7). It is generally accepted that insulin antibodies are not demonstrable by immunological methods in patients who have not previously been treated with insulin, and it is also accepted that insulin antibodies invariably arise after parenteral insulin therapy for some time.

The cause has not been definitely elucidated. There are several possibilities

- (1) that the antigenicity is caused by lacking species specificity,



- (2) that in the course of extraction the insulin alters chemically, acquiring antigenic properties during the procedure,
- (3) that owing to its manner of administration, viz introduction into subcutaneous tissue with traumatization of the tissue, and in a concentration up to a million times higher than the plasma level of insulin, the insulin sets up an immunological reaction directed at an otherwise non antigenic molecule

Re 1 It has proved possible to produce antibody also by the use of species specific insulin (4, 14)

Re 2 In the immunological technique used, the natural insulin in plasma reacts like the extracted insulin

Re 3 At present, this view seems to me to be the most likely one, as there are cellular signs of delayed immune reactions, specific binding of the antigen to vessels and cell membranes, as well as antibodies in the plasma. In many respects this reaction is reminiscent of an autoimmune disease in which the organism also forms antibodies to a molecule which is not antigenic under normal conditions

In my opinion, the possibility cannot be ruled out that the chronic allergic reaction induced by the insulin therapy is a contributory cause of the late diabetic complications in insulin-treated patients. On the other hand, it has been definitely demonstrated that such complications also develop in diabetics who are not treated with insulin. If this latter group should represent an autoallergic condition, it is of a 'submethodolog-

ical" degree or it is due to another antigen than that in the insulin treated patients, who can naturally be imagined to be subject to two chronic allergic processes

## SUMMARY

Insulin therapy has prolonged the lives of patients suffering from diabetes with a tendency to ketosis. In these patients the duration of diabetes has been increased at least ten times after the advent of insulin therapy. Moreover, insulin therapy is of great importance as a temporary measure during intercurrent diseases and in the event of surgical procedures on diabetics who are not on permanent insulin therapy.

The chemistry of insulin has been elucidated in all essentials. The amino acid sequence is known, and insulin can now be synthesized. The physiological action of insulin still remains unelucidated.

The clinical use of insulin has been characterized by the development of highly purified insulins absorbed at different rates from the injected depot.

Untoward effects of insulin are, in part, hypoglycaemia with its complex of acute symptoms and signs, mainly from the central nervous system, and in part local changes at the sites of injection. Such changes consist in microscopic abnormalities of the fatty tissue, delayed immune reactions, small haemorrhages, formation of connective tissue, and in rare cases lipodystrophy. Furthermore, the blood of insulin treated patients contains antibodies directed at insulin. This formation of antibodies is presumably due to the unphysiological way in which insulin is administered.

## REFERENCES

- 1 Appelgren, L E, Soremark R & S Ullberg (1963) *Biochim Biophys Acta* 66 144
- 2 Berson M A, Yalow R S, Bauman A, Rothschild M A & K Newerly (1956) *J Clin Invest* 35 170
- 3 Bessman S P (1966) *Am J Med* 40 740
- 4 Brunfeldt K & J E Poulsen (1953) Reports of Steno Memorial Hospital and the Nordisk Insulinlaboratorium V, 51
- 5 Brunfeldt K & T Deckert (1964) *Acta Endocrinol* 47 353
- 6 Cori C F (1946) *Harvey Lectures Ser* 41 253
- 7 Deckert, T (1965) Reports of the Steno Memorial Hospital and the Nordisk Insulinlaboratorium VII 7
- 8 Fischer, A M & D A Scott (1936) *J Pharmacol & Exp Therap* 58 93
- 9 Hagedorn H C, Jensen B, Norman Krarup N B & I Wodstrup (1936) *J Am Med Ass* 106 177
- 10 Hallas Møller K, Petersen K & J Schlichtkrull (1951) *Ugeskr f Læger* 113 1761
- 11 Krarup Niels B (1935) Clinical Investigations into the Action of Protamine Insulin G E & Gad Copenhagen
- 12 Poulsen Jacob E (1941) Studies on the Ketosis in Diabetes Mellitus The Copenhagen Denmark
- 13 Renold A E, Soeldner S, Steinke J *Giba Found Coll on Endocrinol* 15 122-134 1964
- 14 Tietze F, Mortimore G E & N R Lomax (1962) *Biochim Biophys Acta* 59 336



## POSTPRANDIAL BLOOD SUGAR RISE IN DIABETICS

*M Jersild*

Determinations of blood sugar level and of sugar in the urine are indispensable in evaluating the treatment in diabetics.

It is desirable to obtain values approaching normal as far as possible. There has always been a disagreement, however, about where to fix the limit for satisfactory regulation. During ambulatory treatment it is generally not possible to arrange more than a single blood sugar determination per day. In this case the fasting blood sugar is usually preferred as guidance for treatment, perhaps together with one or two blood sugar determinations before the main meals. Occasionally, only determinations of sugar in the urine are used.

It is often rather surprising to find a high sugar excretion in a patient where the above mentioned blood sugar values are quite satisfactory. Consequently, one might suppose that the patient has a low

renal threshold for sugar if the postprandial rise in blood sugar is not borne in mind.

The blood sugar rise 1 hour after breakfast has been found to be remarkably high in diabetics—also when compared with the rise after the other main meals which contain relatively more carbohydrates.

The postprandial blood sugar values after all meals were recorded in 16 diabetics during hospitalisation. 11 blood sugar determinations were performed in each patient in 24 hours. Of the 16 patients, 6 were treated with one insulin injection a day, 9 patients with 2 injections, and 1 patient did not get any insulin. The average age of the patients was 32 years. The average duration of the diabetes was 14 years. The results are seen in *table I*. The largest postprandial blood sugar rise was found af

TABLE I

*Postprandial blood sugar rise in 16 patients and average carbohydrate content in meals*

	Time of day	Average of blood sugar (mg%)	Average carbohydrate content of meals (g)
1h after breakfast	9	108	37
1h after lunch	12 <sup>30</sup>	31	59
1h after tea	16	30	23
1h after dinner	18 <sup>30</sup>	70	58
1h after evening	22	28	13

ter breakfast (108 mg per cent), although this meal had a lower carbohydrate content than lunch and dinner. The carbohydrate content of breakfast in Denmark represents on an average 20 per cent of the total carbohydrate intake.

In order to determine the rise in the blood sugar after breakfast (at 8 o'clock) in a larger number of diabetics—with or without insulin treatment—the postprandial values were recorded one hour after breakfast in 312 consecutively hospitalized patients during a period of 6-7 days. 2013 blood sugar determinations, measured by the Hagedorn Jensen method, made one hour af-

ter breakfast, were used in these investigations.


The age distribution is seen in *fig 1*. The majority of the patients are younger than 40 years of age.

The duration of the diabetes is on an average between 5 and 10 years.

The rise in blood sugar from 8 to 9 o'clock in the morning is on an average 90 mg per cent. The fall from 9 o'clock to 11.30 (before lunch) is on an average 104 mg per cent.

In *fig 2* the patients are classified according to the postprandial blood sugar levels one hour after breakfast.

One third of the patients (group I) had



*Fig 1*

Age and sex distribution in 312 diabetics




Fig 2

Postprandial blood sugar values 1h after breakfast

Group I 106 pts with values 110-230 mg%

Group II 105 pts with values 231-270 mg%

Group III 101 pts with values >270 mg%




Fig 3

Age distribution in the 3 groups

postprandial blood sugar values  
 from 110 to 230 mg per cent  
 Another third (group II)  
 from 231 to 270 mg per cent  
 The last third (group III)  
 from 271 to 370 mg per cent

In the following, the question will be examined whether these 3 groups show any correlation to other clinical manifestations of the disease

Fig 3 shows the age distribution in the above mentioned 3 groups. The conclusion is that there is no correlation between the postprandial blood sugar rise and the age of the patients. It might be supposed that the young diabetics with unstable blood sugar were to be found mainly in group III, but this is not the case.

Fig 4 shows that the postprandial

blood sugar rise is not correlated to the duration of the diabetes. The average duration in group I is 13 years, in group II 12 years, and in group III 15 years.

However, a significant correlation is found between the postprandial blood sugar rise and the age of the patients at the onset of the diabetes (*table II*). The diabetics with juvenile onset were found more frequently in group III (84 per cent) with the highest postprandial blood sugar values than in group I (67 per cent) with the lowest values, and the maturity onset diabetics were found more frequently in group I (33 per cent) than in group III (16 per cent).

The carbohydrate content of the breakfast is not correlated to the blood sugar rise (*table III*). In group I, II, and III the average carbohydrate content of the breakfast is practically the




Fig 4  
 Duration of diabetes in the 3 groups

same (37 g) As expected, the sugar in the urine (*table IV*) during 24 hours is higher in group III (32 g) than in group I (11 g)

The obese patients are found more frequently in group I (*table V*), these patients generally belonging to the ma-

turity onset, non insulin treated, stable diabetics

The frequency of retinopathy and nephropathy in the 3 groups is seen in *table VI* practically the same incidence of retinopathy (average 57 per cent) was found in the three groups, whereas

TABLE II

*Age at onset in the 3 groups*

Group	I	II	III
<40 years per cent of pts	67	72	84
>40 years per cent of pts	33	28	16
Total no of pts	106	105	101

TABLE III

*Carbohydrate in breakfast*

Group	I	II	III
Av grams	36	37	38

TABLE IV

*Urinary sugar in the 3 groups*

Group	I	II	III
No of pts	103	104	97
Urinary sugar av grams/24 h	11	19	32

TABLE V

*Overweight in the 3 groups*

Group	I	II	III
≤10 % overweight per cent of patients	32	25	10

TABLE VI

*Long term diabetic manifestations in the 3 groups*

Group	I	II	III
% retinopathy	57	58	56
% nephropathy	25	15	9



nephropathy occurred more frequently in group I than in group II and III. It is difficult to give an entirely acceptable explanation of this phenomenon, but the relative prevalence of obese patients with maturity onset diabetes in group I should be considered.

The treatment in the three different groups has also been investigated (*table VII*). In the insulin treated patients, the average insulin dose was almost the same in all three groups. One daily injection is given more frequently (63 per cent) in group I than in group III (40 per cent). The contrary was the case in the two injection therapy. 14 of the patients did not receive any insulin treatment. Of these, 12 were found in group I and 2 in group II. This means—as suspected—that the non insulin treated patients with a stable blood sugar also had the smallest postprandial blood sugar rise.

The highest postprandial blood sugar values are found in the unstable diabetics. This has also been demonstrated by evaluating the other blood sugar values of the day by means of the M value (5).

### Discussion

The pronounced postprandial blood sugar rise after breakfast has been recorded previously by the author (2, 3).

By means of continuous blood sugar determinations, Chaptal, Guillaumot and Morel (1) in 1964 demonstrated this considerable blood sugar rise in children in spite of a breakfast relatively poor in carbohydrates. Sindoni (6), in 104 diabetics, found an average blood sugar rise of 100 mg per cent 2 hours after the breakfast.

Mirouze et al (4) demonstrated the marked oscillations of the blood sugar during the day and night by means of continuous blood sugar determinations. The highest values were found 1/2 hour to 2 hours after the main meals, and in the labile diabetics they were only slightly influenced by the type of insulin used or the time when the injection was given.

An explanation of the pronounced postprandial blood sugar rise after breakfast may be the higher level of blood corticosteroids during the morning than in the evening. A Somogyi effect following a nightly hypoglycemia should not be overlooked.

### Conclusion

The postprandial blood sugar rise is highest after breakfast, in spite of this meal containing relatively little carbohydrate.

The higher content of corticosteroids

TABLE VII

*Insulin dose and No. of insulin injections in the 3 groups*

Group	I	II	III
No. of pts	94	103	101
Insulin av. dose i.u.	31	34	36
1 inj. per cent of pts	63	54	40
2 inj. per cent of pts	37	46	60

in the blood during the morning hours may be the cause of this phenomenon. In two-thirds of the diabetics, the postprandial blood sugar values after breakfast increased to more than 230 mg per cent.

The highest postprandial blood sugar rise was found in diabetics with juvenile onset of the disease. This blood sugar rise could not be avoided even when the patients were given 2 insulin injections per day.

## REFERENCES

- 1 Chaptal J, Guillaumot J R & Morel G  
*La Presse Medicale* 72: 2047 1964
- 2 Jersild M. *Vorduk Kongres f Int Med*  
Copenhagen June 8-11 1964
- 3 Jersild M. Assoc de Diabetologues de  
Langue Francaise Paris mai 1966 *Le  
Diabete* 14: 225 1966
- 4 Mirouze J, Jaffiol C & Sany C. *Path  
Biol (Paris)* 11: 553 1963
- 5 Schlichtkrull J, Munck O & Jersild M  
*Acta Med Scand* 177: 93 1965
- 6 Sindoni A Jr. *Am J Digest Dis* 13:  
178 1946



## EXTRAPANCREATIC AND INTRAPANCREATIC ACTION OF ANTIDIABETIC SULPHONYLUREAS A REVIEW

by

*Joop Madsen*

Since the early work of Loubatieres, an enormous literature has appeared on the mechanism of action of the antidiabetic sulphonylureas and on their clinical application. Thus, a bibliography only on tolbutamide published in 1965 (129) contained more than 1700 numbers. The commonly accepted conclusion of this work has been that the hypoglycemic sulphonylureas lower the blood sugar by stimulating the insulin secretion of the  $\beta$ -cells in the islets of Langerhans. The purpose of the present paper is to call attention to a number of findings that cannot be explained by a pancreatic locus of action and to discuss the hypoglycemic effect of the sulphonylureas on the background of these experiments.

The chemical composition of the antidiabetic sulphonylureas is shown in fig. 1. Apparently there is no principal difference in the mechanism of action of these compounds so that they will be treated as one group in the following. Extensive reviews are available of the literature up to 1960-61 on the mechanism of action of the sulphonylureas (34, 38, 81).

### *$\beta$ -cell stimulation by sulphonylureas*

As early as 1944, Loubatieres (71) demonstrated that p-aminobenzenesulfa-midothiodiazol (2254RP) caused hypoglycemia in dogs, and that this effect depended on the presence of pancreas or part of it in the animal. Loubatieres reported in the same paper that one-tenth of a hypoglycemic dose would elicit a fall in blood glucose level, if injected into the artery leading to the pancreas, and he found an increase in liver glycogen after 2254RP, as after insulin. He concluded that the compound lowered the blood sugar by stimulating the insulin secretion of the  $\beta$ -cells in the islets of Langerhans.


Following the appearance of carbutamide and tolbutamide in the midfifties, a great amount of work was done on the mechanism of their hypoglycemic action, largely confirming the early work of Loubatieres on 2254RP.

It was shown that the sulphonylureas were inactive in the pancreatectomized, non insulin treated dog (14, 23, 41, 55, 61, 86, 94), cat (46), rabbit (58), rat (27), toad (55) and man (33).


It was further demonstrated that the responsiveness of alloxan diabetic animals to sulphonylureas was inversely related to the severity of the diabetes so that severely diabetic animals would not respond while animals with a milder diabetes would react to sulphonylureas with a hypoglycemic response though less so than normal animals (1 10 15 30 72 82 92). Similarly the reaction of animals with a metahypophysary diabetes would be reduced according to the severity of the diabetic state (68 74 90). It was concluded that the hypo-

glycemic sulphonylureas depended on the presence of functioning  $\beta$  cells for their ability to lower the blood sugar.

This conclusion was supported by statistical comparison of the sulphonylurea responsiveness in populations of diabetics differing with respect to age sex age at the beginning of their diabetes duration of the disease and their insulin requirements. It was found that the patients who responded to sulphonylurea treatment were those whose diabetes developed at a mature age who had only been sick for a short number of years.




5-aminobenzenesulfonyl isopropyl isothiazolidine-4-carboxylate  
(4 M)




5-aminobenzenesulfonyl tert-butyl isothiazolidine-4-carboxylate  
(22 M)




4-aminobenzenesulfonyl n-butyl isothiazolidine-4-carboxylate  
(C 2000 M)



4-aminobenzenesulfonyl n-pentyl isothiazolidine-4-carboxylate  
(100 M)



4-chlorobenzenesulfonyl n-butyl isothiazolidine-4-carboxylate  
(100 M)




N-(3-amino-4-methylbenzenesulfonyl)-cyclohexylurea  
(Lohmeyer 1944)




N-(4-acetylbenzenesulfonyl)-cyclohexylurea  
(Aceto 1944)



N-(4-methylthiobenzenesulfonyl)-cyclohexylurea  
(Lohmeyer 1944)



N-(4-methylthiobenzenesulfonyl)-hexahydroazepinylurea  
(Toll 1944)



N-(4-methylthiobenzenesulfonyl)-cycloheptylurea  
(Cycl 1944)

Fig 1

In diabetic sulphonamides and sulphonylureas

and whose insulin requirements were modest. The same correlation was found between the parameters mentioned above and the amount of extractable insulin recovered from diabetic patients at autopsies (17, 138, 139). Thus, a similarity was evident between the responsiveness to sulphonylureas and the availability of insulin in the pancreas.

Histologic examination of the islets of Langerhans after administration of sulphonylureas showed a degranulation of the  $\beta$ -cells and characteristic changes in their nuclei. A survey of 42 investigations on this subject is given in (81). Since the  $\beta$ -cell granule consists of insulin or insulin precursors, the degranulation indicates that sulphonylureas trigger a release of preformed insulin from the pancreas. This interpretation is supported by measurements of extractable insulin in pancreas of calves (103), dogs (113) and rats (37) before and at various time intervals after sulphonylurea administration.

An increase in plasma insulin like activity after sulphonylurea administration has been demonstrated by the rat hemidiaphragm (3, 11, 53, 101, 123, 130) and rat epididymal fat pad (102) techniques as well as by immunological methods (140) and *in vivo* assays (4, 44). Perfused isolated pancreas (84) as well as incubated slices of pancreas (20) release more insulin under the influence of sulphonylureas than in the control period.

Finally, a number of insulin effects have been recorded *in vivo* as well as *in vitro* after the administration of sulphonylureas. Among these is a reduction of the glucose output of the liver (9, 28,

59, 60, 109, 119, 121), which can also be seen after slow, intraportal infusion of small amounts of insulin (12, 28, 59, 79). An increased extrahepatic glucose uptake has been more difficult to demonstrate. It has been done, however, but Butterfield et al (21), Searle et al (120, 122) have shown that both tolbutamide and insulin increase  $C^{14}O_2$  production from a trace dose of  $C^{14}$ -glucose in normal men as well as in sulphonylurea responsive diabetics.

The findings listed above constitute the main body of evidence on which the conclusion is based that the antidiabetic sulphonylureas exert their hypoglycemic effect by stimulation of the insulin secretion from the  $\beta$ -cells of the pancreas. Many investigators have failed to reproduce insulin effects by the administration of sulphonylureas. This difficulty, however, is explained by the different effects of insulin given intravenously as a single injection and insulin secreted slowly into the portal circulation.

#### *Extrapancreatic action of sulphonylureas*

A number of findings, however, cannot be explained by a pancreatic action of the antidiabetic sulphonylureas. Many investigators have produced blood sugar falls by the administration of sulphonylureas to pancreatectomized (13, 56, 61, 114, 116, 119, 128) or severely alloxan-diabetic (2, 114, 116) animals treated by small amounts of insulin. Chronic administration of sulphonylureas to pancreatectomized dogs will reduce their insulin requirements (24, 61, 111, 115, 118, 124, 136). Kurtz et al (64) found that tolbutamide injected intravenously

into dogs within 10 minutes after total pancreatectomy, would elicit a blood sugar fall, while no significant effect could be detected if the injection was given 1-2 hours after pancreatectomy. Obviously the presence of insulin and not the presence of an intact pancreas is the condition for the hypoglycemic effect of the sulphonylureas.

This extrapancreatic "insulin potentiating" effect of sulphonylureas is not only seen when the compounds are given to insulin-treated animals without functioning  $\beta$  cells, but also if the insulin sensitivity of such animals is investigated in acute experiments with and without sulphonylurea given simultaneously (25, 69, 75, 93, 94). This insulin potentiating action has also been demonstrated in diabetics who were insensitive to sulphonylureas given alone (69, 89). Increased insulin sensitivity has been reported during chronic sulphonylurea treatment of unresponsive diabetic patients (126) and pancreatectomized or alloxan diabetic dogs (112). Experiments by Caren & Corbo (25) on pancreatectomized dogs indicate that the demonstration of this sulphonylurea-effect depends on the dosage of insulin. Insulin must be administered in a suitably small dose, otherwise no difference can be shown between animals receiving insulin and animals receiving insulin + sulphonylurea. This fact may account for the numerous futile attempts that have been made to demonstrate this insulin sulphonylurea synergism in pancreatectomized humans (29, 33, 45, 83), dogs (41, 86, 94) and cats (4b) as well as in alloxan-diabetic rabbits (125) and rats (36, 67, 88, 110).

Experiments by Schambye & Tarding (119) using the glucose- $C^{14}$  dilution method showed that the blood sugar fall after tolbutamide given intravenously to insulin treated pancreatectomized dogs was caused by an inhibition of the glucose output by the liver. Another hepatic, insulin potentiating action of carbutamide has been demonstrated by Lamprecht & Trautschold (66). Though without effect when given alone, carbutamide reinforces the effect of small doses of insulin, so that—like much higher doses—they normalize triosephosphate metabolism in livers of hunger-diabetic rats. Insulin potentiating effects on the liver have also been reported by Colwell (26).

The "insulin potentiating effect", however, can not only be localized to the liver. This is apparent from experiments of Houssay et al (57), Madsen (80) and Creutzfeldt et al (32). In eviscerated dogs, cats and rats, they have shown that falls in blood sugar can be produced if tolbutamide is injected into animals whose blood sugar has been maintained constant or increasing by means of a constant rate glucose infusion, and to which minute amounts of insulin have been administered (fig 2).

In the cat experiments it could be calculated that the glucose utilization in eviscerated animals given insulin 0.01 unit/kg i.v. + tolbutamide 100 mg/kg i.v. exceeded the utilization in eviscerated animals given only insulin, by 25 per cent  $\pm$  SEM 6.5 per cent. In hepatectomized cat, with intact pancreas, in which the blood sugar was maintained constant or slightly increasing by means of a constant rate glucose infusion, tol

butamide 100 mg/kg i.v. increased glucose utilization by 38 per cent  $\pm$  SEM 6.1 per cent. The difference between the tolbutamide effect on glucose utilization in hepatectomized cats with an intact pancreas and in eviscerated cats without a pancreas, but treated with minute doses of insulin, is not significant ( $P < 0.1$ ). Thus, it cannot be excluded that the tolbutamide effect in the hepatectomized cat is entirely extrapancreatic.

In the experiments of Houssay et al. as in those of Madsen, it was found that the amount of insulin given was critical for the tolbutamide effect. Thus, an increase in insulin dosage from 0.01 to 0.02 units/kg markedly reduced the tolbutamide effect in eviscerated cats.

A number of authors (95, 99, 104, 105) have found that sulphonylureas increase the glucose uptake of isolated skeletal muscle from normal rats. At the same time oxygen uptake (95, 104) and  $C^{14}O_2$  production from labelled glucose

(12, 47, 104) are increased. An *in vitro* effect of tolbutamide has also been described (70) in fat pads from animals with intact pancreas. Rafaelsen & Lundbæk have observed an increased glucose uptake by diaphragms from alloxan diabetic rats (106). The possibility cannot be excluded, however, that minute amounts of insulin remained in their preparations.

Summarizing it may be concluded that the hypoglycemic sulphonylureas can indeed lower the blood sugar level by increasing extrahepatic glucose utilization by a mechanism that requires the presence of small amounts of insulin, but not of the pancreas. In the following this effect will be called the insulin-potentiating effect of the sulphonylureas. What can the mechanism of this effect be? Mirsky et al. (91) and Tamai & Kizuma (127) have advanced the hypothesis that the sulphonylureas lower the blood sugar by inhibition of enzymatic




Fig 2

Insulin potentiating effect of tolbutamide in eviscerated glucose infused cats. Injection of insulin or insulin + tolbutamide was performed at the arrow. Average values are marked  $\pm$  SEM. The differences between the two animal groups are statistically significant ( $P < 0.05$ ) from 40 minutes after the injection. (From 81)



insulin degradation. However, since the usual hypoglycemic concentrations of sulphonylureas do not inhibit "insulinase" (16, 133), and since other compounds have a powerful insulinase inhibiting effect without being hypoglycemic (137), this theory must be regarded as obsolete. Nor can a decreased production or effect of anti-insulinary hormones be the explanation, since neither removal of the pituitary, thyroid, adrenal or sex glands diminishes the hypoglycemic effect of the sulphonylureas (73). On the contrary this is increased after adrenalectomy (10, 23, 55, 108, 134). It has been suggested that insulin might be of importance for the penetration of sulphonylureas into the cells (52), and that an especially active sulphonylurea-insulin complex might be formed (31, 69), but neither of these theories has been supported by any experimental evidence. Experiments designed to demonstrate such a sulphonylurea-insulin complex were negative (23, 81).

It must be considered whether interference with other insulin antagonists could explain the insulin potentiating effect of the sulphonylureas. Two of these antagonists, however, depend on the presence of an intact pituitary gland, namely Bornstein's  $\beta$ -lipoprotein factor (19) and Vallance Owen's synalbumin antagonist (131, 132). Since the sulphonylureas are fully active in the absence of the pituitary, these factors can be left out of consideration. The same is the case for Field & Stetten's  $\alpha$  globulin (39) which has only been demonstrated during diabetic acidosis. Lowy et al (76) have described an insulin antago-

nist in the serum albumin. This factor resembles Vallance Owen's synalbumin, except in that it does not depend on the presence of pituitary. Whether the sulphonylureas interfere with this factor is unknown.

#### *Inhibition of insulin inactivation by plasma components*

A number of findings strongly suggest that insulin is present in normal as well as diabetic plasma in different forms, some of which are biologically and/or immunologically inactive.

While added insulin from man or ox moves with albumin and  $\alpha$  globulin in electrophoresis (5, 107), plasma insulin-like activity (ILA) can be detected in all electrophoretic fractions, mainly in the albumin- $\alpha$  globulin fraction and in the  $\beta$ - $\gamma$  globulin fraction (77). These findings suggest that part of the insulin is bound to some other protein.

The availability of anti-insulin sera has permitted the distinction between ILA that can be inhibited by anti-insulin and ILA that will not be inhibited by anti-insulin. Another distinction between insulin-like activities in plasma can be obtained by simultaneous ILA determinations using rat diaphragms and rat adipose tissue as test objects. The rat diaphragms will give lower ILA's than the adipose tissue, and the ILA determined on muscle will all be anti-insulin suppressible, while the higher values obtained with the adipose tissue have a suppressible and a non-suppressible component. In addition to these fractions, serum contains 'hidden ILA' (43, 78), ILA that cannot be detected

biologically or immunologically in untreated serum

Part of the non suppressible and hidden ILA can be converted to suppressible ILA by acid ethanol extraction (117) or by dialysis (78) Thus, it can be regarded as well established that at least part of the non suppressible ILA is really insulin

Antoniades (5, 7) has reported that a Dowex 50 cation exchange resin will retain part of the ILA as measured by the adipose tissue method, while nearly all ILA as measured with rat diaphragm will run through ("free insulin") After elution of the retained ILA, it can be shown to be non suppressible by anti-insulin and to move with the  $\beta$ ,  $\gamma$  globulins in electrophoresis ("bound insulin") "Bound insulin" was shown to be a complex of insulin and a protein with isoelectric point about pH 10 By various treatments, "free insulin" can be split from this complex Antoniades has also found "bound insulin" in extracts from pancreas (8)

That non-suppressible insulin consists of particles with a higher molecular weight than suppressible insulin is also evident from the work of Samaan et al (117), who found that immunologically suppressible insulin could ultrafiltrate, while non suppressible ILA could not

An extensive review on the state of insulin in plasma is outside the scope of this paper For such a review, including a discussion of the possible identity of insulin fractions described by different authors, the reader is referred to the recent study by Lyngsoe (78) However, it may be concluded that a significant part of plasma insulin is present in high

weight molecular form, possibly bound to plasma proteins, protected from anti-insulin, inactive towards muscle preparations but in part active on adipose tissue In the following, this ILA will be called "bound insulin" With this expression the author does not particularly mean the "bound insulin" described by Antoniades, unless this is specifically stated

Looking for a mechanism to explain the extrapancreatic, extrahepatic, insulin-dependent hypoglycemic action of the sulphonylureas, it would be natural to consider an effect on the "bound insulin" If the sulphonylureas are able to release free insulin from "bound insulin", they would increase the concentration of insulin effective on skeletal muscle

This theory has first been put forward by Krah1 (63) and it has been mentioned as a possibility by Linke (69) Krah1 supports the hypothesis by the finding that sulphonylureas increase the glucose uptake by isolated diaphragms, if they are incubated in normal plasma, but not if they are incubated in buffer Details of these experiments have not been published Lacy (65) reported that tolbutamide added *in vitro* at a concentration of 100 mg per cent increased the ILA (fat pad technique) of sera from 8 of 12 insulin treated diabetic patients, and from 6 of 13 non diabetic patients This tolbutamide concentration is 3 times the concentration used in the cat experiments reported on p 112 and 12-15 times therapeutic concentrations Hasselblatt (50) has reported that tolbutamide added at a concentration of 20 mg per cent to serum from normal, thyroxin

treated rats will significantly increase the ILA (measured on rat diaphragm). This increase was found to depend on the dietary state of the animal, being most pronounced 6-10 hours after feeding. Estimating ILA in normal guinea pig sera by net gas exchange by rat adipose tissue, Otto & Korner (98) found that the ILA was increased by addition of tolbutamide to the serum. If exogenous insulin was added, no tolbutamide effect could be detected. Thus, a parallel is seen to the experiments in eviscerated (57, 80) or pancreatectomized (25) animals, where the tolbutamide effect depends on the presence of insulin in very small amounts. Several unsuccessful attempts have been made to repeat Hasselblatts experiments in other laboratories (35, 62, 100).

In this connection, another finding of Hasselblatt et al (51) is of interest, namely that tolbutamide inhibits the binding of bromsulphalein to serum proteins.

Antoniades et al (6) have examined the content of 'free' and "bound insulin" in the blood of non diabetic and non insulin dependent diabetics before and after intravenous injection of tolbutamide. In 7 out of 13 non diabetic cases they observed a pronounced increase in the concentration of "free" and a fall in the concentration of 'bound insulin' after the tolbutamide injection. In 4 cases the effect was mild, and in two no effect of tolbutamide was seen. Of 9 diabetic patients, 3 showed a mild the rest a pronounced effect. While the increase in "free" insulin may be due to an increased secretion of insulin from the pancreas the fall in 'bound

insulin" suggests a dissociation or an otherwise increased utilization of 'bound insulin' under the influence of tolbutamide.

Gundersen et al (49) have found that the presence of heparin in serum will cause a dissociation of "bound insulin". Using this method, Gundersen examined sera from non-diabetics and non-insulin requiring diabetic patients before and after oral tolbutamide tests, finding no appreciable effect on the dissociation of "bound" insulin (48).

An antagonistic effect on the binding of insulin to anti insulin sera has been reported by Hasselblatt (50). Lacy (65) found that addition of tolbutamide to sera from guinea pigs immunized with crystalline ox insulin increased the ILA of the serum. However, tolbutamide would not split ox insulin antibody complexes. Similarly, Otto and Korner (98) found that tolbutamide would not prevent the binding of added insulin to insulin antibodies, although tolbutamide would increase the ILA of sera from immunized animals, to which insulin had been added. From these experiments they concluded that the sulphonylureas do not liberate bound exogenous insulin, but somehow activate endogenous, inactive insulin in the serum.

When labelled insulin was injected into diabetic patients, the activity disappeared faster from plasma if the patients were treated with tolbutamide, than if they were not (18). Since tolbutamide treatment did not accelerate the elimination of labelled metabolites, it is unlikely that tolbutamide increased insulin degradation. However, the results may support the concept of an inhibited

binding of insulin to plasma components

Many cases have been reported of lowered insulin requirements in insulin resistant diabetics during sulphonylurea treatment (54, 85, 87, 96, 97). Such reductions amounting to several hundreds of insulin units daily can hardly be explained by an increased insulin secretion. However, they may be explained by an inhibited binding of insulin to plasma proteins (antibodies?). During tolbutamide treatment of a resistant patient, Friedlander & Bryant (40) found that the insulin binding effect of serum was markedly reduced. Hasselblatt (50) found that tolbutamide added *in vitro* at a concentration of 22 mg per cent would significantly decrease the insulin binding effect of serum from an insulin resistant patient. Full neutralization of the insulin binding effect was reached at a concentration of 70 mg per cent (10 times therapeutic concentrations).

Finally, a paper by Wallenfels et al (135) should be mentioned here. They found that addition of carbutamide prevents the aggregation of insulin molecules that otherwise takes place in the presence of Zn. Based on these findings the authors suggest that carbutamide and other sulphonylureas may be able to loosen bindings of insulin to other proteins, i.e. serum proteins. They consider that sulphonylureas break up insulin aggregates in the  $\beta$ -cells thereby rendering insulin soluble and able to leave the cells.

## DISCUSSION

The findings mentioned in the previous

section are not unequivocal, and many of them have been difficult to reproduce. They do however point towards the fact that sulphonylureas somehow activate or potentiate inactive insulin present in plasma. On the background of our increasing knowledge of 'bound' insulin in plasma, it seems a reasonably well-founded hypothesis that the sulphonylureas promote a liberation of "bound" to "free" insulin. It has more experimental support than any other theory put forward to explain the insulin dependent effect of the sulphonylureas in pancreatectomized and eviscerated animals.

Reviewing the experimental evidence on which the  $\beta$ -cell stimulation theory is based (p 109-111), it will be seen that most of these findings can as well be explained by insulin potentiation. This applies to the increased ILA in pancreatic veins as well as in other parts of the circulation, to the observation of insulin effects on hepatic as well as extrahepatic metabolism and to the necessity of functioning  $\beta$ -cells in the patient or experimental animal. The histological changes in the  $\beta$ -cells and particularly the measurements of extractable insulin in pancreas before and after sulphonylurea administration must however be taken as proof of an increased secretion of insulin under influence of the sulphonylureas. Thus, their mechanism of action is twofold: partly stimulating insulin secretion, partly activating or releasing inactive, bound insulin extrapancreatically.

Little is known about the relative contribution of these two mechanisms to the hypoglycemia seen in intact humans

- 23 Bander, A & Scholz J *Deutsch Med Wschr* 81 889, 1956
- 24 Campbell J *Canad Med Ass J* 74 967 1956
- 25 Caren R & Carbo L *J Clin Invest* 36 1546 1957
- 26 Colwell Jr, A R *Metabolism* 13 1310 1964
- 27 Cox R W Henley E D & Williams R H *Diabetes* 5 366 1956
- 28 Craig J W Drucker W R, Miller, M Woodward Jr H & Molzahn V *Ann N Y Acad Sci* 74 537 1959
- 29 Craig J W & Miller M *Diabetes* 6 77 1957
- 30 Creutzfeldt W & Bottcher K *Deutsch Med Wschr* 81 896 1956
- 31 Creutzfeldt W Detering L & Welte O *Deutsch Med Wschr* 82 1564 1957
- 32 Creutzfeldt W Deutsche U & Söling H H *Klin Wschr* 39 790 1961
- 33 Creutzfeldt W Kummerle F & Kern E *Deutsch Med Wschr* 84 541 1959
- 34 Creutzfeldt W & Söling H D *Ergebn inn Med u Kinderheilk* 15 1 1960
- 35 Ditschuneit H in discussion Oberhase K & Jahnke K Ed *Fortschritte der Diabetesforschung* Georg Thieme Verlag Stuttgart p 73 1963
- 36 Dulin W E & Johnston R L *Ann N Y Acad Sci* 71 177 1957
- 37 Dulin W E & Miller W L *Diabetes* 8 199 1959
- 38 Duncan L J P & Baird J D *Pharmacol Rev* 12 91 1960
- 39 Field J B & Stetten de W jr *Diabetes* 5 371 1956
- 40 Friedlander E O & Bryant M D *Amer J Med* 26 139 1959
- 41 Fritz J B Morton J V Weinstein M & Levine R *Metabolism* 5 744 1956
- 42 Garattini S Paoletti R & Tressan L *Arzneimittelforsch* 8 477 1958
- 43 Gjedde F In *Adv Alestr Short Communications First International Congress of Endocrin Copenhagen 1960 Acta Endocrin Suppl* 51 1243 1960
- 44 Goetz F C & Egdahl R H *Fed Proc* 17 55 1958
- 45 Goetz F C Gilbertsen A S & Josephson V *Metabolism* 5 788 1956
- 46 Gordon, M F Buse, J F & Lukens, F D W *Diabetes* 6 7, 1957
- 47 Goto, Y & Lukens F D *Diabetes* 10 52, 1961
- 48 Gundersen K *Diabetes* 15 663, 1966
- 49 Gundersen K & Lin B J *Diabetes* 14 805, 1965
- 50 Hasselblatt A *Metabolism* 12 302 1963
- 51 Hasselblatt A Hukuhara T & Ziergler J *Klin Wschr* 43 220 1965
- 52 Hasung A W *Metabolism* 8 593 1959
- 53 Holt C v Holt, L v Kracht B Kroner M & Kuhnau J *Science* 125 735, 1957
- 54 Houssay A Klinische Erfahrungen mit D 860 - Sitzung der argentinischen Gesellschaft für Diatologie in Verbindung mit der argentinischen Gesellschaft für Diabetes am 29 Oktober 1956 in Buenos Aires
- 55 Houssay B A & Penhos J C *Metabolism* 5 727 1956
- 56 Houssay B A, Penhos J C Toedossio N Bowkett J & Apelbaum *Ann N Y Acad Sci* 71 12 1957 a
- 57 Houssay B A Penhos J C Urgotti F Theodoros N Apelbaum J & Bowkett J *Ann N Y Acad Sci* 71 25 1957 b
- 58 Hultquist G Nathorst Windahl G & Johansson D *Nord Med* 58 1873 1957
- 59 Jacobs G Reihard G Goodman jr F H Friedman B & Weinhouse S *Diabetes* 7 358 1958
- 60 Kibler R F & Gordon G J *Lab Clin Med* 48 824 1956
- 61 Kirtley W R Radolfo A S & Root M A *Diabetes* 5 351 1956
- 62 Kerp L Creutzfeldt W & Steinhilber S In Oberhase K & Jahnke K Ed *Fortschritte der Diabetesforschung* George Thieme Verlag Stuttgart II 57 1963
- 63 Krahl M E *Perspect Biol Med* 1 69 1957 b
- 64 Kurtz M Holtzman Ch M & Meilman E J *Clin Invest* 38 902 1959
- 65 Lacy P E *Diabetes* 11 suppl 1 1962

- 66 Lamprecht W & Trautschold I *Arzt mittelforsch* 8 462 1958 a
- 67 Lang E & Sherry S *Metabolism* 5 733 1956
- 68 Lazarus S ■ & Volk E W *Endocrinology* 62 292 1958
- 69 Linke A *Deutsch Med Wschr* 85 2069 1960 b
- 70 Lopez Quijada C R Candela R & R Candela J L *Med Exp* 6 65 1962
- 71 Loubatieres A *C R Soc Biol (Paris)* 138 766 1944
- 72 Loubatieres A Boyard P & Fruteau de Lacroix C *J de Physiol* 48 618 1956
- 73 Loubatieres A Boyard P Fruteau de Lacroix C & Sassine A *C R Des Seances de l'Acad des Sci* 242 2044 1956 a
- 74 Loubatieres A Boyard P Fruteau de Lacroix C & Sassine A *J de Physiol* 48 620 1956 b
- 75 Loubatieres A Boyard P Fruteau de Lacroix C Sassine A & Alric R *C R Soc Biol* 150 1601 1956
- 76 Lowy C Blanchard G & Phear D *Lancet* 1 802 1961
- 77 Lyngsoe J *Acta Med Scand* 175 401 1964
- 78 Lyngsoe J Seruminsulin a review *Diss Acta Med Scand* 179 suppl 441 1965
- 79 Madison L L Combes B Adams R & Strickland W *J Clin Invest* 39 507 1960
- 80 Madsen J *Proc Soc Exp Biol Med* 105 273 1960 b
- 81 Madsen J Om de »antidiabetiske« sulfonylurininstoffers virkningsmekanismer *Diss Copenhagen* 1964
- 82 Magyar I Marton I Mathe Z & Refi es P *Hertai Z Ges Inn Med* 13 210 1958
- 83 McCullagh E P & Goebert H W *Diabetes* 8 315 1959
- 84 Mehnert H Schafer G Kahampetsoz G Stuhlfonth H & Engelhardt W *Klin Wschr* 40 1146 1962
- 85 Menchel J & Diengott D *Israel Med J* 18 128 1959
- 86 Mihich E & Prino G *Arch Int Phar macodyn* 110 443 1957
- 87 Miller M & Craig J W *Metabolism* 5 868 1956
- 88 Miller W L Krake J J & Vander Brook M J *J Pharmacol Exp Ther* 119 513 1957
- 89 Mirsky I A & Diengott D *J Clin Endocr* 17 603 1957
- 90 Mirsky I A Gitelson S & Perissutti G *Ann N Y Acad Sci* 74 499 1959
- 91 Mirsky I A, Perissutti G & Diengott D *Metabolism* 5 156 1956
- 92 Mirsky I A Perissutti G & Gitelson S *Ann N Y Acad Sci* 71 103 1957
- 93 Mohnike G *Arzneimittelforsch* 6 388 1956
- 94 Mohnike G Bibergeil H & Czyzyk A *Deutsch Med Wschr* 82 1579 1957
- 95 Mohnike G Knitsch W Boser H Werner G & Werner S *Deutsch Med Wschr* 82 1580 1957
- 96 Moorhouse J A & Hark R M *Metabolism* 5 847 1956 a
- 97 Moorhouse J A & Hark R M *Clin Res Proc* 4 124 1956 b
- 98 Otto H & Horner A In Oberdisse H & Jahnke K Ed *Fortschritte der Diabetes forschung* Georg Thieme Verlag Stuttgart p 62 1963
- 99 Pallone E & Vasalle M *Folia Endocr* 9 775 1956
- 100 Pfeiffer E F in discussion Oberdisse H & Jahnke K Ed *Fortschritte der Diabetesforschung* Georg Thieme Verlag Stuttgart p 73 1963
- 101 Pfeiffer E F Pfeiffer M Ditschuneit H & Chang Su Ahn *Ann N Y Acad Sci* 82 479 1959
- 102 Pfeiffer E F Renold A E Martin D B Dagenais Y Meakin J W Nelson D H Shoemaker G & Thorn G W Untersuchungen über die Rolle des Pankreas in Wirkungsmechanismus blutzuckersenkender Sulfonylharnstoffe I *Diabetes Mellitus* Stuttgart 1959
- 103 Pfeiffer E F Steigerwald H Sandrit ter W Bander A Nager A Becker U & Retiene K *Deutsch Med Wschr* 82 1568 1957
- 104 Fletcher A Grey K F & Strassle R

- Helv Physiol Pharmacol Acta* 15 C 30 1957
- 105 Rafaelsen O J *Metabolism* 8 195, 1959
- 106 Rafaelsen O J & Lundback K *Metabolism* 8 757, 1959
- 107 Randle P J & Taylor, K W *The Lancet* 2 996 1958
- 108 Rausch Stroumann J G & Kracht J *Arch Deutsch Ges Inn Med* 62 518 1956
- 109 Reckant L & Fischer G L *Ann N Y Acad Sci* 71 62, 1957
- 110 Rice *Diabetes* 8 89 1957
- 111 Ricketts H T Wildberger, H L & Schmid H *Ann N Y Acad Sci* 71 170 1957
- 112 Rodrigues Munon de Oya *Rev Clin Esp* 66 303 1957
- 113 Root M A *Diabetes* 6 12 1957 a
- 114 Root M A *J Pharmacol* 119 468 1957 b
- 115 Root M A Anderson R C & Welles J S *Metabolism* 8 56, 1959
- 116 Root M A Sigal jr M V & Anderson R C *Diabetes* 8 7 1959
- 117 Saaman A A Fraser R & Dempster W J *Diabetes* 12 339 1963
- 118 Schambye P *Diabetes* 6 146 1957 (74 104)
- 119 Schambye P & Tarding F *Ann N Y Acad Sci* 74 557 1959
- 120 Searle G L Mortimore G E Buck lev R & Reilly W A *Trans Ass Amer Physicians* 71 236 1958
- 121 Searle G L Mortimore G E Buck lev R E & Reilly W A *Diabetes* 8 167 1959
- 122 Searle G L Palmer R D & Reilly W A *Metabolism* 9 88 1960
- 123 Selzer H E & Smith W L *Clin Res* 8 85, 1960
- 124 Sirek A Sirek O V Hanus, Y Monk house F C & Best C H *Diabetes* 8 284, 1959
- 125 Stewart G A *Ann Endocr (Par)* 18 230, 1957
- 126 Strauzenberg S E & Haller, H *Deutsch Med Wschr* 84 1097 1959
- 127 Tammya K & Kizima K *Arzneimittel forsch* 8 479 1958
- 128 Tizabi A & Seuss S Z *Ges Inn Med* 13 314, 1958
- 129 Tucker H A *Oral Antidiabetic Therapy 1956-65 with particular Reference to Tol butamide (Orinase)* Charles C Thomas Springfield Ill 1965
- 130 Vallance Owen J Joplin G F & Fraser, R *Lancet* II 384 1959
- 131 Vallance Owen J & Lilley, M D *Lancet* I 804, 1961 a
- 132 Vallance Owen J & Lilley M D *Lancet* I 806, 1961 b
- 133 Vaughan, M *Science* 123 885 1956
- 134 Volk B W Wessensfeldt S Lazarus S S & Goldner, M G *Metabolism* 5 894 1956
- 135 Wallenfels K Sund H & Burchard W *Biochem Zschr* 335 315 1962
- 136 Wildberger H L & Ricketts H T *Metabolism* 8 585 1959
- 137 Williams R H *Diabetes* 6 23, 1957
- 138 Wrenshall G A & Best C H *Canad Med Ass* 74 968 1956
- 139 Wrenshall G A & Hamilton J D *Ann N Y Acad Sci* 71 154 1957
- 140 Yalow R E Black H Willazon M B Berson S A *Diabetes* 9 356 1960

## THE IN VIVO REACTIONS OF THE SMALL BLOOD VESSELS TO DIABETES MELLITUS

by

*Jorn Ditzel*

Diabetes mellitus of long standing is characterized by clinical signs which can be attributed to a generalized degeneration of the small blood vessels. The histological changes in these lesions share certain similarities in various organs, characterized by endothelial proliferation, hyalinization and periodic acid Schiff (PAS) positivity. For many years the structural changes were thought to be limited to the renal glomerular and retinal capillaries, but it is now recognized that the lesions are much more widely distributed. The designation "diabetic microangiopathy" has gained acceptance for this distinctive systemic disease of the microvasculature.

Much has been learned from the morbid anatomy of this condition. However, if one accepts the development of diabetic microangiopathy as a slow chain of events from the earliest evidence of diabetes, further elucidation of this process is most likely to come from dynamic observations of the micro-vascular system at an early stage of the disease. Such detailed studies of the *in vivo* changes of the terminal blood vessels in diabetic subjects have recently been reported. Based particularly on biomicroscopic ob-

servations of the bulbar conjunctiva, it has been demonstrated that severe functional alterations of the vascular bed may be observed from the onset of diabetes and even in close relatives to diabetics (prediabetics?). These reversible changes appear to be precursors of the degenerative vascular changes, and observations indicate that similar reversible changes in other tissues participate in the mechanism of the development of the long term diabetic syndrome (21).

It is the purpose of this paper to review our present day knowledge of the *in vivo* reactions of the small blood vessels observed in particular detail in the conjunctiva of diabetic patients.

### EARLY STUDIES OF THE CONJUNCTIVAL VESSELS

*Historical aspect.* The conjunctival vessels in diabetics have been under scrutiny for many years. However, because many of the studies were performed with unacceptable methods, and the results presented in the form of vague statements without supporting objective clinical data, the significance of most of these investigations is difficult to assess. Hirsch-



berg (25) in 1890 was the first to refer to the conjunctival vessels in diabetics by his brief mentioning that conjunctival haemorrhages were more liable to occur in diabetic than in non diabetic persons. This observation has not been confirmed in later studies (43, 19) Streiff (40), Zeller (46), and Lohlein (35) all commented upon the presence of changes of a degenerative nature in the conjunctival vessels of patients with renal diseases, diabetes mellitus, rheumatoid arthritis, arteriosclerosis and anemia. Koby (30) mentioned that considerable dilatation of the conjunctival veins was frequently observed in diabetics.

*Do microaneurysms identical to those of the retina occur in the conjunctiva?*

It was, however, the discovery of the microaneurysms in the small retinal venous channels as an important feature of diabetic retinopathy (4) which first gave impetus to the study of the conjunctival vessels of diabetics. Friedenwald (22), using the corneal microscope, studied the conjunctival vessels *in vivo* in 60 patients with diabetic retinopathy. Only one "microaneurysm" was found in this series, and Friedenwald mentioned that similar aneurysm-like dilatations occasionally could be seen in non-diabetic subjects. In contrast to this result McCulloch & Pashby (36) claimed the occurrence of a high incidence of "aneurysms" analogous to the retinal microaneurysms in the conjunctival vessels of diabetics. In studying with the slit-lamp the conjunctival vessels of 100 elderly diabetics with and without diabetic retinopathy and 50 hospitalized

non diabetic patients, they recognized the incidence of "aneurysms" to be 55 per cent among the diabetics compared with 14 per cent among the non-diabetics. A higher incidence of "aneurysms" occurred in the diabetics with retinopathy (62 per cent) than in the diabetics with no retinopathy (48 per cent). The authors suggested that the "aneurysms" in the vessels of the conjunctiva were part of a generalized vascular disease, diabetes mellitus, affecting the retina, kidney glomeruli, and particularly the islets of Langerhans. Weinstein & Forgacs (45) briefly mentioned, without supporting data, that they were able to confirm the finding of McCulloch & Pashby. However, their presentation of microphotographs showed marked variation in shape of the conjunctival "aneurysms" over a short period of time, and thus presented a contrasting feature to the structural changes of the microaneurysms in the retina. Cook (8), using a slit lamp, studied *in vivo* the conjunctival vessel of 250 diabetics with and without retinopathy and 250 non-diabetic subjects of comparable ages. He found a slightly increased incidence of conjunctival "aneurysms" in the diabetic group (34.8 per cent) as compared with the control group (29 per cent). The difference between the two was not significant and the greater incidence in the diabetic subjects was ascribed to the greater incidence of hypertension in this group. However, the following considerations detract from the value of this investigation. The term "aneurysm" was not applied to capillary microaneurysms, but to fusiform, saccular and irregular dila-

tations of unspecified small vessels Cook's illustrations showed that these changes were observed in the pericorneal vessels. These vessels of the conjunctiva are a unique type, because they have to provide nutrition for the avascular cornea and are situated in that part of the conjunctiva which is constantly exposed to air and occasional trauma. One objection valid for all the studies of the conjunctival vessels of diabetics mentioned is that the subjects used were mainly elderly diabetics in whom changes in the vascular bed due to aging and hypertension are superimposed upon the possible diabetic vascular changes. It is well recognized that aneurysm like dilatations in the venules are manifestations of the aging process even in healthy subjects (42, 29). In reinvestigating the question as to whether capillary microaneurysms similar to those in the retina occur in the conjunctival vessels of diabetics, Ditzel & Duckers (15) examined 70 diabetic children and 70 healthy children. In this study a microaneurysm was defined as a globular capillary sacculaton with visible afferent and efferent vessels. Not a single case of such microaneurysms was found in either the diabetic or the non-diabetic group. In addition, in a study of 150 normotensive diabetics and 90 healthy subjects, evenly divided as to sex and with ages varying from 16 to 75 years, no specific conjunctival lesions analogous to those occurring in the diabetic retina could be found (11). Les tradet & Labram (33), by biomicroscopy, observed conjunctival aneurysms in only one case among one hundred young diabetics (1 per cent) and in 4 cases among 205 control subjects (2 per cent).

Davis & Landau (9) investigated the conjunctival vessels in 551 persons, consisting of 75 patients with diabetes, 145 with hypertension, 100 with arteriosclerosis and 161 with different chronic medical diseases and 65 healthy subjects. Aneurysms as defined by the work by Ditzel & Duckers (15) were found in 8 per cent among the diabetics and in 1 per cent among the non-diabetics, frequencies which do not differ significantly from each other. They noted also like Weinstein & Forgacs and Cook that the "aneurysms" changed in shape, and in this way they differed from the retinal aneurysms. Chazan et al (7) examined the bulbar conjunctiva for "micropools" in mothers who had given birth to babies weighing more than 4 kilos, 8 to 10 years prior to the study. They found a high incidence of micropools in younger women, but the micropools were found as commonly in mothers with normal glucose tolerance test as in mothers with diabetes.

*In summary.* There exists some controversy as to the presence and incidence of aneurysm like dilatation in the conjunctiva of diabetic subjects. The reason for this discrepancy undoubtedly stems from a lack of definition of what is considered an "aneurysm", in that some investigators under the designation aneurysms or micropools include the frequently occurring fusiform or sacular dilatation of small venules. It appears justifiable to conclude that in diabetics there are no changes in the conjunctiva analogous with the retinal microaneurysms. Since Ashton (1) pointed out the apparent absence of such microaneurysms in any tissue other than the

retina, it appears that the formation of retinal microaneurysms is related in some way to local factors, such as a high cellular metabolism in combination with the special capillary morphology, arrangement and high capillary pressure in the retinal tissue (12)

### THE CONJUNCTIVAL CHANGES AS PART OF THE DIABETIC MICROANGIOPATHY

Although no microaneurysms can be found in the bulbar conjunctiva, other changes of a reversible or irreversible nature have been described and may provide data applicable to the microangiopathy of diabetes

If the vascular changes in any tissue are to be accepted as a part of the diabetic microangiopathy they must satisfy the following requirements. Firstly, the changes must occur considerably more frequently in a group of diabetic patients than in an otherwise comparable group of non-diabetic subjects. Secondly, the incidence of the changes must increase with the duration of diabetes, and thirdly their incidence in the group must increase in diabetics with retinopathy and nephropathy. Do the conjunctival changes satisfy these requirements?

The individual features indicative of degenerative changes in the bulbar conjunctiva, such as arteriolar and venular irregularities, venular sacculations and hyaline infiltration occur more frequently in the diabetic than in the corresponding non-diabetic group (13-19). Besides this category of changes capillary elongation increased venular arteriolar diameter ratio (V/A ratio) and microscopic

oedema preponderated among the diabetics. The difference between the degree of conjunctival changes in diabetics and non-diabetics was highly significant, particularly in the younger age groups ( $p < 0.01$ ). Lestrade & Labram (33) confirmed this result in a study of the conjunctival vessels of 100 young diabetic subjects. In an analysis made on data obtained from examination of 70 diabetic children, Ditzel & Duckers (15) found a positive correlation between the degree of conjunctival change and the duration of the disease. This correlation was not influenced by either the sex or the age of the children. Jannert & Olbert (26), using a classification of the conjunctival vascular changes similar to that used by Ditzel & Sagild (11), studied 225 diabetics. When the material was subdivided into 156 patients with less than 8 years duration and 69 patients with more than 8 years duration of diabetes, they found that the incidence of more severe conjunctival changes was significantly greater in the patients with the longer duration. It was further shown that a significantly positive correlation existed between the changes in the conjunctival tissue and the presence of retinopathy. Ditzel (19) in a 'blind study' investigated the conjunctival changes in 60 younger diabetics with diabetic nephropathy or retinopathy or both, and in 35 diabetics of corresponding ages without late diabetic manifestations. The conjunctival changes were significantly more often of a severe degree among the group of patients with retinopathy or nephropathy than among diabetics without these late diabetic vascular manifestations. It was

demonstrated that the relation between the occurrence of conjunctival changes and nephropathy or retinopathy did not simply reflect a common dependence on the duration of diabetes.

In a few cases, Funahashi & Fink (23) have also shown histologically that the conjunctival changes may be associated with PAS positive thickenings of the capillary walls similar to the histological changes of small blood vessels elsewhere in the diabetic patient. Further histological studies of the conjunctival vessels in diabetes are badly needed.


*In summary* No degenerative lesions occur in the conjunctival tissue which are specific to diabetes. However, the difference between the incidence and distribution of conjunctival changes in diabetics and non-diabetics is marked, and particularly so in the younger age groups. The degree of conjunctival changes is positively correlated to increasing duration of diabetes and the presence of retinopathy and/or nephropathy. The conjunctival changes can therefore be considered a part of the diabetic microangiopathy.

#### FUNCTIONAL CHANGES IN THE CONJUNCTIVAL VESSELS

Ditzel & co-workers (15, 16, 17, 18), Bech et al (5), Lestrade & Labram (33), Rees et al (37) have all observed that besides morphologic changes, reversible alterations also take place in the conjunctival vessels of diabetic persons. The change most frequently observed was a reversible dilatation (loss of vascular tone) of the collecting- and post capillary venules. When the general di-

latation became marked, it extended into the venous part of the capillaries, and localized fusiform sacculations were formed in the collecting venules. There occurred some redistribution of flow from the "true capillaries to the arteriolar-venular shunts" (20). As the venules became engorged, evidence of microscopic oedema was observed (Vascular Pattern Change I) (Figure 1). Some diabetics, particularly cases with long duration of their disease or cases with nephropathy and hypertension, may demonstrate a characteristic avascular pattern (Vascular Pattern Change II) (15). In this group the arterioles are markedly constricted. Most true capillaries are closed and the tissue is ischemic. The direct arteriolar-venular communications (shunt vessels) remain open, and become a dominant feature of the vascular topography (Figure 2). The rate of blood flow is considerably decreased, including that in the arterioles, and pronounced erythrocyte aggregation is usually present. The most harmful effect of the loss of venular tone is a decrease in the linear rate of blood flow through the microvasculature and pathological permeability. The continuous seepage of plasma components through endothelium leads to oedema and over a prolonged time to hyaline mucoid changes in the tissue (15, 16). The most harmful consequence of the prolonged constriction of arterioles and capillaries and shunting of blood would be prolonged hypoxia and subnutrition.

If the observed pathophysiological pattern deviations are to be considered a part of the diabetic microangiopathy (a *functional microangiopathy*), they must



*Fig 1*

The reversibility of venular dilatation(s) and congestion (Vascular Pattern Change I) in a juvenile diabetic subject (Magnification approx  $60\times$ )




Fig 2

The conjunctival vascular bed showing Vascular Pattern Change II in a young diabetic subject. Note the ischemia of the tissue (arteriole  $a$  venule  $v$ ). Most of the true capillaries ( $c$ ) are closed but the arteriolar-venular communications are open ( $pc$ ). (Magnification approx 70  $\times$ )

also satisfy the following requirements

1) The pattern changes must occur considerably more frequently in a group of diabetic patients than in an otherwise comparable group. 2) Their incidence in the group must increase with the duration of diabetes. 3) Their incidence in the group must increase in diabetics with retinopathy and nephropathy. All these three requirements have been shown to be fulfilled for the pathophysiological response changes (15, 17). Figure 3 indicates the incidence of Vascular Pattern Change I in various groups of diabetic and non-diabetic subjects. The venular dilatation was present in 2 per cent of the healthy children as opposed to

47 per cent of 70 diabetic children. Vascular Pattern Change I could be seen even in young diabetics whose disease was of recent onset. In a selected group of 75 supposedly normal children of juvenile diabetic mothers in whom an oral glucose tolerance test (GTT) was made independently of the study of the small blood vessels, venular dilatation was observed in 65 per cent of those with abnormal GTT (chemical diabetes), as opposed to 29 per cent (16 cases) of the children with normal GTT (10). Of even more interest was the finding that among the 16 cases with normal GTT, all of whom showed Vascular Pattern Change I, 3 developed overt diabetes.




Fig 3

Incidence of venular dilatation (Vascular Pattern Change I) in the bulbar conjunctiva in different groups of individuals (see text)

and one showed a border-line diabetic GTT when reexamined 3 years later

14 More recently, Camerini-Davalos et al (16) in a study of subjects with a history of diabetes in both parents or who were identical twins of diabetic patients found that the mean widest V/A ratio in 92 per cent of these subjects (prediabetics) showed values above

2.81 which is the mean of the normals  $\pm 2$  SD. Rees & co-workers (37) demonstrated the reversibility of the venular dilatation in the conjunctiva of young newly discovered diabetics after insulin and dietary treatment had started. In cases of short term diabetes, fluctuations in the venular dilatation might occur over the day but the venular anomaly tended to become fixed in the majority

of diabetics with a duration of 15 years or more (18). The presence of conjunctival venular dilatation in diabetics, measured by different methods, has been confirmed by Bech et al (5), Lestrade & Labram (33) and Landau & Davis (31). Ditzel & Duckers (15) demonstrated a significant association between the presence of dilated venules and microscopic oedema of the conjunctival tissue, indicating an abnormal permeability through these small vessels even in juvenile diabetics early during the disease. In studying 70 unselected diabetic children, divided into two groups according to the duration of diabetes, Ditzel & Duckers (15) found that Vascular Pattern Change I occurred more frequently among those with a longer du

ration of diabetes, and the presence of abnormal vascular patterns was related significantly to the duration of diabetes ( $p < 0.01$ ) Ditzel, Sargeant & Hadley (17) evaluated the incidence of abnormal vascular patterns in 60 young diabetics showing retinopathy and/or nephropathy and in 69 diabetics without such complications (Table 1) Abnormal vascular patterns were found significantly more frequently among the diabetics with retinopathy and/or nephropathy (83 per cent) than among diabetics without such lesions (51 per cent) In general, among the 60 young diabetics with vascular complications, those who showed Normal Vascular Pattern demonstrated only minimal vascular disease as compared to those diabetics who showed Vascular Pattern-Changes I and II Even though the duration of diabetes was comparable in the groups under investigation, the diabetics who exhibited Normal Vascular Pattern appeared to have a much better prognosis with respect to the rate of development of their vascular disease than the young diabetics demonstrating Vascular Pattern Change II

*In summary* Severe functional vascu-

lar changes have been demonstrated in the microvasculature of the conjunctiva in diabetics, leading to an impairment and a redistribution of flow in the microcirculation Vascular Pattern-Change I, commonly found in young diabetics, is characterized by a loss of tone of the venules and the venous part of the capillaries associated with exudation Vascular Pattern Change II, occasionally observed in long term diabetics, is characterized by marked arteriolar constriction and capillary closure Vascular Pattern Changes I and II are significantly related to the presence of microscopic conjunctival exudation The incidence of Vascular Pattern-Changes I and II increased significantly with the duration of diabetes, but Vascular Pattern Change I occurred even in diabetics with a short duration of their disease The degree of venular dilatation tended to reverse as dietary intake and insulin effect improved the metabolic disturbance Young diabetics with long term diabetic microangiopathy showed a significantly more severe vascular pattern abnormality than those diabetics not showing retinopathy and/or nephropathy These correlations support the supposition that the func-

TABLE 1

*Abnormal Vascular Responses in Young Diabetics With Retinopathy and/or Nephropathy and in Young Diabetics Without Such Lesions*

	60 Young Diabetics With Clinical Microangiopathy	69 Young Diabetics Without Clinical Microangiopathy
Normal Vascular Pattern	17 %	49 %
Vascular Pattern Change I	63 %	48 %
Vascular Pattern Change II	20 % } 83 %	3 % } 51 %



nal changes are a part of the diabetic microangiopathy (a *functional microangiopathy*)

### COMPARISON OF MICROVASCULAR CHANGES IN THE CONJUNCTIVA WITH THOSE IN OTHER VASCULAR BEDS

*Skin* As the conjunctiva and the subcutaneous tissue are anatomically and embryologically related, and their blood vessels react similarly to vasomotor drugs (38-27), it is of interest to compare the functional, vascular changes in the conjunctiva with those found in other surface areas of diabetics.

It is well known that many diabetics have flushed faces (rubeosis). Skin colour, in general, is mainly determined by the amount of colour transmitted through the skin from the venous plexus situated in the corium. Weil (44) studied the mucosa of the cheek and the capillaries of the fingernail bed in a number of diabetic patients. He found in both surface areas that the venous part of the capillaries and particularly the venules in approximately 50 per cent of the diabetics were considerably dilated. He contended that this was caused by a loss of tone. Modern monographs on diabetes usually pay little attention to the clinical sign of rubeosis, possibly because its assessment is difficult in many cases. However, it should be noted that Lundbäck (34) found this phenomenon in as high as 47 per cent of 163 long-term diabetics. More recently Gnielso & Wertheimer-Kapinski (24) found that rubeosis may not even be related to overt diabetes, as a high incidence was found in

latent diabetes. A deliberate search for diabetes among 150 patients with "red faces" revealed 39 new cases, mainly of latent diabetes. In another recent study Landau & Davis (31) found changes characterized by a dilatation of the venous part of the capillaries in the nail-bed in 49 per cent of 75 diabetics, but only in 10 per cent of 65 control subjects.

*Retina* Since the changes in the retina are the first decisive sign of the long-term diabetic sequelae, it is of interest to examine whether microvascular alterations similar to those directly observed in the conjunctiva occur in the retina of patients with diabetes. Due to technicalities, however, such a direct comparison is not possible. The ophthalmoscope affords much less magnification than the device applied to the conjunctival microcirculation. Therefore, caliber changes in the terminal arterioles, the capillaries and smaller venules cannot be disclosed in the retina. Only when the changes involve the small veins can these be observed with the ophthalmoscope. However, when the retinal veins are studied, it would appear that there are striking similarities between the pattern of changes occurring in the conjunctiva and in the retina. Larsen (32) studied diabetics serially with the modern retina camera and reported that fullness or dilatation of the retinal veins might be observed, even from the onset of diabetes. During the first years of the disease the fullness and dilatation of the retinal veins were reversible, but later on venous dilatation was prone to be more permanent. The reversibility of the dilatation of the retinal veins appeared to be related to the degree of regulation of the metabolic

disturbance. More recently Jutte (28) carefully measured the retinal veins by the method of Lobeck and found that the retinal veins were dilated in 43 per cent of 100 juvenile diabetics. The dilatation increased with the duration of diabetes during the first 10 years. An increase in vein diameter occurred during periods of poor regulation, but was reversible with correction of the diabetic metabolic disturbance. In many juvenile diabetics, Jutte as well as Thiel (41) observed that the dilatation extended into the small venules and "capillaries" (rubeosis retinae). Because of the reversibility of the changes in cases of short-term diabetes, Jutte considered the dilatation a functional change. He suggested that the capillary venous dilatation was produced by some alteration in the metabolism of the retinal tissue and that the dilatation on the venous side of the microcirculation caused prolonged venous stasis. It is well known that the formation of capillary microaneurysms is not absolutely specific to diabetes, but has been clinically and histologically demonstrated in a variety of non-diabetic clinical disorders associated with prolonged retinal venous stasis. This indicates that the aneurysms may be related to factors common to many diseases which are present to a particular degree in the diabetic state (20, 2, 3). Skovborg et al. (39) have reported on a comparative study of vessel diameters in the retina, measured from the negative of retinal photographs of 492 juvenile diabetic and healthy subjects. The preliminary results of this large scale study indicate that a venous dilatation occurs prior to any other retinal change and

that the increase in venous diameter is significantly correlated to the duration of diabetes. The results thus support and extend the finding by Jutte. There is also evidence of a functional disorder of the glomerular capillaries in young diabetics early during their disease, as indicated by increased glomerular filtration rates. These studies have been surveyed in another publication (21).

### CONCLUSION

Direct *in vivo* observations of the reactions of the small blood vessels in the bulbar conjunctiva, skin, and retina of diabetic patients demonstrate severe functional changes in the microvasculature early during the course of their disease and prior to any signs of the clinical microangiopathy. The common features of these functional changes are a loss of normal vascular tone and increased permeability. This functional microangiopathy is intimately related to the development of the clinical, degenerative microangiopathy. It is therefore suggested that the functional changes are precursors of the degenerative vascular changes and participate in the mechanism of the development of the long term diabetic syndrome.

### REFERENCES

- 1 Ashton N. *Brit J Ophth* 33 407 1949
- 2 Ashton N. *Brit J Ophth* 35 189 1951
- 3 Ashton N. Diabetic retinopathy in disorders of carbohydrate metabolism. Ed A Pyke. Pitman Medical Publishing Co Ltd 1962 p 195
- 4 Ballantyne, A J & Loewenstein A. *Brit J Ophth* 28 593 1944

- 5 Bech H., Hansen E. Lorentzen, S. E. & Lundbæk H. *Diabetes* 9 441 1960
- 6 Camerini Davalos R. A. Caulfield J. B. Rees S. B. Lozano-Castaneda O. Valdivia S. & Marble A. *Diabetes* 12 508, 1963
- 7 Chazan H. I., Eliahar Y. Brzezinski A. & Davis E. *Diabetes* 13 291 1964
- 8 Cook C. A. G. *III Int. Cong. Ophth. Acta Canada USA* 3 1878 1954
- 9 Davis E. & Landau J. *Harefuah (J Med Ass Israel)* 54 169 1960
- 10 Ditzel J. White P. & Duckers J. *Diabetes* 3 99 1954
- 11 Ditzel J. & Sagild L. *New Engl J Med* 250 587 1954
- 12 Ditzel J. & White P. *J Chron Dis* 3 253 1956
- 13 Ditzel J. *Circulation* 14 386 1956
- 14 Ditzel J. White P. & Sargeant, L. *Acta Genet* 7 101 1957
- 15 Ditzel J. & Duckers J. *Acta paed* 46 535 1957
- 16 Ditzel J. & Moinat P. *Diabetes* 6 307 1957
- 17 Ditzel J. Sargeant, L. & Hadley W. B. *Arch Int Med* 101 912 1958
- 18 Ditzel J. Beaven D. & Renold A. E. *Metabolism* 9 400 1960
- 19 Ditzel J. The conjunctival vessels in diabetes mellitus Copenhagen Munksgaard 1962
- 20 Ditzel J. *Brit J Ophth* (in press)
- 21 Ditzel J. Functional microangiopathy preceding the clinical microangiopathy in diabetes mellitus. Submitted for publication.
- 22 Friedenwald J. S. *Am J Ophth* 33 1187 1950
- 23 Funahashi T. & Fink, A. I. *Am J Ophth* 55 504 1963
- 24 Citelson S. & Wertheimer Kaplinski N. *Diabetes* 14 201 1965
- 25 Hirschberg J. *Dtsch Med Wschr* 16 1181 1940
- 26 Janetzki H. & Oberst F. R. Bericht 59 Zusammenk. Deutsche Ophth. Gesellschaft. Heidelberg 1955 p 35
- 27 Jeffords J. V. & Stalworth J. M. *Angiology* 7 445 1956
- 28 Jutte A. Über die Erweiterung des Netzhautnerven bei jugendlichen Diabetikern. In *Diabetische Angiopathie* (editor G. Mohrnick. Akademie Verlag Berlin) 1964
- 29 Knusel W. *J Geront* 12 429, 1957
- 30 Koby A. Slit lamp microscopy of the living eye 2nd edition London 1930, p 87
- 31 Landau J. & Davis E. *Lancet* II 731, 1960
- 32 Larsen H. W. Diabetic retinopathy Copenhagen Steno Memorial Hospital press 1960
- 33 Lestrade H. & Labram C. *Presse Medicale* 68 107 1960
- 34 Lundbæk H. Long term Diabetes Ophthalmological section in collaboration with V. A. Jensen Copenhagen Munksgaard 1953
- 35 Löhlein W. Handbuch der speziellen pathologischen Anatomie Elfter Band, 1928
- 36 McCulloch C. & Pashby, T. J. *Brit J Ophth* 34 495 1950
- 37 Rees S. B. Camerini Davalos R. A. Caulfield J. B. Lozano-Castaneda O. Cervantes-Amezquita A. Taton J. Pometta D. Krauthammer J. P. & Marble A. Pathophysiology of microangiopathy in diabetes mellitus in Ciba Foundation Colloquia on Endocrinology vol. 15 Churchill Ltd London 1964
- 38 Robertson H. S. Wolf H. G. *Am J Med Sci* 219 534 1950
- 39 Skovborg F. Ditzel J. Lauritzen E. Nielsen, Aa. V. *Diabetologia* 1 135 1965
- 40 Streiff J. *Klin Mbl Augenheilk* 53 395 1914
- 41 Thiel R. Der Diabetes Mellitus ein Gefäßproblem? *Klin Mbl Augenheilk* Beiheft 25 1956
- 42 Vogt A. Lehrbuch und Atlas der Spaltlampenmikroskopie des lebenden Auges 3. Enke Stuttgart 1941 II 142
- 43 Waite J. H. & Beetham, W. P. *New Engl J Med* 212 367 1935
- 44 Weil A. J. *Klin Wschr* 3 209 1924
- 45 Weinstein P. & Forgacs J. *Brit J Ophth* 35 479 1951
- 46 Zeller K. *Klin Mbl Augenheilk* 66 609 1921

## CAPILLARY DIFFUSION CAPACITY FOR SODIUM IN SKELETAL MUSCLE IN LONG-TERM JUVENILE DIABETES MELLITUS

by

*Jens Trap Jensen, Joseph S Alpert, Garcia del Rio and  
Niels A Lassen*

Characteristic vascular lesions have been described in a number of tissues in patients with juvenile diabetes mellitus. These lesions could in many cases be correlated with the clinical signs of long-term diabetes and it appears that the vascular lesions constitute a morphological basis for the long term diabetic syndrome. The most specific vascular lesion is capillary microangiopathy. The initial morphological changes consist of thickening of the basement membrane and periendothelial deposition of PAS positive material. Goldenberg et al (4) first described this microangiopathy in skeletal muscle capillaries. This observation was confirmed by Pedersen and Olsen (16) in a material of skin and muscle biopsies. They pointed out that the lesions were diffuse but arranged segmentally. Electron microscopic studies of muscle capillaries (2, 5, 26) have shown the occurrence of patchy thickening of the basement membrane often with vacuolised rarefactions. Although much attention has been paid to the morphological changes in

diabetic microangiopathy, very little is known concerning the physiological behaviour of these thickened capillary basement membranes.

Ismail et al (7) observed reduced permeability to albumin in patients with diabetes in a study of transcapillary protein diffusion. Rossing (20), however, was unable to confirm this observation. Decreased water filtration in diabetic pregnant women was described by Spetz (23) who measured the capillary filtration rate for water by plethysmography on the forearm.

This investigation presents evidence of increased capillary permeability for the sodium ion in skeletal muscle of patients with long term juvenile diabetes. This evidence was obtained using the  $^{24}\text{Na}$  and  $^{133}\text{Xe}$  local clearance techniques (10, 11) in patients with clinical signs of diabetic angiopathy.

### MATERIAL AND METHODS

Thirteen non-diabetic subjects (3 females and 10 males) ages 21-40 years

(mean 29.1 years) were studied as one control group. These subjects had neither family histories of diabetes mellitus, nor evidence of glucose in the urine, nor any symptoms of arterial disease in the lower extremities at the time of the examination.

Seven patients (3 females and 4 males) with recently-diagnosed juvenile diabetes mellitus, ages 16-25 years (mean 19.3 years) with symptoms of the disease during not more than three years (mean duration 1.9 years) were studied as a second control group. All patients were treated with insulin and none had ketosis, clinical signs of diabetic angiopathy or disorders affecting the cardiovascular system at the time of the examination.

Twenty-five patients (12 females and 13 males) ages 17-45 years (mean 31.6 years) with juvenile diabetes mellitus diagnosed before the age of 20 years, of long duration (10-37 years, mean 24.0 years) constituted the long-term diabetic group. All patients were treated with insulin and none had ketosis at the time of the examination. Normal peripheral pulses were present in the lower extremities in all cases. All patients had diabetic retinopathy as evaluated in table 1. Thirteen patients had nephropathy, the diagnosis of which was based on the simultaneous presence of a raised serum creatinine level and proteinuria. Seventeen patients had neuropathy, the diagnosis of which was based on the presence of symptoms and signs of altered sensibility and abolished tendon reflexes in the lower extremities.

A normal maximum blood flow in hyperemic skeletal muscle is the basis

for the calculation of the capillary diffusion capacity for sodium as mentioned below (11). In routine clinical evaluations done in this laboratory maximum  $^{133}\text{Xe}$  clearance values in the anterior tibial muscle greater than 35.0 ml/100 g/min indicate a normal maximum blood flow in that muscle. Therefore all diabetic patients included in this study were selected to have a maximum  $^{133}\text{Xe}$ -clearance value equal to or greater than 35.0 ml/100 g/min \*).

### Methods

One tenth ml of normal saline containing 50  $\mu\text{C}$  of  $^{133}\text{Xe}$  in solution and 20  $\mu\text{C}$  of  $^{24}\text{Na}$  was injected into the thickest part of the tibialis anterior muscle. In one group the two isotope solutions were mixed prior to injection, i.e., the two clearances were measured simultaneously. In a second group the  $^{133}\text{Xe}$  clearance was measured first, followed immediately by a measurement of the  $^{24}\text{Na}$  clearance. Details regarding the mode of injection have been given elsewhere (11).

The local clearances of  $^{133}\text{Xe}$  and  $^{24}\text{Na}$  were followed by scintillation detectors coupled to pulse height analyzers and ratemeters with time constants of approximately five seconds. Direct writing logarithmic potentiometers were used. In all clearance studies two 51 mm

\*). This series comprises patients from Dispebjerg Hospital, Medical Department II, Statens Blindemuseum, Hvidovre Hospital and Sørensen Memorial Hospital, Copenhagen. The authors wish to express their gratitude to the chief physicians of the above mentioned institutions for allowing us to examine their patients.

Mean  $m$  clearance rates for  $^{23}\text{Na}$  and  $^{24}\text{Na}$  capillary diffusion capacity for sodium and time  
from cuff release to maximum  $^{23}\text{Na}$  clearance in 25 long standing dialyses

Case No.	Sex	Age (yr)	Duration of Dialysis (hr)	Dialysis Compartment		Maximal clearance rates ml/(kg min)		Capillary flow ml/min	T to max clearance in min
				R (no-poly)	N (no-poly)	$^{23}\text{Na}$	$^{24}\text{Na}$		
1	F	45	35	++	+	35.2	14.6	11.1	0.18
2	F	30	29	++	+	79.0	14.0	9.4	0.16
3	F	33	29	++	+	44.0	11.6	10.5	0.30
4	M	25	19	++	+	67.0	17.4	12.0	0.20
5	M	45	25	++	+	37.2	16.1	12.4	0.13
6	F	31	30	++	+	80.0	13.3	8.7	0.10
7	M	17	10	+	0	44.4	14.4	10.3	0.20
8	F	27	12	+	0	42.0	15.2	11.1	0.26
9	F	37	28	++	0	43.0	8.8	5.8	0.32
10	M	31	30	++	+	35.9	13.2	9.8	0.08
11	M	25	23	++	+	84.0	16.1	10.6	0.12
12	F	43	31	++	0	47.2	16.8	12.3	0.10
13	M	33	22	++	+	42.0	13.1	9.4	0.10
14	F	38	29	++	0	13.0	9.0	6.0	0.28
15	M	26	24	++	+	85.0	11.0	9.2	0.10
16	M	25	19	+	0	51.0	12.1	8.8	0.12
17	M	39	36	+	0	47.2	10.7	7.2	0.28
18	F	33	16	+	0	44.3	11.1	7.7	0.08
19	M	35	17	++	+	36.0	11.0	10.5	0.08
20	F	20	17	+	0	18.0	11.0	9.9	0.10
21	M	37	29	++	0	52.0	10.5	7.0	0.31
22	M	31	19	++	0	16.0	7.0	1.6	0.60
23	M	20	16	++	0	75.0	8.9	5.3	0.50
24	F	42	37	++	+	48.0	12.3	8.5	0.10
25	F	22	12	+	0	47.2	12.1	8.6	0.08
Mean		31.6	21.0			52.2	12.9	11.1	0.20
SD		8.0				15.9	2.7	2.2	0.15

The clearance of  $^{23}\text{Na}$  and  $^{24}\text{Na}$  is given as a percentage of the maximal clearance of  $^{23}\text{Na}$  in the dialysis compartment. The clearance of  $^{24}\text{Na}$  is given as a percentage of the clearance of  $^{23}\text{Na}$  in the dialysis compartment.

thick crystals (one for each leg) were used for the  $^{24}\text{Na}$  high energy gamma ray detection whereas two 3 mm thick crystals were employed to measure the  $^{133}\text{Xe}$  low energy gamma rays

Initial counting rates averaged approximately 5,000 cps for  $^{133}\text{Xe}$  and approximately 1,000 cps for  $^{24}\text{Na}$ . In the simultaneously measured clearance curves a ca 10 per cent correction for the  $^{24}\text{Na}$  gamma rays detected by the  $^{133}\text{Xe}$  channel was applied. In the independent clearance studies no cross-over occurred since the sodium channel was completely insensitive to the  $^{133}\text{Xe}$  gamma emissions.

All patients were studied while lying on their backs with their legs suspended in a fixed position relative to the crystals. After the injection of the isotope solution, and after a short rest period, a cuff placed just above the knee was suddenly inflated to a pressure of 250–300 mm Hg.

During the induced ischemia the patients moved the ankle joint by doing full force dorsiflexion/plantarflexion movements. After ca 80–100 movements further exercise was impossible because of pain and muscle fatigue. At this point, after 2–5 minutes of ischemia, the cuff's pressure was abruptly released and during the subsequent period of reactive hyperemia the isotope clearance was followed for approximately 5 minutes.

Total radiation dosage to the gonads from  $^{24}\text{Na}$  is approximately 80 mrad. Radiation dosage from  $^{133}\text{Xe}$  is negligible (12).

### Calculations

#### The clearance rates

For both tracers the rate of decrease of the concentration per gram of tissue,  $dC/dt = C'$ , can be expressed by applying the Fick principle to 100 g of muscle

$$100 C' = -f C_v \quad (1)$$

where  $f$  is the blood flow in millilitres per 100 g per minute in the injected area and  $C_v$  the corresponding venous concentration. This equation does not contain on its right hand side a term for the rate of supply ( $f C_a$ ) since recirculation is negligible.

The clearance rate,  $Cl$ , in milliliters per 100 g per minute, is defined according to Renkin (17, 18, 19) in analogy with the clearance concept in kidney physiology.  $Cl$  is that imaginary volume of blood in ml/100 g/min that would have contained the amount of tracer leaving 100 g of tissue ( $f C_v$ ) if complete diffusion equilibrium had occurred. At equilibrium  $C_{v\text{equil}} = C/\lambda$  where  $\lambda$  is the tissue-blood partition coefficient, i.e.  $\lambda = (C/C_v)_{\text{equil}}$ . According to these definitions,

$$f C_v = Cl C_{v\text{equil}} = Cl C/\lambda$$

Inserting this in equation (1) one obtains  $Cl = 100 \lambda (-C'/C)$  ml of blood/100 g/min. (2)  $\lambda_{Na}$  equals about 0.5 ml/g as it is given by the ratio of the tissue sodium concentration, ca 40  $\mu\text{Eq/g}$  to that of whole blood, ca 80  $\mu\text{Eq/g}$ . (11)  $\lambda_{Xe}$  equals about 0.7 ml/g in blood of normal hemoglobin concentration (3).

$-C'/C$  is the relative rate of decrease of tissue isotope concentration which can be expressed

$-C'/C = -d \ln C/dt = \ln (10) (-d \log C/dt)$ , i.e.  $-C'/C$  equals the natural logarithm of 10 (2.30) times the slope of the logarithmically recorded curve, this slope being measured in fractions of one decade (see fig. 1)

#### Time from cuff release to maximum $^{133}\text{Xe}$ clearance

As shown in fig. 1 time to maximum  $^{133}\text{Xe}$  clearance was read directly in

minutes from the time of cuff release to the beginning of the steepest rectilinear part of the  $^{133}\text{Xe}$  clearance curve

#### Capillary diffusion capacity for sodium

According to Renkin (17, 18, 19) the capillary diffusion capacity for sodium ( $\text{CDC}_{\text{Na}}$ ) is defined as the uni-directional flux of the sodium ion from the tissue into the capillary lumen. It is expressed in the unit, milliliters of plasma per 100 g skeletal muscle per minute, i.e. it corresponds to the amount

### Sodium-24 and Xenon-133 clearance curves in a healthy subject obtained by means of a logarithmic potentiometer




Fig. 1

The graph indicates a period of cuff obstructed blood flow in the leg during which muscular work is carried out for two minutes. The slope  $D_1$  after release of cuff pressure is 8 per cent of one decade on the logarithmic potentiometer. Maximal  $^{24}\text{Na}$  clearance is consequently  $115.008 = 9.2$  ml per 100 g per min. The maximum slope  $D_2$  is 32 per cent of one decade and consequently maximal  $^{133}\text{Xe}$  clearance is  $161.032 = 51.5$  ml per 100 g per min. Maximum reactive hyperemia sets in 0.40 min after release of cuff pressure.



of sodium contained in this volume of plasma. The  $CDC_{Na}$  can be estimated in hyperemic skeletal muscle, where the back diffusion of sodium is small (14). In fact at infinitely high blood flow the capillary concentration of  $^{24}Na$  would remain zero and hence the plasma clearance of sodium would be equal to  $CDC_{Na}$ .

$$CDC_{Na} = (1-Ht) Cl_{Na} \text{ ml of plasma/} \\ 100 \text{ g muscle/min (3)}$$

According to the above considerations only one value of  $Cl_{Na}$  was calculated from the recorded curve, viz., the value obtained during the period of maximum reactive hyperemia. The time interval during which maximum muscle blood flow prevailed was read from the steepest rectilinear part of the  $^{133}Xe$  clearance curve. This period usually lasted from 0.5 to 1.5 min. after release of the femoral cuff, and typically the sodium clearance curve was also practically linear during this interval. In all cases the curve was therefore approximated by a straight line (see fig. 1).

As  $CDC_{Na}$  is the unidirectional flux of  $^{24}Na$ , a correction is made for the back diffusion of  $^{24}Na$  from the capillary blood. The back diffusion is proportional to the mean capillary concentration of  $^{24}Na$  which under the special conditions studied (viz. of fairly incomplete exchange) can be taken to be approximately half of the end capillary concentration of  $^{24}Na$ . On this basis it can be shown (13) that if the local blood flow is given by the simultaneous  $Cl_{Na}$  then

$$CDC_{Na} = \\ (1-Ht) Cl_{Na} \frac{1}{1-1/2 Cl_{Na}/Cl_{Xe}} \\ \text{ml/100 g/min}$$

where  $Ht$  is the hematocrit of the blood. The capillary diffusion capacity as here calculated is expressed in terms of the number of milliliters of plasma whose sodium passes unidirectionally across the capillary membrane in 100 grams of muscle during one minute.

## RESULTS

All values reported for maximum clearance rates of  $^{133}Xe$  and  $^{24}Na$ , the  $CDC_{Na}$  and the time from cuff release to maximum  $^{133}Xe$  clearance are averages of the two values obtained independently from each leg.

### *$^{133}Xe$ clearance*

The maximum blood flow in the anterior tibial muscle during reactive hyperemia after ischemia and exercise, as judged by the mean maximum  $^{133}Xe$  clearance, did not differ significantly within the three groups studied here.

As shown in table 2 no statistically significant difference in the mean time from cuff release to maximum  $^{133}Xe$  clearance was observed between non-diabetics (0.38 min) and recently-diagnosed diabetics (0.34 min). In contrast a highly significant reduction to 0.20 minutes was observed in this variable in the long standing diabetic group. The mean time to maximum  $^{133}Xe$  clearance did not differ significantly be-

TABLE 2

1. A comparison of the results for the two groups of subjects, namely, the control group and the group with a recent diagnosis of diabetes mellitus, in terms of the capillary diffusion capacity for sodium.

Case no.	Age (yr)	Duration of diabetes (yr)	Mean value		Capillary diffusion capacity (ml/min/100 g)	Time of examination
			Na	Cl		
Long standing diabetes	31.6 SD 8.0	24.0	52.2 SD 15.9	12.9 SD 2.7	9.1 SD 2.2	0.70 SD 0.15
Recently diagnosed diabetes	19.3 SD 2.0	1.9	60.5 SD 10.4	8.0 SD 1.3	5.2 SD 0.85	0.34 SD 0.12
Non-diabetics	29.1 SD 6.5		55.6 SD 9.6	9.9 SD 1.0	6.6 SD 0.80	0.38 SD 0.10
Statistical Analysis						
Long standing diabetes vs. non-diabetics			n.s.	$P < 0.001$	$P < 0.001$	$P < 0.001$
Long standing diabetes vs. recently diagnosed diabetes			n.s.	$P < 0.001$	$P < 0.001$	$P < 0.001$
Recently diagnosed diabetes vs. non-diabetics			n.s.	$P < 0.002$	$P < 0.002$	n.s.

n.s. = not significant.

tween various subgroups of the patients with long standing diabetes. Parameters according to which these subgroups were selected included age, sex, duration of diabetes and severity of diabetic complications (retinopathy, nephropathy and neuropathy). It is of special interest (see discussion) that no significant difference ( $p > 0.5$ ) was observed in the average time to maximum  $^{133}\text{Xe}$  clearance between seventeen long standing diabetic patients with diabetic neuropathy (0.18 (S.D. 0.17) minutes) and eight patients without this complication (0.26 (S.D. 0.22) minutes).

#### *$^{24}\text{Na}$ clearance*

The mean clearance rates for  $^{24}\text{Na}$  differed highly significantly between non diabetics (9.9 ml/100 g/min) and recently-diagnosed juvenile diabetics (8.0 ml/100 g/min) on the one hand and juvenile diabetics of long standing (12.9 ml/100 g/min) on the other hand. The relatively small, uniform group of patients with recently-diagnosed diabetes had a significantly lower ( $p < 0.005$ ) mean age as well as significantly lower mean  $^{24}\text{Na}$  clearance compared to the non diabetic group. Subgroups of the patients with long standing diabetes did not differ significantly with respect to mean clearance rates for  $^{24}\text{Na}$ .

#### *Capillary diffusion capacity for sodium*

As shown in table 2 and fig. 2 mean  $\text{CDC}_{\text{Na}}$  differed highly significantly between non diabetics (6.6 ml/100 g/min) and recently diagnosed diabetics (5.2

ml/100 g/min) as opposed to juvenile diabetics of long standing (9.1 ml/100 g/min). The mean  $\text{CDC}_{\text{Na}}$  value in the group of patients with recently diagnosed diabetes was found to be significantly lower than in the group of non diabetic patients. No significant difference was found between subgroups of the long-standing diabetic patients (see above).

## DISCUSSION

An important factor in capillary exchange is the permeability of the capillary membrane, the diffusion capacity of which is known to be strikingly different for different substances. Renkin (17, 18, 19) found that potassium and rubidium encounter a distinct resistance to transcapillary diffusion in hyperemic skeletal muscle. Nevertheless cations diffuse far more rapidly across the capillary membrane than proteins, the exchange of which is very slow and probably occurs through sparsely distributed large pores (9). On the other hand, the transcapillary filtration rate for water vastly exceeds the diffusion rate for cations.

#### *Transcapillary diffusion of sodium in diabetics*

Following Renkin (17, 18, 19) the capillary blood flow in hyperemic skeletal muscle is so rapid that the clearance rate of intramuscularly injected  $^{24}\text{Na}$  represents a measure of the unidirectional sodium flux from tissue to capillary blood. Thus unidirectional sodium flux is here expressed as  $\text{CDC}_{\text{Na}}$ .

and is given in milliliters of plasma per 100 g skeletal muscle per minute, i.e. the flux of sodium equals the amount of sodium (in mEq) in a given plasma volume

The  $CDC_{Na}$  values within the long-standing diabetic group exhibit great variance with some values overlapping into the range of the non diabetic group. In this connection it is of interest that

the histological studies of skeletal muscle mentioned in the introduction also reported that some patients with clinical signs of severe diabetic complications lacked the characteristic morphological changes of diabetic microangiopathy (2, 16, 26)

We have not been able to find reports of the morphology of skeletal muscle capillaries in recently diagnosed juvenile




Fig 2

Comparison of capillary diffusion capacity for sodium in non diabetics, recently diagnosed diabetics and in diabetics of long duration  
 observations ● mean value — and SD (hatched)

Maximum reactive hyperemia sets in more quickly in the long term diabetics than in the non diabetics or in the recently diagnosed diabetics who not differ significantly. It is suggested that this finding is also due to the diabetic microangiopathy present in the patients with long term diabetes.

# ACKNOWLEDGEMENT

Supported by a grant from King Christian X Foundation

# REFERENCES

- 1 Angenæs O & Moe H *Diabetes* 10 253 1961
- 2 Bencosme S A West R O Kerr J W & Wilson D L *Amer J Med* 40 67 1966
- 3 Conn H L Jr *J Appl Physiol* 16 1065 1961
- 4 Goldenberg, S Alex M Joshi R A & Blumenthal, H T *Diabetes* 8 261 1959
- 5 Holte G *Arch Klin Chir* 295 253 1960
- 6 Honey G E Pryse Davies J & Roberts D M *Quart J Med* 31 473 1962
- 7 Ismail A A Khalifa K & Madwar, K R *Lancet* ii 810 1965
- 8 Karlfors T *Thesis Tryckab Halmstad* Sweden 1966
- 9 Landis E M & Pappenheimer J R *Hand book of Physiology* II 961 1963
- 10 Lassen N A Lindbjerg I F & Munck O *Lancet* I 686 1964
- 11 Lassen N A *J Clin Invest* 43 1805, 1964
- 12 Lassen N A Radioaktive Isotope in Klinik und Forschung 5th International Symposium Bad Gastein Austria IV 37 1965
- 13 Lassen N A *Radioisotopes in Medical Diagnosis* Chapter 20 Ed E H Belcher & H Vetter In preparation
- 14 Lassen N A *Acta Physiol Scand Suppl* In press 1967
- 15 Munck, O Lindbjerg I F Binder C Lassen N A & Trap-Jensen J *Diabetes* 15 323 1966
- 16 Pedersen J & Olsen H *Acta Med Scand* 171 551, 1962
- 17 Renkin E M *Amer J Physiol* 197 1203 1959
- 18 Renkin E M & Rosell S *Acta Physiol Scand* 54 241 1962
- 19 Renkin E M *Fed Proc* 24 1092 1965
- 20 Rossing N *Lancet* ii 1188 1965
- 21 Scott D J, Dollery C T Hill D W Hodge J V & Fraser R *Brit Med J* i 811 1964
- 22 Skovborg F & Lauritsen E *Brit Med J* 2 1160 1965
- 23 Spetz S *Acta Obst & Gyn Scand* 44 suppl I 1965
- 24 Thomsen Aa Chr *Thesis Munksgaard* Copenhagen 1965
- 25 Weber H W & Wicht C L *S African J Lab & Clin Med* 8 83 1962
- 26 Zacks S I Peques J J & Elliott F A *Metabolism* 11 381 1962
- 27 Østerbye Hansen R *Diabetologia* 1 97 1965

## COAGULABILITY IN DIABETICS

by

*Flemming Valdorf Hansen*

• The coagulability of the blood is one of the factors which could be considered to play a role in the production of arterial thrombi

Diseases such as coronary occlusion are observed earlier and with greater incidence in diabetics (22) than in non-diabetics, it was therefore considered reasonable to compare the coagulability in these two groups

The first studies appeared around 1950 (9, 10). These suggested that the blood in diabetics possessed an increased power of coagulability, a so-called hypercoagulability. Shortened heparin resistance time and increased fibrinogen content in the blood were demonstrated in a group of diabetics whose condition was not specified in further detail

In 1957, Introzzi & de Nicola (13) found an elevated thromboelastographic index in patients with diabetes of old age, and this hypercoagulability in diabetes of mature onset was confirmed by the Modena group (2, 3, 16, 17, 23), among others in 1961. However there were also reports that the coagulability of the blood was normal in such cases (20), and that the coagulability in diabetics was even reduced (11)

One of the best studies from the point of view of coagulation technique was published in 1963 by Egeberg (7). He demonstrated the presence of hypercoagulability in diabetics, and showed that it was due to an increase in the content of the following coagulation factors: I (fibrinogen), V (proaccelerin) and VIII (antihæmophilia factor A). Others have found increased factor VII (proconvertin) content in the blood of diabetics (2).

In the majority of studies, no attempts seem to have been made to seek for correlations between diabetes control, diabetes duration and diabetic vascular complications. Where such studies have been made, the patient groups have consisted mainly of elderly patients with diabetes of a few years' duration, or the information as to the clinical conditions has been inadequate, with limited possibility of revealing possible correlations.

### AUTHOR'S INVESTIGATIONS

#### *Material and methods*

*Factor I* (fibrinogen) was examined by Jacobsson's technique (14). Mean value 223 mg per cent, standard deviation 8

*Factor VII (Proconvertin)* was determined by a method proposed by Aas (1) Mean value 75 per cent, standard deviation 11

*Heparin resistance test* this was performed in special test tubes, clean and unused Daily control tests were made on thawed normal plasma with thawed, standardized heparin The coagulation system consisted of 0.5 ml citrated, platelet rich plasma, + 0.1 ml heparin (10 units/ml) incubated for 6 minutes and 25 mM calcium chloride solution then added The coagulation time was a triple coagulation time determination with pilot test by Waaler's method (24) Mean value 5.11 minutes, standard deviation 0.20

*Coagulation studies* these were performed blind on coded blood samples at  $37.5^{\circ}\text{C} \pm 1^{\circ}$  All determinations were started within one hour of taking blood samples Blood and plasma samples were stored in an iced water bath and centrifuged in a refrigerated centrifuge Only perfect venepunctures were accepted

*Recalcification test* this was carried out and read off essentially as a heparin resistance test The coagulation system consisted of 0.5 ml citrated platelet-rich plasma + 0.5 ml citrate solution (citrate concentration 0.4 meq/liter, ionic strength 0.154, pH 7.35) This was incubated for 6 minutes and 0.5 ml pre-heated calcium chloride solution was then added Mean value 3.25 minutes, standard deviation 0.17

*Silicon treatment* needles were siliconed in 1/2 per cent Monocote (Armour lab, Hapden Park, Eastbourne, England) Constriction pipettes were siliconed

with an 0.2 per cent solution of Dow Corning Z 4141 (Dow Corning Corporation, Midland, Michigan, U S A) Silicon treatment was carried out in a special room, pipettes and needles were resincoated after being used once, and the latter were ground each time before use

*Thrombin time determinations* these were done as described by Hjort & Stormorkin (12) A daily check was performed with thawed thrombin on thawed normal plasma The coagulation system consisted of 0.2 ml citrated plasma rich in platelets + 0.2 ml citrate solution (see above), incubated for 3 minutes and thrombin solution (3.7 NIH units/ml) then added Mean value 29 seconds, standard deviation 1

*Patient material* Age distribution and duration of diabetes in the 106 patients is shown in fig 1 and fig 2 As seen, there were few elderly diabetics, only 16 patients (15 per cent) being over 50 years, and of these only 2 over 60 years There were many patients, however, with a long duration of diabetes, 31 per cent of the patients had a duration of diabetes of 25 years or more In 55 patients, the diabetes had started before the age of 16 years Among the other patients, only one was over the age of 40 years when diabetes was diagnosed Only one patient was controlled without insulin

*Normal material* This was selected so that it corresponded to the diabetic group as far as concerned sex, age and occupation When it appeared that the results of the coagulation studies were independent of the sex and age of the normal subjects, the various groups of dia-

betic patients were compared with the normal material as a whole

*Studies in diabetic patients with diabetes mellitus without clinically recognizable complications*

This group comprised 17 women and 19 men. The mean age was 33 years and the age varied from 15 to 60 years. The mean duration of diabetes was 17 years, with a variation from a few months to 43 years. Seven patients had had diabetes mellitus for less than 1 year, 7 had had it for 1 to 10 years, 11 had had it from 11 to 20 years, 11 from 21 to 30 years and 6 more than 30 years. The




Fig 1

Age distribution of the 106 patients comprising the material




Fig 2

Duration of the diabetes in the 106 patients comprising the material

highest age at which the diabetes had been found was forty years. All patients required insulin. None suffered from intercurrent disease, and in no case was ketosis demonstrated within the last 14 days prior to the investigation.

The mean values for heparin resistance and recalcification time in the diabetes group were respectively, 4.17 minutes and 2.41 minutes. The values for normal subjects were, respectively, 5.11 minutes and 3.25 minutes. The figures differed to a significant degree,  $p < 0.001$  in both cases. The mean values for thrombin time, factor VII per cent and fibrinogen content were normal in these patients.



The recalcification time was shortened significantly with duration of diabetes,  $p = 0.02$ . There was also a certain probability that the factor VII content was increased with duration of diabetes. The latter relationship was significant if all values were included,  $0.02 < p < 0.05$ , but only at the limit of significance,  $0.05 < p < 0.10$ , if an extreme value was rejected.

No statistically significant relationship was demonstrated between the blood sugar and the results of the coagulation studies.

#### *Studies in patients with simple diabetic retinopathy*

Employing the terminology of Ehlers (8), a distinction was made only between proliferative and simple retinopathy.

In the group based on the latter form of retinopathy there were 13 men and 5 women, with a mean age of 40 years and a mean duration of diabetes of 23 years. There were only 5 patients with simple retinopathy as an isolated vascular complication, while 10 of the patients had nephropathy.

The mean values for heparin resistance time and recalcification time were, respectively, 4.51 minutes and 2.81 minutes and were significantly lower than the figures for the normal group, 5.11 minutes and 3.25 minutes,  $0.02 < p < 0.05$  and  $0.01 < p < 0.02$ , respectively. In these diabetic patients, the fibrinogen in the blood was significantly increased in relation to that in normal subjects. The means were, respectively, 312 mg per cent and 223 mg per cent,  $p < 0.001$ .

The results of the other coagulation studies did not differ significantly in the two groups.

The fibrinogen content of the blood was also found to be significantly raised in relation to that in diabetics without clinically recognizable complications. The means were, respectively, 312 mg per cent and 223 mg per cent,  $p < 0.001$ . The mean of the recalcification times in diabetics with simple retinopathy, 2.81 minutes, was significantly greater, however, than the value in diabetics without clinically recognizable complications, which was 2.41 minutes,  $0.002 < p < 0.01$ . There were no other significant differences between the results of the coagulation studies in these groups.

#### *Studies in patients with proliferative diabetic retinopathy*

This group included 12 men and 8 women. In 16 patients, the visual acuity was  $< 6/9$  in both eyes. The mean age was 37 years. The mean duration of diabetes was 20 years. Only 4 patients had proliferative retinopathy as sole complication to the disease. Of the remaining patients, 13 had nephropathy and 6 had uraemia.

The heparin resistance times and the recalcification times were significantly reduced, the means being, respectively, 4.35 minutes and 2.54 minutes for diabetics with proliferative retinopathy, 5.11 minutes and 3.25 minutes for normal subjects,  $0.02 < p < 0.05$  and  $p < 0.001$ , respectively. The fibrinogen content and the factor VII content in the blood were also significantly elevated.

Diabetics with proliferative retinopathy had mean values of 362 mg per cent and 98 per cent. The corresponding figures for the normal group were 223 mg per cent and 75 per cent,  $p < 0.001$  and  $0.01 < p < 0.02$ , respectively.

In contrast to the other results, the thrombin times were found prolonged in patients with proliferative diabetic retinopathy. The mean value in these patients was 32 seconds, in normal subjects 29 seconds,  $0.01 < p < 0.02$ .

In comparison with diabetics without clinically recognizable complications, patients with proliferative retinopathy were also found to have a significantly elevated fibrinogen content,  $p < 0.001$ , the mean value for the latter group being 362 mg per cent, against 223 mg per cent for the former. The mean for the factor VII value in the blood of diabetics with proliferative retinopathy was 99 per cent, which was significantly greater, however, than the mean value for diabetics without clinically recognizable complications, if the extreme value of 350 per cent referred to on page 150 was omitted in the case of the latter group of patients. The other tests showed no significant differences between these groups of diabetics.

#### *Studies in patients with diabetic nephropathy*

The criterion used for nephropathy was the definition used by Wilson et al. (25). There were 17 men and 10 women in this group with a mean age of 35 years and a mean duration of diabetes of 20 years. Only one patient had isolated nephropathy, all the others had vascular

complications. Retinopathy was present in 23 patients. Nine of the patients had uraemia.

Just as in the other groups of diabetics, the heparin resistance times and recalcification times were significantly reduced when compared with normal values, the mean values being respectively, 4.26 minutes and 2.58 minutes, against normal values of 5.11 minutes and 3.25 minutes. In both cases,  $p < 0.001$ . The mean values for the results of the fibrinogen and factor VII determinations were, respectively, 360 mg per cent and 96 per cent, significantly greater than the normal mean values of 223 mg per cent and 75 per cent,  $p$  values being respectively  $p < 0.001$  and  $p = 0.01$ . The mean value for the thrombin time, 33 seconds, was significantly greater than the normal value, 29 seconds,  $p < 0.001$ .

The fibrinogen content of the blood was also significantly greater in patients with nephropathy than in patients without clinically recognizable complications. The mean values were 360 mg per cent and 223 mg per cent, respectively,  $p < 0.001$ . The factor VII values were only significantly increased in patients with nephropathy if the extreme value mentioned on page 150 was excluded. A comparison of thrombin times in these groups also showed a significant prolongation in diabetics with nephropathy, 33 seconds, in comparison with the value of 30 seconds in diabetics without clinically recognizable complications,  $p < 0.001$ . The heparin resistance times and the recalcification times did not differ significantly in the two groups.

A relationship was sought between the protein pattern, serum cholesterol

and serum creatinine on the one hand, and the results of the different coagulation studies on the other hand. The sole correlation found showed a relationship between elevated serum creatinine and elevated fibrinogen content in the blood,  $0.02 < p (r = 0) < 0.05$

*Studies in patients with diabetic nephropathy without simultaneous proliferative retinopathy*

This group of 9 men and 5 women had fewer and less advanced vascular complications than the others in the group with nephropathy.

The mean age was 34 years, the mean duration of diabetes 22 years. With some few exceptions, coagulability showed the same features as in the entire group with nephropathy. The mean value of the factor VII content, however, did not differ significantly from that of the normal material.

Comparison with diabetics without clinically recognizable complications also showed no significant difference for the mean value of factor VII per cent, whereas the recalcification times were increased in diabetics with nephropathy without simultaneous proliferative retinopathy. The means for these patients were 2.76 minutes, for diabetics without clinical complications 2.41 minutes,  $0.02 < p < 0.05$ .

*Studies in patients with cardiovascular complications*

These patients were not primarily grouped according to special criteria. They were mainly patients who apparently

did not primarily have diabetic complications, in spite of a long duration of disease. On further examination, however, they were found to have moderate vascular complications, such as changes in the ECG, hypertension or intermittent claudication. To a greater degree than in the groups already studied, the complications in these patients could well be due to changes in the great vessels. For this reason, therefore, they were collected into a special group. The group consisted of 8 men and 7 women. The mean age was 48 years. The mean duration of diabetes was 30 years, 6 of the patients had retinopathy, none had nephropathy.

The only difference between the coagulation in this group and in the group of diabetics without clinically recognizable complications was that these patients had an elevated blood fibrinogen content 282 mg per cent. This was significantly greater than both that of normal subjects and diabetics without clinically recognizable complications, 223 mg per cent. The  $p$  values were  $0.002 < p < 0.01$  and  $0.01 < p < 0.02$ , respectively.

*Supplementary investigations*

Ten patients were examined prior to and during insulin-induced hypoglycaemia. No significant changes in coagulation were found as a result of any of the methods employed.

Ten patients were also examined during severe ketosis. Seven of them underwent a control examination from 1 to 4 weeks after termination of the ketosis. A test of the urine during the ketosis

showed that the patients had a + Gerhard's reaction. According to Poulsen's studies (21), this signifies a ketone content in the blood of at least 11 mg per cent.

The factor VII content of the blood was found to be significantly elevated during ketosis, with mean values of respectively 66 per cent and 49 per cent,  $0.002 < p < 0.01$ . The mean heparin resistance time and recalcification time during ketosis were 4.00 minutes and 2.17 minutes, respectively, and outside the period of ketosis, 4.46 minutes and 2.63 minutes, respectively. Calculation of significance showed that the difference between these results lay at the boundary of significance. The results of the other coagulation studies showed no significant changes during ketosis.

An examination was made of the possible influence of saturated and unsaturated fats on coagulation. Nineteen patients were examined before and about 2½ hours after a standard fat rich meal of about 1000 Kcal. All patients were subjected to this load of saturated and unsaturated fats, on various days. No changes could be found in the coagulation picture as a result of these fat loads.

### Discussion

The findings in diabetics without clinically recognizable complications are difficult to compare with the results obtained in other investigations. Among investigators to date only Angeli et al. (4) have examined the conditions in such a group of patients. It should be mentioned in this connection that the beds in the Steno Memorial Hospital are oc-

cupied mainly by diabetes patients admitted to routine control or to fine adjustment of their diabetes control.

In contrast to this, it must be regarded as unusual for diabetic patients to be hospitalized in a medical department without either poor control before admission, or vascular complications of their disease. None of the previous studies state that the investigations were made in special hospitals for diabetics. In the present material, those patients who on examination (often ambulant) were found to be without clinically recognizable complications, may thus quite well have differed from the diabetic patients examined by other investigators.

Angeli et al. (4) found normal global tests, elevated fibrinogen content, but prolonged thrombin time, in diabetics without complications. These investigators had studied 10 diabetics less than 40 years of age with "severe" diabetes without complications. Investigators such as Ottaviani & Redi (20) found completely normal coagulation in diabetics. The majority of previous investigators, however, have reported that diabetics had in general reduced global test times. Practically all found elevated fibrinogen content in the blood of all diabetics, while only Alberini et al. (2) demonstrated elevated factor VII content in 90 per cent of their patients with diabetes of late onset.

However, the discrepancies between the different results in earlier coagulation studies in diabetics, and the discrepancies between these results and the results presented here, cannot be explained solely by differences in the clinical condition of the patients, even

though this can contribute to obscuring the matter. Technical differences are difficult to evaluate, as in most cases methods were used which are not essentially different.

In general, it may be concluded that the shortened global test times found in this study in diabetics without clinically recognizable complications, have not previously been demonstrated with certainty in such patients. However, shortened global test times have often been found among groups of diabetics whose characteristics have not been specifically defined. On the other hand, increasing shortening of the recalcification time with increasing duration of diabetes has not been demonstrated previously. This may have some relation to the fact that in the present study, there were many patients who had a long duration of diabetes, without clinically recognizable complications. Egeberg, who had also examined some of these patients, reported that the material included 3 patients with recent, untreated diabetes. These may have had a greater or lesser content of ketones in the blood, and may thus have distorted the picture.

In the present study, all diabetics with vascular complications had an elevated blood fibrinogen content, while heparin resistance times and recalcification times were of the same order of magnitude as in diabetics without complications. In the groups with simple retinopathy and nephropathy without simultaneous proliferative retinopathy, the recalcification times were prolonged even by comparison with diabetics without complications. In 14 diabetics with one or more unspecified complications localized to

the eyes, kidneys, heart or peripheral vessels, Angeli et al found shortened recalcification times. This is in poor agreement with the present results, but on the other hand there is good agreement with the present finding that the fibrinogen content of the blood in diabetics with vascular complications is greater than in diabetics without such complications.

In the groups classed according to nephropathy and proliferative retinopathy, the coagulation characteristics were found to be very uniform. This is natural, as 13 of the patients were included in both groups. The increase in factor VII found in these two groups has not been described so far. Alberini et al (2), as mentioned, found increased factor VII content in the majority of their patients, but it was stated expressly that none of these had proliferative retinopathy. Among other authors who have examined diabetics for factor VII in the blood should be mentioned Egeberg (7) and Ottaviani & Redi (20), the latter also examining 5 patients with proliferative retinopathy. Both these last mentioned authors, however, found normal factor VII content in diabetics.

The prolonged thrombin time in relation to diabetes without clinically recognizable complications, and demonstrated in the present study, was only found in groups in which all patients had diabetic nephropathy. This suggests that the prolonged thrombin time is related to the nephropathy. A prolonged thrombin time in patients with vascular diabetic complications has previously been found only by Angeli et al (4). These authors, however, found even

more prolonged thrombin times in diabetics without complications, where the present author found normal thrombin times

One study has been made on the coagulation characteristics of patients with diabetic ketosis. In their 4 patients, 2 of whom also had cerebral apoplexy, however, Cantelli et al (6) found an increased blood coagulation power when measured by thrombo-elastography. Animal experiments (5, 19) have also shown that prolonged ingestion of ketone substances results in increased coagulability of the blood. On the other hand, medicament induced acidosis of brief duration has not been found to result in changes in the coagulation characteristics (15). The patients in the present study had had their ketosis for varying lengths of time, presumably of ten for weeks. In spite of this, there were only modest changes in the coagulation characteristics.

It is quite uncertain whether the demonstrated changes in the coagulation characteristics have any significance for the greater incidence of arterial thrombi in diabetic. It should be mentioned, however, that more recent studies (18) suggest that fibrinogen has an influence on the platelet adhesiveness. This is presumably one of the decisive factors for thrombus formation in the circulating blood.

## SUMMARY

A study is presented of coagulation in 106 diabetics and a comparable normal material. The majority of the patients were juvenile diabetics, and 1/3 had a duration of diabetes of 25 years or more. Reduced recalcification times and heparin resistance times were found in all diabetic groups.

The recalcification time was shortened with increasing duration of diabetes, but the results of the global tests were independent of the vascular complications of diabetes. The factor VII content was normal in the group of diabetics without clinically recognizable complications. However, if all values including an extreme observation were used in the calculation, the factor VII content in the blood was increased with duration of diabetes. The factor VII content was increased both in diabetics with nephropathy and in patients with diabetic ketosis.

The fibrinogen content was normal in patients with uncomplicated diabetes mellitus, but increased in all patients with one or other form of vascular diabetic complications.

The thrombin times were prolonged in patients with diabetic nephropathy. These patients, however, when evaluated by all other tests, were in a hypercoagulable state.

TABLE I  
Return of results of coagulation studies in diabetes

	Normal group	Diabetics with no recognizable complications	Diabetics with simple retinopathy	Diabetics with proliferative retinopathy	Diabetics with nephropathy	Diabetics with nephropathy and glomerulonephropathy	Diabetics with cardiovascular complications
Mean age	35	33	40	37	35	34	48
Duration of diabetes		17	23	20	20	22	30
Recalcification time (mins)	3.25	2.4 <sup>1)</sup>	2.8 <sup>1) 2)</sup>	2.5 <sup>4)</sup>	2.58 <sup>1)</sup>	2.76 <sup>1)</sup>	2.47 <sup>1)</sup>
Heparin resistance time (mins)	5.11	4.17 <sup>1)</sup>	4.51 <sup>1)</sup>	4.53 <sup>1)</sup>	4.26 <sup>1)</sup>	4.40 <sup>1)</sup>	4.46 <sup>1)</sup>
Thrombin time (secs)	29	30	30	32 <sup>1)</sup>	33 <sup>1) 2)</sup>	32 <sup>1) 2)</sup>	29
Factor VII (%)	75	73	79	99 <sup>1) 2)</sup>	96 <sup>1) 2)</sup>	93	75
Fibrinogen content (mg%)	223	223	312 <sup>1) 2)</sup>	362 <sup>1) 2)</sup>	360 <sup>1) 2)</sup>	329 <sup>1) 2)</sup>	282 <sup>1) 2)</sup>

<sup>1)</sup> Results significantly different from the normal group.

<sup>2)</sup> Results significantly different from the group of diabetics without clinically recognizable complications.

<sup>3)</sup> Dependent on extreme observation.

N.B. The recalcification times and the factor VII % are compared with diabetics without clinically recognizable complications with a mean duration of disease of 26 years.

## REFERENCES

- 1 Aas K. Prokonvertin og konvertin. *Undersøkelser over blodets koagulasjon med spesielt henblikk på prokonvertin og konvertin* Disputats Oslo 1952
- 2 Alberini B G C Lasagna & G Tedeschi *Progr Med (Nap)* 17 430 1961a
- 3 Alberini B G Tedeschi G C Lasagna & L Schiavi *Riforma Med* 17 957 1961b
- 4 Angeli G B Alberini & G C Lasagna *Riforma Med* 74 10 1960
- 5 Brahmarkar M M & M C Nath *Amer J Physiol* 204 653 1963
- 6 Cantelli T M Morsani & M La Paglia *Progr Med (Nap)* 14 466 1958
- 7 Egeberg O *Scand J Clin Lab Invest* 15 533 1963
- 8 Ehlers H *Acta Ophthal (kbbh)* 31 289 1953
- 9 Giannico O & P Marrazza *Policlinico (Prat)* 53 573 1948
- 10 Giannico O & P Marrazza *Progr Med (Nap)* 1950 6 466 1950
- 11 Grott J V *Schweiz. Med Wochr* 77 48 1947
- 12 Hjort P & H Stormorken. A study of the in vitro and in vivo effects of a synthetic heparin like anticoagulant Dextran Sulphate *Scand J Clin Lab Invest* 1957 suppl 29
- 13 Introzzi P & F De Nicola *Diabetes* 6 433 1957
- 14 Jacobsson Kjell. Studies on fibrinogen I. Studies on the determination of fibrinogen in human blood plasma *Scand J Clin Lab Invest* 1955 suppl 14
- 15 Kronberger L *Klin Med (Wien)* 18 135 1963
- 16 Lasagna G C B Alberini & G Tedeschi *Progr Med (Nap)* 17 698 1961a
- 17 Lasagna G C G Tedeschi B Alberini & L Schiavi *Riforma Med* 15 765 1961b
- 18 McLean J R R E Maxwell & D Hertler *Nature (Lond)* 202 605 1964
- 19 Nath M C & M Brahmarkar *Amer J Physiol* 202 545 1962
- 20 Ottaviani P & F Redi *Giorn Clin Med* 39 290 1958
- 21 Poulsen J E. *Studies on the ketosis in diabetes mellitus* Thesis Copenhagen 1941
- 22 Root H F E F Bland W H Gordon & P D White *J A M A* 113 27 1939
- 23 Schiavi L G Tedeschi B Alberini G C Lasagna A Mucci & D Forlani *Minerva Oftal* 3 53 1961
- 24 Waaler B A *Scand J Clin Lab Invest* 9 322 1957
- 25 Wilson J L H F Root & A Marble *New Engl J Med* 245 513 1951





## LONG-TERM EXPERIMENTAL INSULIN-DEFICIENCY DIABETES

### — A MODEL OF DIABETIC ANGIOPATHY ?

by

*Knud Lundbæk, T Steen Olsen, H Orskov  
and Ruth Østerby Hansen*

In those parts of the world where insulin treatment and well organized medical care are available, the fate of the diabetic patient depends on the rapidity with which diabetic angiopathy develops, and on its severity. There is some clinical evidence that meticulous attention to the control of the metabolic abnormality affords a certain degree of protection against angiopathy, but the great majority of apparently reasonably well controlled patients nevertheless end up with severe eye lesions, and ultimately perish from vascular disease of the kidneys, heart and central nervous system.

The role of hypoinsulinism—relative or absolute—in the development of diabetic angiopathy is still unknown. The study of patients with hypoinsulinism not due to diabetes mellitus, e.g. pancreaticotomized patients, is difficult and has led to contradictory results. It follows, therefore, that several attempts have been made to produce diabetic angiopathy experimentally by inducing a state of hypoinsulinism in animals. The results of these studies have shown that lack of

insulin leads to the development of severe changes in the kidneys, an *insulin deficiency nephropathy*. Much less is known about the state of the retina and the nervous system in experimental diabetes, mainly because relatively few extended studies have been published in these fields.

In the following a survey will be given of our own findings in experimental diabetes, together with a review of the relevant work published from other laboratories.

### THE FINDINGS

#### *The kidneys*

Most studies of experimental nephropathy have been performed in *rats*. In 1950 Beveridge & Johnson (6) published a study of a large group of alloxan diabetic rats after 7 to 22 months of diabetes. The interpretation of their results is difficult. In all of their diabetic rats on a basal diet they noticed "pyelonephritis" (chronic inflammatory cells, in-

creased amount of fibrous tissue, dilated tubules), however, similar changes although less marked, were found in no less than two thirds of their control animals. More or less completely hyalinized glomeruli were seen frequently, but the authors do not specify the incidence of this abnormality in diabetic and non-diabetic animals. Foglia et al (14) induced diabetes in rats by pancreatectomy, and found glomerular lesions in 88 per cent of the animals after 2-12 months of hyperglycemia. The mesangial areas were increased and the walls of the capillaries were thickened. There were no noticeable alterations of the afferent arterioles, other vessels of the kidney or of the interstitial tissue. Mann et al (24) found clear-cut abnormalities in the glomeruli of untreated alloxan diabetic rats after 6 to 30 months of diabetes. They emphasized that the changes observed differed from those of human diabetic nephropathy, by the absence of collagenous tissue formation. In 1959 Janes (18) reported on the occurrence of diffuse and localized thickening of the basement membrane of the glomeruli in alloxan diabetic rats after 3 months, and severe changes after 6 months. Green-

berg (17) reported "capillary basement membrane thickening" after 3 months of alloxan diabetes. Later on, the changes were more severe and the occurrence of localized, pale staining masses was noted, as well as fusion of capillaries. Rather late in the disease the lesions became PAS positive. The walls of the arterioles were thickened after 8 months, but were without PAS positive material.

From our laboratory, Ørskov et al (28) described the structure of the glomeruli in alloxan diabetic rats. The experiments were carried out on rats intravenously alloxanized with and without temporary renal clamping. The study included several control groups, e.g. with and without different kinds of insulin, with and without renal clamping, etc. Macroscopically the kidneys of the diabetic animals were enlarged. The average weight of the kidneys of the diabetic rats was greater than that of the non-diabetics. Lesions occurred after 10 months of experimental diabetes and were more severe after 15 months (Table 1). The early change consisted of diffuse, fairly uniform PAS-positive thickening of the glomerular capillary walls and widening of the mesangial re-

TABLE I  
*Glomerular changes in relation to duration of diabetes*

Grades of severity	Controls	Diabetic rats Duration of diabetes			Total
		5 mo	10 mo	16 mo	
+++	0	1	0	5	5
++	0	0	3	2	5
+	1	0	12	0	13
0	35	22	5	0	62
total	36	22	20	7	




Fig 1

Glomerulus from a rat with diabetes of 10 months duration. The glomerular lesion is diffuse of moderate degree.

gions (Fig 1). This lesion was very similar to the diffuse glomerulosclerosis of human diabetes. The more advanced stages showed essentially the same process but in the severest cases a localized, PAS positive, hyaline substance was also seen (Fig 2). The accumulations were 'sausage shaped', and the impression by light microscopy was that the capillary lumina were filled with cellular and acellular masses. Typical nodules of the

kind present in human diabetes were not observed.

(Osterby Hansen et al, 1967)

The results obtained did not suggest that administration of insulin or the alloxan injections were responsible for the glomerular lesions. The changes observed in the diabetic animals were not present in age matched controls.

However, later experience has shown that somewhat similar glomerular ab-




Fig. 2

Glomerulus from a rat with alloxan diabetes of 15 months duration. The maximal degree of glomerular lesion encountered.

normalities occur in *very old* non diabetic rats (24 months), although the severest degrees have not been encountered.

Histochemical investigations of this glomerulopathy in diabetic rats (Steen Olsen et al. (27 a) showed that the deposits consisted of a glycoprotein which did not contain glycogen, amyloid or acid mucopolysaccharides. Lipid was demonstrated in a few glomeruli with pronounced changes. The severest lesion

with "sausage shaped" deposits showed histochemical similarity to the so called exudative lesions (capsular drop, fibrinoid cap and arteriolar hyaline) of human diabetic glomerulopathy. Experimental lesions of milder degree showed both structural and histochemical similarity to the human diffuse lesion.

A number of the diabetic rats in our study showed moderate interstitial fibrosis and lymphocytic infiltration as well

as dilated tubules with protein casts and epithelial degeneration. These changes were most pronounced in a group of rats in which the kidneys were not protected against the alloxan by clamping off the renal vessels. Thus direct alloxan damage seemed to be an important factor in the development of tubular and interstitial changes. However, it is likely that part of these changes were secondary to the glomerular lesions (ischemia in areas supplied with blood from the degenerating glomeruli).

A few reports have appeared concerning kidney changes in other animals with experimental diabetes.

Lukens & Dohan (23) described a case of experimental pituitary diabetes lasting for 5 years in a dog. At autopsy, typical Himmelstiel-Wilson lesions were seen in the glomeruli. Ricketts and co-workers (35) studied the kidneys in 10 dogs made diabetic by subtotal pancreatectomy, and 8 treated with pituitary extract after subtotal pancreatectomy. After 1-8 years' observation, diffuse glomerulosclerosis was noted in well controlled as well as in poorly controlled animals. The glomerular lesion was described as a thickening of the intercapillary stroma and of the capillary walls. Similar changes occurred in the controls which were older than the diabetic animals, but much less frequently. Lipid deposits in the glomeruli were noted in poorly controlled diabetic dogs. True nodular changes were never seen.

Beaser et al. (2, 3) followed the development of the kidney lesions in alloxan diabetic golden hamsters for up to two years. They observed glomerular changes similar to the diffuse form of

human glomerulosclerosis, increasing in severity with the duration of diabetes. In addition they noted the appearance of a "pyelonephritis" quite similar to the changes we observed in the interstitial tissue of our alloxan diabetic rats. They do not present evidence that these changes were caused by a chronic bacterial infection of the renal parenchyma. They emphasized the absence of significant changes in the vascular walls of the small renal vessels, a finding compatible with ours. The nephropathy in these hamsters was more severe in animals poorly controlled with insulin. In older control animals they found "stiffening of glomerular walls," a picture differing from that of the diabetic animals.

Bloodworth (8) gave a detailed report of his investigation on 10 dogs made diabetic with pituitary growth hormone or alloxan, and maintained with insulin for 1-5 years. Diffuse glomerulosclerosis developed in all the dogs, as described by Ricketts et al. (35), but in contradistinction to the findings of these investigators, Bloodworth found nodular changes, identical to those of severe human glomerulosclerosis, in 7 of the 10 diabetic dogs but in only one of 9 control animals. He also noted other glomerular changes characteristic of the spontaneous disease in human beings, such as exudative lesions, arterial sclerosis, and tubular changes.

Summarizing the light microscopic observations of several authors, it can be stated that it is possible to induce glomerular changes in various laboratory animals by means of insulin deficiency diabetes. In most cases this lesion is diffuse and consists of a PAS positive thickening

of the capillary wall as well as an increase of the mesangial areas. This stage is similar to diffuse diabetic glomerulopathy in the human. There are some differences of opinion as to the time required to produce these lesions, a fact which may be explained by differences in experimental conditions and species. In the rat, the most severe diabetic lesions appear as focal, partially fusing, homogenous PAS-positive areas suggesting deposits in capillary loops. These areas do not have the same appearance as nodular Kimmelstiel-Wilson lesions in the human subject. Histochemically, they are similar to the so called exudative lesions in human diabetic nephropathy. In the dog, it seems to be possible to produce nodules very similar to those of the human disease. In striking contrast to what happens in the diabetic patients, most experimental animals do not develop severe PAS-positive thickening of the juxta glomerular arterioles. Also here the dog constitutes an exception.

There are only few reports in the literature on *electron microscopic* studies of experimental glomerulopathy.

Bloodworth in the paper discussed above (8) described the ultrastructure of the glomeruli in dogs with experimental diabetes. The mildest change was a thickening of the basement membrane. He did not measure the basement membrane but estimated it to be 2-4 times thicker than in normal animals. The more advanced stage was characterized by an abnormal amount of basement membrane material in the mesangial areas. The author thinks that this process, which leads to the development of typi-

cal Kimmelstiel-Wilson nodules, is essentially the same in the dog as in diabetic patients.

Gibbs et al (16) have published a short report on their *electron microscopic findings in alloxan diabetic monkeys*. In one animal, after 73 months of diabetes, accumulation of basement membrane-like material in the mesangial areas of the glomeruli and thickening of the peripheral basement membrane was observed. Similar, although rather less marked alterations were found in some animals with diabetes of 19-55 months' duration. High carbohydrate diet or low insulin dosage seemed to favour the development of these changes.

In our *electron microscopic* studies of glomeruli from alloxan diabetic rats (Østerby Hansen et al (29)) the findings by light microscopy were confirmed, i.e. thickening of the capillary walls and increase in mesangial areas. Furthermore, several ultrastructural abnormalities were encountered. We have observed localized 'spikes' on the epithelial side of the peripheral basement membrane, occurring rather constantly in pairs with a more electron dense material in the basement membrane between two adjacent spikes (Fig. 3). Reconstructions based on serial sections showed that these profiles represented 'moon crater' like formations on the epithelial surface of the basement membrane. A more diffuse thickening was present in some glomeruli. In some cases a definite increase in mesangial areas was observed, sometimes consisting of cellular elements (Fig. 4), sometimes made up mainly of basement membrane material. This material showed increased electron density




Fig 3

Section through a moon crater formation on the glomerular basement membrane (Bm). Two spikes (S) are projecting towards the epithelial cell (Ep). An electron dense fibrillar material is seen in the basement membrane between the spikes (arrow) and in the cytoplasm of the epithelial cell immediately adjacent (En) endothelial cell (Us) urinary space (Cap) capillary lumen. Vestopal embedding. Uranyl acetate stain.

in some of the diabetic animals. The epithelial cells were severely altered, showing accumulations of large inclusions, giant lysosomes, and in the severest cases containing closely packed Golgi complexes and cisterns of endoplasmic

reticulum. Fusion of foot processes was present in only a few glomeruli.

The 'moon craters' on the epithelial side of the basement membrane have not been described before in human or experimental diabetes, or in any other





Fig 4

The electron microscopical picture of a part of a sausage shaped accumulation (compare Fig 3). Several mesangial cells (M) and basement membrane branches (Bmb) constitute a large area in a capillary loop close to the capsule of Bowman (Bow). Vestopal embedding. Double staining with uranyl magnesium acetate and lead citrate.

condition but similar changes have been observed recently in biopsy specimens from diabetic patients (Østerby Hansen (31)). The mesangial increase in basement membrane material as well as the diffuse thickening of the peripheral basement membrane found by Bloodworth in

dogs, Gibbs et al in monkeys, and Østerby Hansen et al in rats, seem to be very similar to the electron microscopic lesion in human diabetic glomerulopathy.

#### *The eyes*

Alloxan diabetic rats and rabbits regu-

larly develop severe cataracts in the course of a few months (Bailey et al (1)—Bellows & Shoch (4)—Patterson (32)—Naidorff et al (27)—Bounds et al (9))

Berggren & Brohn (5) tried to provoke abnormalities in retinal vasculature in alloxan diabetic rabbits by exposure to low oxygen pressure. Increased capillary tortuosity appeared after the procedure in diabetic as well as in non-diabetic animals. No microaneurysms were observed. The duration of diabetes in these animals was only 3–12 weeks.

Gernitzen et al (15) found no changes in the eyes of 5 alloxanized rats after 11 months of diabetes.

Janes & Bounds (19) have published a detailed description of the anatomy of the blood vessels of normal rat eyes. In 1957 Janes & Ellis (20) gave a report of their studies of the ocular changes in alloxan diabetic rats. They noticed the occurrence of engorgement and dilatation of the iris blood vessels, eventually leading to hyphema and proliferation of corneal vessels. These changes were always preceded by cataract formation. In a later paper (Janes (18)) the author also described the condition of the retina in alloxan diabetic rats. On ophthalmoscopy, retinal hemorrhages were observed in only one of 200 animals. However, the time of observation was only 2–3 months. Retinitis proliferans-like changes were seen in injected specimens from 2 rats. A more common finding was a failure of the retinal capillaries to fill normally during injection. It was found that the ocular changes—especially in the anterior segment—were closely relat-

ed to glomerular abnormalities in the kidneys, as described above.

Kirchner & Leopold (21) also applied an injection technique, studying flat preparations of retinae from alloxan diabetic rats injected with silver nitrate. Their brief report concerns a pilot study of 12 rats with a duration of diabetes of 3 months. Six of the rats were given a high fat diet and in 4 of these the retinal preparations showed a "localized reticular thinning" of the capillary walls.

Musacchio et al (25) studied the vascular tree of the retina in rats after 6–16 months of alloxan diabetes. They found a pronounced venous and arterial dilatation and mention "papillary vessels or vascular stars", without describing these phenomena in detail. In a later paper (26) they confirmed the dilatation and reported the finding of arterial aneurysms in 2 out of 3 severely diabetic rats. The changes observed were correlated to the degree and duration of diabetes.

Levene et al (22) reported a study of the retina in 10 "95 per cent pancreatectomized" rats. The diabetic state of the animals was characterized by an abnormal glucose-cortisone-tolerance test. The animals survived without insulin treatment for as long as 27 months. Only minor abnormalities developed in these old rats. The positive findings were thickening and hyalinization of arterioles seen in ordinary histological sections and increase in PAS-staining of arterioles in trypsin digested, flat preparations of retinae. In control rats less than 20 months old, no abnormalities were observed.




Fig 6a

Normal retinal capillary system. India ink injection specimen. Retinal flat preparation.

diabetic rats. The cataract is probably identical with the human diabetic cataract, but there is no precise correlate in human pathology to the anterior segment abnormalities in rats. They may be caused by changes in the vessels at the root of the iris, perhaps similar in kind to those of the iris vessels producing rubeosis iridis in human diabetic patients.

The typical diabetic retinopathy seen in long term diabetic patients does not develop in alloxan diabetic animals. Severe phlebotomy, haemorrhages and soft or hard exudates are unusual findings. A few microaneurysms have been observed by some investigators. The very peculiar capillary tangles mentioned

above, sometimes combined with retinal degeneration, have not been described before.

It is noteworthy that the entire series of ocular abnormalities observed in long term diabetic rats in our laboratory have also been observed in very old non diabetic rats in the same way as the kidney lesions described above.

#### *Peripheral nerves*

Bischoff (7) has studied the ultrastructure of the Schwann cells in hamsters 4 weeks after alloxanization. He observed severe cytoplasmic degeneration with lipid inclusion bodies. Similar studies in acute human diabetes are not available.




Fig 6b

Numerous capillary tangles from a rat after 10 months of diabetes Indian ink injection Retinal flat preparation Left part capillary tangle at higher magnification

### *The brain*

In a small series of long term diabetic rats, Reske-Nielsen et al (31) observed degeneration of the brain, as well as many open capillaries with strong PAS positive walls and focal thickenings. These changes also occurred in age matched control animals, but were more pronounced in the diabetic rats. Pseudocalcinosis of the corpus striatum was present in 2 out of 7 diabetic rats, but in none of 5 controls.

The brain abnormalities noted have some similarity to those described in long term juvenile diabetics (Reske Nielsen et al (33)), but the study has to be extended to larger groups of animals.

### THE SIGNIFICANCE OF THE FINDINGS

There is no doubt that alloxan diabetes and other types of experimental insulin deficiency diabetes lead to the development of a severe and widespread disease in rats and some other animals. The evidence available on the kidney changes is particularly convincing undoubtedly because more attention has been paid to this organ than to any other. Controlled studies have shown that these changes are not due to the toxic action of alloxan (28).

The question is whether these vascular abnormalities are to be regarded as the animal correlate of diabetic angiopathy.

in human subjects. Obviously there are considerable differences, especially in the ocular changes, and even the very similar changes in the kidneys are not quite identical to those in human glomerulosclerosis.

The point at issue is, of course, to what extent it is permissible to argue about the pathogenesis of diabetic angiopathy on the basis of these experimental findings.

If the classical diabetic glomerulosclerosis and retinopathy had been produced in experimental insulin deficiency diabetes in animals, this would certainly have been a very strong argument in favor of the hypothesis that vascular changes developing in diabetic patients are *caused by* lack of insulin. On the other hand, it would have afforded an argument *against* the hypothesis that the proneness to develop angiopathy is a primary part of the inherited trait of diabetes mellitus.

As a matter of fact the experimental diabetic angiopathy has some similarities to, but is definitely not identical with, human diabetic angiopathy. However, even if the pathogenesis of experimental insulin deficiency angiopathy and clinical diabetic angiopathy were the same, absolute morphological identity could hardly be expected.

At any rate, in our opinion, the existence of a severe angiopathy in long-term alloxan diabetic animals must be accepted as a positive argument thrown into the scale in favor of the hypothesis of secondary angiopathy. The importance of this interpretation—practically as theoretically—is too obvious to need further elaboration.

Our finding that changes similar to those produced by long term insulin deficiency in alloxan diabetic rats are also present in *very old* non diabetic animals is very puzzling. It seems to lead us directly back to the old clinical concept of the twenties and thirties, that vascular disease in diabetic patients is "merely an enhancement of the aging processes".

This concept is, of course, untenable to day in view of the fact that old non-diabetic patients actually do not develop diabetic retinopathy, nephropathy, etc. On the other hand, the important results of modern survey studies of whole populations (10, 11, 36) may have some significance for the present situation in the field of experimental angiopathy. It is now well known that diabetes mellitus, in the sense of a defined carbohydrate intolerance, increases in incidence as people get older. Our very old control rats were not studied for evidence of decreased carbohydrate tolerance. They did not have glycosuria, but it is a well established fact that abnormal glucose tolerance is very common in old people without glycosuria.

It is hardly possible to make meaningful the question whether a female white rat kept in a single cage in a laboratory for 2 years is "older" than an old man or woman in our present society. Nevertheless, in a speculative mood, one might consider the possibility that the changes observed in the two-year-old non diabetic rat are the equivalent of the retinopathy etc., which *would* develop in old people (the majority of them) who have a diabetic glucose tolerance curve, if they lived on for another 20 or 40 years.

But quite apart from the argumenta-

tive force of the findings discussed in the field of pathogenesis, and apart from speculations, it seems to us that further comparative work on long term insulin deficiency diabetes and on animal senescence offers reasonable chances of producing interesting new results and concepts in diabetology

## REFERENCES

- 1 Bailey C C Bailey O T & Leech R S *New England J Med* 230 533 1944
- 2 Beaser S B Sak M F & Sommers S C *Metabolism* 12 704 1963
- 3 Beaser S B Donaldson G W McLoughlin R J & Sommers S C *Diabetes* 13 49 1964
- 4 Bellows J G & Shoch D E *Am J Ophthalm* 33 1555 1950
- 5 Berggren L & Brodin S E *Acta ophthalm* 34 391 1956
- 6 Beveridge J M R & Johnson S H *Brit J Exper Path* 31 280 1950
- 7 Bischoff A Electronmicroscopic studies of peripheral nerves in alloxan diabetic hamsters Prelim report Diabetes Symposium Zürich February 1967
- 8 Bloodworth J B M Jr *Arch Path* 79 115 1965
- 9 Bounds C W Jr Janes R G & Leinfelder P J *A M A Arch Ophthalm* 54 564 1955
- 10 College of General Practitioners *Brit Med J I* 1497 1962
- 11 College of General Practitioners *Brit Med J II* 655 1963
- 12 Engerman R L & Bloodworth J B M Jr *Arch Ophthalm* 73 205 1965
- 13 Engerman R L Meyer R K & Buesseler J A *Am J Ophthalm* 58 965 1964
- 14 Foglia V G Mancini R E & Cardesa A F *A M A Arch Path* 50 75 1950
- 15 Gerritzen F Noach E L van Wijhe M & Valk L E *Acta Endocrinol* 25 91 1957
- 16 Gibbs G E Wilson R B & Gifford H *Diabetes* 15 258 1966
- 17 Greenberg S E A M A *Arch Path* 73 263 1962
- 18 Janes R G A M A *Arch Path* 67 386 1959
- 19 Janes R G & Bounds C W *Am J Anat* 96 357, 1955
- 20 Janes R G & Ellis P P A M A *Arch Ophthalm* 57 218 1957
- 21 Kirschner R & Leopold I H A M A *Arch Ophthalm* 64 681 1960
- 22 Levene R, Lazzarini Robertson A Foglia V G & Singer J A M A *Arch Ophthalm* 70 253 1963
- 23 Lukens F D W & Dohan F C *Arch Path* 41 19 1946
- 24 Mann G V Goddard J W & Adams L *Amer J Path* 27 857 1951
- 25 Musacchio I T L Palermo N & Rodriguez R R *Acta Physiol Latinam* 11 79 1961
- 26 Musacchio I T L Palermo N & Rodriguez R R *Lancet I* 146 1964
- 27 Naidoff D Pincus I J Town A E & Scott B H *Am J Ophthalm* 39 510 1955
- 27a Olsen T Steen Ørskov H & Lundbæk K *Acta path et microbiol* 66 1 1966
- 27b Ørskov H Nielsen K Steen Olsen T Rafalsen O & Lundbæk K *Diabetologia I* 172 1965
- 29 Østerby Hansen E Steen Olsen T Lundbæk K & Ørskov H To be published 1967
- 30 Østerby Hansen R Leddet T Lundbæk K Steen Olsen T & Ørskov H To be published 1967
- 31 Østerby Hansen R To be published 1967
- 32 Patterson J W *Am J Ophthalm* 35 68 1952
- 33 Reske Nielsen E Lundbæk K & Rafalsen O J *Diabetologia I* 233 1965
- 34 Reske Nielsen E Lundbæk K & Rafalsen O J To be published 1967
- 35 Ricketts H T Test C E Petersen E H Lants H Tupikova N & Steiner P E *Diabetes* 8 298 1959
- 36 Sharp C L Butterfield W J H & Keen H *Proc R Soc Med* 57 193 1964



## CAUSES OF PERINATAL DEATH IN DIABETIC PREGNANCY

### A CLINICO PATHOLOGICAL ANALYSIS

by

*Lars Molsted Pedersen and Jorgen Pedersen*

Analysis of perinatal deaths is hampered by the fact that the cause of death in stillborn babies can only rarely be demonstrated. Some have severe congenital malformations, but most of them do not show any anatomical lesions at autopsy. Besides, many such infants are macerated or are not autopsied for other reasons. In contrast, consecutive autopsy studies of infants dying during the neonatal period are valuable.

To obtain as much information as possible about perinatal deaths, a clinico-pathological analysis is necessary in which information about clinical events and conditions of pregnancy and delivery is combined with that obtainable at autopsy.

While several causes contributing to the high perinatal mortality in diabetic pregnancy are known (3, 5, 6, 8), it is still a common opinion that unsuspected and unexplainable foetal and neonatal death is seen more frequently in offspring of diabetic mothers than in a non diabetic population. In order to investigate this, autopsy records and records of complications during pregnancy, delivery and the

neonatal period have been analysed in a consecutive series of perinatal deaths in infants of diabetic mothers. The complications and causes of death in two decades have been compared, finally, an analysis has been made of causes of death as demonstrated at autopsy in a recent consecutive series of infants dying neonatally.

### MATERIAL AND METHODS

During the 20-year period 1946-65, 167 of the 846 infants born of diabetic mothers (birthweight 1000 g and more) in the Royal Maternity Department B, Rigshospitalet, Copenhagen, died in the perinatal period. 136 diabetic women had one, 11 had two, while 3 women each had 3 infants dying perinatally. The period of supervision and treatment during pregnancy varied greatly.

The case records of mother and infant as well as the autopsy record of the infant were carefully studied with respect to complications which might explain or help to explain perinatal death. Furthermore, one of us (J P) has been con-



sultant in diabetes to the department during the 20-year period and personal notes had been taken of several of the infants dying perinatally

The total material of 167 infants comprised 98 stillborn and 69 neonatal deaths. However, since microscopy of the organs in infants dying neonatally was first started as a routine in 1960, the consecutive neonatal autopsy material comprises only 35 infants from the period January 1960 to October 1966

### DEFINITIONS

*Perinatal mortality* Stillbirths and neonatal deaths within 10 days after delivery of babies weighing 1000 g and over

*Fatal congenital malformations* Those which sufficiently explain intrauterine death or are incompatible with extrauterine life for more than 10 days. The occurrence of congenital malformation in offspring of diabetic mothers has been discussed in a previous paper (9)

*Premature* Birthweight less than 2500 g

*Pre-coma* Diabetic acidosis with a venous plasma standard bicarbonate below 10 meq/l

*Severe acidosis* Venous plasma standard bicarbonate 10–17 meq/l

*Toxaemia* 2 of the following 3 signs present

- 1) B P  $\geq$  140/90 for at least 3 days before delivery
- 2) More than 0.05 per cent albuminuria for at least 24 hours before delivery
- 3) Moderate oedema or weight gain  $\geq$  15 kg

*Clinical pyelonephritis* Urinary tract

infection with an acute elevation of temperature exceeding 39° C, confirmed by culture of the urine

*Neglectors* This term covers three groups of diabetic women. Those a) in labour at first attendance in the department, b) with psychopathy or mental retardation, c) with poor social conditions and attending late in pregnancy

*PBSP (Prognostically Bad Signs during Pregnancy) classifications* (8) This classification comprises one or more of the following—just mentioned—signs occurring during pregnancy: 1) Clinical pyelonephritis, 2) precoma or severe acidosis, 3) toxæmia and 4) "neglectors". In contrast to White's (10) widely used classification of pregnant diabetics, which is based on factors present prior to the occurrence of pregnancy, the PBSP classification includes complications which become evident during pregnancy

### RESULTS

Table I shows the results of the clinicopathological analysis. In 98 infants or nearly 60 per cent, one or more complications were found which fully explain death. In 54 infants, or about 30 per cent, complications contributing to death were found, whereas in 15 infants or about 10 per cent, no complications or cause of death could be demonstrated. In the last mentioned group, death was as unexplained as it was unexpected.

*Comments to Table I* Each infant is entered under only one heading, even though 2 or more of the complications in question occurred in 45 per cent.

*Fatal obstetrical complications* include 4 groups. A) 7 large infants

TABLE I

*Clinico pathological analysis of 167 perinatal deaths in infants of diabetic mothers*

Complications	Causes of death					
	Primary		Contributing		None	
	No	Per cent	No	Per cent	No	Per cent
Fatal congenital malformation	23	13.8	—	—	—	—
Obstetrical complication	24	14.4	—	—	—	—
PBSP	47	28.1	31	18.5	—	—
Bad obstetrical history	—	—	9	5.5	—	—
Other	4	2.4	14	8.3	—	—
None	—	—	—	—	15	9.0
Total	98	58.7	54	32.3	15	9.0

(birthweight more than 4000 g) in whom difficulties with delivery of the head and/or severe shoulder dystocia occurred. Forceps were used in 5 cases, while compression of the umbilical cord occurred in 2 deliveries. B) In 6 vaginal deliveries a variety of obstetrical operations were used on account of abnormal presentations or positions. C) Abruptio placentae (3), prolapse of the cord (2) and placenta praevia (1) account for six additional deaths, while D) the last 5 fatal obstetrical complications comprise induction of labour extended over several days and/or complicated labour followed by intrauterine or early neonatal death.

With PBSP complications as a primary cause of death, infants died in direct connection with the occurrence or aggravation of one or more of the complications, either in utero, or neonatally after onset of spontaneous labour.

As a primary cause of death other complications accounting for four deaths were kernicterus (1), sepsis (1), thrombocytopenia hereditaria (1) and severe hepatitis in the mother (1).

In the next column, PBSP complica-

tions did not occur directly connected temporally with death, nevertheless the pregnancy was 'marked', since perinatal mortality is more than 30 per cent in pregnancies in which PBSP occurs, as opposed to 7 per cent in those without PBSP being present (8).

The group 'bad obstetrical history' includes 9 women who in their diabetic state had borne only infants dying perinatally, a group of diabetic women known to have a greater incidence of foetal death, although the cause is unknown (5).

"Other complications" in this column comprise 5 pregnancies in which identical circumstances appeared. Uncertainty of the stage of pregnancy and entirely wrong estimation of the size of the foetus—hence labour was induced either too late or too early with subsequent intrauterine death or delivery of a very premature baby, respectively 3 pregnancies belonged to White's class F without additional complications, while a variety of complications accounted for a further 2 pregnancies.

In 15 women (9 per cent) without major complications, the course of preg-

nancy and delivery was uneventful, but perinatal death occurred quite unexpectedly 5 infants with a birthweight of 2500 g or more died neonatally with symptoms of respiratory distress 10 infants died in utero from 7 to 3 weeks before calculated term Only two had a birthweight less than 2500 g, and no common features could be found for the 10 infants

In Tables II and III the material has been divided into 2 ten year periods, 1946 to 55 with a total of 285 infants including 63 perinatal deaths, and 1956 to 65 with a total of 561 infants including 104 perinatal deaths The incidence of fatal congenital malformations and obstetrical complications, respectively, is compared in the two periods (Table II) Over 10 years, congenital malformations have doubled, while ob-

stetrical complications as a cause of death have decreased to one fifth

The incidence of PBSP was almost identical in the two periods (Table III), but there are marked differences between the four groups constituting PBSP Clinical pyelonephritis and toxæmia have increased while precoma and the group "neglectors" have decreased through the years

In table IV we have compared our material of autopsied infants dying neonatally during the period 1960-65 with a corresponding six-year material (1959-64) from Boston Lying in Hospital (7) Several interesting features can be observed in this table There is no significant difference in neonatal mortality, in the Boston material, however, the neonatal period was 30 days The distribution of causes of deaths is similar in the two ma-

TABLE II

*Fatal congenital malformations and obstetrical complications in two periods (material 167 infants)*

Period	No. of deaths	Fatal congenital malformations		Fatal obstetrical complications	
		Per cent of			
		Deaths	Total no. of infants	Deaths	Total no. of infants
1946-1955	63	7.9	1.7	27.0	6.3
1956-1965	104	17.3	3.2	6.7	1.2

TABLE III

*Prognostically bad signs during pregnancy (PBSP) in two periods (material 167 infants)*

Period	No. of deaths	Clinical pyelonephritis	Toxæmia	Precoma or severe acidosis	Neglectors	Total
		Per cent of death				
1946-1955	63	3.2	11.1	25.4	9.5	49.2
1956-1965	104	8.7	19.2	13.5	3.1	44.5

terials, with infections as one possible exception

The combined material undoubtedly gives a true picture of the causes of neonatal death during recent years. Half the deaths were due to hyaline membrane disease and other respiratory problems, one fourth of the deaths were due to congenital malformations and one fourth to other causes including infection, extreme prematurity and birth injury.

### DISCUSSION

The classification of perinatal death (Table I) is mainly based on the clinical circumstances that precede death. Information from the autopsy records was only used in the case of kernicterus and in a few cases of congenital malformation. Death was unexplained (and unexpected) in 9 per cent of the infants dying, or in 18 per cent of the total number of infants of diabetic mothers. Baird et al (1) studied 1008 infants dying perinatally in a maternity hospital during the period 1938 to 1952,

and Fairweather et al (4) studied 549 infants from an English city in the period 1960 to 1962. Both studies used a clinico-pathological classification which in many respects was similar to that applied in the present study. In the two materials, unexplained death in relation to the perinatal mortality was 33 and 18 per cent, respectively, as compared to 9 per cent in our material, and 13 and 0.7 per cent, respectively, as a percentage of the total number of infants, as compared to 1.1 per cent in the diabetic material (Table V).

In contrast to the general opinion, it would appear that the incidence of unsuspected and unexplainable perinatal deaths is no higher in diabetic pregnancy than in the population at large. The erroneous general opinion has no doubt been influenced too much by the high perinatal mortality in infants of diabetic mothers.

The decrease in fatal obstetrical complications, precoma and acidosis during the last decade illustrates the better management and control of pregnant dia-

TABLE IV  
*Primary cause of neonatal death at autopsy<sup>1)</sup>*

Cause of death	Boston material ) 39 deaths (8 per cent) among 473 infants	Copenhagen material ) 35 deaths (9 per cent) among 383 infants	Materials combined
Hyaline membrane disease	18 (46)	15 (43)	33 (45)
Respiratory problems (pneumonia, pulmonary haemorrhage, atelectasis)	3 (8)	5 (14)	8 (11)
Congenital malformation	10 (26)	11 (31)	21 (28)
Infection	1 (3)	1 (3)	2 (3)
Extreme prematurity	1 (2.5)	1 (3)	2 (3)
Other	1 (2.5)	2 (6)	3 (4)
Totals	39 (100)	35 (100)	74 (100)

<sup>1)</sup> adopted from Hubbell et al (1965)

<sup>2)</sup> percentage of deaths in parentheses

TABLE V

*Unexplained death in relation to perinatal mortality and total number of infants*

Material	Perinatal mortality Per cent	Unexplained death in relation to perinatal mortality Per cent	Unexplained death in relation to the total number of infants Per cent
Present series 846 infants of diabetic mothers	19.7	9	1.8
Baird et al (1954) 26116 unselected infants from a maternity hospital	3.8	33	1.3
Fairweather et al (1966) 14698 unselected infants from an English city	3.8	III	0.7

betic women. The rise in toxæmia in the same period is in good accordance with the increasing number of patients belonging to White's group D and I with vascular complications who were seen during the period. This also applies to the increase in fatal congenital malformations, since we have observed a strong positive correlation of congenital malformations with maternal vascular complications (9).

From previously published autopsy series (2, 3, 7) and the present material (Table IV), the fact emerges that 50 per cent of neonatal deaths had hyaline membrane disease with pulmonary atelectasis as the sole demonstrable patho-anatomical cause of death. In the other half (with and without hyaline membrane present), major causes of death were demonstrated: fatal congenital malformation, birth injuries, inflammatory lesions and miscellaneous causes.

These results underline the familiar fact that the respiratory distress syndrome is still the crux of management of the neonate of diabetic women, and furthermore, that congenital malformation plays a significant role as a cause of death.

## SUMMARY

Causes of perinatal death were analysed from a clinico-pathological point of view in a consecutive series of 167 infants of diabetic mothers. In 60 per cent the perinatal deaths were not unexpected and fully explained. In 30 per cent the not unexpected deaths could not be definitely explained, while in about 10 per cent the deaths were unexpected as well as unexplainable. The last figure is similar to, or less than figures given for the population at large.

Fatal congenital malformations have doubled, while fatal obstetrical complications as a cause of death have decreased to one fifth during the last 10 years. During the same period, clinical pylonephritis and toxæmia have increased, whereas precoma and severe acidosis and the state of being a "neglector" have decreased considerably as causes of death.

An autopsy study of causes of death in infants of diabetic mothers, dying neonatally during recent years (1960-1966), was in good accordance with an American investigation. Half of the deaths were due to hyaline membrane

disease and other respiratory problems, one fourth were due to congenital malformation and one-fourth to other causes including infection, extreme prematurity and birth injuries

# ACKNOWLEDGEMENTS

We wish to thank dr Inge Tygstrup who personally performed the lung microscopy and kindly gave her assistance with pathological problems

# REFERENCES

- 1 Bard D Walker J & Thomsen A M (1954) *Journ Obstet Gynaec Brit Emp* 61 433
- 2 Cardell B S (1953) *Journ Obstet Gynaec Brit Emp* 60 834
- 3 Driscoll E G Benirschke K & Curtis G W (1960) *Amer J Dis Child* 100 818
- 4 Fairweather D V I Russel J K Andersson G S Bird T Miller D G & Percy P A M (1966) *Lancet* I 1940
- 5 Gellis S S & Hsia D Y Y (1959) *Amer J Dis Child* 97 1
- 6 Hagbard L (1956) *Acta Obstet et Gynec Scand* 35 suppl 1
- 7 Hubbell J P Muirhead D M & Drorbaugh J E (1965) *Med Clin North Am* 49 1035
- 8 Pedersen J & Pedersen L M (1965) *Acta Endocr* 50 70
- 9 Pedersen L M Tygstrup I & Pedersen J (1964) *Lancet* I 1124
- 10 White P (1949) *Amer J Med* 7 609



# SUBJECT INDEX

- Adipose tissue blood flow 85
- Adrenalectomy sulphonylurea effect in 114
- Alloxan diabetes 110 159
- Antihæmophilia factor 147
- Autoimmunological aspects 29
  - cellular insulin antibodies 35
  - changes in insulin molecular structure 30
  - humoral insulin antibodies 34
  - in long standing diabetes 37
  - insulins 35
  - isoantibodies 33
- Basement membrane thickening 133
- Blood coagulation 147
- Carbutamide 110
- Chinese hamster D M in 21
- Chlorpropamide 110
- Congenital malformations in D M 179
- Conjunctival vessels in D M 124
- Consanguinity 21
- Cortisone glucose tolerance test in offspring of diabetics 20
- Fibrinogen in D M 147
- Fœtal death in D M 175
- Genetics of D M 17
- Genotype phenotypical characteristics of the diabetic 24
- Glomerulopathy in experimental D M 159
- Glucose tolerance test diabetic twins 17 18
- Heparin insulin in plasma 116
- Heparin resistance time in D M 150
- Inheritance mode of in D M 19
- Insulinase resistance in D M 21
- Insulinase sulphonylurea effect on 114
- Insulin action
  - on brain 76 77
  - on central nervous system 75
  - on spinal cord 76
- Insulin antibodies
  - cellular 35
  - humoral 34
  - isoantibodies 33
- Insulin biosynthesis 54
- Insulin clinical use 92
- Insulin deficiency in D M 159
- Insulin in plasma 43 68
  - immunologically active 43
  - insuline complex 46
  - non suppressible ILA 44
- Insulin in spinal fluid 79
- Insulin in urine 68
- Insulin iodine labelling 56 60 62 63 66
- Insulin secretion 53
- Insulin sensitivity sulphonylureas 112
- Insulin storing 53
- Insulin undesirable effects 93
- Insulin like activity (ILA) 43 47
  - effect of sulphonylurea on 114
  - in plasma fractions 48
- Insulinitis 33
- Kimmelstiel Wilson lesion 164
- Microaneurysm in D M 124
- Microangiopathy functional 127
- Microangiopathy in D M 123
- Morbid risk general population 19
- Mouse D M in 21
- Mucopolysaccharide deposition 159
- Nervous system in experimental D M 170
- Pancreatectomy 111
- Postprandial blood glucose 102
  - in juvenile D M 106
  - in stable D M 103
- Prediabetic state blood vessels in 123
- Pregnancy in D M 175
- Proconvertin in D M 148
- Recalcification time 150
- Retinopathy and microangiopathy 132
- Sodium capillary diffusion in D M 133
- Sodium diffusion in D M 134
- Sulphonylureas  $\beta$ -cell stimulation 109
  - in D M 109
  - insulin like activity 114
- Synalbumin insulin antagonist 22
- Thrombocytes in D M 155
- Tolazamide 110
- Tolbutamide 110
- Twins D M in 17
- $^{131}$ Xenon clearance in D M 136













# ACTA MEDICA SCANDINAVICA

SUPPLEMENTUM

## DIABETES IN S

A clinico-statistical, epidemiological  
study of hospital patients and

By

ALBERT GRÖNBERG, M.D., M.Sc.,  
M.D., M.Sc., M.D., M.Sc.

# ACTA MEDICA SCANDINAVICA

has been published since 1919 as a continuation of *Nordiskt Medicinskt Arkiv*, founded in 1869 by Axel Key. The first volume of *Acta Medica Scandinavica* is therefore numbered LII (52).

The chief editors have been Axel Key 1869—1900, C. G. Santesson 1901—1915, I. Holmgren 1916—1957 and Burger Strandell 1958 to date.

*Acta Medica Scandinavica* publishes original research papers in the field of internal medicine. Priority will be given to authors from countries which are represented on the editorial board. Contributors from those countries should submit their papers to a representative of the country in question. Contributors from other countries should send their papers to the Editor at the address below.

Submission of a manuscript for publication will be held to imply that the paper has not been published elsewhere and that, if accepted, it will not be republished in any other journal in the same or similar form, without the Editor's written consent.

Papers will be published in English, French or German at the authors' choice, followed by a summary in English.

The manuscripts shall be in final form as submitted. They shall be typewritten with double spacing and broad left hand margin.

If a paper exceeds 16 printed pages, the cost for the excess pages shall be borne by the author. No paper shall exceed 24 printed pages.

## Subscription

The annual subscription to the journal, covering two volumes each of 5 numbers, is 140 Sw. crowns or U.S. \$27.25, including postage in the Scandinavian countries and in Holland 120 Sw. crowns.

*Address for subscriptions and all communications*

ACTA MEDICA SCANDINAVICA

P. O. Box 2052, Stockholm 2

---

Requests for duplicate copies of numbers that have gone astray can only be considered if made within a fortnight of the receipt of the following number.

# DIABETES IN SWEDEN

A clinico-statistical, epidemiological and genetic study  
of hospital patients and death certificates

By

ALBERT GRONBERG, TAGE LARSSON and JAN JUNG

---

STOCKHOLM 1967



English text revised by RICHARD COX

Albert Gronberg M D

Formerly Physician in Chief

Department of Internal Medicine County Hospital Vanersborg

Address Styrmansgatan 2 Vanersborg Sweden

Tage Larsson M D F L

Chairman of the Medical Research Council of the Swedish Life Offices

Member of the International Statistical Institute and the Commission of Neurogenetics of the World Federation of Neurology

Address Karlbergsvagen 44 II Stockholm Va Sweden

Jan Jung F L

Senior Statistician and Executive Member of the Research Council for Actuarial Science and Insurance Statistics

Address Tranvagen 13 Saltsjobaden Sweden

## Foreword

---

The Medical Research Council of the Swedish Life Offices was founded in 1950 with the objects of promoting medico-actuarial research and supporting scientific studies in fields of medicine concerned with diseases which according to available statistics, have a particular bearing on the economy of the life insurance companies.

For several years research grants have been given to basic research of problems connected with diabetes mellitus. On the suggestion of Dr Arthur Engel, Director General of the National Board of Health and Chairman of the Advisory Board of the Council, and Dr Albert Grönberg, Physician in Chief at the Department of Internal Medicine of the County Hospital at Vänersborg, the Council decided to sponsor a retrospective study of certain Swedish hospital data on diabetes mellitus. The planning of this study was performed in collaboration between a great many medical and statistical experts, in particular the physicians in-chief at the

departments of internal medicine of the investigation hospitals selected. Drs Albert Grönberg at Vänersborg, Olle Hogeman at Falun, Ian Lundholm at Östersund and Otto Östberg at Vaxjö, and the statisticians Drs Per Olof Berge, Jan Jung, Tage Larsson and Carl Philipson.

For the technical data processing the equipment of the Hansa Insurance Group has kindly been made available under the supervision of Mr Bertil Eklund.

The study of the clinical material has been supplemented with a special processing of population statistics on causes of death, a parallel investigation by Dr Larsson with regard to cerebrovascular disease has recently been published.

Further a discussion of the genetic problems in diabetes mellitus has been included in the present study.

It is the hope of the Council that this volume will prove of interest to both clinicians and research workers.




Fig 1 Map of Sweden

# Contents

---

Foreword	3
List of tables	8
(List of figures p 274)	
Explanation of terms and symbols	12
Introduction	15
<b>I General aspects on diabetes mellitus (DM) and treatment practices in Sweden</b>	18
The organization of health services in Sweden	18
Treatment practices in respect of DM	20
The diagnosis of DM	24
The hospital series studied	27
Classification by age at onset	29
Some factors of importance for the development and course of DM	30
<b>II Material for the clinical study of DM</b>	33
General aspects	33
Selection of hospitals	35
The scope of the clinical material	42
Admission rates and domicile	52
Frequency of admissions	58
<b>III Mortality among DM patients</b>	61
Material and methods	61
Mortality by age	62
Mortality in separate years	63
Mortality and duration	63
Mortality and age at onset	64
Inferences from the mortality study of DM patients	65
<b>IV Mortality and morbidity risks for DM and its prevalence in Sweden</b>	66
General aspects	66
The material	69
Statistics on mortality from DM	70

Total mortality	70
Mortality from DM in the whole country 1961-63	72
Possible gaps in the registration of DM	77
Registration of DM as the primary cause of death and the frequency of autopsies by sex and age	80
Frequency of autopsies by cause	80
Mortality from DM by county and in rural and urban areas	82
Primary cause for deaths with DM as a contributory cause	93
Registered mortality from DM before 1961	97
Mortality from DM in 1965	103
The completeness and representativity of the data on mortality from DM	105
Morbidity risks for DM and its prevalence in Sweden	106
Selective factors connected with excess mortality	107
Minimum estimate from total death share	108
Minimum estimate from death share above a certain age	108
Assessment based on assumptions concerning excess mortality	109
Number of diabetics in Sweden	113
Excess mortality	116
Morbidity risks for DM	117
Life-table expectancy for DM	118
Inferences from the study of death certificates	119
<b>V Patients, symptoms and complications</b>	121
Age at onset	121
Hyperglycaemia, glucose tolerance tests	122
Glycosuria, "control"	124
Heredity	126
Overweight	127
Constitutional type	130
Blood pressure	132
Menarche childbirth and menopause	138
Menarche	138
Menopause	139
Pregnancies before the onset of DM	139
Pregnancies after the onset of DM	141
Perinatal mortality	142
Acute complications	142
Acute infections	143
Diabetic coma and pre-coma	143
Hypoglycaemia hypoglycaemic coma	145
Tuberculosis	145
Chronic urinary tract infections	147

<b>VI</b>	<b><i>Treatment</i></b>	<b>149</b>
	Diet therapy	150
	Insulin therapy	153
	Type of insulin	155
	Number of injections	155
	Quantity of insulin	157
	Complications and preventive measures	162
	Working capacity	163
	Oral hypoglycaemic agents	164
<b>VII</b>	<b><i>Late complications</i></b>	<b>167</b>
	Diabetic retinopathy (Rd)	167
	Diabetic retinopathy in the hospital series	169
	Prevalence of retinopathy among DM patients	172
	Incidence of retinopathy	172
	Retinopathy frequency and cause of exit	173
	Retinopathy frequency with regard to hospitals and epochs	176
	The occurrence of different retinopathy states	177
	Retinopathy and control	178
	Diabetic nephropathy (Pd)	180
	Diabetic nephropathy in the hospital series	180
	Prevalence of nephropathy among DM patients	181
	Incidence of nephropathy	181
	Nephropathy frequency with regard to hospitals and epochs	187
	The occurrence of different nephropathy states	187
	Diabetic neuropathy (Ud)	189
	Diabetic neuropathy in the hospital series	192
	Prevalence of neuropathy among DM patients	192
	Neuropathy frequency with regard to hospitals and epochs	193
	The occurrence of different types of diagnoses of neuropathy	193
	Osteopathy	195
	Vascular lesions	196
	Other diseases	197
	Thyrotoxicosis	197
	Allergic diseases	198
	Tumours	198
	Rheumatoid arthritis	198
	Fernicious anaemia	199
<b>VIII</b>	<b><i>Rating of DM risks in life and health insurance in Sweden</i></b>	<b>201</b>
	General developments	201
	Technical methods	203

Premiums for standard risks	203
Rating of DM risks 1945-67	204
Remaining mean expectation of life	207
Group life insurance	208
Group health insurance	210
Present situation and further considerations	210
<b>IX <i>Genetics of DM</i></b>	214
Current conceptions and discussions	214
Sex differences	226
The theory of sex linked dominance	228
Probability evaluations	230
Autosomal dominance	230
Autosomal recessiveness	231
Sex linked dominance	232
Numerical example	233
Genealogical statistics	235
The Kristianstad studies	235
The data published by Harris (1950)	240
Special investigation at Falun (W)	242
Follow up investigation at Vanersborg (P)	242
Discussion	248
The high prevalence of the DM genotype	252
Inferences from the genetic analysis	253
<b><i>Summary and conclusions</i></b>	255
<b>References</b>	262
<b>List of figures</b>	274

## Tables

---

1	Registration periods and annual number of first admissions	41
2	Population and number of patients by year of first admission	42
3	Population and number of patients by age at and year of first admission	45
4	Aggregate admission rates 1946-50 and 1951-55	46
5	Age at onset first registration and first admission to investigation hospital	47
■	Average interval from onset to first registration and first admission	48

7A	Registrations by age groups at onset and duration of DM	49
7B	Patients by age at onset and registrations by age at onset and duration of DM	50
8	Mean age in groups by sex hospital, age at onset and duration	52
9	Registrations by age groups at onset and duration, grouped by first calendar year within the registration period (epoch)	53
10	Survey of course of registration	54
11	Population and first admissions geographical distribution	56
12	Population 1950 first admissions 1946-55 and aggregate admission rates 1946-55 by district	57
13	Number of admissions and average annual frequency of admissions by sex, duration and age at onset	58
14	Variations in admission frequency between hospitals and epochs	59
15	Mortality of DM patients by sex and age 1946-55	62
16	Mortality of DM patients by sex and calendar year 1946-55	63
17	Mortality of DM patients by sex and duration 1946-55	64
18	Mortality of DM patients by sex and age at onset 1946-55	64
19	Deaths from DM in Sweden 1961-63	70
20	General death rates by sex and age 1946-65	71
21	Population total deaths deaths from DM and death shares by sex and age 1961-63	73
22	Death rates for different causes by sex and age 1961-63	75
23	Number of deaths from diabetes and cerebrovascular disease percentage primary diagnosis and percentage autopsies by sex and age 1961-63	79
24	Age-standardized comparison between observed and expected number of autopsies 1961-63	83
25	Age standardized mortality ratios by sex and county for all causes of death, and for the primary causes diabetes (A63) cerebrovascular disease (A70) and arteriosclerotic and degenerative heart diseases (A81) 1959-62	84
26	Age standardized comparison between observed and expected number of deaths from DM by sex and domicile (county, rural, urban) 1961-63	86
27	Age standardized comparison between observed and expected number of deaths from DM by sex and domicile (certain areas) in groups by age 1961-63	88
28	Distribution by primary cause of deaths with DM as a contributory cause 1961-63	95
29	Mortality from DM (main cause primary cause) by sex and age 1911-63	99
30	Age standardized comparison between observed and expected mortality from DM (primary cause) 1951-63	100
31	Death shares for DM (primary cause) by county 1955-64	102
31A	Deaths by sex and multiple causes 1965	103
31B	Mortality from DM by sex and age 1965	104
31C	Age-standardized comparison of mortality from DM in 1961-63 and 1965	104
32	Assessment of morbidity risks for DM and its prevalence in Sweden 1961-63	111
33	Calculated number of diabetics in Sweden (average for years 1961-63)	113



34	Morbidity risks for DM	117
35	Life table expectancy for DM	119
36	Age at onset of DM averages and percentage distributions	121
37	Percentage distribution by control (glycosuria) within groups by sex age at onset and duration	125
38	Percentage distribution by control (glycosuria) within groups by sex age at onset and hospital duration 0-4	125
39	Diabetic relatives of DM patients at Vänersborg	126
40	Overweight among DM patients at Vänersborg in the general population of Bergen and among hospital patients at Karlskoga by sex and age	128
41	Overweight among DM patients at Vänersborg by sex, age at onset and duration	129
42	Distribution by registered constitutional type	131
43	Frequency of hypertension in duration groups 0-4 and 10-14 by sex and age	134
44	Frequency of hypertension by sex age at onset and duration	136
45	Pregnancies before first admission Duration 0-4 Vänersborg	140
46	Pregnancies after first admission. Vänersborg	141
47	The occurrence of pre-coma and coma by sex, age at onset and duration	144
48	Diet by sex hospital age at onset and duration	150
49	Insulin treated patients by sex hospital age at onset and duration	152
50	Type of insulin by sex age at onset and duration	156
51	Number of insulin injections per day by sex, hospital age at onset and duration	158
52	Quantity of insulin per day by sex hospital age at onset and duration	160
53	Increased prevalence of diabetic retinopathy since the introduction of insulin therapy (after Dardenne 1962)	168
54	Percentage frequency of diabetic retinopathy by sex age at onset and duration (after Kornerup 1955)	168
55	Registered state of retinopathy by sex age at onset duration epoch and hospital	170
56	Frequency of retinopathy by sex age at onset and duration	173
57	Calculated incidence and prevalence of retinopathy by sex, age at onset and duration	174
58	Standard comparison of retinopathy frequency by sex and cause of exit	175
59	Standard comparison of retinopathy frequency by sex hospital and epoch	175
60	Frequency of retinopathy observed at hospitals P W and Z in the later epoch by sex age at onset and duration	177
61	Frequency of different states of retinopathy in the later epoch by duration both sexes	177
62	Intensity of retinopathy by duration both sexes	178
63	Standard comparison between hospitals of states of retinopathy in the later epoch both sexes	178
64	Frequency of retinopathy by sex, age at onset hospital and treatment, durations 10-14 and 15-19	179
65	Registered state of nephropathy by sex age at onset duration epoch and hospital	182

66	Frequency of nephropathy by sex age at onset and duration	184
67	Changes in the registered state of nephropathy by sex age at onset and duration	185
68	Calculated incidence and prevalence of nephropathy by sex age at onset and duration	186
69	First appearance of renal insufficiency by sex age at onset and duration	187
70	Standard comparison of nephropathy frequency by sex hospital and epoch	188
71	Standard comparison of states of nephropathy by hospital and by epoch	188
72	Registered state of neuropathy by sex age at onset, duration epoch and hospital	190
73	Frequency of neuropathy by sex age at onset and duration	192
74	Standard comparison of neuropathy frequency by sex hospital and epoch	193
75	Standard comparison between hospitals of diagnosis of neuropathy, both sexes	194
76	Frequency of neuropathy observed at hospitals W and Z in the later epoch by sex age at onset and duration	194
77	Frequency of vascular lesions by sex and age	196
78	Standard comparison of vascular lesion frequency by sex age at onset and duration	197
79	Assumed mortality for standard risks according to life tables D28 D37 D55 and M64	204
80	Rating of uncomplicated DM risks in individual life insurance from 1956 onwards and calculated mean expectation of life Males	207
81	Mean expectation of life in the general Swedish population 1961-65 according to life table M64 for standard risks and with ratings H1 H2 H3 and H4 Males and females	208
82	Probability evaluations for autosomal dominance and autosomal recessiveness (from Larsson & Sjögren 1966)	231
83	Probability evaluations for sex linked dominance with frequency of DM genotype among females 13 per cent	234
84	Registered prevalence of DM in Kristianstad County (L) by sex domicile and age 1954 (after Silver 1958)	236
85	Comparison of aggregate morbidity risks according to inventory of Kristianstad County (L) 1954 and with assessment based on mortality statistics 1961-63	237
86	DM relatives of DM probands by sex and age of proband (from data published by Harris 1950)	239
87	DM relatives of DM probands by type of mating (from data published by Harris 1950)	241
88	DM relatives of DM probands by type of mating (data from Falun W)	243
89	DM relatives of DM probands by type of mating (data from Vanersborg P)	244
90	Families with at least three affected probands and sibs of probands Vanersborg	246

## Explanation of terms and symbols

---

DM = Diabetes mellitus

*Grouping by age at onset (O) and duration (D)* As a rule the clinical data are grouped by 5 year classes according to age at onset of DM (0-4 5-9 etc) and by 5 year groups according to the duration of DM (0-4 5-9 etc) In order to save space the following notations are sometimes used in respect of groups by duration

a = 0-4  
b = 5-9  
c = 10-14

d = 15-19  
e = 20-24  
f = 25-

*Age* Where the age at a certain event is calculated as the difference between the calendar year of the event and the calendar year of birth the expression *age* is applied Where the exact age is rounded off downwards the expression *attained age* is used If the material has been primarily classified into 5 year groups by age at onset and duration the patient's age has generally been calculated by adding the age at onset and the duration (both in 5 year groups) where this procedure has been applied the expression *average age* is used *Example* age at onset 20-24 (average 22) duration 15-19 (average 17) hence average age 39

*Onset type (T)* To a great extent it has proved suitable to concentrate the grouping by age at onset into three types viz.

Juvenile onset (J) = age at onset 0-14  
Early adult onset (A) = age at onset 15-39  
Late onset (L) = age at onset 40-

*Sex* With a few exceptions all data are given by sex

M = Males  
F = Females

*Geographical notations* County (domicile) is denoted by the capital letter used in registration numbers for motor vehicles (cf Fig 1) For the sake of clarity however Älvsborg County is denoted by PQ (not by the official letter P alone) P is used for the northern part and Q for the southern part

*Admission areas of the investigation hospitals*

P = Älvsborg County northern part (Fig 2 p 36)  
G = Kronoberg County (Fig 3 p 38)  
W = Kopparberg County (Fig 4 p 39)  
Z = Jämtland County (Fig 5 p 40)

*Geographical division of the admission areas* (cf Figs 2-5) see Table 11 p 56

**Investigation hospitals** For convenience and since no misunderstanding is possible the geographical notations have been applied to the four county hospitals covered by the clinical study viz.

- P = Vänersborg  
G = Växjö  
W = Falun  
Ö = Östersund

**Investigation periods**

The clinical series in the main 1931-56 (cf Table 1 p 41)

Mortality in the clinical series 1946-55

The population study on mortality (causes of death) 1961-63

**Epoch (E)** For the analysis of certain time trends the clinical series has been divided into two epochs viz.

E1 or earlier epoch = duration periods beginning in 1949 or earlier

E2 or later epoch = duration periods beginning in 1950 or later

**Clinical data** can concern the presence or absence of a certain complication the maximum value the mean value etc as will be stated in the text

**Occasion** (occasion card) = the data registered during a certain admission (as inpatient or as outpatient)

**Registration** (duration card) = the data registered at occasions during a given 5 year duration period

**Late complications**

Rd = Diabetic retinopathy (Retinopathia diabetica)

Pd = Diabetic nephropathy (Nephropathia diabetica Proteinuria diabetica)

Ud = Diabetic neuropathy (Neuropathia diabetica)

(The letter N has been avoided in this connection instead the third letters have been used viz P and U respectively)

**Causes of death** Since 1951 the statistics on causes of death in Sweden have been presented in accordance with the WHO scheme *Manual of the international statistical classification of diseases injuries and causes of death* Geneva 1948 and 1949 Certain amendments have been adopted in particular some from 1960 with regard to the delimitation between accidents and disease when stating the primary (underlying) cause of death As a rule the data given here refer to the Intermediate List (the A list) The following notations are used (abbreviations in *italics*)

I	Infective and parasitic diseases (A1-A43)	<i>Infect</i>
II	Neoplasms (A44-A60)	<i>Neopl</i>
D	Diabetes mellitus (A63 = 260)	<i>Diab</i>
VI	Diseases of the nervous system and sense organs (A70-A78)	<i>Nerv</i>
C	Cerebrovascular disease (A70 = 330-334)	<i>Cerebr</i>
VII	Diseases of the circulatory system (A79-A86)	<i>Circ</i>
VIII	Diseases of the respiratory system (A87-A97)	<i>Resp</i>

IX.	Diseases of the digestive system (A98-A107)	<i>Digest</i>
X	Diseases of the genito-urinary system (A108-A114)	<i>Gen urin</i>
Oth.	Other diseases (A61-A62 A64-A69, A115-A135)	<i>Oth dis</i>
XVI	Symptoms, senility and ill-defined conditions (A136-A137)	<i>Unknown</i>
XVII	Accidents poisoning, and violence other than suicide (AE138-AE147 AE149-AE150)	<i>Accidents</i>
XVIII	Suicide (AE148)	<i>Suicide</i>
Viol.	XVII + XVIII	<i>Violence</i>

Unless otherwise stated all statistical data in Chapter IV refer to the period 1961-63

#### *Abbreviations in Chapter IV*

- P =  $3 \times$  average population 1961-63  
 T = Number of deaths 1961-63  
 D = Number of deaths from DM 1961-63  
 C = Number of deaths from cerebrovascular disease 1961-63  
 T/P = Death rate (as a rule given by sex and age)  
 D/T = Share of deaths from DM (as a rule given by sex and age)  
 D<sub>i</sub>P = Death rate for DM

Area u = urban r = rural

Classification of causes of death (annexed lower-case letter)

- p = primary (underlying) cause  
 c = contributory cause (or complication)  
 t = total =  $p + c$

Autopsy (annexed lower-case letter)

- a = autopsy performed

#### *General remarks*

Other abbreviations are explained in the tables in which they are used

Population data for a calendar year refer to the end of the year

In some of the tables exaggerated exactitude has to a certain extent been used

In order to avoid obscurity simple plotting of class data is used in the figures although in many instances histograms would have been appropriate

#### *Currency*

All amounts are in Swedish kronor in 1967 the equivalent of 1 000 kronor is about £ 70 sterling or 195 U.S. dollars.

#### *Symbols*

- per cent  
 — magnitude nil  
 data not available or too small to permit calculation  
 = category not applicable

## Introduction

The present study concerns *clinical diabetes mellitus* (DM) in Sweden

It is a widespread opinion that the incidence of DM has been increasing during later decades possibly for both genetic and environmental reasons. It is also widely held that although early deaths from DM can to a great extent be prevented or postponed thanks to insulin therapy the incidence of late complications in the form of retinopathy, nephropathy and neuropathy is steadily rising. In some quarters it is maintained that insufficient dietetic control has largely contributed to this development.

There are three main ways of approaching these important problems:

(a) epidemiological population studies in order to evaluate the prevalence of DM (and various DM complications) by sex and age

(b) statistical mortality studies in order to evaluate the significance of DM (and its various complications) as a cause of death hence the excess mortality for diabetics and in order to evaluate the prevalence of DM among deaths by sex and age

(c) clinical studies of DM patients in order to evaluate the course of the disease by time, sex, age at onset, duration and treatment including among

other things the incidence of various complications

In some counties in Sweden screening investigations on a large scale have been performed or are in progress, with a view to ascertaining the prevalence (by sex and age) of clinically manifest diabetes and of suspected prediabetes (diabetic glycosuria, hidden diabetes and in addition, renal glycosuria)

In certain university clinics (departments of internal medicine, ophthalmology and paediatrics) there have been performed thorough studies of late complications in long standing diabetes and of the special features encountered in child diabetes. There have also been a number of investigations of hospital patients dealing with variations by time (hence comparison between different periods) and by treatment (hence comparison between different diets, different types of insulin etc.). Some of these studies will be reviewed and discussed in the following chapters.

As a matter of fact, current opinions concerning the morbidity risk and the prevalence of DM in different groups by sex and age and the excess mortality for diabetics by age at onset and duration are not supported by reliable investigations in Sweden but are mainly based on

experience from other countries, especially the USA. With regard to late complications and the role of diet, etc the results obtained diverge in many respects and this can, at least in part, be ascribed to a series of selective factors. In what follows a fairly large amount of space will be devoted to the analysis of such selective factors, in particular those occurring in retrospective studies of clinical material.

The material used in this investigation consists of mortality statistics and hospital records only: no screening or other population studies were performed.

Since 1951, the WHO classification of causes of death has been applied in Sweden but deaths from DM were also registered in the older classification schemes. In fact during a certain period the instructions for the statistical classification contained the rule that if the deceased person had not succumbed from violence (accident, suicide, homicide) or cancer and had been afflicted with diabetes, diabetes should always be considered the cause of death. Although this practice was abandoned many years ago it long had—and still has—the effect that as a general rule doctors making out a death certificate will mention DM—as the primary cause or as a contributory cause—whenever they are aware that the deceased person was afflicted with diabetes. Until 1960 the processing of the statistical data on causes of death referred to primary causes alone but since the beginning of 1961 data on contributory causes and complications have been included. The material from the years 1961–63, in all 3 324 deaths with DM as the primary

cause and 7,273 deaths with DM as a contributory cause, is analysed in Chapter IV.<sup>1</sup>

For the study of hospital patients—inpatients as well as outpatients—there were selected, for special reasons, four medium sized general hospitals in different parts of Sweden. These are the county hospitals of Vänersborg (in Älvsborg County, P), Växjö (in Kronoberg County, G), Falun (in Kopparberg County, W) and Östersund (in Jämtland County, Z). The registration covers only the departments of internal medicine at these hospitals, hence not the paediatric departments. The reasons for selecting these hospitals will be presented in Chapter II. In all, this material covers 3,759 patients registered at the hospitals as afflicted with DM, mainly during the period 1931–56, with a total of about 45 200 admissions (or readmissions) and a total of about 19 700 observation years.

The data in the case records for these patients were transferred to punched cards (one for each separate admission, *occasion card*) and processed by computers into *duration cards* (one for each 5 year duration period, reckoned from the calendar year of onset of DM). These duration cards, in all 7,385 were in their turn used for the further processing of the data. The results of the analysis performed with regard to course and complications are given in Chapters V–VII.

For all 3 759 patients it was investi-

<sup>1</sup> Recently the Central Bureau of Statistics published detailed data on mortality patterns by primary cause in Sweden in 1961–63 (Bolander 1967).

gated whether they were still living at the end of 1955 or had died before that date and in the latter case, the year of death. This information was used for an analysis of the mortality of DM patients during the period 1946-55, covering in all 16 440 observation years and 398 deaths during the period. The results of this mortality study are presented in Chapter III.

In Chapter I a general discussion of clinical aspects on DM and Swedish practices in the treatment of the disease is given and in Chapter VIII the rating of DM risks in life and health insurance in Sweden is discussed.

The results from the analysis in Chap-

ter IV reveal that the prevalence of DM is far greater than has hitherto been considered to be the case. The life table expectancy for DM can be assessed at nearly 5 per cent for males and over 10 per cent for females; probably the total morbidity risk for DM is about 6.5 per cent for males and about 13 per cent for females. The implications of these findings for the theories of the genetic aetiology of DM are analysed in Chapter IX.

The general planning and scope of the investigation, statistical aspects on the projection, adaptation and judgment of clinical research and certain preliminary results of the clinical study have been reported earlier (Grönberg 1962, Larsson 1962, Jung 1962).



# General aspects on diabetes mellitus and treatment practices in Sweden

As mentioned in the Introduction the present study is mainly concerned with two problems viz the symptoms and course of clinically diagnosed DM and the incidence and prevalence of clinically (or patho-anatomically) diagnosed DM in Sweden. The study of the first of these problems is based on all patients admitted to the departments of internal medicine at certain county hospitals during periods beginning around 1930 and ending around 1956 (inpatients as well as outpatients). The study of the second problem is based on statistics concerning causes of death for the period 1961-63 (primary causes as well as contributory causes).

Of Swedish studies dealing with child diabetes may in the present connection in particular be mentioned those by Lichtenstein (1938, 1939, 1949, 1949-50), Lichtenstein & Larsson and Ploman (1952), Engleson (1954), Körnerup and Ström (1958), Y. Larsson (1962), Y. Larsson and Sterky (1962), Bergstrand, Furst, Y. Larsson and Sterky (1962), and Sterky (1963).

As a background certain data on the organization of health services in Sweden will be given and some general aspects concerning the treatment practices in Sweden in respect of DM will be discussed.

## The organization of health services in Sweden

With regard to the organization of the Swedish health services, it should be mentioned that all activities in the field of public health and medical care in Sweden are either operated or supervised by public authorities. The *National Board of Health* is the principal instrument of the state for governing, superintending and promoting the activities and the work of the institutions pertaining to this field. The main part of the administration of the somatic health services rests with local authorities. The county councils, 25 in number, or in six of the largest cities the borough councils, are responsible for seeing that the sick receive the hospital care required in addition within their field of responsibility fall the organizations concerning district public health nurses, district midwives, public dental care, etc. Until now, the state has administered the organization concerning the district medical officers (who receive a certain salary, are entitled to a state pension and have to follow a special tariff in charging fees).

At the end of 1930 when the population of Sweden was 6.14 million, there

were 2 376 authorized physicians, of whom 1 448 (including the district medical officers) were working in public service 791 were private practitioners and 137 had retired At the end of 1956, when the population was 7 34 million, the number of authorized physicians had increased to 6 045, of whom about 300 had retired From an international angle, the number of doctors may appear to be very low, but it should be pointed out that the number of qualified nurses and other medical personnel is large In 1956 there were more than 18,000 qualified nurses and the other medical personnel numbered over 83 000 (not including administrative and domestic staff at hospitals)

At the end of 1956, the number of beds in hospitals was about 107,500 of which 63 700 were in somatic hospitals (43,800 in mental hospitals and institutions for oligophrenics and epileptics) Of these 63,700 beds all but 1,600 were operated by public authorities In 1956 there were 910 000 admissions of inpatients at somatic hospitals (including homes for the chronically diseased) with a total of 18 86 million bed days These figures mean that on average 51,500 inpatients a day were treated in somatic hospitals At general hospitals proper (with 34,500 beds) the number of inpatients a day was 28 700 On average these latter hospitals were visited on each working day by 14 500 outpatients (not including patients at X ray departments) who were treated at polyclinics organized either by the authority responsible for the inpatients care or by the physicians in accordance with an agreement between them and the author-

ity, the first mentioned system applies to the four county hospitals included in the present study

Under the Swedish social security system health insurance has been compulsory since 1955 As a rule this insurance covers all fees charged for treatment in the public ward of a hospital three quarters of the fees for medical treatment of outpatients and the doctor's fees for treatment of patients outside the hospitals (limited however to three quarters of the amounts shown in the special tariff mentioned earlier) and the patient's necessary travel expenses (above 4 or 5 Swedish kronor) In addition this insurance covers loss of income during periods of illness (according to the rules introduced in 1955 about two thirds of the daily earnings corresponding to income up to 22 000 kronor a year, except in respect of the first three days, as from 1967 the coverage has been increased) To a great extent, these benefits are supplemented by means of private insurance (cf Alvarson 1966)

For medicines prescribed by a doctor the insurance covers 50 per cent of any cost exceeding 3 kronor Certain medicines among them insulin, are free of charge

Prior to 1955 health insurance was not compulsory but the majority of the active population had arranged for a similar coverage in respect of hospital care (where the fees charged for treatment in the public ward were very low anyhow) other medical treatment, and in certain although in general modest sum to compensate for loss of income

The international economic crisis of the early thirties affected Sweden less

than many other developed countries and during the last 30 years employment has been high. The standard of living has greatly improved, especially during the last few decades.

It may be said by way of summary that during the period studied there were no substantial economic obstacles to the obtaining of medical care in hospitals or from physicians.

### Treatment practices in respect of DM

With regard to the pre insulin era it may suffice to mention that dietetic regulations were ordinarily used in uncomplicated cases of maturity-onset DM. As a rule it was considered satisfactory when glucose in the urine was below 1 per cent.<sup>1</sup> Little attention was paid to the existence of acidosis. The diagnosis was based on anamnestic data and the presence of glycosuria. Blood sugar tests were not generally applied until the middle of the 1920's. It may further be remarked that patients with maturity onset DM often sought medical aid at a comparatively late stage of the disease, a common reason for doing so was the occurrence of carbuncles or threatening gangrene.

Since 1923 insulin treatment has been generally available in Swedish hospitals. Thus at the beginning of the period covered by our hospital series insulin therapy had been used for about seven years and Swedish doctors were familiar with the efficacy of the new remedy and with the techniques of the treatment. The results had been excellent. It is therefore

not surprising that most authorities were convinced that the main problems concerning the cause of DM and its treatment had been solved. The cause was a deficiency of insulin and the therapy should be administration of insulin at least for patients who had presented persisting glycosuria or hyperglycaemia. In many quarters the pessimism that—before the discovery of insulin—had prevailed with regard to the prognosis of DM was transformed during the twenties into an almost unbounded optimism. The high degree of success obtained even in rather severe cases with early onset of DM, was considered to justify this attitude, it should be remembered that at that time there was a very poor knowledge of the late course of juvenile DM.

The most impressive results of the insulin treatment were those observed in the management of acute complications such as ketosis and diabetic coma.

The type of insulin available in 1930 was what we now term regular insulin. Although this insulin was of good quality it had not the same degree of purity as has the insulin of today.

During the early thirties there appeared in the literature papers concerning renal damage and eye diseases which were considered to be connected with DM. In the patho-anatomical field great attention was paid to the clearly recognizable renal syndrome described by Kimmelstiel & Wilson (1936). From the social point of view interest was focused on the retinal changes—diabetic retinopathy—with its often very severe consequences in the form of reduced vision or

<sup>1</sup> For convenience this expression 1 per cent is used to denote 1 g sugar per 100 cc of urine.

blindness. Whereas nephropathy and retinopathy were much discussed the occurrence of diabetic neuropathy does not seem to have been closely studied during this period.

A valuable addition to the insulin therapy had been obtained in the middle of the thirties when Hagedorn and his co-workers (1936) succeeded in preparing protamine insulin and protamine zinc insulin. These are more slowly dissolved and absorbed than regular insulin, they act longer and may keep the blood sugar fairly normal for 24 hours (maximum duration 34-36 hours) whereas the maximum duration of regular insulin is 6-8 hours only. By introducing long acting insulin it was hoped that the insulin treatment could be reduced to one injection a day. To a certain extent this proved possible although many physicians held the view that one insulin injection daily did not give sufficiently good control of the disease.

The diets that had been evolved during the pre insulin period still played a predominating role at the beginning of the thirties. It proved very difficult to decide what position to take up concerning the diet for patients receiving insulin treatment. The prevailing attitude was that the carbohydrate intake should be restricted so much that the glycosuria was eliminated or at least reduced to a very low amount. However because a considerable reduction in the supply of carbohydrates gave rise to acidosis it was not possible to carry these restrictions beyond a certain limit. At the same time it was necessary that nutrition should be sufficient to keep the body weight at an acceptable level. The reduction of car-

bohydrates was therefore largely compensated for by means of an increased supply of fat.

In the literature from this period there are often references to the oat days recommended by von Noorden (1917) together with a drastic reduction of bread and other carbohydrates the patient was prescribed oatmeal porridge and other oat products on certain days in order to prevent the occurrence of acidosis. The diets recommended by Allen and by Joslin represent different technical procedures with the purpose of eliminating or reducing glycosuria and avoiding acidosis. Allen emphasized the importance of a low fat intake he considered a high fat diet dangerous fat being the mother substance of the ketone bodies. Fasting days were included in both these treatments.

In Sweden Karl Petren (Professor of Internal Medicine at the University of Lund) had suggested a diet that was widely used during the years preceding the discovery of insulin.<sup>1</sup> His prescriptions included a marked restriction of carbohydrate intake however a number of vegetables containing carbohydrates were allowed in free quantities. In practice it was white cabbage to which this unrestricted consumption came to apply. The most prominent difference in comparison with other diets was that Petren permitted his patients a large intake of fat he did not consider a daily consumption of 300 grammes of fat to be detrimental for in his opinion such an intake would not be accompanied by any increased production of ketone bodies. In Petren's treatment there were included

<sup>1</sup> Cf. Wilder 1955

fat and vegetable days during which the patient was forbidden to eat other carbohydrates than those present in the vegetables. It is noteworthy that a great many diabetics kept their disease under good control with this diet which differs so radically from what is nowadays considered to be the most suitable regimen for diabetics. The report of Petrén (1923) concerning his wide experience from the treatment of diabetic patients appeared at the time when insulin therapy began its triumphal progress all over the world.

The question of the most suitable amount of carbohydrates to include in the diabetes diet has been much discussed. At the Scandinavian Congress of Internal Medicine in Oslo in 1931 Norwegian experts argued in favour of an increase of the daily intake from about 100 grammes, which was at that time the most common recommendation to 250 grammes or more. Bang (1929) had found that urobilinuria which was considered to be due to a disturbed liver function was increased when the supply of carbohydrates was reduced so much that acidosis occurred. Bang and several other speakers at the congress held the view that an insufficient intake of carbohydrates could give rise to liver damages through hunger acidosis. Many have opposed this view but today Bang can be considered to have been right although he exaggerated the risks of liver damage arising in this way.

In Sweden there were in the 1930s several advocates of a free diet among them Söderling (1935), Lichtenstein (1938, 1939) and Møllerström (1939). As Professor of Paediatrics at Karolinska Institutet Lichtenstein had often met with

the great difficulties connected with the administration to children of a strictly regulated diet. In his opinion it was more important to keep the child in mental and psychological balance than it was to eliminate glycosuria and to keep blood sugar at the normal level. Møllerström (1939) considered that a sufficient administration of insulin could as a rule be arranged resulting in a good state for the diabetic without any restrictions in respect of his usual food. During the thirties there were considerable divergences concerning the suitability or unsuitability of the free diet.

Quite naturally, the discussion with regard to dietary regulations was more moderate in respect of maturity-onset DM than it was in respect of juvenile DM. Certainly it was maintained that for the former category a well regulated diet could help to prevent or postpone the occurrence of gangrene, and that with such a diet neck carbuncles would not occur or would take a less malignant course but these questions did not engage the protagonists in the same way as did the divergent opinions concerning the appropriate treatment of juvenile diabetes. As a rule the doctor was satisfied if the control of maturity-onset diabetes resulted in a 24-hour urinary excretion of glucose that did not exceed 1 per cent. It should be remembered that in those days no sulpha preparations or antibiotics were available. Infections of various kinds were important factors influencing the mortality among diabetics.

During the Second World War the supply of food was scarce and the most important foodstuffs were rationed. On the basis of observations of the inci-

dence of new cases of DM and the mortality from diabetes during this experiment in nutritional physiology it was argued that a reduced intake of food would prevent or postpone the onset of DM and would have a favourable effect in respect of the course of the disease. There were also adduced data from the First World War, for instance from Germany and Finland which were interpreted as indicating a reduced incidence of new cases and a lower mortality from diabetes during this period. Although the bearing of these statistics must be regarded as rather limited, there is no doubt that they led to greater interest being taken in the weight problems as regards diabetics.<sup>1</sup> The opinion that one of the objectives in the treatment of DM should be to combat overweight is nowadays generally accepted and the correctness of this view is borne out both by physiological experiments and by clinical observations.

At the end of our registration period viz around 1956 the methods of treatment had been largely stabilized. The general view was that the diabetic diet should be adequate from the viewpoint of nutritional physiology but low in calories. There was unanimity that overweight should be combated. As a consequence of this attitude towards overweight particular interest was given to the fat intake. In certain quarters it was held that this should be low and should preferably consist of polyunsaturated fatty acids, it was considered that this would bring about a favourable effect by reducing the cholesterol content in the blood. This in turn would have an advantageous effect in regard to the dia-

betic vascular lesions. The so called late complications—retinopathy, nephropathy, and neuropathy—were the object of intense study. In 1956 the general view was that these late complications were real consequences of DM and were mainly ascribable to an unsatisfactory control of the disease.

The general opinion today (1967) is that retinopathy and nephropathy are assignable to a vascular change—diabetic microangiopathy. Patho-anatomically, this lesion is characteristic, and it is regarded as specific for DM. During the last years it has been found that the presence of microangiopathy can already be established before the clinical picture of DM has developed. By this it is proved that the so-called late complications from the kidneys and the eyes are not to be interpreted as a consequence of clinical diabetes with a long duration but are vascular changes which run their course parallel with the clinical disease. It is still an open question whether the treatment and control of DM has any influence on the occurrence and course of the late complications mentioned. It is obvious, however, that from the statistical point of view there is a correlation between the duration of DM on the one hand and the prevalence and severity of the vascular changes on the other, in evaluating this correlation due account should of course be taken of mortality and other selective factors.

When giving advice to their diabetic patients Swedish doctors—like their colleagues in other countries—generally emphasize the importance of regular

<sup>1</sup> Cf I Vartiainen and O Vartiainen (1944) Saltzman (1945) and I Vartiainen (1947)

habits and the salutary effect of proper exercise. In these respects no changes in practice occurred during the period studied but of course there must have been individual differences connected with the character of the examinations and the length of the treatment, the symptoms and course of the disease, the patient's occupation and working capacity, as well as with the doctor's temperament and general attitudes.

## The diagnosis of DM

Around the end of our registration period, Elliott P. Joslin (1953) applied the following definition of DM: Diabetes is an hereditary disease in which there is an increase of sugar in the blood and excretion of sugar in the urine. It is dependent upon disease of the pancreas, particularly of groups of cells called the islands of Langerhans which have close connection with several other glands in the body. The secretion of the islands of Langerhans—insulin—not only promotes the normal storage of glycogen (animal starch) in the liver, muscles and skin and the combustion of glucose (sugar) in the tissues but also exerts a control upon the transformations of protein and fat. Thus at that time the conceptions concerning the mechanism of DM were largely the same as those prevailing in the twenties.

As stated already, our series of DM patients consists of persons admitted to the departments of internal medicine at four county hospitals. After the establishment of separate paediatric departments, children afflicted with DM are not

included unless they have attained an age of about 15 years; these patients will then as a rule be taken over by the departments of internal medicine.

In respect of juvenile diabetes the onset of DM is generally connected with marked acute symptoms. In respect of adults the onset is less alarming and often insidious but more or less typical symptoms—in the form of thirst, hunger, emaciation, loss of weight, weakness, frequent urination, itching, boils or carbuncles, 'sweet breath' odour, etc.—will often cause the patient to seek medical advice (either as an outpatient at a hospital or by consulting a physician outside the hospital). In developed cases, the symptoms are in general sufficiently clear to be interpreted as being due to DM; however, since for patients with symptoms of the kind mentioned urine examination is routine, the doctor will base his preliminary diagnosis on the occurrence of glycosuria. Unless this glycosuria can be eliminated by means of simple dietary regulation, the patient will as a rule be remitted to a hospital for further investigation, in particular by means of blood sugar tests.

Through the routine urine examination the occurrence of glycosuria will often be observed when a patient is seeking medical advice for reasons other than subjective symptoms indicative of DM. This applies not only to the clientele of doctors outside the hospitals but also for instance to patients in surgical and gynecological departments at hospitals. In some cases an eye examination may reveal retinal changes which are interpreted as indicative of DM and the patient will be remitted to the depart-

ment of internal medicine for further examination

The definitive clinical diagnosis of DM is primarily based on the occurrence of glycosuria and hyperglycaemia. All patients included in our hospital series have presented both glycosuria and hyperglycaemia.

During the whole registration period a positive test of glycosuria (i.e. the presence in the urine of a reducing substance) has been considered indicative of DM.

Hyperglycaemia has been considered to exist where the fasting blood sugar (i.e. the blood sugar after at least 10 hours of fasting) is 0.11 per cent or more.<sup>1</sup> Stress has been laid on the requirement that the patient shall have eaten a sufficient amount of carbohydrates during the days preceding the test.

In the early twenties there were elaborated comparatively easy and reliable methods for serial determinations of blood sugar, and glucose tolerance tests (GTT) were brought into use in the diagnosis of DM. At the hospitals here studied glucose tolerance tests—oral, intravenous or both—have been applied where the diagnosis has not already been established on the basis of the fasting blood sugar. In the case of normal fasting blood sugar and negative test of glycosuria, glucose tolerance tests have as a rule been performed only if there is information (from a doctor or from the patient himself) about sugar in the urine on earlier occasions. A fairly common experience has been a positive oral test and a negative intravenous one, but sometimes the opposite has applied. In general a clearly normal outcome of the

oral tests has been considered to exclude the diagnosis DM.

The techniques used in respect of the glucose tolerance tests will be commented upon in a later section (cf p. 122). It may suffice to mention in this connection that the evaluation has been based in particular on the 2-hour value.

In respect of the diagnosis of DM among patients admitted to a hospital there are only a few alternative diagnoses to take into consideration.

Glucose will be found in the urine when the blood sugar level exceeds the renal threshold. However, there are individual variations and also variations with age. A young diabetic will often present glycosuria with a blood sugar of 0.13 to 0.15 per cent, whereas an elderly diabetic may have a blood sugar level of 0.18 per cent or more without showing glycosuria. It is often technically difficult to arrive at a fair degree of certainty concerning the renal threshold. In renal glycosuria this threshold is lowered and then glycosuria is persistent even if there is no hyperglycaemia. Persons with renal glycosuria are often remitted to a hospital for investigation, especially if they are seeking a health certificate (in connection with an application for a driving licence, life insurance, etc.) or where glycosuria has been observed at a routine urine examination by the patient's own physician. As already mentioned in our series, patients without hyperglycaemia are not included.

General or specific starvation may give rise to ketosis. Since ketonuria is one of the first evidences of incipient DM, there

<sup>1</sup> For convenience this expression 0.11 per cent is used to denote 110 mg sugar per 100 cc blood.



may sometimes be a risk of overdiagnosing. In the case of acute infections, children may present acetonuria often in combination with sweet breath, headache, nausea and vomiting. Old people who do not eat a sufficient amount of carbohydrates and proteins may develop acidosis and acidosis may appear as a sequela of nephritis and certain other diseases. Often in these cases a glucose tolerance test made immediately will give a result recalling diabetes. However, when carbohydrates are administered to the patient during several days (200 grammes or more daily) the glucose tolerance test will show a normal picture. As already mentioned, it has been a routine procedure at the hospitals studied to arrange that in uncertain cases the patient shall receive an ample supply of carbohydrates during three days before the determination of the fasting blood sugar; in this way the majority of the potential instances of starvation without diabetes will be eliminated.

*Alimentary glycosuria* (accidental glycosuria) caused for instance by the intake of large amounts of sugar may be observed. As a rule these patients are treated by simple dietetic regulation, viz. no sugar or sweets. In general, as a safety measure, they have been put under surveillance, although with progressively longer intervals between the control examinations (increasing to six months or more).

What is sometimes called *pregnancy glycosuria* can be regarded as an expression of a temporary overproduction of growth hormones. In such cases the blood sugar level is in general normal, but slight hyperglycaemia may sometimes

occur. As a rule, the presence of glycosuria is established at the routine examinations of the maternity welfare services. The diabetogenic effects of growth hormones are currently the object of intensive research, but in pregnancy glycosuria the glucose tolerance tests will in general show normal values (cf. Hagbard 1956).

Disturbances of the hormone balance connected with the *climacteric* may act as precipitating factors for the onset of DM. In respect of these patients the diagnostic criteria and the treatment procedures have not deviated from those applied to other DM patients.

*Mental and psychological stress* may precipitate acute diabetic symptoms, sometimes to a very marked degree, and a clear remission will often occur. In these cases, the normal diagnostic criteria are applied, but restrictivity is observed in respect of the treatment—the primary prescriptions being dietetic regulation and if appropriate sedatives. Insulin therapy is regularly postponed until the circumstances are considered to have become stabilized.

*Cushing's disease* (adrenal cortical hyperfunction) may cause glycosuria, hyperglycaemia and hypertonia, often to a very marked degree. In this disease the diabetic signs are to be regarded as symptoms of the underlying disease. In general, the patients are admitted because of hypertonia. Diagnostic criteria are, among others, obesity, moon face, increased excretion of 17-ketosteroids in the urine and disturbances of the electrolytic balance. The treatment is that of the underlying disease (as a rule epinephrectomy).

Starvation cases in need of closer observation as to the possibility of DM have been comparatively rare. The same applies to alimentary glycosuria. Cushing's disease is seldom found. Certain other states which may cause diabetes-like symptoms, for instance physical trauma, poisoning and pancreatic cancer, have not given rise to any diagnostic difficulties in the present series. Among patients seeking medical advice because of disturbances of the carbohydrate metabolism, glycosuria and subjective diabetic symptoms, the frequency of renal glycosuria may be assessed at about 2 per cent. Hence the quantitative significance of the problems of differential diagnostics is comparatively small.

With regard to the differential diagnosis it may be added that in children with an acute onset of clearly diabetic symptoms there may sometimes occur a remission with normal blood sugar values even in glucose tolerance tests; this remission may last for some months, exceptionally for a year or more. It has been a routine procedure during the whole period studied that these children are kept under close observation.

In the literature on diabetes one often meets with the expression *prediabetes*. There are few problems that have given rise to such intense discussions as the concept and definition of *prediabetes*. Goldner (1962) is of opinion that this concept should be eliminated if it is intended to cover those situations where a slight disturbance of the carbohydrate metabolism can be ascertained but is not of such a degree as to warrant the clinical diagnosis DM. Goldner holds the view that all these cases should be classified as

DM. Extensive research during the last few years has led to a modified definition; it is argued that the diagnosis *prediabetes* should be reserved for cases without disturbed carbohydrate metabolism but with signs indicative of a probable onset of DM earlier or later. The signs in question are vascular symptoms in the form of microangiopathy, and the occurrence in the blood of insulin-affinitive substances ('factors'), for instance synalbumin. In certain quarters it is held that a woman who gives birth to a child weighing 4.5 kg or more belongs to the group of *prediabetics*. *Prediabetes* under the concepts mentioned in this paragraph is not included in our series.<sup>1</sup>

### The hospital series studied

As will have appeared from this short survey, the admissions to the hospitals studied cannot be regarded as wholly representative of the total population of diabetics in Sweden. In the areas covered by the hospitals there will be a number of diabetic patients who are not admitted because a doctor regards it as appropriate to keep the patient in a sufficiently good state by means of dietetic regulation and general advice alone. Of course, there are in addition a number of persons with a clinically manifest diabetes who do not seek medical advice at all—at least during the initial period of the disease—and for whom the diagnosis will be made only if

<sup>1</sup> According to the terminology recommended by the World Health Organization (W.H.O.) *prediabetes* should be used in retrospect when reviewing a case to describe the period of time from conception to the diagnosis of an episode of DM.

they seek a doctor or are admitted to a hospital because of intercurrent disease

Further, owing to geographical factors, communications etc., the extent to which a county hospital covers different parts of its admission area will vary. In the distant parts of this area, the patients may find it more convenient to go to another county hospital that is closer to their homes or is more easily accessible and they may to some extent prefer to go to a local hospital. The biases arising from these circumstances will be discussed in a later connection; however it should be emphasized that in the main the patients admitted to the county hospitals studied can be regarded as fairly representative of persons who show DM to a degree that—where thorough clinical examination is performed—will be classified as an instance of clinically manifest DM.

The material for our study of clinical DM derives from a period when the therapy was based solely on dietary control, general health measures and insulin. The oral remedies that came into use after 1955 were either not applied at all or applied only (to a small extent) during the latter part of the registration period. However, because oral medicines nowadays play a not inconsiderable role in the treatment of DM, they will be taken up for discussion in a later connection (cf p. 164).

Whereas during the registration period the diagnostic procedures were practically the same at each of the four hospitals studied (as well as in most other Swedish hospitals) there were certain differences with regard to the treatment practices and the scope of the control

examinations both in time and between the hospitals. In particular, the attention paid to the investigation (and registration) of late complications presents some clear discrepancies, which will be analysed in detail in a later section. So far as treatment is concerned, the most relevant differences apply to the intervals between two consecutive control examinations. However, it should be emphasized that this type of differences is primarily (though rather fortuitously) connected not with the hospitals *per se* and the views of the doctors but with such external factors as the distance from the patient's home to the hospital, the patient's occupation, communications and so on.

Where a definite diagnosis of DM had been made, the treatment was to a great extent determined by the occurrence or absence of acidosis. Patients showing acidosis were regularly hospitalized (*viz.* taken as inpatients) for thorough scrutiny and adaptation; if acidosis could not be eliminated, insulin treatment was as a rule introduced. On the other hand, if there was no acidosis, attempts were generally made to arrive at satisfactory control by means of increased dietetic regulation. Often this was done chiefly for psychological reasons: the patient must become convinced of the advantage of dietary restrictions. Insulin therapy should not be resorted to on weak indications; if later on insulin is deemed appropriate, the ground must have been prepared. As a rule these patients were treated as outpatients with renewed control after a week or a fortnight. If the control examination did not reveal glycosuria or acidosis, the dietary treatment

was carried on, with renewed control every month or, later, with an interval from two to three months. When indicated the patient was taught to perform urinary tests himself. If a control examination revealed the presence of acidosis, the patient was hospitalized for ten days or a fortnight, as a rule insulin treatment proved to be indicated. Nowa days with persistent glycosuria but in the absence of acidosis, recourse is generally had to oral treatment (sulfonylureas) during the registration period, there may have existed certain differences with regard to these cases, viz. as to whether the most suitable treatment for a certain patient would be continued attempts with dietetic regulation or the introduction of insulin therapy (cf. for instance Gronberg 1961, 1963).

## Classification by age at onset

There is no unambiguous parameter by which the various types of DM can be classified. In the present study we have chosen to group the patients by age at onset of DM. This procedure has been deemed to give the most suitable basis for a non selective division in respect of the general clinical picture and course of DM. One group consists of patients who had become afflicted before the age of 15; this group comprises instances of juvenile onset diabetes alone (*juvenile diabetes*). One group consists of patients who had become afflicted at an age of 40 or more; this group can be regarded as comprising instances of maturity onset diabetes alone (*late diabetes*). Finally, an intermediate group consists of patients

who fell ill in the age interval 15–39, in this group there are both patients who would have been classified by other investigators as instances of juvenile diabetes and patients who may be regarded as instances of late diabetes; however since a division into only two groups would have entailed certain disadvantages and might be said to overemphasize the significance of the age of onset we preferred to work with such an intermediate group (termed, in the absence of a more appropriate designation, *early adult diabetes*). Where a finer division is called for, the patients are grouped into 5 year classes by age of onset (0–4, 5–9 etc.)<sup>1</sup>

The clinical characteristics of the type of DM ordinarily seen in youth and adolescence differ in many respects from those found in adult patients, especially if the onset has taken place in middle age or at an advanced age. In particular there is a marked difference as regards the liability to ketosis: the DM of youth and adolescence being ketosis prone and the DM of the elderly being ketosis-resistant.

In 1956 Bertram put forward the theory that a proper classification of DM could be made on the basis of the patient's tendency to obesity (cf. Bertram, Bendfeldt & Otto 1956). The lean type which is often found among young diabetics was termed by him 'Insulinmangel diabetes', whereas the fat type was termed 'Gegengregulations diabetes'. However, Bertram's theory is not supported by later studies concerning the mechanism of the insulin secretion.

<sup>1</sup> Concerning the definition of the expressions 'age at onset', 'attained age' and 'average age' cf. p. 12.

## Some factors of importance for the development and course of DM

As already stressed exercise is an important factor in the treatment of DM. On the medal instituted by Elliott P Joslin in 1947—the Quarter Century Victory Medal for Health which is given to patients who after 25 years duration of DM are free from late complications—there is the inscription **INSULIN EXERCISE DIET**<sup>1</sup>. Joslin wanted to emphasize that in his view these factors were basic in the treatment of DM and particularly with regard to the prognosis of the disease. He always advised his patients to practise permanently and regularly some kind of strenuous muscular activity. He was convinced that muscular effort brought about increased combustion in particular of carbohydrates and thus in every respect an ameliorated metabolic situation.

During recent years experience has in different ways provided evidence that Joslin was right on this point. His idea was that the muscular activity directly caused an increased oxidation of glucose in the muscle cells and in consequence a reduced blood sugar level. It is certain however that the actual situation is far more complicated. Goldstein (1965) is of opinion that the muscular tissues produce what he terms a muscular activity factor which causes a reduction of the blood sugar level; this would at least in part explain the beneficial effect on DM of hard physical work. A doctor who has had the opportunity of surveying a large number of diabetics over a long period cannot possibly remain unaware that

heavy work often has very advantageous effects on the actual state of health of a great many of his patients. It is possible that for these physically hardworking diabetics the prognosis with regard to late complications is better than for other patients, but it is difficult to arrive at definite statistical evidence in this respect.

In 1889, von Mering and Minkowski were able to prove the existence of a connection between the carbohydrate metabolism and the cell islands in the pancreas that had been detected by Langerhans in 1869. In 1921 came the discovery of insulin. A considerable proportion of the research activity in the DM sphere is still devoted to investigations concerning the formation of insulin, its secretion and its physiological actions.

For many years clinicians, biochemists, physiologists, histologists and pathologists have been engaged in theoretical and experimental research projects dealing with different aspects of DM. A comprehensive picture of the present activity in these fields in Sweden is given in the papers from the Wenner Gren Center Third International Symposium (Brolin, Hellman & Knutson 1964).

Vascular changes of different kinds have long interested diabetologists. In this field research has been focused on the connections between arteriosclerosis and DM as well as on the specific diabetic microangiopathy. It is still an open question whether DM really promotes

<sup>1</sup> The medal is awarded by the Diabetic Fund of the Boston Safe Deposit and Trust Company upon recommendation of its Advisory Committee. Cf. Elliott P. Joslin, *Diabetic Manual for the Doctor and Patient*, 9th ed. 1953, pp. 215-217. —We find it noteworthy that Joslin put Exercise next to Insulin but ahead of Diet.

the occurrence of arteriosclerotic changes. Several authorities claim that diabetics are considerably more exposed to cardiac infarctions than are comparable non-diabetics. The appearance of gangrene in the toes has long been considered ascribable to DM, however, no definite proof of the assumed causality seems to exist. The general opinion of today is that the arteriosclerosis found in diabetics does not differ patho-anatomically from the arteriosclerosis of non-diabetics.

There is an abundant literature concerning the significance of atheromatous changes, hypercholesterolaemia and hyperlipaemia in DM patients. However, in our hospital series the registration in the case records is not sufficiently informative, and therefore the problems connected with atherosclerosis, blood cholesterol level and blood lipid values will not be taken up for analysis.

Since the electron microscope became available, the study of diabetic microangiopathy has attracted great interest. Bloodworth Jr (1963) showed that the vascular changes that are found in the smallest vessels of the kidneys, the eyes and the skin are in principle the same. The essential change is a thickening of the capillary basement membrane. This change has been considered to be so specific that a measurement of the thickness of the membrane would be decisive for making the diagnosis DM. Levine (1964) regarded the analysis of a small biopsy from the lobule of the ear to be sufficient for determining whether or not the patient had prediabetes. However, according to Lundbæk (1965) the measurement of the thickness of the basement membrane is far more complicated

than was thought earlier. Bloodworth Jr (1965) has in some respects corrected his interpretation from 1963. However, although adequate routine procedures are not yet available, it seems beyond doubt that electron microscope techniques will be helpful in the diagnosis of DM at an earlier stage than has hitherto been possible.

Over a long period attempts have been made to explain the neurological changes often observed in elderly diabetics as caused by vascular lesions of the peripheral nerves (Fagerberg 1959). Definite proof of the correctness of this hypothesis is still lacking. Through investigations by Olsson, Sæve, Söderbergh, Angervall and Sourander (1967) it has been shown that juvenile diabetics too present spinal and cerebral changes which can hardly be attributed to vascular lesions, either of arteriosclerotic origin or connected with microangiopathy.

According to several investigations it is not uncommon that in the case of ulceration of the feet diabetics show grave signs of diabetic neuropathy but only slight circulatory disturbances ascribable to vascular lesions. Further it is common that such trophic ulcers are accompanied by skeletal changes (Gronberg 1966, 1966a). This syndrome is known as diabetic osteopathy. It has been dealt with by Bailey and Root (1947), Azerad, Lubetzki, Stuhl and Slotine (1961), G. Bergqvist (1963) and others. Studies are in progress with the purpose of elucidating the cause of these changes. Probably there is a disturbance in the function of the autonomic nervous system.

Until some years ago it was the generally accepted view that DM is a disease

which is due to the incapability of the body cells to transform carbohydrates and is therefore especially expressed in the form of glycosuria. Nowadays fat and fat metabolism are considered to be more important than was assumed earlier. The fatty tissue was supposed to be a means of storing reserve energy, this store could be drawn upon according to need but otherwise it was thought to be inactive. Investigations performed in recent years have revealed, however, that the fatty tissue is highly active and that for this activity it requires comparatively large amounts of insulin. Swedish research workers have made interesting contributions in this field. Svanborg (1965) has investigated the role of fatty acids in the circulation of fat. Björntorp (1965) has analysed the fat metabolism within the body cells and Östman (1965) has arrived at valuable results with regard to the endogenous fatty acid metabolism in diabetics.

The mechanism of the development of DM is investigated from several aspects and by different methods.

Luft and co-workers have devoted much attention to the role of the hypophysis for the occurrence of diabetes (Luft 1965, 1965, 1965, Luft & Cerasi 1964, Iklos & Luft 1960, 1962, Almqvist Hall, Lindstedt, Lindsten, Luft & Sjöberg 1964, Iklos, Luft, Gemzell & Almqvist 1962). They have shown that the administration of a sufficiently large dose of human growth hormone gives rise to clear diabetes with hyperglycaemia as well as acidosis. Earlier studies by Luft, Iklos, Gemzell and Olivecrona (1958) have given valuable information concerning the role of the hypophysis

for the development of diabetic retinopathy.

Levine and Luft (1964) have analysed the relationship between growth and the diabetogenic effects of growth hormone. Their theory is that there exist two factors, one of which (the real growth hormone) promotes the protein synthesis in the presence of insulin while the other factor (termed the adipokinetic factor) is effective in respect of the fat transportation (cf. also Forsman & Gemzell 1959).

With regard to the mechanism for the development of DM it should be mentioned that a quite different theory has been set forth by Vallance Owen (1963).<sup>1</sup> In the blood he has found a special factor—termed synalbumin—which according to him is capable of binding insulin and of making it inactive to a certain extent. An amount of synalbumin in the blood exceeding 1.25 per cent is regarded by Vallance Owen as a clear sign of subclinical diabetes, allowing the definite conclusion that the patient will sooner or later develop manifest DM. There have been divergent opinions concerning the validity of Vallance Owen's theory, but that discussion falls outside the scope of the present study, which is concerned with clinical diabetes alone.<sup>2</sup>

The significance of genetic factors for the occurrence of DM has been studied and discussed for a very long time. Certain problems regarding the hereditary nature of DM will be treated in Chapter IX.

<sup>1</sup> Cf. also Vallance Owen, Dennes & Campbell 1958, Vallance Owen & Ashton 1963, Levine 1964a, Vallance Owen 1965 and Arvill, Westberg, Jonsson, Hood & Ahren 1966.

<sup>2</sup> The genetic aspects (cf. Vallance Owen 1966) are taken up for discussion in Chapter IX.

# Material for the clinical study of DM

## General aspects

Often, an analysis of case records concerning patients afflicted with a certain form of disease covering a sufficiently long period will afford a valuable basis for conclusions with regard to the symptomatology of the disease the results of different types of treatment and the prognostic value of the clinical data. However, since in general there are important selective factors of various kinds—for instance, factors connected with diagnostic practice diagnostic accuracy and the completeness of the case records or due to differences by sex age, marital state and domicile in respect of the admission rates and to changes with time of these rates—the material taken up for study has to be chosen with great care, a close scrutiny of the data will as a rule be necessary so that the effects of the biases arising from these differences and changes can be properly evaluated.

For several reasons the possibilities of performing such period investigations and of evaluating the selective factors occurring may be considered to be particularly favourable in Sweden not least in respect of diabetes mellitus and other chronic diseases. For 150 years Sweden has had the good fortune not to be in-

volved in war and also to have been spared major domestic upheavals. The population is very homogeneous both with regard to ethnic origin and religion and from the social point of view. The Swedish population statistics have a very long history, and information is to a great extent available for fairly small geographical districts so that it is possible to compare statistical data which concern the investigation series with corresponding data for the general population. The official registration of the population is very efficient and reliable the parish-register system is so devised that it is possible to follow internal migration. As already mentioned there have not existed any serious economic obstacles to the obtaining of medical care in hospitals or from physicians. In the hospitals the case records are as a rule relatively comprehensive and they are easily accessible for research workers (Cf Larsson 1965 Larsson & Sjögren 1954, Sjögren & Larsson 1965).

At the projection adaptation and judgment of medical clinical research there are certain statistical aspects which can be and ought to be taken into consideration. It should for instance be borne in mind that the topics studied are not a random choice but an intentional



selection from the total \* population of possible investigation objects. Complications arise owing to selective basic material, disappearances from observation, exclusions and bias, and by time lag at registration and diagnosis. Usually, however, the main problem is not how to eliminate selective factors—on the contrary it may often be sound investigation economy to introduce such factors—but how to be able to evaluate their effect.

Gradual or sudden changes of the circumstances prevailing in a society—taken in a wide sense—will often give rise to complications which are difficult to survey and may lead to erroneous conclusions. Such changes may be social economic or purely demographic (rising standards of living, investments in respect of hospital facilities, urbanization, industrialization, etc.) but they may also be psychological or medical (altered attitudes, the use of new drugs in general therapeutic practice, new treatment procedures, ameliorated diagnostic techniques, etc.). Changed legislation (for instance the introduction of compulsory health insurance from 1955) and exceptional disturbances (war epidemics, etc.) may influence medico statistical data—sometimes by introducing a displacement effect (acceleration or delay).

An important factor is that persons who are now old lived in their earlier years in conditions which in several respects were widely different from those applying to the younger age groups of today. For instance, there was earlier a high mortality from tuberculosis, for diabetics the excess mortality was much heavier before the discoveries of insulin, sulpha preparations and antibiotics than

it has been during the last two decades. Because of these circumstances—but particularly because of the great intensification of internal migration, resulting in an altered pattern for the choice of marriage partner—there has occurred a successive change in the gene composition of the population, with an increased prevalence of heterozygotes and a reduced prevalence of homozygotes in the younger generations (cf. Larsson 1965).

In a way, the use of hospital series may be said to present a number of specific difficulties. An exceptional or undue inclusion or exclusion of mild cases or severe cases may easily give rise to false conclusions. If a registration is made over a certain period, the structure of the material will as a rule be quite different depending on whether the registration covers all patients, admissions or first admissions. In respect of many diseases a hospital series does not reflect the prevalence or incidence of the disease in the population. Many patients may be cared for by physicians outside the hospitals, and others do not seek medical advice at all. The distance to the hospitals, their capacity (for instance if there is a scarcity of beds) and the availability of alternatives (general practitioners, specialists outside the hospitals) are also of importance. The introduction of new treatment procedures for certain forms of disease may shorten the stay in hospital and this may in turn give room for an increased admission of patients afflicted with another disease, although for this latter form there have been no changes, either in respect of the incidence or in respect of treatment and the length of hospitalization.

When investigating a limited geographical area several selective factors may be operating. In Sweden generally there has been a flow of migrants from the countryside to urban localities and also from smaller agglomerations to larger ones. In the main, this migration comprises the younger groups of working age. Very often, the migration tendency for persons afflicted with a certain disease differs markedly from that of other persons of the same age (the general population).

If the investigation covers only part of the country or only a certain type of hospital, it should be taken into account that the diseased persons can apply for hospital care outside the investigation area or go to hospitals of another type. For instance, diabetics who are blind or severely disabled may be underrepresented in series from general hospitals because they seek care at special hospitals (schools for the blind, homes, rehabilitation clinics, etc.).

Whether or not the diseased persons will be admitted to a hospital may depend in part on the severity of the disease but also partly on such factors as age, sex, marital state, domicile and communications. For instance, in respect of diseases which demand bed stay but do not necessitate an operation it is quite usual that a hospital series comprises more married women than married men (even though the prevalence and severity of the disease do not present any sex differences). In respect of mothers with infant children the selective effect may sometimes be the opposite with lower admission rates than for other women or men. Further, the occurrence of inter-

current disease and psychological traits ('temperament') may play a part. Obviously, then, for hospital series one should be cautious about drawing conclusions concerning the coincidence of diseases (the correlation of diseases).

Very often there are reasons for taking into account the complications which arise from delayed registration and delayed diagnosing. The disease may have begun at a certain point of time but the patient does not come to a hospital until he has had the disease for a certain period (which may vary according to sex, age at onset, etc.). Sometimes the diagnosis cannot be made until the disease has gone on for a certain time but then it will often be possible to establish that it began several years earlier. It is worth mentioning that statistically speaking the patients are immortal during such a period of delay.

## Selection of hospitals

The origin of the present clinical study is that one of us (Albert Grönberg) had planned to perform a survey of the patients personally treated by him at the county hospital of Vänersborg during the period 1931-57, in all more than 800 cases of DM. However, it was considered highly desirable to cover a larger series of patients and so, on the suggestion of the Director General of the National Board of Health Dr Arthur Engel, the registration was extended to comprise three other county hospitals.

The population of Älvsborg County in which Vänersborg is situated, was 313 311 in 1930 and 369 679 in 1956. There are



Fig 2 Map of Ålvsborg County (PQ)

P1 (a b) P2 (c d) P3 (e f g) — Cf Table II p 56

● general hospital

□ cottage hospital

three county hospitals (Vänersborg Borås and Alingsås) Vänersborg Hospital covers the northern part of the county with a population of about 130 000 in 1930 and about 145 000 in 1956. The admission area borders on the City of Gothenburg, but it should be noted that Gothenburg belongs to another county (Gothenburg and Bohus County) during the period studied it was a rule (except in instances of a very acute onset of disease) that patients should be treated at a hospital within the county where they had their domicile. This applies to out patients as well as to inpatients.

In 1930 Vänersborg Hospital had 138 beds with a total of 2 364 admissions of inpatients and 47 900 bed-days. In 1956 the corresponding figures were 525 beds with 11 791 admissions and 172 800 bed days of these 525 beds 108 were in the department of internal medicine. There had been established separate departments of paediatrics and of ophthalmology in 1947.

In addition to the county hospitals of which Borås had 240 beds in 1930 and 603 beds in 1956 and Alingsås had 130 beds in 1930 and 181 beds in 1956 there are some local hospitals (cottage hospitals) and homes for chronically diseased patients in the northern part of the county these local hospitals are Ämal (30 beds in 1930 36 beds in 1956) Bäckefors (32 and 102 beds respectively) and Trollhättan (24 and 39 beds).

In the planning of the present clinical study of DM certain selective factors could be controlled and in the first place this applied to the selection of hospitals. Among other things the following criteria could be used:

(a) There should be one dominating hospital for the relevant parts of the admission area.

(b) The physician in chief of the department of internal medicine should be one with great interest in the problems of DM and long experience of the treatment of diabetics.

(c) There should not be competition with other hospitals where interest was focused on the treatment of diabetics or with private practitioners specializing in this field.

(d) The population should be comparatively stable with a low rate of internal migration over the boundaries of the area, at least in the age groups above 30.

(e) The selected hospitals should be suitably spread over the country.

Quite clearly Vänersborg Hospital and the northern part of Älvsborg County fulfilled the requirements (a)–(d). Thorough discussions with experts of different kinds and a scrutiny of demographic statistics argued strongly in favour of the further selection of the county hospitals of Växjö in Kronoberg County in the south, Falun in Kopparberg County in the middle of Sweden and Östersund in Jämtland County in the north.

At Falun Arthur Engel had been head of the department of internal medicine during the period 1943–52. In 1953 he had been succeeded by Dr Olle Hogeman (who was assistant physician in-chief there in 1949–52). At Växjö Dr Otto Östberg had been head of the department of internal medicine since 1939, and both he and several of his pupils had undertaken special research concerning DM (Wallman Carlsson 1950, Englund 1954). At Östersund Dr Ian Lundholm was physician in-chief of the department of internal medicine from 1930 to 1960, after his retirement the position was held by Dr Leif Thorling from 1960 to 1963.

Drs Hogeman, Östberg and Lundholm willingly accepted the proposal




Fig 3 Map of Kronoberg County (G)

G1 (a) G2 (b c d e f), G3 (g) — Cf Table 11 p 56

that their hospitals should be included in the investigation. We take the opportunity here to thank them as well as Dr Engel and Dr Thorling for their excellent cooperation, valuable suggestions and stimulating discussions.

Växjö Hospital covers the greater part of Kronoberg County which had 155 551 inhabitants in 1930 and 159 291 inhabitants in 1956. In 1930 the hospital had 140 beds with a total of 2 213 admissions of inpatients and 52 700 bed-days. In 1956 the figures were 374 beds with 10 650 admissions and 129 400 bed-days, of these 374 beds 107 were in the department of internal medicine. There had been established separate departments of paediatrics in 1940 and of ophthalmology in 1955.

The south-western part of Kronoberg County is covered by a non-specialized general hospital at Ljungby with 90 beds in 1930 and 108 beds in 1956.

In addition to the hospitals at Växjö and

Ljungby there are in Kronoberg County two cottage hospitals: one at Lenhovda (27 beds in 1930, 34 beds in 1956) and the other at Tingsryd (13 and 61 beds respectively).

Falun Hospital covers Kopparberg County with a certain exception for the south-eastern part (see next paragraph). The population of Kopparberg County was 249 717 in 1930 and 281 197 in 1956. In 1930, Falun Hospital had 239 beds with a total of 4 696 admissions of inpatients and 102 200 bed-days. In 1956 the figures were 496 beds with 13 192 admissions and 150 200 bed-days of these 496 beds 122 were in the department of internal medicine. There had been established departments of paediatrics in 1943 and of ophthalmology in 1922.

The south-eastern part of Kopparberg County is partly covered by hospitals at Avesta (70 beds in 1930, 140 beds in 1956), Smedjebacken (38 and 31 beds) and Ludvika (60 and 165 beds). Further in the middle of the county there is a non-specialized general hospital at Mora with 80




Fig 4 Map of Kopparberg County (W)

W1 (a) W2 (b c d) W3 (e f g h i) W4 (j k) — Cf Table 11 p 56

beds in 1930 and 103 beds in 1956 There are also in Kopparberg County a number of cottage hospitals with a total of 149 beds in 1930 and 317 beds in 1956

Östersund Hospital covers the whole of Jamtland County with the exception of the south-eastern part (see next paragraph) The population of the county was 134 514 in 1930 and 143 854 in 1956 In 1930 Öster

sund Hospital had 172 beds with a total of 3 115 admissions of inpatients and 67 700 bed days In 1956 the figures were 375 beds with 10 650 admissions and 132 700 bed days of these 375 beds 96 were in the department of internal medicine There had been established separate departments of paediatrics in 1943 and of ophthalmology in 1940 In the south-eastern part of Jamtland County there is a non specialized general



Fig 5 Map of Jämtland County (Z)

Z1 (a) Z2 (b c d e f g) Z3 (h) — Cf Table 11 p 46

Table 1 Registration periods and annual number of first admissions

Hospital	Registration period	Population of area thousands			Average annual number of first admissions					
		1940	1950	1960	1931-35	1936-40	1941-45	1946-50	1951-55	1956-57
P Vänersborg	1931-57	133	141	149	10	15	22	36	64	56
G Vaxjö	1930-55	151	158	159	4	14	20	54	54	
W Falun	1932-57	248	267	286	6	9	22	56	80	78
Z Östersund	1930-56	139	144	140	14	26	36	57	69	88*
Total		671	710	734	34	64	100	203	267	

\* 1956 only

hospital at Sveg it had 72 beds in 1930 and 116 beds in 1956. Further there are in the county two cottage hospitals: one at Gaddede (13 beds in 1930, 16 beds in 1956) and the other at Strömsund (22 and 80 beds).

Vänersborg, Vaxjö, Falun and Östersund are all county towns (capitals of their respective counties).

Östersund (14 153 inhabitants in 1930, 23 790 in 1956) is the only town in Jämtland County. In Kronoberg County there is besides Vaxjö (9 699 and 22 381 inhabitants) only the town of Ljungby (4 320 and 8 112 inhabitants). In Kopparberg County there are in addition to Falun (13 369 and 18 453 inhabitants) a number of other towns. The largest town is Borlänge (17 124 and 25 009 inhabitants) and in the south-eastern part of the county there are also the towns of Ludvika (5 052, 11 706), Säter (2 175, 4 287), Hedemora (3 801, 5 653) and Älvsborg (5 166, 9 896). In the northern part of Älvsborg County there are three towns: viz Vänersborg (8 942 inhabitants in 1930, 17 511 in 1956), the nearby Trollhättan (15 014, 29 317) and Åmål (6 765, 8 635).

The location of the counties and hospitals selected is shown in the maps Fig 1 (p. 4) and Figs 2-5 (pp. 36, 38, 39, 40).

In view of the purpose of the investigation—viz to study the *chicotele* of DM patients at general hospitals with regard to the symptoms and course of

the disease—we were anxious to secure a series that covered all existing groups by age and duration. Not least were we interested in the outcome of the disease in patients belonging to the higher age groups, and especially in patients with a comparatively late onset of the disease. Therefore it was clear that we ought not to restrict ourselves to studying only patients who fell ill during a limited period of time or only patients who during a limited period had reached a certain disease duration. The registration covers all patients during a certain period—patients who applied to the hospitals in connection with the onset of DM and were diagnosed there as well as patients who came to the hospitals later on among them both persons who had migrated into the area after the onset of the disease and instances of delayed hospital registration (for instance if the patient had for several years been treated by a physician outside the hospital).

Table 1 shows the registration periods used, the population of the admission areas in 1940, 1950 and 1960 and the average annual number of first admissions to the hospital in question of patients afflicted with DM (inpatients as well as outpatients clinically diagnosed



Table 2 Population and number of patients by year of first admission

Hospital and area	Sex	Population thousands			Number of patients							
		1940	1950	1960	Year of first admission							
					All	1940-49	1950-59	1960-69	1970-79	1980-89	1990-99	2000-09
B Älvsborg County (northern part)	M	67.4	71.9	77.1	408	7	29	44	55	75	138	60
	F	65.3	69.5	72.3	459	3	23	33	56	107	184	53
G Kronoberg County	M	77.5	81.1	81.3	304	6	11	28	40	103		116
	F	73.9	76.6	77.6	433	5	10	40	58	167		153
W Kopparberg County	M	125.8	135.3	145.1	470	1	13	28	49	109	200	70
	F	122.7	131.8	141.0	566	8	15	19	63	175	200	86
Z Jämtland County	M	72.1	74.3	72.0	498	2	36	68	86	113	154	39
	F	66.7	69.8	67.8	621	7	33	60	92	171	191	67
Total	M	342.8	362.6	375.5	1 680	16	89	168	230	400	608	169
	F	328.6	347.7	358.7	2 079	23	81	152	269	620	728	206
	M+F	671.4	710.3	734.2	3 759	39	170	320	499	1 020	1 336	375

Location of areas: see map Fig. 1 p. 4

in connection with the admission or with DM already diagnosed at another hospital or by a doctor outside the hospital, provided that the diagnosis DM was confirmed)

## The scope of the clinical material

Table 2 gives the population and the number of patients by hospital, sex and year of first admission to the hospital. The total series covers 3 759 patients of whom 1 680 are males and 2 079 are females.

In the planning of the data registration the following questions could be asked:

(a) What data were available in the case records?

(b) Which data should be extracted?

(c) To what extent might there be incompleteness in the registration?

(d) Which data were of particular interest to research workers dealing with different aspects of DM?

(e) What number of cases of different types could one expect to find and what possibilities might there be of arriving at conclusive results with a series of the size to be expected? (At that time we did not know the exact number of patients, given in Table 2 but our assessment proved to be fairly correct.)

(f) What comparisons in respect of the occurrence of disease in the general population might be needed and what data could be taken from other sources?

(g) How complete should the extracts from the case records be and to what extent should we take the risk of possibly being compelled to go back to the primary data for supplementary registration?

(h) In what respects should the data from the case records be supplemented

by additional information from other quarters?

(i) How should the extracts from the case records be arranged?

(j) In what way should these extracts be grouped so as to be easily handled?

(k) What definitions and divisions should be applied in the processing of the material?

In view of our general knowledge of hospital records and population statistics in Sweden our special knowledge of the selected hospitals, scrutiny of the case records and the character of DM, we were aware that the final processing of the data should be made with a division by sex and by at least two of the three variables age at onset, the patient's age and the duration of the disease. Taking into account the ages and durations to be expected we found it most suitable to use differences between calendar years—hence to define *age* as the difference between the actual year and the patient's birth year and *duration* as the difference between the actual year and the year of onset. We decided to use 5 year groups and to make the tabulations with the two arguments *age at onset* and *duration of the disease*.

We were aware that the time (the epoch) for a certain registration in the case records might play a considerable part—with regard to the nature and completeness of entries and in several other respects. Therefore the *epoch* (the calendar year) was included in the registration.

We were aware that there could exist differences between the four hospitals in part due to the age composition of the

population in the admission areas, the communications etc.

The scope of the extracts to be made was decided upon in the course of thorough discussions between the physicians-in-chief of the hospitals, several other physicians and statistical experts. Dr Carl Philipson devoted much time to elaborating the plan for the code lists and the technical methods for the processing of the data. He also gave instructions and surveyed the coding work. We take this opportunity to express our sincere thanks to Dr Philipson for his most valuable contributions during this part of the investigation.

With regard to every occasion (admission) concerning which there were relevant entries in the case records the data were extracted and converted into punched cards (*occasion cards*). The instructions for these extracts comprise the following headings (the classifications used will be evident from the following chapters).

Hospital  
Sex  
Date of birth  
Year of onset of DM  
Year of occasion  
Marital state  
Height  
Weight  
Constitutional type  
Working capacity  
Blood pressure systolic  
Blood pressure diastolic  
Visits to hospitals  
Glycosuria  
Hyperglycaemia  
Hypoglycaemia  
Acidosis  
Non protein nitrogen  
Creatinine in blood

Serum protein  
Other laboratory tests

Infections  
Tumours  
Liver diseases  
Rheumatoid arthritis  
Allergic diseases  
Vascular changes  
Cushing's syndrome  
Thyrototoxicosis  
Other endocrine dysfunctions

Dietetic prescriptions  
Insulin type  
Insulin quantity per day  
Insulin dosages per day

Retinopathy  
Nephropathy  
Neuropathy

Menarche  
Menstruation frequency and intensity  
Libido potency  
Menopause  
Partus month  
Delivery complications  
Weight of child

Diabetic relatives (specified)

In addition the extracts contained information on the name and address of the patient and the number of the case record

To a certain extent the case record data were supplemented by interrogating the patients still under control (this was done at Vanersborg in particular). For a certain number of patients who prior to their admission to the hospital had been treated at other hospitals or by physicians outside the hospitals supplementary information was obtained and included in the occasion cards; however, annotation was always carried out with regard to the year of first admission to the hospital.

On the basis of the occasion cards the data were processed to give a summary of the registrations during each 5-year period of duration reckoned from the onset of DM. Hence the first duration period covers the calendar year of onset and the subsequent four calendar years; the second duration period covers the following five calendar years and so on. In the main, in addition to the year and age of onset (occasion card 0) and the year and age of first admission we wanted to study the state (*the status*) of the patient during the duration period—either the maximum deviation from normal or the average for the occasions registered within the period—and *the change* observed within the period in comparison with the observations during the preceding one.

As already mentioned the number of patients was 3 759. The total number of admissions (first admissions and re-admissions) was 45 217 and the total number of registration periods (duration cards) was 7 385. In all the series may be said to represent about 19,700 observation years or rather more than 5 years per patient (cf p 60).

The distribution of the patients by sex, hospital age at first admission to the hospital and year of first admission is shown in Table 3. It should be noticed that the low numbers for first admissions during the 1950s of patients below age 15 is ascribable to the fact that the registration does not comprise the paediatric departments. In Sweden there have been made a series of thorough investigations concerning juvenile hospital patients with DM and we therefore thought it advantageous to concentrate

Table 3 Population and number of patients by age at and year of first admission

Sex and age at first admission	Hospital and area	Population thousands			Number of patients							
		1940	1950	1960	All	Year of first admission						
						1934-30	1931-35	1936-40	1941-45	1946-50	1951-55	1956-57
Males												
0-14	P	13.6	16.2	17.4	35	1	10	8	8	8	-	-
	G	16.7	18.7	17.8	31	2	2	4	10	12	1	-
	W	24.6	31.6	33.4	26	-	4	5	7	7	3	-
	Z	16.4	19.0	16.6	26	-	6	8	6	4	2	-
	Total	71.3	85.5	85.2	118	3	22	25	31	31	6	-
15-39	P	27.6	25.5	25.2	124	5	15	15	18	23	36	12
	G	31.1	28.0	25.5	85	4	8	13	10	24	26	-
	W	51.9	46.9	47.0	148	-	5	11	22	34	64	12
	Z	30.1	26.1	22.8	102	-	12	19	26	22	17	6
	Total	140.7	126.5	120.5	459	9	40	58	76	103	143	30
40-64	P	18.7	22.5	25.6	164	1	4	18	26	33	55	27
	G	21.5	25.0	27.2	117	-	1	8	15	46	47	-
	W	36.7	42.8	47.8	220	1	4	10	15	50	106	34
	Z	19.2	21.7	23.5	221	2	15	27	35	51	75	16
	Total	96.1	112.0	124.1	722	4	24	63	91	180	283	77
65--	P	6.5	7.7	8.0	85	-	-	3	3	11	47	21
	G	8.2	9.4	10.8	71	-	-	3	5	21	42	-
	W	11.6	14.0	16.9	76	-	-	2	5	18	27	24
	Z	6.4	7.5	9.1	149	-	3	14	19	36	60	17
	Total	32.7	38.6	45.7	381	-	3	22	32	86	176	62
Females												
0-14	P	12.9	15.3	15.3	30	2	5	10	7	6	-	-
	G	15.8	17.6	16.9	29	3	2	7	10	6	1	-
	W	23.9	30.3	31.5	29	1	5	4	8	10	1	-
	Z	15.6	18.2	15.6	27	2	4	6	11	4	-	-
	Total	68.2	81.4	79.3	115	8	16	27	36	26	2	-
15-39	P	25.9	23.7	23.3	84	1	9	6	12	18	26	12
	G	27.8	25.4	24.4	65	2	4	6	4	25	24	-
	W	40.3	44.8	44.6	117	5	5	4	20	39	34	10
	Z	26.7	24.1	21.8	64	1	8	11	8	13	16	7
	Total	120.7	118.0	114.1	330	9	26	27	44	95	100	29
40-64	P	19.0	22.2	24.1	212	-	9	14	31	59	92	27
	G	21.3	23.8	25.1	183	-	4	22	36	65	56	-
	W	37.3	42.2	46.5	274	2	5	8	31	91	98	39
	Z	18.1	20.5	21.6	267	3	15	26	42	79	70	23
	Total	95.7	108.7	117.3	956	5	33	70	140	294	325	89
65--	P	7.5	8.3	9.6	113	-	-	4	6	24	65	14
	G	9.0	9.8	11.2	156	-	-	5	8	71	72	-
	W	12.2	14.5	18.4	146	-	-	3	4	35	67	37
	Z	6.2	7.0	8.8	263	1	6	17	31	75	96	37
	Total	34.9	39.6	48.0	678	1	6	29	49	205	300	88

Table 4 Aggregate admission rates 1946-50 and 1951-55

	Sex	Age limit	P		G		W		Z	
			1946-50	1951-55	1946-50	1951-55	1946-50	1951-55	1946-50	1951-55
First admissions (residents within the area)	M		74	130	100	116	107	195	111	154
	F		103	178	166	151	173	199	169	191
Aggregate admission rate per cent	M	40	0.7	0.6	0.6	0.5	0.5	0.4	0.6	0.3
		50	1.0	1.0	0.9	0.7	0.7	1.0	0.8	0.6
		65	1.3	1.8	1.5	1.4	1.1	1.7	1.9	2.1
		80	1.6	3.6	2.1	2.9	1.4	2.3	3.4	4.5
	F	40	0.5	0.5	0.6	0.4	0.5	0.4	0.4	0.4
		50	0.8	0.9	0.9	0.7	0.7	0.6	0.6	0.7
		65	1.8	2.7	2.0	1.8	1.6	1.8	2.5	2.5
		80	2.7	5.1	4.1	3.9	2.2	3.0	5.8	6.7

our study exclusively on patients admitted to departments of internal medicine. The increase in the number of first admissions with time especially in the higher age groups is in part a reflection of the changing age composition of the population (and the increase in population number) but in the main it is ascribable to other factors, such as better communications augmented hospital facilities and a general rise in "the consumption standards in respect of medical care, this last mentioned phenomenon is seen for many other types of disease, and it should not be interpreted as an expression of an increase by time of the incidence of DM (for a certain group by sex and age). This question will be examined in a later connection.

Using the admission figures for the periods 1946-50 and 1951-55 as shown in Table 3 (but with a division by 5 year age groups) and the data concerning the age distribution of the population in the admission areas (viz the northern part of Älvsborg County and the whole of

the counties of Kronoberg, Kopparberg and Jamtland) the aggregate admission rates up to certain ages for the two periods have been calculated in Table 4, in principle, these rates show the probability that a person in the area will be admitted to the hospital and diagnosed as being afflicted with clinically manifest DM, provided (1) that he does not 'escape' by dying before the age mentioned and before admission takes place, and (2) that the circumstances with regard to admission remain throughout as they were during the period in question. (Hence, in this latter respect, the suppositions are similar to those applied when calculating a mortality table for a certain period of time.) As will be seen from the table, for the period 1951-55 the aggregate admission rate up to age 80 was 4.5 per cent for males and 6.7 per cent for females in Jamtland County and 3.6 and 5.1 per cent, respectively, in the northern part of Älvsborg County, but was considerably lower in Kronoberg County (2.9 and 3.9 per cent) and in Kopparberg County (2.3 and 3.0 per cent). However

Table 5 Age at onset, first registration and first admission to investigation hospital

Sex and age	Hospital												Total		
	P			G			W			Z					
	O	R	A	O	R	A	O	R	A	O	R	A	O	R	A
<b>Males</b>	408	408	408	304	304	304	470	470	470	498	498	498	1 680	1 680	1 680
0-4	8	7	7	11	4	4	6	-	-	4	2	2	29	13	13
5-9	19	20	16	12	10	10	11	6	6	9	9	9	59	45	41
10-14	21	20	12	23	17	17	26	20	20	23	11	15	95	75	64
15-19	25	25	27	20	23	21	34	28	28	15	15	17	94	91	93
20-24	14	15	17	13	20	21	27	28	28	24	24	23	78	87	89
25-29	24	24	28	15	12	12	28	33	33	22	21	20	89	90	93
30-34	27	27	29	15	17	17	34	28	27	20	17	19	96	89	92
35-39	27	26	23	14	14	14	30	31	32	22	22	23	93	91	92
40-44	32	31	36	19	20	19	41	39	37	26	24	24	118	114	116
45-49	28	25	31	24	22	21	49	43	45	30	30	28	131	120	116
50-54	36	37	31	28	22	25	49	53	53	41	39	39	154	151	148
55-59	39	37	42	27	29	28	45	40	40	63	60	56	174	166	166
60-64	31	34	33	19	23	24	33	51	45	63	68	74	146	176	176
65-69	38	38	43	23	24	22	25	32	38	50	55	50	136	149	153
70-74	24	26	24	20	24	23	20	30	30	40	40	43	104	120	120
75-79	13	15	17	15	16	18	3	6	6	34	40	40	65	77	81
80-84	-	-	-	5	6	7	1	2	2	12	14	15	18	22	24
85-89	-	-	-	-	-	-	-	-	-	-	-	1	-	-	1
90-	-	1	1	1	1	1	-	-	-	-	-	-	1	2	2
<b>Females</b>	459	459	459	433	433	433	566	566	566	621	621	621	2,079	2,079	2,079
0-4	7	5	5	5	4	4	8	4	4	3	2	2	23	15	15
5-9	19	17	13	16	13	12	24	11	9	14	13	13	73	54	47
10-14	16	17	12	19	12	13	23	15	16	15	12	12	73	56	53
15-19	17	16	18	14	9	9	21	25	22	15	15	15	67	65	64
20-24	17	15	15	18	18	18	24	20	21	12	9	9	71	62	63
25-29	14	11	15	10	15	15	20	25	26	11	14	13	55	65	69
30-34	19	21	24	9	10	9	27	25	27	9	11	12	64	67	72
35-39	12	12	12	15	14	14	19	21	21	16	16	15	62	63	62
40-44	17	14	14	19	13	13	37	25	25	20	20	19	93	72	71
45-49	36	40	40	36	33	33	40	41	40	29	24	23	141	138	136
50-54	52	52	52	44	37	36	67	52	52	58	47	48	221	188	183
55-59	66	66	64	48	46	45	85	76	77	83	83	82	282	271	268
60-64	60	62	62	48	58	56	111	111	80	102	103	95	273	304	293
65-69	46	47	49	11	66	69	11	68	69	107	114	112	279	295	299
70-74	36	37	35	40	51	50	32	59	58	79	82	83	187	229	228
75-79	21	22	11	24	26	29	11	15	15	39	45	52	95	108	119
80-84	3	4	4	4	6	6	1	2	3	5	7	9	13	19	22
85-89	1	1	2	1	2	2	1	1	1	4	4	5	7	8	10

O = Onset R = First registration A = First admission to investigation hospital

as will be shown below, there are considerable differences in respect of the extent to which the hospitals cover different parts of their admission areas

Table 5 gives the distribution by sex and hospital of age at onset, age at first registration and age at first admission to the investigation hospital (with 5-year

Table 6 Average interval from onset to first registration and first admission

Average interval from onset years	Hospital								Total		
	F		G		W		Z		M	F	M+F
	M	F	M	F	M	F	M	F			
First registration (R-O)	07	09	20	26	40	35	15	10	21	19	20
First admission (A-O)	15	13	23	28	41	36	18	14	25	22	23

age groups) and in Table 6 are shown the average age differences between first registration and onset, and between first admission and onset. The average time that elapsed from onset to first registration is 2.0 years and the average time from onset to first admission is 2.3 years. The intervals are shortest at Värnersborg and are short at Östersund also, whereas they are considerably longer at Falun.

Tables 7-10 give an account of the composition of the registrations (the duration cards).

In Table 7B for each of the four hospitals the number of registrations by sex and 5 year periods is shown for 5 year classes by age at onset and for the three types by age at onset mentioned already, viz 0-14 (juvenile onset), 15-39 (early adult onset) and 40 or over (late onset). In addition the table gives an account of the number of patients by age at onset—for all patients and for those who have not been registered within the first duration group (0-4 years).

In Table 7A the data of Table 7B are concentrated and rearranged showing by sex and the three types by age at onset the number of registrations within different duration groups. It should be noticed that in the highest duration group (25 years and over) a patient may

occur more than once (for instance if there are registrations both with duration 25-29 and with duration 30-34).

For the three types by age at onset (juvenile, early adult, late) Table 8 gives the mean age by sex, hospital and 5-year duration groups (0-24 years). Because of the rise with time in the number of first admissions, and the correlation between mortality and age, there is among patients with late onset DM only a comparatively small increase of the mean age with duration. Further, it should be noted that among these patients the mean age is a good deal higher at Östersund (Z) and lower at Falun (W) than corresponds to the average for the four hospitals taken together.

In Table 9 the data of Table 7A are split into two parts being grouped according to whether the first calendar year within the registration period falls before 1950 or after 1949. As will appear in a later connection, the findings concerning the occurrence of late complications show conspicuous divergences between the hospitals and still more conspicuous divergences between the observations from different periods of time (epochs). In view of the scope of the material we have chosen to divide the series by epoch into two parts of suitable size—3 288 registrations (duration cards)

Table 7A Registrations by age groups at onset and duration of DM

Age at onset	Hospital	Males (registrations)							Females (registrations)						
		All	Duration						All	Duration					
			0-4	5-9	10-14	15-19	20-24	25+		0-4	5-9	10-14	15-19	20-24	25+
0-14	P	197	47	43	40	35	18	14	150	39	37	32	21	10	11
	G	120	33	32	26	17	6	6	112	28	29	29	14	8	4
	W	129	23	29	30	23	17	7	136	31	26	32	20	17	10
	Z	102	30	22	25	12	7	6	87	27	23	21	13	2	1
	Total	548	133	126	121	87	48	33	485	125	115	114	68	37	26
15-39	P	350	115	86	59	39	24	27	209	73	54	35	17	11	18
	G	197	66	47	30	28	18	8	148	42	33	28	20	13	12
	W	315	115	70	51	34	17	28	271	82	65	45	32	26	21
	Z	213	90	49	33	23	12	6	145	54	34	23	19	8	7
	Total	1 075	386	252	173	124	71	69	772	251	186	131	88	58	58
40+	P	480	234	129	64	35	12	6	644	336	191	76	26	9	8
	G	300	165	79	32	14	8	2	588	286	175	83	36	7	1
	W	425	214	113	58	29	8	3	667	312	201	96	46	11	1
	Z	570	331	148	58	23	9	1	831	489	215	85	34	8	2
	Total	1 775	944	469	212	101	37	12	2 730	1 423	782	340	142	33	10
Total	P	1 027	396	258	163	109	54	47	1 002	448	282	143	64	30	35
	G	617	264	158	88	59	32	16	848	356	237	140	70	17	17
	W	869	352	212	139	86	42	38	1 074	425	292	173	111	54	32
	Z	885	451	219	116	58	28	13	1 063	570	272	129	66	16	10
	Total	3 398	1 463	847	506	312	156	114	3 987	1 799	1 093	585	298	128	94

in the earlier epoch and 4 097 registrations in the later epoch

To a great extent the analysis of the clinical findings will be made in the form of standard comparisons the calculation of the expectations being based on total frequencies (by sex age at onset, and duration) and the numbers (by hospital etc.) given in Tables 7-9

In order to be able to analyse the mortality in our hospital series all patients who were not registered as deceased in the case records and had not visited the hospitals after the end of the observation period were traced with the aid of the population registers and if necessary, by means of letters to the incumbents of their home parishes, until

it could be ascertained whether they were living at the end of the investigation period or had died (in which case information on the date of death was obtained)

Table 10 gives a survey of the course of registration of the patients (by sex and the three types by age at onset) As will be seen from the table 3 262 patients were registered with duration 0-4 years Of these 269 died within the duration period (before January 1 1956) Another 47 patients moved during the period (ending before 1956) they were not registered in a later period but it was ascertained that they were living on January 1, 1956 A further 1,111 patients belonged to a period ending after 1955 and were living on January 1 1956 The



Table 7B Patients by age at onset, and registrations by age at onset and duration of DM

Hospital and age at onset	Patients				Registrations (in 5 year period) duration													
	M		F		M							F						
	All	Not dur 0-4	All	Not dur 0-4	0-4	5-9	10-14	15-19	20-24	25-		0-4	5-9	10-14	15-19	20-24	25-	
P 0-4	8	-	7	2	8	8	8	8	1	-		5	5	5	4	4	4	
5-9	19	-	19	1	19	19	19	14	7	2		18	16	16	12	3	3	
10-14	23	3	16	-	20	17	13	13	10	12		16	16	11	5	3	3	
15-19	25	-	17	1	25	18	12	8	6	8		16	10	8	3	3	4	
20-24	14	1	17	2	13	11	7	5	3	4		15	14	9	4	2	4	
25-29	24	-	14	1	24	21	13	11	8	5		13	8	4	2	3	8	
30-34	27	-	19	1	27	23	16	6	5	7		18	14	9	5	1	1	
35-39	27	1	12	1	26	13	11	9	2	3		11	8	5	3	1	1	
40-44	32	2	17	1	30	23	20	10	4	-		16	12	8	4	1	1	
45-49	28	2	36	-	26	17	8	5	2	1		36	22	9	6	4	3	
50-54	36	-	52	-	36	21	14	9	3	2		52	37	17	4	2	2	
55-59	39	2	66	1	37	28	12	7	3	3		65	37	24	8	2	-	
60-64	31	1	60	-	30	15	5	3	-	-		60	34	8	-	-	-	
65-69	38	-	46	-	38	10	4	1	-	-		46	21	5	1	-	-	
70-74	24	-	36	-	24	12	-	-	-	-		36	20	3	2	-	-	
75-79	13	-	31	-	13	3	1	-	-	-		21	8	2	1	-	-	
80-84	-	-	3	-	-	-	-	-	-	-		3	-	-	-	-	-	
85-89	-	-	1	-	-	-	-	-	-	-		1	-	-	-	-	-	
0-14	50	3	42	3	47	43	40	35	18	14		39	37	32	21	10	11	
15-39	117	2	79	6	115	86	59	39	24	27		73	54	35	17	11	18	
40-	241	7	338	2	234	129	64	35	12	6		136	191	76	26	9	6	
Total	408	12	459	11	396	258	163	109	54	47		448	282	143	54	30	35	
G 0-4	11	6	5	1	5	4	6	4	2	2		4	4	4	3	1	1	
5-9	12	3	16	2	9	9	10	7	2	-		14	11	13	8	5	-	
10-14	23	4	19	9	19	19	10	6	2	-		10	14	12	3	2	3	
15-19	20	2	14	7	18	16	10	12	8	2		7	11	6	3	3	5	
20-24	13	1	18	5	12	8	5	4	3	2		13	9	6	7	4	2	
25-29	15	3	10	5	12	8	6	6	5	4		5	4	4	2	2	5	
30-34	15	2	9	1	13	6	5	3	1	-		8	6	4	4	1	-	
35-39	14	3	15	6	11	9	4	3	1	-		9	6	8	4	3	-	
40-44	19	2	19	4	17	12	9	6	2	-		15	14	7	3	1	1	
45-49	24	3	36	9	21	15	6	3	3	-		27	24	18	9	1	-	
50-54	28	7	44	9	21	12	7	2	2	2		35	35	23	10	4	-	
55-59	27	2	48	9	25	12	6	3	1	-		39	28	17	8	1	-	
60-64	19	-	48	3	19	7	2	-	-	-		45	28	10	4	-	-	
65-69	23	2	63	6	21	13	2	-	-	-		57	24	6	1	-	-	
70-74	20	-	40	-	20	6	-	-	-	-		40	14	2	1	-	-	
75-79	15	-	24	1	15	2	-	-	-	-		23	8	-	-	-	-	
80-84	5	-	4	-	5	-	-	-	-	-		4	-	-	-	-	-	
85-89	-	-	1	-	-	-	-	-	-	-		1	-	-	-	-	-	
90-	1	-	-	-	1	-	-	-	-	-		-	-	-	-	-	-	
0-14	46	13	40	12	33	32	26	17	6	6		28	29	29	14	8	4	
15-39	77	11	66	24	66	47	30	28	18	8		42	33	28	20	13	12	
40-	181	16	327	41	165	79	32	14	8	2		286	175	83	36	7	1	
Total	304	40	433	77	264	158	88	59	32	16		356	237	140	70	28	17	

Table 7B Continued

Hospital and age at onset	Patients				Registrations (in 5-year period) duration															
	M		F		M								F							
	Not dur 0-4		Not dur 0-4																	
	All		All		0- 4	5- 9	10- 14	15- 19	20- 24	25- 29			0- 4	5- 9	10- 14	15- 19	20- 24	25- 29		
W																				
0-4	11	6	8	4	-	2	2	2	4	1			4	4	4	4	4	4	3	
5-9	19	12	24	12	7	10	12	12	11	5			12	11	11	8	11	11	2	
10-14	26	10	23	8	16	17	16	9	5	1			15	11	10	8	7	5		
15-19	34	13	21	5	21	9	11	11	7	17			16	10	4	5	6	7		
20-24	27	4	24	10	23	14	12	7	4	2			14	14	12	10	7	5		
25-29	28	6	20	3	22	15	8	4	2	5			17	13	9	2	2	2		
30-34	34	9	27	7	25	16	9	4	-	2			20	18	11	10	6	5		
35-39	30	6	19	4	24	16	11	8	4	2			15	10	9	5	5	2		
40-44	41	10	27	16	31	22	15	6	2	3			21	22	15	12	5	1		
45-49	49	11	40	11	38	20	11	9	3	-			29	23	15	7	4	-		
50-54	49	11	67	18	38	21	15	9	3	-			49	36	23	14	1	-		
55-59	45	10	85	17	35	17	9	4	-	-			68	48	22	11	1	-		
60-64	33	2	63	13	31	15	4	1	-	-			50	33	14	2	-	-		
65-69	25	5	63	11	20	13	3	-	-	-			52	29	11	-	-	-		
70-74	20	3	32	2	17	5	1	-	-	-			30	8	1	-	-	-		
75-79	3	-	11	-	3	-	-	-	-	-			11	2	-	-	-	-		
80-84	1	-	1	-	1	-	-	-	-	-			1	-	-	-	-	-		
85-89	-	-	1	-	-	-	-	-	-	-			1	-	-	-	-	-		
0-14	51	28	55	24	23	29	30	23	17	7			31	26	32	20	17	10		
15-39	153	38	111	29	115	70	51	34	17	28			82	65	45	32	26	21		
40-	266	52	400	111	214	113	58	29	8	3			312	201	96	46	11	1		
Total	470	118	566	141	352	212	139	86	42	38			425	292	173	98	54	32		
Z																				
0-4	4	1	3	1	3	2	3	3	1	-			2	1	3	1	-	-		
5-9	9	-	14	2	9	6	7	2	2	1			12	10	9	7	-	1		
10-14	23	5	15	2	18	14	15	7	4	5			13	12	11	5	2	-		
15-19	15	1	15	1	14	5	3	4	1	-			14	11	11	5	1	-		
20-24	24	4	12	4	20	9	10	7	4	3			11	8	3	3	3	4		
25-29	22	1	11	3	21	10	8	4	1	-			8	8	4	4	2	2		
30-34	20	5	9	-	15	11	7	5	3	1			9	2	2	2	1	1		
35-39	22	2	16	1	20	14	5	3	3	2			15	7	8	5	1	-		
40-44	26	5	20	1	21	10	5	5	3	1			19	13	6	4	1	2		
45-49	30	4	29	5	26	18	8	3	2	-			24	19	9	6	1	-		
50-54	41	5	38	11	36	19	11	4	1	-			47	35	22	11	3	-		
55-59	63	6	83	6	57	28	16	7	1	-			77	41	23	6	1	-		
60-64	63	1	102	11	62	25	9	3	2	-			91	43	14	3	-	-		
65-69	50	4	107	1	46	21	7	1	-	-			106	38	8	3	-	-		
70-74	40	3	79	2	37	15	1	-	-	-			77	23	3	1	-	-		
75-79	34	-	39	-	34	10	1	-	-	-			39	3	-	-	-	-		
80-84	12	-	5	-	12	2	-	-	-	-			5	-	-	-	-	-		
85-89	-	-	4	-	-	-	-	-	-	-			4	-	-	-	-	-		
0-14	36	11	32	5	30	22	25	12	7	11			27	23	21	13	11	1		
15-39	103	13	63	9	90	49	33	23	12	11			54	34	23	19	8	7		
40-	359	28	526	37	331	148	58	23	9	1			489	215	85	34	6	2		
Total	498	47	621	51	451	219	116	58	28	13			570	272	129	66	16	10		

Table 8: Mean age in groups by sex hospital age at onset and duration

Duration	Hospital	Juvenile onset 0-14		Early adult onset 15-39		Late onset 40	
		M	F	M	F	M	F
0-4	P	10.3	10.4	29.7	28.5	60.1	61.9
	G	11.1	10.1	28.0	28.9	62.0	63.6
	W	12.5	10.8	29.3	29.2	57.4	61.1
	Z	11.5	11.0	29.4	29.3	63.7	65.0
	Total	11.1	10.6	29.2	29.0	61.1	63.1
5-9	P	15.0	15.3	34.1	33.6	62.4	65.3
	G	16.3	15.7	32.3	32.9	62.8	64.7
	W	16.6	15.3	35.1	34.3	60.9	63.4
	Z	16.7	16.4	36.0	32.5	66.6	66.0
	Total	16.0	15.7	34.8	33.5	63.4	64.9
10-14	P	19.6	19.7	39.6	38.1	63.4	67.4
	G	19.8	20.4	37.0	39.4	62.8	65.9
	W	21.3	19.9	38.7	40.0	63.1	65.4
	Z	21.4	20.4	39.2	39.7	68.0	67.9
	Total	20.4	20.1	38.8	39.3	64.4	66.6
15-19	P	24.7	24.2	44.4	44.3	67.7	70.9
	G	24.6	24.0	40.6	43.8	64.7	70.1
	W	25.5	25.0	42.7	44.0	66.4	67.3
	Z	25.7	25.5	43.1	43.7	69.7	70.6
	Total	25.0	24.7	42.8	43.9	67.4	69.5
20-24	P	31.5	28.5	47.8	47.2	71.1	71.8
	G	29.0	29.6	44.6	47.8	70.2	72.6
	W	29.3	29.9	46.1	48.4	69.6	68.1
	Z	31.1	34.0	50.2	47.8	72.3	72.3
	Total	30.4	29.7	47.0	48.0	70.9	70.8

The number of registrations (patients in the duration group) is given in Table 7A

remaining 1 835 patients in duration group 0-4 years were registered in a later period too. Of these 1 835 patients however only 1 695 were registered in the subsequent period (duration 5-9 years) the remaining 140 did not return until a later period. In addition to the 1 695 patients from the first duration period there appeared in the second duration period 235 new patients—thus patients who paid their first visit to the hospital (with the diagnosis DM) after the disease had been manifest for 5-9 years (the difference between the calendar year of admission and the calendar year

of onset). At the bottom of the table there are totals for all duration periods taken together. Of the 3 759 patients, 634 died before January 1, 1956, and 101 moved but were living on that date. 3,024 patients were registered in a period ending after 1955 and were still living on January 1 1956.

### Admission rates and domicile

Although the registration hospitals are well-equipped specialized hospitals and in many respects dominate their

Table 9 Registrations by age groups at onset and duration grouped by first calendar year within the registration period (epoch)

Age at onset	Epoch	Hospital	Males (registrations)							Females (registrations)						
			All	Duration						All	Duration					
				0-4	5-9	10-14	15-19	20-24	25+		0-4	5-9	10-14	15-19	20-24	25+
0-14	E1 (-1949)	P	116	43	31	20	15	3	4	92	37	29	16	7	2	1
		G	71	28	21	13	7	2	-	73	27	22	15	6	2	1
		W	68	19	21	17	8	2	1	76	30	15	12	10	7	2
		Z	68	27	17	14	7	2	1	61	27	20	10	4	-	-
		Total	323	117	90	64	37	9	6	302	121	88	53	27	11	4
	E2 (1950-)	P	81	4	12	20	20	15	10	58	2	8	16	14	8	10
		G	49	5	11	13	10	4	6	39	1	7	14	8	6	3
		W	61	4	8	13	15	15	6	60	1	11	20	10	10	8
		Z	34	3	5	11	5	5	5	26	-	3	11	9	2	1
		Total	225	16	36	57	50	39	27	183	4	29	61	41	26	22
15-39	E1 (-1949)	P	178	78	47	28	13	9	3	93	44	25	9	6	4	5
		G	112	47	28	19	15	2	1	76	27	16	17	10	4	2
		W	122	51	26	20	9	2	14	127	47	30	21	17	8	3
		Z	123	69	26	17	5	3	3	80	30	23	15	8	4	-
		Total	535	245	127	84	42	16	21	376	148	94	62	41	21	10
	E2 (1950-)	P	172	37	39	31	26	15	24	115	29	29	26	11	7	13
		G	85	19	19	11	13	16	7	72	15	17	11	10	9	10
		W	193	64	44	31	25	15	14	144	35	35	24	15	17	18
		Z	90	21	23	16	18	9	3	65	24	11	8	11	4	7
		Total	540	141	125	89	82	55	48	396	103	92	69	47	37	48
40+	E1 (-1949)	P	162	98	35	21	3	2	3	195	128	42	17	5	1	2
		G	124	79	24	12	6	3	-	282	170	66	40	6	-	-
		W	123	69	29	18	5	1	1	197	116	45	25	10	1	-
		Z	276	173	59	28	12	4	-	393	249	87	42	13	2	-
		Total	685	419	147	79	26	10	4	1 067	663	240	124	34	4	2
	E2 (1950-)	P	318	136	94	43	32	10	3	449	208	149	59	21	8	4
		G	176	88	55	20	8	5	2	306	116	109	43	30	7	1
		W	302	145	81	40	24	7	2	470	196	156	71	36	10	1
		Z	294	158	89	30	11	5	1	438	240	128	43	21	4	2
		Total	1 090	525	322	133	75	27	8	1 663	760	542	216	108	29	8
Total	E1 (-1949)	P	456	219	113	69	31	14	10	380	209	96	42	18	7	8
		G	307	154	73	44	28	7	1	431	224	104	72	22	6	3
		W	313	139	76	55	22	5	16	400	193	90	58	37	17	5
		Z	467	269	102	59	24	9	4	534	306	130	67	25	8	-
		Total	1 543	781	364	227	105	35	31	1 745	932	420	239	102	36	16
	E2 (1950-)	P	571	177	145	94	78	40	37	622	239	186	101	46	23	27
		G	310	110	85	44	31	25	15	417	132	133	88	48	22	14
		W	556	213	136	84	64	37	22	674	232	202	115	61	37	27
		Z	418	182	117	57	34	19	9	529	264	142	62	41	10	10
		Total	1 855	682	483	279	207	121	83	2 242	867	663	346	196	92	78

admission areas it is quite natural with a graphical differences with regard to the disease of the type that DM represents the admission rates—connected with communications (and improved communica-

Table 10 Survey of course of registration

Duration	Type of change (+ increase - decrease)	Registrations							
		M				F			
		All	Age at onset			All	Age at onset		M + F
			0 14	15- 39	40		0 14	15 39	
0-4	+ New	1 463	133	386	944	1 799	125	251	1 423
	Total	1 463	133	386	944	1 799	125	251	1 423
	- Deceased	103	2	7	94	166	-	5	161
	- Moved	28	3	8	17	19	-	3	16
	- Living	504	9	104	391	607	7	70	530
	- Continued	828	119	267	442	1 007	118	173	716
5-9	+ Continued	758	111	236	411	937	102	157	678
	+ New	89	15	16	58	146	13	29	104
	Total	847	126	252	469	1 083	115	186	782
	- Deceased	57	-	-	57	90	1	-	89
	- Moved	10	1	7	2	15	4	4	7
	- Living	366	21	104	241	501	20	67	414
10-14	- Continued	414	104	141	169	477	90	115	272
	+ Continued	450	106	158	186	518	100	119	299
	+ New	56	15	15	26	67	14	12	41
	Total	506	121	173	212	585	114	131	340
	- Deceased	33	1	5	27	63	8	4	51
	- Moved	4	1	1	2	10	5	1	4
15-19	- Living	207	43	64	100	263	41	52	170
	- Continued	262	76	103	111	249	60	74	115
	+ Continued	279	79	111	89	265	63	79	123
	+ New	33	8	13	12	33	5	9	19
	Total	312	87	124	101	298	68	88	142
	- Deceased	28	6	5	17	45	8	2	35
20-24	- Moved	9	3	1	5	5	1	1	3
	- Living	147	37	56	54	139	31	33	75
	- Continued	128	41	62	25	109	28	52	29
	+ Continued	137	42	64	31	113	30	53	30
	+ New	19	6	7	6	15	7	5	3
	Total	156	48	71	37	128	37	58	33
25-	- Deceased	14	3	3	8	11	4	3	4
	- Moved	-	-	-	-	-	-	-	-
	- Living	92	29	41	22	69	17	27	25
	- Continued	50	16	27	7	48	16	28	4
	+ Continued	94	27	56	11	75	21	45	9
	+ New	20	6	13	1	19	5	13	1
Total	Total	114	33	69	12	94	26	58	10
	- Deceased	6	-	2	4	18	4	12	2
	- Moved	1	-	1	-	-	-	-	-
	- Living	71	24	41	6	58	18	35	5
	- Continued	36	9	25	2	31	4	11	3
	+ Continued	94	27	56	11	75	21	45	9
Total	+ New	20	6	13	1	19	5	13	1
	Total	114	33	69	12	94	26	58	10
	- Deceased	6	-	2	4	18	4	12	2
	- Moved	1	-	1	-	-	-	-	-
	- Living	71	24	41	6	58	18	35	5
	- Continued	36	9	25	2	31	4	11	3
Total	+ Continued	1 718	365	625	728	1 908	316	453	1 139
	+ New	1 680	183	450	1 047	2 079	169	319	1 591
	Total	3 398	548	1 075	1 775	3 987	485	772	2 730
	- Deceased	241	12	22	207	393	25	26	342
	- Moved	52	11	11	26	49	10	11	30
	- Living	1 387	163	410	814	1 637	134	284	1 219
Total	- Continued	1 718	365	625	728	1 908	316	453	1 139
	+ Continued	1 718	365	625	728	1 908	316	453	1 139
	+ New	1 680	183	450	1 047	2 079	169	319	1 591
	Total	3 398	548	1 075	1 775	3 987	485	772	2 730
	- Deceased	241	12	22	207	393	25	26	342
	- Moved	52	11	11	26	49	10	11	30

tions, for instance the development of motoring) the capacity and location of other hospitals etc., and connected with the age and occupation of the patient the occurrence of intercurrent disease, and so on

For the admission areas of the four hospitals the geographical distribution of the domiciles of the patients is shown in Table 11. The divisions used are (the present) towns and certain rural districts (*härads tingslag*, mainly based on the socio-economic geographical grouping applied at the census of 1930). By sex, the table shows the population in 1950, and the number of first admissions (all, and during the periods 1946-50 and 1951-55). In the columns to the right are given certain relative figures viz the ratio all first admissions : population in 1950.

On the basis of the location of the towns and districts, and the quotients mentioned, the towns and districts have been taken together as indicated in Table 11 on the left (cf Figs 2-5). For these areas (four in Kopparberg County, three in each of Älvsborg, Kronoberg and Jämtland Counties) Table 12 gives the population by sex and age in 1950 and the number of first admissions during the period 1946-55 of residents within the area by sex and age. On the basis of these data the aggregate admission rates up to certain ages have been cal-

culated; they are shown at the bottom of Table 12.

For area P1 (the towns of Vänersborg and Trollhättan) the aggregate admission rates up to age 80 were 4.0 per cent for males and 6.5 per cent for females. For area P2 (the rural districts of the province of Västergötland which are covered by Vänersborg Hospital) the figures are lower viz 3.0 and 3.7 per cent, and for area P3 (the province of Dalsland) they are still lower, or 2.0 and 2.6 per cent.

Växjö (area G1) is a comparatively small town, but the figures agree well with those found for Vänersborg and Trollhättan (P1). Area G3 (the south-western part of Kronoberg County, with the town of Ljungby) shows very low admission rates (0.7 and 1.2 per cent); this can be explained by the fact—known before the investigation started—that DM patients from this area are regularly admitted to the hospital at Ljungby. For the rest of Kronoberg County the aggregate admission rates up to age 80 were 3.1 per cent for males and 4.7 per cent for females.

For Falun town (W1) the corresponding rates are 5.1 and 6.1 per cent. For the south-eastern part of the county (Västerbergslagen W4) the figures are very low, 0.9 and 0.7 per cent; in this area the great majority of the DM patients go to the hospital at Ludvika.

Table 10. Explanations

+ New	= Not registered in earlier period
+ Continued	= Registered in earlier period
- Deceased	= Not registered in later period, deceased before January 1 1956
- Moved	= Period ending before January 1 1956, not registered in later period, living on January 1 1956
- Living	= Period ending after December 31 1955, living on January 1 1956
- Continued	= Registered in later period

Table 11 *Population and first admissions geographical distribution*

District and location	Name of town or rural area	Population 1940		First admissions						First admissions (all) per thousand population (1950)	
		thousands									
		M	F	1946 50		1951 55		All		M	F
P1	a Vanersborg town	7.8	8.5	4	17	25	23	59	71	7	9
	b Trollhattan town	12.2	11.9	14	32	28	50	88	121	7	10
P2	c Flundre Vane Bjärke	11.3	10.5	13	11	24	37	78	83	7	8
	d Ale	8.3	7.8	10	8	13	15	34	30	4	4
P3	e Sundal Valbo Nordal	14.8	13.9	15	17	21	23	68	61	5	4
	f Arnäl town	4.0	4.1	7	8	7	10	20	26	5	6
	g Tossbo Vedbo	13.5	12.8	11	10	12	20	48	51	4	4
	Outside P			1	4	8	8	13	16		
	Total	71.9	69.5	75	107	138	184	408	459	6	7
G1	a Vaxjo town	9.3	10.8	19	32	17	29	48	76	5	7
G2	b Kunnevald	7.1	6.6	11	25	9	14	27	54	4	7
	c Konga	12.6	11.5	21	20	18	23	61	67	5	6
	d Uppvidinge	12.8	11.6	13	25	16	28	48	83	4	7
	e Norrvidinge	4.1	3.8	6	12	11	12	18	30	4	8
	f Allbo	15.5	14.3	25	42	36	32	82	91	5	7
G3	g Sunnerbo (incl. Ljungby town)	19.7	18.0	5	10	9	13	17	29	1	2
	Outside G			3	1	-	2	3	3		
	Total	81.1	76.6	103	167	116	153	304	433	4	6
W1	a Falun town	7.8	9.1	16	25	26	30	68	85	9	9
W2	b Falu norra tingslag	10.9	10.6	12	19	14	21	41	59	4	6
	c Nedansiljan	18.5	18.5	17	29	28	40	75	103	4	6
	d Ovensiljan	18.7	17.2	5	6	19	12	29	24	2	1
W3	e Näs Malung	14.8	13.9	4	12	9	12	27	39	2	3
	f Borlänge town	10.9	10.8	17	37	25	20	70	84	6	7
	g Falu södra tingslag	7.2	6.7	10	10	12	17	30	47	4	7
	h Älsta Säter Hedemora towns	8.4	8.9	12	15	19	17	46	51	5	6
	i Folkare Hedemora tingslag	16.9	16.2	9	12	25	21	46	46	3	3
W4	j Ludvika town	5.4	4.9	4	4	8	4	14	10	3	2
	k Vasterberglagen	15.8	15.0	1	4	10	5	15	14	1	1
	Outside W			2	2	5	1	9	4		
	Total	135.3	131.8	109	175	200	200	470	566	3	4
Z1	a Östersund town	10.2	11.4	22	39	29	34	93	122	11	11
Z2	b Revsund Brunflo Nas	9.5	8.7	12	20	13	39	56	94	6	11
	c Ragunda	8.1	7.4	13	22	14	16	52	62	11	9
	d Hammerdal	8.8	7.9	11	13	20	25	48	64	5	8
	e Lit Rodön	9.5	8.8	15	25	19	19	64	88	7	10
	f Jamtlands västra tingslag	15.3	14.6	26	31	42	45	131	133	8	11
	g Berg	4.2	3.6	8	14	10	12	30	42	7	11
Z3	h Sveg, Hede	8.7	7.4	4	5	7	1	16	13	11	2
	Outside Z			2	2	-	-	8	3		
	Total	74.3	69.8	113	171	154	191	498	621	7	9

Location of areas see maps Figs 2-5 pp 36 38 39 40

Table 12 Population 1950, first admissions 1946-55 and aggregate admission rate, 1946-55 by district

Sex	Age	District												
		P1	P2	P3	G1	G2	G3	W1	W2	W3	W4	Z1	Z2	Z3
Population 1950 thousands														
M	0-14	4.7	4.5	7.0	2.3	11.8	4.6	1.9	11.2	13.7	4.8	2.7	14.2	2.1
	15-39	7.9	6.7	10.9	3.6	17.7	6.7	2.9	16.1	20.2	7.7	4.0	19.0	3.1
	40-49	2.9	3.0	4.8	1.3	7.6	2.8	1.2	7.0	8.7	3.2	1.3	7.4	1.2
	50-64	2.9	3.2	5.7	1.4	8.7	3.2	1.2	8.2	9.8	3.5	1.5	8.9	1.4
	65-	1.6	2.2	3.9	0.7	6.3	2.4	0.6	5.6	5.8	2.0	0.7	5.9	0.9
	Total	20.0	19.6	32.3	9.3	52.1	19.7	7.8	48.1	58.2	21.2	10.2	55.4	8.7
F	0-14	4.5	4.1	6.7	2.2	11.2	4.2	1.8	10.8	13.2	4.5	2.5	13.7	2.0
	15-39	7.9	6.1	9.7	4.4	15.2	5.8	3.5	15.1	19.2	7.0	4.6	16.9	2.6
	40-49	3.0	2.7	4.4	1.5	6.8	2.5	1.3	6.7	8.2	2.9	1.6	6.7	1.0
	50-64	3.1	3.2	5.8	1.6	8.3	3.1	1.6	8.2	9.8	3.5	1.8	8.3	1.1
	65-	1.9	2.2	4.2	1.1	6.3	2.4	0.9	5.5	6.1	2.0	0.9	5.4	0.7
	Total	20.4	18.3	30.8	10.8	47.8	18.0	9.1	46.3	56.5	19.9	11.4	51.0	7.4
First admissions 1946-55 (residents within the area)														
M	0-14	-	1	7	2	9	2	1	2	4	3	1	5	-
	15-39	17	16	24	11	32	6	11	29	46	8	4	29	6
	40-49	10	10	6	3	22	2	10	11	31	6	2	23	2
	50-64	21	15	20	12	49	3	13	32	45	5	27	69	1
	65-	23	18	16	8	54	1	7	21	16	1	17	77	2
	Total	71	60	73	36	166	14	42	95	142	23	51	203	11
F	0-14	3	2	1	1	5	1	2	2	7	-	-	4	-
	15-39	18	11	12	13	30	4	5	25	37	6	10	18	-
	40-49	9	12	12	4	23	2	7	8	21	3	6	17	1
	50-64	57	22	34	15	65	11	27	46	68	7	29	104	1
	65-	35	24	29	28	110	5	14	46	40	1	11	138	4
	Total	122	71	100	61	233	23	55	127	173	17	73	281	6
Aggregate admission rate 1946-55 per cent														
M	40	0.6	0.7	0.7	0.9	0.6	0.3	1.1	0.5	0.7	0.4	0.3	0.4	0.4
	50	1.0	1.1	0.9	1.2	0.8	0.4	1.9	0.7	1.0	0.6	0.5	0.7	0.6
	65	2.1	1.8	1.4	2.5	1.7	0.6	3.5	1.3	1.7	0.8	3.3	2.0	0.7
	80	4.0	3.0	2.0	4.2	3.1	0.7	5.1	1.8	2.3	0.9	7.0	3.9	1.0
F	40	0.7	0.6	0.4	0.8	0.6	0.3	0.6	0.5	0.6	0.2	0.4	0.4	0.0
	50	1.1	1.0	0.6	1.2	0.9	0.4	1.1	0.6	0.9	0.3	1.0	0.6	0.1
	65	3.8	2.1	1.5	2.5	2.1	0.9	3.6	1.5	2.0	0.6	3.5	2.6	0.3
	80	6.5	3.7	2.6	6.2	4.7	1.2	6.1	2.7	3.0	0.7	7.8	6.4	1.0

For the remainder of the county there are considerable local differences as can be seen from Table 11, on the whole the figures are similar to those found for Dalsland but are lower than in the Västergötland part of Älvsborg County and in the main admission area for Växjö Hospital. The explanation lies partly in

the existence of local hospitals and partly in the relatively large distances to the hospital at Falun.

Östersund (Z1) which like Växjö and Falun is a comparatively small town presents very high admission rates—up to age 80 no less than 7.0 per cent for males and 7.8 per cent for females. For



the south-eastern part (Z3, in the province of Härjedalen) the figures are low, 10 per cent for both males and females from this area the DM patients generally go to the hospital at Sveg. For the remainder of the admission area (Z2 the rural parts of the province of Jämtland) the figures are high viz. 3.9 and 6.4 per cent, in spite of the long distances to Östersund from certain parts of the area. However, in view of the geographical features of Jamtland and the adjacent provinces the position of Östersund as the centre of the province is very marked. It should be noticed in addition that the admission of DM patients in the advanced age groups is at a higher level at Östersund than at the other hospitals studied. At least in part this difference may be regarded as a consequence of the

circumstance just mentioned, a great many of the inhabitants in Jämtland have special reasons (other than disease) for visiting Östersund, whereas in respect of parts of the admission areas of the hospitals at Vanersborg Värmland and Falun there are 'competing towns' (with in or outside the admission areas).

## Frequency of admissions

The total number of registrations (duration cards) is 7,385. However, for some patients there exist gaps in the series of registrations, these gaps may be due to migration (the patient being away from the area over a whole registration period), but for mild cases they may also be the result of a state of good control,

Table 13 Number of admissions and average annual frequency of admissions by sex, duration and age at onset

Sex	Duration	Age at onset						All ages	
		0-14 (J)		15-39 (A)		40- (L)			
		<i>a</i>	<i>f</i>	<i>a</i>	<i>f</i>	<i>a</i>	<i>f</i>	<i>a</i>	<i>f</i>
M	0-4	1 492	5.0	3 044	3.9	5 703	3.1	10 239	3.5
	5-9	884	1.7	1 303	1.4	2 192	1.5	4 379	1.5
	10-14	650	1.5	830	1.5	906	1.5	2 386	1.5
	15-19	421	1.5	657	1.6	457	1.7	1 535	1.6
	20-24	238	1.7	362	1.7	146	1.8	746	1.7
	25-	106	1.1	383	1.8	42	1.4	531	1.6
	Total	3 791	2.2	6 579	2.1	9 446	2.2	19 816	2.2
F	0-4	1 534	5.8	2 201	4.2	9 107	3.2	12 842	3.5
	5-9	1 067	2.3	1 126	1.7	4 039	1.7	6 232	1.7
	10-14	890	2.4	826	1.9	1 767	1.8	3 483	2.0
	15-19	494	2.3	565	2.0	714	1.9	1 773	2.0
	20-24	237	2.1	335	1.8	153	1.9	725	1.9
	25-	116	1.7	291	2.0	39	1.5	446	1.9
	Total	4 338	2.9	5 344	2.4	13 819	2.3	25 501	2.4

*a* = number of admissions

*f* = average annual number of admissions per patient

Table 14 Variations in admission frequency between hospitals and epochs

Hospital	Sex	Epoch				Total	
		E1 (1949)		E2 (1950)			
		a	q	a	q	a	q
B	M	2 490	0 86	2 854	0 93	5 344	0 89
	F	2 275	0 82	3 492	0 93	5 767	0 88
	M+F	4 765	0 84	6 346	0 93	11 111	0 89
G	M	2 273	1 16	1 909	1 12	4 182	1 14
	F	3 396	1 16	2 623	1 06	6 019	1 11
	M+F	5 669	1 16	4 532	1 08	10 201	1 13
W	M	2 446	1 27	3 239	1 05	5 685	1 13
	F	3 314	1 19	4 189	1 03	7 503	1 10
	M+F	5 760	1 22	7 428	1 04	13 188	1 11
Z	M	2 266	0 79	2 339	1 02	4 605	0 89
	F	2 982	0 84	3 230	1 01	6 212	0 92
	M+F	5 248	0 82	5 569	1 02	10 817	0 91
Total	M	9 475	0 98	10 341	1 02	19 816	1 00
	F	11 967	1 00	13 534	1 00	25 501	1 00
	M+F	21 442	0 99	23 875	1 01	45 317	1 00

a = number of admissions

q = quotient between observed and expected number of admissions expected number calculated from the overall admission frequencies by sex duration and age at onset

needing no hospital visits. The total number of 5 year gaps is 250 and thus the maximum observation time spanned by our series would be  $5 \times (7\,385 + 250) = 38,175$  years for the 3,759 patients or about 10 years per patient.

As may be seen from Table 6 the average time interval from onset to first admission is 2.3 years and on average it may be assumed that the last observation period for a patient does not cover more than 2.5 years. Thus the effective observation time must be considerably shorter than 38 000 years in this connection it should be observed that the number of first admissions shows a marked increase with time. An approximate calculation may be performed on the basis of the following assumptions

(a) For each patient, his first and last registration (duration card) is considered to represent 2.5 observation years.

(b) If a patient is registered in one period only, the observation time is considered to be one third of the period, corresponding to the hypothesis that times of entrance and exit are evenly distributed and independent.

(c) If there is a gap in the sequence of registrations the patient is considered to have left observation in the middle of the preceding period and to have again come under observation in the middle of the following period.

The total observation time during the duration period  $d$  will then be determined through the formula

$$\frac{1}{3}t_d = c_d - \frac{1}{2}f_d - \frac{1}{2}l_d + \frac{1}{3}s_d - \frac{1}{2}(g_{d-1} + g_{d+1})$$

where

$\Pi$  = observation time in years  
 $c$  = number of duration cards  
 $f$  = number of first registrations  
 $l$  = number of last registrations  
 $s$  = number of single cards (first and last registration)  
 $g$  = number of gaps (period missing)

Summing over all periods we obtain (using capital letters for the sums over all periods)

$$\frac{1}{5} T = C - P + \frac{1}{3} S - G$$

where  $P (=F=L)$  = the number of patients

In this way, the total effective observation time may be assessed at 19 700 years or on average somewhat more than 5 years per patient

In Table 13 by dividing the number of admissions into the figures for the observation time the annual frequency of admissions is determined. The data are given by sex, age at onset and duration.

The types by age at onset—juvenile, early adult and late—represent about 17, 27 and 56 per cent of the total time. The lowest duration group, 0–4 years, covers about one half of the total observation time.

The annual frequency of admissions shows a consistent picture according to duration, viz. high figures during the first duration period and later 1.5 to 2 admissions per annum, during the first duration period the frequency of admissions is higher among juvenile diabetics than among diabetics with early adult onset and higher among these than among patients with late onset. For the whole series the average annual frequency of admissions is 2.3.

The variations in admission frequency between the four hospitals and the two epochs (–1949, 1950–) are shown in Table 14. The observed numbers of admissions have been divided into the expected numbers, viz. those which would have obtained if the overall admission frequencies by sex, duration and age at onset had been applicable throughout the whole material. As will be seen from the table the variations by sex are very slight, the admission frequencies are higher at Vaxjö (G) and Falun (W) than at Vänersborg (P) and Östersund (Z). There has occurred a levelling out in so far as the quotients observed/expected are closer to unity in the later epoch (1950–) than they were in the earlier epoch (–1949).

## Mortality among DM patients

### Material and methods

One of the aims of this investigation has been to study the mortality of the DM patients. In order to get a suitable series several difficulties had to be overcome. In the first place we had to secure correct periods of observation. Some of the physicians with the aim of providing the fullest possible data had taken the trouble to assemble earlier reports about their patients from other hospitals and from physicians outside the hospitals and included these reports in their own material. However valuable this supplementary information may have been for the clinical study it had the drawback of introducing immortal persons into our material. Obviously if these patients had died before their first visit to the investigation hospital in question, they would never have entered our series. For this reason we have limited the mortality study to a period beginning in 1946 as we know that from this year onwards the immortality effect is negligible.

For Växjö (G) the registration period ends with the year 1955, and we therefore decided to restrict the mortality study to the 10 year period 1946-55.

Our preliminary examination of the punched cards showed an astonishing

low number of registered deaths. It was evident that the hospitals had not been able to register complete information about deaths among their diabetic patients. For 1,440 out of the 3,759 patients we did not know for certain if they were living at the end of 1955. In the first place we asked the hospitals involved to complete their data as fully as possible. In order to try to clear up the remaining uncertain cases we had to write a great many letters to the county registration offices and to the parishes where the patients had last been domiciled. In this way we ultimately succeeded in getting almost complete information and in the total series no fewer than 464 previously 'unknown' deaths were recorded.

In all, our material for the period 1946-55 covers 160 male deaths in 7,498 observation years and 238 female deaths in 8,942 observation years. To admit the subdivisions needed the material was treated in the following way. For each sex the observation time was split according to calendar year, duration in 5 year intervals and attained age in one year intervals. The observation times were for every age multiplied by the corresponding death rate of the Swedish population in the period 1946-55 (for

Table 15 Mortality of DM patients by sex and age 1946-55

Attained age	Number of observation years		Number of deaths				Death rate per thousand		Mortality ratio	
			M		F					
	M	F	O	E	O	E	M	F	M	F
0- 4	3	3	-	00	-	00	-	-	-	-
5- 9	41	40	-	00	-	00	-	-	-	-
10-14	196	200	-	01	-	01	-	-	-	-
15-19	430	417	-	05	1	03	-	2	-	3.6
20-24	497	448	1	08	6	04	2	13	1.2	14
25-29	527	365	3	08	5	04	8	14	3.6	13
30-34	596	340	5	11	5	04	8	15	4.7	12
35-39	562	360	1	12	-	07	2	-	0.8	-
40-44	586	410	4	17	2	10	7	5	2.3	2.0
45-49	591	527	3	28	3	20	5	6	1.1	1.5
50-54	648	727	7	48	9	43	11	12	1.5	2.1
55-59	619	975	16	74	14	88	26	15	2.2	1.6
60-64	689	1 225	18	120	26	179	26	21	1.5	1.5
65-69	625	1 226	26	182	53	301	42	44	1.4	1.8
70-74	492	969	30	239	50	413	61	52	1.3	1.2
75-79	289	527	30	229	41	383	104	78	1.3	1.1
80-84	99	141	15	125	17	168	159	121	1.2	1.0
85-89	7	42	1	14	6	78	143	143	0.7	0.8
90-	1	-	-	01	-	-	-	-	-	-
Total	7 498	8 942	160	112.2	238	170.6			1.4	1.4

O = Observed number of deaths

E = Expected number of deaths according to mortality in the general Swedish population 1946-55 (for males and females respectively)

males and females respectively) and these expected numbers of deaths were then added within 5 year intervals of age and compared with the observed numbers of deaths. This means that if the diabetics had strictly followed the population mortality (and the population mortality had been stable over the 10 year period) the observed number of deaths should for every subdivision be equal to the calculated expected number. As this quality is preserved under any additions we are entitled to make all combinations needed. The quotient between the observed number of deaths and the number expected according to the population mortality is termed the *mortality ratio*.

## Mortality by age

The results of the calculation in respect of mortality by sex and age are shown in Table 15. The table gives, by 5 year age groups, the number of observation years within the period 1946-55, the observed and expected numbers of deaths, the death rate for DM patients, and the mortality ratio. Admittedly, the number of deaths is not very large but nevertheless the figures seem to give a good picture of the circumstances prevailing in a series of DM patients who have been admitted to specialized county hospitals in Sweden. When evaluating the data it should not be overlooked that to a certain extent the existence of

Table 16 Mortality of DM patients by sex and calendar year 1946-55

Year	All durations				Duration 0-4 years			
	Number of deaths		Mortality ratio		Number of deaths		Mortality ratio	
	M	F	M	F	M	F	M	F
1946	10	14	2.0	2.3	2	6	1.1	2.4
1947	11	15	1.9	1.9	5	6	2.1	1.7
1948	9	12	1.3	1.3	5	4	1.6	0.9
1949	11	21	1.1	1.8	5	9	1.4	1.5
1950	16	16	1.7	1.1	7	9	1.6	1.2
1951	16	18	1.5	1.0	8	9	1.5	1.0
1952	23	34	1.8	1.6	12	6	2.0	0.6
1953	21	23	1.4	1.0	7	6	1.0	0.5
1954	19	48	1.0	1.7	8	23	1.1	1.8
1955	26	37	1.3	1.2	9	9	1.3	0.9
1946-50	55	78	1.6	1.6	24	34	1.6	1.4
1951-55	105	160	1.4	1.3	44	53	1.4	1.0
1946-55	160	238	1.4	1.4	68	87	1.4	1.1

DM has been revealed in connection with the patient's seeking medical advice for other diseases (intercurrent disease)

Adding over all ages we find a total mortality ratio of  $160/112.2 = 1.43$  for males and  $238/170.6 = 1.39$  for females. When considering these figures one should bear in mind that the comparison with the population mortality is made for each sex separately. Thus the total relative increase in mortality is almost identical for the two sexes.

## Mortality in separate years

The development of the treatment of diabetes during the last decades gives particular interest to the question whether there exists a trend in the mortality ratio during the period studied. In order to throw light on this matter the total material has been divided simultaneously into calendar years 1946-55 and into 5 year duration periods. For most com-

binations the expected number of deaths is too small to allow a statistical judgment and therefore the figures are given only for the combined durations and for the initial duration period 0-4 years (Table 16).

For the combined durations the mortality ratios oscillate around the total values with a decreasing tendency. This supports the assumption that the mortality decrease among diabetics is parallel to the development in the general population. Our material is too small however to permit a comparison of the rates of decrease.

## Mortality and duration

In view of the weak trend with regard to time we could study the influence of duration from the marginal figures of the above mentioned simultaneous table. These data are shown in Table 17.

There exists a tendency of a slight

**Table 17** *Mortality of DM patients by sex and duration 1946-55*

Duration	Number of deaths		Mortality ratio	
	M	F	M	F
0-4	68	87	1.4	1.1
5-9	36	57	1.2	1.2
10-14	23	37	1.4	1.4
15-19	19	38	2.0	3.0
20-24	10	9	2.4	2.9
25-	4	10	1.1	5.6
Total	160	238	1.4	1.4

increase for males and a clear increase for females. This result might be interpreted as supporting the pessimistic opinion that although modern treatment has succeeded in eliminating the initial risks combined with diabetes it has not been able to neutralize the effect of late complications especially those of renal type, which still seem to be a frequent consequence of diabetes. However it is well known that diabetes varies much in severity and this makes it necessary to separate so far as possible classes of different severity. In addition it should be remembered that in our series the great majority of cases with late onset belong to the shortest duration groups.

## Mortality and age at onset

If we look at the general mortality (Table 15) there is an obvious tendency for the mortality ratio to decrease with age. Comparing, for instance, ages below 60 and ages 60 and over we find that the mortality ratio decreases from 1.9 to 1.3 for males and from 2.4 to 1.3 for females. This could be the effect of different mortality ratios according to different ages of onset, which would agree with the general experience that cases of diabetes appearing early, especially before puberty, often have a bad prognosis whereas on the other hand a large number of old people show definite symptoms of diabetes without signs of complications and in many instances do not even have to use insulin. For this reason we have studied our material according to age at onset. Since in the mortality study the exact age of onset was not included we have used approximate classes constructed from 5 year intervals of attained age  $x$  to  $x+4$ , and 5 year intervals of duration  $d$  to  $d+4$  which make up an interval for age at onset from  $x-d-4$  to  $x-d+4$ . Within this

**Table 18** *Mortality of DM patients by sex and age at onset 1946-55*

Age at onset	Duration	Number of deaths		Mortality ratio		
		M	F	M	F	M+F
0-19	All	7	14	3.2	11.7	6.2
15-44	All	11	20	1.1	3.1	1.9
40-	0-4	66	85	1.4	1.1	1.2
	5-9	36	57	1.3	1.2	1.2
	10-14	18	28	1.3	1.1	1.2
	15-	22	34	1.8	2.5	2.2
	All	142	204	1.4	1.3	1.3
Total		160	238	1.4	1.4	1.4

interval we get a triangular distribution with the mean  $x-d$  the consecutive intervals overlap. The results are shown in Table 18.

Although the expected number of deaths for the juvenile and early adult types of diabetes is small the clear picture emerges that juvenile diabetes shows an impressively high mortality ratio, whereas late diabetes containing cases with onset at age 40 or over shows a mortality ratio of about 1.3. For this latter type a division is made according to duration, too. As can be seen from the table the mortality ratio is around 1.2 for durations below 15 years but higher or on average 2.2, for durations 15 years or over. It may be noted that the high mortality ratio of the juvenile diabetics only slightly affects general mortality, because of the comparatively low prevalence of the disease and the low general mortality in the actual ages. In other words the high mortality ratio at younger ages does not imply a high absolute mortality.

### **Inferences from the mortality study of DM patients**

Compared with the population mortality the diabetics in our hospital series show a mortality ratio of about 1.4 (all ages taken together). For juvenile diabetics the mortality ratio is considerably higher (order of magnitude 6.0) and for diabetics with age at onset 40 or over it

is about 1.3. For late diabetes the mortality ratios are about 1.2 for durations below 15 years and about 2.2 for durations 15 years or over.

It should be remembered, however that selective factors, in particular the detection of DM in connection with other diseases may influence the results of statistics on mortality of DM patients who have been admitted to hospital. On the other hand it should be taken into account that there may occur a certain selection of another kind, inasmuch as severely disabled persons may be under-represented in a general hospital series. Nevertheless, the results indicate that the excess mortality of diabetics in general is less than is usually considered to be the case. These problems will be further discussed in Chapters IV and VIII.

There are a great many investigations concerning the mortality of DM patients based mostly on hospital series and insurance material. On the whole, they show a higher mortality, and even a higher excess mortality in comparison with the general population than has been found in the present series. On the other hand the sex and age pattern of the excess mortality in our series seems to agree fairly well with other statistics. It would fall outside the scope of the present study to discuss these statistics and here we will only make a reference to a recent study from Birmingham by Hayward and Lucena (1965) and the very interesting discussion of their paper



# Mortality and morbidity risks for DM and its prevalence in Sweden

## General aspects

In view of the varying conditions obtaining in the registration of new cases of DM it is very difficult to arrive at a definite assessment of the morbidity risks for DM at different ages—even if these risks do not change with time. As is well known from screening procedures and other inventories, and as will be shown in greater detail in a later section, at a given point of time there will generally be at least as many instances of manifest DM that are undiagnosed as there are instances of 'diagnosed' DM. Here the term 'diagnosed' is taken to mean persons who have been told by a physician that they have diabetes and the term undiagnosed to mean persons who have manifest diabetes but do not know it (cf. Fisher & Vavra 1964).

Of course, circumstances are by no means the same all over the world, and even within one country they may vary considerably between different areas; there are a great many factors of importance with regard to the dividing line between diagnosed and undiagnosed instances of DM, and it is not to be expected that this boundary will not change with time. So far as Sweden is

concerned, some of these factors are as follows (in several respects the situation is fairly similar in most other developed countries)

- 1 Both absolutely and relatively the number of doctors and the number of beds in hospitals have steadily increased

- 2 Laboratory tests of urine and blood have become routine procedures

- 3 Because of rising standards and improved communications, visits to doctors and at hospitals have become more frequent

- 4 In the compulsory health insurance scheme introduced in 1955, a doctor's certificate is required when claims are made in respect of a period of illness exceeding seven days

- 5 The prevalence of DM, and hence the general knowledge of the disease has gradually increased, owing partly to progress in therapy (directly, through insulin and better dietetic treatment indirectly through new methods for preventing and curing other diseases by means of sulpha preparations antibiotics antihypertensive drugs etc.), and partly to the general decline in mortality and the altered age composition of the population

6 In several districts systematic detection campaigns have been performed (on a more or less general basis) routine controls are made in connection with the preventive maternity welfare activities, and regular health control is becoming more frequent (in particular for employees over say, 40 years of age)

This list could easily be greatly extended but the examples given will probably be sufficient to show that a registered increase with time of the prevalence or incidence of diagnosed DM (in a certain group by sex and age) can not—at least without thorough analysis—be taken as evidence of an increasing prevalence or incidence of DM in the population (in this group by sex and age) Naturally, the *overall* prevalence of DM will increase as a consequence of the displacement upwards of the age composition of the population this effect will be accentuated if the relative excess mortality of diabetics is becoming weaker In the same way it is obvious that the *overall* incidence of DM will increase, since the morbidity risk for DM increases markedly with age

Nevertheless whatever the situation in regard to diagnosed and undiagnosed instances of DM may be at a given point of time, many of the undiagnosed cases then existing will be diagnosed later on either because the disease itself causes the afflicted person to go to a hospital or to consult a doctor outside the hospitals or because the person in question becomes afflicted with other diseases and on seeking medical aid is found to have DM This latter situation will be more common

(a) when it becomes more frequent that diseased persons seek medical aid,

(b) when it becomes more frequent that tests of urine and blood are analysed

(c) where doctors have sufficient time to investigate the patient's symptoms etc ,

(d) where doctors have contacts with the family members of DM patients and inquire into their state of health and if it is called for, test them with regard to the possible presence of DM

As a rule, the knowledge concerning the existence of chronic diseases is greatest at the latest possible point in the person's medical history i.e. immediately before or immediately after his death (before, since the doctor can then have the patient's own description of symptoms and can perform clinical examinations laboratory tests etc , after, since there may be an autopsy)

The recording of deaths is always more complete than is the recording of various forms of disease As a rule the available statistical data on mortality are considerably more accurate than are the available statistical data on morbidity Generally speaking both the knowledge of a disease and the registration of a disease become more complete and accurate as the individual grows older At any rate this must be true as regards chronic diseases and very malignant diseases In both these cases a careful scrutiny of mortality statistics may prove to be the most efficient method for arriving at conclusive results concerning the morbidity

For quite different reasons *diabetes mellitus* and *cerebrovascular disease* seem

to be especially promising topics, where the study of *mortality* is intended to throw light on *morbidity* (Larsson 1967)

*Diabetes mellitus* may be regarded as a permanent disease recovery is very rare (if it occurs at all). On the other hand, apart from instances of very early onset, DM *per se* can hardly be regarded as an ultimate cause of death, although it is often registered as the primary (underlying) cause. Where the existence of DM is known to the certifying doctor, the conditions in Sweden (and the traditions and training of Swedish doctors) will guarantee that the presence of DM will be stated in the death certificate (as the primary cause or more often, as a contributory cause) <sup>1</sup>

*Cerebrovascular disease* (stroke apoplectic insult) is as a rule easily recognizable even by laymen. The morbidity risks for cerebral haemorrhage as well as for cerebral embolism and thrombosis are very low at younger ages. In the age group 50-54 the death rate for cerebrovascular disease (primary cause contributory cause or complication) is about 0.5 per thousand. The morbidity risk increases heavily with age. The outcome is often fatal and if the patient recovers (fully or partly) there may in many cases occur one or more further insults. Even where such a recurrence does not take place it may be assumed that the previous attack will as a rule be reported in the death certificate as a contributory cause thus in this respect the occurrence of an apoplectic insult may be regarded as establishing a permanent situation.

Hence in the main, it can be assumed that the Swedish statistical data on causes of death are much more complete and reliable in respect of both clinically diagnosed diabetes mellitus and cerebrovascular disease than in respect of most other diseases, *provided that not*

*only the primary cause but also contributory causes and complications are included in the statistics.* The character of these diseases will make it possible—in different ways—to perform an assessment of the morbidity risks by sex and age on the basis of mortality statistics. Especially for the older age groups, such indirect determination seems to be considerably more reliable than direct determination on the basis of morbidity statistics of different kinds (hospital and health insurance data, cross section inventories, screening procedures, questioning of physicians, statistics on insulin consumption).

The main object of the present chapter is to investigate the homogeneity and general characteristics of the recording of deaths from DM, and to perform an assessment of the morbidity risks for DM by sex and age <sup>2</sup>. In Chapter IX, some comments will be made on the conclusions that can be drawn with regard to the importance of genetic factors for the aetiology of DM <sup>3</sup>.

<sup>1</sup> Where the certifying doctor and his colleagues did not interview the deceased person and do not have any contacts with the family members there may of course be a gap in the registration of diagnosed DM even if an autopsy is performed. As will be seen in what follows this situation will occur mainly in the largest cities and in respect of sudden death (accidents acute illness suicide) especially for persons dying outside their district of domicile.

<sup>2</sup> For convenience the expression *death from DM* is used to cover all cases where DM is stated as the primary cause of death or as a contributory cause.

<sup>3</sup> A parallel study has been made in respect of cerebrovascular disease. Tage Larsson *Mortality from cerebrovascular disease in Stroke Thule International Symposia* Nordiska Bokhandeln Forlag Stockholm 1967 pp 15-40. For comparison some data from this study will be included in the tables.

## The material

Since 1951 the statistics on causes of death in Sweden have been presented in accordance with the WHO scheme *Manual of the international statistical classification of diseases, injuries and causes of death* (Geneva 1948 and 1949). Certain amendments have been adopted, in particular from 1960 with regard to the delimitation between accidents and disease when stating the primary (underlying) cause of death (cf Larsson 1965, p. 69). As a rule the data given in the present chapter refer to the Intermediate List (the A list).

There are three categories of forms used for reports on causes of death viz certificate (*dödsbevis*), notification (*dödsorsaksavi*) and report from abroad (*dödsorsaksuppgift*).

The certificate signed by a physician, is compulsory for deaths occurring in urban areas, for deaths in rural districts a certificate is issued if a doctor has attended the deceased during his last illness or has examined the body after death.

Up to 1960 the statistics dealt solely with primary (underlying) cause. Since 1961 however, the Central Bureau of Statistics has made a registration of complications and contributory causes of death in addition to the primary cause. The tape records include a maximum of 3 complications and a maximum of 4 contributory causes (stated according to the detailed WHO list). Further, there are registered date of birth, sex, marital status, domicile, date of death, character of report (certificate etc.) and whether an autopsy was performed or not.

For the present study of mortality from diabetes mellitus (and the parallel study of mortality from cerebrovascular disease) a special processing of these tape records for the years 1961–63 was performed.<sup>1</sup> The scope of this material is shown in Table 19. It covers 10 597 deaths from DM (primary or contributory cause, 4 379 males and 6 238 females) or 4.7 per cent of the total number of deaths in 1961–63 (males 3.6 per cent, females 5.9 per cent). Otherwise all data given in the following sections are based on published official statistics.

During the period 1961–63 there occurred in Sweden 226 806 deaths (120 462 males, 106 344 females). The statistics on causes of death are based on certificates for 97.64 per cent of these deaths (notifications 2.04 per cent, reports from abroad 0.32 per cent). In 35.4 per cent of all deaths an autopsy was performed.

The available information on causes of death has steadily become more complete. Thus for the period 1961–63 the group 'symptoms, senility and ill-defined conditions' (XVI) contains no more than 1.31 per cent of all deaths.

As will be seen from Table 19, during the period 1961–63 there were registered 3 324 deaths with DM as the primary cause and no fewer than 7 273 deaths with DM as a contributory cause. In view of the nature of DM it is evident from these figures alone that statistics

<sup>1</sup> For reasons of economy in this processing the age at death was calculated as the difference between the calendar year of death and the calendar year of birth. Where the exact age is rounded off downwards the expression *attained age* is used.

Table 19 Deaths from DM in Sweden 1961-63

Cause of death		Primary cause		Contributory cause		Total		
		M	F	M	F	M	F	M+F
Number of deaths		120 462	106 344			120 462	106 344	226 806
Cause unknown	XVI	1 277	1 704			1 277	1 704	2 981
Diabetes	A63 = 260	1 419	1 905	2 940	4 333	4 359	6 238	10 597
Diabetic coma	260 1	93	129	11	16	104	145	249
Gangrene	260 4	235	296	93	123	328	419	747
Nephropathy without hypertonia	260 5	181	212	36	56	217	268	485
Other specified		114*	134*	37	54	151	188	339
Not specified	260 0	796	1 134	2 763	4 084	3 559	5 218	8 777
* Other specified (primary cause)	Hyperglycaemic coma (260 2) 9 M + 7 F Acidosis (260 3) 6 + 4 Nephropathy with hypertonia (260 6) 60 + 61 Retinopathy (260 7) 20 + 37 Cataract (260 8) 0 + 1 Other complications (260 9) 19 + 24							

which are based exclusively on primary causes of death must be treated with the utmost caution

Where DM is stated as the primary cause complications are specified (i.e. given with codes 260 1-260 9) for 42 per cent of the deaths where DM is stated as a contributory cause, complications are specified for only 7 per cent of the deaths. Taking primary and contributory causes together we find that complications are specified for no more than 17 per cent of the deaths. Hence, it can be concluded that on the whole the information in the death certificates concerning complications must be very incomplete.<sup>1</sup>

<sup>1</sup> It should be noticed, however, that the actual situation is far better than is indicated by the adduced percentages. Where unspecified DM (260 0) is given as the primary cause of death there are often statements about one or more contributory causes where unspecified DM is given as a contributory cause there is always information on the primary cause and to a not inconsiderable extent about other contributory causes.

Interest should be focused on the total (DM as the primary or a contributory cause) and not on the subgroups

## Statistics on mortality from DM

Certain statistical data on mortality from DM in Sweden will be presented in the following tables (Tables 21-31). To a great extent these tables speak for themselves, and therefore the comments given here can be kept very brief (for general comments, cf. Larsson 1965).

### Total mortality

As a background Table 20 shows the general death rates by sex and age for 5 year periods 1946-65 for the 3 year period 1961-63, and for the separate years 1956-65. Seen against the trend, mortality was comparatively high in 1962 and comparatively low in 1961 and

Table 20 General death rates by sex and age 1946-65

Sex and year	Death rate per 10 000 of the average population on age group (inter. ed. age)																																	
	0	1	2	3	4	5	9	10-14	15	18	0	24	25	29	30	34	35	39	40-44	45	49	54	55	59	60-64	65	69	70	74	75	79	80		
<b>Males</b>																																		
1946-50	270	19	12	19	13	13	13	12	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
1951-55	218	15	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	
1956-60	190	13	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	
1961-65	172	10	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	
1961-63	176	11	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	
1956	190	14	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	
1957	199	14	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	
1958	181	12	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	
1959	192	12	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	
1960	189	11	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	
1961	177	11	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
1962	176	11	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	
1963	174	10	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	
1964	159	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
1965	149	9	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	
<b>Females</b>																																		
1946-50	208	15	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	
1951-55	167	13	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	
1956-60	145	10	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	
1961-65	132	7	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	
1961-63	133	7	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	
1956	155	11	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	
1957	155	9	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	
1958	136	10	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	
1959	138	10	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	
1960	142	10	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	
1961	137	7	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	
1962	131	8	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	
1963	132	7	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	
1964	124	7	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	
1965	121	7	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	

Deaths under 1 year of age per 10 000 live births

\* Deaths under 1 year of age per 10 000 live births

1963, together, the three years 1961-63 may be said to represent a 'normal' level for mortality

### *Mortality from DM in the whole country 1961-63*

Table 21 gives—by sex and 5 year age groups—the average population 1961-63, the total number of deaths and the numbers of deaths from unknown cause and from the primary cause DM (260-A63-Dp, with separate data on the subgroup 'not specified', 260-0), further, the shares of deaths from unknown cause and from DM (primary cause) are stated. At the bottom of the table and in Fig 6 the shares of deaths from DM—primary cause as well as total—are shown.<sup>1</sup> The absolute numbers of deaths from DM by sex and age are given in Table 23.

Both for males and for females, the share of deaths from DM (primary as well as contributory cause Dt/T) at younger ages rises markedly with age to reach a peak of about 5 per cent for males and about 8 per cent for females in the age groups 30-34 and 25-29 respectively then there is a marked decrease to a minimum of about 2 per cent in the age group 45-49 and after that a fairly even rise to a new maximum of nearly 6 per cent for males and nearly 9 per cent for females in the age groups 75-79 and 70-74. In the most advanced ages there is again a fairly even decrease, to a share below 2 per cent in the age group 90 and over. The variation of the death shares gives an impression that there exists a certain gap in the registration of DM among deaths in the most

advanced age groups (an *age gap*), the high shares at younger ages reflect an existing excess mortality among persons afflicted with DM (cf p 62).

In Table 22 death rates by sex and age 1961-63 for different groups of causes are calculated. At the bottom of the table the death rates for DM—primary cause as well as total—are shown.<sup>2</sup>

The death rates for DM (Dt/P) by sex and age are illustrated in Fig 7, in addition there are shown the total death rates (irrespective of cause, T/P) in the younger age groups and, for comparison the death rates for violence (accidents and suicide).<sup>3</sup> Up to age 60, mortality from DM is higher for males than for females, in the age interval 60-90 it is lower for males than for females. Up to age 65 for the males, and up to age 55 for the females, mortality from DM is far below mortality from violence. At age 70, mortality from DM is of the same order of magnitude as the total mortality at ages about 35 for males and about 45 for females. Before 60, mor-

<sup>1</sup> Account has been taken of the gaps arising from the registration of deaths as due to unknown cause (XVI). It should be noticed that the data are grouped by age (not by attained age) and are given per 10 000 deaths (not per 1 000 deaths).

<sup>2</sup> Account has been taken of the gaps due to deaths from unknown cause (XVI) but otherwise the figures are wholly based on *uncorrected* data for the whole country: the implications of geographical differences in respect of recording (and, possibly morbidity from DM) will be discussed in a later section. The data refer to attained age and are given per 1 000 000 of the average population in the group (exaggerated exactitude).

<sup>3</sup> The figures concerning violent deaths refer to primary cause alone but according to the rules adopted in 1960 violence will generally be recorded as the primary cause of death and not as a contributory cause (cf Table 31A p 103).

Table 21 Population total deaths, deaths from DM and death shares by sex and age 1961-63

Average population Cause of death		0.003 x average population number of deaths and share of deaths in age group (attained age)																
		All ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79
3 x average population	P	11 318	800	819	894	963	754	668	694	769	828	794	794	696	591	471	351	241
thousands	F	11 368	757	773	830	921	730	649	686	758	814	783	788	721	636	534	422	295
Number of deaths primary cause																		
All causes	T	120 462	3 476	415	340	866	833	738	894	1 316	1 968	3 083	5 084	7 451	10 974	14 065	17 213	19 619
	F	106 344	2 487	272	239	366	318	391	508	797	1 353	2 204	3 370	4 799	6 928	10 476	15 194	19 440
Unknown cause	M	1 277	6	-	1	4	7	2	9	8	11	16	17	17	33	43	64	136
XVI	F	1 704	5	1	1	2	3	1	2	2	6	7	9	7	16	27	73	144
DM	M	1 419	-	-	3	4	11	35	38	38	48	32	73	97	132	169	214	247
260=A63=Dp	F	1 905	-	2	1	4	9	28	30	19	26	19	45	70	162	283	389	418
DM not specified	M	796	-	-	1	2	2	14	10	11	11	11	34	51	78	108	129	157
260 0	F	1 134	-	2	-	1	1	5	4	6	13	9	17	31	83	172	254	268
Percentage of 260 = Dp																		
DM not specified	M	56	-	-	33	50	18	40	26	29	23	34	47	53	59	64	60	64
260 0	F	100	-	100	0	25	11	18	13	32	50	37	38	44	51	61	65	64
Per 1 000 deaths																		
Unknown cause	M	11	2	-	3	5	8	3	10	6	6	5	3	2	3	3	4	7
XVI	F	16	2	4	4	5	9	3	4	4	4	4	3	1	2	3	5	7
DM	M	12	-	-	9	5	13	47	43	29	24	10	14	13	12	12	12	13
260=A63=Dp	F	18	-	7	4	11	18	72	59	24	19	9	13	15	23	27	26	22
DM per 10 000 deaths (known causes) groups by age*																		
Primary cause	M	119	-	-	93	49	104	420	480	317	236	113	136	134	121	123	126	127
Dp	F	182	-	36	85	114	253	695	628	250	201	111	140	133	221	278	259	226
Primary or contributory cause	M	166	-	-	93	62	116	490	515	381	376	206	273	310	345	408	446	478
Dt	F	596	-	108	85	142	253	802	688	329	219	171	256	368	612	790	886	794

\* Deaths from unknown cause (XVI) have been proportionately distributed over known causes within their group by sex and age






Fig 6 Shares of deaths from DM by sex and age 1961-63

tality from DM is below 0.4 per thousand and before 50 it is below 0.1 per thousand. At younger ages, the death shares from DM, as shown in Fig 6, are large not because mortality from DM is high but because total mortality is low.

In particular for deaths occurring at advanced ages the certifying doctor has a certain choice when stating the causes of death. Very often the deceased person may have been afflicted with two

or more different diseases and opinions concerning the importance of the patient's disease history may vary. In addition the doctor's knowledge of this disease history may be more or less complete (for instance depending on whether he has been the patient's family doctor, whether he has examined the patient, whether he has interviewed family members, etc). Also, the post mortem examination may be more or less penetrating (inspection only,

**Table 2.2** Death rates for different causes by sex and age 1961-63

Deaths per 100,000 of average population (a not year)																						
Cause of death	Sex	Ages	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89	90	
All causes	M	1064	435	51	38	90	110	129	171	238	388	640	1084	1858	2984	4908	8154	13440	21161	34434		
	F	935	329	35	28	40	44	60	74	105	166	281	427	666	1089	1958	3603	6582	11670	18841	30712	
Primary cause	I	M	12	5	1	1	2	2	1	4	5	7	9	14	18	28	35	50	65	110	147	
Infect	F	7	5	1	1	1	2	2	2	3	4	5	6	9	11	17	27	40	52	82		
Neopl.	II	M	206	13	7	7	10	11	15	22	28	51	83	152	274	472	759	1088	1531	2164	2405	
	F	190	9	8	7	7	8	14	22	43	76	136	195	281	386	549	750	1025	1408	1693	1792	
D ab	M	13	0	0	0	1	3	6	5	5	5	4	8	14	22	36	61	103	143	166	138	
260-A63=Dp	F	17	0	0	0	1	4	5	3	3	2	6	10	25	34	54	92	143	160	193	124	
Nerv	VI	M	132	10	2	2	3	2	4	7	12	16	27	53	94	171	341	681	1281	2203	3356	4902
	F	153	8	2	2	3	4	7	8	14	28	52	80	145	317	660	1265	2240	3297	4795		
Circ	VII	M	433	1	1	1	3	5	9	24	45	105	217	427	802	1300	2174	3708	6256	10551	18599	
	F	371	1	1	2	2	6	6	9	19	43	73	159	338	698	1486	2976	5617	9912	17366		
Resp	VIII	M	58	24	3	2	2	2	3	3	6	8	16	29	64	105	244	502	1068	2077	4241	
	F	56	20	3	1	3	1	2	3	3	4	5	9	16	30	77	179	440	945	1694	3309	
D gest	IX	F	44	16	1	0	2	2	2	6	9	13	22	31	55	86	130	213	316	497	672	1010
G en u r n	X	M	36	1	1	1	2	3	5	3	9	8	14	19	28	46	77	168	312	586	938	1570
	F	21	1	1	1	1	2	3	3	7	9	14	19	26	36	53	79	115	192	236	394	
O th d s	M	42	335	5	5	7	3	3	4	4	8	15	23	38	53	67	104	132	274	385		
	F	38	255	6	3	5	6	6	5	5	8	12	16	24	31	48	77	107	168	270	399	
V olence	M	88	30	30	19	59	81	68	65	22	79	99	109	117	129	148	162	232	346	628	1037	
V VII + VIII	F	41	19	12	9	17	17	17	18	19	23	26	31	31	37	55	81	174	387	777	1475	
Diabetes per 100,000 of the average population																						
Primary cause	M	127		3	4	12	45	59	52	55	42	55	42	55	42	55	609	1027	1436	1883	1343	
	F	170		1	2	4	11	40	45	25	32	23	57	85	231	525	897	1461	1610	2073	1382	
Primary or contributory cause	M	389		3	5	13	52	63	61	75	76	165	326	615	1191	2140	3881	5699	6327	6233		
	F	557		4	2	5	11	46	49	33	18	45	106	234	641	1488	3069	5127	7014	8328	5590	

\* Calculated from data by age but not otherwise graduated. Throughout deaths from unknown cause (XVII) have been proportionately distributed over known causes within the group by sex and age.




Fig 7 Death rates for DM (Dt) violence (V) and all causes (T) by sex and age 1961-63

autopsy (macroscopic or microscopic brain examination) even where an autopsy is performed by a trained pathologist there may be a choice in respect of the patho-anatomical diagnosis for instance one connected with the skill and the special interests of the pathologist in question

However provided that the occurrence of DM is mentioned in the certificate this choice does not involve any real obstacles in the present connection. Of course, the opinion of the certifying

doctor may influence the classification of the disease—i.e. whether it is recorded as the primary cause or as a contributory cause—and hence there may arise certain types of bias in the statistics on primary causes of death.<sup>1</sup> In the processing of both primary and contributory causes the only relevant source of error is omission, arising either because the doctor (or other informant) is unaware

<sup>1</sup> It should be mentioned that a thorough scrutiny and revision of the certificates is made by the Central Bureau of Statistics

of the occurrence of DM or because his statements do not contain sufficient information<sup>1</sup> The general characteristics of DM, and the conditions obtaining in Sweden, make it rather unlikely that such omission will occur to any considerable extent<sup>2</sup>

Lombard and Joslin (1958) investigated the death certificates for 1 000 DM patients, diagnosed at the Joslin Clinic who died in 1950-57 For 33 per cent DM was recorded as the underlying cause of death for 44 per cent DM was otherwise registered and for 23 per cent it was not mentioned at all The authors make the following general statements which are of great interest in the present connection

Studies of long term trends of death rates were made more difficult by the adoption in 1948 of the sixth revision of the *Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death* The earlier edition of the *Manual* gave priority to certain causes of death if they appeared on the death certificate The sixth revision takes as the cause to be coded the underlying cause of death as stated by the certifying physician irrespective of the causes that previously had priority

Formerly if a certificate mentioned both diabetes and coronary artery disease the cause of death was always tabulated as a death from diabetes whereas a certificate that mentioned cancer and diabetes was always called a cancer death Since the adoption of the sixth revision the position of the diseases on the death certificate determines which one will be called the underlying cause of death As a result of this new classification the number of registered deaths from diabetes decreased appreciably

It is probable that the sixth classification is far superior to the earlier one for indicating the underlying causes of death but unless tables are published showing secondary causes of death also a study of diabetes from the death records can be misleading

The authors conclude

The reported number of deaths from diabetes represents approximately a third of the number of persons dying with the disease Nearly a quarter of those dying with the disease do not have the word diabetes on their death certificates either as an underlying cause of death or as an other significant condition<sup>3</sup>

It is evident that diabetes morbidity cannot be well estimated from the death records that long term trends can be misleading and that a part of the increase in the number of deaths from coronary artery disease is apparent rather than real

The students of the disease would be benefited greatly if physicians would include diabetes as one of the conditions present at the time of death and if the compilers of statistics from death records would make it a routine matter to publish combined causes of death

### *Possible gaps in the registration of DM*

The problems may be formulated as follows Let us denote (in groups by sex, age, domicile, etc.)

<sup>1</sup> The third possibility viz. that the occurrence is entered in the certificate but is not included among the data in the tape records is not applicable in respect of DM

<sup>2</sup> According to estimates made by Joslin (Joslin *et al* 1959) for 28 per cent of all his diabetic patients in the U.S.A. diabetes was not mentioned anywhere in the death certificates Lancaster and Maddox (cf. statement by J. Mallins *J. Inst. Actuaries* 91:3 1965 p. 327) discussion of the paper by Hayward & Lucena) reckoned with regard to their diabetic patients in Australia that for 33 per cent of the males and 50 per cent of the females diabetes was not mentioned at all in the death certificates However as already mentioned the tradition and training of Swedish doctors will guarantee that the omissions are at a lower level in Sweden — Certain data from Oslo recently given by Westlund (1966) will be discussed in a later connection (p. 96)

Dp = deaths with DM registered as the *primary* cause

Dc = deaths with DM registered as a *contributory* cause

Dt = Dp + Dc = *total registered* deaths with DM registered as a cause of death

Dn = deaths where the deceased person was afflicted with DM but the disease was *not registered* as a cause of death

Dm = Dt + Dn = *all* deaths with DM

In part, the *completeness* of the data can be elucidated by means of a study of the connections between certain series by sex and age, viz the frequency to which registered DM is recorded as the primary cause of death (the quotients Dp/Dt) the frequency of autopsies (the quotients Da/D) the geographical differences (the quotients O/E where O is the observed number and E is the expected number calculated on the hypothesis of geographical homogeneity of the figures by sex and age) and the frequency to which DM is registered as a contributory cause for different primary causes of death

Is it possible by scrutinizing the variations of the data mentioned above for the known series Dp Dc and Dt, to arrive at conclusions concerning the magnitude of Dn and Dm?

In so far as current views concerning the prevalence of DM are based on mortality statistics they have been based solely (or at least mainly) on those concerning Dp. However we know that among deaths in 1961-63 the overall quotient Dp/Dt is no more than 0.314 and, further that this quotient varies markedly by sex age domicile, etc

Therefore it is obvious, as already stressed, that conclusions based on data concerning Dp must be made with great caution, in fact, it is only where surprisingly high figures (for absolute numbers death shares or death rates) are found that sure conclusions can be drawn

Can the possible "skewness" (the variability by sex, age domicile, etc) of the quotients Dt/Dm be evaluated when the skewness of the quotients Dp/Dt is known?

Can the probable gaps in the registration be evaluated, for instance in the form Dm/Dt, hence the factor by which the observed figures are to be multiplied, or in the form Dm - Dt, hence the additions to be made to the observed numbers? Can there be stated minimum or maximum limits (or both) for these factors or additions?

The gaps may vary with sex age, domicile cause of death etc. In the following analysis the evaluations will be made separately for each sex. For convenience, the possible gaps may be systematized in five categories, viz

(a) *age gaps*, connected with variations of the completeness of the registration by age,

(b) *cause gaps*, connected with incomplete registration of DM as a contributory cause for certain types of primary cause of death

(c) *domicile gaps* connected with geographical variations (by county between rural and urban areas, etc) in the completeness of the registration,

(d) *time gaps*, connected with a possible underregistration during the period 1961-63 and

Table 23 Number of deaths from diabetes and cerebrovascular disease, percentage primary diagnosis, and percentage autopsies by sex and age 1961-63

Sex	All ages	Number of deaths percentage primary diagnosis and percentage autopsies in age group (per)																			
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89	90-94	
Number of deaths																					
Dp	M	1419	-	-	3	4	9	30	41	40	45	33	65	98	127	169	213	247	185	94	16
	F	1905	-	1	2	4	8	26	31	19	26	18	46	61	147	280	379	431	264	136	26
Dc	M	2940	-	-	1	1	5	3	8	17	27	66	129	236	392	538	686	551	222	58	
	F	4333	-	2	-	1	-	4	3	6	5	17	38	108	261	515	916	1084	883	411	79
Dt	M	4349	-	-	3	5	10	35	44	48	62	60	131	227	363	561	751	933	736	316	74
	F	6238	-	3	2	5	8	30	34	25	31	35	84	169	408	795	1295	1515	1147	547	105
Ct	M	19183	16	4	7	21	16	22	33	70	123	200	412	738	1178	1989	2985	4117	3944	2456	862
	F	22544	4	3	9	13	15	19	44	50	101	209	432	623	1081	2071	3519	4974	4960	3132	1284
Primary diagnosis as percentage of total																					
Dp/Dt	M	32.6	100	80	90	86	93	83	73	55	50	43	50	43	35	30	28	26	25	10	22
	F	30.5	33	100	80	87	91	76	84	51	55	36	37	35	29	28	23	25	25	25	25
Cp/Ct	M	70.7	50	75	43	52	38	59	67	77	76	73	75	71	72	69	70	71	70	70	72
	F	71.1	25	33	56	54	40	68	73	76	75	77	76	74	72	71	71	71	71	70	74
Autopsies per cent																					
Dpa/Dp	M	35.7	100	100	50	78	53	51	58	44	45	46	50	39	41	37	28	22	15	0	0
	F	32.7	100	100	75	50	69	61	37	62	39	54	48	42	40	30	28	21	15	12	12
Dca/Dc	M	30.3	100	100	100	100	100	0	50	53	52	55	50	41	36	35	27	22	11	3	3
	F	27.8	100	100	100	75	67	67	60	59	42	41	34	36	32	27	20	18	11	11	11
Dta/Dt	M	32.1	100	100	100	80	54	48	46	47	48	50	40	36	36	36	27	22	12	3	3
	F	29.3	100	100	80	50	77	62	44	61	49	49	43	37	37	31	27	21	18	11	11
Cta/Ct	M	28.9	94	75	100	90	88	86	76	74	72	63	63	59	46	41	35	25	18	13	9
	F	26.0	100	100	100	77	80	89	77	69	63	61	50	43	35	32	24	18	13	9	9
graduated M+F		27.3	68	80	90	80	80	77	74	71	64	62	55	44	38	33	25	18	13	9	9

(c) *general underregistration*, irrespective of age, cause, domicile and time (which of course cannot be analysed on the basis of statistics on mortality and causes of death alone)

### *Registration of DM as the primary cause of death and the frequency of autopsies by sex and age*

In Table 23 there are shown—in addition to the total numbers of deaths from DM by sex and age ( $D_p$ ,  $D_c$   $D_t$ )—the registration of DM as the primary cause of death (the quotients  $D_p/D_t$ ) and the frequency of autopsies (the quotients  $D_{pa}/D_p$ ,  $D_{ca}/D_c$   $D_{ta}/D_t$ ) by sex and age. For comparison certain corresponding data are given for cerebrovascular disease viz the number of deaths ( $C_t$ ) primary diagnosis as a share of the total ( $C_p/C_t$ ) and the frequency of autopsies ( $C_{ta}/C_t$ ). On the last line of the table there are calculated graduated frequencies  $C_{ta}/C_t$  by age (but with both sexes taken together) to be used for certain standard calculations.<sup>1</sup>

By sex and age the frequencies to which DM and cerebrovascular disease are recorded as the primary cause (the quotients  $D_p/D_t$  and  $C_p/C_t$ ) are illustrated in Fig. 8.

The absolute numbers of deaths before age 40 are small and the figures may have been considerably affected by chance fluctuations. After age 40 the frequency figures show a marked decrease for DM but a comparatively slight decrease for cerebrovascular disease; there are no apparent differences between males and females. A consequence of these trends by age is that for DM a study of

primary causes of death will give a very "skew picture, with an underestimation of mortality from DM which gradually becomes more serious with increasing age because of this type of 'skewness' it is evident that statistics based on primary causes of death alone may lead to erroneous conclusions in respect of the age variations of the prevalence of DM.<sup>2</sup>

The autopsy frequencies for deaths from DM (total  $D_{ta}/D_t$ ) and for deaths from cerebrovascular disease (total  $C_{ta}/C_t$ ) are shown in Fig. 9. Under age 70, the autopsy frequencies are lower for DM than for cerebrovascular disease; in the higher age groups the frequency figures are fairly similar. There are no apparent differences between males and females. The frequencies show a steady decrease with age.<sup>3</sup>

### *Frequency of autopsies by cause*

Table 24 shows—in the form of age standardized comparisons for the whole

<sup>1</sup> For the lowest age groups the figures are based on official statistics concerning the frequency of autopsies in Groups XIV (A127–A129) and XV (A130–A135).

<sup>2</sup> From Fig. 8 it can be seen that with regard to the relative significance of cerebrovascular disease in different age groups the risks for false conclusions on the basis of the Swedish statistics on primary causes of death are considerable.

<sup>3</sup> Since there are great geographical differences in respect of autopsy frequencies—with particularly high figures in the largest cities and very low figures in certain counties (cf. p. 90)—the variability of these series for the whole country is lower than would have been the case in a homogeneous series. On the other hand it should not be overlooked that the age distribution of the population varies between the counties: the older age groups are over-represented in the rural parts of most counties and under-represented in the large cities.




Fig 8 Frequency of primary diagnosis for DM (Dp/Di) and cerebrovascular disease (Cp/Ct) by sex and age 1961-63

country—the frequency of autopsies for different causes of death (the graduated quotients  $Ct_a/Ct$  by age given in Table 23 being used as standard)

The autopsy frequencies are highest for digestive diseases (69 %) and high also for the group other diseases (55 % about 60 per cent of this group are infant deaths Groups XIV and XV) infective diseases (51 %) genito urinary diseases (47 %) violence (45 %) and neoplasms

(41 %) For DM as primary cause the percentage is 34, for DM as primary or contributory cause it is 30. However as can be seen from the age standardized figures, the high autopsy frequencies for 'other diseases' (violence and neoplasms) are in the main explained by the age composition of these deaths. After age standardization the autopsy figures for digestive diseases stand out as very high (index 189 with total deaths = 100), also






Fig 9 Frequency of autopsies for DM (Dta/Dt) and cerebrovascular disease (Cta/Ct) by sex and age 1961-63

above the average are genito urinary diseases (index 129) infective diseases (109) respiratory diseases (104) and neoplasms (101) For DM as primary or contributory cause the index is 91

### *Mortality from DM by county and in rural and urban areas*

During earlier periods there were great differences in respect of mortality as be-

tween the large cities and the country as a whole Successively, these differences have decreased, and nowadays there are no significant differences to be found for the females During the period 1951-60 the death rates for males above 35 were higher in Stockholm than in all Sweden, the excess mortality was about 20 per cent at ages 35-44 and 30 per cent in the higher age groups

For the 4 year period 1959-62 the

Table 24 Age standardized comparison between observed and expected number of autopsies 1961-63

Cause of death	Number of deaths	Autopsies		Raw index	Observed number of autopsies as percentage of expected number	
		Number	Percentage of deaths		(a)	(b) (c)
<i>Primary cause</i>						
Infect I	2 132	1 081	50.7	143	117	109
Neopl II	44 317	18 077	40.8	115	109	101
Diab D	3 324	1 128	33.9	96	96	90
Nerv VI	31 927	8 165	25.6	72	90	83
Circ VII	90 059	26 894	29.9	84	106	99
Resp VIII	12,832	3 792	29.6	84	112	104
Digest IX	9 450	6 527	69.1	195	203	189
Gen urin X	6 393	3 000	46.9	132	139	129
Other dis	8 989	4 957	55.1	156	103	95
Unknown XVI	2 981	136	4.6	13	25	23
Violence XVII + XVIII	14 402	6 547	45.5	129	111	83
Total	226 806	80 304	35.4	100	108	100
<i>Diabetes</i>						
Dp	3 324	1 128	33.9	96	96	90
Dc	7 273	2,095	28.8	81	100	93
Dt	10 597	3,223	30.4	86	111	91
<i>Cerebrovascular disease</i>						
Cp	29 600	7 440	25.1	71	112	85
Cc	12,127	3 964	32.7	92	120	111
Ct	41 727	11 404	27.3	77	100	93
Raw index	(a) = Percentages adjusted to give 100 for total deaths					
Expected	(b) = Calculated with graduated quotients $C_a/C_t$ by age (for the whole country)					
	(c) = Adjusted to give 100 for total deaths					

Central Bureau of Statistics has published special data on mortality by counties giving age standardized mortality ratios by sex and primary cause of death an extract from these statistics is given in Table 25, covering all deaths and deaths from diabetes A63, cerebrovascular disease A70, and arteriosclerotic and degenerative heart diseases A81.<sup>1</sup>

The geographical variations in respect of deaths from DM (*primary cause*) are illustrated in Fig 10 in the form of a profile diagram. In view of the results with regard to DM (primary and contrib-

utory cause) during the period 1961-63, the "official" order of the counties has been modified (G has been moved after K, and Y and Z have been interchanged). The diagram shows the age-standardized mortality ratios for DM, and the quotients between the DM ratios and the corresponding ratios for all causes of death.

<sup>1</sup> It should be noticed that 10-year age groups were used; this may result in spurious effects but for the present purpose of elucidating certain geographical differences in mortality (primary cause) the data can be regarded as sufficiently accurate.

**Table 25** *Age standardized mortality ratios by sex and county for all causes of death, and the primary causes diabetes (A63), cerebrovascular disease (A70), and arteriosclerotic and degenerative heart diseases (A81) 1959-62*

County	Standardized mortality ratio 1959-62 (primary cause)							
	All causes		A63		A70		A81	
	M	F	M	F	M	F	M	F
A	120	96	109	75	84	76	121	99
B	99	100	102	115	90	98	98	100
C	92	97	78	104	73	81	93	94
D	100	104	113	139	114	116	99	107
E	101	105	113	128	100	98	105	115
F	99	100	129	134	99	108	93	105
G	85	94	98	66	82	97	83	94
H	92	101	113	122	101	112	94	100
I	103	112	129	106	120	113	86	103
K	91	98	58	92	80	87	94	100
L	88	92	88	67	90	93	84	82
M	97	91	62	60	88	82	93	84
N	89	91	88	82	96	88	97	106
O	101	94	95	90	97	83	106	99
PQ	94	98	120	93	92	96	96	97
R	96	107	120	93	120	122	90	106
S	102	107	112	139	122	125	104	105
T	103	105	105	115	124	120	99	97
U	98	104	130	117	96	95	96	108
W	103	106	123	122	113	116	107	105
X	104	105	111	124	108	109	105	103
Y	106	110	91	94	127	135	103	106
Z	94	102	82	114	100	122	92	93
AC	105	113	96	133	106	127	115	116
BD	106	112	108	133	119	133	106	116
Total	100	100	100	100	100	100	100	100

*Number of deaths*

M	156 306	1 782	18 311	47 468
F	140 022	2 368	21 901	36 525

For each sex the ratios show the observed number of deaths as a percentage of the expected number, calculated on the age distribution in the county and the death rates for the whole country (10-year age groups)

From *Mortality by counties 1959-62* Central Bureau of Statistics Official Statistics of Sweden Population and Vital Statistics Stockholm 1964

As can be seen from Table 25 in Stockholm City (A) the male and female ratios for total deaths are 1.20 and 0.96. However, for DM both ratios are considerably lower viz 1.09 and 0.75. A similar situation with lower ratios for DM than for total deaths applies to Gothenburg and Bohus County (O) and Malmöhus County (M), which include the cities of Gothenburg and Malmö and to Blekinge County (K), Kristianstad County (L), Halland County (N) and Västernorrland County (Y). The opposite relation, with higher ratios for DM than




Fig 10 Age standardized mortality ratios (R) by sex and county for DM (primary cause) and quotients (Q) between these and corresponding ratios for all causes 1959-62

for total deaths, is valid in respect of most counties in the middle of Sweden (D, E F H, S, T U, W, X) <sup>1</sup>

In Table 26 for the period 1961-63 an age standardized comparison between the counties (rural and urban areas separated) is performed in respect of deaths from DM. It should be stressed that this comparison is based on death shares (D/T) and not on death rates (D/P). The table gives the number of deaths (Dp and Dt) by sex and county and further the share of primary cause (Dp/Dt), the quotients of observed and expected number of deaths from DM (O/E for Dp and Dt) and the frequency of autopsies. In Table 27 this type of comparison is made for certain large age groups; this comparison is restricted to show the rural and urban figures for

Sweden and for certain groups of counties, viz Stockholm City (A), Stockholm and Uppsala Counties (B C), the remainder of middle and south-eastern Sweden (a broad belt covering the counties D E F, H I K P Q R, S T, U, W X Z), the south western part (the counties G L, M N, O) and the

<sup>1</sup> According to Marks (1961) in the U.S.A. there exist great regional differences in the certification of causes of death among older persons. For instance the highly urbanized states or those with or close to medical centres have low rates for cerebral vascular disease while the predominantly agricultural or rural states record high rates. There is an inverse correlation between the number of internists per 100 000 population and the level of death rates from degenerative conditions. In New York State the mortality from cerebral vascular disease is relatively, much less in New York City than in the area outside the city. Cf also Lew (1957) and Ustvedt (1959).

Table 26 Age standardized comparison between observed and expected number of

County	Number of deaths				100 Dp/Dt		100 O/E				Autopsies per cent			
	M		F		M	F	M		F		M		F	
	Dp	Dt	Dp	Dt			Dp	Dt	Dp	Dt	Dp	Dt	Dp	Dt
All Sweden	1 419	4,359	1 905	6 238	33	31	100	100	100	100	36	32	33	29
Rural	768	2 339	1 061	3 410	33	31	104	101	110	107	27	22	25	21
Br	47	113	63	151	42	42	109	111	121	91	47	32	32	26
Cx	19	57	22	72	33	31	119	110	103	102	68	46	68	43
Dr	19	67	40	104	28	38	94	103	148	116	38	28	17	16
Er	36	134	61	200	27	31	113	131	139	136	17	22	28	20
Fr	35	127	51	166	28	31	119	137	137	134	14	13	25	19
Gr	31	76	24	81	41	30	118	90	72	71	29	29	33	30
Hr	35	123	68	201	28	34	107	119	155	134	17	13	7	7
Jr	10	36	8	36	28	22	111	128	65	89	10	8	12	19
Kr	16	61	25	89	26	28	94	114	110	116	13	10	12	12
Lr	38	114	45	156	33	29	95	89	85	111	26	21	24	21
Mr	30	104	37	128	29	29	73	79	69	71	37	29	19	21
Nr	17	51	24	89	33	27	87	81	100	110	18	12	8	13
Or	21	84	29	100	25	29	70	87	77	80	38	26	28	23
PQc	67	167	78	212	40	37	150	117	125	101	40	31	35	29
Rr	41	130	45	174	32	26	118	117	93	108	20	25	13	22
Sr	43	130	73	220	33	33	102	98	136	123	5	10	22	24
Tr	38	100	41	111	42	37	142	106	114	94	18	22	24	15
Ur	24	70	35	117	34	30	126	120	136	138	42	34	31	33
Wr	39	133	53	231	29	23	90	97	87	116	28	19	21	17
Xr	45	126	60	217	36	28	115	104	115	127	31	21	25	18
Yr	27	96	60	178	28	34	64	72	112	99	26	20	30	27
Zr	22	77	34	117	29	29	87	98	113	120	18	16	15	17
ACr	31	91	47	127	34	37	85	82	112	94	32	31	40	33
BDr	37	82	38	133	45	29	129	97	108	118	22	13	32	18

northernmost part (the counties Y AC, BD) This grouping is based on the data in Table 26

A general feature to be seen from Table 26 is that the variability of the quotients O/E is considerably reduced when the comparison is based on both primary and contributory cause (Dt) and not on the primary cause (Dp) alone However even with the comparison based on Dt certain counties show quotients O/E that are markedly below the average This

applies in particular to Stockholm City (0 81 for males and 0 67 for females), and to the counties in the south western part of Sweden (G L, M, N, O rural 0 86 and 0 82, urban 0 89 and 0 88) The urban autopsy percentages are high in the counties comprising the three largest cities (A, O, M) and in the counties H C, PQ and AC With the exception of PQ (Älvsborg County) these counties show comparatively low shares for deaths from DM In rural Sweden this share

deaths from DM by sex and domicile (county rural, urban) 1961-63

County	Number of deaths				100 D <sub>r</sub> /D <sub>t</sub>		100 O/E				Autopsies per cent			
	M		F		M	F	M		F		M		F	
	D <sub>p</sub>	D <sub>t</sub>	D <sub>p</sub>	D <sub>t</sub>			D <sub>p</sub>	D <sub>t</sub>	D <sub>p</sub>	D <sub>t</sub>	D <sub>p</sub>	D <sub>t</sub>	D <sub>p</sub>	D <sub>t</sub>
Urban	651	2 020	844	2,828	32	30	95	99	90	93	45	43	42	39
Au	127	372	141	487	34	29	81	81	62	67	66	62	65	60
Bu	39	86	47	112	45	42	130	98	112	83	59	51	30	31
Cu	11	39	24	63	28	38	75	88	107	87	45	56	67	51
Du	26	82	43	149	32	29	106	111	126	135	23	34	16	30
Eu	44	151	85	209	29	30	113	127	118	119	30	32	21	23
Fu	45	115	39	140	39	28	184	154	118	131	18	21	15	19
Gu	-	5	7	21	0	33	0	30	89	84	80	57	62	
Hu	19	54	17	71	35	24	142	134	90	116	26	20	18	18
Iu	5	9	4	17	56	24	200	114	105	133	20	44	0	0
Ku	4	31	13	53	13	25	35	88	81	100	25	26	15	4
Lu	7	27	8	39	26	15	72	90	43	81	22	67	38	
Mu	49	188	65	314	26	21	64	81	62	92	37	48	55	46
Nu	12	35	18	49	34	37	102	98	115	95	33	17	22	20
Ou	76	240	92	295	32	31	92	99	85	84	75	68	64	65
PQu	28	64	43	97	44	44	115	89	126	89	68	42	54	33
Ru	23	72	15	72	32	21	144	145	66	97	35	28	40	26
Su	23	75	38	99	31	38	116	124	150	119	22	21	16	12
Tu	21	86	43	118	24	36	84	115	129	109	33	26	35	25
Uu	24	67	29	94	36	31	113	110	105	105	50	39	32	34
Wu	15	46	22	63	33	35	106	106	113	111	40	39	27	24
Xu	22	70	30	114	31	26	97	102	101	116	32	31	17	28
Yu	13	45	16	62	29	26	81	104	83	99	15	33	30	39
Zu	4	14	6	19	29	32	100	114	100	98	0	29	17	21
ACu	7	22	11	28	32	39	99	107	121	98	14	36	73	81
BDu	7	25	12	43	28	28	63	80	90	104	29	28	17	16

O = Observed number

E = Expected number calculated with the age distribution of all deaths (by sex and domicile) and the observed shares of deaths from D<sub>p</sub> and D<sub>t</sub> respectively by sex and age in the whole country

exceeds the average (the index O/E for D<sub>t</sub> being 1.01 for males and 1.07 for females) whereas it is below the average in urban Sweden (index 0.99 for males and 0.93 for females). However, as can be seen from Tables 26 and 27, this urban deficit is mainly due to the largest cities for the towns in A, O and M the index figures are 0.86 for males and 0.77 for females and for the towns outside A, O and M they are 1.11 and 1.07, respectively, against 1.01 and 1.07 in rural

Sweden—in spite of the fact that the frequency of autopsies is considerably higher in these latter towns than in rural Sweden.

A closer scrutiny of Tables 26 and 27 reveals a number of interesting details. The index figures O/E for D<sub>t</sub> are remarkably low for Stockholm City (A) and comparatively low for Stockholm County (B) and urban Uppsala County (Cu), whereas they are high for Södermanland County (D) Östergötland

**Table 27** Age-standardized comparison between observed and expected number of deaths from DM by sex and domicile (certain areas) in groups by age 1961-63

Domicile		Number of deaths					100 O/E for Dt				Autopsies Dt per cent				
		All ages	Age				All ages	Age			All ages	Age			
			0-49	50-64	65-79	80+		0-64	65-79	80+		0-64	65-79	80+	
Males															
Sweden		4 359	267	721	2 245	1 126	100	100	100	100	32	47	33	18	
Rural		2 339	131	346	1 173	689	101	105	99	99	22	34	24	11	
Urban		2 020	136	375	1 072	437	99	96	101	101	43	59	42	29	
A	u	372	24	79	207	62	81	77	83	76	62	72	62	48	
B C	r	170	12	23	87	48	94	92	93	98	36	74	32	17	
	u	125	15	23	59	28	95	115	86	97	53	76	53	21	
Central belt	r	1 471	85	211	718	457	112	118	108	115	20	28	23	11	
	u	936	65	165	482	224	118	117	116	117	30	48	26	20	
South west	r	429	21	64	219	125	86	97	88	77	24	39	24	14	
	u	495	25	91	271	108	89	81	94	88	55	66	56	39	
Y, AC BD	r	269	13	48	149	59	82	80	87	72	22	28	25	7	
	u	92	7	17	53	15	98	83	108		33	54	26	20	
Females															
Sweden		6 238	173	661	3 605	1 799	100	100	100	100	29	44	32	19	
Rural		3 410	81	349	1 974	1 006	107	110	108	104	21	36	23	12	
Urban		2 828	92	312	1 631	793	93	91	92	95	39	53	40	29	
A	u	487	20	44	259	164	67	58	61	85	60	70	60	57	
B C	r	223	8	18	130	67	94	79	96	97	32	50	37	15	
	u	175	8	23	100	44	85	103	84	76	38	65	42	11	
Central belt	r	2 195	50	235	1 265	645	119	126	118	116	19	32	21	11	
	u	1 315	34	169	756	356	113	122	111	112	24	39	24	13	
South west	r	554	11	48	323	172	82	81	86	75	21	37	24	11	
	u	718	24	61	437	196	88	74	94	83	52	69	55	39	
Y AC BD	r	438	12	48	256	122	103	102	100	109	26	47	27	14	
	u	133	6	15	79	33	101	91	101	106	36	57	37	21	

O = Observed number

E = Expected number calculated with the age distribution of all deaths (by sex and domicile) and the observed shares of deaths from Dp and Dt respectively by sex and age in the whole country

Central belt = D F F H I L, PQ R S T U W X, Z

South west = G L, M N O

County (E) Jonköping County (F) and Västmanland County (U) the same applies to the towns in Örebro County (Tu). In these latter counties there are large towns and well-equipped hospitals (which are not university clinics). Further, most index figures are comparatively low in the south western part of Sweden but

high in Kalmar County (H) which is characterized by a very low frequency of autopsies.

In respect of the northern counties a certain time lag in the general decline of mortality should be taken into account. Further, as the results are chiefly determined by circumstances obtaining at




Fig 11 Frequency of primary diagnosis for DM and cerebrovascular disease by sex and domicile 1961-63

higher ages inequalities in the patterns of migration over a long period may influence the data in various ways (selective out migration a skewness in the age composition which is not sufficiently eliminated when 5 year age groups are used, etc)

The geographical variations are illustrated in Figs 11, 12 and 13

By sex and domicile Fig 11 shows—in the form of a profile diagram—the quotients of primary cause for DM ( $Dp/Dt$ ) and for comparison, the corresponding quotients for cerebrovascular disease ( $Cp/Ct$ ). In the same way Fig 12 gives the quotients between observed and expected numbers of deaths from DM ( $O/E$  for  $Dt$ ) and the frequency of autopsies ( $Dta/Dt$ ). It should be noticed that the

population of Gotland County (I) is small, and that the population of the urban parts of Kronoberg County (Gu) and Jämtland County (Zu) is small too. In the counties A, C, M, O and AC there are universities with faculties of medicine and university clinics. As will appear from Fig 11, the quotients of primary cause for cerebrovascular disease ( $Cp/Ct$ ) are low in Stockholm City (Au) and in the urban parts of Uppsala County (Cu), Gothenburg and Bohus County (Ou) and Malmöhus County (Mu). The quotients of primary cause for DM stand out as particularly low in urban Malmöhus County (Mu), however taking into account the age composition of the population and the variation of the quotients with age (cf Fig 8).






Fig 12 Quotients between observed and expected numbers of deaths from DM, and frequency of autopsies by sex and domicile 1961-63

it is evident that they are low also for Stockholm City (Au) and urban Gothenburg and Bohus County (Ou)

Both for DM and for cerebrovascular disease the variability of the quotients of primary cause appears to be more connected with domicile than with sex and age. Although in respect of age the variations are large they seem in the main to follow the same general pattern all over the country. The variations in respect of domicile may therefore be assumed to be connected with differences in practice for the choice concerning which of two or more causes of death should be stated as the primary cause. For instance it may be observed that in Älvsborg County (PQ) the comparatively high quotients for DM are accompanied by comparatively low quotients for cerebrovascular disease in respect of deceased persons with both these diseases

there may have been a preference for stating DM as the primary cause

In Fig 13 the correlation between the observed and expected absolute numbers is shown for Dt with relative figures the differences in population size between the counties may be overlooked. As will be seen from Fig 13, the 'deficits' are particularly large for females in Stockholm City (Au), but they are large also for males in Stockholm City and for certain other groups (for instance males in Mu and Yr, females in Ou, Mr and Mu). On the evaluation of the diagram the random error of the observed number (of a magnitude approximately equal to the square root of the expected number) should be taken into account. If it is assumed that there is in fact geographical homogeneity in respect of mortality from DM and, further, that the gaps are solely due to 'underregistration' in cer-



tain counties (mainly Stockholm City and the counties in the south western part of Sweden) the expected numbers would increase by about 15 per cent for males and about 20 per cent for females, as is indicated by the thick lines in the diagram. In addition to these *domicile gaps* there may of course be other types of underregistration all over the country, for instance in respect of sudden death and possibly, in respect of the most advanced age groups (cf Figs 6 and 7), these questions will be discussed in a later connection.

Very likely, there is a real gap in the registration of deaths from DM in so far as in the three largest cities interest has been focused on certain other causes of deaths (for instance neoplasms and diseases of the circulatory and digestive systems) the personal contacts between the certifying doctor and the deceased patient and his family may to a greater extent have been comparatively weak (or even absent) and possibly the certificates will sometimes give particular stress to the patho-anatomical findings. The alternative explanation that mortality from DM really is lower in the three largest cities than in most other towns in Sweden seems highly improbable.<sup>1</sup>

It should be remembered that the majority of the inhabitants in the higher age groups in the three largest cities were not born in the cities but have moved there generally in adolescence or at their younger working ages. Therefore the genetic composition of the popula-

tion of Stockholm, Gothenburg and Malmö cannot deviate considerably from that of the general Swedish population (at least in so far as such a common disease as DM is concerned).

In a way, the most interesting differences in Tables 26 and 27 are between the south western part of Sweden and the 'central belt', already described. The rural indices O/E for Dt are 0.86 and 1.12 for males and 0.82 and 1.19 for females, the urban indices (of which the first mentioned ones include the cities of Gothenburg and Malmö) are 0.89 and 1.18 for males, and 0.88 and 1.13 for females. Hence, the quotients between the 'south western' and the 'central belt' indices will be rural 0.77 for males and 0.69 for females, urban 0.75 for males and 0.78 for females, or on average 0.75. It is interesting to notice here that these quotients are fairly similar for both sexes.

As may be seen from Table 27 and is further elucidated by the following table, the quotients are also fairly similar for different age groups.

Sex	Area	All ages	Age		
			0-64	65-79	80-
<i>O/E for Dt</i>					
<i>South western part</i>					
M	r	0.86	0.97	0.88	0.77
	u	0.83	0.81	0.94	0.88
F	r	0.82	0.81	0.86	0.75
	u	0.88	0.74	0.94	0.83
<i>Central belt</i>					
M	r	1.12	1.18	1.08	1.15
	u	1.18	1.17	1.16	1.17
F	r	1.19	1.26	1.18	1.16
	u	1.13	1.22	1.11	1.12
<i>Quotient south western part to central belt</i>					
M	r	0.77	0.82	0.81	0.67
	u	0.75	0.69	0.81	0.75
F	r	0.69	0.64	0.73	0.65
	u	0.78	0.61	0.85	0.74

<sup>1</sup> It might be noted that the same situation was established in respect of cerebrovascular disease with low quotients O/E for Ct in Au Ou and Nu (and also in Cu).

On the basis of the statistical data the possibility cannot be excluded that there exists a real difference in so far as the prevalence of DM is lower in the south-western part of Sweden than in the rest of the country—possibly 15 or 20 per cent lower. However, in view of the homogeneity of the Swedish population the more likely explanation seems to be that the diagnosing of DM or its reporting in the death certificates (or both) has been more complete in the central belt than in south western Sweden (and in Stockholm City).

To sum up with a certain reservation regarding the south-western part of the country, it seems warrantable to conclude that in Sweden there does not exist any real geographical difference in respect of mortality—and morbidity—from DM (apart from the time lag already mentioned) and further, that the statistical records—after due correction for the gaps connected with unknown cause—contain a certain underestimation of mortality from DM (primary or contributory cause). This geographical underestimation may be assessed at about 15 per cent of the number of registered deaths from DM (primary or contributory cause) for males and about 20 per cent for females.<sup>1</sup>

### *Primary cause for deaths with DM as a contributory cause*

Table 28 shows the distribution by primary cause of deaths with DM as a contributory cause. In all, among deaths other than those for which DM was registered as the primary cause, 3.3 per cent were reported to have had DM as a con-

tributory cause (males 2.5 per cent females 4.1 per cent). Particularly high percentages are found for diseases of the circulatory system (3.4 and 5.7), respiratory diseases (3.5 and 5.3), and diseases of the nervous system and sense organs (3.3 and 4.9), in addition, for females the percentage is high for diseases of the genito-urinary system (2.7 and 5.7). On the other hand, the figures for neoplasms are very low (1.0 and 1.4). Among these deaths with DM as a contributory cause the frequency of autopsies stands out as low for the primary causes infective diseases and diseases of the genito-urinary system (cf. Table 24) in comparison with the figures concerning cerebrovascular disease as a contributory cause, the frequency of autopsies also stands out as low for neoplasms as the primary cause.

However, the distribution by age is not the same for deaths from different primary causes, and therefore some sort of age standardization is warranted. This is made on the basis of the idea (in general quite unrealistic) that the registered primary cause is not a cause of death but solely a way of classifying deaths.<sup>2</sup> The index figures in Table 28 give the quotient between the observed number of deaths from DM (as a contrib-

<sup>1</sup> It is quite obvious that the statistics on primary cause of death give a considerable underestimation of the occurrence of DM in the three largest cities. The same applies to cerebrovascular disease in respect of Au, Öu and Mä (and also Cu).

<sup>2</sup> If blue eyes were without significance for mortality but blue eyes was always recorded as the primary cause of the death and the real (underlying) cause was always recorded as a contributory cause then the distribution by contributory cause in this group would agree with the distribution by cause of all deaths (other than "blue eyes").

utory cause) and the number that would have been registered if the shares of deaths from DM (Dt/T) by sex and age had been applicable irrespective of the primary cause of death.<sup>1</sup> The age-standardized index must be low, if the primary cause is a real cause of death which is not (or is only slightly) correlated with DM. It may be high in either of two cases, viz. if the registered primary cause is not a real cause of death and if there is a correlation between the registered primary cause and DM. As will be seen from the table, the index figures are very low for violent deaths among males and for neoplasms, and low also for the remainder group 'other diseases', for diseases of the digestive system and for violent deaths among females. They are high for circulatory and respiratory diseases and in respect of females, for diseases of the genito-urinary system. In the main, these results are in agreement with current views concerning the connections between DM and diseases of the circulatory system and the results obtained in previous studies concerning the importance for mortality statistics of variations in the incidence of respiratory diseases in particular influenza epidemics (cf. Larsson 1965). In the evaluation of the data in Table 28 due regard must be paid to the heterogeneity of the reports on causes of death (the underestimation of the occurrence of deaths from DM in Stockholm City and the probable underestimation of this occurrence in the south-western part of Sweden).

In the parallel study of mortality from cerebrovascular disease a similar analysis was performed with regard to the distribution by primary cause of deaths

with cerebrovascular disease as a contributory cause. For comparison, the corresponding autopsy percentages and index figures are stated in Table 28. As will be seen from the table, the index figures are exceptionally high for the primary cause DM and very low for neoplasms.<sup>2</sup>

An interesting approach to the study of the prevalence of DM, and the mortality and causes of death among diabetic patients has been made in Denmark by Dreyer and Hey (1953, 1954). Their evaluation is based on a register of DM patients who during the period 1944-48 received special rationing cards for saccharine. The prevalence rate was found to be 0.43 per cent (males 0.38 females 0.47), a higher prevalence was registered in the towns (0.52 per cent) than in the rural areas (0.34 per cent). At ages 65-69 the prevalence figures in the towns were 2.06 per cent for males and 2.34 per cent for females; in the rural areas they were 0.95 and 1.87, respectively.

For 15 400 diabetics living at the end of 1948 there occurred in the period January 1, 1949-June 30, 1951 (hence within 2.5 years) a total of 1 539 deaths (670 males 869 females). According to the rules then followed for the classification of causes of death DM should always be given as the primary cause unless cancer, tuberculosis or violence was mentioned in the certificate. The authors performed a correction (reclassification) in so far as all deaths from DM, where a secondary cause was stated, were attributed to this cause. Further a calculation was undertaken of the expected number of deaths in the relevant period.

<sup>1</sup> This method of calculation implies a certain bias in so far as the occurrence of diseases other than DM as a contributory cause is not taken into account but for the purpose of age standardization it is quite sufficient.

<sup>2</sup> In one sense the figures for diabetes are especially interesting: they give an impression that—weighed with the age distribution of deaths from cerebrovascular disease—diabetes does not cause any appreciable increase of mortality.

Table 28 *Distribution by primary cause of deaths with DM as a contributory cause 1961-63 For comparison certain corresponding data are given also for deaths with cerebrovascular disease as a contributory cause*

Primary cause	Total number of deaths	Deaths from DM by age						Antipsiles for deaths from DM			Index for DM by age					Deaths from cerebrovascular disease	
		Number De Dp						Num ber	Percent age	Da	per cent					Autopsies	In dex
		All ages	0-34	35-49	50-64	65-79	80				All ages	0-34	35-49	50-64	65-79		
<b>Males</b>	<b>T</b>																
Infect	I	1 335	1	5	12	18	—	15	39	—	23	10	24	26	83	47	19
Neopl	II	23 059	1	4	44	126	60	111	37	—	27	10	24	26	38	52	12
Nerv	VI	14 769	1	6	51	288	140	118	24	—	85	44	80	92	79	26	—
Circ	VII	11 598	—	28	257	920	456	473	28	—	90	71	89	92	87	32	39
Resp	VIII	6 511	1	1	16	113	94	60	27	—	95	74	99	100	100	26	62
Digest	IX	4 884	1	2	23	57	21	76	68	—	63	25	66	61	73	66	22
Gen urin	X	4 035	1	2	12	59	34	34	31	—	71	—	65	78	70	31	37
Other dis	XI	4 739	—	3	8	17	4	13	41	—	46	—	47	53	34	58	31
Unknown	XVI	1 277	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Violence	XVII	9 836	4	1	8	11	13	17	39	—	15	5	11	23	44	42	14
Subtotal		119 083	10	52	431	1 616	1 031	892	30	—	68	24	60	73	74	35*	32*
Diab	Dp = A63	1 419	87	118	290	629	295	506	36	—	(259)	—	—	—	—	36	96
Total		120 462	97	170	721	2 245	1 326	1,398	32	—	100	100	100	100	100	26	100
<b>Females</b>																	
Infect	I	797	1	2	3	15	12	10	29	—	79	—	18	26	59	36	18
Neopl	II	21 258	—	6	45	187	55	95	32	—	24	10	18	26	29	54	10
Nerv	VI	17 113	—	2	66	515	253	173	21	—	78	27	71	79	78	24	—
Circ	VII	41 461	1	9	221	1 344	770	619	26	—	93	57	122	90	92	29	43
Resp	VIII	6 321	2	—	16	195	123	81	25	—	92	—	94	100	83	18	49
Digest	IX	4 566	1	2	16	110	45	95	55	—	63	53	66	62	51	17	—
Gen urin	X	2 358	—	5	25	110	25	55	41	—	100	—	106	105	95	41	38
Other dis	XI	4 250	2	2	8	15	7	19	56	—	27	35	39	21	29	47	22
Unknown	XVI	1 704	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Violence	XVII	4 566	—	—	7	54	55	54	47	—	53	0	25	59	87	38	29
Subtotal		104 439	10	38	407	2 515	1 373	1 203	28	—	71	23	63	72	77	31*	33*
Diab	Dp = A63	1 905	72	63	254	1 090	426	622	33	—	(149)	—	—	—	—	25	77
Total		106 344	82	91	661	3 605	1,799	1,825	29	—	100	100	100	100	100	24	100

Index = Quotient between observed number of deaths from DM and the number that would have been registered if the shares for death from DM (Di/T) by sex and age had been applicable irrespective of the primary cause of death (and corresponding calculation for deaths from cerebrovascular disease) \* In the two columns to the right the subtotals refer to deaths from all primary causes except Cp

on the assumption that the mortality (by sex, age and primary cause of death) was the same as in the population as a whole. The overall mortality ratio (the quotient between observed and expected number of deaths) was found to be  $670/368 = 1.82$  for males and  $869/501 = 1.73$  for females. The mortality ratio for cancer was  $62/69 = 0.90$  for males and  $87/100 = 0.87$  for females. Of all deaths 97 per cent were classified as due to cancer. In a study of death certificates in which DM is mentioned Heintzelmann (1952) found no more than 4.8 per cent of deaths from cancer. Drever and Hey consider it likely that the occurrence of DM will often be neglected where cancer is the primary cause of death.

With regard to contributory causes there are no reasons for assuming that the records exaggerate the occurrence of DM. On the other hand where the records are based on notification or where the certifying doctor has inspected the body but has not seen the patient before death there may occur a certain overdiagnosing in respect of deaths from the primary cause cerebrovascular disease especially because sudden death from diseases of the circulatory system may have erroneously been interpreted as death from cerebrovascular disease. However the quantitative effect of this overdiagnosing must be comparatively slight (cf Larsson 1965, 1967).

The statistics for different primary causes of death on the occurrence of DM as a contributory cause give a clear impression that there is an under-registration of DM for at least deaths from the primary causes neoplasms (II) and violence ((accidents and suicide XVII - XVIII). The indices given in Table 28 for all primary causes except DM are 0.68 for males and 0.71 for

females, in respect of neoplasms the figures are 0.27 and 0.24, and for violence they are 0.15 and 0.53, respectively. Further, there seems to be an under-registration for the remainder group 'other diseases' with indices 0.46 and 0.27, and possibly also a slight under-registration for digestive diseases with indices 0.63 for both sexes. Although there may be an association (or even a causal connection) between DM and the quantitatively dominating groups circulatory diseases (indices 0.90 and 0.93) and diseases of the nervous system and sense organs (indices 0.85 and 0.78) it does not seem likely that there really is a strong negative connection between DM and the first mentioned categories of causes of death implying for instance that the presence of DM would give a certain degree of protection against neoplasms or that neoplasms would give a protection against DM, nor does it seem likely that DM protects against accidents and suicide to a marked degree—although psychological arguments may be adduced in favour of a theory that certain effects of this kind exist (in addition, it should be observed that insulin has anti-depressive effects).

For comparison certain results from the comprehensive study by Westlund (1966) may be mentioned. Westlund investigated diabetic patients resident in Oslo, Norway who had been registered for the first time in thirteen hospital departments in Oslo during the period 1925-54. The patient file was matched with lists of deaths in Oslo and Aker for 1937-39 and 1941-55. Patients discharged alive were subjected to a mortality follow up (until 1961). The completeness of the death certificates for 2,664 deceased diabetic patients can be seen from the following table (after Westlund's Table V).

Primary cause of death	Number of deaths	DM mentioned per cent
Tuberculosis	93	72
Tumour	247	54
DM	311	96
Apoplexy	472	68
Coronary	545	63
Resp	209	71
Digest	96	45
Gen urin	127	74
Suicide	13	31
Accident	57	53
Other or unknown	494	64
Total	2 664	67

\* Underlying cause of death as revised on basis of all available information

A highly interesting feature is revealed from the variation of the index figures with age. In Table 28 a division has been made into four age groups viz 0-49, 50-64, 65-79 and 80 and over.

In respect of violence the total index is 0.15 for males and 0.53 for females, for the age group 0-49, the indices are 0.05 for males (5 deaths with DM as a contributory cause against 112 expected) and 0 for females (36 deaths with DM as a contributory cause expected but none registered) at ages 80 and over the index figures for violence are 0.44 for males and 0.87 for females. Here it should be remembered that deaths from accidents in particular at younger ages often occur outside the town or district where the deceased person was domiciled.

For both sexes there is a marked rise with age in the index figures not only for deaths from violence but also for deaths from neoplasms. According to the rules for the classification of causes of deaths violence should as a rule be stated as the primary cause. According to earlier principles the same should apply in respect of cancer (except in the event of coincidence with death from violence) and

therefore it seems likely that the low index figures for neoplasms should be interpreted as mainly due to a real underregistration of DM.<sup>1</sup>

Taking into account the geographical distribution of deaths from different primary causes, it can be estimated that the underregistration of DM as a contributory cause in the case of certain groups of primary causes of death—the *cause gaps*—amounts to about 10 per cent for males and about 8 per cent for females (in addition to the domicile gaps of 15 and 20 per cent, respectively) for both sexes a gap of 7 per cent relates to neoplasms as the primary cause, whereas 3 per cent for males and less than 0.5 per cent for females relate to violent deaths. In this assessment, account has been taken of the geographical variations of the registered mortality from neoplasms and violence (primary cause).

### *Registered mortality from DM before 1961*

It is often said that the prevalence of DM (in a certain group by sex and age) has been increasing with time which would imply that mortality from DM has been increasing with time.<sup>2</sup> With regard

<sup>1</sup> As can be seen from Table 28 the index figures in respect of deaths with cerebrovascular disease as a contributory cause are very low for the primary causes neoplasms and violence. In fact these experiences support the theory that there is a real underregistration of contributory causes for the primary causes neoplasms and violence.

<sup>2</sup> For some groups by sex and age the rising prevalence might have been counterbalanced by reduced excess mortality but in respect of the death shares this cannot apply to all age groups at higher ages the excess mortality for diabetics must have been fairly moderate.



to Sweden available statistics on primary (main) causes of death give a clear impression of a rising mortality from DM at ages above 70, for ages below 70 the picture is more complicated. However, since the statistics do not contain any information on *contributory causes of death* it has been almost impossible to arrive at conclusive data.

In Table 29 a survey is given for 10-year periods 1911-60 and the 3-year period 1961-63. The data are based on published official statistics concerning deaths from DM (main or primary cause), total deaths and population. The average annual number of deaths from DM and the death shares and death rates for DM are given by sex in 5- or 10-year groups by age. Ages above 70 are taken together (for the period before 1948 statistics by cause of death with a finer age division are not available). It should be noticed that the classification rules were altered from 1931 and again as already mentioned from 1951 (and in some respects from 1960).

The decrease in the death rates from 1921-30 to 1931-40 (for ages below 70 or 60) may in part be connected with altered rules for selecting which of two or more diseases should be stated as the main cause of death (hence in fact a certain transference of DM from main cause to contributory cause). The decrease from 1931-40 to 1941-50 (like the rise of the death rates thereafter) has been ascribed to the rationing of food during the Second World War. Whether this is the real explanation (or part of it) cannot however be decided on the basis of statistics on primary causes of death alone.

As already mentioned Westlund (1956) has performed a comprehensive study of the incidence of DM in Oslo. He summarizes his results as follows:

For ages below 30 the incidence has remained practically constant throughout the period 1925-54. There is an incidence maximum at age 15-19 in both sexes. At older ages there is a pronounced drop in incidence during the 1940-45 war and a return to pre-war levels is completed by 1946. The pre-war level is not exceeded, however, except in age groups 70 and over. The post-war rise in incidence is probably due to more efficient case finding.

It has already been mentioned that in 1961-63 the death shares are high for the younger adult ages. As can be seen from Table 29 this situation did not exist in 1931-40. It has been brought about through the marked decline in total mortality in these age groups shown in Table 20 (cf. Larsson 1965). Further, it is interesting to notice that at ages 5-14 the death shares have gone down markedly in spite of the general decrease of mortality at these ages.

The trend in the death rates does not indicate a real increase of mortality from DM. The observed increase at ages above 70 can be wholly explained from successively more complete registration. If so it may be warrantable to conclude that there has been a successively more complete registration for deaths at working ages also and that this has been largely counterbalanced by a reduction of the excess mortality for diabetics.

The developments after the introduction of the W.H.O. code in 1951 are elucidated in Table 30 in which the number of deaths from DM (primary cause) is shown over the years 1951-63. Using the death shares ( $Dp/T$ ) by sex and age

Table 29 Mortality from DM (main cause, primary cause) by sex and age 1911-63

Sex Attained age	Average annual number of deaths from DM										Death share DM deaths per thousand deaths										Death rate DM deaths per 100 000 population												
	1911-1920					1921-1930					1931-1940					1941-1950					1951-1960					1961-1963							
	0	10	20	30	40	50	60	70	80	90	0	10	20	30	40	50	60	70	80	90	0	10	20	30	40	50	60	70	80	90			
<b>Males</b>																																	
0-4	10	10	5	3	1	-	-	-	-	-	1	2	2	1	1	1	-	-	-	-	3	4	2	1	0	0	0	0	0	0	0		
5-9	16	15	7	2	0	-	-	-	-	-	15	25	18	10	2	10	2	-	-	-	5	5	3	1	0	0	0	0	0	0	0		
10-14	20	17	6	2	2	1	1	1	1	1	25	34	17	11	11	11	9	5	3	6	6	6	2	1	1	1	0	0	0	0	0		
15-19	25	18	7	2	2	1	1	1	1	1	18	19	11	7	8	5	5	3	1	9	7	6	3	1	1	1	0	0	0	0	0		
20-29	32	23	7	6	16	15	15	15	15	15	9	10	4	5	27	29	29	29	29	29	7	5	1	1	1	3	3	3	3	3	3		
30-39	32	23	10	7	22	25	25	25	25	25	12	12	6	5	24	34	34	34	34	34	9	6	2	2	1	4	4	5	5	5	5		
40-49	78	22	13	9	21	27	27	27	27	27	12	10	6	4	12	16	16	16	16	16	10	7	3	2	4	4	5	5	5	5	5		
50-59	46	42	36	21	34	57	57	57	57	57	14	14	10	6	9	13	13	13	13	13	20	17	12	6	8	8	11	11	11	11	11		
60-69	62	83	78	48	100	100	100	100	100	100	12	16	13	7	10	12	12	12	12	12	36	42	36	18	22	28	28	28	28	28	28		
70-	60	90	118	92	164	247	247	247	247	247	5	6	7	5	8	11	11	11	11	11	45	61	71	50	71	94	94	94	94	94	94		
Total	331	343	287	192	331	473	473	473	473	473	8	10	8	5	9	12	12	12	12	12	12	12	9	6	9	13	13	13	13	13	13		
<b>Females</b>																																	
0-4	8	9	4	1	1	-	-	-	-	-	1	2	2	1	1	1	-	-	-	-	3	3	2	0	0	0	0	0	0	0	0		
5-9	16	15	6	3	1	1	1	1	1	1	16	29	22	17	12	12	7	7	7	7	6	6	3	1	0	0	0	0	0	0	0		
10-14	23	20	10	4	2	0	0	0	0	0	27	38	33	34	26	4	4	4	4	4	8	7	4	2	1	0	0	0	0	0	0		
15-19	19	16	8	4	2	1	1	1	1	1	14	18	12	15	15	11	11	11	11	11	7	6	3	2	1	0	0	0	0	0	0		
20-29	28	21	10	9	16	12	12	12	12	12	10	10	6	10	55	52	52	52	52	52	6	4	2	2	3	3	3	3	3	3	3		
30-39	23	17	10	7	19	16	16	16	16	16	9	9	6	6	31	38	38	38	38	38	6	4	2	1	4	3	3	3	3	3	3		
40-49	25	24	14	11	14	15	15	15	15	15	11	11	6	6	10	13	13	13	13	13	8	7	3	2	3	3	3	3	3	3	3		
50-59	43	48	48	30	37	38	38	38	38	38	14	16	15	10	13	14	14	14	14	14	16	17	15	8	8	8	8	8	8	8	8		
60-69	65	112	133	92	125	149	149	149	149	149	13	10	23	18	21	26	26	26	26	26	32	48	55	32	36	36	38	38	38	38	38		
70-	58	122	206	164	271	403	403	403	403	403	4	7	11	8	12	17	17	17	17	17	33	65	99	73	99	125	125	125	125	125	125		
Total	308	404	449	325	488	635	635	635	635	635	7	11	12	9	14	18	18	18	18	18	11	13	14	10	13	13	13	13	13	13	13		

Main (primary) cause of death 1911-30 code 47 1931-50 code 2360 1951-63 WHO code 260 = A63

\* Main (primary) cause of death 1911-30 code 47 1931-50 code 2360 1951-63 WHO code 260 = A63

Table 30 Age standardized comparison between observed and expected mortality from DM (primary cause) 1951-63

Year	Annual number of deaths from DM (primary cause)						100 O/E for Dp					
	Males			Females			Males			Females		
	Rural	Urban	All	Rural	Urban	All	Rural	Urban	All	Rural	Urban	All
1951	162	115	277	268	195	463	86	83	66	76	71	74
1952	204	138	342	299	212	511	86	75	81	90	77	84
1953	151	128	279	266	239	505	63	67	65	78	84	81
1954	149	126	275	263	202	465	63	67	65	79	72	76
1955	159	148	307	233	181	414	68	77	72	73	64	69
1956	172	144	316	239	187	426	72	71	72	75	64	70
1957	195	156	351	250	234	484	79	75	77	75	79	77
1958	180	149	329	265	216	481	77	73	75	82	73	78
1959	229	169	398	284	260	544	97	83	91	90	88	89
1960	233	207	440	293	293	586	94	93	94	89	94	91
1951-55	165	131	296	266	206	472	69	70	70	79	74	77
1956-60	202	165	367	266	238	504	84	79	82	82	80	81
1961-63	256	217	473	354	281	635						
1951-55	Corrected for deaths from unknown cause (XVI)						74	71	73	85	75	80
1956-60							86	80	83	83	81	83
1961-63							104	95	100	110	90	100

1961-63 as standard and multiplying these shares by the total numbers of deaths by sex and age in each of the years 1951-60 the expected numbers of deaths from DM (primary cause) have been calculated the quotients between the observed and the expected numbers are given in the table for all Sweden and for rural and urban areas <sup>1</sup>

As will be seen from the table there is a distinct increase in the index figures. During the period 1951-55 the figures—corrected by proportionate distribution of deaths from unknown cause (XVI) over known causes (within each group by sex and age)—were on average 0.73 for males and 0.80 for females during the period 1956-60 they had risen to 0.83 and 0.83 respectively whereas during the period 1961-63 they are by definition 1.00. The urban figures are lower than the rural ones (0.71 and 0.75 against

0.74 and 0.85 in 1951-55, 0.80 and 0.81 against 0.86 and 0.85 in 1956-60, 0.95 and 0.90 against 1.04 and 1.10 in 1961-63)

These great changes cannot reasonably be explained as being due to a real increase in the prevalence of DM (by sex and age) but must be ascribed to a successively more complete registration of DM in part connected with an augmented interest in the diagnosing of the disease and possibly to a successively growing inclination among certifying doctors to state DM as the primary cause of death (and not as a contributory cause)

For comparison certain statistics from the U.S.A. may be mentioned

<sup>1</sup> For the separate years 1951-60 no correction was made for deaths from unknown cause (XVI). For the 5 year periods 1951-55 and 1956-60 there are also given corrected values (deaths from unknown cause being proportionately distributed over known causes within each group by sex and age)

Moriyama (1964) in his thorough analysis of death rates by cause over the period 1930-60 emphasizes that the diabetic mortality trend is difficult to assess because of the major changes in the disease classification procedures in 1949. For white males and females aged 45-54 the registered death rates for DM fell from about 0.18 and 0.30 per thousand in 1930-39 to less than 0.10 around 1955. A similar pattern was seen in the age group 55-64 with a decrease from about 0.6 to 0.3 per thousand for males and from about 1.1 to 0.4 per thousand for females.

Klebba (1966) studying mortality trends in 1954-63 reports an increase of the general death rate for DM from 0.156 per thousand in 1954 to 0.172 per thousand in 1963 or by 10 per cent. For white males the increase was about 12 per cent (from 0.127 to 0.142); there was comparatively little change for white females (increase from 0.188 to 0.192). For non-white males and females the relative increase over the 10-year period was marked viz. over 40 per cent in both sexes (from 0.098 to 0.139 for males and from 0.181 to 0.254 for females). The changes for certain age groups can be seen in the following table:

Year	Death rate for DM (underlying cause) per 100 000 population in groups by age and sex							
	45-54		55-64		65-74		75-84	
	M	F	M	F	M	F	M	F
1954	10	12	29	47	70	112	131	172
1955	10	12	30	44	71	111	131	166
1956	10	12	31	44	71	111	130	169
1957	10	12	29	46	72	112	128	167
1958	11	12	30	44	73	108	129	170
1959	11	12	31	44	72	106	134	171
1960	12	12	32	44	76	108	145	178
1961	11	11	31	40	75	106	139	181
1962	12	12	33	41	79	107	141	175
1963	12	12	33	41	80	107	145	182

United States After Klebba (1966)

The developments in the different countries are elucidated in Table 31. The

table states for the years 1955-64, the share of deaths from DM (primary cause), both sexes are taken together, and no age standardization is made. At the bottom of the table are given figures for groups of countries. In addition the total numbers of deaths in 1955 and 1964 are given.

As can be seen from the table, the series for Stockholm City (A) does not show any increase with time; the same applies to Uppsala County (C) and Malmöhus County (M). For the south-western counties (G, L, M, N, O) taken together, there was found a certain increase from 9 per thousand in 1955-57 to about 12 per thousand in 1961-64. For the northernmost counties (Y, AC, BD) the shares have risen from about 9 per thousand in 1955-57 to about 15 per thousand in 1961-64, and for the central belt there has occurred a gradual rise from 12 to about 18 per thousand. For total deaths from DM (Dt) in 1961-63 too the death shares are lower in Stockholm City and in the south-western counties than in the central belt, although the relative differences are less marked than in respect of primary cause alone. It is very likely therefore, that there has occurred—except for Stockholm City—a certain transfer from the classification of DM as a contributory cause to its classification as the primary cause of death. It must be regarded as quite out of the question that the series in Table 31 are an expression of a real increase in the prevalence of DM and they must not be taken as evidence for the existence of real differences in respect of the prevalence of DM in different parts of the country.

Table 31 *Death shares for DM (primary cause) by county 1955-64*

County	Number of deaths thousands		Deaths from DM (primary cause) per thousand deaths									
	1955	1964	1955	1956	1957	1958	1959	1960	1961	1962	1963	1964
A	72	87	10	9	14	11	14	13	10	12	10	10
B	33	39	10	11	11	12	16	12	15	18	19	17
C	16	17	16	11	14	13	9	13	17	14	14	11
D	21	25	10	11	8	10	16	18	21	15	17	20
E	36	39	11	15	14	15	17	17	18	14	21	19
F	27	28	11	14	12	15	18	20	17	21	22	18
G	15	17	19	14	15	8	13	8	18	9	10	12
H	25	26	14	10	8	16	16	15	21	14	20	25
I	07	07	13	6	20	16	6	16	16	17	9	18
J	14	17	13	9	17	8	12	11	8	13	15	8
L	24	28	7	10	7	6	11	11	12	11	12	16
M	56	65	9	10	10	10	9	9	10	8	10	12
N	17	17	9	9	9	13	12	7	14	13	15	16
O	51	61	7	7	8	7	12	14	13	14	11	14
PQ	35	38	14	14	12	15	12	13	17	18	21	17
R	26	27	11	16	18	12	12	15	16	13	15	16
S	31	33	13	10	11	11	15	17	19	15	21	18
T	26	26	11	10	10	14	12	15	19	14	19	24
U	20	21	8	14	14	14	18	16	14	20	20	21
W	28	31	9	14	10	13	19	16	14	16	12	19
X	29	32	13	10	12	14	14	13	18	17	13	16
Y	28	30	6	5	11	9	8	12	15	13	12	16
Z	13	15	10	9	12	13	17	12	13	13	18	17
AC	20	21	5	6	8	10	9	14	17	18	11	15
BD	18	20	13	9	9	11	15	18	14	15	17	19
Rural	379	389	9	11	11	12	14	13	16	15	16	
Urban	307	378	11	10	12	11	13	14	14	14	14	
Total	686	767	11	11	11	11	13	14	15	14	15	16
A	72	87	10	9	14	11	14	13	10	12	10	10
B C	49	56	12	11	12	12	14	13	16	17	17	15
Central belt	337	365	12	12	12	13	15	15	17	16	18	19
South west	162	188	9	9	9	8	11	11	12	11	11	14
Y AC BD	66	70	8	7	10	8	11	14	15	15	13	16

Obviously the question of a possible *time gap* in the statistics on deaths from DM (primary and contributory cause) during the period 1961-63 cannot be answered through the available data on mortality by primary cause. On the other hand it should be emphasized that there is nothing in the statistics to support a theory that there has been an increase of the prevalence of DM (in a certain group by sex and age) apart from the effects arising from the reduction of the excess mortality among diabetics.

As mentioned already, for the period 1961-63 the quotient  $Dp/Dt$  is less than one third, furthermore, this quotient shows great variation with age, and there are considerable differences by domicile. It cannot be decided with certainty whether or not the 'skewness' of the quotient has changed with time since only the numerator and not the denominator in the quotient is known. From Tables 29-31 it can be concluded that the registration of DM as the primary cause of death must have been markedly

less complete in earlier periods than in 1961-63. Although it cannot always be regarded as incorrect to draw conclusions from such biased samples as the data on deaths from the primary cause DM represent it must, from a purely methodological standpoint be a necessary condition that the nature and magnitude of the existing biases can be properly evaluated.<sup>1</sup> Estimates, sometimes quite good ones have been made about the representativity of the data on primary causes of death—one may say in the form of guesses based on general knowledge—but as far as we know a study of the problems on the basis of quantitative observations has not been carried out previously.

### Mortality from DM in 1965

Recently the Central Bureau of Statistics published its report on causes of death in 1965. For the first time data on contributory causes (and complica-

tions) have been included for the whole country and with division by sex (but not with division by age) the recorded statements on causes of death (primary cause a maximum of 3 complications and a maximum of 4 contributory causes) are presented according to the Detailed List. On the basis of these statistics Table 31A has been prepared by groups of causes it shows the total number of statements on causes of death and the distribution by type (p = primary cause, c = complication c = contributory cause). As will be seen from the table DM as the primary cause (Dp) covers 31 per cent of all statements regarding DM (Dt). The percentages are particularly high for suicide (males 89 females 97) neoplasms (89, 91) and, in respect of males, for accidents (83-54).

<sup>1</sup> Seen against the statistics presented in Tables 21-28 the data in Tables 29-31 may in part serve as a warning against the use of certain types of biased samples.

Table 31A Deaths by sex and multiple causes 1965

Cause of death		Number of statements								p as percentage of total	
		Total		p		c		s			
		M	F	M	F	M	F	M	F	M	F
Infect	I	765	547	389	251	87	91	289	205	51	46
Neopl	II	8 895	7 911	7 908	7 200	—	—	987	711	89	91
DM	D	1 810	2 490	565	769	—	—	1 245	1 721	31	31
Nerv	VI	7 322	8 459	4 598	5 462	745	1 007	1 979	1 990	63	65
Circ	VII	24 291	21 603	17 458	14 317	2 638	2 928	4 195	4 358	72	66
Resp	VIII	7 807	6 644	2 767	2 499	3 067	2 661	1 973	1 484	35	38
Digest	IX	3 595	3 607	1 631	1 617	813	813	1 151	1 177	45	45
Gen urin	X	3 698	1 932	1 281	809	713	339	1 704	784	35	42
Other dis		4 441	4 363	1 616	1 351	257	276	2 568	2 736	36	31
Unknown	XVI	355	430	355	430	—	—	—	—	100	100
Accidents*	XVII	2 871	1 969	2 395	1 067	40	15	436	887	83	54
Suicide	XVIII	1 077	405	1 068	391	—	—	9	14	99	97
Total		66 927	60 360	42 031	36 163	8 360	8 130	16 536	16 067	63	60

p = primary (underlying) cause

c = complication

c' = contributory cause

\* including homicide (p 35 males 21 females)

Table 31B Mortality from DM by sex and age 1965

Attained age	Death shares for DM (per thousand) 1961-63				Number of deaths 1965				Expected number of deaths from DM 1965			
	Dp		Dt		All		Dp		Dp		Dt	
	M	F	M	F	M	F	M	F	M	F	M	F
0-4	-	-	-	-	1 093	828	1	-	-	-	-	-
5-9	-	7	1	10	145	81	1	-	-	0.6	0.1	0.8
10-14	9	4	9	9	107	66	-	1	1.0	0.3	1.0	0.6
15-19	5	11	7	15	299	134	3	1	1.5	1.5	2.1	2.0
20-24	13	28	15	31	330	126	-	3	4.3	3.5	5.0	3.9
25-29	47	72	49	79	274	117	4	11	12.9	8.4	13.4	9.2
30-34	43	59	50	65	311	168	12	14	13.4	9.9	15.6	10.9
35-39	29	24	38	32	473	272	21	10	13.7	6.5	17.1	8.7
40-44	24	19	31	23	681	491	15	9	16.3	9.3	21.1	11.3
45-49	10	9	21	18	984	699	14	9	9.8	6.3	20.7	12.6
50-54	14	13	28	27	1 784	1 095	21	16	25.0	14.2	50.0	29.6
55-59	13	15	31	39	2 581	1 606	26	28	33.6	24.1	80.0	62.6
60-64	12	23	35	63	3 820	2 342	45	64	45.8	53.9	133.7	147.5
65-69	12	27	41	80	4 970	3 503	73	114	59.6	94.6	203.8	280.2
70-74	12	26	45	88	6 166	5 002	106	136	74.0	130.1	277.5	440.2
75-79	13	22	47	78	6 744	6 549	92	176	87.7	144.1	317.0	510.8
80-84	10	13	41	59	5 985	6 408	77	114	59.8	83.3	245.4	378.1
85-89	8	10	25	40	3 722	4 602	42	46	29.8	46.0	93.0	184.1
90-	4	4	15	16	1 562	2 074	12	17	6.2	8.3	23.4	33.0
Total	12	18	37	60	42 031	36 163	565	769	494.4	644.9	1 519.9	2 126.1

Number of deaths 1965 Dt 1 810 males 2 490 females

Expected number of deaths from DM 1965 calculated with death shares for DM observed during the period 1961-63

In Table 31B a standard calculation has been performed in order to compare the registered mortality from DM in 1965 with the data from our study for the period 1961-63. The main results are shown in Table 31C.

The statistics from 1965 are not sufficient for definite conclusions. The registered increase in mortality from DM (by 15 to 20 per cent as compared with the data for the period 1961-63) may in part be ascribable to chance fluctuations.

Table 31C Age standardized comparison of mortality from DM in 1961-63 and 1965

Attained age	Observed number of deaths from DM				Expected number (standard 1961-63)				Quotient O/E per cent			
	Dp		Dt		Dp		Dt		Dp		Dt	
	M	F	M	F	M	F	M	F	M	F	M	F
0-24	5	5			7	6	8	7	74	83		
25-49	66	53			66	40	88	53	100	131		
50-74	271	358			238	317	745	960	114	113		
75-	223	353			183	282	679	1 106	122	125		
Total	565	769	1 810	2 490	494	645	1 520	2 126	114	119	119	117

but it seems likely that the main reason is a more complete registration of DM in the death certificates. Unfortunately, the published data do not permit an analysis of the increase in respect of Dt with a division by age or with geographical divisions (different counties rural and urban areas). Nevertheless the statistics from 1965 clearly support the results obtained concerning the incidence and prevalence of DM in Sweden (which are based on statistics from 1961-63).

### The completeness and representativity of the data on mortality from DM

From the preceding analysis it has appeared that the magnitude of the *domicile gaps* can be assessed at about 15 per cent for males and about 20 per cent for females. It is extremely unlikely that the prevalence of DM in Stockholm City (in groups by sex and age) is mentionably below the corresponding figures for the central belt.<sup>2</sup> As already stated it cannot be ruled out with certainty that the prevalence of DM is in fact lower in the south western part of Sweden than in the rest of the country but it seems very difficult to accept that the real differences are as large as the statistical data indicate. The circumstances obtaining in Gothenburg and Malmö (with populations at the end of 1962 numbering 411,000 and 238,000 or with suburbs included 503,000 and 250,000 respectively) are in many respects similar to those of Stockholm (population 802,000 with suburbs in Stockholm County included 1,133,000). A scrutiny of Tables 25-27 and Figs

8-13 gives strong support for the view that the lower figures found for the south western counties are wholly ascribable to underregistration.

The magnitude of the *cause gaps*, in addition to the effects of the domicile gaps has been assessed at about 10 per cent for males and about 8 per cent for females. These cause gaps are mainly ascribable to an underregistration of DM among deaths from neoplasms and violence.

In the comparisons made, the observed death shares and death rates for DM (primary and contributory cause) have been utilized. Hence, no correction has been applied for the general underregistration of deaths from DM all over the country. As will be seen from the next section the remaining *age gaps* can be assessed at about 10 per cent of the observed numbers for males and about 19 per cent for females.

The mortality data from the period 1961-63 can be regarded as normal and there are no indications of a quantitatively significant time trend in respect of the incidence of DM.

The filling up of the domicile gaps can be regarded as a mere correction of the observations for the whole country to the level observed for the central belt. The filling up of the cause gaps can be regarded as a mere correction of the observations to the level observed for primary causes of death other than neoplasms and violence. The filling up of the age gaps

<sup>2</sup> If environmental factors play a role in the development of DM it would rather be thought—in view of the clinical picture of the disease—that the morbidity risks and the death rates for DM would be higher in the large cities than in the less urbanized areas.



can be regarded as a mere correction of the observations to the level observed for ages below 80 (taking into account the existing excess mortality for diabetics). With these three corrections, the total observed figures for the prevalence of DM among deaths should be increased by about one third (35 %) for males and by about half (52 %) for females. It should be stressed that these figures are based on the analysis of *registered data on deaths from DM* (primary or contributory cause) and that it is quite out of the question that there has occurred any overregistration of such deaths.

Whether the data on DM as a primary or contributory cause of death are sufficiently complete for the central belt in respect of deaths from other primary causes than neoplasms and violence at ages below 80 cannot be decided on the basis of a statistical analysis. In other words the remainder of the possible general underregistration cannot be evaluated and the data obtained with the corrections mentioned above must be regarded as minimum figures for the prevalence of DM (among deaths). However, it seems likely that the remaining underestimation (the general underregistration) must be fairly moderate.

### Morbidity risks for DM and its prevalence in Sweden

The knowledge of the prevalence of DM among deaths (by sex and age) does not give definite information concerning the prevalence of DM among living persons (by sex and age) since the factor death implies—or may imply—a selec-

tion. Mortality among diabetics may deviate considerably from mortality among non diabetics (or mortality in the general population). In fact, we do know that mortality among DM patients treated at hospitals as well as among diabetics taking out life insurance protection is higher than mortality in the general population and among 'normal' insured persons, there exist many investigations in these fields some of them for fairly recent periods of time (cf., for instance, Marks 1963, Hayward & Lucena 1965). However knowing the excess mortality among diabetics (by sex and age) it is possible to calculate on the basis of the prevalence of DM among deaths at a certain point of time, the prevalence of DM among living persons at that time (by sex and age). It is then also possible to calculate, on the basis of these prevalence figures, the morbidity risks for DM (by sex and age)<sup>1</sup>—provided

(a) that the morbidity risks do not change with time (or, more precisely have not changed in the period during which the deceased persons have been living under the risk of developing DM)

(b) that the excess mortality (by sex and age) does not change with time

(c) that the registration of deaths from DM is equally complete in all groups (by sex and age)

However deviations from the pure model in the three respects mentioned

<sup>1</sup> From the medico-genetic viewpoint the aggregate morbidity risk (up to a given age) is the most suitable measure of morbidity (cf. Larsson & Sjögren 1954, Larsson, Sjögren & Jacobson 1963). It gives the probability that a person will develop the disease if he lives long enough (i.e. is not rescued by dying from another cause).

are capable of being evaluated with sufficient accuracy at any rate, for all practical purposes

### *Selective factors connected with excess mortality*

The calculations below refer to the period 1961-63 corrections for gaps connected with domicile cause and old age will be applied at the final stages Before presenting the results of the calculations some special points on the representativity of the period 1961-63 and the effects of changes in excess mortality may be mentioned

(a) There is a heavy excess mortality among persons becoming afflicted with DM at younger ages (juvenile diabetics) With regard to the number of deaths among diabetics however, the effect of this excess mortality is very slight, since the proportion of juvenile diabetics is rather insignificant (As can be seen from Table 23 in the 3 year period 1961-63 the number of deaths from DM below age 40 was 145 males and 107 females or 3.3 and 1.7 per cent respectively, of the total registered number of deaths from DM)

(b) Among juvenile diabetics—and to a great extent among persons becoming afflicted with DM at adult ages too—the excess mortality was markedly higher in the pre insulin era than it has been since the introduction of insulin in general therapeutic practice Further, if we restrict the comparison to patients showing the same severity of symptoms the excess mortality must have been reduced after the introduction in general therapeutic practice of penicillin and antibiotics

(which occurred in Sweden around 1942 and 1948 respectively) since in earlier periods infective diseases influenza and pneumonia were on average more dangerous to diabetics than to the population in general (of the same sex and age)

(c) The diagnostic techniques—not least in respect of laboratory facilities—have gradually become more accurate and more easy to handle Both absolutely and relatively the numbers of doctors nurses and beds in hospitals have increased communications in particular the availability of motor cars have improved largely These and other similar factors have contributed to the effect that in the population of diagnosed diabetics there has occurred a gradual admixture of comparatively mild cases which would not have been included under the conditions prevailing before and during the Second World War

(d) On the other hand it should be remembered that an excess mortality from a certain disease will often imply a positive selection of survivors in so far as, relatively speaking there will be more deaths among persons who are severely afflicted with the disease than among persons who have the disease in a milder form at least this must in general apply to chronic diseases causing (or connected with) excess mortality<sup>1</sup>

(e) Among persons who died during the period 1961-63 there are very few diabetics who became afflicted before insulin therapy was available however if the earlier survival rates had been augmented by the use of insulin, this would have meant only a small addition to the number of diabetics in the popula-

<sup>1</sup> Cf Prawitz 1954

tion of 1961-63, even in the absence of excess mortality, the great majority of persons who became afflicted with DM before 1923 would not have survived as long as until 1961

(f) The antiselection against the aberrant gene (or genes) which conditions (or may be assumed to condition) the occurrence of DM may have been reduced —by means of insulin therapy or, more generally, through reduction of the excess mortality, by means of advances in obstetrics (preventive maternity welfare, etc.), and as a result of general voluntary birth control. However the role of these changes must be quite insignificant in respect of the prevalence of DM and the number of deaths among diabetics. Juvenile diabetics are few and forty years is too short a time for genetic factors of this nature to acquire any effect worth mentioning.

(g) Both during the period 1961-63 and in certain preceding years there were undertaken screening procedures in respect of DM. Further as already mentioned the introduction of obligatory health insurance in 1955 may have caused an acceleration in the diagnosing of new cases of DM. However since we are dealing here with *the registered prevalence of DM among deaths* and not with *the registered incidence of new cases of DM* these factors will not have any disturbing effects on the analysis.

### *Minimum estimate from total death share*

During the period 1961-63 DM was recorded for 4.67 per cent of all deaths in Sweden (males 3.62 per cent, females

5.87 per cent) related to deaths from known causes the share of deaths from DM is 4.73 per cent (males 3.66 per cent, females 5.96 per cent). Since there are no reasons whatsoever for assuming that the excess mortality for diabetics in general was more heavy during this period than in preceding years, it can immediately be concluded that the total morbidity risk for DM must exceed 3.6 per cent for males and 5.9 per cent for females. If the assessment of the gaps (connected with domicile, cause, and old age) is applied the figures should be increased by 35 and 52 per cent, respectively, and hence the total morbidity risk for DM must exceed 4.9 per cent for males and 9.0 per cent for females.

### *Minimum estimate from death share above a certain age*

Unless mortality among persons afflicted with DM is lower than mortality in the general population the death shares for DM above a certain age will always (under stable conditions) give a minimum figure for the total morbidity risk, if onset does not occur after the age in question. The share will give a minimum figure for the aggregate morbidity risk up to that age. These shares are shown in Table 32 for deaths above age 50 the figures are 3.9 per cent for males and 4.3 per cent for females and for deaths above age 65 they are 4.1 and 6.6 per cent respectively (as compared with 3.7 and 6.0 per cent for all deaths from known causes). Applying the same gap correction as above we arrive at the minimum figures 5.5 per cent for males and 10.1 per cent for females.

## Assessment based on assumptions concerning excess mortality

In order to evaluate the prevalence of DM among living persons, we must make reasonable assumptions concerning the excess mortality (by sex and age) for diabetics. There will in fact be certain possibilities of checking that these assumptions are consistent with the results from the mortality statistics since the aggregate morbidity risk up to a certain age cannot decrease with increasing age.

The assumptions concerning the excess mortality at ages before say 40 or 50 will have a comparatively slight effect for the assessment of the total prevalence of DM in the population. At higher ages say above 60 or 65 the excess mortality must be fairly moderate and at advanced ages say above 80 or 85, the excess mortality if any can be neglected in view of the obvious age gaps in the registration of deaths from DM. Guided by the results obtained in Chapter III with regard to the excess mortality among DM patients admitted to the investigation hospitals, and the trends by age in the death shares and death rates for DM registered in 1961-63 we have selected as a working hypothesis a smooth series of mortality ratios (the quotients by sex and age between the death rate for DM and the general death rate), for simplicity the mortality ratios are assumed to be equal for males and females but since the general death rates are higher for males than for females this implies that the *absolute* excess mortality is assumed to be higher for males. Intentionally the series of mortality ratios has been chosen in such a way that there should not be any

exaggeration of the total number of diabetics in the population (i.e. the level of the mortality ratios is rather too high than too low). Because this smooth series (denoted A) does not fulfil the criterion that the aggregate morbidity risk shall be a never-decreasing function of age the calculations are also performed with a modified series (denoted B)<sup>1</sup>.

The series are as follows

Attained age	Assumed mortality ratio for persons with DM	
	A	B
-24	5	5
25-29	5	12
30-34	5	9
35-39	4	4
40-44	3	2.5
45-49	2	1.5
50-54	1.6	1.4
55-59	1.4	1.3
60-64	1.1	1.25
65-69	1.2	1.2
70-74	1.15	1.15
75-79	1.1	1.1
80-84	1.05	1.05
85-	1	1

The assessment of the prevalence of DM in the population (average during the period 1961-63 hence representing the middle of 1962) is then arrived at by simply dividing the death shares for DM by these mortality ratios.

In the assessment of the aggregate morbidity risks for DM the excess mortality must be taken into account in another respect too. The diabetics who in a certain age group are eliminated by the excess mortality would have been living in the next age group (as diabetics since DM can be regarded as a perma-

<sup>1</sup> The modifications are restricted to the age interval 25-64 under 25 the registered numbers of deaths from DM is low (in total 32 males and 65 females).

ment disease) if mortality had been the same among diabetics as in the general population.<sup>1</sup> Therefore the extra deaths among diabetics should be carried forward to the next age group and be included there (as diabetics exposed to the excess mortality prevailing in this age group).<sup>2</sup>

The results of the calculations are shown in Table 32. In addition to the basic absolute numbers—population (three times the average population in 1961–63 in thousands) and registered deaths from DM (total during the 3 year period 1961–63 primary or contributory cause)—the table shows the death rates for DM per 100 000 population, the death shares for DM per 1 000 deaths (related to deaths from known causes and adjusted to division by attained age). Further the death shares for DM are shown for all ages above the lower class limit (above 0, above 5, above 10, etc.).

On the basis of the assumed mortality ratios (series A and B) stated in the table the prevalence of DM per 1 000 population and the absolute number of diabetics in the population (at the middle of 1962 in hundreds) have been calculated as shown in the table. Two series of data refer to Assumption A, viz. one without correction for registration gaps (other than those related to deaths from unknown cause XVI) and the other with correction for the domicile and cause gaps already discussed. A third series refers to Assumption B with correction for the domicile and cause gaps and in addition a correction for age gaps. The correction for age gaps is made on the simple assumption that at ages above 75 the prevalence of DM cannot be lower

than the prevalence obtaining in the age groups 75–79 for males and 70–74 for females.<sup>3</sup> Since the assumed mortality ratios A and B are the same for ages above 65, the correction for age gaps will also be valid for the A series. <sup>4</sup>

<sup>1</sup> Strictly speaking this applies to generations not to simultaneously living persons, but if the population is stationary the results will be the same. For the assessments made here the deviations from stationary conditions are without significance.

<sup>2</sup> At ages where the excess mortality from DM is high the prevalence of DM is low and general mortality is low. Therefore the figures for the prevalence of DM at a certain age will be only slightly below the aggregate morbidity risk for DM up to that age (the relative underestimation being less than 2 per cent).

With sufficient accuracy the aggregate morbidity risk  $m_x$  up to age  $x$  can be calculated with the formula ( $D$  = deaths from DM,  $T$  = total deaths,  $P$  = population,  $r$  = mortality ratio for diabetics,  $x$  = age)

$$m_x = \frac{D_x}{T_x r_x \left( 1 - \sum_{y=0}^x \frac{r_y - 1}{r_y} \frac{D_y}{P_y} \right)}$$

or

$$m_x = \frac{D_x}{T_x r_x} \left( 1 + \sum_{y=0}^x \frac{r_y - 1}{r_y} \frac{D_y}{P_y} \right)$$

Here  $D_x/T_x$  is the share of deaths from DM and  $D_x/T_x r_x$  is the prevalence of DM in the population. In the factor between brackets  $D/P$  is below 0.01 per cent up to the age group 45–49 and  $(r-1)r$  is assumed to be at the most 0.2 for ages above 65. For all ages under 60 the product (without correction for registration gaps) is below 0.01 per cent and the maximum is 0.047 per cent (for females in the age group 75–79).

<sup>3</sup> In respect of diseases which are genetically conditioned (or for other reasons affect only a certain part of the population) and cause (or are connected with) excess mortality there may occur a decrease in prevalence (especially if the morbidity risk at higher ages is zero or low). However in respect of DM the incidence of onset of the disease at higher ages is comparatively large and the excess mortality is comparatively low.

Table 32 Assessment of morbidity risks for DM and its prevalence in Sweden 1961-63

0.003 x average population mortality data for DM and 0.01 x number of living diabetics by attained age																						
Excess mortality	Sex	All ages	Age groups																			
			0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89	90+	
3 x average population thousands	M	11 318	800	819	804	963	754	668	694	769	828	794	794	696	591	471	351	241	129	129	12	
Deaths from DM primary or contributory cause	F	11 368	757	773	870	922	730	649	686	748	814	783	788	721	636	534	422	295	163	66	19	
Death rate for DM per 100 000 population	M	4 359	-	-	3	5	10	35	44	48	62	60	131	227	363	561	751	933	736	316	74	
per 1 000 deaths*	F	6 238	-	-	3	2	5	8	10	34	25	31	35	84	169	408	795	1 295	1 515	1 475	105	
Death share for DM per 1 000 deaths*	M	39	-	-	0	0	1	1	5	6	6	7	8	16	33	61	119	214	388	570	633	
Ditto with all higher age groups included**	F	56	-	-	0	0	1	1	5	5	3	4	5	11	23	64	149	309	513	701	833	
Assumed mortality ratio per cent	M	37	-	-	1	9	7	15	49	50	38	31	21	28	31	35	41	45	47	41	25	
Assumed excess mortality per thousand	F	60	-	-	10	9	15	31	79	65	32	23	18	27	39	63	80	78	59	40	16	
DM per 1 000 population uncorrected	M	37	38	18	18	18	18	38	38	38	38	38	39	39	40	41	41	40	34	25	17	
Ditto corrected for domicile and cause gaps	F	60	61	61	61	62	62	62	62	62	62	62	62	63	64	66	66	65	58	48	35	
Ditto corrected also for age gaps	A	500	500	500	500	500	500	500	500	500	500	500	500	500	500	500	500	500	500	500	500	
Aggregate morbidity risk per thousand	B	500	500	500	500	500	500	500	500	500	500	500	500	500	500	500	500	500	500	500	500	
0.01 x number of diabetics uncorrected	M	13	2	2	4	4	4	12	10	5	4	2	2	3	3	5	8	7	8	7	0	
Ditto corrected for domicile and cause gaps	F	20	1	1	2	2	7	6	3	3	2	1	2	2	3	4	5	7	6	0	0	
Ditto corrected also for age gaps	A	17	-	-	2	1	2	10	10	10	11	10	17	22	27	34	39	43	40	29	17	
Aggregate morbidity risk per thousand	B	26	-	-	2	2	3	12	13	12	14	13	21	28	33	43	49	54	50	36	21	
0.01 x number of diabetics uncorrected	M	17	-	-	3	2	4	7	21	18	11	10	11	20	34	60	78	99	92	74	55	
Ditto corrected for domicile and cause gaps	F	27	-	-	2	2	3	5	7	12	16	17	24	30	34	43	49	55	55	55	55	
Ditto corrected also for age gaps	A	446	-	-	2	2	4	7	9	10	11	12	15	23	36	63	78	99	99	99	99	
Aggregate morbidity risk per thousand	B	697	-	-	2	2	3	5	7	12	16	17	24	30	35	43	49	55	55	55	55	
0.01 x number of diabetics uncorrected	M	446	-	-	5	4	6	12	24	24	30	27	45	51	52	53	45	35	17	5	1	
Ditto corrected for domicile and cause gaps	F	562	-	-	6	5	9	12	35	32	21	22	42	63	100	108	108	71	31	9	1	
Ditto corrected also for age gaps	A	921	-	-	7	5	7	27	30	31	38	34	57	64	65	67	57	44	22	6	1	
Approximate random error per cent	B	573	-	-	7	6	11	16	44	40	27	28	54	81	128	138	139	91	40	12	1	
	M	921	-	-	7	5	7	11	17	17	31	45	46	65	69	68	67	57	44	23	9	
	F	58	71	45	35	18	17	20	18	17	13	9	7	5	4	4	3	3	4	6	12	
	A	58	71	45	35	18	17	20	18	17	13	9	7	5	4	4	3	3	4	6	12	

\* Deaths from unknown cause (XVI) have been proportionately distributed over known causes within their group by sex and age.

\*\* For instance the figures entered in column 40-44 refer to all deaths at ages 40-44 over (40-)




Fig 14 Assessment of the prevalence of DM in Sweden by sex and age 1961-63  
See Table 32, p 111 and text pp 109-113

Table 33 Calculated number of diabetics in Sweden (average for years 1961-63)

Attained age	Population thousands		Calculated average number of diabetics, thousands							
			M				F			
	M	F	A		B		A		B	
			u	d c	d c a	d c a	u	d c	d c a	d c a
0-49	2 661	2 574	14.2	17.9	17.9	16.9	16.4	20.8	20.8	18.2
50-64	694	715	14.8	18.6	18.6	20.2	20.5	26.3	26.3	28.1
65-79	354	417	13.3	16.8	16.8	16.8	28.7	36.8	37.6	37.6
80-*	64	83	2.3	2.9	3.4	3.4	4.1	5.3	8.2	8.2
Total	3 773	3 789	44.6	56.2	56.7	57.3	69.7	89.2	92.9	92.1

\* Extrapolation of the morbidity risks indicates a further age gap (extrapolation gap) of about 0.3 for males and 3.2 for females

A B = assumptions concerning excess mortality (see Table 32)

u = uncorrected data

d c = corrected for domicile and cause gaps in registration

d c a = corrected for domicile cause and age gaps in registration

nally the table gives the calculated aggregate morbidity risks with Assumption B, as will be seen, the figures are practically identical with the prevalence series (corrected for domicile cause and age gaps) <sup>1</sup>

For the sake of simplification the corrections for the domicile and cause gaps have been made proportionately over all age groups. As will have appeared already, the domicile gaps are positively and the cause gaps negatively correlated with age. However, since the assumptions in respect of the excess mortality at younger ages are rather arbitrary, and the number of registered deaths is low, it has not been considered justifiable in the present connection to apply correction factors which vary with age.

The relative random errors of the calculated prevalence figures are approximately proportional to the inverted square root of the registered number of deaths. For convenience, these latter quantities are shown in the table. Of course, the systematic errors (due to

erroneous assumptions concerning the excess mortality) may be quite considerably larger.

The results from the assessment of the prevalence of DM in the population are illustrated in Fig. 14.

### Number of diabetics in Sweden

A summary of the calculations concerning the number of diabetics in the Swedish population (average 1961-63) is given in Table 33. As can be seen from the table, the difference between Assumptions A and B is of little importance for the assessment of the number of living diabetics.

Fig. 14 gives a strong impression that it must be unrealistic to accept that the aggregate morbidity risk for DM does not increase after the age of 80. Because of the unquestionable age gaps (already taken into account) it is not

<sup>1</sup> As already mentioned the relative difference between the aggregate morbidity risk and the prevalence is always less than 2 per cent.



possible, on the basis of the mortality statistics alone, to arrive at definite conclusions concerning the rise of the aggregate morbidity risk for DM at advanced ages. From our hospital series and from other data we know that onset of DM may sometimes occur at ages above 80, according to Table 5 this applies to 11 per cent of the patients in the hospital series but since the admission rate decreases markedly with age (at least in the higher age groups) the real share of very late onset must be considerably greater. An extrapolation of the curves for the morbidity risks indicates that at age 90 the aggregate morbidity risks are at least 6.5 per cent for males and about 13 per cent for females. This would mean that the correction for age gaps made in Table 33 should be increased by about 300 for males and 3 200 for females giving—with Assumption B—a total number of diabetics of 57 600 males and 95 300 females in the average population of 1961-63 or 1.53 and 2.52 per cent respectively of the population.

It has sometimes been said that the prevalence of DM in the adult Swedish population is between 1.5 and 2 per cent such statements may be regarded as rough estimates (in part with the character of guesses). According to the analysis made here the figures for ages 15 and over are 1.90 per cent for males and 3.10 per cent for females and 2.50 per cent for both sexes taken together.

It can be calculated that because of the changing age distribution (and the increase in population) the absolute numbers of diabetics will increase by 0.7 per cent annually for males and by 1.4 per cent annually for females. At the end of

1965 there would thus have been about 159,000 diabetics in Sweden (59,000 males and 100 000 females), or 2.05 per cent of the total population (7.77 million).

For the sake of completeness reference may be made to some earlier investigations concerning the prevalence of DM in Sweden. Most of the authors stress that their estimates should be regarded as minimum figures not infrequently, however, the data are given in a form which may invite erroneous conclusions about the reliability of the results.

On the basis of questionnaires answered by persons who received extra rationing cards during the Second World War Jorpes and Kallner (1942) recorded an overall prevalence of 0.163 per cent (rather plausible as a minimum figure).

A more extensive questionnaire was sent out in June 1943. On the basis of the answers and data concerning insulin consumption Dahlberg, Jorpes, Kallner and Lichtenstein (1947) calculated that in 1944 the number of diabetics in Sweden was at least 18 500 (or 0.28 per cent) this figure is regarded as a little too low. For the City of Stockholm a special and more detailed inquiry was made the frequency of DM was found to be 0.506 per cent for males and 0.457 per cent for females. By applying the Stockholm prevalence rates by sex and age to the whole country the total number of diabetics in Sweden was estimated to be 31 000. The authors conclude that in 1944 the number of diabetics in Sweden exceeds 22 500 but is less than 31 000 (or between 0.34 and 0.47 per cent).<sup>1</sup>

A Swedish governmental committee (1948) estimated the number of diabetics in Sweden to be between 35 000 and 40 000 (0.51-0.58 per cent of the total population).<sup>2</sup>

<sup>1</sup> Hanssen (1946) investigated the occurrence of DM in Bergen, Norway during the period 1925-41. He estimated the prevalence of DM in 1941 at 0.38 per cent (0.32 per cent for males 0.42 per cent for females).

<sup>2</sup> 1943 års sockersjukutrednings betänkande angående sockersjukvården i riket. *Statens Offentliga Utredningar 1948:33* Stockholm 1948 pp 1-191.

In Kristianstad County (L) in the south of Sweden Silver (1958) made a search for DM cases by means of hospital records and questionnaires sent to general practitioners (cf p 235), he registered an overall prevalence of 0.51 per cent

Using screening tests in connection with an extensive X-ray examination of the population of Blekinge County (K) aged 10 years or over Schersten (1961) registered a DM frequency of 1.7 per cent applying corrections for certain gaps he arrived at the estimate 1.9 per cent (related to persons above 10 years of age) Related to the total population the corresponding figures would be 1.4 per cent and 1.6 per cent

Munke (1964) in a continuation of Schersten's study reports the prevalence of DM in the general population of Blekinge County to be 1.5 per cent

In his excellent popular book on DM and its treatment in adults Bo Andersson (1966) discusses Schersten's study and concludes that the data indicate an overall DM prevalence of 1.5 per cent In addition Andersson mentions preliminary results of a screening investigation in Norrbotten County (BD) which indicates a prevalence of 1.4 per cent However Andersson considers it probable that these figures are too low everyone working on DM is impressed by the fact that elderly persons may often be free from glycosuria in spite of a considerably increased blood sugar level A net to catch diabetics which is made of yarn from urinalysis alone will according to Andersson always prove to be too coarse meshed and therefore many diabetics will escape detection in this type of screening procedures

It is interesting to note that these Swedish figures are in good agreement with statistics and estimates for corresponding periods from other parts of the world (cf Schliack 1965 cf also Spiegelman & Marks 1946 Marks 1947 1961a Fox 1952, Newill 1963)

Fisher and Vavra (1964) report the prevalence of diagnosed (known) DM in the USA in 1959-61 to be 0.98 per cent (males 0.92 females 1.04) In addition according to their estimates the rate of

undiagnosed (undetected) DM is 0.81 per cent These latter data are also given by age (but not by sex) a comparison with our results is shown in the following table

Attained age	Prevalence of DM per 1 000 population			
	Sweden		United States	
	Uncorr	Corr	Diagn	Total
0-24	1.7	2.1	1.0	1.7
25-44	10.7	10.6	5.0	10.2
45-54	12.9	19.9	15.2	33.1
55-64	30.2	40.5	31.4	55.6
65-74	53.0	67.8	42.4	68.6
75-	49.2	90.2	37.5	62.0
All	15.1	20.2	9.8	17.9

\* Calculated from statistics on causes of death 1961-63 (Tables 32 and 33)

Uncorr	Assumption A concerning excess mortality no correction for registration gaps
Corr	Assumption B concerning excess mortality corrected for domicile cause and age gaps in registration

\*\* Source Fisher and Vavra (1964) *Public Health Service Publication No 1168*

Diagn	Diabetes reported in interviews July 1959-June 1961 Division of Health Statistics National Center for Health Statistics US Public Health Service
Undiagn	Estimates prepared on basis of studies and surveys by Diabetes and Arthritis Program Division of Chronic Disease US Public Health Service
Total	Diagn + Undiagn

As will be seen from the table the prevalence figures given by Fisher and Vavra for diagnosed DM are much lower than our corrected data and a good deal lower than our uncorrected data (both of which are based on death certificates and hence refer to diagnosed DM) Their total prevalence figures including undiagnosed DM agree very well with our results for the age group 65-74 for ages 45-64 their estimates are higher and for ages 75 and over they are appreciably lower than our figures

## Excess mortality

With the age composition of the population in 1961-63 the assumptions would imply an overall excess mortality of 14 per cent (16 per cent for males 13 per cent for females). A comparison between the registered (observed) numbers of deaths from DM and the expected numbers is shown in the table below.

Seen against the background of statistics from hospitals and insurance companies the assumption of an average excess mortality for diabetics (all ages taken together) of 14 per cent may appear too low. Nevertheless irrespective of any theories concerning the magnitude of the excess mortality we know that the prevalence of DM at ages above 65—corrected for domicile and cause gaps, and corrected for unquestionable age gaps at ages above 75 (to the level found for males at ages 75-79 and for females at ages 70-74)—must be at least 5.5 per cent for males and 10.1 per cent for females. An assumption that the average excess mortality at ages above 65 would exceed 14 per cent is not consistent with these data. If the excess mortality at

higher ages was greater than was assumed for the calculations in Table 32, this would imply that the age gaps must be larger, the estimated number of diabetics at these ages would remain approximately unchanged. Modified assumptions concerning the excess mortality at ages below 65 will change not only the estimated numbers of diabetics but also the curves for the aggregate morbidity risks, and as can be seen from Fig. 14 there is not much room for such modifications. Whatever reasonable alterations are made, they will not greatly affect the results concerning the total number of diabetics.

Taking into account the random errors, the curves for Assumption B in Fig. 14 meet the criterion that the aggregate morbidity risk shall be a non-decreasing function of age. It is possible to elevate the curves a little between ages 40 and 60, and it is possible to lower the curves a little for ages under 45. This means that the excess mortality in the four age groups 40-44, 45-49, 50-54 and 55-59 may be *less than* the 150, 40 and 30 per cent respectively included in Assumption B, and that the excess

Age and age	Number of deaths from DM				Mortality ratio O/E	
	O		E			
	M	F	M	F	M	F
0-49	267	173	92	51	2.92	3.43
50-64	721	661	578	537	1.25	1.23
65-79	2,245	3,603	1,993	3,204	1.13	1.13
80-	1,126	1,799	1,092	1,745	1.03	1.03
Total	4,359	6,238	3,755	5,537	1.16	1.13

O = Observed number of deaths from DM (primary or contributory cause) 1961-63

E = Expected number of deaths from DM calculated from the uncorrected numbers of living diabetics (assessment according to Assumption B not given in Table 31) and the death rates for the general population 1961-63 (Table 22)

mortality in the age groups 25-29, 30-34, 35-39 and 40-44 may be more than the 1 100, 800 300 and 150 per cent included in Assumption II For ages below 25 there are very few observations (36 registered deaths from DM, 18 males II females) the curves for the aggregate morbidity risks allow assumptions about the excess mortality in the interval 0-1 000 per cent

It has already been stressed that when general mortality is low, the relative excess mortality may appear to be great although the difference between the mortality of diabetics and that of the general population is fairly moderate In Table 32 are shown the additions to general death rates which are implied in Assumption II

The insurance problems will be discussed in Chapter VIII

### *Morbidity risks for DM*

According to the foregoing analysis the aggregate morbidity risk for DM up to age 50 can be estimated at 2 per cent (possibly a little more for males and a little less for females) On the whole, the observations for ages below 50 do not indicate any irregularities with regard to the distribution by onset (cf Fig 14 and Table 32)<sup>1</sup> Hence for ages below 50 the average annual morbidity risk (the probability of becoming afflicted with DM) may be estimated at 0.4 per thousand After age 50 the morbidity risks are markedly higher in particular for females with increasing age the risk for females rises in the age interval 50-64, and then goes down again A—somewhat simplified—summary of the change

*Table 34 Morbidity risks for DM*

Attained age	Annual morbidity risk for DM per thousand (graduated averages)		Age	Aggregate morbidity risk for DM per thousand (graduated figures)	
	M	F		M	F
—49	0.4	0.4	40	12	11
50-54	1.3	2.0	50	21	19
55-59	1.3	3.6	55	27	30
60-64	1.3	4.4	60	34	48
65-69	1.3	4.0	65	41	70
70-74	1.2	3.0	70	47	90
75-79	1.1	2.4	75	53	105
80-84	1.0	1.6	80	58	117
85-89	0.4	1.0	85	63	125
90—			90	65	130

of the morbidity risks with age is given in Table 34

In order to avoid misunderstanding, it should be emphasized again that the data presented here are wholly based on

(a) reports of deaths from DM (primary or contributory cause) in the death certificates

(b) analysis of probable gaps in these reports, connected with underregistration in certain geographical areas (mainly Stockholm City and the south western part of Sweden), with underregistration for certain primary causes of death (mainly neoplasms and violence) and with underregistration among deaths at advanced ages (mainly above 80) and

(c) reasonable assumptions concerning the excess mortality among diabetics

Hence the results refer to instances of *clinically diagnosed diabetes* and to instances of diabetes which—if not clinically diagnosed—are of a similar type

<sup>1</sup> There are in fact observations (from other fields) about such irregularities for instance connected with puberty but their quantitative effects can be neglected here

Quite naturally mild diabetic symptoms which do not in any noteworthy degree interfere with normal somatic functions will often escape registration. What is discussed here is the degree of changes that is ordinarily found in clinically diagnosed DM.

During the last decades medical progress has been great as regards most diseases of the younger ages but has been (though not inconsiderable) less marked in respect of diseases of old age. There are reasons for assuming that prophylactic and therapeutic measures as well as medical research will in the future be directed to a greater extent than now to the needs of the older age groups and that this will affect both morbidity and mortality from disease. The prospects of a continued reduction of morbidity and mortality at all ages—and consequently for males at advanced ages also—may be estimated as favourable. There is nothing in the statistical results that argues against the hypothesis that at all ages there will be a decrease in morbidity and mortality from each of the major groups of causes—diseases of the circulatory system, neoplasms and diseases of the nervous system and sense organs (cerebrovascular disease). For many reasons it seems warrantable to estimate that during the next few decades there will occur a decline in mortality in the older age groups that relatively speaking will be greater than the decline that took place in the first two decades after the end of the Second World War (cf. Larsson 1965). However it does not seem likely that such changes *per se* will appreciably influence the prevalence of DM (in a certain group by sex and age).

It is not unreasonable to expect that the intensive research in different fields that is being carried on in respect of DM may result in a postponement of the onset of the disease (if not in prevention) and then there will occur a reduction of the prevalence at least at younger ages and in the middle ages and a displacement "to the right" of the curves for the aggregate morbidity risk.

Nevertheless the changing age structure of the population will inevitably be accompanied by an increase in the number of deaths from DM. Whatever reasonable assumptions are made concerning a decline in mortality and a postponement of the onset of DM, this number will increase from about 5,100 per annum in 1961–63 (primary and contributory causes, corrected for registration gaps) to more than 6,000 per annum around 1980 unless the introduction of new prophylactic or therapeutic measures causes special delay effects; the number of deaths from DM (primary and contributory causes) will exceed 7 per cent of all deaths.

### *Life-table expectancy for DM*

Often where estimates concerning the prevalence of DM are made they include not only persons afflicted with DM (*diagnosed* as well as "*undiagnosed*") but also persons thought likely to become afflicted with DM later on (unless saved by dying before the onset of DM)—*prediabetics*. To avoid misunderstanding it should be emphasized that the statistics presented here do not include *prediabetics*.

The calculation of the aggregate mor-

Table 35 Life table expectancy for DM

Age	Life table expectancy for DM up to age stated, per cent	
	M	F
25	11	10
50	2.0	1.9
55	2.5	2.9
60	3.1	4.5
65	3.6	6.5
70	4.1	8.1
75	4.4	9.2
80	4.7	9.9
85	4.8	10.1
90	4.8	10.2
Whole life	4.8	10.3

idity risks presented above may be said to include prediabetics, hence, the total prevalence of diabetics and prediabetics in the Swedish population can be estimated at about 6.5 per cent for males and 13 per cent for females. However, a great many of these persons will never develop DM because of death before the onset of the disease. An expression of the probability that a newborn child will become afflicted with DM during his lifetime is arrived at by determining the life table expectancy for DM. The calculation shown in Table 35 is based on the life tables for the Swedish population for the 5-year period 1960-64.

## Inferences from the study of death certificates

Mortality statistics which are based on data concerning both primary (underlying) causes of death and contributory causes can be utilized for estimating the prevalence and incidence of DM in the

general population. At least in the case of Sweden, the analysis of such mortality statistics seems to be the most efficient method for determining the morbidity risks for DM and the prevalence (at adult ages) of clinically manifest DM by sex and age.

Mortality statistics which are based on data concerning primary causes of death alone on the other hand are not sufficiently informative (in respect of DM). The number of deaths for which DM is given as the primary cause does not cover more than 30-35 per cent of the total number of deaths for which the occurrence of DM is stated in the certificates (as the primary cause of death or as a contributory cause). The percentage varies markedly with age, it shows considerable geographical variations and, in addition, considerable variations with time.

A special processing of data from death certificates for the 3 year period 1961-63 was performed and the resulting statistics were analysed in detail with regard to sex, age, the primary cause of death, and domicile. The period 1961-63 presented normal mortality (viewed against the trend) and it cannot reasonably be suspected that the data are disturbed by any acceleration or delay effects.

There exist gaps in the recording of DM in the death certificates, connected with variations of the completeness of the registration by age, primary cause of death and domicile. In the main, however, these gaps are capable of being evaluated—apart from the possible occurrence of a general underregistration irrespective of age, cause, domicile and time.

The prevalence of DM recorded in the death certificates is lower in Stockholm City and in the south western part of Sweden (which includes the cities of Gothenburg and Malmö) than in other parts of the country. Apart from the (rather unlikely) possibility of a lower prevalence of DM in south western Sweden, the statistics give clear evidence that the total morbidity risk for clinically manifest DM (the aggregate morbidity risk up to age 90) must exceed 5.5 per cent for males and 10 per cent for females. With reasonable assumptions concerning the age gaps occurring at advanced ages and the excess mortality among diabetics, the best estimate seems to be that the total morbidity risk for clinically manifest DM (the risk up to age 90) is at least 6.5 per cent for males and about 13 per cent for females. The aggregate risk up to age 50 is 2.1 per cent for males and 1.9 per cent for females, and up to age 70 it is 4.7 per cent for males and 9.0 per cent for females.

The life table expectancy at birth for contracting clinically manifest DM is calculated at 4.8 per cent for males and 10.3 per cent for females.

At the end of 1965 the number of persons with clinically manifest DM must have been about 159 000 (59 000 males and 100 000 females) or 2.05 per cent of the total population (1.52 per cent for

males, 2.57 per cent for females). For ages 15 and over the percentage is 2.60 (1.95 for males 3.24 for females).

It should be emphasized that all these data apply to *clinically manifest DM* and are wholly based on reports of deaths from DM (primary and contributory causes) in the death certificates, analysis of probable gaps in these reports (connected with underregistration in certain geographical areas, for certain primary causes of death and for deaths at advanced ages) and reasonable assumptions concerning the excess mortality among diabetics.

The overall excess mortality among persons with clinically manifest DM cannot reasonably exceed 15 per cent (which, however, does not preclude that at ages below 50 the average excess mortality can be 200 per cent or more).

In our opinion the results reported in this chapter with regard to the morbidity risks for DM and its prevalence in Sweden at adult ages are to be considered as adequate and very reliable.<sup>1</sup>

<sup>1</sup> Of course it cannot be ruled out on the basis of mortality statistics alone that in reality the prevalence of clinically manifest DM may be a *little* higher. Hence from a purely theoretical point of view our results should be designated as giving minimum figures. As will have appeared from the preceding discussion however, the general underregistration can be expected to have been comparatively moderate.

# Patients, symptoms and complications

As already stated the material for our clinical study covers 3 759 patients—inpatients as well as outpatients—registered at the four county hospitals of Vänersborg (P) Värje (G) Falun (W) and Östersund (Z), in the main over the period 1931–56. All these patients presented both glycosuria and hyperglycaemia.

## Age at onset

Data on the age at onset of DM are included in Tables 5 and 7. The age distributions must of course be seen against the background of the size and age composition of the population in the admis-

sion areas. Further, it should be taken into account that our series comprises only patients admitted to departments of internal medicine. As a concentrated description of the series certain data on age at onset are shown in Table 36. In addition to the absolute numbers of patients by sex, hospital and types by age at onset (juvenile 0–14, early adult 15–39, late 40 and over) there are given by sex and hospital the percentage distributions by age at onset. Further, the mean age at onset is shown by sex, hospital and types by age at onset.

The types with juvenile, early adult and late onset cover 11, 27 and 62 per cent of the males and 8, 15 and 77 per cent of

Table 36 Age at onset of DM: averages and percentage distributions

Sex and age at onset	Number of patients					Percentage distribution by age at onset					Mean age at onset				
	Hospital					Hospital					Hospital				
	All	P	G	W	Z	All	P	G	W	Z	All	P	G	W	Z
<i>Males</i>															
0–14	183	50	46	51	36	10.9	12	15	11	7	8.8	8.5	8.3	9.0	9.6
15–39	450	117	77	153	103	26.8	29	25	33	21	27.2	27.7	26.4	27.0	27.5
40–	1 047	241	181	266	359	62.3	59	60	56	72	58.5	57.9	59.3	54.9	61.2
Total	1 680	408	304	470	498	100.0	100	100	100	100	44.7	43.2	43.2	40.8	50.5
<i>Females</i>															
0–14	169	42	40	55	32	8.1	9	9	10	5	8.5	8.1	8.8	8.4	8.9
15–39	319	79	66	111	63	15.3	17	13	20	10	26.7	26.5	26.5	27.0	26.9
40–	1 591	338	327	400	526	76.6	74	76	70	85	60.4	59.8	60.7	58.0	62.5
Total	2 079	459	433	566	621	100.0	100	100	100	100	51.1	49.3	50.7	47.1	56.2



the females. The shares for late onset are considerably higher at Östersund (Z) viz 72 per cent for males and 85 per cent for females and they are somewhat lower at Falun (W), viz 56 and 70 per cent, than at Vänersborg (P) and Växjö (G).

The average age at onset is 44.7 for males and 51.1 for females. It is higher at Östersund (50.5 and 56.2) and lower at Falun (40.8 and 47.1) while Vänersborg (43.2 and 49.3) and Växjö (43.2 and 50.7) occupy an intermediate position. With regard to the three types by age at onset the figures are very similar in the juvenile onset and the early adult-onset groups, whilst certain differences similar to those found for the whole series are seen in the late onset group with higher average ages at Östersund and lower average ages at Falun. Since the share of patients with late onset is also higher at Östersund and lower at Falun the differences become more accentuated for the whole series, irrespective of age at onset.

## Hyperglycaemia, glucose tolerance tests

In planning the study much time was devoted to discussing whether the blood sugar values registered should be included in the data processing and, if so, how.

The fasting blood sugar level is a valuable diagnostic criterion: most textbooks agree that in healthy persons it should not exceed 0.11 per cent. However when dealing with DM patients many of whom are treated with insulin or other antidiabetic remedies the blood sugar will often be influenced in a way that is very difficult to evaluate (at least

quantitatively). It is a fairly frequent phenomenon that a well balanced DM patient (‘good control’) sometimes presents a high fasting blood sugar value although the treatment has been kept wholly unchanged, generally the explanation is that during the night the patient has had hypoglycaemia—of which he himself is unaware—and that this has started a strong reaction (‘Gegenregulation’) with secretion of glucagon resulting in considerable hyperglycaemia.

Since for these reasons a statistical analysis of blood sugar values found in a series of the type studied here did not seem to be of any real significance, we decided to leave them out of the registration. A classification of the patients on the basis of, for instance, their average blood sugar value during a certain duration period could scarcely be expected to be efficient and so we limited the registration to cover the occurrence of hyperglycaemia (and hypoglycaemia).<sup>1</sup>

As a rule the blood sugar has been determined according to Hagedorn Jensen or, during the early thirties according to Folin-Wu. The methods of Bang and Somogyi-Nelson have been applied only exceptionally.

According to Somogyi-Nelson the known non-glucose reducing substances are eliminated before the true blood sugar is determined. However these non-glucose reducing substances occur in the blood from diabetics and non-diabetics in equal quantities (Haunz & Keranen 1950).

Hyperglycaemia has been considered to be present where the fasting blood sugar exceeds 0.11 per cent.

<sup>1</sup> A study of blood glucose levels in adults in the U.S.A. has recently been published by Garst (1966). Cf. also Nilsson *et al.* 1964, 1967.

Oral glucose tolerance tests (GTT) have been applied in doubtful cases

Several investigators have used glucose quantities of 1 to 175 grammes per kg body weight. Others have recommended a dose of 50 to 200 grammes irrespective of the body weight. In the present series a dosage of 1 gramme per kg body weight has as a rule been applied.

Experience has shown that the results depend on the quantity of glucose to only a slight degree provided that it is not too small (below 25 grammes). Generally, a series of blood sugar tests are taken viz. after 30 45 60 75, 90 120 and 180 (sometimes also 240) minutes.

On the evaluation of the results, special attention has been paid to the preceding fasting value and particular importance has been attached to the 2 hour value. If the test is to be considered normal, this must not exceed the fasting value.

Care has been taken to ensure that the patient shall have eaten a sufficient amount of carbohydrates during the days before the test.

The oral GTT has been the topic of many discussions and varying technical procedures have been employed. It has been argued that the test may be ameliorated by giving the glucose dose in two parts with half an hour's interval. Fajans and Conn (1954 1961 1965) have administered cortisone before supplying the glucose in order to increase the reliability of the test.

The intravenous GTT seems to have been introduced by Jørgensen and Plum in 1922. Apparently however it was difficult to arrive at a generally accepted interpretation of the results and so the method was abandoned. It was reinvestigated by Hamilton and Stein in 1942 and during the last ten years there have been many studies of the techniques of the intravenous GTT and its

diagnostic value for instance by Iklos and Luft (1957) and Lunell (1966).

Hamilton and Stein (1942) showed that within 25-60 minutes after the injection of 20 grammes glucose intravenously the blood sugar values decreased exponentially with time (hence that in this interval the logarithms of the blood sugar values were a linear function of the time) this rate of removal of glucose  $k$  is lower among diabetics than among non-diabetics. If the blood sugar value is denoted by  $C$  and the time (in minutes) after the injection by  $t$  the percentage rate  $k$  is determined from the formula

$$k = -100 \frac{d(\ln C)}{dt}$$

In healthy subjects  $k$  is below 1.0 (A  $k$  value of 1.0 corresponds to a reduction of the blood sugar value to one half in 69.3 minutes).

Quite apart from other aspects it is of course very convenient to be able to use a concentrated measure such as the quantity  $k$  in the analysis of blood sugar data.

Samols (1965) has shown that after the injection of 25 grammes glucose there is found a marked increase of the insulin content in the blood plasma. This indicates that the value of  $k$  is an expression of the quantity of insulin that can be mobilized.

Unfortunately the intravenous GTT is not physiologically adequate as is the case with the oral test. Injected directly into the blood, the glucose does not pass through the stomach and the intestinal mucous membrane as glucose and all its mother substances do under physiological conditions. In a sense the ultimate purpose of studies of the carbohydrate metabolism should be to arrive at information concerning the ability of the body to utilize carbohydrates when making use of all available resources and in this respect the oral test seems to be more appropriate than the intravenous one.

Dupre and Beck (1964 1966) have shown that an agent obtained from porcine duodenal mucosa biologically distinguishable from secretin and pancreozymin causes a significant reduction in the rate of glucose

disappearance in healthy men. This material contained no immunologically active insulin. The results support the theory that humoral secretion of the intestines is involved in the normal response to ingestion of glucose.

It will be seen to be a clear disadvantage of the intravenous GTT that factors of this kind cannot be taken into account.

Intravenous GTT has been used in our hospital series to only a comparatively small extent. Therefore, a discussion of the value of this test in clinical practice would fall outside the scope of the present study.

A review article covering the recent literature on the release of insulin as mediated by secretin, glucagon and other gastrointestinal hormones has recently been published by Jorpes and Mutt (1967).

## Glycosuria, "control"

In the literature, especially in papers from the Joslin clinic, there are often detailed data on different degrees of control. As a rule both the blood sugar level and the urinary excretion of glucose are taken into account. Use is made of such expressions as excellent control, good control, fair control, poor control.

The problems concerning the degree of control have in a sense become more complicated during recent years, as already mentioned. It has been shown that the fatty tissue plays an important role in respect of the DM metabolism. During the period from which our material originates the treatment of DM was largely directed to the elimination of hyperglycaemia and glycosuria. As a rule there are in the case records entries con-

cerning the 24 hour urinary excretion of glucose, the average of these values for admissions (occasions) during each 5 year duration period has been taken as an expression of the degree of control obtained in the period. In view of the character of the registrations a more exact parameter of a quantitative nature cannot be applied. According to the averages mentioned the registrations (duration cards) have been classified into three types viz:

Degree of control	Urinary excretion of glucose per 24 hours
Good	Not exceeding 25 grammes
Fair	26-50 grammes
Poor	Exceeding 50 grammes

Using this terminology, Tables 37 and 38 show the percentage distribution by control\* (glycosuria) within groups by sex, age at onset and duration and—for durations 0-4—within groups by sex, age at onset and hospital.

To avoid misunderstanding it should be stressed that the expression control is not applied here to give information concerning the time intervals between the patient's visits to the hospital but is solely intended to characterize the status of the patient in respect of the occurrence of glycosuria.

As will be seen from Table 37 the control has been better among patients with late onset than among patients with juvenile or early adult onset. In the last-mentioned groups the control seems to have been somewhat better in the higher durations than during the first 5 or 10 years after the onset of DM and somewhat better among males than among females. In the late onset group on the

**Table 37** *Percentage distribution by "control" (glycosuria) within groups by sex age at onset and duration*

Sex and duration	Juvenile onset (0-14)				Early adult onset (15-39)				Late onset (40-)			
	No	Control ( )			No	Control ( )			No	Control ( )		
		Good	Fair	Poor		Good	Fair	Poor		Good	Fair	Poor
<b>Males</b>												
0-4	133	47	28	25	386	46	31	23	944	61	28	11
5-9	126	46	25	29	252	51	29	20	469	66	21	13
10-14	121	54	31	15	173	60	23	17	212	64	22	14
15-19	87	60	22	18	124	64	23	13	101	66	27	7
20-24	48	56	21	23	71	70	17	13	37	57	26	16
25-	33	76	18	6	69	66	25	9	12	92	-	8
Total	548	53	26	21	1 075	54	27	19	1 775	63	25	12
<b>Females</b>												
0-4	125	47	35	18	251	40	36	24	1 423	72	21	7
5-9	115	44	35	21	186	46	31	23	782	67	24	9
10-14	114	51	27	22	131	46	37	17	340	69	24	7
15-19	68	47	40	13	88	53	34	13	142	72	22	6
20-24	37	54	38	8	58	60	30	10	33	73	21	6
25-	26	73	12	15	58	74	19	7	10	80	20	-
Total	485	49	33	18	772	48	33	19	2 730	71	22	7
Urinary excretion of glucose per 24 hours					Good control : not exceeding 25 g							
					Fair control : 26-50 g							
					Poor control : exceeding 50 g							

**Table 38** *Percentage distribution by "control" (glycosuria) within groups by sex, age at onset and hospital duration 0-4*

Sex and hospital	Juvenile onset (0-14)				Early adult onset (15-39)				Late onset (40-)			
	No	Control ( )			No	Control ( )			No	Control ( )		
		Good	Fair	Poor		Good	Fair	Poor		Good	Fair	Poor
<b>Males</b>												
P	47	58	19	23	115	55	27	18	234	67	23	10
G	33	36	18	46	66	47	12	41	165	71	15	14
W	23	35	30	35	115	24	41	35	214	35	41	24
Z	30	50	50	-	90	60	39	1	331	67	31	2
Total	133	47	28	25	386	46	31	23	944	61	28	11
<b>Females</b>												
P	39	43	44	13	73	45	26	27	336	73	22	5
G	28	43	21	36	42	52	19	24	286	82	10	8
W	31	23	55	22	82	27	47	26	312	52	10	8
Z	27	15	15	-	54	45	44	11	489	79	21	-
Total	125	47	35	18	251	40	36	24	1 423	72	21	7

other hand the control has been better exist marked differences between the four among females than among males hospitals The registered frequency of

From Table 38 it is evident that there poor control at duration 0-4 years is

higher at Falun (W) and Vaxjo (G) than at Vanersborg (P). It is very low at Östersund (Z) or 2 per cent against an average of 17 per cent for the other three hospitals, in part this difference is due to the composition of the series, with comparatively many cases of late onset at Östersund. The registered frequency of "good control" is fairly similar at the hospitals of Vanersborg (P), Vaxjo (G) and Östersund (Z) but considerably lower at Falun (W) where on the other hand the figures for "fair control" are comparatively high.

## Heredity

It has long been assumed that there are important hereditary factors in DM, and therefore it has been a routine procedure to interrogate the patients and if possible their family members about the occurrence of DM among relatives.

However, the completeness of the entries in the case records varies consider-

ably. At Vaxjo (G) both positive and negative answers have regularly been registered. At Falun (W) "interesting information is carefully recorded, in particular where several family members and relatives have been reported as afflicted with DM, whereas in general less interesting information is omitted. At Östersund (Z) the registration seems to have been very incomplete, and for this reason the material was supplemented by a special questioning of patients visiting the hospital in 1958. At Vanersborg (P), finally, interviews have been performed over a long period.

The prevailing opinion among clinicians has been that hereditary DM is conditioned by an autosomal recessive gene. Hence it is natural that interest has been concentrated on the occurrence of DM among the sibs of the patients. It is also understandable that the registration often does not give full information concerning the sex of the affected relatives and their exact blood relationship to the patients.

Table 39 Diabetic relatives of DM patients at Vanersborg

	Male patients					Female patients				
	All	Age at onset				All	Age at onset			
		0-14	15-39	40			0-14	15-39	40	
Number of patients	408	50	117	241		459	42	79	338	
Ditto: information available	388	48	115	225		421	36	71	314	
Number of patients with DM among relatives										
Paternal	63	12	24	27		60	7	19	34	
Maternal	70	12	23	35		70	6	10	54	
Both sides	13	5	6	2		14	1	2	11	
Total	120	19	41	60		116	12	27	77	
Percentage of patients with DM among relatives										
Paternal	16	25	31	12		14	19	27	11	
Maternal	18	25	20	16		17	17	14	17	
Both sides	3	10	5	1		3	3	3	4	
Total	31	40	36	27		34	33	38	24	

for instance there are many data of the type child, 'two sibs, cousin, maternal cousin, 'brother's children etc

A summary of the data from Vänersborg in respect of the information concerning DM among relatives other than sibs and children is given in Table 39. Answers were obtained for 388 of the 408 male patients and 421 of the 459 female patients, the percentages are calculated on the basis of these answers.

DM among relatives other than sibs and children was registered for 31 per cent of the male patients and 28 per cent of the female patients. The information is less complete for patients with late onset (27 and 24 per cent) than for patients with juvenile or early adult onset (37 and 36 per cent). On the paternal side DM was registered for 16 per cent of the male patients (for 13 per cent on the paternal side alone) and for 14 per cent of the female patients (for 11 per cent on the paternal side alone). On the maternal side (the maternal side alone) DM was registered for 18 (15) per cent of the male patients and for 17 (14) per cent of the female patients.

For patients with DM relatives on the paternal side (63 males and 60 females) the mean number of paternal DM relatives is 1.3. For patients with DM relatives on the maternal side (70 males and 70 females) the mean number of maternal DM relatives is 1.2.

These data seem to argue in favour of a theory of autosomal inheritance. However, it should be kept in mind that in several instances it is a question of comparatively distant relatives (for instance a paternal first cousin). The problem of the hereditary nature of DM will be subjected

to closer scrutiny in Chapter IX, in this connection data from two of the investigation hospitals will also be presented.

## Overweight

The problem of overweight among DM patients has interested diabetologists for many years. Both in his textbook *Treatment of Diabetes* and elsewhere, Joslin has emphasized that overweight plays an important role for the occurrence of clinical DM. He points out that overweight precedes the onset of DM, after which there is often a loss of weight; this may be either a result of a diet poor in calories or a consequence of the reduced ability of the body to metabolize the administered carbohydrates.

The classification by overweight is performed by comparison with the normal weight according to Broca's formula  $W = H - 100$ , where  $H$  is height (in cm) and  $W$  is weight (in kg). Overweight is considered to exist where the registered weight exceeds the normal value by 10 kg or more.<sup>1</sup>

Data on the height of the patients are not always registered; in particular there are gaps concerning the children. Among patients aged 21-60 the mean values of the registered height are  $173.8 \pm 0.34$  cm for males and  $161.4 \pm 0.25$  cm for females. These values are significantly below the figures found for the general Swedish population. However, it seems likely that the data on height have been more completely registered in the case of low stature than in the case of average

<sup>1</sup> For patients under 20 years of age modified criteria were applied.




Fig 16 Frequency of obesity by sex, age at onset and duration  
The plotting is made against the mean ages given in Table 41

skoga (in Örebro County T) With Broca's formula, overweight is considered to exist where the registered weight exceeds the normal value by 11 kg or more

Boe, Humerfelt and Wedervang in their extensive study of the general population of the city of Bergen, Norway, registered the height, weight and blood pressure of 9 783 men and 13 845 women; this part of their series relates to 1951. The authors determined the 'normal' weight with the formula  $W = 0.00228 H^3$  but since the presentation of the data is excellent it is easy to calculate the frequencies of overweight 10 kg or more according to Broca's rule.

The data are illustrated in Figs 15 and 16.

As can be seen from Table 40 and Fig 15 the three series show a rather similar picture in respect of males, whereas in respect of females the frequency of obesity is lower among the DM patients than in the general population of Bergen and among the Karlskoga patients. Evidently the DM patients do not present over

weight to an extent that exceeds what is to be found in the general population or among 'ordinary' patients in a department of internal medicine. Whether or not there has been a higher frequency of overweight among the DM patients *before* the onset of the disease is a question that cannot be determined on the basis of the registered data.

Jorde (1961) has performed a comprehensive survey of DM patients in Bergen; his results show overweight frequencies by sex and age which on the whole agree well with the figures found by Boe, Humerfelt and Wedervang for the general population.

## Constitutional type

As was to be expected, the case records in respect of constitutional type proved to be very incomplete. It is only natural that in a registration which is intended to show anamnestic data of relevance for the onset and development of a disease and clinical

data of importance for the treatment to be applied, "normal" findings should be omitted if they are not considered to be particularly interesting (or, for one reason or another, the registration is intentionally designed to include the data in question)

On the basis of the entries in the case records we have tried to differentiate between four body types viz (a) asthenic, (b) pyknic, (c) athletic, and (d) hormonal

The expression "hormonal type" here to denote patients who are of small stature, often with a certain overactivity and an infantile mentality—a type which is not seldom seen in diabetic children to a certain extent these findings recall Cushing's disease<sup>1</sup>

The results of this classification of patients with duration 0-4 years

<sup>1</sup> In addition there are included in this type some patients with Turner's syndrome

Table 42 Distribution by registered constitutional type

Sex and age at onset	Hospital	Number of patients (duration 0-4)						Percentage distribution			
		Total	Constitutional type				Non speci- fied	Asth	Pykn.	Athl.	
			Non speci- fied	Asth.	Pykn.	Athl.					Horm
<i>Males</i>											
0-14	P	47	46	-	-	1	-	98	-	-	2
	G	33	32	1	-	-	-	97	3	-	-
	W	23	21	2	-	-	-	91	9	-	-
	Z	30	25	5	-	-	-	83	17	-	-
15-39	P	115	95	15	2	2	1	83	13	2	2
	G	66	47	15	2	1	1	71	23	3	3
	W	115	109	5	-	1	-	95	4	-	1
	Z	90	53	29	7	-	1	59	32	8	-
40-	P	234	190	10	22	12	-	81	4	9	5
	G	165	127	14	12	11	1	77	8	7	7
	W	214	202	8	3	-	1	94	4	1	-
	Z	331	232	33	60	6	-	70	10	18	2
	Total	1 463	1 179	137	108	34	5	81	9	7	2
	P G Z	1 001	744	116	105	32	4	74	12	10	3
<i>Females</i>											
0-14	P	39	37	-	-	-	2	95	-	-	-
	G	28	28	-	-	-	-	100	-	-	-
	W	31	24	2	1	-	3	81	6	3	-
	Z	27	24	1	1	-	1	89	4	4	-
15-39	P	73	64	4	3	1	1	88	5	4	1
	G	42	34	7	1	-	-	81	17	2	-
	W	82	79	3	-	-	-	96	4	-	-
	Z	54	30	16	7	-	1	56	30	13	-
40-	P	336	275	6	47	3	5	82	2	14	1
	G	286	231	13	41	-	1	81	5	14	-
	W	312	299	4	7	1	1	96	1	2	0
	Z	489	284	21	180	-	4	58	4	37	-



shown in Table 42. The data are given by sex, hospital and age at onset (juvenile, early adult, late). As will be seen from the table, the information in the case records is not sufficient to allow a classification into one of the four body types mentioned for more than 19 per cent of the males and 22 per cent of the females. It can further be seen that the data from the four hospitals differ markedly in several respects (which may serve as a warning against the use of case record data without a close scrutiny of the material). Falun (W) shows a considerably lower share of specified types than do the other three hospitals. Östersund (Z) presents comparatively high percentages for the pyknic type (or, rather, a more complete specification).

Obviously it is difficult to draw definite conclusions from the data adduced in Table 42, but it might be said that they are consistent with current views that among diabetics the asthenic type preponderates at younger ages, whilst the pyknic type is frequently found in late onset diabetes.

## Blood pressure

In a way it is somewhat surprising that in general textbooks on DM little attention is paid to the questions of blood pressure and hypertension. As a rule, statistical data on the distribution by blood pressure for different categories of diabetics are lacking.

In *The treatment of diabetes mellitus* (Joslin, Root, White & Marble 1959) Root and Bradley write as follows (p. 427):

The harmful effects of persistent arterial hypertension in the diabetic have long been known. As is generally true, systolic hypertension, especially in females, has proven less serious than elevation of diastolic pressure.

The sequence of events is important: (1) *Diabetes itself* produces hypertension of the renal type because of its influence on the premature development of arteriolar disease in the kidney; (2) Diastolic hypertension, whether (a) of the essential or 'primary' type, (not caused by diabetes) or (b) produced by renal arteriolar disease (caused in part by diabetes) accelerates atherosclerosis.

Mårtensson (1950), in a study of cardiovascular and renal findings in long standing DM, considers hypertension to be present when the systolic blood pressure exceeds 150 mm Hg or the diastolic pressure exceeds 90 mm Hg. However, in the processing of the data he uses the systolic pressure alone. The series covers 110 males and 109 females aged 16-84 with a duration of DM 15-34 years. Mårtensson found hypertension to be present for 48 per cent of the males and 65 per cent of the females.

Lundbæk (1953), investigating long-term diabetes in a series of 164 patients, found hypertension in 48 per cent of the patients. Hypertension was considered to exist where the systolic pressure was more than 150 mm Hg or the diastolic pressure was more than 100 mm Hg. Lundbæk found significant differences between males and females with a higher prevalence of hypertension among females, especially those above 50 years of age, no correlation between the duration of DM (in the interval 15-25 years) and hypertension was found.

In a study dealing with atrophic skin lesions in the lower extremities of diabetics, Melin (1964) gives data on hyper-

tension His series covers 293 patients (130 males and 163 females) aged 10-90, hypertension is defined as a diastolic pressure of 100 mm Hg or over The prevalence of hypertension increased with age but was not found to be connected with the duration of DM The prevalence was higher among females than among males at ages over 60 it was 57 per cent (47 out of 82) and 34 per cent (14 out of 41) respectively

At the departments of internal medicine in the Swedish county hospitals it is a routine procedure at least for inpatients for the blood pressure to be measured and registered With regard to diabetics who are examined or treated as outpatients it is a rule that as far as possible measurements and registrations of blood pressure should be performed There are certain gaps in the case records but a scrutiny has revealed that such gaps are generally found only for patients who at a later examination (or at an examination some weeks or months before) have had "normal blood pressure There are very few patients for whom no entry at all is found in a 5 year registration period (duration 0-4 5-9 etc) For these reasons absence of information during a registration period has been interpreted as representing "normal blood pressure

It is nowadays generally agreed that an evaluation of the occurrence of hypertension in DM patients should be based on the diastolic pressure

In transferring the case record data on diastolic pressure to the duration cards we used the arithmetic mean of the registrations during each admission and then again the arithmetic mean of these during each registration period At both

these procedures the values were grouped into classes with the range 10 mm Hg Thus implies that on average the class limits are 75, 85, 95, 105 etc which was considered advantageous because there was an obvious tendency to state the values in "whole tens" (70, 80, 90, 100, etc)<sup>1</sup> Hence with the direct use of the single measurements there would have arisen a large difference between for instance the two frequency series 100 and over and over 100 The method adopted can be said to constitute a graduation which at least approximately eliminates the effects of the "rounding-off" in the primary data

In Table 43 data on diastolic blood pressure are shown by sex and age at durations 0-4 and 10-14 years The table shows the prevalence of diastolic pressures of at least 95 and at least 105 mm Hg The frequency of hypertension increases with age, at ages above 40 the frequency is higher among females than among males An interesting feature is that at ages above 40 the frequency of hypertension is significantly higher among patients with DM duration 0-4 years than among patients of the same age with DM duration 10-14 years It should be noticed here that in each of the two duration groups a patient is counted only once but that the greater part of the

<sup>1</sup> It may be noted that the same phenomenon is to be seen in the expert study on blood pressure in men aged 50 recently published by Tibblin (1967) Tibblin applied very strict rules for the measurements The blood pressure was read to the nearest 5 mm Hg more precise readings were considered to be of little value Nevertheless for 841 men the diastolic and systolic pressures were even multiples of 5 in no fewer than 467 cases (55.5 per cent) and 439 cases (53.4 per cent) respectively

patients with duration 10-14 are also included with duration 0-4

The frequency figures in Table 43 are illustrated in Fig 17

For the three types by age at onset (juvenile, early adult, late) data on the frequency of hypertension are given in Table 44 by sex and the duration of DM For juvenile onset there is seen an obvious rise in the frequency with duration, in particular from duration 5-9 to duration 15-19, here the age effect found in Table 43 must be insignificant For early adult onset the rise in frequency, which can be seen from the table, is fairly similar, but from Fig 17 it is apparent that the greater part of it is due to the age effect For late onset finally, the frequency is markedly higher at duration 0-4 years than at duration 5 years or over It might be suspected that this was due to peculiarities in respect

of the age distribution, viz. that the patients with duration 0-4 are older than are the patients with duration 5 and over However, this is not the case, in Table 44 there is stated the mean age of the patients in each group by sex, age at onset and duration (below 25 years), as can be seen, the 'selection' in respect of age composition, arising from deaths and the gradually increasing admission of elderly patients, gives the result that from duration 0-4 to duration 5-9 the mean age goes up for males by 2.3 years (from 61.1 to 63.4) and for females by 1.8 years (from 63.1 to 64.9) Thus, there is a displacement in the age composition, since the mean age does not increase by 5 years, but there must be another type of selection too The data do not admit of a judgment being made between the three possible explanations, viz. (1) that

Table 43 Frequency of hypertension in duration groups 0-4 and 10-14 by sex and age

Average age	Males						Females					
	Number with duration		Diastolic blood pressure per cent				Number with duration		Diastolic blood pressure per cent			
			Dur 0-4		Dur 10-14				Dur 0-4		Dur 10-14	
	0-4	10-14	95-	105-	95	105	0-4	10-14	95-	105-	95-	105-
4	16		-	-			15		-	-		
9	44		-	-			56		4	4		
14	73	19	3	-	11	-	54	16	4	-	25	6
19	78	48	3	-	17	13	53	56	9	2	21	7
24	81	54	3	-	20	4	50	42	8	2	24	10
29	79	36	8	-	19	8	43	24	15	3	13	13
34	80	34	15	1	6	-	55	30	7	2	17	7
39	81	35	15	5	23	3	50	21	18	4	10	-
44	99	37	30	11	24	11	71	26	41	14	27	8
49	111	31	36	11	19	13	116	30	57	28	41	13
54	131	49	46	21	24	8	183	36	68	36	36	17
59	144	33	53	27	42	18	249	51	63	38	55	35
64	142	47	44	15	40	26	246	51	66	43	56	40
69	125	43	57	28	42	28	261	86	72	42	55	29
74	98	20	63	32	35	30	183	46	69	47	63	35
79	65	16	55	29	25	13	94	25	74	41	48	28
84-	19	4	21	11	-	-	20	11	75	30	36	27
Total	1 463	506	33	14	25	12	1 799	585	54	31	41	22





Fig 17 Frequency of hypertension by sex and age

(a) Diastolic blood pressure 95 or over

(b) Diastolic blood pressure 105 or over

B1=Bergen Group 1 (1950) B2=Bergen Group 2 (1951)

Table 44 Frequency of hypertension by sex, age at onset and duration

Age at onset	Duration	Males						Females					
		All	Mean age	Diastolic blood pressure				All	Mean age	Diastolic blood pressure			
				Number		Per cent				Number		Per cent	
				95-	105-	95-	105-			95-	105-	95-	105-
0-14	0-4	133	11.1	2	-	2	-	125	10.6	4	2	3	2
	5-9	126	16.0	7	-	6	-	115	15.7	12	2	10	8
	10-14	121	20.4	21	8	17	7	114	20.1	26	9	23	8
	15-19	87	25.0	20	11	23	13	66	23.0	23	9	34	13
	20-24	48	30.4	13	7	27	15	37	29.7	16	6	43	16
	25-	33		7	3	20	9	26		6	2	23	8
	Total	548		70	29	13	5	485		87	30	18	6
15-39	0-4	386	29.2	33	4	9	1	251	29.0	28	6	11	2
	5-9	252	34.8	24	7	10	3	186	33.3	20	5	16	3
	10-14	173	38.8	32	12	18	7	131	39.3	30	11	23	8
	15-19	124	42.8	33	15	27	12	88	46.2	35	15	40	17
	20-24	71	47.0	20	8	28	11	58	48.0	27	11	47	19
	25-	69		28	11	41	16	58		28	12	48	21
	Total	1 075		170	57	16	5	772		177	60	23	8
40-	0-4	944	61.1	446	199	47	21	1 423	63.1	940	546	66	38
	5-9	469	63.4	173	81	37	17	782	64.9	409	217	52	28
	10-14	212	64.4	74	42	35	20	340	66.6	181	109	53	32
	15-19	101	67.4	38	21	38	21	142	69.3	80	46	56	32
	20-24	37	70.9	11	7	30	19	33	70.8	16	9	48	27
	25-	12		4	1	33	8	10		4	3	40	30
	Total	1 775		746	351	42	20	2 730		1 630	930	60	34
All	Total	3 398		986	437	29	13	3 987		1,894	1 020	48	26

the treatment brings about a reduction of hypertension, at least for a certain share of the patients, (2) that there is an excess mortality among DM patients with hypertension and (3) that there is a selective admission in so far as among new cases of DM there is a greater probability of seeking aid at a county hospital if the patient is hypertensive than if he is not. Very likely the frequency data are influenced by all these circumstances—and possibly their relative importance may be different for different parts of the series (the four investigation hospitals, the distance from the patient's home to the hospital, and so on).

The data in Table 44 are illustrated in

Fig 18 (for durations below 25 years), in order to take into account the age effect, the plotting is made against the mean ages given in the table.

As stated already in connection with the discussion of obesity, the Bergen study by Boe, Humerfelt and Wedervang is not only thorough (as is often the case with epidemiological investigations) but also is published in a way that makes it possible for others to utilize the data after rearrangement (which is not the case with a great many other such investigations). From their data we have calculated the frequencies of diastolic blood pressure 95 and over, and 105 and over, in Fig 17 these data are compared with our




Fig 18 Frequency of hypertension by sex age at onset and duration

figures for DM patients as shown in Table 43

Tibblin's study of a representative sample of 50-year-old men in Gothenburg (1967) may be used for comparison. As already mentioned (p 133) the blood pressure was read to the nearest 5 mm Hg. The distribution according to diastolic pressure was as follows

Diastolic pressure	-80	85	90	95	100	105	110-	Total
Number	205	117	178	129	70	44	98	841

The frequencies of diastolic pressure 105.0 or over and 95.0 or over would thus be 14 per cent and 33 per cent respectively

Freedman, Moulton and Spencer (1958) investigated the occurrence of hypertension (diastolic blood pressure of 100 mm Hg or more) in diabetic patients attending the University College Hospital Clinic in London and a control general hospital popula-

tion. According to the authors a strong impression was gained that hypertension was more common in diabetics than in the general hospital population. Their statistical analysis revealed that this was largely a false impression up to 69 years of age in both sexes; there was no significant difference in the hypertension frequencies. By sex and age their data are summarized in the following table (see next page)

Although the frequency figures for hypertension (diastolic blood pressure 95 and over or 105 and over) may appear to be high it can be seen from Fig 17 that they agree fairly well with the frequencies existing in the general population. The differences may in part be caused by the selective factors already mentioned and it does not seem justifiable to conclude from the data adduced

Attained age	Number of patients				Hypertensive per cent			
	M		F		M		F	
	G	D	G	D	G	D	G	D
0-29	188	98	244	98	1	~	~	~
30-39	180	70	227	68	1	1	4	1
40-49	178	74	236	111	5	7	10	6
50-59	147	105	239	211	14	16	23	17
60-69	98	65	161	133	23	31	36	37
70-	36	16	97	51	31	81	38	92
Total	827	428	1,204	672	8	13	15	21

G = General hospital population (controls)

D = Diabetic patients

Hypertensive = Diastolic blood pressure 100 mm Hg or more

After Freedman Moulton and Spencer (1958)

here that DM *per se* causes hypertension. From a series of clinical studies it will appear that the specific renal complications of DM (diabetic nephropathy) do not give rise to hypertension until the pathological changes have progressed so far that renal insufficiency occurs.

## Menarche, childbirth, and menopause

Data on the age at menarche and menopause are not systematically included in the case records. On the whole, the registration seems to have been restricted to cover the occurrence of late menarche and early menopause. At Vänersborg (P) special interviews were made in 1956-60 for a series of unselected patients who visited the hospital for control during that period.

Data on pregnancies before and after the onset of DM (or before and after the first admission to the hospital) and on the weights of the children are registered to a great extent but not in a form suited to statistical processing. There are ob-

viously gaps in respect of the registration of abortions, and often the mother's age at childbirth (or the age of the child) is not given for children born before the first admission to the hospital. Therefore, the analysis will be restricted to the Vänersborg material, where so far as possible information has been assembled from earlier visits to other hospitals and supplemented by means of 'retrospective' interviews.

## Menarche

At Vänersborg, interview answers were obtained from 147 patients, viz. 27 with juvenile onset, 43 with early adult onset, and 75 with late onset. In these three groups menarche at age 16 or over was registered for 56 per cent, 16 per cent and 32 per cent, the mean age at menarche was 15.9, 14.0 and 15.0, respectively. For the 17 patients with age at onset below 10 the mean age at menarche was 16.3.

In Sweden as in many other countries, a gradual lowering of the menarche age has occurred during the last few decades. In evaluating the figures for early adult

and late onset DM this circumstance must be taken into account. In respect of juvenile onset DM it is apparent that the menarche often occurs later than is the case in the general population.

### *Menopause*

In the Vänersborg series there are in all 338 female patients with late onset DM. For 233 of these, aged 48 or over, information concerning the age at menopause was obtained from the case records or at interviews. Five patients (2 per cent) had their menopause before age 43 and in all 40 (17 per cent) had it before age 48.<sup>1</sup>

Only few of the patients with early adult-onset DM, and none of the patients with juvenile DM had reached the age of 48. Data were obtained for nine such patients, four of these had their menopause before age 48.

As is the case for menarche there is a time trend for menopause, but in the opposite direction the mean age at menopause seems to be gradually increasing. Nevertheless the data may be interpreted to indicate a tendency that on average the menopause occurs somewhat earlier among diabetics than in the general population. The material is not sufficiently large, however, for a quantitative evaluation of this effect. In addition it should not be overlooked that there can occur a selective element in so far as women with early menopause may be more prone to seek medical advice at a hospital than are women in general if

they have DM (even in a mild form) it is very likely that the disease will be diagnosed in connection with their hospital visit.

### *Pregnancies before the onset of DM*

Of the 459 female patients in the Vänersborg series 448 are registered in the duration period 0-4 years (39 juvenile onset, 73 early adult onset, 336 late onset). For these Table 45 shows the frequency of patients with previous pregnancy, the numbers of pregnancies, live births and overweight children (birth weight 4 500 grammes or over) and the mean number of live births per patient and per mother (woman with previous pregnancy), the data refer to the time of first admission and are given by age at onset.

The total number of pregnancies is 808, and the total number of live births is 768. It can be concluded that there must be a certain underregistration in respect of the number of abortions (and stillbirths). For the 336 women with age at onset 40 or over, the average number of children (live births) was 2.1 per woman and 3.4 per mother, no more than 62 per cent of these women had been pregnant. However in this connection it should be taken into account that during the relevant years before the Second World War both the marriage rate and the birth rate were low in Sweden. There was an increase of the marriage rate at the end of the thirties and in 1944-45 the birth rate was very high though this was connected more with what may be termed a displacement effect than with an increase of the total number of children per family during the

<sup>1</sup> According to recent statistics from the U.S.A. (MacMahon & Worcester 1966) among women not having had operative menopause 29 per cent had natural menopause before age 48.



Table 45 Pregnancies before first admission Duration 0-4, Vanersborg

Age at onset	Number of patients	With previous pregnancy		Number of			Mean number of live births per		Overweight children as percentage of live births
		Number	Per cent	Preg- nancies	Live births	Over- weight children	patient mother		
0-14	39	-	-	-	-	-	-	-	-
15-24	31	2	6	4	4	-	0.1	2	-
25-29	13	7	54	7	6	2	0.5	1	33
30-34	18	10	56	20	20	5	1.1	2.0	25
35-39	11	7	64	19	19	-	1.7	2.7	-
40-44	16	11	69	29	29	7	1.8	2.6	24
45-49	36	21	58	63	61	4	1.7	2.9	7
50-54	52	35	67	112	107	17	2.1	3.1	16
55-59	65	45	69	156	145	11	2.2	3.2	8
60-64	60	43	72	171	158	14	2.6	3.7	9
65-69	46	19	41	72	68	11	1.5	3.2	16
70-74	36	21	58	91	88	2	2.4	4.2	2
75-	25	14	56	64	63	3	2.5	4.5	5
0-14	39	-	-	-	-	-	-	-	-
15-39	73	26	36	50	49	7	0.7	1.9	14
40-	336	209	62	758	719	80	2.1	3.4	10
Total	448	235	52	808	768	76	1.7	3.3	10
Overweight children birth weight 4 500 g or over									

whole reproductive period. For comparison it may be mentioned that in existing marriages in Sweden in 1935/36 contracted after 1900 the frequency of families with children was 92 per cent where the duration of marriage was 20-35 years and 90 per cent where the duration was 15-19 years, in marriages with children, the average number of children was 4.4 and 3.4 respectively (Sjoststrand 1940).

Although there may exist selective elements in respect of the admission of DM patients to hospitals which are directly or indirectly connected with marital state and the number of children it is apparent that the data in Table 45 do not support a theory that the fertility of prospective DM patients is higher than the fertility in corresponding groups of the general population.<sup>1</sup> This theory is not

infrequently advanced in the literature, but in the main it seems to be based on a misinterpretation of the existing statistical data. Usually these statistics refer to the number of sibs of DM patients however, it is not taken into account that the

<sup>1</sup> In the *Health Examination Survey 1960-62* the U.S. National Center for Health Statistics reports certain findings which may be interpreted as indicating that the average number of children is larger for diabetic women than for non-diabetic women (O'Sullivan & Gordon 1966). Blood glucose levels were found to be unrelated to marital status and childbearing, but with increasing parity there was a rise in the (age adjusted) prevalence of diabetes. According to the authors available data seem to favour the conclusion that pregnancy has no role in the causation or earlier appearance of diabetes. The *Health Examination Survey* confirms the tendency toward higher parity among diabetic women without providing an explanation for it. To attribute this increase in family size to an altered fertility rate or to some subtle psychosocial factors would be purely speculative.

probability of at least one child in a family being registered as a DM patient is generally greater in a large family than in a small one (theoretically the only exception would be complete registration over a very long period)

If  $n_s$  is the number of families with  $s$  children and  $h$  is the whole life expectancy of a new born child being admitted to hospital because of DM the number  $h_s$  of families with  $s$  children in which at least one child will be admitted is

$$h_s = n_s [1 - (1 - h)^s]$$

or, where  $h$  is small,

$$h_s \approx n_s \cdot h \cdot s$$

Hence the average number of children in the families will be

$$\bar{s} = \frac{\sum s \cdot n_s}{\sum n_s} = \frac{\sum h_s}{\sum s}$$

[not  $\frac{\sum s \cdot h_s}{\sum h_s}$ ]

The frequency of overweight children (4 500 grammes or over) does not show any clear tendency to vary with the age at onset of DM. Nor did a scrutiny of the data reveal any clear variation with the

family size. For the whole series the frequency is 10 per cent.

### *Pregnancies after the onset of DM*

For the Vänersborg series the total number of children born to female DM patients after the first admission amounts to 45. Rearranging the data in Table 7B to show the distribution by average age (calculated from 5 year group by age at onset and 5 year group by duration) we find that in all there are 272 registrations (duration cards) which represent reproductive ages. A survey of the data is given in Table 46, in which the registrations, the number of live births and the number of overweight children are shown according to the average age of the patients. Further an approximate calculation of the birth rate by age has been made, for comparison, corresponding figures for the general population are shown (because of the great variation of the birth rates during the period these figures have been rounded off). In the evaluation of the table it should be observed that to a certain extent the fertility data for the DM patients are selective in so far as DM

Table 46 *Pregnancies after first admission Vänersborg*

Average age	Number of data on cards	Approximate number of observation years	Number of live births	Number of overweight children	Approximate birth rate per thousand	
					DM patients	General population 1940
19	37	145	—	—	—	65
24	52	220	7	—	32	130
29	52	220	14	—	64	120
34	47	200	19	3	85	90
39	46	170	4	2	24	40
44	38	160	1	—	6	10
Total	272	1 115	45	5		

might have been detected in connection with pregnancy and that this has then been the reason for admission, in particular this seems to apply to the group with average age 34 where 7 of the 19 children were born within the first duration period

It is evident from the table that the fertility of female DM patients is far below that of the general population

The frequency of overweight children (5 out of 45) agrees with that found among children born before the onset of DM (or, strictly speaking before the first admission)

### *Perinatal mortality*

As already stated, there must be gaps in the registration of abortions. The Vänersborg series covers a long period of time, during which there was a marked decline in early infant mortality (cf Larsson 1965) and considerable advances in the treatment of pregnant diabetic women. The material from the investigation hospitals is not sufficiently large to permit a quantitative analysis of these developments.

Pedersen (1954) investigated the perinatal mortality among children of diabetic mothers for the periods 1926-46 and 1947-52. His series comprises 230 mothers with 305 pregnancies and 309 children. In 1947 Pedersen introduced a careful observance of pregnant diabetics with frequent controls of diet and insulin; the treatment also comprised a rather long period of hospitalization before delivery. In the 38th week rupture of membranes or caesarean section (12 cases) was performed. Pedersen reports a decrease of

mortality from 38 to 27 per cent for children weighing 2,500 grammes or less, and from 30 to 20 per cent for children weighing more than 2,500 grammes.

A further decrease in perinatal mortality is reported by Pedersen (1965) viz 18 per cent for a series of 306 infants in 1959-63, and 14 per cent for 90 births in 1946-64, where the mothers were controlled 150 days or more before the calculated term. Drury (1966) reports a perinatal mortality of 10 per cent.

Problems related to pregnancy, delivery and mortality among diabetic mothers, and mortality among children of diabetic mothers are treated in a series of Swedish investigations, for instance those by Andersson (1950), Andersson and Swanberg (1961), Bergman (1953), N. Bergqvist (1954), Brosset and Werko (1950), Hagbard (1956), Lunell (1966), Sundelin (1938), and Svanteson (1953).

The qualitative impression from our hospital series is in line with Pedersen's findings, but other factors, too, must have contributed to the improved outcome of pregnancies among diabetic mothers, for instance the availability of effective antibiotics and, not least, the steady amelioration of maternity and child welfare organization in Sweden.

### *Acute complications*

At any rate before the introduction in general therapeutic practice of sulphur preparations and antibiotics, diabetics were in general more often and more severely afflicted with infections than were non-diabetics. The entries in the case records concerning infections are included

in the occasion cards, but not with the intention that these data should be processed separately although the greater part of the material belongs to a period when sulphur preparations and antibiotics were utilized an analysis of the data on infections would have only a limited historical interest. However, we wanted to evaluate the occurrence of ketosis against the background of simultaneous infections.

### *Acute infections*

Data on the registered frequency of infections in each 5-year duration period (reckoned from the onset of DM) are included in Table 47. Of course it should be remembered that the registration mainly covers infections which have been found at the patient's visits to the hospital, the time intervals between these visits are in general shorter in the case of juvenile or early adult onset than in the case of late onset and they are in general shorter immediately after the first admission than they are later on.

### *Diabetic coma and pre-coma*

In respect of acidosis and ketosis we have refrained from processing the data on mild acidosis. As is well known mild acidosis may often be a transient symptom, the significance of which is generally very difficult to evaluate. The data which are given in Table 47, comprise solely instances where there has been ketosis to such a degree that an unquestionable disturbance of consciousness has occurred. The less severe cases where the patient has been able to speak and to answer questions, albeit only by an effort

are classified as pre-coma. Where complete unconsciousness has been present the case is classified as diabetic coma.

In the whole series there are registered 370 instances of pre-coma or coma. For no fewer than 284 (77 per cent) of these the case records contain entries on infection. It is generally agreed that infections are often the provoking factor for ketosis (cf. Joslin, Root, White & Marble 1959). These 370 instances of ketosis refer to 312 registrations (duration cards), several patients have in a 5 year duration period had more than one attack of pre-coma or coma. A survey of the registrations is given in Table 47 by sex, age at onset (juvenile, early adult, late) and duration. For a given duration period each patient is counted only once and the number of patients with registration of both ketosis and infection is related to the total number of patients in the duration period as well as to the number of patients with at least one registered infection during the period. The first mentioned quotient will give a minimum expression for the occurrence of ketosis, the last mentioned quotient, on the other hand, may be assumed to give a fairly correct value for the frequency (in a 5-year duration period) of at least one instance of ketosis.

As will be seen from the table ketosis (among patients with infection) has been registered for 2 per cent of the males and 4 per cent of the females with late onset DM, for 8 and 12 per cent in the early-adult onset type and for 20 and 24 per cent, respectively in the juvenile-onset type. For the juvenile diabetics the frequencies are higher, viz. 31 and 32 per cent in the duration group 0-4 years. For the early adult- and the late-onset types

Table 47 The occurrence of pre coma and coma by sex, age at onset and duration

Sex	Age at onset	Duration	Registrations (duration cards)						Occasions of ketosis		
			Total	With infection			Ketosis Pd Cd				
				All	Per cent age I/T	No	Percentage of		No	Pd Cd	Cd
							T	I			
M	0-14	0-4	133	110	83	34	26	31	43	10	
		5-9	126	73	58	17	13	23	21	1	
		10-14	121	60	50	3	2	5	3	1	
		15-19	87	32	37	4	5	12	5	2	
		20-24	48	22	46	2	4	9	2	-	
		25-	33	9	27	-	-	-	-	-	
		Total	548	306	56	60	11	20	74	14	
	15-39	0-4	386	244	63	22	6	9	23	6	
		5-9	252	110	44	11	4	10	12	2	
		10-14	173	67	39	4	2	6	4	-	
		15-19	124	47	38	2	2	4	2	-	
		20-24	71	22	31	3	4	14	4	-	
		25-	69	17	25	-	-	-	-	-	
		Total	1 075	507	47	42	4	31	45	8	
	40-	0-4	944	499	53	10	1	2	12	7	
		5-9	469	185	39	2	0	1	2	-	
		10-14	212	83	39	4	2	5	5	-	
		15-19	101	34	34	1	1	3	1	-	
		20-24	37	12	32	2	5	17	2	-	
		25-	12	5	42	-	-	-	-	-	
		Total	1 775	818	46	19	1	2	22	7	
	All	Total	3,398	1 631	48	121	4	7	141	29	
F	0-14	0-4	125	119	95	38	30	32	48	8	
		5-9	115	86	75	22	19	26	31	8	
		10-14	114	70	61	14	12	20	22	5	
		15-19	69	45	66	9	13	20	9	3	
		20-24	37	20	54	1	3	5	1	-	
		25-	26	8	31	-	-	-	-	-	
		Total	485	348	72	84	17	24	111	24	
	15-39	0-4	251	167	67	28	11	17	31	12	
		5-9	186	92	49	8	4	9	11	1	
		10-14	131	64	49	7	5	11	8	1	
		15-19	88	44	50	6	7	14	6	1	
		20-24	58	21	36	1	2	5	1	-	
		25-	53	25	43	1	2	4	1	-	
		Total	772	413	54	51	7	12	56	15	
	40-	0-4	1 423	804	57	31	2	4	32	12	
		5-9	782	328	42	17	11	5	22	5	
		10-14	340	149	44	5	1	2	3	-	
		15-19	142	68	48	5	4	7	5	11	
		20-24	33	16	43	-	-	-	-	-	
		25-	10	5	50	-	-	-	-	-	
		Total	2,730	1,370	50	56	11	4	62	19	
	All	Total	3 987	2,131	53	191	5	9	229	38	

Pd = diabetic pre-coma Cd = diabetic coma

no such difference is to be found in respect of pre-coma whereas the registered instances of coma mainly fall within the duration group 0-4 years (37 out of 49)

### *Hypoglycaemia, hypoglycaemic coma*

When transferring the case record data to the occasion cards the occurrence of a blood sugar value below 0.06 per cent was classified as an instance of hypoglycaemia. In addition the occurrence of hypoglycaemic coma was registered.

During the later part of the investigation period hypoglycaemic coma (insulin coma) was seen only exceptionally on average one or two cases per annum were registered at each of the four departments of internal medicine. The frequency may be somewhat higher at departments of paediatrics in particular during the adjustment of the insulin therapy.

There are DM cases in which at the initial stages the production of insulin may be increased to such a degree as to result in hypoglycaemia. However cases of this type are rare. Otherwise, hypoglycaemia is regularly not a symptom (a sequela) of DM but a consequence of the treatment of the disease, in particular the administration of insulin. Mild episodes of hypoglycaemia—insulin reactions—have occurred fairly often in the present series especially during the earlier part of the investigation period.

As a rule the treatment of hypoglycaemia has been an adjustment of the administration of insulin, with a lower dose in the case of heavy muscular work or reduced food intake. Occasionally, it has been found appropriate to give the

patient a suitable quantity of sugar or other carbohydrates.

Hypoglycaemic coma, with a blood sugar value of 0.04 per cent or less has regularly been treated by injection intravenously of glucose and glucagon or norepinephrine.

During the first decades of insulin therapy, at least the consequences of hypoglycaemic states seem to have been underestimated. Campbell, who worked together with Banting and Best when insulin was taken into therapeutic use appears to have been the first research worker to study the clinical problems connected with hypoglycaemia, his excellent paper on hypoglycaemia and hyperinsulinism (1958) is of great interest. In recent years, the occurrence of certain cerebral changes after hypoglycaemia has been reported (Fahlgren, Andersson & Lundmark 1957; Hartmann, Wohltmann, Holowach & Caldwell 1960; Green 1963; Roberts 1964).

### **Tuberculosis**

In order to detect instances of pulmonary tuberculosis and other types of tuberculosis there has been developed in Sweden a systematic activity at central and local dispensaries (about 60 and 650 in number) and X-ray examinations on a large scale are undertaken (from 400 000 to 800 000 a year). The number of new findings of tuberculosis entered into the registers of central dispensaries has gradually decreased from about 3.1 per thousand inhabitants in 1943-44 to less than 0.5 per thousand in 1961-65. In 1961-63 the average annual number of new cases

was 3 769 (0 50 per thousand inhabitants) of which 2,604 (0 34 per thousand) were instances of pulmonary tuberculosis

The death rate for tuberculosis (A1-A5) as the primary cause of death was 0 81 per thousand in 1936-40, 0 69 in 1941-45 0 39 in 1946-50 0 16 in 1951-55 and 0 08 in 1956-60 the latest available statistics, for the year 1965 show a rate of 0 046 per thousand (males 0 063, females 0 029)

As already mentioned (p 103), the Central Bureau of Statistics has recently published certain data on causes of death in 1965, which include not only primary (underlying) causes but also complications and contributory causes As in respect of DM, tuberculosis (TB) does not appear as a complication but solely as the primary cause (TBp) or as a contributory cause (TBc) An extract of these statistics is shown in the following table (where as usual the annexed letter t stands for p + c)

1965	M	F	M + F
Average population thousands	3 862	3 872	7 734
Number of deaths T	42 031	36 163	78 194
Death rate per thousand	10 85	9 34	10 11
Number of deaths			
TBp	242	113	355
TBt	438	237	675
Dp	565	769	1 334
Dt	1 810	2 490	4 300
Death rate per thousand			
TBp	0 06	0 03	0 05
TBt	0 11	0 06	0 09
Dp	0 15	0 20	0 17
Dt	0 47	0 64	0 56
Death share per cent			
TBp	0 58	0 31	0 45
TBt	1 04	0 66	0 86
Dp	1 34	2 13	1 71
Dt	4 31	6 89	5 50

Among deaths in 1961-63 with DM as a contributory cause in all 2 940 males and 4,333 females there were 24 and 27 or 1 2 per cent and 1 6 per cent, respectively for which tuberculosis was stated as the primary cause From the 1965 table it can be seen that the total death shares for TBp are half of these values

As is apparent from these statistical data, the problems concerning the association of DM and TB have lost much of their interest in consequence of the gradual decline in the incidence and prevalence of TB, and the gradual increase in the overall prevalence of DM (due to reduced excess mortality among diabetics and changed age structure of the population) During earlier periods, a great many papers have been devoted to the study of these problems Root (1934) made a thorough review of the pertinent literature Of 1,121 diabetic autopsies 319 or 28 4 per cent revealed active tuberculosis, in a general series of 51,705 autopsies 22 9 per cent showed tuberculosis Taking into account that (for the periods studied) tuberculosis as well as diabetes entailed a comparatively heavy increase of the mortality risk Root concludes that active tuberculosis was found in diabetics at autopsy between two and three times as frequently as expected

In connection with the study by Silwer (1958) on the frequency of diabetics in Kristianstad County (L cf p 235) Oscarsson and Silwer (1958) investigated the prevalence of pulmonary tuberculosis among registered diabetics living on March 15, 1954 Of 1 326 diabetics, 1,270 were examined roentgenologically Pulmonary tuberculosis (not including clearly healed processes) was found for 46 or

3.6 per cent of these diabetics. A comparison with the prevalence of pulmonary tuberculosis in the general population of the county (according to records at the dispensaries on December 31 1953) is shown in the following table

Attained age	Frequency of diabetes per cent	Number and frequency of pulmonary tuberculosis			
		Diabetics		Population	
		No.	per cent	No.	per cent
0-9	0.06	—	0.0	50	0.1
10-19	0.17	2	3.5	101	0.3
20-29	0.22	8	8.5	359	1.0
30-39	0.21	4	5.3	580	1.6
40-49	0.38	9	7.1	459	1.3
50-59	0.85	5	2.1	365	1.3
60-69	1.59	9	2.5	216	0.9
70-	1.71	11	3.6	159	0.8
Total	0.51	46	3.6	2289	0.9

After Oscarsson and Silwer (1958)

The frequency of pulmonary tuberculosis among diabetics aged 30 or over was about 3.5 times as high as the corresponding frequency in the general population. The frequency of diabetes among patients with pulmonary tuberculosis was also about 3.5 times as high as the corresponding frequency in the general population (46 observed cases against 13.2 expected).

Oscarsson and Silwer conclude that diabetes especially when severe favours the development of tuberculosis; the tendency is most obvious in patients who have had diabetes for a fairly long time. Therefore all diabetics should be regularly examined by chest X-ray so that any co-existing pulmonary tuberculosis may be discovered at an early stage.

At the county hospitals included in our clinical study X-ray control has been a routine procedure (as a rule once a year). There are comparatively few instances of

tuberculosis registered in the series which is due, at least in part, to the fact that the diagnosing of tuberculosis has preceded the onset of DM. Patients with active pulmonary tuberculosis are regularly treated at special hospitals (sanatoria). For this reason and because of the marked decline in the tuberculosis morbidity and mortality a statistical analysis of our series in respect of tuberculosis would be rather biased and of very limited value. In the main it can be stated that nowadays tuberculosis is no real problem in the treatment of DM patients although such patients as well as other diseased persons should of course still be subjected to X-ray control at suitable intervals.

## Chronic urinary-tract infections

Long standing urinary tract infections occur rather frequently among DM patients especially in females. The diagnostic techniques in respect of these infections have been markedly improved during the last ten years and this has resulted in a rise in the number of registered cases. Previously urine sediment was studied directly by microscopy and the results were evaluated mainly on the basis of the occurrence of leukocytes. It was considered that infections of the urinary tract were 3-4 times as common in diabetics as in non-diabetics.

After the introduction of procedures in which quantitative analysis of bacterial culture from urine is utilized it has been possible to diagnose bacteriuria with greater accuracy. In an unselected out-patient series of 269 diabetics and 260 comparable non-diabetic controls, Vejls-



gaard (1965, 1965) found that 18.8 per cent of the diabetic females and 7.9 per cent of the non-diabetic females had bacteriuria (with more than  $10^5$  colonies/ml urine). For males the figures were very low (0.7 and 1.1 per cent, 1 and 3 instances of bacteriuria). Vejlsgaard concludes that it does not appear possible to correlate infection of the urinary tract with DM *per se* but that it seems likely that diabetic vascular disease is a contributory factor in the development of urinary infection in diabetic patients.

As in respect of tuberculosis, a statistical analysis of our series would be of historical interest only, bacterial culture from urine has been made only in excep-

tional cases. Reference may be made to the studies by Vejlsgaard (1965, 1965), Huvos & Rocha (1959), Isacson (1965), Oseasohn, Liebow and Newill (1964), Parrish (1965), Silagy (1962), and Szucs Cserhati, Csapó and Balazs (1960).<sup>1</sup>

The occurrence of certain other diseases (thyrotoxicosis, allergic diseases, malignant tumours, rheumatoid arthritis, and pernicious anaemia) will be discussed in Chapter VII (pp. 197-200).

---

<sup>1</sup> Reference may also be made to a study of renal complications and urinary tract infections among hospital patients with DM at the Turku University Central Hospital (Kasanen & Forsström 1964).

# Treatment

In the treatment of DM the main objective is to get the metabolic disturbance under proper control and to attain a metabolism comparable to that obtaining in healthy subjects. Before the discovery of insulin and its introduction into general therapeutic practice, treatment was restricted to dietary procedures. During that period—and long afterwards—DM was considered to be a disease consisting chiefly in a reduced capability of the body cells to metabolize carbohydrates. Consequently it was only natural that the dietary prescriptions were aimed at cutting down the carbohydrate supply, the control of the disease was almost entirely directed to the carbohydrate metabolism. The patient should not present urinary excretion of glucose and he should have a blood sugar level comparable to that of healthy persons. To a great extent this objective has been maintained where insulin therapy is applied.

Unfortunately the attainment of the goal thus set has proved far more difficult than was at first thought. It has often been impossible to adapt the patient's working conditions to the diet in a way that would serve to keep a stable good control in respect of urinary glucose excretion and blood sugar content.

Nowadays the great majority of clinicians agree that DM therapy should

be designed to keep the patient's body weight at what is deemed to be normal and to secure the administration of such amounts of calories, vitamins, metals, etc., as are sufficient for an adult patient to carry on his ordinary work and for a child to develop along lines as normal as possible. Hence it is obvious that the therapy must be adapted to the needs and circumstances of the individual patients and must be suitably modified if substantial changes in these needs and circumstances should occur (cf. Gronberg 1963). In the main these views agree with those expressed by Odén already in the 1930s (Odén 1939).

A penetrating discussion of the therapeutic problems would fall outside the scope of the present study. Good surveys of these problems have been published by prominent diabetologists for instance in the volumes edited by Danowski (1964), Ellenberg and Rifkin (1962), Leibel and Wrenshall (1965), Oberdisse and Jahnke (1963) and Williams (1960) and in the classical textbook of Joslin, Root, White and Marble (1959).

A thorough review of current conceptions concerning endocrine defects in DM and the metabolic effects of insulin is given by Renold and Cahill Jr (1966).

Our hospital series originates from a period when insulin, exercise and diet

were the only general means applied in the treatment of DM, the use of oral remedies which is nowadays common, will be discussed in a later section

## Diet therapy

On the basis of the entries in the case records the patient has in respect of each

Table 48 Diet by sex, hospital, age at onset and duration

Age at onset	Duration	Hospital	Males						Females					
			Number	Diet ( )					Number	Diet ( )				
				III	1	2	3	2		0	1	2	3	2
0-14	0-4	P	47	4	70	26			39	10	57	33		
		G	13	6	85	9			28	7	88	7		
		W	23	4	87	9			31	6	88	6		
		Z	30	73	27	-			27	66	30	4		
		Total	133	20	67	13			125	21	65	14		
	5-9	P	43	-	72	28	58	16	37	-	70	30	46	16
		G	32	3	88	9	75	9	29	-	97	3	62	3
		W	29	-	100	-	59	-	26	-	96	4	77	4
		Z	22	4	82	14	27	-	23	-	87	13	30	4
		Total	126	2	84	14	57	8	115	-	86	14	54	8
	10-14	P	40	-	82	18	58	8	32	3	66	31	44	16
		G	26	-	85	15	62	8	29	-	97	3	76	-
		W	30	-	100	-	70	-	32	3	97	-	59	-
		Z	25	8	88	4	28	-	21	10	85	5	33	-
		Total	121	2	88	10	55	4	114	4	85	11	54	4
	15-19	P	35	-	81	17	57	3	21	-	38	88	19	10
		G	17	-	94	6	41	-	14	-	100	-	79	-
		W	23	-	96	4	74	-	20	-	100	-	88	-
		Z	12	-	83	17	50	-	13	-	92	8	46	-
		Total	87	-	90	17	57	1	68	-	79	21	50	3
15-39	0-4	P	115	10	37	53			73	10	38	52		
		G	66	3	74	23			42	7	86	7		
		W	115	3	95	2			82	5	91	4		
		Z	90	49	45	6			54	46	50	4		
		Total	386	16	88	21			251	16	66	18		
	5-9	P	86	1	36	63	26	44	54	-	37	63	17	44
		G	47	2	70	28	51	17	33	3	85	12	42	3
		W	70	-	99	1	88	1	65	1	97	2	79	2
		Z	49	6	88	6	45	-	34	-	85	15	32	-
		Total	252	2	70	28	50	19	186	1	75	24	46	14
	10-14	P	59	5	37	58	22	36	35	-	34	66	17	46
		G	30	-	63	37	30	17	28	-	86	14	43	-
		W	51	4	92	4	69	-	45	-	98	2	73	88
		Z	33	-	100	-	39	-	23	-	87	13	35	4
		Total	173	3	70	27	40	15	131	-	76	24	45	14
	15-19	P	39	3	46	51	18	28	17	-	18	82	-	47
		G	28	-	89	11	29		20	-	80	20	35	5
		W	34		97	3	68	3	32	3	97	-	62	-
		Z	23	4	96	-	39	-	19	-	100	-	37	-
		Total	124	2	79	19	38	10	88	1	79	20	39	10

Continued

Table 48 Continued

Age at onset	Duration	Hospital	Males					Females						
			Number	Diet ( )					Number	Diet ( )				
				0	1	2	1*	2*		0	1	2	1	2
40-	0- 4	P	234	9	36	55			336	7	32	61		
		G	165	11	92	2			286	3	11	11		
		W	214	1	98	1			312	2	97	1		
		Z	331	40	58	2			489	34	61	5		
		Total	944	17	68	15			1423	15	67	18		
	5- 9	P	129	4	25	71	17	53	191	-	13	87	8	59
		G	79	-	94	6	81	4	175	1	10	10	67	7
		W	113	-	98	2	69	1	201	-	99	1	71	1
		Z	148	3	93	4	45	-	215	8	83	9	46	2
		Total	469	2	76	22	49	15	782	11	71	26	48	17
	10-14	P	64	-	31	69	11	45	76	1	8	91	4	57
		G	32	-	88	12	69	11	83	-	11	16	49	6
		W	58	-	100	-	66	-	96	1	98	1	71	-
		Z	58	2	88	10	45	3	85	2	87	11	44	2
		Total	212	0	75	25	44	16	340	1	72	27	44	15
	15-19	P	35	-	34	66	11	34	26	-	27	73	4	31
		G	14	-	79	21	36	7	36	-	86	14	36	8
		W	29	-	100	-	72	-	46	-	96	4	59	2
		Z	23	4	96	-	52	-	34	-	85	15	50	-
		Total	101	1	73	26	42	13	142	-	78	22	41	8

Diet in the duration period 0 = entirely free  
1 = partially regulated  
2 = totally regulated

\* = unchanged code since first admission (there are only 13 patients 0\*)

admission been classified under one of the following five headings which so far as possible refer to the actual diet (not to the prescribed diet)

(a) entirely free diet (including sugar, sweets, etc)

(b) free diet with limitation of sugar and sugar containing products but with out other restrictions

(c) normal diet without sugar and sweets

(d) partially regulated diet free from sugar and sweets

(e) totally regulated diet with fixed daily amounts of carbohydrates lipids and proteins

It was thought that in this way it might be possible to arrive at an at least approximate idea of the types of food the DM patients were taking. Quite naturally, the borderlines are not always clear cut this proved to apply in particular to the divisions between groups (b) (c) and (d). When processing the occasion cards into duration cards we therefore decided to use three classes only, viz

(0) entirely free diet (a)

(1) partially regulated diet (b, c, d)

(2) totally regulated diet (e)

The data for the durations 0-4 5-9 10-14 and 15-19 years are given in Table

Table 49 *Insulin treated patients by sex, hospital age at onset and duration*

Duration	Hospital	Juvenile onset (0-14)				Early adult onset (15-39)				Late onset (40+)			
		Number		Insulin (%)		Number		Insulin (%)		Number		Insulin (%)	
		M	F	M	F	M	F	M	F	M	F	M	F
0-4	P	47	39	96	97	115	73	92	89	234	336	57	56
	G	33	28	100	100	66	42	98	95	165	286	84	74
	W	23	31	91	97	115	82	85	89	214	312	62	53
	Z	30	27	100	100	90	54	88	89	331	489	60	58
	Total	133	125	97	98	386	251	91	90	944	1423	64	60
5-9	P	43	37	100	100	86	54	95	94	129	191	81	78
	G	32	29	100	100	47	33	100	97	79	175	92	78
	W	29	26	100	100	70	65	97	97	113	201	70	62
	Z	22	23	100	100	49	34	94	100	148	215	80	81
	Total	126	115	100	100	252	186	96	97	469	782	80	75
10-14	P	40	32	100	100	59	35	98	100	64	76	80	91
	G	26	29	100	100	30	28	100	96	32	83	88	80
	W	30	32	100	100	51	45	96	93	58	96	91	81
	Z	25	21	100	100	33	23	100	100	58	83	83	88
	Total	121	114	100	100	173	131	98	97	212	340	85	85
15+	P	67	42	99	100	90	46	99	83	53	41	72	83
	G	29	26	100	100	54	45	98	100	24	44	83	95
	W	47	47	96	100	79	79	82	89	40	58	97	81
	Z	25	16	100	100	41	34	93	100	33	42	85	88
	Total	168	131	98	100	264	204	93	92	150	185	83	89

48 by sex, hospital and age at onset (juvenile early adult late). In addition to the number of patients (duration cards) there are shown the percentage distribution by type of diet during the period in question and further the percentages of patients who have remained on diet (1) or (2) since their first admission.

In the first duration period (0-4 years) entirely free diet was practised for 15-20 per cent of the patients. At Vänersborg (P) Växjö (G) and Falun (W) the figures are below 10 per cent whilst at Östersund (Z) they are much higher especially for juvenile diabetics. In the following duration periods (5 years or more) entirely free diet was used only exceptionally. For juvenile diabetics totally regulated diet was applied to rather more than a quar-

ter of the patients at Vänersborg and to less than 10 per cent of the patients at the other three hospitals. For diabetics with early adult or late onset, totally regulated diet was used at Vänersborg for more than half of the patients, at the other three hospitals totally regulated diet was applied to a comparatively small extent.

In the duration group 10-14 years about 60 per cent of the patients under observation carried on with the diet introduced after the first admission. However it should be remembered that in this respect the material may be biased in so far as patients who are reluctant to follow the doctor's prescriptions may be more prone to vanish than are patients who are willing and able to cooperate.

## Insulin therapy

By sex hospital age at onset and duration Table 49 shows the frequency of patients treated with insulin. Roughly speaking insulin therapy was applied to all patients with juvenile onset DM to about 90 per cent of the patients with early adult onset DM, and to more than 50 per cent of the patients with late-onset DM. Insulin therapy was used more frequently at Växjö (G) than at the three other hospitals. It can further be seen from the table that for patients with late-onset DM the frequency figures increase markedly with increasing duration. Very likely this is an expression of certain selective factors: it is conceivable that many patients who are able to manage their DM by means of diet and exercise alone will prefer to obtain the necessary control examinations outside the county hospital if they have easy access to a doctor or a local hospital in or near their place of residence. In addition it is likely that the increase with time of the number of first admissions has brought about an 'admixture' of comparatively mild cases in the first duration group (0-4 years). Finally, it should be noticed that the tabulation relates to the use of insulin during each 5 year registration period. There are many instances where a patient was kept on diet for one or two years and then was prescribed insulin, if insulin was taken at all during the period the patient is counted as 'with insulin'.

As already mentioned the oldest part of the present series originates from a time when only regular insulin was available but since about 1935 it has been possible to use long acting insulin.

Both types were widely used. At first, it was considered that the two types should be injected separately hence, if a patient had insulin with two doses a day three or four injections were needed. However, it turned out that many patients—with or without the doctor's permission—mixed the two preparations and took the injections twice a day. The consequence of this was that the treatment came to comprise more long acting insulin and less rapid acting insulin, protamine zinc insulin contains an excess of protamine and zinc which binds regular insulin. Thus there could be no certainty about the duration time of the mixture but nevertheless the results were as a rule satisfactory.

With regard to the objective of the treatment the views among clinicians still differ. There are physicians who are of opinion that—by means of a strict diet and an ample supply of insulin—the DM patients should be kept at a normal blood sugar level and be free from sugar in the urine. Others consider that no more insulin should be administered than is necessary to keep the urinary excretion of glucose below 30 grammes per day and that the blood sugar level should not be reduced so much that hypoglycaemia may occur. There seem to be special arguments in favour of this latter view among other things, recent observations have shown that hypoglycaemia may cause cerebral damage (cf p 145).

It is rather difficult to describe briefly the techniques used during the investigation period for the administration of insulin. It might be said that each patient had his individual way of taking the insulin and that each of the doctors had

his own views concerning how and when the insulin injections should be given. With some generalization the following pattern can be said to emerge

(a) *Juvenile onset*

Dietary regulation alone was rare. Generally the onset of the disease is acute and accompanied by considerable ketosis, and therefore even a dietary treatment of short duration may be dangerous. As a rule treatment with regular insulin in two or more doses daily was introduced without delay during the earlier part of the investigation period; rather large doses were often given. Usually proper control was rapidly established and as soon as the acidosis had been eliminated attempts were made to arrive at an adequate adjustment of the insulin treatment—sometimes a delicate problem. Often the patient and his family were anxious to have the insulin injections reduced as much as possible and preferably discontinued. The doctor, having reasons for trying to keep good control, preferred that injections should be given at least twice a day. Even where the doctor felt that one injection with long acting insulin would not be wholly appropriate, he had often to compromise in order to secure that at least some insulin treatment would be continued. Quite often those patients who were given their insulin once a day got on surprisingly well in spite of large urinary excretion of sugar (and large quantities of urine); it is a strange and still unexplained phenomenon that many young DM patients can tolerate without any great discomfort a condition of high blood sugar, large quantities of urine and large urinary excretion of sugar. How-

ever, it has frequently been seen in the present series that trouble occurred when the patients attained the age of 15 or 16 and then an adjustment to two injections a day, possibly with a mixture of regular and long acting insulin, proved essential—a change that sometimes necessitated intense and tiresome discussions.

(b) *Early adult onset*

As already pointed out, this category (with age at onset 15–39) should be regarded as an intermediate group. Some of the patients presented typical juvenile DM. Others, especially those who fell ill at ages 25–39, displayed a clinical picture similar to the DM of old age.

In respect of those patients who had DM of the juvenile type, the treatment was on the whole similar to that described in connection with patients with onset below age 15. For the other patients it was characteristic that the onset of DM was less acute (although not really insidious) than the occurrence of the disease was often revealed incidentally and—above all—that the patients were acidosis resistant and far more stable in respect of blood sugar level and other symptoms than were juvenile diabetics. Of these patients the great majority were treated initially by dietary regulation with the dual purpose of arriving at conclusive data on carbohydrate balance etc. and convincing the patient that insulin treatment was deemed appropriate. Sometimes the dietary regulation was sufficient to keep the patient under good control for many years. When insulin had to be used, recourse was generally had to

long acting insulin with one daily injection. Quite often this worked excellently. However many patients could not be kept under good control in this way and in these cases the treatment was regularly adjusted to comprise two injections a day—ordinarily with a mixture of regular and long acting insulin, in particular this mixture technique was applied after the introduction of N P H insulin (non protein Hagedorn) which can be given together with regular insulin without any disadvantages.

#### (c) *Late onset*

As a rule the onset of DM is insidious or at any rate is less alarming than among juvenile diabetics, there is no tendency to acidosis. Often the endogenous production of insulin is preserved, at least during the first years after the onset of the disease. Not seldom the occurrence of DM was revealed in connection with intercurrent disease.

As a rule the treatment started with dietary regulation along the lines described under (b). However as will be seen from Table 49 there were a great many patients with late onset DM for whom insulin treatment was considered warranted. The criteria applied at Växjö (G) in this respect seem to have been different from those applied at the three other hospitals.

In this group it often proved adequate to keep the treatment at one daily injection of long acting insulin. It was a common experience that the administration of insulin could without disadvantage be restricted to a comparatively small dose. An additional motive for this choice was that for social reasons it is

often desirable to make the insulin treatment as easy as possible, many of the patients were old and in need of help with the injections, and of course it is more convenient for a district nurse or a family member to give one injection daily instead of two. Here, too it was often a question of compromises.

As will have appeared from this description the insulin treatment registered in our hospital material cannot be regarded as an expression of a scientifically founded system but rather as representing a series of practical considerations regarding which one may say that they functioned much better than one could justifiably have expected.

### Type of insulin

By sex, age at onset and duration, Table 50 shows the percentage distribution according to the type of insulin given. The table refers to patients treated with insulin during each registration period and a grouping is made into three categories viz

- (1)=regular insulin alone
- (2)=both regular and long acting insulin either with a change over the period or with parallel administration (with separate injections or more commonly with injection of mixture)
- (3)=long acting insulin alone

### Number of injections

For patients who had been prescribed insulin in a duration period Table 51



Table 50 Type of insulin by sex age at onset and duration

Age at onset	Duration	Males treated with insulin							Females treated with insulin						
		Number	Type of insulin ( )						Number	Type of insulin ( )					
			1	2	3	1*	2	3		1	2	3	1*	2*	3
0-14	0-4	129	30	61	9				123	38	55	7			
	5-9	126	29	51	20	15	35	4	115	22	65	13	14	39	2
	10-14	121	22	56	22	11	22	3	114	18	67	15	9	26	3
	15-19	85	21	60	19	13	12	2	68	18	73	9	6	22	1
	20-24	48	27	58	15	17	10	-	37	19	76	5	11	8	-
	25-	32	41	28	31	16	6	6	26	31	54	15	4	19	-
	Total	541	27	55	18				483	24	65	51			
15-39	0-4	351	23	60	17				226	26	60	14			
	5-9	241	26	53	21	17	39	5	180	22	59	19	16	38	3
	10-14	170	26	54	20	15	26	3	127	14	71	15	10	29	2
	15-19	121	27	51	22	14	17	1	86	17	62	21	10	19	-
	20-24	68	26	50	24	15	6	1	54	17	55	28	9	11	2
	25-	56	41	41	18	16	2	4	48	21	54	25	8	10	2
	Total	1 009	26	54	20				721	21	61	11			
40-	0-4	607	16	48	35				848	15	49	36			
	5-9	376	16	43	41	8	26	19	584	13	47	40	5	25	17
	10-14	180	16	42	42	6	16	17	289	17	46	37	6	19	9
	15-19	89	17	41	42	6	4	12	127	13	44	43	2	13	9
	20-24	29	10	42	38	3	14	-	29	10	52	38	3	17	-
	25-	7	29	57	14	14	-	-	8	25	75	-	12	-	-
	Total	1,285	16	46	38				1 885	15	48	37			

Type of insulin used during the period  
 1 = regular  
 2 = mixed or with charge during the period  
 3 = long acting

\* = unchanged code since first admission to the hospital

gives the percentage distribution according to the number of insulin injections per day. It should be noticed that the data are averages of the number of injections stated in respect of admissions during the registration period in question; admissions resulting in dietary regulation alone are included (i.e. they are not excluded from the denominator). Further, it should be noticed that the data refer to registered prescriptions (or corrected registration data on prescriptions); the patients may have applied a different frequency of injections without telling the doctor, and it is of course impossible to correct the data for deviations of this kind. On the whole it seems likely how-

ever that the patients took care to follow the prescriptions.<sup>1</sup>

The data in Table 51 are given by sex, hospital, age at onset (juvenile, early adult, late) and 5 year duration periods (0-19 years).<sup>2</sup>

As will be seen from Table 51 there are considerable differences between the four

<sup>1</sup> It is quite another matter that a number of patients who did not come back to the hospital might have sought advice from other doctors or hospitals, in order to obtain an "easier" treatment.

<sup>2</sup> There are in all 17 registrations for which data on the number of injections during the period are lacking; for convenience these "gaps" have been distributed proportionately within their respective group by sex, hospital, age at onset and duration.

hospitals. Looking at the first duration period (0-4 years) we find that as regards juvenile-onset DM one injection per day was applied at Östersund (Z) for more than half of the patients, the corresponding figures at the three other hospitals vary around 20 per cent. In respect of early adult-onset DM one injection per day was applied for nearly three quarters of the patients at Östersund (Z) and for about two thirds of the male patients and half of the female patients at Falun (W) but only for one third of the patients at Växjö (G) and one fifth of the patients at Vänersborg (P). As regards late-onset DM one injection daily was applied for about 90 per cent of the patients at Östersund and about 80 per cent of the patients at Falun and Växjö but for no more than about 40 per cent of the males and 60 per cent of the females at Vänersborg. In part these differences are a reflection of geographical and demographic dissimilarities between the admission areas of the hospitals. It is pointed out by the authors that patients with juvenile-onset DM at Östersund had a longer duration of disease. Nevertheless, it is considered that there were no differences in the divergences between the different physicians with regard to the use of available insulin.

## Quantity of insulin

There are no laboratory methods available which make it possible to measure by routine procedures the re-

quirements of daily insulin supply to a DM patient. By means of rather complicated investigations it is however possible to determine whether or not a patient has a preserved capacity of producing insulin.

During the first few years after the introduction of insulin into therapeutic practice it was considered that the amount of insulin needed was proportional to the quantity of carbohydrates administered. One I U (international unit) of insulin was regarded as capable of bringing about the combustion of 4 grammes of carbohydrates. This rule of thumb however has not proved tenable.

The decision concerning the insulin quantity to be given to a patient was generally based on a number of clinical observations regarding blood sugar level, urinary excretion of glucose, presence or absence of acidosis, quantity of urine, body weight and—not least—the patient's own statements as to his condition and symptoms. In the present series adjust-

## E P P A T A

table 2

For explanation asterisks see page 42 in text

table 5 p 7-32

CO<sub>2</sub> not in mEq/L but in mM/L

table 37

\* protein concentrations in g/Kg F<sub>2</sub>O

\*\* number of samples from which correlation between water content and protein concentration was calculated

the insulin treatment should be made fairly soon after the first discharge. On the other hand it is evident that a great

many patients were kept at the dose of insulin that was settled during their first hospital stay

Of course to a certain extent concurrent complications such as infections, operations, etc., led to a temporary ad

Table 51 Number of insulin injections per day by sex, hospital, age at onset and duration

Age at onset	Duration	Hospital	Males treated with insulin				Females treated with insulin			
			Number	Injections per day ( )			Number	Injections per day ( )		
				1	2	3		1	2	3
0-14	0-4	P	45	20	67	13	38	8	79	13
		G	33	15	76	9	28	18	64	18
		W	21	29	71	-	30	17	83	-
		Z	30	56	37	7	27	52	28	20
		Total	129	29	62	9	123	22	88	12
	5-9	P	43	2	82	16	37	3	73	24
		G	32	28	53	19	29	14	52	34
		W	29	21	76	3	26	15	77	8
		Z	22	68	23	9	23	56	35	9
		Total	126	25	62	13	115	19	61	20
	10-14	P	40	5	90	5	32	3	94	3
		G	26	31	57	12	29	21	65	14
		W	30	27	73	-	32	28	72	-
		Z	25	40	56	4	21	52	43	5
		Total	121	23	72	5	114	24	71	5
	15-19	P	34	15	79	6	21	5	95	-
		G	17	12	76	12	14	21	79	-
		W	22	32	68	-	20	40	60	-
		Z	12	67	33	-	13	54	31	15
		Total	85	26	69	5	68	28	69	3
15-39	0-4	P	106	23	72	5	65	15	82	3
		G	65	33	51	16	40	30	60	10
		W	101	65	33	2	73	53	46	1
		Z	79	72	27	1	48	72	26	2
		Total	351	48	47	5	226	42	54	4
	5-9	P	82	11	82	7	51	2	84	14
		G	47	23	68	9	32	31	53	16
		W	68	66	33	1	63	63	37	-
		Z	46	60	38	2	34	44	41	15
		Total	243	38	57	5	180	37	54	9
	10-14	P	58	2	91	7	35	3	97	-
		G	30	20	67	13	27	30	66	4
		W	49	51	47	2	42	55	43	2
		Z	33	64	36	-	23	81	35	4
		Total	170	31	64	5	127	36	62	2
	15-19	P	38	3	83	14	17	6	82	12
		G	27	22	74	4	20	75	70	5
		W	33	39	61	-	30	60	40	-
		Z	23	61	39	-	19	79	16	5
		Total	121	28	67	5	86	45	50	5

Continued

Table 51 : Continued

Age at onset	Duration	Hospital	Males treated with insulin				Females treated with insulin			
			Number	Injections per day ( )			Number	Injections per day ( )		
				1	2	3		1	2	3
40-	0- 4	P	133	41	59	-	188	59	39	2
		G	138	80	20	-	213	81	19	-
		W	133	83	16	1	163	78	20	2
		Z	200	91	9	-	284	117	12	1
		Total	604	76	24	0	848	78	21	1
	5- 9	P	105	29	71	-	149	42	57	1
		G	73	80	19	1	136	74	25	1
		W	79	86	14	-	125	78	21	1
		Z	119	86	14	-	174	87	11	2
		Total	376	69	31	0	584	70	29	1
	10-14	P	51	22	78	-	69	25	75	-
		G	28	64	36	-	66	70	25	5
		W	53	75	25	-	78	69	31	-
		Z	48	85	13	2	76	77	23	-
		Total	180	61	38	1	289	60	39	1
	15-19	P	28	25	71	4	22	23	72	5
		G	12	50	42	8	35	54	46	-
		W	28	89	11	-	37	70	30	-
		Z	21	75	25	-	33	75	25	-
		Total	89	60	38	2	127	59	40	1
Number of injections per day (average for all admissions during the registration period)			1 = one or less 2 = more than one but not more than two 3 = more than two							

justment of the insulin dose. As far as possible these intermediary doses have been excluded from the data given below concerning the average daily quantity of insulin.

It is considered that a healthy person has a daily endogenous insulin production of 40-60 I U. Therefore we have chosen to classify the registered administration of insulin into the following three categories:

- (1) 40 I U or less
- (2) 41-80 I U
- (3) more than 80 I U

By sex, hospital age at onset (juvenile, early adult, late) and 5 year duration groups (duration 0-19 years) Table 52

shows the percentage distribution of the patients who during the duration period in question took insulin according to the average daily quantity of insulin prescribed at each admission. It should be noticed that the averages relate to *all* admissions (occasion cards) in the period and hence even those admissions where no insulin treatment was prescribed. Patients without insulin during all admissions (viz. average value 0) are not included; the table deals solely with patients who took insulin during the duration period. As already mentioned, intermediary doses have as far as possible been excluded from the calculation of the averages.

As will be seen from the table, there is

(G) and Falun (W) occupy an intermediate position. At Växjö the amounts are comparatively large for early adult onset DM but comparatively small for late onset DM whereas the opposite can be said to apply in respect of Falun.

## Complications and preventive measures

Data on the occurrence of glycosuria ('control') have already been given in Chapter V (Tables 37 and 38) and the observations with regard to overweight and blood pressure have also been discussed there (Tables 40 and 41, Tables 43 and 44).

### *Acute complications*

Data on the occurrence of ketosis, diabetic precoma and diabetic coma during different duration periods are given in Chapter V (Table 47), and only a few comments will be added here.

The generally accepted view is that ketosis is due to a disturbance of the fat metabolism. Triglycerides and fatty acids do not undergo complete combustion; the oxidation stops at too early a stage and in consequence a poisoning with  $\beta$ -hydroxybutyrate, acetoacetate and acetone occurs.

Before (and immediately after) the introduction of insulin therapy diabetic coma was a common cause of death among DM patients; nowadays, however, fewer than 1 per cent of the diabetics die from diabetic coma.

Before the introduction into general therapeutic practice of insulin, sulphur preparation and antibiotics, acute infec-

tions—in particular streptococcal infections—were serious complications, nowadays they play a very small role since they can be kept under control by means of available remedies.

### *Late complications*

As already mentioned in Chapter I the occurrence of the so-called late complications of DM—diabetic retinopathy, diabetic nephropathy, and diabetic neuropathy—has attracted much attention during the last few decades. It is considered that retinopathy and nephropathy, and in part neuropathy are due to or connected with specific capillary changes—diabetic microangiopathy. Knowledge of the cause and origin of these changes is still rather limited but it has been established that microangiopathy is often present already at the time when it is possible to make the clinical diagnosis DM (cf. for instance Rifkin & Leiter 1962).

There have been divergent opinions concerning the proper prophylactic and therapeutic measures to be taken with regard to the late complications. A central topic in the discussions has been the role played by the diet. Definite proofs that a strictly regulated diet prevents the late complications or makes their course milder do not seem to have been given and in fact it must be extremely difficult to arrive at such proofs. A less debated question has been whether the application of different types of insulin therapy might entail different consequences for the development and course of late complications.

Vascular diseases constitute an important problem in clinical diabetes re-

search. It has long been considered that to a great extent DM patients are prone to develop vascular diseases especially atherosclerosis with cardiac infarctions. For this reason attention has been directed to the role of lipids in the occurrence of vessel damage. Through thorough studies Kinsell and co-workers (1965) have shown that the blood cholesterol can be kept at a low level by means of a suitable diet with small amounts of fat preferably in the form of polyunsaturated fatty acids. Yet it seems to be an open question whether or not this level is of the same significance for all DM patients. It may be taken as certain that a reduction should be aimed at so far as DM patients with pathologically increased blood cholesterol are concerned. Possibly it is not equally certain that a depression below normal level will be beneficial.

Recent investigations—for instance by Östman (1965)—have revealed that the lipid tissues consume comparatively large quantities of insulin. These findings are additional arguments for the prescription of a diet poor in fat and for a general reduction of fat deposits, i.e. a comparatively low body weight.

With the present state of knowledge it has not been possible to arrive at unambiguous conclusions concerning the aetiology of the late complications of DM or even concerning the effects of therapeutic measures on the course of these complications. DM is a disease where much attention must be given to each individual patient and it would not be advisable to perform prospective studies

over long periods involving differential treatment of strictly comparable patients. Retrospective studies of patients who have been treated differently—for instance at different hospitals or at the same hospital during different periods of time—are as a rule difficult to evaluate, that a number of selective factors occur (or at least may be suspected to occur) has been shown in the previous chapters. The quantitative data from our series in respect of late complications will be presented and discussed in Chapter VII.

### Working capacity

On the whole it might be stated that the working capacity of the majority of DM patients does not differ from that of comparable persons in the general population. For DM patients of working age the diet and the administration of insulin do not in ordinary situations interfere with their working capacity. With the availability of sulpha preparations and antibiotics the absence from work in the case of infections need not be longer for diabetics than for non-diabetics. Of course, stay in hospital for adjustment of the treatment and for training will imply an extra loss of working days, but on the other hand this will at least to a great extent be compensated by the necessity for many diabetics to lead a very regular life and—often—their demand for physical activity.

The real obstacle to the working capacity of diabetics is the loss of visual acuity which may be caused through retinopathy. From the socio-economic point of view it can be said that the possible reduc-

tion of vision is decisive for the appraisal of the working capacity of a diabetic. With the introduction in Sweden of a general system for invalidity survivors and old age pensions the reluctance—or even in certain quarters, refusal—of employers to engage diabetics has largely disappeared although a few traces of the earlier views still remain. Factors contributing to the change for the better have been the establishment of effective organizations for occupational guidance and for the retraining of partially incapacitated persons and the general situation on the labour market which has been characterized by high employment and manpower shortage during the whole postwar period. Before the Second World War (and even for some time afterwards) there was a much greater disinclination than now to employ diabetics in positions carrying pension rights.

Other late complications may of course cause in severe cases a considerable decrease or even a total loss of working capacity but then the disease will in general have progressed so far that the remaining expectation of life is much reduced.

The crucial complication in respect of length of life is nephropathy as long as the kidney functions are not too greatly disturbed the diabetic is ordinarily able to carry on his work and when renal insufficiency has developed the patient will in general have only a short time left.

Neuropathy has not proved to entail any appreciable loss of working capacity mainly because of the peculiar circumstance that pareses of importance do not occur. As a rule diabetics with neuropathy are able to walk and move un-

constrainedly, in spite of an often considerably reduced sensation in feet and legs. Generally there is a degeneration which disturbs deep sensation and sensitivity to pain, whereas sensitivity to contact is comparatively well preserved.

With regard to the type of work, it is interesting to note that a great many of the DM patients in our series were anxious to be able to keep on with an occupation involving heavy muscular exertion.

### Oral hypoglycaemic agents

As early as 1914, long before the discovery of insulin, it had been found in experiments that an animal on which parathyroidectomy had been performed not only developed tetany as a consequence of disturbed extracellular calcium balance but also presented hypoglycaemia. Watanabe (1918) associated the latter phenomenon with the occurrence of an increased amount of guanidine in the blood and this became the starting point for attempts to treat DM with guanidine preparations. During the thirties trials were made (Synthalin) but it was not until 1958 that such preparations—in particular phenylethylbiguanide (Dibem, Phenformin, DBI)—were at all frequently brought into use. They have been applied at the investigation hospitals in addition to insulin in difficult cases and have been well tolerated by the patients (cf. Evaldsson & Grönberg 1961).

In 1946 Loubatières observed that patients who were treated with sulphonamides because of infections sometimes displayed drowsiness which was shown to be due to hypoglycaemia. Loubatières

(1946) was able to prove that the reduction in blood sugar level was connected with the patient's production of insulin, when pancreatectomy was performed on experimental animals no similar effect was to be seen. On the basis of these observations a number of sulphonylurea preparations has been produced and brought into use for stimulating the  $\beta$  cells of the Langerhans islands to produce more insulin (cf Creutzfeldt & Soling 1961). At the investigation hospitals several of these (Carbutamide or BZ 55, Tolbutamide or D860 Chlorpropamide or Diabinese) have been applied in particular to replace or postpone the administration of insulin in cases of late onset DM. Investigations have shown that the frequency of complications is approximately the same for all these different sulphonylureas (Östman & Gronberg 1964).

Recently a sulphapyrimidine preparation has been introduced (Lycanol or Gondafon). Its effects seem to be comparable to those of the sulphonylureas (Gronberg Krook & Sjöholm 1967).

As already mentioned, oral hypoglycaemic agents were used to only a small extent at the investigation hospitals during the period covered by our clinical series. From the last years of the 1950s up to the present time the following treatment procedures have been practised:

(a) Biguanides have been used to supplement insulin treatment of juvenile and early adult onset DM especially where it has proved difficult to arrive at satisfactory control or where it has been desirable to restrict the injections to one or two days.

(b) Patients with late-onset DM treated with diet only, are nowadays often prescribed appropriate doses of sulphonylurea. If this does not prove to give satisfactory control biguanide is added and by means of this the resort to insulin can usually be avoided or at least postponed for years.

(c) Where patients who have been given sulphonylurea (with or without the combination with biguanide) prove to need insulin the oral remedies are regularly withdrawn, and the treatment is then diet and insulin alone. In certain cases an additional dose of biguanide can be prescribed after some time on the indications mentioned above under (a).

(d) In the case of patients with marked overweight, biguanide is sometimes given as the only remedy.

The general statement can be made with regard to the oral agents that they are valuable instruments for the treatment of DM in certain situations, but they cannot be used as real *substitutes* for insulin.

Smedby (1966) investigated a sample of the Swedish population (persons born on February 15) with regard to prescriptions paid for wholly or partly by the national health insurance (cf § 19) in 1963. There were registered 206 DM patients who had taken out insulin and oral hypoglycaemic agents with the following distribution:

Age	Insulin alone	Insulin plus oral	Oral alone	Total
<44	41	5	3	49
45-64	24	8	34	66
65-	28	3	60	91
Total	93	16	97	206



In a study of the greater part of Norrbotten County (BD) Meyer Lie and Smedby (1967) arrived at the following results in respect of medicine provided free of charge in 1963

Age	In u in or Insulin + oral	Oral alone	Total
0-14	46	3	49
15-44	300	27	327
45-64	275	396	671
65-74	158	338	496
75-	77	185	262
Total	856	949	1 805

Approximately the number of persons receiving DM medicines free of charge amounted to 0.75 per cent of the population. At ages 65 and over the prevalence figures were about 2.7 per cent for males and 4.5 per cent for females.

It should be borne in mind that a great many elderly diabetics are treated by means of dietary prescriptions and do not receive either insulin or oral hypoglycaemic agents and hence the prevalence of DM must be higher than indicated by these percentages.

The incidence of persons receiving free DM medicines for the first time in 1963 was about 1.1 per cent. In the age group 65-74 the incidence figures were 4.6 per cent for males and 6.0 per cent for females and at ages 75 and over they were still higher, viz. 5.1 per cent for males and 9.8 per cent for females.

In the evaluation of these latter figures it should be borne in mind that in respect of patients receiving DM medicines free of charge for the first time it is likely that there is in Norrbotten County an acceleration effect (as has probably been the case in most other counties in the past ten years).

## CHAPTER VII

# Late complications

Basically the clinical part of this study is a *retrospective* investigation of *actual* registrations made over a long period at four carefully selected county hospitals in different parts of Sweden. During the period studied the physicians in chief at the departments of internal medicine in all these hospitals have taken great interest in the treatment of DM patients.

In our opinion the results obtained from the analysis of the data on late complications are highly illuminating in so far as they prove the necessity of the utmost caution in the use of hospital register data (even very extensive case records) for conclusions concerning geographical differences and changes with time of the incidence and prevalence of late complications of DM (and of other similar hospital data). Intentionally the presentation in this chapter will be devised to illustrate the difficulties obtaining in these respects, this part of the analysis will mainly be made by means of *standard comparisons*.

### Diabetic retinopathy (Rd)

The first known description of a case of retinopathy was published in 1855 by Jaeger (cf. Fischer 1957). As the grave

cases of Rd mostly appear after a diabetes duration of one or two decades it was not until insulin treatment had been in use for many years that the importance of Rd as a complication of DM was generally known. Since then Rd has been the subject of extensive research dealing with the symptoms, treatment and prognosis of Rd and studying the factors which may affect its development and course (cf. for instance Caird and Garrett 1963, Granstrom 1947, Gronberg and Svanteson 1951, Nordlow, Gronberg and Svanteson 1953, Lundbæk 1955, Mårtensson and Palm 1950, Deckert 1960, Engel 1950, Johnsson 1959 and 1960, Jokipii 1953, Jorde 1961).

Reports on the general frequency of Rd differ widely. The diagnosis of Rd depends on the definition used, the available technical resources and the knowledge and competence of the investigator. As the development of Rd is correlated strongly to the duration of DM and weakly to the patient's age, the older reports where these factors are not separated are often not comparable, owing to bias in the selection of patients. A rough survey of research results during the last four decades is given in Table 53 quoted from Dardenne (1962).

We shall confine ourselves to a short

**Table 53** *Increased prevalence of diabetic retinopathy since the introduction of insulin therapy (after Dardinne 1962)*

Author	Country	Year	Number of diabetics	Cases with diabetic retinopathy	
				Number	Percentage
Wagener & Wilder	U.S.A	1921	300	44	14.7
Gray	Great Britain	1933	500	66	13.2
Wagener <i>et al</i>	U.S.A	1934	(1 952)	187	17.7
Waite & Beetham	U.S.A	1935	2 002	372	18.0
Braun	Germany	1937	697	115	16.5
Hanum	Denmark	1939	966	195	20.2
Mc Kee	Canada	1941	2 350	476	20.2
Wagner	U.S.A	1945	1 021	312	30.6
Barnes	U.S.A	1950	220	80	36.0
Heinsius	Germany	1952	620	203	32.5
Appel <i>et al</i>	Germany	1952	338	130	38.6
Aarseth	Norway	1953	288	121	42.0
Scott	Great Britain	1953	140	60	40.0
Porstmann & Wiese	Germany	1954	720	326	45.3
Dollfu	France	1954	1 303	681	52.4
Cowan <i>et al</i>	U.S.A	1955	500	216	43.2
Kornerup	Sweden	1955	1 000	468	46.8
Palomar	Spain	1956	416	175	42.0
Ashton	Great Britain	1957	203	137	67.0

review of the paper by Kornerup (1955) mentioned in the table Kornerup studied the occurrence of Rd among 518 male and 482 female diabetics treated at certain Stockholm clinics during the years 1945-53. The patients are classified by age at onset (0-14 15-40 41+) and the material is divided into 5 year groups by the duration of DM.

In those cases where Kornerup did not find retinopathic changes by direct ophthalmoscopy in mydriasis the patients were re-examined in monochromatic light with a wavelength of 5 720 Å. Of the 988 cases where the fundi could be examined with certainty, 462 or 46.8 per cent had some form of Rd. At the time this figure was considered high compared

**Table 54** *Percentage frequency of diabetic retinopathy by sex, age at onset and duration (after Kornerup 1955)*

Duration	Males				Females			
	Age at onset			All	Age at onset			All
	0-14	15-40	41+		0-14	15-40	41+	
0	0	0	9	4	0	3	7	5
1-4	29	18	9	15	18	7	17	13
5-9	67	53	42	53	25	50	46	43
10-14	82	73	67	76	80	72	77	76
15-19	90	93	73	89	65	90	78	77
20-24	79	70	83	77	85	83	75	83
25+	86	85	25	75	75	100	-	83
All	74	49	31	51	54	42	36	42

with other investigations for instance that by Aarseth (1953) giving 42 per cent and that by Engleson (1954) giving 33 per cent. Kornerup indicates the severity of Rd with the code numbers 0 for no changes, 1 for haemorrhagic, 2 for exudative and 3 for proliferative changes. These codes have been used also in our clinical series. He makes the important observation that fundus hypertonicus and Rd are two different and independent morbid states. For later comparison Kornerup's Table V is reproduced (our Table 54).

Many other works deserve to be mentioned. Often, however, the published data are not sufficiently extensive to admit comparisons. Some works treat only special forms of Rd: this applies for instance to the paper by Root, Mirsky and Ditzel (1959) where 847 cases of proliferative Rd are studied among 44 249 patients of the Joslin Clinic.

In certain cases Rd causes blindness. The number of diabetically blind persons in Sweden is not known. In the U.S.A. the number has been estimated at 29 000 making 8.4 per cent of all blind persons and about 1 per cent of all known diabetics. Estimating the number of Swedish diabetics at 159 000 (cf p. 114) we should thus expect about 1 600 diabetically blind persons in Sweden. In 1963 the Swedish Association of the Blind had 737 persons registered as diabetically blind; it considers that this number represents about 50 per cent of all diabetically blind persons in Sweden. If we draw the conclusion that the total number exceeds 1 500, the great importance of this sociomedical problem is evident.

### *Diabetic retinopathy in the hospital series*

From the case records the particulars regarding retinopathy were converted into the corresponding occasion card according to the code used by Kornerup (1955).

- 0 = no sign of Rd
- 1 = haemorrhagic Rd
- 2 = exudative Rd
- 3 = proliferative Rd

Departments of ophthalmology were created at Falun in 1922, at Östersund in 1940 and at Vänersborg in 1947, but at Växjö not until 1955. It was therefore not to be expected that the registrations for different years and hospitals should be consistent. Our misgivings in this respect were later confirmed.

The diagnoses covered by the codes 1, 2 and 3 do not represent an irreversible progress in time or a strict gradation according to severity, but for several reasons we have treated the data as if this were the case. If any of the occasion cards forming the basis of a duration period of five years contained codes for positive findings of Rd, the highest of these codes was carried to the duration card for this period. If for a patient Rd had been diagnosed and coded in an earlier duration period, the code was carried to his succeeding duration card not only if no ophthalmoscopy had been made during this latter period, but also if absence of Rd had been reported by the code 0, or the Rd had been denoted by a lower code number.

The motive for adopting this principle was mainly that for many mild cases some duration cards were based on one

Table 55 Registered state of retinopathy by sex age at onset duration epoch and

ODE	Hospital and state of retinopathy															
	Vänersborg P				Västra G				Eken W				Östersund Z			
	0	1	2	3	0	1	2	3	0	1	2	3	0	1	2	3
Total																
0-3																
1-3																
Males																
J a 1	43	-	-	-	28	-	-	-	19	-	-	-	27	-	-	-
2	4	-	-	-	5	-	-	-	4	-	-	-	3	-	-	-
b 1	30	1	-	-	21	-	-	-	20	1	-	-	17	-	-	-
2	11	1	-	-	9	2	-	-	8	-	-	-	5	-	-	-
c 1	111	2	-	-	10	2	-	1	13	4	-	-	14	-	-	-
2	13	7	-	-	11	2	-	-	9	3	-	1	9	2	-	-
d 1	11	4	-	-	6	1	-	-	7	1	-	-	7	-	-	-
2	6	13	1	-	4	3	3	-	4	10	1	-	4	1	-	-
e 1	2	1	-	-	2	-	-	-	1	1	-	-	2	-	-	-
2	4	10	1	-	1	2	1	-	4	9	-	2	3	1	1	-
f 1	3	1	-	-	-	-	-	-	1	-	-	-	1	-	-	-
2	1	6	2	1	3	-	2	1	2	4	-	-	4	1	-	-
A a 1	78	-	-	-	47	-	-	-	49	1	1	-	69	-	-	-
2	16	1	-	-	19	-	-	-	64	-	-	-	20	1	-	-
b 1	47	-	-	-	28	-	-	-	23	3	-	-	26	-	-	-
2	34	5	-	-	17	2	-	-	37	6	1	-	21	2	-	-
c 1	27	1	-	-	16	3	-	-	16	2	2	-	14	2	1	-
2	16	12	1	1	7	2	2	-	20	10	1	-	13	3	-	-
d 1	13	-	-	-	8	6	1	-	6	2	1	-	4	-	1	-
2	9	13	4	-	4	4	1	1	11	14	-	-	6	9	3	-
e 1	6	1	-	-	2	-	-	-	2	-	-	-	2	1	-	-
2	7	7	1	-	2	8	6	-	6	7	2	-	4	2	3	-
f 1	3	-	-	-	1	-	-	-	13	1	-	-	2	1	-	-
2	14	7	2	1	1	3	2	1	9	4	1	-	3	-	-	-
L a 1	95	2	1	-	79	-	-	-	66	3	-	-	169	2	2	-
2	123	10	3	-	84	1	1	-	136	7	2	-	146	10	2	-
b 1	33	1	1	-	22	1	1	-	27	2	-	-	58	1	-	-
2	77	15	2	-	53	1	1	-	73	9	2	-	78	10	1	-
c 1	19	1	-	1	11	-	1	-	13	4	1	-	26	2	-	-
2	21	17	3	2	16	1	3	-	25	8	7	-	21	8	1	-
d 1	3	-	-	-	6	-	-	-	5	-	-	-	12	-	-	-
2	16	9	5	2	7	-	1	-	11	9	3	1	6	4	1	-
e 1	2	-	-	-	2	1	-	-	1	-	-	-	4	-	-	-
2	7	3	-	-	4	-	1	-	5	2	-	-	4	1	-	-
f 1	2	1	-	-	-	-	-	-	1	-	-	-	-	-	-	-
2	3	-	-	-	2	-	-	-	2	-	-	-	1	-	-	-
State of Rd ■ no findings 1 haemorrhagic 2 exudative 3 proliferative																
Age at onset (O) J 0-14 A 15-39 L 40-																

or very few occasions often without connection with the diabetes. To accept these registrations where no examination by an ophthalmologist had been

made would probably introduce more errors in the data for calculating the incidence and prevalence of Rd than our simple procedure does.

O D E	Hospital and state of retinopathy																					
	Vänersborg F				Väspö III				Falun W				Östersund Z				Total					
	0	1	2	3	0	1	2	3	0	1	2	3	0	1	2	3	II	1	2	3	0-3	1-3
Females																						
J a 1	37	-	-	-	27	-	-	-	30	-	-	-	27	-	-	-	121	-	-	-	121	-
2	2	-	-	-	1	-	-	-	1	-	-	-	-	-	-	-	4	-	-	-	4	-
b 1	27	2	-	-	21	1	-	-	15	-	-	-	20	-	-	-	81	3	-	-	86	3
2	7	1	-	-	7	-	-	-	9	2	-	-	3	-	-	-	26	3	-	-	29	3
c 1	12	3	1	-	12	2	1	-	9	3	-	-	9	1	-	-	42	9	2	-	53	11
2	6	10	-	-	11	1	2	-	9	10	-	1	8	3	-	-	34	24	2	1	61	27
d 1	5	1	1	-	6	-	-	-	7	1	1	1	1	1	2	-	19	3	4	1	27	8
2	2	10	2	-	4	1	3	-	3	4	1	2	6	2	1	-	15	17	7	2	41	26
e 1	1	1	-	-	1	1	-	-	3	3	1	-	-	-	-	-	5	5	1	-	11	6
2	3	3	2	-	2	4	-	-	1	5	3	1	2	-	-	-	8	12	5	1	26	18
f 1	-	1	-	-	1	-	-	-	1	1	-	-	-	-	-	-	2	2	-	-	4	2
2	4	5	1	-	1	-	2	-	2	4	1	1	1	-	-	-	8	9	4	1	22	14
A a 1	43	1	-	-	27	-	-	-	47	-	-	-	30	-	-	-	147	1	-	-	148	1
2	29	-	-	-	14	-	1	-	33	2	-	-	24	-	-	-	100	2	1	-	103	3
b 1	22	3	-	-	13	3	-	-	27	3	-	-	21	2	-	-	83	11	-	-	94	11
2	21	8	-	-	14	2	1	-	33	2	-	-	11	-	-	-	79	12	1	-	92	13
c 1	8	1	-	-	14	3	-	-	18	3	-	-	13	1	1	-	53	8	1	-	54	9
2	9	15	2	-	7	3	1	-	14	9	1	-	6	2	-	-	36	29	4	-	69	33
d 1	5	1	-	-	8	1	1	-	14	3	-	-	7	-	1	-	34	5	2	-	41	7
2	2	8	1	-	4	5	1	-	6	7	2	-	8	2	1	-	20	22	5	-	47	27
e 1	3	-	1	-	3	-	1	-	6	3	-	-	2	2	-	-	14	5	2	-	21	7
2	2	4	1	-	5	1	3	-	9	7	1	-	3	1	-	-	19	13	5	-	37	18
f 1	5	-	-	-	2	-	-	-	3	-	-	-	-	-	-	-	10	-	-	-	10	-
2	8	4	1	-	9	1	-	-	9	7	2	-	5	2	-	-	31	14	3	-	48	17
L a 1	123	5	-	-	165	3	2	-	112	3	1	-	237	7	4	1	637	18	7	1	663	26
2	188	19	1	-	111	1	4	-	179	15	2	-	210	21	9	-	688	56	16	-	760	72
b 1	36	6	-	-	64	1	1	-	39	6	-	-	80	5	2	-	219	18	3	-	240	21
2	127	17	4	1	97	9	3	-	124	30	2	-	101	22	5	-	449	78	14	1	542	93
c 1	17	-	-	-	34	4	2	-	16	8	1	-	36	5	1	-	103	17	4	-	124	21
2	30	26	1	2	35	5	3	-	41	26	4	-	25	14	4	-	131	71	12	2	216	85
d 1	4	1	-	-	5	1	-	-	7	2	1	-	9	3	1	-	25	7	2	-	34	11
2	6	12	3	-	21	3	6	-	15	18	3	-	11	9	1	-	53	42	13	-	108	55
e 1	1	-	-	-	-	-	-	-	1	-	-	-	2	-	-	-	4	-	-	-	4	-
2	3	3	1	1	4	1	2	-	5	4	1	-	1	2	-	1	13	10	4	2	29	16
f 1	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	-	-	-	2	-
2	3	-	1	-	1	-	-	-	-	1	-	-	-	1	1	-	4	2	2	-	8	4
Duration (D) a 0-4 d 15-19 Epoch (E) 1 duration periods beginning 1949 or earlier																						
b 5-9 e 20-24 2 duration periods beginning 1950 or later																						
c 10-14 f 25-																						

As the patients in two consecutive duration groups are not identical the registrations of retinopathic state in the duration cards are not sufficient to ad-

mit conclusions concerning the course of Rd in a general diabetic population. For this reason the individual changes of state from one duration period to the

Table 62 *Intensity of retinopathy by duration both sexes*

Duration	Intensity of retinopathy (with haemorrhagic = 1 exudative = 2, proliferative = 3)			
	All diabetics		Retinopathic diabetics	
	Our series	Kornerup	Our series	Kornerup
0-4*	0.09	0.17	1.6	1.2
5-9	0.17	0.67	1.3	1.4
10-14	0.47	1.40	1.5	1.8
15-19	0.72	1.62	1.7	1.9
20-24	0.77	1.57	1.8	2.0
25-	0.63	1.43	2.0	1.9

\* Kornerup 1-4 years

been allotted the weights 1 2 and 3 respectively. Thus we obtain the comparison shown in Table 62.

From the discussion in the preceding section it follows that we should expect lower intensities among all diabetics. If however the differences were due mainly to incomplete registration in our series of the easy cases of haemorrhagic Rd our material ought to show a higher intensity among the retinopathic patients. This is clearly not the case and the most probable explanation is that even in the later epoch our registrations

regarding the different types are not as complete as those of Kornerup.

For the later epoch Table 63 shows the registrations at the four hospitals compared with the expected values calculated from the frequencies for all hospitals combined. From the table it can be seen that hospital G, with its low retinopathy frequency, has comparatively more advanced cases than the other hospitals, and that the two hospitals P and W with the highest overall frequencies have comparatively fewer advanced cases. These facts support the conjecture that even among the diagnosed cases of Rd the registrations of the type of Rd have not been as uniform as intended.

### *Retinopathy and control*

The question of the influence of treatment and control on the course of the late complications has not been definitely answered.

To get an idea of the factors which might be of interest in connection with this important problem we made a special calculation where for the durations 10-14 and 15-19 years the fre-

Table 63 *Standard comparison between hospitals of states of retinopathy in the later epoch both sexes*

Hospital	Diagnosed type of retinopathy							
	Haemorrhagic		Exudative		Proliferative		All types	
	Exp.	Obs.	Exp.	Obs.	Exp.	Obs.	Exp.	Obs.
P	226.2	281	46.7	47	7.4	11	290.3	339
G	139.0	68	34.7	39	4.4	3	178.1	130
W	230.0	255	57.6	45	7.1	7	294.7	307
Z	145.8	137	35.0	33	4.1	2	184.9	172
Total	741.0	741	184.0	184	23.0	23	948.0	948

Table 64 Frequency of retinopathy by sex age at onset, hospital and treatment durations 10-14 and 15-19

	Duration 10-14						Duration 15-19					
	Males			Females			Males			Females		
	Total	With Rd		Total	With Rd		Total	With Rd		Total	With Rd	
	num-ber	per-cent		num-ber	per-cent		num-ber	per-cent		num-ber	per-cent	
Total material	506	128	25	585	186	32	312	136	44	298	132	44
Hospital												
Vanersborg P	163	49	30	143	61	43	109	51	47	64	40	62
Vaxjo G	88	17	19	140	27	19	59	24	41	70	22	31
Falun W	139	43	31	173	66	38	88	42	49	98	46	47
Östersund Z	116	19	16	129	32	25	58	19	33	66	24	36
Age at onset												
0-14	121	24	20	114	38	33	87	38	44	68	34	50
15-39	173	44	25	131	42	32	124	53	51	88	34	39
40-	212	60	28	340	106	31	101	35	35	142	64	45
Weight at onset												
normal	494	124	25	552	174	32	310	135	44	294	130	44
overweight*	12	4	33	33	12	36	2	1	50	4	2	50
Diet regulated												
strictly	64	20	31	73	24	33	26	11	42	23	16	70
not strictly	442	108	24	512	162	32	286	125	44	275	116	42
Daily dose of insulin												
0-39 I U	166	46	28	249	71	29	81	29	36	115	55	48
40- I U	340	82	24	336	115	34	231	107	46	183	77	42
* Compared with the normal weight according to Broca (weight in kg equal to length in cm minus 100) the following excess weight has been considered as overweight												
Age at onset	Duration 10-14					Duration 15-19						
0-34	5 kg or more					10 kg or more						
35-	10 kg or more					15 kg or more						

quencies of Rd were studied in groups by hospital and age at onset and with simultaneous dichotomizations regarding weight at onset diet and daily insulin dose. The limitation to the two durations 10-14 and 15-19 years was warranted by the comparatively few cases of Rd in the lower durations and the low number of patients in the higher durations. The resulting table did not show any tendencies differing from normal random fluctuations. As the table is rather extensive an extract showing

only some marginal frequencies is given in Table 64. From the table it can be clearly seen that the differences according to treatment are insignificant in comparison with the large differences between hospitals which differences have been discussed earlier in this chapter.

Either from the complete table or from the extract (Table 64) it is possible to prove or disprove connections between treatment and the development of retinopathy. Nevertheless we think that the data support our belief that even if such



connections exist no treatment hitherto used in general hospitals will decisively improve or retard the retinopathic changes among the diabetics

## Diabetic nephropathy (Pd)

The diagnosis diabetic nephropathy (Pd) is partly clinical partly patho-anatomical<sup>1</sup>

The patho-anatomical designation is limited to renal lesions, caused by those capillary changes characteristic of diabetes which are now termed diabetic microangiopathy (cf Rifkin & Leiter 1962). It should be remembered that this renal disorder (Kimmelstiel Wilson's syndrome) can hardly be diagnosed clinically.

Through studies of biopsies it is known that signs of diabetic nephropathy may appear long before the diagnosed onset of DM and without any albuminuria being present.

If as in this study the occurrence of persistent albuminuria is considered as the clinical manifestation of Pd it is obvious that the complication will be diagnosed at a comparatively advanced stage.

Studies on the prevalence of diabetic nephropathy have been made among others by Mårtensson (1950) and Johnson (1959-1960). Alwall, Ekelund and Oras (1950) have investigated certain problems connected with intercapillary glomerulosclerosis (Kimmelstiel Wilson's syndrome). Among Swedish investiga-

tions of the renal function in diabetic nephropathy mention may be made in particular of those by Hogeman (1948) and by Bucht, Ek and Werkö (1956).

Hogeman (1948) made a thorough study of the renal function in 12 patients with uncomplicated DM and 12 patients who had diabetic nephropathy with proteinuria and positive urinary sediment as well as elevated blood pressure and retinal changes. Renal function in uncomplicated DM was found to be normal. For the patients with nephropathy there was a change in renal function towards pathologically decreased values; the same results were found in non-diabetic patients with malignant hypertension. Despite this similarity the patients with nephropathy showed a better prognosis than those with malignant hypertension. The insulin clearance, the diodrast clearance and the filtration fraction (the relation between the insulin and diodrast clearances) were low in diabetic nephropathy, whereas on the contrary a high filtration fraction is a common phenomenon in nephrosclerosis and hypertension. The author is of opinion that the mechanism causing the decrease in renal function is entirely different and that the malignant phase of diabetic nephropathy consists of intercapillary glomerulosclerosis.

## Diabetic nephropathy in the hospital series

In the occasion cards the following states of Pd were coded:

- 0 = no persistent albuminuria,
- 1 = persistent albuminuria without signs of renal insufficiency
- 2 = renal insufficiency

The term *persistent albuminuria* signifies here that albuminuria had been observed on three consecutive occasions. In the preceding section it was pointed out

<sup>1</sup> Cf. e.g. Berkman (1962) and Thomsen (1965).

that the adoption of the occurrence of persistent albuminuria as a criterion for the diagnosis diabetic nephropathy will imply a comparatively late diagnosis. Our definition of the concept persistent albuminuria will further delay the registration of Pd for patients who seldom visit the hospitals. For patients who have been admitted only once or twice even a pronounced albuminuria will escape classification as Pd. We must thus expect to register a lower prevalence and a later incidence of Pd than are usually found in investigations made by specialists with large resources.

From the occasion cards belonging to one duration period, the highest code occurring has been transferred to the corresponding duration card.

### *Prevalence of nephropathy among DM patients*

The states of Pd as registered in the duration cards are shown in the basic Table 65. From these data the prevalence of Pd during the total investigation period has been calculated in Table 66.

Table 66 of the nephropathy prevalence shows main features resembling those of the retinopathy prevalence in Table 56. The frequency of renal disorders has a maximum after 15-24 years duration and shows a slight decrease in the highest duration group. Of course this does not imply that a diabetic with Pd may expect a recovery from his renal disorder after 25 years duration. The decrease is mainly due to the selection caused by the death of patients with renal

insufficiency or a generally malignant course of DM. This selection is, however, obscured by a lack of homogeneity in the registrations for different hospitals and during the period studied. As in the case of retinopathy, we shall therefore study the incidence of Pd and the inhomogeneities just mentioned.

### *Incidence of nephropathy*

The changes in the state of Pd between consecutive duration periods were registered according to the code defined earlier in respect of Rd. For Pd the main results are shown in Table 67. A striking feature in the table is the recoveries registered in 144 duration cards (73 males and 71 females). That so many diabetics with permanent albuminuria in one duration period should be free from this symptom during the following period seems to be unlikely. The recoveries are probably due to incomplete registration. This remark seems valid also for the two instances of female diabetics registered as free from earlier renal insufficiency.

From Table 67 can be calculated the incidence of Pd, as shown by the following example for males with age at onset 0-14 years (type J) during duration 5-9 years (duration b). Out of the 111 diabetics observed during the previous duration period also 92 have shown no Pd whilst 7 earlier unaffected patients have had Pd diagnosed in the current duration period. The incidence rate for this group of patients is thus 7 divided into 99 or 7.1 per cent. If the incidence rate were interpreted as the risk of a diabetic having Pd

Table 65 Registered state of nephropathy by sex age at onset duration epoch and

			Hospital and state of nephropathy																	
O	D	E	Vänersborg P			Västerås G			Falun W			Östersund Z			Total					
			0	1	2	0	1	2	0	1	2	0	1	2	0	1	2	0-2	1-2	
Males																				
J	a	1	33	10	-	28	-	-	16	3	-	27	-	-	104	13	-	117	13	
		2	4	-	-	5	-	-	4	-	-	3	-	-	16	-	-	16	-	
	b	1	24	7	-	20	1	-	15	6	-	17	-	-	76	14	-	90	14	
		2	9	3	-	10	1	-	8	-	-	5	-	-	32	4	-	36	4	
	c	1	12	8	-	9	3	1	13	4	-	12	2	-	46	17	1	64	18	
		2	11	9	-	8	5	-	12	1	-	11	-	-	42	15	-	57	15	
	d	1	10	5	-	6	1	-	6	2	-	4	2	1	26	10	1	37	11	
		2	10	9	1	4	6	-	9	4	2	5	-	-	28	19	3	50	22	
	e	1	2	1	-	1	1	-	1	1	2	-	-	-	5	3	1	9	4	
		2	7	6	2	2	2	-	9	4	2	4	1	-	22	13	4	39	17	
	f	1	4	-	-	-	-	-	1	-	-	1	-	-	5	1	-	6	1	
		2	7	3	-	5	1	-	4	1	1	4	1	-	20	6	1	27	7	
A	a	1	64	13	1	46	1	-	49	2	-	68	1	-	227	17	1	245	18	
		2	14	3	-	19	-	-	56	8	-	20	1	-	129	12	-	141	12	
	b	1	42	5	-	27	1	-	23	3	-	25	1	-	117	10	-	127	10	
		2	16	3	-	18	1	-	41	3	-	23	-	-	118	7	-	125	7	
	c	1	23	5	-	16	3	-	18	1	1	17	-	-	74	9	1	84	10	
		2	27	2	2	8	1	2	26	3	2	16	-	-	77	6	6	89	12	
	d	1	11	2	-	11	3	1	8	1	-	4	1	-	34	7	1	42	8	
		2	18	8	-	7	2	4	16	7	2	14	1	3	55	18	9	81	27	
	e	1	7	2	-	2	-	-	2	-	-	3	-	-	14	2	-	16	2	
		2	8	6	1	10	4	2	13	1	1	8	1	-	39	12	4	55	16	
	f	1	2	1	-	1	-	-	13	1	-	3	-	-	19	2	-	21	2	
		2	18	6	-	4	2	1	11	3	-	3	-	-	36	11	1	48	12	
L	a	1	84	14	-	79	-	-	61	6	2	171	2	-	395	22	2	419	24	
		2	102	34	-	82	3	1	128	14	3	153	2	3	465	53	7	525	60	
	b	1	29	6	-	22	2	-	28	1	-	58	1	-	137	10	-	147	10	
		2	71	21	2	49	3	3	70	13	1	86	3	-	276	40	6	322	46	
	c	1	16	5	-	11	1	-	15	3	-	27	1	-	69	10	-	79	10	
		2	12	10	1	18	2	-	33	5	2	27	2	1	110	19	4	133	23	
	d	1	1	2	-	5	1	-	3	1	1	11	1	-	20	5	1	26	6	
		2	20	9	3	8	-	-	18	6	-	10	1	-	56	16	3	75	19	
	e	1	1	1	-	3	-	-	1	-	-	4	-	-	9	1	-	10	1	
		2	11	2	-	4	1	-	5	2	-	5	-	-	22	5	-	27	5	
	f	1	3	-	-	-	-	-	1	-	-	-	-	-	3	1	-	4	1	
		2	2	1	-	2	-	-	2	-	-	1	-	-	7	1	-	8	1	
State of Pd			0 no persistent albuminuria 1 persistent albuminuria 2 renal insufficiency															Age at onset (O)		
																		J 0-14		
																		A 15-39		
																		L 40		

for the first time during the duration period the denominator should properly be corrected for the reduction of observation time caused by those of the 99 who

have left the investigation before the end of the duration period. Disregarding this correction we confine ourselves to stating that the incidence rates calculated are on

# hospital

## Hospital and state of nephropathy

II	D	E	Vänersborg P			Växjö G			Falun W			Östersund Z			Total				
			0	1	2	0	1	2	0	1	2	0	1	2	0	1	2	0-2	1-2
Females																			
J	a	1	25	12	-	26	1	-	26	4	-	27	-	-	104	17	-	121	17
		2	1	1	-	1	-	-	1	-	-	-	-	-	3	1	-	4	1
	b	1	18	11	-	21	1	-	11	4	-	20	-	-	70	16	-	86	16
		2	5	3	-	7	-	-	10	-	-	3	-	-	25	4	-	29	4
	c	1	8	8	-	11	4	-	7	5	-	10	-	-	36	17	-	53	17
		2	9	7	-	13	1	-	13	4	3	10	1	-	45	13	3	61	16
	d	1	3	3	1	3	3	-	4	4	2	2	1	1	12	11	4	27	15
		2	7	6	1	6	2	-	3	3	4	8	-	1	24	11	6	41	17
	e	1	-	2	-	2	-	-	1	5	1	-	-	-	3	7	1	11	8
		2	5	1	2	2	3	1	6	3	1	2	-	-	15	7	4	26	11
	f	1	-	1	-	-	1	-	1	1	-	-	-	-	1	3	-	4	3
		2	9	1	-	1	1	1	4	3	1	1	-	-	15	5	2	22	7
A	a	1	32	12	-	27	-	-	37	10	-	29	1	-	125	23	-	148	23
		2	19	10	-	15	-	-	34	1	-	24	-	-	92	11	-	103	11
	b	1	20	5	-	15	1	-	24	5	1	23	-	-	82	11	1	94	12
		2	23	6	-	17	-	-	35	-	-	11	-	-	86	6	-	92	6
	c	1	9	-	-	16	1	-	13	7	1	13	1	1	51	9	2	62	11
		2	17	7	2	8	2	1	19	4	1	8	-	-	52	13	4	69	17
	d	1	5	1	-	7	3	-	10	6	1	7	1	-	29	11	1	41	12
		2	6	3	2	6	3	1	12	2	1	9	1	1	33	9	5	47	14
	e	1	2	1	1	2	2	-	6	2	1	3	1	-	13	6	2	21	8
		2	6	1	-	6	3	-	11	5	1	3	1	-	26	10	1	37	11
	f	1	5	-	-	2	-	-	2	1	-	-	-	-	9	1	-	10	1
		2	7	3	3	8	2	-	14	3	1	6	-	1	35	8	5	48	13
L	a	1	120	8	-	157	12	1	106	9	1	244	5	-	627	34	2	663	36
		2	158	48	2	113	2	1	165	28	3	233	6	1	669	84	7	760	91
	b	1	36	5	1	44	1	1	42	3	-	85	2	-	227	11	2	240	13
		2	105	39	5	100	5	4	138	18	2	125	3	-	468	43	11	542	74
	c	1	15	2	-	36	3	1	18	6	1	39	3	-	108	14	2	124	16
		2	38	19	2	38	4	1	60	9	2	41	2	-	177	34	5	216	39
	d	1	5	-	-	6	-	-	7	1	2	12	1	-	30	2	2	34	4
		2	11	10	-	22	4	4	25	9	2	20	-	1	78	23	7	108	30
	e	1	1	-	-	-	-	-	1	-	-	2	-	-	4	-	-	4	-
		2	4	3	1	6	1	-	6	4	-	3	1	-	19	9	1	29	10
	f	1	2	-	-	-	-	-	-	-	-	-	-	-	2	-	-	2	-
		2	4	-	-	-	1	-	-	1	-	2	-	-	6	2	-	8	2
Duration (D)		a	0-4			d	15-19			Epoch (E)		1 duration periods beginning 1949 or earlier							
		b	5-9			e	20-24					2 duration periods beginning 1950 or later							
		c	10-14			f	25-												

the low side compared with the risks discussed

From these incidence rates the prevalence of Pd has been calculated under

the unrealistic hypothesis that the incidence as well as the prevalence are the same for patients observed during two consecutive duration periods as for pa-

Table 66 : Frequency of nephropathy by sex, age at onset and duration

Duration	Percentage frequency of nephropathy (states 1 and 2)							
	Males				Females			
	Age at onset			All	Age at onset			All
	0-14	15-19	20-24		0-14	15-19	20-24	
0-4	10	8	9	9	14	14	9	10
5-9	14	7	12	11	17	10	11	13
10-14	27	13	16	17	29	21	16	20
15-19	38	28	25	30	47	30	23	31
20-24	44	25	16	29	51	33	30	38
25+	24	20	17	21	38	24	20	28
All	23	13	12	14	27	18	12	15

tients entering or leaving the investigation. The calculation has been performed as described earlier in respect of Rd. The results are given in Table 68 and are compared with the prevalences observed according to Table 66.

The difference between the prevalence as calculated from the incidence rates and the observed prevalence implies that the frequency of Pd among patients leaving the investigation is higher than that of those remaining. In the similar situation in the case of retinopathy it was shown that this effect was not due to the mortality of the worst cases but could be explained by the progress in diagnostics and more complete registration. As will appear in the following section the increase in prevalence of diagnosed Pd is of a much smaller magnitude than in respect of retinopathy. Unlike retinopathy Pd is an important cause of death for diabetics. It is therefore probable that the difference between calculated and observed prevalence of Pd is due largely to the death of diabetics with pronounced nephropathy.

Table 68 gives the calculated incidence rates of nephropathy. Owing to the

special purpose of this table, even the registrations of Pd at duration 0-4 years were used under the oversimplified hypothesis that persistent albuminuria does not occur before the onset of DM. The distributions of the new cases show some interesting characteristics. There is a high incidence rate of Pd at duration 0-4 years, followed by a fairly even distribution with a maximum at the durations 15-19 or 20-24 years. This picture might correspond to different diagnostic situations. In cases where albuminuria has been an indication of diabetes, it is evident that Pd will in general appear early in the registrations. In most cases the original admission and diagnosis have been connected with the occurrence of acidosis and glycosuria, and signs of albuminuria have gradually appeared.

These general characteristics of the incidence rates for Pd may to a certain extent reflect an uncertainty regarding the exact year of onset, with resulting vagueness in the definition of duration. The comparatively high percentage of well-defined retinopathy in the lowest duration group gives support to the

**Table 67** *Changes in the registered state of nephropathy by sex age at onset and duration*

Sex and age at onset	Duration	Type of change in state of nephropathy							Total
		0 No Pd	1 Recovery	2 Improvement	3 Unchanged	4 New Pd	5 Aggravation	- New patients	
<i>Males</i>									
0-14	0-4							133	133
	5-9	11	4	-	8	7	-	15	126
	10-14	71	6	-	11	18	-	15	121
	15-19	43	5	-	16	13	2	8	87
	20-24	24	-	-	8	11	4	6	48
	25-	19	1	-	7	-	-	6	33
15-39	0-4							386	386
	5-9	204	15	-	4	13	-	16	252
	10-14	130	7	-	4	15	2	15	173
	15-19	78	4	-	8	19	2	13	124
	20-24	42	4	-	7	9	2	7	71
	25-	39	5	-	5	7	-	13	69
40-	0-4							944	944
	5-9	354	10	-	20	25	2	58	469
	10-14	151	6	-	8	19	2	26	212
	15-19	66	1	-	12	8	2	12	101
	20-24	24	1	-	5	1	-	6	37
	25-	6	4	-	-	1	-	1	12
<i>Females</i>									
0-14	0-4							125	125
	5-9	78	6	-	9	9	-	13	115
	10-14	66	5	-	13	15	1	14	114
	15-19	28	5	-	16	10	4	5	68
	20-24	13	3	-	10	2	2	7	37
	25-	10	3	-	7	-	1	5	26
15-39	0-4							251	251
	5-9	130	13	-	9	5	-	29	186
	10-14	90	4	-	8	16	1	11	131
	15-19	53	3	1	8	10	4	9	88
	20-24	33	2	-	11	6	1	5	58
	25-	30	3	1	5	3	3	13	58
40-	0-4							1 423	1 423
	5-9	585	17	-	20	53	3	104	782
	10-14	248	6	-	11	32	2	41	340
	15-19	91	1	-	10	19	2	11	142
	20-24	20	-	-	4	5	1	3	33
	25-	8	-	-	-	1	-	1	10

suspicion that especially in the case of late DM the year of first admission has sometimes been substituted for the unknown or uncertain year of onset

The codes of change used in Table 67 are not sufficiently specified to admit an

evaluation of the first appearance of renal insufficiency as this appearance may be coded as either new or aggravated Pd The cases are too few to admit a reliable calculation of incidence rates but a special list was made from which Table

Table 68 *Calculated incidence and prevalence of nephropathy by sex age at onset and duration*

Sex and age at onset	Duration	Patients with no Pd in earlier periods		Incidence of Pd $I_d = \frac{n}{t}$	Prevalence of Pd per cent	
		Total number $t$	With Pd diagnosed in period $r$		Calculated $P_d$	Observed (Table 66)
<i>Males</i>						
0-14	0-4	133	13	0.0977	18	10
	5-9	99	7	0.0707	15	14
	10-14	99	18	0.1818	31	27
	15-19	56	13	0.2321	47	38
	20-24	30	6	0.2000	57	44
	25-	18	-	-	57	24
15-39	0-4	386	30	0.0777	8	8
	5-9	218	13	0.0596	13	7
	10-14	145	15	0.1034	22	13
	15-19	97	19	0.1959	37	28
	20-24	51	9	0.1765	48	25
	25-	46	7	0.1522	56	20
40-	0-4	944	84	0.0890	9	9
	5-9	379	25	0.0660	15	12
	10-14	170	19	0.1118	24	16
	15-19	73	8	0.1096	33	25
	20-24	25	1	0.0400	35	16
	25-	7	1	0.1429	45	17
<i>Females</i>						
0-14	0-4	125	18	0.1440	14	14
	5-9	87	9	0.1034	23	17
	10-14	81	15	0.1852	37	29
	15-19	38	10	0.2632	54	47
	20-24	15	2	0.1333	60	51
	25-	10	-	-	60	33
15-39	0-4	251	34	0.1350	14	14
	5-9	135	5	0.0365	17	10
	10-14	106	16	0.1509	29	21
	15-19	63	10	0.1587	40	30
	20-24	39	6	0.1538	50	33
	25-	33	3	0.0909	54	24
40-	0-4	1423	127	0.0892	9	9
	5-9	678	53	0.0831	16	11
	10-14	280	32	0.1143	26	16
	15-19	110	19	0.1727	39	23
	20-24	25	5	0.2000	51	30
	25-	9	1	0.1111	57	20

69 is reproduced to be compared with the column With Pd diagnosed in period in Table 68. Thus new patients in durations above 0-4 years are not included as we do not know when the recorded insufficiency appeared. Com-

paring the figures with the change codes 4 and 5 in Table 67 it is remarkable that in many cases insufficiency is recorded without preceding registration of persistent albuminuria. The existence in the lowest duration group of 18 cases of

Table 69 First appearance of renal insufficiency by sex age at onset and duration

Duration	Males (registrations)				Females (registrations)			
	Age at onset			All	Age at onset			All
	0-14	15-39	40-		0-14	15-39	40-	
0-4	-	-	9	9	-	-	9	9
5-9	-	-	4	4	-	-	10	10
10-14	-	7	4	11	2	5	2	9
15-19	3	5	3	11	7	5	7	19
20-24	4	3	-	7	2	1	1	4
25-	-	1	-	1	1	1	-	2
Total	7	16	20	43	12	12	29	53

renal insufficiency supports the above-mentioned suspicions about the exactitude of the year of onset

### *Nephropathy frequency with regard to hospitals and epochs*

From the exact frequencies behind the rounded off percentages in Table 66 we have calculated the number of nephropathy diagnoses which would have been expected if the registered prevalence had been the same at all hospitals and in the two epochs studied. For each sex the expected numbers for the four hospitals and the two epochs have been compared with the observed numbers. The quotients observed/expected or the standardized indices are shown in Table 70.

The difference in registered prevalence between the two epochs is illustrated by the increase of the standardized index from 83 to 112 per cent for males and from 86 to 110 per cent for females. Roughly speaking the registered prevalence has gone up by about 30 per cent.

In view of our experiences regarding the completeness of old case record registrations we are not prepared to conclude that the prevalence of Pd among

diabetics has changed. As a certain number of patients observed in the earlier epoch are survivors from the pre insulin era they may represent a selected group of comparatively mild cases of DM. The increase in Pd could thus represent the adaptation to a higher level corresponding to the reduction in diabetes mortality. The time variation is however insignificant compared with the almost startling differences between the hospitals: the standardized nephropathy indices being at Östersund (Z) 28, at Växjö (G) 71, at Falun (W) 114, and at Vänersborg (P) 166 per cent. Thus the prevalence of Pd at Vänersborg is found to be about six times the prevalence at Östersund.

### *The occurrence of different nephropathy states*

In order to get a more complete picture the standard comparison has been performed separately for each of the two states: persistent albuminuria and renal insufficiency. As the figures for males and females show identical patterns we confine ourselves to giving the main results for both sexes taken together, as



*Table 70 Standard comparison of nephropathy frequency by sex hospital and epoch*

Sex and hospital	Number of patients (registrations) showing nephropathy								
	Epoch						Total		
	E1 (1949)			E2 (1950-)					
	Exp	Obs.	O/E	Exp	Obs.	O/E	Exp	Obs.	O/E
<i>Males</i>									
P	59.3	88	148	89.7	147	164	149.0	235	158
G	39.7	20	50	46.9	47	100	86.6	67	77
W	42.0	42	100	81.4	91	112	123.4	133	108
Z	55.1	13	24	53.9	20	37	109.0	33	30
Total	196.1	163	83	271.9	305	112	468.0	468	100
<i>Females</i>									
P	55.1	74	134	95.1	188	198	150.2	262	174
G	59.3	36	61	66.8	48	72	126.1	84	67
W	64.0	111	131	106.8	118	110	170.8	202	118
Z	68.1	18	26	70.8	20	28	138.9	38	27
Total	246.5	212	86	339.5	374	110	586.0	586	100
<i>Both sexes</i>									
P	114.4	162	142	184.8	335	182	299.2	497	166
G	99.0	56	57	113.7	95	84	212.7	151	71
W	106.0	126	119	188.2	209	111	294.2	335	114
Z	123.2	31	25	124.7	40	10	247.9	71	28
Total	442.6	375	85	611.4	679	111	1054.0	1054	100

shown in Table 71. The high prevalence figures at hospital P are dominated by cases of albuminuria whilst the sub-normal prevalence of nephropathy at hospital G conceals a high standardized frequency of renal insufficiency. This inconsistency is very difficult to explain by reference to different selection or

*Table 71 Standard comparison of states of nephropathy by hospital and by epoch*

Hospital Epoch	Number of patients (registrations) showing nephropathy								
	Persistent albuminuria without renal insufficiency			Renal insufficiency			Total nephropathy		
	Exp	Obs.	O/E	Exp	Obs.	O/E	Exp	Obs.	O/E
<i>Hospital</i>									
P	260.8	461	177	39.4	36	111	299.2	497	166
G	184.8	119	64	27.9	32	114	212.7	151	71
W	253.5	281	111	40.7	54	133	294.2	335	114
Z	217.9	56	26	30.0	15	40	247.9	71	28
<i>Epoch</i>									
E1 (1949)	373.9	447	84	48.7	28	58	442.6	375	85
E2 (1950-)	523.1	570	109	89.3	109	123	611.4	679	111
Total	917.0	917	100	137.0	137	100	1054.0	1054	100

different treatment of the patients. In contrast with these hospitals the hospitals W and Z show for both states of Pd and for both epochs frequencies which are consistently high (W) or low (Z). Whether this difference is caused by different selection of patients by different treatment or by varying accuracy in diagnosis and case record registration it is highly remarkable that differences of the magnitude shown in Table 71 can occur between Swedish county hospitals headed by DM specialists during a period with no discontinuities or marked divergences in opinion regarding the treatment of DM.

### Diabetic neuropathy (Ud)

Compared with retinopathy and nephropathy, the diabetic neuropathy (Ud) is difficult to diagnose. The symptoms are generally not sufficiently clear cut to admit a positive statement that a diabetic does or does not suffer from Ud. There is no general agreement about the genesis and the patho-anatomical picture of this complication or about its treatment.

Schrader and Weinges (1961) surveyed the peripheral neurological disorders among diabetics, some of which were reported as early as in 1864 by de Calvi. The reported prevalence of Ud among diabetics varied between 10 and 100 per cent. The variation is probably due to varying definitions of the disease, varying investigation techniques and differently selected patients. The authors estimated the prevalence of neuropathy among diabetics at about 50-60 per cent. Their

paper contains a fairly complete bibliography.

Smith (1961) reported frequencies of Ud varying between 5 and 24 per cent among 1 200 diabetic hospital patients.

In his study of neuropathy and diabetic control, Ellenberg (1960) sums up as follows:

1 Neuropathy may occur during good control.

2 There may be simultaneous onset of neuropathy and the symptoms of uncontrolled glycosuria.

3 The neuropathy is unrelated to the duration or severity of the diabetes.

4 Neuropathy may be the initial clinical manifestation of diabetes, unattended by symptoms of hyperglycemia and glycosuria.

5 The paradoxical precipitation of neuropathy following institution of good control by diet, insulin and tolbutamide has been observed.

6 Neuropathy may follow stress situations; in these instances a relatively constant latent period exists.

In a later paper, Ellenberg (1961) has maintained that absent deep reflexes is a diagnostic clue in unsuspected diabetes (cf. also Ellenberg 1964, 1966). It seems probable that Ellenberg's assertions regarding the early diagnosis of DM and the influence of the treatment on the development of neuropathy are correct. However, even today the views of experts on DM are not unanimous.<sup>1</sup>

Somlo, Csapo and Szucs (1962) found 55 per cent Ud among 500 diabetics, although the material gives no information about age or duration. Dolman (1963) estimated the Ud frequency re-

<sup>1</sup> Fagerberg, Petersén, Steg and Wilhelmsson (1963) emphasize that motor disturbances are common in diabetic neuropathy and that their frequency rises with the duration of DM as well as with the degree of diabetic angiopathy.

**Table 15** *Standard comparison between hospitals of diagnosis of neuropathy both sexes*

Hospital	Type of diagnosis							
	Subjective		Objective		Subj. and obj.		All types	
	Exp.	Obs.	Exp.	Obs.	Exp.	Obs.	Exp.	Obs.
P	191.2	63	41.9	21	19.3	22	252.4	106
G	141.9	23	31.3	17	14.9	9	188.1	49
W	190.9	361	42.3	54	19.7	5	252.9	420
Z	193.0	270	42.5	66	20.1	38	255.6	374
Total	717.0	717	158.0	158	74.0	74	949.0	949

(2) or subjective and objective symptoms simultaneously (3) For each hospital the relative occurrence of the different codes showed the same picture for males and females and for the two epochs. The differences between the hospitals are therefore illustrated in Table 75 based on the combined data.

The varying occurrence of the different codes of diagnosis is not in itself surprising. The need for case record data on subjective symptoms when objective symptoms have been found and *vice versa* may be differently judged even by careful doctors. Thus the Ud diagnoses have been based upon subjective symp-

toms to a greater extent at hospital W than at hospital Z but the total frequencies are of the same order of magnitude. In hospitals P and G on the other hand very few diagnoses are based on subjective symptoms alone indicating a more restrictive attitude towards the diagnosing of mild or undecided cases as instances of Ud.

Assuming that the data from hospitals W and Z in the later epoch are based on comparatively complete records Table 76 computed from Table 72, may be considered as a maximum estimate of the neuropathy prevalence about 1955 at hospitals where even mild subjective

**Table 76** *Frequency of neuropathy observed at hospitals W and Z in the later epoch by sex, age at onset and duration*

Duration	Percentage frequency of neuropathy							
	Males				Females			
	Age at onset			All	Age at onset			All
	0-14	15-39	40-		0-14	15-39	40-	
0-4		7	23	23		10	23	22
5-9		7	34	25		13	27	25
10-14	4	19	36	25	19	41	35	33
15-19	30	33	37	34	42	27	33	34
20-24	40	29		32		24		34
25-				29		32		32
All	19	17	31	26	29	22	27	26

symptoms are considered as expressions of neuropathy. Although the data in some groups are too limited to permit the calculation of percentages, a comparison with Table 73 shows that these estimates of the frequency of neuropathy are practically twice as large as the frequencies registered for the total series. With the concept adopted at hospitals W and Z, the overall frequency of neuropathy among diabetic patients would have been about 26 per cent. Nevertheless, this frequency is far below some figures given in the literature.

### Osteopathy

Diabetic osteopathy may be regarded as a syndrome within the clinical picture of diabetic neuropathy, with trophic ulcers and various changes of the foot skeleton (cf p 31). Osteitis osteomyelitis, osteoarthritis, Charcot joints and in some cases osteoporosis may be present.

Diabetic osteopathy and diabetic gangrene may present difficult diagnostic problems. The following table gives a schematic picture in respect of the clinical characteristics.

Symptoms	Diabetic osteopathy	Diabetic gangrene
Pulse (arteria dorsalis ped.)	Generally normal	Often lacking
Oscillometry	Normal	Low amplitudes
Skin temperature	Normal	Cold feet and toes
X ray of foot skeleton	Osteoporosis	Normal
Claudication intermittens	Rarely found	Frequently observed
Sensibility	Generally low or lacking	Vibration sensitivity often reduced
Pains	None	Severe

At the annual meeting of the American Diabetes Association in 1966, one of us (Gronberg 1966a) described four female diabetics with osteopathy (cf also Grönberg 1966).

Clinical data	Patient (female)			
	(1)	(2)	(3)	(4)
Year of birth	1931	1929	1900	1918
Age at onset of DM	11	22	32	13
Control	Poor	Fair	Good	Good
Age 1966 (age at death)	35	37	66	48
Working capacity		Good	Good	Good
Duration of DM at onset of				
retinopathy	14	7	14	20
neuropathy	16	10	17	22
nephropathy	18	-	-	-
trophic ulcers	24	12	16	31
bone lesions	16	12	24	33
Treatment (see below)		+	+	-

Arteriography, oscillometry and plethysmography were not significantly abnormal in these patients.

Patients (2) and (3) were treated with intra arterial infusion of D-ampicillin for ten days (4 grammes per day). Heparin and ergotamine were added to the infusions. The results were surprisingly good. The chronic trophic ulcers of the two patients, who had had lesions for several years, showed complete healing without recurrence for several months.

The syndrome of osteopathy is estimated to occur in about 5 per cent of all diabetics. There is no correlation with occlusive vascular disease (cf p 31). Infections and traumata are the most prominent factors affecting the course of diabetic osteopathy.

The problem of the cause of trophic ulcers has not yet been solved. Loss of

pain sensitivity in the feet may be of importance in the development. Possibly, the skeletal lesions may parallel the ulceration (cf. Ellenberg 1964) and they might not, as is usually assumed, be sequelae to infections of the ulcers.

Very likely the reduced sensitivity to pain has the result that the patients with diabetic osteopathy often are far less incapacitated than would be expected in view of the severe character of the trophic ulcers and skeletal changes.

## Vascular lesions

Under this heading are included pathological states other than retinopathy (Rd) and nephropathy (Pd) which are regarded as caused by vascular changes. This category would include cardiovascular diseases such as coronary infarction, angina pectoris, cardiac insufficiency (not connected with organic heart lesion due to rheumatoid arthritis) and the like, and peripheral disturbances such as gangrene and angiospasm. Of course the group is rather heterogeneous, but on the other hand it is obvious that a hospital series of the present type must be biased in so far as the first admission to the hospital after the onset of DM is to a fairly large extent connected not with the occurrence of DM but with the symptoms arising from the vascular lesion.

Since a proper evaluation of this bias is not possible, it is not justifiable to perform a detailed analysis of different subgroups.

The frequency of registered occurrence of vascular disease by sex and age is shown in Table 77.

Table 77: Frequency of vascular lesions by sex and age

Average age	Number of patients		With vascular lesions per cent	
	M	F	M	F
4	16	15	—	—
9	60	70	—	—
14	135	118	0.7	—
19	210	174	0.5	—
24	213	173	0.5	2.3
29	211	147	1.4	2.0
34	224	148	1.8	4.1
39	217	148	1.4	3.4
44	227	154	2.6	3.2
49	243	237	4.1	8.0
54	282	334	7.1	9.6
59	297	476	12.5	14.7
64	305	521	12.8	17.9
69	264	534	20.5	20.8
74	205	384	27.3	24.2
79	131	198	26.0	26.3
84—	44	62	15.9	33.9
Total	3 284	3 893	8.4	13.2

On the basis of the frequencies by sex and age, a standard calculation with division of the series by age at onset and duration was performed. As can be seen from Table 78, only slight deviations from pure age dependence were found.

In the literature it is often maintained that although the vascular lesions are not specific for DM, they have a tendency to appear earlier in diabetics than in non-diabetics. Naturally it is very difficult to arrive at definite evidence for the correctness of such a statement—even in prospective studies of a population series. The only conclusion that can be drawn on the basis of our data is that they do not give rise to a supposition that vascular lesions found in diabetics should generally be regarded as sequelae of DM.<sup>1</sup>

<sup>1</sup> Cf. also the discussion on p. 163.

**Table 78** *Standard comparison of vascular lesion frequency by sex, age at onset and duration*

Sex and duration	Age at onset									All		
	0-14 (J)			15-39 (A)			40- (L)					
	N	O	E	N	O	E	N	O	E	N	O	E
<i>Males</i>												
0-4	133	1	0.5	386	2	4.3	944	115	124.8	1 463	118	129.6
5-9	126	-	0.6	252	3	4.0	469	61	68.9	847	64	73.5
10-14	121	-	0.7	173	3	3.9	212	37	33.4	506	40	38.0
15-19	87	3	0.8	124	5	3.9	101	27	18.7	312	35	23.4
20-24	48	1	0.8	71	5	3.2	37	13	7.6	146	19	11.5
0-24	515	5	3.3	1 006	18	19.3	1 763	253	253.4	3 284	276	276.0
<i>Females</i>												
0-4	125	-	0.0	251	2	6.0	1 423	246	239.6	1 799	248	245.6
5-9	115	-	0.0	186	2	5.5	782	141	142.0	1 083	143	147.5
10-14	114	2	1.0	131	7	5.7	340	65	65.7	585	74	72.4
15-19	68	2	1.2	88	7	5.0	142	22	29.9	298	31	36.1
20-24	37	2	1.1	58	9	4.1	33	7	7.2	128	18	12.4
0-24	459	6	3.3	714	27	26.3	2 720	481	484.4	3 893	514	514.0

N = Number of registrations (duration cards)  
 O = Observed number of patients with vascular lesion registered in the duration period  
 E = Expected number calculated on the basis of observed frequencies by sex and age (Table 77)

## Other diseases

As mentioned in Chapter II (p. 44) the material for the clinical study of DM contains extracts from the case records about entries concerning the occurrence of other diseases. A brief account of the data in respect of thyrotoxicosis, allergic diseases, tumours and rheumatoid arthritis will be given in the following sections. The data refer to the registered occurrence on one or more occasions during a given 5 year duration period of the diseases in question. With regard to all these diseases the numbers registered are rather small, no clear differences were found between the four investigation hospitals and therefore the figures will be given for the series taken as a whole. As already stated the total number of

registrations (duration cards) is 3 398 for males and 3,987 for females (cf. Table 7A, p. 49).

## Thyrotoxicosis

There are 19 registrations of thyrotoxicosis among males and 96 among females, or 0.6 per cent and 2.4 per cent, respectively. The magnitude of the percentages, as well as the higher prevalence among females than among males, is in accordance with what is ordinarily found both in the general population and among diabetics.

It has long been known that thyrotoxicosis is often accompanied by glycosuria. Whether this glycosuria is to be regarded as a manifestation of DM is still an open question.

## Allergic diseases

There are 40 registrations of allergic diseases among males and 42 among females or 1.2 per cent and 1.1 per cent, respectively. Here, allergic skin reactions to insulin are not included. In the great majority of cases the disease is bronchial asthma. The occurrence of allergic diseases is evenly distributed over the observation series without any clear dependence on age or the duration of DM.

Helander (1948) studied the occurrence of DM among 3151 patients with bronchial asthma and the occurrence of bronchial asthma among 3236 patients with DM. The patients had been treated during the period 1937-54 in the allergy department and two departments of internal medicine of the Sahlgrenska Sjukhuset in Gothenburg. The overall prevalence of DM among patients with bronchial asthma was 1.14 per cent, and the overall prevalence of bronchial asthma among patients with DM was 1.10 per cent; this latter prevalence was the same for DM patients below and above 60 years of age.

Helander quotes a series of earlier investigations which with a few exceptions seem to indicate an antagonism between DM and bronchial asthma (or allergy). It has been suggested that this antagonism might be due to low blood glucose levels in asthmatics on account of accelerated insulin production. On the basis of his own data, however, Helander arrives at the conclusion that the incidence of bronchial asthma among diabetics and the incidence of DM among asthmatics correspond entirely to the incidence of the two conditions in the general population.

Our figures are in agreement with those obtained by Helander.

Summarizing his conclusions from the scrutiny of the individual case reports, Helander makes the following statements:

(1) ACTH (adrenocorticotrophic hormone) may induce or in any case permanently aggravate DM.

(2) The onset of bronchial asthma is sometimes accompanied by diminution of the symptoms of previously existing DM and *vice versa*.

(3) In some patients with both bronchial asthma and DM the disorders alternate.

(4) Insulin in small doses may aggravate bronchial asthma in occasional patients, both when DM is present and when it is not.

Therefore according to Helander, it would seem that in some patients the two disorders are antagonistic but this antagonism does not as previously supposed influence the incidence of one disorder in patients having the other. Instead it seems to involve certain hormonal functions.

## Tumours

In all there are 37 registrations of malignant tumours among males and 88 among females or 1.1 per cent and 2.1 per cent respectively (of the number of duration cards). Here it should be taken into account however that the occurrence of malignant tumours implies 'a bias' in so far as (because of excess mortality) these patients have a lower probability than others of being included in the subsequent 5 year duration periods. In the duration group 0-4 there are 19 registrations of malignant tumours among males and 40 among females or 1.3 and 2.2 per cent respectively (of the number of patients with DM duration 0-4 years). The prevalence figures increase with age but otherwise they are independent of the age at onset of DM and the duration of the disease.

## Rheumatoid arthritis

There are 31 registrations of rheumatoid arthritis among males and 94 among

females, or 0.9 and 2.4 per cent, respectively. The prevalence figures increase with age but otherwise they are independent of the age at onset of DM and the duration of the disease.

According to Engel and Roberts (1966) the prevalence of rheumatoid arthritis in the general population of the USA increases markedly with age: from 0.3 per cent at ages 18-24 to about 6 per cent at ages 55-64 (males 4 per cent, females 8 per cent) and about 19 per cent at ages 75-79 (males 14 per cent, females 23 per cent). For the age groups 18-79 taken together the prevalence figures are 1.7 per cent for males and 4.6 per cent for females, counting only 'classical and definite' cases (but not those designated as 'probable') the figures are 0.5 and 1.4 per cent. Taking into account the age distribution of the patients in our series it can be concluded that rheumatoid arthritis seems to occur as frequently among DM patients as it does in the general population.

In a series of 34 patients with both DM and rheumatoid arthritis with average duration of DM 11.1 years and of rheumatoid arthritis 12.2 years, Powell and Field (1964) found a very low incidence and a high regression rate of diabetic retinopathy.<sup>1</sup> According to the authors this may be an influence of the one disease or the other, or it may be due to the large doses of salicylates which these patients have been taking for many years, or to some other factor.

### *Pernicious anaemia*

At Vänersborg (P) a special inventory was made over the period June 1 1931-June 1, 1958 with regard to patients treated in the department of internal medicine for pernicious anaemia (cf. Sundberg & Grönberg 1960). In all 314 cases were registered; of these, 21 or 6.7 per cent had shown clinically manifest DM. Of the patients with both diagnoses, 8 were males

and 13 were females. The mean age at onset of pernicious anaemia was 61.2 years, and the mean age at onset of DM was 62.0 years. For 4 males and 8 females, DM was not present at the onset of pernicious anaemia but developed later after an average interval of 6.8 years. For one female the diseases were diagnosed simultaneously in 1958 (the patient had no subjective symptoms of DM). The remaining 4 males and 4 females had had DM for an average period of 8.2 years before the onset of pernicious anaemia.

Of the 314 patients with pernicious anaemia about 40 per cent are males and 60 per cent are females.<sup>2</sup> The registration of the occurrence of DM among these patients must have been practically complete.

At admission because of pernicious anaemia or at the later point of time when DM appeared, the mean age of the 21 patients with both diagnoses was 65.1 years (males 61.5 years, females 67.4 years). As can be seen from Table 34 (p. 117) the aggregate morbidity risk for

<sup>1</sup> For 4 of the 34 patients retinopathy of mild degree was registered at the patient's last visit; another 8 patients had on an earlier visit showed either a single exudate or a streak haemorrhage or a few microaneurysms but had no retinopathy on one or more subsequent visits including the last. Of 9 patients with a DM duration of 15 years or more only one presented retinopathy.

<sup>2</sup> In 1950 Mosbech (1951) registered a prevalence of pernicious anaemia of 1.0 per thousand population in Odense County, Denmark; the prevalence was 0.8 per thousand among males and 1.2 per thousand among females.

On the basis of the prevalence figures by age given by Mosbech the aggregate morbidity risk for pernicious anaemia up to age 80 may be estimated at about 0.4 per cent for males and about 0.6 per cent for females.



DM up to age 65 is 4.1 per cent for males and 7.0 per cent for females.

As is indicated by these figures alone, there is in fact good agreement between the observed number of diabetics among patients with pernicious anaemia and the expected number (calculated on the basis of the morbidity risks for DM in the general population as shown in Table 34).

In our DM series covering a total of 867 patients (408 males, 459 females) at Vänersborg Hospital over the period 1931-57, the age distribution of the patients would lead us to expect at the most 10 instances of pernicious anaemia.

However, taking into account that the proportion of admissions to hospital must be considerably larger in respect of pernicious anaemia than in respect of DM, the registration of 20 cases with both diseases during this period should not be interpreted to indicate an association between them.<sup>1</sup>

---

<sup>1</sup> In the previous paper (Sundberg & Grönberg 1960) it was concluded that there might be a common denominator for the two diseases although the series was not sufficiently large to permit definite conclusions in this respect. In accordance with the conceptions then current concerning the prevalence of DM, the occurrence of 21 DM cases among 314 patients with pernicious anaemia was considered to justify this statement.

## Rating of DM risks in life and health insurance in Sweden

### General developments

Towards the end of the nineteenth century interest began to be shown in several countries in the insurance of substandard risks. In 1898 a Scandinavian committee was set up to study statistical and other problems relating to this field. In the early years of the present century there arose in various quarters the belief that a more advanced form of cooperation would favour a rapid and satisfactory solution. Sweden was one of the countries where these views first led to concrete measures. In 1915 it was decided that the Sverige Reinsurance Company should be the central organization for the insurance of substandard risks (cf. Strom & Svensson 1965, Lars son 1965a).

The functions of the Sverige as regards the insurance of substandard risks were to be twofold viz. to rate the risks and to reinsure them.

For the purpose of rating the risks the Appraisal Council of the Sverige (*Centrala riskprövningsnämnden*) was formed.

The reinsurance of substandard risks

is based on the idea of concentrating the internal part of the whole business—rating of risks, calculations of premiums, surrender values, premium reserves and extra bonus, technical and statistical analyses etc.—within the Sverige, whereas all contacts with the policyholders are managed by the direct writing companies. It was thought that the pooling of the business by means of compulsory reinsurance would make it easier to accept the hazardous substandard risks than if each company was alone responsible for its risks. In addition it would be possible to avoid unsound competition and to gain a wider statistical experience more rapidly.

The rating and the reinsurance with the Sverige did not include all substandard risks. The slightly substandard risks which the companies had already been in the habit of granting continued in the main to be handled by them. These risks are termed B risks, while those substandard risks which are accepted by the Sverige are called C risks, and the standard risks are termed A risks. Risks which are not accepted by the Appraisal Council

may be accepted in accordance with the decisions of the Comira ("Cooperation internationale pour les assurances sur la vie des risques graves")—D risks<sup>1</sup> Risks which are not accepted at all will here be denoted R risks

In 1938 draft proposals for general directives with regard to the rating of risks were presented (by the medical director of the Sverige Dr. Folke Lindstedt). These "guidelines" formed the basis of the underwriting manual which is now followed by all Swedish life and long-term health insurance companies in respect of individual insurance. The manual as it exists in its current version has been evolved as the result of a number of revisions often effected at intervals of two or three years.

Already when the C-risk insurance of the Sverige was initiated, there was an effort to use data collected through statistical investigations in order to classify and rate the risks in a way that would result in extra premiums that would be as correct as possible. However uncertainty in respect of the prognosis due to insufficient experience meant that the risk appraisal remained very strict for a long time.

During the course of the years considerable alleviations of the appraisal have been effected thanks to the general improvement of the prognosis of most diseases that has been brought about by medical progress and raised standards of living. Another important factor in this connection is that there has taken place a change of opinion as to the aim of the risk appraisal. More and more the predominant attitude has been that the rating should not be stricter than is

required to guard the company against undue speculation. With the aid of statistics about the frequency of substandard risks of different kinds it has been shown that the substandard risks are not of such financial importance that the achievement of this aim might be considered unfair from the point of view of the standard risks.

Hitherto these views have mainly been applied in respect of II risks (slightly impaired risks) in individual insurance and in respect of group insurance. As regards C risks (moderately and severely impaired risks) in individual insurance, the extra premiums are still adjusted so as to correspond to the increased risk, but nevertheless an important change has taken place. Whereas earlier the view was that the substandard risk premium should include a safety margin of roughly the same relative magnitude as does the standard risk premium it is now considered appropriate that the substandard risk premium shall include a safety margin of the same absolute magnitude as does the standard risk premium. This change of attitude and the actual improvement in the prognosis for the majority of diseases have enabled considerable reductions of extra premiums to be made in the case of C risks also.

It should be added that all extra profits for substandard risks are distributed to the policyholders in question as a supplement to the ordinary bonus.

<sup>1</sup>From 1957. Prior to that, D risks were accepted in cooperation between the Sverige and the corresponding companies in Denmark (Dana), Finland (Varma) and Norway (Norske Folk). From 1966 the Sverige accepts all D risks with sums not exceeding 50 000 kroner "for its own".

## Technical methods

For C risks, the Sverige at first applied supplements which can be interpreted as an approximation to percentage mortality increases but after some time pure percentage increases were adopted. In 1945 a new system was introduced: the extra premiums were based on an additive supplement to the force of mortality (T risks) or on a combination of an age supplement and a constant supplement to the force of mortality (H risks). In the latter case, however, the relation between the two supplements was chosen in such a way that the result was approximately a percentage mortality increase (however not of the net risk premium but with certain loadings for expenses included).

During a long period it was usual to restrict the insurance term for substandard risks by fixing a maximum final age. This form of limitation has been extensively used in the case of diseases where mortality at advanced ages has been regarded as especially high, for instance circulatory diseases. Diabetics have been subject to particularly severe limitations in this respect, a maximum final age of 45 or 50 years has not been unusual. This system has now been completely abandoned: as from 1956 there are no restrictions concerning the insurance term for diabetics.

In 1956 the percentage increases for diabetics were substituted by age supplements.

In 1958 a new type of increase was introduced in respect of diabetics (S risks). Diabetics were then rated with premiums which were based on an assumed extra mortality of the same type as

that used in the case of H risks, but with greater importance attached to the age supplement which gave the mortality curve a steeper appearance. According to the rules of 1964 the constant supplement was fixed at 1 per thousand whereas the minimum age supplement was 3 years and the maximum one—used if the onset of DM had occurred before 10 years of age—was 20 years. When the age at onset was 40 years or over and other findings were normal, the rating was H1 (age supplement 5 years, constant supplement 1 per thousand).

Partly on the basis of preliminary results from the present study a considerable liberalization of the appraisal of DM risks was introduced in 1966. The S risk rating was abandoned and H risk supplements were applied in respect of diabetics (cf. below).

As from 1964 H risks are rated with permanent extra premiums which are based on an assumed extra mortality composed of an age supplement and a constant supplement as follows:

Rate	Life insurance		Waiver of premium per cent	Health insurance (for DM) per cent
	Age supplement years	Constant supplement per thousand		
H1	5	1	50	50
H2	8	2	100	75
H3	11	3	140	100
H4	13	4	180	100

## Premiums for standard risks

There have been several reductions in the mortality tables for standard risks. Therefore if the rules for rating substandard risks had been kept unchanged,

the introduction of a new mortality table would as a rule have caused considerable alleviation of the supplements for sub standard risks

The mortality tables applied in individual life insurance for standard risks (A risks) are shown in Table 79

*Table 79 Assumed mortality for standard risks according to life tables D28, D37 D55 and M64*

Age	Force of mortality per thousand according to life table					
	D 28		D37		D55	
	M	F	M	F	M	F
15	4.1	3.3	1.0	0.7	0.7	0.7
20	4.3	3.4	1.1	0.8	0.8	0.8
25	4.6	3.7	1.2	1.0	0.9	0.9
30	5.1	4.1	1.5	1.2	1.0	1.0
35	5.8	4.8	1.9	1.6	1.3	1.3
40	7.1	5.9	2.6	2.2	1.7	1.7
45	9.0	7.7	3.8	3.2	2.4	2.4
50	12.0	10.6	5.8	4.9	3.5	3.5
55	16.8	15.3	9.2	7.5	5.3	5.3
60	24.4	22.9	15.0	11.9	8.2	8.2
65	36.5	35.2	24.8	18.9	13.0	13.0
70	55.6	55.3	41.5	30.2	20.7	20.7
75	85.9	87.8	69.8	48.6	33.2	33.2
80	133.9	140.5	117.9	78.5	53.5	53.5
85	210.0	225.9	199.6	126.9	86.4	86.4
90	330.6	364.5	338.3	205.5	139.7	139.7

## Rating of DM risks 1945-67

A brief account of the rating rules for DM in individual insurance from 1945 onwards is given in the following paragraphs. For the sake of brevity the older rules with regard to maximum final age are omitted. It should be stressed that the rules are not applied mechanically but with due regard to the circumstances in the individual case this can be done without disadvantages because the rating is made by a central institution.

Percentage supplements given in the

tables refer to assumed force of mortality. Thus 200 per cent means that the mortality at each age is estimated to be three times the assumed mortality at the same age among standard risks (with certain loadings for expenses included).

## A Manual of 1945

- (1) Within 6 months from diagnosis postponement for 3 months
- (2) Insulin treatment no complications

Age at application	Appraisal for life insurance
-19	R (reexamination at 20)
20-49	supplement 250-200 per cent
50-	supplement 200-150 per cent
all ages	wavier of premium R
With long observation period certain alleviation	

- (3) Insulin treatment complications  
R or increased supplement
- (4) Dietetic treatment alone  
as above with reduction 50-100 per cent
- (5) Alimentary glycosuria with increased blood sugar level but without other diabetic symptoms  
supplement 150-50 per cent

## B Manual of 1947

- (1) Within 6 months from diagnosis postponement for 6 months
- (2) Insulin treatment no complications

Age at application	Appraisal for life insurance
-14	B
15-19	at least 5 years of observation 250 per cent
20-29	250-200 per cent
30-49	200-150 per cent
50-	150- 75 per cent
With long observation period reduction 25 per cent	

- (3) Insulin treatment complications  
R or increased supplement waiver of premium II
- (4) Dietetic treatment alone long observation time  
possibly some alleviation
- (5) Alimentary glycosuria with increased blood sugar level but without diabetic 2 hour value and without other diabetic symptoms  
75 per cent - normal

## C Manual of 1949

- (1) Within 6 months from diagnosis  
postponement for 11 months
- (2) Insulin treatment no complications

Age at application	Appraisal for life insurance
-14	R
15-19	at least 5 years of observation 250 per cent waiver of premium R
20-29	250-200 per cent waiver of premium R or increased supplement
30-49	200-150 per cent ditto
50-	150- 75 per cent ditto
DM with onset after age 50 is rated as milder than DM with earlier onset	

- (3) Insulin treatment complications  
R or additional increase by 20-50 per cent
- (4) Dietetic treatment alone long observation time  
alleviation of condition stated above by 25-50 per cent
- (5) Alimentary glycosuria with increased blood sugar level 200 mg per 100 cc or more but without diabetic 2 hour value and without other diabetic symptoms  
75 per cent - normal

## D Manual of 1956

Where glycosuria has been recorded once new urinalysis is asked for With more than

one positive value glucose tolerance test is made

- (1) Renal or alimentary glycosuria  
normal
- (2) DM Insurance granted not earlier than 6 months after the diagnosis Questionnaire to be filled up by the applicant If the sum exceeds 20 000 kronor, special certificate from physician required  
The rules given below are applied with increased supplement where control has been insufficient or the applicant presents overweight or is prone to infections
- (a) No vascular complications diabetic ocular changes or albuminuria

Age at application	Percentage increase to force of mortality for life insurance with duration of DM at application (years)			
	5	6-10	11-20	21
-14	R	R	R	R
15-24	300-250	D-300	D	R-D
25-34	250-150	300-250	D-300	R-D
35-44	150- 50	250-150	300-250	D-300
45-54	50	100- 50	250-150	300-200
55-	50	50	150- 50	200-100

At the calculation of premiums these percentage increases are substituted by age supplements (cf Table 80)

Waiver of premium 100-50 per cent where extra rating of life insurance does not exceed 200 per cent otherwise R

- (b) Where vascular complications diabetic ocular changes or albuminuria are present  
P

## E Manual of 1958

Where glycosuria has been recorded once new urinalysis is asked for With more than one positive value glucose tolerance test is made

- (1) Renal or alimentary glycosuria  
normal
- (2) DM Insurance granted not earlier than 11 months after the diagnosis Questionnaire to be filled up by the applicant

If the sum exceeds 20 000 kronor, special certificate from physician required

The rules given below are applied with increased age supplement 2-3 years where control has been insufficient or the applicant presents overweight or is prone to infections

- (a) No vascular complications no diabetic ocular changes and no albuminuria

	Age at onset of DM				
	1-9	10-19	20-29	30-39	40-
Life insurance	S4	S3	S2	S1	H1
Waiver of premium	R	R	150	100	50

- (b) Where vascular complications diabetic ocular changes or albuminuria are present  
R

Where ocular changes are very mild insurance may be granted possibly with extra age supplement 2-3 years

## H Manual of 1966

Where glycosuria has been recorded once, new urinalysis and test of fasting blood sugar are asked for. With more than one positive value glucose tolerance test is made (if the sum is small fasting blood sugar value alone is considered sufficient)

- (1) Renal or alimentary glycosuria normal
- (2) DM Life insurance (including waiver of premium) as a rule granted as soon as the diagnosis is made and the disease is under control health insurance granted not earlier than 6 months after the diagnosis. Questionnaire to be filled up by the applicant. If the sum exceeds 25 000 kronor (life insurance) or 300 kronor monthly (health insurance) special certificate from physician required

The supplements given below are applied

- (a) No vascular ocular or renal symptoms

- (a1) Good control without complications

Age at application	Age at onset of DM	Life insurance	Waiver of premium per cent	Health insurance per cent
-15		H4	R	R
16-30		H3	150	100
31-45	-39	H2	100	75
	40-	H1	50	50
46-	-54	H1	50	50
	55-	H0*	25	25

\* H0 does not *per se* cause increased premium however with two different impairments H0 the rating is H1

## F Manual of 1960

As Manual of 1958 (E)

## G Manual of 1964

As Manuals of 1958 (E) and 1960 (F) but with changed values for the supplements

Supplement	S1	S2	S3	S4
<i>Manuals of 1958 (E) and 1960 (F)</i>				
Age supplement years	8	13	17	22
Constant supplement per thousand	3.6	3.6	3.6	3.6
<i>Manual of 1964 (G)</i>				
Age supplement years	9	13	17	20
Constant supplement per thousand	1	1	1	1

- (a2) Severe cases - insufficient control overweight or proneness to infections in particular urinary infections life insurance as a rule with increase one step in the table under (a1) - H0 to H1, H1 to H2 etc waiver of premium and health insurance as a rule R

- (b) With vascular complications diabetic ocular changes or albuminuria

# (b1) Ocular changes alone (retinopathy) : Remaining mean expectation of life

mild ocular changes (occasional microaneurysms) as (a),  
proliferative changes R  
other changes as a rule as (a2)

## (b2) Albuminuria

intermittent findings with observation time at least 10 years as (a2)  
otherwise as a rule R

## (b3) Hypertension

appraisal as (a) and addition of separate supplements according to the rules applied in respect of hypertension

In order to illustrate the rating of DM risks Table 80 gives certain data about the remaining mean expectation of life at ages 20 30 40 50 and 60 for males. The data refer to the rating of diabetics with a disease duration at application of 15 or 5 years according to the Manuals of 1956 1960 (=1958) 1964 and 1966. It is assumed that no complications have been registered or in other words that the rating is the most liberal one. For comparison are shown the corresponding expectations according to the life tables

**Table 80** Rating of uncomplicated DM risks in individual life insurance from 1956 onwards, and calculated mean expectation of life Males

Manual Life table	Duration of DM	Age at application					
		20	30	40	50	60	
Rating							
DM	1956	15	+ 29 yrs	+ 23 yrs	+ 17 yrs	+ 12 yrs	+ 8 yrs.
		5	+ 27 yrs	+ 17 yrs	+ 9 yrs	H1	H1
	1960	15	S4	S3	S2	S1	H1
		5	S3	S2	S1	H1	H1
	1964	15	S4	S3	S2	S1	H1
		5	S3	S2	S1	H1	H1
	1966	15	H3	H3	H2	H1	H1
		5	H3	H3	H2	H1	H0
	Remaining mean expectation of life years						
	DM	1956	15	25.8	22.4	19.1	15.4
5			27.5	27.5	25.8	21.0	13.7
1960		15	30.0	26.0	21.3	17.6	13.7
		5	34.0	29.2	25.2	21.0	13.7
1964		15	35.9	29.8	24.7	20.0	15.6
		5	38.5	33.2	28.1	23.1	15.6
1966		15	41.9	33.6	28.4	23.1	15.6
		5	41.9	33.6	28.4	23.1	19.4
Standard risks		D55	52.4	43.0	33.7	24.9	16.8
		M64	55.4	45.9	36.6	27.7	19.4
Population	1941-45	51.2	42.6	33.6	25.0	17.2	
	1946-50	52.1	43.0	33.8	25.0	17.1	
	1951-55	53.1	43.7	34.4	25.4	17.4	
	1956-60	53.5	44.0	34.7	25.6	17.5	
	1961-65	53.6	44.1	34.7	25.6	17.5	



*Table 81 Mean expectation of life in the general Swedish population 1961-65, according to life table M64 for standard risks and with ratings H1 H2 H3 and H4 Males and females*

Age	Remaining mean expectation of life years											
	Population 1961		M64		H1		H2		H3		H4	
	M	F	M	F	M	F	M	F	M	F	M	F
20	53.6	57.2	55.4	59.3	49.3	52.9	45.4	48.9	41.9	45.1	39.3	42.5
25	48.9	52.3	50.7	54.5	44.8	48.4	41.2	44.6	37.8	41.0	35.4	38.5
30	44.1	47.4	45.9	49.7	40.3	43.9	36.9	40.3	33.6	36.9	31.4	34.6
35	39.4	42.6	41.2	45.0	35.9	39.4	32.6	36.0	29.6	32.8	27.5	30.6
40	34.7	37.8	36.6	40.1	31.5	35.0	28.4	31.8	25.6	28.8	23.7	26.8
45	30.1	33.1	32.1	35.7	27.2	30.6	24.4	27.6	21.7	24.8	20.0	22.9
50	25.6	28.6	27.7	31.2	23.1	26.4	20.5	23.6	18.1	21.0	16.5	19.3
55	21.4	24.1	23.4	26.8	19.2	22.3	16.8	19.7	14.6	17.4	13.2	15.8
60	17.5	19.8	19.4	22.6	15.6	18.5	13.5	16.1	11.6	14.0	10.4	12.6
65	13.9	15.8	15.8	18.7	12.3	14.9	10.5	12.9	8.8	11.0	7.8	9.8
70	10.7	12.1	12.4	15.1	9.5	11.7	7.9	10.0	6.6	8.4	5.8	7.4
75	8.0	9.0	9.5	11.8	7.1	9.0	5.8	7.5	4.7	6.2	4.1	5.4
80	5.8	6.4	7.1	9.0	5.1	6.6	4.1	5.4	3.3	4.4	2.8	3.8
85	4.2	4.6	5.1	6.7	3.6	4.8	2.8	3.8	2.2	3.0	1.9	2.6
90	2.9	3.3	3.6	4.8	2.4	3.3	1.9	2.6	1.5	2.0	1.2	1.7

applied for standard risks in individual life insurance (D55 from September 1955 to August 1964 M64 from September 1964) and according to life tables for the general Swedish population from 1941-45 to 1961-65

In Table 81 are shown the mean expectation of life in the general population 1961-65 and according to life table M64 the data are given separately for males and females concerning standard risks as well as with ratings H1 H2 H3 and H4

## Group life insurance

Group life insurance was introduced in Sweden in 1948. In view of the rapid developments which have taken place both with regard to the number of insured persons and with regard to the size of the coverage the rules for obtaining group life insurance and the practice applied for

the risk appraisal are of great interest in the present connection. A brief and somewhat simplified account is given below as a general fact it can be stated that nowadays the great majority of the diabetics in the active age groups have substantial amounts of group life protection and further, that the great majority of the juvenile diabetics become insured when they enter the labour market. Certain restrictions exist as regards eligibility for insurance (cf. below) but there are no special limitations on the validity of the insurance, and no extra premiums are charged for substandard risks.

The type of group life insurance first introduced—*regular group life insurance*—is granted to groups of persons who are employed by the same employer or belong to a certain organization (instituted to take care of the interests of the members in their capacity of economically active persons). In addition this type of group life insurance has been extended to cover students' organ-

izations. As a rule a group must comprise at least 25 persons and at least 75 per cent of those entitled to insurance.

In 1961 there was introduced by collective agreements between associations of private employers and white-collar trade unions, another type of group life insurance—*occupational group life insurance*—which for the members of the employers' association gives coverage to their employees (irrespective of whether they are members of the union or not). From 1963 similar arrangements have been made for blue-collar employees (workers) in private industry, and for all state and municipal employees.

To a great extent regular group life insurance and occupational group life insurance for private employees include the wife (and nowadays also the husband) of the insured member. From 1965 (and 1967) the same applies to the other categories of occupational group life insurance.

For access to occupational group life insurance the only condition is that there shall exist an employment with the state, a local government authority or an employer who is a member of an employers' organization. Hence there are no restrictions concerning DM or other diseases, unless the state of health has been an obstacle to employment. Nor are there any restrictions attached to the state of health of the spouse. The basic amounts insured are 31 500 kronor for the employed person (up to age 55 with a gradual reduction to 4 000 kronor in the age interval 65–67) and 2 000 kronor for the spouse of an insured person (if there are children below 17 years of age). Including supplementary amounts to be paid if there are children below age 21 (9 000 and 4 500 kronor respectively for each child below age 17, gradual reduction for children aged 17–21) the average amount per employed person is about 44 500 kronor.

In regular group life insurance the sums insured vary from comparatively small amounts up to 100 000 kronor or over but they are always fixed according to general rules (for instance the same sum for all members of the group or sums in proportion

to the annual earnings). Generally there is also insurance for the wife (and sometimes for the husband) of the insured person. The average amount per person (group members/spouses) is about 20 000 kronor.

Provided that the adhesion to a regular group life insurance is obligatory or the group is very large and entry takes place without delay the same rules are in the main applied in respect of the eligibility for insurance as in occupational group life insurance. In the event of optional joining of the group or entry after delay certain conditions with regard to the applicant's state of health are to be fulfilled. For a new group or for a general increase of the sums insured in an existing group it is sufficient that the applicant can establish that he is wholly capable of doing work and that during the preceding 12 months he has not been ill for periods longer than 14 days in unbroken succession. These rules are used if the applicant is below 60 years of age and the amount does not exceed 60 000 kronor. In other cases a questionnaire (health declaration) is to be filled up and the appraisal is made according to rules similar to those given in the Manual for individual insurance. However in respect of DM standard rating is substituted not only for H0 but also for H1 and H2. If the insurance applied for cannot be granted with standard rating according to these lines insurance up to a total sum of 60 000 kronor may be accepted or entry may be postponed or refused (and the applicant can then have recourse to individual insurance).

When a person carrying group life insurance leaves the group (for instance because the group contract expires because the insured person transfers to other work without getting a group insurance or in respect of spouses because of the death of the group member or of divorce) there is a right to take out individual insurance corresponding to the expired coverage or the reduction in coverage without any conditions with regard to health examination.

At the end of 1960 the total amount of group life insurance in force was 11.1 billion (thousand million) kronor as compared with

a total amount of 22.4 billion kronor individual life insurance

At the end of 1967 the total amounts of group life insurance and individual life insurance may be estimated at about 150 billion kronor and about 30 billion kronor, respectively. Of the first mentioned sum about 35 billion kronor relate to regular group life insurance and 115 billion kronor to occupational group life insurance (including the group life protection for state employees which is given in accordance with a special law and not in the form of an ordinary insurance policy).

## Group health insurance

With regard to health insurance it should be kept in mind that the Swedish social security system includes both in validity *pensions and health insurance* on a compulsory basis (cf p 19).<sup>1</sup> Nevertheless group health insurance is developing rapidly. In this field the particular problems of risk appraisal have been solved by means of a clause which restricts the payments under the insurance in cases of working incapacity caused by disease (accident) that has occurred before the issue of the policy. The payments under the policy (including stipulated waiting period) are limited to cover at the most a period equal to the time that has elapsed since the latest date before the issue of the policy at which the disease (accident) or sequelae thereof caused incapacity or treatment (prescription) was given by a physician. Deduction is made for periods after the issue of the policy during which the disease (accident) or sequelae thereof have caused working incapacity.

If for example the policyholder was treated by a doctor six months before the

issue of the policy and was thereafter capable of doing work but falls ill when the policy has been in force for three years he will be entitled to payments for a maximum period of three and a half years. If his incapacity lasts for two years he will after a further period of one year be entitled to payments for a maximum period of two and a half years ( $3.5 - 2 + 1$ ).

The clause may be excluded if the applicant gives a satisfactory health declaration which is accepted by the company.

## Present situation and further considerations

DM is a common disease. As can be seen from Table 35, the life table expectancy for DM up to age 70 is about 4 per cent for males and about 8 per cent for females. The number of diabetics in Sweden below age 70 can be estimated at about 110 000 (cf Table 32).

Social and economic developments have meant that nowadays diabetics who possess working capacity are employed under the same conditions as non diabetics. The mobility of the population has greatly increased both with regard to change of residence and with regard to change of type of activity: persons move from the countryside to the large towns and other agglomerations; self employed persons become employees and

<sup>1</sup> *National Insurance Act* promulgated at the Royal Palace in Stockholm May 25 1962. Revised translation July 1966. Swedish Ministry of Health and Social Affairs. Esselte AB 1966 pp 1-56. — The booklet contains the text of the National Insurance Act with amendments having come into force not later than January 1 1967.

employees become 'self employed'. Very often these changes lead to an interest in—or a need for—higher insurance protection. Similar effects arise as a result of increasing costs of living as well as increasing real income.

As will have appeared from the preceding sections the rating of DM risks in individual insurance has been largely liberalized, especially in the revisions of the Manual that were undertaken in 1964 and 1966. The rapid growth of group life and group health insurance have largely contributed to the effect that diabetics nowadays generally have considerable insurance protection as belonging to groups for which the participation is secured through agreements between the parties of the labour market through legislation (for state employees) or through membership of an organization of "self-employed persons, a students organization or the like. No extra premiums are charged for substandard risks in these types of insurance. Probably in Sweden the average diabetic has a higher life and health insurance coverage and more liberal insurance conditions than is the case in most other countries.

However, the interest for coverage in the fields of life and health insurance is to a great extent connected not with the absolute needs alone but rather with the 'relative needs', viz. the comparison with other persons in a similar economic situation. Therefore it may be said that neither the extension of the insurance coverage under the Swedish social security system nor the developments within group life and group health insurance have eliminated the problems connected with the granting of individual insurance

to persons with an impaired state of health.

There is a demand that people shall as far as possible be eligible for life and health insurance protection not only at younger ages but also at comparatively high working ages.

Against the background of these needs and demands it must be considered highly desirable that the appraisal rules applied by the life and health insurance companies should be made very liberal. It may even be maintained that extra premiums should be charged only in order to guard the corps of policyholders as a whole against losses from *undue* speculation; the primary goal should be not to apply appropriate extra premiums to persons who are substandard risks, but solely to prevent them from taking out higher insurance protection than they would have done if their state of health had been normal. Where measures against such a counterselection are needed in the interest of the whole body of policyholders it will as a rule be sufficient to apply comparatively low extra premiums preferably over the initial period of the insurance term.

A secondary question is to what extent the risk appraisal should be taken into account in respect of the distribution of bonus to different categories of policyholders. The goal should be to arrive at a proper balance between strict equity and solidarity which enables simple and consistent solutions to be arrived at.

The prognosis of DM is heterogeneous; medical experts are of opinion that it is extremely difficult to make an individual prognosis even for diabetics who have been the object of thorough clinical

examinations over a long period. The uncertainty is still greater in respect of new cases. Nevertheless, provided after a number of observation years the disease has not become complicated by nephropathy or severe ocular or vascular changes, there seems nowadays to be general agreement that *on average* the prognosis is in the main favourable. In the age interval 55-69 the excess mortality of diabetics cannot reasonably be assumed to exceed 30 per cent, and at higher ages their excess mortality is still lower (less than 20 per cent).

In respect of life insurance the most serious complication in DM is the occurrence of nephropathy. There seems to be unanimity among experts that as a rule diabetics with clear nephropathy should not be granted individual life insurance. The occurrence of retinopathy is not *per se* considered an obstacle to life insurance, probably the excess mortality for diabetics with retinopathy—without the combination with nephropathy—is slight. From the point of view of health insurance, on the other hand, due account must be taken of the risks of seriously impaired visual acuity.

Hypertension does not seem to be a greater risk in otherwise healthy diabetics than in non-diabetics.

On the basis of these considerations one of the present authors (Larsson, chairman of the Board Delegation of the Sverige) has suggested that new rules for the appraisal of DM risks in individual insurance should be tried on the following lines:

(a) Cardiovascular changes should be rated according to ordinary rules.

(b) Loss of visual acuity should be rated according to ordinary rules.

(c) Where ocular changes—beyond aneurysms and slight exudates—are present there should be applied in respect of waiver of premium and health insurance a clause for loss of visual acuity or a comparatively high extra premium, otherwise, the rating should be made without regard to the ocular changes.

(d) Where the occurrence of permanent or recurrent albuminuria has been established, the application should be refused, or possibly a special type of policy with "graded limitation" (gradually increasing insurance sum up to the full amount after a suitable number of years) might be issued, in the presence of nephropathy, the special circumstances in the individual case should be taken into proper account (the sum insured, the applicant's reason for seeking insurance, occupation, degree of control, etc.).

(e) Apart from the restrictions stated above, the premiums for diabetics should be based on supplements, which would be gradually reduced according to the age at onset of DM and the duration of the disease until H0 for age at onset above 40 and duration above 5 years; for age at onset 30-39 and duration above 10 years; for age at onset 20-29 and duration above 15 years, and for lower age at onset and duration above 20 years. Reduction of the higher supplements should be granted automatically or, possibly, after verifying that nephropathy has not developed.

(f) Possibly a premium system of this kind should be combined with altered rules for the distribution of bonus, for instance an appropriate allocation of the

extra bonus among policyholders who have reached the H0 class<sup>1</sup>

This proposal—and several others—were thoroughly discussed at the 1966 revision of the Manual but at that time the statistical analysis presented in Chapter IV, was not sufficiently complete and it was considered preferable to undertake a liberalization more in accordance with traditional lines

It is our hope that the present study will

be of use to the medical directors, actuaries and other experts of life and health insurance companies in the further discussion of a revision of the appraisal rules in respect of DM

---

<sup>1</sup> Such a method for the allocation of bonus cannot be regarded as inconsistent with the principle of equity since it is equivalent to a system where the extra bonus is continually invested as single premium for a pure capital insurance (to be paid in the event of survival but not in the case of death)

## Genetics of DM

## Current conceptions and discussions

There are many reports concerning familial occurrence of DM and the possible significance of genetic factors for the aetiology of the disease. Various genetic mechanisms have been considered such as recessiveness or dominance of an autosomal major gene (with incomplete or irregular penetrance) and multifactorial inheritance. It has also been suggested that an aberrant major gene may cause juvenile DM in homozygotes whereas the milder maturity onset DM develops in heterozygotes.

However so far as we have been able to find the great majority of these reports are based on observations (or hypotheses) of the morbidity risks for DM that lie far below the figures found by us. Further the sex differences with regard to the morbidity risks (at ages above 50) are generally assumed to be comparatively small. As an example the following series of prevalence rates may be quoted: it refers to estimates concerning the frequency of recognized DM which are based on household interviews of the civilian non institutionalized population in 1,000 sampling units throughout the U.S.A.<sup>1</sup> For comparison the correspond-

ing figures from our assessment in Chapter IV are shown.<sup>2</sup>

Attained age	Prevalence of DM per thousand population			
	U.S. National Health Survey 1957-59		Swedish mortality statistics 1961-63	
	M	F	M	F
0-24	1.1	0.7	(2)	(2)
25-44	4.9	3.8	11	11
45-54	11.2	13.7	21	19
55-64	25.2	31.5	32	49
65-74	34.4	50.3	45	87
75-	31.5	38.8	54	99

<sup>1</sup> Primary and contributory causes of death corrected for gaps: excess mortality according to Assumption II of Tables 32 and 34.

According to Fritz Lenz (1923) it seems likely that in some families the mode of inheritance is dominant but that there are also recessive genes which may condition the occurrence of DM. In spite of the higher prevalence among males than among females Lenz does not consider a sex linked transmission to be probable.<sup>3</sup>

<sup>1</sup> U.S. National Health Survey 1960. Health Statistics. Diabetes reported in interviews. United States July 1957-June 1959. Public Health Service Publication No. 584-B21 pp. 1-22.

<sup>2</sup> The age distribution (within the age groups) is not the same in the two series but considering the large differences this is of minor importance only.

<sup>3</sup> Lenz states that the frequency of DM among males is more than twice as high as among females.

Cambridge (1928-1934) studied 1 000 DM cases and found a family history of the disease in 396 of these. He tried to classify the pedigrees according to whether they were the product of recessive or dominant inheritance and arrived at the conclusion that the recessive type developed earlier in life than the dominant type. Thus early-onset DM might in general be due to homozygosis for a recessive gene, whereas late-onset DM should probably be regarded as being caused by a (different) dominant gene.

Then Bergh (1938-1939) investigated the state of health of twins in monozygotic co-twins of DM patients she found a much higher concordance rate than in dizygotic co-twins.

Hanhart (1939-1947-1950-1951-1953) made a series of thorough family investigations concerning the heredity of DM. His results are considered to speak decidedly in favour of the theory of a recessive mode of inheritance.

Penrose and Watson (1945) presented data indicating the greater incidence of DM in like-sexed sibs. They seem to be of opinion that DM is primarily conditioned by an autosomal dominant gene but that there exists in addition a secondary modifying gene which is sex-linked (recessive). Their interesting paper will be discussed later (p. 229).

In a study of a considerably larger series which included part of the sample studied by Penrose and Watson Thompson and Watson (1952) failed to confirm the finding of a sex-linked tendency; the authors conclude that their data are suggestive of inheritance by a single autosomal recessive gene.

At the request of a Swedish governmental committee (cf. p. 114) von Hofsten (1948) surveyed the current views concerning the heredity of DM and connected problems. His discussion is mainly hypothetical but is nevertheless of great interest in the present connection.

In von Hofsten's opinion it is proved that to a great extent probably in the majority of cases DM is inherited. There are families in which the only way of interpreting the data seems to be the acceptance of mono-hybrid dominant transmission. On the other hand it seems possible that the most frequent form of DM is inherited as a mono-hybrid recessive trait but there are alternative explanations which might be equally probable. The disease may be conditioned by a dominant gene which is manifested only in the case of constitutional weakness of one kind or the other or in the presence of certain environmental influence. Further it is not proved that the apparently recessive form of DM is unitary; it is possible and not unlikely that there exist at least two different types of recessive DM.

On the basis of assumptions concerning the frequency of the diabetic genotype in the general population and concerning the fertility of diabetics, von Hofsten discusses the implications of a reduced antiselection against the aberrant gene (due to reduced excess mortality and increased relative fertility among diabetics).<sup>1</sup> Whichever assumptions are made with a prevalence of the DM genotype ranging from 0.3 per cent to 4 per cent and a reproduction of the DM genotype between 90 and 75 per cent of that of the general population, von Hofsten arrives at what he considers unacceptable values for the mutation rate (from normal to diabetic gene). Therefore the suspicion cannot be avoided that to a greater extent than geneticists generally assume DM is not hereditary or is ascribable to non-specific genes; several other genes with different action might be expressed in the form of DM also or might entail a certain disposition for the development of DM.

In his discussion with regard to eugenic

<sup>1</sup> It is worth noting that according to von Hofsten a value of 0.6 per cent for the frequency of the DM genotype in the general population appears *a priori* very high. In another connection he says: If the frequency is assumed to be so unreasonably high as 4 per cent.



measures von Hofsten III opposed to sterilization but he advises against marriages between diabetics and further states that a diabetic should hardly marry a person whose father or mother or sibs have DM. Fertile matings between two diabetics should always be regarded as unsuitable. However, he emphasizes that it is improper, not to say irresponsible, to arouse apprehensions which are based solely on uncertain suppositions. For instance II is anything but desirable that healthy persons should be given the impression that there exists a probability of 50 or 25 per cent of their developing DM or that healthy parents without any known instances of DM in their families should, after having got a child with DM, have to be worried that their other children will develop the disease.

Harris (1949, 1950) underlines that data from hospital admissions tend to underestimate the relative frequency of the late onset cases in the general population and overestimate the relative frequency of the juvenile cases. Juvenile cases are generally severe and are all or nearly all sent to hospital clinics for investigation or treatment. Late onset cases are very often quite mild and many of them probably never find their way at any time to a hospital clinic. An exact age at onset distribution could be arrived at only by a very elaborate population survey.

On the basis of detailed family data for a series of 1241 DM probands Harris concludes that there is a true positive sib-sib correlation with respect to the age at onset of DM. This implies that the disease is heterogeneous, the early-onset and late-onset cases being determined by different gene combinations. On the other hand it is apparent that mild cases of late onset occur not infrequently among the parents and other relatives of the severe juvenile and young adult forms of DM although there appears to be little or no parent-child correlation with respect to age at onset. This evidence does hardly accord with the view that we are dealing with two genetically distinct and separate diseases. Nor is it

consistent with an explanation accounting for the variation in age at onset on the basis of autosomal modification.

In the early onset cases there is evidence of an increase in parental consanguinity (greater than that in the general population) this observation suggests that many if not all of the juvenile and young adult cases are probably to be regarded as homozygotes for a single mutant gene. The finding that no such rise in parental consanguinity in the late onset cases could be detected implies that these cases could not in the main be regarded as homozygous for the same gene.

One hypothesis which might give a reasonable description of the observations is that many of the mild late onset cases could be regarded as heterozygous for a gene which in homozygous form gives rise to the severe early onset type of DM. The distribution of the homozygous and heterozygous cases both in respect to age at onset and to severity would be presumed to overlap to a certain extent. There would be incomplete manifestation, particularly of the heterozygotes which would be dependent on environmental factors and genetic background. However it is possible that the high sib-sib and low parent-child correlations with respect to age at onset may in part at least be accounted for by modification due to common recessive autosomal modifying gene or genes or to allelic modifiers.

The question whether we have to deal with a single gene pair or an allelic series remains open as also does the problem whether mutant genes at more than one locus may not be producing similar end results. The exact conditions of manifestation and the influence of environmental factors will also require detailed study.

The views expressed by Kemp (1951) in his well known textbook *Genetics and Disease* can be summarized as follows.

The prevalence of DM is about 0.4 per cent in the USA, England, Norway and Denmark. The registered prevalence has been rising during the past 50 years or so owing to improved diagnostic possibilities.

the increased longevity of the population in general and particularly of diabetics as well as the fact that diabetics can now have more children than previously. The prevalence is highest (2-4 per cent) among women aged 60-79. The morbidity risk is 1-5 per cent for males and 2-7 per cent for females. The average risk for the whole population has been calculated at about 6 per cent.

It is probable that the majority of diabetic cases are hereditary and that there exist two or more genes which can produce DM. There must be at least one gene for the juvenile form and one for the senile form, but it is more reasonable to suppose that there exists a series of allelic diabetogenic genes. Nor can we exclude the possibility that mutations in quite different places can give rise to disorders of the carbohydrate metabolism which it is impossible to distinguish from one another by clinical methods. There seems however to be a genetic relationship between the different forms of DM.

After having mentioned the theory advanced by Harris (cf. p. 216) that juvenile DM might be due to a gene present in the homozygous form and that the same gene in heterozygous form might produce senile DM, Kemp continues: 'The conditions are however hardly so simple. Older theories to the effect that all cases of diabetes depend either on a single recessive gene or on a single irregularly dominant gene have now been abandoned.'

Joslin (1953) in his *Diabetic Manual for the Doctor and Patient* states without reservation that the tendency to diabetes is inherited as a recessive trait.

Barthels (1953) on the basis of a review of the literature concludes that an estimate of potential diabetics at 6 per cent (of the American or Danish population) would not be too high. If the assumption of recessive inheritance is correct for all diabetes of obscure aetiology, the number of carriers of the gene in the population would be in the order of 25 per cent.

Lamy, Frezal and de Grouchy (1957) investigated the incidence of DM among relatives of 500 probands. No correlation was found between maternal age or parity and the incidence of DM. For the severe insulin-treated diabetics, whether juvenile or late, there was found consanguineous marriages in the parents. DM among both paternal and maternal relatives and an increased prevalence of DM among the sibs if one parent was diabetic. The authors conclude that severe DM, whether juvenile or late, is due to the homozygous action of a gene which in the heterozygous condition leads to mild adult DM.

Lamy, Frezal and Rey (1961) adduced the supplementary theory that in addition to the main gene there exists a number of modifying genes which affect the expression of the major gene. With a great many of these secondary genes present, DM might occur even in the absence of the major gene.

Grunnet (1957) made an extensive study of the prevalence of DM among relatives of DM probands. Grunnet is of opinion that there exists a type of late-onset DM which is inherited as a dominant trait. In addition there are other types of hereditary DM in which both mild cases with late onset and severe juvenile cases occur. The fact that the frequency figures are higher for sibs than for parents gives rise to the conclusion that part of these cases are ascribable to homozygosity for a recessive gene or to the combined action of several genes.

White (1959) seems to be firmly of opinion that the potentiality for developing DM is inherited as an autosomal recessive trait. She supports her views primarily upon five facts:

- (1) the concordant occurrence of DM in similar twin mates
- (2) the statistically greater frequency of DM in close blood relatives of diabetics than in those of control populations
- (3) the demonstration of Mendelian ratios of the recessive type in large series of cases selected at random

(4) the demonstration of expected ratios in presumably latent (tested) cases

(5) the fact that the incidence of DM in genealogies of diabetics behaves as a recessive trait

Steinberg (1959) estimated that about 5 per cent of the population of the USA is genetically liable to DM. He emphasizes that in all sets of data that are presented so that comparisons can be made it is found that twice as many sibs of DM probands are diabetic if one parent is diabetic than if neither parent is diabetic. dominant inheritance does not lead to such a pattern. According to Steinberg susceptibility to DM is probably inherited as a recessive character. This hypothesis is the only one consistent with the several large samples of family data that have been published. It is not clear from the available data whether homozygosity at only one locus or at any one of two or more loci will cause susceptibility to DM.

Widukind Lenz (1961) makes a series of interesting remarks concerning the difficulties of distinguishing between recessiveness and dominance in respect of common genes. His starting point is that about 2-4 per cent of the population in Western Europe and the USA become afflicted with DM (in general at fairly high ages). Twin studies have revealed that about 50 per cent of the co-twins of monozygotic twins with DM do not become afflicted and Lenz therefore assumes that at least 8 per cent of the population carry the genetic disposition for DM and hence in the case of recessiveness the gene frequency would be 0.28. About 40 per cent of the population would be heterozygotes. Then it would often happen that a homozygote (developing DM) marries a heterozygote. In this case it is to be expected that 50 per cent of the children will be homozygotes and pseudodominant inheritance would not be an exception but a rather common situation.

According to Clarke (1962) the most widely held view is that DM is inherited as an autosomal recessive trait but that the

gene has only 20 per cent penetrance. However, with regard to the statistics adduced by Pincus and White (1934) and by Steinberg and Wilder (1952) which show a good fit to the expected ratios Clarke makes the remark that, with a penetrance of only 20 per cent it is impossible to be sure that the genotype of the parents has, in fact, been scored correctly.

The alternative possibility is that diabetes is controlled multifactorially. By analogy with other diseases the commonness of the condition makes this hypothesis likely. Supporters of this view point out that there is no clear-cut division between normal and abnormal glucose tolerance tests. It may be queried, however, whether this test reflects the primary action of the gene.

Clarke's conclusion is that since the matter is undecided there is a good case for further investigation (cf. also Clarke 1961).

The data given by Nilsson (1962, 1964) will be discussed in a later section (p. 237).

Simpson (1964) made a thorough genetic analysis of family data for 2,645 probands from a register of diabetics in Canada (cf. also Simpson 1962). The observed numbers of diabetics among sibs, parents and children are compared with expectations for the general population (observations from three small towns in Ontario and a city in the Province of Prince Edward Island). According to the author her data suggest that the hereditary basis for DM is multifactorial.<sup>1</sup>

Pfandler (1964) in his comprehensive review of the genetics of metabolic disorders, seems to favour the explanations put forward by Grunnet. Pfandler states that many geneticists hold the view that family studies as well as statistical data speak in favour of simple recessiveness: the same gene would be responsible for the juvenile

<sup>1</sup> It should be remarked, however, that the expectations are calculated from prevalence figures that are lower than those found by us (cf. p. 111) for males the maximum prevalence applied is 3.90 per cent (at ages 70-79) and for females it is 4.47 per cent (at ages 60-69).

and the late forms of DM. If there are instances of DM which are conditioned by dominant genes these are at least less frequent. The occurrence of heterogeneity is not proved. Against these theories stands the hypothesis adduced by Grunnet of a heterogenic and possibly polygenic causation of DM.

On the other hand Arthur G. Steinberg, who has devoted several studies to the genetic problems of DM (Steinberg & Wilder 1952; Steinberg 1955, 1958, 1959, 1961, 1965) has presented data which do not fit the hypothesis of multifactorial inheritance.

With regard to the theory that early-onset diabetes is due to the effects in homozygotes of a recessive gene which in heterozygotes leads to late-onset diabetes, Steinberg (1965) reports several investigations concerning the incidence of diabetes in offspring which in his view reveal facts incompatible with this hypothesis. In series published by Harris (1950) and by Steinberg and Wilder (1952) the frequency of diabetics among parents of patients becoming afflicted before age 30 was found to be 3.3 and 5.0 per cent respectively, whereas among parents of patients becoming afflicted after age 30 the corresponding frequencies were 6.2 and 11.4 per cent. Although—as Steinberg points out—in these series the parents of the late-onset diabetics are on average older than those of the early-onset diabetics, the deviations from expectation must be considered to argue against the theory—according to which the frequency of diabetes among the

parents of patients with early onset should be greater than the frequency among the parents of patients with late onset. A further argument against the theory was the fact that the prevalence of diabetes among the sibs was greater when one parent was diabetic than when neither parent was diabetic. The data adduced by Steinberg are shown in the table below.

On the basis of data from the literature concerning the prevalence of diabetes among the sibs of diabetic patients, Steinberg makes a comparison between the situation where one parent is diabetic and the situation where neither parent is (known to be) diabetic. The data cover a total of 3,923 and 21,774 sibs respectively. Of these 11.4 and 4.4 per cent were diabetic; the quotient between the percentages being 2.58. From this Steinberg concludes that a simple working hypothesis, not necessarily correct but one which fits the data, is that susceptibility to diabetes is due to homozygosis for a recessive gene.

For the subsequent analysis it seems warrantable to give a quantitative example of the assumptions involved in the use of such a quotient as the basis for conclusions concerning the mode of inheritance of DM.

With unbiased registration of the patients' complete knowledge about the genotype of the parents, the same average family size and the same age

Series	Patient's age at onset	Number of sibs, and frequency of diabetes among sibs of the patients, per cent					
		One parent diabetic		Neither parent diabetic		Total	
		No.	%	No.	%	No.	%
Harris 1950	0-29	48	18.8	971	3.5	1,019	4.1
	30-	327	10.7	2,446	4.1	2,773	4.4
Thompson & Watson 1952	0-29	57	15.8	425	6.4	482	7.5
	30-	714	15.3	3,411	7.8	4,125	9.1
Steinberg & Wilder 1952	0-29	92	14.1	736	5.0	828	6.0
	30-	1,528	11.2	5,928	4.6	7,456	6.0

Prevalence of the diabetic genotype $r^2$	Prevalence of the diabetic gene $r$	Prevalence of diabetic phenotype among parents with diabetic genotype		Ratio between the prevalence of diabetic genotype in sibs with diabetic parent and that in sibs with neither parent diabetic	
		(1)	(2)	(1)	(2)
0.02	0.1414	0.58	0.56	2.95	2.86
0.03	0.1732	0.48	0.46	3.05	2.93
0.04	0.2000	0.41	0.40	3.13	3.04
0.07	0.2646	0.31	0.30	3.33	3.24
0.10	0.3162	0.26	0.25	3.48	3.40
0.13	0.3606	0.23	0.22	3.62	3.54

distribution for the sibs the expected value of the quotient would be 2.0. If in addition, there had been complete knowledge about the genotype of the sibs (and they had been classified accordingly) the frequencies of diabetics among them would have been 50 and 25 per cent (instead of 11.4 and 4.4 per cent).

Let us for simplicity assume that of parents with diabetic genotype the fraction  $r$  is included in the diabetic phenotype  $A$  (= affected) and the fraction  $j = 1 - r$  is included in the non diabetic phenotype  $U$  (= unaffected) which with complete ascertainment of their state of health will imply that they have reached an age corresponding to 100% per cent of the total morbidity risk. Let us further assume that the conditions in respect of unbiased registration and the same average family size are fulfilled. Denoting the prevalence of the recessive gene by  $r$  and the prevalence of the allelic "normal" gene by  $d = 1 - r$  we get the distributions by type of mating shown in the following table:

Phenotype of mating	Frequency of mating stated in the general population	Distribution by type of parental mating of sibs of diabetic probands
$A \times A$	$r^2 \cdot x^2$	$4r^2 \cdot x^2 (1 + r)^2$
$A \times U$	$2rx (d + r)$	$4rx (d + 2r) (1 + r)^2$
$U \times U$	$(d + r)^2$	$(d + 2r)^2 (1 + r)^2$
Total	1	1

With the assumptions made, the number of sibs can be utilized for determining  $r$ . We have a total of 25,697 sibs of whom 21,774 are in families with neither parent phenotypically diabetic and 3,923 in families with one parent diabetic; for illustration we can take this latter figure to represent (1) either only one parent diabetic or (2) one or both parents diabetic.

With different values  $r^2$  for the prevalence of the diabetic genotype in the general population we get the frequencies given at the top of this page.

As will be seen from this table the ratio 2.58 found by Steinberg must be regarded as low, although the theoretical value with unbiased registration and complete knowledge of genotypes is 2.0 in (1) and somewhat less or  $2(4 - 4r)/(4 - 3r)$  in (2). An interesting feature is that the ratios show a comparatively small variation with the gene frequency  $r$ .

At a symposium on the genetics and epidemiology of chronic diseases in 1963 an interesting paper concerning the evaluation of genetic factors in DM by Neel, Fajans, Conn and Davidson (1965) was presented. The authors summarize their results as follows:

The data obtained once again confirm the familial nature of diabetes but

in the strict and formal sense are not proof of a genetic predisposition although by exclusion this seems highly probable. It is shown that in the diabetically predisposed (offspring of conjugal diabetics) there are highly significant changes in the mean glucose tolerance curve in the 10-29 age interval. This fact can be utilized in the analysis of family data. Assuming a genetic basis then the results of our analyses do not favor the hypothesis that diabetes is due to homozygosity for a single recessive gene unless one is willing to assign a frequency of 0.20-0.25 to the recessive genotype. There appear to be valid reasons for discarding other simple genetic hypotheses. The data are consistent with a multigenic (multifactorial) hypothesis although the apparently very high proportion of affected offspring from conjugal diabetics remains a troublesome point. This is explicable if the living conditions of the current generation have lowered the threshold of phenotypic expression of the diabetic genotype below that of the paternal generation.

The data adduced by Neel Fajans, Conn and Davidson are based in part on the results of glucose tolerance tests of individuals in a community in Michigan. The values of the tests did not show a bimodal distribution. Similarly the tests of the offspring of families with a diabetic child and at least one normal parent did not show bimodality. Were predisposition to diabetes determined by a simple genetic mechanism—and reflected by an abnormal glucose tolerance test—a bimodal distribution would be expected. A further argument for the theory of multifactorial heredity was that the test data indicated that there were too many diabetic offspring in these families for predisposition to diabetes to be due to recessive inheritance.

In this latter respect Steinberg (1965) objects that while it may be true that all diabetics have abnormal glucose tolerance tests it is probably not true that all those with abnormal glucose tolerance tests are diabetic or prediabetic. The thorough study made by Neel Fajans, Conn and David

son gives valuable knowledge concerning the variability of the outcome of glucose tolerance tests. However although glucose tolerance tests are useful in the diagnosing of DM they are not the diagnosis.<sup>1</sup>

Jorgensen (1966) underlines the difficulties in the genetic analysis of DM connected with the high prevalence of the disease, the great variability of the disease picture and the strong age dependence of the clinical manifestation. The age corrections which are necessary for numerical calculations are complicated and in addition very uncertain.

Jorgensen does not exclude the possibility that sometimes there may be found special genetic types of DM with monohybrid transmission but considers the great majority of cases of DM to be due to a multifactorial system of additive genes with threshold effects.

(1) The variability of blood sugar level with unnoticeable and unclear transition from still healthy conditions via prediabetic states to clinically manifest DM is adduced as one argument in general monohybrid genetic diseases show far less variability than do polygenic diseases.

(2) A second argument is the frequent

<sup>1</sup> Certainly the theory that subnormal intellectual capacity—as indicated by an IQ below say 100 per cent or below 90 or 80—is conditioned by an aberrant major gene can be disproved by a similar type of analysis. In the main intellectual capacity is a graded character to a great extent connected with multifactorial inheritance. However as is well known there are many forms of oligophrenia which are conditioned by single gene mutations (cf. for instance Sjogren & Larsson 1949, 1957, 1967) or by chromosome aberrations.

Height is a graded character with clear elements of multifactorial inheritance; this does not preclude among persons of short stature the occurrence of instances of dwarfism which is conditioned by a major gene.

Although senility may be mainly connected with multifactorial inheritance and exogenous factors, essential senile dementia is conditioned by a major gene (Larsson, Sjogren & Jacobson 1963).

occurrence of isolated cases but on the other hand = clearly increased morbidity risk among relatives as compared with that of the general population

(3) A third argument is that there is good agreement between the morbidity risks for parents and sibs and further that the morbidity risks among more distant relatives decrease rapidly (which does not occur to the same extent in the case of monohybrid dominance)

(4) A fourth argument is given by reference to the results of twin research Jorgensen quotes data from the literature according to which the concordance rate for monozygotic twins is more than four times the concordance rate for dizygotic twins (93/151 or 62 per cent and 43/334 or 13 per cent respectively)

(5) Finally it is stated that a series of investigations have shown that there is an increased frequency of DM among persons with blood group A Jorgensen considers it possible that the A blood group gene is the first of the factors to be identified in the multifactorial genetic system of DM (and several other multifactorially conditioned diseases)

In connection with these five points it will merely be commented here that not only diseases with multifactorial inheritance but also diseases conditioned by a dominant major gene may show great variability with regard to age at onset symptoms and course There are different opinions among experts about the possibility of an association between DM and blood group A The statistical results in respect of the frequency of isolated cases the concordance between twins and the morbidity risks among relatives will depend on the magnitude of the morbidity risk for DM in the general population and the shape of the morbidity risk curve These questions will be further discussed in a later section

Pavel and Pieptea (1966) investigated the occurrence of DM in three or four successive generations in the families of diabetics registered with the Antidiabetic Centre of Bucharest Among 12 000 patients there were 3 430 cases which are interpreted as being hereditary (the remaining isolated cases are said to be *des cas de diabete acquis*) Excluding 42 pedigrees with DM on both the paternal and the maternal side and 4 pedigrees containing consanguineous marriages there remained for analysis 113 pedigrees with DM consecutively over three generations and 4 pedigrees with DM consecutively over four generations The number of affected persons in the different generations is as follows

Number of diabetics in Generation				Number of pedigrees
C	P	GP	GGP	
2	7	2	1	1
1	5	2	1	1
1	3	1	1	1
1	2	3	1	1
4	1	1	-	1
3	1	1	-	4
2	1	1	-	19
1	2	1	-	6
1	1	1	-	83
Total				117

C = children P = parent (and sibs of parent)  
 GP = grandparent (and sibs of grandparent)  
 GGP = greatgrandparent

Of the 1 079 families known to the Centre during 14-25 years and for which there were three known generations of adults 88 or 8.2 per cent presented DM in three consecutive generations of the 253 families known and checked during 23-25 years and for which there were four known generations of adults 3 or 1.2 per cent presented the disease in four consecutive generations

The authors consider that their data speak directly in favour of a true dominant transmission of DM

For a total of 276 transmissions from parent to child (grandparent to parent etc) the sex relations are as follows

from father to son	50
from father to daughter	41
from mother to son	78
from mother to daughter	107
Total	276

With regard to the sex proportion among the affected parents reference is made to a previous study (Pavel Pieptea & Vasilescu 1966) according to which the predominant role of the mothers in the transmission of DM is ascribable to selective factors of a non genetic nature (cf p 228)

From the five pedigrees reproduced in the paper (one over three generations four over four generations) the following transmission lines can be seen

from father to son	5
from father to daughter	5
from mother to son	8
from mother to daughter	15
Total	33

On the basis of his findings that diabetics have more synalbumin antagonism to insulin than have normal subjects Vallance Owen (1966) studied the synalbumin antagonism among relatives of diabetics

Ninety seven members of nine families were examined of whom 58 were found to be synalbumin positive (of these 16 had overt carbohydrate intolerance) In addition the author studied 206 other persons viz healthy volunteers patients with ischaemic heart disease and unselected hospital patients suffering from a variety of other conditions The author gives a diagram concerning the glucose uptake values (above the basal level) for these 303 individuals the diagram shows a bimodal distribution from which fact it is concluded that two phenotypes exist in the population synalbumin positive and synalbumin negative individuals This in turn suggests inheritance of two alternative alleles at a single locus

Vallance-Owen's paper contains pedigrees for the nine case families On the following grounds the author concludes that excessive synalbumin antagonism (the state of being synalbumin positive) is inherited as an autosomal dominant character

(a) There are several single pedigrees covering three generations including both synalbumin positive and synalbumin negative members which have the typical characteristics of this type of inheritance

(b) Synalbumin positive individuals have always had a similarly affected parent so far as it has been possible to ascertain this in these family series

(c) There is a 1:1 distribution of affected members in the sibships available for analysis

According to Vallance Owen the observations indicate that there are many constituted diabetics who will never develop carbohydrate intolerance and that there are many more people so constituted than had been previously realized Whether or not a synalbumin positive individual develops carbohydrate intolerance may well depend upon environmental and physiological factors for the synalbumin antagonist is dependent upon the pituitary-adrenal system The already increased antagonism can be even further increased under certain conditions notably the growth spurt pregnancy infection the menopause mental stress or when adrenal corticosteroids are administered

The results obtained by Vallance Owen are highly interesting (and highly stimulating for further research in the genetics of DM) However there are some questions to be asked in respect of the data

Of 98 hospital patients selected at random 25 were synalbumin positive However the bimodal distribution of the glucose uptake values seems to indicate that the prevalence in the general population of synalbumin positive individuals is much higher than 25/98 or 27 per cent The distribution covers 97 individuals from the case families of whom 58 were synalbumin positive and a further 206 individuals So far as



can be seen from the diagram more than half of these 206 individuals must have been synalbumin positive

Further the composition of the matings in the nine case families appears to be very peculiar. There are in all 21 matings in which *one* of the spouses is synalbumin positive (6 males 15 females) in 15 the other spouse is synalbumin negative (9 males 6 females), and in the remaining 6 the spouse was not tested (6 males). Among the parents of synalbumin positive children in 18 matings *one* parent is synalbumin positive in 13 the other parent is synalbumin negative and in 5 was not tested. Such a distribution must be regarded as extremely unlikely if the prevalence of synalbumin-positive individuals in the general population exceeds 50 per cent and it is also very unlikely if the prevalence is of the order of magnitude 27 per cent.

It may be remarked that a definite proof of Vallance Owen's theory of an autosomal dominant gene (synalbumin-positive) as being necessary for the development of essential DM does not *per se* solve the problems connected with the genetics of DM. Irrespective of whether the prevalence of persons carrying this autosomal dominant gene exceeds 50 per cent or is lower (in the order of magnitude 27 per cent) there remain the circumstances that the morbidity risk for clinically manifest DM is about 6.5 per cent for males and about 13 per cent for females. Hence one will have to resort to supplementary hypotheses to explain the gap between the prevalence of the synalbumin positive genotype and the morbidity risk for DM among

females and to explain the further deficit among males. *One* possible hypothesis would be that there are different genes—a 'main gene' for developing DM and a 'conditioning gene' for being synalbumin positive (or, which is the same an inhibitory gene for being synalbumin negative). A consequence of this hypothesis would then be that, if the prevalence of the synalbumin positive genotype is 50 per cent the prevalence of the main DM genotype among females would be not 13 per cent but 26 per cent. In a way this higher prevalence would give support to the theory that the 'main' DM gene might be sex linked, since it will be the more easy to explain the occurrence of affected pairs father-son the more frequent the DM gene is in the general population. However speculations of this kind should preferably be postponed until there are sufficient data concerning the frequency in the general population of synalbumin-positive individuals.<sup>1</sup>

Renold and Cahill Jr (1966) give a concentrated account of genetic considerations

<sup>1</sup> Arvill Westberg, Jonsson Hood and Åhrén (1966) report the testing of human albumin prepared by means of two different procedures from blood of seven normal persons and three diabetic subjects viz. the glucose uptake of the rat diaphragm and the distribution of  $\alpha$  amino-isobutyric acid in the intact levator ani muscle of immature male rats. Albumin fractions prepared in accordance with the trichloroacetic acid-ethanol procedure used by Vallance-Owen showed in some cases an insulin antagonistic activity whereas other fractions did not show any insulin antagonism. Albumin prepared as described by Michael (1962) constantly showed a high insulin like activity but no antagonism. Albumin preparations from diabetic subjects examined in accordance with Vallance-Owen did not show insulin antagonism.

in respect of DM (with a good bibliography) They discuss the well known diabetes surveys by Wilkerson and Krall (1947-1953) and Wilkerson Krall and Butler (1959) from Oxford Mass and review evidence for the hereditary nature of diabetic potential — twin studies by Then Bergh (1938-1939) and White (1959) the genealogical studies by Hanhart (1950-1951-1953) and the investigations by Penrose and Watson (1945) Harris (1950) Steinberg (1955-1959-1961) and Steinberg and Wilder (1952) The authors summarize the genetic aspects as follows

1 Diabetes mellitus may be defined as a metabolic disorder characterized by hyperglycemia Although hyperglycemia is not present from birth in the great majority of instances there is excellent evidence to indicate that the potentiality to develop diabetes mellitus is inherited Best available evidence suggests that the mode of inheritance is a simple recessive one with incomplete penetrance As yet this evidence is not conclusive

2 Genealogies which do not seem consistent with the simple recessive mode of inheritance may be the result of the very high incidence of the diabetic gene combined with inability to recognize its presence prior to the development of hyperglycemia It has been estimated that in the United States about 5 per cent of the population is homozygous (dd) for the gene determining the susceptibility for diabetes Available information does not suggest that the major clinical forms of diabetes are genetically distinct the rare syndrome of hypotrophic diabetes being a probable exception

In a very interesting paper on multifactorial inheritance in relation to normal and abnormal traits Fraser Roberts (1961) discusses the genetic component in the causation of common diseases (primarily against the background of data on arterial pressures essential

hypertension and duodenal ulceration) He states Theoretically it might be maintained that a gene producing its effect after reproductive life might become common, for natural selection is not operating against it It might even be argued perhaps, that those whose forbears do not live too long are at selective advantage But in fact the diseases and mortality of post reproductive life show little if any evidence of simple Mendelian ratios Fraser Roberts quotes the findings of Doll and Buch (1950) that 11.5 per cent of brothers of men with duodenal ulceration were similarly affected against an expected figure of 5.5 per cent in the general population of comparable ages and then continues "In instances such as these it is possible to invoke a dominant or intermediate, gene of low penetrance It is true that the presence or absence of disease is an all or none phenomenon but there could be a threshold and it seems more plausible to suppose that as a general rule degrees of underlying genetic resistance or susceptibility will ultimately be found to be multifactorial"

However although these statements undoubtedly have a wide bearing there is now evidence that monohybrid Mendelian inheritance of diseases with a high age at onset occurs a well known example is *Huntington's chorea* The same applies to *essential tremor* and *essential torsion dystonia* (autosomal dominance Larsson & Sjögren 1960 1966) and to *essential senile dementia* (probably autosomal dominance Larsson Sjogren & Jacobson 1963)

Widukind Lenz (1961) emphasizes the fact that in general the action of a homo

zygotic gene pair is extremely constant, there are practically no examples of recessive diseases with irregular penetrance or greatly variable expressivity.

It might be argued that against the background scheduled by Lenz, the general clinical picture of DM—the greatly different course in respect of the occurrence of late complications<sup>1</sup> and, in particular the variability with regard to the age at onset—deviates so much from the ordinary picture found in diseases that are conditioned by monohybrid recessive genes that this mode of inheritance should not be considered at all. However with the data hitherto reported in the literature the hypothesis of autosomal dominance will be as good as or better than the hypothesis of autosomal recessiveness.<sup>2</sup> Hence in respect of the significance of Lenz's arguments—which in fact seems to be great—they cannot be used against the theory that DM is conditioned by a major gene but only to rule out the theory that this gene is recessive.

A common problem in human genetics—and in medical statistics in general—is the ascertainment of phenotypes. In a sense Fraser Robert's statement that the presence or absence of disease is an all or none phenomenon may be regarded as being connected with the definition of disease for statistical purposes more than with the biological aspects. At least in the case of diseases with insidious onset the threshold concept is important—or rather is necessary. Often at a certain point of time it is impossible to make sure whether a certain person is afflicted with a certain disease or not at a later period of time

it may be possible not only to diagnose the disease with a high degree of accuracy but also to ascertain that it began several years earlier. In practice, this situation occurs to a large extent in respect of DM with onset at higher ages. Further, even in respect of clinical DM the criteria used for the delimitation may vary, where "prospective" cases ('prediabetes') are included the definitions may become vague or even inappropriate for statistical analysis.

## Sex differences

It has been shown that the morbidity risks for DM must be much higher than has been presumed in earlier analyses of the genetics of DM, and that for females the total morbidity risk (or the aggregate risk up to age 80 or 90) is about twice the corresponding risk for males. Against this background it is very tempting to proceed to speculate whether the higher morbidity risk for females is in some way sex-connected (or to a certain extent sex limited)—for instance through effects of pregnancy, estrogenic hormones or the like—or whether the explanation might be that DM is (at

<sup>1</sup> In respect of common diseases with onset at advanced ages a differentiation between dominant and recessive inheritance is very difficult to perform by means of comparisons between the incidence figures registered among parents, sibs and children of affected individuals (cf. Larsson, Sjögren & Jacobson 1963; Larsson & Sjögren 1966). This fact has often been overlooked in the discussions concerning the possible genetic causation of DM (viz. whether it might be ascribable to dominance or recessiveness of an autosomal major gene). Numerical data are given in Table 82, p. 231.

least in the majority of cases) conditioned by a *sex linked* dominant gene (located on the X chromosome)

Among factors which are known or may be suspected to influence the onset or course of DM (or both) mention may in the present connection be made of the following

(a) pregnancy, delivery and gestation menstruation and menopause which are strictly limited to the female sex

(b) puberty, which in a sense is more sudden in the female than in the male sex

(c) endocrine disturbances thyrotoxicosis etc., some of which are more frequent among females than among males

(d) muscular work, which is considered to be on average heavier among males than among females (although at higher ages the opposite situation may apply)

(e) overweight which is considered to be more frequent among elderly women than among elderly men (although at younger adult ages the opposite situation may apply),

(f) diseases of the circulatory system which are more frequent or at any rate more dangerous among males than among females

With unbiased statistical series—or series for which the biases can be evaluated—relating to the incidence and prevalence of DM by sex and age, marital status and number of children (or pregnancies) for women and the type of occupation it would be possible to investigate the theory of a sex connection of DM in these respects. The problems concerning the significance of overweight

and concurring diseases for sex differences in the incidence of DM are more complicated not least because the registration (diagnosing) of DM is often made in connection with the occurrence of an intercurrent disease which calls for a visit to a doctor or to a hospital possibly the best way of studying these problems would be to analyse death records<sup>1</sup>

Further, it should be remembered that—according to the results presented in Chapter IV—the incidence of DM must be fairly equal for males and females up to the age of 50 the largest sex differences in incidence (and the highest morbidity risks) are found for the age groups 55–69 (cf Table 32 p 111, and Table 34 p 117)<sup>2</sup>

Malins, FitzGerald and Wall (1965) studied the sex ratio (M/F) among newly diagnosed diabetics at the Diabetic Clinic of Birmingham General Hospital over the period 1930–63. They found a marked increase in this ratio from 1945–49 to 1961–63 viz from 0.48 to 0.89. For the three age groups 35–49, 50–64 and 65–79 the (standardized) ratios increased from 0.65 to 1.78 from 0.44 to 0.96 and from 0.38 to 0.78 respectively. The authors discuss several possible explanations. It is stated that the changed pattern does not appear to be the result of any difference in the type of diabetic patients admitted to the hospital.

<sup>1</sup> However overweight is recorded in death certificates to only a very small extent and previous diseases are not recorded unless they are reckoned as the primary or a contributory cause of death.

<sup>2</sup> It might be remarked that in the older literature it is often stated that DM is more common among men than among women (cf note 214). It is thus only natural that attention was not given to the possibility that the mode of inheritance for DM might be sex linked dominance.

Obviously, reliable incidence data may in many connections be more informative than prevalence data not least because they reflect mainly what has happened during a given period. Nevertheless it must always be kept in mind that—in respect of a disease like DM—there will often be considerable acceleration and delay effects (cf p 166). Our results with regard to the morbidity risks (which are based on a study of death certificates for the whole of Sweden in 1961–63 and hence relate to the prevalence of DM cf Table 34, p 117) show a much lower (standardized) sex ratio M/F than would follow from the Birmingham incidence figures over the period 1930–63.

Pavel Pieptea and Vasilescu (1966) studying the transmission of DM in 3,883 hereditary cases, conclude that the disease is more often inherited through the mother (62 per cent) than through the father (38 per cent).<sup>1</sup> The authors are of opinion that there exist diabetogenic extrahereditary influences due to the mother which must be considered in investigation into the genetics of DM.

## The theory of sex-linked dominance

It is well established that sex-connected factors—or factors in respect of which there are sex differences in prevalence—may play a considerable part with regard to the symptomatology of DM, the course of the disease, the occurrence of complications, etc. Yet it seems difficult to accept the idea that such factors are the basic constituents for the occurrence of DM, since a great many investigations have shown that—at least

to a great extent—DM is genetically conditioned.

However, the problem of the interaction of heredity and sex connected features like those mentioned above is a complicated one. Supposing that DM is really conditioned by a major gene and that this is autosomal (dominant or recessive), we have to presume a gene frequency that explains the highest prevalence. We shall have to seek for sex connected factors which can explain the deficit in the prevalence of DM among males (*inhibiting factors*), not for sex connected factors which may accelerate the onset or augment the prevalence among females (*precipitating factors*) since in the latter case we have to make the additional assumption that to a great extent DM is not conditioned by an aberrant major gene but—at least in females—must often have a purely non-genetic origin or be due to multifactorial inheritance. Looking at the list above, it seems very difficult to accept that the occurrence of diseases of the circulatory system will counteract the development of DM. It is conceivable that hard work might postpone the development of DM, and that pregnancy, endocrine disturbances, etc. might accelerate it, but in that case it seems likely that the sex difference in respect of DM would largely refer to the shape of the risk curves and not to the aggregate risks up to ages 80 or over.

Undoubtedly, a simpler theory will be that not only the occurrence of DM but also the occurrence of a sex difference in the total morbidity risk for DM is

<sup>1</sup> Cf also the subsequent study by Pavel and Pieptea 1966 (see p 222).

genetically conditioned. So far as we know, all earlier analyses of the genetic aspects of DM are based on assumptions of a comparatively low total morbidity risk for the disease (or in other words a comparatively low prevalence of the aberrant gene or genes). Further, it has not always been realized or if realized has not been sufficiently taken into account that individuals with the genetic constitution for being able to develop DM are often registered as non-diabetics (because available information has been inadequate or because the probability of developing DM has been underestimated).<sup>1</sup>

Penrose and Watson (1945) investigated a series of 442 diabetic patients each of whom had one or more close relatives who were similarly affected.

The analysis of the sibs of these patients revealed a significant tendency in sibships either for the brothers to be diabetic and the sisters to be non-diabetic or for the sisters to be diabetic and the brothers to be non-diabetic. The numbers of diabetic pairs were: brothers 104, brother and sister 193, sisters 179.

According to Penrose and Watson there are at least three plausible genetic explanations for the tendency of DM to affect females in one sibship and males in another viz. (1) partial sex linkage of the main genetic factor, (2) complete sex linkage of a gene responsible for the diabetic predisposition, comparatively rare but common enough to alter sib-pair frequencies significantly, and (3) sex linkage of a secondary gene which modifies the severity of the condition as expressed by the age of onset.

These three hypotheses are distinguishable by examining the corresponding parent-child relationships. Partial sex linkage should not disturb the frequencies of the parent-child pairs. A sex-linked main factor would alter the frequencies of the types of pairs

so that inheritance from father to son would not occur. Evidence for a sex-linked modifier would be that the age of onset or the severity of the disease is more similar in unlike-sexed than in like-sexed diabetic parent-child pairs.

The authors state that a survey of the literature with reference to the question of the sexes of parent-child affected pairs proved to be disappointing. Many papers failed to record the sexes of both members of the affected pairs. Their own series gives 45 father and son, 51 father and daughter, 57 mother and son, and 78 mother and daughter. For seven pedigrees reproduced in the paper, the corresponding numbers are 2, 11, 8, and 1 respectively.

One of these pedigrees recorded by Bortz (1934) contains 10 diabetics. An affected man had four affected daughters and two unaffected sons; these four daughters had children viz. (a) an affected son and two unaffected daughters, (b) an unaffected daughter, (c) an unaffected son, and (d) two affected sons, of whom one had an unaffected daughter and four unaffected sons. An unaffected sister and an unaffected brother of the first mentioned man had an affected daughter and an affected son, respectively.

All pedigrees show the same general tendency for the unlike-sexed transmitting parent to be affected and the like-sexed transmitting parent to be recorded as unaffected. "It is reasonable to assume that a number of the apparently normal parents in these and other family groups might have proved to be potential diabetics if they had been more thoroughly investigated or if they

<sup>1</sup> It is obvious, that the recording of DM among family members of DM patients is often very incomplete. An example given by Neel and Schull (1954) may be quoted as an illustration. A truthful, interested and intelligent female DM patient supplied the information that her mother had DM but that her father and her ten sibs had not DM. Yet glucose tolerance tests administered to eight of the sibs revealed that four of them had DM. Kluwe, Merritt, Ho and Biese (1957) found that males' sibs report lower proportions of families with diabetes among relatives than do female sibs.

had survived a sufficient length of time for the disease to have become manifest

Penrose and Watson conclude that the analysis of the parental relationships in their series suggests that the hypothesis of a sex linked modifying gene is the most likely of the three put forward by them. In the majority of the pedigrees, the primary factor might be a single dominant gene. Possibly there is also a summation effect of additive dominant factors.

In our opinion the pedigrees are rather to be interpreted as speaking in favour of monohybrid sex linked dominant inheritance.

Bartels (1953) gives a series of pedigrees one of which deserves to be quoted. An unaffected man whose father and two sisters presented DM had an affected son and an unaffected daughter. However his wife had DM. Since, according to our results, the prevalence of the DM genotype among females would be about 13 per cent it must be fairly common that the son of a diabetic father marries a woman who may transmit the DM gene to her children.

Pfandler (1964) gives a thorough description of the family studies made by Hanhart and reproduces eleven selected pedigrees from various papers of his. There is no doubt that these pedigrees must be interpreted as indicating monohybrid autosomal recessive inheritance if DM is a comparatively rare disease. However a scrutiny of the pedigrees under the assumption that the total morbidity risk for DM is high (about 6.5 per cent among males and 13 per cent among females) gives a very strong impression that in these pedigrees the mode of inheritance is monohybrid sex linked dominant.

## Probability evaluations

The simplest hypothesis will be that all instances of DM can be ascribed to the action of a unitary single-gene mutation.<sup>1</sup> Let us investigate the consequences of such a hypothesis in respect of (a) autosomal dominance, (b) autosomal recessiveness and (c) sex linked dominance.

As before let  $d$  denote the frequency of a certain dominant gene  $D$  and  $r = 1 - d$  the frequency of the allelic recessive gene  $R$ . With panmixia in the population and the same fertility in all types of mating the following formulae are valid for autosomal dominance and autosomal recessiveness (cf. Larsson & Sjogren 1966).

### Autosomal dominance

In the general population the probability  $G$  of a certain person being  $DD$  or  $DR$  (i.e. of the DM genotype) is

$$G = d(2-d)$$

For a  $DD$  or  $DR$  individual, the probabilities of a (certain) child, a (certain) parent or a (certain) sib being  $DD$  or  $DR$  are

$$C = P = \frac{1+d-d^2}{2-d}$$

$$S = \frac{4+8d-6d^2+d^3}{4(2-d)}$$

<sup>1</sup> In medical genetics there are many examples showing that the same phenotypical picture or very similar pictures may be caused by different single-gene mutations (as for instance in the case with retinitis pigmentosa) and that the same phenotypical picture may be caused by single-gene mutations as well as by exogenous factors (as for instance in the case with microphthalmia and anophthalmia cf. Sjogren & Larsson 1949).

For different values of  $G$  (the frequency of the DM genotype) in the interval 0.01 to 0.25 the corresponding values of  $d$ ,  $P$  and  $S$  are shown in Table 82

Table 82 Probability calculations for autosomal dominance and autosomal recessiveness (from Larsson & Sjögren 1966)

G	Autosomal dominance			Autosomal recessiveness	
	$d$	$P$	$S$	$r$	$S$
0.01	0.0050	0.5038	0.5044	0.1000	0.3025
0.02	0.0101	0.5075	0.5088	0.1414	0.3257
0.03	0.0151	0.5113	0.5132	0.1732	0.3441
0.04	0.0202	0.5151	0.5176	0.2000	0.3600
0.05	0.0253	0.5189	0.5220	0.2236	0.3743
0.06	0.0305	0.5227	0.5264	0.2449	0.3874
0.07	0.0356	0.5266	0.5308	0.2646	0.3998
0.08	0.0408	0.5304	0.5352	0.2828	0.4114
0.09	0.0461	0.5343	0.5396	0.3000	0.4225
0.10	0.0513	0.5381	0.5441	0.3162	0.4331
0.11	0.0566	0.5420	0.5485	0.3317	0.4434
0.12	0.0619	0.5459	0.5530	0.3464	0.4532
0.13	0.0673	0.5499	0.5574	0.3606	0.4628
0.14	0.0726	0.5538	0.5619	0.3742	0.4721
0.15	0.0780	0.5577	0.5664	0.3873	0.4812
0.16	0.0835	0.5617	0.5709	0.4000	0.4900
0.17	0.0890	0.5657	0.5753	0.4123	0.4986
0.18	0.0945	0.5697	0.5798	0.4243	0.5072
0.19	0.1000	0.5737	0.5843	0.4359	0.5155
0.20	0.1056	0.5777	0.5889	0.4472	0.5236
0.21	0.1112	0.5817	0.5934	0.4583	0.5317
0.22	0.1168	0.5858	0.5979	0.4690	0.5395
0.23	0.1225	0.5899	0.6024	0.4796	0.5473
0.24	0.1282	0.5940	0.6070	0.4899	0.5550
0.25	0.1340	0.5981	0.6115	0.5000	0.5625

$G$  Probability for the general population of an individual being DD or DR ( $G$ ) or being RR ( $G'$ )

#### Autosomal dominance

- $d$  Frequency of the dominant gene  $D$  in the general population  
 $P$  Probability of a parent of a DD or DR individual being DD or DR  
 $S$  Probability of a sib of a DD or DR individual being DD or DR

#### Autosomal recessiveness

- $r$  Frequency of the recessive gene  $R$  in the general population  
 $P$  Probability of a parent of an RR individual being RR  
 $S$  Probability of a sib of an RR individual being RR

#### Autosomal recessiveness

In the general population, the probability  $G$  of a certain person being RR (ie of the DM genotype) is

$$G = r$$

For an RR individual the probabilities of a (certain) child, a (certain) parent or a (certain) sib being RR are respectively

$$C = P = S$$

$$S = \frac{(1+r)r^2}{4}$$



Mating (Father $\times$ Mother)	Frequency of mating	Probability of a child being D DD or DR		Frequency of children being D DD or DR	
		Son	Daughter	Sons	Daughters
D $\times$ DD	$d^2$	1	1	$d^2$	$d^2$
D $\times$ DR	$2d^2r$	1/2	1	$d^2r$	$2d^2r$
D $\times$ RR	$dr^2$	—	1	—	$dr^2$
R $\times$ DD	$d^2r$	1	1	$d^2r$	$d^2r$
R $\times$ DR	$2dr^2$	1/2	1/2	$dr^2$	$dr^2$
R $\times$ RR	$r^2$	—	—	—	—
Total	1			$d$	$d(1+r)$

For different values of  $G$  (the frequency of the DM genotype) in the interval 0.01 to 0.25 the corresponding values of  $r$ ,  $P'$  and  $S$  are shown in Table 82

being D, and a certain female being DD or DR are

$$G_m = d$$

$$G_f = d(2-d)$$

### Sex-linked dominance

With the notations previously adopted and assuming panmixia in the population and the same fertility in all types of mating we get the simple scheme for sex linked dominance given at the top of this page

With the aid of this scheme we can easily calculate the following probabilities

In the general population, the probabilities  $G_m$  and  $G_f$  of a certain male

For a D male and for a DD or DR female the table below shows the probabilities of a (certain) son the father and a (certain) brother being D, and a (certain) daughter, the mother and a (certain) sister being DD or DR—the index before the capital letter denoting the sex of the proband, and the index after it denoting the sex of the relative in question. At the bottom of the table there are given the averages for relatives with the simplified assumption that among the children and sibs of probands both sexes are equally frequent

Relative	Male proband	Female proband
son or father	$mC_m = mP_m = d$	$fC_m = fP_m = \frac{1}{2-d}$
daughter or mother	$mC_f = mP_f = 1$	$fC_f = fP_f = \frac{1+d-d^2}{2-d}$
brother	$mS_m = \frac{1+d}{2}$	$fS_m = \frac{1+2d-d^2}{2(2-d)}$
sister	$mS_f = \frac{1+2d-d^2}{2}$	$fS_f = \frac{3-d^2}{2(2-d)}$
child or parent	$mC = mP = \frac{1+d}{2}$	$fC = fP = \frac{1+d}{2}$
sib	$mS = \frac{2+3d-d^2}{4}$	$fS = \frac{1+d}{2}$

C P S Probability for a child parent or sib of a proband being D (male) or DD or DR (female)

In the general population the probabilities of a male being D and of a female being DD or DR are  $d$  and  $d(2-d)$  respectively, and hence—if the sex proportion in the population is  $g/(1-g)$ —the sex proportion among the carriers of the D gene will be  $g/(1-g)(2-d)$ . Neglecting the deviation from equality in the general population and hence putting  $g/(1-g) = 1$  we get for a random sample of probands

Relative	Male and female probands taken together (with frequency of	
	males $\frac{1}{3-d}$	females $\frac{2-d}{3-d}$
son or father	$C_m = M_m = \frac{1+d}{3-d}$	
daughter or mother	$C_f = P_f = \frac{2+d-d^2}{3-d}$	
brother	$S_m = \frac{2+3d-d^2}{2(3-d)}$	
sister	$S_f = \frac{2+d-d^2}{3-d}$	
child or parent	$C = P = \frac{1+d}{2}$	
sib	$S = \frac{6+5d-3d^2}{4(3-d)}$	

### Numerical example

When investigating the theory of a genetic aetiology for DM we can assume—in accordance with the results obtained in Chapter IV

- (a) Autosomal dominance  $G = 0.13$
- (b) Autosomal recessiveness  $G = 0.13$
- (c) Sex linked dominance  $G_f = 0.13$

The assumptions for  $G$  and  $G$  imply that—for one reason or another—there must be an inhibition of the manifestation of DM among males. Assumptions

which are consistent with the findings for males viz  $G$  and  $G = 0.065$  would imply that we reject the theory that DM is caused by a single gene mutation about half of all instances of DM among females (but none among males) would then have to be explained as being caused by exogenous factors (or by multifactorial inheritance). However it is hard to accept either of these explanations. As already emphasized the morbidity risks are fairly similar for males and females up to about age 50 and it seems rather difficult to find arguments to support a theory of the existence of strong acting inhibitors among males at the higher ages. Since the greater part of the total morbidity risk refers to ages above 55 it seems highly improbable that exogenous factors or multifactorial inheritance could double the risk for females but not be active at all in respect of males. From these aspects the theory of sex linked dominance does not cause any trouble one does not have to resort to any assumptions concerning different degrees of manifestation in males and females or concerning different aetiological patterns for the two sexes.

With the  $G$  values given above we get the figures shown in Table 83

As will be seen from Table 83 the discrimination between autosomal dominance and autosomal recessiveness may be difficult to perform by means of the study of the frequency of DM among parents, children and sibs of afflicted persons in parents and children the expectations for the DM genotype are 0.55 and 0.36 respectively and in sibs they are 0.56 and 0.46.

In the same way it is even more difficult to differentiate between autosomal and

**Table 83** *Probability evaluations for sex linked dominance with frequency of DM genotype among females 13 per cent*

	Frequency				
	Autosomal dominance M F	Autosomal recessiveness M F	Sex linked dominance		
			M	F	M + F
<i>General population</i>					
DM genotype	0.13	0.13	0.0673	0.13	0.0986
DM gene	0.0673	0.3606	0.0673	0.0673	0.0673
<i>Relative of person (proband) with DM genotype</i>					
Father son			0.0673	0.5174	0.3639
Mother daughter			1	0.5499	0.7034
Brother			0.5336	0.2924	0.3746
Sister			0.5650	0.7750	0.7034
Parent child	0.5499	0.3606	0.5336	0.5336	0.5336
Sib	0.5574	0.4628	0.5493	0.5336	0.5390

*Italics* Assumption concerning the frequency of DM genotype in accordance with the results in Chapter IV (cf. Table 34 p. 117) in the case of autosomal inheritance the highest figures (viz. those for females) are applied

In taking (weighted) averages the sex proportion among children is assumed to be equal for the DM genotype in the case of sex linked dominance the proportion  $M/F = 1/(2-d) = 0.3410/0.6590$

sex linked inheritance when the observation series are given without division by sex (the largest inequalities being the expectations 0.36 for autosomal recessiveness and 0.53 for sex linked dominance in respect of parents and children and the expectations 0.46 for autosomal recessiveness and 0.54 for sex linked dominance in respect of sibs)

Further it can be seen from Table 83 that in family analysis of sex linked dominance the differences between relatives—males and females taken together—of male probands and relatives of female probands are very small (the largest inequality being the expectations 0.55 and 0.53 in respect of sibs). A family analysis of the differences between brothers and sisters of DM patients—irrespective of their sex—would require a fairly large series (the expectations being 0.37 and 0.70). Theoretically an analysis of fathers or sons on the one hand and mothers or daughters on the other (with expectations 0.36 and 0.70) might be somewhat better but it is not easy to arrive at reliable series of this kind the recording of the state of health is often incomplete for the parents and for the children the passed morbidity risk is often only a small fraction of the total risk

Even with a division of the series studied by sex of proband and sex of relative the differentiation between autosomal and sex linked inheritance may be complicated since great problems are involved in ascertaining large family series for which the selective biases can be duly evaluated. With sex linked dominance the expectations are 0.29 for brothers of female probands and 0.77 for sisters of female probands. The sibs of male probands do not in practice give any differentiation at all (the expectations being 0.53 for brothers and 0.56 for sisters).

One effective way of disproving the theory of sex linked dominance is to study the parents and children of male diabetics. In a random sample all their mothers and daughters but only 7 per cent of their fathers and sons will be of the DM genotype. With unbiased complete registration such disparities between different child-parent combinations by sex would be easy to discover. However the real circumstances are far more complex. In many series the knowledge of DM among parents not only is incomplete but is complete in an irregular way and there may sometimes be a great many selective factors

of different kinds which are not easy to evaluate. For a definite conclusion based on statistics concerning fathers and sons of male diabetics it is important that the ascertainment of the probands shall have been unbiased in so far as the occurrence of DM in the father or the son has not contributed to the registration of the proband. A conclusion based on statistics concerning mothers and daughters of male diabetics may be more difficult because the registration of DM may be so incomplete among the mothers and the daughters may be so young that the deviation of the registered prevalence from the theoretical one (viz all belonging to the DM genotype) cannot be ascertained as statistically significant.

### Genealogical statistics

In all the abundant literature on the heredity of DM very few large series have been published with a simultaneous division by sex of proband and sex of relatives (and also stating the exact relationships between the probands and the relatives in question).

To a great extent, published pedigrees give a clear impression of sex linked dominance *nota bene* if the DM genotype has a comparatively high prevalence in the general population (cf pp 229-230). Of course it should not be overlooked that the morbidity risks (at ages above 50) are considerably higher for females than for males irrespective of the aetiology of DM (conditioned by a major gene or several different major genes due to multifactorial inheritance or environmental factors, combinations of these) there will on average be a higher prevalence of DM among female relatives—of DM probands and of unaffected probands—than among male

relatives. Due account being taken of the passed morbidity risk, transmission from mother to child will be recorded more frequently than transmission from father to child. Transmission from paternal grandmother will be recorded more frequently than transmission from paternal grandfather etc. Thus there may arise a false impression of sex linked dominance.

In their series of 1 631 probands Thompson and Watson (1952) found 39 transmissions from father to son, 36 from father to daughter, 64 from mother to son and 91 from mother to daughter. They emphasize that the tendency for DM to appear more frequently in the like sexed than in the unlike sexed parents of diabetic probands is a statistical phenomenon explicable on the basis of the relative numbers of males and females affected and that (according to their data) no genetic correlation obtains between the sex of the proband and the sex of the affected parent—Among the sibs the number of diabetic pairs were brothers 95, brother and sister 217, sisters 175.

As already mentioned only a few series of genealogical statistics on DM have been published with sufficiently complete divisions by sex. In the subsequent four sections, the studies by Nilsson (1962, 1964 dealing with male probands) and by Harris (1950 cf p 216) will be reviewed and certain data from two of the investigation hospitals (Falun, W Vänersborg, P) will be presented.

### The Kristianstad studies

In 1953-54 Silver made a thorough inventory of all known diabetics in Kristianstad County (L). For the County Hospital at Kristianstad which in 1943 was the only one with a special department of internal medicine a search was made of the records

Table 84 Registered prevalence of DM in Kristianstad County (L) by sex, domicile and age 1954 (after Silver 1958)

Sex and attained age	Number of diabetics			Diabetics per thousand population		
	Total	Rural	Urban	Total	Rural	Urban
<i>Males</i>						
0-4	2	1	1	0.2	0.1	0.4
5-9	13	11	2	1.2	1.2	0.9
10-19	12	28	4	1.7	1.9	1.2
20-29	45	38	7	2.5	2.7	1.8
30-39	44	37	7	2.3	2.5	1.7
40-49	81	61	20	4.5	4.2	5.8
50-59	102	86	16	7.2	7.3	7.2
60-69	146	117	29	12.8	12.8	13.0
70-79	114	95	19	16.3	16.0	18.6
80+	19	15	4	9.4	8.8	13.1
Total	598	489	109	4.6	4.6	4.4
<i>Females</i>						
0-4	1	1	-	0.1	0.1	-
5-9	12	11	1	1.1	1.3	0.5
10-19	27	22	5	1.6	1.6	1.5
20-29	31	23	8	1.8	1.9	1.7
30-39	33	25	8	1.8	1.8	1.9
40-49	52	43	9	3.0	3.2	2.4
50-59	146	113	33	9.6	9.2	11.4
60-69	229	180	49	18.7	18.1	21.1
70-79	169	131	38	22.0	20.8	28.3
80+	28	21	7	11.0	10.1	15.8
Total	728	570	158	5.7	5.7	5.8
<i>Both sexes</i>						
Total	1 326	1 059	267	5.1	5.1	5.1

of the previous ten years the records of other hospitals in the county where departments of internal medicine were established after 1943 were also searched. It appeared that most of the general practitioners in this county usually referred all newly discovered cases of glucosuria or suspected diabetes to a hospital for investigation and care. Before the introduction of compulsory health insurance in 1955 all diabetics in the county received insulin free of charge on presentation of a certificate issued by a hospital doctor. In addition to the inventory of hospital records questionnaires were sent to all doctors in the county not working in hospitals and also to certain doctors outside Kristianstad County who it was thought might possibly be treating diabetes domiciled in the county.<sup>1</sup>

On the cross-section day (March 15 1954)

there were registered in all 1 326 known instances of DM (5.1 per thousand population). The data by sex domicile and age are shown in Table 84.

As already stated this is a thorough study probably constituting the most complete scrutiny made in Sweden by recourse to hospital records and interviews. It should be emphasized that in principle it is a period study over ten years not merely a cross-section registration. In addition the figures are presented in a direct form related to the proper population data.

<sup>1</sup> In an introductory remark Silver criticizes the use of mortality statistics for deducing data on morbidity to avoid any misunderstanding it should be emphasized that what he is attacking is the use of data on the primary cause of death alone and so far as that is concerned his structures are quite just (in respect of DM).

Table 85 Comparison of aggregate morbidity risks according to inventory of Kristianstad County (L) 1954 and with assessment based on mortality statistics 1961-63

Attained Age	Aggregate morbidity risk per thousand				Quotient (I) ( ) per cent	
	(I) Calculation based on inventory of Kristianstad County 1954		( ) Assessment based on Swedish mortality statistics 1961-63		M	F
	M	F	M	F		
10	1.4	1.4				
20	2.1	1.8				
30	2.4	1.8				
40	3.4	2.5	12	11	28	23
50	5.8	6.0	31	19	28	31
60	10.0	13.4	34	48	29	28
70	14.5	19.4	47	90	31	22
80			58	117		
90			65	130		

(1) Interpolation from the prevalence figures given by Silwer (1958)

(2) Table 34 p. 117

If Silwer's data by sex and age are transferred to give the passed morbidity risks the series given in Table 85 is obtained for comparison the assessments from Chapter IV are shown. As will be seen from the table the quotients between the figures from the inventory in Kristianstad County referring to 1954 (in fact a period study) and those from our assessments for all Sweden referring to 1961-63 are of the order of magnitude 0.3. Although—according to Chapter IV—there might be a real underrepresentation of DM in the south western part of Sweden it is quite impossible to modify the assumptions so that the quotients will exceed 0.5. The conclusion is that in spite of the thoroughness observed the scrutiny must have largely underestimated the prevalence of DM (in the age groups relevant here) it would seem viewed relatively that this underestimation is the same for both sexes in rural and urban areas and (at ages below 70 or rather below 75) irrespective of age.<sup>1</sup>

Silwer's risk figures were utilized by Sven E. Nilsson (1962, 1964) in the genetic part of a study on the genetic and constitutional aspects of DM. Nilsson deals with three series of probands viz.

A 119 males with manifest DM aged 17-25 and resident in Kristianstad County (L) or Malmöhus County (M)

Br 237 unaffected males with DM reported in the family aged 18-19 and resident in Kristianstad County

Bc 238 controls to Group Br without DM reported in the family

The registers of the departments of internal medicine in all hospitals in Scania were searched for male diabetics born during the period 1934-42.<sup>2</sup> For these birth groups the military registers were searched for notes on diabetes (reason for exemption from service). In all 154 persons were registered in these ways (104 from both sources, 15 from the hospitals alone and 35 from the military registers alone; these latter were

<sup>1</sup> According to Nilsson *et al.* (1967) the recorded prevalence of DM was 37 per cent higher in 1965 than in 1954 (Silwer's data) the increase was about 43 per cent for males, about 36 per cent for females aged 20-39 or 60-79 and 13 per cent for females aged 40-59.

<sup>2</sup> Scania the southernmost province of Sweden covers Malmöhus County (M) and Kristianstad County (L).

excluded)<sup>1</sup> Nilsson is of opinion that the 119 probands cover about 90 per cent of all male diabetics in this age group resident in Scania at the end of 1959.

In all the number of men liable to registration for military service in Kristianstad County (strictly speaking in the 6th military registration district) amounted in 1959 to 2 834. Excluding 155 who were registered elsewhere and a further 20 who were already exempt on medical grounds and did not present themselves for registration there remained 2 659 conscripts. For 243 of these DM among relatives (sibs, parents, sibs of parents, grandparents and first cousins) was reported on registration. For them, as well as the controls and the probands in series A questionnaires were sent to the mothers inquiring *inter alia* about diabetes among relatives, number of relatives of different types and the ages of the probands, parents and grandparents. Of the mothers of the probands 89, 90 and 71 per cent in series A, Br and Bc respectively, cooperated. The 18 year-old probands (in series Br and Bc) proved to possess but meagre knowledge of various familial details of relevance. In contrast the middle aged mothers gave extensive information on illnesses, the members of the family had had, on weights etc. Of the 243 conscripts primarily assigned to Group Br 15 proved to have been erroneously classified as having diabetes, relatives of the 243 controls assigned to Group Bc 9 were reported by their mothers to have diabetic relatives. After corrections for these errors the numbers were 237 and 238, as stated above. Series Br represents rather less than 9 per cent (237/2659) of the total group (B) from which the samples are taken.

The number of relatives recorded as affected with DM is shown in the following table; allowance should be made for lack of cooperation on the part of the mothers.

In testing his observations against expectations (with autosomal recessiveness and autosomal dominance) Nilsson uses the technique of introducing total morbidity risks (aggregate risks up to about age 80 for females) and penetrance factors which

Category of relatives	Number of known diabetics in Series		
	A*	Br	Bc
Brother	7	6	
Sister	2	4	
Father	8	26	
Mother	2	17	
Paternal uncle	10	19	-
Paternal aunt	5	15	1
Maternal uncle	5	11	2
Maternal aunt	3	12	1
Paternal grandfather	7	24	2
Paternal grandmother	7	44	2
Maternal grandfather	7	20	2
Maternal grandmother	8	48	1
First cousin	2	38	-

\* Relating to information concerning 101 diabetic conscripts

are different in the series A and B. The highest assumptions concerning the prevalence of the DM genotype are 25 per cent (recessiveness) and 5 per cent (dominance). Obviously, these prevalence figures are too low and therefore a discussion of Nilsson's calculations will fall outside the scope of the present analysis. It may suffice here to quote his conclusion:

An autosomal recessive mode of inheritance seemed to be the most likely transmission of diabetes mellitus. Then the mutant allele would occur at about 30 per cent of the general population of the investigated area. Penetrance would occur during lifetime in about 70 per cent of male and 90 per cent female homozygotes. If penetrance occurs among heterozygotes it appears to be low.

Dominant inheritance seemed to be less likely but could not be excluded. The proportion of pathogenic alleles can then be calculated to be of the order of 0.05 with penetrance among about 25 per cent in male and 30 per cent in female gene carriers.

In Nilsson's series A there are reported 8 fathers with manifest DM, whereas—accord-

<sup>1</sup> The number of 139 conscripts exempted from military service owing to DM corresponds to 3 per thousand of the total number of male conscripts in Scania.

Table 86 DM relatives of DM probands by sex and age of proband (from data published by Harris 1950)

Proband's sex and age at onset of DM	Number of probands	Category of relatives															Total
		Fa	FF	FM	FB	FS	Mo	MF	MM	MB	MS	B	S	So	Da		
Number of relatives																	
All	1 241	1 241					1,241					3 877		1 418			
Living		453					560					7 967		1,290			
Dead		788					681					860		128			
Number of relatives with DM																	
All	1,241	46	10	20	30	25	79	15	25	74	46	67	99	5	5	496	
Living		9		3	6	5	17	2	4	5	4	43	67	4	5	174	
Dead		37	10	17	24	20	62	13	21	19	42	24	32	1		322	
Male proband	536	18	3	11	12	13	74	4	8	9	17	17	73	4	2	180	
Living		6	-	2	1	4	11		1	1	1	20	17	3	2	69	
Dead		12	3	9	11	9	13	4	7	8	11	12	11	1		111	
0-9	89	-	1	4	2	1	1		5		1	6	1			22	
10-19	85	6	-	1	4	2	4	1		1	1	2	1			23	
20-29	91	1	-	2	2	2	2		1	3	1	7	1			26	
30-39	117	4	2	3	3	3	9	2	1	1	2	7	10		2	49	
40-49	88	4	-	1	1	5	6	1	1	4	2	6	6	3		40	
50-59	75	3	-	-	-	-	2				3	4	6			18	
60-69	10	-	-	-	-	-						1	1			2	
70-79	1	-	-	-	-	-											
Female proband	705	28	7	9	18	12	55	11	17	15	34	35	71	1	3	316	
Living		3		1	5	1	6	2	3	4	3	73	50	1	3	105	
Dead		25	7	8	13	11	49	9	14	11	31	12	21			211	
0-9	62	1	1	2	4	1		1	2	2	2	1	2			19	
10-19	100	3	2	4	5	4	2	3	7	5	4	5				44	
20-29	98	6		1	5		7	2	4	4	6	5	9			49	
30-39	106	6	3				18	1	1	2	6	9	11		1	60	
40-49	129	3	1		1	5	13	2	1		7	11	21		1	66	
50-59	172	8	-	2	1	2	14	2	2		9	1	23	1		69	
60-69	36	1	-	-	-	-	1					1	5		1	9	
70-79	2	-	-	-	-	-										-	
Fa=father Mo=mother FF=father's father FM=father's mother FB=father's brother FS=father's sister MF=mother's father etc Br=brother Si=sister So=son, Da=daughter—FR (MR)=parents and sibs of father (mother)																	

ing to our results concerning the passed morbidity risk and assuming sex linked dominance—the expected number should be about 2 (average age about  $50 \cdot 0 \cdot 021 \times 119 = 2 \cdot 5$ ). In this series there are registered only 11 mothers with manifest DM against an expected number of 17 ( $0 \cdot 019 \times 119 \cdot 013 = 17 \cdot 4$  if the average age of the mothers is 50 if it is 45 the expected number would be about 14). However

since 11 per cent of the mothers did not answer the questionnaire the low observed figure might be largely due to selection.

In series B there are 6 diabetics among the 2 659 probands 6 affected brothers and 4 affected sisters these figures do not deviate from expectation. There are 26 affected fathers against 55 expected but only 17 affected mothers against 50 expected (on the basis of sex linked dominance).



occurrence of DM among the parents of the probands and therefore the recording of 18 affected fathers (6 living 12 deceased) of male probands may be taken as an argument against the theory of sex linked dominance (as the sole aetiology of DM) — It might be observed in addition that there are recorded remarkably few affected mothers of male probands (24 11 living 13 deceased) it does not appear unlikely that the knowledge concerning DM among deceased parents has been more complete for the fathers than for the mothers

A survey of the different types of mating is given in Table 87 (based on the aforementioned appendix) As can be seen from the table there are several cases against the theory of sex linked dominance The recorded transmission is in 12 instances from father to male proband in 4 from father to brother of proband and in another 4 from male proband to son Further there is transmission in 25 instances from unaffected father with affected mother or sib to male proband in 3 from paternal grandfather to male proband and in 5 from paternal grandfather to female proband (In all these instances DM was not recorded in other lines)

### *Special investigation at Falun (W)*

Dr Hugeman has kindly put at our disposal a number of pedigrees in all 277 based on interviews with DM patients and their relatives It should be emphasized that the selection of patients is wholly unbiased from the viewpoint of sex combinations However the number of corresponding patients without DM relatives is not available and possibly some patients with an affected sib (but without other DM relatives) have not been recorded

A survey of the data is given in Table 88 As can be seen from a comparison with Table 87, the series is of about the

same size as that published by Harris (277 and 336 probands with DM among relatives respectively, 496 relatives with DM in each series)

Where DM is not recorded in other lines, the transmission is in 20 instances from father to male proband, in 4 from father to brother of proband and in 2 from male proband to son Further, there is transmission in 18 instances from unaffected father with affected mother or sib to male proband in 2 from paternal grandfather to male proband and in 3 from paternal grandfather to female proband

### *Follow-up investigation at Vanersborg (P)*

For 818 of the 867 patients included in our clinico statistical study, data on the number of sibs had been registered in the case records For 483 of these 818 patients it was quite clear that no close relative (parent, grandparent sib of parent, sib, child or spouse) had been reported as being afflicted with DM

For the remaining 335 patients the case records were searched (up to the beginning of 1967) and all 'new' information was collected Parallel to this patients for whom the information was not sufficiently specified were traced and interviewed Rather many patients had died, but in these cases interviews were made (in person, by telephone or by letter) with close relatives (or, exceptionally, with other persons, for instance a daughter in law)

A survey of the different types of mating recorded for the parents of the 818 probands is given in Table 89

Table 88 *DM relatives of DM probands by type of mating (data from Falun W)*

DM among relatives	Number of probands	Number of relatives with DM														
		Fa	FF	FM	FB	FS	Mo	MF	MM	MB	MS	B	S	So	Da	Total
Male proband	(133)	23	3	3	11	15	39	8	17	24	15	29	34	2	3	226
Both sexes	4	3	1	—	1	1	2		2			1	1			12
Fa+Mo	2	2	1		—	1	2						1			7
Fa+MR	1	1	—		—				1			1				3
FR+Mo			—													
FR+MR	1		—		1				1							2
Paternal side	40	20	2	3	10	14						6	14		1	70
Fa	20	20			1	2	4					2	10		1	40
FR	20		2	2	8	10						4	4			30
Maternal side	70						37	8	15	24	15	10	13			122
Mo	37						37	1	3	8	5	8	11			73
MR	33							7	12	16	10	2	2			49
Neither side												12	8	2	2	22
Subs children	19											12	6	2	2	22
None																
Female proband	(144)	30	3	6	11	19	53	2	9	8	31	36	51	5	6	270
Both sexes	7	5			1	2	5		1		3	2	5	1		25
Fa+Mo	4	4				1	4					2	3	1		15
Fa+MR	1	1									3					4
FR+Mo	1					1	1						2			4
FR+MR	1		—		1				1							2
Paternal side	46	25	3	6	10	17						9	8			78
Fa	25	25			1	3	5					2	7			43
FR	21		3	5	7	12						7	1			35
Maternal side	65						48	2	8	8	28	11	16	2	5	128
Mo	48						48	2	2	5	19	11	13	1	4	105
MR	17								3				3	1	1	23
Neither side												14	22	2	1	39
Subs children	26											14	22	2	1	39
None																
Total	(277)	53	8	9	22	34	92	10	26	32	46	65	85	7	9	496
Abbreviations	see Table M p 239															

Abbreviations see Table III p. 239

Where DM is not recorded in other lines the transmission is in 24 instances from father to male proband in 25 from father to brother of proband and in 3 from male proband to son. Further there is transmission in 17 instances from unaffected father with affected mother or

sub to male proband in 3 from paternal grandfather to male proband and in 3 from paternal grandfather to female proband.

It should be noticed that in principle the Vanersborg series is a *proband registration* and that thus each family is

Table 89 *DM relatives of DM probands by type of mating (data from Vänersborg, P)*

DM among relatives	Number of probands	Number of relatives with DM														Total
		Fa	FF	FM	FB	FS	Mo	MF	MM	MB	MS	Br	Si	So	Da	
Male proband	386	28	3	2	11	18	38	3	3	18	16	64	59	3	11	277
Both sides	10	4	—	—	4	2	3	—	1	5	3	1	9	—	—	32
Fa+Mo	1	1	—	—	—	—	1	—	—	—	—	—	—	—	—	2
Fa+MR	3	3	—	—	—	—	—	—	—	1	2	1	4	—	—	11
FR+Mo	2	—	—	—	2	—	2	—	—	—	—	—	4	—	—	8
FR+MR	4	—	—	—	2	2	—	—	1	4	1	—	1	—	—	11
Paternal side	44	24	3	2	7	16						19	9	—	—	80
Fa	24	24	—	1	1	3						15	6	—	—	50
FR	20		3	1	6	13						4	3	—	—	30
Maternal side	57						35	3	2	13	12	18	15	1	5	104
Mo	35						35	—	—	8	3	14	12	—	2	74
MR	22							3	2	5	9	4	3	1	3	30
Neither side	275											26	26	2	6	60
Sibs children	46											26	26	2	6	60
None	229															
Female proband	432	28	4	5	12	13	29	4	2	17	21	69	72	8	6	290
Both sides	10	4	—	1	3	4	5	1	—	3	4	5	6	1	—	37
Fa+Mo	3	3	—	—	—	—	3	—	—	—	—	—	1	—	—	7
Fa+MR	1	1	—	—	—	—	—	—	—	—	1	2	3	—	—	7
FR+Mo	2	—	—	—	2	—	2	—	—	—	—	3	2	—	—	9
FR+MR	4	—	—	1	1	4	—	1	—	3	3	—	—	1	—	14
Paternal side	45	24	4	4	9	9						15	16	—	—	81
Fa	24	24	1	—	3	2						10	7	—	—	47
FR	21		3	4	6	7						5	9	—	—	34
Maternal side	49						29	3	2	14	17	24	14	3	2	103
Mo	24						24	—	1	6	6	10	7	3	1	58
MR	25							3	1	8	11	14	7	—	1	45
Neither side	328											25	36	4	4	69
Sibs children	52											25	36	4	4	69
None	276															
Total	818	56	7	7	23	31	67	7	5	35	37	133	131	11	17	567

Abbreviations see Table 86 p 239

counted as many times as there are probands in the sibship further if for instance both the father and a son of his are probands there will be counted two transmissions from father to son (viz an affected son of a male proband

and an affected father of a male proband) It is apparent, however, that the registration of probands in a family (because of admission to the investigation hospital) does not occur at random Often the questioning of a patient (and his spouse

and relatives) leads to the admission of other affected family members. In addition, it is likely that the observance with regard to DM from the side of the patients and their family members (and the knowledge of the symptoms of the disease) may lead to an earlier detection of DM and—often—to admission to the same hospital.

The mean number of sibs of the probands is 5.3 (both for male probands and for female probands). Using the formula given on p. 141 the average family size is found to be 3.8 (probands and their sibs).

The exact distributions by age of the

parents and by sex and age of the sibs are not known since the registration of the sex and age of unaffected parents and sibs is very incomplete. Approximately the distributions in question can be estimated on the basis of the age distribution of the probands and general data concerning the age difference between parent and child and the distribution by sex in different age groups. Using these approximate distributions and applying the morbidity risk figures for the general population (Tables 32 and 34) and the probability evaluations in Table 85 the following comparison between observed and expected numbers is obtained.

Category	Number of relatives with DM and quotient O/E (per cent)									
	Observed number		Autosomal dominance		Autosomal recessiveness		Sex linked dominance		General population	
	O	E	O	E	O	E	O	E	O	E
<i>Male probands</i>										
Fathers	28	140	20	99	28	17	161	17	163	
Mothers	38	135	28	88	43	244	16	32	119	
Parents	66	275	24	187	35	261	25	49	135	
Brothers	64	81	79	76	84	78	82	10	653	
Sisters	59	64	92	53	111	65	91	15	393	
Sibs	123	145	85	129	95	143	86	25	496	
<i>Female probands</i>										
Fathers	28	169	17	119	24	159	18	21	135	
Mothers	29	166	17	109	27	166	17	39	74	
Parents	57	335	17	228	25	323	17	60	98	
Brothers	111	111	62	91	76	58	119	13	515	
Sisters	72	93	77	77	94	151	48	22	333	
Sibs	141	204	69	168	84	202	67	35	403	
<i>All probands</i>										
Fathers	56	309	37	218	26	176	32	38	142	
Mothers	67	301	22	197	34	410	16	71	94	
Parents	123	610	20	415	30	586	21	109	113	
Brothers	131	192	69	167	80	136	119	23	583	
Sisters	131	157	111	130	101	216	61	37	358	
Sibs	264	349	76	297	89	352	75	60	441	

The expectation figures are approximations (based on estimated distributions by sex and age.) Due account has been taken of the point of time at which the information concerning the occurrence of DM among parents and sibs was obtained.

Table 90: Families with at least three affected probands and sibs of probands 1a-

Fam No	Proband			Relatives with DM		Affected sibs		Unaffected sibs		Note
	Sex	Born	Ag	Paternal side	Maternal side	Br	Si	Br	Si	
1	m	1896	D69							
	f	1897	D68	Fa	MS	1+1	1+3	2	2	Mo died at 91 in 1958
2	m	1882	D84							
	f	1885	L82	FB	Mo	1+0	1+2	2	-	
3	f	1901	L66	FB	Mo	2	1+0	2	3	
4	m	1899	D62	Fa	-	1+3	2	3	1	Mo died at 55 in 1918
5	f	1909	L58	Fa						
				FS	-	3	1+1	1	1	Mo died at 75 in 1949
6	f	1888	L79	Fa						
				FF						
				FB	-	-	1+3	6	1	Mo died at 52 in 1918
7	f	1893	L74	Fa	-	3	1+0	2	2	Mo died at 53 in 1914
8	m	1891	L76	Fa	-	1+2	-	1	4	Mo died at 68 in 1924
9	m	1900	L67	Fa	-	1+2	-	1	1	Mo died at 64 in 1934
10	m	1903	L64	Fa	-	1+1	1	1	1	Mo died at 73 in 1953
11	m	1905	D55							
	m	1914	L53	Fa	-	2+1	-	3	2	Mo died at 61 in 1938
12	m	1928	L39							
	f	1934	L33							
	f	1937	L30	Fa	-	1+0	2+0	1	2	Mo living age 69
13	m	1935	L32	Fa						
				FB						
				FS	-	1+1	1	2	1	Mo living age 54
14	f	1883	L84							
	f	1894	L73	FS	-	2	2+1	3	-	Mo died at 74 in 1936
15	m	1898	L69	FS	-	1+0	2	1	-	Mo died at 81 in 1958
16	f	1905	D59	FR	-	-	1+2	2	-	Mo died at 59 in 1936
17	f	1890	D73	-	Mo	4	1+2	1	5	
18	m	1895	D63	-	Mo	1+2	3	2	-	Sister's son DM
19	m	1890	L77							
	f	1901	L66							
	m	1904	L63	-	Mo	2+0	1+1	1	1	3 So+Da DM (Fam 21)
20	f	1894	N60	-	Mo	1	1+2	5	3	Da DM
21	m	1926	L41							

In the series there are in all 44 proband families with at least three affected sibs (probands and sibs of probands). An account of these families is given in Table 90. For each proband are shown sex, year of birth and age (at death, or at the latest point of time when information was obtained). For each family data are given concerning relatives with DM (on the paternal side, on the maternal side) and number and sex of affected and unaffected sibs.

In the 44 families there are 56 probands (27 males, 29 females) and 113 other affected sibs (56 males, 57 females) or in all 169 affected sibs (83 males, 86 females), the number of unaffected sibs is 167 (89 males, 78 females).

It should be noticed that the majority of the probands are comparatively old, 16 males (of 27) and 20 females (of 29) are aged 60 or over, 16 males and 18 females were born in 1900 or earlier. Against this background it may appear

Fam. No	Proband			Relatives w/ h DM		Affected sibs		Unaffected sibs		Note
	Sex	Born	Age	Father nat side	Mother nat side	P	S <sub>1</sub>	Br	Si	
	m	1931	L36							
	m	1913	L34							
	f	1940	L27	-	Mo					
					2 MB					
22	f	1882	D84	-	MS	3+0	1+0	-	-	
23	f	1889	N60	-	MR	2	1+2	2	1	
24	m	1893	L74	-	MR	2	1+2	3	2	
25	f	1901	L66	-	MB	1+2	1	1	1	
26	f	1895	N60	-	MB	3	1+1	1	-	
27	f	1908	D59	-	MR	1	1+1	-	1	
				-	MF	1	1+1	4	2	
28	f	1885	L82	-	-	4	1+3	2	-	
29	f	1878	D88	-	-	1	1+2	2	5	
30	f	1889	D67	-	-	1	1+2	2	1	Brother & daughter DM
31	f	1880	N72	-	-	-	1+2	1	4	
32	f	1883	N56	-	-	-	1+2	1	1	
33	m	1884	N58	-	-					
	m	1898	N46	-	-	2+1	-	1	1	
34	f	1886	N69	-	-	-	1+2	1	2	
35	m	1887	N71	-	-	1+2	-	1	4	
36	m	1888	N62	-	-	1+1	1	1	1	
37	m	1888	D78	-	-	1+2	-	1	3	
38	m	1889	D76	-	-	1+0	2	3	1	
39	m	1894	D62	-	-	1+1	1	6	5	
40	f	1897	N58	-	-	-	1+2	4	2	
41	m	1909	L58	-	-	1+0	2	3	2	
42	m	1910	L57	-	-	1+1	1	3	3	2 So + Da DM (fam 13)
43	f	1918	L49	-	-	2	1+0	-	1	
44	f	1929	L38	-	-	1	1+1	4	4	

In this table sex of proband is denoted by lower-case letter (m=male f=female)

Age is given at death (D) in 1967 (L) or at last observation (N for families not interviewed)

For affected sibs the table shows the number of probands + the number of other affected sibs

Abbreviations see Table 86 p 239

peculiar that the sex ratio M : F (among the probands as well as among their affected sibs) is almost equal (83 : 86)<sup>1</sup>. Obviously, both the admissions to the hospital and the information obtained with regard to the occurrence of DM among the sibs are (or have been) selective in so far as a larger proportion of the diabetic males than of the diabetic females has been recorded.

It is reasonable to assume that the same phenomenon—and to an even

higher degree—has applied in respect of the recording of DM among the parents, the grandparents and the sibs of the parents.

As can be seen from Table 87 transmission from father to son (with out DM on the maternal side also) is recorded in nine families (Fam 4, 5, 7-13). In these nine families there are 28 male probands

<sup>1</sup> In all there are 137 male and 136 female probands (cf Table 87).

and 16 male sibs affected with DM. In these families the mother's age (at death or in 1967) is remarkably low (53, 54, 55, 61, 64, 68, 69, 73, 75). Apparently, the arguments against the theory of sex-linked dominance are not so strong as might be concluded from a study of Table 89 alone.<sup>1</sup>

## Discussion

Hitherto there seem to have been no studies performed with a view to investigating whether statistical data on DM and its familial occurrence might be compatible with a theory of sex-linked dominance. There are several reasons for this.

(a) Epidemiological research on DM has largely been concerned with its incidence and prevalence by sex and age, the excess mortality from DM, the fertility of diabetics and possible racial, geographical and social differences in respect of prevalence, mortality and fertility.

(b) Evaluations of the results of family studies have largely been based on the hypothesis that DM is a comparatively rare disease; most investigators seem to have tested their empirical data against the theory that the prevalence of the DM genotype is of the order of magnitude 3-4 per cent (or even less).

(c) The shape of the morbidity risk curves has not been sufficiently known. As stressed for instance by Jorgensen (cf p. 221) the 'age corrections' which are necessary for numerical calculations are complicated and in addition, very uncertain.

(d) Most clinicians working on DM have encountered a number of instances where a father and his son are both afflicted with DM. In conformity with their conceptions concerning the prevalence of DM, they must regularly have ruled out the possibility of sex-linked heredity (if they have considered it at all). The common experience of clinicians is in fact quite sufficient for a definite conclusion that DM cannot to any great extent be conditioned by a sex-linked gene with a prevalence of the DM genotype in the general population of 3-4 per cent or less.

(e) Although it has been realized that DM is more frequent among females than among males (at higher ages), the discussion among clinicians concerning the sex differences has mainly been focused on possible precipitating factors (pregnancy, hormones etc.). On the other hand, geneticists who have analysed material of different kinds on DM have often tried to explain deviations from expected values as resulting from reduced manifestation (incomplete penetrance).

As will have appeared from the data adduced in the preceding sections, there have been recorded comparatively many transmissions from father to son and comparatively few transmissions from mother to son (viewed against expectations based on a theory that DM is conditioned by a monohybrid sex-linked dominant gene). It should be taken into account, however, that the series studied are in principle *proband selections* and

<sup>1</sup> Data for a similar scrutiny of the series covered by Tables 87 and 88 are not available.

that the registration of probands (as well as the detection of secondary cases among their family members) is in general biased in a very complicated way. It is apparent that both the admission rates and the detection rates vary considerably, not only by sex and age but also—which gives rise to a serious evaluation problem—by time.

Naturally it will be more difficult to eliminate the theory of sex linked dominance if DM may be caused not only by hereditary factors but also by exogenous factors. As already mentioned there are several examples of diseases where—with present knowledge—it is not possible to make a differentiation between cases of genetic and non genetic origin by means of clinical analysis alone.

In the same way it will be more difficult to eliminate the theory of sex linked dominance if DM may be caused also by hereditary factors of another kind (an autosomal major gene multifactorial inheritance). As already mentioned there are several examples of diseases where—with present knowledge—it is not possible to make a differentiation between cases of different genetic origin by means of clinical analysis alone.

In the general discussion of hereditary factors in DM special attention has been given to the occurrence of DM among the offspring of parents who are both known to have been diabetic. With autosomal recessiveness, all children should be of the DM genotype whereas with autosomal dominance this would apply only to a certain fraction of the children (75 per cent if the DM gene is rare). With sex linked dominance all daughters and a certain fraction of the sons (50 per cent if the DM gene is rare) would belong to the DM genotype. Obviously if

the study of offspring from these matings cannot discriminate between autosomal recessiveness and autosomal dominance it is not very likely that it could exclude sex linked dominance.

Viewed relatively at least the problems involved in the genetic analysis of rare recessive diseases (which are often malignant) and of dominant diseases with early onset (which except for new mutations cannot be very malignant) are fairly simple. On the other hand in respect of diseases for which the onset often occurs at higher ages and which are not rare (in the general population or in certain areas) there will as a rule be great difficulty in reaching unambiguous conclusions. Very often the observations may be interpreted in different ways: a hypothesis that fits the data will not necessarily be true (and very likely it is not true if it is a complicated one and has been specially constructed to fit the data).

As already stated DM is so common a disease that it is difficult to distinguish—by means of statistical analysis of the morbidity among relatives—between autosomal dominance and autosomal recessiveness.

The total morbidity risk for DM (the prevalence of the DM genotype) seems to be markedly higher among females than among males. On the other hand taking into account the effects of selective migration and selective registration it can be demonstrated that no real sex differences of this kind exist in respect of essential senile dementia (Larsson, Sjogren & Jacobson 1963), the quantitatively preponderant forms of cerebrovascular disease (Larsson 1967), essential tremor (Larsson & Sjogren 1960) and torsion dystonia (essential dystonia, Larsson & Sjogren 1966).



The two last mentioned diseases are rare in the general population but in the special areas of investigation they are not rare.<sup>1</sup> It has been ascertained that these diseases are conditioned by single gene mutations and that for both the mode of inheritance is autosomal dominance the exclusion of the possibility of recessiveness is based on a close scrutiny of pedigrees.

Essential senile dementia is conditioned by an aberrant single gene mutation the mode of inheritance being autosomal. The prevalence of the genotype in the general population is about 12 per cent (hence in the case of dominance the gene frequency would be 6 per cent and in the case of recessiveness it would be about 35 per cent). There do not exist sufficient data to allow a discrimination between the two possibilities; it may be regarded as a matter of opinion whether a conclusion on this matter could be based on general knowledge concerning the action of monohybrid genes.

As already mentioned in the parallel study of essential tremor cerebrovascular disease (Larsson 1965) it was found that the morbidity risks for cerebrovascular disease do not show any marked differences. In the main—apart from the occurrence of time lag and selective diagnosing—there did not seem to exist any geographical differences. In view of the general characteristics of the Swedish population and the completeness of the records on causes of death it was suggested that the quantitatively preponderant forms of cerebrovascular disease are to a great extent conditioned by genetic factors—possibly an interaction of autosomal major genes (or even one major gene) and multifactorial inheritance. The trend figures (and general knowledge concerning the action of genes) were considered to argue in favour of a supposition that these major genes are dominant. However a definite statistical proof of these theories is very difficult to accomplish. Cerebrovascular diseases are common with onset at advanced ages. For deceased patients there generally do not exist detailed hospital records (as is

the case in respect of a great many deceased patients afflicted with senile dementia or DM) and the diagnostic demarcation from diseases of the circulatory system has not always been made with sufficient accuracy. In respect of diseases of the circulatory system there are great differences between the sexes as well as important geographical differences. Finally there are undoubtedly certain environmental factors which play a part in the ultimate breakdown the variation of the monthly figures as well as the differences between 'influenza periods' and periods free from influenza give evidence that both climatic conditions and virus infections may precipitate (or accelerate) the onset of an apoplectic insult.<sup>2</sup>

The theory that cerebrovascular disease is conditioned by an autosomal monohybrid gene would require that in the general population the frequency of the aberrant gene should be about 0.4 in the case of dominance and about 0.8 in the case of recessiveness. With such a high frequency of the aberrant gene the probability that a (certain) sib or a (certain) parent of an afflicted individual has the genotype for developing cerebrovascular disease would be close to 0.8 irrespective of whether the mode of inheritance is dominant or recessive.<sup>3</sup> Hence the only way of arriving at conclusive results concerning the mode of inheritance would be the analysis of pedigrees and a thorough study of the outcome of different types of mating.

With these examples of diseases with comparatively late onset conditioned by autosomal monohybrid genes (of which three are ascertained beyond reasonable

<sup>1</sup> In the general population of the greater part of the parish of Xsjo (see map p. 4) the prevalence of the tremor genotype was nearly 10 per cent.

<sup>2</sup> As is well known there are many resemblances between certain virus infections and the action of aberrant major genes (cf. Sjogren & Larsson 1949; Larsson 1965).

<sup>3</sup> Dominance: sib 0.798, parent 0.775; recessiveness: sib 0.81, parent 0.80.

doubt the fourth may at the present be considered as more or less hypothetical) it might be questioned whether it is likely that DM may be conditioned by a sex linked gene. However, all four examples refer to the brain, in general it may be presumed that sex differences in respect of inherited diseases of the brain are rare. Primarily, DM is connected with hormones and metabolism, possibly also with the structure of body cells and the blood circulation to them. Therefore it does not seem *a priori* unlikely that the sex differences in respect of the morbidity risks for DM may be genetically conditioned (hence are sex differences in respect of the prevalence of the DM genotype), this of course does not mean that the shape of the morbidity risk curves may not be influenced—in males as well as in females—by exogenous factors and by the general genetic equipment of the individual (most likely, in that case, factors connected with multifactorial inheritance).

The theory of sex linked dominance in respect of the majority of instances of clinically manifest DM—*essential diabetes mellitus*—does not exclude either the possibility that there exist morbid states recalling DM which are conditioned by other major genes (dominant or recessive) or the possibility that there exist diseases characterized by carbohydrate intolerance which are caused by environmental factors or are due to multifactorial inheritance.

The high morbidity risks recorded for females (at ages above 50) can be considered as a challenge for further research. With better material it will be

possible to ascertain (beyond reasonable doubt)

(a) that to a fairly great extent DM is due to exogenous factors or

(b) that to a great extent—for one reason or another—DM does not develop in elderly males of the DM genotype or

(c) that a great many elderly males are in fact afflicted with DM or

(d) that to a great extent DM is conditioned by a major sex linked dominant gene.

Irrespective of whether one or more than one of these possibilities will prove to be the explanation of the epidemiological data, the significance for future "DM policy" is obvious. This applies not only to diagnosing and treatment but also for instance to prognostic evaluations, genetic counselling, the attitudes of diabetics in selecting marriage partners or deciding in respect of reproduction etc.

Possibly, thorough clinical studies of daughters of diabetic fathers and mothers of diabetic sons may yield conclusive data in respect of the validity of the hypothesis that—at least to a fairly great extent—DM is conditioned by a major sex linked dominant gene and contribute to better knowledge about the clinical variability of the disease.<sup>1</sup>

<sup>1</sup> In respect of diseases with late onset and great variability in the symptom picture it is often impossible to make a sure diagnosis on the basis of clinical observations alone. If the disease is found to be hereditary a close scrutiny of pedigrees will make it possible to arrive at a definite diagnosis even for cases with abortive symptoms or otherwise deviating from the normal clinical type (cf. Larsson & Sjogren 1960, 1966).

## The high prevalence of the DM genotype

Before the discovery of insulin (or, more precisely before insulin was taken into general therapeutic use) DM was in many cases a highly malignant disease. Irrespective of the mode of inheritance there must have been an antiselection against the aberrant gene, and this for at least two reasons viz (1) the excess mortality among juvenile diabetics and diabetics of reproductive age and (2) the often fatal outcome of pregnancies among diabetic women. On the other hand Fraser Roberts may be right in his statement (cf p 225) that it might be argued perhaps, that those whose forbears do not live too long are at selective advantage. In other words, the excess mortality among diabetics over say, 50 years of age may not only have been without significance for the transmission of the DM gene but have increased the children's possibilities for reproduction.<sup>1</sup>

In a very interesting discussion concerning the pathogenesis of DM Neel (1962, 1964) underlines that there is a considerable body of evidence which suggests that the growth and development of the individual predisposed to DM is accelerated. According to Neel this raises the possibility that in the early phases of the natural history of DM there is at some stage during the post prandial cycle a greater than normal availability of insulin resulting in what in agricultural circles would be termed a thrifty animal. It is argued that what we now must regard as an over production of insulin antagonists or anti insulins with unfortunate consequences was at an earlier stage in man's evolution, an asset in that it was an important energy-conserving mechanism when food intake was irregular and obesity rare.

Neel Fajans Conn and Davidson (1965) hold that the high frequency of the genotype predisposing to so serious a disease as DM presents a genetic riddle.

As already mentioned (p 215) von Hofsten discusses the implications of mutation pressure and antiselection in respect of DM he suspects that to a greater extent than geneticists generally assume DM is not hereditary or is ascribable to non specific genes.<sup>2</sup>

In a sense, the problems with regard to the high prevalence of the DM genotype and its selective advantages and disadvantages will be much simpler, if it is accepted that the prevalence is high, with high morbidity risks at ages over 50 than if it is assumed that a considerable fraction of the total risk relates to younger ages. As will have appeared already (cf Table 34, p 117) the passed morbidity-risk at age 50 is for males about 30 per cent and for females about 15 per cent of the total morbidity risk (the prevalence of the DM genotype in the general population 6.5 per cent for males 13 per cent for females). Therefore the effect of excess mortality before age 50 cannot reasonably have caused more than a modest antiselection against the DM genotype possibly of the magnitude 2-4 per cent per generation.

To some extent there must have existed an effect in the opposite direction for mar

<sup>1</sup> In a predominantly agrarian country such as Sweden was until recently there was a social and economic need for the peasants to be married whereas most sons and daughters at home were single (cf Larsson & Sjogren 1966).

<sup>2</sup> It should be remarked that in general the magnitude of the mutation rate (from normal to aberrant gene) is considerably overestimated. At any rate this applies in respect of common aberrant genes. Presumably the mutation rate from normal to DM gene is very low.

riages in which both spouses were of the DM genotype (which may be supposed to have comprised 4-5 per cent of all marriages with at least one spouse of the DM genotype). In the case of the wife's death the husband often married a younger woman and thus he got a longer reproductive period.

The argument has been adduced that formerly the conditions of life—often characterized by hard physical work and scarcity of food—have counteracted the development of DM and that this would explain why the DM gene has not been eliminated. It is often stated that the prevalence of DM is far lower in the poor countries than in the highly industrialized countries of the western world. Quite apart from the validity of the statistics on which these views are based it is not at all unlikely that exercise and certain dietary precautions may offset or reduce the DM symptoms and possibly also postpone the onset of the disease. However, as far as Sweden is concerned with its demographic developments and homogeneous population, the similarity of the prevalence data in different parts of the country gives a direct indication that the prevalence of the DM genotype must have been (at least) of approximately the same order of magnitude several hundred years ago as it is nowadays.<sup>1</sup>

### Inferences from the genetic analysis

Summarizing the results so far obtained the following can be stated

1 The discussions concerning the possibility that DM is conditioned by

an aberrant major gene have to a great extent been based on assumptions concerning the prevalence of the DM genotype in the general population of 3-4 per cent (or less) among both males and females. Observations have not given decisive results in many series the data are compatible with recessiveness as well as with dominance and incomplete manifestation. The possibility of dominant sex linked inheritance does not seem to have been taken into consideration.

2 The morbidity risks are considerably higher than has hitherto been generally assumed.

3 The total morbidity risk of females is about twice that of males.

4 Existing data on the occurrence of DM among relatives of DM patients are not sufficient for a discrimination between recessiveness and dominance to be made.

5 There is strong evidence against the theory of an aberrant major gene which in homozygotes causes early onset diabetes and in heterozygotes causes late onset diabetes.

6 General experience concerning the action of genes argues against the theory that DM is caused by a recessive major gene.

7 With autosomal inheritance the explanation of observed sex differences in respect of the prevalence of DM may be either incomplete manifestation in

<sup>1</sup> Assuming a net antiselection of 3 per cent per generation and disregarding the effects of chance fluctuations it can be calculated that in 1570 when the population of Sweden was 0.9 million the prevalence of the DM genotype would have been about 50 per cent higher than it is nowadays.

males or the occurrence of additional cases of exogenous aetiology in females

8 It seems probable that the general response to glucose tolerance tests should be regarded as a graded character, possibly connected with multifactorial inheritance

9 Existing *epidemiological* data can be explained by different genetic hypotheses viz

(a) autosomal dominance, with either *reduced manifestation among males* or the occurrence of exogenous cases—to a fairly large extent—among females,

(b) autosomal recessiveness, with either reduced manifestation among males or the occurrence of exogenous cases—to a fairly large extent—among females,

(c) sex linked dominance without any supplementary hypotheses,

(d) multifactorial inheritance with either reduced manifestation among males or the occurrence of exogenous cases—to a fairly large extent—among females

10 Hitherto no studies seem to have been performed with a view to investigating whether statistical data on DM and its familial occurrence might be compatible with a theory of sex linked dominance

11 As far as we can see existing *epidemiological* data agree very well with this theory

12 As a rule, published family data do not give a sufficient basis for eliminating the hypothesis of sex linked dominance since they rarely use simultaneous division by sex of proband and sex of relative

13 Four series of genealogical statistics are analysed Although these series—in one way or another—seem to give arguments *against* a theory that DM is in general conditioned by a sex linked dominant gene it cannot be ruled out that this result is ascribable to selective recording of probands and selective detection of secondary cases in the families

14 General knowledge concerning the action of dominant major genes and concerning the clinical manifestations of DM does not exclude the possibility that to a certain extent DM may have a non-genetic aetiology On the other hand, it is reasonable to conclude that the majority of all instances of DM should be considered as being conditioned by genetic factors

15 The high morbidity risks recorded for females constitute a challenge for research The implications for future DM policy are obvious, irrespective of whether *to a great extent*

(a) DM is due to exogenous factors

(b) DM is conditioned by one or several autosomal genes but does not develop in elderly males,

(c) DM is an equally common disease among elderly males as it is among elderly females or

(d) DM is conditioned by a major sex linked dominant gene

16 Possibly clinical studies of daughters of diabetic fathers, and mothers of diabetic sons, may lead to enhanced knowledge of both the genetic characteristics of DM and the clinical variability of the disease

## Summary and conclusions

1 The present study deals with *clinically manifest diabetes mellitus (DM)*. The material used consists of hospital records and mortality statistics, no screening or other population studies were performed.

2 A general discussion of clinical aspects on DM and Swedish practices in the treatment of the disease is given.

3 For the study of hospital patients—inpatients as well as outpatients—there were selected for special reasons, four medium sized general hospitals in different parts of Sweden. These are the county hospitals of Vänersborg (P), Vaxjö (G), Falun (W) and Östersund (Z). In all this material covers 3 759 patients registered at the hospitals as afflicted with DM, mainly during the period 1931–56 with a total of about 45,200 admissions or readmissions and a total of about 19,700 observation years.

4 The admission rates by sex and age and for different parts of the areas covered by the four hospitals are scrutinized in order to evaluate possible selective factors. In other respects, too, a fairly large amount of space is devoted

to the analysis of selective factors in particular those occurring in retrospective studies of clinical material.

5 All patients included in our hospital series have presented both glycosuria and hyperglycaemia (cf p 25). In general a clearly normal outcome of the oral glucose tolerance tests has been considered to exclude the diagnosis DM. In the hospital series there are only a few patients for whom alternative diagnoses have had to be taken into consideration. Among patients seeking medical advice because of disturbances of the carbohydrate metabolism glycosuria and subjective diabetic symptoms the frequency of renal glycosuria has been about 2 per cent. Quite generally it can be stated, that the quantitative significance of the problems of differential diagnostics has been comparatively small.

It should be borne in mind that the frequency figures with regard to the occurrence of different symptoms and complications refer to DM patients admitted to general hospitals during a certain period of time, the composition of a hospital series may be considerably changed, for instance, if "detecting procedures" are undertaken on a large

scale, or if the capacity of the hospitals to take care of new patients is greatly increased. However, the effects of such changes will concern the prevalence of intercurrent disease more than DM *per se*, since the main bias in the present series seems to be that many persons with clinically manifest DM were admitted to the hospitals *because* they were afflicted with another disease.

In the main the patients admitted to the county hospitals can be regarded as fairly representative of persons who show DM to a degree that—where thorough clinical examination is performed—will be diagnosed as an instance of clinically manifest DM.

6 In the hospital series the patients were classified by age at onset of DM into three types viz age at onset 0–14 (juvenile onset), 15–39 (early adult onset) and 40 or over (late onset). As a rule the data in the clinico-statistical tables are given with simultaneous division by sex, hospital, onset type and duration (5 year groups, reckoned from the year of onset of DM).

7 In the present series, the control has been better among patients with late onset than among patients with juvenile or early adult onset.

8 The DM patients did not present overweight to an extent that exceeds what is to be found in the general population. (Whether or not there was a higher frequency of overweight among the DM patients *before* the onset of the disease cannot be determined on the basis of the registered data.)

9 With regard to constitutional type the data are consistent with current views that among diabetics the asthenic type preponderates at younger ages, whilst the pyknic type is frequently seen in late onset DM.

10 The frequency figures (by sex and age) for hypertension agree fairly well with the frequencies existing in the general population. The differences found may in part be due to selective factors and it does not seem justifiable to conclude, on the basis of the data on blood pressure, that DM *per se* causes hypertension.

11 In respect of juvenile onset DM, menarche often occurs later than it does in the general population. The data indicate that on average the menopause tends to occur somewhat earlier among diabetics than in the general population.

The data do not support the theory that the fertility of diabetics, before the onset of DM, is higher than the fertility in corresponding groups of the general population. This theory, which is not infrequently advanced in the literature, seems in the main to be based on a misinterpretation of the existing statistical data.

After the onset of DM the number of children born to female DM patients is far below the corresponding number for females in the general population.

12 The insulin treatment applied cannot be regarded as an expression of a scientifically founded system but rather as representing a series of practical con-

siderations, concerning which it might be said that they functioned much better than could justifiably have been expected.

There were comparatively large divergences between the attitudes of the physicians with regard to the most suitable insulin treatment—or, rather with regard to what compromises could be considered acceptable.

Roughly speaking insulin therapy was applied to all patients with juvenile onset DM to about 90 per cent of the patients with early-adult onset DM and to more than 60 per cent of the patients with late-onset DM (Table 49 p 152). For patients with late-onset DM the frequency figures increase markedly with increasing duration. Very likely however this is an expression of selective factors (see p 153).

13 Among patients with infections ketosis was registered for 2 per cent of the males and 4 per cent of the females with late onset DM, for 8 and 12 per cent in the early adult onset type and for 20 and 24 per cent respectively in the juvenile onset type. For the juvenile diabetics the frequencies are higher—viz 31 and 32 per cent—in the duration group 0-4 years.

During the later part of the investigation period hypoglycaemic coma was seen only exceptionally.

14 With the present state of knowledge it has not been possible to arrive at unambiguous conclusions concerning the aetiology of the so-called late complications of DM—retinopathy, nephropathy and neuropathy. It is obvious however that from the statistical point

of view there is a correlation between the duration of DM on the one hand and the prevalence and severity of the vascular changes on the other.

There have been divergent opinions concerning the proper prophylactic and therapeutic measures to be taken with regard to the late complications. A central topic in the discussions has been the role played by the diet. Definite proofs that a strictly regulated diet prevents the late complications or makes their course milder do not seem to have been given.

Our data concerning the incidence and prevalence of late complications show conspicuous divergences between the hospitals and even more conspicuous divergences between the observations from different periods of time (epochs). In our opinion, the results obtained from the analysis of the data on late complications in the four hospital series are highly illuminating in so far as they prove the necessity of the utmost caution in the use of hospital register data (even very extensive case records) for conclusions concerning geographical differences and changes with time in the incidence and prevalence of late complications of DM concerning connections with the age of the patients and the duration of the disease and concerning the effect of different treatments applied.

DM is a disease where much attention must be given to each individual patient and it would not be advisable to perform prospective studies over long periods involving differential treatment of strictly comparable patients. Retrospective studies of the occurrence of late complications in patients who have been treated differently—at different



hospitals or at the same hospital during different periods of time—are often very difficult to evaluate, our statistical analysis gives a series of examples with regard to the biases and other selective factors that might occur in respect of the admission of patients and their readmissions, in respect of the diagnostic criteria applied and in respect of the recording of clinical observations

15 The diagnosis of diabetic retinopathy depends on the definitions used, the available technical resources and the knowledge and competence of the investigator. The development of diabetic retinopathy is correlated strongly to the duration of DM and weakly to the patient's age. Older reports where these factors are not separated are often not comparable owing to bias in the selection of patients. Therefore it is only natural that reports on the general frequency of diabetic retinopathy differ widely.

In our series, there is a striking increase with time (epoch) in the total frequency of retinopathy. The increase appears uniformly for all durations including the first years after onset, and therefore cannot be explained by unfortunate consequences of modern treatment. The main effect must be ascribed to general progress in the diagnostics of retinopathy and to more complete registration in the case records.

The frequency of retinopathy, as diagnosed at Swedish county hospitals seems to be best represented by the figures given in Table 60 (p 177).

From our data it is not possible to prove or disprove connections between

treatment and the development of retinopathy. Nevertheless, the data seem to support the theory that no treatment hitherto used in general hospitals will decisively improve or retard the development of retinopathic changes among the diabetics.

16 There is an increase with time (epoch) in the total frequency of nephropathy. However, as can be seen from Table 71, p 188 the time variation is small compared with the almost startling differences between the investigation hospitals, the (standardized) prevalence found at Vänersborg (P) being about six times the prevalence recorded at Östersund (Z).

17 The prevalence of neuropathy shows the same general pattern as does the prevalence of retinopathy and nephropathy. There are great differences between the investigation hospitals (see Table 75, p 194). With the concept adopted at Falun (W) and Östersund (Z), the overall frequency of neuropathy would have been about 26 per cent.

The general features of the frequency of neuropathy are not incompatible with a hypothesis that this frequency depends not on the duration of DM but only on the patient's age (cf Table 76 p 194).

18 With regard to vascular lesions other than retinopathy and nephropathy, only slight deviations from pure age dependence were found. The data in our series do not give rise to a supposition that these other vascular lesions found in diabetics should generally be regarded as sequelae of DM.

19 A study of the mortality among the patients in the hospital series during the 10-year period 1946-55 was made covering in all 16 440 observation years and 398 deaths during this period

Compared with the population mortality, the diabetics in the hospital series show a mortality ratio of about 1.4 (all ages taken together). For juvenile diabetics the mortality ratio is considerably higher (order of magnitude 6.0) and for diabetics with age at onset 40 or over it is about 1.3

20 A special processing of all death certificates in Sweden 1961-63 was performed, covering primary causes of death as well as contributory causes and complications. In all there were registered 3,324 deaths with DM as the primary cause and 7,273 deaths with DM as a contributory cause.

The period 1961-63 presented normal mortality (viewed against the trend) and it cannot reasonably be suspected that the data are disturbed by any acceleration or delay effects.

For comparison data on mortality and causes of death based on official statistics, are discussed.

In the analysis of the data from the death certificates for the 3-year period 1961-63 the resulting statistics were studied in detail with regard to sex, age, the primary cause of death and domicile.

There exist gaps in the death certificates connected with variations of the completeness of the registrations by age, primary cause of death and domicile. The prevalence of DM recorded in the death certificates is lower in Stockholm City and in the south western part of

Sweden than in other parts of the country. It is lower in the highest age groups than at ages 70-74 and 75-79. The registration of DM as a contributory cause is less frequent for deaths from the primary causes neoplasms and violence than for deaths from other primary causes.

21 On the basis of a detailed scrutiny of the data the most adequate estimate is found to be that the total morbidity risk for clinically manifest DM (the aggregate morbidity risk up to age 90) is about 6.5 per cent for males and about 13 per cent for females. The aggregate risk up to age 50 is 2.1 per cent for males and 1.9 per cent for females and up to age 70 it is 4.7 per cent for males and 9.0 per cent for females. The life table expectancy at birth for contracting clinically manifest DM is calculated at 4.8 per cent for males and 10.3 per cent for females.

22 There has been an increase in the number of first admissions with time especially in the higher age groups. In part this is a reflection of the changing age composition of the population (and the increase in population number) but in the main it is ascribable to other factors such as better communications, augmented hospital facilities and a general rise in the consumption standards in respect of medical care.

23 It is calculated that at the end of 1965 the number of persons in Sweden with clinically manifest DM was about 159 000 (59 000 males and 100 000 females) or 2.05 per cent of the total population (1.52 per cent for males

2.57 per cent for females) For ages 15 and over, the percentage is 2.60 (1.95 for males, 3.24 for females)

As a result of the changing age structure and the growth of population the number of diabetics in Sweden will show an annual increase by about 0.7 per cent for males and 1.4 per cent for females or by about 2,000 a year

24 The overall excess mortality among persons with clinically manifest DM cannot reasonably exceed 15 per cent, this, however, does not preclude that at ages below 50 the average excess mortality can be 200 per cent or more

25 The rating rules applied by the Swedish life and health insurance companies with regard to DM are presented and the problems connected with the insurance of diabetics are discussed

The rating of DM risks in individual insurance has been gradually liberalized especially in revisions undertaken in 1964 and 1966 Suggestions with regard to further liberalization are adduced

The rapid growth of group life and group health insurance has largely contributed to the effect that diabetics nowadays generally have considerable insurance protection as belonging to groups for which the participation is secured through agreements between the parties of the labour market through legislation (for state employees) or through membership of an organization As a rule diabetics obtain group life insurance without any restrictions at all, if they possess working capacity when joining the group

It is probable that in Sweden the aver-

age diabetic has a higher life and health insurance coverage and more liberal insurance conditions than in the case in most other countries

26 Current conceptions with regard to the genetic aetiology of DM are reviewed and analysed The discussions of the possibility that DM is conditioned by an autosomal major gene have regularly been based on assumptions concerning the prevalence of the DM genotype in the general population of 3-4 per cent (or less) among both males and females Observations have not given decisive results, in many series the data are compatible with recessiveness as well as with dominance and incomplete manifestation Existing data on the occurrence of DM among relatives of DM probands are not sufficient for a discrimination between recessiveness and dominance to be made

However, as is evident from our analysis of mortality statistics (death certificates), the morbidity risks for DM are far greater than has hitherto been considered to be the case and are far greater among females than among males The implications of these findings with regard to the theories concerning the genetic aetiology of DM are analysed

27 Hitherto no studies seem to have been performed with a view to investigating whether epidemiological and genealogical data on DM and its familial occurrence might be compatible with a theory of *sex linked dominance*

Existing epidemiological data can be explained by different genetic hypotheses

(a) autosomal dominance, with either reduced manifestation among males or the occurrence of exogenous cases among females,

(b) autosomal recessiveness with either reduced manifestation among males or the occurrence of exogenous cases among females

(c) sex linked dominance

(d) multifactorial inheritance with either reduced manifestation among males or the occurrence of exogenous cases among females

According to our results from the analysis of death certificates *epidemiological statistics* argue distinctly in favour of a theory that hereditary DM is in general conditioned by a monohybrid dominant sex linked gene

Four series of *genealogical statistics* are analysed—two series from the literature by Nilsson (1962 1964) and by Harris (1950), a special investigation at Falun (W) and a follow up investigation at Vänersborg (P). Although these four series—in one way or another—seem to give arguments against a theory that DM is in general conditioned by a sex linked major gene it cannot be ruled out that this result is ascribable to selective recording of probands and selective detection of secondary cases in the families

28 General experience concerning the action of genes argues against the theory that DM is conditioned by a recessive major gene

General knowledge concerning the action of dominant major genes and concerning the clinical manifestations of DM does not exclude the possibility that to a certain extent DM may have a non genetic aetiology. It seems likely however, that the majority of all instances of DM are conditioned by genetic factors

29 The high morbidity risks recorded for females constitute a challenge for research. The implications for future DM policy are obvious irrespective of whether to a great extent

(a) DM is due to exogenous factors

(b) DM is conditioned by one or several autosomal genes but does not develop in elderly males

(c) DM is an equally common disease among elderly males as it is among elderly females or

(d) DM is conditioned by a major sex-linked dominant gene

Possibly *clinical studies* of daughters of diabetic fathers and mothers of diabetic sons may lead to enhanced knowledge of both the heredity of DM and the clinical variability of the disease

## References

Abbreviations of titles of periodicals in accordance with *World Medical Periodicals* published by the World Medical Association 1961 printed by The Thanet Press Margate Kent England

- AARSETH, S (1953) Cardiovascular renal disease in diabetes mellitus: *Acta med scand* Suppl 281 pp 1-252
- ALMQVIST S, HALL K, LINDSTEDT, S, LINDSTEN J, LUFT R & SJÖBERG, H E (1964) Effects of short term administration of physiological doses of human growth hormone in three patients with Turner's syndrome *Acta endocr (Kbh)* 46 451-464
- ALVARSON A (1966) Memorandum on development of health insurance in Sweden. In *Svensk Forsäkrings Årsbok 1966* ed by Tage Larsson the Swedish Insurance Institute Stockholm pp 25-32
- ALWALL N, EKELOUND C & ORAS L (1950) Intercapillary glomerulosclerosis (Kimmelstiel Wilson's disease) *Acta med scand* 136 5 359-370
- ANDERSSON B (1950) Diabetes and pregnancy *Acta med scand* 138 4 259-278
- (1963) Diabetikervårdens framtida organisation och diabetikernas socialmedicinska problem. En utredning verkställd på uppdrag av Medicinalstyrelsen *Social medicinsk Tidskrifts skriftserie* No 30 pp 1-31
- (1966) *Sockersjuka och dess behandling hos vuxna* 4th ed Natur och Kultur Stockholm pp 1-243
- ANDERSSON B & SWANBERG H (1961) Diabetes och graviditet *Opusc med (Stockh)* 6 1 7-16
- ARVILL, A, WESTBERG G, JONSSON K A, HOOD B & ÅHRÉN K (1966) Insulin like activity and insulin inhibitory effect of human albumin fractions studied with two biological test methods *Diabetologia* 2 4, 253-259
- AZERAD E, LUBETZKI J, STUHL L & SLOTTNE G (1961) Les osteopathies du diabète. Le pied diabétique. In *4<sup>e</sup> Congrès de la Fédération internationale du diabète*, Vol I pp 421-431 discussion pp 432-433, ed by Michel Demole. Éditions Médecine et Hygiène Geneva
- BAILEY, C C & ROOT H F (1947) Neuro pathic foot lesions in diabetes mellitus *New Engl J Med* 236 397-401
- BANG O (1929) Klinische Urobilin Studien in Sonderheit an normalen und leber gesunden Personen. Die Wirkung koh lenhydratknapper Kost auf die Urobilinausscheidung. Die Urobilinurie der Diabetiker *Acta med scand* Suppl 29 pp 1-203
- BANTING F S, BEST C H, COLLIP J B, CAMPBELL W R & FLETCHER A A (1922) Pancreatic extracts in the treatment of diabetes mellitus. Preliminary report *Canad med Ass J* 2 141-146. Reprinted 1962 in *Canad med Ass J* 87 20, 1062-67
- BARTELS E D (1953) Endocrine disorders. In *Clinical genetics* ed by Arnold Sorsby pp 529-543 Butterworth London
- BAUR E, FISCHER E & LENZ F (1923) *Menschliche Erblchkeitslehre* (Grundriss der menschlichen Erblchkeitslehre und Rassenhygiene Bd I) Lehmann Munich pp 1-442+appendix
- BECKER P E ed (1964) *Humangenetik*

- Ein kurzes Handbuch in fünf Bänden  
Bd. III I Stoffwechselkrankheiten etc.  
Thieme, Stuttgart pp 1-719
- BERGMAN P (1953) Diabetes och graviditet  
*Nord Med* 49 5 165-168
- BERGQVIST G (1963) Arthropathia dia-  
betica *Opusc med (Stockh)* 8 5 152-  
154
- BERGQVIST N (1954) The growth of juvenile  
diabetics *Acta endocr (Abh)* 15 2  
133-165
- (1954) The influence of pregnancy on  
diabetes *Acta endocr (Kbh)* 15 2  
166-181
- (1954) The gonadal function in male  
diabetics *Acta endocr (Abh)* Vol 15  
Suppl 18 pp 1-29
- (1954) The gonadal function in female  
diabetics *Acta endocr (Abh)* Vol 15  
Suppl 19 pp 1-20
- BERGSTRAND C G FÜRST P LARSSON Y  
& STERKY G (1962) Serum haptoglobin  
in juvenile diabetes *Scand J clin Lab  
Invest* 14 629-632
- BERKMAN J I (1962) Pathology In *Clinical  
diabetes mellitus* ed by Max Ellen-  
berg and Harold Rifkin pp 123-136  
McGraw Hill New York
- BERTRAM F BENDFELDT E & OTTO H  
(1956) Indikationen und Erfolge der  
peroralen Behandlung des Diabetes  
mellitus mit einem Sulfonylharnstoff  
derivat Bericht über 335 Fälle *Dtsch  
med Wschr* 81 274-278
- BEST C H (1960) Epochs in the history of  
diabetes In *Diabetes with a chapter on  
hypoglycemia* by 54 authors ed by  
Robert H Williams pp 1-13 Paul B  
Hoebner New York
- (1962) The future of diabetes In *Clinical  
diabetes mellitus* ed by Max Ellen-  
berg and Harold Rifkin pp 430-437  
McGraw Hill New York
- BURNSTORF P (1965) The effect of nicotinic  
acid on adipose tissue metabolism *in  
vitro Metabolism* 14 7 836-840
- BLOODWORTH JR, J M B (1963) Diabetic  
microangiopathy *Diabetes* 12 2 99-114
- (1965) Ultrastructural demonstration of  
basic similarities between human diabetic  
glomerulosclerosis, glomerulonephritis  
and systematic lupus erythematosus  
*Diabetes* 14 7 441-442
- BOE J HUMERFELT S & WEDERVANG F  
(1957) The blood pressure in a popula-  
tion Blood pressure readings and height  
and weight determinations in the adult  
population of the city of Bergen *Acta  
med scand* Vol 157 Suppl 321 pp  
1-336
- BOLANDER A M (1967) Mortality patterns  
by cause in Sweden in 1961-1963  
*Statistical reports Be* 1967 2 1-158  
National Central Bureau of Statistics  
Stockholm
- BORTZ E L (1934) Heredity and the pro-  
phylactic treatment of diabetes *Med Clin  
Amer* 18 269-286
- BROLIN S E HELLMAN B & KNUTSON H  
ed (1964) The structure and metabolism  
of the pancreatic islets *Wenner Gren  
Center International Symposium Series*  
Vol. 3 Pergamon Press Oxford, pp  
1-528
- BROSSET A & WERKO L (1950) Diabetes  
mellitus och graviditet *Nord Med* 44  
43 1710-16
- BLUCH H Ek J & WERKO L (1956)  
Renal function studies in diabetic  
nephropathy *Scand J clin Lab Invest*  
8 309-318
- BRIDGEMAN W J ed (1962) *Methodology in  
human genetics* Holden Day San Fran-  
cisco pp 1-436
- CAIRD F I & GARRETT C J (1963)  
Prognosis for vision in diabetic retinop-  
athy *Diabetes* 12 5 389-397
- CAMMIDGE P J (1928) Diabetes mellitus  
and heredity *Brit med J* 2 738-741
- (1934) Heredity as a factor in the aetiol-  
ogy of diabetes mellitus *Lancet* 1, 393-  
395
- CAMPBELL, W. R. (1958) Hypoglycemia and  
hyperinsulism. *Canad med Ass J* 79 9  
760-767
- CLARK, C A (1961) The genetics of dia-  
betes mellitus *Diabetes* 10 3 175-177
- (1962) *Genetics for the clinician* Black-  
well Oxford pp 1-294

- CREUTZFELDT, W & SOLING H D (1961) *Oral treatment of diabetes (A clinical experimental review)* Springer, Berlin pp 1-192
- DAHLBERG G JORPES E KALLNER S & LICHTENSTEIN A (1947) Diabetes mellitus in Sweden Statistical data on the number of diabetics their state of health working capacity diet and treatment *Acta med scand Suppl* 188 pp 1-67
- DANOWSKI, T E ed (1964) *Diabetes mellitus: diagnosis and treatment* Prepared by the Committee of Scientific Publications and the Committee of Professional Education of the Amer Diab Ass New York pp 1-209
- DARDENNE, U (1962) The therapeutic applications of anabolic steroids in ophthalmology *Acta endocr (Abh)* Suppl 63 pp 154-174
- DECKERT T (1960) Late diabetic manifestations in pancreatogenic diabetes mellitus *Acta med scand* 168 5-6 439-446
- DOLL, H & BUCH J (1950) Hereditary factors in peptic ulcer *Ann Eugen (London)* 15 135-146
- DOLMAN C L (1963) The morbid anatomy of diabetic neuropathy *Neurology* 13 2 135-142
- DREYER K & HEY A (1953) Forekomst og fordeling af diabetes mellitus i Danmark *Ugeskr Læg* 115 27 1069-73
- (1954) Dødelighedsforhold blandt diabetikere *Ugeskr Læg* 116 7 273-276
- DRURY M I (1966) Pregnancy in the diabetic *Diabetes* 15 11 830-835
- DUPRÉ J A & BECK J C (1964) An intestinal hormone affecting glucose disposal in man *Lancet* 2 672-673
- (1966) Stimulation of release of insulin by an extract of intestinal mucosa *Diabetes* 15 8 555-559
- ELLENBERG M (1960) Diabetic neuropathy a consideration of factors in onset *Ann intern Med* 52 5 1067-75
- (1961) Absent deep reflexes A diagnostic clue in unsuspected diabetes *Amer J med Sci* 242 1072 183-189
- (1964) Diabetic neuropathy, with special reference to visceral neuropathy *Advanc intern Med* 12 11-32
- (1966) Neurologic complications and functional abnormalities in diabetes *NY St J Med* 66 12, 1642-48
- ELLENBERG, M & RIFKIN, H ed (1962) *Clinical diabetes mellitus* McGraw Hill New York, pp 1-448
- ENGEL, ARNOLD & ROBERTS JEAN (1966) Rheumatoid arthritis in adults United States 1960-1962 — U S Department of Health Education and Welfare Vital and Health Statistics Data from the National Health Survey *Public Health Service Publication* No 1000 Series 11, No 17 pp 1-43
- ENGEL ARTHUR (1950) Sena diabeteskomplikationer *Nord Med* 43 22 902-908
- ENGEL ARTHUR & LARSSON TAGE ed (1967) *Stroke* Thule International Symposia Nordiska Bokhandels Forlag Stockholm pp 1-288
- ENGLESON G (1954) Studies in diabetes mellitus *Acta paediat (Uppsala)* Vol 43 Suppl 97, pp 1-163
- EVALDSSON U & GRONBERG A (1961) Ett diabetis behandlat diabetesmaternal *Opusc med (Stockh)* 6 8 248-250
- FAGERBERG S E (1959) Diabetic neuropathy A clinical and histological study on the significance of vascular affections *Acta med scand* Vol 164 Suppl 345 pp 1-99
- FAGERBERG, S E PETERSÉN I STEO G & WILHELMSEN L (1963) Motor disturbances in diabetes mellitus A clinical study using electromyography and nerve conduction velocity determination *Acta med scand* 174 6, 711-716
- FÄHLGREN H, ANDERSSON II & LUNDMARK C (1957) Prolonged unconsciousness in connection with an attack of hypoglycemia *Acta med scand* 68 2 97-101
- FAJANS S S & CONN J W (1954) An approach to the prediction of diabetes mellitus by modification of the glucose tolerance test with cortisone *Diabetes* 3 3 296-304

- (1961) Comments on the cortisone glucose tolerance test *Diabetes* 10 1 63-67
- (1965) Prediabetes subclinical diabetes and latent clinical diabetes: interpretation diagnosis and treatment In *On the nature and treatment of diabetes* ed by H S Leibel and G A Wrenshall pp 641-656 Excerpta Medica Foundation Congress Series No 84 Amsterdam
- FISCHER F (1957) Der erste Fall von Retinopathia diabetica *Wien med Wschr* 107 47 969-972
- FISHER G F & VAVRA H M (1964) Diabetes source book - U S Department of Health Education and Welfare Public Health Service Division of Chronic Disease Diabetes and Arthritis Program *Public Health Service Publication* No 1168 pp 1-48
- FORSMAN O & GENZELL C A (1959) Plasma levels of growth hormone in patients with diabetes mellitus hypercholesterolaemia and liver diseases *Acta endocr (Abh)* 32 480-490
- FOX J R (1952) The incidence of diabetes mellitus and glycosuria in 19 358 college students *J Lancet* 72 479-481 500
- FREEDMAN P MOULTON R & SPENCER A G (1958) Hypertension and diabetes mellitus *Quart J Med* 27 106 293-305
- GARST C C (1966) Blood glucose levels in adults United States 1960-1962 - U S Department of Health Education and Welfare Vital and Health Statistics Data from the National Health Survey *Public Health Service Publication* No 1000 Series 11 No 18 pp 1-25
- GOLDNER M (1962) Carbohydrate metabolic abnormalities in prediabetes (Introductory lecture presented at a Symposium on prediabetes arranged by the New York Diabetes Association New York October 1962)
- GOLDSTEIN M S (1965) Muscular exercise and subsequent glucose utilization In *On the nature and treatment of diabetes* ed by H S Leibel and G A Wrenshall pp 308-320 Excerpta Medica Foundation Congress Series No 84 Amsterdam
- GRANSTRÖM K O (1947) Nomenclature in retinal changes associated with internal diseases - particularly hypertensive diseases and diabetes mellitus *Acta med scand Suppl* 196 pp 40-44
- GREEN J (1963) The activation of electroencephalographic abnormalities by tolbutamide induced hypoglycemia *Neurol og (Minneapolis)* 13 3 192-200
- GRÖNBERG A (1961) Om aktuella diabetesproblem *Sienska Lak Tidn* 58 39 2747-52
- (1962) Bearbetning av ett stort diabetesmaterial från lasaretten i Vänersborg Vaxjö Falun och Östersund *Nord Med* 67 18 576-578
- (1963) Synpunkter på behandlingen av diabetes mellitus *Opusc med (Stockh)* 8 5 133-137
- (1966) Osteopathia diabetica Klinik och terapi *Nord Med* 75 10 283-284
- (1966a) Diabetic osteopathy *Diabetes* 15 7 534-535
- GRÖNBERG A KROOK H & SJÖHOLM M (1967) Glycodiazin (Lycanol) Klinisk provning (In press)
- GRÖNBERG A & SVANTESON G (1951) Fall av retinopathia diabetica som gått till läkning *Sienska Lak Tidn* 48 35 2005-12
- GRUNNET J (1957) Heredity in diabetes mellitus A proband study *Opera ex Domo Biologiae Hereditariae Humanae Universitatis Hafniensis* Vol 39 Munksgaard Copenhagen pp 1-128
- HAGBARD L (1956) Pregnancy and diabetes mellitus *Acta obstet gynec scand* Vol 35 Suppl 1 pp 1-180
- HAGEDORN H C NORMAN JENSEN H KRARUP N H & WODSTRUP I (1936) Protamine insulin *Acta med scand* Suppl 78 pp 678-684
- HAMILTON B & STEIN A F (1942) Measurements of intravenous blood sugar curves *J Lab clin Med* 27 491-497
- HANHART E (1939) Nachweis der ganz vorwiegend einfach recessiven Vererbung des Diabetes mellitus *Erbarzt* 6 5-15
- (1947) Neue Beiträge zur Kenntnis der



- Vererbung des Diabetes mellitus *Hel med Acta* 14 243-262
- (1950) Neue Forschungsergebnisse über die Vererbung des Diabetes mellitus sowie Anhaltspunkte für seine primäre Genese im Stammhirn Zehnter Jahresbericht der Schweizerischen Gesellschaft für Vererbungsforschung, *Arch Klaus Stift Vererb Forsch* 25 586-598
  - (1951) Zur Vererbung des Diabetes mellitus *Schweiz med Wschr* 81 46 1127-31
  - (1953) Die erbliche Anlage der Zuckerkrankheit heutiger Stand *Dtsch Z Verdau u Stoffwechselkr* 13 145-147
- HANSEN P (1946) Diabetes mellitus in Bergen 1925-1941 A study of morbidity mortality causes of death and complications *Acta med scand* Vol 125 Suppl 178 pp 1-179
- HARRIS H (1949) The incidence of parental consanguinity in diabetes mellitus *Ann Eugen (London)* 14 293-300
- (1950) The familial distribution of diabetes mellitus a study of the relatives of 1241 diabetic probands *Ann Eugen (London)* 15 2 95-119
- HARTMANN SR A F VOPLMAN H J, HOLOWACH J & CALDWELL, M M (1960) Studies in hypocalcemia *J Pediatr* 56 2 211-231
- HAUNZ E A & KERANEN D C (1950) Clinical interpretation of blood sugar values A study of Folin Wu Somogyi Nelson and Wilkerson Hefmann blood sugar determinations in 100 subjects *Proc Amer Diab Ass* 10 200-216
- HAYWARD R E & LUCENA B C (1965) An investigation into the mortality of diabetics *J Inst Actuaries* 91 3 286-315 discussion 316-335
- HEINTZELMANN F (1952) Dödeligheden af Diabetes mellitus i Danmark 1947-49 *Ugeskr Læg* 114 18 555-560
- (1952) Dödsårsager ved Diabetes mellitus *Ugeskr Læg* 114 18 560-565
- HELANDER E (1958) Asthma and diabetes *Acta med scand* 162 3 165-174
- HOFSTEN N VON (1948) Sockersjukans (Diabetes mellitus) arflighetsförhållanden och därmed sammanhängande sporsmål In 1943 års sockersjukutrednings betänkande angående sockersjukvården i riket pp 150-161 *Statens offentliga utredningar* 1948 33, Stockholm
- HOGEMAN O (1948) Renal function in diabetic nephropathy *Acta med scand* Vol 132 Suppl 216b pp 1-17
- HUVOS A & ROCHA H (1959) Frequency of bacteriuria in patients with diabetes mellitus *New Engl J Med* 261 24, 1213-16
- IKKOS D & LUFT R (1957) On the glucose tolerance test *Acta endocr (Kbh)* 25 3, 312-334
- (1960) Aspects of the metabolic action of human growth hormone *Ciba Foundation Colloquia of Endocrinology* 13 106-129
  - (1962) Effects of short term administration of large doses of human growth hormone on carbohydrate metabolism in adult non diabetic, hypophysectomized women studies with <sup>14</sup>C-labelled glucose *Acta endocr (Kbh)* 39 567-583
- IKKOS D LUFT R, GEMZELL, C A & ALMQVIST, S (1962) Effect of human growth hormone on glucose tolerance and some intermediary metabolites in man *Acta endocr (Kbh)* 39 547-566
- ISACSSON S O (1965) Diabetes och urinvägsinfektioner *Nord Med* 74 48 1225-26
- JOHANSSON S (1959) Sträng diabetesterapi betydelse för att fördröja uppkomsten av nephropati och retinopati En jämförande efterundersökning av två enligt olika principer behandlade material *Nord Med* 62 27, 1005-09
- (1960) Retinopathy and nephropathy in diabetes mellitus comparison of the effects of two forms of treatment *Diabetes* 9 1 1-8
- JOKEPH S G (1953) Late complications of diabetes *Ann Med intern Fenn* 42 3, 185-198
- JORGENSEN G (1966) Zur Genetik des idiopathischen Diabetes mellitus *Dtsch med J* 17 13 393-400

- JORGENSEN S & PLUM T (1922) Nogle Erfaringer med intravenøse Glykosinjektioner *Ugeskr Læg* 84 45 1525-46
- JORDE R (1961) The diabetes survey in Bergen Norway, 1956 An epidemiologic study and a study of blood sugar values related to sex age and weight *Acta Universitatis Bergensis Series medica* No 1 pp 1-165
- JORPES E & KALLNER S (1942) Resultatet av 20 års insulinbehandling En enquete till de sockersjuka under det tredje krigsåret *Svenska Lak-Tidn* 39 43 2634-48
- JORPES E & MUTT, V (1967) Sekretin och glukagon som regulatorer för insulinin söndringen till blodet *Nord Med* 77 10 301-304
- JOSLIN E P (1953) *Diabetic manual for the doctor and patient* 9th ed Lea & Febiger Philadelphia pp 1-315
- JOSLIN E P ROOT H F WHITE P & MARBLE, A (1959) *The treatment of diabetes mellitus* 10th ed Lea & Febiger Philadelphia pp 1-798
- JUNG J (1962) Synpunkter på bearbetning och analys av diabetesundersökningens material *Nord Med* 67 18 582-585
- KASANEV A & FORSSTRÖM, J (1964) Njur komplikationer vid diabetes *Nord Med* 73 43 1264-65
- KEMP T (1951) *Genetics and disease* Munksgaard Copenhagen pp 1-330
- KIDMELSTIEL, B & WILSON G (1936) Inter-capillary lesions in the glomeruli of the kidney *Amer J Path* 12 83-97
- KINSELL, L W SCHLIERF G & HAN Y (1965) Hyperglycæmia in association with gross or occult abnormality of carbohydrate tolerance *Diabetes* 14 7 458
- KLEBBA A J (1966) Mortality trends in the United States 1954-1963 - U S Department of Health Education and Welfare Vital and Health Statistics Data from the National Vital Statistics System *Public Health Service Publication* No 1000 Series 20 No 2 pp 1-57
- KLINT C R MEINERT C L HO I P & BRIESE, F W (1967) Study of familial patterns of reported diabetes Evaluation of questionnaire data *Diabetes* 16 1 40-50
- KÖRNERUP T (1955) Studies in diabetic retinopathy An investigation of 1 000 cases of diabetes *Acta med scand* 153 2 81-101
- KÖRNERUP T & STRÖM L (1958) Vitamin B<sub>12</sub> and retinopathy in juvenile diabetics *Acta paediat (Uppsala)* 47 646-651
- LAMY M FRÉZAL, J & DE GROUCHY J (1957) Resultats d'une enquete sur l'hérédité du diabète sucré *Rev franç Etud Clin Biol* 2 907-919
- LAMY M FRÉZAL, J & REY J (1961) Héredité du diabète sucré *Journées Ann Diabet Hotel Dieu* 2 5-15
- LARSSON T (1962) Planering bearbetning och resultatbedomning vid medicinsk klinisk forskning, belyst av diabetesundersökningen *Nord Med* 67 18 578-582
- (1965) Mortality in Sweden *Acta genet Suppl ad Vol* 15 pp 1-140 Karger Basel
- (1965a) The Sverige-Men ideas and activities In *Sverige Reinsurance Company 1914-64* pp 7-46 Ivar Hægströms Tryckeri Stockholm.
- (1967) Mortality from cerebrovascular disease In *Stroke Thule International Symposia* ed by Arthur Engel and Tage Larsson pp 15-40 Nordiska Bokhandeln Forlag, Stockholm.
- LARSSON T & SJÖGREN T (1954) A methodological psychiatric and statistical study of a large Swedish rural population *Acta psychiat et neurol scand Suppl* 89 pp 1-250 Munksgaard Copenhagen
- (1960) Essential tremor A clinical and genetic population study *Acta psychiat et neurol scand. Suppl* 144 pp 1-176
- (1966) Dystonia musculorum deformans A genetic and clinical population study of 121 cases *Acta neurol scand Suppl* 17 ad Vol 42, pp 1-232
- LARSSON T SJÖGREN T & JACOBSON E (1963) Senile dementia A clinical socio-medical and genetic study *Acta psychiat scand Vol* 39 Suppl 167 pp 1-259

- LARSSON Y (1962) The organization and functions of a clinic for juvenile diabetes *Acta paediat (Uppsala)* Vol 51 Suppl 135 pp 137-143
- LARSSON Y & STERRY, G (1962) Long term prognosis in juvenile diabetes mellitus *Acta paediat (Uppsala)* Vol 51 Suppl 130, pp 1-76
- LEIBEL II S & WRENSHALL G A ed (1965) *On the nature and treatment of diabetes* Excerpta Medica Foundation Congress Series No 84 Amsterdam pp 1-805
- LENZ F (1923) Die krankhaften Erbanlagen In *Menschliche Erblchkeitslehre* by Erwin Baur Eugen Fischer and Fritz Lenz pp 155-326 Lehmann Munich
- LENZ W (1961) *Medizinische Genetik Eine Einführung in ihre Grundlagen und Probleme* Thieme, Stuttgart pp 1-197
- LEVINE R (1964) History of etiology of diabetes mellitus *Arch Path* 78 10 405-408
- (1964a) Analysis of the actions of the hormonal antagonists of insulin *Diabetes* 13 4 362-365
- LEVINE R & LUFT R (1964) The relation between the growth and diabetogenic effects of the so-called growth hormone of the anterior pituitary *Diabetes* 13 6 651-655
- LEW E A (1957) Some implications of mortality statistics relating to coronary artery disease *J chron Dis* 6 192-209
- LICHTENSTEIN A (1938) Om behandling av barndiabetes utan kostinskränkning *Nord med T* 15 17 677-680
- (1939) Cinq années d'expérience de l'alimentation libre dans le diabète infantile *Acta paediat (Uppsala)* 24 171-176
- (1949) Diet in diabetes in childhood *Advanc Pediat* 4 1-38
- (1949) The treatment of diabetes in childhood *Arch Dis Childh* 24 237-244
- LICHTENSTEIN A LARSSON Y & PLOMAN, K G (1952) Degenerative vascular complications in juvenile diabetes mellitus treated with free diet *Diabetes* 1 6, 449-458
- LOMBARD, H L & JOSLIN E P (1958) Underlying causes of death of 1000 patients with diabetes *New Engl J Med* 259 19 924-926
- LOUBATIERES A (1946) Étude physiologique et pharmacodynamique de certains dérivés sulfamidés hypoglycémisants *Arch int Physiol* 54, 174-177
- LUFT, R (1965) Menschliches Wachstumshormon und menschlicher Diabetes *Triangel (De)* 7 2-7
- (1965) Indications that human growth hormone plays a role in diabetes mellitus and diabetic retinopathy In *On the nature and treatment of diabetes* ed by B S Leibel and G A Wrenshall pp 496-500 Excerpta Medica International Congress Series No 84 Amsterdam
- (1965) Human growth hormone and the control of blood glucose concentration *Israel J Med Sci* 1 6, 1277-83
- LUFT, R & CERASI E (1964) Effect of human growth hormone on insulin production in panhypopituitarism *Lancet* 2 124-126
- LUFT R IKKOS, D GEMZELL, C A & OLIVECRONA H (1958) Effect of human growth hormone in hypophysectomized human subjects *Lancet* 1 721-722
- LUNDBÆK K (1953) *Long term diabetes The clinical picture in diabetes mellitus of 15-25 years duration with a follow up of a regional series of cases* Munksgaard Copenhagen, pp 1-197 + appendix
- (1955) Diabetic retinopathy in newly diagnosed diabetes mellitus *Acta med scand* 152, 53-60
- (1965) Nephropathy in diabetic subjects In *On the nature and treatment of diabetes* ed by B S Leibel and G A Wrenshall pp 436-446 Excerpta Medica Foundation Congress Series No 84 Amsterdam
- LUNELL N O (1966) Intravenous glucose tolerance in women with previously complicated pregnancies *Acta obstet gynec scand* Vol 45, Suppl 4 pp 1-89
- MACMAHON III & WORCESTER J (1966)

- Age at menopause United States 1960-1962 - U.S. Department of Health Education and Welfare Vital and Health Statistics Data from the National Health Survey *Public Health Service Publication* No 1000 Series 11 No 19 pp 1-20
- MALINS J M FITZGERALD M G & WALL M (1965) A change in the sex incidence of diabetes mellitus *Diabetologia* 12 121-124
- MARAS H H (1947) Recent statistics on diabetes and diabetics *Med Clin N Amer* 31 369-386
- (1961) Characteristics and trends of cerebral vascular disease In *Psychopathology of aging* pp 69-99 Grune & Stratton New York
- (1961a) Current concepts in diabetes mellitus vital statistics *N Y St J Med* 61 602-616
- (1963) *Longevity and mortality of diabetics* Paper presented at the Annual Meeting of the Amer Publ Hlth Ass
- MARTENSSON J (1950) The prognosis of diabetes mellitus A study of 221 patients surviving at least 15 years *Acta med scand* 137 5 335-354
- (1950) Cardiovascular and renal findings in long standing diabetes mellitus A study of 221 patients surviving at least 15 years *Acta med scand* 138 2 94-107
- MARTENSSON J & PALM L (1950) Ocular findings in long standing diabetes mellitus Report of 163 cases of at least 15 years duration - Papers dedicated to Professor Martin Odin on his sixtieth birthday June 13, 1950 *Acta med scand* Suppl 246 pp 154-165
- MELIN H (1964) An atrophic circumscribed skin lesion in the lower extremities of diabetics *Acta med scand* Suppl 423 pp 1-75
- MEYER LIE A & SMEDBY H (1967) Kro niska sjukdomars förekomst belyst genom försäkringskassans registrering av kostnadsfria läkemedel (In press)
- MICHAEL, S E (1962) The isolation of albumin from blood serum or plasma by means of organic solvents *Biochem J* 82 212-218
- MÖLLERSTRÖM J (1939) Diet och diabetes *Acta paediat (Uppsala)* 25 206-219
- MORIYAMA, I M (1964) The change in the mortality trend in the United States - U.S. Department of Health Education, and Welfare Vital and Health Statistics Analytical Studies *Public Health Service Publication* No 1000 Series 3 No 1 pp 1-43
- MOSBECH J (1951) Om hyppigheden av perniciös anæmi Tælling af patienter i Odense Amt december 1950 *Ugeskr Læg* 113 39 1297-1301
- MUNKKE A (1964) A mass survey to trace previously unknown diabetes mellitus A preliminary report *Acta med scand* 176 2 169-179
- NEEL J V (1962) Diabetes mellitus a thrifty genotype rendered detrimental by progress? *Amer J hum Genet* 14 353-362
- (1964) The genetic basis for diabetes mellitus In *Conference on Small Blood Vessel Involvement in Diabetes Mellitus* ed by M D Superstein A R Colwell and K Meyer pp 295-301 Amer Inst of Biol Sciences Washington DC
- NEEL J V FAJANS S S CONY J W & DAVIDSON R T (1965) Diabetes mellitus Under 'The evaluation of genetic factors in selected illustrative diseases in *Genetics and the epidemiology of chronic diseases* ed by J V Neel M W Shaw and W J Schull US Department of Health Education and Welfare *Public Health Service Publication* No 1163 pp 105-132
- NEEL J V & SCHULL W J (1954) *Human heredity* University of Chicago Press Chicago pp 1-361
- NEWELL V A (1963) Present concepts of incidence and prevalence *Diabetes* 12 6 554-559
- NILSSON S E (1962) Genetic and constitutional aspects of diabetes mellitus *Acta med scand* Suppl 375 pp 1-96
- (1964) On the heredity of diabetes mellitus and its interrelationship with some other diseases *Acta genet* 14, 97-124

- NILSSON S E, LINDHOLM H BULOW S, FROSTBERG N, EMILSSON T & STEN KULA G (1964) The Kristianstad survey 1963-1964 Studies in a normal adult population for variation and correlation in some clinical anthropometric and laboratory values especially the peroral glucose tolerance test *Acta med scand* Vol 177, Suppl 428, pp 1-54
- NILSSON S E, NILSSON J II, FROSTBERG N & EMILSSON T (1967) The Kristianstad Survey II Studies in a representative adult diabetic population with special reference to comparison with an adequate control group *Acta med scand* Suppl 469 pp 1-42
- NOORDEN C VON (1917) *Die Zuckerkrankheit und ihre Behandlung* 7th ed, Hirschwald Berlin pp 1-634
- NORDLOW W, GRONBERG A & SVANTE SON G (1953) Sexualhormonterapi vid retinopathia diabetica *Nord Med* 49 21 742-744
- OBERDISSE K & JAHNKE K ed (1963) *Fortschritte der Diabetesforschung* Thieme Stuttgart pp 1-136
- ODIN M (1939) Den dietetiska behandlingen av diabetes mellitus *Nord Med* 4 45 3316-26
- OLSSON I, SÄVE SÖDERBERGH J, ANGERVALL, L & SOURANDER P (1967) Patho anatomical study of the central and peripheral nervous system in diabetes of early onset and long duration (In press)
- OSCARSSON P N & SILWER, H (1958) Incidence of pulmonary tuberculosis among diabetics Search among diabetics in the County of Kristianstad *Acta med scand* Vol 161 Suppl 335 pp 23-48
- OSEASHOV II, LIEBOW, I M & NEWELL V A (1964) Incidence of bacteriuria and urinary tract infection in a group of diabetic women *Amer J med Sci* 247 1106, 661-664
- ÖSTMAN J (1965) *The endogenous fatty acid metabolism in diabetes* Studies on the metabolism of human adipose tissue *in vitro* and on the effect of inhibition of mobilization of free fatty acids on the glucose metabolism A methodological experimental and clinical investigation Almquist & Wiksells Boktryckeri Uppsala pp 1-37
- ÖSTMAN, J & GRONBERG A (1964) Biverkningar vid oral diabetesbehandling med sulfonylurea *Nord Med* 72 47 1388-96
- O SULLIVAN, J II & GORDON, T (1966) Childbearing and diabetes mellitus United States 1960-1962 - U S Department of Health Education and Welfare Vital and Health Statistics Data from the National Health Survey *Public Health Service Publication* No 1000 Series 11, No 21, pp 1-19
- PARRISH J A (1965) Urinary infection in diabetic outpatients *Lancet* 2, 414-415
- PAVEL I & PIEPTEA R (1966) Étude sur le diabète héréditaire au cours de 3 et 4 générations successives *Diabetologia* 2 4, 281-285
- PAVEL I, PIEPTEA R & VASILESCU V (1966) Contribution extrahéréditaire de la mère diabétique dans la transmission du diabète héréditaire *Acta diab latina* 3 1, 46-50
- PEDERSEN J (1954) Fetal mortality in diabetic pregnancies *Diabetes* 3 3 199-204
- (1965) Perinatal mortality in babies of diabetic mothers In *On the nature and treatment of diabetes* ed by B S Leibel and G A Wrenshall pp 722-726 Excerpta Medica Foundation International Congress Series No 84 Amsterdam
- PENROSE L S & WATSON E M (1945) A sex linked tendency in familial diabetes *Proc Amer Diabetes Ass* 5 163-177 discussion 178-179
- PETREN K (1923) Diabetesstudier Med bidrag av C SMITH E ÖYSTERSTROM M ODIN och H MALMROS Copenhagen pp 1-956
- PFÄNDLER U (1964) Stoffwechselkrankheiten In *Humangenetik* ed by Peter Emil Becker Bd III 1 pp 1-150 Thieme Stuttgart
- PINCUS G & WHITE, P (1933) On the inheritance of diabetes mellitus I An

- analysis of 675 family histories *Amer J med Sci* 186 1-14
- (1934) On the inheritance of diabetes mellitus II Further analysis of family histories *Amer J med Sci* 188 159-168
  - (1934) On the inheritance of diabetes mellitus III The blood sugar values of the relatives of diabetics *Amer J med Sci* 188 782-790
- POWELL M D U & FIELD R A (1964) Diabetic retinopathy and rheumatoid arthritis *Lancet* 2, 17-18
- PRAWITZ H (1954) Investigation of mortality from different causes of death as a basis for fore-casting the future trend In *Svenska Aktuarietforeningen femito år Festschrift till erinran om försäkrings matematisk verksamhet i Sverige* pp 45-106 Svenska Aktuarietforeningen Stockholm (Almqvist & Wiksells Uppsala)
- RENOUD A E. & CAHILL JR G F (1966) Diabetes mellitus In *The metabolic basis of inherited disease* ed by John M Stanbury James M Wyngaarden and Donald S Fredrickson 2nd ed pp 69-108 McGraw Hill New York
- RIFKIN H & LEITER, L (1962) Diabetic microangiopathy In *Clinical diabetes mellitus* ed by Max Ellenberg and Harold Rifkin pp 360-373 McGraw Hill New York
- ROBERTS H J (1964) The syndrome of narcolepsy and diabetogenic hyperinsulism in the American negro *J nat med Ass (NY)* 56 1 18-42
- ROBERTS J A FRASER (1961) Multifactorial inheritance in relation to normal and abnormal human traits *Brit med Bull* 17 3 241-246
- ROOT H F (1934) The association of diabetes and tuberculosis Epidemiology pathology treatment and prognosis *New Engl J Med* 210 1 1-13
- ROOT H F & BRADLEY R F (1959) Cardiovascular renal disease In *The treatment of diabetes mellitus* ed by Elliott P Joslin Howard F Root Priscilla White and Alexander Marble pp 407-450 Lea & Febiger Philadelphia
- ROOT H F MIRSKY S & DITZEL J (1959) Proliferative retinopathy in diabetes mellitus *J Amer med Ass* 169 903-909
- SALTZMAN F (1945) Statistiska uppgifter rörande sockersjuka under krigstiden *Nord Med* 26 16 852-853
- SAMOLS E (1965) Immunochemical aspects of insulin In *On the nature and treatment of diabetes* ed by M S Leibel and G A Wrenshall pp 227-246 Excerpta Medica Foundation Congress Series No 84 Amsterdam
- SCHERSTÉN B (1961) Untersuchung über die Diabetesfrequenz in einem schwedischen Bezirk von 145 000 Einwohnern *Proc IV Congr Int Diab Fed Geneva* pp 249-252 Éditions Médecine et Hygiène Geneva
- SCHLIACK V (1965) Über die Diabetes Morbidität *Dtsch med Wschr* 90 32 2321-37
- SCHRADER A & WEINGES K (1961) Peripher neurologische Erkrankungen beim Diabetes mellitus *Internist (Berlin)* 2, 100-105
- SILAGY J M (1962) Urogenital complications in diabetes *NY St J Med* 62 10 1665-70
- SILVER H (1958) Incidence of diabetes mellitus in a Swedish county Survey of diabetics in the County of Kristianstad *Acta med scand* Vol 161 Suppl 335 pp 5-22
- SIMPSON N E (1962) The genetics of diabetes a study of 233 families of juvenile diabetics *Ann hum Genet* 26 1-21
- (1964) Multifactorial inheritance a possible hypothesis for diabetes *Diabetes* 13 5 462-471
- SIPERSTEIN M D COLWELL, A R & MEYER K ed (1964) *Small blood vessel involvement in diabetes mellitus* Proceedings of the Conference on Small Blood Vessel Involvement in Diabetes Mellitus Warrenton Va, March 25-27 1963 pp 1-317 Amer Inst of Biol Sciences Washington D C

- SIÖGREN T & LARSSON T (1949) Microphthalmos and anophthalmos with or without coincident oligophrenia. A clinical and genetic statistical study *Acta psychiat et neurol scand Suppl* 56, pp 1-103 Munksgaard Copenhagen
- (1957) Oligophrenia in combination with congenital ichthyosis and spastic disorders. A clinical and genetic study *Acta psychiat et neurol scand Suppl* 113 pp 1-112 Munksgaard, Copenhagen
- (1965) Population genetics in clinical research *Acta psychiat scand* 41 3 333-347
- (1967) A clinical and genetic population study of oligophrenia in a north Swedish isolate. Preliminary report *Acta psychiat scand* (In press)
- SJÖSTRAND J (1940) *Den aktenskapliga fruktsamheten i Sverige* Isaac Marcus Boktryckeri Stockholm pp 1\*-100\* 1-56
- SJÖVALL H (1952) Studier rörande fetma. Ett sjukhusmaterial *Svenska Lak Tidsn* 49 37, 2296-2306
- SMEDDY B (1966) Receptundersökningen 1963. Årskonsumtionen av läkemedel för ett urval av personer avspeglad i ett receptmaterial. In 1961 års sjukförsäkringsutrednings betänkande II. Läkemedelsförmänen, pp 173-224 *Statens Offentliga Utredningar* 1966 28 Stockholm
- SMITH K (1961) Diabetic neuropathy *Postgrad Med* 30 223-228
- SÖDERLING H (1935) Behandlung der Zuckerkrankheit im Kindesalter ohne Diateinschränkungen *Acta paediat (Uppsala)* Suppl 2 pp 1-41
- SOMLÓ Z, CSAPÓ G & SZÜCS S (1962) Neurological complications of diabetes mellitus *Med Welt* 46 2463-65
- SORSBY A ed (1953) *Clinical genetics* Butterworth London pp 1-603
- SPIEGELMAN M & MARKS H H (1946) Age and sex variations in the prevalence and onset of diabetes mellitus *Amer J publ Hlth* 36 26-33
- STANBURY J B, WYNGAARDEN J B & FREDRICKSON D S ed (1966) *The metabolic basis of inherited disease* 2nd ed, McGraw Hill, New York pp 1-1434
- STEINBERG, A G (1955) Heredity and diabetes *Eugen Quart* 2 26-30
- (1958) Heredity and diabetes *Diabetes* 7 3 244-245
- (1959) The genetics of diabetes: a review *Ann NY Acad Sci* 82 2 197-207
- (1961) Heredity in diabetes mellitus *Diabetes* 10 4 269-274
- (1965) Genetics and diabetes. In *On the nature and treatment of diabetes* ed by B S Leibel and G A Wrenshall pp 601-608 discussion pp 609-611 *Excerpta Medica Foundation Congress Series No 84* Amsterdam
- STEINBERG A G & WILDER R M (1952) A study of the genetics of diabetes mellitus *Amer J hum Genet* 4 113-135
- STERKY G (1963) Diabetic schoolchildren *Acta paediat (Uppsala)* Suppl 144 pp 1-39
- STROM L & SVENSSON Å (1965) Rating and insurance of substandard risks. In *Sverige Reinsurance Company 1914-64* pp 109-131 Ivar Hæggströms Tryckeri Stockholm
- SUNDBERG A & GRÖNBERG A (1960) Diabetes mellitus and pernicious anaemia *Acta med scand* 166 2 147-150
- SUNDELIN, G (1938) Diabetes och graviditet *Nord med T* 16 32, 1239-48
- SVANBORG A (1965) Störningar i fettsyraomsättningen vid diabetes *Nord Med* 73 21 501-503
- SVANTESSON G (1953) Diabetes och graviditet *Nord Med* 49 15 533-536
- SZÜCS S, CSERHATI I, CSAPÓ G & BALAZS V (1960) The relation between diabetes mellitus and infections of the urinary tract. A clinical qualitative and quantitative bacteriological study based upon 300 diabetics and 200 controls *Amer J med Sci* 240 2 186-191
- THEN BERGH H (1938) Die Erbbiologie des Diabetes mellitus. Vorläufiges Ergebnis der Zwillingsuntersuchungen *Arch f Rassen u Gesellschaftsbiol* 32 289-340

- (1939) Zur Frage der psychischen und neurologischen Erscheinungen bei Diabeteskranken und deren Verwandten *Z ges Neurol Psychiat* 165 278-283
- THOMPSON M W & WATSON E M (1952) The inheritance of diabetes mellitus *Diabetes* 1 4 268-275
- THOMSEN A C (1965) *The kidney in diabetes mellitus* A clinical and histological investigation based on renal biopsy material Munksgaard Copenhagen pp 1-337
- TIBBLIN G (1967) High blood pressure in men aged 50 A population study of men born in 1913 *Acta med scand Suppl* 470 pp 1-84
- USTVEDT H J (1959) Mortality from cerebrovascular accidents in Norway in relation to mortality from cardiovascular renal disease *Acta med scand* 163 4, 305-327
- VALLANCE OWEN J (1963) Antagonists of insulin In *Fortschritte der Diabetesforschung* ed by K Oberdisse and K Jahneke pp 10-17 Thieme Stuttgart
- (1965) Insulin antagonists In *On the nature and treatment of diabetes* ed by B S Leibel and G A Wrenshall pp 340-353 Excerpta Medica Foundation Congress Series No 84 Amsterdam
- (1966) The inheritance of essential diabetes mellitus from studies of the synalbumin insulin antagonist *Diabetologia* 2 4 248-252
- VALLANCE OWEN J & ASHTON W L (1963) Cardiac infarction and insulin antagonism *Lancet* 1 1226-28
- VALLANCE-OWEN J DENNES E & CAMPBELL P N (1958) Insulin antagonism in plasma of diabetic patients and normal subjects *Lancet* 2 336-338
- VARTIAINEN I (1947) Changes in diabetic death rate in Finland *Ann Med intern Fenn* 36 1 191-197
- VARTIAINEN I & VARTIAINEN O (1944) Studien über den Diabetes mellitus in Finnland III Das Vorkommen des Diabetes *Acta med scand* 119 4-5 364-379
- VEJLSGAARD R (1965) Bakteriuri hos patienter med diabetes mellitus *Ugeskr Læg* 127 34 1044-50
- (1965) Signifikant bakteriuri i relation til sene diabetiske karlidelser *Ugeskr Læg* 127 34 1050-54
- WALLMAN CARLSSON C (1950) Erfarenheter från 10 års diabetesbehandling vid Vaxjö lasarett *Nord Med* 43 3 127-128
- WATANABE C K (1918) Studies in the metabolic changes induced by the administration of guanidine bases I Influence of injected guanidine hydrochloride upon blood sugar content *J Biol Chem* 33 253
- WESTLUND K (1966) Incidence of diabetes mellitus in Oslo Norway 1925 to 1954 Report No 11 of the Life Insurance Companies Institute for Medical Statistics at the Oslo City Hospitals *Brit J prev soc Med* 20 3 105-116
- WHITE P (1956) Natural course and prognosis of juvenile diabetes *Diabetes* 5 6 445-450
- (1959) Evidence in favor of the theory that diabetes is inherited In *The treatment of diabetes mellitus* by Ellrott P Joslin Howard F Root Priscilla White and Alexander Marble pp 48-63 Lea & Febiger Philadelphia
- WILDER R M (1955) Karl Petrén A leader in pre insulin dietary therapy of diabetes *Diabetes* 4 2 159-160
- WILLERSON H L C & KRALL L P (1947) Diabetes in a New England town study of 3516 persons in Oxford Mass *J Amer med Ass* 135 209-216
- (1953) Diabetes in a New England town report of 4 years progress study of the Oxford Mass diabetes survey of 1946-1947 *J Amer med Ass* 152 1322-29
- WILKERSON H L C KRALL L P & BUTLER F K (1959) Diabetes in a New England town III A comprehensive baseline study in Oxford Mass *J Amer med Ass* 169 910-914
- WILLIAMS R H ed (1960) *Diabetes with a chapter on hypoglycemia* by 54 authors Paul B Hoeber New York pp 1-793



- SJÖGREN T & LARSSON T (1949) Microphthalmos and anophthalmos with or without coincident oligophrenia. A clinical and genetic statistical study *Acta psychiat et neurol scand Suppl* 56, pp 1-103 Munksgaard Copenhagen
- (1957) Oligophrenia in combination with congenital ichthyosis and spastic disorders. A clinical and genetic study *Acta psychiat et neurol scand Suppl* 113 pp 1-112 Munksgaard Copenhagen
- (1965) Population genetics in clinical research *Acta psychiat scand* 41 3 333-347
- (1967) A clinical and genetic population study of oligophrenia in a north Swedish isolate. Preliminary report *Acta psychiat scand* (In press)
- SJÖSTRAND J (1940) *Den äktenskapliga fruktsamheten i Sverige* Isaac Marcus Boktryckeri Stockholm, pp 1\*-100\* 1-56
- SJÖVALL, B (1952) Studier rörande fetma. Ett sjukhusmaterial *Svenska Lak Tidsn* 49 37 2296-2306
- SMEDBY, B (1966) Receptundersökningen 1963. Årskonsumtionen av läkemedel för ett urval av personer avspeglad i ett receptmaterial. In 1961 års sjukförsäkringsutrednings betänkande II. Läkemedelsför månen pp 173-224. *Statens Offentliga Utredningar* 1966 28 Stockholm
- SMITH K (1961) Diabetic neuropathy *Postgrad Med* 30 223-228
- SÖDERLING H (1935) Behandlung der Zuckerkrankheit im Kindesalter ohne Diät einschränkungen. *Acta paediat (Uppsala)* Suppl 2 pp 1-41
- SOMLÓ Z, CSAPÓ G & SZÜCS B (1962) Neurological complications of diabetes mellitus *Med Welt* 46 2463-65
- SORSBY A ed (1953) *Clinical genetics* Butterworth London pp 1-603
- SPIEGELMAN M & MARKS H H (1946) Age and sex variations in the prevalence and onset of diabetes mellitus *Amer J publ Hlth* 36 26-33
- STANBURY J H, WYNGAARDEN J B & FREDRICKSON D S ed (1966) *The metabolic basis of inherited disease* 2nd ed McGraw Hill New York, pp 1-1434
- STEINBERG A G (1955) Heredity and diabetes *Eugen Quart* 2, 26-30
- (1958) Heredity and diabetes *Diabetes* 7 3, 244-245
- (1959) The genetics of diabetes: a review *Ann NY Acad Sci* 82 2, 197-207
- (1961) Heredity in diabetes mellitus *Diabetes* 10 4 269-274
- (1965) Genetics and diabetes. In *On the nature and treatment of diabetes* ed by H S Leibel and G A Wrenshall pp 601-608 discussion pp 609-611. *Excerpta Medica Foundation Congress Series No 84* Amsterdam
- STEINBERG A G & WILDER R M (1952) A study of the genetics of diabetes mellitus *Amer J hum Genet* 4 113-135
- STERKY G (1963) Diabetic schoolchildren *Acta paediat (Uppsala)* Suppl 144 pp 1-39
- STROM L & SVENSSON, Å (1965) Rating and insurance of substandard risks. In *Sverige Reinsurance Company 1914-64* pp 109-131 Ivar Hæggströms Tryckeri Stockholm
- SUNDBERG A & GRÖNBERG A (1960) Diabetes mellitus and pernicious anaemia *Acta med scand* 166 2 147-150
- SUNDELIN G (1938) Diabetes och graviditet *Nord med T* 16 32 1239-48
- SVANBORG A (1965) Störningar i fettsyra omsättningen vid diabetes *Nord Med* 73 21 501-503
- SVANTESON G (1953) Diabetes och graviditet *Nord Med* 49 15 533-536
- SZÜCS S, CSERHATI I, CSAPÓ G & BALAZS V (1960) The relation between diabetes mellitus and infections of the urinary tract. A clinical qualitative and quantitative bacteriological study based upon 300 diabetics and 200 controls *Amer J med Sci* 240 2 186-191
- THEN BERGH, H (1938) Die Erbbiologie des Diabetes mellitus. Vorläufiges Ergebnis der Zwillingsuntersuchungen *Arch f Rassen- u Gesellschaftsbiol* 32 289-340

## The Medical Research Council of the Swedish Life Offices

---

### *Members*

- ALVARSON ALLAN Manager  
(Livförsäkringsaktiebolaget Thule the Skandia Group)
- BERGE PER OLOF F L Deputy Managing Director  
(Stadernas Allmänna Försäkringsbolag Hansa the Hansa Group)
- LARSSON GÖSTA F K Manager and Chief Actuary  
(Svenska Personals Pensionskassan)
- LARSSON TAGE M D F L Deputy Managing Director *chairman*  
(Livförsäkringsaktiebolaget Thule the Skandia Group)
- LINDBLOM SVEN GUNNAR F L Deputy Managing Director  
(Livförsäkringsbolaget Hansa ömsesidigt the Hansa Group)
- LINDWALL LARS F K Manager  
(Folksam ömsesidig livförsäkring the Folksam Group)
- LUNDBERG OVE F D Managing Director  
(Sjukförsäkringsaktiebolaget Eir)
- PALMBLAD BERNDT F K Deputy Managing Director  
(Livförsäkringsbolaget Trygg ömsesidigt av 1899 the Trygg Fylgta Group)
- STROM LARS M B Medical Director  
(Återförsäkringsaktiebolaget Sverige)

### *Advisory Board*

- ENGEL ARTHUR M D Director General *chairman*  
National Board of Health Stockholm
- HULTQUIST GÖSTA M D Professor of Pathology  
University of Uppsala
- KLOGLBERG ERIC M D Professor of Neurology  
Karolinska Institutet (Royal Medical School) Stockholm
- LINDERHOLM HÅKAN M D Professor of Physiology  
University of Umeå
- ROMANUS RAGNAR M D Professor of Surgery  
University of Gothenburg
- WALDENSTRÖM JAN M D Professor of Internal Medicine  
University of Lund Malmö



# ACTA MEDICA SCANDINAVICA

SUPPLEMENTUM 478

## PLASMINOGEN AND UROKINASE DETERMINATION BASED ON THE LYSIS TIME METHOD

*Purification of the Substrates — Kinetic and Methodological Studies*

By

WALTER BERG

GÖTEBORG 1967



# ACTA MEDICA SCANDINAVICA

SUPPLEMENTUM 478

## PLASMINOGEN AND UROKINASE DETERMINATION BASED ON THE LYSIS TIME METHOD

*Purification of the Substrates — Kinetic and Methodological Studies*

BY

WALTER BERG

GÖTEBORG 1967

# ACTA MEDICA SCANDINAVICA

has been published since 1919 as a continuation of Nordiskt Medicinskt Arkiv, founded in 1869 by Axel Key. The first volume of Acta Medica Scandinavica is therefore numbered LII (52).

The chief editors have been Axel Key 1869—1900, C. G. Santesson 1901—1915, I. Holmgren 1916—1957 and Birger Strandell 1958 to date.

Acta Medica Scandinavica publishes original research papers in the field of internal medicine. Priority will be given to authors from countries which are represented on the editorial board. Contributors from those countries should submit their papers to a representative of the country in question. Contributors from other countries should send their papers to the Editor at the address below.

Submission of a manuscript for publication will be held to imply that the paper has not been published elsewhere and that, if accepted, it will not be republished in any other journal in the same or similar form, without the Editor's written consent.

Papers will be published in English, French or German at the author's choice, followed by a summary in English.

The manuscripts shall be in final form as submitted. They shall be typewritten with double spacing and broad left hand margin.

If a paper exceeds 16 printed pages the cost for the excess pages shall be borne by the author. No paper shall exceed 24 printed pages.

## Subscription

The annual subscription to the journal covering two volumes each of 6 numbers, is 140 Sw. crowns or U. S. \$ 27.25 *including postage* in the Scandinavian countries and in Holland 120 Sw. crowns.

*Address for subscriptions and all communications*

ACTA MEDICA SCANDINAVICA

P. O. Box 2052 Stockholm 2

---

Requests for duplicate copies of numbers that have gone astray can only be considered if made within a fortnight of the receipt of the following number.

*From the Department II of Medicine (Head Professor Erik Wassen) Sahlgrenska  
Hospital University of Göteborg Göteborg Sweden*

**PLASMINOGEN AND UROKINASE  
DETERMINATION BASED ON THE LYSIS  
TIME METHOD**

*Purification of the Substrates — Kinetic and Methodological Studies*

BY

**WALTER BERG**

**GÖTEBORG 1967**





## Introduction

## Contents

PART ONE	
I	Purification of the Substrates
II	Purification of human fibrinogen and plasminogen by means of gel filtration
III	Human and bovine plasminogen-free thrombin purified by means of gel filtration and ion exchange chromatography
IV	Purification of thrombin on Sephadex G-75, G-50, and G-25
V	Further purification and concentration of thrombin on a CM-Sephadex column
VI	Preparation of human plasminogen suitable as substrate for quantitative determination of plasminogen activators
VII	Euglobulin precipitate as starting material
VIII	Gel filtration of euglobulin on Sephadex G-200
IX	Further purification of plasminogen on DEAE-Sephadex
X	Additional properties of the plasminogen preparation
XI	Methods
XII	Result
PART TWO	
I	Kinetic and Methodological Studies
II	Plasminogen assay by means of the lysis time method
III	Recording the end point of the clot lysis
IV	Activation of plasminogen
V	Formation of fibrin
VI	Lysis of the fibrin
VII	The over-all reaction
VIII	The relationship between the lysis time and the plasmin concentration
IX	Significance of the fibrin concentration
X	The assay

V	A method to correct for the continuing activation during the second stage in a two-stage assay Exemplified by urokinase activation of plasminogen determined by the lysis time method	28
	The mathematical procedure	29
	The formulae	30
	The use of the formulae in fibrinolysis	30
	Experimental verification	31
	The rate constant	31
VI	Urokinase activation of plasminogen and spontaneous inactivation of the formed plasmin A kinetic study	32
	The activation rate	33
	The maximal activity	34
	The influence of the temperature on the rate	35
	The rate equation	35
	The inactivation of the formed plasmin	35
	The over-all reaction of activation and inactivation	36
VII	Theoretical basis and standardization of the one-stage lysis time method for determination of urokinase	36
	Theory and development of a formula for a one-stage assay	36
	Experimental verification of the formula	37
	The influence of various plasminogen concentrations	38
	The influence of various fibrinogen concentrations	38
	The method	39
	General summary and conclusion	40
	Acknowledgements	42
	References	43

The present dissertation is a summary and discussion of the following publications

Purification of the Substrates  
(Part One)

- I Berg, W and K Korsan-Bengtzen Separation of human fibrinogen and plasminogen by means of gel filtration  
Thrombos Diathes haemorrh (Stuttg) 9 151 (1963)
- II Berg, W., K Korsan-Bengtzen, and J Ygge Human and bovine plasminogen free thrombin, purified by means of gel filtration and ion exchange chromatography  
Thrombos Diathes haemorrh (Stuttg) 15 501 (1966)
- III Berg, W, K Korsan-Bengtzen, and J Ygge Preparation of human plasminogen suitable as substrate for quantitative determination of plasminogen activators  
Thrombos Diathes haemorrh (Stuttg) 15 511 (1966)

Kinetic and Methodological Studies  
(Part Two)

- IV Berg, W, K Korsan-Bengtzen and J Ygge Plasminogen assay by means of the lysis time method  
Thrombos Diathes haemorrh (Stuttg) 14 127 (1965)
- V Berg, W A method to correct for the continuing activation during the second stage in a two stage assay Exemplified by urokinase activation of plasminogen determined by the lysis time method  
Thrombos Diathes haemorrh (Stuttg) In press
- VI Berg W Urokinase activation of plasminogen and spontaneous inactivation of the formed plasmin A kinetic study  
Thrombos Diathes haemorrh (Stuttg) In press
- VII Berg, W K Korsan Bengtzen and J Ygge Theoretical basis and standardization of the one stage lysis time method for determination of urokinase  
Thrombos Diathes haemorrh (Stuttg) In press

These papers will be referred to by their Roman numerals



## Introduction

The transformation of fibrinogen into fibrin is caused by the proteolytic enzyme thrombin, which is the result of a complex chain of promotive as well as inhibitory enzyme reactions (Davie and Ratnoff 1964, Macfarlane 1964 a, 1964 b, 1966) The fibrin in turn is degraded by another proteolytic enzyme, plasmin, which also is the result of a chain of enzyme reactions, also promotive as well as inhibitory In the blood, one may assume that there is a complex equilibrium of all these opposing reactions of activation and inhibition, of polymerization and degradation (Stafford 1964) It has also been suggested (Astrup 1956 a, 1956 b, 1962) that there is a continuous formation and lysis of fibrin

To study these reactions in blood is extremely difficult because of the great complexity of the reactions Quantitative determinations of the individual factors involved are also difficult to perform because all the activating and inhibiting factors are present simultaneously

As some of these factors can be purified, parts of the systems and the isolated reactions can be studied and information as to the course of the reactions can be obtained This information can form the basis for further studies of the same reactions in blood The isolated reactions can also be used to construct

specific quantitative methods to determine the various factors

The determination of the individual factors in the coagulation system ultimately depends on the activation of prothrombin into thrombin, which usually is determined by means of the clotting of fibrinogen Likewise, the activity of the individual components of the fibrinolytic system can be assessed on the basis of the amount of plasmin generated from plasminogen during the testing procedure The ability of this plasmin to lyse a fibrin clot, the lysis time method, is often used to determine the amount of plasmin However, in this method the fibrin clot is usually formed in the presence of plasmin Thus, the determination of plasmin by means of fibrin clot lysis involves a combination of the coagulation and the fibrinolysis which increases the complexity of the method

Various other methods exist Those commonly used are based on the ability of plasmin to split casein or synthetic esters However, fibrin is often preferred as substrate because it is the physiological substrate for plasmin and thus expresses the fibrinolytic activity of plasmin The esterolytic activity obtained with synthetic esters as substrates does not seem to be identical with the

fibrinolytic activity (Markus and Ambrus 1960 a)

In the last decade, great interest has also been focused on the plasminogen activator, urokinase, a normal constituent of human urine. It has been suggested that urokinase excretion in some way is related to the release of the plasminogen activator from the tissue into the blood or produced by the kidney. Therefore, the urokinase excretion has been studied in various diseases, especially in thromboembolic disorders (a review has been made by von Kaula 1963, chapter 8). Attention has also been drawn to the use of urokinase in therapeutically induced fibrinolysis. As a result of the growing significance of urokinase it has become of great importance to develop a sensitive and accurate method for quantitative determination of urokinase.

When plasmin, the activated form of plasminogen, is determined by means of the lysis time method an expression of the fibrinolytic activity is obtained. Therefore, we have adopted the principles of this method for determination of plasminogen and urokinase.

The aim of this work is an analysis of the influence of the various factors participating in the fibrinolysis and kinetics of the urokinase activation of

plasminogen. The practical performance of the methods is based on the results obtained.

In this work the methods have been applied to a "purified system". However, the results of the investigations have also been used to determine plasminogen in plasma (Berg, Korsan-Bengtson, and Ygge 1966).

If lysis of the fibrin is used to measure plasminogen, it is of great importance that the fibrinogen and thrombin are not contaminated with plasminogen. This has been emphasized by Astrup (1956 b), Sherry, Fletcher and Alkjaersig (1959), Flute (1964) and MacKav (1964). If the urokinase amount is determined by means of plasminogen activation it is also essential to have a plasminogen which is soluble at neutral pH and at physiological ionic strength and which has a low spontaneous plasmin activity.

In compliance with this, simple methods for preparation of fibrinogen, plasminogen-free thrombin and a soluble plasminogen with a low spontaneous activity have been elaborated.

Thus, the work is divided into two parts. Part One describes the preparation of the substrates while Part Two discusses the kinetic studies and the assays.

## PART ONE

### Purification of the Substrates

#### I Separation of human fibrinogen and plasminogen by means of gel filtration

A plasminogen-free fibrinogen is a pre-requisite for using fibrin as substrate in quantitative determinations of plasminogen. However, most of the available fibrinogen preparations are contaminated with plasminogen (Blomback and Blomback 1956).

To separate fibrinogen from plasminogen has been difficult. According to Remmert and Cohen (1949), plasminogen has a tendency to form complexes with other proteins and this phenomenon has been considered to be responsible for the difficulties (Bergstrom and Wallén 1961).

Several methods to separate fibrinogen from plasminogen have been tried. The fibrin-contaminating plasminogen has been inactivated by heating the fibrin to 85°C (Lassen 1953). This method, however, cannot be used for fibrinogen. In order to achieve the required purity, Markus and Ambrus (1960 a) found it necessary to repeat the precipitation three times according to the method of Laki (1951) which is based on precipitation with phosphate buffer and ammonium sulphate. A fibrinogen substantially free from plasmi-

nogen and plasmin has been obtained by precipitation with diethylether (Keckwick, Mackay, Naunce and Record 1955). Charcoal, Dacro G 60, has been used by Maxwell, Nickel and Lewandowski (1962) to remove plasminogen from fibrinogen. A lysis time of 13—24 hours was obtained. Nauniga and Guest (1964) used carbon to remove contaminating plasminogen. As L-lysine and  $\epsilon$ -aminocaproic acid increase the solubility of plasminogen, precipitation with ethanol in the presence of L-lysine or  $\epsilon$ -aminocaproic acid removed the contaminating plasminogen (Bergstrom and Wallén 1961, Mosesson 1962). Separation of plasminogen from fibrinogen by means of ion exchangers of cellulose type has been used by Mosesson and Finlaysson (1963) and Godal and Lüscher (1960) using gradient chromatography on DEAE-cellulose. Complete separation was not obtained, however. We have also tried ion exchangers of the cellulose type but without success. Gel filtration on Sephadex G-200 has been used by Straughn and Wagner (1966) to characterize fibrinogen. No investigation was made to find out whether the



gel filtration separated plasminogen from fibrinogen. Plasma and Cohn's Fraction I were separated by Lewis (1964) on Sephadex G-200 to estimate the molecular weight of the various coagulation factors and of plasminogen. Our findings of a good separation of plasminogen from fibrinogen by means of Sephadex G-200 were confirmed by him.

The great difference in molecular size between fibrinogen and plasminogen was the reason why we tried separation by means of gel filtration. This method is described in Paper I. A fibrinogen with a high degree of purity (Blomback *et al* 1956) was used as starting material. The gel filtration was performed at room temperature on a Sephadex G-200 column with a salt-buffer solution of 0.2 M Tris HCl and 0.2 M NaCl (1:5). A better result was obtained at room temperature than at  $+4^{\circ}\text{C}$ . This is in accordance with the findings of Godal *et al* (1960) on DEAE-cellulose. The fibrinogen and the plasminogen contaminant came in two well separated peaks. The fibrinogen was tested with various urokinase concentrations because it was not known whether high urokinase concentrations inhibited plasminogen activation or not as does streptokinase. The first and the last part of the fibrinogen peak seemed to contain traces of fibrinolytic activity which gave a lysis time of about 4 days compared with more than 14 days for the rest of the peak. The contamination of the last part was certainly caused by overlapping of the plasminogen peak. The cause of the contamination of the first part is

not definitely known. One possibility is that plasminogen traces formed complex with fibrinogen and these large molecules came in front of the fibrinogen molecules. However, separation of fibrinogen from greater molecules probably did not take place. Laurent and Killander (1964), however, found an available gel volume for fibrinogen. According to the authors, this was within the error of the method. Straughn *et al* (1966) found the same volume for fibrinogen as for Dextran 2000 which has a molecular weight of about 2 000 000.

The experiment described in paper I was done with a small column. For purification on a larger scale, a column with a diameter of 10 cm and a length of 100 cm was used. On this column, 1 g fibrinogen could be purified each time.

As the assays in which the fibrinogen was used were performed in buffers of physiological ionic strength and with pH 7.4, the buffer used in the preparation was later changed to NaCl and Tris HCl (1:4), pH 7.4 and ionic strength 0.15 M. The same good separation was obtained.

The preparation of plasminogen-free fibrinogen described in Paper I is easy to perform. If highly purified fibrinogen such as that prepared according to Blomback *et al* (1956) is used as a starting material, the procedure consists of one gel filtration on Sephadex G-200. If a large column is used, the purification can be done on a large scale. It is not necessary to add L-lysine or  $\epsilon$ -amino caproic acid to the buffer.

## II Human and bovine plasminogen-free thrombin purified by means of gel filtration and ion exchange chromatography

To obtain a plasminogen-free clot, it is necessary that both the fibrinogen and the thrombin are free from plasminogen. It has been very difficult to separate thrombin completely from plasminogen. Even highly purified preparations (Kor-san-Bengtzen and Ygge 1961, Magnusson 1965 a) contain plasminogen traces. It is believed that some fibrinolytic activity can be ascribed to the thrombin molecule itself (Guest and Ware 1950, Brakman, Klug and Astrup 1964). However, the fibrinolytic activity seems to depend on the degree of purity. Thus, preparations of high purity have shown fibrinolytic activity only at high concentrations (Guest *et al* 1950).

Several methods have been tried to prepare plasminogen-free thrombin. Acid precipitation was used by Hude-man (1940). Markus and Ambrus (1960 b) used stepwise alcohol precipitation and selective inactivation of the plasminogen by means of  $\beta$ -mercaptoethylenamine. Hink and MacDonald (1962) used fractional precipitation with ammonium sulphate while De Vreker, Vermeylen and Verstrate (1962) used column chromatography. Brakman *et al* (1964) used chromatography on Amberlite IRC-50. All these methods gave preparations with traces of fibrinolytic activity.

A method to prepare a plasminogen-free thrombin is described in Paper II. The purification was started with adsorption of fresh human or bovine plasma to  $\text{BaSO}_4$  (Bordet and Delange

1912). As prothrombin adsorbs to  $\text{BaSO}_4$  while only traces of plasminogen are adsorbed, this procedure separated the main part of the plasminogen from the prothrombin. Thus crude prothrombin was eluted from  $\text{BaSO}_4$  with citrate. Human brain thromboplastine and  $\text{CaCl}_2$  were used to activate the human crude prothrombin. Calf brain thromboplastine was used to activate the bovine prothrombin. After dialysing 24 hours against distilled water and high speed centrifugation the crude thrombin was purified by means of gel filtration on Sephadex G-75. Further purification and concentration were performed by means of adsorption to a small column of the cationic exchanger CM-Sephadex A-50. The buffer was 0.1 M Tris-HCl pH 7.4. Stepwise elution was performed. The thrombin was eluted with a salt-buffer solution of 0.5 M NaCl and Tris HCl, pH 8, at the proportion 4:1.

Testing with the lysis time method showed that the final preparation did not contain plasminogen. Activation was done with urokinase.

The commercial thrombin preparation Topostasine, which contains a large plasminogen amount was also used as a starting material. This thrombin could not be separated completely from plasminogen.

### Purification of thrombin on Sephadex G-75, G-50, and G-25

Purification of human prothrombin has been done on Sephadex G-200 in

0.15 M  $\text{CaCl}_2$  (Magnusson 1965 b). Traces of contaminants could be removed by chromatography on DEAE-cellulose. Purification of thrombin has been done by means of Sephadex G-25 (Strassle 1963). Fibrinolytic activity was found after the peak which contained clotting activity.

In our investigations, gel filtration of the crude thrombin prepared from the eluted  $\text{BaSO}_4$  adsorbed plasma and of the commercial preparation 'Topostasine' was performed on Sephadex G-75, G-50, and G-25. The best separation of thrombin from the main part of the inert protein was obtained with Sephadex G-75.

The final thrombin preparation contained no plasminogen if crude thrombin prepared from the  $\text{BaSO}_4$  elution was used as a starting material. This crude thrombin, however, contained only traces of plasminogen and the distribution of plasminogen and thrombin in the elution pattern could not be so clearly demonstrated. The commercial thrombin 'Topostasine' which contains a large plasminogen amount, was used to investigate the separation of thrombin from plasminogen. Overlapping was seen between the plasminogen and the thrombin and the final preparation still contained plasminogen. This overlapping was caused by the plasminogen peak which was elongated compared with the thrombin peak. Thus, the gel filtration with Sephadex G-75 could only separate plasminogen from thrombin if the crude thrombin contained small plasminogen amounts. An elongated plasminogen peak is also observed

when euglobulin is gel filtrated with Sephadex G-200 (III). The cause of this is unknown. Protein interaction causing adsorption to other proteins or elongated molecules are probable explanations.

With Sephadex G-75 the thrombin was so well separated from the protein with larger molecules than those of thrombin that it was expected that separation with Sephadex G-50 would also be successful. This was verified.

With Sephadex G-25 thrombin was not separated from protein consisting of larger molecules than those of thrombin. However, there was a peak after the thrombin. The peak contained no fibrinolytic activity. Thus, the findings of Strassle (1963) could not be verified. As the best separation from inert protein was obtained with Sephadex G-75, this was used as the standard method.

Plasminogen seems to have a tendency to adsorb to thrombin because it is difficult to separate it completely from thrombin even with CM-Sephadex although purified plasminogen does not adsorb to CM-Sephadex at 0.3 M Tris HCl, pH 7.4.

Gel filtration with Sephadex G-75 seems to be well suited to separate plasminogen from thrombin, because Sephadex G-75 has an exclusion limit at a molecular weight of 40,000 and thrombin has a molecular weight which probably is lower than 30,000 (Magnusson 1965 a, Schrier, Bromfield, and Scheraga 1962, Cohley and Scheraga 1961, Laki and Gladner 1964). Plasminogen possibly has a molecular weight of about 100,000.

Separation with gel filtration is de-

pendent on the size of molecules (Laurent and Killander 1964) The separation obtained with Sephadex G-50, which has an exclusion limit at a molecular weight of about 10,000, indicates that the molecular weight of thrombin is lower than 10,000 As no separation from greater molecules than those of thrombin was obtained with Sephadex G-25, which has an exclusion limit at a molecular weight of about 4000, the molecular weight of thrombin probably is higher than 4000 These findings are in accordance with Cohley *et al* (1961) who found a molecular weight of about 7000 for the thrombin monomer by ultracentrifugation A similar figure was obtained by Laki *et al* (1964) who analysed the aminoacid sequences Magnusson (1965 c), however, did not obtain these results

The application of gel filtrated thrombin on a CM-Sephadex column for further purification was performed at an ionic strength of 0.1 M It would be of great advantage to perform the gel filtration also at this ionic strength However, there was a marked adsorption to the Sephadex With Sephadex G-25, the adsorption was almost complete This adsorption phenomenon can be used for preparation because the thrombin can be eluted with 0.5 M NaCl However this procedure does not seem to have any advantage compared with the use of CM Sephadex

The adsorption phenomenon may explain why thrombin can be separated from protein of greater molecular weight by means of Sephadex G 50 At an ionic strength of 0.5 M, there may be a

retardation of the molecules during the passage of thrombin through the Sephadex column which may give the impression that a small molecule is involved

#### Further purification and concentration of thrombin on a CM-Sephadex column

The chromatography of thrombin on ion exchangers has been commonly used The cationic exchanger Amberlite IRC-50 was used by Rasmussen (1955) while Miller (1959), Miller and Copeland (1962), and Seegers (1962) used IRC-50-Rivanol Phosphate cellulose was used by Seegers and Landaburu (1960) and DEAE-cellulose by Magnusson (1965 a) Cationic exchangers such as CM-cellulose absorb thrombin, but Seegers *et al* (1960) and Seegers (1962) found that activity was lost in the process of chromatography A short CM-cellulose column was used by Korsan-Bengtson and Ygge (1961), which seemed to minimize the loss of activity

The thrombin obtained from the gel filtration was dialysed against 0.1 M Tris-HCl, pH 7.5 and the whole bulk was applied on a short column of CM-Sephadex All the thrombin was adsorbed but some inert protein passed through In the next step more inert protein was eluted with 0.3 M Tris-HCl pH 8 The thrombin was eluted with 0.5 M NaCl-Tris HCl, pH 8 With 1 M NaCl, an additional small amount of inert protein was eluted, but no thrombin could be found

One great advantage in using CM-Sephadex to separate plasminogen from

thrombin is that plasminogen does not adsorb to CM Sephadex at this ionic strength and pH

A short column was used because the yield of thrombin activity decreases on a long column. The thrombin from the gel filtration was concentrated in this manner as the adsorption capacity of CM Sephadex is great.

The thrombin was stored at +2 to +4° C because freeze-drying and freezing decrease the activity. The final preparation contained about 30 000 NIH units/mg tyrosine and thus was among the preparations with the highest activity. Magnusson (1965) obtained 2100 NIH units/mg protein (which is about 20 300 NIH units/mg tyrosine). Seegers (1962) obtained 45 000 NIH

units/mg tyrosine. An activity as high as 99 400 Iowa units (which is about 59 000 NIH units\* /mg tyrosine) was obtained by Miller and Copeland (1962).

The preparation obtained from the CM Sephadex chromatography contained about 600 NIH units/ml. In spite of this high thrombin concentration no fibrinolytic activity was observed if crude thrombin from the BaSO<sub>4</sub> adsorbed plasma was used as a starting material. However, when Topostasine which contains more plasminogen was used, traces of fibrinolytic activity still remained in the final preparation. Rechromatography or re-filtration on Sephadex G 75 may possibly have separated these last plasminogen traces from Topostasine. Such experiments were not performed, however.

### III Preparation of human plasminogen suitable as substrate for quantitative determination of plasminogen activators

There is an extensive amount of literature describing the preparation of plasminogen. A review has been made by Wallen (1962 a), Bergstrom (1963 b) and MacGay (1964). Only a short survey of previous works which have connection with the method described in Paper III will be presented here.

If plasminogen is to be used as a substrate in a quantitative determination of urokinase, it is essential that the plasminogen preparation is soluble at physiological ionic strength and at neutral pH and that it contains only minimal plasmin amounts.

Plasminogen has usually been prepared from Cohn's Fraction III by means of precipitation with strong mineral acids and alkali according to the method of Kline (1953). This plasminogen is insoluble and unstable at neutral pH and physiological ionic strength. However, addition of lysine and ε-aminocaproic acid increases the solubility. These substances have been used in the preparation procedure by Alkjaer, e.g. Fletcher and Sherry (1959), Wallen and Bergstrom (1960), Wallén (1962 b) and Hagan *et al.* (1960). Derechin (1961) prepared plasminogen that was soluble at neutral pH from outdated human plasma. Mineral acid was avoided.

\* Tyrosine content 10.4% (Miller *et al.* 1962)

\*\* 0.60 NIH unit = 100 Iowa unit (Magnusson 1965)

Slotta, Michl, and Santos (1962) prepared plasminogen from Cohn's Fraction III by means of extraction with lysine buffer at pH 9 and gel filtration on Sephadex G-25. This plasminogen, which they called 'Native', was easily soluble in the physiological pH range. Slotta *et al* (1962) and Slotta and Gonzales (1964) have pointed out that this 'Native' plasminogen was different from the plasminogen prepared with strong mineral acids and strong alkali. Alkjaersig (1964) prepared plasminogen from Cohn's Fraction III and euglobulin with acid extraction and  $\epsilon$ -aminocaproic acid without the use of mineral acids. Further purification was performed by means of DEAE-cellulose or DEAE-Sephadex. The plasminogen exposed to mineral acids differed in solubility and stability from the plasminogen prepared by means of  $\epsilon$ -aminocaproic acid which increased the solubility and stability. The preparation also exhibited differences in their ultracentrifugal and electrophoretic behaviour.

In the method described in Paper III, the euglobulin prepared from fresh human plasma was used as a starting material. The purification was performed by means of gel filtration on Sephadex G-200 and chromatography on DEAE-Sephadex.

#### Euglobulin precipitate as starting material

Cohn's Fractions II and III are commonly used as a starting material for plasminogen purification. Alcohol precipitation may result in denaturation of

plasminogen. To obtain a plasminogen as 'native' as possible, we preferred to use an isoelectric euglobulin precipitate from plasma as starting material. Euglobulin precipitation has previously been used by Milstone (1941) and Alkjaersig (1964).

Plasma from healthy blood donors was chosen. The spontaneous fibrinolytic activity, determined by means of euglobulin lysis time, is generally low in normal human blood. The plasma was left for 30 minutes at  $+37^{\circ}\text{C}$  before the preparation was started. The spontaneous, fibrinolytic activity of the final preparation seemed to be low when this procedure was used, possibly because of inactivation of plasmin.  $\text{BaSO}_4$  was added to the plasma to absorb prothrombin which was later used for thrombin preparation (II). Euglobulin was then precipitated from the plasma by diluting the plasma with 19 parts of distilled water and by adjusting the pH to 5.3 with acetic acid.

#### Gel filtration of euglobulin on Sephadex G-200

Gel filtration of highly purified plasminogen on Sephadex G-200 has been performed by Wallen (1962 c). Two peaks which both contained fibrinolytic activity were obtained. Slotta, Michl, and Santos (1962) used Sephadex G-25. A separation from small molecules was obtained. A plasminogen prepared according to a modified method of Kline was separated by Robbins and Summaria (1963) on Sephadex G-50 and G-75 column equilibrated with 0.0005 N HCl.

pH 3.5 Two peaks were obtained. The second peak contained plasminogen.

Lewis (1964) performed gel filtration of Cohn's Fraction I and obtained a good separation of plasminogen from fibrinogen on Sephadex G-200. He also performed gel filtration of plasma on Sephadex G-100 and G-75 equilibrated with NaCl-Tris buffer pH 8 but minimal or no separation of plasminogen from proteins with larger molecules than those of plasminogen was observed.

Shulmann, Alkjaersig, and Sherry (1958) have found the molecular weight of human plasminogen to be 143,000. Davies and Englert (1960) reported a molecular weight of 83,000 which is in agreement with the findings of Bergstrom (1963 a) in bovine plasminogen. Because of the relatively high molecular weight of plasminogen, separation from greater molecules than those of plasminogen could not be expected with Sephadex G-75 and G-50.

Sephadex G-200, which has an exclusion limit at a molecular weight of 200,000, seemed to be best suited for separation of plasminogen and was therefore chosen in the present experiments.

Gel filtration of euglobulin on Sephadex G-200 in the salt buffer solution 0.5 M NaCl and 0.1 M Tris HCl (4.1) pH 8 gave four peaks. The plasminogen, however, was distributed over a rather wide range. The three last peaks contained plasminogen. Despite this wide range of plasminogen a separation from the main part of the inert protein was obtained because the major protein peak contained no plasminogen.

The wide plasminogen distribution was seen also in the purification of thrombin (II) and is possibly caused by an elongated molecule. Adsorption to other proteins may also be an explanation. Increasing the ionic strength to 1 M NaCl did not give better results. The same plasminogen distribution was obtained by Lewis (1964).

#### Further purification of plasminogen on DEAE-Sephadex

The chromatography of plasminogen on ion exchangers has previously been done on DEAE-cellulose (Alkjaersig 1960, Derechin 1962, Wallén and Bergstrom 1959, 1960, Slotta and Gonzales 1964). CM-cellulose has also been used by Hagan, Ablondi, and DeRenzo (1960), and by Wallén *et al* (1959). DEAE-cellulose has been used by Wallén (1962 c).

The anionic exchanger DEAE-Sephadex has previously been used by Robbins and Summaria (1963) and Robbins, Summaria, Elwyn and Barlow (1965) as well as Alkjaersig (1960 and 1964). According to Robbins *et al* (1963) plasminogen was adsorbed at pH 8 to 9 in a Tris-lysine buffer with an ionic strength of 0.07 and eluted by increasing the ionic strength of the buffer to 0.17 with NaCl. The lysine in the buffer was considered essential.

In the present experiments, the eluate from the gel filtration containing plasminogen was divided into two parts. Each of them, after dialysing against 0.1 M Tris, pH 8, was chromatographed separately on the DEAE-Sephadex co

lumn The first part contained more protein than the second The plasminogen content was about the same in both A small column of Sephadex (30×70 mm) which was equilibrated with 0.1 M Tris, pH 8 was used At the application all the plasminogen and all the protein in the second part were adsorbed to the column, while some inert protein in the first part passed through

The elution was performed in two steps In the first step the plasminogen was eluted with 0.3 M Tris-HCl, pH 8 The plasminogen activity and the protein amount were almost the same in both parts The second step was performed with a salt-buffer solution of 0.5 M NaCl and 0.1 M Tris-HCl, pH 8 Only inert protein was eluted The plasminogen content in the two parts was almost the same and, consequently, all the eluate from the gel filtration containing plasminogen could be applied on the DEAE-Sephadex column in one step

In addition to being purified, the highly diluted plasminogen from the gel filtration was also concentrated by means of this procedure The final preparation contained about 100 CU/mg tyrosine and was easily soluble at physiological pH and ionic strength

The chromatography was performed without using  $\epsilon$ -aminocaproic acid or L-lysine in the buffer A small column and stepwise chromatography gave the best results and were most practical A large column and gradient elution was tried but without success The plasminogen came in several peaks The plasminogen from the experiment above was

re chromatographed on a large column and with a gradient A further separation seemed to occur, but the plasminogen activity decreased

### Additional properties of the plasminogen preparation\*

The purpose of the work described in Paper III was to develop a simple method for preparation of a plasminogen with a high solubility and a low spontaneous activity (plasmin)

The plasminogen preparation was highly soluble as pointed out before Lyophilization decreased the activity only slightly and the solubility did not change The activity of the lyophilized preparation which was stored at  $-20^{\circ}\text{C}$  did not decrease for several months However, lyophilization in some way changed the properties of the plasminogen because freeze-dried plasminogen could not be eluted from the DEAE-Sephadex at 0.3 M Tris-HCl

To obtain information about the purity of the preparation, gel electrophoresis and immunoelectrophoresis have been performed Moving boundary electrophoresis of a highly purified preparation has previously been performed by Sgouris, Inman, and McCall (1960) They identified two components The faster component constituted 75–80% of the total and was thought to represent the plasminogen Slotta *et al* (1962) found three components in Kline's plas-

\* The author is grateful to Doc Bengt Johanson Division of Clinical Chemistry, Psychiatric Research Department St. Lars Sjukhus Lund for the performance of the gel electrophoresis and immunoelectrophoresis





Fig 1 Agaroselectrophoresis of plasminogen to the left To the right the fibrin-urokinase slide which shows the lysis zone of fibrin

minogen. In their 'native' plasminogen, seven components were observed. Robbins and Summaria (1963) found the plasminogen (prepared by a modified method of Kline) to be homogenous in ultracentrifugation. But electrophoretic analysis revealed two components. Immunoelectrophoresis and gel diffusion showed one component. Two components were also found by Shulman *et al* (1958) with electrophoresis and by Hagan *et al* (1960) who used immunoelectrophoresis of rabbit antiplasminogen serum. Wallén (1962 c), in his highly purified preparation, identified two components, both containing plasminogen and moving very near each other if

starch gel electrophoresis was performed with  $\epsilon$ -aminocaproic acid acetate buffer, pH 4. A single component was seen at pH 2.1.

The plasminogen obtained by the method described in Paper III was analysed by means of agarose electrophoresis and immunoelectrophoresis against anti-human serum.

### Methods

Agarose electrophoresis was performed according to the method of Wieme (1959) with one modification. Agarose (Behringwerke) was used.



Fig 2 Immunoelectrophoresis of plasminogen against anti human serum

*Identification of plasminogen* in the agaros electrophoresis was done with slides covered with a film of agar containing fibrinogen and urokinase. These slides were prepared as follows:

1 ml plasminogen free fibrinogen (0.2%) was mixed with 0.2 ml urokinase, 100 Ploug units/ml. 0.5 ml 2% agar was added to the mixture, melted and warmed to  $+50^{\circ}\text{C}$ . 0.2 ml thrombin 10 NIH units/ml, was added to the agar. Immediately after mixing the solution was poured on glass slides of the same size as those used for electrophoresis. The slides were incubated at  $+37^{\circ}\text{C}$  for 2 hours and then stored at  $+4^{\circ}\text{C}$  until use.

When the electrophoresis was completed the plasminogen was identified by placing the fibrin urokinase slides over the electrophoresis slides and incubating for 30 minutes at  $+37^{\circ}\text{C}$ . Then the fibrin urokinase slide was removed and the fibrin was stained. A clear zone was seen where the formed plasmin had digested the fibrin.

Immunoelectrophoresis of the plasminogen was performed against anti human serum. The method of Scheidegger (1955) modified by Clausen, Dencker, and Svennerholm (1964) was used. Before application the plasminogen was concentrated three times.

The plasminogen preparation used was that obtained from DEAE Sephadex. The activity of the preparation was about 30 CU/ml.

### Result

In the agaros electrophoresis, two main components were seen (cf Fig 1). The first (a) had the same moving velocity as transferrin which was used as reference substance. The other component (b) was smaller and is scarcely reproduced in the figure. On the slide, still two trace components which could not be reproduced in the figure could be seen in front of the main component. On the fibrin urokinase slide, there was a

rather broad clearness which belonged to the main component and possibly also to the component behind this

The immunoelectrophoresis is shown in Fig. 2. Small precipitate lines can be observed in the  $\alpha$ - $\beta$  region. The lines possibly represent impurities. No attempt was made to identify the lines. Accordingly, the preparation was not

homogenous. The finding of two components in the agarose electrophoresis agrees with the results of other authors. According to the immunoelectrophoresis, there were traces of several impurities. In spite of the simplicity of the preparation method, it is comparable with the best preparations previously made as far as impurities are concerned.

## PART TWO

### Kinetic and Methodological Studies

#### IV Plasminogen assay by means of the lysis time method

The quantitative determination of plasminogen is based on the measurement of plasmin, the activated form of plasminogen. As plasmin splits not only fibrin but also some other proteins and synthetic esters, a great number of substrates have been used to determine plasmin. The most commonly used substrates have been fibrin (Loomis George, and Ryder 1949, Astrup and Mullertz 1952) casein (Remmert and Cohen 1949) and synthetic esters (Troll, Sherry, and Wachman 1954, Roberts 1958).

The common methods with fibrin as substrate are the fibrin plate method (Astrup *et al* 1952) and the methods based on clot lysis (the lysis time method).

In the commonly used lysis time method plasminogen is activated into plasmin by means of streptokinase or urokinase in a first stage. In a second stage, fibrinogen and thrombin are added and a fibrin clot is formed in the presence of plasmin. The plasmin lyses the formed fibrin, and the time for complete lysis of the clot (lysis time, T) depend on the amount of plasmin present in the clot.

Several methods in which the plasmin activity is determined by means of the lysis of a preformed clot have been described. However, the formation of the clot in the presence of plasmin is followed by a much more rapid lysis, as compared with the clot which is formed before plasmin is added.

#### Recording the end-point of the clot lysis

A visual observation of the end point of the fibrin lysis can be difficult and several methods have been worked out to increase the accuracy of the determination of the clot lysis. The test tube has been shaken to obtain air bubbles in the clot which disappear when the clot is lysed (Ambrus 1960). Glass beads have been placed on top of the clot and the time required for the beads to reach the bottom has been used as a measure of the clot lysis (Kjeldgaard and Ploug 1957 a). Determination of substances soluble in trichloroacetic acid obtained by lysis of fibrin or fibrinogen after a certain time has been used by Bergstrom and Wallen (1961), Mosesson and Fin-

lysson (1963) and Mackay (1964) Determination of the opacity of the clot has also been used (Pennel 1960) Astrup and Egeblad (1965) and Egeblad (1966) have used thrombelastography. However, direct observation of the disappearance of the fibrin is commonly used and gives a high degree of accuracy by a skilled person.

We have investigated the accuracy of the observation of the clot lysis on the part of two of our laboratory assistants who read the lysis time of ten different plasminogen amounts each of which was activated with the same urokinase amount. To avoid the influence of the decay of urokinase or plasminogen during the investigation the assistants performed the same assay approximately at the same time. The watch glasses were covered to avoid the influence of previous tests and of each other. Double determinations were made. The results are shown in Table 1.

Table 1 Lysis time assays performed by two laboratory assistants. Lysis time is expressed in seconds.

Sample	Asst. 1	Asst. 2
1	220	207 237
2	143 143	325 325
3	354 395	389 394
4	1 570	549 530
5	543 555	546 545
6	696 696	683 695
7	688 715	707 709
8	945 975	935 967
9	21 997	984 989
10	133 13	1319 1323

The standard deviation ( $s$ ) was calculated according to the formula

$$s = \sqrt{\frac{\sum (x_i - \bar{x})^2}{2n}}$$

where  $\sum (x_i - \bar{x})^2$  is the sum of the difference between each pair of duplicates and  $n$  the number of duplicates. The standard deviation was  $\pm 8.5$  sec. The lysis time of the samples varied from 200 sec to 1330 sec.

A comparison between the precision of the two laboratory assistants was made. The standard deviation of the average difference from zero was calculated according to the Student's  $t$  test

$$t = \frac{\bar{d} - 0}{S_d} \sqrt{n}$$

where  $\bar{d}$  is the average difference between the two assistants and  $S_d$  is the corresponding standard deviation,  $n$  is the number of duplicates.  $t$  was found to be 0.94. The value for  $t$  at the 5 per cent level was 2.26 at 9 degrees of freedom. Thus no significant difference between the assistants was observed.

### Activation of plasminogen

As previously pointed out the determination of plasminogen by means of a two stage assay in which the formed plasmin is incorporated into the clot involves the following reactions:

In the first stage activation of plasminogen into plasmin

In the second stage formation of fibrin from fibrinogen and degradation of the formed fibrin by means of the plasmin formed in the first stage

The activation of plasminogen into plasmin is performed as a separate reaction. Streptokinase is commonly used as activator. However, the maximal plasmin activity obtained from a certain plasminogen concentration depends on the streptokinase amount used. Besides activating plasminogen, streptokinase also inactivates the formed plasmin (Blix 1961).

The investigations presented in Paper IV verify that the maximal plasmin activity is obtained only with a certain streptokinase concentration. There is a relationship between the maximal plasmin activity and the streptokinase amount necessary to obtain this activity. If this optimal streptokinase concentration is exceeded, a lower activity is obtained.

Different forms of streptokinase-activated plasminogen have been suggested by Markus and Ambrus (1960 a) and, according to Markus and Werkheiser (1964), a small streptokinase amount activates plasminogen into plasmin enzymatically. This plasmin is later bound stoichiometrically to streptokinase in a streptokinase-plasmin complex which has a lower fibrinolytic and caseinolytic activity, but which still has maximal TAME activity. This complex also has activator activity for bovine plasminogen.

High urokinase concentrations do not inhibit plasmin. Thus urokinase ought to be preferred as activator. The plasmin activity increases with the urokinase concentration and very high concentrations are necessary to obtain maximal plasmin activity at  $+37^{\circ}\text{C}$ . In purified

systems, it is possible to obtain a higher activity with urokinase than with streptokinase.

As can be expected from an enzymatic reaction, Kjeldgaard and Ploug (1957) obtained the same final plasmin activity with various urokinase amounts if casein was present in the reaction mixture and if the reaction was performed at  $+4^{\circ}\text{C}$ . Without casein we found various levels of plasmin activity for the first 5 hours if suboptimal urokinase concentrations were used. This will be further discussed in Paper VI.

With streptokinase concentrations and with urokinase, the activation is rapid and maximal plasmin activity is obtained within the first five minutes. If longer activation times are used the inactivation will be pronounced.

### Formation of fibrin

The plasmin formed in the first stage is determined in the second stage. This stage consists of the clot formation and the clot lysis.

The formation of fibrin from fibrinogen by means of thrombin has been studied extensively in the last decade. It is assumed that four polypeptides, two fibrinopeptides A and two fibrinopeptides B, are split off by thrombin and that a polymerization is started. The various steps of the fibrinogen fibrin conversion have been studied by Blomback (1958), Blomback and Laurent (1958), Scheraga and Ehrenpreis (1958), Laki and Gladner (1964) and others. Reviews have been made by Scheraga *et al* (1958) and Laki *et al* (1964).




Fig 3 The initial velocity of fibrin formation determined by clotting time A shows the fibrin formation plotted against time for three thrombin concentrations B shows the relationship between the thrombin concentration and the clotting time

The rate of the over-all reaction of the fibrin formation might influence the reaction of the clot lysis. The fibrin formation has been studied by determining the fibrin amount at intervals. Formaldehyde was used to stop the polymerization according to a method described by Scheraga *et al* (1958). It was found that the over-all reaction of the fibrin formation at constant thrombin follows a simple, first-order reaction with respect to time. As pointed out by Scheraga *et al* (1958), however, this reaction is in fact very complicated.

A study of the fibrin formation with two different thrombin concentrations showed that the rate increased with increasing thrombin concentration. The relationship between the initial velocity and the thrombin concentration can be estimated by determining the clotting time. It can be assumed that at constant fibrinogen concentration, the same fibrin

amount is necessary to form a visible clot and that the clotting time will depend on the thrombin concentration. If the fibrinogen concentration is not too low, the clotting time expresses the initial velocity which is schematically shown in Fig 3 A.

$$v = \frac{Fc}{Tc} \quad (1)$$

where  $v$  is the initial velocity and  $Fc$  is the fibrin concentration at the clotting time ( $Tc$ ). If the clotting time is plotted against the thrombin concentration, the middle of the curve approximately follows the equation (Seegers 1962)

$$\frac{Fc}{Tc} = kE \quad (2)$$

where  $E$  is the thrombin concentration and  $k$  the rate constant. On a log x log graph, a straight line is obtained which is schematically shown in Fig 3 B. In




Fig 4 The initial velocity of fibrinolysis determined by the lysis time A shows how the initial fibrin degradation is proportional to the lysis time B shows the relationship between lysis time and plasmin concentration

this range of thrombin concentrations, the rate of fibrin formation will be

$$\frac{dF}{dt} = v = \frac{F_c}{T_c} = kE \quad (3)$$

Thus, the formation approximately follows a first-order reaction with respect to thrombin. At higher thrombin concentrations, a deviation from this simple equation is seen (Seegers 1962). However, if a high thrombin concentration is used, this reaction is so rapid that the reaction is of little importance for the over all reaction which is pointed out below

### Lysis of the fibrin

The formed plasmin lyses the fibrin clot and the time for complete lysis depends on the plasmin amount. The rate of the spontaneous disappearance of fibrin formed from plasma has been

studied by Fernley (1960) and in a purified system by Pennel (1960). Both determined the opacity of the clot. The disappearance was not linear. After liquefaction of the fibrin, lowering of the temperature to stop the reaction, and precipitation, Mosesson and Finlayson (1963) found that the increase in absorbance of light at 280 mμ of the supernatant fluid was linear with time until about 10% of the initial clottable protein remained. This is in accordance with our findings with respect to the release of perchloric acid soluble substances from lysis of a fibrin clot, which was determined by means of increase of absorbance at 280 mμ. There was a linear relationship with time which continued after the clot was lysed. The decrease in the fibrin amount in the clot was also studied by measuring the amount of remaining fibrin at intervals. To avoid degradation of the fibrin



during the determination, the reaction was stopped with formaldehyde. A control experiment was performed which showed that formaldehyde added to the clot immediately stopped the action of plasmin.  $\epsilon$ -aminocaproic acid was also tried but without success. The decrease in fibrin was found to be approximately linear with respect to time and, accordingly, of zero order.

### The over-all reaction

The over-all reaction of the formation and the degradation of fibrin is the result of two consecutive reactions. The formation follows a first order reaction while the degradation follows a zero-order reaction with respect to time. The equation of the over-all reaction at constant thrombin and plasmin will be

$$F = F_0 (1 - e^{-k_1 E t}) - k_2 P t \quad (\text{IV } 6)$$

where  $F$  is the fibrin amount at the time  $t$ ,  $F_0$  is the initial fibrinogen concentration,  $E$  is thrombin, and  $P$  is plasmin.  $k_1$  and  $k_2$  are rate constants. If the thrombin concentration is high, the coagulation will be rapid and  $e^{-k_1 E t}$  will be negligible. Thus the equation for the over-all reaction will be

$$F = F_0 - k_2 P t \quad (\text{IV } 7)$$

The course of the over-all reaction has been studied in an experiment in which a high and a low thrombin concentration were used. With the high thrombin concentration, practically the whole course of the reaction followed the zero order. However, the lysis time was almost the same with the low as with the

high thrombin concentration. This was not expected. The cause was possibly that, besides a fibrinolysis, a fibrinogenolysis occurred which had approximately the same rate.

### The relationship between the lysis time and the plasmin concentration

The relationship between the initial reaction rate of the fibrinolysis and the plasmin concentrations can be obtained by determining the lysis time at various plasmin concentrations which is schematically shown in Fig. 4. If the degradation is of zero order with respect to time and a high thrombin concentration is used, the over-all reaction follows equation (IV 7). The initial reaction rate ( $v$ ) is (Fig. 4)

$$-v = -\frac{dF}{dt} = -\frac{F_0}{T} \quad (4)$$

where  $F_0$  is the initial fibrinogen concentration and  $T$  the lysis time. The relationship between the lysis time ( $T$ ) and the plasmin concentration ( $P$ ) has experimentally been shown to be

$$\frac{1}{T} = \frac{kP}{F_0} \quad (\text{IV } 8)$$

within a certain region. Accordingly

$$-v = -\frac{dF}{dt} = kP \quad (5)$$

The rate of fibrin lysis is proportional to the plasmin concentration.

Kjeldgaard and Ploug (1957 b) found a linear relationship between the inverse of the lysis time and the plasmin concentration. Astrup and Egeblad (1965) found a linear relationship between the

lysis time and the plasmin concentration in the log x log scale. The slope of the line was about -1.5. Thrombelastography was used to determine the lysis time.

In the present experiments, there was an inverse proportionality between the plasmin concentration (P) and the lysis time (T) according to the equation

$$T = \frac{F_0}{k} \cdot \frac{1}{P} \quad (\text{IV } 8)$$

or

$$\log T = -\log P + \log \frac{F_0}{k}, \quad (\text{IV } 9)$$

The logarithmic form of this equation shows that there is a linear relationship between log of the lysis time and log of the plasmin concentration. The slope of the line is -1. This relationship is valid only within a certain part of the line. At high plasmin concentrations, the lysis of the clot is difficult to observe accurately. At low plasmin concentrations, an inactivation occurs which increases the lysis time. If inactivation occurs, the slope will be greater than -1, which is seen for instance if the streptokinase concentrations are too high. If activation occurs, the slope will be less than -1 which is shown in Paper VII.

The findings of Astrup *et al* (1965) are difficult to compare with our results as thrombelastography and direct observation of lysis are very different methods.

#### Significance of the fibrin concentration

According to equation (IV 8) the lysis time is proportional to the fibrino-

gen concentration while, according to equation (IV 9), the fibrin concentration ( $F_0$ ) determines the distance of the line from origin. At constant plasmin the lysis time increases linearly with the fibrinogen concentration. Thus, smaller plasminogen amounts can be determined with greater accuracy when a low fibrinogen concentration is used. The concentration, however, cannot be lower than 0.04 %, otherwise the clot will be so tiny that observation of the lysis will be difficult.

#### The assay

As previously mentioned, the assay is performed as a two stage method. In the first stage the plasminogen is activated with either streptokinase or urokinase. If streptokinase is used, an optimal concentration giving maximal activation must be found.

After maximal activation, thrombin and fibrinogen are added. The thrombin is added first to avoid fibrinogenolysis. A high thrombin concentration and a low fibrinogen concentration are used. The lysis time is recorded and the plasmin concentration is read from a standard curve.

The standard curve of the assay is easy to construct as the slope of the curve is -1 if log of the lysis time is plotted against log of the plasmin concentration. It is sufficient to know one plasmin concentration and its lysis time. As casein units are most commonly used the plasminogen concentrations are expressed in these units.

In conclusion, it can be said

Direct observation of the clot lysis can be performed with great accuracy by trained persons. There is an inverse proportionality between the lysis time and the plasmin concentration. The standard curve is easy to construct as the slope is  $-1$  in the  $\log \times \log$  scale. This relationship is valid only within a certain range of plasminogen concentrations. The fibrinogen concentration is an important factor. Low concentrations

give shorter lysis time and higher sensitivity.

If streptokinase is used as activator, there is a certain relationship between the plasminogen concentration and the optimal streptokinase concentration. Inactivation occurs if this optimal concentration is exceeded. Urokinase gives a slightly higher activity while high concentrations do not inactivate the plasmin formed.

#### V A method to correct for the continuing activation during the second stage in a two-stage assay. Exemplified by urokinase activation of plasminogen determined by the lysis time method

The common principle to determine the total amount of an inactive precursor of an enzyme by means of a two-stage method is to completely activate the precursor in the first stage and then determine the activated enzyme in the second stage. Plasminogen, e.g., is completely activated by urokinase or streptokinase in a first stage. Then the plasmin formed is determined in a second stage as described in Paper IV.

However, it is difficult to follow the course of a reaction by this method. In many of the quantitative two-stage methods used in coagulation and fibrinolysis, all the reacting substances are proteins and there are no simple methods to stop the reaction in the first stage without inactivating the product formed or the substrate left. It is difficult, e.g., to follow the course of the urokinase activation of plasminogen into plasmin by means of the lysis time method. If determination of the plasmin formed is

performed before complete activation, the reaction will continue in the second stage during lysis of the fibrin clot. Thus, both the plasmin formed in the first stage and that formed in the second stage are recorded during the determination.

If the data obtained from a kinetic study of a reaction are plotted according to the usual formulae for different orders of reactions, there will be a deviation from the usual graphs and the amount of product at any time cannot be calculated. With respect to fibrinolysis, attempts have been made to stop the reaction before the determination. In activation experiments with urokinase and plasminogen, Alkjaersig, Fletcher, and Sherry (1958) stopped the reaction by precipitating the formed plasmin with 1 M NaCl. The urokinase remained in the supernatant. This method was unsuccessful in the present experiments. The reason for this may be that the

above authors used plasminogen prepared according to a modified method of Kline (1953), which possibly is denaturated and has other physical properties. With the plasminogen prepared according to our method (cf. Paper III) the plasmin was inactivated.

According to Kjeldgaard and Ploug (1957) 'fast methods such as the lysis time method' minimize the activation during the determination. However, it is clearly shown in the experiment described in Paper V, which deals with urokinase activation of plasminogen, that a considerable activation occurs during the determination.

The formulae calculated in Paper V take into account the activation which continues during the determination. Thus, it is not necessary to stop the reaction. If the reaction follows any of the different orders given in Paper V, it is possible to calculate the plasmin amount formed until the moment the determination is started. No such method has previously been described, at least not with in the fields of coagulation and fibrinolysis.

### The mathematical procedure

To simplify the calculation, it is assumed that the reaction follows the same order in the first stage as in the second stage. Certainly this may not always be the case. The rate equation during the determination in the second stage may be more complicated. However, if the determination does not last too long the error will be minimal if the

reaction is approximated to the same order within both stages.

The mathematical development has been based on the urokinase activation of plasminogen. The rate equation was integrated within two intervals: first, from zero incubation time until the determination was started (the first stage); secondly, during the determination (the second stage). The first equation is substituted in the second and the following equation is obtained:

$$\ln P_m - \ln (P_m - P_T) = k_1 U t + k_2 U T \quad (V 5)$$

where  $P_m$  is the maximal plasmin activity and  $P_T$  is the recorded activity;  $t$  is the reaction time and  $T$  the duration of the determination = lysis time.  $U$  is the urokinase concentration,  $k_1$  is the rate constant of the reaction in the first stage and  $k_2$  is the rate constant in the second stage. The presence of the clot in the second stage will change the rate constant. This has also been shown experimentally. An expression for the rate constant ( $k_2$ ) in the second stage is obtained from equation (V 5) if the incubation time is zero:

$$k_2 = \frac{\ln P_m - \ln (P_m - P_{t_0})}{U T_{t_0}} \quad (V 7)$$

where  $T_{t_0}$  is the duration of the second stage (lysis time) at zero incubation time.  $P_{t_0}$  is the recorded data at  $t = 0$ . In practice this is performed by doing the test as a one-stage assay. When this is done, the activation proceeds only during the determination (second stage).

If  $k_2$  is substituted in equation (V 5), the formula for a first-order reaction will be obtained.

## The formulae

Formulae have been calculated for reactions of first, second and zero order reactions. The formula for a first order reaction has the following form

$$-\ln \left(1 - \frac{P_t}{P_m}\right) = -\ln \left(1 - \frac{P_t}{P_m} + \frac{T}{T_m} \ln \left(1 - \frac{P_m}{P_m}\right)\right) = k_1 U t = A \quad (V 9)$$

where  $P_t$  is the activity at the time  $t$  when the second stage is started and  $P_T$  is the activity recorded when the reaction in the first stage has proceeded for the time  $t$ .  $T$  is the duration of the determination in the second stage (lysis time).  $P_{10}$  is the activity recorded at zero incubation time and  $T_{10}$  is the duration of the determination when the determination is done at zero incubation time, i.e. when the whole reaction proceeds only during the determination or when a one-stage assay is performed  $k_1$  is the rate constant.

If a second-order reaction goes according to the stoichiometric formula



the formula is

$$\ln \frac{(b - x_t) a}{(a - x_t) b} = \ln \frac{(b - x_T) a}{(a - x_T) b} - \frac{T}{T_{10}} \ln \frac{(b - x_{10}) a}{(a - x_{10}) b} = k(b - a) t = A \quad (V 14)$$

$x_t$  is the activity of the product obtained at the time  $t$  and  $x_T$  the activity recorded.  $x_T$  also contains the activity

formed during the determination.  $x_{10}$  is the activity recorded at zero incubation time.  $a$  and  $b$  are the maximal activities.

For a zero-order reaction the following formula is obtained

$$a_t = x_T - \frac{T}{T_m} a_{10} = kt \quad (V 16)$$

In principle, all the formulae have the same form. They consist of the difference of two expressions. The first is the usual formulae containing the recorded data. The second expression is a correction factor containing the data recorded at zero incubation time multiplied by the ratio of the duration of the determination at the time  $t$  and the duration at zero incubation time.

If the expression for a first order reaction is called  $A$  according to equation (V 9)

$$-\ln \left(1 - \frac{P_t}{P_m}\right) = A \quad (V 9)$$

the activity at the moment the determination starts ( $P_t$ ) can be calculated according to the following equation

$$P_t = P_m (1 - e^{-A}) \quad (V 10)$$

At zero incubation time  $P = P_{10}$  and  $T = T_{10}$  which substituted in equation (V 9) gives  $A = 0$  and then  $P_t = 0$ . If the reaction approaches completion,  $A \rightarrow -\infty$  and then  $P_t \rightarrow P_m$ . The other formulae can be analysed in a corresponding manner.

## The use of the formulae in fibrinolysis

If plasminogen is activated with urokinase and the plasmin formed is deter-

mined by means of the lysis time method, the relationship between the plasmin activity and the lysis time is expressed by the following equation

$$P = \frac{F}{k_3 T} \quad (\text{IV } 8)$$

where  $P$  is the plasmin activity,  $F$  the fibrinogen,  $T$  the lysis time and  $k_3$  the rate constant. If the various plasmin activities are expressed by means of their lysis time and substituted in (V 9) the following equation is obtained

$$-\ln \left(1 - \frac{T_m}{T_t}\right) = -\ln \left(1 - \frac{T_m}{T}\right) + \frac{T}{T_{10}} \ln \left(1 - \frac{T_m}{T_{10}}\right) = k_1 U t = A \quad (\text{V } 12)$$

where  $T$  is the lysis time recorded after the incubation time  $t$  and  $T_t$  is the lysis time if the reaction could be stopped at this moment.  $T_m$  is the lysis time of maximal activity obtained with the urokinase  $U$ .

If the reaction follows a first-order reaction with respect to time a straight line from origin will be seen if  $A$  is plotted against time. The slope of the line is the rate constant multiplied by the urokinase concentration (VI).

The plasmin activity at the time the determination is started can be calculated according to the formula

$$\frac{1}{T_t} = \frac{1 - e^{-A}}{T_m} \quad (\text{V } 13)$$

or expressed as  $P_t$

$$P_t = \frac{F(1 - e^{-A})}{k_3 T_m}$$

## Experimental verification

An experiment in which plasminogen was activated with urokinase in a first stage was performed. At time intervals, aliquots were taken from the reaction mixture and the plasmin formed was determined by means of the lysis time method in a second stage. The activation was performed at  $+15^\circ \text{C}$  at which temperature the inactivation is minimal. The determination of the plasmin formed was done at  $+37^\circ \text{C}$ . If the recorded data are plotted against the reaction time, the curve does not start at origin. As early as at zero incubation time, there is a fibrinolytic activity which represents the activation during the determination in the second stage. If the recorded data, corrected according to formula (V 13), are plotted in the same manner the curve starts at origin. The two curves approach each other and join at the maximal activity (Fig. V 1). If  $A$  is calculated according to the formula above and is plotted against the reaction time, a straight line is obtained which indicates a first-order reaction with respect to time (Fig. V 2).

### The rate constant

The rate constant ( $k_1$ ) before and during the determination ( $k_2$ ) is not the same. This has been shown experimentally. An expression for  $k_2$  was obtained from equation (V 7) which can be written

$$\ln \frac{P_m}{P_m - P_{10}} = k_2 U T_{10}$$

or if the lysis time is substituted

$$-\ln \left(1 - \frac{T_m}{T_{t0}}\right) = k_2 UT_{t0} \quad (\text{V } 18)$$

Various plasminogen amounts were activated with a fixed amount of urokinase. Then the plasmin activity was determined by means of the lysis time method at zero incubation time, i.e., the test was performed as a one-stage assay.

If  $-\ln \left(1 - \frac{T_m}{T_{t0}}\right)$  was plotted against  $T_{t0}$ , a straight line was obtained. The slope of the line was an expression for the rate constant of the reaction during the determination ( $k_2$ ).

The rate constant of the reaction before the determination was started could be obtained from the formula for A (V 12) which, plotted against the reaction time, gave a straight line. The slope of the line was an expression for the rate constant ( $k_1$ ). These two lines had different slopes. The temperature was the same in both experiments. One cause of the difference between the two constants is probably the presence of a fibrin network which impedes the collision of the plasminogen and activator molecules.

## VI Urokinase activation of plasminogen and spontaneous inactivation of the formed plasmin. A kinetic study

The urokinase activation of plasminogen has previously been found to follow a first-order enzymatic reaction (Sgouris, Taylor, and McCall 1956, Sherry and Alkjaersig 1956, Alkjaersig, Fletcher, and Sherry 1958, Kjeldgaard and Ploug 1957). Plasmin was found to be highly labile and the activation was performed in the presence of casein (Kjeldgaard *et al.* 1957) which protects plasmin from inactivation (Kline 1954). Alkjaersig *et al.* (1958) found that glycerol, too, protected plasmin from inactivation. Thus, glycerol was used in their experiment with trypsin activation of plasminogen. However, the urokinase activation was performed without glycerol because the activation time was so short that minimal inactivation was presumed to take place.

When log of the plasmin activities was plotted against time according to a first-order reaction, Kjeldgaard and Ploug

(1957) found that the slopes of the lines were proportional to the urokinase concentrations. Alkjaersig *et al.* (1958) found a linear relationship between the initial reaction velocity and the urokinase concentration. A first-order activation kinetics was demonstrated over a wide range of initial plasminogen concentrations. If the initial velocities were plotted according to Lineweaver and Burk (1934), a straight line which did not pass through origin was obtained, indicating an enzyme reaction. The plasmin activity was determined by means of a caseinolytic assay after stopping the reaction by means of precipitation with 1 M NaCl.

Kjeldgaard and Ploug (1957) found the same final activity if a constant plasminogen was activated with various urokinase concentrations, also indicating an enzymatic reaction. The activation had to be performed in the presence of a

casein concentration as high as 2.5% and at a temperature between  $\pm 0^\circ$  and  $+4^\circ$  C. The activation was continued for 60 hours. If the casein concentration was lower, the same level was not obtained with the different urokinase concentrations. Sgouris, Taylor, and McCall (1956) also obtained the same activity if the activation was performed at a temperature between  $\pm 0^\circ$  and  $+2^\circ$  C without casein. The final level was not reached until 39 days for the lowest urokinase concentration.

Paper VI shows that, after the first hour, different activity levels which are approximately constant in the next 4 hours are obtained. These levels are proportional to the urokinase concentration.

The formed plasmin is sensitive to higher temperatures as inactivation occurs. Then the overall reaction rate is the difference between the rate of activation and of inactivation.

### The activation rate

In the investigations described in Paper VI, various plasminogen amounts were activated with a fixed amount of urokinase. These activation studies form the basis for the urokinase determination method which is performed at  $+37^\circ$  C (VII). This is the reason why activation has been performed at this temperature although an inactivation which causes a deviation from the first order occurs. However, the influence of the inactivation in the initial part of the reaction is minimal.

The activity of the plasmin formed was determined by means of the lysis

time method (IV) and expressed as the reverse of lysis time. The data recorded were corrected for activation of plasminogen during the determination according to the method described in paper V. There was a constant error owing to the use of  $\frac{1}{T_m}$  in the formula. Because of

the inactivation  $\frac{1}{T_m}$  was lower than the maximal activity. However,  $\frac{1}{T_m}$  was

proportional to the plasminogen concentration. Thus, the relationship between the initial velocities was not influenced. Proportionality was found between the initial reaction rate and the plasminogen concentration which is in agreement with the findings of Kjeldgaard *et al* (1957) and Alkjaersig *et al* (1958).

In an enzymatic reaction, the relationship between the initial velocity and the substrate concentration follows a hyperbolic function. At low substrate concentrations the function is approximately rectilinear. At high substrate concentrations, the velocity slows up and approaches a level value, the maximal velocity. This maximal velocity could not be obtained with the urokinase concentration used in this experiment. When the plasminogen concentration was increased further, the plasmin activity became too high to be determined with the lysis time method. When the urokinase concentration was lowered to one Ploung unit/ml a maximal velocity was obtained with 30 CU/ml. Kjeldgaard and Ploung (1957) and Alkjaersig *et al* (1958) could not obtain maximal velocity with the



high urokinase concentration they used in their experiment. The low solubility of their plasminogen also made the use of such high concentrations impossible.

With respect to the substrate, the activation thus followed a first-order reaction only within a certain range of plasminogen concentrations. At high concentrations, a maximal velocity was reached according to an enzymatic reaction following Michaelis-Menten's principle.

If a fixed plasminogen amount was activated with various urokinase concentrations the initial velocity was proportional to the urokinase concentration within a wide range of concentrations. Thus, the initial rate was of a first order with respect to urokinase which is in agreement with the findings of Kjeldgaard and Ploug (1957) and Alkjaersig *et al.* (1958). When the time course of the reaction was plotted according to a first-order reaction straight lines were obtained and the slopes of the lines were proportional to the urokinase concentrations which also is in agreement with the findings of Kjeldgaard and Ploug.

### The maximal activity

In an enzymatic reaction, the final level of product is independent of the amount of enzyme. According to this, Kjeldgaard and Ploug (1957) found that the plasmin level was independent of the urokinase concentration in the presence of casein. This is in agreement with the findings of Sgouris *et al.* (1956) who did not use protective agents but who performed the activation at still lower tem-

peratures ( $\pm 0^\circ$  to  $+2^\circ$  C). The final levels were reached after several days.

In the present work an experiment is described in which a fixed plasminogen amount was activated with various urokinase concentrations. The activation was performed at  $+4^\circ$  C. Despite this low temperature different activity levels were obtained already in the first hour. During the next 4 hours the levels changed very little. A slow activity increase was seen, however, but still after 4 days different activity levels were observed. Thus, the main part of the activation took place during the first hour, and different activity levels which were proportional to the urokinase amount were obtained. The cause of these different activity levels seen in the experiment described is not known. At  $+4^\circ$  C the inactivation is minimal. At higher temperatures than  $+4^\circ$  C an inactivation occurs which causes an equilibrium between activation and inactivation. An expression for this equilibrium can be obtained from the rate equation for the over-all reaction of activation and inactivation (VI.7)

$$\frac{dB}{dt} + k_2 B = k_1 U P_m e^{-k_3 U t}$$

where B is the plasmin activity at the time t, U is the urokinase concentration and  $P_m$  the maximal activity if no inactivation occurs.  $k_1$  and  $k_2$  are rate constants. The maximal activity can be

obtained by setting  $\frac{dB}{dt} = 0$ . Then

$$B_{max} = \frac{k_1 U e^{-k_3 U t_{max}}}{k_2} P_m$$

Accordingly, at constant plasminogen ( $P_m$ ),  $B_{max}$  is dependent on the urokinase concentration ( $U$ ) and the expression  $e^{k_1 t} \max$  in which  $t_{max}$  is the time it takes for the maximal activity to be reached. If  $t_{max}$  decreases at the same proportion as  $U$  increases this expression will be constant and the maximal activity will depend on the urokinase concentration.

### The influence of the temperature on the rate

The activation at different temperatures shows the typical behaviour of an enzymatic reaction. The rate increases to a maximum, in this case at  $+42^\circ\text{C}$ , then it rapidly decreases.

### The rate equation

The rate of the urokinase activation of plasminogen is in accordance with Michaelis-Menten's principle. Thus there is a proportionality both between the initial velocity and the enzyme concentration (urokinase) and between the initial velocity and the substrate concentration (plasminogen) at low substrate concentrations. With respect to plasminogen, this is in accordance with a first order reaction. At high plasminogen concentrations the reaction follows a zero order.

As pointed out before, the reaction does not go to completion at least not during the first five hours. Different activity levels proportional to the urokinase concentration are obtained if a fixed plasminogen amount is activated

with various urokinase concentrations.

If a low plasminogen concentration is used and if the influence of the inactivation is disregarded the enzymatic equation can be approximated to a first-order reaction with respect to time. Thus, it can be written

$$-\ln\left(1 - \frac{P}{P_m}\right) = Ukt$$

where  $P_m$  is the maximal activity obtained with the urokinase  $U$ ,  $P$  the activity of plasmin at the time  $t$ , and  $k$  the rate constant.

### The inactivation of the formed plasmin

A mathematical model for the kinetics of the inactivation of enzymes has been set up by Reiner (1959). The kinetics of the inactivation of several enzymes has been investigated (Laidler 1958). The rate of the spontaneous inactivation of plasmin however, has not been studied previously.

In the present work, it is shown that the inactivation is enhanced by increasing temperatures. Between  $+4^\circ\text{C}$  and  $+15^\circ\text{C}$  the inactivation is negligible during the first 4 hours but at higher temperatures the inactivation increases rapidly.

The time course of the inactivation was studied at  $+37^\circ\text{C}$ . With the plasminogen concentration and conditions used in the experiment the inactivation followed approximately a first-order reaction with respect to time. However, there was a deviation from the first order during the later part of the reaction. With increasing time, the inactivation

tion slowed up, possibly because the denaturated plasmin protected the residual plasmin

### The over-all reaction of activation and inactivation

If plasminogen is activated with urokinase at  $+37^{\circ}\text{C}$ , the formed plasmin will simultaneously be inactivated. If the plasminogen concentrations are not too high the activation will follow a first-order reaction with respect to time as pointed out before. The time course of the inactivation of the formed plasmin will also approximately follow a first order. Thus, the rate equation of the over-all reaction will be a differential equation equal to the sum of these two rates and the plasmin amount at the time  $t$  can be found by integrating the

rate equations according to the method of Lagrange (Sjostrand 1961)

$$B = \frac{k_1 U}{k_2 - k_1 U} P_m (e^{-k_1 U t} - e^{-k_2 t})$$

where  $B$  is the plasmin amount at the time  $t$ ,  $U$  is the urokinase amount and  $P_m$  is the maximal plasmin activity obtained by performing the activation at  $+4^{\circ}\text{C}$ .  $k_1$  is the rate constant of the activation and  $k_2$  the rate constant of the inactivation.

An experiment which showed that the data obtained nearly followed a theoretical curve calculated according to the equation was performed.

The inactivation was minimal during the initial part of the over-all reaction. Thus, a one stage method is preferable for the determination of urokinase activity.

## VII Theoretical basis and standardization of the one-stage lysis time method for determination of urokinase

Various methods have been used to determine urokinase. Celander and Guest (1955, 1960) and Kjeldgaard and Ploug (1957 a) used the one-stage lysis time method. The fibrin plate method according to Astrup and Mullertz (1952) has also been widely used. A casein method has been used by von Kaulla (1963) to determine urokinase in urine.

The theoretical development and practical performance of a quantitative determination of urokinase in a purified system by means of the lysis time method are described in Paper VII.

### Theory and development of a formula for a one-stage assay

The method is based on the studies of urokinase activation of plasminogen described in Paper VI. As pointed out in this work, the urokinase activation of plasminogen follows a first-order reaction if the plasminogen concentration is not too high, otherwise the reaction follows a zero order.

According to the findings reported in Paper VI it is desirable to use the initial part of the reaction during which the inactivation of the formed plasmin is mi-

nimal Therefore, it was decided to use a one stage lysis time method in which the activation of plasminogen proceeds within the clot It was also presumed that the activation, at least during the initial part of the reaction when the inactivation is negligible, follows the first-order equation

$$\frac{dP}{dt} = k_1 U (P_m - P) \quad (\text{VII } 1)$$

where  $P$  is the formed plasmin and  $P_m$  is the maximal activity obtained with the urokinase concentration  $U$  which is assumed to be constant during the reaction  $k_1$  is the rate constant and  $t$  is the reaction time Integration gives

$$-\ln(1 - \frac{P}{P_m}) = k_1 U t \quad (\text{VII } 2)$$

$-\ln(1 - \frac{P}{P_m})$  can be expressed as a series

$$\frac{P}{P_m} + \frac{1}{2} \left( \frac{P}{P_m} \right)^2 + \frac{1}{3} \left( \frac{P}{P_m} \right)^3 + \dots$$

If  $\frac{P}{P_m}$  is small the series can be approximated to the first term, which substituted in the equation above gives

$$\frac{P}{P_m} = k_1 U t \quad (\text{VII } 4)$$

If the lysis time

$$t = T$$

and the expression for  $P$  (Paper IV)

$$P = \frac{F}{V_3 T} \quad (\text{IV } 8)$$

in which  $F$  is the fibrinogen concentration and  $k_1$  the rate constant, are substituted

in equation (VII 4) and the logarithmic form is used, the following expression is obtained

$$\log T = -\frac{1}{2} \log U - \frac{1}{2} \log P_m + \frac{1}{2} \log \frac{F}{k_1} \quad (\text{VII } 7)$$

Because equation (VII 1) was developed on the assumption that the urokinase concentration was constant, the above expression is a solution of equation (VII 2) Consequently, all the terms on the right side are constants and the expression tells us that with these urokinase, plasminogen, and fibrinogen concentrations the lysis time is  $T$

#### Experimental verification of the formula

The possibility to use the expression above as a formula for a one-stage assay of urokinase has been investigated experimentally The range of urokinase, plasminogen, and fibrinogen concentrations where the relationship expressed by formula (VII 7) is valid has also been found experimentally

It has been shown in Paper VI that there is a proportionality between the urokinase concentration and the initial velocity of plasmin formation If the formed plasmin ( $P$ ) is small compared with the maximal activity ( $P_m$ ), the reaction takes place within the initial velocity range and the relationship between lysis time ( $T$ ) and urokinase ( $U$ ), according to formula (VII 7) is valid However, if the urokinase ( $U$ ) is varied

the maximal plasmin activity ( $P_m$ ) will also vary even with constant plasminogen because the maximal activity ( $P_m$ ) depends on the urokinase amount as well as on the plasminogen amount

The expression (VII 7) can be used as an equation if a straight line with the slope  $-0.5$  is obtained when  $\log$  of the lysis time plotted against  $\log$  of the urokinase concentration at constant plasminogen and fibrinogen. This has been verified experimentally. Thus, the expression (VII 7) can be used as a formula for the urokinase assay within the range of the urokinase concentration used.

Astrup and Egeblad (1965) and Egeblad (1966) found a characteristic difference between the clot lysis produced by preformed plasmin and that produced by plasminogen activators in a one-stage assay. They also found a linear relationship if  $\log$  of the lysis time was plotted against  $\log$  of the urokinase concentration. The slope of the line was about  $-0.5$ . Their lysis time was read from a thrombelastogram. Celander and Guest (1960) used a one-stage method for the determination of urokinase. A slope of  $-0.6$  was obtained from their figure.

#### The influence of various plasminogen concentrations

It has to be emphasized that the slope  $-0.5$  is an approximation which will be valid only within a certain range of urokinase and plasminogen concentrations because the series transformation of the equation (VII 2) was made on

the presumption that the ratio plasmin/maximal plasmin activity ( $P/P_m$ ) was small. Therefore, it is necessary to use a high plasminogen concentration, but not so high that the reaction follows a zero order.

According to formula (VII 7), a straight line with the slope  $-0.5$  should also be obtained if the maximal plasmin activity ( $P_m$ ) is varied.  $P_m$  is proportional to the plasminogen concentration if the urokinase amount is constant.

An experiment which verifies the validity of the equation for plasminogen concentrations between 1 CU and 10 CU is presented in the present work. At lower plasminogen concentrations, there will be a deviation from the straight line. This may be caused by inactivation of the formed plasmin because of a long lysis time, or that the quotient  $\frac{P}{P_m}$  is so small that the approximation is not valid. Higher plasminogen concentrations than 10 CU have not been investigated.

#### The influence of the fibrinogen concentration

If the formula (VII 7) is written

$$\log T = -\frac{1}{2} \log U + \frac{1}{2} \log \frac{F}{k k_3 P_m}$$

it is evident that the last term denotes the distance of the curve from origin. If the maximal plasmin amount ( $P_m$ ) is constant, the distance will depend on the fibrinogen concentration ( $F$ ). With low fibrinogen concentrations, the line will be nearer to origin and a shorter lysis

time will be obtained. Thus the low fibrinogen concentrations increase the sensitivity of the method. This can also be shown by plotting  $\log F$  against  $\log T$ . A straight line with the slope  $+0.5$  will be obtained. This is verified experimentally.

### The method

If the plasminogen, urokinase, and fibrinogen concentration ranges mentioned above are used, a practical method to determine urokinase in a system with purified components will be obtained.

The determination is performed by means of a one-stage assay. Equal volumes of plasminogen, thrombin, urokinase, and fibrinogen are added in the order mentioned to minimize the fibrinogenolysis. The urokinase and the fibrinogen should be added almost at the same time to obtain a real one-stage assay. The volume of each component is

usually 0.1 or 0.2 ml. The temperature is  $+37^{\circ}\text{C}$  and the pH is 7.4. The lysis time of the formed clot is recorded and the urokinase concentration is read from a standard curve.

The standard curve can be constructed easily as the slope is  $-0.5$ . The curve is standardized with urokinase of known concentration. A one-stage lysis time assay is performed with a known urokinase concentration. The lysis time obtained is plotted against the urokinase concentration on a  $\log \times \log$  paper. Through this point, a straight line with the slope  $-0.5$  is drawn.

It is not necessary to know the exact plasminogen concentration but concentrations close to 5 CU/ml should be used. As previously pointed out, a low fibrinogen concentration increases the sensibility of the test. A concentration of 0.05% gives high sensitivity. With this low fibrinogen concentration, the lysis of the clot can still be observed with good accuracy if a high thrombin concentration is used.

the maximal plasmin activity ( $P_m$ ) will also vary even with constant plasminogen because the maximal activity ( $P_m$ ) depends on the urokinase amount as well as on the plasminogen amount

The expression (VII 7) can be used as an equation if a straight line with the slope  $-0.5$  is obtained when  $\log$  of the lysis time plotted against  $\log$  of the urokinase concentration at constant plasminogen and fibrinogen. This has been verified experimentally. Thus, the expression (VII 7) can be used as a formula for the urokinase assay within the range of the urokinase concentration used.

Astrup and Egeblad (1969) and Egeblad (1966) found a characteristic difference between the clot lysis produced by preformed plasmin and that produced by plasminogen activators in a one-stage assay. They also found a linear relationship if  $\log$  of the lysis time was plotted against  $\log$  of the urokinase concentration. The slope of the line was about  $-0.5$ . Their lysis time was read from a thrombelastogram. Celander and Guest (1960) used a one-stage method for the determination of urokinase. A slope of  $-0.6$  is obtained from their figure.

#### The influence of various plasminogen concentrations

It has to be emphasized that the slope  $-0.5$  is an approximation which will be valid only within a certain range of urokinase and plasminogen concentrations, because the series transformation of the equation (VII 2) was made on

the presumption that the ratio plasmin/maximal plasmin activity ( $P/P_m$ ) was small. Therefore, it is necessary to use a high plasminogen concentration, but not so high that the reaction follows a zero order.

According to formula (VII 7), a straight line with the slope  $-0.5$  should also be obtained if the maximal plasmin activity ( $P_m$ ) is varied.  $P_m$  is proportional to the plasminogen concentration if the urokinase amount is constant.

An experiment which verifies the validity of the equation for plasminogen concentrations between 1 CU and 10 CU is presented in the present work. At lower plasminogen concentrations, there will be a deviation from the straight line. This may be caused by inactivation of the formed plasmin because of a long lysis time, or that the quotient  $\frac{P}{P_m}$  is so small that the approximation is not valid. Higher plasminogen concentrations than 10 CU have not been investigated.

#### The influence of the fibrinogen concentration

If the formula (VII 7) is written

$$\log T = -\frac{1}{2} \log U + \frac{1}{2} \log \frac{F}{k_2 k_3 P_m}$$

it is evident that the last term denotes the distance of the curve from origin. If the maximal plasmin amount ( $P_m$ ) is constant, the distance will depend on the fibrinogen concentration ( $F$ ). With low fibrinogen concentrations, the line will be nearer to origin and a shorter lysis

mately follows a first-order reaction with respect to time. Consequently, the over-all reaction can be approximated to two consecutive first-order reactions.

2. that in a one-stage system in which plasminogen is activated into plasmin simultaneously with the formation and lysis of a fibrin clot, there is a rectilinear function in a log x

log system between the urokinase concentration and the lysis time of the fibrin clot. This function is an approximation applicable only within a certain concentration range. The slope of the curve is  $-0.5$ .

13. that the relationship between the urokinase concentration and the lysis time can be used in a quantitative urokinase assay.



## Acknowledgements

These investigations were carried out at the Coagulation Laboratory of Medical Department II, Sahlgrenska Hospital, Göteborg

I wish to express my sincere gratitude to the Head of the Department, Professor Erik Wassén, for making it possible for me to perform these investigations and for his keen interest, very valuable criticism, and encouraging support

I am also greatly indebted to Med dr Kristoffer Korsan-Bengtson, who introduced me to the field of fibrinolysis and with whom I have had many stimulating discussions in connection with the preparation of this work

I should also like to thank Dr Johan Ygge whose valuable suggestions and discussions have been of great value to me

Techn Lic and Med kand Lennart Appelgren, Docent Bengt Johansson, Docent Alvar Svanborg and Docent Ragnar Österberg have read the manuscript and have contributed with helpful advice and valuable criticism To these colleagues, I express my sincere thanks

The technical assistance of Mrs Maj Olausson, Irene Andersson and Stina Gartman is gratefully acknowledged

Finally, I wish to thank Mrs Catherine Bergholtz for translating some of the summaries into French as well as Mrs Catrin Wagner and Miss Gunnel Henriksen for typing the manuscript

The investigations were supported by grants from the Medical Faculty of the University of Göteborg

# References

- ALBERTY R A The rate equation for an enzymic reaction P D Boyer H Lardy and K. Myrback *The Enzymes* vol I page 143 Academic Press New York 1958
- ALKJAERISIG N The purification of human and bovine plasminogen *Fed Proc* 19 59 (1960)
- ALKJAERISIG N The purification and properties of human plasminogen *Biochem J* 93 171 (1964)
- ALKJAERISIG N A P FLECHTER S SHERRY The activation of human plasminogen. *J Biol Chem* 233 86 (1958)
- ALKJAERISIG N A P FLECHTER S SHERRY  $\epsilon$  aminocaproic acid an inhibitor of plasminogen activation *J Biol Chem* 234 832 (1959)
- AMERLS C M Panel discussion Assay technique *Am J Cardiol* 6 447 (1960)
- ASTAUF T The biological significance of fibrinolysis *Lancet* 2 565 (1956a)
- ASTAUF T Fibrinolysis in the organism *Blood* 11 781 (1956b)
- ASTAUF T Fibrinolysis a fundamental process in physiology *Proceedings of the Eight Congress of the European Society of Haematology* Wien 1961 pt 2 p 439 Karger Basel (1962)
- ASTAUF T & EGESLAD Thrombelastographic patterns produced by fibrinolytic agents incorporated in fibrin *Am J Physiol* 209 84 (1965)
- ASTAUF T S MULLERTZ The fibrin plate method for estimating fibrinolytic activity *Arch Biochem Biophys* 40 346 (1952)
- BERG W & KORSAN BENGTSSEN J YOGGE Determination of plasminogen in human plasma by the lysis time method *Thrombos Diathes haemorrh* (Stuttg) 16 1 (1966)
- BERGSTROM K Studies on plasminogen and urokinase Dissertation Stockholm (1963a)
- BERGSTROM K Preliminary studies on purified bovine plasminogen preparations A terminal amino acid sequences isoelectric point and activation with urokinase *Arkiv Kemi* 21 547 (1963b)
- BERGSTROM K P WALLIN Removal of contaminating plasminogen from purified bovine fibrinogen *Arkiv Kemi* 17 503 (1961)
- BLIX E Studies on the fibrinolytic system in the euglobulin fraction of human plasma *Scand J Clin Lab Invest* 13 suppl 58 (1961)
- BLOMBACK B Studies on fibrinogen Its purification and conversion into fibrin *Acta Phys Scand* 43 suppl 148 (1958)
- BLOMBACK B M BLOMBACK Purification of human and bovine fibrinogen *Arkiv Kemi* 10 415 (1956)
- BLOMBACK B T C LAURENT A terminal and light scattering studies on fibrinogen and its transformation to fibrin *Arkiv Kemi* 12 99 (1958)
- BORDET J L DELANGE La coagulation du sang et la genese de la thrombine *Ann Inst Pasteur* 26 737 (1912)
- BRACKMAN P P KILG T ASTAUF Fibrinolytic activity of thrombin preparations *Thrombos Diathes haemorrh* (Stuttg) 11 234 (1964)
- CELANDER D H M M GUEST Purification and properties of a urinary activator of plasma profibrinolysin *Fed Proc* 14 26 (1955)
- CELANDER D H M M GUEST The biochemistry and physiology of urokinase *Am J Cardiol* 6 409 (1960)
- CLAUSEN J S J DENCKER L SVENNERHOLM Proposed standardization of analysis of cerebrospinal fluid proteins *Acta Neurol Scand* 40 suppl 10 (1964)
- COHLPT M A H A SCHERAGA Aggregation of thrombin *Arch Biochem Biophys* 9 428 (1961)
- DAVIS E W O D RATNOFF Waterfall sequence for intrinsic blood clotting *Science* 149 1310 (1964)
- DAVIES M C M E ENGLERT Physical properties of highly purified human plasminogen *J Biol Chem* 235 1011 (1960)
- DERECHEN M The assay of human plasminogen with casein a substrate *Biochem J* 78 443 (1961)
- DERECHEN M Purification of human plasminogen *Biochem J* 82 241 (1962)
- DE VREEKER R A C VERMILLEN M VERSTRATE Purification of thrombin for use as a fibrinolytic ly inert reagent *Protides Biol Fluids Proc Colloq* 10 343 (1962)
- EGESLAD K Effects of epsilon amino caproic on fibrin clot lysis *Thrombos Diathes haemorrh* (Stuttg) 15 173 (1966)
- FLUTE P T The assessment of fibrinolytic activity in the blood *Brit med Bull* 20 195 (1964)
- FERNLEY G R Spontaneous fibrinolysis *Am J Cardiol* 6 371 (1960)
- GODAL H C E F LLSCHER Chromatography of human fibrinogen *J Clin Lab Invest* 12 47 (1960)

- GUEST M M A G WARE. Fibrinolytic activity of purified thrombin. *Science* 112 21 (1950)
- HAGAN J J F H ARLENDE E C DE RENZO. Purification and biochemical properties of human plasminogen. *J Biol Chem* 235 1005 (1960)
- HINK H J J L Mc DONALD. Preparation of profibrinolysin free fibrinogen and thrombin from human plasma. *Nature* 194 1050 (1962)
- HUGENIN S. Thrombaurkung und Fibrinolyse in gereinigten Gerinnungssystemen. *Kolloid Z* 92 189 (1940)
- KAULLA K N. Chemistry of thrombolysis in human fibrinolytic enzymes. Charles C. Thomas Publishers 1963 page 96-111
- KACKWICK R A M E. MACKAY M H NANCE, R R RECORD. The purification of human fibrinogen. *Biochem J* 60 671 (1955)
- KJELDGAARD N O J. PLOGG. Urokinase an activator of plasminogen from human urine I Isolation and properties. *Biochem Biophys Acta* 24 278 (1957a)
- KJELDGAARD N O J. PLOGG. Urokinase an activator of plasminogen from human urine II Mechanism of plasminogen activation. *Biochim Biophys Acta* 24 283 (1957)
- KLINE D L. The purification and crystallization of plasminogen (profibrinolysin). *J Biol Chem* 204 949 (1953)
- KLINE D L. Studies on the purification and activation of plasminogen (profibrinolysin). *Yale J Biol Med* 26 365 (1954)
- KORAN BENGTSEN K J YGE. Purification of human thrombin on a carboxymethylcellulose column. *Scand J Clin Lab Invest* 15 591 (1961)
- LAIDLER K J. The chemical kinetics of enzyme action. Chapter II. At the Clarendon Press Oxford, 1958
- LARI K. The polymerization of proteins. The action of thrombin on fibrinogen. *Arch. Biochem. Biophys* 32 317 (1951)
- LARI K J A GLADNER. Chemistry and physiology of the fibrinogen-fibrin transition. *Physiol Rev* 44 127 (1964)
- LASSER M. Heat denaturation of plasminogen in the fibrin plate method. *Acta Phys Scand* 27 373 (1953)
- LAURENT T J HILLANDER. The theory of gel filtration and its experimental verification. *J Chromatol* 14 317 (1964)
- LEWIS H J. Separation and molecular weight estimation of coagulation and fibrinolytic proteins by Sephadex gel filtration. *Proc. Soc. exp. Biol. Med.* 116 120 (1964)
- LINWEAVER H D BURK. The determination of enzyme dissociation constants. *J Amer. Chem. Soc.* 56 658 (1934)
- LOOMIS E C C. GEORGE JR A RYDER. Fibrinolysin and antifibrinolysin. Biochemical concentration of antifibrinolysin. *Arch. Biochem. Biophys* 20 444 (1949)
- MAGFARLANE R G. The development of ideas on fibrinolysis. *Brit. med. Bull.* 20 173 (1964a)
- MAGFARLANE R G. An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier. *Nature (London)* 202 498 (1964b)
- MAGFARLANE R G. The basis of the cascade hypothesis of blood clotting. *Thrombosis Diathesis haemorrh. (Stuttgart)* 15 591 (1966)
- MACKAY M. Fractionation and standardization of plasma fibrinolytic components. *Brit. med. Bull.* 20 189 (1964)
- MAGNUSSEN S. Preparation of highly purified bovine thrombin and termination of its N-terminal amino acid residues. *Arkiv Kemi* 24 349 (1965a)
- MAGNUSSEN S. Purification of prothrombin from human oxerated plasma fraction II + III (Cohn's method 6). *Arkiv Kemi* 24 367 (1965b)
- MAGNUSSEN S. Edman degradation of components of the bovine and human prothrombin-thrombinsystem. *Arkiv Kemi* 24 367 (1965c)
- MAJNLISS J V STENSTROM S DANIELSON. Matematisk analys. Del I. Page 612. Natur och Kultur Stockholm (1951)
- MARRAS G C M AMERLI. On the formation of different types of plasmin by streptokinase activation. *J Biol Chem* 235 1673 (1960a)
- MARRAS G C M AMERLI. Selective inactivation of the plasminogen contaminant in thrombin. *Nature* 188 582 (1960b)
- MARRAS G W E. WERKHEIMER. The interaction of streptokinase with plasminogen. I. Functional properties of the activated enzyme. *J Biol Chem* 239 2637 (1964)
- MAYWELL R E V S NICKEL V LEWANDOWSKI. Preparation of plasminogen-deficient fibrinogen and thrombin. *Biochem Biophys Res Commun.* 7 50 (1967)
- MILLER K D. Rivanol resin and the isolation of thrombin. *Nature (London)* 184 450 (1959)
- MILLER K D W H COPELAND. Isolation of human thrombin. *Proc. Soc. exp. Biol. Med.* 111 512 (1962)
- MILSTONE H. A factor in normal human blood which participates in streptococcal fibrinolysis. *J Immunol* 47 109 (1941)
- MOSESSON M W. The preparation of human fibrinogen free of plasminogen. *Biochem Biophys Acta* 57 204 (1962)
- MOSESSON M W J S FINLAYSON. Biochemical and chromatographic studies of certain activities associated with human fibrinogen preparations. *J Clin. Invest.* 42 747 (1963)
- NAUNINGA L B M M GUEST. On the interaction of fibrinolysin (plasmin) with the inhibitors and fibrinolysin and soy bean trypsin inhibitor. *Arch. Biochem. Biophys* 103 542 (1964)
- PENNEL R H. Panel discussion on Assay technique. *Am J Cardiol.* 6 448 (1960)

- RASMUSSEN P H Purification of thrombin by chromatography *Biochim Biophys Acta* 16 157 (1955)
- REINER J M Behavior of enzymes systems Burgess publ Co Minneapolis (1959)
- REMMERT L F P P COHEN Partial purification and properties of a proteolytic enzyme of human serum *Chem J Biol* 181 431 (1949)
- ROBERTS T S Measurement of the rate of plasmin action on synthetic substrates *J Biol Chem* 232 285 (1958)
- ROBBINS K C L SUMMARI Purification of human plasminogen and plasmin by gel filtration on Sephadex and chromatography on DEAE Sephadex *J Biol Chem* 238 952 (1963)
- ROBBINS K C L SUMMARI D ELWYN G H BARLOW Further studies on the purification and characterization of human plasminogen and plasmin *J Biol Chem* 240 541 (1965)
- SCHNEIDEGGER J J Une micro-méthode de l'immuno-electrophorèse *Int Arch Allergy* 7 103 (1955)
- SCHRIER E E C A BROOMFIELD H A SCHERAGA Molecular weight of bovine thrombin *Arch Biochem Biophys Suppl* 1309 (1962)
- SEELERS W H Prothrombin Harvard University Press 410 (1962)
- SEELERS W H R H LANDAUER Purification of prothrombin and thrombin by chromatography on cellulose *Canad J Biochem* 38 1405 (1960)
- SGOURIS J T J K INMAN A B McCALL Starch gel and moving boundary electrophoresis of highly purified profibrinolysin *Biochem Biophys Res Com* 2 40 (1960)
- SGOURIS J T H L TAYLOR A B McCALL Urokinase activation of human plasminogen *Abstr 129th Meeting Am Chem Soc* 13 c (1956)
- SCHERAGA H A S ERENPREIS Kinetics of the fibrinogen—fibrin conversion IVth international Congress of Biochemistry Vienna 1958
- SHERRY S N ALKJAERISG Studies on the activation of human plasminogen (profibrinolysin) *J clin Invest* 35 735 (1956)
- SHERRY S A FLETCHER N ALKJAERISG Fibrinolysis and fibrinolytic therapy in man *Phys Revs* 39 343 (1959)
- SHULMAN S N ALKJAERISG S SHERRY Physicochemical studies on human plasminogen (profibrinolysin) and plasmin (fibrinolysin) *J Biol Chem* 233 91 (1958)
- SJOSTRAND O Differential och integralkalkyl samt plananalytisk geometri Page 94 Akademiforlaget Gumperts Goteborg (1961)
- SLOTTA K H II GONZALES Native plasminogen *Biochemistry J* 285 (1964)
- SLOTTA K H II MICHEL II G SANTOS Comparative studies on native and acid treated plasminogen *Biochim Biophys Acta* 58 459 (1962)
- STAFFORD J L Fibrinolysis and intrinsic haemostasis *Brit med Bull* 20 179 (1964)
- STRAUCH W H WAGNER A simple method for preparing fibrinogen Thromb Diath haemorrh (Stuttg) 16 198 (1966)
- STRASSLE R Chromatographie von Thrombin *Biochim Biophys Acta* 73 462 (1963)
- TROLL W S SHERRY J WACHMAN The action of plasmin on synthetic substrates *J Biol Chem* 203 85 (1954)
- WALLÉN P Studies on plasminogen Dissertation Stockholm (1962a)
- WALLÉN P Studies on the purification of human plasminogen I The preparation of a partially purified human plasminogen with a low spontaneous activity *Arkiv Kemi* 19 451 (1962b)
- WALLÉN P Studies on the purification of human plasminogen II Further purification of human plasminogen on cellulose ion exchangers and by means of gel filtration and Sephadex *Arkiv Kemi* 19 469 (1962c)
- WALLÉN P A BERGSTROM Effect of lysine on the purification of human plasminogen on cellulose ion exchangers *Acta Chem Scand* 13 1464 (1959)
- WALLÉN P A BERGSTROM Purification of human plasminogen on DEAE-cellulose *Acta Chem Scand* 14 217 (1960)
- WIEME R J An improved technique of agar-gel electrophoresis on microscope slides *Clin Chim Acta* 4 317 (1959)





GÖTEBORG 1967  
ORSTADIUS BOKTRYCKERI AKTIEBOLAG  
9673







# ACTA MEDICA SCANDINAVICA

SUPPLEMENTUM 479



## STUDIES ON SYNOVIAL FLUID IN ARTHRITIS

- I THE TOTAL COMPLEMENT ACTIVITY  
II THE OCCURRENCE OF MONONUCLEAR CELLS  
WITH *IN VITRO* CYTOTOXIC EFFECT

BY

HELGE HEDBERG

---

LUND 1967

# ACTA MEDICA SCANDINAVICA

has been published since 1919 as a continuation of *Nordiskt Medicinskt Arkiv*, founded in 1869 by Axel Key. The first volume of *Acta Medica Scandinavica* is therefore numbered LII (52).

The chief editors have been Axel Key 1869—1900, C. G. Santesson 1901—1915, I. Holmgren 1916—1937 and Birger Strandell 1938 to date.

*Acta Medica Scandinavica* publishes original research papers in the field of internal medicine. Priority will be given to authors from countries which are represented on the editorial board. Contributors from those countries should submit their papers to a representative of the country in question. Contributors from other countries should send their papers to the Editor at the address below.

Submission of a manuscript for publication will be held to imply that the paper has not been published elsewhere and that, if accepted, it will not be republished in any other journal in the same or similar form, without the Editor's written consent.

Papers will be published in English, French or German at the authors' choice, followed by a summary in English.

The manuscripts shall be in final form as submitted. They shall be typewritten with double spacing and broad left hand margin.

If a paper exceeds 16 printed pages, the cost for the excess pages shall be borne by the author. No paper shall exceed 24 printed pages.

## Subscription

The annual subscription to the journal, covering two volumes, each of 6 numbers, is 140 Sw. crowns or U.S. \$ 27.25, including postage, in the Scandinavian countries and in Holland 120 Sw. crowns.

*Address for subscriptions and all communications:*

ACTA MEDICA SCANDINAVICA

P. O. Box 2052, Stockholm 2

---

Requests for duplicate copies of numbers that have gone astray can only be considered if made within a fortnight of the receipt of the following number.

ACTA MEDICA SCANDINAVICA

SUPPLEMENTUM 479

STUDIES ON SYNOVIAL FLUID  
IN ARTHRITIS

I THE TOTAL COMPLEMENT ACTIVITY  
II THE OCCURRENCE OF MONONUCLEAR CELLS  
WITH *IN VITRO* CYTOTOXIC EFFECT

BY

HELGE HEDBERG

LUND 1967

# ACTA MEDICA SCANDINAVICA

has been published since 1919 as a continuation of *Nordiskt Medicinskt Arkiv*, founded in 1869 by Axel Key. The first volume of *Acta Medica Scandinavica* is therefore numbered LII (52).

The chief editors have been Axel Key 1869—1900, C. G. Santesson 1901—1915, I. Holmgren 1916—1957 and Birger Strandell 1958 to date.

*Acta Medica Scandinavica* publishes original research papers in the field of internal medicine. Priority will be given to authors from countries which are represented on the editorial board. Contributors from those countries should submit their papers to a representative of the country in question. Contributors from other countries should send their papers to the Editor at the address below.

Submission of a manuscript for publication will be held to imply that the paper has not been published elsewhere and that, if accepted, it will not be republished in any other journal in the same or similar form, without the Editor's written consent.

Papers will be published in English, French or German at the authors' choice, followed by a summary in English.

The manuscripts shall be in final form as submitted. They shall be typewritten with double spacing and broad left hand margin.

If a paper exceeds 16 printed pages, the cost for the excess pages shall be borne by the author. No paper shall exceed 24 printed pages.

## Subscription

The annual subscription to the journal, covering two volumes, each of 6 numbers, is 140 Sw. crowns or U.S. \$ 27.25, including postage, in the Scandinavian countries and in Holland 120 Sw. crowns.

*Address for subscriptions and all communications*

ACTA MEDICA SCANDINAVICA

P. O. Box 2052, Stockholm 2

---

Requests for duplicate copies of numbers that have gone astray can only be considered if made within a fortnight of the receipt of the following number.

# Contents

General introduction	5
<i>Part I The total complement activity</i>	
Introduction	9
Materials and methods	10
Chapter 1 Selection of a method for assessment of the relative synovial fluid complement (C ) activity	19
Chapter 2 The C activity of synovial fluid in various inflammatory arthropathies	24
Chapter 3 The C activity of different synovial fluid samples derived from the same patient	28
Chapter 4 The synovial fluid C activity and some laboratory and clinical data	32
Chapter 5 The C activity of synovial fluid and the duration of effusion	40
Chapter 6 The C level of serum	43
Chapter 7 The C activity of synovial fluid and the rheumatoid factor (PF) tests	47
Chapter 8 Discussion	63
Summary (Part I)	77
<i>Part II The occurrence of mononuclear cells with in vitro cytotoxic effect</i>	
Introduction	81
Materials and methods	84
Chapter 1 Cytotoxicity tests with exudate mononuclears	90
Chapter 2 Results of cytotoxicity tests with exudate mononuclears in relation to duration of effusion	101
Chapter 3 Cytotoxicity tests with cultures of human kidney as target	103
Chapter 4 Cytotoxicity tests with blood mononuclears	106
Chapter 5 Discussion	107
Summary (Part II)	113
General summary	114
Acknowledgments	116
References	117
Appendix	128

This work is in part based on the following publications which will be referred to in the ordinary way

HEDBERG H, NORRÉN A, LUNDQVIST A and WZFLIN B Depression of hemolytic complement activity of synovial fluid in adult rheumatoid arthritis *Acta med scand* 173 347—351 1961

HEDBERG H Studies on the depressed hemolytic complement activity of synovial fluid in adult rheumatoid arthritis *Acta rheum scand* 9 163—193 1963

HEDBERG H The depressed synovial complement activity in adult and juvenile rheumatoid arthritis *Acta rheum scand* 10 109—127 1964

HEDBERG H and KALLÉN B Studies on mononuclear cells obtained from synovial fluid in patients with different types of arthritis Cytotoxic effect on tissue-cultured human fibroblasts *Acta path microbiol scand* 69 177—188 1964a

HEDBERG H and KALLÉN B Further *in vitro* studies on the cytotoxic effect of mononuclear cells from synovial fluid in arthritis *Acta univ lund* 11 8 1—14 1964b

*Printed in Sweden*

*Berlinska Boktryckeriet*

*June 1967*

## General introduction

Complement known to be involved in several immunological reactions has been studied for years especially because of its potential cytotoxic capacity in human diseases where an immunological genesis has been suspected

Most clinical studies on complement and complement components have been made on serum

During the past few years interest has increasingly focused on *in vitro* cytotoxic reactions mediated by lymphoid cells. Such reactions were first observed in experimental conditions where lymphoid cells from immunized animals were found to elicit a cyto-

toxic reaction on tissue cultures of those cells against which the animals had been immunized. The *in vitro* technique has made possible studies on various human diseases *eg* multiple sclerosis, ulcerative colitis and systemic lupus erythematosus. In these studies the lymphoid cells were separated from peripheral blood.

In patients with arthritis and effusion there is an opportunity to study a body fluid that has presumably been in close contact with the lesions of the tissues surrounding the joint space. This was the main reason why synovial fluid rather than blood was studied in the present investigation.





FROM THE LABORATORY OF HAEMATOLOGY DEPARTMENT OF INTERNAL MEDICINE,  
AND THE DEPARTMENT OF RHEUMATOLOGY UNIVERSITY HOSPITAL, LUND SWEDEN

---

## I THE TOTAL COMPLEMENT ACTIVITY



# Introduction

In various diseases where immune reactions have been suspected to play a pathogenetic role the total C' activity of serum has been studied (see reviews by OSLEF 1961, LACHMANN 1963, MÜLLER LEBERHARD NILSSON DALVIASSO POLLEY and CALCOTT 1966, RAPP and BORSOS 1966). Reduced C' levels of serum have been reported for example in active systemic lupus erythematosus (SLE), acute glomerulonephritis and in some cases of acquired haemolytic anaemia.

In rheumatoid arthritis (RA) on the other hand most investigations have shown the C' level of serum to be raised (VAUGHAN BAYLES and FAVOUR 1951, SCHUBART, EWALD, SCHROEDER, ROT, SCHILD, BHATNAGAR and PULLEN 1965 and others), whereas in a few studies the C' level of serum in RA has been found to be normal (LAURELL and GRUBB 1958) or slightly reduced (PERLICK 1962, GEIDEL, SELLE and SCHABINSKY 1964).

However it is well established that the C' activity of synovial fluid is often suppressed in RA, sometimes equally pronounced as in cases of SLE and SLE like syndromes (PEKIN and ZVAIFLER 1962, HEDBERG, NORDEN, LUNDQUIST and AFZELIUS 1961, PEKIN and ZVAIFLER 1964, BARNETT, BIEVENSTOCK and BLOCH 1964, HEDBERG 1963, 1964, FOSTIROPOULOS, AUSTEN

and BLOCH 1965, FISH, MICHAEL, GEWURZ and GOOD 1966).

Since our first studies some additional observations have been made and the series comprising RA patients has been extended. In order to obtain a better survey the results on the whole series of arthropathies studied are presented below. The results on such a fairly large series as the present one of 100 RA patients were in fact accumulated for the purpose of clarifying the relation between synovial fluid C' activity and rheumatoid factor (RF) titre in RA. In none of the mentioned reports all of which dealt with series of RA smaller than the present one was any relation found between the two parameters in RA.

The present study of the total C' activity of synovial fluid was inspired specifically by the demonstration by LACHMANN, MÜLLER LEBERHARD, KUNDEL and PARONETTO (1962) that one of the C' components ( $\beta_{1c}$ ) and immunoglobulins were concomitantly bound to the renal lesions of SLE. If in RA mechanisms similar to those in SLE were involved it was presumed that a local fixation of C' during the passage of serum proteins through the inflamed synovial membrane would manifest itself by a reduction of the C' activity of synovial fluid.



had back symptoms suggesting a diagnosis of ankylosing spondylitis. Nor were psoriatic changes of the skin and/or nails found in any of the patients accepted as RA in the absence of a positive rheumatoid factor (RF) test. L.F. cell tests were made in 60 out of the 100 RA patients. 58 turned out negative and 2 doubtful. These tests were made predominantly when SLE or SLE like syndromes could be suspected.

Instead of classifying the RA cases into definite and classical RA as proposed by the above mentioned authors the RA cases were classified as follows:

*RA with nodules* if the patients had subcutaneous nodules at the time of examination. All patients in this group had shown a positive RF test at least once. Two patients with a concomitant psoriasis (SSC\* titres 256 and 1024 respectively) were included in this group. This group totalled 27 patients: all adults, 18 females and 9 males.

*'SSC pos' RA* if a positive SSC test had been observed at least once. In most patients the SSC test had repeatedly turned out positive. Included in this group were 49 adults, 29 females and 20 males and 7 with juvenile RA, all girls.

*SSC neg RA* if no positive SSC test had been observed. In many patients belonging to this group the SSC test remained negative when the tests were repeated one to three years after examination. In several of these patients the SSC test turned out negative repeatedly (3 to 7 times). Included in this group were 12 adults, 9 females

and 3 males, and 5 juveniles, 2 girls and 3 boys.

The reason for considering RA patients with subcutaneous nodules as a separate group of RA will be mentioned below. Once this group was separated it was necessary to use a classification other than that of 'classical and definite RA'. A distinction between 'SSC pos' and 'SSC neg' RA was made in order to attach importance to the SSC test.

The classification used must to some extent be considered arbitrary for e.g. the following reasons: the varying time between onset of joint symptoms and appearance of a positive RF test (see Dixon 1960); the inconstancy of subcutaneous nodules and the varying frequency with which the SSC tests had been made.

Except some of the patients with early RA for less than a year all RA patients examined showed the usual pattern of X ray changes compatible with diagnosis of RA. In the group of SSC neg RA 15 of 17 patients showed X ray changes including erosions; one (incompletely examined) showed destruction of cartilage alone.

The mean age of the adult patients in the three RA groups discerned was similar being 51 (range 38—67) in RA with nodules, 51 (range 26—69) in SSC pos RA and 52 (range 33—64) in SSC neg RA.

### *Systemic lupus erythematosus (SLE) and SLE like syndromes*

Nine females aged 19—55 (mean 40) were labelled SLE or SLE like syn-

\* SSC = sensitized sheep cell (see methods)

# Materials and methods

## *The clinical material*

### *Mode of selection*

Almost all patients studied had been hospitalized at least once because of joint disease. The majority of patients with inflammatory arthropathies had been admitted to the Department of Rheumatology, University Hospital of Lund (during the years 1962 to 1966), the single special department for rheumatic diseases in the southern part of Sweden.

With the exception of some of the patients with lesions of the menisci where synovial fluid was secured at arthrotomy, synovial fluid was aspirated from a joint with signs of effusion, generally the knee joint. In most cases fluid was aspirated as a therapeutic measure in association with subsequent intra-articular injection of corticosteroids.

Fluid was not aspirated from joints injected during the two weeks preceding examination (two exceptions).

Hemolytic samples were not accepted, traces of admixture with erythrocytes were disregarded.

RA patients with effusion of short duration and SLE patients were specifically looked for as were RA patients

with subcutaneous nodules during the later part of the study. Except for the limitations mentioned there was no deliberate selection. Thus fluids from patients with different degrees of activity of the disease and with synovitis of different degrees of intensity were studied.<sup>2</sup> When fluids from several joints were aspirated simultaneously, the patient was represented by fluid from the knee joint or if fluids from both knee joints were aspirated, by fluid from the right knee joint.

The clinical material totalled 174 patients, 147 had adult and 27 juvenile forms of arthropathies.

### *Rheumatoid arthritis (RA)*

Cases of adult and juvenile arthritis were accepted as RA if they satisfied at least 3 of the criteria proposed by ROSES, BENNETT, COBB, JACOB and JESSAR (1958) and if they showed a symmetrical involvement of at least the small joints of hands and/or feet. None of the patients accepted as RA

<sup>2</sup> Attempts to evaluate the intensity of synovitis were made by means of clinical criteria such as tenderness, joint heat and pains on passive motion. As a "measure" of the activity of the disease as a whole the ESR (WESTERCRANS) was used.

with peripheral polyarthritis. All had bilateral X ray changes of the sacro iliac joints, 5 also had X ray changes of the spine three of these had bony ankylosis of the spine. Two with slight to moderate pains and stiffness of the lower back (no signs of prostatic vesiculitis) lacked detectable X ray changes of the spine. Two of the patients (X ray changes of the spine) had signs of active prostatic vesiculitis and some had fibrotic changes of the prostate and/or vesicles.

Three juveniles all with bilateral sacro ilitis and atypical polyarthritis were included as ankylosing spondylitis. Two had squaring of the vertebrae and one pronounced destruction of the bone in the upper cervical spine. The pain and stiffness of the back were slight to moderate. Two were boys with onset of peripheral joint symptoms at 9 and 11 respectively and one was a girl with onset at 12.

### *Uro polyarthritis*

Eight males aged 17—53 (mean 30) fulfilled the criteria proposed by OLIPHANT (1960) for a diagnosis of uro polyarthritis. Five with acute forms had a full Reiter syndrome and 3 all with active prostatic vesiculitis had chronic forms. One of the latter had and two lacked signs of sacro ilitis.

### *Psoriatic arthropathy*

In one girl and 13 adults 5 females and 8 males the disease was labelled psoriatic arthropathy. All had negative RF tests in serum and synovial fluid. Subcutaneous nodules were not present. Ten patients with skin and

nail changes had arthritis involving the distal interphalangeal joints. X ray films of these joints taken on 7 of the patients showed erosions or bony ankylosis.

In four of the (adult) patients all with sacro iliac arthritis the distal interphalangeal joints were not involved. In conformity with BAKER, GOLDING and THOMPSON (1963) these patients were accepted as cases of probable psoriatic arthropathy.

All patients except one had typical skin changes. In one of the patients with probable psoriatic arthropathy psoriasis was confined to the nails (cultures for pathogenic fungi negative). The psoriatic nature of the arthritis and the nail changes in this patient was also suggested by a highly abnormal glucose tolerance test (see REEDS, FUSARO and FISHER 1964). Highly abnormal or equivocal glucose tolerance tests were observed in several of the patients with psoriatic arthropathy, including one of the other patients labelled probable psoriatic arthropathy although so far never in sero positive RA (16 patients). All 14 patients of this group were treated together as one group of psoriatic arthropathy if not otherwise stated.

### *Other sero negative inflammatory arthropathies*

One male aged 34 had a sero negative polyarthritis associated with ulcerative colitis—One female, aged 25 had a transient arthritis of one knee joint probably most closely related to post infectious rheumatism of the type de-



scribed by JOSSON (1960) —One male aged 38 had a solitary arthritis verified by biopsy —One boy aged 17 had a transient effusion of the knee joint without other signs of arthritis

One patient with onset of joint symptoms at 15 had an atypical polyarthritis with predominant involvement of the large joints —One boy with onset of peripheral joint symptoms at 10 had a polyarthritis of non-RA type associated with ulcerative colitis and psoriasis: there was no involvement of the steriodine joints nor of the distal interphalangeal joints —One boy aged 12 had a septic arthritis of the knee joint (culture of synovial fluid showed growth of group A streptococci)

#### *Oligo arthritis (juvenile)*

Eight juveniles, 4 girls and 4 boys, all with a fairly mild arthritis involving a few joints alone were accepted as oligo arthritis essentially according to ASSETT and BYWATERS (1962). These authors considered oligo arthritis one form of probable STILL'S disease.

A few patients originally included were excluded because of doubt as to the diagnosis. One (adult) patient with RA was excluded because of recently made ipsilateral synovectomy.

#### *Methods*

The synovial fluid was allowed to clot for two hours at room temperature and was then centrifuged.

Venous blood simultaneously drawn was treated in the same way.

The samples were preserved at about  $-70^{\circ}\text{C}$ .

*Determination of the no. of C<sup>14</sup>H<sub>5</sub> units per ml* was performed according to a micro method described by WASSERMAN and LIVING (1961).

*Diluent* Isotonic Veronal buffer (pH 7.2–7.3) containing 0.0005M  $\text{MgCl}_2$ , 0.00015M  $\text{CaCl}_2$  and 0.1 per cent gelatin was used as diluent for all reagents.

*Sheep erythrocytes* Equal amounts of sheep blood and modified ALSTEDT'S solution (ALSTEDT and ALSTEDT 1941) were mixed and kept aseptic at  $+2$ – $+4^{\circ}\text{C}$  for 3–6 days before use.

Before use the sheep erythrocytes were washed until the supernatant was free from microscopically detectable hemolysis. The suspension of erythrocytes was adjusted so as to give an extinction value of 710–810 at 404–412 m $\mu$  when diluted 1/16 (after complete hemolysis with distilled water). Minor variations of the 100 per cent hemolysis extinction were of no importance. In one series of determinations the mean extinction for 100 per cent hemolysis was 800 and the standard deviation 0.29; in this series no relation was found between the 100 per cent hemolysis extinction and the G level of a serum sample repeatedly determined.

*Sensitized sheep erythrocytes (I A)* were prepared by mixing the standardized suspension of erythrocytes with an equal volume of ambocaptor diluted 1/40 000. The mixture was incubated at  $37^{\circ}\text{C}$  for about 30 minutes during moderate shaking. One ml of the same ambocaptor was used throughout the study.

MILGROM (1963a) described an agar gel diffusion technique for distinguishing IgG and IgM haemolysins. Agarose gel plates containing sheep erythrocytes were prepared and wells for C and amboceptor were made both reagents being used undiluted. The plates were incubated for 20 hours at 4°C and for one hour at 37°C. By this technique it could be shown that the amboceptor used contained one single detectable sensitizing component. This component yielded a strong and distinct haemolytic zone close to the amboceptor well and far from the C well suggesting that the sensitizing component was of IgM rather than of IgG type.

Furthermore pre-treatment of the amboceptor with 0.2M cystein HCl (final dilution) at room temperature for 4 hours (pH 7.3 no subsequent dialysis) resulted in almost complete disappearance of the haemolytic zone indicating that the sensitizing component was a macroglobulin (see DEITSCH and MORTON 1957). Appropriate control experiments suggested that cystein HCl did not in itself appreciably inhibit the haemolysis of LA by C. This procedure was known from previous studies completely to destroy the RF activity (by the latex test) of RA sera while the anti-streptolysin activity of human IgG was scarcely affected (HEDBERG unpublished observations).

From the above mentioned results it was concluded that the sensitizing capacity of the amboceptor used was predominantly due to its content of anti-sheep erythrocyte haemolysins of the IgM type.

The haemolytic C' activity was assayed in a total volume of 0.8 ml which contained 0.1 ml of the standard suspension of EA (about  $6 \times 10^7$  EA/ml) and varying volumes of diluent and primary dilutions of sample (constriction pipets) according to the following scheme:

Sample (ml)	0.2	0.3	0.4	0.5	0.6
Diluent (ml)	0.5	0.4	0.3	0.2	0.1
EA (ml)	0.1	0.1	0.1	0.1	0.1

Before the samples were finally diluted primary dilutions of serum—generally 1:500—and of synovial fluid—generally 1:300—were made. These primary dilutions of the sample were kept in ice water until finally diluted.

The mixture of LA and dilutions of the sample was incubated at  $37^\circ\text{C} \pm 0.1^\circ\text{C}$  for 60 min during moderate and continuous shaking. After incubation remaining erythrocytes were spun down, the extinction of the clear supernatant was read in 1 cm microcuvettes (1 ml) at 408–412 mμ in a Beckman DU spectrophotometer. The degree of haemolysis was expressed in per cent of the 100 per cent haemolysis after the latter had been corrected for spontaneous haemolysis.

By use of von Krogh's formula the 50 per cent haemolysis end point was determined graphically as described by MAYER (1961). Only haemolysis percentages between 18 and 82 were accepted. Generally three observations were obtained between 18 and 82 per cent haemolysis. The regression line was drawn by eye, the observations between 18 and 82 per cent haemolysis were not allowed to deviate (vertically) more than 10 per cent from the corresponding value of the ordinate on the regression line. If this happened or if only two points or less between 18 and 82 per cent haemolysis were obtained the determination was repeated. In order to avoid interaction by heterophile antibodies at low dilutions of synovial fluid with an extremely low number of CH<sub>50</sub> units such fluids were considered to contain 32 CH<sub>50</sub> units (see HEDBERG 1963).

Table 1 Standard deviation (SD) of the determination of the number of C.H<sub>50</sub> units in 10 sera used as a control of the haemolytic system. Below the control sera are listed in chronological order

	Control serum number									
	1	2	3	4	5	6	7	8	9	10
No. of determinations	17	17	22	36	3	22	24	17	21	29
Mean	1125	1511	1105	1086	903	851	1006	1191	1175	1203
SD	72	115	75	129	43	51	70	134	63	21
Coefficient of variation	6.3	7.5	6.7	11.9	4.7	6.0	6.9	11.2	5.3	1.8*

\* During the period when each control serum was used there was no tendency towards a change of titre level with time. Coefficient of variation = SD in per cent of the mean.

One a fractional dilution interspersed between the standard dilutions.

In several instances the haemolytic activity was determined on two occasions. The standard error of 22 such double determinations on serum was  $\pm 6.5$  per cent (of the lowest value) for determinations on synovial fluid the standard error was  $\pm 8.3$  per cent for 16 double determinations. See also Tables I and III.

Leaving the blood or synovial fluid at room temperature for 5 hours instead of 2 did not influence the haemolytic activity nor did treatment with hyaluronidase (HYALAS® Leo 120 viscosity reducing units per ml for 20 min at 37°C). Inactivation of the sample (56°C/30 min) treatment with immunoprecipitates or zymosin completely abolished the haemolytic activity.

At each determination of the no. of C units per ml a control serum was included. As shown in Table I the methodological error of these deter-

minations was small. It was also evident from the results concerning the control sera which covered a period of about 4 years that the stability of the test system used must be considered good.\*

The protein content of serum and synovial fluid was determined either by a KJELDAHL method (MILNER and HOLCHES 1945) or by a biuret method (KINGSLEY, REINHOLD STEWARD GILMAN and WRIGHTSIBALDI 1953). The two methods showed good agreement.

The protein pattern of serum and synovial fluid was determined by paper electrophoresis according to the method described by JALILFAR, JAL

The standard error of a single determination =  $\sqrt{\frac{d^2}{N}}$  where  $d$  is the differences observed and  $N$  the number of double determinations (DANIELSSON 1940).

The present study started in May 1962.

RELL and SKOOG (1956) At this procedure 20  $\mu$ l of synovial fluid was applied on the paper instead of the ordinary 10 used for serum synovial fluid was applied after treatment with hyaluronidase as described above

**Rheumatoid factor tests** The sensitized sheep cell (SSC) test was made according to the method of WINBLAD (1952) as modified by THULIN (1955)\* The SSC titre was determined in whole serum alone A titre of 64 was considered positive a titre of 32 doubtful and a titre lower than 32 clearly negative

The latex fixation (or agglutination) titre (SINCER and PLOTZ 1956) was determined on the euglobulin fraction of serum and synovial fluid, the latter being pre-treated with hyaluronidase as described above

Euglobulin was prepared either by the procedure described by ERICSSON, VOLKIN, CRAIG COOPER and NEURATH (1947) or by dialysis against distilled water for 16–18 hours at 2–4°C (pH 5.5–6.5) Euglobulin fractions prepared according to the two methods yielded comparable titres

The euglobulin fraction diluted 1/10 to 1/320 was contained in a volume of 0.2 ml using a glycine buffer as diluent (pH 8.2–8.4)

One and the same batch of human gamma globulins (KABI Stockholm) and one and the same batch of latex particles (Dow Chemical Co 0.81 micron) were used throughout the study

The reproducibility of the determination of the latex titre of synovial fluid was essentially comparable to

that previously described for the serum titre (HEDBERG 1961) Whereas the latex titres in non RA arthritides provided reproducible a tendency could be traced in RA for the synovial fluid titres to be less reliable in the titre range <10–40 than at higher titres In 3/4 of the fluids with latex titres below 80 attempts were made to make the titres more reliable by determining the titre twice or sometimes three times A titre obtained twice was accepted, occasionally in the case of a two tube difference the intermediate titre was accepted as the true one A latex titre of 20 in serum or synovial fluid was considered positive

**Intracellular activity** of serum was determined according to a method described by JOHANSSON (1967) by means of indirect fluorescent antibody technique About 35 per cent of the tests were made in connection with examination the remainder 1–3 years later The latter tests showed a distribution over different arthritis groups which was comparable to that of the former

**Statistical methods** Besides conventional parametric methods use was made of 'non parametric methods' (SIEGEL 1956)

SPEARMAN'S  $\rho$  stands for SPEARMAN'S rank order correlation coefficient (corrected for ties)

When frequencies had to be compared the  $\chi^2$  test was used if possible

\* Routine tests performed at the Department of Clinical Bacteriology University Hospital Lund Head Professor H GRUBB

Routine tests performed at the State Laboratory of Bacteriology Stockholm

In this case the values of  $\chi^2$  as well as of  $p$  were given

If the  $\chi^2$  test could not be used the exact test for  $2 \times 2$  tables was used. In this case the  $p$  values solely were given

The different significance levels were symbolized as follows

+ =  $0.01 < p \leq 0.05$  = probable

+ + =  $0.001 < p \leq 0.01$  = significant

+ + + =  $p \leq 0.001$  = highly significant

## Selection of a method for assessment of the relative synovial fluid complement (C') activity

In order to make comparisons between different patients or groups of patients possible it was necessary to use relative values of the synovial fluid C' activity rather than the number of C units per ml synovial fluid as they stand.

In arthropathies labelled osteoarthritis lesions of the menisci and loose body of the knee joint it was *a priori* assumed that C' was not involved in these pathological changes.

In these arthropathies (in total 17 cases subgroups A—C of Appendix Table I) there seemed to be a connection between the number of C units of serum (C<sub>s</sub>) and the number of C units of synovial fluid (C'<sub>sf</sub>) the degree of correlation was statistically significant ( $r = +0.637$   $p < 0.01$  Fig 1). Some degree of correlation was also obtained between C'<sub>sf</sub> and the protein content of synovial fluid ( $r = +0.478$   $p = 0.05$  Fig 1) whereas the correlation between the latter parameter and C<sub>s</sub> was very low ( $r = -0.112$ ).

The partial correlation between C<sub>sf</sub> and C<sub>s</sub> after correction for the influence of the protein content of synovial fluid was statistically highly significant ( $r = +0.810$   $p < 0.001$ ).

These results were compatible with

the assumption that in the arthropathies in question the total C' activity of synovial fluid derived from blood serum and that serum C here passed through the capillaries, subsynovial tissues and the synovial membrane without being appreciably changed.

In the whole series of arthropathies studied the C<sub>s</sub> and the protein content of synovial fluid varied considerably as did the C'<sub>sf</sub>.

If the synovial fluid serum ratio for the number of C' units (C'<sub>sf</sub>/C<sub>s</sub>) instead of C<sub>sf</sub> alone was related to the protein content of synovial fluid the degree of correlation was statistically highly significant ( $r = +0.731$   $p = 0.001$  Fig 1).

The degree of correlation between the quotient C'<sub>sf</sub>/C<sub>s</sub> and the protein content of synovial fluid ( $r = +0.731$ ) was not statistically different from that for the relation C'<sub>s</sub> to C<sub>sf</sub> ( $r = +0.637$ ) nor from that for the relation C'<sub>sf</sub> to total protein content of synovial fluid ( $r = +0.478$ ). Yet the relation C<sub>sf</sub>/C<sub>s</sub> to the protein content of synovial fluid was used for the estimation of the relative synovial fluid C activity because this relation took into account each of the three parameters considered to be relevant.




Fig. 1 Relation  $C_{SF}$  to concentration of total protein of synovial fluid (A)  $C_{SF}$  to  $C_S$  (B)

and  $C_{SF}$  to  $C_S$  to concentration of total protein of synovial fluid (C)

$C_{SF}$  = No. of C units per ml synovial fluid

$C_S$  = No. of C units per ml serum

○ = primary observations in 9 cases of osteoarthritis, 6 of lesions of the menisci, 1 of loose body of the knee joint and 1 of traumatic synovitis. The regression lines and the  $r$  values were based on these 17 primary observations

● = additional observations in osteoarthritis

• = observations in 4 healthy adults

For the 17 cases considered the relation  $C'_{SF} : C'_S (\bar{Y})$  to the protein content of synovial fluid in g per 100 ml ( $\bar{X}$ ) fitted the regression line  $\bar{Y} = 0.013 + 0.098\bar{X}$  or approximately  $\bar{Y} = 0.1\bar{X}$ .

By making use of this relation the relative synovial fluid  $C'$  activity could be estimated. For example if the protein content of synovial fluid was 4.00 g per 100 ml the expected value of  $C'_{SF} : C'_S (\bar{Y})$  was 0.40. If the observed value of  $C'_{SF} : C'_S$  was 0.30, the relative synovial fluid  $C'$  activity was estimated at  $0.30/0.40 = 0.75$ . For the sake of convenience the values of the synovial fluid  $C'$  activity thus obtained were multiplied by 100 whereby the relative synovial fluid  $C'$  activity became simply called 'synovial fluid  $C'$  activity', directly expressed the activity in per cent of the expected.

In relation to  $C'$  activities estimated in two other ways and especially in relation to the number of  $C$  units alone the estimation procedure used yielded a variation of the synovial fluid  $C'$  activity values which was fairly low at least within the group of 17 cases considered (Table II).<sup>1</sup>

The synovial fluid  $C'$  activity expressed as described fulfilled the following requirements

- 1) In the whole series of arthropathies studied as well as within various arthritis groups discerned the synovial fluid  $C'$  activity varied independently of the variation of the protein content of synovial fluid and also independently of the variation of the  $C_{II}$  at least in non RA seronegative arthritides

**Table II** Mean and standard deviation (SD) for various estimates of the  $C$  activity of synovial fluid 17 cases (9 of osteoarthritis II of lesions of the menisci and 1 of loose body of the knee joint and 1 of traumatic synovitis)

$C_{SF} = C_{II_{50}}$  units per ml synovial fluid

$C_S = C_{II_{50}}$  units per ml serum

$TP_{SF}$  = total protein of synovial fluid (g/100 ml)

Base for the estimation	Mean	SD
Relation $C_{SF} : C_S$ to $TP_{SF}$	1.013	$\pm 0.181$ (17.9) <sup>1</sup>
Relation $C_{SF}$ to $C_S$	0.343	$\pm 0.101$ (29.4)
Relation $C_{SF}$ to $TP_{SF}$	12.01	$\pm 3.33$ (27.8)
$C_{SF}$ alone	4.22	1.77 (34.2)

<sup>1</sup> SD in per cent of the mean

- 2) The synovial fluid  $C'$  activity could be determined with an acceptable degree of reproducibility (Table III)

It may be added that when in the cases of osteoarthritis subsequently aspirated synovial fluids were studied these showed a synovial fluid  $C'$  activity

Retaining the  $\bar{Y}$  values as expressing the  $C_{SF} : C_S$  ratio measures for  $\bar{X}$  other than the protein content of synovial fluid were also tried for example the globulin content of synovial fluid and the synovial fluid serum ratio for the total globulins as well as that for the  $\alpha$  globulins. However these other measures for  $\bar{X}$  were found not to be superior to that used i.e. the protein content.






Fig. 1. Relation  $C_{SF}$  to concentration of total protein of synovial fluid (A),  $C_{SF}$  to  $C_S$  (B) and  $C_{SF} / C_S$  to concentration of total protein of synovial fluid (C).

$C_{SF}$  = No. of C units per ml synovial fluid

$C_S$  = No. of C units per ml serum

- primary observations in 9 cases of osteoarthritis, 6 of lesions of the menisci, 1 of loose body of the knee joint and 1 of traumatic synovitis. The regression lines and the  $r$  values were based on these 17 primary observations.
- additional observations in osteoarthritis
- observations in 4 healthy adults

comparable to that first found (Fig 1)

A few normal synovial fluids were examined for comparison (Fig 1) These showed comparatively low C activities of 67 66 66 and 56 respectively in association with protein concentrations below 2 g per cent<sup>2</sup> However these values were not considered to be suppressed as judged from the confidence limits used (see below)

**SUMMARY** In order to make a comparison between patients or groups of patients possible a method was devised for the assessment of the (relative) synovial fluid C' activity This activity could be determined with an acceptable degree of reproducibility

<sup>2</sup> It is doubtful whether or not the estimation procedure really failed at low protein concentrations Possibly these low protein fluids were not strictly comparable to those with a higher protein content with respect to the relative concentration of globulins the latter of which are known to contain the C components so far isolated (MILLER EBERHARD NILSSON DALMASO POLLEY and CALCOTT 1966)

*Table III* Standard levels in  $\text{NAD}^+$  of the serum of the synovial fluid & twenty & act of in three samples serum include to

(1) - Normal different activities of the serum  
 (2) - Normal  $\text{H}_2\text{O}$  and  $\text{H}_2\text{O}$  and synovial fluid  
 (3) - Normal  $\text{H}_2\text{O}$  and  $\text{H}_2\text{O}$  and serum  
 (4) - Total protein of synovial fluid banded

(1) -  $\frac{\text{act of}}{\text{act of}} \times 100$   
 (2) -  $\frac{\text{act of}}{\text{act of}} \times 100$

Patient number	Sample No. 1				Sample No. 2				Sample No. 3			
	act of	act of	act of	act of	act of	act of	act of	act of	act of	act of	act of	act of
1	17.3	0.13	0.13	0.13	1.2	0.13	0.13	0.13	1.0	0.13	0.13	0.13
2	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13
3	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13
4	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13
5	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13
6	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13
7	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13
8	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13
9	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13
10	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13
Mean	17.3	0.13	0.13	0.13	1.2	0.13	0.13	0.13	1.0	0.13	0.13	0.13
SD	1.1	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13
SD in	1.1	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13	0.13
percent of the mean	1.2%	0.13%	0.13%	0.13%	1.2%	0.13%	0.13%	0.13%	1.2%	0.13%	0.13%	0.13%

Table IV Lower confidence limits for synovial fluid C activity in 27 cases of non PA inflammatory arthropathies subgroups D (7 cases) E (8 cases) and F (4 cases) of Appendix Table I 3 cases of juvenile ankylosing spondylitis and one of septic arthritis (Appendix Table V)

SD = standard deviation

Deviation from the mean (93.8)	Synovial fluid C activity values		Definition
	limits	range	
-1 SD (26.6)	67.2	>67	non suppressed
-1.96 SD (52.1)	41.7	42-66	
-2.58 SD (68.5)	25.3	41-25	suppressed at the 1-5 per cent level
		<25	suppressed at the 1 per cent level

oligo arthritis SLE and SLE like syndromes were treated together as one group of miscellaneous arthropathies

As mentioned above the latter seemed to constitute a homogeneous group with respect to the synovial fluid C activity

As to the three RA groups discerned the lowest synovial fluid C activities were found in the group of RA with nodules and the highest in the group labelled SSC neg RA The group labelled SSC pos RA showed intermediate values (Fig 2)

Statistical analysis<sup>1</sup> (WILCOXON'S T test<sup>4</sup>) showed that the synovial fluid C activity values in the group of SSC pos RA were highly significantly higher than those in RA with nodules and significantly lower than those in the group of SSC neg RA (Fig 3) The outstanding low synovial fluid C activity in RA associated with nodules was the reason why RA with nodules was discerned as a separate group

The synovial fluid C activity in RA with nodules closely agreed with that found in the group of SLE or SLE like syndromes (Fig 3) where most patients showed extremely low synovial fluid C activities (Fig 2) In the latter group the estimated value of the synovial fluid C activity of 45 in one of the patients was probably erroneously high (see Appendix Table VI) This case is disregarded below

For reasons previously mentioned it was decided to use maximized values of the synovial fluid C activity when the no of CH<sub>20</sub> units of synovial fluid was extremely low Such maximized values appeared predominantly in RA with nodules and in the group of SLE and SLE like syndromes (Appendix Tables II and VI) The highest maximized value amounted to 14 Thus all fluids with a C activity of 11 or less—whether maximized values were concerned or not—were considered to have a C activity of 14 when individual values were considered in the statistical analysis

<sup>1</sup> (=MANN-WHITNEY'S U test) without correction for ties

# The C' activity of synovial fluid in various inflammatory arthropathies

The individual values of the synovial fluid C' activity are given in Appendix Tables I-VII together with some other data.

Within the respective arthritis groups concerned juvenile and adult forms showed comparable synovial fluid C' activities (see Fig. 2). For this reason no distinction was made between juveniles and adults. Females and males belonging to the same diagnostic group showed similar C' activities of synovial fluid.

Various non RA arthritides such as ankylosing spondylitis, urethral arthritis as well as some other non RA arthritides (subgroup I of Appendix Table I) showed on an average very similar synovial fluid C' activities with means of about 100 (Appendix Tables I and V). They were thus indistinguishable from those found in cases of osteoarthritis and lesions of the menisci etc. (subgroups A, B and C in Appendix Table I). In the latter case (subgroups A+B+C) however the variance was probably lower than that in the inflammatory arthropathies mentioned above (variance ratio 2.1;  $p < 0.01$ ).

With respect to the protein content and the white blood cell counts the

synovial fluids in the non RA inflammatory arthropathies mentioned were comparable to those in RA (see below).

The group consisting of the non RA inflammatory arthropathies mentioned (totalling 21 cases) served as a reference group with which other arthritis groups could be compared. The synovial fluid C' activity values in the reference group were symmetrically distributed around a mean of about 94. The mean and dispersion in this group also served as a basis for grouping of the synovial fluids and for the definitions (which for the sake of convenience are) used below (Table IV). Owing to the smallness of this group the limits and the definitions are uncertain and merely tentative.

Two other groups of seronegative inflammatory arthropathies, psoriatic arthropathy and (juvenile) oligoarthritis both showed on an average synovial fluid C' activities essentially comparable to those found in urethral arthritis and ankylosing spondylitis (Fig. 3).

Fig. 2 shows the C' activity of synovial fluid in the whole series of various arthropathies studied. Arthropathies other than RA, psoriatic arthropathy




Fig 3 Significance levels (P by Wilcoxon's T test) for the difference in synovial fluid C activity between SSC pos RA and some other arthritides  
C = The C activity of the median  
N = No of cases

with nodules 32/56 for SSC pos RA and 4/17 for SSC neg RA

sero negative arthritides mentioned above

The group labelled SSC pos RA showed significantly lower synovial fluid C activities in relation to SSC neg RA

The lowest synovial fluid C activities observed in RA is a whole highly significantly lower than those found in SSC pos RA appeared in the group labelled RA with nodules. Here the synovial fluid C activities were on an average as markedly suppressed as those observed in a small group of SLE or SLE like syndromes

**SUMMARY** Mean C activities of synovial fluid ranging from 80 to 110 —indistinguishable from those found in osteo arthrosis and lesions of the menisci—were found in the following arthritides: ankylosing spondylitis, uro poly arthritis (Reiter's syndrome), psoriatic arthropathy and (juvenile) oligo arthritis.

The group labelled SSC neg RA showed synovial fluid C activities essentially comparable to those found in psoriatic arthropathy and other

## The C' activity of different synovial fluid samples derived from the same patient

In order to study the intra-individual variation of the synovial fluid C' activity, synovial fluids were simultaneously aspirated from different joints of the same patient. In this way a comparison could be made between the C' activity of two fluids derived from each of 23 RA patients (Appendix Table VIII). The results (Table V) showed that the average C' activity of the new series of fluids thus obtained (generally from the left knee joint) was comparable to that of the first series of fluids (generally from the right knee joint). In relation to the between-patient variance, which was similar to that for the whole series of RA, the between-joint variance was significantly lower (Table V). This corresponded to some degree of correlation between the C' activity of the two fluids (simultaneously aspirated

Spearman's  $r_s = +0.46$ ,  $p < 0.02$ ). On the other hand, in approximately 2/3 of the patients (Appendix Table VIII) the difference in C' activity between the two fluids exceeded the methodological error, expressed as 2 standard deviations (see Table III). In several cases the difference was considerable (Appendix Table VIII).

In several patients synovial fluid

was aspirated from different joints (of the same patient) either simultaneously or on different occasions. The results summarized in Table VI showed that in all arthritis groups concerned except SSC pos RA the distribution of the synovial fluid C' activity of the 2nd joint series was very similar to that of the 1st joint series.

In arthritides other than RA 8 patients showed a non-suppressed C' activity in both synovial fluids, while one with probable psoriatic arthritis showed a suppressed C' activity in both synovial fluids (Table VI).

As already mentioned, new synovial fluids aspirated in cases of osteoarthritis showed non-suppressed C' activities as high as those of the synovial fluids initially aspirated (Fig. 1).

In RA with nodules as well as in SSC neg RA it was found that both synovial fluids from each patient showed either a suppressed or a non-suppressed C' activity. In RA with nodules tenosynovitis fluid was studied in three patients; all showed suppressed C' activities with values of 33, 16 and 6 respectively. From these results and the distribution of the synovial fluid C' activities in RA with nodules (Table VI) it was concluded that

Table V Comparison between the C activities of different synovial fluids simultaneously aspirated from different joints of the same RA patient (see Appendix Table VIII). For comparison the series of primary observations in RA is included. Fluids with maximized C activity values (C units/ml below 32) are not included

Fluids from	No of cases	C activity of synovial fluid	Mean $\pm$ SEM <sup>1</sup>	Analysis of variance of the data of Appendix Table VII				
				Source	Degree of freedom	Mean square	Variance ratio	P
Different joints	23	1st joint <sup>2</sup>	44.1 $\pm$ 0.93	Joints	1	230.13	0.76	> 0.2
		2nd joint <sup>3</sup>	39.6 $\pm$ 4.61	Patients	22	1009.74	3.272	< 0.0
				Error	22	303.63		
				Total	45			
Different patients	92	(1st joint <sup>3</sup> )	42.0 $\pm$ 3.06	Inter individual variance = 562.3				

<sup>1</sup> Standard error of the mean  
Generally the right knee joint

<sup>2</sup> Generally the left knee joint

Table VI Distribution of the C activity values of synovial fluids aspirated from different joints of the same patient either simultaneously or on different occasions

Diagnosis	No of observations	Synovial fluid from	C activity of synovial fluid			
			< 2	2-41	42-66	> 66
RA with nodules	8	1st joint	4	2	1	1
	8	2nd joint	5	1	1	1
SSC pos PA	19	1st joint	8	8	2	1
	19	2nd joint <sup>1</sup>	3	5	7	4
SSC neg RA	4	1st joint	1	3	—	1
	4	2nd joint	1	3	—	1
Psoriatic arthropathy	4	1st joint	1	—	—	3
	4	2nd joint	1	—	—	3
Miscellaneous arthropathies*	5	1st joint	—	—	1	4
	5	2nd joint	—	—	2	3

<sup>1</sup> Distribution non significantly different from that of the 1st joint series ( $\chi^2 = 4.61$  p = 0.10 2 degrees of freedom)

\* Chronic uric polyarthritis 1 ankylosing spondylitis 2 and oligo arthritis 2



in this group a suppressed C activity was a fairly consistent phenomenon in synovial fluids of various sources.

In SSC pos RA on the other hand the 2nd joint series showed a tendency towards a higher synovial fluid C activity in relation to that of the 1st joint series (Table VI). In this group several patients showed a suppressed C activity in synovial fluid from one joint and a high and non-suppressed one in fluid from another joint. The results here suggested a random variation.

When in SLE and SLE-like syndromes new fluids were aspirated, these showed suppressed C activities comparable to those initially found. In two of these patients totally seven fluids (five from different joints) showed C activities of 13, 23, 32, 18, 20, 32 and 8 respectively. In a third patient with an SLE-like syndrome and a probably erroneously high synovial fluid C activity, synovial fluids from three different joints all showed a number of C units that was lower than 32.

In addition to a between joint variation a within joint variation was present, the latter being studied by aspiration of fluid from the same joint on different occasions. In 22 RA patients' the synovial fluids first aspirated showed a C activity (mean 52.2, standard error of the mean  $\pm 8.20$ ) which was on an average similar to that of the subsequently aspirated fluids (mean 47.5, standard error of the mean 5.67). In this series of observations the between patient variance, which was comparable to that for the whole series of RA, was slightly

( $p < 0.10$ ) larger than the within joint variance. Here too the results suggested a random variation, especially in the subgroup labelled SSC pos RA.

When in RA fluids were aspirated on different occasions from the same joint, some degree of correlation was found between the C activity of the first fluid and that of the second (SPEARMAN  $\rho = +0.36$ ,  $p = 0.05$ ). No relation was found between the length of interval (mean about 14 months) between aspirations of fluid and the difference in C activity observed. The largest differences amounting to about 100 were observed in two RA patients where the interval between aspiration of fluid was half a month and three years respectively. In both instances the synovial fluid C activity had decreased from about 130 to about 30. One was a case of RA with nodules which initially showed an exceptionally high synovial fluid C activity (long standing synovitis). The other was a case of SSC pos RA with highly intense synovitis (evident also microscopically) of both knee joints for about 6 months, associated with a moderate to pronounced destruction of cartilage. Fluids were aspirated from both joints, one from the right knee joint showed a C activity of 10 and the other from the left knee joint a C activity of 127. After two weeks the C activity of synovial fluid from the latter joint had decreased to 23. In another case of SSC pos RA a marked decrease from 93 to 21 of the synovial

Tablets with maximized values of the synovial fluid C activity not included.

fluid C' activity was also observed during the course of a few weeks. The first fluid was aspirated after a few days duration of effusion and the second two weeks later.

In 9 non RA patients, 11 with psoriatic arthropathy and 3 with ankylosing spondylitis, synovial fluid was aspirated from the same joint on different occasions. All except one of these 18 synovial fluids showed a non suppressed C' activity. In one patient with probable psoriatic arthropathy the synovial fluid initially aspirated showed a C' activity of 37 and when aspirated later on an activity of 58.

When marked intra individual differences were found in the case of fluids derived from the same joint or from different joints the differences could not be related to any detectable difference in intensity of synovitis nor to the time for previously given intra articular injections of corticosteroids.

**SUMMARY** Synovial fluid aspirated from different joints of the same patient or from the same joint on dif-

ferent occasions were studied. In non RA inflammatory arthropathies such as psoriatic arthropathy, ankylosing spondylitis and polyarthritis and oligoarthritis the C' activity of synovial fluid from different joints was almost consistently non suppressed.

The results suggested that in RA with nodules as well as in SLE and SLE like syndromes the C' activity of fluids from different joints was more consistently suppressed than in SSC and RA.

When in RA as a whole additional fluids were aspirated some degree of correlation was found between the C' activity of the second fluid and that of the first fluid. This was true whether the fluids were aspirated from the same joint or from different joints. In both cases the results suggested a random variation of the synovial fluid C' activity values.

Presumably no bias was introduced through representing each patient by one single randomly selected synovial fluid.



about 1, as shown in Table VIII essentially similar values were found at different synovial fluid C' activity levels. This result suggested that in most cases the bulk of gamma globulins in synovial fluid derived from blood plasma. Obviously a local production of minute amounts of gamma globulins would not be detected by the ordinary paper electrophoretic method used. The possibility that different proteins of synovial fluid may have different elimination rates could also be mentioned as a cause of the sometimes high ratio between the gamma globulins of synovial fluid and those of serum.

#### *White blood cell counts (total leucocytes per mm<sup>3</sup> synovial fluid)*

In addition to cases of osteoarthritis where the lowest cell counts were observed (mostly below 1000) synovial fluid cell counts were determined in 91 essentially unselected cases (Table IX).

The overall results showed that, neither in RA as a whole nor in the other arthritides studied was there any relation between the C' activity and the cell counts of synovial fluid (Table IX).

The three RA groups discerned which differed from each other in synovial fluid C' activity showed on an average very similar synovial fluid cell counts amounting to about 16 000 (Table IX).

Within the group labelled SSC pos RA a (non significant) tendency could be traced towards higher cell counts when the C' activity decreased where

as in the group of SSC neg RA the few fluids with C' activities below 42 showed fairly low cell counts comparable to those found in SLE and SLE like syndromes (Table IX). Clinical as well as laboratory data (negative ANF and LL cell tests) however argued against these few cases of SSC neg RA being SLE or SLE like rather than RA.

Most patients studied especially those with RA had had long standing effusion often for years. It could indeed be argued whether the effusion in these cases might not often be secondary osteoarthrotic rather than rheumatoid. Although a contribution of secondary osteoarthrotic mechanisms to the effusion could not be excluded the evidence was against a pure secondary osteoarthritis being of major importance. In the whole series of 56 RA patients where cell counts were made counts approaching those found in osteoarthritis i.e. below 3000 were found only in two patients one with a synovial fluid C' activity of 39 and one with an activity of 11. In addition cell counts in RA in the range of 4000 to 6000 seemed to appear as often in early as in long standing effusion. Rheumatoid fluids with a protein content comparable to that of osteoarthrotic fluids showed in relation to these higher cell counts (generally above 5000).

#### *Anticomplementary activity of synovial fluid*

In order to study the presence of anticomplementary activity of synovial fluid especially of fluids with ex

Table 11. White blood cell counts of synovial fluid at different C activity levels  
 Figures in parentheses show no. of cases

Diagnosis	No of cases	White blood cell counts $\times 10^3$ per mm <sup>3</sup>				Mean $\pm$ SEM	Range
		C activity of synovial fluid					
		< 9	9-11	12-66	> 66		
RA synovial nodules	19	10 (14)	219 (7)	51 (1)	110 (1)	10 $\pm$ 2*	27-477
VSCLosis RA	—	29 $\pm$ 6.9 (8)	138 $\pm$ 7.9 (8)	119 (6)	84 (3)	108 $\pm$ 4	76-60.5
SLE non RA	10	64 ( )	74 (1)	5 (1)	70 (0)	100 $\pm$ 3	34-60.9
Total RA	36	17 (4)	100 (17)	11 (10)	177 (10)	108 $\pm$ 1.8	27-66.4
SLE and SLE like synovitis	6	1 ( )	113 ( )	—	—	111 $\pm$ 1.0	17-113
Torsion arthropathy	8	3 (2)	107 ( )	—	150 (5)	181 $\pm$ 6.4	110-60.5
Osteoarthritis	5	—	—	—	258 (5)	258 $\pm$ 10.0	150-61.9
Miscellaneous arthropathies	11	—	—	110 (7)	119 (11)	111 $\pm$ 2.8	38-10.9
Postfectious rheumatism	1	—	—	—	219.0	—	—
Septic arthritis	1	—	—	—	390.0	—	—

\*Standard error of the mean

Mean WBC non significantly higher than that for fluids with higher C activities

Various non RA's no negative arthropathies prelongantly antihypertensive (7) and ureoparthritis (3)

Extremely low C activities a simple non kinetic procedure was used

Fresh as well as heat inactivated fluids (at 56°C 30 min) were added to an equal volume of normal serum or synovial fluid the mixture was appropriately diluted and the hemolytic activity of the mixture found was compared with the expected one (see Table 1). The degree of anticomplementary activity was defined by the deviation

of the activity found from the expected one and expressed in per cent of the latter (see Table 1). Most fluids studied by this technique derived from patients with RA SLE and SLE like syndromes fluids with the lowest C activity were studied in a lower final dilution than those with higher C activities

As regards anticomplementary activity no difference was found be

*Table 1* The anticomplementary activity of synovial fluids with different C' activities. The fresh fluid to be studied containing  $n_1$  C H<sub>50</sub> units/ml was mixed with an equal volume of normal serum containing  $n_2$  C H<sub>50</sub> units/ml. The no. of C H<sub>50</sub> units found ( $n_3$ ) was compared with  $(n_1 + n_2)$  the expected no. of C H<sub>50</sub> units; the deviation given below was expressed in per cent as follows:

$$(n_1 + n_2 - n_3) \times \frac{100}{n_1 + n_2} \quad \text{For heat inactivated fluids (56°C 30 min)}$$

where  $n_1 \approx 0$  the deviation was similarly expressed

Figures in parenthesis = % of heat inactivated fluids

	C' activity of synovial fluid			
	<25	25-41	42-66	>66
No. of fluids	20 (7)	10 (4)	6 (3)	8 (3)
Average deviation	+ 2.71	- 1.44	+ 1.1	+ 7.4
in per cent	$\pm 11.9^1$	$\pm 10.3$	$\pm 11.8$	$\pm 13.0$

<sup>1</sup> SD

between fresh and heat inactivated fluids the latter being included in order to study the synovial fluid in its native state as possible.

As shown in Table 1, where fresh and heat inactivated fluids were treated together no anticomplementary activity was found by the technique used whether the C' activity was suppressed or not. Six of the fluids with C' activities below 25 contained less than 32 C H<sub>50</sub> units per ml.

The results also showed that there was no relation between the RF titre of synovial fluid and the small deviations observed; the latter indeed being consistently within the error of the method.

### *The erythrocyte sedimentation rate (ESR)*

In SLL and SLE like syndromes low synovial fluid C' activities were gener-

ally associated with fairly high ESR values (mean 77) whereas in oligo arthritis non suppressed synovial fluid C' activities were associated with relatively low ESR values (mean 18). In the remaining arthritides studied however the means of the ESR were fairly uniform (44-61) irrespective of the differences in synovial fluid C' activity (Table VI). In addition within the various arthropathies discerned the mean ESR was essentially similar at different synovial fluid C' activity levels (Table VI). This was true whether corticosteroids *per os* or ACTH were given or not (Table VI).

Neither in steroid treated nor in untreated RA was there any correlation between the ESR and the synovial fluid C' activity (Table VII). Thus if the ESR is accepted as a parameter reflecting the disease activity, no relation was found between the latter and

Table VI Erythrocyte sedimentation rate (ESR) at different synovial fluid C activity levels  
 Figures in parenthesis = No. of cases

Diagnosis	Corticosteroids per os or ACTH	C activity of synovial fluid				No. of cases	ESR	
		<20	20-41	42-66	>66		Mean $\pm$ SEM	Range
SLE and SLE like syndromes	-	69 (2)	120 (1)	—	—	6	78	—
	+	76 (3)	—	—	—	7	76	21-106
RA with nodules	-	36 (6)	30 (3)	—	—	9	54 $\pm$ 7.3	24-61
	+	60 (13)	93 (2)	46 (2)	68 (1)	18	63 $\pm$ 9.9	27-73
SSC pos RA	-	37 (10)	71 (11)	31 (13)	32 (8)	42	58 $\pm$ 4.0	11-61
	+	31 (6)	61 (2)	31 (2)	29 (1)	14	51 $\pm$ 6.4	20-61
SSC neg RA	-	68 (2)	—	73 (4)	46 (1)	12	50 $\pm$ 9.8	17-61
	+	—	—	—	31 (2)	3	71	16-71
Psoaritic arthropathy	-	61 (1)	81 (2)	—	33 (8)	11	60 $\pm$ 11.1	13-71
	+	—	—	—	63 (7)	7	63	20-71
Oligo arthritis	-	—	—	—	16 (7)	7	16	3-23
	+	—	—	—	31 (1)	1	31	—
Miscellaneous arthropathies	-	—	—	37 (4)	37 (19)	23	71 $\pm$ 7.3	31-121
	+	—	—	—	31 (2)	2	31	41-61

Standard error of the mean

Various (non RA) arthritides—subgroups D-1 of Appendix Table I and corresponding juvenile cases of Table I

the synovial fluid C activity. The same was true of various non RA arthritides.

As concerns the intensity of the synovitis the result was similar no clear cut relation was found between the intensity of synovitis and the synovial fluid C activity. Only high synovial fluid C activities were noted in some patients with very intense synovitis and *vice versa*. The reservation here is that it is difficult to obtain but a rough estimation of the intensity of synovitis.

### Antinuclear factors (ANFs) in sera

A test for ANFs (in serum) was made not only in SLE and SLE like syndromes and in psoriatic arthropathy but also in 68 per cent of the RA patients.

The tests in RA were made with comparable frequency at different synovial fluid C activity levels.

In addition to SLE and SLE like syndromes a positive test for ANFs was found in an appreciable proportion of the RA patients with nodules (Table VII). In this group of RA a

Table VII Frequency of positive antinuclear factor (ANF) test in serum at different synovial fluid C activity levels

Diagnosis	No of cases	Positive ANF test (serum)	C activity of synovial fluid			
			<2	2-41	42-66	>66
SLE and SLE like syndromes	9	8/9	8/8	0/1	—	—
RA with nodules	21	12/21 <sup>1</sup>	8/14	3/1	0/2	1/1
SSC pos RA	34	10/34	1/11	2/10	4/7	1/6
SSC neg RA	13	1/13	0/2	0/2	1/4	0/3
Total RA	68	23/68	11/27	5/16	5/13	2/12
Psoriatic arthropathy	11	4/11	1/1	0/2	—	3/8

Frequency probably higher than that in SSC neg RA ( $\chi^2=6.30$   $p<0.05$ )

positive test for ANFs occurred probably more often than in the group of SSC neg RA ( $p<0.05$  Table VII) whereas in SSC pos RA an intermediate frequency was found.

Within the three RA groups discerned as well as in RA as a whole the frequency of a positive test for ANFs seemed to vary irregularly in relation to the synovial fluid C' activity levels (Table VII). Four out of 11 psoriasis patients showed a positive test for ANFs in 3 out of these 4 the synovial fluid C' activity was higher than 66 (Table VII).

In 0 patients who had or had had keratoconjunctivitis sicca there seemed to be a coincidence of a positive test for ANFs and an extremely suppressed synovial fluid C' activity. One had a synovial fluid C' activity of 26, and the others had values ranging from 7

to 13. Three of the patients belonged to the group SLE or SLE like syndromes and 6 were RA patients all but one with nodules.

**SUMMARY** Attempts were made to relate the synovial fluid C activity to various parameters such as the protein content and the concentration of gamma globulins in synovial fluid, the white blood cell counts of synovial fluid, anticomplementary activity of synovial fluid, the ESR and the presence of antinuclear factors in serum. No obvious relation was found between the parameters mentioned and the synovial fluid C' activity nor between the latter and the intensity of synovitis.

In addition to SLE and SLE like syndromes an extremely suppressed synovial fluid C activity seemed to coincide with a positive test for ANFs (in serum) in RA with nodules especially if the patient had or had had keratoconjunctivitis sicca.

<sup>1</sup> The occurrence of keratoconjunctivitis sicca in the present series was not specifically looked for.



# The C' activity of synovial fluid and the duration of effusion

In most RA patients with an effusion of less than 6 months duration effusion had lasted either for 2 months or less or for more than 3 1/2 months. Owing to this somewhat uneven distribution it was decided to use a dividing line of 3 months for distinguishing between 'early' and 'long standing' effusion<sup>1</sup>.

In the largest group of RA i.e. that of SSC pos RA three patients with effusion for 3 1/2 to 6 months showed an average synovial fluid C' activity of 35 which closely agreed with that of 31 for five patients with effusion for 7 to 12 months. In long standing effusion for more than 12 months the average synovial fluid C' activity for 37 patients was very similar i.e. 37. In the following account all effusions lasting for more than three months will therefore be treated together as long standing.

In the group of miscellaneous non RA arthritides as a whole (subgroups D—F of Appendix Table I and corresponding juvenile cases of Appendix Table V) no clear cut relation was found between the C' activity of synovial fluid and the duration of effusion. The findings in psoriatic arthropathy were essentially similar (Appendix

Table VII). Occasionally e.g. in ankylosing spondylitis and urethral polyarthritis a tendency could be traced towards a somewhat lower synovial fluid C' activity in instances of long standing effusion as compared with that in early one (Appendix Tables I and V).

In the small group of SLE and SLE-like syndromes C' activity of synovial fluid was found to be equally suppressed in early as in long standing effusion (Appendix Table VI). Two of the patients with early effusion had had effusion for only 3 and 5 days respectively. Both showed synovial fluid C' activities below 25.

In the group of RA with nodules only three patients had early effusion all three showing extremely low C' activities comparable to those found in most instances of long standing effusion (Table VIII). However none of these patients presented a fresh effusion of only a few days duration—effusion had lasted for about 8 to 10 weeks. In two of the three patients

The term duration of effusion was defined by the interval between the first appearance of effusion and the time of aspiration of fluid. In most cases it seemed to be essentially synonymous with the duration of synovitis.

Table VIII Distribution of the synovial fluid C activity values in early effusion of less than 3 months duration and in long standing effusion of more than 3 months duration. Figures in parenthesis = % of cases with effusion of less than 3 weeks duration

Diagnosis	No of cases	Duration of effusion in months	C activity of synovial fluid			
			<25	25-41	42-66	>66
SLE and SLE like syndromes	4	<3	3 (2)	1	—	—
	5	>3	5	—	—	—
RA with nodules	3	<3	3	—	—	—
	24	>3	16	5	2	1
SSC pos RA	11	<3	1	4 (1)	2	4 (2)
	45	>3	15	12	13	5
SSC neg RA	3	<3	—	1 (1)	1	1
	14	>3	2	1	3	8
Total RA	17	<3	4	5 (2)	3	5 (2)
	83	>3	33	18	18	14

with early effusion synovial fluid was aspirated from another joint where effusion had lasted for 2 and 4 weeks respectively. Both of these additional synovial fluids showed extremely low C activities of 9 and 7 respectively.

As judged from the few observations made in early effusion in the group of SSC neg RA these showed synovial fluid C activities similar to those found in long standing effusion (Table VIII). One patient with a synovial fluid C activity of 36 had a fresh effusion of 2 days duration. In this patient effusion of both knee joints had appeared simultaneously (during hospitalization) fluid derived from the other knee joint showed a C activity of 39. In this case slight to moderate capsular swelling had been noted before exudation and the patient had had morning stiffness and pains

in both knee joints for one to two months.

In the group of SSC pos RA 11 patients presented early and 45 long standing effusion (Table VIII). The average synovial fluid C activity in early effusion of  $54.7 \pm 7.93^*$  was probably higher than that of  $36.6 \pm 3.46$  in long standing ( $t=2.09$   $p<0.05$ ). This difference in C activity between early and long standing effusion was reflected by a somewhat different distribution of the C activity values only one out of 16 fluids with a C activity below 25 was aspirated during early effusion—in this case 2 to 3 weeks after the appearance of effusion—whereas of C activities above 66 4 out of 9 fluids belonged to the group of early effusion (Table VIII). Two out

\* Standard error of the mean

of the 4 fluids mentioned were aspirated after effusion for 2 days or less; only one additional patient showing a synovial fluid C activity of 41 had a similar fresh effusion for only 2 days. The other two fluids with a C activity above 60 were aspirated after effusion of 2 to 3 weeks duration. The most intense synovitis in early effusion (for 2 days) was associated with a synovial fluid C activity of 97.

In 5 of 7 patients with SSC pos RA and 1 not fluid from their joints with early effusion were studied two to three weeks after about 2 weeks and two to three weeks. The results here agreed with those of the primary observations. The average C activity of these 5 fluids was 61 (range 41 to 87) as compared with that of about 30 for the 11 primary observations in early effusion.

In two patients with SSC pos RA and early effusion the C activity was followed for a period of four to five months. In one with 3 weeks effusion the C activity gradually decreased from 49 to 37 to 2. In the other in this sense synovial fluids from the knee joints were studied after a further 33 and 44 to 95 and 21 weeks after the C activity rose from non-suppressed values of 60 and 87 respectively. In two patients with RA and no lesions similarly studied the samples as rated from the joint initially studied during early effusion showed a fall in activity as long as those initially found.

In two patients with seropositive RA and no lesions in effusion one with nodules and one without the mean C activity of the synovial fluid at the first study about 100 was observed.

In 5 of 10 the RA as a whole of some degree of mild to moderate severity as judged between the duration of effusion and the synovial fluid C activity during the first 6 months of exudation. SPERMATOPHYTES: 0.40 < 0.005.

The lower synovial fluid C activity in RA 17 cases as compared with that in non-RA seronegative arthritis 17 cases (30.4 vs 4.3) was a statistically significant difference.

and first during the first 3 months of exudation (p < 0.001 by Wilcoxon's Test). A significant difference did not exist during the first 10 days of exudation.

**SUMMARY** In RA and the group of SLE and SLE-like syndromes fresh effusions of only 2 days duration or less were studied only in 6 patients. A significant suppression of the C activity of synovial fluid was observed only in two of these patients. One had a typical SLE and the other in SLE-like syndrome. Of the remaining four patients—RA without nodules—two showed high or non-suppressed C activities and two C activities that were suppressed at the 5 per cent level.

In addition to SLE and SLE-like syndromes extremely suppressed synovial fluid C activities were consistently found only in the group of RA with nodules during the first three months of exudation. However in the latter case synovial fluids were studied only when the exudation had lasted for two weeks or more.

In SSC pos RA the largest group studied the C activity was found to be higher during the first three months of exudation than in more long-standing effusion.

In RA as a whole the evidence was equivocal rather than in favour of a suppression of the total C activity of synovial fluid probable at the 5 per cent level. It remains an early phenomenon during the course of exudation. On the other hand during the first 3 months of exudation this activity was found to be on an average highly significantly lower in RA than in non-RA seronegative arthritides.

## The C' level of serum

Since some kind of association was found between the C' level of serum and the ESR it was necessary briefly to consider this relation first. Steroid treated patients (including a few receiving ACTH instead of corticosteroids) and untreated ones will be dealt with separately.

Table IV shows the means of the ESR and the C' level of serum in some untreated arthropathies as well as in a group of healthy controls. The results which suggested a connection between the ESR and the C' level of serum indicated that in the group of miscellaneous non RA arthritides the mean C' level of serum as well as the mean ESR were raised to about the same levels as in RA (Table IV).

In steroid treated as well as in untreated RA no relation was found between the C' level of serum and the SSC or latex titre of serum.

Table V shows the means of the C' level of serum and the ESR at (three) different synovial fluid C' activity levels.

In relation to the few cases of untreated SLE and SLE like syndromes untreated RA with almost equally low synovial fluid C' activities seemed to

show higher C' levels of serum and lower ESR values (Table V).

In steroid treated RA comparable amounts of corticosteroids were given at different synovial fluid C' activity levels the daily mean doses (as prednisolone) from lower to higher levels being 4.0, 3.6 and 3.7 mg in SLE and SLE like syndromes higher doses of on an average 10 mg were given ACTH—on an average 60 IU/week—instead of corticosteroids was given equally often at the three synovial fluid C' activity levels discerned.

The mean C' level in the group of steroid treated RA ( $1129 \pm 41.9$ ) was probably lower than that ( $1221 \pm 25.9$ ) in the group of untreated RA ( $t=1.97$ ,  $p=0.05$ ) the mean ESR in both groups was 56.

In the small group of SLE and SLE like syndromes the C' level of serum seemed to be lower in untreated than in steroid treated patients whereas the ESR was comparable with means of 78 and 76 respectively (Table V). In one of the patients with a typical SLE a higher C' level of serum of 910 (ESR 46) was observed during treatment.

Standard error of the mean

Table VI The mean C level of serum (C R<sub>0</sub> units/ml) and the mean ESR in various arthropathies 1 or comparison a group of healthy controls was included—No treatment with corticosteroids per os or with ACTH

Subject	No. of cases	ESR	C level of serum
		Mean $\pm$ S.E.M. <sup>a</sup>	Mean $\pm$ S.E.M. <sup>a</sup>
Healthy controls	73	7.8 $\pm$ 0.24	921 $\pm$ 2.6
Subgroups A—C of Appendix Table I	14	13.7 $\pm$ 7.0	1174 $\pm$ 62.8 *
Oligo arthritis	"	16.4 $\pm$ 0.3	1141 $\pm$ 99.7
Miscellaneous non RA arthritides <sup>b</sup>	23	23 $\pm$ 1.0	1261 $\pm$ 16.3 *
RA	62 <sup>c</sup>	26 $\pm$ 3.6	1221 $\pm$ 20.9

<sup>a</sup> Standard error of the mean

\* Subgroups D—F of Appendix Table I and corresponding (n n l y) juvenile cases of Appendix Table I

<sup>b</sup> Probably higher than the mean for healthy controls ( $p < 0.01$ )

Highly significantly higher than the mean for healthy controls ( $p < 0.001$ )

<sup>c</sup> One juvenile with verified amyloidosis excluded

with ACTH as compared with that of 346 (ESR 30) without ACTH (or steroids)

In untreated RA synovial fluids with the lowest C activity (below 25) were found to be associated with a mean C level of serum (1138  $\pm$  37.7) which was probably lower than that (1261  $\pm$  16.3) of the group of miscellaneous non RA arthritides ( $t = 2.01$ ,  $p < 0.05$ , Table VI)

In steroid treated RA the results were principally similar (Table VI). At higher synovial fluid C activities i.e.  $> 25$  the mean C level of serum in RA essentially agreed with that of the group of sero negative miscellaneous arthropathies whether steroid treated

or untreated patients were considered (Table VI)

The correlations between the C level of serum the ESR and the synovial fluid C activity are reported in Table VII

In untreated RA as well as in a group consisting of various (untreated) non RA sero negative arthropathies the only correlation found was a positive one between the C level of serum and the ESR (Table VII)

In steroid treated RA on the other hand where no correlation was found between the C level of serum and the ESR the only correlation found was a

<sup>a</sup> Standard error of the mean

Table 11 The mean C level of serum (C H<sub>30</sub> units/ml) and the mean ESR in RA and in SLE and SLL like syndromes. Non RA miscellaneous arthritides included for comparison

Diagnosis	Corticosteroids per os or ACTH	C activity of synovial fluid	No of cases	C level of serum Mean $\pm$ SEM <sup>1</sup>	ESR Mean $\pm$ SEM <sup>1</sup>
Miscellaneous non RA arthritides <sup>2</sup>	—	>41	23	1261 $\pm$ 46.3	53 $\pm$ 7.5
RA	—	>41	24	1212 $\pm$ 39.1	48 $\pm$ 4.7
RA	—	25—41	16	1329 $\pm$ 51.5	67 $\pm$ 7.3
RA	—	<25	18	1133 $\pm$ 33.7 <sup>3</sup>	59 $\pm$ 7.1
SLE and SLE like syndromes	—	25—41	1	1057 —	140 —
	—	<25	2	868 $\pm$ 175.3	69 $\pm$ 19.7
Miscellaneous non RA arthritides	+	>41	6	1403 $\pm$ 102.0 <sup>4</sup>	55 $\pm$ 12.7
RA	+	>41	11	1319 $\pm$ 74.1 <sup>4</sup>	42 $\pm$ 4.8
RA	+	25—41	7	1248 $\pm$ 36.7	72 $\pm$ 12.1
RA	+	<25	10	975 $\pm$ 46.1	57 $\pm$ 5.3
SLE and SLE like syndromes	+	<25	3	1207 —	76 —

<sup>1</sup> Standard error of the mean

<sup>2</sup> Various non RA sero negative arthritides (group 4 of Table 11)

<sup>3</sup> Significantly higher than 1133 ( $p < 0.01$ )

<sup>4</sup> Probably lower than the mean of 1261 for miscellaneous arthropathies ( $p \sim 0.05$ )

<sup>5</sup> Highly significantly higher than 975 ( $p < 0.001$ )

positive one between the C level of serum and the synovial fluid C activity (Table 11).

**SUMMARY** In untreated RA (no steroids) as well as in a group of non RA sero negative (untreated) arthropathies the C level of serum was found to be positively correlated to the ESR although not to the synovial fluid C activity.

In untreated RA with an extremely suppressed synovial fluid C activity

(values below 25) the mean C level of serum was probably lower than that in non RA sero negative arthritides.

In steroid treated RA where no correlation was found between the C level of serum and the ESR a positive correlation was observed between the C level of serum and the synovial fluid C activity.

In RA no relation was found between the C level of serum and the RF titres of serum.

Table VII Correlations (SPEARMAN'S  $r$ ) between the C level of serum ( $C'_S$ ) erythrocyte sedimentation rate (ESR) and C activity of synovial fluid ( $C'_{act-SF}$ )

Diagnosis	Relation considered	No. of cases	Steroids or ACTH	SPEARMAN'S $r$
Rheumatoid arthritis	$C'_S$ to ESR	62	-	+0.32
		37	+	+0.07
	$C'_S$ to $C'_{act-SF}$	62	-	+0.09
		37	+	+0.06 **
	$C'_{act-SF}$ to ESR	62	-	-0.10
		37	+	-0.20
Miscellaneous non RA arthropathies <sup>1</sup>	$C'_S$ to ESR	41	-	+0.40
	$C'_S$ to $C'_{act-SF}$	41	-	+0.09
	$C'_{act-SF}$ to ESR	41	-	+0.01

<sup>1</sup> Groups 2-4 of Table VII

## The C' activity of synovial fluid and the rheumatoid factor (RF) tests

Evidence has been presented above that the synovial fluid C' activity is suppressed almost exclusively in syndromes where a positive RF test is a characteristic feature i.e. in RA and SLE or SLE like syndromes. Further more even within the group of RA a whole relatively low C activities were found to be associated with a high frequency of clearly elevated RF titres. At relatively high C activities on the other hand such titres were observed only occasionally (Table XVII). The association with the RF titre was—as shown in Table XVII—statistically highly significant. This was true of each of the RF titres determined i.e. the SSC titre of serum and the latex titres of serum and synovial fluid. This relation between the synovial fluid C' activity and the RF titres will be considered in detail below.

Obviously the low frequency of positive RF tests at relatively high synovial fluid C activities (above 66 Table XVII) was due to the fact that here the bulk consisted of cases labelled SSC neg. RA with their low frequency of positive RF tests (0/17 by SSC test and 4/17 by the latex tests Appendix Tables IV and V). On the other hand it should be noted that among the en-

tire series of 100 patients accepted as RA only 13 (with negative RF tests at the time of examination) had shown a consistently negative SSC<sub>s</sub> test. Five of these 13 were juvenile with a relatively early onset of joint symptoms (Appendix Table V) where sero negativity is the rule. Eight were adult females (=9 per cent of the whole series of adult RA) of whom one had early and transient, and seven long standing arthritis. These seven like four out of five juveniles all had erosive arthritis satisfying 6 or more of the criteria proposed by ROPES *et al.* (1958).

Because the SSC<sub>s</sub> titre seemed to be modified by previous treatment with gold salt the RF titres in gold treated RA will be considered briefly below.

<sup>1</sup> The following abbreviations were used: SSC<sub>s</sub> test for the sensitized sheep cell (SSC) test on whole serum; latex<sub>s</sub> test and latex<sub>sf</sub> test for the latex agglutination tests on the euglobulin fraction of serum and synovial fluid respectively. Although some kind of covariation similar to that described by WINBLAD (1960) seemed to exist between the three RF titres determined there was no absolute agreement. In addition the latex tests were more sensitive than the SSC<sub>s</sub> test (see Appendix Tables II-VI). For these reasons each of the three RF titres determined will be considered separately below.



Table VII Distribution of the RF titres at different synovial fluid C activity levels in 100 cases of RA

RF test	RF titre	No of cases	C activity of synovial fluid				$\chi^2$	P
			<20	20-40	40-60	>60		
SSC <sub>S</sub> <sup>1</sup>	<20	27	1	6	7	13	29.91 <sup>2</sup>	<0.001
	20-40	26	10	6	9	1		
	>40	41	22	11	5	3		
	>60	41/100	22/37	11/23	5/21	3/19		
Latex <sub>S</sub> <sup>2</sup>	<20	22	2	2	3	15	27.03 <sup>3</sup>	<0.001
	20-40	33	6	10	6	1		
	>40	45	23	11	12	2		
	>60	45/99	23/36	11/23	12/21	2/19		
Latex <sub>SF</sub> <sup>2</sup>	<20	23	2	2	4	15	30.22 <sup>3</sup>	<0.001
	20-40	22	6	10	4	2		
	>40	52	23	10	12	2		
	>60	52/97	23/36	10/22	12/20	2/19		

<sup>1</sup> SSC<sub>S</sub> = SSC titre of whole serum

<sup>2</sup> Latex<sub>S</sub> = latex agglutination titre of the euglobulin fraction of serum the titre not determined in one case

<sup>3</sup> Latex<sub>SF</sub> = latex agglutination titre of the euglobulin fraction of synovial fluid the titre not determined in three cases

<sup>4</sup> Six degrees of freedom

<sup>5</sup> Four degrees of freedom at each titre level fluids with C activities above 40 were amalgamated to one group

The SSC<sub>S</sub> titre in gold treated and untreated RA patients is reported in Table VIII. Only cases of RA with nodules (A) and SSC pos RA (B) were considered. Untreated refers to RA patients never treated with gold salts and to those treated more than five years before examination. The SSC<sub>S</sub> titre in the former patients was highly significantly increased above that in patients treated within three years before examination. The three RF titres determined were all non significantly

lower in patients treated more than five years before examination than they were in patients never treated with gold salts.

As shown in Table VIII SSC<sub>S</sub> titres below 32 in group A as well as in group B were found with some preponderance in patients who had received gold therapy during the three years preceding examination. When groups A and B were combined the incidence of such low titres was significantly lower in patients treated

Table VIII The RF titres of serum (by the SSC<sub>5</sub> and latex<sub>5</sub> tests) and synovial fluid (Latex<sub>5F</sub> test) in relation to previous treatment with gold salts

Diagnosis	No of cases	Time for previous gold therapy (years)	SSC <sub>5</sub> titre				
			≥16	32	64	128—256	≥12—1024
A	16	>5 <sup>1</sup>	—	2	3	5	11
RA with nodules	7	3—5	—	—	2	—	1
	8	<3	4	1	—	2	1
II SSC pos RA	10	>5 <sup>1</sup>	6	6	6	15	7
	8	3—5	1	1	4	1	1
	8	<3	5	1	—	1	1
A+B	56	>5 <sup>1</sup>	6	8	9	20	13
	11	3—5	1	1	6	1	2
	16	<3	9	2	—	3	2
			Latex <sub>5</sub> titre				
			≤10	20	40	80	≥160
A+B	55	>5 <sup>1</sup>	4	2	12	16	21
	11	3—5	1	—	3	4	3
	16	<3	4	1	3	5	3
			Latex <sub>5F</sub> titre				
			≤10	20	40	80	≥160
		56	6	7	6	16	21
		9	—	—	3	2	4
		15	3	3	2	3	4

<sup>1</sup> >5 includes patients not previously treated with gold salts as well as two patients (both with elevated RF titres) examined during gold therapy. In this group (>5<sup>1</sup>) there was no significant difference in RF titres between untreated and gold treated patients.

<sup>2</sup> SSC<sub>5</sub> titres below 32 highly significantly more frequent than in the >5 group ( $p < 0.001$ ).

during the past three years than in untreated ones ( $p < 0.001$ ). In some of the patients negative SSC<sub>5</sub> titres had been observed before treatment if these patients were excluded the corresponding difference was significant at the 2 per cent level. Patients treated with gold salts three to five years before

examination seemed to show an intermediate distribution of the SSC<sub>5</sub> titres (Table VIII).

The latex<sub>5</sub> as well as the latex<sub>5F</sub> titre showed only a statistically non significant

More intense gold salt therapy and more recent treatment seemed to be associated with the lowest SSC<sub>5</sub> titres.

Table VII Correlation (SIEFMAN'S *r*) between synovial fluid C' activity and RF titre  
 Figures in parenthesis = No. of cases

RF test	Disease	A No gold therapy <sup>1</sup>			B Gold therapy <sup>1</sup>		
		No of cases	Type of effusion			No of cases	Type of effusion
			Early	Long standing	Early and long standing		Early and long standing
	The whole series <sup>2</sup>	174	-0.44 (37)	-0.51 (59)	-0.53 (171)	32	-0.07
SSC <sub>5</sub>	RA as a whole	1	-0.47 (16)	-0.5 (22)	-0.5 (11)	29	-0.12
	RA w nodules and SSC pos RA	56	0.47 (13)	-0.3 (13)	-0.40 (30)	27	-0.09
	The whole series	173	0.1 (36)	-0.27 (87)	0.1 (103)	72	-0.16
L test <sub>5</sub>	RA as a whole	0	0.45 (16)	0.51 (22)	-0.59 (11)	29	-0.07
	RA w nodules and SSC pos RA	55	0.31 (13)	0.31 (12)	-0.39 (11)	27	-0.03
	The whole series	174	-0.45 (37)	0.1 (89)	-0.53 (174)	70	-0.06
Jo	RA as a whole	71	-0.19 (16)	-0.45 (22)	-0.41 (71)	97	-0.40
	nodules pos RA	56	0.19 (17)	0.17 (12)	0.18 (30)	24	-0.3

<sup>1</sup> 1 = 5 years preceding examination

<sup>2</sup> 1 = 1 SLE like syndromes psoriatic arthropathy oligo arthritis and various non negative arthropathies listed in Appendix Tables I and II

titres to be lower than 40 which gold salts had been given during the three years preceding examination  $p > 0.10$  Table VIII)

In order to obtain a group of RA patients in whom the RF titres especially the SSCs titres could be accepted as being uninfluenced—or only negligibly influenced—by previous gold therapy

a limit of five years rather than three was used although the three year limit—not the five year one—was statistically justified RA patients who had received gold salts during the five years preceding examination are referred to below as treated

The synovial fluid C' activity at different RF titre levels in untreated RA




Fig 4 Relation synovial fluid C activity to RF titre of serum by the sensitized sheep cell (SSC) test—100 cases of RA and 20 of miscellaneous sero negative inflammatory arthropathies such as ankylosing spondylitis, uro polyarthritis etc (subgroups D E F of Appendix Table I and corresponding juvenile cases of Appendix Table V)

A No gold therapy during the 5 years preceding examination

B Gold therapy during the 5 years preceding examination


The upper line in the Fig is drawn 1 standard deviation below the mean for the group of non RA sero negative miscellaneous arthritides the lowest two lines represent the 0 and 1 per cent limits used (see Table IV)

and in a group of miscellaneous sero negative arthropathies is graphically demonstrated in Figs 4 A—6 A. As shown in these figures RA cases with nodules generally occupied the lower range of the synovial fluid C' activity especially at high titre levels.

In untreated RA as well as in the whole series of untreated arthropathies the degree of correlation between the synovial fluid C activity and the RF

titre was statistically highly significant (Table XIX). In a diagnostically certain group of RA consisting of RA with nodules and SSC pos RA the results were moreover similar except for the relation synovial fluid C activity to latex titre (Table XIX).

Also in the case of the remitting arthropathies studied (arbitrarily treated together in Fig 7) the results fitted in with some kind of association be



Relation synovial fluid C' activity to RF titre of serum by the latex test—The same symbols as in Fig. 4

low in the synovial fluid C' activity and the RF titre. Most patients with a synovial fluid C' activity below 25—predominantly SLL and SLL-like syndrome—showed elevated RF titres by two or three of the RF tests used. At higher synovial fluid C' activities, however, most patients—predominantly oligoarthritides and psoriatic arthropathy—showed consistently negative RF tests.

In conformity with the results in RA, suppressed synovial fluid C' activities in association with negative or low RF titres were observed in some of the gold-treated patients with SLL-like syndromes (Figs 4–7). However, a similarly low synovial fluid C' activity of 18 in association with nega-

tive RF tests was found in one patient with a typical SLE, not treated with gold salts (fresh effusion for a few days). The arthritis in this case gradually subsided and corticosteroids could be avoided; the RF titres of serum remained negative.

In the whole series of 125 untreated inflammatory arthropathies, only 2 showed a suppressed synovial fluid C' activity (below 12) in association with negative RF tests. One was the SLL case just mentioned; one was a juvenile with SSC, negative RA and a synovial fluid C' activity of 28 and three were cases of probable psoriatic arthropathy (Appendix Table VII). In two of the latter three cases the latex titre was 10. In the remaining, totally 44




Fig 6 Relation synovial fluid C' activity to RF titre of synovial fluid by the latex test—The same cases and symbols as in Fig 4

cases of inflammatory arthropathies not labelled RA, SLE or SLE like syndromes the latex<sub>50</sub> titre was <10. The RF titres of serum in these cases were consistently negative.

On the other hand, in appreciable proportion of the RA patients with elevated RF titres, especially those with elevated latex titres, showed a synovial fluid C' activity not considered to be suppressed (Figs 4 A—6 A).

By way of comparison a group of miscellaneous sero negative arthritides was included in Figs 4 A—6 A. In untreated RA with negative tests for RFs in serum and synovial fluid the average synovial fluid C' activity of  $78.5 \pm 5.60$  (standard error of the mean) was very similar to that of  $92.8 \pm 4.04$  for

miscellaneous sero negative arthritides (47 cases oligo arthritis and psoriatic arthropathy included).

In the present series of RA as well as in several others (see below) the latex test was found to be more sensitive than the SSC test. In the whole series of gold treated and untreated RA patients 33 showed a clearly negative SSC<sub>5</sub> test (titre below 32). 12 out of these 33 showed an elevated latex<sub>50</sub> titre (Table XX). The reverse i.e. an elevated SSC<sub>5</sub> titre in association with a negative latex<sub>50</sub> (or latex<sub>50</sub>) titre appeared only occasionally.

It is of interest that among the 33 RA patients mentioned an elevated latex<sub>50</sub> titre (in association with a clearly negative SSC<sub>5</sub> titre) appeared 11




Fig 1. Relation synovial fluid C' activity to RF titre in psoriatic arthropathy (13 adults and 1 juvenile), oligo arthritis (8 juveniles) and in SLE and SLE-like syndromes (10 adults). In three of the latter marked with + gold salts had been given during the 3 years preceding examination.

SSC<sub>5</sub> TITRE = RF titre of serum by the sensitized sheep cell test

LATEX<sub>5</sub> TITRE = RF titre of serum by the latex test

LATEX<sub>SF</sub> TITRE = RF titre of synovial fluid by the latex test

most exclusively when the synovial fluid C' activity was lower than 67 and probably more often when this activity was suppressed (values lower than 42) than when it was non suppressed ( $p=0.05$ , Table 11). The result was the same if instead of the latex<sub>5</sub> titre the latex<sub>SF</sub> was considered. If both these titres were considered only 2 out of 11 RA patients with a suppressed synovial fluid C' activity

showed entirely negative tests for RFs in serum and synovial fluid (Table 11). One was a case of juvenile sero-negative RA with onset of joint symptoms at nine (Table 1) and one was a case of adult gold-treated RA. Among the 33 RA patients with a clearly negative SSC<sub>5</sub> titre the synovial fluid C' activity was somewhat lower in gold-treated than in untreated ones ( $p=0.12$  by WILCOXON'S T test).

Table XV The latex titre of serum (Latex<sub>S</sub>) and synovial fluid (Latex<sub>SF</sub>) at different synovial fluid C activity in 33 RA patients with a clearly negative SSC titre of serum (titre below 32)

Previous gold therapy <sup>1</sup>	No of cases	C activity of synovial fluid	Latex <sub>S</sub> titre					Frequency of elevated latex titres		
			<10	10	20	40	>40	Latex <sub>S</sub> titre >10	Latex <sub>SF</sub> titre >10	Latex <sub>S</sub> and Latex <sub>SF</sub> titres
-	11	>66	9	2	—	—	—	0/11	0/11	0/11
-	6	42-66	2	—	—	2	2	4/6	4/6	4/6
-	3	20-41	1	—	1	1	—	2/3	1/3	2/3
-	1	<20	—	—	—	1	—	1/1	1/1	1/1
+	4	>66	3	—	1	—	—	1/4	1/4	1/4
+	1	42-66	—	1	—	—	—	0/1	0/1	0/1
+	3	20-41	—	1	—	—	2	2/3	2/2	3/3
+	4	<20	2	—	—	1	1	2/4	3/4	3/4
- and +	10	>66	12	2	1	—	—	1/10	1/10	1/10
	7	42-66	2	1	—	2	2	4/7	4/7	4/7
	6	20-41	1	1	1	1	2	4/6	3/6	5/6
	5	<20	2	—	—	2	1	3/5	4/5	4/5
- and +	15	>66	12	2	1	—	—	1/15	1/15	1/15
	18	≤66	5	2	1	5	5	11/18 (p<0.01)	11/17 (p<0.01)	13/18 (p<0.01)
- and +	22	>41	14	3	1	2	2	5/22	5/22	5/22
	11	≤41	3	1	1	3	3	7/11 (p=0.05)	7/10 (p=0.03)	9/11 (p<0.01)

<sup>1</sup> During the 5 years preceding examination

In the case of SLE and SLE like syndromes 4 patients showed a clearly negative SSC<sub>S</sub> test in three of these the latex titre was elevated in serum and/or in synovial fluid in one—with a typical SLE—all three tests for RIs were negative. In this group all patients except one showed extremely suppressed synovial fluid C activities. As said above this patient showed a probably erroneously high C activity of 45 (Appendix Table VI).

In gold treated RA patients (Figs

4B-6B) some degree of correlation was found between the synovial fluid C activity and the latex<sub>SF</sub> titre although not between the former parameter and the SSC<sub>S</sub> or latex<sub>S</sub> titre (Table XIV).

In the group of RA consisting of RA with nodules and SSC pos RA the lower SSC<sub>S</sub> titres in gold treated patients were associated with a somewhat lower rather than a higher synovial fluid C activity (p~0.50) in relation to that for untreated ones.



As mentioned in ch 5 a distinction was made between early and long standing effusion. In the whole series of untreated arthropathics the results in early effusion showed that here as well as in long standing effusion the variation of the synovial fluid C' activity could be related to a corresponding variation of the RF titres (Table XIX). Lower degrees of correlation between the synovial fluid C' activity and the RF titres were obtained (Table XIX) in the smaller series of early effusion in RA as a whole as well as in the group of RA consisting of RA with nodules and SSC pos RA.

The relation between synovial fluid C' activity and RF titres in early effusion of untreated arthropathics is demonstrated separately in Fig 8 A) though the degree of correlation was statistically significant (Table XIX) several cases of RA without nodules showed fairly high synovial fluid C' activities in association with elevated RF titres of serum. In early effusion of RA with nodules extremely low synovial fluid C' activities were associated with moderately or markedly elevated RF titres of serum (Fig 8). This result in RA with nodules as well as the tendency towards high synovial fluid C' activities in proportion to the elevated RF titres of serum in instances of early effusion in RA without nodules were confirmed by the results of additional observations on synovial fluid from a joint other than that primarily studied (Fig 8).

However in sero positive RA the duration of effusion during the first six months of exudation also seemed

to be of importance for the degree of suppression of the C' activity of synovial fluid (CHAPTER 5). Owing to the limited series of observations it was not possible to decide which of the two parameters was the predominant one.

The results in RA seemed to be compatible with the assumption that the C' activity of synovial fluid during the first time of exudation was to some extent related to the RF titre and to some extent to the duration of effusion.

In a few cases studied during the first months of exudation (6 of RA and one of an SLI like syndrome) were additional observations made after varying intervals. These observations represented new fluids derived from the joint initially studied. In a few instances fluids from another joint were included for the sake of comparison (Fig 9).

In two cases of SSC pos RA, where the interval exceeded 12 months the fluids aspirated later on showed a similar or slightly higher C' activity as compared with that initially found during the early phase of exudation. In these two cases the RF titres either decreased or remained at the same low level (Fig 9). In one of these cases a lower C' activity was found in a fluid aspirated (on an earlier occasion) from another joint early during the exudation. This lower activity was associated with elevated RF titres (Fig 9).

In one case of an SLI like syndrome where the arthritis ran an intermittent course the interval between




Fig 8 Relation synovial fluid C activity and RF titre in early effusion of less than 3 months duration. Thirty six patients (no gold therapy during the 3 years preceding examination) 16 with RA (additional observations on synovial fluid from a joint other than that initially studied are marked by circles) 3 with SLE or SLE like syndromes and 17 with various seronegative non RA arthritides (trauma polyarthritis ankylosing spondylitis psoriatic arthropathy oligo arthritis etc.)

the two aspirations was almost 3 years. In this case a moderate increase of the synovial fluid C activity (from 13 to 32) was found to be associated with unchanged RF titres of serum and with a probable decrease of the RF titre of synovial fluid (Fig 9).

In two cases of RA with nodules early effusion and high RF titres of serum it was found that initially extremely low synovial fluid C activities

were followed by equally low activities after one or two months. During this time the RF titres of serum remained essentially unchanged at the same high level. In one of these cases the latex<sub>SF</sub> titre increased from 10 to 80 (Fig 9).

In one of two patients with SSC positive RA studied during the early phase of exudation a sudden and transient suppression of the synovial fluid C ac-




Fig 9 RF titres and synovial fluid C activity in some cases started early during exudation as well as later on after varying intervals. The titres by the three RF tests (SSC<sub>5</sub>/latex<sub>5</sub>/latex<sub>57</sub>) are given at each point symbolising the C activity. Six cases of RA and one of SLE like syndrome labelled 'SLE?' in the Fig. (1). Unbroken lines connect observations on the same joint, broken lines connect observations on different joints of the same patient. Note the change of the scale in the lower part representing RA with nodules.

tivity was followed after 3 to 4 months by a probable increase of the latex titre and a non significant (one tube) increase of the RF titres of serum. The C activity of synovial fluids aspirated from the other knee joint seemed to behave similarly in these synovial fluids however the latex titre remained unchanged and negative in the other patient with SSC pos RA initially showing a synovial fluid C

activity of 42 there seemed to be a slight and gradual decrease of the activity during the subsequent three months. In this case the RF titres of serum and synovial fluid remained essentially unchanged at the same moderately elevated level (Fig 9).

Because of the observed correlation between the synovial fluid C activity and the RF titres the three RA groups —RA with nodules, SSC pos RA and

Table VI Significance levels (P by Wilcoxon's T test) for the differences in synovial fluid C activity and RF titres. Three groups of RA: RA with nodules (16 cases), SSC pos RA (10 cases) and SSC neg RA (15 cases). For comparison the group of psoriatic arthropathy is included (14 cases). Patients who had received gold salts during the 5 years preceding examination were not included.

Groups compared	C activity of synovial fluid	SSC <sub>S</sub> titre	Latex <sub>S</sub> titre	Latex <sub>SF</sub> titre
RA with nodules and RA without nodules <sup>1</sup>	0.000007	0.003	0.01*	0.02*
RA with nodules and SSC pos RA	0.00008	0.08	0.19	0.01*
RA with nodules and SSC neg RA	0.00072	0.000002	0.00003	0.001
RA with nodules and Psoriatic arthropathy	0.00001	0.000003	0.000001	0.00002
SSC pos RA and SSC neg RA	0.0016	0.000004	0.000004	0.00006
SSC pos RA and Psoriatic arthropathy	0.0003	0.0000007	0.0000001	0.0000004
SSC neg RA and Psoriatic arthropathy	0.16	0.70	0.20	0.48

<sup>1</sup> = SSC pos RA and SSC neg RA

\* If gold treated patients were included comparable P values were obtained (P=0.008 and 0.02 respectively)

<sup>†</sup> If gold treated patients were included similar non significant differences were obtained (P=0.17 and 0.58 respectively)

SSC neg RA which differed significantly in the synovial fluid C activity (Fig. 3)—should be expected to differ also in respect of the RF titres. As expected from the definition of the three RA groups this was to some extent the case especially as regards the RF titres of serum (only patients not treated with gold salts during the five years preceding examination were considered) (Table VII).

RA with nodules showed RF titres which differed only non significantly

from those found in the group of SSC pos RA (Table VII). The latter group however was defined by a criterion which is known to be a characteristic feature of the former i.e. that of a positive SSC<sub>S</sub> test. Anyhow as judged from the present series RA with nodules could be separated from SSC pos RA more effectively by the synovial fluid C activity than by the RF titres (Table VII).

On the other hand if a distinction was made between RA with nodules

Table VIII The synovial fluid serum ratio for the latex titre at different synovial fluid C activity levels 74 cases of RA and 6 of SLE and SLL like syndromes Gold treated patients included

Figures in parenthesis = cases of early effusion

Diagnosis	C activity of synovial fluid	No of cases	Synovial fluid serum ratio for the latex titre				
			<1/2	1/2	1	2	>2
RA with nodules	>66	1	—	—	1	—	—
	42—66	1	1	—	—	—	—
	20—41	0	—	2	3	—	—
	<20	10 (3)	2 (1)	0 (2)	0	1	2
	Total	22	3	2	4	1	2
RA without nodules <sup>1</sup>	>66	4 (2)	1 (1)	—	2 (1)	1	—
	42—66	16 (0)	1 (1)	3	6 (3)	3	3 (1)
	20—41	16 (3)	3 (1)	2 (1)	6 (1)	0	3
	<20	16 (1)	—	3 (1)	0	6	2
	Total	52	5	6	14	10	8
SLE and SLL like syndromes	20—41	1 (1)	—	—	—	—	1 (1)
	<20	0 (2)	1	—	3 (1)	—	1 (1)
	Total	6	1	—	3	—	2
RA SLE and SLL like syndromes	>66	0	1	—	3	1	—
	42—66	17	2	3	6	3	3
	20—41	22	3	4	9	2	4
	<20	35	3	8	13	7	0
	Total	80	9	15	31	13	12

SSC pos RA and SSC neg RA

and RA without nodules (=SSC pos RA and SSC neg RA) the lower synovial fluid C activity in the former group was associated with RA titres of serum (SSCs and latex titres) significantly higher than those in the group of RA without nodules (Table VII) there was however still no difference as regards the latex titres. This means that in (untreated) RA patients with nodules the latex titre of synovial fluid was low in proportion to that of serum.

The group of psoriatic arthropathy, included for the sake of comparison in Table VII agreed most closely with the RA group labelled SSC neg RA with regard to the synovial fluid C activity and the RA titres.

When the individual values of the synovial fluid serum ratio for the latex titres was considered in the whole series of RA SLE and SLL like syndromes (previous gold treatment was neglected) this ratio—below called RFSS ratio—was found to be essen-

Table XVIII Means and (inter individual) variances of the synovial fluid C activity values in RA at different SSC titre levels in serum 60 RA patients (gold treated patients and cases of maximized values not included)

	SSC titre of serum			
	<16 <sup>3</sup>	32-64	128-256	>12-1024
No. of cases	11	15	18	13
Means	77.9	40.1	31.9	23.3
Variances	501.5	284.8	509.2	135.1
Variance ratio <sup>2</sup>	3.71	2.11	3.77	—

<sup>2</sup> Only cases with negative latex titres in serum and synovial fluid  
The variance at the highest titre level in the denominator

trally distributed symmetrically around a mean of about 1 (Table XVII unlimited values from 2 to 1/2 were not included see Appendix Tables II-VI)

Although the  $RF_{SFS}$  ratio must be subject to a considerable methodological error it is perhaps worth mentioning that there was a tendency in RA for this ratio to be lower than 1 in instances of early effusion ( $\chi^2=4.08$   $p<0.05$  Table XVII). However there was no relation between the  $RF_{SFS}$  ratio and the synovial fluid C activity whether early effusion or long standing was considered. In both cases the synovial fluid C activity values seemed to be related to the presence of nodules rather than to the  $RF_{SFS}$  ratio (Table XVII). This result was confirmed by the results of additional observations (see Fig. 8).

As shown in Figs 4 A-6 A the average synovial fluid C activity in RA seemed gradually to decrease when the RF titre increased. With respect to the SSC titre of serum though not to the latex titres of serum and synovial

fluid the inter individual variation of the synovial fluid C activity tended to be low when the titre was maximally elevated (Table XVIII see also Figs 4 A-6 A).

As mentioned already the synovial fluid C activity was subject to a sometimes considerable intra individual variation. The degree of this variation seemed to some extent to be related to the SSC titre of serum. For example five patients had SSC titres of serum of >12-1024 four out of these (three with nodules) had synovial fluid C activities of 11-31 and only small between joint differences corresponding to a between joint variance of 23.3 were found. In one of these four patients the C activity of a tenosynovitis fluid was 6. In the fifth patient exceptionally high C activities of 129 and 89 respectively were noted in synovial fluids from both knee joints. At intermediate (32-256) and clearly negative SSC titre levels the inter articular and also the intra articular variances

were comparable to the inter individual ones

**SUMMARY** RA patients treated with gold salts during the years preceding examination showed a lower sensitized sheep cell (SSCs) titre of serum in relation to untreated ones. For this reason a distinction was made between gold treated and untreated patients.

In the whole series of various untreated inflammatory arthropathies studied as well as in untreated RA a whole a high degree of negative correlation was found between the synovial fluid C activity and the SSCs titre.

By relating the synovial fluid C activity to the latex titres of serum and synovial fluid instead of to the SSCs titre the connection between the syno-

viol fluid C' activity and the RF titre was confirmed.

Sero negative inflammatory arthropathies other than RA, SLE and SLE like syndromes showed on an average synovial fluid C activities only non significantly higher than those found in untreated RA with negative RF tests.

Untreated RA patients with nodules showed highly significantly lower synovial fluid C activities and significantly higher RF titres of serum than RA patients without nodules.

In cases of a clearly negative SSCs test in gold treated and untreated RA patients the appearance of elevated latex titres in serum and/or in synovial fluid was almost exclusively confined to patients with suppressed synovial fluid C activity.

## Discussion

The present study like that of PEKTY and ZVAIFLER (1964) yielded evidence for the passage of 'whole' C of serum into the joint space essentially in proportion to the amount of serum protein passing into the joint space. This refers to various sero-negative non-RA arthropathies as well as to normal subjects. In the present study each of the three parameters considered to be of importance was taken into account: the number of C units per ml of synovial fluid ( $C_{SF}$ ) and serum ( $C_S$ ) and the total protein content of synovial fluid ( $TP_{SF}$ ). The C activity of synovial fluid was expressed as  $(C_{SF} \times 1000) / (C_S \times TP_{SF})$ . The relative C activity of synovial fluid thus obtained yielded a value directly expressing the C activity in per cent of the expected. The C activity of synovial fluid could be determined with an acceptable degree of reproducibility (Table III). By the use of the relative C activity of synovial fluid (below called C activity of synovial fluid) rather than the number of CH<sub>50</sub> units per ml synovial fluid as they stand a comparison between patients or groups of patients became possible.

Various mechanisms might be responsible for the suppression of the C activity of synovial fluid for example

inactivation of C by antigen-antibody complexes or by aggregated IgG solely.

BOYDEN, NORTH and GALLNER stated (1965) that the role played by C in phagocytosis is obscure. FOSTIROPOULOS, ALSTEN and BLOCH (1965) discussed phagocytosis as a possible cause of the suppression of C activity especially in RA where synovial fluid leucocytes are known to phagocytose aggregates of RF and IgG (ASTORGA and BOLLET 1964; HOLLANDER, RAYSON, RESTIFO and LUSSIER 1964). However leucocytes containing such aggregates were found also in some of the cases of psoriatic arthropathy and ankylosing spondylitis where the synovial fluid C activity is generally non-suppressed. FOSTIROPOULOS, ALSTEN and BLOCH (1965) took the absence of a consistent reduction of synovial fluid C2 titres in gouty effusions as evidence against phagocytosis as a C-utilizing mechanism of importance for the suppression of the synovial fluid C activity.

The occurrence in *ra* rheumatoid

ZVAIFLER and PEKTY (1963) had also shown that in cases of osteoarthrosis, Reiter's syndrome and gout the synovial fluid serum ratio for the classical C components equalled that for the total C activity.

\* The expected value of  $C_{SF} / C_S = TP_{SF} \times 1/10$



synovial fluid of a variety of essentially lysosomal enzymes is presumably in part related to phagocytosis (HAMMILAN, SANDSON and SCHURLAT 1963 and others see review by JISSAN 1966). Some of these enzymes are proteolytic and might in some way have a bearing on the suppression of the synovial fluid C' activity. However rheumatoid synovial fluids have been reported to contain on an average less pepsin and cathepsin than do fluids from patients with osteoarthritis and traumatic hyalrthritis. Moreover the trypsin activity was comparable in the three types of fluids studied (VINTIO 1960).

Another proteolytic enzyme, plasmin has recently been suggested capable of inactivating C by simple proteolytic cleavage of C components (LAURFLE, LUNDH and MAIMQUIST 1965) rather than by converting C 1 to C 1 esterise (which is known to destroy C 2 and C 4) as previously supposed. However in synovial fluid with a suppressed C' activity neither plasmin activity nor plasmin inhibitors could be detected (BLDBERG 1964).

The C' activity of synovial fluid in RA is well as in the other arthritides studied was found to vary independently of its white blood cell counts and the concentration of gamma globulins. This agrees essentially with the results of PEKIN and ZWIFLER (1964) and IOSTINOPOULOS, AUSTIN and BLOCH (1964). Noteworthy are the relatively low white blood cell counts in the group of SLE and SLE like syndromes in which most synovial fluids showed extremely suppressed C' ac-

tivities. The tendency towards low white blood cell counts in SLE as well as the average cell count in rheumatoid synovial fluid found in the present study, agree with previous reports (e.g. JOHANSEN and SYLVEST 1961, HOLLANDER, JESSAN and McCARTY 1961).

In the present study as well as in the studies by PEKIN and ZWIFLER (1964) and by IOSTINOPOULOS, AUSTIN and BLOCH (1963) it was found that incubation of rheumatoid synovial fluids (with a suppressed C' activity) with serum or synovial fluid showing a non suppressed C' activity did not result in a decrease of the latter. Similar results were obtained with non RA fluids all of which had a non suppressed C' activity. In these experiments the concentration of synovial fluids with a suppressed C' activity was higher than that of fluids with a non suppressed activity although lower than at the determination of the number of C'H<sub>50</sub> units.

Kinetic studies similar to those made on RA sera by HOFFER, LITVIN and KAHN (1963) were made on heat inactivated (56°C for 30 minutes) synovial fluid diluted 1:10 (final dilution)\*. The results showed that 9 non

\* The synovial fluid was pre incubated with 4 C'H<sub>50</sub> units (diluted normal serum) at 37°C. Samples were drawn from this mixture every 10 minutes during 60 minutes whereafter the hemolytic activity was determined after an additional incubation time of 60 minutes at 37°C. In these kinetic studies where the hemolytic C' activity was determined in a larger volume than that used in the routine determinations each C' unit roughly corresponded to 10 units in the routine determinations.

RA synovial fluids predominantly derived from patients of ankylosing spondylitis and uro polyarthritis, did not inhibit the haemolysis of EA by 4 C units. Ten out of twelve rheumatoid fluids significantly inhibited haemolysis 4 out of these 10 fluids inhibited about 2—2 1/2 C' units and 6 inhibited about 3 units. The two fluids that lacked detectable inhibitory capacity had both a suppressed C' activity with values of 21 and 29 respectively as had 11 of the 10 rheumatoid fluids (C' activities below 25) that inhibited haemolysis. One of the latter had a C' activity of 94 there was no macroscopically detectable agglutination of EA (HEDBERG and NORDE unpublished observations).

The results of the mentioned kinetic studies on rheumatoid synovial fluid did not support a close connection between the C' inhibiting capacity and the C activity of synovial fluid.

In most instances of a suppressed synovial fluid C activity the number of CH<sub>50</sub> units was determined in synovial fluid considerably more diluted (1:50 or more see Appendix Tables II—VI) than those subjected to kinetic studies (1:10). In the former case—at dilutions of 1:50 or more—the anticomplementary activity was probably lower than that in the latter case (dilution 1:10). On the other hand the possibility cannot be excluded that some anticomplementary activity was lost by heat treatment of synovial fluid at 56°C for 30 minutes. This reservation is based on the observation by FROMM HAGEN and FLDENBERG (1962) that heat treatment of serum at an only

slightly higher temperature of 60°C can reduce its anticomplementary activity. It is difficult to decide whether the mentioned *in vitro* findings might have any bearing on an *in vivo* depression of the synovial fluid C' activity.

A gamma macroglobulin that inhibited C' fixation was isolated from RA sera by HEIMER LEVIN PRIMACK CORCOS and NOSENZO (1962). This inhibitor as well as heat inactivated whole serum from RA patients also inhibited haemolysis of EA by C' the C' inhibiting capacity of RA serum remained unchanged after absorption of RF (HEIMER LEVIN and KAHN 1963). Even if it has not been shown it seems possible that the C' inhibiting capacity of rheumatoid synovial fluid is analogous to that of RA serum with its generally raised C level. Another possibility is that rheumatoid synovial fluid can contain traces of aggregated IgG.

In some rheumatoid synovial fluids suppressed C activities were found to be associated with negative or only weakly positive RF titres by the latex test. On the other hand a considerable proportion of the rheumatoid synovial fluids with markedly elevated latex titres showed non suppressed C' activities comparable to those sometimes found in the group of non RA arthritides (Fig 6). In the mentioned kinetic studies on rheumatoid synovial fluid no relation was found between the C inhibiting capacity and the RF titre.

In the present study no relation was found between the C' level of serum and the RF titre. The same is true of several other studies (LAURELL

and GRIEB 1958, SCHUBART, I WILD, SCHROEDER ROTSCCHILD BHATAVADEKAR and PULLFV 1965 and others), where the C' level of serum was determined in samples considerably less diluted than in the present one. The data mentioned argue against the possibility that RF had interfered in the determination of the number of C'H<sub>50</sub> units in synovial fluid. RF is known to interact with antibodies of the IgG type whereas in determinations of the haemolytic C' activity C' interacts presumably predominantly with antibodies of the IgM type coating the surface of the sheep erythrocytes (ZYAHLER and BLOCH 1962, ULSTRUP 1962, SCHMID and ROITT 1965 and others). By use of a technique described by WILCROFT (1963) it could be shown that the unboceptor used in the present study contained one single detectable sensitizing component. This component diffused slowly (in agarose) and was therefore assumed to represent IgM rather than IgG antibodies.

ZYAHLER (1966) recently suggested that the suppression of the C' activity in rheumatoid synovial fluids might reflect a local antigen-antibody reaction possibly involving intracellular factors (ANFs). In the present study the lowest synovial fluid C' activities were found in a group of SLE and SLE-like syndromes and in RA patients with nodules. In addition to the group of SLE and SLE-like syndromes a positive test for ANFs in serum was found predominantly in RA patients with nodules. A similar observation has been made by BARNETT, LEDDY, CONDEMI and LAUCHMAN (1965).

Nevertheless, neither in the group of RA with nodules nor in the two other RA groups discerned or in psoriatic arthritis was any connection found between the synovial fluid C' activity and the presence of ANF activity in serum (Table VII). Furthermore in a limited series of patients, detectable ANF activity in synovial fluid was found exclusively in those with a positive test for ANFs in serum (HIDBERG 1964). Similar results have been published by BARNETT, BIRNBAUM and BLOCH (1961). These authors suggested that the failure to detect ANF activity in all rheumatoid synovial fluids might be attributable either to a failure of ANF formation or to excess of nuclear antigen.

In RA patients treated with gold salts at least once during the past few years the SSC titre of serum proved lower than in untreated ones. This result essentially agrees with previous reports (see PIERSELLI, HESS and ZIFF 1967). A similar tendency, though statistically non-significant, could be traced in the latex titres of serum and synovial fluid (Table VIII). None of the RA patients studied was in complete remission; the clinical activity of the disease was considered comparable in gold-treated and untreated patients. In sero-positive RA (by the SSC test) the synovial fluid C' activity was non-significantly lower in gold-treated than in untreated patients. As a consequence of the mentioned influence of gold therapy on the RF titre, especially the SSC titre of serum, the relation between synovial fluid C' activity and RF titre in RA could be strictly eval-

uated only in patients not treated with gold salts during the years preceding examination. Below, such patients are referred to as 'untreated'.

Within the group of 71 untreated RA patients of the present study a negative correlation was established between the synovial fluid C' activity on the one hand and each of the three RF titres determined on the other side (the SSC titre of serum and the latex titres of serum and synovial fluid). This means that when the RF titre was markedly elevated the synovial fluid C was generally markedly suppressed. On the other hand when the RF titres in RA were negative the synovial fluid C activity was high or non suppressed and essentially comparable to that found in various sero-negative non RA arthropathies such as uro polyarthritis, ankylosing spondylitis, psoriatic arthropathy and (juvenile) oligoarthritis (ASELL and BLYWATERS 1962).

The findings in juveniles and adults were very similar especially as regards the relation between RF titre and synovial fluid C activity (Appendix Tables I and III-IV). For this reason no distinction was made between juvenile and adult arthropathies.

In the present series of various arthritides as well as in RA as a whole no relation was found between the synovial fluid C' activity values and the intensity of synovitis nor between these values and the time for previous ly given intra articular injection or other therapeutic measures employed (corticosteroids, *per os* ACTH, salicylate, phenylbutazone, chloroquine

etc.) In steroid treated as well as in untreated RA no relation was found between the synovial fluid C' activity and the ESR (Table VII).

It should be noted that among the 100 patients accepted as RA only 13 had shown consistently negative RF tests. Five out of these 13 were juveniles with a fairly early onset of joint symptoms (on an average at about  $4\frac{1}{2}$  years) where sero negativity is the rule (BLYWATERS, CARTER and SCOTT 1959, SIEVERS AND OVEN AND WAGNER 1963).

The inverse relationship between the RF titre of serum and the synovial fluid C' activity was perhaps most clearly manifest in the group of (untreated) RA patients with subcutaneous nodules. In relation to RA patients (untreated) without nodules these patients—with nodules—showed significantly higher RF titres of serum and highly significantly lower synovial fluid C' activities (Table VI). The RF titre of synovial fluid (by the latex test) however was essentially comparable in the two RA groups compared (Table VI). The higher RF titres of serum in RA with nodules agree with previous reports (SIEVERS 1963 and others).

As mentioned already the results in normal subjects and in most instances of effusion in cases of sero negative non RA arthropathy indicated that whole C' of serum passed through the capillaries and the subsynovial and synovial tissues into the joint space without being appreciably changed. In cases of sero positive arthropathy, on the other hand suppressed and some

times extremely suppressed synovial fluid C' activities were observed. These results indicate a local binding of C' as a possible cause of the suppression of the synovial fluid C' activity in sero positive arthropathies.

It is known that gamma globulins, aggregated (denatured) by means of heat treatment or by chemical treatment exert a strong anticomplementary activity (OHLBACH 1945, ISHIZAKA and ISHIZAKA 1960, FROMMELT and FUDENBERG 1962). It has been suggested that the interaction between antigen and antibody is accompanied by a structural change (denaturation) of the antibody molecule which is presumably the prerequisite for C' fixation (ROBERT and GRABAR 1957, ISHIZAKA and CAMPBELL 1959). Physically denatured IgG and antigen antibody complexes fix C' components in the same sequence and to essentially the same extent (ISHIZAKA, ISHIZAKA and BORSOS 1961).

Evidence for C' being *in vivo* bound to the rheumatoid synovial membrane has been presented by RODMAN, WILLIAMS, BILKA and MÜLLER EBENHARD (1964). By means of immunofluorescence technique two C' components ( $\beta_{1C}$  and  $\beta_{1E}$ ) could be demonstrated in rheumatoid synovial membrane although not in normal one. The localization of these C' components corresponded most closely with deposits of IgG. Similar results have since been reported by FISH, MICHAEL, GLWURZ and GOOD (1966). These studies suggest that the synovial membrane deposits of IgG contained IgG in an aggregated form and that *in vivo* bind-

ing of C' had appeared for this reason. Previous studies by KALLAN and VAUGHAN (1962) also suggested that the synovial membrane deposits of IgG which were more marked in RA than in other arthropathies studied, contained IgG in an aggregated form.

Of the classical C' components studied in rheumatoid synovial fluid, C'1 and C'4 ( $\beta_{1E}$ ) have been found to be suppressed (ZAVITZ and PRIN 1963, IOSTROPOULOS, AUSTIN and BLOCH 1965), in addition the latter authors found C'2 to be low too.

MÜLLER EBENHARD and NILSSON described (1960) a conversion product ( $\beta_{1A}$ ) of  $\beta_{1C}$  which could be identified by means of immunoelectrophoresis. A distinct  $\beta_{1A}$  line however seemed to be a rare phenomenon in rheumatoid synovial fluid: only one out of 18 such fluids showed a distinct  $\beta_{1A}$  line (HEDEBERG unpublished observations).

When examining synovial fluid for  $\beta_{1A}$ , it was found that several fluids with extremely suppressed C' activities lacked  $\beta_{1C}$  in amounts detectable by the immune serum used. Estimation by OUCHTERLONY technique proved the concentration to be low (HEDEBERG unpublished observations). This result has subsequently been confirmed by quantitative methods (LUNDH 1965 b).

The location of two C' components ( $\beta_{1C}$  and  $\beta_{1E}$ ) in the rheumatoid synovial membrane both of which are present in low concentrations in synovial fluid with a suppressed total C' activity supports the idea of a local binding of C' as a cause of the low synovial fluid C' activity.

Most authors nowadays consider RFs to be antibodies directed against slightly altered or denatured IgG (see review by KUNKIL and WILLIAMS 1964). Results published by MELLORS, HEIMER, CORCOS and HORNCOLD (1959), McCORMICK (1963) and BRAUN, STEINER, RIEGLER and PAKESCH (1962), suggest that RFs are synthesized by plasma cells at various sites such as the inflamed synovial membrane, lymph nodes, subcutaneous nodules and bone marrow.

KAPLAN (1963) has suggested that the formation of RFs is initiated by the presence in rheumatoid tissue lesions of IgG in an aggregated form. The above mentioned evidence for C' components being bound to probably aggregated IgG in rheumatoid synovial membrane combined with the inverse relationship between synovial fluid C' activity and RF titres demonstrated in the present study consequently support KAPLAN's hypothesis for the RF formation.

In short the relationship between a suppressed synovial fluid C' activity and an elevated RF titre seems compatible with the assumption that both phenomena are to some extent secondary to the presence of denatured IgG in the inflamed synovial membrane. This hypothesis which is closely related to that of KAPLAN (1963) was adopted by the author.

In a study dealing with the characteristic sero negativity in patients with psoriatic arthropathy LASSUS, MUSTAKALLIO, LAINE and WAGER (1964) suggested the presence in such cases of some factor preventing the formation

of macroglobulins including RF and/or promoting their breakdown. The high and non suppressed synovial fluid C' activity found in psoriatic arthropathy involving the distal interphalangeal joints suggests that here— as in other sero negative non RA arthropathies—the stimulus for the formation of RFs is essentially lacking at least in the inflamed synovial membrane.

Suppressed synovial fluid C' activities in psoriatic arthropathy were observed among the (four) doubtful cases where involvement of the distal interphalangeal joint was lacking. Three out of these four patients showed suppressed synovial fluid C' activity and two of these three detectable RF activity in synovial fluid whereas all four showed entirely negative serum tests for RF. In the series of patients with psoriatic arthropathy studied by LASSUS, MUSTAKALLIO, LAINE and WAGER (1964) elevated RF titres (of serum) were found almost exclusively among cases where the distal interphalangeal joints were not involved. The frequency of elevated RF titres was however relatively low (about 30 per cent).

Attempts to demonstrate immunoglobulins and C (as  $\beta_2$ ) in the skin lesions of psoriasis and various other dermatoses have failed (HALSBECK and CORMANN 1964). By way of contrast in SLE IgG and  $\beta_2$  have been demonstrated to be concomitantly present in

\* Against a coincidence of RA and psoriasis argued the entirely negative serum tests for RFs combined with the absence of a typical RA distribution of the joint changes.

the skin lesions (KALSBECK and CORMANN 1964) as well as in visceral lesions (LACHMANN MÜLLER EBFRIHARD, KUNKEL and PARONETTO 1962, PARONETTO and KOIFLER 1965). Several authors have emphasized that the concomitant presence of C' components and immunoglobulins in a tissue lesion suggests, but does not prove, that C' is bound because of a local antigen-antibody reaction (see for example LACHMANN *et al* 1962). A denaturation of IgG not induced by impact of a serologic reaction should be expected to result in fixation of C' not distinguishable from that induced by such an impact.

DAVIS (1966) suggested a common mechanism involving the C' system in RA and SLE. Several observations however argue that the mechanism(s) underlying the activation of the C system in RA can be different from that in SLE. For example, the C level of serum is low in active SLE and generally raised in active RA (for refs see DAVIS 1966). The reverse response of the C level of serum in RA (decrease) and in SLE (increase) after administration of ACTH (VAUGHAN, BAYLES and IYVOUR 1951 a 1951 b) also suggests that different mechanisms can be operating in the two syndromes.

The results of the present limited series of SLE and SLE-like syndromes where the synovial fluid C' activity was more consistently suppressed than in RA as a whole suggested that the C' system was early involved during the course of joint exudation (Table VIII).

In RA a suppression of the total C' activity of synovial fluid seemed to be a late phenomenon in the present study as well as in that of PEKIN and ZIAIFLER (1964). These observations agree with the assumption that the deposits of IgG in early rheumatoid synovitis (KAPLAN 1963) predominantly consist of non aggregated IgG. In agreement with this assumption are the observations that in early rheumatoid synovitis in contrast to longstanding IgM (KAPLAN 1963) as well as RF synthesizing plasma cells (MELLORS 1963) could scarcely be demonstrated—presumably because the stimulus for RF formation in the form of aggregated IgG was weak or lacking.

Differences in sedimentation constants and precipitability in the cold between the RFs in SLE and those in RA have been demonstrated (STARTZ and SCHLOSSMAN 1957, BLACK GOLDIN POSKE and MALMÖD 1959, STARTZ and HEDMAN 1963). Most authors have reported elevated RF titres in 30–40 per cent of SLE sera. LEONHARDT (1964) found an even lower incidence.

In SLE associated with arthritis on the other hand, as well as in SLE-like syndromes where arthritis is a more prominent feature the RF titres tended to be higher and more often elevated (LEONHARDT 1964 and others). In conformity with these findings was the relatively high incidence of elevated RF titres in the present limited series of SLE and SLE-like syndromes where all patients had arthritis. In one case of typical SLE (no gold therapy) entirely negative RF tests were combined with extremely sup

pressed synovial fluid C' activity (fresh effusion of 3 days duration) In this case the arthritis gradually subsided the SSCs test remained negative at re examination 3 years later

In the whole series of 125 patients with various inflammatory arthropathies not treated with gold salts during the years preceding examination only 5 showed entirely negative tests for RFs combined with suppressed synovial fluid C' activity Out of these 5 patients only one had RA (juvenile crisis of SSC neg. RA with onset of joint symptoms at 9 years) one was a case of typical SLE just mentioned and three were crises of probable psoriatic arthropathy one of the latter showed a non suppressed C' activity when re examined These exceptions to the rule of a connection between the RF titre and the synovial fluid C' activity merely suggest that different mechanisms resulting in suppression of the synovial fluid C' activity may be operating

The other type of exception to this rule i.e. that of a non suppressed synovial fluid C' activity combined with elevated RF titres seemed to appear with some preponderance in instances of early effusion in RA with out nodules (Fig 8) However also in early effusion a connection was found between the RF titre and the synovial fluid C' activity if the whole series of various arthritides was considered (Fig 8)

Because of the established relation between the RF titre and the synovial fluid C' activity the antibody nature

and *in vitro* reactivities of RFs will be briefly considered below

In human sera different types of anti IgG antibodies may be discerned KUNKEL and TAN (1964) listed 4 main types of which RFs and anti antibodies in MILGROM's sense (MILGROM DUBISKI and WOZNICZKO 1956) are of specific interest as regards the interpretation of the phenomenon of suppressed synovial fluid C' activity

Anti antibodies in MILGROM's sense in contrast to RFs react only with IgG denatured by the impact of serologic reaction not with native or physically denatured IgG, they are also rare in human sera and hardly ever seen in RA sera (MILGROM DUBISKI and WOZNICZKO 1956 ANDRESEN 1963 MILGROM 1963 b)

Serum factors resembling human RFs can be induced experimentally in rabbits by immunization with physically denatured autochthonous IgG in FREUND's adjuvant (MILGROM and WITESKY 1960a McCLUSKEY MILLER and BENACERRAF 1962 CATSOULIS ROTSCCHILD ORATZ and FRANKLIN 1965)

In most of the mentioned experiments RF like substances were formed which showed preferential reactivity with xenogeneic IgG In this respect as well as in sedimentation constant—7S instead of 19S—the RF like substances differed from human RFs (KUNKEL and TAN 1964 CATSOULIS ROTSCCHILD ORATZ and FRANKLIN 1965)

RF like substances induced by immunization with papain split autochthonous IgG (WILLIAMS and KUNKEL 1963) were also predominantly of the



7S type although their reactivity against allogeneic (rabbit) IgG was comparable to that against xenogeneic (human)

Prolonged immunization of rabbits with foreign antigens such as *E. coli* and *B. subtilis* results in the appearance of RF like substances of a macroglobulin type which react primarily with allogeneic denatured IgG (ABRUZZO and CHRISTIAN 1961). Similar results have been reported by AHO and WAGER (1961) who used ovalbumin as an immunizing agent. These anti IgG antibodies showed cross reactivity with human IgG. Immunization of rabbits with  $\beta$  haemolytic streptococci, however, resulted in the appearance of RF like substances reacting much stronger with xenogeneic than with allogeneic IgG (MILGROM and WITEBSKY 1960 b). The stimulus for the formation of the RF like antibodies was assumed to be denatured autochthonous IgG in these experiments (with foreign antigens) denatured by the impact of a serologic reaction.

It is not clear from the above mentioned experiments which—if any—of the experimentally induced RF like substances should be considered true counterparts to human RFs (KUNKEL and TAN 1964). Yet MILGROM (1964) as well as KUNKEL and TAN (1964) were inclined to consider the RF like substances induced by immunization with bacteria as most closely related to human RFs.

RF activity is directed against those papain fragments of human (fragment F) and rabbit (fragment III) IgG which lack antibody combining site

(FRANKLIN 1961, GOODMAN 1961 and others). Anti antibodies, on the other hand are directed against those papain fragments of human and rabbit IgG on which the antibody combining site is located (FUDENBERG, GOODMAN and MILGROM 1964).

The RF like substances induced by hyperimmunization of rabbits with bacteria were directed against the 'non antibody' fragment of rabbit IgG (fragment III) (CHRISTIAN 1963).

The Gm(a) and Gm(b) sites are contained in the non antibody fragment of human IgG (FRANKLIN, FUDENBERG, MELITZER and STANWORTH 1962, HARBOT, OSTLUND and KUNKEL 1962).

In view of the above mentioned data and some pertinent observations of Gm(f) GRUBB, KRONVALL and MÅRTENSSON (1965) stated that immunological findings in RA draw attention to the I piece (the non antibody fragment) of IgG. As mentioned the suppression of the synovial fluid C reactivity is interpreted as essentially being secondary to binding of C to presumably aggregated IgG in the rheumatoid synovial membrane. If this interpretation is correct it is of interest that in the non antibody fragment of human (and rabbit) IgG is also contained the C' fixation site (as well as the skin irritating capacity of aggregated IgG) (TARANTA and FRANKLIN 1961, TARANTA, FRANKLIN and OLARI 1962, ISHIZAKA 1963).

It should be noted that unaggregated papain fragments of IgG capable of inducing formation of RF like substances when injected in rabbits (WIL-

LIAMIS and KUNKEL 1963), were in themselves unable to fix C' (ISHIZAKA 1963). Nor are the reactions between RFs and the non antibody fragment of human IgG (see review of KUNKEL and TAN 1964) or between RFs and aggregated human whole IgG (HEIMFEL and LEVIN 1963) accompanied by a demonstrable fixation of C'.

Experimental evidence has been presented (BUTLER GLEICH and VAUGHAN 1962 and others) to show that RFs react primarily with human IgG and that part of the RFs also cross reacts with animal IgG. In RA this is reflected by a higher degree of sensitivity of the latex test as compared with that of the SSC test (AHO 1961, SIEVERS 1963 and others). The result was similar in the present study although the two tests here were not strictly comparable because the latex titre was determined in the euglobulin fraction of serum and synovial fluid and the SSC titre in whole serum.

It is of interest that at clearly negative SSC titres of serum (below 32) where the higher sensitivity of the latex test was most evident the occurrence of elevated latex titres in serum or synovial fluid was almost exclusively confined to patients with a suppressed synovial fluid C' activity (Table XX). This result suggests that a response to denatured autologous IgG is more easily detected by a test system where allogeneic IgG is the reactant i.e. the latex system than by a test system where xenogeneic (rabbit) IgG is the reactant i.e. the SSC system. As already mentioned such a reactivity pattern of human RFs fits

in most closely with that of the RF like substances induced by immunization with bacteria.

In the whole series of sero positive arthropathies the RF titre of synovial fluid by the latex test was on an average comparable to that of serum. Slight to moderate deviations were essentially found equally often in both directions (Table XVII). Similar results have been demonstrated in other series (e.g. ROBINSON, EISENBERG and CROFTON 1963). In RA with nodules and extremely low synovial fluid C' activities the latex titre of synovial fluid tended to be low in relation to that of serum (Table XVII). The data presented by FOSTIROPOULOS, ALSTEN and BLOCH (1960) pointed in the same direction although the titre differences were more pronounced. This was perhaps a manifestation of the affinity of RF as well as of C' to denatured IgG (DAVIS and BOLLET 1964, MARGROV and SCHULTZ 1960 and others) both having possibly been bound to denatured IgG during the passage through the synovial and subsynovial tissues.

In the present study however a similar tendency towards a low latex titre of synovial fluid in relation to that of serum was observed in instances of early effusion in RA without nodules in these cases often combined with a non suppressed synovial fluid C' activity (Table XVII). The interpretation of this result is difficult one possibility is that in these instances of early effusion in RA the permeability of the periarthritic tissues for RFs was reduced. Another possibility is affinity between RFs and (probably) native IgG. However because of the methodological errors involved in determinations of the latex titre too much importance should not be attached to the above mentioned doubtful differences between the latex titre in serum and that in synovial fluid.

Evidence suggestive of an *in vivo* affinity of RFs as well as of C' to presumably aggregated IgG has recently been presented by FISH, GEWURTZ and

GOOD (1966) synovial membrane specimens from some RA patients showed (immuno fluorescence technique) deposits in the same area of IgG and C' (as  $\beta_{1c}$ ) whereas specimens from other RA patients showed deposits of IgG and RF. In more than half the number of the RA patients the deposits of C' and IgG had a focal distribution. Because of the latter observation and the lack of knowledge about the mechanism(s) underlying exudation in RA, it is not possible to decide to which extent the C' activity of synovial fluid is representative of the synovial and subsynovial tissues as a whole. At present it can merely be assumed that a suppression of the synovial fluid C' activity essentially reflects the occurrence in these tissues of free denatured IgG not previously blocked by C' and/or by RFs.

The extent to which various sites of RF formation contribute to the total activity of the pool of circulating RFs is entirely unknown.

The extremely suppressed synovial fluid C' activity in most instances of markedly elevated RF titres suggests that in RA aggregated IgG can be continuously formed in considerable amounts in the inflamed rheumatoid synovial membrane. If this is true, the extremely low synovial fluid C' activities suggest as the titres do that the stimulus for RF formation can be very strong.

Especially at moderately elevated SSC titres it was found in some patients that synovial fluid from one joint showed a very low C' activity whereas fluid from another joint showed a very high C' activity. It is not

known whether or not this sometimes considerable intra individual variation of the synovial fluid C' activity could to any extent be ascribable to a situation where all aggregated IgG was blocked and hence no C' was trapped during the passage through the synovial membrane. Presumably as suggested above the degree of suppression of the synovial fluid C' activity can be interpreted as a function of the rate by which free (non blocked) aggregated IgG is formed in the synovial membrane. In any case the observed synovial fluid C' activity was found to be on an average lower at moderately elevated RF titres than at entirely negative ones.

Among untreated RA patients with negative RF titres in serum and synovial fluid only one out of 15 (11 adults and 4 juveniles) showed suppressed synovial fluid C' activity. As already mentioned this occurred in a girl with onset of joint symptoms at 9. The incidence of 1/4 of a suppressed synovial fluid C' activity in the present limited series of sero negative juvenile RA was not distinct from that of 3/7 reported by FISCH, MICHAEL, GEWURZ and GOOD (1966). The almost consistently non suppressed synovial fluid C' activity in (untreated) RA with negative RF tests supports the idea that here stimulus for RF formation in the form of aggregated IgG in sufficient amounts in the synovial and subsynovial tissues was essentially lacking. The same is true of the whole group of various sero negative arthritides (Fig. 2) except for the doubtful cases of psoriatic arthropathy, where, as mentioned, elevated RF titres are sometimes found.

According to the hypothesis that suppressed synovial fluid C' activity essentially reflects the presence in the

synovial and subsynovial tissues of stimulus for RF formation in the form of aggregated IgG, a suppression of the synovial fluid C' activity during an early sero negative phase of RA is expected to precede the appearance of a positive RF test. The present study does not shed light on the question of whether or not this is the case. The results seemed to point in the expected direction only in one RA patient where synovial fluids from both knee joints were studied early during the exudation. In this patient, however, the suppression of the synovial fluid C' activity was transient (Fig 9).

It is hard to explain the reason for the frequently negative SSC titre of serum combined with elevated latex titres and suppressed synovial fluid C' activity in patients treated with gold salts during the years preceding examination. This finding is compatible with one or more of the following explanations: a modified denaturation of IgG resulting in essentially unaffected formation of RFs with *in vitro* reactivity against human IgG but no detectable formation of RFs with reactivity against rabbit IgG (in the SSC test) or a failure to respond to stimulus for formation of RFs with reactivity against rabbit IgG (in the SSC test) or an increased elimination of formed RFs with reactivity against rabbit IgG. Recent observations by PERSELLIN, HESS and ZIFF (1967) argue against the second alternative. They found that intense gold treatment did not influence various types of immune response *in vivo* such as formation of humoral antibodies (rabbits)

and delayed hypersensitivity (guinea pigs). Nor was the induction of RF like substances affected.

As already mentioned previous reports failed to demonstrate a clear cut relation between the synovial fluid C' activity and the RF titre in RA. In view of (a) the considerable inter- and intra individual variation of the synovial fluid C' activity at different RF titre levels (except for the highest SSC titres) and the influence of previous gold therapy on the RF titre especially the SSC titre it seems conceivable to ascribe this failure to the series of RA having been too small.

The raise of the C' level of serum in widespread inflammatory processes can be interpreted as a non specific reaction resembling the appearance of various acute phase reactants in blood plasma (FISCHEL 1953). Although the results concerning the C level of serum in RA were far from clear it is worth mentioning that in untreated RA the result agreed with such an interpretation: the C level of serum correlated with the ESR (SPEARMAN'S  $r = +0.32^*$ ). The findings in a group of various (untreated) non RA sero negative arthropathies were similar (SPEARMAN'S  $r = +0.40^*$ ).

Steroid treated and untreated RA with extremely suppressed synovial fluid C' activities (values below 25) showed mean C levels of serum lower than those for corresponding non RA sero negative arthritides ( $p < 0.05$ ). The means of the LSR in the groups compared were comparable. The result in untreated patients with SLE or SLE like syndromes was similar.

In contrast to untreated RA, steroid treated RA showed no correlation between the C' level of serum and the ESR (SPEARMAN'S  $r = +0.07$ ). In this group (of steroid treated RA) a highly significant degree of correlation was found between the C' level of serum and the synovial fluid C' activity (SPEARMAN'S  $r = +0.56^{**}$ ).

The results mentioned were compatible with an increased C' consumption reflected in a low C level of serum. Other possibilities however, can not be ruled out for example anticomplementary activity and an inhibited synthesis of one or more of the C' components. In addition no correlation was found in untreated RA between the C' level of serum and the synovial fluid C' activity.

LAURELL and GRUBB (1958) found the titres of the classical C' components to be essentially normal in RA sera. As mentioned, some of these (C'1, C'2 and C'4) as well as  $\beta_{1C}$  a moiety of the classical C'3, have been showed to be suppressed in rheumatoid synovial fluid.

LUNDH (1965a) found that in conditions other than active SLE RA and acute glomerulonephritis  $\beta_{1C}$  behaved essentially like an acute phase reactant. In RA, however the  $\beta_{1C}$  concentration in serum was normal rather than raised. This observation together with the often low concentration of  $\beta_{1C}$  in rheumatoid synovial fluid fits in with the idea that a local consumption of this component is a cause of the relatively low serum concentration.

## Summary (part I)

- 1 Relative values of the C' activity of synovial fluid rather than the number of C' units were used \* This made a comparison between patients or groups of patients possible
- 2 The essential finding of the present study was the establishment within the fairly large group of RA of a highly significant degree of negative correlation between the synovial fluid C' activity and the RF titres of serum and synovial fluid
- 3 In RA with negative RF tests at the time of examination the synovial fluid C' activity was found to be only non significantly lower than that in a miscellaneous group consisting of the above mentioned non RA sero negative arthritides This refers specifically to patients not treated with gold salts during the years preceding examination In gold treated patients where the SSC titre of serum (though scarcely the latex titres of serum and synovial fluid) seemed to be modified downwards several patients showed suppressed synovial fluid C' activities combined with a clearly negative SSC test
- 4 In instances of a clearly negative SSC test in gold treated and untreated patients the latex titres of serum and/or synovial fluid were found to be elevated almost exclusively when the synovial fluid C' activity was suppressed
- 5 In relation to RA without nodules RA with subcutaneous nodules showed highly significantly lower synovial fluid C' activities and significantly higher RF titres of serum
- 6 Like a small group of SLE and SLE like syndromes RA as a whole showed on an average lower synovial fluid C' activities than did various non RA sero negative arthritides such as ankylosing spondylitis, urethral polyarthritis, psoriatic arthropathy and oligoarthritis (juvenile)
- 7 In the small group consisting of a few typical cases of SLE and predominantly of SLE like syndromes the synovial fluid C' was

The relative synovial fluid C' activity was defined as  $(C_{SF} \times 1000) / (C_S \times TP_{SF})$  where  $C_{SF}$  and  $C_S$  stands for the number of CH<sub>50</sub> units per ml synovial fluid and serum respectively and  $TP_{SF}$  for the protein content of synovial fluid in g per cent

on an average extremely low and comparable to that found in RA with nodules. In this group too, low synovial fluid C' activities were in most cases combined with elevated RF titres.

8 The results tended to show that a suppression of the C' activity of synovial fluid was a late phenomenon in RA and probably an early one in the group of SLE and SLE like syndromes.

9 The C' activity of synovial fluid showed no clear relation to parameters other than the RF titre, such as anticomplementary ac-

tivity, white blood cell counts of synovial fluid and the concentration of gamma globulins of synovial fluid nor to the intensity of synovitis. The ESR and antinuclear activity of serum.

10 The result as regards the fairly close association between the phenomenon of a suppressed synovial fluid C' activity and the phenomenon of elevated RF titres was discussed. Both phenomena may be secondary to the presence of deposits of aggregated (denatured) IgG in the synovial membrane.

## II THE OCCURRENCE OF MONONUCLEAR CELLS WITH *IN VITRO* CYTOTOXIC EFFECT





# Introduction

Under appropriate conditions experimentally induced autoimmune diseases such as allergic encephalitis (EAE) (PATERSON 1960 STONE 1961, ÅSTRÖM and WAKSMAN 1962) and nephrosis (HESS ASHWORTH and ZIFF 1962 HEYMANN HUNTER HACKEL and CUPPAGE 1962) can be transferred by means of immune lymphoid cells<sup>1</sup> whereas transfer with immune serum has failed. Successful attempts to transfer experimental autoimmune thyroiditis with lymphoid cells have been reported by some authors (FELIX DAVIES and WAKSMAN 1961 GOODMAN 1962 KOFFLER and PARONETTO 1965) whereas others have failed (ROSE KITE DOEBBLER and BROWN 1963). Similarly transplantation immunity can be passively transferred by immune lymphoid cells (for refs see GOWANS 1965). WAKSMAN and WENNERSTEN (1963) were able to transfer experimental adjuvant arthritis by means of lymphoid cells.

These successful transfer experiments principally similar to the transfer of delayed hypersensitivity by means of immune lymphoid cells first described by LANDSTEINER and CHASE (1942) and CHASE (1945) demonstrated the pathogenetic role played by the

lymphoid cells. However humoral factors *e.g.* humoral antibodies produced by the transferred living lymphoid cells (see HARRIS 1965) might have mediated the tissue damage (KRETSCHMER and PEREZ TAMAYO 1962 KARUSH and EISEN 1962). Evidence against as well as in favour of involvement of humoral factors—derived from the transferred lymphoid cells—has been reported (see NAJARIAN and FELDMAN 1962 1963 KRETSCHMER and PEREZ TAMAYO 1962).

Lymphoid cells from immunized animals have been shown to be capable of inducing cytotoxic effects on tissue cultures of the cells against which the animals had been immunized. For example in EAE immune lymphoid cells have been shown to exert a cytotoxic effect on cultured glia cells (KOPROWSKI and FERNANDES 1962 BERG and KALLÉN 1963) similar *in vitro* cytotoxic effects have been described in experimentally induced autoimmune neuritis (WINKLER 1965) and autoimmune nephrosis (HOLM 1966).

<sup>1</sup> Lymphoid cells or mononuclears refer to such cells of various sources such as spleen lymph node thoracic duct and peripheral blood. Immune lymphoid cells derived from immunized animals.

1967) and also in experimental autoimmune thyroiditis (ROSE and DOEBBLER and BROWN 1963, BJÖRK LUND 1964). In transplantation immunity similar observations have been made by GOVARTS (1960) and WILSON (1963), whereas some other attempts to demonstrate *in vitro* cytotoxicity have failed (for refs see WILSON 1963).

In a series of other experimental conditions, immune lymphoid cells have been shown capable of exerting cytotoxic effects on various normal and neoplastic target cells in tissue culture (ROSLAU and MOON 1961, 1964, 1966, ROSENAU 1963, BRONZ 1964, MÖLLER 1965a, b, WILSON 1965a and others).

Most authors mentioned above observed only slight damage to cultured target cells when these were exposed to non immune lymphoid cells. However moderate to strong cytotoxic effects (on xenogenic or allogeneic target cells) have been reported (e.g. by GINSBLER and SACHS (1965) and by HOLTZER (1966). HOLM and PERLMANN (1966) using a quantitative technique for the determination of the cytotoxic effect found xenogenic non immune lymphoid cells to be moderately cytotoxic whereas allogeneic as well as syngeneic non immune lymphoid cells only occasionally exerted a slight cytotoxic effect. The latter study was made with various combinations of lymphoid cells and target cells from rats and mice. In a subsequent investigation by HOLM and PERLMANN (1967) normal human blood lymphocytes were studied for

their cytotoxic effect on allogeneic liver cells on an average only a slight cytotoxic effect was observed (incubation time 24 hours). Essentially similar results have been reported when normal human blood lymphocytes were added to allogeneic fibroblast cultures (HIRSCHHORN, FIRSCHMAN and BACH 1965, MÖLLER, BECKMAN and LUNDQVIST 1966). Nevertheless by prolonged exposure (2 to 7 days) of the human fibroblast cultures to allogeneic blood lymphocytes strong cytotoxic effects appeared under this condition even autochthonous lymphocytes were often found to be cytotoxic (MÖLLER, BECKMAN and LUNDQVIST 1966).

The introduction of *in vitro* models has made studies also on clinical materials possible (see review by ROITT and DONIACH 1967). It is of interest that in multiple sclerosis blood mononuclears have been shown to exert a cytotoxic effect on cultured glia cells comparable to that previously described in LAE (BERG and KALLÉN 1964). In HASHIMOTO's thyroiditis LING, ACTON, ROITT and DONIACH (1965) were unable to demonstrate that blood mononuclears exerted a cytotoxic effect on cultures of thyroid cells. Their result with lymphoid cells in experimental autoimmune thyroiditis which differed from those of ROSE et al. (1963) and BJÖRKLUND (1964) were also negative.

In ulcerative colitis PERLMANN and BROBERGER (1963) have demonstrated that blood mononuclears are capable of inflicting a cytotoxic effect on tissue cultures of colon cells. This result has

been confirmed by WATSON QUICLEY and BOLT (1966)

The present investigation was designed as an approach to the question of whether or not lymphoid cells from arthritis patients can exert an *in vitro* cytotoxic effect similar to that described above. It was assumed that lymphoid cells deriving from the inflamed tissues surrounding the joint space are less diluted in synovial fluid than in blood. For this reason lymphoid cells separated from synovial fluid were studied.

Since our first reports on exudate mononuclears (HEDBERG and KALLEN 1964 a b) additional observations have been made. In order to obtain a better survey the results on the whole series of patients will be reported below. In rheumatoid arthritis (RA) BRAUN, STEINER, DIENSTL and EIBL (1963) had previously demonstrated a slight cytotoxic effect of lymph node cells on human amnion cells in tissue culture.

## Materials and methods

### *The clinical material*

Besides the selection principles described in Part I some additional criteria were required for the performing of cytotoxicity tests. One requirement was that the number of separated exudate mononuclears should be sufficient to make at least one test, i.e.  $2.0 \pm 0.3 \times 10^6$  mononuclears. Because of the low recovery of mononuclears in the separation process a volume of synovial fluid of at least 10 ml generally at least 20 ml was required.

Another requirement was that the suspension of separated exudate mononuclears should contain at least 85 per cent mononuclear cells. The limit of 85 per cent was arbitrary.

If the recovery was too low or if the admixture with polymorphonuclears exceeded 15 per cent the initially accepted patient was excluded. This happened in about 1/3 of the cases intended for study.

The clinical material comprised 113 patients: 103 had adult and 10 juvenile forms of arthropathies. Out of the 113 patients 75 belonged to the series described in Part I. The patients were classified as described in Part I.

*RA with nodules* 16 adults: 11 females and 5 males

*SSC pos RA* 43 patients: 20 females, 19 males and 4 girls

*SSC neg RA* 5 patients: 2 females both with negative latex tests, 2 males both with positive latex tests, and one boy with negative latex tests

*SLE and SLE like syndromes* 9 adults: 8 belonging to the series of Part I, these 8 cases are listed in Appendix Table VI as nos 2—4 and 6—10. The added patient was a male with positive tests for LE cells and ANFs, the score according to LEONHARDT (1964) was 10.

*Oligo arthritis* (juvenile) one girl and two boys, two belonged to the series of Part I, the added patient was a boy, aged 8 with arthritis of knee joints alone. The RF tests were negative.

*Ankylosing spondylitis* 11 patients (neg RF tests) out of whom 9 were adult males aged 28—51 (mean 37). Of the adults five had pronounced and four slight to moderate stiffness of the spine, all had X-ray changes of the sacro iliac joints and seven had changes of the spine too.

Two had had juvenile forms with peripheral arthritis for 9 and 7 years respectively (onset of joint symptoms

<sup>1</sup> Standard deviation

at 9 and 12 respectively), both had X ray changes of the sacro iliac joints as well as of the spine (squaring of the vertebrae), they had slight to moderate pain of the back and slight limitation of movement the peripheral arthritis (highly active since onset with an essentially continuous course) involved more joints as compared with that in the adult patients although the finger joints were spared the RF tests on serum had been consistently negative for years and the latex test on synovial fluid was negative in both instances at the time of examination. The peripheral arthritis was associated with but slight X ray changes.

*Uro polyarthritis* (definition OLHA GEN 1960) 7 patients with an essentially acute form of the syndrome all males aged 17—41 (mean 21) four had a full and 3 an incomplete REITER syndrome, one of the latter and one of the former had a positive gonococcal C fixation test. All had active prostatic vesiculitis and negative RF tests—Included in this group was a male aged 25 with iritis and peripheral polyarthritis involving one knee one ankle and one sternoclavicular joint. The arthritis had appeared in connection with a period of diarrhoea. This patient, who had been ill for 4 months lacked signs of prostatic vesiculitis. The sacro iliac joints were normal.

*Osteoarthritis* 4 patients 3 females aged 51—62 and one male aged 59. All showed roentgenograms and synovial fluid cell counts compatible with the diagnosis.

*Gouty arthritis* 1 female aged 71 with tophi and elevated uric acid in

serum (several values above 8 mg per cent).

*Psoriatic arthropathy* 13 patients. Twelve belonged to the series of Part I these cases are listed in Appendix Table VII as nos 1—2 4—6 and 8—14. The added patient was a male aged 51 with seronegative arthritis for years (no nodules) involving among others the distal inter phalangeal joints and the sacro iliac joints. In four of the 13 patients the diagnosis was considered only probable because the distal inter phalangeal joints were not involved (see Part I). Below the 13 patients are considered together as one group of psoriatic arthropathy.

#### *Revision of the diagnosis*

In three patients the diagnosis had to be revised. Two females originally labelled atypical polyarthritis and SSC neg RA respectively subsequently developed psoriatic skin and nail changes and involvement of the terminal phalangeal joints the RF tests remained negative they were included in the mentioned group of psoriatic arthropathy.

A third patient (male) originally labelled chronic uro polyarthritis (signs of active prostatic vesiculitis sacro ilitis sero negative peripheral arthritis (for 7 years) confined to knees and wrists negative RF test) developed all most generalized arthritis transient nodules and positive RF tests a month after the initial examination this patient was included as SSC pos RA.

#### *Methods*

*The principle of the test system* After treatment of the synovial fluid with

hyaluronidase\* (120—150 viscosity reducing units/ml 37°C 15—20 min) and heparinization (about 50 IU/ml) the mononuclear cells were separated on cotton wool (WALKER and PALMER 1962). The white blood cells not adsorbed to the cotton wool were washed twice with PARKER 199. The suspension obtained was standardized to contain  $2.0 \pm 0.3 \times 10^6$  cells/ml. As already mentioned, only suspensions consisting of at least 85 per cent mononuclears were accepted.

The standardized suspension of mononuclears was preserved at 37°C for a varying time (1/2 hour to about 4 hours) before 1 ml of the suspension (about  $2 \times 10^6$  cells) was added to cultures of human skin fibroblasts.

Primary cultures of human fetal fibroblasts were used. Fibroblast cultures were initiated from explants of skin from abortuses 20—25 cm long. Small pieces of non trypsinized skin were placed directly on the glass bottom of LEIGHTON tubes. After 15—30 minutes a fluid medium was added consisting of 5 per cent chick embryo extract, 20 per cent adult human serum and 75 per cent PARKER 199 and containing penicillin (50 IU/ml) and streptomycin (50  $\mu$ g/ml). Good growth of spindle shaped fibroblasts was usually obtained within a few days and dense mats of fibroblasts soon formed. The medium was changed regularly but cultures were not used for tests during the first 4 days after the last medium change. Incubation 37°C. No other temperatures were tried.

The cultures were studied with phase contrast microscope. Before ad-

ding of mononuclears (day 0) part of the culture showing good growth was selected and photographed, the suspension of mononuclears was added and incubated with the culture for 15—20 hours, the culture was rinsed with prewarmed PARKER 199 and a new photograph (day 1) of the same selected part of the culture was taken. The culture was then incubated for a further 20—24 hours, this time with those mononuclears alone that had not been rinsed away. If after this last incubation (day 2) the culture remained unchanged, photographing was occasionally omitted. For further technical details the reader is referred to a previous report (HEDBERG and KALLÉN 1964).

By comparing day 1 and day 2 photographs with the day 0 photograph the degree of cytotoxicity could be (roughly) estimated. A simple score—0, '+', and '++'—was used as shown and described in Figs 1—2. Only a '++' reaction (on day 1 or day 2) was considered significant, in most instances of a '++' reaction this appeared on day 1. Cytotoxicity in this test system was defined as the capacity of the mononuclears to detach the fibroblasts from the glass.

The initially selected field of the monolayer culture seemed to be essentially representative of the whole cul-

\* HYALAS® LEO kindly supplied throughout the study by A/B LEO Helsingborg Sweden. This preparation is known to be free from proteolytic enzymes.

\* In the first part of the study the suspension was standardized to contain  $1-3 \times 10^6$  cells/ml.

Da 0                      Day 1                      Day 2




Fig. 1 Photographs of fibroblast cultures before addition of exudate mononuclears (day 0) 15–20 hours later (day 1) of the same microscopic field and after an additional 20–24 hours (day 2). Three cases of RA. Cytotoxicity score: A 0 B 0 C.



Day 0

Day 1

Day 2






Fig 2 Photographs of fibroblast cultures on day 0 day 1 and day 2 (see Fig 1) Three cases of  $\eta$  or at  $\eta$  arthropathy  
Cytotoxicity score for all three tests = + +

ture with respect to the outcome of the test, in some of the tests scored + minor variations seemed to occur in different parts of the culture when the tests were scored '0 or ++ no consistent difference between different parts of the culture was observed

In the first series of patients studied (HEDBERG and HALLÉN 1964 a b) the diagnosis of the patient was unknown when the test result was evaluated. In the remainder corresponding to about half the number of patients (as well as in the repeated tests) the diagnosis was known. The distribution of positive cytotoxicity tests over different arthritis groups was essentially one and the same in both cases. When repeated tests were made the patient was represented by the first one made. Some tests were made with the patient's whole serum or IgG present as described below. The IgG fraction prepared from whole serum by chromatography on DEAE cellulose according to the technique described by SOBER, GUTTER, WICKOFF and PETERSON (1956) was immunoelectrophoretically pure (see HEDBERG and HALLÉN 1964 b).

Trypan blue technique (ENGELFRIET and BRITTON 1965) was used to estimate the viability of the mononuclears after separation and also in a few experiments for study of the fibroblasts which had been detached from the glass. In a series of 25 consecutive determinations on an average 10 per cent of the separated mononuclears were found trypan blue positive (range for 24 determinations 3—16 per cent; one alone showed 25 per cent). Similarly separated blood mononuclears consistently yielded less than 5 per cent trypan blue positive cells.

The recovery of crude mononuclears at the separation process amounted on an average to about 1 per cent. As mentioned before a low recovery or admixture with polymorphonuclears fairly often made a cytotoxicity test impossible sometimes rapid coagulation despite heparinization made a separation of mononuclears impossible.

The RF and ANF tests were those described in Part I. The latex titre of synovial fluid was not consistently determined in this series of patients.

## Cytotoxicity tests with exudate mononuclears

### a) Findings in various arthropathies

As mentioned above, only tests scored ++ were considered significant, whereas tests scored 0 or + were considered negative (see Materials and Methods).

*Positive tests* (score = ++ ) were found predominantly in SLL or SLF like syndromes and in psoriatic arthropathy, some RA patients especially those with nodules and one of the patients with ankylosing spondylitis also showed a positive test (Table I).

*Negative tests* (scored 0 or in a few cases +) were obtained in 10 out of 11 patients with ankylosing spondylitis and in 8 with uro polyarthrititis (Table I). These 19 cases are considered as a reference group below. Four adults with osteo arthrosis and one with gouty arthritis associated with osteo arthrosis, three juveniles with oligo arthrititis and a considerable proportion of the RA patients (44 out of 64) also showed negative tests (Table I).

Among the 44 RA patients with negative tests a weak or doubtful test (scored +) was observed in three. Similar doubtful cytotoxic effects were observed in two out of 10 cases of ankylosing spondylitis. In the remaining

patients, totally 69, all tests were scored 0.

The cytotoxic effect seemed to be preceded by clustering of the mononuclears (contactual agglutination) on the surface of the fibroblasts (Fig. 3).

The above mentioned weak cytotoxic effects scored + were associated with contactual agglutination. Contactual agglutination without detectable cytotoxic effect (score=0) were noted in three cases alone (of RA) <sup>1</sup>.

In the group of SLF and SLF like syndromes as well as in psoriatic arthropathy positive cytotoxicity tests were found highly significantly more often than in the reference group (Table I).

In RA as a whole the frequency of positive cytotoxicity tests was probably higher than that in the group of ankylosing spondylitis and uro polyarthrititis used as a reference ( $p=0.03$ , Table I).

<sup>1</sup> Contactual agglutination in association with a cytotoxic effect as a routine studied only 15-20 hours after the addition of exudate mononuclears to the fibroblast cultures seemed to be somewhat more impressive in psoriatic arthropathy than in other arthritides where cytotoxic effects were found.

*Table 1* Frequency of positive cytotoxicity tests (scored + +) with exudate mononuclears in various arthropathies

Diagnosis	No of cases	Frequency of pos tests	P <sup>a</sup>
SLE and SLL like syndromes	9	9/9	0.000003
Psoriatic arthropathy	17	10/13	0.000009
RA with nodules	16	9/16	0.002
SSC pos RA	43	11/43	0.10
SSC neg RA	5	0/5	—
Ankylosing spondylitis	11	1/11	—
Lupoid arthritis	8	0/8	—
Osteoarthritis	4	0/4	—
Gouty arthritis	1	0/1	—
Oligo arthritis (juvenile)	3	0/3	—

<sup>a</sup> The frequency of positive tests was compared with that of 1/19

In SSC pos RA however the largest group of RA the results showed only a non significant tendency towards a higher incidence of positive cytotoxicity tests as compared with that of the reference group ( $p=0.10$  Table I)

Within the group of RA as a whole patients with subcutaneous nodules showed positive cytotoxicity tests significantly more often than did patients without ( $p=0.002$  Table I)

#### *b) Cytotoxicity tests made with different fibroblast cultures as targets*

Experiments were performed in which exudate mononuclears were simultaneously added to different fibroblast

cultures (Table II). The cultures derived from three sources: fetal and adult skin and adult rheumatoid synovial membrane.

As shown in Table II the test results with the cultures of fetal skin agreed closely with those obtained with the other two types of (on an average older) cultures in one instance a weak cytotoxic effect (in association with confluent agglutination) was obtained with the culture of adult skin where no detectable cytotoxic effect was found in the culture of fetal skin (Table II).

Different fetal skin cultures of the same or different age and source also



(Score on day 2 = +)



(Score on day 2 = +)



(Sore on day 2 = ++)



(Sore on day 2 = ++)

**Fig 3** Contactual agglutination on fibroblasts exposed for 7 1/2—13 hours to exudate mononuclears (4 patients)

*Table II* Results of simultaneous challenge of different fibroblast cultures with exudate mononuclears alone. Aliquots of the suspension of mononuclears were simultaneously added to the different cultures

Figures in parenthesis = Age of the cultures in days

RA = Rheumatoid arthritis

PsA = Psoriatic arthropathy

■ = no cytotoxic effect

+ = doubtful cytotoxic effect

++ = strong cytotoxic effect

Diagnosis	Source of fibroblast cultures			
	Fetal skin		Adult skin	Synovial membrane (rheumatoid)
RA	0 (2)	0 (9)	— <sup>1</sup>	—
PsA	++ (5)	0 (5)	—	—
RA	0 (6)	0 (6)	—	—
PsA	++ (7)	++ (7)	—	—
RA	++ (11)	++ (17)	—	—
PsA	0 (14)	0 (21)	—	—
RA	++ (28)	++ (30)	—	—
PsA	++ (7)	++ (7)	++ (32)	—
RA	++ (9)	—	++ (60)	—
RA	0 (13)	—	0 (60)	—
RA	0 (13)	—	+	(40)
RA	++ (12)	—	—	++ (33)
PsA	0 (19)	—	—	0 (28)
Discrepancy	Clear cut	1/8	—	—
	Doubtful	—	1/4	—

<sup>1</sup> Not done

yielded identical test results in all except one out of 8 similarly made tests (Table II)

When cytotoxicity tests were repeated with one day old mononuclears (preserved overnight at 37°C) and with one day older fetal fibroblast cultures the results were similar in 8 cases the mononuclears remained non cytotoxic and in five out of six cases of cytotoxic mononuclears these were

found to retain their cytotoxicity overnight

The test results when different fibroblast cultures were challenged with exudate mononuclears (Table II) as well as the test results in the whole series of patients (Table I) were independent of the ages of the cultures. The variation of the density of the fibroblast mats when different cultures were simultaneously challenged

with mononuclears (Table II) was presumably similar to that when the primary tests on the whole series were made (Table I). No attempts were made to determine the ratio mononuclears/target cells.

*c) Cytotoxicity tests with exudate mononuclears secured on different occasions from the same patient, and the test results in relation to various treatments*

Treatment with corticosteroids *per os* or with ACTH (Table IV) like other conventional therapy, did not seem to influence the test results. This was true also of various combinations of therapeutic agents. Whether or not recently given intra-articular injections of corticosteroids might have had any importance for the test results will be considered below.

In 43 patients exudate mononuclears secured on two or more occasions were tested for their cytotoxicity, in all 73 additional tests were made in these patients (Table III).

In Table III the results of the additional tests can be compared with those of the primary tests. No distinction was made between mononuclears derived from the same joint and those from different joints of the same patient. No relation was found between the test results and the time between the different tests nor was there any appreciable change of the clinical state (disease activity and intensity of synovitis) of the patient between the different tests.

In SLE or SLE-like syndromes the

results of the additional tests agreed with those of the primary tests: consistently positive tests were obtained (Table III). Similarly, consistently negative tests were obtained in cases belonging to the group of 'miscellaneous arthropathies' studied by repeated tests (Table III). In both these groups of patients, the results of the primary tests (Table IV) as well as those of the additional ones seemed to be unrelated to intra-articular injections given at least two weeks before examination. In SLE or SLE-like syndromes positive tests were observed 2–3 weeks after such injections.

In RA and especially in psoriatic arthropathy discrepant test results were observed (Table III).

In psoriatic arthropathy where 10 out of 13 initial tests turned out positive most tests were made with mononuclears derived from joints not injected for several months or from non-injected joints (Table IV). In two of the three cases of a negative test intra-articular injections had been given 3 and 6 weeks respectively before examination (Table IV).

In these two cases three new tests made at least 10 weeks after the last injection of corticosteroid turned out positive twice and doubtful once (Table III). The doubtful test made 5 months after the last injection like the strongly positive tests though not the negative ones made after 3 and 11 weeks respectively, was probably associated with contractural agglutination.

= Ankylosing spondylitis, spondyloarthritides and osteoarthritis

*Table III* Results of two or more cytotoxicity tests made on different occasions with exudate mononuclears alone derived from one and the same patient (no distinction was made between mononuclears from the same joint and those from different knee joints)

Diagnosis	No of cases	Primary tests			Subsequent tests			Discrepancy <sup>1</sup>			
		Cytotoxicity score			No of tests	Cytotoxicity score			No	Doubtful	Clear cut
		0	+	++		0	+	++			
SLE and SLE like syndromes	5	—	—	—	9	—	—	9	5/5	0/5	0/5
Psoriatic arthropathy	6	2	—	—	3	—	1	2	0/2	1/2	1/2
		—	—	3	4	—	1	3	2/4	1/4	1/4
		—	—	1	4	3	—	1			
		Total						2/6	2/6 (0) <sup>2</sup>	2/6 (2)	
RA with nodules	11	2	—	—	8	8	—	—	5/5	0/5	0/5
		3	—	—	4	4	—	—			
		—	—	6	7	3	1	3	2/6	1/6	3/6
		Total						7/11	1/11 (0)	3/11 (0)	
SSC pos RA (11)		1	—	—	5	5	—	—	5/7	1/7	1/7
		5	1	—	6	4	—	2			
SSC neg RA (1)	12	—	—	2	7	—	—	7	3/5	1/5	1/5
		—	—	3	3	1	1	1			
		Total						8/12	2/12 (2)	2/12 (0)	
Total RA	23	11	1	—	23	21	—	2	10/12	1/12	1/12
		—	—	11	17	4	2	11	5/11	2/11	4/11
		Total						15/23	3/23	5/23	
Ankylosing spondylitis	4	3	1	—	7	7	—	—	3/4	1/4	0/4
Lro poly arthritis	2	2	—	—	2	2	—	—	2/2	0/2	0/2
Osteo arthrosis	3	3	—	—	4	4	—	—	3/3	0/3	0/3
		Total							30/43	6/43	7/43

Clear cut doubtful and no=Differences scored + + + and ■ respectively

<sup>2</sup> Figures in parenthesis indicate instances of discrepant test results where the weaker cytotoxic reaction appeared after more recently given intra articular injections of corticosteroid than did the stronger one



In two experiments with cytotoxic mononuclears it was found that  $1-2 \times 10^6$  mononuclears per ml elicited a cytotoxic effect whereas  $0.5 \times 10^6$  or less were inefficient

Cytotoxic mononuclears that were preserved at  $37^\circ\text{C}$  overnight retained their cytotoxicity in five out of six experiments

Heat treatment at  $56^\circ\text{C}$  for 30–60 min which rendered the mononuclears trypan blue positive extinguished the cytotoxic effect (5 experiments), as did heat treatment at  $100^\circ\text{C}$  for 1 min (1 experiment)

Freezing and thawing also extinguished the cytotoxic effect (three experiments)

Adding of fresh blood donor serum (diluted 1:2 to 1:4) or fresh guinea pig serum (diluted 1:10) resulted in extinction of the cytotoxic reaction Preliminary experiments suggested that the extinguishing effect of a fresh hypogammaglobulinaemic serum used as a source of C (in the dilutions 1:5 or 1:10) was less pronounced as compared with that of fresh guinea pig serum

Similarly when the tests were made in the presence of the patient's fresh serum (diluted 1:2 or in one case 1:4) the cytotoxic reaction was extinguished in 6 out of 8 RA patients in all 3 with psoriatic arthropathy and in 1 out of 3 with SLE or SLE like syndromes Serum in itself was non cytotoxic\*

In most cases heat inactivation ( $56^\circ\text{C}$  30 min) did not modify the protecting capacity of fresh patient serum in 9 out of 12 cases heat inactivated serum provided protection Also blood donor

serum retained its protective effect after heat inactivation Adding of a 6 per cent solution of human albumin (w/v) had no protective effect nor had the patient's (non cytotoxic) IgG fraction in amounts of 1.1 to 3.1 mg per ml in 10 out of 11 similar experiments

The absence of a detectable contactual agglutination in cases of a protective effect of serum suggested that serum can in some way interfere with the contactual agglutination step of the cytotoxic reaction

In 8 cases of RA with a negative cytotoxicity test fresh hypogammaglobulinaemic serum, diluted 1:10 or in one case 1:2, was added as a source of C to non cytotoxic exudate mononuclears No detectable cytotoxic effect appeared in the presence of added C'

Some tests were made with mononuclears combined with phytohemagglutinin (PHA), an agent known to provoke strong contactual agglutination A purified preparation of PHA was used in an amount of  $10 \mu\text{g/ml}$  which in itself was essentially without detectable cytotoxic effect\*

\* In this limited series there was no relation between the protective effect of serum and the ABO group of the patient Nor was there any relation between the results of the cytotoxicity tests and the ABO group

\* The PHA preparation was kindly placed at my disposal by Dr Jan Borjeson Thirty  $\mu\text{g}$  per ml of the preparation exerted a moderate to strong cytotoxic effect on the cultured fibroblasts whereas  $10 \mu\text{g}$  induced degeneration of only a few fibroblasts Mitosis of human lymphocytes ( $2 \times 10^6$  per ml) was initiated by  $1-2 \mu\text{g}$  per ml of the preparation Three of the PHA tests (with exudate mononuclears) were made with Difco's PHA M

In 4 out of 5 experiments where primarily non cytotoxic exudate mononuclears were combined with PHA a strong cytotoxic effect scored ++ appeared

ROSENAU (1963) studied the effect of polylysine another agent known to induce strong contactual agglutination. This type of agglutination however, was not followed by any cytotoxic effect (allogeneic test system). Similarly, when polylysine<sup>4</sup> was added to primarily non cytotoxic exudate mononuclears in the present (allogeneic) test system no detectable cytotoxic effect appeared (5 experiments).

Identical results were obtained when instead of non cytotoxic exudate mononuclears non cytotoxic peripheral blood mononuclears were used (separated as described below). PHA aggregation (11 experiments) although not polylysine aggregation (3 experiments) yielded a strong cytotoxic effect.

#### *e) Relation to laboratory and clinical data*

Low recovery of mononuclears in the separation process often too low for making a single test and/or admixture with polymorphonuclears, exceeding 15 per cent seemed to be associated with one or more of the following factors (perhaps most predominant in long lasting effusion in RA) pronounced capsular thickening extremely turbid synovial fluid and fluid rich in clots. The tests repeated in one and the same patient (Table III) were made almost exclusively in long lasting synovitis.

The sometimes discrepant test results observed exclusively in instances of long standing effusion could not be clearly related to a variation of the above mentioned factors.

The question must be left open whether or not the separation process which as mentioned yielded a low recovery of exudate mononuclears might have had any importance as a selection mechanism.<sup>7</sup>

In RA the following tendencies in the results of the cytotoxicity test could be traced: a tendency towards positive tests in instances of a rapidly developing effusion and in cases of instability of the knee joint. The test results could not be clearly related to any of the following parameters: the intensity of the synovitis, the ESR (see Table IV), the white cell count or the differential count of synovial fluid. The test results in relation to duration of effusion will be reported in a following chapter.

In the group of RA and in that of SLE and SLE like syndromes (Table V) no relation was found between the SSC titre of serum and the occurrence of positive cytotoxicity tests. In RA

<sup>4</sup> Poly L lysine HCl MA (Mann Res. Lab. Inc. NY) was used in an amount of 1 µg/ml. This amount in itself non cytotoxic elicited a strong contactual agglutination; it did not inhibit the cytotoxic reaction when added to primarily cytotoxic mononuclears.

<sup>5</sup> An incubation of 40—45 hours was used as a routine because initial studies suggested this time to be sufficient.

<sup>7</sup> Attempts to separate the exudate mononuclears by glass wool filtration (BRANDT BÖRJESEN, NORDEEN and OLSSON 1962) were unsuccessful.

Table 1 Frequency of positive cytotoxicity tests with exudate mononuclears alone at different SSC titre levels

	No of cases	SSC titre in serum			
		≤16	32-64	128-256	512-1024
RA	61	1/12	8/18	7/22	4/12
SLE and SLE like syndromes	9	3/3	1/1	1/1	4/4
Psoriatic arthropathy	13	10/13	—	—	—

only a non significant tendency ( $p=0.09$ ) was found towards a higher frequency of positive tests when the SSC titre was 32 or higher than at lower titres (Table 1). The results were similar if the latex titre was considered instead of the SSC titre.

A positive test for ANFs in serum appeared in RA patients with a positive cytotoxicity test as often as in those with a negative one. In both cases a positive test for ANFs appeared in about 1/3 of the patients. The appearance of a positive test for ANFs (in RA) was most clearly related to the presence of subcutaneous nodules.

**SUMMARY** In various arthropathies exudate mononuclears were tested for their capacity to elicit a cytotoxic effect on tissue cultures of human embryonic fibroblasts. Non trypsinized primary cultures were used, only clear cut effects were considered significant.

The test system yielded reproducible results essentially identical test results were obtained when fibroblast cul-

tures of the same or of various origin and age were simultaneously challenged with exudate mononuclears.

Positive cytotoxicity tests were found predominantly in SLE and SLE like syndromes (9/9) and in psoriatic arthropathy (10/13). Some RA patients (20/64), especially those with nodules (9/16), also showed positive tests.

Negative tests were obtained in all but one of 19 cases of ankylosing spondylitis and uro polyarthritis. Four cases of osteoarthritis and three of juvenile oligo arthritis also showed negative tests.

When the tests were repeated in one and the same patient consistently positive tests were obtained in the group of SLE and SLE like syndromes and consistently negative ones in ankylosing spondylitis uro polyarthritis and osteoarthritis. Some cases of RA and psoriatic arthropathy showed discrepant test results.

No relation was found between the test results and the intensity of the synovitis or the disease activity as judged from the ESR.

## Results of cytotoxicity tests with exudate mononuclears in relation to duration of effusion

Although the number of observations in early effusion (of less than 3 months duration) was limited in each of the arthritis groups discerned attempts were made to relate the results of available cytotoxicity tests to the duration of effusion.

In SLE and SLE like syndromes the shortest duration of effusion was one of 2 weeks and one of 5 months. In both instances as in long standing effusion of this group positive tests were obtained (Table VI).

In psoriatic arthropathy five patients had effusion for 1 month or less. Four of these showed positive cytotoxicity tests (Table VI). In long standing effusion all psoriasis patients showed a positive cytotoxicity test at least once.

In RA as a whole positive cytotoxicity tests appeared somewhat more rarely in early than in long standing effusion ( $p=0.18$  Table VI). Six RA patients all sero positive like 8 with non RA arthritis (uro polyarthritis

Table VI Frequency of positive cytotoxicity tests with exudate mononuclears alone in relation to duration of effusion

Diagnosis	No of cases	Duration of effusion in weeks					
		<1	1-4	5-11	12-26	27-52	>52
SLE and SLE like syndromes	9	—	—	1/1	1/1	2/2	3/3 ( $p=0.004$ )
Psoriatic arthropathy	13	0/1	4/4	—	—	1/1	3/7 ( $p=0.034$ ) <sup>1</sup>
Rheumatoid arthritis	64	0/3	0/3	2/5	1/4	2/2	15/47 ( $p=0.26$ ) <sup>1</sup>
Miscellaneous arthritides <sup>2</sup>	22	0/5	0/3	0/2	0/1	0/1	1/10

<sup>1</sup> The frequency of positive tests in effusion of more than a year's duration was compared with that of 1/10.

<sup>2</sup> Ankylosing spondylitis 11 uro polyarthritis 8 and oligo arthritis 3.

and ankylosing spondylitis) had effusion of less than a month's duration. All showed negative cytotoxicity tests (Table VI).

In long standing effusion of more than a year's duration the incidence of positive cytotoxicity tests was found to be higher in psoriatic arthropathy and in SLE and SLE like syndromes as compared with that in the group of miscellaneous arthritides ( $p < 0.05$ , Table VI). In RA on the other hand, there was only a tendency towards a higher incidence of positive tests ( $p = 0.26$ , Table VI).

When effusion had lasted for only a month or less the incidence of positive cytotoxicity tests in psoriatic arthropathy (4/5) seemed to be higher

than that in RA (0/6), and also higher than that in non RA miscellaneous arthritides (0/8,  $p < 0.03$ , Table VI).

It should be added that in most cases of RA, exudation was fairly persistent once it had started. In most of the other arthritides and especially in SLE and SLE like syndromes exudation tended to be more intermittent.

**SUMMARY** Available observations showed that in psoriatic arthropathy a positive cytotoxicity test seemed to be an early phenomenon during the course of exudation.

In RA positive cytotoxicity tests tended to be even more rare in early than in long standing effusion.

## Cytotoxicity tests with cultures of human kidney as target

As a preliminary approach to the question of the organotypic specificity of the cytotoxicity of the exudate mononuclears, some tests were made with kidney cells as target. Kidney (human fetal) was selected as an epithelial organ which generally showed a fairly good outgrowth when cultured by the tissue culture technique used. Small pieces of kidney cortex were placed on the glass bottom of LEIGHTON tubes whereafter the same tissue culture medium as that used for initiation of the fibroblast cultures was added. The medium was changed regularly and always as a matter of routine after 48 hours. Cultures of varying ages (4 to 18 days) were used.

In about half the number of tests kidney and fibroblast cultures of the same age were simultaneously challenged with exudate mononuclears. Owing to scarcity of exudate mononuclears a few tests were made with kidney cultures alone as target.

In (sero positive) RA (no nephropathy) the kidney cultures were found to be damaged as often as the fibroblast cultures (Table VII). In three cases the fibroblast cultures alone and in two the kidney cultures alone were damaged (Table VII).

In psoriatic arthropathy on the other hand the skin cultures but not the kidney cultures were damaged when exposed to exudate mononuclears (Table VII).

In two single cases of SLL like syndrome (no nephropathy) similarly studied the result agreed with that obtained in psoriatic arthropathy: the fibroblast cultures alone were damaged.

In two cases of ankylosing spondylitis and two of uro polyarthritis neither the kidney cultures nor the fibroblast cultures were damaged.

When in a few instances the cytotoxicity tests with kidney cells as targets were repeated the results were reproduced.

In the tests with kidney cultures those explants were selected and photographed which contained only a few fibroblast like cells. In one case of RA and one of psoriatic arthropathy it was found that at some of the other explants containing more fibroblast like cells the exudate mononuclears had clustered around these but not around the epithelial cells (Fig. 4).

**SUMMARY** Cultures of human kidney and those of (human) fibroblasts



Day 0



Day 1 (score on day 0 = 0)



Day 1



Day 1 (score = + +)

Continual agglutination  
on fibroblast like cell  
of kidney culture (day 1)



Fig. 4 Simultaneous challenge of 7 days' cultures of kidney cells and of fibroblasts with exudate mononuclears in a case of psoriatic arthropathy

*Table 111 Results of simultaneous challenge of primary cultures of fetal human kidney and those of fetal human skin fibroblasts with exudate mononuclears alone No trypsin treatment The mean age of the two types of cultures was 12 days Approximately half the number of tests in each group was made with cultures of the same age and source The cytotoxicity score is given*

Diagnosis	No of cases	Type of target cells	
		Kidney	Skin fibrobl
Isoriatic arthropathy	6	0	++
	1	0	ND <sup>1</sup>
	Total scored ++	0/7	6/6
RA with nodules	3	++	++
	2	++	0
	1	0	++
	1	0	ND <sup>2</sup>
	Total scored ++	5/7	4/6
RA without nodules	1	++	++
	2	0	++
	1	0	0
	Total scored ++	1/4	3/4
Uro poly arthritis	2	0	0
Ankylosing spondylitis	1	0	0
	1	0	ND <sup>3</sup>
SLE like syndrome	1	0	++

were simultaneously challenged with exudate mononuclears

In RA (10 cases) the kidney cultures were damaged as often as the fibroblast cultures

In psoriatic arthropathy (6 cases) fibroblast cultures alone were damaged Similarly in two single cases of SLE like syndromes the fibroblast cultures alone not those of kidney cells, were damaged

<sup>1</sup> Not done a previously made test had yielded a cytotoxicity score of ++

<sup>2</sup> Not done



## Cytotoxicity tests with blood mononuclears

Mononuclears were separated from heparinized venous blood in the same way as that used for separation of exudate mononuclears, except that the bulk of erythrocytes was allowed to sediment in 1.2 per cent dextran (Macrodex, Pharmacia Sweden) for 40–50 min at room temperature. As in the tests with exudate mononuclears an amount of  $2 \times 10^6$  mononuclears per ml and test was used.

Cytotoxicity tests with blood mononuclears which were made exclusively in cases of psoriatic arthropathy, RA and SLE and SLE like syndromes almost consistently yielded a negative result whether exudate mononuclears had elicited a cytotoxic effect or not (Table VIII). A positive test with blood mononuclears was obtained only in two cases: one of RA (negative test with exudate mononuclears) and one of psoriatic arthropathy (positive tests with exudate mononuclears twice). The tests with blood mononuclears and those with exudate mononuclears were made on different occasions.

Admixture with erythrocytes did not seem to influence the test results. In a few (negative) tests most of the contaminating erythrocytes had been lysed by hypotonic (0.35 per cent) saline according to a procedure described by JANOWSKI, ROSENBAUM and MOON

*Table VIII* Frequency of positive cytotoxicity tests with blood mononuclears alone. For comparison the results of tests made with exudate mononuclears alone are included

Diagnosis	No of cases	Exudate mono-nuclears	Blood mono-nuclears
SLE or SLE like syndromes	5 2	5/5 — <sup>1</sup>	0/5 0/2
Psoriatic arthropathy	9	9/9	1/9
Rheumatoid arthritis	3 4 2	3/3 0/4 — <sup>1</sup>	0/3 1/4 0/2
Total	25	17/21	2/25

<sup>1</sup> Tests not made

(1964). In some of the negative tests the suspension of blood cells had been pre-treated with hyaluronidase.

**SUMMARY** Cytotoxicity tests made with blood mononuclears instead of with exudate mononuclears were performed on 25 patients (7 with SLE or SLE like syndromes, 9 with psoriatic arthropathy and 9 with RA). In 17 out of these 25, previously made tests with exudate mononuclears had turned out positive. All tests with blood mononuclears except two (one case of psoriatic arthropathy and one of RA) turned out negative.

## Discussion

Several methods have been developed for the quantitation of the cytotoxicity of lymphoid cells (see HOLM 1967). Such methods involve the use of certain ratios lymphoid cells/target cells as well as various techniques for the determination of the number of target cells damaged.

Monolayer technique comparable to that used in the present investigation has been found useful in several studies (GOVAERTS 1960 KOPROWSKI and FERNANDES 1962 BERG and KALLÉN 1963 1964 BJÖRKLUND 1964 HIRSCHHORN FIRSCHEN and BACH 1965 KAKULAS 1966 and others). Related to the present technique is also the plaque technique (monolayer) used by MÖLLER and MÖLLER (1965) and MÖLLER BECKMAN and LUNDGREN (1966). In the latter technique however the ratio lymphoid cells/target cells is presumably subject to less variation than that in ordinary monolayer technique.

A simple non quantitative monolayer technique was used in the present study which was designed as an approach to the question of whether exudate mononuclears can exert a cytotoxic effect on cultured fibroblasts in arthritis. The intention was that if clear cut results were obtained and especially if distinct differences ap-

peared between different form of arthritis the results would serve as a basis for further studies preferably performed by quantitative techniques.

It may be mentioned that even under strictly standardized experimental conditions marked intra individual variations can appear in the cytotoxicity of lymphoid cells (HOLM and PERLMANN 1967) presumably because of the high degree of sensitivity of the method used ( $Cr^{51}$  release).

The present test system presumably ensured that essentially strong effects alone were revealed. This refers to the capacity of the mononuclears to detach the fibroblasts from the glass. Studies on the supernatant of cultures suggested that this effect would not necessarily result in the killing of all loosened fibroblasts.

The fibroblasts were cultured directly on glass whereby cell damage induced by enzymatic tissue disintegration was avoided (EDWARDS and FOGH 1959 LEVINSON and GREEN 1965).

Since the first cytotoxicity tests made with exudate mononuclears yielded obvious differences between different forms of arthritis the procedure initially used (see Materials and methods) was retained.

When fibroblast cultures of different sources and ages were simultaneously

## General Summary

The present study of synovial fluid in various arthropathies deals with two phenomena one the suppression of the C' activity, the other the occurrence of mononuclear cells with a capacity to elicit a cytotoxic effect on tissue cultured human fibroblasts. Although the cytotoxic reaction elicited by exudate mononuclears had certain features in common with that elicited by immune lymphoid cells in various experimental conditions it is an open question whether the cytotoxicity of exudate mononuclears is analogous to that of immune lymphoid cells.

In order to provide a survey an attempt was made to summarize the synovial fluid findings in Table I. For comparison the conventional serum tests for RFs and ANIs were included.

Thus totally four reactivities were considered the RF and ANI activity of serum the activation of the C' system as determined by the C activity of synovial fluid and the occurrence in this fluid of mononuclears with an *in vitro* cytotoxic effect.

For the sake of convenience various non RA sero negative arthropathies such as ankylosing spondylitis, urethral polyarthritis, osteoarthritis, lesions of the menisci etc. were treated together

as one group of 'miscellaneous arthropathies'. Included in this group were also cases of oligo arthritis.

As shown in Table I different patterns could to some extent be discerned in different types of arthritis though various degrees of overlapping were evident too.

In the heterologous group of non RA sero negative 'miscellaneous arthropathies' all patients showed a non suppressed synovial fluid C' activity considered to be essentially normal. In this group only one patient (with ankylosing spondylitis) out of 27 showed a positive cytotoxicity test.

In psoriatic arthropathy the outstanding result (Table I) was the occurrence of exudate mononuclears with an *in vitro* cytotoxic capacity, the other reactivities being present in a low frequency or entirely absent. A suppressed synovial fluid C activity appeared in some patients where arthritis did not involve the terminal interphalangeal joints.

The *in vitro* cytotoxicity of exudate mononuclears in this group was directed against fibroblasts but not against kidney cells. Positive cytotoxicity tests seemed to appear early in

Table 1 Summary of synovial fluid findings For comparison the conventional serum tests for RFs and ANFs are included—a simple score is used where

0 = an incidence of about 0 per cent

(+) = an incidence of about 10–15 per cent

+ = an incidence of about 25 per cent

++ = an incidence of about 50 per cent

etc

Diagnosis	Serum findings		Synovial fluid findings			
	Positive ANF test	Positive RF test	Suppressed C' activity <sup>1</sup>		Cytotoxic exudate mononuclears	
			Duration of effusion		Duration of effusion	
			< 3 months	> 3 months	< 3 months	> 3 months
Psoriatic arthropathy	+	0	(+)	+	+++	+++
SLE and SLE like syndromes	++++	+++	++++	++++	*	++++
RA with nodules	++	++++	++++	++++	*	++
RA without nodules	+	+++	++	++	(+)	+
Total RA	+	+++	++	++	(+)	+
Miscellaneous arthropathies <sup>2</sup>	*	0	0	0	0	(+)

<sup>1</sup> At the 5 per cent level

<sup>2</sup> Predominantly ankylosing spondylitis, spondyloarthritis, osteoarthritis (only a few cytotoxicity tests), lesions of the menisci (no cytotoxicity tests) and juvenile oligoarthritis (only a few cytotoxicity tests)

this group of patients 4 out of 5 with effusion of less than a month's duration showed positive tests

Tests with blood mononuclears turned out negative in 8 out of 9 psoriasis patients

In the group of SLE and SLE like syndromes all four reactivities occurred in a fairly high frequency (Table 1). The patients in this group

showed extremely suppressed synovial fluid C' activities and all (totally 9) showed positive cytotoxicity tests with exudate mononuclears whereas tests with blood mononuclears turned out negative

A suppressed synovial fluid C' activity seemed to be an early phenomenon in this group of patients

The organotypic specificity of the positive cytotoxicity tests however as

well as the occurrence of such tests in instances of early effusion, remain to be determined. So far only two cytotoxicity tests were made with kidney cells as target both turned out negative.

In *rheumatoid arthritis* the essential finding was the presence of a highly significant degree of negative correlation between the synovial fluid C' activity and the RF titre. This was true of each of the three RF titres determined: the SSC titre of (whole) serum and the latex titre (euglobulin fraction) of serum and synovial fluid.

The inverse relationship between the synovial fluid C' activity and the RF titres was most clearly manifest in the group of RA with subcutaneous nodules. In this group the synovial fluid C' activity was highly significantly lower and the RF titres of serum significantly higher as compared with corresponding parameters in RA patients without nodules. The RF titre of synovial fluid (by the latex test), however, was similar in the two groups compared.

The results suggested that a depressed synovial fluid C' activity in different joints of the same patient was a more consistent phenomenon when the SSC titre of serum was markedly elevated. At intermediate SSC titres the intra-individual variance like the inter-individual one was considerable.

The results suggested that in RA a suppression of the synovial fluid C' activity (probable at the 5 per cent level) is a late phenomenon during the course of exudation.

Positive cytotoxicity tests in RA appeared in a fairly low frequency of about 30 per cent. Most positive tests appeared in patients with subcutaneous nodules.

In early effusion positive cytotoxicity tests tended to appear even more rarely than in long standing.

In this group of patients the cytotoxicity of exudate mononuclears was directed against kidney cells as well as against fibroblasts.

### *Acknowledgments*

My sincere thanks are due to the former Head of the Department of Rheumatology, Professor Gunnar Edström and to the present one Associate Professor Kjare Berglund for invaluable support and for facilitating the present study in various ways.

My sincere gratitude also goes to Associate Professor Anna Brita Laurell, Professor Bengt Hallén and to Associate Professor Åke Nordén for fruitful discussions and to Professor C. E. Quensel and Fil. kand. Lennart Pelttersson for much help with the statistical treatment.

To Mrs Asta Lundquist, Miss Barbro Afzelius and Miss Ingrid Bengtsson I am especially grateful for excellent technical assistance.

This investigation was supported by grants from Statens Medicinska Forskningsråd, Reservationsanslaget för främjande av ograduerade forskares verksamhet, Riksföreningen mot Reumatism: "Alfred Österlunds stiftelse", "Albert Pålssons fond" and from "Konung Gustaf V:s 80-årsfond".

# References

- ABRUZZO J L and CHRISTIAN C L The induction of a rheumatoid factor like substance in rabbits *J exp Med* 114 791—806 1961
- ANO K The problem of the antibody nature of the rheumatoid factor *Ann Med exp Fenn* 39 1—60 suppl 7 1961 Thesis
- ANO K and WAGER O Production of anti antibodies in rabbits *Ann Med exp Fenn* 39 79—87 1961
- ALSEVER J B and AINSLIE R B A new method for the preparation of dilute blood plasma and the operation of a complete transfusion service *N Y St J Med* 41 126—133 1941
- ANDRESEN P H Relation between anti antibodies and Gm agglutinins *Transfusion* 3 211—213 1963
- ANSELL B M and BYWATERS L G L Diagnosis of probable Still's disease and its outcome *Ann rheum Dis* 21 263—262 1962
- ASTORCA G and BOLLET A J Diagnostic specificity and possible pathogenetic significance of inclusion body cells in synovial fluid *Arthr and Rheum* 7 288—289 1964
- BAKER H GOLDING D N and THOMPSON M Atypical polyarthritis in psoriatic families *Brit med J* 2 348—352 1963
- BARNETT E V BIENENSTOCK J and BLOCH K J Antinuclear factors in synovial fluid Possible participants in the rheumatoid inclusion body *Arthr and Rheum* 7 726 1964
- BARNETT E V LEDDY J P CONDEMI J J and VAUGHAN J H Antinuclear factors in rheumatoid arthritis *Ann N Y Acad Sci* 124 996—993 1965
- BFRG O and KALLÉN B White blood cells from animals with experimental allergic encephalomyelitis tested on glia cells in tissue culture *Acta path microbiol scand* 35 33—42 1963
- BFRG O and KALLÉN B Effect of mononuclear blood cells from multiple sclerosis patients on neuroglia in tissue culture *J Neuropath exp Neurol* 23 550—559 1964
- BJÖRKLUND A Testing *in vitro* of lymphoid cells from rats with experimental autoimmune thyroiditis *Lab Invest* 13 120—127 1964
- BLACK A GOLDIN M POSKE R M and MALMED L Differentiation between rheumatoid arthritis and systemic lupus erythematosus by sheep cell agglutination tests *Arthr and Rheum* 2 99—103 1959
- BOYDEV S V NORTH R J and FALLENER S M In Ciba Foundation Symposium on Complement p 190—213 G E W WOLFE TENHOLME and J KNIGHT Eds J & A Churchill Ltd 1965
- BOYDEV S V and SORKIN M The adsorption of antigen by spleen cells previously treated with antiserum *in vitro* *Immunology* 3 272—283 1960
- BRANDT L BÖRJESEN J NORDEN Å and OLSSON I Separation of the lymphocytes from peripheral blood by means of a glass wool column A method for *in vitro* culture of lymphocytes *Acta med scand* 172 459—462 1962
- BRAUNSTEFNER H DIENSTEL F and FIBI M Cytolyse durch Lymphoidzellen von Patienten mit primär chronischer Polyarthritidis *klin Wochr* 41 889—891 1961
- BRALNSTEINER H RICHTER R and PAKISCH

- Γ Immunfluoreszenz Untersuchungen an Knochenmarksausstrichen bei primär chronischer Polyarthritis *Klin Wschr* 10 1139—1141 1962
- BRODZ H D Interaction of immune lymphocytes *in vitro* with normal and neoplastic tissue cells *Cell Biol* 10 164—170 1964
- BUTLER JR V P GLEICH G J and VAUGHAN J H An immunochemical basis for the cross reactivity of rheumatoid factor with animal gamma globulins *Arthr and Rheum* 5 104 1962
- BIWATERS E G L CARTER M E and SCOTT F E T Differential agglutination titre (D A T) in juvenile rheumatoid arthritis *Ann rheum Dis* 18 220—232 1959
- CATSOLLIS E A ROTHSCHILD M A ORATZ M and FRANKLIN E C Gamma globulin metabolism in rabbits immunized with autologous denatured gamma globulin *Arthr and Rheum* 8 38—49 1965
- CHASE M W The cellular transfer of cutaneous hypersensitivity to tuberculin *Proc Soc exp Biol (NY)* 59 134—135 1945
- CHRISTIAN C L Rheumatoid factor properties of hyperimmune rabbit sera *J exp Med* 118 827—844 1963
- DAHLBERG G Statistical methods for medical and biological students George Allen & Unwin Ltd London 1940
- DAVIS H J S A hypothetical common mechanism in systemic lupus erythematosus and rheumatoid arthritis *Arthr and Rheum* 9 631—637 1966
- DAVIS H J B and BOLLET A J Protection of a complement sensitive enzyme system by rheumatoid factor *J Immunol* 92 139—144 1964
- DEUTSCH H E and MORTON J I Dissociation of human serum macroglobulins *Science* 125 600—601 1957
- DIXON A St J Rheumatoid arthritis with negative serological reaction *Ann rheum Dis* 19 200—228 1960
- EDWARDS G A and FOGH J Micromorphologic changes in human amnion cells during trypsinization *Cancer Res* 19 608—611 1959
- ENGELFRIET C P and BRITTEN A The cytotoxic test for leucocyte antibodies A simple and reliable technique *Vox Sang* 10 660—674 1965
- FRICKSON J C VOLKIN E CRAIG H W COOPER G R and NEURATH H Biologic false positive reactions in serologic tests for syphilis II Preparations and properties of serologically active serum euglobulin fractions obtained by iso electric precipitation *Amer J Syph* 31 374—386 1947
- FELIX DAVIES D and WAKSMAN B H Passive transfer of experimental immune thyroiditis in the guinea pig *Arthr and Rheum* 4 416—417 1961
- FISCHEL E C Serum complement as an indication of the presence and degree of inflammatory reaction in various diseases *J clin Invest* 32 568 1953
- FISH A J MICHAEL A F GEWURZ H and GOOD R A Immunopathologic changes in rheumatoid arthritis synovium *Arthr and Rheum* 9 267—280 1966
- FOSTIROPOLLOS G ALSTEN K F and BLOCH K J Total hemolytic complement ( $CH_{50}$ ) and second component of complement (C2b) activity in serum and synovial fluid *Arthr and Rheum* 8 219—232 1965
- FRANKLIN E C The interaction of rheumatoid factors and gamma globulins *Atti del V congresso della lega internazionale contro il reumatismo II* 804—805 1961
- FRANKLIN E C FUDENBERG H MELTZER M and STANWORTH D R The structural basis for genetic variations of normal human  $\gamma$  globulins *Proc nat Acad Sci* 48 914—922 1962
- FROMMHAGEN L H and FUDENBERG H The role of aggregated  $\gamma$  globulins in the anti-complementary activity of human and animal sera *J Immunol* 89 336—343 1962
- FUDENBERG H H GOODMAN J W and MILGROM F Immunochemical studies on rabbit anti antibody *J Immunol* 92 227—233 1964

- GEIDEL H, SELLE K and SCHABINSKI G  
Untersuchungen über den differentialdiag-  
nostischen Wert der Komplementbestim-  
mung bei rheumatischen und pararheuma-  
tischen Erkrankungen *III Inn Med* 19 68—  
73 1964
- GERLIGHT R M, ROSENAL W and MOON  
H D *In vitro* transfer of immunity by  
ribosomes *J Immunol* 97 700—709 1966
- GRUBERG H and SACHS L Destruction of  
mouse and rat embryo cells in tissue cul-  
ture by lymph node cells from unsensitized  
rats *J cell comp Physiol* 66 199—207  
1965
- GOODMAN J W Reaction of rheumatoid sera  
with fragments of papain-digested rabbit  
gamma globulin *Proc Soc exp Biol (NY)*  
106 822—825 1961
- GOODMAN H C Discussion in Mechanisms  
of tissue damage in experimental autoim-  
mune disease In *Mechanism of cell and  
tissue damage produced by immune reac-  
tions* p 109 P GRABAR and P VITSCHER  
Eds Benno Schwabe and Co Basel 1962
- GOYAERTS A Cellular antibodies in kidney  
homotransplantation *J Immunol* 85 516—  
522 1960
- GOWANS J L The role of lymphocytes in  
the destruction of homografts *Brit med  
Bull* 21 106—110 1965
- GRUBB R, KROVALL G and VIRTENSSON  
L *Some aspects of the relations between  
rheumatoid arthritis, antigamma globulin  
factors and the polymorphism of human  
gamma globulin* *Ann NY Acad Sci* 121  
865—872 1965
- HAMERMAN D, SANDSON J and SCHLBERT  
M Biochemical events in joint disease  
*J Chron Dis* 16 835—852 1963
- HARBOE M, OSTERLAND C K and KUNKEL  
H G Localization of two genetic factors  
to different areas of  $\gamma$  globulin molecules  
*Science* 136 970—980 1962
- HARRIS T N Cellular sources of antibody  
A review of recent developments *Med  
Clin N Amer* 49 1517—1531 1965
- HEDBERG H The latex fixation titer in re-  
missions of rheumatoid arthritis *Acta  
rheum scand* 7 43—47 1961
- HEDBERG H Studies on the depressed hemo-  
lytic complement activity of synovial fluid  
in adult rheumatoid arthritis *Acta rheum  
scand* 9 165—193 1963
- HEDBERG H The depressed synovial comple-  
ment activity in adult and juvenile rheu-  
matoid arthritis *Acta rheum scand* 10  
109—127 1964
- HEDBERG H and KALLÉN B Studies on  
mononuclear cells obtained from synovial  
fluid of patients with different types of  
arthritis Cytotoxic effect on tissue-cultured  
human fibroblasts *Acta path microbiol  
scand* 177 62—71 1964
- HEDBERG H and KALLÉN B Further *in  
vitro* studies on the cytotoxic effect of  
mononuclear cells from synovial fluid in  
arthritis *Acta univ Lund II* no 8 1964 b
- HEDBERG H, NORDEN A, LUNDQVIST A and  
AFZELIUS B Depression of hemolytic com-  
plement activity of synovial fluid in adult  
rheumatoid arthritis A preliminary report  
*Acta med scand* 175 347—351 1964
- HEIMER R and LEVIN F Inhibition of com-  
plement fixation by rheumatoid sera *Ann  
NY Acad Sci* 124 879—883 1965
- HEIMER R, LEVIN F M and KAHN M F  
Inhibition of complement fixation by hu-  
man serum II The activity of a  $\gamma_{1M}$  globu-  
lin and rheumatoid factor in complement  
fixation reactions *J Immunol* 91 866—  
872 1963
- HEIMER R, LEVIN F M, PRIMACK A.,  
CORCOS J M and VOSKIZO C Inhibition  
of complement fixation by human serum  
*J Immunol* 99 393—399 1962
- HESS E N, ASHWORTH C T and ZIFF M  
Transfer of an autoimmune nephrosis in  
the rat by means of lymph node cells  
*J exp Med* 115 421—437 1962
- HEYMAN W, HEYER J L, P HACKEL,  
D B and CUPPAGE F Transfer of experi-  
mental autoimmune nephrosis in rats  
*Proc Soc exp Biol (NY)* 111 565—573  
1962
- HIRSCHHORN K, FIRSCHER I L and BACH  
F H Immune response of human periph-  
eral blood lymphocytes *in vitro* In *Histo*



- compatibility Testing p 131—138 P S RUSSEL and H J WINN Eds Publication 1229 Nat Ac Sci Washington 1963
- HOLLANDER J L JESSAR R A and MC CARTY D J Synovial analysis An aid in arthritis diagnosis Bull rheum Dis 12 263—264 1961
- HOLLANDER J L RAWSON A J RESTIFO R A and LUSSIER A J Studies on the pathogenesis of rheumatoid joint inflammation Arthr and Rheum 7 314—315 1964
- HOLM G *In vitro* cytotoxic effects of lymphoid cells from rats with experimental autoimmune nephrosis Clin exp Immunol 1 45—60 1966
- HOLM G Studies on the *in vitro* cytotoxicity of lymphoid cells Thesis Balder Stockholm 1967
- HOLM G and PERLMANN P Phytohaemagglutinin induced cytotoxic action of unsensitized immunologically competent cells on allogeneic and xenogeneic tissue culture cells Nature 207 818—821 1965
- HOLM G and PERLMANN P Quantitative studies on phytohaemagglutinin induced cytotoxicity by human lymphocytes against homologous cells in tissue culture Immunology 12 525—538 1967
- HOLM G PERLMANN P and WERNER H Phytohaemagglutinin induced cytotoxic action of normal lymphoid cells on cells in tissue culture Nature 203 841—843 1964
- HOLTZER J Delayed type hypersensitivity Thesis Elinkwijk Utrecht 1966
- ISHIZAKA K Gamma globulin and molecular mechanisms in hypersensitivity reactions In Progr Allergy 7 pp 32—106 P KALLOS and H H WASSMAN Eds S Karger Basel/ New York 1963
- ISHIZAKA K and CAMPBELL D H Biologic activity of soluble antigen antibody complexes V Change of optical rotation by the formation of skin reactive complexes J Immunol 83 318—326 1959
- ISHIZAKA K and ISHIZAKA T Biologic activity of aggregated  $\gamma$  globulin II A study of various methods for aggregation and species differences J Immunol 85 163—171 1960
- ISHIZAKA T ISHIZAKA K and BORSOS T Biological activity of aggregated  $\gamma$  globulin IV Mechanism of complement fixation J Immunol 87 433—438 1961
- JANOWSKI D S ROSENBAUM W and MOON H H Isolation of immunologically competent lymphocytes from sensitized mouse spleens Proc Soc exp Biol (NY) 115 77—79 1964
- JESSAR R A In Arthritis and allied conditions p 74 J I HOLLANDER Ed Lea & Febiger Philadelphia 1966
- JOHANSEN P E and SYLVEST O Synovial fluid changes in degenerative joint disease, rheumatoid arthritis and traumatic arthritis Acta rheum scand 7 240—248 1961
- JONSSON J Non group A streptococci in rheumatic patients and their possible significance in postinfectious rheumatism Acta rheum scand 6 3—24 1960
- JONSSON J The incidence of antibodies to a soluble nuclear antigen in the sera of patients with systemic lupus erythematosus and rheumatoid arthritis estimated with the mixed haemadsorption technique Clin exp Immunol 2 415—426 1967
- KAKELAS H A *In vitro* destruction of skeletal muscle by sensitized cells Nature 210 1115—1118 1966
- KALSBEER G L and CORMAN E H Bound complement in the skin of patients with chronic discoid lupus erythematosus and systemic lupus erythematosus Lancet ii 178—180 1964
- KAPLAN M H Discussion in The site of formation of rheumatoid factor Arthr and Rheum 6 467—480 1963
- KAPLAN M H and VAUGHAN J Conference on host response Mechanisms in rheumatoid arthritis Arthr and Rheum Found Summary of Conference Series 6 57—65 1962
- KARLISH G and EISEN H A theory of delayed hypersensitivity Science 136 1032—1039 1962

- KINGSLEY G R REINHOLD J G STEWARD  
V S GILMAN L and WEICHELBAUM T E  
Total protein albumin and globulin in  
Standard methods of clinical chemistry J  
84-97 Acad Press NY 1963
- KOFLER H and PARONETTO F Transfer of  
experimental autoimmune thyroiditis in  
hartley guinea pigs Fed Proc 24 370  
1965
- KOPROWSKI H and FERNANDES M V Auto  
sensitization reaction in vitro Contactual  
agglutination of sensitized lymph node cells  
in brain tissue culture accompanied by de  
struction of glial elements J exp Med  
116 467-476 1962
- KRETSCHMER R H and PÉREZ TANAYO R  
The role of humoral antibodies in rejection  
of skin homografts in rabbits II Passive  
transfer of transplantation immunity by  
sensitized lymph node cells within diffusion  
chambers J exp Med 116 870-896 1962
- KUNEL H G and TAN I M Autoanti  
bodies and disease In Advances in im  
munology 4 351-395 1964 Acad Press  
NY/London
- KUNEL H G and WILLIAMS R C Rheu  
matoid arthritis Ann Rev Med 15 37-52  
1964
- LACHMANN P J Complement In Clinical  
aspects of immunology pp 246-263 P G  
H GELL and H A COOMBS Eds Black  
well Oxford 1963
- LACHMANN P J MILLER EBERHARD H J  
KUNEL H G and PARONETTO F The  
localization of in vivo bound complement  
in tissue sections J exp Med 115 63-82  
1962
- LANDSTEINER A and CHASE M W Experi  
ments on transfer of cutaneous sensitivity  
to simple compounds Proc Soc exp Biol  
(NY) 49 688-690 1942
- LARSON D Systemic lupus erythematosus  
Brown and Co Boston Mass 1961
- LESSLIS A MUSTAKALLIO K K LAINE V  
and WAGER O The lack of rheumatoid  
factor in psoriatic arthritis Acta rheum  
scand 10 69-76 1964
- LAURELL A B and GRUBB R Complement  
complement components properdin and  
agglutination promoting factors in rheu  
matoid arthritis Acta path microbiol  
scand 43 310-320 1968
- LAURELL A B LUNDH B and MÄRMQUIST  
J Inability of a highly purified strepto  
kinase preparation to inactivate comple  
ment in serum Acta path microbiol scand  
III 318-328 1965
- LAURELL C B LAURELL S and SKOOG V  
Buffer composition in paper electrophore  
sis Clin Chem 2 99-111 1956
- LEONHARDT T Family studies in systemic  
lupus erythematosus Acta med scand  
suppl 416 1964 Thesis
- LEVINSON C and GREY J W Cellular in  
jury resulting from tissue disaggregation  
Exp Cell Res 39 309-317 1965
- LING N R ACTON A B RORTY I M and  
DONACH D Interaction of lymphocytes  
from immunized hosts with thyroid and  
other cells in culture Brit J exp Path 46  
343-359 1965
- LUNDH B  $\beta_{1C}$  globulin and trypsin inhibi  
tors in systemic lupus erythematosus and  
rheumatoid arthritis Acta univ Lund II  
no 25 1965a
- LUNDH B Studies on serum  $\beta_{1C}$  globulin  
Acta univ Lund II no 27 1965b Thesis
- MAYER M Complement and complement  
fixation In Experimental Immunochemis  
try II 153 E A KABAT and M M MAYER  
Eds C C Thomas Springfield Ill 1961
- MCCLESKEY R T MILLER F and BENACER  
RAF B Sensitization to denatured auto  
logous gamma globulin J exp Med 115  
253-273 1962
- MCCORMICK J N An immunofluorescence  
study of rheumatoid factor Ann rheum  
Dis 22 1-10 1963
- MELLORS R C Discussion In The site of  
formation of rheumatoid factor Arthr and  
Rheum 6 473 1963
- MELLORS R C HEINER R CORCOV J and  
KORNGOLD I Cellular origin of rheu  
matoid factor J exp Med 110 875-886  
1959
- MILCROM F Discussion in Structure and

- and genetics of immune globulins In Immunopathology IIIrd International Symposium p 77 P GRABAR and P A MIESCHER Eds Schwabe & Co Basel/Stuttgart 1963 a
- MILGROM F Discussion in Experimental production of rheumatoid factor Arthr and Rheum 6 408—412 1963 b
- MILGROM F Anti antibody and rheumatoid factor Proc 9th Congr int Soc Blood Transf Mexico 1962 pp 33a—340 1964
- MILGROM F DUBISKI S and WOZNICZKO G Human sera with anti antibody Vox Sang 1 172—183 1966
- MILGROM F and SCHULTZ R T Serodiagnosis of rheumatoid arthritis based on inhibition of anticomplementariness of denatured fraction II Int Arch Allergy 27 338—345 1965
- MILGROM F and WITEBSKY E Studies on the rheumatoid and related serum factors I Autoimmunization of rabbits with gamma globulin J Amer med Ass 174 56—63 1960 a
- MILGROM F and WITEBSKY E Rabbit antibodies against  $\gamma$  globulins resembling the rheumatoid factor Fed Proc 19 197 1960 b
- MILLER L and HOUGHTON J A The Kjeldahl determination of the nitrogen content of amino acids and proteins J biol Chem 159 373—383 1945
- MILLER EBERHARD H J and NILSSON U Relation of a  $\beta_1$  glycoprotein of human serum to the complement system J exp Med 111 217—234 1960
- MILLER EBERHARD H J NILSSON U R DALMASSO A P POLLFA M J and CALCOTT M A A molecular concept of immune cytotoxicity Arch Path 82 205—217 1966
- MÖLLER E Contact induced cytotoxicity by lymphoid cells containing foreign isoenzymes Science 147 873—879 1965 a
- MÖLLER E Antagonistic effects of humoral isoantibodies on the *in vitro* cytotoxicity of immune lymphoid cells J exp Med 112 11—23 1965 b
- MÖLLER G BECKMAN V and LUNDGREN G *In vitro* destruction of human fibroblasts by non immune lymphoid cells Nature 212 1203—1207 1966
- MÖLLER G and MÖLLER E Plaque formation by non immune and irradiated lymphoid cells on monolayers of mouse embryo cells Nature 208 260—263 1965
- NAJARIAN J S and FELDMAN J D Passive transfer of transplantation immunity I Tritiated lymphoid cells II Lymphoid cells in Millipore chambers J exp Med 115 1083—1093 1962
- NAJARIAN J S and FELDMAN J D Passive transfer of transplantation immunity III Inbred guinea pigs J exp Med 117 449—456 1963
- OLHAGEN B Studies on thermostable anti complementary human sera Acta med scand suppl 162 1945 Thesis
- OLHAGEN B Chronic uro polyarthritis in the male Acta med scand 168 339—345 1960
- OSLER A G Functions of the complement system Advan Immunol 1 131—210 1961
- PARONETTO F and KOFFLER D Immuno fluorescent localization of immunoglobulins complement and fibrinogen in human diseases I Systemic lupus erythematosus J clin Invest 44 1657—1664 1965
- PATERSON P V Transfer of allergic encephalomyelitis in rats by means of lymph node cells J exp Med 111 119—135 1960
- PELIN T J and ZVAIFLER N J Measurement of hemolytic complement in synovial fluids Ann Meet Am Rheum Ass p 20 1962
- PELIN T J and ZVAIFLER N J Hemolytic complement in synovial fluid J clin Invest 43 1372—1382 1964
- PERLICK E Zur pathogenetischen Bedeutung der Serumkomplement Aktivität bei Autoimmunisationskrankheiten Verh dtsch Ges inn Med p 572—577 1962
- PERLMANN P and BROBFERGER O *In vitro* studies of ulcerative colitis II Cytotoxic action of white blood cells from patients on human fetal colon cells J exp Med 117 717—733 1963

- PERNELLIN H H, HESS L V and ZIFF M Effect of a gold salt on the immune response *Arthr and Rheum* 10 99—106 1967
- RAPP H J and BORISOV T Complement re search *J Amer med Ass* 194 1317—1321 1966
- REEDS R L, FISARO R M and FISHER I Psoriasis vulgaris I A clinical survey of the association with diabetes mellitus *Arch Derm* 89 203—208 1964
- ROBERT B and GRABAR P Dosage des groupements thiol proteiques dans des reactions immunochimiques *Ann Inst Pasteur* 97 46—61 1957
- RODMAN W W, WILLIAMS R C, BILKA P J and MILLER LBERHARD H J Immunofluorescent localization of B<sub>1</sub>C and B<sub>1</sub>E globulin complement components in synovial tissues from rheumatoid arthritis patients *Arthr and Rheum* 7 749 1964
- RODMAN G P, EISENBEIS C H and CREIGHTON A S The occurrence of rheumatoid factor in synovial fluid *Amer J Med Sc* 182—188 1963
- ROITT I M and DONIACH D Delayed hypersensitivity in autoimmune disease *Brit med Bull* 23 60—71 1967
- ROPES M W, BENNETT G A, COBB S, JACOB R and JESSAR R A 1958 revision of diagnostic criteria for rheumatoid arthritis *Bull rheum Dis* 9 173—176 1958
- ROSE N R, KITE J H JR, DOEBBLER T K and BROWN H C *In vitro* reactions of lymphoid cells with thyroid tissue In *Cell bound Antibodies* p 19—31 H AMOS and H KOPROWSKI Eds Wistar Institute Press Philadelphia 1963
- ROSENAL W Interaction of lymphoid cells with target cells in tissue culture In *Cell bound Antibodies* p 75—80 H AMOS and H KOPROWSKI Eds Wistar Institute Press Philadelphia 1963
- ROSENAL W and MOON H D Lysis of homologous cells by sensitized lymphocytes in tissue culture *J nat Cancer Inst* 27 471—477 1961
- ROSENAL W and MOON H D The inhibitory effect of hydrocortisone on lysis of homologous cells by lymphocytes *in vitro* *J Immunol* 89 422—426 1962
- ROSENAL W and MOON H D The specificity of the cytolytic effect of sensitized lymphoid cells *in vitro* *J Immunol* 93 910—914 1964
- ROSENAL W and MOON H D Studies on the mechanism of the cytolytic effect of sensitized lymphocytes *J Immunol* 96 80—84 1966
- SCHMIDT F R and ROITT I M Inhibition of complement action by rheumatoid factor *J Lab clin Med* 66 1019 1963
- SCHUBART A F, EWALD H W, SCHROEDER W C, ROTHSCHILD H J, BHATNAGAR, D V and PULLEN P K Serum complement levels in rheumatoid arthritis A longitudinal study of 43 cases with correlation of clinical and serological data including rheumatoid factor and thermolabile inhibitor of the FII LP test *Ann rheum Dis* 24 439—450 1965
- SIEGEL S: *Nonparametric statistics for the behavioral sciences* McGraw Hill Inc New York/Toronto/London 1956
- SIEVERS K The rheumatoid factor in definite rheumatoid arthritis *Acta rheum scand suppl* 9 1965 Thesis
- SIEVERS K, ARONSON P, AHU E and WAGER O Serological patterns in juvenile rheumatoid arthritis *Rheumatism* 19 88—93 1963
- SINGER J M and PLOTZ C M The latex fixation test I Application to the serologic diagnosis of rheumatoid arthritis *Amer J Med* 21 888—892 1956
- SOBER H A, GUTTER F J, WICKOFF M M and PETERSON E A Chromatography of proteins II Fractionation of serum protein on anion exchange cellulose *J Amer chem Soc* 78 756—763 1956
- STONE S H Transfer of allergic encephalomyelitis by lymph node cells in inbred guinea pigs *Science* 134 619—620 1961
- SVARTZ N and HEDMAN S Are the macroglobulins giving rise to a positive sheep

- cell test in different diseases identical? *Acta med scand* 173 249—250 1963
- SIARTZ N and SCHLOSSMAN A Agglutination of sensitized sheep erythrocytes in disseminated lupus erythematosus *Ann rheum Dis* 16 73—75 1957
- TARANTA A and FRANKLIN E C Complement fixation by antibody fragments *Science* 131 1961—1962 1961
- TARANTA A FRANKLIN E C and OVARI Z Studies of  $\gamma$  globulin fragments in C fixation immune hemolysis and passive cutaneous anaphylaxis *Fed Proc* 21 21 1962
- TAYLOR H E and CULLING C F A Cytopathic effect *in vitro* of sensitized homologous and heterologous spleen cells on fibroblasts *Lab Invest* 12 884—894 1963
- TELLIN A E The reaction of streptococcal agglutination relative to the RAS factor in rheumatoid arthritis *Acta rheum scand* 1 22—30 1955
- TRAYANOVA T G SLUA I I and SYET MOLODAVSKY G J Destruction of human cells in tissue culture by lymphocytes from patients with systemic lupus erythematosus *Lancet* i 402—404 1966
- LESTRUP J C The sensitizing factor in the Waaler Rose system *Acta path microbiol scand suppl* 101 213—214 1962
- WASSMAN B H and WEFNERSTEN C Passive transfer of adjuvant arthritis in rats with living lymphoid cells of sensitized donors *Int Arch Allergy Appl Immunol* 29 120—130 1963
- WALKER H I and PALMER J G Separation of lymphocytes from blood *Blood* 20 109 1962
- VARGO T Proteolytic enzymes of synovial fluid with special reference to intra articular applied hydrocortisone *Ann Med exp fenn* 38 91—99 1960
- WATSON D W QUIGLEY A and BOLT R J Effect of lymphocytes from patients with ulcerative colitis on human adult colon epithelial cells *Gastroenterology* 51 983—993 1966
- VAUGHAN J H BAILES T B and FAIVOR C H Serum complement in rheumatoid arthritis *Amer J med Sci* 212 186—192 1951a
- VAUGHAN J H BAILES T B and FAIVOR C B The response of serum gamma globulin level and complement titer to adrenocorticotrophic hormone (ACTH) therapy in lupus erythematosus disseminatus *J Lab clin Med* 57 698—702 1951b
- WASSERMAN E and LEVINE L Quantitative micro complement fixation and its use in the study of antigenic structure by specific antigen antibody inhibition *J Immunol* 87 290—295 1961
- WILLIAMS R C JR and LUKAEL H G Antibodies to rabbit  $\gamma$  globulin after immunizing with various preparations of autologous  $\gamma$  globulin *Proc Soc exp Biol (NY)* 112 554—561 1963
- WILSON D B The reaction of immunologically activated lymphoid cells against homologous target tissue cells *in vitro* *J cell comp Physiol* 62 273—280 1963
- WILSON D B Quantitative studies on the behavior of sensitized lymphocytes *in vitro* I Relationship of the degree of destruction of homologous target cells to the number of lymphocytes and to the time of contact in culture and consideration of the effects of isomune serum *J exp Med* 121 143—166 1965a
- WILSON D B Quantitative studies on the behavior of sensitized lymphocytes *in vitro* II Inhibitory influence of the immune suppressor murine on the destructive reaction of sensitized lymphoid cells against homologous target cells *J exp Med* 122 167—172 1965b
- WILSON D B and WEAVER E E Quantitative studies on the behavior of sensitized lymphoid cells *in vitro* III Conversion of normal lymphoid cells to an immunologically active status with RNA derived from isologous lymphoid tissue of specifically immunized rats *J Immunol* 97 312—316 1966

- WINBLAD S Studies on agglutination of sensitized sheep cells in rheumatoid diseases I Agglutination titer after primary absorption of serum by sheep cells Acta med scand 149 456—457 1952
- WINBLAD S Studies on different laboratory tests for the rheumatoid arthritis serum factor I Evaluation of different agglutination methods for whole serum cold precipitable and euglobulin serum fractions Acta path microbiol scand 49 499—511 1960
- WINKLEP B F *In vitro* demyelination of peripheral nerve induced with sensitized cells Ann NY Acad Sci 122 287—296 1965
- WINKLER G F and ARNASON B G Anti serum to immunoglobulin A inhibition of cell mediated demyelination in tissue culture Science 153 75—76 1965
- ZVAIFLER N J A speculation on the pathogenesis of joint inflammation in rheumatoid arthritis Arthr and Rheum 8 289—293 1965
- ZVAIFLER N J and BLOCH K J Rheumatoid factor—an inhibitor of the complement fixation reaction Arthr and Rheum 5 127 1962
- ZVAIFLER N J and PEKIN T J Jr Complement components in synovial fluids Clin Res 11 180 1963
- ÅSTRÖM H E and WARESMAN B H The passive transfer of experimental allergic encephalomyelitis and neuritis with living lymphoid cells J Pathol Bact 83 89—106 1962



Factorial effects	SS	df	MS	F	Mean	SS	df	MS	F	Mean
Block	00	1	00	1160	100	00	1	00	10	100
Block	470	1	470	1397	100	00	1	00	10	100
Block	00	1	00	1160	100	00	1	00	10	100
Block	310	1	310	1477	100	00	1	00	10	100
Block	486	1	486	1089	100	00	1	00	10	100
Block	344	1	344	1077	100	00	1	00	10	100
Block	0	1	0	1111	100	00	1	00	10	100
Block	470	1	470	1397	100	00	1	00	10	100

Block	470	1	470	1397	100	00	1	00	10	100
Block	470	1	470	1397	100	00	1	00	10	100
Block	470	1	470	1397	100	00	1	00	10	100
Block	470	1	470	1397	100	00	1	00	10	100
Block	470	1	470	1397	100	00	1	00	10	100
Block	470	1	470	1397	100	00	1	00	10	100
Block	470	1	470	1397	100	00	1	00	10	100
Block	470	1	470	1397	100	00	1	00	10	100
Block	470	1	470	1397	100	00	1	00	10	100
Block	470	1	470	1397	100	00	1	00	10	100

Block	470	1	470	1397	100	00	1	00	10	100
Block	470	1	470	1397	100	00	1	00	10	100
Block	470	1	470	1397	100	00	1	00	10	100
Block	470	1	470	1397	100	00	1	00	10	100
Block	470	1	470	1397	100	00	1	00	10	100
Block	470	1	470	1397	100	00	1	00	10	100
Block	470	1	470	1397	100	00	1	00	10	100
Block	470	1	470	1397	100	00	1	00	10	100
Block	470	1	470	1397	100	00	1	00	10	100
Block	470	1	470	1397	100	00	1	00	10	100

Factorial effects



Appendix Table II BA WITH NODULI'S 27 adult patients Laboratory and clinical data

Total prot of synovial fluid g per 100 ml	C' units per ml		C' g	C activity of synovial fluid <sup>2</sup>	F <sup>3</sup> R <sup>3</sup>	S <sup>4</sup> C titre (serum) <sup>4</sup>	Index aggl titre <sup>5</sup>	Duration of the disease (years)
	synov (C <sup>3</sup> sp)	serum (C <sup>3</sup> S) <sup>1</sup>						
3.10	1145	1734 +	0.66	129	69	312 <sup>xx</sup>	80/80	7
3.32	262	1208 -	0.22	66	61	61	40/<10	13
3.70	214	1251 -	0.17	46	31	10 <sup>xx</sup>	10/<10	7
4.00	167	1210 +	0.13	79	48	32	40/20	1
5.73	244	1389	0.18	31	96	<10 <sup>xx</sup>	80/80	7
5.70	256	1472 -	0.17	30	65	32 <sup>xx</sup>	40/40	8
4.44	155	1299 +	0.12	27	99	61	80/40	10
3.22	97	1173 +	0.09	26	38	512	20/20	20
3.78	115	1068 +	0.11	20 <sup>3</sup>	55	2.6	100/100	10
4.16	77	971 +	0.09	10 <sup>4</sup>	123	1024	>320/160	7
4.69	95	1016 -	0.09	111	85	512	40/10	12
4.14	72	1170 -	0.06	14	62	1024	160/80	7
3.78	65	1322 +	0.05	13	52	512	>320/160	10
4.11	52	598 -	0.05	111	45	2.6	160/80	7

4.59	64	990	0.06	13	7.3	< 10 <sup>xx</sup>	40/100	15
2.69	72	1107 +	0.03	11	77	512 <sup>xx</sup>	10/40	9
4.79	12	1000 +	0.00	11	34	64	--/20	31
3.99	64	1000 +	0.06	11	125	10 <sup>xx</sup>	100/80	11
4.01	33	801 -	0.01	9	24	61 <sup>xx</sup>	160/—	14
3.56	39	1282 -	0.00	8	59	129 <sup>xx</sup>	80/320	17
3.97	46	1010	0.01	8	76	128	80/80	9
3.24	40	990	0.01	8	55	128	80/160	10
3.10	31	909 +	0.01	7	33	64 <sup>xx</sup>	100/100	19
4.50	72	979 +	0.03	7	56	246 <sup>xx</sup>	> 120/20	1
4.70	92	1070	0.03	7	27	< 10 <sup>xx</sup>	80/40	10
4.60	32	1109 -	0.03	6	44	129	160/80	12
3.23	72	1106	0.03	6	33	72	100/100	6
Mean 4.63	130	1107	0.10	Median 13	60	—	—	8.5

1 + and - indicate the results of a test for ANI's in serum

2 Figures to the left represent *effusion* for less than 3 months (= early effusion)

Italicized figures represent patients receiving corticosteroids *per os* or A.C.H.

x = gold treatment at least once during the 4th or the 5th year preceding examination

xx = gold treatment at least once during the three years preceding examination

\* Titre of serum/titre of synovial fluid

† Concomitant psoriasis

Appendix Table III SSC 105 HA 49 adult patients Laboratory and clinical data

Total prot of synovial fluid g per 100 ml	C units per ml		C <sub>SP</sub>	C <sub>S</sub>	C activity of synovial fluid*	I SR*	SSC titre (serum)*	Index aggl titre*	Duration of the disease (years)
	synov fluid (C <sub>SP</sub> ) <sup>1</sup>	serum (C <sub>S</sub> ) <sup>1</sup>							
3.8	114	1214 -	0.31		93	16	<16	<10/<10	0
5.00	183	1042 +	0.47		94	41	<16x	<10/<10	12
6.01	619	1047 -	0.37		94	87	<16x	20/20	7
2.89	410	1500 -	0.27		93	101	16	10/<10	15
3.78	421	1269 -	0.33		97	27	128	40/<10	0.0
4.69	400	1099	0.37		76	28	128	100/100	18
3.98	299	1230	0.24		71	29	<16	<10/10	8
1.18	340	1194 -	0.23		67	52	12	10/20	12
5.80	426	1099	0.39		66	39	61x	40/10	5
0.22	600	1387 -	0.38		61	40	12	80/≥320	8
3.42	403	1277	0.32		59	80	64x	80/-	0
3.00	414	1613 +	0.26		52	52	2.6	100/100	16
3.79	358	1282	0.30		52	61	128	100/40	1
3.07	312	1263 -	0.23		49	63	<16	10/20	9
3.07	297	1363 +	0.19		49	14	1024	80/100	30
4.30	220	1033	0.21		47	64	12	100/80	9
1.63	220	1023	0.21		45	72	16	100/100	10
3.88	141	810	0.17		44	11	64	10/100	5
5.21	264	1220	0.22		42	70	72	80/100	5
4.07	268	1623 +	0.17		42	35	128	80/20	7
4.78	268	1334 +	0.20		42	34	64	40/40	12
3.07	331	1513 -	0.23		41	110	512	80/80	0.9
3.83	315	1497	0.23		39	90	128	100/40	6

1.88	377	1724 -	0.22	37	50	12%	80/80	7
1.00	215	1250	0.17	34	61	61	40/40	4
1.33	200	1176	0.18	34	70	128	20/40	8
4.71	196	1250 -	0.10	31	95	112	100/100	8
4.87	103	1096 -	0.11	31	11	61	40/20	0.2
1.71	195	1320 -	0.14	30	70	2.26	> 100/10	1.1
0.11	221	1250 -	0.18	29	29	1.98	40/110	16
5.87	190	1131 -	0.17	22	112	< 16%	> 120/-	1
0.67	152	1310 +	0.19	28	60	16%	10/20	0
0.10	180	1389 -	0.18	28	88	< 16	40/160	7
4.70	140	190 +	0.12	26	90	72%	40/100	33
4.01	118	1170	0.10	25	20	129%	80/80	15
5.11	116	1181	0.11	22	23	61	100/80	7
5.03	110	1214	0.10	20	49	72%	40/100	14
5.44	124	1250 -	0.10	19	51	12%	80/160	23
4.15	41	619 -	0.07	11	30	512	40/80	11
5.14	104	1999 +	0.09	10	47	112	80/90	4
5.11	58	1061 -	0.09	16	71	250	80/100	13
4.6	66	975 -	0.07	16	48	512%	> 120/100	0
4.0	50	905	0.06	13	50	04	80/100	10
4.55	75	1214 -	0.06	17	41	129%	80/160	8
1.23	70	1220	0.06	11	90	2.46	80/80	0.8
5.00	57	1200 +	0.05	10	11	61%	80/160	7
5.5	54	1670 +	0.06	10	70	12%	160/160	1.4
3.70	95	1010 -	0.03	9	23	< 16%	< 10/40	9
5.14	95	1331 -	0.03	5	112	61%	80/80	11
Mean	401	211	1930	0.19	Median	34	57	70

114 and 125 Appendix Table II

Table 1 and 2 see Appendix Table II

Appendix Table I SSC ME RA 12 adult patients I laboratory and clinical data

Total prot of synovial fluid (g per 100 ml)	C units per ml		C SF C' S	C activity of synovial fluid <sup>a</sup>	I SR <sup>a</sup>	SSC titre (serum) <sup>a</sup>	I titre <sup>a</sup> tit <sup>a</sup>	Duration of the disease (yrs)
	synov	serum (C S) <sup>a</sup>						
1.12	442	1111 -	0.10	97	91	<10 - <sup>a</sup>	<10/<10	8
1.49	377	1111 -	0.52	91	75	<10 -	<10/<10	13
1.11	118	1214	0.14	96	51	<10 -	<10/<10	10
1.11	601	1305 -	0.44	86	22	<10 -	<10/<10	0.5
2.49	277	1197 -	0.23	50	17	<10 -	10/<10	12
1.79	209	1000 -	0.21	60	11	10 -	40/80-20	7
1.79	203	1407 -	0.19	56	14	<10 -	50/80	14
1.33	317	1219 +	0.28	53	50	<10 -	<10/<10	1.9
0.22	183	809 -	0.23	41	20	<10 -	<10/<10	13
0.20	303	1563 -	0.10	76	115	<10 -	20/<10	7
0.02	147	118 -	0.12	20	99	<10 -	40/40	14
4.42	74	1092 -	0.07	16	37	<10 - <sup>xx</sup>	<10/<10	7
Mean 4.67	330	1192	0.30	Median 58	52	—	—	9.3

— and — are Appendix Table II \* — indicates negative SSC test at re examination 1—3 years later

Appendix Table 3 JOINT ARTHRITIDES 26 patients I laboratory and clinical data

Total prot of synovial fluid (g per 100 ml)	C units per ml		C SF C' S	C activity of synovial fluid <sup>a</sup>	I SR <sup>a</sup>	SSC titre (serum) <sup>a</sup>	I titre <sup>a</sup> tit <sup>a</sup>	Duration of the disease (yrs) <sup>a</sup>
	synov	serum (C S) <sup>a</sup>						
SSC pos RA								
1.12	2.40	928 <sup>a</sup>	0.27	87	61	16xx	<10/<10	5.5
4.67	2.16	1037 -	0.25	54	47	72	50/50	0.15
4.24	274	1119	0.18	42	31	2.66	50/100	0.811
1.20	227	1401	0.16	31	72	512xx	160/80	0.14
1.10	162	1210	0.13	25	17	512	160/100	2.12
1.70	137	1194 -	0.11	23	51	1024	160/80	2.10
0.05	96	1000	0.10	18	39	72	160/80	1.12
Mean 4.61	200	1119	0.17	Median 31	57	—	—	3.02

[illegible]

Appendix Table 11 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) and SLE-LIKE SYNDROMES: 10 adult patients (clinical and laboratory data)

Age and sex	LE cell test <sup>a</sup>	LE titre	Total prot of synovial fluid (g per 100 ml)	C' units per ml		C' 5% fluid <sup>a</sup>	C' 5% serum (C 5%)	C' 5% synovial fluid <sup>a</sup>	C' 5% serum	1:20 <sup>a</sup>	1:40 <sup>a</sup>	SSC titre (serum) <sup>a</sup>	SSC titre (synovial fluid) <sup>a</sup>	Duration of joint symptoms (years)
				C' max	C' min									
18 F	+	+	4.76	98	1104+	0.03	1.9	1.7	1.7	<16	<16	<16	<16	1.2
22 F	+	+	3.56	<32	516+	0.06	1.3	1.3	1.3	512 <sup>xx</sup>	>320/160	>320/160	>320/160	4
50 F	+	-	4.78	41	1017+	0.04	9	6.5	6.5	<16	40/40	40/40	40/40	2.5
11 F	+	-	5.41	<32	414+	0.03	14	120	120	2.0	160/40	160/40	160/40	7
50 F	+	-	4.86	<32	996+	0.03	7	87	87	32 <sup>xx</sup>	16/10	16/10	16/10	6
13 M	+	-	2.79	<32	1316+	0.02	9	93	93	512	50/80	50/80	50/80	10
22 F	-	+	4.45	132	1471+	0.03	30	102	102	10 <sup>xx</sup>	90/50	90/50	90/50	0
37 F	-	-	3.78	<32	193+	0.17	4.0	29	29	16	90/320	90/320	90/320	11
70 F	-	-	4.63	71	1166+	0.06	13	21	21	<16 <sup>xx</sup>	<16/20	<16/20	<16/20	1.3
11 F	-	-	5.67	193	1037-	0.17	30	120	120	32	90/320	90/320	90/320	0.3

C' 5% see Appendix Table II

<sup>a</sup> According to Tinismander (1964)

Appendix Table VII PSORIASIC ARTHROPATHY 14 patients 13 adult and one juvenile (the fourth case) all with negative tests for RFs in serum and synovial fluid Laboratory and clinical data

Total prot of synovial fluid (g per 100 ml)	C units per ml		C <sub>50</sub> C <sub>5</sub>	C activity of synovial fluid	ESR	Duration of arthritis (years)
	synov fluid (C <sub>50</sub> )	serum (C <sub>5</sub> )				
4.80 <sup>1</sup>	1129	1849 - <sup>2</sup>	0.01	127	112	8
4.03 <sup>1</sup>	610	1399 +	0.11	109	53	2
4.44 <sup>1</sup>	422	996	0.16	101	13	11
4.20 <sup>1</sup>	281	129 +	0.12	100	32	11
4.96 <sup>1</sup>	511	1163	0.19	97	68	11
4.81 <sup>1</sup>	612	1342 -	0.12	94	29	8
3.28 <sup>1</sup>	414	1419 -	0.31	87	22	3
4.22 <sup>1</sup>	407	1149 +	0.22	77	111	11
3.38	332	1292 -	0.26	77	43	2
6.40 <sup>1</sup>	862	1997 -	0.16	72	101	1
3.67 <sup>1</sup>	327	962	0.34	97	39	1
4.11 <sup>1</sup>	204	1244 -	0.16	39	122	27
6.00 <sup>1</sup>	292	1322 -	0.22	17	32	7
4.79 <sup>1</sup>	<32	1292 +	0.02	2	61	13
Mean 4.27	499	1270	0.27 Median	90	61	7.0

<sup>1</sup> Involvement of the distal interphalangeal joints

<sup>2</sup> Sacro-iliac arthritis

Symphysis—no sacro-iliac arthritis

<sup>3</sup> Squaring of the vertebrae—no sacro-iliac arthritis

<sup>4</sup> W.F. test, early effusion and treatment with corticosteroids per os or with ACTH are marked as in Appendix Table II

Appendix Table VIII The C activity of different synovial fluids serially aspirated from different joints of the same P.E. patient

Joint 1	Joint 2	Joint 1	Joint 2	Joint 1	Joint 2	Joint 1	Joint 2
129	49	22	01	27	21	20	10
97	44	72	78	31	09	16	22
71	77	2	24	21	28	13	9
58	09	46	67	21	29	10	12
67	24	77	67	22	20	9	8
29	27	39	29	27	2		

<sup>1</sup> General in the right knee joint

<sup>2</sup> General in the left knee joint





# ACTA MEDICA SCANDINAVICA

SUPPLEMENTUM 480

## STUDIES OF SMALL VESSELS IN PATIENTS WITH DIABETES

A CLINICAL, HISTOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY  
OF DIABETIC AND NON DIABETIC SUBJECTS WITH SPECIAL REFERENCE  
TO THE OCCURRENCE OF VARIOUS PLASMA PROTEINS  
IN THE DERMAL VESSEL WALLS

BY

*OLLE LARSSON*

# ACTA MEDICA SCANDINAVICA

has been published since 1919 as a continuation of *Nordiskt Medicinskt Arkiv*, founded in 1869 by Axel Key. The first volume of *Acta Medica Scandinavica* is therefore numbered LII (52).

*The chief editors have been* Axel Key 1869—1900, C. G. Santesson 1901—1915, I. Holmgren 1916—1957 and Birger Strandell 1958 to date.

*Acta Medica Scandinavica* publishes original research papers in the field of internal medicine. Priority will be given to authors from countries which are represented on the editorial board. Contributors from those countries should submit their papers to a representative of the country in question. Contributors from other countries should send their papers to the Editor at the address below.

Submission of a manuscript for publication will be held to imply that the paper has not been published elsewhere and that, if accepted, it will not be republished in any other journal in the same or similar form, without the Editor's written consent.

Papers will be published in English, French or German at the authors' choice, followed by a summary in English.

The manuscripts shall be in final form as submitted. They shall be typewritten with double spacing and broad left hand margin.

If a paper exceeds 16 printed pages, the cost for the excess pages shall be borne by the author. No paper shall exceed 24 printed pages.

## Subscription

The annual subscription to the journal, covering two volumes, each of 6 numbers is 140 Sw. crowns or U. S. \$ 27.25, including postage in the Scandinavian countries and in Holland 120 Sw. crowns.

*Address for subscriptions and all communications*

ACTA MEDICA SCANDINAVICA

P. O. Box 2052 Stockholm 2

---

Requests for duplicate copies of numbers that have gone astray can only be considered if made within a fortnight of the receipt of the following number.

ACTA MEDICA SCANDINAVICA  
SUPPLEMENTUM 480

FROM THE DEPARTMENT OF MEDICINE (HEAD PROFESSOR NILS TORNBLOM M D)  
AND THE INSTITUTE OF PATHOLOGY II (HEAD PROFESSOR STURF FALAMFR M D)  
UNIVERSITY OF UMEÅ UMEÅ 6 SWEDEN

STUDIES OF SMALL VESSELS  
IN PATIENTS WITH DIABETES

A CLINICAL, HISTOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY  
OF DIABETIC AND NON DIABETIC SUBJECTS WITH SPECIAL REFERENCE  
TO THE OCCURRENCE OF VARIOUS PLASMA PROTEINS  
IN THE DERMAL VESSEL WALLS

By

*OLLE LARSSON*



# CONTENTS

Introduction	5
 CHAPTER I	
Brief survey of the literature on morphological changes in small blood vessels in patients with diabetes mellitus	7
Distribution in the body	7
Light microscopic changes	7
Ultrastructural changes	9
Histochemistry	10
Chemical analysis	10
Immunohistochemical investigations	11
Summary	16
 CHAPTER II	
Earlier immunofluorescent studies on the distribution of various plasma proteins in the human skin	18
 CHAPTER III	
Material and methods	20
Investigated subjects	20
Clinical and laboratory investigations	21
Histochemical and immunohistochemical investigations	22
Semiquantitative grading of staining reactions in small dermal vessel walls	26
Statistical methods	27
Summary	28
 CHAPTER IV	
Sources of error	29
Possible sources of error in the technical performance	29
Errors in the semiquantitative grading	30
Summary	35
 CHAPTER V	
The results of the immunofluorescent localization of various plasma proteins in the skin, apart from the small vessels	36
Healthy subjects	36

Patients with diabetes mellitus	38
Other patients	38
Summary	39

## CHAPTER VI

The results of the PAS-staining of small dermal vessel walls	40
Morphology	40
Matched non diabetic subjects	40
Patients with diabetes mellitus	41
Patients with diseases other than diabetes mellitus	44
Summary	44

## CHAPTER VII

The results of the immunofluorescent localization of $\gamma$ G-globulin in small dermal blood vessels	47
Morphology	47
Matched non diabetic subjects	47
Patients with diabetes mellitus	48
Patients with diseases other than diabetes mellitus	50
The ESR and the amount of circulating $\gamma$ globulin in the various groups of immunofluorescent staining of $\gamma$ G-globulin in small vessel walls	50
Summary	50

## CHAPTER VIII

The results of the immunofluorescent localization of some plasma proteins other than $\gamma$ G globulin in small dermal vessel walls in diabetic and non-diabetic subjects	55
Morphology	55
Differences between apparently healthy subjects and patients with diabetes mellitus	55
The influence of the duration of diabetes	57
Summary	57

## CHAPTER IX

General Discussion	58
Observations in PAS-treated sections	58
Immunohistochemical investigations	59
The immunogenic theory of pathogenesis	61
Summary	63
References	64

In recent years many studies have been devoted to the distribution and the appearance of changes in small blood vessel walls in diabetes mellitus as seen under the light and electron microscopes. Several histochemical, chemical, and immunohistochemical investigations have been carried out in an attempt to elucidate their nature.

The present investigation was initiated by observations made by Odén & Tornblom (1959) in cooperation with Müller Eberhard (1959). Using an immunoelectrophoretic technique, they were able to demonstrate that mechanically isolated, washed hyaline glomeruli from diabetic kidneys absorbed anti-human serum protein sera whilst similarly treated glomeruli from apparently normal non-diabetic kidneys did not do so to the same extent. Furthermore, Freedman *et al* (1960) and others, who used the fluorescent antibody technique, were able to show that human  $\gamma$  globulin was localized in the region of the vascular glomerular basement membrane and in other minor vessels of the diabetic kidney.

Many investigators have shown that small blood vessels in apparently normal skin from patients with diabetes become involved in the diabetic "microangiopathy" at an early stage of the disease and in a high proportion.

As it is easy to obtain large series of skin biopsies, these observations pre-

sented the possibility of studying the possible localization of  $\gamma$  globulin (and other plasma proteins) in small blood vessel walls more systematically in biopsy material from patients with diabetes mellitus and from non-diabetic individuals.

The present investigation represents an extension of two preceding reports (Larsson & Melin, 1964, Larsson, 1966).

It comprises the following:

1. An histological study of the PAS-reaction of small dermal blood vessels by means of light microscopy in patients with diabetes and in matched non-diabetic individuals.

2. An immunohistochemical study of the occurrence of  $\gamma$ G globulin in the walls of small dermal blood vessels in patients with diabetes mellitus and in matched non-diabetic individuals.

3. An attempt to detect any clinical features of the diabetic state which may influence the periodic acid Schiff (PAS) reaction and the localization of  $\gamma$ G globulin in the vessel walls.

4. An immunohistochemical study of the occurrence of some other plasma proteins in the walls of small dermal vessels in patients with diabetes mellitus and in matched non-diabetic individuals.

The immunohistochemical studies were performed by means of the fluorescent antibody technique.



The object of these four parts of the study was to obtain a more thorough knowledge of the frequency and nature of the small blood vessel involvement in patients with diabetes mellitus

5 In various other diseases, *e g* glomerulonephritis, systemic lupus erythematosus (SLE) and rheumatoid arthritis (Douglas, 1965, Rodman *et al* 1967), as well as in experimental hy-

pertensive vascular disease in rats (*cf* Giese, 1966)  $\gamma$ -globulin, complement and/or other plasma proteins have been demonstrated in blood vessel walls. During the course of this investigation skin biopsies from a few patients with some diseases other than diabetes mellitus were therefore studied in order to obtain a basis for comparison with the results in patients with diabetes and in apparently healthy individuals

## CHAPTER I

### BRIEF SURVEY OF THE LITERATURE ON MORPHOLOGICAL CHANGES IN SMALL BLOOD VESSELS IN PATIENTS WITH DIABETES MELLITUS

#### *Distribution in the body*

The earlier literature dealing with changes in small blood vessels in the kidney and the eye in diabetes mellitus has been reviewed by Ashton (1958). In recent years many investigators have described basically similar, probably non arteriosclerotic changes in small blood vessels in diabetes — «diabetic microangiopathy» — in various organs. Thus small vessel involvement has been found in the peripheral and central nervous systems (cf Fagerberg 1959 and Reske Nielsen *et al* 1965) in intramural vessels of the heart (Blumenthal *et al* 1960) in vasa vasorum (cf Angervall *et al* 1966) in skeletal muscles (cf Bentosme *et al* 1966 Siperstein *et al* 1966) in synovial membranes (Aagaes & Hagensen 1959) in the digestive tract (cf Angervall & Sæve Soderbergh 1966) and in exocrine and endocrine glands (cf Berns *et al* 1964 Funk 1965 Angervall & Sæve Soderbergh 1966). Reports on dermal blood vessel changes have been listed in Table 1.

Many problems in connection with the vascular changes in diabetes have recently been discussed by Siperstein *et al* (1964) Berkman & Rifkin (1966) Stary (1966) and Warren *et al* (1966).

#### *Light microscopic changes*

A thickening of the peripheral vessel wall has been considered to be a characteristic finding in diabetes (cf Siperstein *et al* 1964). This thickening is most clearly visible in capillaries but is also seen in arterioles and venules. The PAS staining (McManus, 1946) has been widely used to study the changes in small blood vessels. The lesions in small dermal blood vessels in diabetes was first described in more detail by Aagaes & Moe (1961). Their findings have to the greater part been confirmed by others (Table 1).

The PAS positive thickening can either be seen as a homogenous thickening of the entire periendothelial vessel wall or as a thickened and sometimes split up basement membrane. Occasionally pericytes are seen encased in the basement membrane. The changes are further characterized by an uneven, segmental distribution (Pedersen & Olsen 1962). Seemingly normal and conspicuously altered vessels may be observed in the same specimen.

In some studies the wall thickness has been arbitrarily graded (Barson & Lacy 1964 Angervall *et al* 1965 Pieri *et al* 1965 Sæve Soderbergh *et al*, 1967) sometimes based on micrometer

TABLE 1 Microangiopathy in dermal vessels in diabetics

Biopsy/Necropsy/ Amputation	Site	Light Microscopy	Electron Microscopy	Thickened Vessel Wall	Endothelial Proliferation	Positive Diabetics (%)	Positive Non diabetics	Number Invest- igated Diabetics	Reference	
1	A	Leg	+	+	+	63 %	5 %	51	Goldenberg <i>et al</i>	1959
2	B/N	Thumb Toe	+	(+)	+	71 %	1/8	24	Aagaens & Moe	1961
3	II	Fore arm	+	+	+	79 %	1/13	19	Handelsman <i>et al</i>	1962
4	B/A	Leg	+	+	+	63 %		20	Pedersen & Olsen	1962
5	II	Toe	+	+	—	50 %	17 %	40	Weber & Wicht	1962
II	N		+	+	—				Bloodworth	1963
7	II	Finger	+	+		60 %	0 %	10	Boysen Møller <i>et al</i>	1963
II	B/N	Leg	+	+		82 %	0/5	11	Melin	1964
9	N/A	Toe	+	(+)	+	88 %	23 %	18	Banson & Lacy	1964
10	B	Hand	+	+		91 %	14 %	24	Faerman <i>et al</i>	1954 1963
11	B	Fore- arm	+	+		++	+	44	Bercovici <i>et al</i>	1964
12	B		+	+		++	?	(27)	Garrachon <i>et al</i>	1965
13	B/A	Leg	+	+	+	90 %	6 %	52	Moore & Frew	1965
14	N	Leg	+	+	+	68 %	21 %	50	Funk	1965
15	B	Ear	+	+	—	100 %	3/15	38	Pieri <i>et al</i>	1965
16	B	Foot	+	(+)	+	++	+	65	Angervall <i>et al</i> , Sæve Soderbergh <i>et al</i>	1965 1967
17	II	Finger	(+)	+	+/-	+/-	+/-	13	Frieden <i>et al</i>	1966
18	B	Fore arm	+	(+)	+	53 %	7 %	30	McMillan <i>et al</i>	1966
19	II	Finger	+	+	+	100 %	1/10	11	Durand & Durand	1966
20	II	Fore arm	(+)	+	+	++	+	31	Pardo <i>et al</i>	1966
21	II	Ear	(+)	+	+	++	+	35	Otto <i>et al</i>	1967
22	II	Fore arm		+	+	+/-	+/-	21	Yodaiken <i>et al</i>	1967

(+) indicates that the main results and conclusions of the study concerned are not based primarily on this particular investigation.

measurements of selected capillaries (Bercovici *et al* 1964)

Although as a rule thickened vessel walls have been a common finding in diabetic subjects these changes are by no means limited to the diabetic state, as emphasized by Bercovici *et al*

(1964), «the presence or recent history of even minor skin complaints may drastically alter the light microscopic interpretation of microangiopathy in the skin»

Changes in endothelial cells, especially in arterioles and small arteries, are

considered by some to be a rather characteristic lesion in diabetes (*cf* Blumenthal *et al*, 1964). The lesion is described as a proliferation of the cells. These are often enmeshed in fine PAS-positive fibrils. It has been suggested that the lesion has an «immunogenic» basis. It can occur in such diseases as chronic glomerulonephritis, systemic lupus erythematosus, rheumatoid arthritis and malignant lymphomas. It has also been observed in homografts. Likewise, Blumenthal *et al* (1964) found a similar lesion in rabbits immunized with bovine insulin. The findings in diabetes have been confirmed by some and questioned by others (Table 1, Warren *et al*, 1966).

Other investigators have stressed that changes in the pericytes may be of etiologic importance for the development of the small blood vessel lesions in diabetes mellitus (*cf* Kimmelstiel 1966, Yodaiken *et al*, 1967, S  ve Soderbergh *et al*, 1967). Others maintain that the connection of the function of the pericytes to the vascular changes in diabetes mellitus is still unsubstantiated (Oliveira 1966).

### Ultrastructural changes

Ultrastructural studies have confirmed the presence of focal thickenings of capillary walls in patients with diabetes. They have also confirmed that similar changes occur in non-diabetic individuals (Bloodworth, 1962, Friederici *et al*, 1966).

Under the electron microscope an uneven thickening and sometimes a splitting up of the periendothelial base-

ment membrane can be seen together with an accumulation of basement membrane like material in the perivascular space. In advanced lesions the accumulation of substances, probably lipid- and protein rich has been noted. The «basement membrane» observed under the light microscope probably consists of both the ultrastructurally defined periendothelial basement membrane and the seemingly amorphous material in the perivascular cuff of the dermal capillaries (Pardo *et al*, 1966, Otto *et al*, 1967).

Careful measurements of different parts of the basement membrane of dermal capillaries (Friederici *et al*, 1966, Pardo *et al*, 1966, Otto *et al*, 1967) and of the peripheral glomerular basement membrane (  sterby Hansen, 1965, Kimmelstiel *et al*, 1966) in sections from diabetic and non diabetic subjects have shown great variations in the basement membrane width in both groups with overlapping frequency distribution curves of the membrane thickness.

In the skin at least the overlapping in wall thickness of small blood vessels in diabetic and non diabetic subjects, observed both under the light and electron microscopes makes it difficult to state with any certainty how early in the course of the diabetic disease the described vessel changes can be seen. Several investigators have maintained that changes in small dermal vessels are an early manifestation of diabetes mellitus, and that they can be observed long before the disease becomes manifest (*cf* Camerini Davalos, 1965, Gar-

rachon *et al*, 1965, Faerman *et al*, 1965) It is clinically well known that the frequency of observed vascular lesions (e.g. retinopathy), increases in proportion to the duration of diabetes mellitus (*cf* Ashton, 1958) However, an increase in the small dermal blood vessel thickness in proportion to the duration of the disease was not found by some investigators (Pedersen & Olsen, 1962, Banson & Lacy, 1964, Friederici *et al*, 1966, Yodaiken *et al*, 1967) whilst others did find a connection between the vessel wall thickness and the duration of diabetes (Aagaas & Moe, 1961, Weber & Wicht, 1962, Bercovici *et al*, 1964, Moore & Frew, 1965, Funk, 1965, McMillan *et al*, 1966, Otto *et al*, 1966, S ve Soderbergh *et al*, 1967) The disagreement may be due to the fact that the connection is difficult to show in a small series In the former group of studies referred to above, the number of diabetic subjects examined varied between 13 and 21, whilst in the latter group the number was from 24 to 65

### Histochemistry

It has not been possible to demonstrate any significant qualitative differences in the composition of small blood vessels between diabetic and non diabetic subjects by histochemical methods Neither fibrinoid nor amyloid can as a rule be demonstrated in small vessel lesions in diabetes Exsudative lesions in the kidneys and severe arterial lesions in the gastro intestinal tract give staining reactions which indicate the presence of a mixture of protein and fat, »fibrinoid«

(Lendrum, 1963, Angervall & S ve Soderbergh, 1966) Localized clumps of dark osmiophilic material, probably lipid, have been observed under the electron microscope in the basement membrane of muscle capillaries in diabetes (Bencosme *et al*, 1966) In this respect, the histochemical resemblance to findings in lipoglycoproteinosis may be noted (Falkmer *et al*, 1966) The amount of acid mucopolysaccharides did not seem to increase in small vessels in diabetes The results of the colloidal iron reaction of Rinehardt and Abul-Ha was negative (Goldenberg *et al* 1959)

Small vessel walls from diabetic and non diabetic subjects stain red when the PAS reaction is performed The reaction cannot be eliminated by pre-treatment of the tissue with amylase In paraffin embedded sections, subsequently deparaffinized with fat solvents, this reaction is considered to be discriminating in detecting glycoproteins (*cf* Spiro, 1963)

### Chemical analysis

Normal human glomerular basement membranes have been analyzed using different methods (Windrum *et al*, 1955, Robb Smith, 1957) A main constituent seems to be carbohydrate rich proteins with a high hydroxyproline content belonging to the reticulin collagen group of proteins These substances give PAS positive staining reactions Direct chemical analysis of the content of the normal peripheral capillary wall does not seem to have been performed (Meier 1964, Muir, 1964)

Similar antigenic determinants in the glomerular capillary basement membrane and in capillary basement membranes from other sources may indicate similarities in the chemical composition (Krakower & Greenspon, 1964, Cruickshank, 1964)

Odin & Törnblom (1959) carried out chemical analyses of mechanically isolated washed glomeruli from necropsy material. Glomeruli with severe diabetic nephropathy were compared with those from apparently normal non diabetic kidneys. No great chemical differences were found between the two categories of material. Judging by the hydroxyproline content, about  $\frac{1}{3}$  of the proteins consisted of reticulin collagen like substances. The presence of tryptophane indicated that non collagenous proteins were present. By means of immunoelectrophoresis the diabetic glomeruli were found to contain almost all identifiable serum proteins. Traces of gammaglobulin only were found in the non diabetic glomeruli.

Also Lazarow & Speidel (1964) found that the principal part of the glomerular basement membrane consisted of collagen or collagen like substances both in diabetic and non-diabetic kidneys. The results of amino acid analysis showed that probably no plasma proteins were present in the specimens. As pointed out by Spiro (1964), the prolonged treatment of the glomeruli in alkali may have destroyed or eluted some proteins before the final analysis.

### *Immunohistochemical investigations*

The fluorescent antibody technique provides a fair possibility of identifying and histologically localizing individual or groups of antigenically closely related substances in different tissues.

Using this method, Taft *et al* (1958) found traces of fluorescence indicating the presence of gammaglobulin in the glomerular basement membrane in a biopsy specimen from a patient with diabetes mellitus. Freedman *et al* (1960, 1962) found gammaglobulin in diabetic kidneys not only in the glomerular basement membrane but also in the walls of other blood vessels in the kidney. It was also possible to demonstrate complement with identical localization. The immunofluorescence picture was very similar to that found in kidneys from patients with chronic glomerulonephritis and SLE. These observations have been confirmed by others (Table 2). A survey of the localization of different plasma proteins in various vascular structures in diabetes mellitus is given in Table 3.

The insulin binding capacity of the diabetic vascular lesions in the kidney was tested by Berns *et al* (1962). Fluorescein conjugated bovine insulin was used. In diabetic nodular glomerulosclerosis 95 % of the 25 investigated kidneys showed positive fluorescence in the glomerular lesions. Similar fluorescence was demonstrated in the PAS-positive fibrillar network in vessels with «proliferative» endothelial lesions, in the tubular basement membrane and cells and in Bowman's capsule. This binding was noticed in 13 % of the dia-

TABLE 2 Plasma proteins demonstrated in vascular structures in diabetes mellitus by fluorescent antibody technique

Source of the specimens		Necropsy, Biopsy or Amputation	Diabetics								Other diseases involving the specimens studied								Other specimens studied "Controls"				Reference	Reference Number
			Al	F	C	G	Al	F	C	G	Al	F	C	G	Al	F	C	G						
Kidney	B				1/1								8/23							Taft <i>et al</i> 1958	I			
"	D N				3/3								29/31					0/9		Freedman <i>et al</i> 1960	II			
"	D				1/5								14/67							Mackay <i>et al</i> 1961	III			
"	B N			1/1	1/1							12/12	12/12			0/6	0/6			Freedman <i>et al</i> 1962	IV			
"	N			+	14/41								9/42				0/5			Berns <i>et al</i> 1962	V			
"	N				+ / 20															Moran <i>et al</i> 1962	VI			
"	N				6/6															Burkholder 1965	VII			
"	N			+	6/6															Davies <i>et al</i> 1966	VIII			
Retina	A, N			13/23	0/23*			0/25		0/40			21/25			6/40				Coleman <i>et al</i> 1963	IX			
Pancreas	N			5/16	19/23	0/3	0/2			0/9	2/12		8/14			3/7				Berns <i>et al</i> 1964	X			
Placenta					11/11								5/7			0/5				Burstein <i>et al</i> 1963	XI			
Leg	A				23/39								9/31							Blumenthal <i>et al</i> 1964, 1966	XII			
Skin	B				6/6								2/2			0/2				Larsson & Melin	XIII			
"	D			3/20	6/20	3/20	55/82			2/11	0/11	0/11	7/35							Larsson 1966	XIV			

The figures indicate Number positive/Total number studied

Al Albumin

F<sub>1</sub> Fibrinogen

C Complement

G  $\gamma$  globulin (Anti human globulin serum was used by some)) Binding of Guinea Pig complement *in vitro*

) Low density lipoproteins were demonstrated with identical localization and frequency as fibrinogen

# COMMENTS TO TABLE II

Reference  
number

I	Systemic lupus erythematosus 6/10 Glomerulonephritis 2/9
II	Systemic lupus erythematosus 8/8 Glomerulonephritis 8/8, Scleroderma 4/4 Amyloidosis 1/1 Rheumatoid arthritis 1/1 Uncertain diagnosis 1/1
III	Systemic lupus erythematosus 8/15 Glomerulonephritis 5/21, Toxicosis gravidarum 1/5
IV	Systemic lupus erythematosus 7/7 Glomerulonephritis 4/4
V	Systemic lupus erythematosus 2/3 Amyloidosis 2/7 Myelomatosis 4/5 Nephrosclerosis 1/15
IX	Glaucoma 21/25 (Positive fluorescence in trabecular meshwork)
X	The group «Other diseases involving the studied specimens» includes specimens from non-diabetic individuals with hyaline islets
XI	Rh incompatibility 5/7
XII	The group «Other diseases involving the studied specimens» includes Arteriosclerosis Mlb Bürger Sarcoma Osteomyelitis Cold injuries
XIII	Systemic lupus erythematosus 2/2
XIV	Apparently healthy individuals (35)

betic kidneys without glomerular lesions. The non diabetic kidneys investigated did not show any fluorescence. The study was based on necropsy material and it was not possible to state whether insulin treatment was given to the diabetics or not.

Similar investigations including organs other than the kidney have since been repeated by others (*cf* Table 4).

As can be seen in Table 4, insulin-binding has been demonstrated mostly, but not selectively, in tissues from diabetic subjects.

It has been supposed (Berns *et al*, 1962, Blumenthal *et al*, 1966) that insulin is bound to the tissue by an antigen antibody reaction. Anti insulin antibodies, localized *in vivo* in tissues are thought to bind the conjugated insulin. Some support for this hypothesis has been given by observations that human  $\gamma$  globulin could be demonstrated in the same location where insulin was bound. However, whereas

96 % of the diabetic glomerulosclerotic kidneys showed specific fluorescence when treated with conjugated insulin *in vitro*, localized human globulin could only be demonstrated with the immunofluorescent method in 48 % of the material. Moreover, the fluorescence indicating the presence of human globulin was in most instances rather weak in the nodular lesions of the glomeruli whilst the fluorescence indicating bound insulin in these same lesions was strong (Berns *et al*, 1962). The presence of circulating anti insulin antibodies was only tested in a few of those patients from whom kidney sections were studied later on and the *in vitro* fixation of conjugated insulin was demonstrated. In no case were such antibodies demonstrated (Farrant & Shedden, 1965).

Fluorescein conjugated anti insulin serum was used to study the localization of insulin *in vivo* in specimens from kidney and pancreas (Table 4). In the pancreas insulin was found in



TABLE 3 Immunohistochemical localization of some plasma proteins in vascular and non vascular structures in various organs from diabetic subjects Reference numbers see Table 2

A Localization in the kidney

Ref No	Non glomerular vessel walls				Glomerular capillary BM				Nodular lesions				Exudative lesions			
	Al	Fi	C	G	Al	Fi	C	G	Al	Fi	C	G	Al	Fi	C	G
I																
II				+				(+)								
III								(+)								
IV			+	+			+	+								
V			+	+			+	+								
VI	?	?	+	+	?	?	+	+								
VII	-	+	+	+	+	+	+	+								
VIII	-	+		-	-			-								

B Localization in other organs than the kidney

Ref No	Retina		Islets of Langerhans		Placenta		Amputated legs		Skin biopsy	
	Vessel BM	Micro aneurysms	Vessel wall	Islet tissue	Vessel wall	Other BM	Vessel BM	Small vessel BM	Small vessel BM	Small vessel BM
Al	-	-	-	-	-	-	-	-	-	-
Fi			+	-						
C										
G	+	+	+	+	+	+	+	+	+	+
Ref No	(IX)		(X)		(X)		(XI)		(XII)	(XIX)

Al = Albumin Fi = Fibrinogen C = Complement fractions G =  $\gamma$  globulin ) = *in vitro* binding of guinea pig complement ) = Low density lipoproteins were demonstrated in the same localization and frequency as fibrinogen (+) = Weak specific fluorescence ? = Possible localization not stated

TABLE 4 *In vitro* binding of fluorescein conjugated insulin to blood vessel walls and the demonstration of *in vivo* localized insulin by aid of fluorescein conjugated anti insulin serum

Source of the specimens	Diabetes			Other		Reference	Reference Number
	Necropsy or Amputation	Insulin	Anti insulin	Not treated with insulin	Insulin	Anti insulin	
Kidney	N	27/41	50— 74 %	?	0/56	0/15	Berns <i>et al</i> (1962), Blumenthal <i>et al</i> (1964) V
"	N	+		?			Coleman <i>et al</i> (1962) XV
"	N	28/32		4/9	3/40		Farrant & Sheddon (1965) XVI
Retina	N		4/5	2/2			Burkholder (1965) VII
Pancreas	A N	10/13		?	0/17		Coleman <i>et al</i> (1962) XV
"	N	+		?			Coleman <i>et al</i> (1962) XV
Placenta	N	75/106	6/22	?	13/89	5/19	Berns <i>et al</i> (1964) V
Leg		26/29		?	1/34		Burstein <i>et al</i> (1963) XI
Nervous system	A	14/26		?	9/59		Blumenthal <i>et al</i> (1966) XII
	N	+/6		?			Angervall <i>et al</i> (1965) XVII

+ = Total number not stated

? = Not stated

#### COMMENTS TO TABLE 4

Reference Number

V, VII, X

XVI

VI

See Comments to Table 2

Chronic glomerulonephritis (1) Chronic pyelonephritis (2)

Weakly positive Primary amyloidosis (1), Chronic pyelonephritis (2), rheumatoid arthritis (1)

Rh incompatibility 1/9

normal and hyaline islets and in vessel walls in sections from both diabetic and non-diabetic subjects (Berns *et al*, 1964). In the diabetic kidneys the anti-insulin serum became localized into those sites where conjugated insulin was bound *in vitro*. However, the percentage of positive results was less (Berns *et al* 1962). Burkholder (1965) made similar studies on specimens from necropsy kidneys from five diabetic subjects. He found that the distribution of tissue bound anti insulin serum did not correspond very well with those regions where globulins were localized and where complement fixation *in vitro* was demonstrated.

In most earlier studies listed in Tables 2 and 4, where the fluorescent antibody technique or the technique of studying the *in vitro* localization of conjugated insulin was used, the investigated specimens consisted of material obtained after necropsy or amputation, collected over long periods and probably under varying conditions. Furthermore, in most of those specimens where specific fluorescence was obtained, marked pathological changes were demonstrated in the kidneys, diffuse or nodular glomerulosclerosis in the retinas, microaneurysms in the islets of Langerhans hyaline changes and in amputated legs arteriosclerotic, ischemic or inflammatory changes. Immunofluorescent observations made on these kinds of specimens must be judged with caution. Some investigations dealing with this problem may be cited. Møller (1961) was able to show that conjugated antisera were quickly localized intracellularly in damaged cells. Kent (1966,

1967) found that  $\gamma$ G-globulin, albumin and fibrinogen were localized in ischaemic heart muscle fibres both in experimental heart infarcts in dogs and in human infarcted heart tissue. The proteins could not be eliminated by rinsing in buffered saline; they behaved in an immunologically «bound» fashion. Kent was also able to demonstrate the penetration of albumin into muscle fibres directly adjacent to blood vessels as a post-mortem phenomenon in undamaged tissue.

### Summary

Most studies cited in this chapter indicate that during the course of human diabetes mellitus morphological changes develop in small blood vessels throughout the body. The changes are morphologically similar in different regions when studied under the light and electron microscopes, and their pathogenesis is probably similar. However, it has not been possible to identify any structural or chemical patterns in the affected vessel walls by means of morphological, histochemical or chemical studies, which unequivocally separate the diabetic «microangiopathy» from changes observed in small blood vessels both in apparently healthy subjects and patients with some other diseases. Nor has it been possible, with the aid of these studies and others not cited here, to elucidate the primary cause or causes of these vascular changes, on patients with «secondary» diabetes or on animals (*cf* Berkman & Rifkin, 1966).

To the present author it seemed of great interest that  $\gamma$  globulin (and components of complement) could be identified and found localized in these vascular changes in diabetic subjects. The functions of these substances are fairly well known and their presence in vascular lesions in diabetes might be of etiological importance. However, since most of these immunohistochemical stu-

dies have been performed on specimens obtained by necropsy or amputation, and since no extensive studies have been made of the distribution of  $\gamma$  globulin and other plasma proteins in the vessel walls of patients with short term diabetes and apparently healthy nondiabetic subjects, the importance of these observations is difficult to judge.

## CHAPTER II

### EARLIER IMMUNOFLOUORESCENT STUDIES ON THE DISTRIBUTION OF VARIOUS PLASMA PROTEINS IN THE HUMAN SKIN

As the major part of this investigation deals with the distribution of various plasma proteins in small dermal vessels in diabetic and non diabetic subjects, a short survey of earlier investigations, using the fluorescent antibody technique, of the distribution of plasma proteins in human skin will be given.

Albumin was demonstrated by Gitlin *et al*, (1952) in the subepidermal connective tissue in normal skin. Tissue obtained by necropsy was used. A similar diffuse distribution in the superficial dermal layers was observed by Allansmith & Buell (1965) in skin biopsies from healthy and atopic individuals.

Gitlin *et al*, (1952) also found fractions of  $\beta$ -globulins and fibrin localized extravascularly below the epidermis. No other studies seem to have been published where the fluorescent antibody technique was used to study the distribution of different  $\alpha$ - and  $\beta$  globulins in the normal skin, except for fractions of complement, *vide infra*. Using immunoelectrophoresis, Zimmer *et al* (1960, 1961) found that the dermis contained  $\alpha_1$  and  $\beta$  globulins (three lines) together with  $\gamma$  globulin. Fibrinogen was not observed in the normal skin by Burnham *et al*, (1963).

In apparently normal skin  $\gamma$ G globulin

has been found localized immediately below the epidermis unevenly and diffusely distributed in the connective tissue (Gitlin *et al*, 1952, Burnham *et al*, 1963, Larsson & Melin, 1964, Allansmith *et al*, 1964). Often a band of bright fluorescence indicating the presence of  $\gamma$  globulin was seen immediately beneath the epidermis, in the area of the dermal epidermal junction.  $\gamma$ A- and  $\gamma$ M-globulins have been observed with a similar distribution by Allansmith & Buell (1965). These authors found no difference in the distribution in skin from normal and from atopic individuals.

The presence of immunoglobulins and complement has been shown as characteristic narrow fluorescent lines in the area of the dermal epidermal junction in both apparently normal and pathologically changed skin taken from patients with systemic and discoid lupus erythematosus (Burnham *et al*, 1963, Cormane, 1964, Kalsbeek & Cormane, 1964, Cormane *et al*, 1966, Ten Have-Opbroek, 1966, Tan & Kunkel, 1966).

In the dermal vessel walls  $\gamma$  globulin was observed in skin obtained by necropsy (Gitlin *et al*, 1952), while Larsson & Melin (1964) did not find any fluorescence indicating the presence of this protein in two healthy individuals.

Such a localization was observed, however, in patients with diabetes mellitus and systemic lupus erythematosus. In the latter disease, it has also been found in skin with a typical rash by Tan & Kunkel (1966), and in skin from some patients with nodular vasculitis by

Stringa *et al*, (1966), and Miescher *et al*, (1966).

#### *Summary*

See Chapter V

## CHAPTER III

### MATERIAL AND METHODS

#### *Investigated subjects*

Skin biopsies from 249 subjects were examined. They include the following groups

#### A PATIENTS WITH DIABETES MELLITUS

*Series A* 50 patients. These were selected from the files of the Medical Clinic, Umeå, according to the following criteria: about half had to be below the age of 40 and half above. At the time of the investigation they had to be feeling well and their metabolic balance had to be acceptable. They were called specially for this investigation to the Out patients Department.

*Series B* 72 patients. At the time of the investigation most of them were admitted to the Medical Clinic for regularization of their treatment or for other reasons. In this group one biopsy specimen was lost and only incompletely studied (Biopsy No 1). In the final assessment of the result this patient was excluded.

The object of choosing *Series A* was to try to get a sufficiently large group of diabetic subjects devoid of «secondary» factors (e.g. acidosis, infections, vascular complications such as myocardial infarction or peripheral gangrene, uraemia or oedema), which might influence the state of peripheral small vessels. If only hospitalized patients

were studied (*Series B*) the risk of such an influence seemed great.

Information about patients with diabetes mellitus is given in Table 5.

#### B MATCHED NON DIABETIC SUBJECTS

Each patient in *Series A* was matched with a non diabetic subject according to the following covariables: age, sex and residence. This was accomplished with the help of the official register of residents («Folkbokföringsregistret»). Individuals fulfilling the above criteria and registered close to the selected diabetic patients, were asked to cooperate in the investigation. Three subjects refused: one because of a disabling somatic disease, one because of nervous complaints, and one because of a fear of hospitals. Another subject was excluded because of diabetes. Instead, individuals registered next to these were chosen.

All subjects in this series were investigated by the present author at the Out patients Department. At the time of the investigation all felt well. Slightly elevated blood pressure was recorded in six. Three individuals complained of angina pectoris, one of chronic bronchitis, and three of recurrent urinary infections. One woman was pregnant (beginning of third trimester), and one had been delivered of a healthy child without complications one week earlier.

TABLE 5 Patients with diabetes mellitus

I The number age sex age range median age and known duration of diabetes mellitus

Series	Sex	Number	Age range years	Median age	Known diabetes-duration			
					0-5	5-10	10-15	15- years
A	Male	27	23-64	36	7	11	6	8
	Female	23	18-75	34.5	5	8	6	4
	Total	50	18-75	35	12	14	12	12
B	Male	34	16-80	47	18	3	11	5
	Female	38	4-73	48	14	11	4	9
	Total	72	4-80	48	32	14	12	14
A+B	Total	122	4-80	43.5	44	28	24	26

II The number of patients who had been treated with insulin and who had vascular manifestations

Series			Known diabetes-duration			
			0-5	5-10	10-15	15- years
A+B	Insulin therapy	Number	15	23	21	23
		Per Cent	34	82	87	88
A+B	Vascular manifestations	Number	5	7	18	25
		Per Cent	11	25	75	96

## C OTHER INVESTIGATED PATIENTS

77 patients with various diseases other than diabetes were investigated. For different reasons (*cf* Introduction) patients with glomerulonephritis, systemic lupus erythematosus (SLE), rheumatoid arthritis and hypertensive vascular disease were chosen. A few patients with other diseases and fairly healthy subjects with ill defined minor complaints were in most cases chosen at random for skin biopsy to form a basis of comparison with diabetic patients.

Information about these patients is given in Table 6.

## Clinical and laboratory investigations

All subjects in this study were questioned about diabetic heredity and past or present diseases. A general clinical

examination was performed. The blood pressure was recorded after at least five minutes rest and the figures thus obtained were used in the present study. The eye grounds were examined by the present author. If the results of an expert ophthalmological examination obtained less than one year ago, were available these were used. Any microaneurysms with or without hemorrhages and exudates in the eye grounds were noted as diabetic retinopathy. Loss of reflexes or vibration sense in the legs was recorded. The skin was examined for the presence of the atrophic circumscribed skin lesions described by Melin (1964). Nephropathy was registered in diabetic subjects if proteinuria was observed on repeated occasions and no reasons for kidney involvement other than diabetes were found. Retinopathy



and nephropathy were summed up under the the common title »Vascular manifestations» in Table 5 The duration of any treatment with insulin was recorded It was thought very unreliable to divide diabetic patients into good or poor control groups

TABLE 6 Other investigated patients

Glomerulonephritis	9
Systemic lupus erythematosus (SLE) and SLE like syndromes	15
Rheumatoid arthritis	11
Hypertensive vascular disease	9
Other diseases	33
Total number	77

»Other diseases»: Pyelonephritis (2) proteinuria (1) arteriosclerotic heart disease (2) pernicious anemia (1) chronic myeloid leukemia (1) amyloidosis (3) myasthenia gravis (2), hyperthyroidism (2) malabsorption (4) ulcerative colitis (2) cholecystitis (1) ill defined minor complaints (12)

In most investigated subjects, the haemoglobin values, the leukocyte counts and the values of blood sugar in peripheral blood (glucose oxidase method) were obtained The erythrocyte sedimentation rate according to Westergren — the ESR — for one hour was recorded The presence of proteinuria (Albustix®), glycosuria (Clinistix®) and in diabetic patients the total amount of urinary glucose throughout 24 hours, were investigated Microscopical examination of freshly voided urine was performed In the majority of subjects in series A and the matched non diabetic series the amount of serum protein was studied (paper electrophoresis)

By these investigations it was hoped to get a fairly good concept of the general health of the subjects studied

All the laboratory examinations were performed as ordinary routine samples by the Department of Clinical Chemistry of the University Hospital in Umeå

## Histochemical and immunohistochemical investigations

### A PERFORMANCE OF THE BIOPSIES AND HISTOLOGICAL PREPARATIONS

Punch biopsies with a diameter of 3 to 6 mm were taken from apparently normal skin from the lateral aspect of the proximal third of the lower leg

About half the biopsies were taken after local anesthesia with Xylocain® In the remaining subjects the area was sprayed with ethyl chloride to get anesthesia prior to the biopsy The small wound healed without complications even if the peripheral circulation was insufficient

Preliminary trials were made with quick frozen tissues, subsequently cut on a cryostat microtome However, it was not easy to obtain acceptable sections in this way Morphological details were not very distinct when immunofluorescent stainings were performed and the specimens could not be preserved for a long time Fixing in 10% formalin or in 5% glutaraldehyde was also tried In such sections the non specific fluorescence interfered when the fluorescent antibody technique was used In the main series a slight modification of a method introduced by Sainte Marie (1962) was chosen

All procedures, apart from the actual embedding in paraffin, were performed at about +4°C. The small specimens were immediately washed in cold saline for a few seconds and carefully wiped dry of excess saline. Large specimens were bisected. Fixation was performed in cold 95 % ethanol for 24 hours. After clearing in methyl benzoate (about 20 hours) and passage through xylene (3 hours) the specimens were embedded in paraffin. The blocks were stored under refrigeration until used.

The blocks were cut into 4–5  $\mu$  thick sections. At least three sections were placed on every slide and stained in an identical fashion. The cut sections were deparaffinized by passage for a few minutes, respectively, through two baths of xylene, then through 95 %, 85 % and 70 % ethanol. Finally, the slides were washed for at least 20 minutes in two baths of buffered saline, pH 7.2 (0.01 M  $\text{Na}_2\text{HPO}_4$   $\text{NaH}_2\text{PO}_4$  buffer + 8.5 g  $\text{NaCl}$ /100 ml).

All biopsies were stained with van Gieson's stain and with the PAS procedure (cf. Lillie 1965).

## B PERFORMANCE OF THE FLUORESCENT ANTIBODY TECHNIQUE

After removing excess fluid from the deparaffinized sections, the slides were placed in a moist chamber.

Either »direct» or »indirect» immunofluorescent staining was used (cf. Melors, 1959, Naim, 1962). The reactions took place at room temperature.

The following table shows the principal procedures.

After every application of antiserum, all unbound serum was carefully washed away in a large quantity of buffered saline (composition, see above). The sections were mounted in a »semi-permanent» mounting medium (Rodriguez & Deinhardt, 1960) consisting of a solution of polyvinyl alcohol and glycerol in buffered saline, pH 7.2.

The various antigens studied are listed in Table 7, and the unconjugated and conjugated antisera used in this investigation are listed in Table 8. Fluorescein isothiocyanate was used as a fluorochrome.

The immunological specificity of the antisera was tested by the manufacturers. In most antisera used it was confirmed by immunoelectrophoretic checks, kindly performed by Dr A. Forsgren, Institute of Microbiology, University of Umeå. More sensitive tests were not carried out. In practice it was thought improbable that weak cross reactions with undesired antigens would seriously influence the results of the immunofluorescent investigations.

	Antigen to be demonstrated	Unconjugated antiserum 30 min	Saline pH 7.2 15 min	Conjugated antiserum 30 min	Saline pH 7.2 15 min	Mounting
Direct method	»A»	—	—	anti »A»	+	+
Indirect method	»A»	anti »A»	+	anti anti »A»	+	+

[illegible]

Approximate Molecular weight	Approximate S gar content Total Per cent	Approximate Hexose Per cent
70 000 <sup>(1)</sup>	0.5 <sup>(1)</sup>	15 <sup>(1)</sup>
44 000 <sup>(2)</sup>	41 <sup>(1)</sup>	
165 000—400 000 <sup>(4)</sup>		
(23 000—20 000) × 2—6 <sup>(4)</sup>		
95 000 <sup>(2)</sup>	22 <sup>(1)</sup>	11.5 <sup>(1)</sup>
90 000 <sup>(2)</sup>	5.5 <sup>(1)</sup>	2.5 <sup>(1)</sup>
13—3.2 × 10 <sup>6</sup> <sup>(4)</sup>		
250 000—1 000 000(?) <sup>(4)</sup>		
340 000 <sup>(4)</sup>	5 <sup>(1)</sup>	3 <sup>(1)</sup>
160 000 <sup>(4)</sup>		5 <sup>(1)</sup>
150 000 <sup>(2)</sup>	3 <sup>(1)</sup>	
1 000 000 <sup>(4)</sup>	10 <sup>(1)</sup>	5 <sup>(1)</sup>

RELATIONS TO TABLE 7

- EXPLANATIONS TO TABLE I
- |    |   |  |
|----|---|--|
| 1) | cf Cooper G C p 88 in Putnam (1960)                         |  |
| 2) | cf Phelps R A & Putnam J W p 148 in Putnam (1960)           |  |
| 3) | cf Wenzler R J p 303 in Putnam (1960)                       |  |
| 4) | cf p 495 in "Nägot om blodaggration" AB Kabi Stockholm 1965 |  |
| 5) | cf Wenzler R J p 235 in Siperstein <i>et al</i> (1964)      |  |
| 6) | cf Fredrickson <i>et al</i> (1967)                          |  |
| 7) | cf Bill World Health Organ 30 447 1964                      |  |

TABLE 8 *Antisera used in the fluorescent antibody studies*

## A Unconjugated antisera

Serum No	Source (animal)	Specific human antigen	Cross reactions (immunoelectrophoresis)	Received from
1	Rabbit	Albumin	0	•SEVAC <sup>1)</sup>
2	"	"	0	Behringwerke <sup>2)</sup>
3	"	$\alpha_1$ acid glycoprotein	0	"
4	"	$\alpha_1$ lipoprotein	0	"
5	"	Haptoglobin	0	"
6	"	Transferrin	0	"
7	"	$\beta$ lipoprotein	0	"
8	"	$\beta_2$ protein	0	Dr H. Müller-Eberhard <sup>3)</sup>
9	"	"	II	Dr B. Lundh <sup>4)</sup>
10	"	Fibrinogen	0	•SEVAC <sup>1)</sup>
11	"	$\gamma$ G globulin	0	Umeå <sup>5)</sup>
12	"	"	0	Behringwerke
13	"	"	II	•SEVAC <sup>1)</sup>
14	"	$\gamma$ A globulin	0	"
15	"	$\gamma$ M globulin	0	"

## B Conjugated antisera

Serum No	Source (animal)	Specific antigen	Cross reactions (immunoelectrophoresis)	Received from
16	Rabbit	Human albumin		Behringwerke
17	Sheep	Human $\gamma$ globulin	Albumin	SBL <sup>6)</sup>
18	Rabbit	"	"	SBL
19	Goat	"	$\alpha$ - and $\beta$ globulins (weak)	Microbiol. Ass. <sup>7)</sup>
20	"	Rabbit globulin		"

<sup>1)</sup> •SEVAC<sup>1)</sup> Prague, Czechoslovakia <sup>2)</sup> Behringwerke Marburg Lahn, Western Germany

<sup>3)</sup> Scripps Clinic & Research Foundation La Jolla Calif. USA. <sup>4)</sup> Department of Medicine University of Lund <sup>5)</sup> Institute of Clinical Bacteriology University of Umeå <sup>6)</sup> Professor

A. Fagraeus Statens Bakteriologiska Laboratorium Stockholm <sup>7)</sup> Bethesda Md, USA.

During the course of the study different antisera sometimes had to be used against the same antigen. In such cases parallel stainings with both antisera were performed on a series of sections to get comparable results.

The sections were examined in a Zeiss fluorescence microscope with dark field condenser and UG 2 exciter

filter with a 41 barrier filter. The light source was Osram's HBO 200 W mercury lamp. For photomicrographs Ectachrome High Speed film (EH 135) was used with an exposure time of about 30 seconds.

*Unspecific fluorescence* in the sections was checked in the following ways:

### In the direct procedure

1) The sections were covered for 20 minutes with an unconjugated antiserum. Most specific antigens in the sections were then blocked. Treatment with conjugated antiserum afterwards resulted in only weak or no fluorescence. (Plate II B)

2) Specific antibodies in the conjugated antiserum were neutralized by coincidental application on the sections of both a solution of the specific antigen and the conjugated antiserum. After rinsing no specific fluorescence was present in the sections.

### In the indirect procedure

Here only one conjugated antiserum was used in all tests, namely serum No 20 in Table 8.

3) The sections were only covered with the conjugated antiserum (Plate II D).

4) The sections were first covered with a normal rabbit serum for 30 minutes. After rinsing the conjugated serum was used.

Only in a few instances was a weak unspecific fluorescence noted in epidermis and in epithelial cells of dermal glands when methods 3 and 4 were used. No fluorescence was noted in vessel walls or in dermal connective tissue.

5) When the conjugated goat anti-rabbit globulin serum was replaced by a conjugated rabbit anti-goat globulin serum no fluorescence was obtained.

Most biopsies were stained by both direct and indirect methods to identify

$\gamma$ G globulin. The histological pictures and the intensity of the specific fluorescence were in both instances very similar (Plate II). The same was found to be true when albumin was studied using both processes. The results were reproducible. Moreover, when unconjugated antisera against different antigens were used in the indirect methods, the results were dissimilar (Plates IV—V). This makes a high degree of immunological specificity probable.

However, when it is stated in the present investigation that  $\gamma$ G globulin or other plasma proteins were demonstrated in the sections studied, it must be understood that the immunofluorescent «demonstration» or «staining» of these proteins (antigens) in reality means that conjugated antiserum could be observed specifically «bound» in the sections. The validity of the above-mentioned statements is dependent on the specificity of the antiserum and the possible presence of overlapping antigenic determinants in the tissues.

### Semiquantitative grading of staining reactions in small dermal vessel walls

In this investigation the term «small blood vessels» includes capillaries, venules, and small veins localized immediately under the epidermis or close to dermal glands near the subcutaneous fat. The staining reactions in these vessels were similar. In several sections, both from diabetic and non-diabetic subjects, the immunofluorescent reactions in the small blood vessels differed from those observed in arterioles, small arteries and larger arteries.

and veins (*cf* Plate VI C) Even in such sections, where strong specific fluorescence was noted in the walls of small vessels, other vessel walls were as a rule non fluorescent

The staining reactions in small dermal vessel walls were graded as follows

#### A. THE PAS PROCEDURE (Plate I)

Grade 1 In the majority of vessels the walls were thin with a delicate PAS positive reaction

Grade 2 In many small blood vessels a slight PAS positive thickening of the wall was observed

Grade 3 Most vessel walls were markedly thickened with a heavy PAS positive reaction

Grade 4 A heavy thickening of the majority of the vessel walls was seen, sometimes with a total obliteration of the lumen

Thus the semi quantitative grading of the wall thickness was similar to that adopted by Angervall and co-workers (*cf* Sävje Söderbergh *et al* 1967) The reason why 4 grades instead of 5 — as used by these authors — were used in the main investigation was that the Sainte Marie fixation gave inferior histochemical results compared with *e g* the Bouin fixation permitting only a fairly reliable separation of 4 different stages In a pilot study (*cf* Sources of error) it was found that the outcome of the PAS procedure could be assessed in 5 grades but that this grading was less reproducible

#### B THE IMMUNOFLOUORESCENT STAINING REACTION (Plate III)

Grade 1 No specific fluorescence was seen in vessel walls, or only traces in isolated vessels (— to  $\pm$ )

Grade 2 A rather weak but distinct fluorescence was seen in disseminated small vessels A similar fluorescence could be observed in the surrounding connective tissue (+)

Grade 3 In many small blood vessel walls the fluorescence was distinct and bright Any fluorescence in the surrounding tissue was not so strong (+ +)

Grade 4 The fluorescence was very strong and bright in the majority of the observed small vessel walls It deviated distinctly from that observed in the surrounding tissue (+ + +)

#### STATISTICAL METHODS

The *methods of sampling* employed mean that the samples can be regarded as random samples from different populations The *populations* were

- 1 Patients with diabetes mellitus (Series A and B)
- 2 Matched non-diabetic subjects
- 3 Other investigated patients living in Umeå and its surroundings

The *findings* were as follows

- 1 The results of PAS staining and immunofluorescent demonstration of  $\gamma$ G globulin and some other plasma proteins in small dermal vessel walls in a series of skin biopsies The reactions were graded semiquantitatively The results of both «open» and «blind» assessments were recorded

2 Some anamnestic clinical and laboratory data recorded in the series of subjects on whom the skin biopsies were made

The statistical questions to be considered were

Is there any difference between the immunofluorescent staining of sections prepared according to different methods (Chapter IV)? Are there any differences in the assessments of PAS treated sections by different investigators (Chapter IV)? Are there any differences in 'open' and 'blind' assessments of the immunofluorescent staining or in direct and indirect immunofluorescent stainings (Chapter IV)?

Most patients in the diabetes series II were hospitalized for various reasons while the subjects in the diabetes series A were not. A comparison between the two series had to be made (Chapter IV).

Are there any differences in the staining reactions between the group of diabetic subjects and the group of matched non-diabetic subjects or between the latter group and the group made up of other investigated patients (Chapters VI—VIII)?

The possible influence of some anamnestic clinical and laboratory data on the staining reactions had to be examined (Chapters VI—VIII).

The analytical methods used were as follows:

As a central value the mean with its standard deviation ( $s_x$ ) was employed. This and the confidence interval were calculated according to current formulas (cf. Documenta Geigy 1960). The difference between two population means was tested by means of a sign test or a Student's  $t$  test. The critical values depending on the level of significance and the number of degrees of freedom were taken from current tables. When the computed value coincided with or was greater than that given in the table the difference was statistically significant. The possible influence of some data on the staining results was tested by the Chi square method ( $\chi^2$ ). A few hypotheses were tested by means of a one-way analysis of variance. To test the hypothesis that different investigators differ in their assessments of the staining reactions the effect of differences between patients had to be reduced. Thus the comparison was carried out with a two-way analysis of variance.

The test methods used are given in the various chapters. The critical value is given in brackets after each computed value, or in the headings of the tables.

All tests were performed at the 5% significance level.

## Summary

A clinical examination was performed on 122 patients with diabetes mellitus. Of these 50 were specially called to the Out patients Department. A contrasting sample of 50 non diabetic apparently healthy subjects was selected with the help of the official register of residents, and studied in the same way as the diabetic patients. Furthermore, 77 hospitalized patients with various diseases other than diabetes mellitus were studied. Some laboratory examinations were performed in order to obtain a fairly accurate concept of the general health of the individuals studied.

From all these 249 subjects punch biopsies were taken from apparently normal skin on the lower leg. Sections from these biopsies were prepared and stained by van Gieson's stain and by the PAS procedure. Other sections were studied by means of the fluorescent antibody technique. The performance of this method is described. The primary objective was to identify, with this technique, the possible localization of various plasma proteins in the walls of small dermal vessels.

The results of the PAS treatment and the immunofluorescent stainings were recorded according to a semiquantitative grading. The statistical methods used in the further estimation of the results are described.

# CHAPTER IV

## SOURCES OF ERROR

### *Possible sources of error in the technical performance*

The same region of the lower leg was chosen throughout the whole investigation for the skin biopsies in order to exclude regional variations

Some idea of the magnitude of this source of error was given by a pilot study of eight patients with diabetes. One skin biopsy was taken from the lower leg and another from the shoulder region. Sections from both the biopsies were treated in an identical fashion and simultaneously stained by the PAS procedure and with the indirect method of identifying  $\gamma$ G globulin (cf Table 9). In four patients the PAS stained vessel walls were judged as one grade thinner in the skin from the shoulder region than in that from the leg. A similar one grade difference was noticed in two patients in immunofluorescence stained sections. These differences are rather subtle and barely within the limits of the subjective estimation methods used.

Similarly, in a few patients a comparison was made between biopsies obtained after local anesthesia with Xylocain<sup>®</sup> and with ethyl chloride. No differences in the staining reactions were noted.

In 12 patients a comparison was

made between skin biopsies which were quick frozen and cut on a cryostat microtome washed in buffered saline pH 7.2, and finally treated for 10 minutes with 95% ethanol prior to the immunofluorescence staining and skin biopsies treated as described before according to the modified Sainte Marie method, Table 10. When the first method was used, the fluorescence indicating the presence of  $\gamma$ G globulin in the vessel walls was weaker (1-2 grades) in eight patients. The difference was statistically significant (the sign test).

TABLE 9 Comparison between the staining reactions (PAS staining and immunofluorescent  $\gamma$ G globulin staining) in small vessels in skin biopsies taken from the shoulder region and the lower leg in patients with diabetes mellitus

Patient No	PAS staining		$\gamma$ G globulin staining	
	Shoulder	Leg	Shoulder	Leg
4	4	4	4	4
23	3	3	4	4
169	1	2	2	3
170	1	2	2	3
171	1	2	1	1
173	2	2	3	3
184	3	3	4	4
185	2	3	2	2

This may be explained partially by the greater difficulty in cutting thin



sections from frozen tissues, and the histological details in these sections were indistinct (*cf* Sainte Marie, 1962, Tarrant & Shedden, 1965). Furthermore, in quick frozen unfixed sections most soluble proteins may be washed away prior to the immunofluorescence staining. The staining then in the main demonstrated «bound» proteins.

In this study cold ethanol was used as a fixing fluid. In most histological work this is not an ideal substance to choose. It slowly penetrates the tissues giving them a tendency to shrink and harden and this may cause artifacts. However, the histological similarities of the immunofluorescence stainings in alcohol fixed and in quick frozen blocks seem to indicate that such artifacts did not seriously affect the results. Alcohol is also said to be a useful fixative for preserving many proteins (Lillie, 1965), and it has been used earlier in immunohistochemical studies similar to those reported here (Mellors, 1959, Naim, 1962, Brandzaeg *et al* 1965, 1967).

#### *Errors in the semiquantitative grading*

The biopsy specimens were numbered in chronological order irrespective of diagnosis. Generally two to four weeks elapsed between the time of biopsy and the study of the slides under the fluorescence microscope, and another four to eight weeks before the PAS studies were made. By timing the microscopic examinations thus an attempt was made to prevent knowledge of the diagnosis and the results of the earlier stainings influencing the interpretation of

**TABLE 10** *Direct immunofluorescence staining with goat anti human globulin serum. The results of a comparative study between quick frozen washed skin sections and sections treated according to the modified Sainte Marie method*

No	Immunofluorescence in small vessels (Grade 1-4)	
	Frozen sections (cryostat microtome technique)	Paraffin embedded sections (Sainte-Marie method)
1	2	4
2	1	3
3	2	3
4	2	3
5	3	3
6	1	1
7	1	3
8	1	1
9	1	3
10	1	2
11	2	2
12	2	3

the results. Nevertheless, the microscopic studies must be considered «open» studies, prejudiced by the investigator's knowledge of the source of the material and his desire to achieve some definite result from the study. It therefore seemed important to try to observe if there were any differences between «open» and «blind» assessments of the staining reactions.

#### **A. THE ASSESSMENT OF THE WALL THICKNESS**

«Blind» assessments of 23 slides with PAS treated sections were made, independently of each other, by three

pathologists<sup>1</sup> The changes observed in small blood vessels were graded from 1—5 in a scale previously adopted in similar studies by Angervall and co-workers (cf Sävje-Söderbergh *et al*, 1967) The present author made an independent »open» assessment of the same sections using the same scale The results are given in Table 11

A two-way analysis of variance was made for testing if there were any differences in the expected mean values of the four independent investigators A significant difference was obtained  $F = 4.6$  ( $F_{(3,66)} = 2.8$ )

As can be seen from the Table however, there was never a difference of more than one grade between the assessments of the individual sections by the four observers The results seem to indicate that the present author's assessment of the staining reactions was not seriously prejudiced by his knowledge of the source of the material studied As pointed out earlier, a one grade difference in the assessments is a subtle one and barely within the limits of discrimination of this subjective estimation method The processing of the specimens according to Sainte-Marie (1962) did not give ideal conditions for performing the PAS procedure This fact may also be responsible for the individual variations noted As pointed out in Chapter III a four grade semi-quantitative scale was chosen in the final assessment of the wall thickness in this study

TABLE 11 The grading of 23 PAS-stained sections from skin lesions by four independent investigators A—D The source of the material was known to A, open study, but unknown to the others, »blind» study

Slide No	PAS-stained		Grading 1—5		
	Open		Stained		
	A	B	C	D	
1	4	3	4		4
2	1	1	2		1
3	1	2	2		2
4	2	2	2		2
5	1	2	2		1
6	4	5	4		4
7	2	3	3		3
8	5	5	5		5
9	3	2	3		2
10	1	1	1		1
11	1	2	1		1
12	1	2	1		1
13	3	3	3		3
14	3	3	3		3
15	3	3	3		3
16	3	4	3		3
17	2	2	3		2
18	2	2	3		2
19	3	2	3		2
20	2	2	2		2
21	4	3	4		4
22	3	3	3		2
23	3	4	4		3
Total	57	61	65		56

Lastly the results of this »open» and »blind» study confirm the previous observations by Angervall *et al* (1965) that pathologists (and clinicians) with experience of studying histological changes in skin sections only differ slightly in their estimation of the thickness of small vessel walls in PAS-treated light microscopic slides when a semi-quantitative grading is used

<sup>1</sup> Drs. L. Angervall and J. Sävje-Söderbergh, Institute of Pathology Göteborg and Dr. S. Falkmer, Institute of Pathology Umeå

# B THE ASSESSMENT OF THE IMMUNOFLOUORESCENT STAINING

Newly cut sections were prepared from all skin biopsies in the diabetes mellitus series A and from the series of matched non diabetic subjects. The slides were codified and stained in the following manner

A Direct immunofluorescent staining, Conjugated goat antihuman globulin serum (serum No 19, Table 8) was used

II Indirect immunofluorescent staining  
First layer Rabbit-antihuman  $\gamma$ G globulin serum (serum No 13, Table 8)  
Second layer Conjugated goat anti-rabbit globulin serum (serum No 20, Table 8)

The specific fluorescence in small dermal blood vessel walls was graded as described above. (Grades 1-4)

A «blind» study of the slides was made, and the results then compared

TABLE 12 Matched non diabetic subjects The results of the «open» and «blind» interpretations of the immunofluorescent demonstration of  $\gamma$ G globulin in small dermal vessel walls

Interpretation	Immunofluorescence method	Group No	Fluorescence Grade			
			1	2	3	4
Open	Direct	I	32	14	4	0
Open	Indirect	II	35	15	0	0
Blind	Direct	III	32	8	7	3
Blind	Indirect	IV	32	14	3	1
Groups compared		Chi square value		(t 0.025 = $\pm$ 20)		
I and III		2.4 (78)		< 1.0		
II and IV		3.9 (60)		1.7		
I and II		1.2 (38)		1.7		
III and IV		4.2 (78)		1.0		

TABLE 13 Diabetes mellitus series A The results of the «open» and «blind» interpretation of the immunofluorescent demonstration of  $\gamma$ G globulin in small dermal blood vessels

Interpretation	Immunofluorescence method	Group No	Fluorescence (Grade)			
			1	2	3	4
Open	Direct	I	11	17	17	5
Open	Indirect	II	13	16	11	10
Blind	Direct	III	12	15	19	4
Blind	Indirect	IV	15	15	11	9
Groups compared		Chi square value ( $\chi^2_{0.05} = 7.8$ )		t value (t 0.025 = $\pm$ 20)		
I and III		0.4		< 1.0		
II and IV		0.2		1.0		
I and II		3.1		0		
III and IV		4.4		0.4		

TABLE 14 Diabetes mellitus series A and the series of non-diabetic subjects. Results of the open and blind interpretation of the direct and indirect immunofluorescent staining to demonstrate localized  $\gamma$ -globulin in small bowel vessels in individual subjects. The results of the PAS-staining are also given.

Diabetes mellitus series A					The series of non-diabetic subjects							
Immunofluorescence					Immunofluorescence							
Grade 1-4					Grade 1-4							
Pat No	Pat No	Open Dir	Open Indi	Blind Dir	Blind Indi	PAS Grade 1-4	Pat No	Open Dir	Open Indi	Blind Dir	Blind Indi	PAS Grade
1	4	4	4	3	4	4	133	1	1	1		
2	5	2	2	4	3	3	225	1	1			
3	15	3	3	2	3	3	223	1	1			1
4	25	4	3	3	4	4	14	1	1	1		
5	34	3	4	4	2	2	225	1	1			
6	56	3	4	1	1	3	157	1	1	1		
7	64	4	4	3	4	2	220	2	2			
8	66	4	3	2	3	3	157	1	1	1		1
9	67	1	2	1	2	3	152	1	1	1		
10	80	3	3	2	1	3	15	2	1	1	1	2
11	89	3	4	3	4	3	153	3	2	1		
12	113	2	2	2	2	3	19	1	1	1	2	1
13	126	2	3	4	4	4	151	1	1	1	1	
14	128	4	4	2	1	1	137	1	1	1	2	1
15	130	3	4	2	4	3	129	2	2	2	2	1
16	131	2	3	2	2	3	134	1	2	1		2
17	137	2	3	3	4	4	141	2	2	1	2	
18	138	3	3	3	4	4	154	3	1	1	1	1
19	142	3	4	3	3	3	145	1	1	1	1	1
20	143	2	1	3	3	1	144	1	1	1	2	1
21	145	1	1	1	3	1	190	1	2	1	1	2
22	147	1	3	3	2	3	141	1	2		2	1
23	161	1	1	2	3	2	163	2	1	3	3	1
24	167	2	1	1	1	2	163	1	1	1	1	2
25	164	2	2	2	2	2	165	2	1	1	1	1
26	165	2	1	1	1	2	157	2	2	3	1	2
27	172	3	4	4	2	1	174	1	1	2	1	2
28	175	3	2	2	2	2	160	2	2	2	3	1
29	176	3	3	3	1	1	179	1	1	1	1	2
30	177	2	2	3	1	2	172	1	2	1	1	2
31	181	2	2	3	4	2	193	1	1	2	2	1
32	197	1	1	2	2	2	193	1	1	2	2	1
33	184	3	4	2	3	3	190	1	1	2	1	1
34	185	2	2	2	2	3	158	2	2	4	4	2
35	187	1	1	1	1	1	214	1	1	4	1	2
36	189	2	2	3	3	3	197	1	1	4	1	1
37	194	2	2	3	1	2	166	2	1	2	1	2
38	196	1	2	1	2	3	193	1	1	3	3	1
39	197	3	2	3	2	2	216	3	2	2	1	3
40	204	3	1	3	1	2	191	2	1	3	1	2
41	209	1	1	1	3	2	217	1	1	1	1	2
42	210	3	1	3	1	1	224	3	1	3	2	3
43	211	1	1	1	2	2	219	1	1	1	1	2
44	212	2	2	1	2	2	220	1	1	1	1	1
45	213	2	1	3	1	2	215	2	2	1	1	1
46	221	1	1	1	3	1	228	1	1	1	2	2
47	227	3	2	1	1	1	233	1	1	1	1	1
48	230	3	3	2	2	2	237	1	1	1	1	1
49	236	2	2	3	1	3	23	2	2	3	1	3
50	239	1	1	1	1	2	242	2	2	3	2	2

Dir = Direct staining Indi = Indirect staining

with the results of the earlier »open» study of identically stained slides from the same biopsy specimens. As can be seen from Tables 12 and 13, no significant differences were found between the »open» and »blind» interpretations of the staining reactions in the two series. Therefore, it seems probable that the »open» interpretation of the immunofluorescent stainings in the two series was not seriously prejudiced by the author's knowledge of the source of the material under investigation.

The results for the individual subjects in the study are listed in Table 14.

A comparison was also made between the conclusions obtained by »open» and »blind» interpretations of the direct and indirect stainings in the two series. No significant differences were found. Although the antiserum used in the direct staining gave weak cross reactions with globulins in the  $\alpha$ - and  $\beta$ -groups when tested with immunoelectrophoresis (Table 8), it seems probable that the fluorescence mainly indicated localized  $\gamma$ G-globulin in tissue sections.

As stated previously, the patients with diabetes mellitus were divided into

TABLE 15 Patients with diabetes mellitus. Comparison between the results of the PAS stainings and the indirect staining of  $\gamma$ G globulin in series A and B. The immunofluorescence staining is also compared in the two series in sub groups with different duration of the disease.

Series of subjects studied	Group No	PAS-staining (Grade)			
		1	2	3	4
Series A	I	9	19	17	5
B	II	19	30	17	5
$\gamma$ G globulin staining (Grade)					
A	III	13	16	11	10
II	IV	26	19	21	5
A (Duration 0—5 years)	V	7	5	II	0
II " " "	VI	17	4	8	1
A (Duration 5—10 years)	VII	4	5	2	3
B " " "	VIII	4	II	0	2
A (Duration 10—15 years)	IX	2	2	4	4
B " " "	X	3	3	6	0
A (Duration 15— years)	XI	0	4	5	3
B " " "	XII	2	3	7	2
Series compared	Chi-square value				
I and II	2.8 (78)				
III and IV	5.9 (78)				
V and VI	0.1 (38)				
VII and VIII	0.1 (38)				
IX and X	0.7 (38)				
XI and XII	0.1 (38)				

two series, A and B, cf Chapter III. A comparison was made between the PAS stainings in the two series, and between the «open» interpretation of the indirect  $\gamma$ G globulin stainings in series A and B. No significant differences were obtained. The two series were also divided into four sub groups according to the duration of the disease, and the  $\gamma$ G globulin stainings of the two series in each sub group were compared. No significant differences were obtained.

The results are listed in Table 15.

### Summary

Some possible errors in the technical performance of the staining procedures and the assessment of the results of the stainings were investigated.

Significant differences were found between the results of the immuno fluorescent staining of sections prepared

according to the cryostat microtome technique and according to the Saito-Marie method. Specific fluorescence was seen more often when the latter method was used. No significant difference was found when the two reactions in sections from the lower leg were compared with those from the subcutaneous region.

When PAS treated sections were assessed by four different investigators independent of each other some differences in the results were obtained. The assessment of individual sections, however, differed only at the most one grade, when a five graded scale was used.

An «open» assessment of immuno fluorescence stained sections was compared with a «blind» one. There were no significant differences between the results of the two assessments, neither in the series of diabetic patients, nor in the series of non diabetic subjects.

## CHAPTER V

### THE RESULTS OF THE IMUNOFLUORESCENT LOCALIZATION OF VARIOUS PLASMA PROTEINS IN THE SKIN, APART FROM THE SMALL VESSELS

In the present investigation the distribution of various plasma proteins in different anatomical sites in the skin was studied both in healthy subjects and in patients with diabetes. Some patients with other diseases were also studied. The observations in small vessel walls will be dealt with in more detail in Chapters VII and VIII.

#### *Healthy Subjects*

The results are summarized in Table 16.

#### 1 ALBUMIN

49 subjects. A sometimes bright fluorescence was unevenly distributed within the superficial layers of the dermis. It seemed to be localized around connective tissue fibres. Sometimes a more flocculent distribution was noted. Areas with bright fluorescence could be seen peripherally around groups of small vessels. Not infrequently, a condensation of fluorescence — sometimes as a band — was observed immediately below the epidermis.

#### 2 $\alpha_1$ ACID GLYCOPROTEIN

In most of the 21 subjects studied, no fluorescence was observed. In six subjects a rather weak fluorescence was

noted in the cytoplasm of small groups of cells within, or close to, the walls of small superficial vessels.

#### 3 $\alpha_2$ LIPOPROTEIN

31 subjects. The distribution of specific fluorescence paralleled that observed for albumin, but it was in general weak. Sometimes no fluorescence was observed, or only traces of it. In larger vessels a very delicate, fluorescent net-work was often seen around the endothelial cells. Traces of fluorescence could be seen sometimes in the deeper layers of the walls in these vessels.

#### 4 HAPTOGLOBIN

20 subjects. No fluorescence was observed except occasionally as traces immediately below the epidermis or coating the endothelial cells in blood vessels.

#### 5 TRANSFERRIN

13 subjects. The extravascular distribution was very similar to that of albumin, but the fluorescence was weak.

#### 6 $\beta$ LIPOPROTEIN

19 subjects. No fluorescence was noted outside the blood vessels. A thin fluorescent rim could be seen coating the endothelial lining in blood vessels.

TABLE 16 Healthy subjects Distribution of various plasma proteins in different dermal structures fluorescent antibody technique

	Albumin	α <sub>1</sub> acid glycoprotein	α <sub>2</sub> lipoprotein	Haptoglobulin	Transferrin	β <sub>2</sub> lipoprotein	β <sub>2</sub> globulin	Fibrinogen	γC globulin	γA globulin	γM globulin
<b>Epidermis</b>											
Dermal epidermal junction	+	+	+	+	+	+	+	+	+	+	+
Superficial	+	+	+	+	+	+	+	+	+	+	+
Deep layer	+	+	+	+	+	+	+	+	+	+	+
Glands & Muscles	+	+	+	+	+	+	+	+	+	+	+
Clanular basement membrane	+	+	+	+	+	+	+	+	+	+	+
Plasma cells	+	+	+	+	+	+	+	+	+	+	+
<b>Small blood vessels</b>											
Endothelium	+	+	+	+	+	+	+	+	+	+	+
Vessel wall	+	+	+	+	+	+	+	+	+	+	+
Perivascular cells	+	+	+	+	+	+	+	+	+	+	+
<b>Arteries</b>											
Intima	+	+	+	+	+	+	+	+	+	+	+
Elastic membrane	+	+	+	+	+	+	+	+	+	+	+
<b>Veins</b>											
Media	+	+	+	+	+	+	+	+	+	+	+
Intima	+	+	+	+	+	+	+	+	+	+	+
Media	+	+	+	+	+	+	+	+	+	+	+
<b>Notes</b>											
1 - No fluorescence											
2 - Traces of fluorescence											
3 - Weak fluorescence											
4 - Distinct fluorescence											
5 - Bright fluorescence											
6 - Intense fluorescence											



## 7 $\beta_2$ C GLOBULIN

44 subjects In some specimens traces of fluorescence were observed lining endothelial cells and in the area of the dermal-epidermal junction

## 8 FIBRINOGEN

46 subjects No fluorescence was seen outside blood vessels A network of delicate fluorescence could be found around endothelial cells in larger vessels

## 9 $\gamma$ G GLOBULIN

50 subjects In a few specimens almost no fluorescence was observed in the dermis In most investigated biopsies an unevenly distributed fluorescence was noticed in the dermal connective tissue The distribution was similar to that observed when albumin was studied In general, however, the fluorescence was weak Often, it was only observed immediately below the epidermis as a condensation band quickly fading into deeper layers Small areas with specific fluorescence might be surrounded by zones without any fluorescence A weak fluorescence could be observed in the basement membranes of dermal glands An exceptional finding was some cells with fluorescent cytoplasm probably representing plasma cells

## 10 $\gamma$ A GLOBULIN

In most of the 39 subjects studied no fluorescence was present in the superficial layers of the dermis, or only traces of it Quite often the dermal-epidermal junction fluoresced within restricted areas as a very narrow, well defined band

## 11 $\gamma$ M GLOBULIN

44 subjects Only in exceptional cases was a rather dull fluorescence noticed in the superficial layers of the dermis

### *Patients with diabetes mellitus*

With a few exceptions no essential differences were observed in the distribution and intensity of the fluorescence indicating the presence of the various plasma proteins in healthy subjects and in apparently normal skin from patients with diabetes

It was the author's impression that the fluorescence indicating  $\gamma$ G globulin was more often observed in the dermal-epidermal junction in diabetic than in healthy subjects Similarly, it was often typical of diabetes mellitus that the basement membrane around sweat glands fluoresced distinctly This basement membrane also seemed abnormally thick More often than in healthy subjects clusters of fluorescent plasma cells was noted around small vessels

### *Other patients*

Especially intense fluorescence indicating the presence of albumin could be seen in a few skin sections from oedematous patients

Plasma cells were rather frequently noticed, sometimes abundantly, in patients with rheumatoid diseases and systemic lupus erythematosus Only in two patients with the latter disease were observations made of intranuclear fluorescence indicating  $\gamma$ G globulin in the epidermis (This was also the case with one patient with long term dia

betes) A narrow line of heavy fluorescence was often seen in the dermal epidermal junction in skin taken from patients with systemic lupus erythematosus and a few patients with rheumatoid arthritis The boundaries between this observation and the findings in healthy subjects were indistinct It was the author's impression that the fluorescence indicating the various immunoglobulins was brighter and more often generally distributed in the dermal connective tissue from patients with rheumatoid diseases

The distribution of some of the plasmaproteins in the skin is given in Plates IV—VI

### Summary

There were no distinct histological differences in the distribution of the various plasma proteins studied in skin

from healthy subjects, from patients with diabetes and from patients with some other diseases The often disseminated distribution of specific fluorescence in the connective tissue in individual skins made any quantitative assessment of the fluorescence difficult Fluorescence indicating the presence of some proteins was a constant finding in the structural layers of the dermis, whilst fluorescence indicating the presence of  $\alpha$  and  $\beta$  chains was an exceptional observation (see Table 16)

The observations reported here on the distribution of albumin,  $\beta_2$  globulin, fibrinogen and the various  $\gamma$  globulins in human skin are in the main identical with those reported by other authors earlier (Chapter II) Minor differences might be due to differences in the technical performance of the immunofluorescent staining (cf Chapter IV)

## THE RESULT OF THE PAS STAINING OF SMALL DERMAL VESSEL WALLS

*Morphology*

The histological appearance of the small blood vessels in PAS treated sections did not deviate from the picture which other authors have given previously. A survey of these findings is given in Chapter II. Suffice it to say that the study concentrated on the variations in thickness of the vessel walls. Any possible changes in the endothelial cells were not impressive and the pericytes were not studied in any detail. Plate I illustrates the various grades of PAS staining.

*Matched non diabetic subjects*

In the series of matched non diabetic subjects it was not possible to show any significant differences in the PAS

staining between individuals below the age of 40 and those who were 40 years old or more (Nor was any significant difference found, when subjects below the age of 30 were compared with those above the age of 50). When males and females were compared no significant differences were observed (Table 17).

The possible influence of the blood pressure on the PAS staining was studied. Table 18 gives the mean systolic and diastolic blood pressure in the various groups of PAS staining. The expected means were compared by the aid of a one way analysis of variance. No significant differences between the expected mean pressures were observed [Systolic pressure  $F = 0.7$ , diastolic pressure  $F = 0.6$  ( $F_{2,47} = 3.2$ )].

TABLE 17 *Matched non diabetic subjects. The results of the PAS staining in subjects < 40 years and  $\geq 40$  years of age and in males and females*

Series of subjects studied	PAS staining (Grade)				Total No. series	Chi square value ( $\chi^2 = 6.0$ )	t value ( $t_{0.025} = \pm 2$ )
	1	2	3	4			
< 40 years	18	10	1	0	29	2.0	1.5
$\geq 40$ years	9	10	2	0	21		
Males	13	12	2	0	27	0.7	1.2
Females	14	8	1	0	23		
Total No./Grade	27	20	3	0	50		

TABLE 18 Matched non diabetic subjects Systolic and diastolic blood pressure in different groups of PAS staining

PAS staining (Grade)	Total No/Grade	Mean systolic pressure $\pm$ s.e. x	Mean diastolic pressure $\pm$ s.e. x
1	27	141 $\pm$ 6	87 $\pm$ 2
2	20	139 $\pm$ 6	86 $\pm$ 2
3	3	155 $\pm$ 19	93 $\pm$ 2
4	0	—	—
Total No	50		

### Patients with diabetes mellitus

The possible influence of some factors of the diabetic disease on the wall thickness of small dermal vessels was studied. The results are listed in Table 19. They may be summarized as follows:

Thickened vessel walls were more frequently found in diabetic patients than in apparently healthy non diabetic subjects (Test 1 and 2).

In the non diabetic series eight subjects knew of diabetes among close relatives. This group however, did not significantly deviate from the group of subjects without any known occurrence of diabetes among relatives (Test 3).

The diabetic patients were divided into four sub groups according to the known duration of the disease. Significant differences in wall thickness between the various groups were observed (Test 4). The wall thickness increased with the mean duration of the disease (Figure 1).

Patients with a known duration of less than five years did not deviate significantly in wall thickness from non diabetic subjects (Test 5) whilst in patients with a duration of less than 10

years the difference was significant (Test 6).

When diabetics with a duration of less than 10 years were divided into two groups according to the onset of the disease after the age of 40 years, no difference between the two groups was observed. In patients with a known duration of disease below the grade 3 or 4 thickening of the positive vessel wall was first after eight years. In diabetics with a known duration of 40 or more years, the thickening was noted already within 2 years. Thus the age of onset of the disease was of some importance in the results. In the group with a known onset at the age of 40 years a comparison was made between patients with a known duration of five years and those with a duration of five years or more. No difference was obtained. The influence of the duration of thickening of the vessel wall was difficult to show in the group of onset diabetes.

TABLE 19 The results of the PAS staining of small dermal blood vessels in patients with diabetes mellitus. The results were compared with those for the matched non diabetic series. The influence of known familial occurrence of diabetes was studied in the non diabetic series. In the diabetic series the influence of the known duration of the disease, the age at the onset of the disease and the influence of insulin treatment were studied.

Series of subjects studied	Group No	PAS staining (Grade)				Total No
		1	2	3	4	
Matched non diabetic subjects	I	27	30	3	0	50
Known familial occurrence of diabetes	II	4	3	1	0	8
Familial occurrence not known	III	23	17	2	0	42
Diabetes mellitus Series A	IV	9	19	17	5	50
Diabetes mellitus Series B	V	19	30	17	5	71
Diabetes mellitus Series A + B	VI	28	49	34	10	121
Duration 0-5 years	VII	14	21	6	1	42
Duration 5-10 years	VIII	8	14	7	1	29
Duration 10-15 years	IX	4	7	11	2	24
Duration 15+ years	X	2	7	11	7	26
Onset < 40 years duration < 10 years	XI	10	15	4	1	30
Onset ≥ 40 years duration < 10 years	XII	12	20	8	1	41
Insulin treatment diabetes < 5 years	XIII	5	7	3	0	15
No insulin treatment diabetes < 5 years	XIV	9	14	3	1	27

Test No	Groups compared	Chi square value	t value	Sign test value
1	I and IV	23.8 (7.8)		30 (25)
2	I and VI	22.6 (7.8)	7.0 (20)	
3	II and III		0.7 (20)	
4	VII VIII IX and X	22.4 (12.6)		
5	I and VII	5.1 (6.0)		
6	I and VII+VIII	8.3 (6.0)		
7	XI and XII	0.3 (6.0)		
8	XIII and XIV	0 (3.8)		

FIGURE 1 Patients with diabetes mellitus. The results of the PAS staining of small dermal blood vessels are plotted against the known duration of the disease (logarithm scale). The mean duration and the confidence limits of the mean in each grade of PAS staining are shown. The values are:

PAS staining (Grade)	No	Mean duration (Years)	95 % confidence limits (Years)
1	28	5.8 ± 1.0	3.8 - 7.8
2	49	7.8 ± 1.1	5.6 - 10.0
3	34	13.0 ± 1.4	10.2 - 15.8
4	10	18.0 ± 3.1	11.1 - 24.9



The possible influence of insulin treatment on the development of the PAS positive changes in small vessel walls was studied in diabetics with a known duration of less than five years. There was no significant difference when this group was compared with a similar group of diabetics who had not received insulin treatment (Test 8)

#### *Patients with other diseases than diabetes mellitus*

The wall thickness of small dermal vessels was studied in 77 hospitalized patients with diseases other than diabetes. The results are listed in Table 20. In some groups the number of patients investigated was small. The results must therefore be judged with great caution.

Only in the series of patients with systemic lupus erythematosus or SLE like syndromes and in patients with rheumatoid arthritis was a significant

difference obtained when the groups were compared with the series of matched non diabetic subjects. In the statistical treatment of the results, grades 2—4 were combined because of the smallness of the series.

#### *Summary*

In a series of apparently healthy subjects a slight thickening of the PAS positive vessel walls was seen in 40 % and markedly thickened walls were noted in 6 % of the investigated skin biopsies. In a contrasting series of diabetic patients a slight thickening was seen in 38 % and a marked or heavy thickening in 44 % of the studied biopsies. The difference was statistically significant.

There was no positive influence of age, sex or blood pressure on the wall thickness of the vessels.

FIGURE 2 Patients with diabetes mellitus divided into three groups according to the known age at the onset of the disease. The results of the PAS staining of small dermal vessels are plotted against the known duration of the disease (logarithm scale). The mean duration and the confidence limits of the mean in each grade of PAS staining are shown. The values are

#### *Known onset below the age of 20*

PAS staining (Grade)	No	Mean duration (Years)	95 % confidence limits (Years)
1	9	8 $\pm$ 2.0	3.4 — 12.6
2	13	13.2 $\pm$ 2.6	7.4 — 18.6
3 + 4	20	18 $\pm$ 1.8	14.2 — 21.8

#### *Known onset at the age of 40 or more*

PAS-staining (Grade)	No	Mean duration (Years)	95 % confidence limits (Years)
1	14	4.2 $\pm$ 1	2.0 — 6.4
2	24	4.3 $\pm$ 0.9	2.4 — 6.2
3 + 4	15	9 $\pm$ 1.9	5 — 13





TABLE 20 *The results of the PAS staining of small dermal blood vessels in patients with diseases other than diabetes mellitus. The results were compared with those of the matched non-diabetic series. The various diagnoses in the group «Other diseases» are listed in Table 6*

Group of patients studied	PAS staining (Grade)				Total No./Group	Chi square value ( $\chi^2 = 3.8$ )
	1	2	3	4		
Glomerulonephritis	4	3	2	0	9	0.3
SLE syndrome	3	10	2	0	15	5.4
Rheumatoid disease	2	5	4	0	11	4.6
Hypertension (Mean 221/123)	6	2	0	1	9	0.5
Other diseases	21	11	1	0	33	0.8
Matched non-diabetics	27	20	3	0	50	

In the diabetic series it was noted that the width of the PAS-positive vessel walls increased with the duration of the disease. This was a statistically significant finding in juvenile diabetics with a known onset below the age of 20. In patients with a known onset at age of 40 or more there was no statistically significant difference between patients with a known duration less

than five years and those with a duration of five years or more.

It was not possible to show any influence of known diabetic heredity or of insulin treatment on the vascular changes.

In two groups of patients with SLE and rheumatoid arthritis the vessel walls were significantly thicker than in apparently healthy subjects.

# THE RESULTS OF THE IMMUNOFLOUORESCENT LOCALIZATION OF $\gamma$ G GLOBULIN IN SMALL DERMAL BLOOD VESSELS

## Morphology

The specific fluorescence indicating localized  $\gamma$ G globulin in the small dermal blood vessels was seen in the region of the basement membrane outside the non fluorescent endothelial cells. Sometimes it was seen as a single delicate band, sometimes this was split up into two or more fluorescent layers. In some cases the whole periendothelial wall fluoresced homogenously and sometimes only part of the vascular circumference fluoresced. As a rule both groups of non fluorescent vessels and vessels with various grades of fluorescence were seen in the same sections. The intensity of the specific fluorescence varied significantly in various groups of investigated subjects. Unless otherwise stated only the results of

the indirect immunofluorescent staining are discussed. The morphological picture of direct and indirect fluorescent antibody staining were practically identical.

## Matched non-diabetic subjects

The  $\gamma$ G globulin staining was analyzed in the same way as the results of the PAS treatment (cf Chapter VI).

The results are listed in Tables 21 and 22. As can be seen, no significant differences were obtained between subjects below the age of 40, and those who were 40 or more. (Nor was any significant difference found when subjects below the age of 30 were compared with those above the age of 50). There was no significant difference in reaction between males and females.

TABLE 21 Matched non diabetic subjects. The results of the  $\gamma$ G globulin staining in subjects < 40 years and  $\geq$  40 years of age and in males and females

Subjects studied	$\gamma$ G globulin staining (Grade)				Total No./series	Chi-square value (x = 3.8)	t value (p 0.025 = $\pm$ 2)
	1	2	3	4			
< 40 years	22	7	0	0	29		
$\geq$ 40 years	13	8	0	0	21		
Males	19	8	0	0	27	1.1	0.6
Females	10	7	0	0	23	0.2	0
Total No./Grade	35	15	0	0	50		

The mean systolic and diastolic blood pressures were practically identical in the groups of grade 1 and grade 2 immunofluorescent staining

### *Patients with diabetes mellitus*

The possible influence of various factors of the diabetic disease on the localization of  $\gamma$ G globulin in small dermal vessel walls was studied and the results were treated in the same way as has been described above for the PAS-staining. The results are listed in Table 23

$\gamma$ G globulin was found more often localized in the small vessel walls in the series of diabetic patients than in the series of matched non diabetic subjects. In diabetics the specific fluorescence was frequently strong. These differences were statistically significant (Test 1 and 2)

It was not possible to show any difference between non diabetic subjects who knew of diabetes among close relatives and those who did not know of such an occurrence. The former group was small however (Test 3)

Significant differences were noted in the localization of  $\gamma$ G globulin in diabetics with varying duration of the disease (Test 4). Positive — and often strong — specific fluorescence was the rule among patients with a known duration of 10 years or more. Diabetics with a known duration of one year or less did not deviate significantly from non diabetic subjects ( $\chi^2 = 1.2$  (38)). However, the difference was significant between the latter group and patients with a duration of less than five years

(Test 5) or more. In Figure 3 the results of the  $\gamma$ G globulin staining are plotted against the known duration of the disease. As can be seen the intensity of the specific fluorescence increased with the mean duration of the disease.

When the patients with a known duration of less than 10 years were divided into two groups according to the onset of the disease — before or after the age of 40 — and the groups were compared, no significant difference was obtained (Test 7). As for the results of the PAS staining some influence of the age at the onset on the localization of  $\gamma$ G globulin was noted, Figure 4. In the group of diabetics with an onset below the age of 20 strong specific fluorescence was first noted after seven years duration whilst in the group with a known onset at the age of 40 or more strong fluorescence was noted within one years duration. In this latter group the influence of the duration on the localization of  $\gamma$ G globulin in the vessel walls was not so evident; no significant difference was obtained when patients with a duration of less than five years were compared with those of five years duration or more [ $\chi^2 = 3.33$  (599)]. When patients who had been treated with insulin were compared with those who had not, no significant difference in the specific fluorescence in the vessel walls was seen (Test 8).

TABLE 22 Matched non diabetic subjects Systolic and diastolic blood pressure in the different groups of  $\gamma$ G globulin staining

$\gamma$ G globulin staining (Grade)	Total No/Grade	Mean systolic pressure $\pm$ s.e. $\bar{x}$	Mean diastolic pressure $\pm$ s.e. $\bar{x}$
1	35	143 $\pm$ 5	89 $\pm$ 2
2	15	143 $\pm$ 6	86 $\pm$ 2
3 + 4	0	—	—
Total No	50		

TABLE 23 The results of the staining of  $\gamma$ G globulin in small dermal vessel walls in patients with diabetes The results were compared with those for the matched non diabetic subjects The influence of known familial occurrence of diabetes was studied in the non diabetic series In the diabetic series the influence of the known duration of the disease the age when the disease became evident and the influence of insulin treatment were studied

Series of subjects studied	Group No	$\gamma$ G globulin (Grade)				Total No
		1	2	3	4	
Matched non-diabetic subjects	I	35	15	0	0	50
Known familial occurrence of diabetes	II	6	2	0	0	8
Familial occurrence not known	III	29	13	0	0	42
Diabetes mellitus Series A	IV	13	16	11	10	50
Diabetes mellitus Series B	V	26	19	21	5	71
Diabetes mellitus Series A + B	VI	39	35	32	15	121
Duration 0—5 years	VII	24	9	8	1	42
Duration 5—10 years	VIII	8	14	2	5	29
Duration 10—15 years	IX	5	5	10	4	24
Duration 15— years	X	2	7	12	5	26
Onset < 40 years duration < 10 years	XI	12	9	5	4	30
Onset $\geq$ 40 years duration < 10 years	XII	17	14	8	2	41
Insulin treatment, diabetes < 5 years	XIII	10	3	2	0	15
No insulin treatment diabetes < 5 years	XIV	14	6	6	1	27

Test No	Groups compared	Chi square value	t value	Sign test value
1	I and IV	31.0 ( 7.8)		34 (27)
2	I and VI	32.2 ( 7.8)	8.0 (20)	
3	II and III		0.1 (20)	
4	VII VIII IX and X	35.8 (16.9)		
5	I and VII	11.9 ( 6.0)		
6	I and VII+VIII	—		
7	XI and XII	0.5 ( 6.0)		
8	XIII and XIV	0.9 ( 3.8)		

### *Patients with diseases other than diabetes mellitus*

The results are listed in Table 24. Significantly more positive fluorescence was observed in the small dermal vessel walls in patients with SLE and SLE-like syndromes than in non-diabetic, apparently healthy subjects. When this latter series was compared with other disease groups in this study, no significant differences were seen. As stated before, the small number of patients in many groups makes it necessary to judge the results with caution. In the statistical treatment the grades 2-4 were combined.

### *The ESR and the amount of circulating $\gamma$ -globulin in the various groups of immunofluorescent staining of $\gamma$ G globulin in small vessel walls*

The erythrocyte sedimentation rate (ESR) and the amount of circulating  $\gamma$  globulin (paper electrophoresis) were determined in most patients in the diabetes mellitus series A and in the matched non-diabetic subjects. One value for

ESR was lost in each of the two groups. Paper electrophoresis was not performed on 11 diabetics and on three non-diabetics. The values were grouped and compared according to the results of the fluorescent antibody staining. In the four diabetic groups a one-way analysis of variance was performed while the non-diabetic groups were compared by means of the *t* test. The mean values of the measurements obtained for the various groups are shown in Tables 25 and 26.

No significant differences were obtained.

### *Summary*

In a series of apparently healthy subjects weak fluorescence indicating localized  $\gamma$ G-globulin in small dermal vessel walls was found in 30 % of the skin biopsies studied. In a contrasting series of diabetic patients weak specific fluorescence was noted in 36 % and strong and bright fluorescence in 42 % of the biopsies. The difference was statistically significant.

FIGURE 3 Patients with diabetes mellitus. The results of the  $\gamma$ G globulin staining of small dermal vessel walls are plotted against the known duration of the disease (logarithm scale). The mean duration and the confidence limits of the mean in each grade of  $\gamma$ G globulin staining are shown. The values are:

$\gamma$ C globulin (Grade)	No.	Mean duration (Years)	95 % confidence limits (Years)
1	39	$5.1 \pm 0.8$	3.6 — 6.6
2	35	$9.5 \pm 1.4$	6.7 — 12.3
3	32	$13.1 \pm 1.5$	10.0 — 16.2
4	15	$14.3 \pm 2.3$	9.2 — 19.4

DURATION  
years

30-

20-

10-

5-

1-

$\gamma$ G-GLOBULIN  
grade

1

2

3

4




TABLE 24 The results of the immunofluorescence staining of  $\gamma$ G globulin in small dermal vessel walls in patients with diseases other than diabetes mellitus. The results were compared with those of the matched non diabetic series. The various diagnoses in the group "Other diseases" are listed in Table 6

Group of patients studied	$\gamma$ G globulin (Grade)				Total No/Group	Chi square value ( $\chi^2 = 3.8$ )
	1	2	3	4		
Glomerulonephritis	4	1	4	0	9	27
SLE syndrome	5	7	3	0	15	66
Rheumatoid disease	5	4	2	0	11	24
Hypertension (Mean 221/136)	6	1	2	0	9	01
Other diseases	24	11	2	1	33	01
Matched non diabetics	35	15	11	0	50	

No correlation was noted between the localization of  $\gamma$ G-globulin in small dermal vessel walls and the age, sex, blood pressure, the ESR reaction or the amount of circulating  $\gamma$  globulin, respectively, of the subjects studied. No difference was found between apparently healthy subjects with a known familial incidence of diabetes and subjects with out any knowledge of such an incidence

In the diabetic series the frequency and intensity of the specific fluorescence increased with the duration of the disease. However, in patients with a known onset of the disease at the age of 40 or more there was no significant difference when the subjects with a duration of less than five years were compared with those with a duration of five years or more. In the older

FIGURE 4 Patients with diabetes mellitus divided into three groups according to the known age at the onset of the disease. The results of the identification of  $\gamma$ G globulin in small dermal vessel walls are plotted and shown. The values are (logarithm scale). The mean duration and the confidence limits of the mean in each grade of specific fluorescence are shown. The values are

*Known onset below the age of 20*

$\gamma$ G globulin (Grade)	No	Mean duration (Years)	95 % confidence limits (Years)
1	10	7.4 $\pm$ 1.6	3.7 — 11.1
2	12	13.6 $\pm$ 2.4	8.3 — 18.9
3 + 4	20	18.4 $\pm$ 1.9	14.4 — 22.4

*Known onset at the age of 40 or more*

$\gamma$ G globulin (Grade)	No	Mean duration (Years)	95 % confidence limits (Years)
1	24	4.7 $\pm$ 0.9	2.8 — 6.6
2	15	4.7 $\pm$ 0.7	3.2 — 6.2
3 + 4	14	8.9 $\pm$ 2.1	4.4 — 13.4





TABLE 25 *The mean values of the erythrocyte sedimentation rate (ESR/hour) in the various grades of  $\gamma$ G globulin staining of small dermal vessel walls in patients with diabetes (Series A) and matched non diabetic subjects*

Group of subjects studied	$\gamma$ G globulin (Grade)	Total No/Grade	ESR mm (Mean)	t or F value
Diabetes mellitus (49 subjects)	1	13	13 $\pm$ 5	F = 0.9 (23)
	2	15	11 $\pm$ 2	
	3	11	14 $\pm$ 3	
	4	10	20 $\pm$ 6	
Matched non diabetics (49 subjects)	1	35	9 $\pm$ 1	t = 0.8 ( $\pm$ 20)
	2	14	12 $\pm$ 3	
	3 + 4	0	—	

TABLE 26 *The mean values of the amount of circulating gammaglobulin (paper electrophoresis) in the various grades of  $\gamma$ G globulin staining of small dermal vessel walls in patients with diabetes mellitus (Series A) and matched non diabetic subjects*

Group of subjects studied	$\gamma$ G globulin (Grade)	Total No/Grade	Gammaglobulin (Mean) g/100 ml	t or F value
Diabetes mellitus (39 subjects)	1	12	0.77 $\pm$ 0.05	F = 0.3 (23)
	2	14	0.82 $\pm$ 0.05	
	3	8	0.85 $\pm$ 0.10	
	4	7	0.81 $\pm$ 0.07	
Matched non diabetics (47 subjects)	1	34	0.86 $\pm$ 0.03	t = 0.2 ( $\pm$ 20)
	2	13	0.87 $\pm$ 0.05	
	3 + 4	0	—	

age groups strong specific fluorescence appeared earlier than in juvenile diabetics. Insulin treatment did not appear to have any influence on the localization of  $\gamma$ G globulin in small vessel walls.

In patients with SLE or SLE like syndromes a significant increase in the specific fluorescence was noted when this group was compared with a group of apparently healthy subjects.

# THE RESULTS OF THE IMMUNOFLOUORESCENT LOCALIZATION OF SOME PLASMA PROTEINS OTHER THAN $\gamma$ G GLOBULIN IN SMALL DERMAL VESSEL WALLS IN DIABETIC AND NON DIABETIC SUBJECTS

## Morphology

The plasma proteins studied are discussed in Chapters III and V. In most cases the morphological pattern of the specific fluorescence in small dermal vessel walls was very similar for all plasma proteins studied. The description of the fluorescence given in Chapter VII can be applied to all.

A few exceptions may be noted.

Albumin seemed to be localized more peripherally around the vessel walls as a fluorescent cuff. In such cases hardly any fluorescence was noted in the basement membrane region.

More often than for  $\gamma$ G globulin endothelial cells, or the luminal side of the cells fluoresced when albumin, transferrin, haptoglobin,  $\beta_{1c}$ -globulin and fibrinogen were studied.

Sometimes  $\alpha_1$  lipoprotein was seen stained as bright blobs or small crescents within the walls while the rest of the vessels were non fluorescent.

The fluorescence was graded from 1 to 4 as for  $\gamma$ G globulin.

## *Differences between apparently healthy subjects and patients with diabetes melitus*

The distributions of the various plasma proteins were studied in apparently

healthy, matched non diabetic subjects and compared with those obtained for diabetics, Table 27.

All plasma proteins studied, except albumin, were present in a higher percentage in the diabetic series. The difference was significant for transferrin,  $\beta_{1c}$ -globulin and  $\gamma$ M globulin (Grades 2—4 were combined when albumin, transferrin, fibrinogen,  $\gamma$ A- and  $\gamma$ M globulin were tested and Grades 3—4 when  $\alpha_1$  lipoprotein and  $\beta_{1c}$  globulin were tested. Because of the smallness of the groups,  $\alpha_1$  acid glycoprotein, haptoglobin and  $\beta$  lipoprotein were not tested statistically.) It must be emphasized that the number of subjects studied in some groups was too small to permit any test and to allow any conclusions to be drawn.

However, some observations may be pointed out.

1 With the method used most plasma proteins studied were observed in small dermal vessels in singular, apparently healthy subjects.

2 The same plasma proteins — with the exception of albumin — were seen more frequently in small dermal vessel walls in patients with diabetes.

3 The specific fluorescence indicating the presence of these proteins was more

	Non diabetic subjects					Diabetic patients					Chi square value
	Fluorescence (Grade)				Total No	Fluorescence (Grade)				Total No	
	1	2	3	4		1	2	3	4		
Albumin	35	14	0	0	49	62	16	0	0	78	11 (38)
$\alpha_1$ acid glycoprotein	21	0	0	0	21	16	2	1	0	19	
$\alpha_1$ lipoprotein	20	7	4	0	31	15	9	7	6	37	52 (60)
Haptoglobulin	19	1	0	0	20	14	2	1	0	17	
Transferrin	12	1	0	0	13	10	7	1	0	18	50 (38)
$\beta$ lipoprotein	18	1	0	0	19	18	3	1	0	22	
$\beta_{1c}$ globulin	37	7	0	0	44	44	20	8	1	73	92 (60)
Fibrinogen	43	3	0	0	46	59	12	1	0	72	
$\gamma$ G globulin	35	15	0	0	50	39	35	32	15	121	32 (38)
$\gamma$ A globulin	34	5	0	0	39	41	13	3	1	58	
$\gamma$ M globulin	43	1	0	0	44	45	14	5	1	65	137 (38)

TABLE 28 Patients with diabetes The results of the immunofluorescence staining of some plasma proteins in small dermal vessel walls in patients with a known duration < 10 years and > 10 years

Plasma protein studied	Duration < 10 years (Grade)			Duration > 10 years (Grade)			Chi square value ( $\chi^2 = 3.8$ )
	1	2 — 4	Total No	1	2 — 4	Total No	
Albumin	38	7	45	24	9	33	16
$\alpha_1$ acid glycoprotein	11	0	51	5	3	8	—
$\alpha_1$ lipoprotein	11	7	18	4	15	19	62
Haptoglobin	10	2	12	4	1	5	—
Transferrin	7	4	11	3	4	7	—
$\beta$ lipoprotein	9	3	12	9	1	10	—
$\beta_{1c}$ globulin	27	15	42	17	14	31	07
Fibrinogen	36	6	42	23	7	30	10
$\gamma A$ globulin	31	8	37	10	11	21	85
$\gamma M$ globulin	33	8	39	12	14	26	108

frequently strong in patients with diabetes

In all these respects, the tendency of the observations was similar to that already observed when the distribution of  $\gamma G$  globulin was studied

#### *The influence of the duration of diabetes*

The diabetic patients were divided into two groups, those with a known duration of less than 10 years and those with a duration of 10 years or more. When the two groups were compared, Table 28, significantly more positive results were obtained in the group with a longer duration, when  $\alpha_1$  lipoprotein,  $\gamma A$  and  $\gamma M$  globulins were studied. In all proteins studied except  $\beta$  lipoprotein the same tendency was observed.

#### *Summary*

In apparently healthy non diabetic subjects specific fluorescence indicating localized haptoglobin, transferrin,  $\beta$ -lipoprotein,  $\beta_{1c}$  globulin, fibrinogen,

$\gamma A$  and  $\gamma M$  globulins in small dermal vessel walls was noted only in one or in very few of the skin biopsies investigated. Albumin and  $\alpha_1$  lipoprotein was identified in about 30 % of the investigated biopsies, or to about the same extent as  $\gamma G$  globulin. In some specimens very strong fluorescence indicating localized  $\alpha_1$  lipoprotein was noted.

The frequency of specific fluorescence indicating localized albumin was similar in diabetic and non diabetic subjects. Other plasma proteins studied were seen more frequently in diabetic than in non diabetic subjects. In the former group the specific fluorescence was sometimes strong.

There was an increase in the intensity and frequency of the specific fluorescence of all plasma proteins studied with increasing duration of diabetes, with the exception of  $\beta$  lipoprotein.

The pattern of the observed specific fluorescence was thus very similar to that indicating localized  $\gamma G$  globulin in the vessel walls.

## CHAPTER IX

### GENERAL DISCUSSION

#### *Observation in PAS treated sections*

The observed thickening of the PAS positive dermal vessel walls in diabetic patients is in agreement with the results of previous investigations by others using the same technique (cf Table I). A slight thickening was often noted in non-diabetic, apparently healthy subjects and in patients with diseases other than diabetes. A heavy (grade 4) thickening of the vessel wall was with one exception, only seen in diabetic patients, namely in a 69 year old woman with high blood pressure, 280/100 and a normal oral glucose tolerance test. The observed connection of the diabetic state with a heavy PAS positive thickening of small vessel walls is also in agreement with earlier observations (cf Save-Soderberg *et al*, 1967). As stressed previously, it is not possible in light microscopic studies of this kind to determine whether the thickening is caused by an increased width of the basement membrane proper or of the collagen containing perivascular cuff or whether both these structures are involved (cf Friederici *et al* 1966 Pardo *et al* 1966 Siperstein *et al* 1966).

In the PAS treated sections it was observed that the wall thickness increased with the mean duration of diabetes. This too is in agreement with

the results obtained by others who studied large series of skin biopsies (cf McMillan *et al*, 1966 Otto *et al*, 1966, Save-Soderbergh *et al*, 1967). The positive correlation between the increasing width of the vessel walls and the duration of the disease may not, however, become evident if only patients with adult onset diabetes are studied, *vide infra*.

The results of this study seem to indicate that heavy thickening of the vessel walls could be noted early (within one year) in diabetic patients with a known onset of the disease after the age of 40. In juvenile diabetics with an onset below the age of 20 a similar thickening was not seen until after eight years. The anamnestic data of patients in several previously published studies on small vessel changes in biopsy specimens are incomplete, and the age at the onset of the disease is not mentioned. In most series however, the majority of patients were more than 40 years old. In those series, where the onset of the disease is stated, only a few patients with an onset below the age of 30 were studied. This may contribute to the difficulty in elucidating the possible influence of the duration on the increase of the vessel wall thickness. In genetically prediabetic subjects (both parents were overt

ly diabetic, the fasting blood sugars and oral glucose tolerance test were claimed to be within the normal range) Siperstein *et al* (1966) found ultra structurally a thicker basement membrane in muscle capillaries than in the normal subjects studied. The difference was statistically significant. In overtly diabetic subjects the membranes were significantly thicker than in the pre diabetic individuals studied. This might indicate an influence of the duration of the disease on the basement membrane width. Yet, in the overtly diabetic subjects the thickness was found to be unrelated to the duration of the disease. Neither the age of the subjects studied, nor the age at the onset of the disease are however, included in this study.

Lazarow (1967) found a positive correlation between the duration of diabetes and the width of the glomerular capillary basement membrane, studied under the electron microscope. He found too, that in adult diabetics of recent onset the basement membrane was thicker than in juvenile diabetics of the same duration. Furthermore in young diabetics the basement membrane width did not differ from that of non diabetic subjects. Østerby Hansen (1966) did not find any significant difference in the glomerular peripheral basement membrane width of recent onset juvenile diabetics and of non diabetic subjects. The thickness increased however with the increasing duration of the disease. (Østerby Hansen 1967). The present author's observations are consistent with these studies.

Only two published studies on skin biopsies are devoted to small blood vessel changes in juvenile diabetics (Otto *et al* 1967, Sæve Soderbergh *et al* 1967). In both series a positive correlation was found between the thickness of the small vessel walls and the duration of the disease. The present results conform to this.

The influence of the age at the onset of diabetes on the observed morphological changes in the small blood vessels may be more apparent than real, however. The difference in this respect between juvenile and adult onset diabetics may be due to the high frequency of unrecognized diabetes of long duration in older age groups (*cf* Keen 1966, Anderson, 1966).

In patients with rheumatoid arthritis and systemic lupus erythematosus (SLE) the small vessel walls were also found to be thicker than in apparently healthy subjects. Like diabetes mellitus these diseases are chronic ones and furthermore they are both inflammatory. The basic morphological similarities, observed by Bloodworth (1965) in kidney sections under the electron microscope between diabetic glomerulosclerosis, glomerulonephritis and SLE may be noted in this connection. However, the groups of patients investigated in the present study are too small to allow any further conclusions to be drawn.

#### *Immunohistochemical investigations*

Despite the various sources of specimens used, the various preparatory procedures and staining techniques the results of immunofluorescent investiga-

tions of the possible localization of  $\gamma$ -globulin in diabetic vessel walls indicate that this protein can be identified primarily in the region of the basement membranes in these vessels (cf Tables 3 and 4). Other plasma proteins are studied to a lesser extent (albumin, fibrinogen, low density lipoproteins, fractions of complement) but the results are inconclusive.

In the majority of investigated cases, however, reports on clinical data are lacking or insufficient. The series containing the largest number of cases were made in retrospect on sections obtained from tissue blocks in the files of Departments of Pathology (Berns et al 1962, 1964, Blumenthal et al, 1966). It is therefore, difficult to correlate the findings with clinical data and the natural course of diabetes.

When the studies are made in tissues from kidney, eye, pancreas or amputated legs it is obvious that comparative investigations of identical tissues from healthy individuals are practically impossible. The importance of adequate control series of this kind however is underlined by the results of the present investigation in apparently healthy subjects.  $\gamma$ G globulin was identified in small vessel walls in almost  $\frac{1}{3}$  of the subjects studied. albumin and  $\alpha_2$  lipoprotein were shown in approximately the same degree and haptoglobin, transferrin,  $\beta$  lipoprotein,  $\beta_{1c}$  globulin, fibrinogen,  $\gamma$ A and  $\gamma$ M globulins in only one or very few of these healthy subjects (Table 27). Fibrinogen,  $\beta_{1c}$ -globulin and  $\gamma$ -globulins may all take part in immunological processes. The results of this study stress the importance of

studying more than one or a few of these proteins, when the primary aim of the study is to investigate whether histological changes are of «immunogenic» origin, or not. Conclusions drawn from such studies may be valid but are not necessarily so. The normal passage of serum proteins from circulating blood into the surrounding connective tissue (cf Mancini, 1965), the increased leakage of proteins through the vessel walls and the possible accumulation of these proteins in damaged walls in many types of vascular lesions must be considered (cf Cotran & Majno, 1964, Zweifach, 1964).

In the present investigation a marked relationship was noted between the wall thickness observed in PAS treated sections, and the observed localisation of  $\gamma$ G globulin in small dermal vessel walls. The techniques performed do not allow any absolute quantitations of the results to be made. It cannot be stated whether the observed accumulation of  $\gamma$ G globulin and some other serum globulins are primary or secondary to the observed thickening of the vessel walls.

Localized  $\gamma$ G globulin was noted significantly more often in the total series of diabetic patients than in healthy individuals. The specific fluorescence was more frequently intense in the diabetic series. There was a positive correlation between the duration and the frequency and intensity of the specific fluorescence. A similar difference was noted between the series of juvenile and adult onset diabetics when  $\gamma$ G globulin was studied as was seen in PAS treated sections.

(*vide supra*) Here too, the explanation may be that in older age groups the disease often remains unrecognized for long periods

It has been supposed that aging is associated with a rising incidence of autoimmune reactions and this maybe more so in diabetic subjects (*cf* Blumenthal & Berns, 1964 Ungar *et al*, 1967) »Bound« autoantibodies might then accumulate in the vessel walls and contribute to the strong specific fluorescence indicating  $\gamma$ G globulin, which was observed in short term adult onset diabetics. However,  $\gamma$ G globulin appeared with equal frequency in the vessel walls of healthy subjects above the age of 50 and below the age of 30. With the exception of albumin, the vascular localization of the other proteins studied seemed to be dependent on the duration of diabetes in the same way as that of  $\gamma$ G globulin. As stated earlier, it therefore seems unjustified at present to draw too definite conclusions merely based on the localization of  $\gamma$ G globulin in the vessel walls

Localized  $\gamma$ G globulin was significantly more often to be found in the vessel walls of patients with SLE than in healthy subjects. The results are in keeping with those obtained by others studying the localization in *e.g.* the lesioned skin and in the kidneys (*cf* Chapter II and Tables 2 and 3)

#### *The immunogenic theory of pathogenesis*

In many studies based on cal staining methods (*cf*

1949, Ashton, 1957, Landrum 1963) the accumulation of plasma protein in the vessel walls has been assumed in diabetes mellitus. These methods can not, however, with certainty identify single proteins. The fluorescent antibody technique offers the possibility of identifying small quantities of specific proteins in tissue sections (*cf* Mellors 1959, Nairn, 1962)

The theory was put forward earlier (Starck 1954, Gellman *et al*, 1959) that vascular lesions in diabetes might be caused by immunological reactions and it was substantiated by the identification of  $\gamma$  globulins associated with vascular lesions in diabetic subjects (Odin & Tornblom, 1959, *cf* Table 2). The validity of the theory seemed to be further strengthened by the observations of Berns *et al* (1962) and others (Table 4) that conjugated insulin was bound *in vitro* to the same sites in vascular walls, where *in vivo* localized  $\gamma$ G globulin could be found. Furthermore conjugated anti insulin serum was bound *in vitro* in similar sites as conjugated insulin. Insulin was thought to be the antigen in those antigen antibody reactions that was thought to be of pathogenic importance in the development of the small vessel lesions in diabetes. The insulin could either be a »changed« endogenously produced insulin or introduced into the body during the insulin treatment (*cf* Blumenthal *et al*, 1964)

The present author's own investigations of skin biopsies treated with conjugated insulin, seem to indicate that insulin to dermal structures of



tions of the possible localization of  $\gamma$  globulin in diabetic vessel walls indicate that this protein can be identified primarily in the region of the basement membranes in these vessels (*cf* Tables 3 and 4). Other plasma proteins are studied to a lesser extent (albumin, fibrinogen, low density lipoproteins, fractions of complement) but the results are inconclusive.

In the majority of investigated cases, however, reports on clinical data are lacking or insufficient. The series containing the largest number of cases were made in retrospect on sections obtained from tissue blocks in the files of Departments of Pathology (Berns *et al* 1962, 1964, Blumenthal *et al*, 1966). It is, therefore, difficult to correlate the findings with clinical data and the natural course of diabetes.

When the studies are made in tissues from kidney, eye, pancreas or amputated legs it is obvious that comparative investigations of identical tissues from healthy individuals are practically impossible. The importance of adequate control series of this kind, however, is underlined by the results of the present investigation: in apparently healthy subjects  $\gamma$ G globulin was identified in small vessel walls in almost  $\frac{1}{3}$  of the subjects studied. Albumin and  $\alpha_1$  lipoprotein were shown in approximately the same degree, and haptoglobin, transferrin,  $\beta$  lipoprotein,  $\beta_{1c}$  globulin, fibrinogen,  $\gamma$ A and  $\gamma$ M globulins in only one or very few of these healthy subjects (Table 27). Fibrinogen,  $\beta_{1c}$  globulin and  $\gamma$  globulins may all take part in immunological processes. The results of this study stress the importance of

studying more than one or a few of these proteins, when the primary aim of the study is to investigate whether histological changes are of «immunogenic» origin, or not. Conclusions drawn from such studies may be valid but are not necessarily so. The normal passage of serum proteins from circulating blood into the surrounding connective tissue (*cf* Mancini, 1965), the increased leakage of proteins through the vessel walls and the possible accumulation of these proteins in damaged walls in many types of vascular lesions must be considered (*cf* Cotran & Majno, 1964, Zweifach, 1964).

In the present investigation a marked relationship was noted between the wall thickness observed in PAS treated sections, and the observed localisation of  $\gamma$ G globulin in small dermal vessel walls. The techniques performed do not allow any absolute quantitations of the results to be made. It cannot be stated whether the observed accumulation of  $\gamma$ G globulin and some other serum globulins are primary or secondary to the observed thickening of the vessel walls.

Localized  $\gamma$ G globulin was noted significantly more often in the total series of diabetic patients than in healthy individuals. The specific fluorescence was more frequently intense in the diabetic series. There was a positive correlation between the duration and the frequency and intensity of the specific fluorescence. A similar difference was noted between the series of juvenile and adult onset diabetics when  $\gamma$ G globulin was studied, as was seen in PAS treated sections.

(*vide supra*) Here too, the explanation may be that in older age groups the disease often remains unrecognized for long periods

It has been supposed that aging is associated with a rising incidence of autoimmune reactions and this maybe more so in diabetic subjects (*cf* Blumenthal & Berns, 1964; Ungar *et al*, 1967). «Bound» autoantibodies might then accumulate in the vessel walls and contribute to the strong specific fluorescence indicating  $\gamma$ G globulin, which was observed in short term adult onset diabetics. However,  $\gamma$ G globulin appeared with equal frequency in the vessel walls of healthy subjects above the age of 50 and below the age of 30. With the exception of albumin, the vascular localization of the other proteins studied seemed to be dependent on the duration of diabetes in the same way as that of  $\gamma$ G globulin. As stated earlier, it therefore seems unjustified at present to draw too definite conclusions merely based on the localization of  $\gamma$ G globulin in the vessel walls.

Localized  $\gamma$ G globulin was significantly more often to be found in the vessel walls of patients with SLE than in healthy subjects. The results are in keeping with those obtained by others studying the localization in *e.g.* the lesioned skin and in the kidneys (*cf* Chapter II and Tables 2 and 3).

#### *The immunogenic theory of pathogenesis*

In many studies based of histochemical staining methods (*cf* McManus

1949, Ashton 1957, Lendrum, 1963) the accumulation of plasma proteins in the vessel walls has been assumed in diabetes mellitus. These methods can not, however, with certainty identify single proteins. The fluorescent antibody technique offers the possibility of identifying small quantities of specific proteins in tissue sections (*cf* Mellors, 1959; Nairn 1962).

The theory was put forward earlier (Stärck 1954; Gellman *et al*, 1959) that vascular lesions in diabetes might be caused by immunological reactions and it was substantiated by the identification of  $\gamma$  globulins associated with vascular lesions in diabetic subjects (Odin & Tornblom, 1959, *cf* Table 2). The validity of the theory seemed to be further strengthened by the observations of Berns *et al* (1962) and others (Table 4) that conjugated insulin was bound *in vitro* to the same sites in vascular walls, where *in vivo* localized  $\gamma$ G globulin could be found. Furthermore, conjugated anti insulin serum was bound *in vitro* in similar sites as conjugated insulin. Insulin was thought to be the antigen in those antigen antibody reactions that was thought to be of pathogenic importance in the development of the small vessel lesions in diabetes. The insulin could either be a «changed» endogenously produced insulin or introduced into the body during the insulin treatment (*cf* Blumenthal *et al*, 1964).

The present author's own investigations of skin biopsies treated with conjugated pig insulin seem to indicate that the «binding» of insulin to dermal vessel walls and other structures of

the dermis is dependent on the fixation methods used during the preparation of the sections studied (These investigations are soon to be published) In formalin fixed sections a more selective binding of the insulin to vascular basement membranes — seemingly more so in diabetic subjects — and to dermal connective tissue fibres was noted If the sections were fixed in cold ethanol according to the modified Sainte Marie method the conjugated insulin became bound almost selectively to all kinds of

cells in the sections while almost no fluorescence was seen in the basement membrane regions No differences were observed between diabetic and non diabetic subjects The present author therefore considers that at the moment the results of immunohistochemical investigations of conjugated insulin and anti insulin serum cannot be referred to as support for the theory that insulin is the antigen in the supposed antigen antibody complexes localized in small vessel walls in diabetic subjects

## SUMMARY

On 122 patients with diabetes mellitus skin biopsies were performed and the small blood vessels were studied in PAS treated sections. With the aid of the fluorescent antibody technique the localization of  $\gamma$ G globulin in the vessel walls was investigated. 50 of the diabetic patients were matched with 50 non-diabetic subjects on whom similar studies were performed.

In the diabetic series a thickening of the PAS positive vessel walls was seen significantly differing from the wall thickness in non diabetic subjects. There was a positive correlation between the increase of the wall thickness and the duration of diabetes. This was best seen in patients with a known onset of diabetes below the age of 20.

Similarly  $\gamma$ G globulin was identified significantly more frequently localized in the vessel walls of diabetic than of non diabetic subjects. There was a positive correlation between the frequency and intensity of the specific fluorescence and the duration of the disease. This was best seen in patients

with a known onset of the disease below the age of 20.

The localization of some other plasma proteins in the vessel walls was to a lesser extent also studied using the fluorescent antibody technique. Albumin was found with the same frequency in diabetic and non diabetic subjects. Other plasma proteins studied ( $\alpha_1$  acid glycoprotein,  $\alpha_1$  lipoprotein, haptoglobin, transferrin,  $\beta$  lipoprotein,  $\beta_2$  globulin, fibrinogen, A and  $\gamma$ M globulins) were found more often in diabetic than in non diabetic subjects and more often in long term than in short term diabetics.

The PAS reaction and the localization of  $\gamma$ G globulin in the dermal vessel walls were also studied in 77 patients with various diseases other than diabetes. When compared with healthy subjects significantly thickened vessel walls were only observed in patients with rheumatoid arthritis and systemic lupus erythematosus (SLE) and a significantly higher frequency of localized  $\gamma$ G globulin was only seen in patients with SLE.

Professor Astrid Fagraeus Statens Bakteriologiska Laboratorium Stockholm first introduced me to the fluorescent antibody technique and the various problems connected with this method. She also generously supplied me with some of the ant sera used in this investigation. I have also gratefully received some valuable ant sera from Professor Sven Bergman, Institute of Clinical Bacteriology, Umeå. Dr Bengt Lundh, Department of Medicine, Lund and Dr Hans J. Müller-Eberhard, Scripps Clinic & Research Foundation, La Jolla, Calif.

The facilities of the Department of Clinical

Chemistry, Umeå were generously put at my disposal by Professor Lennart Jacobsson.

The statistical supervision has been performed by Professor Lennart Gustavsson, FK Institute of Statistics, The University of Umeå. My English was revised by Neville Shrimpton, M.A. and Laurie Thompson, M.A. The University of Umeå.

The work was supported by grants from Vasterbotten, Läns Landsting, Umeå, Nordisk Insulinfond, Gentofte, Denmark, and Svenska Diabeterförbundet, Stockholm.

# REFERENCES

- Aagenæs **■** & Høegensen N R Ugeskr Læg 121 572 1959
- Aagenæs Ø & Moe H Diabetes 10 235 1961
- Allansmith M Gosham Yahr M & Buell D N. J Allergy 35 313 1964
- Allansmith M & Buell D N J Immunol 95 951 1965
- Anderson T W. Diabetes 15 3 1966
- Angerall L Fagerberg S E & Saxe Söderbergh J Nord Med 74 1063 1965
- Angerall L Olsson Y Sourander P & Saxe Söderbergh J Nord Med 74 1005 1965
- Angerall L Dahl I & Saxe Söderberg J Path et Microbiol (Basel) 29 431 1966
- Angervall L & Saxe Söderberg J Diabetologia 2 117 1966
- Ashton N Lancet i 1002 1957
- Ashton N Fortschr Augenheilk 8 1 1958
- Banson B & Lacy P C Amer J Path 45 41 1964
- Bencosme S A West R O Kerr J W & Wilson D L Amer J Med 40 67 1966
- Bercovici E Solomon L M & Bierman H Amer J med Sci 248 1 1964
- Berkman J & Rifkin H Ann Rev Med 17 83 1966
- Berns A W Hirata Y & Blumenthal H T J Lab clin Med 60 535 1962
- Berns A W Owens C T Hirata Y & Blumenthal H T Diabetes 11 308 1962
- Berns A W Owens C T & Blumenthal H T J Geront 19 179 1964
- Bloodworth Jr J M B Diabetes 12 99 1963
- Bloodworth Jr J M B Diabetes 14 441 1965
- Blumenthal H T & Berns A W Advanc geront Rex 1 269 1964
- Blumenthal H T Hirata Y Owens C T & Berns A W. p 279 in Siperstein et al (1964)
- Blumenthal H T Berns A W Goldanberg S & Louenstein P W. Circulation 35 98 1966
- Bojsen Møller F Grønbech P & Rostgaard J Diabetes 12 429 1963
- Brandt aeg P & Kraus I W Odont T 73 281 1965
- Brandzaeg P Fjellanger I & Gjeruldsen S T. Immunohistochemistry 4 57 1967
- Burkholder P M Diabetes 14 755 1965
- Burstein R Berns A W Hirata Y & Blumenthal H T Amer J Obstet Gynec 86 66 1963
- Camerns Dalalos R A Med Clin N Amer 49 805 1965
- Coleman S L Becker B & Canaan S. Diabetes 11 375 1962
- Coleman S L & Becker B Amer J Ophthal 55 239 1963
- Cormane R H. Lancet i 534 1964
- Cormane R H Ballieux R E Karlsbeck G L & Haymans W. Clin exper Immunol 1 207 1966
- Catron R S & Majno G Ann N Y Acad Sci 116 750 1964
- Cruckshank B p 171 in Siperstein et al (1964)
- Davies N J Woolf N & Carstairs A J. J Path Bact 92 441 1966
- Documenta Geigy Wissenschaftliche Tabellen 6 Auflage J R Geigy A G Pharmazeutische Abteilung Basel 1960
- Douglas W Ann.rheum Dis 24 40 1965
- Durand M & Durand A Path et Biol 14 1005 1966
- Faerman I Abulafia J Serantes N & Landauer P Acta Diab Latina 2 4 1965
- Fagerberg S E Acta med scand suppl 345 1959
- Falkner S Hofer P A & Hollstrom E. Acta derm venereol Sven Hellström 65 years p 47 1966
- Farrant P C & Shedden W I H Diabetes 14 274 1965
- Fredrickson D S Levy R J & Lees R S. New Engl J Med 276 34 1967
- Freedman P Peters J M & Karl R M. Arch intern Med 105 524 1960
- Freedman P & Markowitz A S J clin Invest 41 328 1962
- Friedrich H R Tucker R & Schwartz T B. Diabetes 15 233 1966
- Funk H U. Diabetologica 1 228 1965

- Fink H U Schweiz med Wschr 95 487 1965
- Garran J Lopez Fernandez R & Molina J Rev clin esp 96 269 1965
- Gilman D G Pan C L Sootill J F Muchke H C & Karik M M Med clin (Bal more) 33 321 1959
- Giese J The Pathogenesis of hypertensive vascular disease Munksgaard Copenhagen 1966
- Glabbe Landng H & Wippl A J exper Med 97 163 1952
- Goderheg S Alex M Joshi R A & Blumenfeld H T Diabetes 8 261 1959
- Goldenberg S Berns A W & Blumenthal H T J Lab clin Med 64 863 1964
- Handelman M B Morone T G & Glzman H Arch intern Med 110 70 1962
- Ten Have Ophoeck A A W Acta derm venereol (Stockh) 46 68 1966
- Kalishiek G L & Cormane R H Lancet 178 1964
- Kalan M H & Vaugha J H Arthr and Rheum 2 3 6 1959
- Keen H Proc roy Soc Med 59 1169 1966
- Kerr S P Amer J Path 48 31 A 1966
- Kerr S P Amer J Path 50 623 1967
- Kimmelstiel P Diabetes 15 61 1966
- Kimmelstiel P Osawa G & Beres J Amer J clin Path 45 21 1966
- Kakower C A & Greenspon S A p 161 in Sperstein et al (1964)
- Laason O & Meln H Acta med scand suppl 423 56 1964
- Laason O Acta med scand 180 783 1966
- Laason H & Sperdel E D 127 in Sperstein et al (1964)
- Laason H Report to the 6th Congr of Internat Diab Fed Stockholm 1967
- Lendrum A L Canad med Ass J 88 442 1963
- Li R D Histopathologic Technique and Practical Histochemistry McGraw Hill Book Company New York 1965
- Mackay I R & Taft L I Aust Ann. Med 10 178 1961
- Mancini R F Int Rev Cytol 14 193 1963
- McCrormack J N Ann. rheum Dis 22 1 1963
- McManus J F A Nature (Lond) 158 202 1946
- McManus J F A Proc Amer diabet Ass 9 303 1949
- McMillan D F F Jaupet D L Roseman W Lee J C & L Jan P H Diabetes 15 251 1966
- Meln H Acta med scand suppl 423 1964
- Mellors R C Anal al C t lo y McGraw Hill Book Company N y York 1959
- Mescler P A Paon t F & Koffler D p 446 in Grabar F e Mesher P A Immunopathology IV Sh h f Co Ba sel 1966
- Moore J M & Fra I D O B t med J 1 19 1965
- Moran T J Kurt S M & Vaque J J Lab Invest 11 240 1962
- M r H p 787 in Cameron M P & O Connor M Aetiology of Diabetes mellitus and its complications Ciba Foundation Colloquia on Endocrinology Volume 15 Boston 1964
- Muller Eberhard H J Od n L & Tornblom N Nord Med 61 813 1959
- Moller G J exp Med 114 415 1961
- Narr R C Fluorescent Protein Tracing E & S Livingstone Ltd Edinburgh & London 1967
- Od n L & Tornblom N Acta Soc Med uppsala 64 313 1959
- de Oliveira F Brit J Ophthal 50 134 1966
- Otto H Tjemann H & Wagner H Klin Wschr 45 299 1967
- Parlo V Perez Stable F & Filer E R Lab Invest 15 1994 1966
- Pedersen J & Ols n S Acta med scand 171 551 1962
- Per A Scapell P T & R o M Diabetologia 1 109 1965
- I tnam F W The Plasma Proteins Volume I Academic Press New York 1960
- Robb Smith A H T J Mt Sna Hosp 24 1155 1957
- Rodman W S Williams H C Blka P J & Muller Eberhard H J J Lab clin Med 69 141 1967
- Rodguez J & Denhardt F Virology 12 316 1960
- Sante Marie G J Histochem. Cytochem. 10 250 1962
- Sperstein N D Colwell Sr A R & Meier K Small blood vessel involvement in dia

- betes mellitus American Institute of Biological Sciences Washington 1964  
 Siperstein M D Unger R H & Madison C C. Trans Ass Amer Phycns 79 330 1966  
 Spiro R G. Diabetes 12 223 1963  
 Spiro R G p 151 in Siperstein et al (1964)  
 Stary H C. Amer J med Sci 252 357 1966  
 Stringa S G Bianchi C & Zingale S B J invest Derm 46 1 1966  
 Starel G. Schweiz med Wschr 84 1440 1954  
 Sule Soderbergh J Angenall L & Fagerberg S L. Diabetologica 3 331 1967  
 Taft L., Dineen J & Mackay I R Aust Ann. Med 7 5 1958  
 Tan E M & Kunkel H G. Arthr and Rheum 9 37 1966  
 Thomsen A Ch. The kidney in diabetes mellitus Munksgaard Copenhagen 1965  
 Ungar B Stocks A E Martin F J R Whittingham S & Mackay I R. Lancet ii 77 1967  
 Warren S LeCompte Ph M & Legg M A. The pathology of diabetes mellitus 4th Ed Lea & Febiger Philadelphia 1966  
 Weber H W & Wicht C L S Afr J Lab clin Med 8 83 1962  
 Windrum G M Kent P W & Eastoe J L. Brit J exp Path 36 49 1955  
 Yodanis R E Seffel H C Rubinstein A N Diabetes 16 191 1967  
 Zimmer J Dub Th & Worringer Fr Bull Soc franç Derm Syph 68 320 1961  
 Zugibe I T. J Histochem Cytochem 11 35 1963  
 Zweisach B W Ann N Y Acad Sci 116 831 1964  
 Østerby Hansen R Diabetologica 1 97 1965  
 Østerby Hansen R Excerpta med (Amst) Internat Congr Series No 140 18 1967













A



B



C



D


PLATE III Skin biopsies. Indirect immunofluorescent staining of  $\gamma$  globulin by means of rabbit anti-human  $\gamma$  globulin serum + conjugated goat anti rabbit globulin serum. The intensity of the fluorescence is graded from 1 to 4 (Orig. magn.  $\times 400$ )

A. No. 141 Age 22 Healthy Grade 1

B. No. 130 Age 21 Diabetes mellitus duration 13 years Grade 2

C. No. 20 Age 28 Diabetes mellitus duration 10 years Grade 3

D. No. 4 Age 35 Diabetes mellitus duration 22 years Grade 4



A



B



C



D

FIGURE IV. Skin biopsies. Localization of various plasma proteins by aid of indirect immunofluorescent staining. All stainings were performed with the same conjugated goat anti rabbit globulin serum. The unconjugated antisera used were: A Serum No 2 B Serum No 3 C Serum No 1 D Serum No 7 listed in Table 8. Original magnification  $\times 400$ .

A No 176 Age 70 Diabetes mellitus duration 5 years. Specific fluorescence indicating albumin diffusely localized in connective tissue.

B No 194 Age 19 Diabetes mellitus duration 9 years. Specific fluorescence indicating  $\alpha_1$  acid glycoprotein localized in perivascular cells.

C No 128 Age 33 Diabetes mellitus duration 20 years. Specific fluorescence indicating  $\alpha_1$  lipoprotein localized in small dermal vessel walls and in the superficial layer of the dermis.

D No 238 Age 46 Healthy. Specific fluorescence indicating  $\beta$  lipoprotein coating the endothelial cells of a small artery and vein.



A



B



C



D

PLATE V Skin biopsies Localization of various plasma proteins by aid of indirect immunofluorescent staining. All stainings were performed with the same conjugated goat anti rabbit globulin serum. The unconjugated antisera used were A. Serum No 9 B. Serum No 10 C. Serum No 14 D. Serum No 15 listed in Table 8.

A. No 5 Age 36 Diabetes mellitus duration 29 years Specific fluorescence indicating  $\beta_2$  globulin localized in small dermal vessel wall and immediately beneath the epidermis. Orig magn  $\times 400$ .

B. No 176 Age 70 Diabetes mellitus duration 5 years Specific fluorescence indicating fibrinogen coating endothelial cells in small vessels.

C. No 179 Age 70 Healthy Specific fluorescence indicating  $\gamma A$  globulin in the area of the dermal epidermal junction. Orig magn  $\times 160$ .


D. No 142 Age 27 Diabetes mellitus duration 8 years Specific fluorescence indicating  $\gamma M$  globulin mainly localized in small vessel walls. Orig magn  $\times 160$ .



A



B



C



D

PLATE VI Skin biopsies Indirect immunofluorescent demonstration of  $\gamma$ G globulin Serum No 12 (Table 8)  
+ conjugated goat anti rabbit globulin serum

A. No. 4 Age 35 Diabetes mellitus duration 22 years Orig magn  $\times 160$

B. No 130 Age 28 Diabetes mellitus duration 12 years Orig magn  $\times 160$

C. No 196 Age 24 Diabetes mellitus duration 13 years Specific fluorescence in small dermal vein no fluorescence in small artery Orig magn  $\times 160$

D. No 25 Age 28 Diabetes mellitus duration 10 years Strong specific fluorescence in small vessels close to sweat glands Orig magn  $\times 400$

